Dossier zur Nutzenbewertung gemäß § 35a SGB V

Resmetirom (Rezdiffra®)

Madrigal Pharmaceuticals EU Limited

Modul 4 A – Anhang 4-I

Resmetirom ist indiziert in Kombination mit Ernährung und Bewegung zur Behandlung von Erwachsenen mit nicht zirrhotischer, nicht alkoholischer Steatohepatitis (MASH), bei denen eine mäßige bis fortgeschrittene Leberfibrose (Fibrosestadien F2 bis F3) besteht.

Weitere Analysen zu den in Abschnitt 4.3.1.3 gezeigten Ergebnissen

Stand: 15.09.2025

Table Of Contents

AMNOG Table SE18.2.1 Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain by Age (Median) (Label Population based o n Modified Intent-to-Treat Population) --->22

AMNOG Table SE18.2.2 Chronic Liver Disease Questionnaire-NASH (SE18): Summary of CLDQ-NASH - MMRM Model by Age (Median) (Label Population ba sed on Modified Intent-to-Treat Population) --->36

AMNOG Table SE18.2.3 Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain by Age (Median) (Label Popul ation based on Modified Intent-to-Treat Population) --->39

AMNOG Table SE18.2.4 Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain by Age (Median) (Label Popula tion based on Modified Intent-to-Treat Population) --->52

AMNOG Table SE18.3.1 Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain by Age (Label Population based on Modif ied Intent-to-Treat Population) --->67

AMNOG Table SE18.3.2 Chronic Liver Disease Questionnaire-NASH (SE18): Summary of CLDQ-NASH - MMRM Model by Age (Label Population based on Modified Intent-to-Treat Population) --->81

AMNOG Table SE18.3.3 Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain by Age (Label Population b ased on Modified Intent-to-Treat Population) --->84

AMNOG Table SE18.3.4 Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain by Age (Label Population ba sed on Modified Intent-to-Treat Population) --->97

AMNOG Table SE18.4.1 Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain by Sex (Label Population based on Modifie d Intent-to-Treat Population) --->112

Table Of Contents

AMNOG Table SE18.4.2 Chronic Liver Disease Questionnaire-NASH (SE18): Summary of CLDQ-NASH - MMRM Model by Sex (Label Population based on Modified Intent-to-Treat Population) --->126

AMNOG Table SE18.4.3 Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain by Sex (Label Population based on Modified Intent-to-Treat Population) --->129

AMNOG Table SE18.4.4 Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain by Sex (Label Population based on Modified Intent-to-Treat Population) --->142

AMNOG Table SE18.5.1 Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain by Ethnicity (Label Population based on Modified Intent-to-Treat Population) --->157

AMNOG Table SE18.5.2 Chronic Liver Disease Questionnaire-NASH (SE18): Summary of CLDQ-NASH - MMRM Model by Ethnicity (Label Population based on Modified Intent-to-Treat Population) --->171

AMNOG Table SE18.5.3 Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain by Ethnicity (Label Population based on Modified Intent-to-Treat Population) --->174

AMNOG Table SE18.5.4 Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain by Ethnicity (Label Population based on Modified Intent-to-Treat Population) --->187

AMNOG Table SE18.6.1 Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain by Weight (Label Population based on Modified Intent-to-Treat Population) --->202

AMNOG Table SE18.6.2 Chronic Liver Disease Questionnaire-NASH (SE18): Summary of CLDQ-NASH - MMRM Model by Weight (Label Population based on Modified Intent-to-Treat Population) --->216

Table Of Contents

AMNOG Table SE18.6.3 Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain by Weight (Label Population based on Modified Intent-to-Treat Population) --->219

AMNOG Table SE18.6.4 Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain by Weight (Label Population based on Modified Intent-to-Treat Population) --->232

AMNOG Table SE18.7.1 Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain by Baseline T2D Status (Label Population based on Modified Intent-to-Treat Population) --->247

AMNOG Table SE18.7.2 Chronic Liver Disease Questionnaire-NASH (SE18): Summary of CLDQ-NASH - MMRM Model by Baseline T2D Status (Label Population based on Modified Intent-to-Treat Population) --->261

AMNOG Table SE18.7.3 Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain by Baseline T2D Status (Label Population based on Modified Intent-to-Treat Population) --->264

AMNOG Table SE18.7.4 Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain by Baseline T2D Status (Label Population based on Modified Intent-to-Treat Population) --->277

AMNOG Table SE18.8.1 Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain by Baseline HbA1C (Label Population based on Modified Intent-to-Treat Population) --->292

AMNOG Table SE18.8.2 Chronic Liver Disease Questionnaire-NASH (SE18): Summary of CLDQ-NASH - MMRM Model by Baseline HbA1C (Label Population based on Modified Intent-to-Treat Population) --->306

AMNOG Table SE18.8.3 Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain by Baseline HbA1C (Label Population based on Modified Intent-to-Treat Population) --->309

Table Of Contents

AMNOG Table SE18.8.4 Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain by Baseline HbA1C (Label Population based on Modified Intent-to-Treat Population) --->322

AMNOG Table SE18.9.1 Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain by Sites that participated in Study MAESTRO-NASH (MGL-3196-11) (Label Population based on Modified Intent-to-Treat Population) --->337

AMNOG Table SE18.9.2 Chronic Liver Disease Questionnaire-NASH (SE18): Summary of CLDQ-NASH - MMRM Model by Sites that participated in Study MAESTRO-NASH (MGL-3196-11) (Label Population based on Modified Intent-to-Treat Population) --->351

AMNOG Table SE18.9.3 Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain by Sites that participated in Study MAESTRO-NASH (MGL-3196-11) (Label Population based on Modified Intent-to-Treat Population) --->354

AMNOG Table SE18.9.4 Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain by Sites that participated in Study MAESTRO-NASH (MGL-3196-11) (Label Population based on Modified Intent-to-Treat Population) --->367

AMNOG Table SE18.10.1 Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain by Baseline Statin (Label Population based on Modified Intent-to-Treat Population) --->382

AMNOG Table SE18.10.2 Chronic Liver Disease Questionnaire-NASH (SE18): Summary of CLDQ-NASH - MMRM Model by Baseline Statin (Label Population based on Modified Intent-to-Treat Population) --->396

AMNOG Table SE18.10.3 Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain by Baseline Statin (Label Population based on Modified Intent-to-Treat Population) --->399

AMNOG Table SE18.10.4 Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain by Baseline Statin (Label Population based on Modified Intent-to-Treat Population) --->412

Table Of Contents

AMNOG Table SE19.2.1 Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain by Age (Median) (Label Population based on Modified Intent-to-Treat Population) --->427

AMNOG Table SE19.2.2 Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain by Age (Median) (Label Population based on Modified Intent-to-Treat Population) --->435

AMNOG Table SE19.2.3 Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain by Age (Median) (Label Population based on Modified Intent-to-Treat Population) --->444

AMNOG Table SE19.3.1 Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain by Age (Label Population based on Modified Intent-to-Treat Population) --->453

AMNOG Table SE19.3.2 Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain by Age (Label Population based on Modified Intent-to-Treat Population) --->461

AMNOG Table SE19.3.3 Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain by Age (Label Population based on Modified Intent-to-Treat Population) --->470

AMNOG Table SE19.4.1 Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain by Sex (Label Population based on Modified Intent-to-Treat Population) --->479

AMNOG Table SE19.4.2 Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain by Sex (Label Population based on Modified Intent-to-Treat Population) --->487

AMNOG Table SE19.4.3 Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain by Sex (Label Population based on Modified Intent-to-Treat Population) --->496

Table Of Contents

AMNOG Table SE19.5.1 Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain by Ethnicity (Label Population based on Modified Intent-to-Treat Population) --->505

AMNOG Table SE19.5.2 Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain by Ethnicity (Label Population based on Modified Intent-to-Treat Population) --->513

AMNOG Table SE19.5.3 Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain by Ethnicity (Label Population based on Modified Intent-to-Treat Population) --->522

AMNOG Table SE19.6.1 Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain by Weight (Label Population based on Modified Intent-to-Treat Population) --->531

AMNOG Table SE19.6.2 Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain by Weight (Label Population based on Modified Intent-to-Treat Population) --->539

AMNOG Table SE19.6.3 Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain by Weight (Label Population based on Modified Intent-to-Treat Population) --->548

AMNOG Table SE19.7.1 Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain by Baseline T2D Status (Label Population based on Modified Intent-to-Treat Population) --->557

AMNOG Table SE19.7.2 Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain by Baseline T2D Status (Label Population based on Modified Intent-to-Treat Population) --->565

AMNOG Table SE19.7.3 Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain by Baseline T2D Status (Label Population based on Modified Intent-to-Treat Population) --->574

Table Of Contents

AMNOG Table SE19.8.1 Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain by Baseline HbA1C (Label Population based on Modified Intent-to-Treat Population) --->583

AMNOG Table SE19.8.2 Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain by Baseline HbA1C (Label Population based on Modified Intent-to-Treat Population) --->591

AMNOG Table SE19.8.3 Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain by Baseline HbA1C (Label Population based on Modified Intent-to-Treat Population) --->600

AMNOG Table SE19.9.1 Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain by Sites that participated in Study MAESTRO-NASH (MGL-3196-11) (Label Population based on Modified Intent-to-Treat Population) --->609

AMNOG Table SE19.9.2 Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain by Sites that participated in Study MAESTRO-NASH (MGL-3196-11) (Label Population based on Modified Intent-to-Treat Population) --->617

AMNOG Table SE19.9.3 Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain by Sites that participated in Study MAESTRO-NASH (MGL-3196-11) (Label Population based on Modified Intent-to-Treat Population) --->626

AMNOG Table SE19.10.1 Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain by Baseline Statin (Label Population based on Modified Intent-to-Treat Population) --->635

AMNOG Table SE19.10.2 Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain by Baseline Statin (Label Population based on Modified Intent-to-Treat Population) --->643

AMNOG Table SE19.10.3 Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain by Baseline Statin (Label Population based on Modified Intent-to-Treat Population) --->652

Table Of Contents

AMNOG Table SE20.2.1 Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component by Age (Median) (Label Population based on Modified Intent-to-Treat Population) --->661

AMNOG Table SE20.2.2 Liver Disease Quality of Life (SE20): Summary of Total LDQOL - MMRM Model by Age (Median) (Label Population based on Modified Intent-to-Treat Population) --->681

AMNOG Table SE20.2.3 Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component by Age (Median) (Label Population based on Modified Intent-to-Treat Population) --->684

AMNOG Table SE20.2.4 Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component by Age (Median) (Label Population based on Modified Intent-to-Treat Population) --->703

AMNOG Table SE20.3.1 Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component by Age (Label Population based on Modified Intent-to-Treat Population) --->724

AMNOG Table SE20.3.2Liver Disease Quality of Life (SE20): Summary of Total LDQOL - MMRM Model by Age (Label Population based on Modified Intent-to-Treat Population) --->744

AMNOG Table SE20.3.3 Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component by Age (Label Population based on Modified Intent-to-Treat Population) --->747

AMNOG Table SE20.3.4 Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component by Age (Label Population based on Modified Intent-to-Treat Population) --->766

AMNOG Table SE20.4.1 Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component by Sex (Label Population based on Modified Intent-to-Treat Population) --->787

Table Of Contents

AMNOG Table SE20.4.2Liver Disease Quality of Life (SE20): Summary of Total LDQOL - MMRM Model by Sex (Label Population based on Modified Intent-to-Treat Population) --->807

AMNOG Table SE20.4.3 Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component by Sex (Label Population based on Modified Intent-to-Treat Population) --->810

AMNOG Table SE20.4.4 Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component by Sex (Label Population based on Modified Intent-to-Treat Population) --->829

AMNOG Table SE20.5.1 Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component by Ethnicity (Label Population based on Modified Intent-to-Treat Population) --->850

AMNOG Table SE20.5.2Liver Disease Quality of Life (SE20): Summary of Total LDQOL - MMRM Model by Ethnicity (Label Population based on Modified Intent-to-Treat Population) --->870

AMNOG Table SE20.5.3 Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component by Ethnicity (Label Population based on Modified Intent-to-Treat Population) --->873

AMNOG Table SE20.5.4 Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component by Ethnicity (Label Population based on Modified Intent-to-Treat Population) --->892

AMNOG Table SE20.6.1 Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component by Weight (Label Population based on Modified Intent-to-Treat Population) --->913

AMNOG Table SE20.6.2Liver Disease Quality of Life (SE20): Summary of Total LDQOL - MMRM Model by Weight (Label Population based on Modified Intent-to-Treat Population) --->933

Table Of Contents

AMNOG Table SE20.6.3 Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component by Weight (Label Population based on Modified Intent-to-Treat Population) --->936

AMNOG Table SE20.6.4 Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component by Weight (Label Population based on Modified Intent-to-Treat Population) --->955

AMNOG Table SE20.7.1 Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component by Baseline T2D Status (Label Population based on Modified Intent-to-Treat Population) --->976

AMNOG Table SE20.7.2Liver Disease Quality of Life (SE20): Summary of Total LDQOL - MMRM Model by Baseline T2D Status (Label Population based on Modified Intent-to-Treat Population) --->996

AMNOG Table SE20.7.3 Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component by Baseline T2D Status (Label Population based on Modified Intent-to-Treat Population) --->999

AMNOG Table SE20.7.4 Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component by Baseline T2D Status (Label Population based on Modified Intent-to-Treat Population) --->1018

AMNOG Table SE20.8.1 Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component by Baseline HbA1C (Label Population based on Modified Intent-to-Treat Population) --->1039

AMNOG Table SE20.8.2Liver Disease Quality of Life (SE20): Summary of Total LDQOL - MMRM Model by Baseline HbA1C (Label Population based on Modified Intent-to-Treat Population) --->1059

AMNOG Table SE20.8.3 Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component by Baseline HbA1C (Label Population based on Modified Intent-to-Treat Population) --->1062

Table Of Contents

AMNOG Table SE20.8.4 Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component by Baseline HbA1C (Label Population based on Modified Intent-to-Treat Population) --->1081

AMNOG Table SE20.9.1 Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component by Sites that participated in Study MAESTRO-NASH (MGL-3196-11) (Label Population based on Modified Intent-to-Treat Population) --->1102

AMNOG Table SE20.9.2Liver Disease Quality of Life (SE20): Summary of Total LDQOL - MMRM Model by Sites that participated in Study MAESTRO-NASH (MGL-3196-11) (Label Population based on Modified Intent-to-Treat Population) --->1122

AMNOG Table SE20.9.3 Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component by Sites that participated in Study MAESTRO-NASH (MGL-3196-11) (Label Population based on Modified Intent-to-Treat Population) --->1125

AMNOG Table SE20.9.4 Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component by Sites that participated in Study MAESTRO-NASH (MGL-3196-11) (Label Population based on Modified Intent-to-Treat Population) --->1144

AMNOG Table SE20.10.1 Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component by Baseline Statin (Label Population based on Modified Intent-to-Treat Population) --->1165

AMNOG Table SE20.10.2Liver Disease Quality of Life (SE20): Summary of Total LDQOL - MMRM Model by Baseline Statin (Label Population based on Modified Intent-to-Treat Population) --->1185

AMNOG Table SE20.10.3 Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component by Baseline Statin (Label Population based on Modified Intent-to-Treat Population) --->1188

AMNOG Table SE20.10.4 Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component by Baseline Statin (Label Population based on Modified Intent-to-Treat Population) --->1207

Table Of Contents

AMNOG Table SE21.2.1 Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component by Age (Median) (Label Population based on Modified Intent-to-Treat Population) --->1228

AMNOG Table SE21.2.2 Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Age (Median) (Label Population based on Modified Intent-to-Treat Population) --->1248

AMNOG Table SE21.2.3 Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component by Age (Median) (Label Population based on Modified Intent-to-Treat Population) --->1269

AMNOG Table SE21.3.1 Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component by Age (Label Population based on Modified Intent-to-Treat Population) --->1290

AMNOG Table SE21.3.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Age (Label Population based on Modified Intent-to-Treat Population) --->1310

AMNOG Table SE21.3.3 Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component by Age (Label Population based on Modified Intent-to-Treat Population) --->1331

AMNOG Table SE21.4.1 Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component by Sex (Label Population based on Modified Intent-to-Treat Population) --->1352

AMNOG Table SE21.4.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Sex (Label Population based on Modified Intent-to-Treat Population) --->1372

AMNOG Table SE21.4.3 Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component by Sex (Label Population based on Modified Intent-to-Treat Population) --->1393

Table Of Contents

AMNOG Table SE21.5.1 Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component by Ethnicity (Label Population based on Modified Intent-to-Treat Population) --->1414

AMNOG Table SE21.5.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Ethnicity (Label Population based on Modified Intent-to-Treat Population) --->1434

AMNOG Table SE21.5.3 Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component by Ethnicity (Label Population based on Modified Intent-to-Treat Population) --->1455

AMNOG Table SE21.6.1 Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component by Weight (Label Population based on Modified Intent-to-Treat Population) --->1476

AMNOG Table SE21.6.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Weight (Label Population based on Modified Intent-to-Treat Population) --->1496

AMNOG Table SE21.6.3 Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component by Weight (Label Population based on Modified Intent-to-Treat Population) --->1517

AMNOG Table SE21.7.1 Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component by Baseline T2D Status (Label Population based on Modified Intent-to-Treat Population) --->1538

AMNOG Table SE21.7.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline T2D Status (Label Population based on Modified Intent-to-Treat Population) --->1558

AMNOG Table SE21.7.3 Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component by Baseline T2D Status (Label Population based on Modified Intent-to-Treat Population) --->1579

Table Of Contents

AMNOG Table SE21.8.1 Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component by Baseline HbA1C (Label Population based on Modified Intent-to-Treat Population) --->1600

AMNOG Table SE21.8.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline HbA1C (Label Population based on Modified Intent-to-Treat Population) --->1620

AMNOG Table SE21.8.3 Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component by Baseline HbA1C (Label Population based on Modified Intent-to-Treat Population) --->1641

AMNOG Table SE21.9.1 Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component by Sites that participated in Study MAESTRO-NASH (MGL-3196-11) (Label Population based on Modified Intent-to-Treat Population) --->1662

AMNOG Table SE21.9.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Sites that participated in Study MAESTRO-NASH (MGL-3196-11) (Label Population based on Modified Intent-to-Treat Population) --->1682

AMNOG Table SE21.9.3 Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component by Sites that participated in Study MAESTRO-NASH (MGL-3196-11) (Label Population based on Modified Intent-to-Treat Population) --->1703

AMNOG Table SE21.10.1 Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component by Baseline Statin (Label Population based on Modified Intent-to-Treat Population) --->1724

AMNOG Table SE21.10.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline Statin (Label Population based on Modified Intent-to-Treat Population) --->1744

AMNOG Table SE21.10.3 Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component by Baseline Statin (Label Population based on Modified Intent-to-Treat Population) --->1765

Table Of Contents

AMNOG Table S1.2.1.1 TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary by Age (Median) (Label Population based on Safety Population) --->1786

AMNOG Table S1.2.1.2 TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary by Age (Median) (Label Population based on Safety Population) --->1807

AMNOG Table S1.2.2 TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Age (Median) (Label Population based on Safety Population) --->1828

AMNOG Table S1.3.1.1 TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary by Age (Label Population based on Safety Population) --->1831

AMNOG Table S1.3.1.2 TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary by Age (Label Population based on Safety Population) --->1852

AMNOG Table S1.3.2 TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Age (Label Population based on Safety Population) --->1873

AMNOG Table S1.4.1.1 TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary by Sex (Label Population based on Safety Population) --->1876

AMNOG Table S1.4.1.2 TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary by Sex (Label Population based on Safety Population) --->1897

AMNOG Table S1.4.2 TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Sex (Label Population based on Safety Population) --->1918

Table Of Contents

AMNOG Table S1.5.1.1 TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary by Ethnicity (Label Population based on Safety Population) --->1921

AMNOG Table S1.5.1.2 TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary by Ethnicity (Label Population based on Safety Population) --->1942

AMNOG Table S1.5.2 TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Ethnicity (Label Population based on Safety Population) --->1963

AMNOG Table S1.6.1.1 TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary by Weight (Label Population based on Safety Population) --->1966

AMNOG Table S1.6.1.2 TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary by Weight (Label Population based on Safety Population) --->1987

AMNOG Table S1.6.2 TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Weight (Label Population based on Safety Population) --->2008

AMNOG Table S1.7.1.1 TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary by Baseline T2D Status (Label Population based on Safety Population) --->2011

AMNOG Table S1.7.1.2 TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary by Baseline T2D Status (Label Population based on Safety Population) --->2032

AMNOG Table S1.7.2 TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Baseline T2D Status (Label Population based on Safety Population) --->2053

Table Of Contents

AMNOG Table S1.8.1.1 TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary by Baseline HbA1C (Label Population based on Safety Population) --->2056

AMNOG Table S1.8.1.2 TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary by Baseline HbA1C (Label Population based on Safety Population) --->2077

AMNOG Table S1.8.2 TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Baseline HbA1C (Label Population based on Safety Population) --->2098

AMNOG Table S1.9.1.1 TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary by Sites that participated in Study MAESTRO-NASH (MGL-3196-11) (Label Population based on Safety Population) --->2101

AMNOG Table S1.9.1.2 TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary by Sites that participated in Study MAESTRO-NASH (MGL-3196-11) (Label Population based on Safety Population) --->2122

AMNOG Table S1.9.2 TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Sites that participated in Study MAESTRO-NASH (MGL-3196-11) (Label Population based on Safety Population) --->2143

AMNOG Table S1.10.1.1 TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary by Baseline Statin (Label Population based on Safety Population) --->2146

AMNOG Table S1.10.1.2 TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary by Baseline Statin (Label Population based on Safety Population) --->2167

Table Of Contents

AMNOG Table S1.10.2 TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Baseline Statin (Label Population based on Safety Population) --->2188

AMNOG Table S2.2.1 TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade by Age (Median) (Label Population based on Safety Population) --->2191

AMNOG Table S2.3.1 TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade by Age (Label Population based on Safety Population) --->2193

AMNOG Table S2.4.1 TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade by Sex (Label Population based on Safety Population) --->2195

AMNOG Table S2.5.1 TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade by Ethnicity (Label Population based on Safety Population) --->2197

AMNOG Table S2.6.1 TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade by Weight (Label Population based on Safety Population) --->2199

AMNOG Table S2.7.1 TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade by Baseline T2D Status (Label Population based on Safety Population) --->2201

AMNOG Table S2.8.1 TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade by Baseline HbA1C (Label Population based on Safety Population) --->2203

Table Of Contents

AMNOG Table S2.9.1 TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade by Sites that participated in Study MAESTRO-NASH (MGL-3196-11) (Label Population based on Safety Population) --->2205

AMNOG Table S2.10.1 TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade by Baseline Statin (Label Population based on Safety Population) --->2207

AMNOG Table S4.2.1 SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Termby Age (Median) (Label Population based on Safety Population) --->2209

AMNOG Table S4.3.1 SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Termby Age (Label Population based on Safety Population) --->2211

AMNOG Table S4.4.1 SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Termby Sex (Label Population based on Safety Population) --->2213

AMNOG Table S4.5.1 SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Termby Ethnicity (Label Population based on Safety Population) --->2215

AMNOG Table S4.6.1 SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Termby Weight (Label Population based on Safety Population) --->2217

AMNOG Table S4.7.1 SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Termby Baseline T2D Status (Label Population based on Safety Population) --->2219

Table Of Contents

AMNOG Table S4.8.1 SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Termby Baseline HbA1C (Label Population based on Safety Population) --->2221

AMNOG Table S4.9.1 SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Termby Sites that participated in Study MAESTRO-NASH (MGL-3196-11) (Label Population based on Safety Population) --->2223

AMNOG Table S4.10.1 SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Termby Baseline Statin (Label Population based on Safety Population) --->2225

AMNOG Table S6.2.1 TEAE (S6): Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term; by Age (Median) (Label Population based on Safety Population) --->2227

AMNOG Table S6.3.1 TEAE (S6): Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term; by Age (Label Population based on Safety Population) --->2229

AMNOG Table S6.4.1 TEAE (S6): Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term; by Sex (Label Population based on Safety Population) --->2231

AMNOG Table S6.5.1 TEAE (S6): Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term; by Ethnicity (Label Population based on Safety Population) --->2233

AMNOG Table S6.6.1 TEAE (S6): Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term; by Weight (Label Population based on Safety Population) --->2235

Table Of Contents

AMNOG Table S6.7.1 TEAE (S6): Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term; by Baseline T2D Status (Label Population based on Safety Population) --->2237

AMNOG Table S6.8.1 TEAE (S6): Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term; by Baseline HbA1C (Label Population based on Safety Population) --->2239

AMNOG Table S6.9.1 TEAE (S6): Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term; by Sites that participated in Study MAESTRO-NASH (MGL-3196-11) (Label Population based on Safety Population) --->2241

AMNOG Table S6.10.1 TEAE (S6): Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term; by Baseline Statin (Label Population based on Safety Population) --->2243

Madrigal Pharmaceuticals, Inc. Page 1 of 14
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE18.2.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=11)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=11)	Change from Baseline DB Placebo (N=11)
CLDQ-NASH						
Baseline						
m	2	11	11			
n	2	10	9			
Mean (SD)	4.50 (0.71)	5.88 (0.70)	5.66 (0.79)			
Median	4.50	6.10	5.40			
IQR: Q1, Q3	4.00, 5.00	5.80, 6.20	5.00, 6.50			
Min, Max	4.0, 5.0	4.3, 6.8	4.9, 6.9			
Week 24						
m	2	8	11			
n	2	7	9	2	7	8
Mean (SD/SE)	5.00 (0.28)	5.69 (0.65)	5.66 (1.10)	0.50 (0.30)	-0.40 (0.33)	0.10 (0.28)
Median	5.00	5.50	5.00	0.50	-0.10	0
IQR: Q1, Q3	4.80, 5.20	5.30, 6.30	4.70, 6.80	0.20, 0.80	-0.90, 0.20	-0.40, 0.20
Min, Max	4.8, 5.2	4.8, 6.7	4.5, 7.0	0.2, 0.8	-2.0, 0.6	-0.7, 1.9
Week 52						
m	2	8	10			
n	1	6	8	1	6	7
Mean (SD/SE)	5.50 (N/A)	5.42 (0.58)	5.78 (0.86)	0.50 (N/A)	-0.83 (0.33)	0.00 (0.21)
Median	5.50	5.40	5.85	0.50	-0.65	0
IQR: Q1, Q3	5.50, 5.50	5.20, 5.90	5.10, 6.45	0.50, 0.50	-1.00, -0.40	-0.50, 0.40
Min, Max	5.5, 5.5	4.5, 6.1	4.5, 6.9	0.5, 0.5	-2.3, 0.0	-0.6, 0.9

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.2.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=11)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=11)	Change from Baseline DB Placebo (N=11)
Abdominal Symptoms						
Baseline						
m	2	11	11			
n	2	10	9			
Mean (SD)	4.65 (0.49)	5.81 (0.95)	5.74 (1.27)			
Median	4.65	5.85	5.30			
IQR: Q1, Q3	4.30, 5.00	5.00, 6.70	5.00, 7.00			
Min, Max	4.3, 5.0	4.3, 7.0	3.7, 7.0			
Week 24						
m	2	8	11			
n	2	7	9	2	7	8
Mean (SD/SE)	5.50 (0.28)	5.71 (0.82)	5.63 (1.29)	0.85 (0.55)	-0.54 (0.37)	0.34 (0.30)
Median	5.50	5.70	5.30	0.85	-1.00	0
IQR: Q1, Q3	5.30, 5.70	5.30, 6.00	5.00, 6.70	0.30, 1.40	-1.40, 0.30	-0.15, 0.65
Min, Max	5.3, 5.7	4.3, 7.0	3.3, 7.0	0.3, 1.4	-1.7, 1.0	-0.3, 2.0
Week 52						
m	2	8	10			
n	1	6	8	1	6	7
Mean (SD/SE)	5.70 (N/A)	5.57 (0.36)	5.63 (1.03)	0.70 (N/A)	-0.78 (0.41)	-0.14 (0.24)
Median	5.70	5.70	5.50	0.70	-1.15	0
IQR: Q1, Q3	5.70, 5.70	5.30, 5.70	5.00, 6.50	0.70, 0.70	-1.40, -0.30	-1.00, 0.30
Min, Max	5.7, 5.7	5.0, 6.0	4.0, 7.0	0.7, 0.7	-1.7, 1.0	-1.0, 0.7

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.2.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=11)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=11)	Change from Baseline DB Placebo (N=11)
Activity						
Baseline						
m	2	11	11			
n	2	10	9			
Mean (SD)	4.10 (0.99)	5.82 (1.00)	5.82 (1.00)			
Median	4.10	5.90	5.80			
IQR: Q1, Q3	3.40, 4.80	5.40, 6.60	5.60, 6.60			
Min, Max	3.4, 4.8	3.6, 7.0	4.2, 7.0			
Week 24						
m	2	8	11			
n	2	7	9	2	7	8
Mean (SD/SE)	4.90 (0.14)	5.43 (0.91)	5.87 (1.26)	0.80 (0.60)	-0.71 (0.45)	0.08 (0.44)
Median	4.90	5.20	6.20	0.80	-0.40	0.10
IQR: Q1, Q3	4.80, 5.00	4.40, 6.60	4.40, 7.00	0.20, 1.40	-1.60, 0.20	-0.80, 0.40
Min, Max	4.8, 5.0	4.4, 6.6	4.0, 7.0	0.2, 1.4	-2.6, 0.8	-1.4, 2.6
Week 52						
m	2	8	10			
n	1	6	8	1	6	7
Mean (SD/SE)	5.60 (N/A)	5.27 (0.84)	6.25 (0.95)	0.80 (N/A)	-1.03 (0.41)	0.40 (0.45)
Median	5.60	4.90	6.60	0.80	-0.80	0.20
IQR: Q1, Q3	5.60, 5.60	4.60, 6.00	5.60, 7.00	0.80, 0.80	-2.00, -0.40	-0.60, 1.80
Min, Max	5.6, 5.6	4.6, 6.6	4.6, 7.0	0.8, 0.8	-2.4, 0.2	-1.0, 2.2

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.2.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=11)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=11)	Change from Baseline DB Placebo (N=11)
Emotional Health						
Baseline						
m	2	11	11			
n	2	10	9			
Mean (SD)	5.30 (0.14)	6.03 (0.95)	5.77 (0.83)			
Median	5.30	6.15	5.80			
IQR: Q1, Q3	5.20, 5.40	6.00, 6.80	5.70, 6.20			
Min, Max	5.2, 5.4	3.8, 6.9	4.1, 6.8			
Week 24						
m	2	8	11			
n	2	7	9	2	7	8
Mean (SD/SE)	5.85 (1.06)	5.74 (1.07)	5.96 (1.09)	0.55 (0.85)	-0.37 (0.45)	0.38 (0.16)
Median	5.85	6.20	6.40	0.55	0.10	0.35
IQR: Q1, Q3	5.10, 6.60	4.40, 6.80	4.70, 6.90	-0.30, 1.40	-1.60, 0.70	0.20, 0.55
Min, Max	5.1, 6.6	4.3, 6.9	4.4, 7.0	-0.3, 1.4	-2.3, 0.8	-0.4, 1.2
Week 52						
m	2	8	10			
n	1	6	8	1	6	7
Mean (SD/SE)	5.30 (N/A)	5.57 (0.65)	5.76 (1.20)	-0.10 (N/A)	-0.72 (0.38)	-0.09 (0.14)
Median	5.30	5.65	5.95	-0.10	-0.45	0.20
IQR: Q1, Q3	5.30, 5.30	5.00, 6.00	5.25, 6.65	-0.10, -0.10	-1.80, -0.10	-0.40, 0.20
Min, Max	5.3, 5.3	4.7, 6.4	3.4, 7.0	-0.1, -0.1	-1.9, 0.4	-0.7, 0.2

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.2.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=11)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=11)	Change from Baseline DB Placebo (N=11)
Fatigue						
Baseline						
m	2	11	11			
n	2	10	9			
Mean (SD)	2.75 (2.47)	5.60 (0.78)	4.70 (1.77)			
Median	2.75	5.65	4.50			
IQR: Q1, Q3	1.00, 4.50	4.80, 6.30	3.80, 5.80			
Min, Max	1.0, 4.5	4.5, 6.7	1.5, 7.0			
Week 24						
m	2	8	11			
n	2	7	9	2	7	8
Mean (SD/SE)	2.65 (2.33)	5.07 (1.12)	4.80 (1.65)	-0.10 (0.10)	-0.40 (0.44)	-0.10 (0.50)
Median	2.65	4.80	4.50	-0.10	0.20	-0.10
IQR: Q1, Q3	1.00, 4.30	4.30, 6.20	3.20, 6.20	-0.20, 0.00	-2.00, 0.40	-1.00, 0.05
Min, Max	1.0, 4.3	3.5, 6.8	2.8, 6.8	-0.2, 0.0	-2.2, 0.5	-1.7, 3.0
Week 52						
m	2	8	10			
n	1	6	8	1	6	7
Mean (SD/SE)	4.50 (N/A)	4.98 (0.82)	4.78 (1.35)	0.00 (N/A)	-0.60 (0.43)	-0.41 (0.30)
Median	4.50	4.80	4.55	0	-0.35	-0.50
IQR: Q1, Q3	4.50, 4.50	4.30, 5.80	4.00, 5.65	0.00, 0.00	-1.20, -0.20	-1.00, 0.00
Min, Max	4.5, 4.5	4.2, 6.0	2.8, 7.0	0.0, 0.0	-2.3, 0.8	-1.3, 1.1

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.2.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=11)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=11)	Change from Baseline DB Placebo (N=11)
Systemic Symptoms						
Baseline						
m	2	11	11			
n	2	10	9			
Mean (SD)	4.55 (0.35)	5.62 (1.25)	5.56 (0.91)			
Median	4.55	5.95	5.50			
IQR: Q1, Q3	4.30, 4.80	5.00, 6.30	5.20, 6.00			
Min, Max	4.3, 4.8	2.7, 7.0	3.8, 7.0			
Week 24						
m	2	8	11			
n	2	7	9	2	7	8
Mean (SD/SE)	4.65 (0.92)	5.73 (0.73)	5.26 (1.36)	0.10 (0.40)	-0.23 (0.29)	-0.19 (0.36)
Median	4.65	5.80	4.70	0.10	0	-0.15
IQR: Q1, Q3	4.00, 5.30	5.30, 6.20	4.30, 6.80	-0.30, 0.50	-1.00, 0.50	-0.80, 0.25
Min, Max	4.0, 5.3	4.5, 6.8	3.5, 7.0	-0.3, 0.5	-1.5, 0.6	-1.7, 1.6
Week 52						
m	2	8	10			
n	1	6	8	1	6	7
Mean (SD/SE)	5.20 (N/A)	5.12 (0.66)	5.58 (1.00)	0.40 (N/A)	-1.03 (0.38)	0.00 (0.30)
Median	5.20	5.00	5.30	0.40	-0.80	0
IQR: Q1, Q3	5.20, 5.20	4.80, 5.70	4.80, 6.55	0.40, 0.40	-1.10, -0.50	-0.70, 0.50
Min, Max	5.2, 5.2	4.2, 6.0	4.3, 7.0	0.4, 0.4	-2.8, -0.2	-1.2, 1.1

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.2.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=11)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=11)	Change from Baseline DB Placebo (N=11)
Worry						
Baseline						
m	2	11	11			
n	2	10	9			
Mean (SD)	5.80 (0.14)	6.32 (0.70)	6.40 (0.41)			
Median	5.80	6.55	6.30			
IQR: Q1, Q3	5.70, 5.90	5.90, 6.90	6.10, 6.70			
Min, Max	5.7, 5.9	5.1, 7.0	5.9, 7.0			
Week 24						
m	2	8	11			
n	2	7	9	2	7	8
Mean (SD/SE)	6.50 (0.71)	6.33 (0.84)	6.34 (0.94)	0.70 (0.40)	-0.17 (0.33)	-0.04 (0.35)
Median	6.50	6.90	6.90	0.70	0.10	0.10
IQR: Q1, Q3	6.00, 7.00	5.60, 7.00	5.90, 7.00	0.30, 1.10	0.00, 0.20	-0.70, 0.70
Min, Max	6.0, 7.0	4.9, 7.0	4.7, 7.0	0.3, 1.1	-2.1, 0.5	-1.6, 1.1
Week 52						
m	2	8	10			
n	1	6	8	1	6	7
Mean (SD/SE)	6.60 (N/A)	6.02 (1.10)	6.63 (0.42)	0.90 (N/A)	-0.72 (0.43)	0.17 (0.16)
Median	6.60	6.40	6.75	0.90	-0.50	0
IQR: Q1, Q3	6.60, 6.60	5.10, 6.90	6.30, 7.00	0.90, 0.90	-0.80, 0.00	0.00, 0.20
Min, Max	6.6, 6.6	4.3, 7.0	5.9, 7.0	0.9, 0.9	-2.7, 0.2	-0.1, 1.1

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.2.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=4)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=4)	Change from Baseline DB Placebo (N=17)
CLDQ-NASH						
Baseline						
m	7	4	17			
n	7	4	16			
Mean (SD)	5.63 (1.67)	5.88 (0.63)	5.83 (0.81)			
Median	6.50	6.00	5.95			
IQR: Q1, Q3	4.70, 6.60	5.45, 6.30	5.50, 6.45			
Min, Max	2.2, 6.8	5.0, 6.5	4.2, 6.8			
Week 24						
m	6	4	16			
n	5	4	16	5	4	16
Mean (SD/SE)	5.90 (1.18)	5.93 (0.62)	5.65 (1.00)	0.18 (0.36)	0.05 (0.23)	-0.18 (0.15)
Median	6.30	5.90	5.85	-0.20	0.20	0
IQR: Q1, Q3	6.30, 6.50	5.40, 6.45	4.95, 6.60	-0.20, 0.00	-0.25, 0.35	-0.30, 0.10
Min, Max	3.8, 6.6	5.3, 6.6	3.8, 6.9	-0.3, 1.6	-0.6, 0.4	-2.2, 0.4
Week 52						
m	6	4	16			
n	6	4	16	6	4	16
Mean (SD/SE)	5.78 (1.60)	5.90 (0.35)	5.82 (1.11)	0.00 (0.11)	0.03 (0.21)	-0.01 (0.23)
Median	6.30	5.90	6.10	-0.05	-0.10	0.20
IQR: Q1, Q3	5.90, 6.60	5.60, 6.20	5.10, 6.70	-0.20, 0.20	-0.30, 0.35	-0.10, 0.30
Min, Max	2.6, 7.0	5.6, 6.2	3.1, 7.0	-0.3, 0.4	-0.3, 0.6	-3.1, 1.3

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.2.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=4)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=4)	Change from Baseline DB Placebo (N=17)
Abdominal Symptoms						
Baseline						
m	7	4	17			
n	7	4	16			
Mean (SD)	5.96 (2.20)	6.68 (0.47)	5.91 (1.28)			
Median	6.70	6.85	6.15			
IQR: Q1, Q3	6.30, 7.00	6.35, 7.00	5.00, 7.00			
Min, Max	1.0, 7.0	6.0, 7.0	3.3, 7.0			
Week 24						
m	6	4	16			
n	5	4	16	5	4	16
Mean (SD/SE)	5.66 (2.09)	6.68 (0.65)	5.67 (1.50)	-0.02 (0.29)	0.00 (0.48)	-0.24 (0.26)
Median	6.30	7.00	6.50	0	0.15	0
IQR: Q1, Q3	6.00, 7.00	6.35, 7.00	4.00, 7.00	-0.40, 0.00	-0.65, 0.65	-0.30, 0.15
Min, Max	2.0, 7.0	5.7, 7.0	3.3, 7.0	-0.7, 1.0	-1.3, 1.0	-2.7, 1.0
Week 52						
m	6	4	16			
n	6	4	16	6	4	16
Mean (SD/SE)	5.60 (2.29)	6.43 (0.56)	5.75 (1.63)	-0.18 (0.08)	-0.25 (0.36)	-0.16 (0.33)
Median	6.30	6.50	6.85	-0.15	0	0
IQR: Q1, Q3	6.00, 7.00	6.00, 6.85	4.50, 7.00	-0.40, 0.00	-0.65, 0.15	0.00, 0.15
Min, Max	1.0, 7.0	5.7, 7.0	2.0, 7.0	-0.4, 0.0	-1.3, 0.3	-5.0, 1.0

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.2.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=4)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=4)	Change from Baseline DB Placebo (N=17)
Activity						
Baseline						
m	7	4	17			
n	7	4	16			
Mean (SD)	5.80 (1.78)	5.75 (1.23)	5.69 (1.03)			
Median	6.60	5.90	5.70			
IQR: Q1, Q3	5.20, 6.80	4.80, 6.70	5.10, 6.60			
Min, Max	2.0, 7.0	4.2, 7.0	3.2, 7.0			
Week 24						
m	6	4	16			
n	5	4	16	5	4	16
Mean (SD/SE)	5.96 (0.75)	5.50 (1.31)	5.30 (1.54)	0.24 (0.64)	-0.25 (0.61)	-0.39 (0.29)
Median	6.00	5.30	5.70	-0.40	0.10	0
IQR: Q1, Q3	5.80, 6.40	4.40, 6.60	5.10, 6.30	-0.40, -0.20	-1.00, 0.50	-1.00, 0.40
Min, Max	4.8, 6.8	4.4, 7.0	1.8, 7.0	-0.6, 2.8	-2.0, 0.8	-3.8, 0.8
Week 52						
m	6	4	16			
n	6	4	16	6	4	16
Mean (SD/SE)	5.83 (1.31)	5.35 (0.96)	5.71 (1.27)	-0.07 (0.33)	-0.40 (0.49)	0.03 (0.24)
Median	6.10	5.40	5.90	-0.10	-0.60	0
IQR: Q1, Q3	5.60, 6.80	4.60, 6.10	4.70, 7.00	-0.60, 0.00	-1.20, 0.40	-0.20, 0.40
Min, Max	3.4, 7.0	4.2, 6.4	3.4, 7.0	-1.0, 1.4	-1.2, 0.8	-2.6, 2.0

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.2.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=4)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=4)	Change from Baseline DB Placebo (N=17)
Emotional Health						
Baseline						
m	7	4	17			
n	7	4	16			
Mean (SD)	5.89 (1.48)	5.58 (0.62)	6.01 (0.83)			
Median	6.70	5.60	6.25			
IQR: Q1, Q3	4.30, 6.90	5.05, 6.10	5.40, 6.75			
Min, Max	3.3, 7.0	4.9, 6.2	4.4, 7.0			
Week 24						
m	6	4	16			
n	5	4	16	5	4	16
Mean (SD/SE)	6.22 (1.10)	5.75 (0.66)	5.81 (1.01)	0.08 (0.26)	0.18 (0.30)	-0.19 (0.14)
Median	6.80	5.70	6.10	0	0.10	-0.10
IQR: Q1, Q3	6.30, 6.80	5.30, 6.20	5.05, 6.65	-0.10, 0.10	-0.30, 0.65	-0.50, 0.15
Min, Max	4.3, 6.9	5.0, 6.6	3.7, 7.0	-0.6, 1.0	-0.4, 0.9	-1.5, 0.7
Week 52						
m	6	4	16			
n	6	4	16	6	4	16
Mean (SD/SE)	5.90 (1.44)	5.88 (0.46)	5.98 (1.16)	-0.25 (0.18)	0.30 (0.23)	-0.03 (0.21)
Median	6.35	5.90	6.35	-0.15	0.25	0
IQR: Q1, Q3	5.60, 6.90	5.55, 6.20	5.20, 6.85	-0.60, 0.00	-0.05, 0.65	-0.30, 0.45
Min, Max	3.2, 7.0	5.3, 6.4	3.3, 7.0	-0.9, 0.3	-0.2, 0.9	-2.5, 1.3

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.2.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=4)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=4)	Change from Baseline DB Placebo (N=17)
Fatigue						
Baseline						
m	7	4	17			
n	7	4	16			
Mean (SD)	5.11 (1.52)	4.75 (1.55)	5.29 (1.32)			
Median	5.70	4.25	5.70			
IQR: Q1, Q3	5.00, 6.00	3.75, 5.75	4.35, 6.00			
Min, Max	1.8, 6.2	3.5, 7.0	2.7, 7.0			
Week 24						
m	6	4	16			
n	5	4	16	5	4	16
Mean (SD/SE)	5.28 (1.00)	4.78 (1.07)	5.16 (1.32)	0.18 (0.40)	0.03 (0.26)	-0.13 (0.29)
Median	5.80	4.50	5.25	0	0.15	-0.10
IQR: Q1, Q3	5.50, 5.80	4.15, 5.40	4.20, 6.50	-0.20, 0.10	-0.35, 0.40	-0.50, 0.60
Min, Max	3.5, 5.8	3.8, 6.3	2.2, 6.8	-0.7, 1.7	-0.7, 0.5	-3.3, 1.5
Week 52						
m	6	4	16			
n	6	4	16	6	4	16
Mean (SD/SE)	5.42 (1.47)	5.08 (0.72)	5.34 (1.32)	0.28 (0.22)	0.33 (0.71)	0.06 (0.31)
Median	5.60	5.40	5.35	0.35	0.50	0.25
IQR: Q1, Q3	5.30, 6.30	4.65, 5.50	4.25, 6.40	-0.30, 0.80	-0.75, 1.40	-0.60, 1.10
Min, Max	2.7, 7.0	4.0, 5.5	2.8, 7.0	-0.4, 0.9	-1.5, 1.8	-2.9, 1.7

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.2.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=4)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=4)	Change from Baseline DB Placebo (N=17)
Systemic Symptoms						
Baseline						
m	7	4	17			
n	7	4	16			
Mean (SD)	5.81 (1.20)	5.80 (1.51)	5.71 (0.86)			
Median	6.30	6.25	5.60			
IQR: Q1, Q3	4.30, 6.80	4.70, 6.90	5.40, 6.60			
Min, Max	4.0, 7.0	3.7, 7.0	3.8, 6.8			
Week 24						
m	6	4	16			
n	5	4	16	5	4	16
Mean (SD/SE)	6.16 (0.95)	6.18 (0.77)	5.60 (1.04)	0.04 (0.20)	0.38 (0.50)	-0.11 (0.20)
Median	6.50	6.25	5.70	0	0.40	-0.05
IQR: Q1, Q3	6.30, 6.70	5.60, 6.75	5.10, 6.50	-0.30, 0.50	-0.40, 1.15	-0.40, 0.25
Min, Max	4.5, 6.8	5.2, 7.0	3.2, 6.8	-0.5, 0.5	-0.8, 1.5	-2.1, 1.2
Week 52						
m	6	4	16			
n	6	4	16	6	4	16
Mean (SD/SE)	5.93 (1.32)	6.00 (0.77)	5.64 (1.17)	-0.13 (0.16)	0.20 (0.48)	-0.06 (0.23)
Median	6.30	5.85	5.75	-0.15	-0.10	-0.05
IQR: Q1, Q3	6.20, 6.50	5.40, 6.60	5.00, 6.65	-0.30, 0.00	-0.40, 0.80	-0.35, 0.35
Min, Max	3.3, 7.0	5.3, 7.0	3.2, 7.0	-0.7, 0.5	-0.6, 1.6	-2.6, 1.5

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.2.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=4)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=4)	Change from Baseline DB Placebo (N=17)
Worry						
Baseline						
m	7	4	17			
n	7	4	16			
Mean (SD)	5.21 (2.42)	6.73 (0.31)	6.43 (0.86)			
Median	6.10	6.80	6.90			
IQR: Q1, Q3	2.60, 7.00	6.50, 6.95	6.00, 7.00			
Min, Max	1.0, 7.0	6.3, 7.0	4.1, 7.0			
Week 24						
m	6	4	16			
n	5	4	16	5	4	16
Mean (SD/SE)	6.20 (1.48)	6.60 (0.80)	6.35 (1.03)	0.60 (0.50)	-0.13 (0.27)	-0.08 (0.18)
Median	7.00	7.00	6.95	0.10	0.05	0
IQR: Q1, Q3	6.40, 7.00	6.20, 7.00	5.85, 7.00	0.00, 0.30	-0.45, 0.20	-0.05, 0.10
Min, Max	3.6, 7.0	5.4, 7.0	3.7, 7.0	0.0, 2.6	-0.9, 0.3	-1.9, 1.3
Week 52						
m	6	4	16			
n	6	4	16	6	4	16
Mean (SD/SE)	5.92 (2.08)	6.70 (0.42)	6.44 (0.87)	0.27 (0.13)	-0.03 (0.06)	0.01 (0.23)
Median	6.75	6.85	6.95	0.20	0	0
IQR: Q1, Q3	6.30, 7.00	6.40, 7.00	6.05, 7.00	0.00, 0.50	-0.10, 0.05	-0.10, 0.35
Min, Max	1.7, 7.0	6.1, 7.0	4.1, 7.0	0.0, 0.7	-0.2, 0.1	-2.9, 1.6

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc. Page 1 of 3
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE18.2.2
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of CLDQ-NASH - MMRM Model
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge’s g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE18.2.2
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of CLDQ-NASH - MMRM Model
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
CLDQ-NASH			
Week 24			
m	2	8	11
n	2	7	8
Baseline Mean (SD)	4.50 (0.71)	6.09 (0.51)	5.69 (0.84)
Analysis Visit Mean (SD)	5.00 (0.28)	5.69 (0.65)	5.79 (1.10)
LS Mean of Change from Baseline (SE)	0.03 (0.70)	-0.33 (0.35)	0.06 (0.29)
95% CI	(-1.47, 1.54)	(-1.09, 0.42)	(-0.56, 0.69)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.03 (0.74)	-0.39 (0.47)	
95% CI	(-1.62, 1.56)	(-1.40, 0.62)	
p-value	0.9696	0.4165	
Corrected Hedge's g Statistics	-0.031	-0.423	
95% CI	(-1.58, 1.52)	(-1.45, 0.60)	
Week 52			
m	2	8	10
n	1	6	7
Baseline Mean (SD)	5.00 (N/A)	6.25 (0.29)	5.76 (0.88)
Analysis Visit Mean (SD)	5.50 (N/A)	5.42 (0.58)	5.76 (0.93)
LS Mean of Change from Baseline (SE)	0.33 (0.62)	-0.70 (0.32)	-0.11 (0.25)
95% CI	(-1.00, 1.67)	(-1.38, -0.02)	(-0.63, 0.42)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.44 (0.66)	-0.60 (0.42)	
95% CI	(-0.98, 1.86)	(-1.49, 0.30)	
p-value	0.5160	0.1743	
Corrected Hedge's g Statistics	0.586	-0.779	
95% CI	(-1.53, 2.70)	(-1.91, 0.35)	
Subgroup*Treatment Interaction p-value	0.9253	0.1373	

Madrigal Pharmaceuticals, Inc. Page 3 of 3
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE18.2.2
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of CLDQ-NASH - MMRM Model
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
CLDQ-NASH			
Week 24			
m	6	4	16
n	5	4	16
Baseline Mean (SD)	5.72 (1.97)	5.88 (0.63)	5.83 (0.81)
Analysis Visit Mean (SD)	5.90 (1.18)	5.93 (0.62)	5.65 (1.00)
LS Mean of Change from Baseline (SE)	0.28 (0.28)	0.17 (0.30)	-0.05 (0.21)
95% CI	(-0.30, 0.85)	(-0.45, 0.79)	(-0.49, 0.38)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.33 (0.29)	0.23 (0.32)	
95% CI	(-0.27, 0.93)	(-0.43, 0.88)	
p-value	0.2643	0.4825	
Corrected Hedge's g Statistics	0.399	0.270	
95% CI	(-0.61, 1.41)	(-0.83, 1.37)	
Week 52			
m	6	4	16
n	6	4	16
Baseline Mean (SD)	5.78 (1.77)	5.88 (0.63)	5.83 (0.81)
Analysis Visit Mean (SD)	5.78 (1.60)	5.90 (0.35)	5.82 (1.11)
LS Mean of Change from Baseline (SE)	0.13 (0.34)	0.14 (0.40)	0.11 (0.25)
95% CI	(-0.58, 0.85)	(-0.69, 0.97)	(-0.40, 0.63)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.02 (0.37)	0.03 (0.43)	
95% CI	(-0.75, 0.79)	(-0.87, 0.93)	
p-value	0.9568	0.9492	
Corrected Hedge's g Statistics	0.020	0.028	
95% CI	(-0.92, 0.96)	(-1.07, 1.12)	
Subgroup*Treatment Interaction p-value	0.9253	0.1373	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE18.2.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

AMNOG Table SE18.2.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Abdominal Symptoms			
Week 24			
m	2	8	11
n	2	7	8
Baseline Mean (SD)	4.65 (0.49)	6.26 (0.72)	5.59 (1.26)
Analysis Visit Mean (SD)	5.50 (0.28)	5.71 (0.82)	5.93 (1.01)
LS Mean of Change from Baseline (SE)	0.24 (0.61)	-0.32 (0.35)	0.19 (0.29)
95% CI	(-1.08, 1.55)	(-1.07, 0.42)	(-0.43, 0.81)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.05 (0.66)	-0.51 (0.48)	
95% CI	(-1.36, 1.46)	(-1.54, 0.51)	
p-value	0.9449	0.3000	
Corrected Hedge's g Statistics	0.051	-0.559	
95% CI	(-1.50, 1.60)	(-1.59, 0.47)	
Week 52			
m	2	8	10
n	1	6	7
Baseline Mean (SD)	5.00 (N/A)	6.35 (0.74)	5.86 (1.08)
Analysis Visit Mean (SD)	5.70 (N/A)	5.57 (0.36)	5.71 (1.08)
LS Mean of Change from Baseline (SE)	0.41 (0.73)	-0.50 (0.35)	-0.15 (0.28)
95% CI	(-1.16, 1.98)	(-1.26, 0.25)	(-0.74, 0.44)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.56 (0.78)	-0.35 (0.46)	
95% CI	(-1.11, 2.24)	(-1.34, 0.64)	
p-value	0.4822	0.4601	
Corrected Hedge's g Statistics	0.672	-0.413	
95% CI	(-1.45, 2.79)	(-1.51, 0.69)	
Subgroup*Treatment Interaction p-value	0.8605	0.1188	

AMNOG Table SE18.2.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Activity			
Week 24			
m	2	8	11
n	2	7	8
Baseline Mean (SD)	4.10 (0.99)	6.14 (0.74)	5.75 (1.05)
Analysis Visit Mean (SD)	4.90 (0.14)	5.43 (0.91)	5.83 (1.34)
LS Mean of Change from Baseline (SE)	-0.17 (1.01)	-0.41 (0.48)	0.04 (0.42)
95% CI	(-2.35, 2.00)	(-1.45, 0.63)	(-0.85, 0.93)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.21 (1.09)	-0.45 (0.64)	
95% CI	(-2.54, 2.12)	(-1.82, 0.93)	
p-value	0.8498	0.4994	
Corrected Hedge's g Statistics	-0.156	-0.343	
95% CI	(-1.71, 1.39)	(-1.36, 0.68)	
Week 52			
m	2	8	10
n	1	6	7
Baseline Mean (SD)	4.80 (N/A)	6.30 (0.67)	5.74 (1.13)
Analysis Visit Mean (SD)	5.60 (N/A)	5.27 (0.84)	6.14 (0.97)
LS Mean of Change from Baseline (SE)	0.22 (0.88)	-0.55 (0.41)	0.22 (0.33)
95% CI	(-1.66, 2.10)	(-1.42, 0.33)	(-0.50, 0.93)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (0.93)	-0.76 (0.54)	
95% CI	(-2.00, 2.00)	(-1.92, 0.39)	
p-value	0.9997	0.1767	
Corrected Hedge's g Statistics	0.000	-0.759	
95% CI	(-2.10, 2.09)	(-1.89, 0.37)	
Subgroup*Treatment Interaction p-value	0.9031	0.2470	

AMNOG Table SE18.2.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Emotional Health			
Week 24			
m	2	8	11
n	2	7	8
Baseline Mean (SD)	5.30 (0.14)	6.11 (0.54)	5.78 (0.89)
Analysis Visit Mean (SD)	5.85 (1.06)	5.74 (1.07)	6.15 (0.99)
LS Mean of Change from Baseline (SE)	0.36 (0.70)	-0.35 (0.39)	0.35 (0.33)
95% CI	(-1.14, 1.86)	(-1.18, 0.47)	(-0.36, 1.06)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.01 (0.77)	-0.70 (0.52)	
95% CI	(-1.63, 1.65)	(-1.82, 0.42)	
p-value	0.9904	0.2004	
Corrected Hedge's g Statistics	0.009	-0.675	
95% CI	(-1.54, 1.56)	(-1.72, 0.37)	
Week 52			
m	2	8	10
n	1	6	7
Baseline Mean (SD)	5.40 (N/A)	6.28 (0.34)	5.76 (0.96)
Analysis Visit Mean (SD)	5.30 (N/A)	5.57 (0.65)	5.67 (1.26)
LS Mean of Change from Baseline (SE)	0.28 (0.69)	-0.71 (0.34)	-0.07 (0.28)
95% CI	(-1.19, 1.76)	(-1.44, 0.02)	(-0.66, 0.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.35 (0.74)	-0.64 (0.46)	
95% CI	(-1.24, 1.94)	(-1.64, 0.35)	
p-value	0.6439	0.1866	
Corrected Hedge's g Statistics	0.414	-0.763	
95% CI	(-1.69, 2.52)	(-1.89, 0.37)	
Subgroup*Treatment Interaction p-value	0.7432	0.0399	

AMNOG Table SE18.2.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Fatigue			
Week 24			
m	2	8	11
n	2	7	8
Baseline Mean (SD)	2.75 (2.47)	5.47 (0.82)	5.10 (1.39)
Analysis Visit Mean (SD)	2.65 (2.33)	5.07 (1.12)	5.00 (1.65)
LS Mean of Change from Baseline (SE)	-0.82 (1.09)	-0.35 (0.51)	-0.11 (0.45)
95% CI	(-3.17, 1.53)	(-1.44, 0.74)	(-1.07, 0.86)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.71 (1.18)	-0.24 (0.68)	
95% CI	(-3.25, 1.82)	(-1.70, 1.22)	
p-value	0.5543	0.7265	
Corrected Hedge's g Statistics	-0.493	-0.175	
95% CI	(-2.06, 1.07)	(-1.19, 0.84)	
Week 52			
m	2	8	10
n	1	6	7
Baseline Mean (SD)	4.50 (N/A)	5.58 (0.84)	5.19 (1.48)
Analysis Visit Mean (SD)	4.50 (N/A)	4.98 (0.82)	4.77 (1.46)
LS Mean of Change from Baseline (SE)	-0.43 (0.83)	-0.49 (0.39)	-0.55 (0.33)
95% CI	(-2.22, 1.35)	(-1.32, 0.34)	(-1.26, 0.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.12 (0.90)	0.07 (0.51)	
95% CI	(-1.80, 2.04)	(-1.03, 1.17)	
p-value	0.8953	0.9004	
Corrected Hedge's g Statistics	0.120	0.067	
95% CI	(-1.98, 2.22)	(-1.02, 1.16)	
Subgroup*Treatment Interaction p-value	0.5403	0.9759	

AMNOG Table SE18.2.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Systemic Symptoms			
Week 24			
m	2	8	11
n	2	7	8
Baseline Mean (SD)	4.55 (0.35)	5.96 (0.70)	5.56 (0.98)
Analysis Visit Mean (SD)	4.65 (0.92)	5.73 (0.73)	5.38 (1.40)
LS Mean of Change from Baseline (SE)	-0.08 (0.77)	-0.18 (0.39)	-0.21 (0.34)
95% CI	(-1.74, 1.58)	(-1.02, 0.65)	(-0.93, 0.52)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.13 (0.83)	0.03 (0.52)	
95% CI	(-1.65, 1.91)	(-1.10, 1.15)	
p-value	0.8814	0.9597	
Corrected Hedge's g Statistics	0.117	0.026	
95% CI	(-1.43, 1.67)	(-0.99, 1.04)	
Week 52			
m	2	8	10
n	1	6	7
Baseline Mean (SD)	4.80 (N/A)	6.15 (0.52)	5.61 (1.04)
Analysis Visit Mean (SD)	5.20 (N/A)	5.12 (0.66)	5.61 (1.08)
LS Mean of Change from Baseline (SE)	-0.23 (0.77)	-0.93 (0.37)	-0.21 (0.32)
95% CI	(-1.87, 1.42)	(-1.73, -0.13)	(-0.89, 0.47)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.02 (0.82)	-0.72 (0.50)	
95% CI	(-1.78, 1.75)	(-1.79, 0.35)	
p-value	0.9841	0.1713	
Corrected Hedge's g Statistics	-0.017	-0.765	
95% CI	(-2.11, 2.08)	(-1.89, 0.36)	
Subgroup*Treatment Interaction p-value	0.9538	0.2113	

AMNOG Table SE18.2.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Worry			
Week 24			
m	2	8	11
n	2	7	8
Baseline Mean (SD)	5.80 (0.14)	6.50 (0.73)	6.44 (0.42)
Analysis Visit Mean (SD)	6.50 (0.71)	6.33 (0.84)	6.40 (0.99)
LS Mean of Change from Baseline (SE)	0.28 (0.71)	-0.22 (0.36)	-0.04 (0.32)
95% CI	(-1.25, 1.81)	(-0.99, 0.55)	(-0.73, 0.65)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.32 (0.78)	-0.18 (0.48)	
95% CI	(-1.35, 2.00)	(-1.22, 0.86)	
p-value	0.6839	0.7162	
Corrected Hedge's g Statistics	0.319	-0.182	
95% CI	(-1.24, 1.87)	(-1.20, 0.83)	
Week 52			
m	2	8	10
n	1	6	7
Baseline Mean (SD)	5.70 (N/A)	6.73 (0.42)	6.46 (0.45)
Analysis Visit Mean (SD)	6.60 (N/A)	6.02 (1.10)	6.63 (0.45)
LS Mean of Change from Baseline (SE)	0.96 (0.81)	-0.73 (0.37)	0.02 (0.31)
95% CI	(-0.78, 2.69)	(-1.52, 0.06)	(-0.65, 0.68)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.94 (0.87)	-0.75 (0.48)	
95% CI	(-0.92, 2.80)	(-1.78, 0.29)	
p-value	0.2966	0.1434	
Corrected Hedge's g Statistics	0.999	-0.812	
95% CI	(-1.15, 3.15)	(-1.95, 0.32)	
Subgroup*Treatment Interaction p-value	0.5396	0.3385	

AMNOG Table SE18.2.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Abdominal Symptoms			
Week 24			
m	6	4	16
n	5	4	16
Baseline Mean (SD)	5.68 (2.62)	6.68 (0.47)	5.91 (1.28)
Analysis Visit Mean (SD)	5.66 (2.09)	6.68 (0.65)	5.67 (1.50)
LS Mean of Change from Baseline (SE)	0.17 (0.46)	0.39 (0.51)	0.03 (0.34)
95% CI	(-0.78, 1.12)	(-0.67, 1.44)	(-0.66, 0.73)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.14 (0.48)	0.35 (0.54)	
95% CI	(-0.86, 1.14)	(-0.76, 1.47)	
p-value	0.7764	0.5154	
Corrected Hedge's g Statistics	0.104	0.262	
95% CI	(-0.90, 1.11)	(-0.84, 1.36)	
Week 52			
m	6	4	16
n	6	4	16
Baseline Mean (SD)	5.78 (2.36)	6.68 (0.47)	5.91 (1.28)
Analysis Visit Mean (SD)	5.60 (2.29)	6.43 (0.56)	5.75 (1.63)
LS Mean of Change from Baseline (SE)	0.07 (0.50)	0.09 (0.60)	0.12 (0.37)
95% CI	(-0.97, 1.12)	(-1.15, 1.33)	(-0.65, 0.88)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.04 (0.54)	-0.02 (0.64)	
95% CI	(-1.16, 1.08)	(-1.35, 1.31)	
p-value	0.9375	0.9705	
Corrected Hedge's g Statistics	-0.029	-0.016	
95% CI	(-0.97, 0.91)	(-1.11, 1.08)	
Subgroup*Treatment Interaction p-value	0.8605	0.1188	

AMNOG Table SE18.2.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Activity			
Week 24			
m	6	4	16
n	5	4	16
Baseline Mean (SD)	5.72 (2.10)	5.75 (1.23)	5.69 (1.03)
Analysis Visit Mean (SD)	5.96 (0.75)	5.50 (1.31)	5.30 (1.54)
LS Mean of Change from Baseline (SE)	0.29 (0.56)	-0.19 (0.60)	-0.34 (0.39)
95% CI	(-0.87, 1.45)	(-1.44, 1.06)	(-1.15, 0.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.63 (0.60)	0.15 (0.65)	
95% CI	(-0.60, 1.87)	(-1.20, 1.51)	
p-value	0.3011	0.8147	
Corrected Hedge's g Statistics	0.406	0.099	
95% CI	(-0.61, 1.42)	(-1.00, 1.20)	
Week 52			
m	6	4	16
n	6	4	16
Baseline Mean (SD)	5.90 (1.93)	5.75 (1.23)	5.69 (1.03)
Analysis Visit Mean (SD)	5.83 (1.31)	5.35 (0.96)	5.71 (1.27)
LS Mean of Change from Baseline (SE)	0.06 (0.44)	-0.34 (0.49)	0.07 (0.34)
95% CI	(-0.86, 0.97)	(-1.35, 0.67)	(-0.64, 0.78)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.01 (0.44)	-0.41 (0.51)	
95% CI	(-0.92, 0.89)	(-1.48, 0.65)	
p-value	0.9769	0.4315	
Corrected Hedge's g Statistics	-0.009	-0.300	
95% CI	(-0.95, 0.93)	(-1.40, 0.80)	
Subgroup*Treatment Interaction p-value	0.9031	0.2470	

AMNOG Table SE18.2.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Emotional Health			
Week 24			
m	6	4	16
n	5	4	16
Baseline Mean (SD)	6.14 (1.59)	5.58 (0.62)	6.01 (0.83)
Analysis Visit Mean (SD)	6.22 (1.10)	5.75 (0.66)	5.81 (1.01)
LS Mean of Change from Baseline (SE)	0.36 (0.26)	0.27 (0.27)	0.06 (0.19)
95% CI	(-0.17, 0.89)	(-0.28, 0.82)	(-0.33, 0.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.29 (0.26)	0.21 (0.29)	
95% CI	(-0.24, 0.83)	(-0.40, 0.81)	
p-value	0.2689	0.4841	
Corrected Hedge's g Statistics	0.386	0.270	
95% CI	(-0.63, 1.40)	(-0.83, 1.37)	
Week 52			
m	6	4	16
n	6	4	16
Baseline Mean (SD)	6.15 (1.42)	5.58 (0.62)	6.01 (0.83)
Analysis Visit Mean (SD)	5.90 (1.44)	5.88 (0.46)	5.98 (1.16)
LS Mean of Change from Baseline (SE)	0.04 (0.34)	0.44 (0.39)	0.22 (0.24)
95% CI	(-0.66, 0.73)	(-0.36, 1.24)	(-0.27, 0.71)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.19 (0.36)	0.22 (0.43)	
95% CI	(-0.93, 0.56)	(-0.67, 1.10)	
p-value	0.6074	0.6173	
Corrected Hedge's g Statistics	-0.196	0.226	
95% CI	(-1.14, 0.74)	(-0.87, 1.32)	
Subgroup*Treatment Interaction p-value	0.7432	0.0399	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE18.2.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Fatigue			
Week 24			
m	6	4	16
n	5	4	16
Baseline Mean (SD)	5.10 (1.85)	4.75 (1.55)	5.29 (1.32)
Analysis Visit Mean (SD)	5.28 (1.00)	4.78 (1.07)	5.16 (1.32)
LS Mean of Change from Baseline (SE)	0.38 (0.43)	0.03 (0.45)	0.17 (0.32)
95% CI	(-0.50, 1.26)	(-0.91, 0.97)	(-0.50, 0.83)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.22 (0.44)	-0.13 (0.49)	
95% CI	(-0.69, 1.13)	(-1.15, 0.88)	
p-value	0.6250	0.7888	
Corrected Hedge's g Statistics	0.171	-0.103	
95% CI	(-0.83, 1.18)	(-1.20, 0.99)	
Week 52			
m	6	4	16
n	6	4	16
Baseline Mean (SD)	5.13 (1.66)	4.75 (1.55)	5.29 (1.32)
Analysis Visit Mean (SD)	5.42 (1.47)	5.08 (0.72)	5.34 (1.32)
LS Mean of Change from Baseline (SE)	0.52 (0.48)	0.32 (0.55)	0.35 (0.36)
95% CI	(-0.47, 1.51)	(-0.81, 1.46)	(-0.39, 1.09)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.17 (0.50)	-0.03 (0.60)	
95% CI	(-0.87, 1.22)	(-1.27, 1.22)	
p-value	0.7337	0.9660	
Corrected Hedge's g Statistics	0.123	-0.018	
95% CI	(-0.82, 1.06)	(-1.11, 1.08)	
Subgroup*Treatment Interaction p-value	0.5403	0.9759	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE18.2.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Systemic Symptoms			
Week 24			
m	6	4	16
n	5	4	16
Baseline Mean (SD)	6.12 (1.22)	5.80 (1.51)	5.71 (0.86)
Analysis Visit Mean (SD)	6.16 (0.95)	6.18 (0.77)	5.60 (1.04)
LS Mean of Change from Baseline (SE)	0.20 (0.39)	0.39 (0.39)	-0.15 (0.29)
95% CI	(-0.60, 1.00)	(-0.42, 1.21)	(-0.75, 0.45)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.35 (0.37)	0.54 (0.41)	
95% CI	(-0.42, 1.12)	(-0.30, 1.39)	
p-value	0.3595	0.1966	
Corrected Hedge's g Statistics	0.303	0.471	
95% CI	(-0.71, 1.31)	(-0.63, 1.58)	
Week 52			
m	6	4	16
n	6	4	16
Baseline Mean (SD)	6.07 (1.09)	5.80 (1.51)	5.71 (0.86)
Analysis Visit Mean (SD)	5.93 (1.32)	6.00 (0.77)	5.64 (1.17)
LS Mean of Change from Baseline (SE)	-0.05 (0.42)	0.22 (0.45)	-0.09 (0.31)
95% CI	(-0.92, 0.81)	(-0.72, 1.16)	(-0.74, 0.56)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.04 (0.42)	0.31 (0.48)	
95% CI	(-0.82, 0.90)	(-0.69, 1.31)	
p-value	0.9298	0.5257	
Corrected Hedge's g Statistics	0.030	0.249	
95% CI	(-0.91, 0.97)	(-0.85, 1.35)	
Subgroup*Treatment Interaction p-value	0.9538	0.2113	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE18.2.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Worry			
Week 24			
m	6	4	16
n	5	4	16
Baseline Mean (SD)	5.60 (2.60)	6.73 (0.31)	6.43 (0.86)
Analysis Visit Mean (SD)	6.20 (1.48)	6.60 (0.80)	6.35 (1.03)
LS Mean of Change from Baseline (SE)	0.34 (0.35)	-0.01 (0.37)	-0.08 (0.25)
95% CI	(-0.37, 1.06)	(-0.78, 0.77)	(-0.60, 0.44)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.42 (0.37)	0.07 (0.39)	
95% CI	(-0.35, 1.19)	(-0.75, 0.89)	
p-value	0.2683	0.8627	
Corrected Hedge's g Statistics	0.420	0.068	
95% CI	(-0.59, 1.43)	(-1.03, 1.16)	
Week 52			
m	6	4	16
n	6	4	16
Baseline Mean (SD)	5.65 (2.33)	6.73 (0.31)	6.43 (0.86)
Analysis Visit Mean (SD)	5.92 (2.08)	6.70 (0.42)	6.44 (0.87)
LS Mean of Change from Baseline (SE)	0.08 (0.34)	0.05 (0.39)	0.00 (0.26)
95% CI	(-0.63, 0.79)	(-0.76, 0.86)	(-0.54, 0.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.08 (0.36)	0.05 (0.41)	
95% CI	(-0.67, 0.84)	(-0.81, 0.91)	
p-value	0.8178	0.9021	
Corrected Hedge's g Statistics	0.083	0.050	
95% CI	(-0.86, 1.02)	(-1.05, 1.15)	
Subgroup*Treatment Interaction p-value	0.5396	0.3385	

AMNOG Table SE18.2.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi-square Test. For this unadjusted analysis, only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.

AMNOG Table SE18.2.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	2 (100)	11 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (50.0)	0	3 (27.3)
No	1 (50.0)	11 (100)	8 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.38	9.47	
95% CI of the inverse odds ratio	(0.02, 8.10)	(0.43, 208.75)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.55	7.00	
95% CI of the inverse risk ratio	(0.10, 2.95)	(0.40, 121.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	22.73	-25.00	
95% CI of the absolute risk difference	(-51.40, 96.85)	(-53.09, 3.09)	
p-value	0.5218	0.1003	
p-value of Breslow-Day Test for Homogeneity [3]	0.4118	0.1308	

AMNOG Table SE18.2.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (9.1)	0
No	2 (100)	10 (90.9)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.30	
95% CI of the inverse odds ratio	NE	(0.01, 8.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.33	
95% CI of the inverse risk ratio	NE	(0.02, 7.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	8.33	
95% CI of the absolute risk difference	NE	(-13.53, 30.20)	
p-value	NE	0.4602	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.2234	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (50.0)	1 (9.1)	1 (9.1)
No	1 (50.0)	10 (90.9)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.10	1.00	
95% CI of the inverse odds ratio	(0.00, 3.15)	(0.05, 18.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.18	1.00	
95% CI of the inverse risk ratio	(0.02, 1.86)	(0.07, 14.05)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	40.91	0.00	
95% CI of the absolute risk difference	(-30.44, 100.00)	(-24.03, 24.03)	
p-value	0.1402	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.0482	0.4063	

AMNOG Table SE18.2.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (18.2)
No	2 (100)	11 (100)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.32	6.05	
95% CI of the inverse odds ratio	(0.05, 37.16)	(0.26, 142.04)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	5.00	
95% CI of the inverse risk ratio	(0.08, 19.75)	(0.27, 93.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.17	-16.67	
95% CI of the absolute risk difference	(-52.19, 43.86)	(-42.28, 8.94)	
p-value	0.8718	0.2170	
p-value of Breslow-Day Test for Homogeneity [3]	0.4927	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (50.0)	0	2 (18.2)
No	1 (50.0)	11 (100)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.22	6.05	
95% CI of the inverse odds ratio	(0.01, 5.28)	(0.26, 142.04)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.36	5.00	
95% CI of the inverse risk ratio	(0.06, 2.36)	(0.27, 93.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	31.82	-16.67	
95% CI of the absolute risk difference	(-41.13, 100.00)	(-42.28, 8.94)	
p-value	0.3259	0.2170	
p-value of Breslow-Day Test for Homogeneity [3]	0.2027	0.2567	

AMNOG Table SE18.2.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	2 (100)	11 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (9.1)	0
No	2 (100)	10 (90.9)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.30	
95% CI of the inverse odds ratio	NE	(0.01, 8.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.33	
95% CI of the inverse risk ratio	NE	(0.02, 7.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	8.33	
95% CI of the absolute risk difference	NE	(-13.53, 30.20)	
p-value	NE	0.4602	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.5177	

AMNOG Table SE18.2.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (9.1)
No	2 (100)	11 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	3.29	
95% CI of the inverse odds ratio	(0.02, 23.31)	(0.12, 89.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	3.00	
95% CI of the inverse risk ratio	(0.04, 14.19)	(0.14, 66.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.17	-8.33	
95% CI of the absolute risk difference	(-41.97, 50.30)	(-30.20, 13.53)	
p-value	0.8494	0.4602	
p-value of Breslow-Day Test for Homogeneity [3]	0.7768	0.2020	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (9.1)	1 (9.1)
No	2 (100)	10 (90.9)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	1.00	
95% CI of the inverse odds ratio	(0.02, 23.31)	(0.05, 18.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	1.00	
95% CI of the inverse risk ratio	(0.04, 14.19)	(0.07, 14.05)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.17	0.00	
95% CI of the absolute risk difference	(-41.97, 50.30)	(-24.03, 24.03)	
p-value	0.8494	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.6505	0.8474	

AMNOG Table SE18.2.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (9.1)
No	2 (100)	11 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	3.29	
95% CI of the inverse odds ratio	(0.02, 23.31)	(0.12, 89.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	3.00	
95% CI of the inverse risk ratio	(0.04, 14.19)	(0.14, 66.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.17	-8.33	
95% CI of the absolute risk difference	(-41.97, 50.30)	(-30.20, 13.53)	
p-value	0.8494	0.4602	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.2165	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (50.0)	0	3 (27.3)
No	1 (50.0)	11 (100)	8 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.38	9.47	
95% CI of the inverse odds ratio	(0.02, 8.10)	(0.43, 208.75)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.55	7.00	
95% CI of the inverse risk ratio	(0.10, 2.95)	(0.40, 121.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	22.73	-25.00	
95% CI of the absolute risk difference	(-51.40, 96.85)	(-53.09, 3.09)	
p-value	0.5218	0.1003	
p-value of Breslow-Day Test for Homogeneity [3]	0.4118	0.1308	

AMNOG Table SE18.2.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (9.1)
No	2 (100)	11 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	3.29	
95% CI of the inverse odds ratio	(0.02, 23.31)	(0.12, 89.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	3.00	
95% CI of the inverse risk ratio	(0.04, 14.19)	(0.14, 66.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.17	-8.33	
95% CI of the absolute risk difference	(-41.97, 50.30)	(-30.20, 13.53)	
p-value	0.8494	0.4602	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (50.0)	0	1 (9.1)
No	1 (50.0)	11 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.10	3.29	
95% CI of the inverse odds ratio	(0.00, 3.15)	(0.12, 89.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.18	3.00	
95% CI of the inverse risk ratio	(0.02, 1.86)	(0.14, 66.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	40.91	-8.33	
95% CI of the absolute risk difference	(-30.44, 100.00)	(-30.20, 13.53)	
p-value	0.1402	0.4602	
p-value of Breslow-Day Test for Homogeneity [3]	0.4709	NE	

AMNOG Table SE18.2.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (5.9)
No	7 (100)	4 (100)	16 (94.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	0.82	
95% CI of the inverse odds ratio	(0.05, 37.53)	(0.03, 23.70)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	0.83	
95% CI of the inverse risk ratio	(0.06, 29.31)	(0.04, 17.48)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.08	1.67	
95% CI of the absolute risk difference	(-23.16, 19.00)	(-27.56, 30.90)	
p-value	0.8540	0.9069	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (14.3)	1 (25.0)	4 (23.5)
No	6 (85.7)	3 (75.0)	13 (76.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.85	0.92	
95% CI of the inverse odds ratio	(0.17, 20.26)	(0.07, 11.54)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.65	0.94	
95% CI of the inverse risk ratio	(0.22, 12.25)	(0.14, 6.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.24	1.47	
95% CI of the absolute risk difference	(-42.09, 23.60)	(-45.51, 48.45)	
p-value	0.6123	0.9505	
p-value of Breslow-Day Test for Homogeneity [3]	0.4118	0.1308	

AMNOG Table SE18.2.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (11.8)
No	7 (100)	4 (100)	15 (88.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.42	1.45	
95% CI of the inverse odds ratio	(0.10, 56.97)	(0.06, 36.06)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.22	1.39	
95% CI of the inverse risk ratio	(0.12, 41.20)	(0.08, 24.50)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.64	-3.89	
95% CI of the absolute risk difference	(-30.80, 15.53)	(-34.66, 26.88)	
p-value	0.5736	0.8193	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.2234	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	3 (17.6)
No	7 (100)	4 (100)	14 (82.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.62	2.17	
95% CI of the inverse odds ratio	(0.16, 79.69)	(0.09, 50.51)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.11	1.94	
95% CI of the inverse risk ratio	(0.18, 53.45)	(0.12, 31.74)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-13.19	-9.44	
95% CI of the absolute risk difference	(-38.01, 11.62)	(-41.47, 22.58)	
p-value	0.3894	0.6221	
p-value of Breslow-Day Test for Homogeneity [3]	0.0482	0.4063	

AMNOG Table SE18.2.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (14.3)	0	2 (11.8)
No	6 (85.7)	4 (100)	15 (88.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	1.45	
95% CI of the inverse odds ratio	(0.06, 10.56)	(0.06, 36.06)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	1.39	
95% CI of the inverse risk ratio	(0.09, 7.68)	(0.08, 24.50)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.52	-3.89	
95% CI of the absolute risk difference	(-27.59, 32.63)	(-34.66, 26.88)	
p-value	0.8652	0.8193	
p-value of Breslow-Day Test for Homogeneity [3]	0.4927	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (14.3)	1 (25.0)	5 (29.4)
No	6 (85.7)	3 (75.0)	12 (70.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.50	1.25	
95% CI of the inverse odds ratio	(0.24, 26.48)	(0.10, 15.11)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.06	1.18	
95% CI of the inverse risk ratio	(0.29, 14.59)	(0.18, 7.48)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-15.13	-4.41	
95% CI of the absolute risk difference	(-48.91, 18.65)	(-52.05, 43.23)	
p-value	0.4367	0.8605	
p-value of Breslow-Day Test for Homogeneity [3]	0.2027	0.2567	

AMNOG Table SE18.2.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (11.8)
No	7 (100)	4 (100)	15 (88.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.42	1.45	
95% CI of the inverse odds ratio	(0.10, 56.97)	(0.06, 36.06)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.22	1.39	
95% CI of the inverse risk ratio	(0.12, 41.20)	(0.08, 24.50)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.64	-3.89	
95% CI of the absolute risk difference	(-30.80, 15.53)	(-34.66, 26.88)	
p-value	0.5736	0.8193	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (50.0)	5 (29.4)
No	7 (100)	2 (50.0)	12 (70.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	6.60	0.42	
95% CI of the inverse odds ratio	(0.32, 137.05)	(0.05, 3.84)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.89	0.59	
95% CI of the inverse risk ratio	(0.31, 78.23)	(0.17, 2.00)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-24.31	20.59	
95% CI of the absolute risk difference	(-51.40, 2.79)	(-32.98, 74.16)	
p-value	0.1746	0.4319	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.5177	

AMNOG Table SE18.2.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (14.3)	2 (50.0)	5 (29.4)
No	6 (85.7)	2 (50.0)	12 (70.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.50	0.42	
95% CI of the inverse odds ratio	(0.24, 26.48)	(0.05, 3.84)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.06	0.59	
95% CI of the inverse risk ratio	(0.29, 14.59)	(0.17, 2.00)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-15.13	20.59	
95% CI of the absolute risk difference	(-48.91, 18.65)	(-32.98, 74.16)	
p-value	0.4367	0.4319	
p-value of Breslow-Day Test for Homogeneity [3]	0.7768	0.2020	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (42.9)	2 (50.0)	7 (41.2)
No	4 (57.1)	2 (50.0)	10 (58.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	0.70	
95% CI of the inverse odds ratio	(0.16, 5.54)	(0.08, 6.22)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	0.82	
95% CI of the inverse risk ratio	(0.34, 2.68)	(0.27, 2.56)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.68	8.82	
95% CI of the absolute risk difference	(-41.81, 45.17)	(-45.47, 63.12)	
p-value	0.9395	0.7483	
p-value of Breslow-Day Test for Homogeneity [3]	0.6505	0.8474	

AMNOG Table SE18.2.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (25.0)	2 (11.8)
No	7 (100)	3 (75.0)	15 (88.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.42	0.40	
95% CI of the inverse odds ratio	(0.10, 56.97)	(0.03, 5.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.22	0.47	
95% CI of the inverse risk ratio	(0.12, 41.20)	(0.06, 4.00)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.64	13.24	
95% CI of the absolute risk difference	(-30.80, 15.53)	(-31.88, 58.35)	
p-value	0.5736	0.4961	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.2165	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (14.3)	1 (25.0)	4 (23.5)
No	6 (85.7)	3 (75.0)	13 (76.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.85	0.92	
95% CI of the inverse odds ratio	(0.17, 20.26)	(0.07, 11.54)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.65	0.94	
95% CI of the inverse risk ratio	(0.22, 12.25)	(0.14, 6.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.24	1.47	
95% CI of the absolute risk difference	(-42.09, 23.60)	(-45.51, 48.45)	
p-value	0.6123	0.9505	
p-value of Breslow-Day Test for Homogeneity [3]	0.4118	0.1308	

AMNOG Table SE18.2.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (11.8)
No	7 (100)	4 (100)	15 (88.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.42	1.45	
95% CI of the inverse odds ratio	(0.10, 56.97)	(0.06, 36.06)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.22	1.39	
95% CI of the inverse risk ratio	(0.12, 41.20)	(0.08, 24.50)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.64	-3.89	
95% CI of the absolute risk difference	(-30.80, 15.53)	(-34.66, 26.88)	
p-value	0.5736	0.8193	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (42.9)	0	4 (23.5)
No	4 (57.1)	4 (100)	13 (76.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.41	3.00	
95% CI of the inverse odds ratio	(0.06, 2.66)	(0.13, 67.29)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.55	2.50	
95% CI of the inverse risk ratio	(0.16, 1.84)	(0.16, 39.05)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	19.33	-15.00	
95% CI of the absolute risk difference	(-22.51, 61.17)	(-48.04, 18.04)	
p-value	0.3437	0.4719	
p-value of Breslow-Day Test for Homogeneity [3]	0.4709	NE	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE18.3.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=21)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=21)
CLDQ-NASH						
Baseline						
m	6	15	21			
n	6	14	18			
Mean (SD)	5.12 (1.78)	5.88 (0.66)	5.66 (0.77)			
Median	5.55	6.10	5.55			
IQR: Q1, Q3	4.00, 6.60	5.80, 6.20	5.00, 6.40			
Min, Max	2.2, 6.8	4.3, 6.8	4.2, 6.9			
Week 24						
m	6	12	20			
n	5	11	18	5	11	17
Mean (SD/SE)	5.34 (1.14)	5.77 (0.62)	5.46 (1.04)	0.42 (0.35)	-0.24 (0.23)	-0.17 (0.19)
Median	5.20	5.50	5.10	0.20	0	-0.10
IQR: Q1, Q3	4.80, 6.30	5.30, 6.30	4.70, 6.50	-0.20, 0.80	-0.60, 0.30	-0.40, 0.10
Min, Max	3.8, 6.6	4.8, 6.7	3.8, 7.0	-0.3, 1.6	-2.0, 0.6	-2.2, 1.9
Week 52						
m	6	12	19			
n	5	10	17	5	10	16
Mean (SD/SE)	5.52 (1.73)	5.61 (0.54)	5.68 (1.08)	0.18 (0.13)	-0.49 (0.25)	-0.04 (0.24)
Median	5.90	5.60	5.90	0.20	-0.35	0.10
IQR: Q1, Q3	5.50, 6.60	5.20, 6.10	4.90, 6.70	0.00, 0.40	-0.80, 0.00	-0.35, 0.40
Min, Max	2.6, 7.0	4.5, 6.2	3.1, 7.0	-0.2, 0.5	-2.3, 0.6	-3.1, 1.3

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.3.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=21)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=21)
Abdominal Symptoms						
Baseline						
m	6	15	21			
n	6	14	18			
Mean (SD)	5.05 (2.24)	6.06 (0.92)	5.63 (1.25)			
Median	5.65	6.35	5.65			
IQR: Q1, Q3	4.30, 6.70	5.00, 6.70	4.70, 7.00			
Min, Max	1.0, 7.0	4.3, 7.0	3.3, 7.0			
Week 24						
m	6	12	20			
n	5	11	18	5	11	17
Mean (SD/SE)	5.20 (1.90)	6.06 (0.87)	5.26 (1.41)	0.40 (0.37)	-0.35 (0.29)	-0.17 (0.27)
Median	5.70	6.00	5.00	0.30	0	0
IQR: Q1, Q3	5.30, 6.00	5.70, 7.00	4.00, 6.70	0.00, 1.00	-1.30, 0.30	-0.30, 0.00
Min, Max	2.0, 7.0	4.3, 7.0	3.3, 7.0	-0.7, 1.4	-1.7, 1.0	-2.7, 2.0
Week 52						
m	6	12	19			
n	5	10	17	5	10	16
Mean (SD/SE)	5.20 (2.40)	5.91 (0.61)	5.34 (1.44)	0.00 (0.19)	-0.57 (0.28)	-0.31 (0.34)
Median	6.00	5.70	5.30	0	-0.65	0
IQR: Q1, Q3	5.70, 6.30	5.70, 6.30	4.70, 6.70	-0.30, 0.00	-1.30, 0.00	-0.15, 0.15
Min, Max	1.0, 7.0	5.0, 7.0	2.0, 7.0	-0.4, 0.7	-1.7, 1.0	-5.0, 1.0

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.3.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=21)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=21)
Activity						
Baseline						
m	6	15	21			
n	6	14	18			
Mean (SD)	5.13 (2.10)	5.80 (1.02)	5.84 (0.91)			
Median	5.80	5.90	5.90			
IQR: Q1, Q3	3.40, 6.80	5.40, 6.60	5.60, 6.60			
Min, Max	2.0, 7.0	3.6, 7.0	4.2, 7.0			
Week 24						
m	6	12	20			
n	5	11	18	5	11	17
Mean (SD/SE)	5.56 (0.96)	5.45 (1.01)	5.50 (1.36)	0.76 (0.60)	-0.55 (0.35)	-0.35 (0.32)
Median	5.00	5.20	5.80	0.20	0	-0.20
IQR: Q1, Q3	4.80, 6.40	4.40, 6.60	4.40, 6.80	-0.20, 1.40	-1.60, 0.20	-1.20, 0.40
Min, Max	4.8, 6.8	4.4, 7.0	2.8, 7.0	-0.4, 2.8	-2.6, 0.8	-3.8, 2.6
Week 52						
m	6	12	19			
n	5	10	17	5	10	16
Mean (SD/SE)	5.72 (1.43)	5.30 (0.83)	6.12 (1.16)	0.24 (0.41)	-0.78 (0.32)	0.25 (0.30)
Median	5.80	5.00	6.60	0	-0.80	0.10
IQR: Q1, Q3	5.60, 6.80	4.60, 6.00	5.40, 7.00	0.00, 0.80	-1.20, 0.00	-0.10, 0.90
Min, Max	3.4, 7.0	4.2, 6.6	3.4, 7.0	-1.0, 1.4	-2.4, 0.8	-2.6, 2.2

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.3.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=21)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=21)
Emotional Health						
Baseline						
m	6	15	21			
n	6	14	18			
Mean (SD)	5.62 (1.32)	5.90 (0.87)	5.77 (0.86)			
Median	5.80	6.05	5.75			
IQR: Q1, Q3	5.20, 6.70	5.20, 6.60	5.20, 6.70			
Min, Max	3.3, 6.9	3.8, 6.9	4.1, 7.0			
Week 24						
m	6	12	20			
n	5	11	18	5	11	17
Mean (SD/SE)	5.82 (1.08)	5.75 (0.90)	5.69 (1.08)	0.32 (0.38)	-0.17 (0.31)	-0.01 (0.16)
Median	6.30	5.80	5.95	0.10	0.10	0.10
IQR: Q1, Q3	5.10, 6.60	5.00, 6.60	4.70, 6.60	-0.30, 1.00	-0.60, 0.70	-0.40, 0.40
Min, Max	4.3, 6.8	4.3, 6.9	3.7, 7.0	-0.6, 1.4	-2.3, 0.9	-1.5, 1.2
Week 52						
m	6	12	19			
n	5	10	17	5	10	16
Mean (SD/SE)	5.60 (1.54)	5.69 (0.57)	5.75 (1.24)	-0.10 (0.14)	-0.31 (0.29)	-0.06 (0.21)
Median	5.60	5.85	6.10	-0.10	-0.15	0
IQR: Q1, Q3	5.30, 6.90	5.30, 6.00	4.70, 6.80	-0.10, 0.00	-0.60, 0.40	-0.30, 0.20
Min, Max	3.2, 7.0	4.7, 6.4	3.3, 7.0	-0.6, 0.3	-1.9, 0.9	-2.5, 1.3

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.3.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=21)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=21)
Fatigue						
Baseline						
m	6	15	21			
n	6	14	18			
Mean (SD)	4.10 (2.18)	5.36 (1.07)	4.92 (1.49)			
Median	4.90	5.35	5.40			
IQR: Q1, Q3	1.80, 5.80	4.50, 6.30	4.00, 5.80			
Min, Max	1.0, 6.2	3.5, 7.0	1.5, 7.0			
Week 24						
m	6	12	20			
n	5	11	18	5	11	17
Mean (SD/SE)	4.02 (1.93)	4.96 (1.06)	4.81 (1.47)	0.16 (0.41)	-0.25 (0.29)	-0.22 (0.33)
Median	4.30	4.70	4.60	0	0.20	0
IQR: Q1, Q3	3.50, 5.50	4.30, 6.20	3.80, 6.20	-0.20, 0.00	-0.70, 0.40	-1.00, 0.20
Min, Max	1.0, 5.8	3.5, 6.8	2.2, 6.8	-0.7, 1.7	-2.2, 0.5	-3.3, 3.0
Week 52						
m	6	12	19			
n	5	10	17	5	10	16
Mean (SD/SE)	5.20 (1.68)	5.02 (0.74)	4.99 (1.40)	0.48 (0.17)	-0.23 (0.39)	-0.16 (0.31)
Median	5.50	5.30	4.80	0.50	-0.25	-0.30
IQR: Q1, Q3	4.50, 6.30	4.30, 5.50	4.00, 6.30	0.20, 0.80	-1.20, 0.80	-0.90, 1.05
Min, Max	2.7, 7.0	4.0, 6.0	2.8, 7.0	0.0, 0.9	-2.3, 1.8	-2.9, 1.7

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.3.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=21)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=21)
Systemic Symptoms						
Baseline						
m	6	15	21			
n	6	14	18			
Mean (SD)	5.40 (1.22)	5.67 (1.27)	5.61 (0.79)			
Median	5.30	5.95	5.50			
IQR: Q1, Q3	4.30, 6.50	5.00, 6.80	5.20, 6.00			
Min, Max	4.0, 7.0	2.7, 7.0	3.8, 7.0			
Week 24						
m	6	12	20			
n	5	11	18	5	11	17
Mean (SD/SE)	5.40 (1.19)	5.89 (0.74)	5.37 (1.20)	0.08 (0.18)	-0.01 (0.26)	-0.18 (0.23)
Median	5.30	6.00	5.25	0	0	-0.30
IQR: Q1, Q3	4.50, 6.50	5.30, 6.50	4.70, 6.70	-0.30, 0.50	-0.80, 0.60	-0.40, 0.20
Min, Max	4.0, 6.7	4.5, 7.0	3.2, 7.0	-0.3, 0.5	-1.5, 1.5	-2.1, 1.6
Week 52						
m	6	12	19			
n	5	10	17	5	10	16
Mean (SD/SE)	5.60 (1.44)	5.47 (0.80)	5.56 (1.03)	-0.02 (0.22)	-0.54 (0.34)	-0.06 (0.25)
Median	6.20	5.40	5.50	0	-0.55	-0.05
IQR: Q1, Q3	5.20, 6.30	4.80, 6.00	4.80, 6.30	-0.30, 0.40	-0.90, -0.20	-0.50, 0.50
Min, Max	3.3, 7.0	4.2, 7.0	3.2, 7.0	-0.7, 0.5	-2.8, 1.6	-2.6, 1.5

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.3.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=21)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=21)
Worry						
Baseline						
m	6	15	21			
n	6	14	18			
Mean (SD)	5.42 (2.24)	6.44 (0.63)	6.23 (0.76)			
Median	5.90	6.70	6.30			
IQR: Q1, Q3	5.70, 7.00	5.90, 6.90	5.90, 7.00			
Min, Max	1.0, 7.0	5.1, 7.0	4.1, 7.0			
Week 24						
m	6	12	20			
n	5	11	18	5	11	17
Mean (SD/SE)	6.12 (1.47)	6.43 (0.80)	6.12 (1.07)	0.80 (0.49)	-0.15 (0.22)	-0.11 (0.23)
Median	7.00	6.90	6.70	0.30	0.10	0
IQR: Q1, Q3	6.00, 7.00	5.60, 7.00	5.30, 7.00	0.00, 1.10	0.00, 0.20	-0.80, 0.70
Min, Max	3.6, 7.0	4.9, 7.0	3.7, 7.0	0.0, 2.6	-2.1, 0.5	-1.9, 1.3
Week 52						
m	6	12	19			
n	5	10	17	5	10	16
Mean (SD/SE)	5.72 (2.27)	6.29 (0.92)	6.32 (0.82)	0.40 (0.18)	-0.44 (0.27)	0.06 (0.24)
Median	6.60	6.70	6.60	0.40	-0.10	0
IQR: Q1, Q3	6.30, 7.00	6.10, 7.00	6.00, 7.00	0.00, 0.70	-0.80, 0.00	-0.05, 0.40
Min, Max	1.7, 7.0	4.3, 7.0	4.1, 7.0	0.0, 0.9	-2.7, 0.2	-2.9, 1.6

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.3.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=7)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=7)
CLDQ-NASH						
Baseline						
m	3	0	7			
n	3	0	7			
Mean (SD)	5.90 (1.04)	N/A	6.04 (0.85)			
Median	6.50	N/A	6.20			
IQR: Q1, Q3	4.70, 6.50	N/A	5.90, 6.70			
Min, Max	4.7, 6.5	N/A	4.3, 6.8			
Week 24						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	6.40 (0.14)	N/A	6.16 (0.80)	-0.10 (0.10)	N/A	0.11 (0.07)
Median	6.40	N/A	6.60	-0.10	N/A	0.10
IQR: Q1, Q3	6.30, 6.50	N/A	5.80, 6.70	-0.20, 0.00	N/A	0.00, 0.30
Min, Max	6.3, 6.5	N/A	4.6, 6.9	-0.2, 0.0	N/A	-0.1, 0.4
Week 52						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	6.30 (0.14)	N/A	6.10 (0.84)	-0.20 (0.10)	N/A	0.06 (0.08)
Median	6.30	N/A	6.20	-0.20	N/A	0.20
IQR: Q1, Q3	6.20, 6.40	N/A	5.60, 6.70	-0.30, -0.10	N/A	-0.10, 0.20
Min, Max	6.2, 6.4	N/A	4.5, 7.0	-0.3, -0.1	N/A	-0.3, 0.2

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.3.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=7)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=7)
Abdominal Symptoms						
Baseline						
m	3	0	7			
n	3	0	7			
Mean (SD)	6.90 (0.17)	N/A	6.43 (1.13)			
Median	7.00	N/A	7.00			
IQR: Q1, Q3	6.70, 7.00	N/A	6.00, 7.00			
Min, Max	6.7, 7.0	N/A	4.0, 7.0			
Week 24						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	6.65 (0.49)	N/A	6.67 (0.75)	-0.20 (0.20)	N/A	0.24 (0.20)
Median	6.65	N/A	7.00	-0.20	N/A	0
IQR: Q1, Q3	6.30, 7.00	N/A	6.70, 7.00	-0.40, 0.00	N/A	0.00, 1.00
Min, Max	6.3, 7.0	N/A	5.0, 7.0	-0.4, 0.0	N/A	-0.3, 1.0
Week 52						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	6.65 (0.49)	N/A	6.61 (1.02)	-0.20 (0.20)	N/A	0.19 (0.14)
Median	6.65	N/A	7.00	-0.20	N/A	0
IQR: Q1, Q3	6.30, 7.00	N/A	7.00, 7.00	-0.40, 0.00	N/A	0.00, 0.30
Min, Max	6.3, 7.0	N/A	4.3, 7.0	-0.4, 0.0	N/A	0.0, 1.0

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.3.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=7)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=7)
Activity						
Baseline						
m	3	0	7			
n	3	0	7			
Mean (SD)	6.00 (0.72)	N/A	5.46 (1.24)			
Median	6.20	N/A	5.40			
IQR: Q1, Q3	5.20, 6.60	N/A	5.00, 6.60			
Min, Max	5.2, 6.6	N/A	3.2, 7.0			
Week 24						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	5.90 (0.14)	N/A	5.51 (1.74)	-0.50 (0.10)	N/A	0.06 (0.27)
Median	5.90	N/A	5.80	-0.50	N/A	0.20
IQR: Q1, Q3	5.80, 6.00	N/A	5.40, 6.80	-0.60, -0.40	N/A	0.00, 0.60
Min, Max	5.8, 6.0	N/A	1.8, 7.0	-0.6, -0.4	N/A	-1.4, 0.8
Week 52						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	6.00 (0.57)	N/A	5.34 (1.12)	-0.40 (0.20)	N/A	-0.11 (0.16)
Median	6.00	N/A	5.60	-0.40	N/A	-0.20
IQR: Q1, Q3	5.60, 6.40	N/A	4.60, 6.20	-0.60, -0.20	N/A	-0.40, 0.40
Min, Max	5.6, 6.4	N/A	3.6, 7.0	-0.6, -0.2	N/A	-0.8, 0.4

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.3.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=7)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=7)
Emotional Health						
Baseline						
m	3	0	7			
n	3	0	7			
Mean (SD)	6.03 (1.50)	N/A	6.30 (0.61)			
Median	6.80	N/A	6.30			
IQR: Q1, Q3	4.30, 7.00	N/A	6.20, 6.80			
Min, Max	4.3, 7.0	N/A	5.1, 7.0			
Week 24						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	6.85 (0.07)	N/A	6.30 (0.74)	-0.05 (0.05)	N/A	0.00 (0.09)
Median	6.85	N/A	6.60	-0.05	N/A	0
IQR: Q1, Q3	6.80, 6.90	N/A	6.10, 6.80	-0.10, 0.00	N/A	-0.20, 0.30
Min, Max	6.8, 6.9	N/A	4.8, 7.0	-0.1, 0.0	N/A	-0.3, 0.3
Week 52						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	6.35 (0.64)	N/A	6.29 (0.87)	-0.55 (0.35)	N/A	-0.01 (0.14)
Median	6.35	N/A	6.80	-0.55	N/A	0
IQR: Q1, Q3	5.90, 6.80	N/A	5.80, 6.90	-0.90, -0.20	N/A	-0.40, 0.40
Min, Max	5.9, 6.8	N/A	4.6, 7.0	-0.9, -0.2	N/A	-0.5, 0.5

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.3.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result: DB MGL-3196 80 mg (N=3)	Visit Result: DB MGL-3196 100 mg (N=0)	Visit Result: DB Placebo (N=7)	Change from Baseline: DB MGL-3196 80 mg (N=3)	Change from Baseline: DB MGL-3196 100 mg (N=0)	Change from Baseline: DB Placebo (N=7)
Fatigue						
Baseline						
m	3	0	7			
n	3	0	7			
Mean (SD)	5.57 (0.51)	N/A	5.49 (1.53)			
Median	5.70	N/A	6.00			
IQR: Q1, Q3	5.00, 6.00	N/A	4.20, 6.80			
Min, Max	5.0, 6.0	N/A	2.7, 7.0			
Week 24						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	5.80 (0.00)	N/A	5.61 (1.20)	-0.05 (0.15)	N/A	0.13 (0.27)
Median	5.80	N/A	5.50	-0.05	N/A	-0.20
IQR: Q1, Q3	5.80, 5.80	N/A	4.20, 6.80	-0.20, 0.10	N/A	-0.40, 0.70
Min, Max	5.8, 5.8	N/A	4.0, 6.8	-0.2, 0.1	N/A	-0.5, 1.5
Week 52						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	5.50 (0.28)	N/A	5.56 (1.14)	-0.35 (0.05)	N/A	0.07 (0.34)
Median	5.50	N/A	6.20	-0.35	N/A	0.20
IQR: Q1, Q3	5.30, 5.70	N/A	4.50, 6.30	-0.40, -0.30	N/A	-0.70, 0.50
Min, Max	5.3, 5.7	N/A	4.0, 7.0	-0.4, -0.3	N/A	-1.5, 1.3

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.3.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=7)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=7)
Systemic Symptoms						
Baseline						
m	3	0	7			
n	3	0	7			
Mean (SD)	5.80 (1.32)	N/A	5.77 (1.09)			
Median	6.30	N/A	5.70			
IQR: Q1, Q3	4.30, 6.80	N/A	5.20, 6.70			
Min, Max	4.3, 6.8	N/A	3.8, 6.8			
Week 24						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	6.55 (0.35)	N/A	5.76 (1.06)	0.00 (0.50)	N/A	-0.01 (0.25)
Median	6.55	N/A	6.00	0	N/A	0.10
IQR: Q1, Q3	6.30, 6.80	N/A	4.70, 6.80	-0.50, 0.50	N/A	-0.40, 0.30
Min, Max	6.3, 6.8	N/A	4.0, 6.8	-0.5, 0.5	N/A	-1.2, 0.9
Week 52						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	6.40 (0.14)	N/A	5.77 (1.32)	-0.15 (0.15)	N/A	0.00 (0.17)
Median	6.40	N/A	6.30	-0.15	N/A	0
IQR: Q1, Q3	6.30, 6.50	N/A	4.70, 6.80	-0.30, 0.00	N/A	-0.40, 0.30
Min, Max	6.3, 6.5	N/A	3.5, 7.0	-0.3, 0.0	N/A	-0.5, 0.8

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.3.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=7)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=7)
Worry						
Baseline						
m	3	0	7			
n	3	0	7			
Mean (SD)	5.20 (2.29)	N/A	6.89 (0.22)			
Median	6.10	N/A	7.00			
IQR: Q1, Q3	2.60, 6.90	N/A	6.90, 7.00			
Min, Max	2.6, 6.9	N/A	6.4, 7.0			
Week 24						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	6.70 (0.42)	N/A	6.94 (0.11)	0.20 (0.10)	N/A	0.06 (0.05)
Median	6.70	N/A	7.00	0.20	N/A	0
IQR: Q1, Q3	6.40, 7.00	N/A	6.90, 7.00	0.10, 0.30	N/A	0.00, 0.10
Min, Max	6.4, 7.0	N/A	6.7, 7.0	0.1, 0.3	N/A	-0.1, 0.3
Week 52						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	6.75 (0.21)	N/A	6.94 (0.11)	0.25 (0.25)	N/A	0.06 (0.10)
Median	6.75	N/A	7.00	0.25	N/A	0
IQR: Q1, Q3	6.60, 6.90	N/A	6.90, 7.00	0.00, 0.50	N/A	-0.10, 0.10
Min, Max	6.6, 6.9	N/A	6.7, 7.0	0.0, 0.5	N/A	-0.2, 0.6

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.3.2
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of CLDQ-NASH - MMRM Model
by Age
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE18.3.2
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of CLDQ-NASH - MMRM Model
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
CLDQ-NASH			
Week 24			
m	6	12	20
n	5	11	17
Baseline Mean (SD)	4.92 (1.91)	6.01 (0.54)	5.68 (0.79)
Analysis Visit Mean (SD)	5.34 (1.14)	5.77 (0.62)	5.51 (1.05)
LS Mean of Change from Baseline (SE)	0.25 (0.48)	-0.09 (0.35)	-0.08 (0.38)
95% CI	(-0.73, 1.23)	(-0.80, 0.62)	(-0.86, 0.70)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.33 (0.38)	-0.01 (0.29)	
95% CI	(-0.44, 1.10)	(-0.61, 0.59)	
p-value	0.3943	0.9706	
Corrected Hedge's g Statistics	0.211	-0.007	
95% CI	(-0.79, 1.21)	(-0.77, 0.75)	
Week 52			
m	6	12	19
n	5	10	16
Baseline Mean (SD)	5.34 (1.89)	6.10 (0.47)	5.71 (0.80)
Analysis Visit Mean (SD)	5.52 (1.73)	5.61 (0.54)	5.67 (1.11)
LS Mean of Change from Baseline (SE)	0.23 (0.51)	-0.34 (0.38)	0.06 (0.40)
95% CI	(-0.82, 1.28)	(-1.11, 0.43)	(-0.76, 0.87)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.17 (0.43)	-0.40 (0.35)	
95% CI	(-0.70, 1.05)	(-1.12, 0.32)	
p-value	0.6894	0.2671	
Corrected Hedge's g Statistics	0.110	-0.263	
95% CI	(-0.90, 1.11)	(-1.06, 0.53)	
Subgroup*Treatment Interaction p-value	0.3053	NE	

AMNOG Table SE18.3.2
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of CLDQ-NASH - MMRM Model
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
CLDQ-NASH			
Week 24			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	6.50 (0.00)	N/A	6.04 (0.85)
Analysis Visit Mean (SD)	6.40 (0.14)	N/A	6.16 (0.80)
LS Mean of Change from Baseline (SE)	-0.06 (0.15)	NE	0.17 (0.12)
95% CI	(-0.45, 0.33)	NE	(-0.14, 0.47)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.23 (0.18)	NE	
95% CI	(-0.70, 0.24)	NE	
p-value	0.2702	NE	
Corrected Hedge's g Statistics	-0.669	NE	
95% CI	(-2.27, 0.93)	NE	
Week 52			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	6.50 (0.00)	N/A	6.04 (0.85)
Analysis Visit Mean (SD)	6.30 (0.14)	N/A	6.10 (0.84)
LS Mean of Change from Baseline (SE)	-0.17 (0.15)	NE	0.12 (0.12)
95% CI	(-0.56, 0.22)	NE	(-0.19, 0.42)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.29 (0.18)	NE	
95% CI	(-0.76, 0.18)	NE	
p-value	0.1788	NE	
Corrected Hedge's g Statistics	-0.846	NE	
95% CI	(-2.47, 0.77)	NE	
Subgroup*Treatment Interaction p-value	0.3053	NE	

AMNOG Table SE18.3.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

AMNOG Table SE18.3.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Abdominal Symptoms			
Week 24			
m	6	12	20
n	5	11	17
Baseline Mean (SD)	4.80 (2.41)	6.41 (0.65)	5.55 (1.24)
Analysis Visit Mean (SD)	5.20 (1.90)	6.06 (0.87)	5.38 (1.36)
LS Mean of Change from Baseline (SE)	0.72 (0.59)	0.23 (0.43)	0.37 (0.46)
95% CI	(-0.49, 1.92)	(-0.65, 1.11)	(-0.56, 1.30)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.34 (0.49)	-0.14 (0.40)	
95% CI	(-0.66, 1.34)	(-0.95, 0.67)	
p-value	0.4870	0.7265	
Corrected Hedge's g Statistics	0.186	-0.079	
95% CI	(-0.81, 1.18)	(-0.84, 0.68)	
Week 52			
m	6	12	19
n	5	10	16
Baseline Mean (SD)	5.20 (2.47)	6.48 (0.64)	5.66 (1.18)
Analysis Visit Mean (SD)	5.20 (2.40)	5.91 (0.61)	5.36 (1.48)
LS Mean of Change from Baseline (SE)	0.56 (0.64)	0.01 (0.47)	0.29 (0.48)
95% CI	(-0.74, 1.86)	(-0.95, 0.96)	(-0.68, 1.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.26 (0.55)	-0.29 (0.46)	
95% CI	(-0.87, 1.39)	(-1.23, 0.65)	
p-value	0.6364	0.5374	
Corrected Hedge's g Statistics	0.139	-0.158	
95% CI	(-0.87, 1.14)	(-0.95, 0.63)	
Subgroup*Treatment Interaction p-value	0.2206	NE	

AMNOG Table SE18.3.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Activity			
Week 24			
m	6	12	20
n	5	11	17
Baseline Mean (SD)	4.80 (2.16)	6.00 (0.90)	5.81 (0.93)
Analysis Visit Mean (SD)	5.56 (0.96)	5.45 (1.01)	5.46 (1.39)
LS Mean of Change from Baseline (SE)	0.29 (0.71)	-0.35 (0.51)	-0.21 (0.54)
95% CI	(-1.15, 1.74)	(-1.39, 0.69)	(-1.32, 0.90)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.50 (0.60)	-0.14 (0.46)	
95% CI	(-0.72, 1.73)	(-1.07, 0.79)	
p-value	0.4076	0.7605	
Corrected Hedge's g Statistics	0.228	-0.066	
95% CI	(-0.77, 1.23)	(-0.83, 0.69)	
Week 52			
m	6	12	19
n	5	10	16
Baseline Mean (SD)	5.48 (2.14)	6.08 (0.91)	5.81 (0.96)
Analysis Visit Mean (SD)	5.72 (1.43)	5.30 (0.83)	6.06 (1.17)
LS Mean of Change from Baseline (SE)	0.24 (0.65)	-0.56 (0.48)	0.38 (0.53)
95% CI	(-1.09, 1.56)	(-1.54, 0.43)	(-0.71, 1.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.14 (0.50)	-0.93 (0.41)	
95% CI	(-1.16, 0.88)	(-1.77, -0.09)	
p-value	0.7826	0.0306	
Corrected Hedge's g Statistics	-0.067	-0.470	
95% CI	(-1.07, 0.94)	(-1.27, 0.33)	
Subgroup*Treatment Interaction p-value	0.6620	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE18.3.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Emotional Health			
Week 24			
m	6	12	20
n	5	11	17
Baseline Mean (SD)	5.50 (1.44)	5.92 (0.61)	5.78 (0.89)
Analysis Visit Mean (SD)	5.82 (1.08)	5.75 (0.90)	5.77 (1.06)
LS Mean of Change from Baseline (SE)	0.44 (0.50)	0.01 (0.37)	0.23 (0.41)
95% CI	(-0.58, 1.47)	(-0.75, 0.77)	(-0.60, 1.07)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.21 (0.40)	-0.22 (0.32)	
95% CI	(-0.61, 1.03)	(-0.87, 0.43)	
p-value	0.6042	0.4883	
Corrected Hedge's g Statistics	0.127	-0.142	
95% CI	(-0.87, 1.12)	(-0.90, 0.62)	
Week 52			
m	6	12	19
n	5	10	16
Baseline Mean (SD)	5.70 (1.46)	6.00 (0.57)	5.77 (0.91)
Analysis Visit Mean (SD)	5.60 (1.54)	5.69 (0.57)	5.71 (1.27)
LS Mean of Change from Baseline (SE)	0.24 (0.53)	-0.12 (0.39)	0.20 (0.42)
95% CI	(-0.84, 1.31)	(-0.91, 0.67)	(-0.66, 1.05)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.04 (0.43)	-0.32 (0.35)	
95% CI	(-0.84, 0.91)	(-1.04, 0.40)	
p-value	0.9339	0.3705	
Corrected Hedge's g Statistics	0.022	-0.204	
95% CI	(-0.98, 1.03)	(-1.00, 0.59)	
Subgroup*Treatment Interaction p-value	0.1317	NE	

AMNOG Table SE18.3.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Fatigue			
Week 24			
m	6	12	20
n	5	11	17
Baseline Mean (SD)	3.86 (2.35)	5.21 (1.12)	5.12 (1.26)
Analysis Visit Mean (SD)	4.02 (1.93)	4.96 (1.06)	4.90 (1.46)
LS Mean of Change from Baseline (SE)	0.01 (0.75)	0.04 (0.52)	0.08 (0.58)
95% CI	(-1.51, 1.54)	(-1.03, 1.11)	(-1.10, 1.25)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.06 (0.60)	-0.03 (0.46)	
95% CI	(-1.28, 1.16)	(-0.97, 0.90)	
p-value	0.9172	0.9397	
Corrected Hedge's g Statistics	-0.027	-0.016	
95% CI	(-1.02, 0.97)	(-0.77, 0.74)	
Week 52			
m	6	12	19
n	5	10	16
Baseline Mean (SD)	4.72 (1.75)	5.25 (1.17)	5.16 (1.29)
Analysis Visit Mean (SD)	5.20 (1.68)	5.02 (0.74)	5.00 (1.44)
LS Mean of Change from Baseline (SE)	0.54 (0.71)	0.09 (0.52)	0.11 (0.57)
95% CI	(-0.91, 2.00)	(-0.97, 1.14)	(-1.06, 1.28)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.43 (0.54)	-0.03 (0.44)	
95% CI	(-0.68, 1.54)	(-0.93, 0.88)	
p-value	0.4324	0.9534	
Corrected Hedge's g Statistics	0.192	-0.012	
95% CI	(-0.81, 1.20)	(-0.80, 0.78)	
Subgroup*Treatment Interaction p-value	0.6370	NE	

AMNOG Table SE18.3.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Systemic Symptoms			
Week 24			
m	6	12	20
n	5	11	17
Baseline Mean (SD)	5.32 (1.35)	5.90 (0.99)	5.61 (0.81)
Analysis Visit Mean (SD)	5.40 (1.19)	5.89 (0.74)	5.43 (1.20)
LS Mean of Change from Baseline (SE)	-0.19 (0.57)	-0.11 (0.43)	-0.44 (0.48)
95% CI	(-1.34, 0.97)	(-0.99, 0.78)	(-1.42, 0.54)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.25 (0.42)	0.33 (0.34)	
95% CI	(-0.61, 1.11)	(-0.37, 1.03)	
p-value	0.5551	0.3443	
Corrected Hedge's g Statistics	0.131	0.180	
95% CI	(-0.87, 1.13)	(-0.58, 0.94)	
Week 52			
m	6	12	19
n	5	10	16
Baseline Mean (SD)	5.62 (1.23)	6.01 (0.97)	5.64 (0.83)
Analysis Visit Mean (SD)	5.60 (1.44)	5.47 (0.80)	5.58 (1.06)
LS Mean of Change from Baseline (SE)	-0.39 (0.60)	-0.63 (0.46)	-0.38 (0.49)
95% CI	(-1.62, 0.84)	(-1.57, 0.31)	(-1.39, 0.62)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (0.48)	-0.24 (0.40)	
95% CI	(-0.98, 0.97)	(-1.05, 0.57)	
p-value	0.9927	0.5456	
Corrected Hedge's g Statistics	-0.002	-0.130	
95% CI	(-1.01, 1.00)	(-0.92, 0.66)	
Subgroup*Treatment Interaction p-value	0.9331	NE	

AMNOG Table SE18.3.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Worry			
Week 24			
m	6	12	20
n	5	11	17
Baseline Mean (SD)	5.32 (2.49)	6.58 (0.60)	6.24 (0.79)
Analysis Visit Mean (SD)	6.12 (1.47)	6.43 (0.80)	6.13 (1.11)
LS Mean of Change from Baseline (SE)	0.33 (0.54)	-0.16 (0.39)	-0.23 (0.43)
95% CI	(-0.77, 1.43)	(-0.96, 0.64)	(-1.11, 0.64)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.56 (0.43)	0.08 (0.33)	
95% CI	(-0.32, 1.45)	(-0.61, 0.76)	
p-value	0.2014	0.8233	
Corrected Hedge's g Statistics	0.326	0.046	
95% CI	(-0.68, 1.33)	(-0.71, 0.80)	
Week 52			
m	6	12	19
n	5	10	16
Baseline Mean (SD)	5.32 (2.49)	6.73 (0.36)	6.24 (0.81)
Analysis Visit Mean (SD)	5.72 (2.27)	6.29 (0.92)	6.30 (0.84)
LS Mean of Change from Baseline (SE)	0.10 (0.56)	-0.44 (0.40)	-0.09 (0.44)
95% CI	(-1.04, 1.24)	(-1.26, 0.39)	(-0.98, 0.80)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.19 (0.45)	-0.35 (0.36)	
95% CI	(-0.73, 1.11)	(-1.08, 0.39)	
p-value	0.6776	0.3423	
Corrected Hedge's g Statistics	0.110	-0.212	
95% CI	(-0.89, 1.11)	(-1.00, 0.58)	
Subgroup*Treatment Interaction p-value	0.5681	NE	

AMNOG Table SE18.3.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Abdominal Symptoms			
Week 24			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	6.85 (0.21)	N/A	6.43 (1.13)
Analysis Visit Mean (SD)	6.65 (0.49)	N/A	6.67 (0.75)
LS Mean of Change from Baseline (SE)	-0.07 (0.27)	NE	0.17 (0.23)
95% CI	(-0.77, 0.62)	NE	(-0.43, 0.77)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.25 (0.35)	NE	
95% CI	(-1.14, 0.65)	NE	
p-value	0.5111	NE	
Corrected Hedge's g Statistics	-0.370	NE	
95% CI	(-1.95, 1.21)	NE	
Week 52			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	6.85 (0.21)	N/A	6.43 (1.13)
Analysis Visit Mean (SD)	6.65 (0.49)	N/A	6.61 (1.02)
LS Mean of Change from Baseline (SE)	-0.15 (0.30)	NE	0.14 (0.24)
95% CI	(-0.91, 0.61)	NE	(-0.48, 0.76)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.29 (0.37)	NE	
95% CI	(-1.25, 0.67)	NE	
p-value	0.4730	NE	
Corrected Hedge's g Statistics	-0.419	NE	
95% CI	(-2.00, 1.16)	NE	
Subgroup*Treatment Interaction p-value	0.2206	NE	

AMNOG Table SE18.3.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Activity			
Week 24			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	6.40 (0.28)	N/A	5.46 (1.24)
Analysis Visit Mean (SD)	5.90 (0.14)	N/A	5.51 (1.74)
LS Mean of Change from Baseline (SE)	-0.88 (0.35)	NE	-0.18 (0.21)
95% CI	(-1.77, 0.01)	NE	(-0.71, 0.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.70 (0.40)	NE	
95% CI	(-1.72, 0.33)	NE	
p-value	0.1408	NE	
Corrected Hedge's g Statistics	-1.156	NE	
95% CI	(-2.82, 0.50)	NE	
Week 52			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	6.40 (0.28)	N/A	5.46 (1.24)
Analysis Visit Mean (SD)	6.00 (0.57)	N/A	5.34 (1.12)
LS Mean of Change from Baseline (SE)	-0.44 (0.38)	NE	-0.45 (0.22)
95% CI	(-1.41, 0.53)	NE	(-1.01, 0.12)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.01 (0.43)	NE	
95% CI	(-1.11, 1.13)	NE	
p-value	0.9814	NE	
Corrected Hedge's g Statistics	0.016	NE	
95% CI	(-1.56, 1.59)	NE	
Subgroup*Treatment Interaction p-value	0.6620	NE	

AMNOG Table SE18.3.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Emotional Health			
Week 24			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	6.90 (0.14)	N/A	6.30 (0.61)
Analysis Visit Mean (SD)	6.85 (0.07)	N/A	6.30 (0.74)
LS Mean of Change from Baseline (SE)	-0.08 (0.13)	NE	0.22 (0.10)
95% CI	(-0.41, 0.25)	NE	(-0.03, 0.47)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.30 (0.16)	NE	
95% CI	(-0.70, 0.11)	NE	
p-value	0.1165	NE	
Corrected Hedge's g Statistics	-1.066	NE	
95% CI	(-2.71, 0.58)	NE	
Week 52			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	6.90 (0.14)	N/A	6.30 (0.61)
Analysis Visit Mean (SD)	6.35 (0.64)	N/A	6.29 (0.87)
LS Mean of Change from Baseline (SE)	-0.67 (0.22)	NE	0.23 (0.13)
95% CI	(-1.23, -0.10)	NE	(-0.11, 0.57)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.89 (0.26)	NE	
95% CI	(-1.56, -0.23)	NE	
p-value	0.0184	NE	
Corrected Hedge's g Statistics	-2.304	NE	
95% CI	(-4.20, -0.41)	NE	
Subgroup*Treatment Interaction p-value	0.1317	NE	

AMNOG Table SE18.3.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Fatigue			
Week 24			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	5.85 (0.21)	N/A	5.49 (1.53)
Analysis Visit Mean (SD)	5.80 (0.00)	N/A	5.61 (1.20)
LS Mean of Change from Baseline (SE)	0.06 (0.47)	NE	0.29 (0.40)
95% CI	(-1.14, 1.27)	NE	(-0.74, 1.33)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.23 (0.60)	NE	
95% CI	(-1.78, 1.32)	NE	
p-value	0.7173	NE	
Corrected Hedge's g Statistics	-0.201	NE	
95% CI	(-1.78, 1.37)	NE	
Week 52			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	5.85 (0.21)	N/A	5.49 (1.53)
Analysis Visit Mean (SD)	5.50 (0.28)	N/A	5.56 (1.14)
LS Mean of Change from Baseline (SE)	-0.21 (0.50)	NE	0.23 (0.41)
95% CI	(-1.49, 1.07)	NE	(-0.84, 1.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.44 (0.63)	NE	
95% CI	(-2.07, 1.19)	NE	
p-value	0.5194	NE	
Corrected Hedge's g Statistics	-0.371	NE	
95% CI	(-1.95, 1.21)	NE	
Subgroup*Treatment Interaction p-value	0.6370	NE	

AMNOG Table SE18.3.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Systemic Symptoms			
Week 24			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	6.55 (0.35)	N/A	5.77 (1.09)
Analysis Visit Mean (SD)	6.55 (0.35)	N/A	5.76 (1.06)
LS Mean of Change from Baseline (SE)	0.16 (0.55)	NE	-0.05 (0.45)
95% CI	(-1.25, 1.57)	NE	(-1.20, 1.10)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.21 (0.63)	NE	
95% CI	(-1.41, 1.83)	NE	
p-value	0.7531	NE	
Corrected Hedge's g Statistics	0.164	NE	
95% CI	(-1.41, 1.74)	NE	
Week 52			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	6.55 (0.35)	N/A	5.77 (1.09)
Analysis Visit Mean (SD)	6.40 (0.14)	N/A	5.77 (1.32)
LS Mean of Change from Baseline (SE)	-0.22 (0.41)	NE	0.03 (0.41)
95% CI	(-1.28, 0.84)	NE	(-1.02, 1.07)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.24 (0.48)	NE	
95% CI	(-1.47, 0.98)	NE	
p-value	0.6301	NE	
Corrected Hedge's g Statistics	-0.212	NE	
95% CI	(-1.79, 1.36)	NE	
Subgroup*Treatment Interaction p-value	0.9331	NE	

AMNOG Table SE18.3.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Worry			
Week 24			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	6.50 (0.57)	N/A	6.89 (0.22)
Analysis Visit Mean (SD)	6.70 (0.42)	N/A	6.94 (0.11)
LS Mean of Change from Baseline (SE)	0.07 (0.07)	NE	0.11 (0.05)
95% CI	(-0.10, 0.24)	NE	(-0.01, 0.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.04 (0.09)	NE	
95% CI	(-0.26, 0.19)	NE	
p-value	0.6945	NE	
Corrected Hedge's g Statistics	-0.270	NE	
95% CI	(-1.85, 1.31)	NE	
Week 52			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	6.50 (0.57)	N/A	6.89 (0.22)
Analysis Visit Mean (SD)	6.75 (0.21)	N/A	6.94 (0.11)
LS Mean of Change from Baseline (SE)	-0.01 (0.11)	NE	0.14 (0.06)
95% CI	(-0.29, 0.26)	NE	(-0.01, 0.30)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.16 (0.13)	NE	
95% CI	(-0.49, 0.18)	NE	
p-value	0.2832	NE	
Corrected Hedge's g Statistics	-0.866	NE	
95% CI	(-2.49, 0.76)	NE	
Subgroup*Treatment Interaction p-value	0.5681	NE	

AMNOG Table SE18.3.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi-square Test. For this unadjusted analysis, only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.

AMNOG Table SE18.3.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (4.8)
No	6 (100)	15 (100)	20 (95.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.76	-4.76	
95% CI of the absolute risk difference	(-13.87, 4.35)	(-13.87, 4.35)	
p-value	0.5860	0.3914	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (33.3)	1 (6.7)	7 (33.3)
No	4 (66.7)	14 (93.3)	14 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	7.00	
95% CI of the inverse odds ratio	(0.15, 6.85)	(0.76, 64.61)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	5.00	
95% CI of the inverse risk ratio	(0.28, 3.61)	(0.69, 36.50)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	-26.67	
95% CI of the absolute risk difference	(-42.77, 42.77)	(-50.45, -2.88)	
p-value	>0.9999	0.0578	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE18.3.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (6.7)	1 (4.8)
No	6 (100)	14 (93.3)	20 (95.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.70	
95% CI of the inverse odds ratio	NE	(0.04, 12.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.71	
95% CI of the inverse risk ratio	NE	(0.05, 10.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.76	1.90	
95% CI of the absolute risk difference	(-13.87, 4.35)	(-13.66, 17.47)	
p-value	0.5860	0.8057	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (16.7)	1 (6.7)	3 (14.3)
No	5 (83.3)	14 (93.3)	18 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	2.33	
95% CI of the inverse odds ratio	(0.07, 9.86)	(0.22, 24.92)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	2.14	
95% CI of the inverse risk ratio	(0.11, 6.82)	(0.25, 18.66)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.38	-7.62	
95% CI of the absolute risk difference	(-30.98, 35.75)	(-27.20, 11.96)	
p-value	0.8849	0.4733	
p-value of Breslow-Day Test for Homogeneity [3]	0.4818	NE	

AMNOG Table SE18.3.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (16.7)	0	4 (19.0)
No	5 (83.3)	15 (100)	17 (81.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	7.97	
95% CI of the inverse odds ratio	(0.11, 13.07)	(0.40, 160.22)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	6.55	
95% CI of the inverse risk ratio	(0.16, 8.40)	(0.38, 113.14)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.38	-17.33	
95% CI of the absolute risk difference	(-36.61, 31.84)	(-36.22, 1.56)	
p-value	0.8947	0.1187	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (33.3)	1 (6.7)	5 (23.8)
No	4 (66.7)	14 (93.3)	16 (76.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	4.38	
95% CI of the inverse odds ratio	(0.09, 4.49)	(0.45, 42.08)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	3.57	
95% CI of the inverse risk ratio	(0.18, 2.80)	(0.46, 27.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	9.52	-17.14	
95% CI of the absolute risk difference	(-32.36, 51.41)	(-39.31, 5.02)	
p-value	0.6387	0.1736	
p-value of Breslow-Day Test for Homogeneity [3]	0.2517	NE	

AMNOG Table SE18.3.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (9.5)
No	6 (100)	15 (100)	19 (90.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	3.97	
95% CI of the inverse odds ratio	(0.07, 39.42)	(0.18, 89.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.59	3.64	
95% CI of the inverse risk ratio	(0.09, 29.34)	(0.19, 70.69)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.22	-8.24	
95% CI of the absolute risk difference	(-27.46, 19.01)	(-24.00, 7.53)	
p-value	0.7494	0.3524	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	3 (20.0)	3 (14.3)
No	6 (100)	12 (80.0)	18 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.46	0.67	
95% CI of the inverse odds ratio	(0.11, 54.32)	(0.11, 3.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.23	0.71	
95% CI of the inverse risk ratio	(0.13, 38.06)	(0.17, 3.07)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.77	5.71	
95% CI of the absolute risk difference	(-33.21, 15.68)	(-19.46, 30.89)	
p-value	0.5580	0.6501	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE18.3.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (16.7)	2 (13.3)	5 (23.8)
No	5 (83.3)	13 (86.7)	16 (76.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.56	2.03	
95% CI of the inverse odds ratio	(0.15, 16.72)	(0.34, 12.24)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.43	1.79	
95% CI of the inverse risk ratio	(0.20, 10.00)	(0.40, 8.00)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.14	-10.48	
95% CI of the absolute risk difference	(-42.09, 27.80)	(-35.53, 14.58)	
p-value	0.7105	0.4336	
p-value of Breslow-Day Test for Homogeneity [3]	0.5893	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (50.0)	3 (20.0)	5 (23.8)
No	3 (50.0)	12 (80.0)	16 (76.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.31	1.25	
95% CI of the inverse odds ratio	(0.05, 2.07)	(0.25, 6.29)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.48	1.19	
95% CI of the inverse risk ratio	(0.16, 1.44)	(0.33, 4.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	26.19	-3.81	
95% CI of the absolute risk difference	(-17.77, 70.15)	(-31.04, 23.42)	
p-value	0.2153	0.7864	
p-value of Breslow-Day Test for Homogeneity [3]	0.0739	NE	

AMNOG Table SE18.3.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (6.7)	3 (14.3)
No	6 (100)	14 (93.3)	18 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.46	2.33	
95% CI of the inverse odds ratio	(0.11, 54.32)	(0.22, 24.92)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.23	2.14	
95% CI of the inverse risk ratio	(0.13, 38.06)	(0.25, 18.66)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.77	-7.62	
95% CI of the absolute risk difference	(-33.21, 15.68)	(-27.20, 11.96)	
p-value	0.5580	0.4733	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (33.3)	1 (6.7)	6 (28.6)
No	4 (66.7)	14 (93.3)	15 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	5.60	
95% CI of the inverse odds ratio	(0.11, 5.59)	(0.60, 52.54)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	4.29	
95% CI of the inverse risk ratio	(0.23, 3.20)	(0.57, 32.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.76	-21.90	
95% CI of the absolute risk difference	(-37.62, 47.14)	(-44.98, 1.17)	
p-value	0.8218	0.1016	
p-value of Breslow-Day Test for Homogeneity [3]	0.4653	NE	

AMNOG Table SE18.3.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	3 (14.3)
No	6 (100)	15 (100)	18 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.46	5.86	
95% CI of the inverse odds ratio	(0.11, 54.32)	(0.28, 122.49)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.23	5.09	
95% CI of the inverse risk ratio	(0.13, 38.06)	(0.28, 91.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.77	-12.78	
95% CI of the absolute risk difference	(-33.21, 15.68)	(-30.28, 4.72)	
p-value	0.5580	0.2049	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (50.0)	0	4 (19.0)
No	3 (50.0)	15 (100)	17 (81.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.24	7.97	
95% CI of the inverse odds ratio	(0.03, 1.63)	(0.40, 160.22)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.38	6.55	
95% CI of the inverse risk ratio	(0.12, 1.25)	(0.38, 113.14)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	30.95	-17.33	
95% CI of the absolute risk difference	(-12.44, 74.34)	(-36.22, 1.56)	
p-value	0.1271	0.1187	
p-value of Breslow-Day Test for Homogeneity [3]	0.8550	NE	

AMNOG Table SE18.3.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	3 (100)	0	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	3 (100)	0	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE18.3.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (14.3)
No	3 (100)	0	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.62	NE	
95% CI of the inverse odds ratio	(0.05, 51.11)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	NE	
95% CI of the inverse risk ratio	(0.08, 29.15)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.25	NE	
95% CI of the absolute risk difference	(-48.46, 35.96)	NE	
p-value	0.7842	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	1 (14.3)
No	3 (100)	0	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.62	NE	
95% CI of the inverse odds ratio	(0.05, 51.11)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	NE	
95% CI of the inverse risk ratio	(0.08, 29.15)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.25	NE	
95% CI of the absolute risk difference	(-48.46, 35.96)	NE	
p-value	0.7842	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4818	NE	

AMNOG Table SE18.3.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	3 (100)	0	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	2 (28.6)
No	3 (100)	0	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.18	NE	
95% CI of the inverse odds ratio	(0.12, 87.92)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.50	NE	
95% CI of the inverse risk ratio	(0.15, 40.67)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-18.75	NE	
95% CI of the absolute risk difference	(-64.38, 26.88)	NE	
p-value	0.4795	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2517	NE	

AMNOG Table SE18.3.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	3 (100)	0	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	2 (28.6)
No	3 (100)	0	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.18	NE	
95% CI of the inverse odds ratio	(0.12, 87.92)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.50	NE	
95% CI of the inverse risk ratio	(0.15, 40.67)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-18.75	NE	
95% CI of the absolute risk difference	(-64.38, 26.88)	NE	
p-value	0.4795	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE18.3.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (14.3)
No	3 (100)	0	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.62	NE	
95% CI of the inverse odds ratio	(0.05, 51.11)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	NE	
95% CI of the inverse risk ratio	(0.08, 29.15)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.25	NE	
95% CI of the absolute risk difference	(-48.46, 35.96)	NE	
p-value	0.7842	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.5893	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	3 (42.9)
No	3 (100)	0	4 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.44	NE	
95% CI of the inverse odds ratio	(0.21, 144.10)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.50	NE	
95% CI of the inverse risk ratio	(0.23, 52.56)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-31.25	NE	
95% CI of the absolute risk difference	(-78.50, 16.00)	NE	
p-value	0.2790	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.0739	NE	

AMNOG Table SE18.3.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	3 (100)	0	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	1 (14.3)
No	3 (100)	0	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.62	NE	
95% CI of the inverse odds ratio	(0.05, 51.11)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	NE	
95% CI of the inverse risk ratio	(0.08, 29.15)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.25	NE	
95% CI of the absolute risk difference	(-48.46, 35.96)	NE	
p-value	0.7842	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4653	NE	

AMNOG Table SE18.3.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	3 (100)	0	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (33.3)	0	1 (14.3)
No	2 (66.7)	0	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	NE	
95% CI of the inverse odds ratio	(0.01, 8.18)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.43	NE	
95% CI of the inverse risk ratio	(0.04, 4.82)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	19.05	NE	
95% CI of the absolute risk difference	(-40.26, 78.36)	NE	
p-value	0.4902	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.8550	NE	

AMNOG Table SE18.4.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result: DB MGL-3196 80 mg (N=3)	Visit Result: DB MGL-3196 100 mg (N=8)	Visit Result: DB Placebo (N=14)	Change from Baseline: DB MGL-3196 80 mg (N=3)	Change from Baseline: DB MGL-3196 100 mg (N=8)	Change from Baseline: DB Placebo (N=14)
CLDQ-NASH						
Baseline						
m	3	8	14			
n	3	8	12			
Mean (SD)	6.47 (0.35)	5.86 (0.51)	5.84 (0.93)			
Median	6.50	6.10	6.05			
IQR: Q1, Q3	6.10, 6.80	5.55, 6.15	5.25, 6.60			
Min, Max	6.1, 6.8	5.0, 6.3	4.2, 6.9			
Week 24						
m	3	7	14			
n	2	7	13	2	7	12
Mean (SD/SE)	6.55 (0.07)	5.76 (0.56)	5.69 (1.06)	-0.10 (0.10)	-0.07 (0.20)	-0.06 (0.09)
Median	6.55	5.50	5.80	-0.10	0	0
IQR: Q1, Q3	6.50, 6.60	5.30, 6.30	4.90, 6.60	-0.20, 0.00	-0.60, 0.30	-0.20, 0.10
Min, Max	6.5, 6.6	5.3, 6.7	3.9, 7.0	-0.2, 0.0	-0.9, 0.6	-0.7, 0.4
Week 52						
m	3	7	14			
n	3	6	13	3	6	12
Mean (SD/SE)	6.37 (0.57)	5.70 (0.44)	5.98 (1.00)	-0.10 (0.15)	-0.25 (0.24)	0.14 (0.14)
Median	6.20	5.75	6.20	-0.20	-0.20	0.20
IQR: Q1, Q3	5.90, 7.00	5.20, 6.10	4.90, 6.80	-0.30, 0.20	-0.80, 0.10	-0.05, 0.30
Min, Max	5.9, 7.0	5.2, 6.2	4.5, 7.0	-0.3, 0.2	-1.0, 0.6	-0.6, 1.3

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.4.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=8)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=8)	Change from Baseline DB Placebo (N=14)
Abdominal Symptoms						
Baseline						
m	3	8	14			
n	3	8	12			
Mean (SD)	6.77 (0.40)	6.05 (1.00)	6.06 (1.27)			
Median	7.00	6.35	7.00			
IQR: Q1, Q3	6.30, 7.00	5.35, 6.85	4.85, 7.00			
Min, Max	6.3, 7.0	4.3, 7.0	4.0, 7.0			
Week 24						
m	3	7	14			
n	2	7	13	2	7	12
Mean (SD/SE)	7.00 (0.00)	5.96 (0.92)	5.67 (1.54)	0.00 (0.00)	-0.34 (0.38)	-0.19 (0.25)
Median	7.00	6.00	6.70	0	0	0
IQR: Q1, Q3	7.00, 7.00	5.70, 7.00	4.70, 7.00	0.00, 0.00	-1.30, 0.30	-0.15, 0.00
Min, Max	7.0, 7.0	4.3, 7.0	3.3, 7.0	0.0, 0.0	-1.7, 1.0	-2.7, 1.0
Week 52						
m	3	7	14			
n	3	6	13	3	6	12
Mean (SD/SE)	6.67 (0.58)	5.85 (0.47)	6.02 (1.32)	-0.10 (0.10)	-0.55 (0.39)	0.05 (0.13)
Median	7.00	5.70	7.00	0	-0.80	0
IQR: Q1, Q3	6.00, 7.00	5.70, 6.00	5.00, 7.00	-0.30, 0.00	-1.30, 0.00	0.00, 0.15
Min, Max	6.0, 7.0	5.3, 6.7	4.0, 7.0	-0.3, 0.0	-1.4, 1.0	-1.0, 1.0

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.4.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result: DB MGL-3196 80 mg (N=3)	Visit Result: DB MGL-3196 100 mg (N=8)	Visit Result: DB Placebo (N=14)	Change from Baseline: DB MGL-3196 80 mg (N=3)	Change from Baseline: DB MGL-3196 100 mg (N=8)	Change from Baseline: DB Placebo (N=14)
Activity						
Baseline						
m	3	8	14			
n	3	8	12			
Mean (SD)	6.67 (0.42)	5.70 (0.76)	5.50 (1.07)			
Median	6.80	5.90	5.60			
IQR: Q1, Q3	6.20, 7.00	5.30, 6.20	5.10, 6.20			
Min, Max	6.2, 7.0	4.2, 6.6	3.2, 7.0			
Week 24						
m	3	7	14			
n	2	7	13	2	7	12
Mean (SD/SE)	6.30 (0.71)	5.11 (0.82)	5.45 (1.58)	-0.30 (0.10)	-0.54 (0.41)	-0.12 (0.22)
Median	6.30	5.20	5.80	-0.30	0	0.20
IQR: Q1, Q3	5.80, 6.80	4.40, 5.60	5.40, 6.20	-0.40, -0.20	-1.60, 0.20	-0.60, 0.30
Min, Max	5.8, 6.8	4.4, 6.6	1.8, 7.0	-0.4, -0.2	-2.0, 0.8	-1.4, 0.8
Week 52						
m	3	7	14			
n	3	6	13	3	6	12
Mean (SD/SE)	6.13 (0.76)	5.30 (0.72)	5.72 (1.23)	-0.53 (0.29)	-0.43 (0.41)	0.12 (0.25)
Median	5.80	5.00	5.60	-0.60	-0.20	0
IQR: Q1, Q3	5.60, 7.00	4.80, 6.00	4.60, 7.00	-1.00, 0.00	-1.20, 0.20	-0.50, 0.40
Min, Max	5.6, 7.0	4.6, 6.4	3.6, 7.0	-1.0, 0.0	-2.0, 0.8	-1.0, 2.0

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.4.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=8)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=8)	Change from Baseline DB Placebo (N=14)
Emotional Health						
Baseline						
m	3	8	14			
n	3	8	12			
Mean (SD)	6.57 (0.32)	6.00 (0.71)	5.91 (1.03)			
Median	6.70	6.05	6.30			
IQR: Q1, Q3	6.20, 6.80	5.55, 6.50	5.05, 6.80			
Min, Max	6.2, 6.8	4.9, 6.9	4.1, 7.0			
Week 24						
m	3	7	14			
n	2	7	13	2	7	12
Mean (SD/SE)	6.80 (0.00)	6.13 (0.57)	5.65 (1.14)	0.05 (0.05)	0.26 (0.22)	-0.16 (0.13)
Median	6.80	6.20	6.10	0.05	0.30	-0.10
IQR: Q1, Q3	6.80, 6.80	5.60, 6.80	4.70, 6.70	0.00, 0.10	-0.40, 0.80	-0.55, 0.20
Min, Max	6.8, 6.8	5.4, 6.9	3.7, 7.0	0.0, 0.1	-0.6, 0.9	-0.9, 0.6
Week 52						
m	3	7	14			
n	3	6	13	3	6	12
Mean (SD/SE)	6.17 (0.74)	5.92 (0.52)	5.99 (1.25)	-0.40 (0.36)	-0.08 (0.38)	0.05 (0.15)
Median	5.90	5.95	6.80	-0.60	0.15	0
IQR: Q1, Q3	5.60, 7.00	5.80, 6.40	4.70, 6.90	-0.90, 0.30	-0.30, 0.40	-0.25, 0.30
Min, Max	5.6, 7.0	5.0, 6.4	3.4, 7.0	-0.9, 0.3	-1.8, 0.9	-0.7, 1.3

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.4.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=8)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=8)	Change from Baseline DB Placebo (N=14)
Fatigue						
Baseline						
m	3	8	14			
n	3	8	12			
Mean (SD)	5.73 (0.45)	5.25 (1.07)	5.25 (1.53)			
Median	5.70	5.15	5.75			
IQR: Q1, Q3	5.30, 6.20	4.60, 6.15	4.00, 6.40			
Min, Max	5.3, 6.2	3.5, 6.7	2.7, 7.0			
Week 24						
m	3	7	14			
n	2	7	13	2	7	12
Mean (SD/SE)	5.65 (0.21)	4.96 (1.21)	5.05 (1.47)	-0.30 (0.40)	-0.09 (0.33)	-0.04 (0.26)
Median	5.65	4.70	4.50	-0.30	0.20	-0.10
IQR: Q1, Q3	5.50, 5.80	3.80, 6.20	4.00, 6.70	-0.70, 0.10	0.00, 0.40	-0.70, 0.60
Min, Max	5.5, 5.8	3.5, 6.8	2.8, 6.8	-0.7, 0.1	-2.0, 0.5	-1.5, 1.5
Week 52						
m	3	7	14			
n	3	6	13	3	6	12
Mean (SD/SE)	5.93 (0.93)	5.20 (0.74)	5.42 (1.40)	0.20 (0.35)	0.12 (0.44)	0.23 (0.26)
Median	5.50	5.40	6.20	0.20	-0.25	0.35
IQR: Q1, Q3	5.30, 7.00	4.30, 5.80	4.20, 6.30	-0.40, 0.80	-0.40, 1.00	-0.60, 1.10
Min, Max	5.3, 7.0	4.3, 6.0	2.8, 7.0	-0.4, 0.8	-1.2, 1.8	-1.3, 1.3

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.4.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=8)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=8)	Change from Baseline DB Placebo (N=14)
Systemic Symptoms						
Baseline						
m	3	8	14			
n	3	8	12			
Mean (SD)	6.37 (0.60)	5.71 (1.05)	5.81 (1.04)			
Median	6.30	5.95	5.85			
IQR: Q1, Q3	5.80, 7.00	5.15, 6.50	5.25, 6.70			
Min, Max	5.8, 7.0	3.7, 6.8	3.8, 7.0			
Week 24						
m	3	7	14			
n	2	7	13	2	7	12
Mean (SD/SE)	6.75 (0.07)	5.79 (0.74)	5.65 (0.94)	0.10 (0.40)	0.23 (0.28)	-0.04 (0.17)
Median	6.75	6.00	5.70	0.10	0.10	0
IQR: Q1, Q3	6.70, 6.80	5.20, 6.20	4.70, 6.30	-0.30, 0.50	-0.30, 0.60	-0.35, 0.25
Min, Max	6.7, 6.8	4.5, 6.8	4.3, 7.0	-0.3, 0.5	-0.8, 1.5	-1.3, 0.9
Week 52						
m	3	7	14			
n	3	6	13	3	6	12
Mean (SD/SE)	6.53 (0.40)	5.47 (0.60)	5.78 (1.14)	0.17 (0.17)	-0.22 (0.38)	0.01 (0.21)
Median	6.30	5.50	5.80	0	-0.55	0
IQR: Q1, Q3	6.30, 7.00	4.80, 6.00	4.80, 6.80	0.00, 0.50	-0.70, -0.20	-0.35, 0.35
Min, Max	6.3, 7.0	4.8, 6.2	3.5, 7.0	0.0, 0.5	-0.9, 1.6	-1.2, 1.5

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.4.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=8)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=8)	Change from Baseline DB Placebo (N=14)
Worry						
Baseline						
m	3	8	14			
n	3	8	12			
Mean (SD)	6.60 (0.61)	6.44 (0.65)	6.56 (0.62)			
Median	6.90	6.70	6.90			
IQR: Q1, Q3	5.90, 7.00	6.10, 6.90	6.20, 7.00			
Min, Max	5.9, 7.0	5.1, 7.0	5.4, 7.0			
Week 24						
m	3	7	14			
n	2	7	13	2	7	12
Mean (SD/SE)	7.00 (0.00)	6.54 (0.72)	6.62 (0.69)	0.05 (0.05)	0.03 (0.17)	0.12 (0.12)
Median	7.00	6.90	6.90	0.05	0.10	0.05
IQR: Q1, Q3	7.00, 7.00	5.60, 7.00	6.70, 7.00	0.00, 0.10	0.00, 0.30	0.00, 0.25
Min, Max	7.0, 7.0	5.4, 7.0	4.6, 7.0	0.0, 0.1	-0.9, 0.5	-0.8, 0.9
Week 52						
m	3	7	14			
n	3	6	13	3	6	12
Mean (SD/SE)	6.73 (0.38)	6.58 (0.39)	6.78 (0.39)	0.13 (0.13)	-0.17 (0.14)	0.23 (0.14)
Median	6.90	6.70	7.00	0	-0.10	0
IQR: Q1, Q3	6.30, 7.00	6.10, 6.90	6.70, 7.00	0.00, 0.40	-0.20, 0.00	0.00, 0.40
Min, Max	6.3, 7.0	6.1, 7.0	5.9, 7.0	0.0, 0.4	-0.8, 0.2	-0.2, 1.6

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.4.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=7)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=7)	Change from Baseline DB Placebo (N=14)
CLDQ-NASH						
Baseline						
m	6	7	14			
n	6	6	13			
Mean (SD)	4.83 (1.65)	5.90 (0.87)	5.70 (0.67)			
Median	4.85	6.00	5.60			
IQR: Q1, Q3	4.00, 6.50	5.80, 6.50	5.20, 6.20			
Min, Max	2.2, 6.6	4.3, 6.8	4.8, 6.7			
Week 24						
m	5	5	13			
n	5	4	12	5	4	12
Mean (SD/SE)	5.28 (1.06)	5.80 (0.81)	5.61 (1.00)	0.42 (0.35)	-0.53 (0.53)	-0.12 (0.26)
Median	5.20	5.90	5.75	0.20	-0.25	-0.05
IQR: Q1, Q3	4.80, 6.30	5.15, 6.45	4.80, 6.55	-0.20, 0.80	-1.30, 0.25	-0.35, 0.15
Min, Max	3.8, 6.3	4.8, 6.6	3.8, 6.9	-0.3, 1.6	-2.0, 0.4	-2.2, 1.9
Week 52						
m	5	5	12			
n	4	4	11	4	4	11
Mean (SD/SE)	5.28 (1.85)	5.48 (0.71)	5.60 (1.04)	0.20 (0.15)	-0.85 (0.49)	-0.17 (0.32)
Median	5.95	5.60	5.80	0.20	-0.40	0
IQR: Q1, Q3	4.05, 6.50	5.05, 5.90	5.30, 6.10	-0.05, 0.45	-1.40, -0.30	-0.30, 0.40
Min, Max	2.6, 6.6	4.5, 6.2	3.1, 6.9	-0.1, 0.5	-2.3, -0.3	-3.1, 0.9

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.4.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=7)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=7)	Change from Baseline DB Placebo (N=14)
Abdominal Symptoms						
Baseline						
m	6	7	14			
n	6	6	13			
Mean (SD)	5.12 (2.29)	6.07 (0.89)	5.66 (1.25)			
Median	5.85	6.35	6.00			
IQR: Q1, Q3	4.30, 6.70	5.00, 6.70	5.00, 7.00			
Min, Max	1.0, 7.0	5.0, 7.0	3.3, 7.0			
Week 24						
m	5	5	13			
n	5	4	12	5	4	12
Mean (SD/SE)	5.06 (1.75)	6.25 (0.88)	5.64 (1.29)	0.32 (0.40)	-0.35 (0.54)	0.09 (0.33)
Median	5.70	6.35	5.80	0.30	-0.50	0
IQR: Q1, Q3	5.30, 6.00	5.50, 7.00	4.50, 6.85	-0.40, 1.00	-1.20, 0.50	-0.30, 0.85
Min, Max	2.0, 6.3	5.3, 7.0	3.7, 7.0	-0.7, 1.4	-1.4, 1.0	-2.3, 2.0
Week 52						
m	5	5	12			
n	4	4	11	4	4	11
Mean (SD/SE)	4.83 (2.57)	6.00 (0.85)	5.34 (1.54)	-0.03 (0.26)	-0.60 (0.46)	-0.38 (0.49)
Median	6.00	6.00	5.70	-0.20	-0.50	0
IQR: Q1, Q3	3.35, 6.30	5.35, 6.65	4.70, 6.70	-0.40, 0.35	-1.35, 0.15	-0.30, 0.40
Min, Max	1.0, 6.3	5.0, 7.0	2.0, 7.0	-0.4, 0.7	-1.7, 0.3	-5.0, 1.0

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.4.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=7)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=7)	Change from Baseline DB Placebo (N=14)
Activity						
Baseline						
m	6	7	14			
n	6	6	13			
Mean (SD)	4.80 (1.85)	5.93 (1.36)	5.95 (0.92)			
Median	5.00	6.30	6.20			
IQR: Q1, Q3	3.40, 6.60	5.40, 7.00	5.60, 6.60			
Min, Max	2.0, 6.8	3.6, 7.0	4.2, 7.0			
Week 24						
m	5	5	13			
n	5	4	12	5	4	12
Mean (SD/SE)	5.40 (0.75)	6.05 (1.15)	5.57 (1.35)	0.68 (0.63)	-0.55 (0.73)	-0.35 (0.44)
Median	5.00	6.40	5.70	0.20	-0.20	-0.30
IQR: Q1, Q3	4.80, 6.00	5.30, 6.80	4.60, 6.80	-0.40, 1.40	-1.50, 0.40	-1.00, 0.50
Min, Max	4.8, 6.4	4.4, 7.0	2.8, 7.0	-0.6, 2.8	-2.6, 0.8	-3.8, 2.6
Week 52						
m	5	5	12			
n	4	4	11	4	4	11
Mean (SD/SE)	5.55 (1.52)	5.30 (1.10)	6.09 (1.13)	0.50 (0.37)	-1.30 (0.41)	0.16 (0.37)
Median	6.00	5.20	6.40	0.40	-1.20	0
IQR: Q1, Q3	4.50, 6.60	4.40, 6.20	5.40, 7.00	-0.10, 1.10	-1.80, -0.80	-0.20, 0.40
Min, Max	3.4, 6.8	4.2, 6.6	3.4, 7.0	-0.2, 1.4	-2.4, -0.4	-2.6, 2.2

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.4.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result: DB MGL-3196 80 mg (N=6)	Visit Result: DB MGL-3196 100 mg (N=7)	Visit Result: DB Placebo (N=14)	Change from Baseline: DB MGL-3196 80 mg (N=6)	Change from Baseline: DB MGL-3196 100 mg (N=7)	Change from Baseline: DB Placebo (N=14)
Emotional Health						
Baseline						
m	6	7	14			
n	6	6	13			
Mean (SD)	5.35 (1.45)	5.77 (1.11)	5.93 (0.62)			
Median	5.30	6.10	5.80			
IQR: Q1, Q3	4.30, 6.90	5.20, 6.60	5.70, 6.20			
Min, Max	3.3, 7.0	3.8, 6.8	4.7, 6.9			
Week 24						
m	5	5	13			
n	5	4	12	5	4	12
Mean (SD/SE)	5.84 (1.10)	5.08 (1.06)	6.10 (0.85)	0.28 (0.39)	-0.93 (0.62)	0.15 (0.19)
Median	6.30	4.70	6.25	-0.10	-0.90	0.30
IQR: Q1, Q3	5.10, 6.60	4.35, 5.80	5.80, 6.75	-0.30, 1.00	-1.95, 0.10	-0.10, 0.45
Min, Max	4.3, 6.9	4.3, 6.6	4.1, 7.0	-0.6, 1.4	-2.3, 0.4	-1.5, 1.2
Week 52						
m	5	5	12			
n	4	4	11	4	4	11
Mean (SD/SE)	5.55 (1.73)	5.35 (0.53)	5.80 (1.07)	-0.10 (0.04)	-0.65 (0.44)	-0.15 (0.27)
Median	6.05	5.35	6.00	-0.10	-0.40	0
IQR: Q1, Q3	4.25, 6.85	5.00, 5.70	5.80, 6.40	-0.15, -0.05	-1.25, -0.05	-0.40, 0.20
Min, Max	3.2, 6.9	4.7, 6.0	3.3, 6.9	-0.2, 0.0	-1.9, 0.1	-2.5, 1.1

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.4.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result: DB MGL-3196 80 mg (N=6)	Visit Result: DB MGL-3196 100 mg (N=7)	Visit Result: DB Placebo (N=14)	Change from Baseline: DB MGL-3196 80 mg (N=6)	Change from Baseline: DB MGL-3196 100 mg (N=7)	Change from Baseline: DB Placebo (N=14)
Fatigue						
Baseline						
m	6	7	14			
n	6	6	13			
Mean (SD)	4.02 (2.11)	5.50 (1.16)	4.92 (1.50)			
Median	4.75	5.50	5.30			
IQR: Q1, Q3	1.80, 5.80	4.50, 6.50	4.20, 5.80			
Min, Max	1.0, 6.0	4.0, 7.0	1.5, 7.0			
Week 24						
m	5	5	13			
n	5	4	12	5	4	12
Mean (SD/SE)	4.08 (1.99)	4.98 (0.91)	5.01 (1.44)	0.26 (0.36)	-0.53 (0.62)	-0.19 (0.43)
Median	4.30	4.65	5.35	0	-0.20	-0.10
IQR: Q1, Q3	3.50, 5.80	4.40, 5.55	4.25, 6.00	-0.20, 0.00	-1.45, 0.40	-0.55, 0.15
Min, Max	1.0, 5.8	4.3, 6.3	2.2, 6.8	-0.2, 1.7	-2.2, 0.5	-3.3, 3.0
Week 52						
m	5	5	12			
n	4	4	11	4	4	11
Mean (SD/SE)	4.80 (1.59)	4.75 (0.76)	4.84 (1.22)	0.28 (0.27)	-0.75 (0.70)	-0.43 (0.38)
Median	5.10	4.75	4.80	0.25	-0.75	-0.40
IQR: Q1, Q3	3.60, 6.00	4.10, 5.40	3.80, 5.70	-0.15, 0.70	-1.90, 0.40	-1.50, 0.30
Min, Max	2.7, 6.3	4.0, 5.5	2.8, 7.0	-0.3, 0.9	-2.3, 0.8	-2.9, 1.7

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.4.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=7)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=7)	Change from Baseline DB Placebo (N=14)
Systemic Symptoms						
Baseline						
m	6	7	14			
n	6	6	13			
Mean (SD)	5.12 (1.22)	5.62 (1.62)	5.51 (0.66)			
Median	4.55	6.00	5.50			
IQR: Q1, Q3	4.30, 6.50	5.00, 7.00	5.20, 5.80			
Min, Max	4.0, 6.8	2.7, 7.0	3.8, 6.5			
Week 24						
m	5	5	13			
n	5	4	12	5	4	12
Mean (SD/SE)	5.32 (1.09)	6.08 (0.81)	5.28 (1.36)	0.04 (0.20)	-0.43 (0.51)	-0.23 (0.31)
Median	5.30	6.00	5.50	0	-0.50	-0.20
IQR: Q1, Q3	4.50, 6.30	5.40, 6.75	3.90, 6.70	-0.30, 0.50	-1.25, 0.40	-0.85, 0.35
Min, Max	4.0, 6.5	5.3, 7.0	3.2, 6.8	-0.5, 0.5	-1.5, 0.8	-2.1, 1.6
Week 52						
m	5	5	12			
n	4	4	11	4	4	11
Mean (SD/SE)	5.30 (1.44)	5.48 (1.16)	5.44 (1.06)	-0.23 (0.23)	-1.03 (0.64)	-0.10 (0.31)
Median	5.70	5.35	5.50	-0.30	-0.65	-0.10
IQR: Q1, Q3	4.25, 6.35	4.70, 6.25	4.70, 6.30	-0.50, 0.05	-1.95, -0.10	-0.50, 0.50
Min, Max	3.3, 6.5	4.2, 7.0	3.2, 6.8	-0.7, 0.4	-2.8, 0.0	-2.6, 1.1

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.4.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=7)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=7)	Change from Baseline DB Placebo (N=14)
Worry						
Baseline						
m	6	7	14			
n	6	6	13			
Mean (SD)	4.72 (2.36)	6.43 (0.67)	6.28 (0.80)			
Median	5.80	6.65	6.30			
IQR: Q1, Q3	2.60, 6.10	5.90, 7.00	6.10, 7.00			
Min, Max	1.0, 7.0	5.4, 7.0	4.1, 7.0			
Week 24						
m	5	5	13			
n	5	4	12	5	4	12
Mean (SD/SE)	6.00 (1.41)	6.23 (1.00)	6.06 (1.19)	0.86 (0.47)	-0.48 (0.54)	-0.24 (0.30)
Median	6.40	6.50	6.85	0.30	0.05	0
IQR: Q1, Q3	6.00, 7.00	5.45, 7.00	5.10, 7.00	0.30, 1.10	-1.05, 0.10	-1.25, 0.35
Min, Max	3.6, 7.0	4.9, 7.0	3.7, 7.0	0.0, 2.6	-2.1, 0.1	-1.9, 1.3
Week 52						
m	5	5	12			
n	4	4	11	4	4	11
Mean (SD/SE)	5.48 (2.52)	5.85 (1.37)	6.17 (0.94)	0.53 (0.19)	-0.85 (0.65)	-0.13 (0.31)
Median	6.60	6.05	6.30	0.60	-0.40	0
IQR: Q1, Q3	4.15, 6.80	4.70, 7.00	5.60, 7.00	0.25, 0.80	-1.75, 0.05	-0.10, 0.00
Min, Max	1.7, 7.0	4.3, 7.0	4.1, 7.0	0.0, 0.9	-2.7, 0.1	-2.9, 1.1

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.4.2
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of CLDQ-NASH - MMRM Model
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

AMNOG Table SE18.4.2
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of CLDQ-NASH - MMRM Model
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
CLDQ-NASH			
Week 24			
m	3	7	14
n	2	7	12
Baseline Mean (SD)	6.65 (0.21)	5.83 (0.54)	5.84 (0.93)
Analysis Visit Mean (SD)	6.55 (0.07)	5.76 (0.56)	5.78 (1.05)
LS Mean of Change from Baseline (SE)	-0.19 (0.36)	-0.10 (0.19)	-0.15 (0.18)
95% CI	(-0.94, 0.56)	(-0.49, 0.30)	(-0.52, 0.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.04 (0.35)	0.05 (0.21)	
95% CI	(-0.78, 0.70)	(-0.39, 0.50)	
p-value	0.9088	0.8097	
Corrected Hedge's g Statistics	-0.063	0.086	
95% CI	(-1.56, 1.43)	(-0.85, 1.02)	
Week 52			
m	3	7	14
n	3	6	12
Baseline Mean (SD)	6.47 (0.35)	5.95 (0.48)	5.84 (0.93)
Analysis Visit Mean (SD)	6.37 (0.57)	5.70 (0.44)	5.98 (1.05)
LS Mean of Change from Baseline (SE)	-0.18 (0.33)	-0.29 (0.22)	0.04 (0.19)
95% CI	(-0.87, 0.51)	(-0.74, 0.17)	(-0.35, 0.43)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.22 (0.32)	-0.33 (0.24)	
95% CI	(-0.91, 0.46)	(-0.84, 0.18)	
p-value	0.4976	0.1893	
Corrected Hedge's g Statistics	-0.335	-0.518	
95% CI	(-1.61, 0.94)	(-1.51, 0.48)	
Subgroup*Treatment Interaction p-value	0.6211	0.6562	

AMNOG Table SE18.4.2
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of CLDQ-NASH - MMRM Model
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
CLDQ-NASH			
Week 24			
m	5	5	13
n	5	4	12
Baseline Mean (SD)	4.86 (1.84)	6.33 (0.40)	5.73 (0.69)
Analysis Visit Mean (SD)	5.28 (1.06)	5.80 (0.81)	5.61 (1.00)
LS Mean of Change from Baseline (SE)	0.22 (0.45)	-0.12 (0.64)	0.12 (0.50)
95% CI	(-0.74, 1.18)	(-1.47, 1.23)	(-0.94, 1.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.09 (0.52)	-0.24 (0.50)	
95% CI	(-1.01, 1.20)	(-1.29, 0.81)	
p-value	0.8625	0.6310	
Corrected Hedge's g Statistics	0.055	-0.139	
95% CI	(-0.99, 1.10)	(-1.27, 0.99)	
Week 52			
m	5	5	12
n	4	4	11
Baseline Mean (SD)	5.08 (2.05)	6.33 (0.40)	5.77 (0.70)
Analysis Visit Mean (SD)	5.28 (1.85)	5.48 (0.71)	5.60 (1.04)
LS Mean of Change from Baseline (SE)	0.23 (0.51)	-0.55 (0.67)	0.07 (0.52)
95% CI	(-0.85, 1.30)	(-1.95, 0.86)	(-1.03, 1.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.16 (0.60)	-0.62 (0.54)	
95% CI	(-1.11, 1.42)	(-1.77, 0.53)	
p-value	0.7980	0.2707	
Corrected Hedge's g Statistics	0.092	-0.353	
95% CI	(-1.05, 1.24)	(-1.50, 0.80)	
Subgroup*Treatment Interaction p-value	0.6211	0.6562	

AMNOG Table SE18.4.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

AMNOG Table SE18.4.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Abdominal Symptoms			
Week 24			
m	3	7	14
n	2	7	12
Baseline Mean (SD)	7.00 (0.00)	6.30 (0.76)	6.06 (1.27)
Analysis Visit Mean (SD)	7.00 (0.00)	5.96 (0.92)	5.87 (1.43)
LS Mean of Change from Baseline (SE)	0.42 (0.67)	-0.15 (0.36)	0.01 (0.31)
95% CI	(-1.00, 1.83)	(-0.91, 0.61)	(-0.65, 0.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.41 (0.70)	-0.16 (0.43)	
95% CI	(-1.06, 1.88)	(-1.05, 0.74)	
p-value	0.5633	0.7182	
Corrected Hedge's g Statistics	0.358	-0.143	
95% CI	(-1.14, 1.86)	(-1.08, 0.79)	
Week 52			
m	3	7	14
n	3	6	12
Baseline Mean (SD)	6.77 (0.40)	6.40 (0.78)	6.06 (1.27)
Analysis Visit Mean (SD)	6.67 (0.58)	5.85 (0.47)	6.11 (1.34)
LS Mean of Change from Baseline (SE)	0.27 (0.43)	-0.35 (0.29)	0.25 (0.26)
95% CI	(-0.63, 1.17)	(-0.96, 0.26)	(-0.28, 0.79)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.02 (0.42)	-0.60 (0.32)	
95% CI	(-0.86, 0.89)	(-1.27, 0.07)	
p-value	0.9671	0.0767	
Corrected Hedge's g Statistics	0.019	-0.684	
95% CI	(-1.25, 1.28)	(-1.69, 0.32)	
Subgroup*Treatment Interaction p-value	0.7693	0.6445	

AMNOG Table SE18.4.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Activity			
Week 24			
m	3	7	14
n	2	7	12
Baseline Mean (SD)	6.60 (0.57)	5.66 (0.81)	5.50 (1.07)
Analysis Visit Mean (SD)	6.30 (0.71)	5.11 (0.82)	5.38 (1.63)
LS Mean of Change from Baseline (SE)	-0.76 (0.79)	-0.66 (0.42)	-0.29 (0.40)
95% CI	(-2.43, 0.90)	(-1.53, 0.21)	(-1.12, 0.54)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.47 (0.74)	-0.37 (0.45)	
95% CI	(-2.04, 1.09)	(-1.32, 0.58)	
p-value	0.5345	0.4289	
Corrected Hedge's g Statistics	-0.326	-0.273	
95% CI	(-1.83, 1.18)	(-1.21, 0.66)	
Week 52			
m	3	7	14
n	3	6	12
Baseline Mean (SD)	6.67 (0.42)	5.73 (0.86)	5.50 (1.07)
Analysis Visit Mean (SD)	6.13 (0.76)	5.30 (0.72)	5.62 (1.23)
LS Mean of Change from Baseline (SE)	-0.53 (0.71)	-0.51 (0.42)	-0.14 (0.39)
95% CI	(-2.02, 0.96)	(-1.38, 0.36)	(-0.95, 0.67)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.40 (0.64)	-0.37 (0.44)	
95% CI	(-1.73, 0.94)	(-1.30, 0.56)	
p-value	0.5420	0.4132	
Corrected Hedge's g Statistics	-0.282	-0.283	
95% CI	(-1.55, 0.99)	(-1.27, 0.70)	
Subgroup*Treatment Interaction p-value	0.6136	0.6904	

AMNOG Table SE18.4.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Emotional Health			
Week 24			
m	3	7	14
n	2	7	12
Baseline Mean (SD)	6.75 (0.07)	5.87 (0.66)	5.91 (1.03)
Analysis Visit Mean (SD)	6.80 (0.00)	6.13 (0.57)	5.75 (1.13)
LS Mean of Change from Baseline (SE)	0.16 (0.43)	0.28 (0.24)	-0.11 (0.23)
95% CI	(-0.75, 1.06)	(-0.22, 0.78)	(-0.60, 0.37)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.27 (0.42)	0.40 (0.26)	
95% CI	(-0.60, 1.15)	(-0.15, 0.94)	
p-value	0.5211	0.1414	
Corrected Hedge's g Statistics	0.327	0.513	
95% CI	(-1.18, 1.83)	(-0.43, 1.46)	
Week 52			
m	3	7	14
n	3	6	12
Baseline Mean (SD)	6.57 (0.32)	6.00 (0.62)	5.91 (1.03)
Analysis Visit Mean (SD)	6.17 (0.74)	5.92 (0.52)	5.96 (1.30)
LS Mean of Change from Baseline (SE)	-0.32 (0.47)	-0.05 (0.32)	0.10 (0.27)
95% CI	(-1.31, 0.68)	(-0.71, 0.62)	(-0.46, 0.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.42 (0.48)	-0.15 (0.36)	
95% CI	(-1.42, 0.59)	(-0.90, 0.61)	
p-value	0.3926	0.6879	
Corrected Hedge's g Statistics	-0.432	-0.158	
95% CI	(-1.71, 0.84)	(-1.14, 0.82)	
Subgroup*Treatment Interaction p-value	0.9361	0.0180	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE18.4.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Fatigue			
Week 24			
m	3	7	14
n	2	7	12
Baseline Mean (SD)	5.95 (0.35)	5.04 (0.96)	5.25 (1.53)
Analysis Visit Mean (SD)	5.65 (0.21)	4.96 (1.21)	5.21 (1.42)
LS Mean of Change from Baseline (SE)	-0.34 (0.69)	-0.06 (0.38)	-0.21 (0.35)
95% CI	(-1.78, 1.11)	(-0.86, 0.74)	(-0.94, 0.52)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.13 (0.69)	0.15 (0.44)	
95% CI	(-1.57, 1.31)	(-0.78, 1.07)	
p-value	0.8558	0.7401	
Corrected Hedge's g Statistics	-0.100	0.125	
95% CI	(-1.60, 1.40)	(-0.81, 1.06)	
Week 52			
m	3	7	14
n	3	6	12
Baseline Mean (SD)	5.73 (0.45)	5.08 (1.05)	5.25 (1.53)
Analysis Visit Mean (SD)	5.93 (0.93)	5.20 (0.74)	5.48 (1.45)
LS Mean of Change from Baseline (SE)	0.12 (0.49)	0.10 (0.33)	0.06 (0.30)
95% CI	(-0.91, 1.15)	(-0.58, 0.79)	(-0.58, 0.69)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.06 (0.45)	0.05 (0.36)	
95% CI	(-0.89, 1.01)	(-0.70, 0.79)	
p-value	0.8927	0.8995	
Corrected Hedge's g Statistics	0.057	0.044	
95% CI	(-1.21, 1.32)	(-0.94, 1.02)	
Subgroup*Treatment Interaction p-value	0.7869	0.9812	

AMNOG Table SE18.4.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Systemic Symptoms			
Week 24			
m	3	7	14
n	2	7	12
Baseline Mean (SD)	6.65 (0.49)	5.56 (1.03)	5.81 (1.04)
Analysis Visit Mean (SD)	6.75 (0.07)	5.79 (0.74)	5.77 (0.88)
LS Mean of Change from Baseline (SE)	0.22 (0.45)	0.07 (0.24)	-0.23 (0.25)
95% CI	(-0.73, 1.17)	(-0.43, 0.56)	(-0.75, 0.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.45 (0.40)	0.30 (0.26)	
95% CI	(-0.39, 1.30)	(-0.25, 0.84)	
p-value	0.2752	0.2701	
Corrected Hedge's g Statistics	0.504	0.362	
95% CI	(-1.00, 2.01)	(-0.58, 1.30)	
Week 52			
m	3	7	14
n	3	6	12
Baseline Mean (SD)	6.37 (0.60)	5.68 (1.07)	5.81 (1.04)
Analysis Visit Mean (SD)	6.53 (0.40)	5.47 (0.60)	5.82 (1.18)
LS Mean of Change from Baseline (SE)	0.07 (0.50)	-0.40 (0.32)	-0.18 (0.28)
95% CI	(-0.97, 1.11)	(-1.07, 0.26)	(-0.78, 0.42)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.25 (0.47)	-0.22 (0.36)	
95% CI	(-0.74, 1.24)	(-0.98, 0.53)	
p-value	0.6013	0.5429	
Corrected Hedge's g Statistics	0.244	-0.231	
95% CI	(-1.02, 1.51)	(-1.21, 0.75)	
Subgroup*Treatment Interaction p-value	0.7002	0.7716	

AMNOG Table SE18.4.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Worry			
Week 24			
m	3	7	14
n	2	7	12
Baseline Mean (SD)	6.95 (0.07)	6.51 (0.66)	6.56 (0.62)
Analysis Visit Mean (SD)	7.00 (0.00)	6.54 (0.72)	6.68 (0.69)
LS Mean of Change from Baseline (SE)	-0.06 (0.31)	-0.08 (0.17)	0.02 (0.16)
95% CI	(-0.70, 0.59)	(-0.44, 0.29)	(-0.31, 0.36)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.08 (0.31)	-0.10 (0.19)	
95% CI	(-0.72, 0.56)	(-0.51, 0.31)	
p-value	0.7937	0.6214	
Corrected Hedge's g Statistics	-0.140	-0.180	
95% CI	(-1.64, 1.36)	(-1.11, 0.75)	
Week 52			
m	3	7	14
n	3	6	12
Baseline Mean (SD)	6.60 (0.61)	6.75 (0.25)	6.56 (0.62)
Analysis Visit Mean (SD)	6.73 (0.38)	6.58 (0.39)	6.79 (0.40)
LS Mean of Change from Baseline (SE)	0.02 (0.24)	-0.15 (0.16)	0.12 (0.15)
95% CI	(-0.47, 0.52)	(-0.49, 0.19)	(-0.19, 0.43)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.10 (0.22)	-0.27 (0.18)	
95% CI	(-0.56, 0.37)	(-0.64, 0.10)	
p-value	0.6721	0.1479	
Corrected Hedge's g Statistics	-0.182	-0.531	
95% CI	(-1.45, 1.09)	(-1.53, 0.46)	
Subgroup*Treatment Interaction p-value	0.3562	0.8127	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE18.4.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Abdominal Symptoms			
Week 24			
m	5	5	13
n	5	4	12
Baseline Mean (SD)	4.74 (2.34)	6.60 (0.42)	5.55 (1.24)
Analysis Visit Mean (SD)	5.06 (1.75)	6.25 (0.88)	5.64 (1.29)
LS Mean of Change from Baseline (SE)	0.19 (0.52)	0.11 (0.74)	0.34 (0.58)
95% CI	(-0.91, 1.30)	(-1.45, 1.67)	(-0.89, 1.56)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.14 (0.57)	-0.22 (0.58)	
95% CI	(-1.35, 1.07)	(-1.45, 1.00)	
p-value	0.8078	0.7033	
Corrected Hedge's g Statistics	-0.074	-0.111	
95% CI	(-1.12, 0.97)	(-1.24, 1.02)	
Week 52			
m	5	5	12
n	4	4	11
Baseline Mean (SD)	4.85 (2.69)	6.60 (0.42)	5.72 (1.15)
Analysis Visit Mean (SD)	4.83 (2.57)	6.00 (0.85)	5.34 (1.54)
LS Mean of Change from Baseline (SE)	0.04 (0.72)	-0.18 (0.88)	-0.04 (0.66)
95% CI	(-1.47, 1.56)	(-2.04, 1.68)	(-1.42, 1.34)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.09 (0.83)	-0.14 (0.79)	
95% CI	(-1.67, 1.84)	(-1.81, 1.53)	
p-value	0.9199	0.8612	
Corrected Hedge's g Statistics	0.039	-0.063	
95% CI	(-1.11, 1.18)	(-1.21, 1.08)	
Subgroup*Treatment Interaction p-value	0.7693	0.6445	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE18.4.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Activity			
Week 24			
m	5	5	13
n	5	4	12
Baseline Mean (SD)	4.72 (2.06)	6.60 (0.80)	5.92 (0.96)
Analysis Visit Mean (SD)	5.40 (0.75)	6.05 (1.15)	5.57 (1.35)
LS Mean of Change from Baseline (SE)	0.02 (0.65)	0.07 (0.84)	-0.12 (0.63)
95% CI	(-1.35, 1.38)	(-1.71, 1.85)	(-1.45, 1.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.13 (0.75)	0.19 (0.72)	
95% CI	(-1.45, 1.72)	(-1.33, 1.71)	
p-value	0.8633	0.8003	
Corrected Hedge's g Statistics	0.062	0.083	
95% CI	(-0.98, 1.11)	(-1.05, 1.22)	
Week 52			
m	5	5	12
n	4	4	11
Baseline Mean (SD)	5.05 (2.22)	6.60 (0.80)	5.93 (1.00)
Analysis Visit Mean (SD)	5.55 (1.52)	5.30 (1.10)	6.09 (1.13)
LS Mean of Change from Baseline (SE)	0.36 (0.56)	-0.92 (0.75)	0.38 (0.61)
95% CI	(-0.82, 1.53)	(-2.50, 0.65)	(-0.90, 1.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.02 (0.65)	-1.30 (0.58)	
95% CI	(-1.40, 1.35)	(-2.53, -0.08)	
p-value	0.9721	0.0384	
Corrected Hedge's g Statistics	-0.012	-0.643	
95% CI	(-1.16, 1.13)	(-1.81, 0.52)	
Subgroup*Treatment Interaction p-value	0.6136	0.6904	

AMNOG Table SE18.4.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Emotional Health			
Week 24			
m	5	5	13
n	5	4	12
Baseline Mean (SD)	5.56 (1.51)	6.00 (0.59)	5.95 (0.64)
Analysis Visit Mean (SD)	5.84 (1.10)	5.08 (1.06)	6.10 (0.85)
LS Mean of Change from Baseline (SE)	0.35 (0.40)	-0.64 (0.54)	0.52 (0.45)
95% CI	(-0.48, 1.19)	(-1.77, 0.49)	(-0.43, 1.47)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.16 (0.44)	-1.16 (0.43)	
95% CI	(-1.09, 0.76)	(-2.06, -0.26)	
p-value	0.7134	0.0148	
Corrected Hedge's g Statistics	-0.110	-0.746	
95% CI	(-1.15, 0.93)	(-1.91, 0.42)	
Week 52			
m	5	5	12
n	4	4	11
Baseline Mean (SD)	5.65 (1.73)	6.00 (0.59)	5.95 (0.67)
Analysis Visit Mean (SD)	5.55 (1.73)	5.35 (0.53)	5.80 (1.07)
LS Mean of Change from Baseline (SE)	0.18 (0.45)	-0.39 (0.56)	0.23 (0.47)
95% CI	(-0.76, 1.12)	(-1.57, 0.78)	(-0.75, 1.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.06 (0.51)	-0.63 (0.47)	
95% CI	(-1.13, 1.02)	(-1.61, 0.36)	
p-value	0.9145	0.1962	
Corrected Hedge's g Statistics	-0.037	-0.405	
95% CI	(-1.18, 1.11)	(-1.56, 0.75)	
Subgroup*Treatment Interaction p-value	0.9361	0.0180	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE18.4.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Fatigue			
Week 24			
m	5	5	13
n	5	4	12
Baseline Mean (SD)	3.82 (2.30)	5.50 (1.47)	5.20 (1.14)
Analysis Visit Mean (SD)	4.08 (1.99)	4.98 (0.91)	5.01 (1.44)
LS Mean of Change from Baseline (SE)	0.04 (0.67)	-0.18 (0.85)	0.15 (0.67)
95% CI	(-1.37, 1.46)	(-1.98, 1.62)	(-1.26, 1.57)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.11 (0.77)	-0.33 (0.73)	
95% CI	(-1.74, 1.52)	(-1.86, 1.20)	
p-value	0.8894	0.6530	
Corrected Hedge's g Statistics	-0.049	-0.142	
95% CI	(-1.09, 0.99)	(-1.27, 0.99)	
Week 52			
m	5	5	12
n	4	4	11
Baseline Mean (SD)	4.53 (1.93)	5.50 (1.47)	5.26 (1.17)
Analysis Visit Mean (SD)	4.80 (1.59)	4.75 (0.76)	4.84 (1.22)
LS Mean of Change from Baseline (SE)	0.23 (0.60)	-0.38 (0.78)	-0.07 (0.65)
95% CI	(-1.04, 1.49)	(-2.02, 1.26)	(-1.44, 1.31)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.30 (0.69)	-0.31 (0.61)	
95% CI	(-1.15, 1.75)	(-1.61, 0.98)	
p-value	0.6702	0.6170	
Corrected Hedge's g Statistics	0.142	-0.144	
95% CI	(-1.00, 1.29)	(-1.29, 1.00)	
Subgroup*Treatment Interaction p-value	0.7869	0.9812	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE18.4.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Systemic Symptoms			
Week 24			
m	5	5	13
n	5	4	12
Baseline Mean (SD)	5.28 (1.29)	6.50 (0.63)	5.51 (0.69)
Analysis Visit Mean (SD)	5.32 (1.09)	6.08 (0.81)	5.28 (1.36)
LS Mean of Change from Baseline (SE)	0.03 (0.57)	-0.40 (0.90)	-0.21 (0.65)
95% CI	(-1.17, 1.23)	(-2.29, 1.49)	(-1.59, 1.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.24 (0.61)	-0.19 (0.69)	
95% CI	(-1.05, 1.54)	(-1.63, 1.26)	
p-value	0.6975	0.7879	
Corrected Hedge's g Statistics	0.113	-0.082	
95% CI	(-0.93, 1.16)	(-1.21, 1.05)	
Week 52			
m	5	5	12
n	4	4	11
Baseline Mean (SD)	5.53 (1.35)	6.50 (0.63)	5.54 (0.72)
Analysis Visit Mean (SD)	5.30 (1.44)	5.48 (1.16)	5.44 (1.06)
LS Mean of Change from Baseline (SE)	-0.28 (0.60)	-0.92 (0.90)	-0.17 (0.66)
95% CI	(-1.54, 0.98)	(-2.82, 0.98)	(-1.57, 1.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.10 (0.66)	-0.74 (0.70)	
95% CI	(-1.49, 1.28)	(-2.22, 0.73)	
p-value	0.8770	0.3017	
Corrected Hedge's g Statistics	-0.048	-0.333	
95% CI	(-1.19, 1.10)	(-1.48, 0.82)	
Subgroup*Treatment Interaction p-value	0.7002	0.7716	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE18.4.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Worry			
Week 24			
m	5	5	13
n	5	4	12
Baseline Mean (SD)	5.14 (2.37)	6.70 (0.54)	6.30 (0.83)
Analysis Visit Mean (SD)	6.00 (1.41)	6.23 (1.00)	6.06 (1.19)
LS Mean of Change from Baseline (SE)	0.51 (0.55)	-0.19 (0.72)	-0.08 (0.59)
95% CI	(-0.64, 1.67)	(-1.71, 1.33)	(-1.33, 1.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.60 (0.62)	-0.10 (0.58)	
95% CI	(-0.71, 1.90)	(-1.32, 1.12)	
p-value	0.3470	0.8598	
Corrected Hedge's g Statistics	0.304	-0.051	
95% CI	(-0.74, 1.35)	(-1.18, 1.08)	
Week 52			
m	5	5	12
n	4	4	11
Baseline Mean (SD)	4.95 (2.69)	6.70 (0.54)	6.30 (0.87)
Analysis Visit Mean (SD)	5.48 (2.52)	5.85 (1.37)	6.17 (0.94)
LS Mean of Change from Baseline (SE)	0.40 (0.59)	-0.68 (0.73)	-0.05 (0.61)
95% CI	(-0.86, 1.65)	(-2.22, 0.86)	(-1.33, 1.23)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.45 (0.69)	-0.63 (0.60)	
95% CI	(-1.01, 1.91)	(-1.90, 0.63)	
p-value	0.5266	0.3071	
Corrected Hedge's g Statistics	0.227	-0.313	
95% CI	(-0.92, 1.37)	(-1.46, 0.84)	
Subgroup*Treatment Interaction p-value	0.3562	0.8127	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE18.4.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi-square Test. For this unadjusted analysis, only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.

AMNOG Table SE18.4.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (7.1)
No	3 (100)	8 (100)	13 (92.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	1.89	
95% CI of the inverse odds ratio	(0.03, 23.53)	(0.07, 51.92)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	1.80	
95% CI of the inverse risk ratio	(0.04, 16.14)	(0.08, 39.64)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.50	-4.44	
95% CI of the absolute risk difference	(-33.29, 38.29)	(-25.76, 16.87)	
p-value	0.8849	0.7029	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (12.5)	3 (21.4)
No	3 (100)	7 (87.5)	11 (78.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.13	1.91	
95% CI of the inverse odds ratio	(0.09, 52.04)	(0.16, 22.20)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.87	1.71	
95% CI of the inverse risk ratio	(0.12, 29.21)	(0.21, 13.86)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.83	-8.93	
95% CI of the absolute risk difference	(-49.67, 28.01)	(-40.35, 22.49)	
p-value	0.6368	0.6014	
p-value of Breslow-Day Test for Homogeneity [3]	0.3614	0.2913	

AMNOG Table SE18.4.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (12.5)	1 (7.1)
No	3 (100)	7 (87.5)	13 (92.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	0.54	
95% CI of the inverse odds ratio	(0.03, 23.53)	(0.03, 9.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	0.57	
95% CI of the inverse risk ratio	(0.04, 16.14)	(0.04, 7.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.50	5.36	
95% CI of the absolute risk difference	(-33.29, 38.29)	(-21.24, 31.95)	
p-value	0.8849	0.6742	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.3973	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (12.5)	1 (7.1)
No	3 (100)	7 (87.5)	13 (92.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	0.54	
95% CI of the inverse odds ratio	(0.03, 23.53)	(0.03, 9.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	0.57	
95% CI of the inverse risk ratio	(0.04, 16.14)	(0.04, 7.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.50	5.36	
95% CI of the absolute risk difference	(-33.29, 38.29)	(-21.24, 31.95)	
p-value	0.8849	0.6742	
p-value of Breslow-Day Test for Homogeneity [3]	0.6857	0.1720	

AMNOG Table SE18.4.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (14.3)
No	3 (100)	8 (100)	12 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	3.40	
95% CI of the inverse odds ratio	(0.05, 36.45)	(0.14, 80.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	3.00	
95% CI of the inverse risk ratio	(0.08, 22.57)	(0.16, 55.72)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.17	-11.11	
95% CI of the absolute risk difference	(-41.66, 33.33)	(-35.19, 12.96)	
p-value	0.8391	0.4256	
p-value of Breslow-Day Test for Homogeneity [3]	0.4759	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (12.5)	4 (28.6)
No	3 (100)	7 (87.5)	10 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	2.80	
95% CI of the inverse odds ratio	(0.13, 70.87)	(0.26, 30.70)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.40	2.29	
95% CI of the inverse risk ratio	(0.16, 35.91)	(0.31, 17.09)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-17.50	-16.07	
95% CI of the absolute risk difference	(-57.35, 22.35)	(-49.01, 16.87)	
p-value	0.4800	0.3869	
p-value of Breslow-Day Test for Homogeneity [3]	0.2231	0.4354	

AMNOG Table SE18.4.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (7.1)
No	3 (100)	8 (100)	13 (92.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	1.89	
95% CI of the inverse odds ratio	(0.03, 23.53)	(0.07, 51.92)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	1.80	
95% CI of the inverse risk ratio	(0.04, 16.14)	(0.08, 39.64)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.50	-4.44	
95% CI of the absolute risk difference	(-33.29, 38.29)	(-25.76, 16.87)	
p-value	0.8849	0.7029	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	3 (37.5)	3 (21.4)
No	3 (100)	5 (62.5)	11 (78.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.13	0.45	
95% CI of the inverse odds ratio	(0.09, 52.04)	(0.07, 3.09)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.87	0.57	
95% CI of the inverse risk ratio	(0.12, 29.21)	(0.15, 2.19)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.83	16.07	
95% CI of the absolute risk difference	(-49.67, 28.01)	(-23.77, 55.91)	
p-value	0.6368	0.4155	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.1905	

AMNOG Table SE18.4.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	2 (25.0)	4 (28.6)
No	3 (100)	6 (75.0)	10 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	1.20	
95% CI of the inverse odds ratio	(0.13, 70.87)	(0.17, 8.66)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.40	1.14	
95% CI of the inverse risk ratio	(0.16, 35.91)	(0.27, 4.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-17.50	-3.57	
95% CI of the absolute risk difference	(-57.35, 22.35)	(-41.79, 34.64)	
p-value	0.4800	0.8564	
p-value of Breslow-Day Test for Homogeneity [3]	0.3086	0.3664	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (33.3)	2 (25.0)	6 (42.9)
No	2 (66.7)	6 (75.0)	8 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	2.25	
95% CI of the inverse odds ratio	(0.11, 20.68)	(0.33, 15.33)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	1.71	
95% CI of the inverse risk ratio	(0.23, 7.11)	(0.45, 6.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.52	-17.86	
95% CI of the absolute risk difference	(-68.83, 49.78)	(-57.51, 21.80)	
p-value	0.7610	0.4023	
p-value of Breslow-Day Test for Homogeneity [3]	0.3879	0.6200	

AMNOG Table SE18.4.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (12.5)	1 (7.1)
No	3 (100)	7 (87.5)	13 (92.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	0.54	
95% CI of the inverse odds ratio	(0.03, 23.53)	(0.03, 9.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	0.57	
95% CI of the inverse risk ratio	(0.04, 16.14)	(0.04, 7.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.50	5.36	
95% CI of the absolute risk difference	(-33.29, 38.29)	(-21.24, 31.95)	
p-value	0.8849	0.6742	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.2534	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (33.3)	1 (12.5)	3 (21.4)
No	2 (66.7)	7 (87.5)	11 (78.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.55	1.91	
95% CI of the inverse odds ratio	(0.04, 8.27)	(0.16, 22.20)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.64	1.71	
95% CI of the inverse risk ratio	(0.10, 4.25)	(0.21, 13.86)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.90	-8.93	
95% CI of the absolute risk difference	(-45.61, 69.42)	(-40.35, 22.49)	
p-value	0.6591	0.6014	
p-value of Breslow-Day Test for Homogeneity [3]	0.4788	0.2913	

AMNOG Table SE18.4.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (7.1)
No	3 (100)	8 (100)	13 (92.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	1.89	
95% CI of the inverse odds ratio	(0.03, 23.53)	(0.07, 51.92)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	1.80	
95% CI of the inverse risk ratio	(0.04, 16.14)	(0.08, 39.64)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.50	-4.44	
95% CI of the absolute risk difference	(-33.29, 38.29)	(-25.76, 16.87)	
p-value	0.8849	0.7029	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (33.3)	0	3 (21.4)
No	2 (66.7)	8 (100)	11 (78.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.55	5.17	
95% CI of the inverse odds ratio	(0.04, 8.27)	(0.23, 114.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.64	4.20	
95% CI of the inverse risk ratio	(0.10, 4.25)	(0.24, 72.29)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.90	-17.78	
95% CI of the absolute risk difference	(-45.61, 69.42)	(-43.89, 8.34)	
p-value	0.6591	0.2579	
p-value of Breslow-Day Test for Homogeneity [3]	0.5025	NE	

AMNOG Table SE18.4.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	6 (100)	7 (100)	14 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (33.3)	0	4 (28.6)
No	4 (66.7)	7 (100)	10 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	6.43	
95% CI of the inverse odds ratio	(0.10, 6.25)	(0.30, 138.25)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	4.80	
95% CI of the inverse risk ratio	(0.21, 3.48)	(0.29, 78.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.76	-23.75	
95% CI of the absolute risk difference	(-39.77, 49.29)	(-52.37, 4.87)	
p-value	0.8314	0.1884	
p-value of Breslow-Day Test for Homogeneity [3]	0.3614	0.2913	

AMNOG Table SE18.4.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (7.1)
No	6 (100)	7 (100)	13 (92.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.44	1.67	
95% CI of the inverse odds ratio	(0.05, 40.54)	(0.06, 46.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	1.60	
95% CI of the inverse risk ratio	(0.06, 30.23)	(0.07, 34.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.86	-3.75	
95% CI of the absolute risk difference	(-27.24, 21.52)	(-26.37, 18.87)	
p-value	0.8281	0.7611	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.3973	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (16.7)	0	3 (21.4)
No	5 (83.3)	7 (100)	11 (78.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	4.57	
95% CI of the inverse odds ratio	(0.11, 16.58)	(0.21, 101.61)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	3.73	
95% CI of the inverse risk ratio	(0.17, 10.00)	(0.22, 63.66)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.76	-17.08	
95% CI of the absolute risk difference	(-41.52, 32.00)	(-44.28, 10.11)	
p-value	0.8073	0.3033	
p-value of Breslow-Day Test for Homogeneity [3]	0.6857	0.1720	

AMNOG Table SE18.4.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (16.7)	0	2 (14.3)
No	5 (83.3)	7 (100)	12 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	3.00	
95% CI of the inverse odds ratio	(0.06, 11.42)	(0.13, 71.31)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	2.67	
95% CI of the inverse risk ratio	(0.09, 7.75)	(0.14, 49.08)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.38	-10.42	
95% CI of the absolute risk difference	(-32.62, 37.38)	(-35.66, 14.82)	
p-value	0.8913	0.4799	
p-value of Breslow-Day Test for Homogeneity [3]	0.4759	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (33.3)	0	3 (21.4)
No	4 (66.7)	7 (100)	11 (78.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.55	4.57	
95% CI of the inverse odds ratio	(0.07, 4.56)	(0.21, 101.61)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.64	3.73	
95% CI of the inverse risk ratio	(0.14, 2.92)	(0.22, 63.66)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.90	-17.08	
95% CI of the absolute risk difference	(-31.51, 55.32)	(-44.28, 10.11)	
p-value	0.5731	0.3033	
p-value of Breslow-Day Test for Homogeneity [3]	0.2231	0.4354	

AMNOG Table SE18.4.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (7.1)
No	6 (100)	7 (100)	13 (92.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.44	1.67	
95% CI of the inverse odds ratio	(0.05, 40.54)	(0.06, 46.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	1.60	
95% CI of the inverse risk ratio	(0.06, 30.23)	(0.07, 34.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.86	-3.75	
95% CI of the absolute risk difference	(-27.24, 21.52)	(-26.37, 18.87)	
p-value	0.8281	0.7611	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	2 (14.3)
No	6 (100)	7 (100)	12 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.60	3.00	
95% CI of the inverse odds ratio	(0.11, 62.57)	(0.13, 71.31)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.33	2.67	
95% CI of the inverse risk ratio	(0.13, 42.44)	(0.14, 49.08)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.52	-10.42	
95% CI of the absolute risk difference	(-36.35, 17.30)	(-35.66, 14.82)	
p-value	0.5443	0.4799	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.1905	

AMNOG Table SE18.4.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (16.7)	0	2 (14.3)
No	5 (83.3)	7 (100)	12 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	3.00	
95% CI of the inverse odds ratio	(0.06, 11.42)	(0.13, 71.31)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	2.67	
95% CI of the inverse risk ratio	(0.09, 7.75)	(0.14, 49.08)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.38	-10.42	
95% CI of the absolute risk difference	(-32.62, 37.38)	(-35.66, 14.82)	
p-value	0.8913	0.4799	
p-value of Breslow-Day Test for Homogeneity [3]	0.3086	0.3664	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (33.3)	1 (14.3)	2 (14.3)
No	4 (66.7)	6 (85.7)	12 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	1.00	
95% CI of the inverse odds ratio	(0.03, 3.20)	(0.07, 13.37)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.43	1.00	
95% CI of the inverse risk ratio	(0.08, 2.37)	(0.11, 9.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	19.05	0.00	
95% CI of the absolute risk difference	(-22.89, 60.99)	(-31.75, 31.75)	
p-value	0.3291	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.3879	0.6200	

AMNOG Table SE18.4.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (14.3)
No	6 (100)	7 (100)	12 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.60	3.00	
95% CI of the inverse odds ratio	(0.11, 62.57)	(0.13, 71.31)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.33	2.67	
95% CI of the inverse risk ratio	(0.13, 42.44)	(0.14, 49.08)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.52	-10.42	
95% CI of the absolute risk difference	(-36.35, 17.30)	(-35.66, 14.82)	
p-value	0.5443	0.4799	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.2534	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (16.7)	0	4 (28.6)
No	5 (83.3)	7 (100)	10 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	6.43	
95% CI of the inverse odds ratio	(0.17, 22.95)	(0.30, 138.25)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.71	4.80	
95% CI of the inverse risk ratio	(0.24, 12.31)	(0.29, 78.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.90	-23.75	
95% CI of the absolute risk difference	(-49.97, 26.16)	(-52.37, 4.87)	
p-value	0.5731	0.1884	
p-value of Breslow-Day Test for Homogeneity [3]	0.4788	0.2913	

AMNOG Table SE18.4.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (14.3)
No	6 (100)	7 (100)	12 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.60	3.00	
95% CI of the inverse odds ratio	(0.11, 62.57)	(0.13, 71.31)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.33	2.67	
95% CI of the inverse risk ratio	(0.13, 42.44)	(0.14, 49.08)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.52	-10.42	
95% CI of the absolute risk difference	(-36.35, 17.30)	(-35.66, 14.82)	
p-value	0.5443	0.4799	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (50.0)	0	2 (14.3)
No	3 (50.0)	7 (100)	12 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.17	3.00	
95% CI of the inverse odds ratio	(0.02, 1.49)	(0.13, 71.31)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.29	2.67	
95% CI of the inverse risk ratio	(0.06, 1.30)	(0.14, 49.08)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	35.71	-10.42	
95% CI of the absolute risk difference	(-8.29, 79.72)	(-35.66, 14.82)	
p-value	0.0910	0.4799	
p-value of Breslow-Day Test for Homogeneity [3]	0.5025	NE	

AMNOG Table SE18.5.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=6)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=6)	Change from Baseline DB Placebo (N=11)
CLDQ-NASH						
Baseline						
m	4	6	11			
n	4	5	10			
Mean (SD)	4.43 (1.90)	5.94 (0.48)	5.74 (0.89)			
Median	4.35	6.10	5.65			
IQR: Q1, Q3	3.10, 5.75	6.10, 6.10	5.20, 6.60			
Min, Max	2.2, 6.8	5.1, 6.3	4.2, 6.9			
Week 24						
m	3	4	11			
n	3	4	10	3	4	10
Mean (SD/SE)	5.07 (1.42)	5.95 (0.66)	5.58 (1.08)	0.73 (0.52)	0.05 (0.25)	-0.16 (0.12)
Median	4.80	5.90	5.40	0.80	0.10	-0.10
IQR: Q1, Q3	3.80, 6.60	5.40, 6.50	4.90, 6.90	-0.20, 1.60	-0.30, 0.40	-0.40, 0.10
Min, Max	3.8, 6.6	5.3, 6.7	3.9, 7.0	-0.2, 1.6	-0.6, 0.6	-0.7, 0.3
Week 52						
m	3	4	11			
n	2	3	9	2	3	9
Mean (SD/SE)	4.80 (3.11)	5.87 (0.25)	5.76 (1.40)	0.30 (0.10)	-0.30 (0.15)	-0.04 (0.41)
Median	4.80	5.90	6.10	0.30	-0.40	0.20
IQR: Q1, Q3	2.60, 7.00	5.60, 6.10	4.60, 6.90	0.20, 0.40	-0.50, 0.00	0.00, 0.40
Min, Max	2.6, 7.0	5.6, 6.1	3.1, 7.0	0.2, 0.4	-0.5, 0.0	-3.1, 1.3

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.5.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Visit Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=6)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=6)	Change from Baseline DB Placebo (N=11)
Abdominal Symptoms						
Baseline						
m	4	6	11			
n	4	5	10			
Mean (SD)	4.83 (2.85)	5.74 (1.13)	5.50 (1.50)			
Median	5.65	5.70	5.65			
IQR: Q1, Q3	2.65, 7.00	5.00, 6.70	4.00, 7.00			
Min, Max	1.0, 7.0	4.3, 7.0	3.3, 7.0			
Week 24						
m	3	4	11			
n	3	4	10	3	4	10
Mean (SD/SE)	4.90 (2.59)	5.85 (0.17)	5.27 (1.52)	0.80 (0.42)	-0.25 (0.48)	-0.23 (0.35)
Median	5.70	5.85	5.00	1.00	-0.50	0
IQR: Q1, Q3	2.00, 7.00	5.70, 6.00	4.00, 7.00	0.00, 1.40	-1.00, 0.50	-0.30, 0.30
Min, Max	2.0, 7.0	5.7, 6.0	3.3, 7.0	0.0, 1.4	-1.0, 1.0	-2.7, 1.3
Week 52						
m	3	4	11			
n	2	3	9	2	3	9
Mean (SD/SE)	4.00 (4.24)	5.80 (0.17)	5.26 (1.89)	0.00 (0.00)	-0.43 (0.72)	-0.44 (0.58)
Median	4.00	5.70	5.30	0	-1.00	0
IQR: Q1, Q3	1.00, 7.00	5.70, 6.00	4.00, 7.00	0.00, 0.00	-1.30, 1.00	0.00, 0.00
Min, Max	1.0, 7.0	5.7, 6.0	2.0, 7.0	0.0, 0.0	-1.3, 1.0	-5.0, 1.0

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.5.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=6)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=6)	Change from Baseline DB Placebo (N=11)
Activity						
Baseline						
m	4	6	11			
n	4	5	10			
Mean (SD)	4.40 (2.17)	5.88 (0.70)	6.04 (0.82)			
Median	4.30	5.80	6.10			
IQR: Q1, Q3	2.70, 6.10	5.40, 6.00	5.60, 6.60			
Min, Max	2.0, 7.0	5.2, 7.0	4.2, 7.0			
Week 24						
m	3	4	11			
n	3	4	10	3	4	10
Mean (SD/SE)	5.47 (1.15)	6.00 (0.71)	5.74 (1.40)	1.33 (0.87)	0.15 (0.25)	-0.30 (0.23)
Median	4.80	6.10	6.10	1.40	0.10	-0.10
IQR: Q1, Q3	4.80, 6.80	5.40, 6.60	4.80, 7.00	-0.20, 2.80	-0.20, 0.50	-0.80, 0.20
Min, Max	4.8, 6.8	5.2, 6.6	2.8, 7.0	-0.2, 2.8	-0.4, 0.8	-1.4, 0.6
Week 52						
m	3	4	11			
n	2	3	9	2	3	9
Mean (SD/SE)	5.20 (2.55)	5.87 (0.81)	6.02 (1.38)	0.70 (0.70)	-0.20 (0.20)	-0.04 (0.35)
Median	5.20	6.00	6.80	0.70	-0.40	0.20
IQR: Q1, Q3	3.40, 7.00	5.00, 6.60	5.40, 7.00	0.00, 1.40	-0.40, 0.20	0.00, 0.20
Min, Max	3.4, 7.0	5.0, 6.6	3.4, 7.0	0.0, 1.4	-0.4, 0.2	-2.6, 1.4

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.5.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=6)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=6)	Change from Baseline DB Placebo (N=11)
Emotional Health						
Baseline						
m	4	6	11			
n	4	5	10			
Mean (SD)	4.88 (1.44)	6.04 (0.64)	5.83 (0.85)			
Median	4.75	6.00	5.85			
IQR: Q1, Q3	3.80, 5.95	6.00, 6.20	5.20, 6.70			
Min, Max	3.3, 6.7	5.1, 6.9	4.4, 6.8			
Week 24						
m	3	4	11			
n	3	4	10	3	4	10
Mean (SD/SE)	5.90 (1.39)	5.88 (1.20)	5.88 (1.04)	0.83 (0.38)	0.05 (0.56)	0.05 (0.15)
Median	6.60	6.10	6.15	1.00	0.50	0.20
IQR: Q1, Q3	4.30, 6.80	4.90, 6.85	5.10, 6.70	0.10, 1.40	-0.65, 0.75	-0.30, 0.40
Min, Max	4.3, 6.8	4.4, 6.9	3.7, 7.0	0.1, 1.4	-1.6, 0.8	-0.7, 0.7
Week 52						
m	3	4	11			
n	2	3	9	2	3	9
Mean (SD/SE)	5.10 (2.69)	5.90 (0.50)	5.83 (1.41)	0.10 (0.20)	-0.17 (0.30)	0.01 (0.36)
Median	5.10	5.90	6.40	0.10	-0.30	0.20
IQR: Q1, Q3	3.20, 7.00	5.40, 6.40	4.40, 6.90	-0.10, 0.30	-0.60, 0.40	-0.30, 0.40
Min, Max	3.2, 7.0	5.4, 6.4	3.3, 7.0	-0.1, 0.3	-0.6, 0.4	-2.5, 1.3

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.5.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=6)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=6)	Change from Baseline DB Placebo (N=11)
Fatigue						
Baseline						
m	4	6	11			
n	4	5	10			
Mean (SD)	3.50 (2.50)	5.66 (0.96)	5.33 (1.40)			
Median	3.40	6.00	5.50			
IQR: Q1, Q3	1.40, 5.60	4.80, 6.30	4.50, 6.80			
Min, Max	1.0, 6.2	4.5, 6.7	2.7, 7.0			
Week 24						
m	3	4	11			
n	3	4	10	3	4	10
Mean (SD/SE)	3.33 (2.25)	5.75 (0.91)	5.13 (1.39)	0.33 (0.71)	0.35 (0.06)	-0.20 (0.30)
Median	3.50	5.70	4.95	0	0.35	-0.10
IQR: Q1, Q3	1.00, 5.50	5.00, 6.50	4.20, 6.80	-0.70, 1.70	0.25, 0.45	-0.60, 0.20
Min, Max	1.0, 5.5	4.8, 6.8	2.8, 6.8	-0.7, 1.7	0.2, 0.5	-1.7, 1.2
Week 52						
m	3	4	11			
n	2	3	9	2	3	9
Mean (SD/SE)	4.85 (3.04)	5.70 (0.36)	5.38 (1.59)	0.85 (0.05)	0.10 (0.35)	-0.04 (0.48)
Median	4.85	5.80	5.70	0.85	-0.20	0.20
IQR: Q1, Q3	2.70, 7.00	5.30, 6.00	4.00, 7.00	0.80, 0.90	-0.30, 0.80	-0.50, 1.00
Min, Max	2.7, 7.0	5.3, 6.0	2.8, 7.0	0.8, 0.9	-0.3, 0.8	-2.9, 1.7

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.5.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Visit Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=6)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=6)	Change from Baseline DB Placebo (N=11)
Systemic Symptoms						
Baseline						
m	4	6	11			
n	4	5	10			
Mean (SD)	4.90 (1.41)	6.06 (0.75)	5.76 (0.77)			
Median	4.30	6.20	5.65			
IQR: Q1, Q3	4.15, 5.65	6.20, 6.30	5.50, 6.30			
Min, Max	4.0, 7.0	4.8, 6.8	4.3, 7.0			
Week 24						
m	3	4	11			
n	3	4	10	3	4	10
Mean (SD/SE)	5.07 (1.44)	5.70 (1.01)	5.72 (1.11)	-0.03 (0.27)	-0.18 (0.33)	-0.04 (0.25)
Median	4.50	5.75	5.50	-0.30	-0.15	-0.05
IQR: Q1, Q3	4.00, 6.70	4.90, 6.50	5.20, 6.80	-0.30, 0.50	-0.65, 0.30	-0.30, 0.50
Min, Max	4.0, 6.7	4.5, 6.8	3.5, 7.0	-0.3, 0.5	-1.0, 0.6	-1.7, 1.2
Week 52						
m	3	4	11			
n	2	3	9	2	3	9
Mean (SD/SE)	5.15 (2.62)	5.63 (0.40)	5.91 (1.32)	-0.35 (0.35)	-0.60 (0.26)	0.09 (0.38)
Median	5.15	5.70	6.50	-0.35	-0.50	0.30
IQR: Q1, Q3	3.30, 7.00	5.20, 6.00	5.30, 7.00	-0.70, 0.00	-1.10, -0.20	-0.10, 0.50
Min, Max	3.3, 7.0	5.2, 6.0	3.2, 7.0	-0.7, 0.0	-1.1, -0.2	-2.6, 1.5

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.5.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=6)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=6)	Change from Baseline DB Placebo (N=11)
Worry						
Baseline						
m	4	6	11			
n	4	5	10			
Mean (SD)	4.13 (2.80)	6.16 (0.79)	6.01 (0.93)			
Median	4.25	5.90	6.10			
IQR: Q1, Q3	1.80, 6.45	5.90, 6.90	5.40, 7.00			
Min, Max	1.0, 7.0	5.1, 7.0	4.1, 7.0			
Week 24						
m	3	4	11			
n	3	4	10	3	4	10
Mean (SD/SE)	5.87 (1.96)	6.40 (0.71)	5.80 (1.22)	1.23 (0.75)	0.18 (0.11)	-0.21 (0.35)
Median	7.00	6.50	5.85	1.10	0.10	0
IQR: Q1, Q3	3.60, 7.00	5.80, 7.00	4.70, 7.00	0.00, 2.60	0.05, 0.30	-1.10, 0.90
Min, Max	3.6, 7.0	5.6, 7.0	3.7, 7.0	0.0, 2.6	0.0, 0.5	-1.9, 1.3
Week 52						
m	3	4	11			
n	2	3	9	2	3	9
Mean (SD/SE)	4.35 (3.75)	6.27 (1.02)	6.09 (1.04)	0.35 (0.35)	-0.33 (0.24)	0.11 (0.43)
Median	4.35	6.70	6.10	0.35	-0.20	0
IQR: Q1, Q3	1.70, 7.00	5.10, 7.00	5.60, 7.00	0.00, 0.70	-0.80, 0.00	0.00, 0.90
Min, Max	1.7, 7.0	5.1, 7.0	4.1, 7.0	0.0, 0.7	-0.8, 0.0	-2.9, 1.6

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.5.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter / Visit / Statistic	Visit Result: DB MGL-3196 80 mg (N=5)	Visit Result: DB MGL-3196 100 mg (N=9)	Visit Result: DB Placebo (N=17)	Change from Baseline: DB MGL-3196 80 mg (N=5)	Change from Baseline: DB MGL-3196 100 mg (N=9)	Change from Baseline: DB Placebo (N=17)
CLDQ-NASH						
Baseline						
m	5	9	17			
n	5	9	15			
Mean (SD)	6.14 (0.67)	5.84 (0.76)	5.79 (0.75)			
Median	6.50	6.00	5.90			
IQR: Q1, Q3	6.10, 6.50	5.80, 6.20	5.00, 6.50			
Min, Max	5.0, 6.6	4.3, 6.8	4.3, 6.7			
Week 24						
m	5	8	16			
n	4	7	15	4	7	14
Mean (SD/SE)	6.08 (0.59)	5.67 (0.63)	5.70 (1.00)	-0.08 (0.11)	-0.40 (0.32)	-0.04 (0.22)
Median	6.30	5.50	5.90	-0.10	-0.10	0
IQR: Q1, Q3	5.75, 6.40	5.30, 6.30	4.70, 6.60	-0.25, 0.10	-0.90, 0.30	-0.10, 0.10
Min, Max	5.2, 6.5	4.8, 6.6	3.8, 6.8	-0.3, 0.2	-2.0, 0.4	-2.2, 1.9
Week 52						
m	5	8	15			
n	5	7	15	5	7	14
Mean (SD/SE)	6.12 (0.43)	5.50 (0.60)	5.83 (0.76)	-0.02 (0.14)	-0.57 (0.35)	0.01 (0.11)
Median	6.20	5.60	5.90	-0.10	-0.30	0
IQR: Q1, Q3	5.90, 6.40	5.20, 6.20	5.30, 6.60	-0.20, 0.00	-1.00, 0.10	-0.30, 0.20
Min, Max	5.5, 6.6	4.5, 6.2	4.5, 6.8	-0.3, 0.5	-2.3, 0.6	-0.6, 0.9

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.5.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=5)	Visit Result DB MGL-3196 100 mg (N=9)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=5)	Change from Baseline DB MGL-3196 100 mg (N=9)	Change from Baseline DB Placebo (N=17)
Abdominal Symptoms						
Baseline						
m	5	9	17			
n	5	9	15			
Mean (SD)	6.34 (0.79)	6.23 (0.79)	6.09 (1.04)			
Median	6.70	6.70	6.30			
IQR: Q1, Q3	6.30, 6.70	6.00, 6.70	5.00, 7.00			
Min, Max	5.0, 7.0	5.0, 7.0	4.0, 7.0			
Week 24						
m	5	8	16			
n	4	7	15	4	7	14
Mean (SD/SE)	6.15 (0.70)	6.19 (1.10)	5.91 (1.30)	-0.20 (0.22)	-0.40 (0.40)	0.08 (0.25)
Median	6.15	7.00	6.70	-0.20	0	0
IQR: Q1, Q3	5.65, 6.65	5.30, 7.00	5.00, 7.00	-0.55, 0.15	-1.40, 0.30	0.00, 0.00
Min, Max	5.3, 7.0	4.3, 7.0	3.3, 7.0	-0.7, 0.3	-1.7, 1.0	-2.3, 2.0
Week 52						
m	5	8	15			
n	5	7	15	5	7	14
Mean (SD/SE)	6.26 (0.48)	5.96 (0.73)	5.98 (1.07)	-0.08 (0.21)	-0.63 (0.31)	0.03 (0.15)
Median	6.30	5.70	6.00	-0.30	-0.30	0
IQR: Q1, Q3	6.00, 6.30	5.30, 6.70	5.00, 7.00	-0.40, 0.00	-1.40, 0.00	0.00, 0.30
Min, Max	5.7, 7.0	5.0, 7.0	4.0, 7.0	-0.4, 0.7	-1.7, 0.3	-1.0, 1.0

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.5.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter / Visit / Statistic	Visit Result: DB MGL-3196 80 mg (N=5)	Visit Result: DB MGL-3196 100 mg (N=9)	Visit Result: DB Placebo (N=17)	Change from Baseline: DB MGL-3196 80 mg (N=5)	Change from Baseline: DB MGL-3196 100 mg (N=9)	Change from Baseline: DB Placebo (N=17)
Activity						
Baseline						
m	5	9	17			
n	5	9	15			
Mean (SD)	6.24 (0.84)	5.76 (1.20)	5.53 (1.09)			
Median	6.60	6.00	5.60			
IQR: Q1, Q3	6.20, 6.80	5.40, 6.60	5.00, 6.60			
Min, Max	4.8, 6.8	3.6, 7.0	3.2, 7.0			
Week 24						
m	5	8	16			
n	4	7	15	4	7	14
Mean (SD/SE)	5.80 (0.59)	5.14 (1.06)	5.35 (1.49)	-0.30 (0.17)	-0.94 (0.48)	-0.19 (0.39)
Median	5.90	4.40	5.80	-0.40	-1.40	0.10
IQR: Q1, Q3	5.40, 6.20	4.40, 6.20	4.40, 6.20	-0.50, -0.10	-2.00, 0.20	-1.20, 0.60
Min, Max	5.0, 6.4	4.4, 7.0	1.8, 7.0	-0.6, 0.2	-2.6, 0.8	-3.8, 2.6
Week 52						
m	5	8	15			
n	5	7	15	5	7	14
Mean (SD/SE)	6.04 (0.54)	5.06 (0.77)	5.81 (1.09)	-0.20 (0.30)	-1.03 (0.42)	0.26 (0.27)
Median	5.80	4.80	6.20	-0.20	-1.20	0
IQR: Q1, Q3	5.60, 6.40	4.60, 5.80	4.80, 7.00	-0.60, 0.00	-2.00, 0.00	-0.40, 0.40
Min, Max	5.6, 6.8	4.2, 6.4	3.6, 7.0	-1.0, 0.8	-2.4, 0.8	-1.0, 2.2

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.5.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Visit Statistic	Visit Result DB MGL-3196 80 mg (N=5)	Visit Result DB MGL-3196 100 mg (N=9)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=5)	Change from Baseline DB MGL-3196 100 mg (N=9)	Change from Baseline DB Placebo (N=17)
Emotional Health						
Baseline						
m	5	9	17			
n	5	9	15			
Mean (SD)	6.46 (0.67)	5.82 (1.01)	5.98 (0.82)			
Median	6.80	6.10	6.20			
IQR: Q1, Q3	6.20, 6.90	5.20, 6.60	5.60, 6.80			
Min, Max	5.4, 7.0	3.8, 6.8	4.1, 7.0			
Week 24						
m	5	8	16			
n	4	7	15	4	7	14
Mean (SD/SE)	6.28 (0.83)	5.67 (0.79)	5.85 (1.04)	-0.25 (0.13)	-0.30 (0.38)	-0.04 (0.17)
Median	6.55	5.80	6.10	-0.20	-0.20	0
IQR: Q1, Q3	5.70, 6.85	5.00, 6.20	4.70, 6.80	-0.45, -0.05	-0.60, 0.40	-0.30, 0.30
Min, Max	5.1, 6.9	4.3, 6.6	4.1, 7.0	-0.6, 0.0	-2.3, 0.9	-1.5, 1.2
Week 52						
m	5	8	15			
n	5	7	15	5	7	14
Mean (SD/SE)	6.10 (0.72)	5.60 (0.61)	5.95 (1.02)	-0.36 (0.17)	-0.37 (0.41)	-0.09 (0.10)
Median	5.90	5.80	6.10	-0.20	-0.10	-0.10
IQR: Q1, Q3	5.60, 6.80	5.00, 6.00	5.80, 6.80	-0.60, -0.10	-1.80, 0.40	-0.40, 0.20
Min, Max	5.3, 6.9	4.7, 6.4	3.4, 7.0	-0.9, 0.0	-1.9, 0.9	-0.7, 0.5

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.5.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=5)	(N=9)	(N=17)	(N=5)	(N=9)	(N=17)
Fatigue						
Baseline						
m	5	9	17			
n	5	9	15			
Mean (SD)	5.46 (0.59)	5.19 (1.14)	4.91 (1.57)			
Median	5.70	5.20	5.50			
IQR: Q1, Q3	5.30, 5.80	4.50, 5.80	3.80, 6.00			
Min, Max	4.5, 6.0	3.5, 7.0	1.5, 7.0			
Week 24						
m	5	8	16			
n	4	7	15	4	7	14
Mean (SD/SE)	5.43 (0.75)	4.51 (0.90)	4.97 (1.50)	-0.08 (0.08)	-0.59 (0.42)	-0.06 (0.37)
Median	5.80	4.50	5.30	-0.10	0	-0.10
IQR: Q1, Q3	5.05, 5.80	3.80, 4.70	4.00, 6.30	-0.20, 0.05	-2.00, 0.30	-0.50, 0.50
Min, Max	4.3, 5.8	3.5, 6.3	2.2, 6.8	-0.2, 0.1	-2.2, 0.5	-3.3, 3.0
Week 52						
m	5	8	15			
n	5	7	15	5	7	14
Mean (SD/SE)	5.46 (0.65)	4.73 (0.67)	5.02 (1.18)	0.00 (0.16)	-0.37 (0.54)	-0.11 (0.25)
Median	5.50	4.30	4.80	0	-0.40	-0.30
IQR: Q1, Q3	5.30, 5.70	4.20, 5.50	4.20, 6.20	-0.30, 0.20	-1.50, 1.00	-0.80, 0.50
Min, Max	4.5, 6.3	4.0, 5.5	2.8, 7.0	-0.4, 0.5	-2.3, 1.8	-1.5, 1.3

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.5.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=5)	Visit Result DB MGL-3196 100 mg (N=9)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=5)	Change from Baseline DB MGL-3196 100 mg (N=9)	Change from Baseline DB Placebo (N=17)
Systemic Symptoms						
Baseline						
m	5	9	17			
n	5	9	15			
Mean (SD)	6.04 (0.78)	5.46 (1.48)	5.58 (0.94)			
Median	6.30	5.70	5.50			
IQR: Q1, Q3	5.80, 6.50	5.00, 6.80	5.20, 6.50			
Min, Max	4.8, 6.8	2.7, 7.0	3.8, 6.8			
Week 24						
m	5	8	16			
n	4	7	15	4	7	14
Mean (SD/SE)	6.23 (0.65)	6.00 (0.60)	5.31 (1.19)	0.13 (0.24)	0.09 (0.38)	-0.20 (0.25)
Median	6.40	6.00	5.70	0.25	0.10	-0.15
IQR: Q1, Q3	5.80, 6.65	5.50, 6.50	4.30, 6.30	-0.25, 0.50	-0.80, 0.80	-0.40, 0.20
Min, Max	5.3, 6.8	5.2, 7.0	3.2, 6.8	-0.5, 0.5	-1.5, 1.5	-2.1, 1.6
Week 52						
m	5	8	15			
n	5	7	15	5	7	14
Mean (SD/SE)	6.10 (0.51)	5.40 (0.95)	5.45 (0.94)	0.06 (0.17)	-0.51 (0.49)	-0.13 (0.17)
Median	6.30	5.30	5.30	0	-0.60	-0.25
IQR: Q1, Q3	6.20, 6.30	4.80, 6.20	4.80, 6.30	-0.30, 0.40	-0.90, 0.00	-0.50, 0.20
Min, Max	5.2, 6.5	4.2, 7.0	3.5, 6.8	-0.3, 0.5	-2.8, 1.6	-1.2, 1.1

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.5.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=5)	Visit Result DB MGL-3196 100 mg (N=9)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=5)	Change from Baseline DB MGL-3196 100 mg (N=9)	Change from Baseline DB Placebo (N=17)
Worry						
Baseline						
m	5	9	17			
n	5	9	15			
Mean (SD)	6.32 (0.59)	6.59 (0.51)	6.69 (0.37)			
Median	6.10	6.70	6.90			
IQR: Q1, Q3	5.90, 6.90	6.40, 6.90	6.30, 7.00			
Min, Max	5.7, 7.0	5.4, 7.0	6.0, 7.0			
Week 24						
m	5	8	16			
n	4	7	15	4	7	14
Mean (SD/SE)	6.60 (0.49)	6.44 (0.90)	6.71 (0.58)	0.18 (0.08)	-0.34 (0.33)	0.04 (0.13)
Median	6.70	6.90	7.00	0.20	0	0
IQR: Q1, Q3	6.20, 7.00	5.40, 7.00	6.70, 7.00	0.05, 0.30	-0.90, 0.20	0.00, 0.20
Min, Max	6.0, 7.0	4.9, 7.0	4.9, 7.0	0.0, 0.3	-2.1, 0.3	-1.4, 0.7
Week 52						
m	5	8	15			
n	5	7	15	5	7	14
Mean (SD/SE)	6.68 (0.28)	6.30 (0.96)	6.75 (0.34)	0.36 (0.17)	-0.49 (0.39)	0.03 (0.05)
Median	6.60	6.70	6.90	0.40	0	0
IQR: Q1, Q3	6.60, 6.90	6.10, 7.00	6.60, 7.00	0.00, 0.50	-0.80, 0.10	-0.10, 0.00
Min, Max	6.3, 7.0	4.3, 7.0	5.9, 7.0	0.0, 0.9	-2.7, 0.2	-0.2, 0.6

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc. Page 1 of 3
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE18.5.2
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of CLDQ-NASH - MMRM Model
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE18.5.2
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of CLDQ-NASH - MMRM Model
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
CLDQ-NASH			
Week 24			
m	3	4	11
n	3	4	10
Baseline Mean (SD)	4.33 (2.32)	5.90 (0.54)	5.74 (0.89)
Analysis Visit Mean (SD)	5.07 (1.42)	5.95 (0.66)	5.58 (1.08)
LS Mean of Change from Baseline (SE)	0.53 (0.33)	0.06 (0.29)	-0.12 (0.17)
95% CI	(-0.18, 1.23)	(-0.56, 0.68)	(-0.48, 0.24)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.65 (0.37)	0.18 (0.36)	
95% CI	(-0.14, 1.44)	(-0.59, 0.95)	
p-value	0.0996	0.6188	
Corrected Hedge's g Statistics	1.116	0.312	
95% CI	(-0.24, 2.48)	(-0.85, 1.48)	
Week 52			
m	3	4	11
n	2	3	9
Baseline Mean (SD)	4.50 (3.25)	6.17 (0.12)	5.80 (0.92)
Analysis Visit Mean (SD)	4.80 (3.11)	5.87 (0.25)	5.76 (1.40)
LS Mean of Change from Baseline (SE)	0.21 (0.83)	-0.27 (0.66)	0.00 (0.38)
95% CI	(-1.58, 1.99)	(-1.69, 1.14)	(-0.80, 0.81)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.20 (0.92)	-0.28 (0.76)	
95% CI	(-1.77, 2.17)	(-1.91, 1.36)	
p-value	0.8274	0.7238	
Corrected Hedge's g Statistics	0.165	-0.225	
95% CI	(-1.37, 1.70)	(-1.53, 1.08)	
Subgroup*Treatment Interaction p-value	0.3433	0.4592	

AMNOG Table SE18.5.2
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of CLDQ-NASH - MMRM Model
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
CLDQ-NASH			
Week 24			
m	5	8	16
n	4	7	14
Baseline Mean (SD)	6.15 (0.77)	6.07 (0.56)	5.81 (0.77)
Analysis Visit Mean (SD)	6.08 (0.59)	5.67 (0.63)	5.78 (0.99)
LS Mean of Change from Baseline (SE)	0.10 (0.39)	-0.19 (0.33)	0.09 (0.26)
95% CI	(-0.71, 0.91)	(-0.87, 0.49)	(-0.45, 0.63)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.01 (0.43)	-0.28 (0.36)	
95% CI	(-0.90, 0.91)	(-1.03, 0.47)	
p-value	0.9893	0.4402	
Corrected Hedge's g Statistics	0.006	-0.290	
95% CI	(-1.11, 1.12)	(-1.20, 0.62)	
Week 52			
m	5	8	15
n	5	7	14
Baseline Mean (SD)	6.14 (0.67)	6.07 (0.56)	5.81 (0.77)
Analysis Visit Mean (SD)	6.12 (0.43)	5.50 (0.60)	5.83 (0.79)
LS Mean of Change from Baseline (SE)	0.19 (0.27)	-0.37 (0.25)	0.14 (0.21)
95% CI	(-0.37, 0.74)	(-0.89, 0.15)	(-0.30, 0.59)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.04 (0.29)	-0.51 (0.25)	
95% CI	(-0.55, 0.64)	(-1.03, 0.01)	
p-value	0.8852	0.0541	
Corrected Hedge's g Statistics	0.053	-0.648	
95% CI	(-0.97, 1.07)	(-1.58, 0.28)	
Subgroup*Treatment Interaction p-value	0.3433	0.4592	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE18.5.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

AMNOG Table SE18.5.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Abdominal Symptoms			
Week 24			
m	3	4	11
n	3	4	10
Baseline Mean (SD)	4.10 (3.00)	6.10 (0.92)	5.50 (1.50)
Analysis Visit Mean (SD)	4.90 (2.59)	5.85 (0.17)	5.27 (1.52)
LS Mean of Change from Baseline (SE)	0.62 (0.55)	-0.54 (0.50)	-0.05 (0.29)
95% CI	(-0.55, 1.79)	(-1.62, 0.54)	(-0.67, 0.58)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.66 (0.61)	-0.50 (0.62)	
95% CI	(-0.64, 1.96)	(-1.82, 0.83)	
p-value	0.2925	0.4343	
Corrected Hedge's g Statistics	0.667	-0.492	
95% CI	(-0.65, 1.98)	(-1.67, 0.68)	
Week 52			
m	3	4	11
n	2	3	9
Baseline Mean (SD)	4.00 (4.24)	6.23 (1.08)	5.70 (1.44)
Analysis Visit Mean (SD)	4.00 (4.24)	5.80 (0.17)	5.26 (1.89)
LS Mean of Change from Baseline (SE)	0.08 (1.20)	-0.72 (0.95)	-0.17 (0.55)
95% CI	(-2.49, 2.66)	(-2.75, 1.32)	(-1.33, 1.00)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.25 (1.30)	-0.55 (1.11)	
95% CI	(-2.55, 3.05)	(-2.94, 1.84)	
p-value	0.8523	0.6287	
Corrected Hedge's g Statistics	0.138	-0.310	
95% CI	(-1.40, 1.67)	(-1.62, 1.00)	
Subgroup*Treatment Interaction p-value	0.1867	0.5974	

AMNOG Table SE18.5.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Activity			
Week 24			
m	3	4	11
n	3	4	10
Baseline Mean (SD)	4.13 (2.58)	5.85 (0.81)	6.04 (0.82)
Analysis Visit Mean (SD)	5.47 (1.15)	6.00 (0.71)	5.74 (1.40)
LS Mean of Change from Baseline (SE)	0.99 (0.58)	0.15 (0.49)	-0.23 (0.29)
95% CI	(-0.26, 2.24)	(-0.91, 1.21)	(-0.86, 0.40)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.22 (0.67)	0.38 (0.61)	
95% CI	(-0.21, 2.65)	(-0.94, 1.70)	
p-value	0.0893	0.5457	
Corrected Hedge's g Statistics	1.199	0.377	
95% CI	(-0.17, 2.57)	(-0.79, 1.54)	
Week 52			
m	3	4	11
n	2	3	9
Baseline Mean (SD)	4.50 (3.54)	6.07 (0.83)	6.07 (0.86)
Analysis Visit Mean (SD)	5.20 (2.55)	5.87 (0.81)	6.02 (1.38)
LS Mean of Change from Baseline (SE)	0.49 (0.75)	-0.22 (0.61)	-0.05 (0.36)
95% CI	(-1.13, 2.10)	(-1.53, 1.09)	(-0.81, 0.72)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.54 (0.84)	-0.17 (0.74)	
95% CI	(-1.26, 2.33)	(-1.76, 1.42)	
p-value	0.5326	0.8222	
Corrected Hedge's g Statistics	0.458	-0.147	
95% CI	(-1.09, 2.00)	(-1.45, 1.16)	
Subgroup*Treatment Interaction p-value	0.3863	0.2473	

AMNOG Table SE18.5.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Emotional Health			
Week 24			
m	3	4	11
n	3	4	10
Baseline Mean (SD)	5.07 (1.70)	5.83 (0.49)	5.83 (0.85)
Analysis Visit Mean (SD)	5.90 (1.39)	5.88 (1.20)	5.88 (1.04)
LS Mean of Change from Baseline (SE)	0.90 (0.41)	-0.32 (0.38)	0.21 (0.22)
95% CI	(0.03, 1.77)	(-1.13, 0.49)	(-0.27, 0.69)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.69 (0.46)	-0.53 (0.47)	
95% CI	(-0.29, 1.68)	(-1.53, 0.48)	
p-value	0.1539	0.2789	
Corrected Hedge's g Statistics	0.914	-0.685	
95% CI	(-0.42, 2.25)	(-1.87, 0.50)	
Week 52			
m	3	4	11
n	2	3	9
Baseline Mean (SD)	5.00 (2.40)	6.07 (0.12)	5.82 (0.90)
Analysis Visit Mean (SD)	5.10 (2.69)	5.90 (0.50)	5.83 (1.41)
LS Mean of Change from Baseline (SE)	0.51 (0.72)	-0.55 (0.58)	0.21 (0.33)
95% CI	(-1.03, 2.05)	(-1.81, 0.70)	(-0.50, 0.93)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.30 (0.78)	-0.77 (0.69)	
95% CI	(-1.37, 1.96)	(-2.26, 0.72)	
p-value	0.7085	0.2872	
Corrected Hedge's g Statistics	0.272	-0.709	
95% CI	(-1.26, 1.81)	(-2.05, 0.63)	
Subgroup*Treatment Interaction p-value	0.0149	0.9789	

AMNOG Table SE18.5.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Fatigue			
Week 24			
m	3	4	11
n	3	4	10
Baseline Mean (SD)	3.00 (2.80)	5.40 (0.88)	5.33 (1.40)
Analysis Visit Mean (SD)	3.33 (2.25)	5.75 (0.91)	5.13 (1.39)
LS Mean of Change from Baseline (SE)	-0.21 (0.60)	0.51 (0.50)	-0.17 (0.29)
95% CI	(-1.49, 1.07)	(-0.56, 1.59)	(-0.79, 0.45)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.04 (0.66)	0.69 (0.61)	
95% CI	(-1.45, 1.38)	(-0.62, 2.00)	
p-value	0.9562	0.2803	
Corrected Hedge's g Statistics	-0.037	0.688	
95% CI	(-1.33, 1.25)	(-0.50, 1.88)	
Week 52			
m	3	4	11
n	2	3	9
Baseline Mean (SD)	4.00 (3.11)	5.60 (0.96)	5.42 (1.46)
Analysis Visit Mean (SD)	4.85 (3.04)	5.70 (0.36)	5.38 (1.59)
LS Mean of Change from Baseline (SE)	0.43 (0.95)	0.32 (0.77)	-0.03 (0.45)
95% CI	(-1.60, 2.46)	(-1.34, 1.97)	(-0.98, 0.93)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.46 (1.04)	0.34 (0.91)	
95% CI	(-1.77, 2.69)	(-1.62, 2.31)	
p-value	0.6663	0.7123	
Corrected Hedge's g Statistics	0.313	0.238	
95% CI	(-1.22, 1.85)	(-1.07, 1.55)	
Subgroup*Treatment Interaction p-value	0.9652	0.2097	

AMNOG Table SE18.5.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Systemic Symptoms			
Week 24			
m	3	4	11
n	3	4	10
Baseline Mean (SD)	5.10 (1.65)	5.88 (0.72)	5.76 (0.77)
Analysis Visit Mean (SD)	5.07 (1.44)	5.70 (1.01)	5.72 (1.11)
LS Mean of Change from Baseline (SE)	-0.22 (0.42)	0.22 (0.40)	-0.19 (0.23)
95% CI	(-1.13, 0.69)	(-0.65, 1.08)	(-0.69, 0.31)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.03 (0.47)	0.41 (0.50)	
95% CI	(-1.04, 0.97)	(-0.67, 1.48)	
p-value	0.9474	0.4291	
Corrected Hedge's g Statistics	-0.040	0.507	
95% CI	(-1.33, 1.25)	(-0.67, 1.68)	
Week 52			
m	3	4	11
n	2	3	9
Baseline Mean (SD)	5.50 (2.12)	6.23 (0.06)	5.82 (0.79)
Analysis Visit Mean (SD)	5.15 (2.62)	5.63 (0.40)	5.91 (1.32)
LS Mean of Change from Baseline (SE)	-0.61 (0.77)	-0.36 (0.67)	-0.25 (0.38)
95% CI	(-2.26, 1.04)	(-1.80, 1.08)	(-1.07, 0.56)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.36 (0.85)	-0.11 (0.79)	
95% CI	(-2.18, 1.46)	(-1.80, 1.59)	
p-value	0.6780	0.8920	
Corrected Hedge's g Statistics	-0.291	-0.088	
95% CI	(-1.83, 1.25)	(-1.40, 1.22)	
Subgroup*Treatment Interaction p-value	0.3251	0.5520	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE18.5.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Worry			
Week 24			
m	3	4	11
n	3	4	10
Baseline Mean (SD)	4.63 (3.19)	6.23 (0.90)	6.01 (0.93)
Analysis Visit Mean (SD)	5.87 (1.96)	6.40 (0.71)	5.80 (1.22)
LS Mean of Change from Baseline (SE)	0.77 (0.56)	0.49 (0.52)	-0.22 (0.31)
95% CI	(-0.43, 1.98)	(-0.62, 1.60)	(-0.89, 0.45)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.99 (0.65)	0.71 (0.64)	
95% CI	(-0.40, 2.38)	(-0.67, 2.09)	
p-value	0.1481	0.2907	
Corrected Hedge's g Statistics	0.939	0.664	
95% CI	(-0.40, 2.28)	(-0.52, 1.85)	
Week 52			
m	3	4	11
n	2	3	9
Baseline Mean (SD)	4.00 (4.24)	6.60 (0.61)	5.98 (0.98)
Analysis Visit Mean (SD)	4.35 (3.75)	6.27 (1.02)	6.09 (1.04)
LS Mean of Change from Baseline (SE)	-0.26 (0.88)	0.05 (0.70)	0.03 (0.39)
95% CI	(-2.15, 1.63)	(-1.44, 1.54)	(-0.82, 0.87)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.28 (0.95)	0.02 (0.83)	
95% CI	(-2.33, 1.76)	(-1.77, 1.81)	
p-value	0.7718	0.9792	
Corrected Hedge's g Statistics	-0.217	0.017	
95% CI	(-1.75, 1.32)	(-1.29, 1.32)	
Subgroup*Treatment Interaction p-value	0.6543	0.2920	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE18.5.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Abdominal Symptoms			
Week 24			
m	5	8	16
n	4	7	14
Baseline Mean (SD)	6.35 (0.91)	6.59 (0.42)	6.02 (1.05)
Analysis Visit Mean (SD)	6.15 (0.70)	6.19 (1.10)	6.10 (1.12)
LS Mean of Change from Baseline (SE)	-0.08 (0.45)	-0.11 (0.38)	0.21 (0.30)
95% CI	(-1.03, 0.86)	(-0.90, 0.69)	(-0.41, 0.84)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.30 (0.51)	-0.32 (0.43)	
95% CI	(-1.35, 0.76)	(-1.21, 0.58)	
p-value	0.5667	0.4728	
Corrected Hedge's g Statistics	-0.258	-0.278	
95% CI	(-1.37, 0.86)	(-1.19, 0.63)	
Week 52			
m	5	8	15
n	5	7	14
Baseline Mean (SD)	6.34 (0.79)	6.59 (0.42)	6.02 (1.05)
Analysis Visit Mean (SD)	6.26 (0.48)	5.96 (0.73)	6.05 (1.07)
LS Mean of Change from Baseline (SE)	0.08 (0.30)	-0.37 (0.28)	0.18 (0.24)
95% CI	(-0.54, 0.69)	(-0.96, 0.22)	(-0.31, 0.68)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.11 (0.32)	-0.56 (0.29)	
95% CI	(-0.78, 0.56)	(-1.16, 0.05)	
p-value	0.7403	0.0690	
Corrected Hedge's g Statistics	-0.121	-0.624	
95% CI	(-1.14, 0.90)	(-1.55, 0.30)	
Subgroup*Treatment Interaction p-value	0.1867	0.5974	

AMNOG Table SE18.5.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Activity			
Week 24			
m	5	8	16
n	4	7	14
Baseline Mean (SD)	6.10 (0.90)	6.09 (1.01)	5.47 (1.10)
Analysis Visit Mean (SD)	5.80 (0.59)	5.14 (1.06)	5.29 (1.53)
LS Mean of Change from Baseline (SE)	-0.06 (0.65)	-0.64 (0.53)	-0.17 (0.41)
95% CI	(-1.41, 1.30)	(-1.74, 0.47)	(-1.02, 0.69)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.11 (0.74)	-0.47 (0.61)	
95% CI	(-1.41, 1.64)	(-1.72, 0.79)	
p-value	0.8800	0.4470	
Corrected Hedge's g Statistics	0.071	-0.300	
95% CI	(-1.04, 1.18)	(-1.21, 0.61)	
Week 52			
m	5	8	15
n	5	7	14
Baseline Mean (SD)	6.24 (0.84)	6.09 (1.01)	5.47 (1.10)
Analysis Visit Mean (SD)	6.04 (0.54)	5.06 (0.77)	5.73 (1.07)
LS Mean of Change from Baseline (SE)	0.20 (0.42)	-0.70 (0.39)	0.25 (0.32)
95% CI	(-0.67, 1.08)	(-1.51, 0.11)	(-0.41, 0.92)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.05 (0.46)	-0.95 (0.40)	
95% CI	(-1.00, 0.90)	(-1.78, -0.12)	
p-value	0.9116	0.0266	
Corrected Hedge's g Statistics	-0.043	-0.797	
95% CI	(-1.06, 0.98)	(-1.74, 0.14)	
Subgroup*Treatment Interaction p-value	0.3863	0.2473	

AMNOG Table SE18.5.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Emotional Health			
Week 24			
m	5	8	16
n	4	7	14
Baseline Mean (SD)	6.53 (0.75)	5.97 (0.69)	6.00 (0.85)
Analysis Visit Mean (SD)	6.28 (0.83)	5.67 (0.79)	5.96 (1.00)
LS Mean of Change from Baseline (SE)	-0.02 (0.39)	-0.15 (0.32)	0.15 (0.26)
95% CI	(-0.83, 0.79)	(-0.82, 0.51)	(-0.39, 0.69)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.17 (0.43)	-0.30 (0.35)	
95% CI	(-1.07, 0.73)	(-1.02, 0.41)	
p-value	0.7000	0.3900	
Corrected Hedge's g Statistics	-0.171	-0.311	
95% CI	(-1.28, 0.94)	(-1.22, 0.60)	
Week 52			
m	5	8	15
n	5	7	14
Baseline Mean (SD)	6.46 (0.67)	5.97 (0.69)	6.00 (0.85)
Analysis Visit Mean (SD)	6.10 (0.72)	5.60 (0.61)	5.91 (1.05)
LS Mean of Change from Baseline (SE)	-0.13 (0.31)	-0.22 (0.28)	0.11 (0.24)
95% CI	(-0.77, 0.51)	(-0.79, 0.36)	(-0.38, 0.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.25 (0.33)	-0.33 (0.29)	
95% CI	(-0.94, 0.44)	(-0.92, 0.26)	
p-value	0.4648	0.2624	
Corrected Hedge's g Statistics	-0.281	-0.378	
95% CI	(-1.31, 0.74)	(-1.29, 0.54)	
Subgroup*Treatment Interaction p-value	0.0149	0.9789	

AMNOG Table SE18.5.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Fatigue			
Week 24			
m	5	8	16
n	4	7	14
Baseline Mean (SD)	5.50 (0.68)	5.10 (1.29)	5.15 (1.30)
Analysis Visit Mean (SD)	5.43 (0.75)	4.51 (0.90)	5.09 (1.47)
LS Mean of Change from Baseline (SE)	0.22 (0.58)	-0.51 (0.48)	0.10 (0.39)
95% CI	(-0.98, 1.43)	(-1.52, 0.49)	(-0.71, 0.90)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.12 (0.64)	-0.61 (0.53)	
95% CI	(-1.21, 1.46)	(-1.71, 0.49)	
p-value	0.8502	0.2621	
Corrected Hedge's g Statistics	0.083	-0.419	
95% CI	(-1.03, 1.19)	(-1.34, 0.50)	
Week 52			
m	5	8	15
n	5	7	14
Baseline Mean (SD)	5.46 (0.59)	5.10 (1.29)	5.15 (1.30)
Analysis Visit Mean (SD)	5.46 (0.65)	4.73 (0.67)	5.04 (1.23)
LS Mean of Change from Baseline (SE)	0.26 (0.41)	-0.30 (0.38)	0.04 (0.32)
95% CI	(-0.58, 1.10)	(-1.09, 0.48)	(-0.63, 0.71)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.22 (0.43)	-0.34 (0.38)	
95% CI	(-0.68, 1.12)	(-1.13, 0.45)	
p-value	0.6143	0.3797	
Corrected Hedge's g Statistics	0.185	-0.285	
95% CI	(-0.84, 1.21)	(-1.20, 0.63)	
Subgroup*Treatment Interaction p-value	0.9652	0.2097	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE18.5.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Systemic Symptoms			
Week 24			
m	5	8	16
n	4	7	14
Baseline Mean (SD)	6.10 (0.89)	5.91 (1.18)	5.59 (0.97)
Analysis Visit Mean (SD)	6.23 (0.65)	6.00 (0.60)	5.39 (1.20)
LS Mean of Change from Baseline (SE)	0.43 (0.43)	0.33 (0.37)	-0.10 (0.31)
95% CI	(-0.46, 1.33)	(-0.45, 1.10)	(-0.73, 0.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.53 (0.47)	0.43 (0.38)	
95% CI	(-0.44, 1.50)	(-0.37, 1.23)	
p-value	0.2668	0.2790	
Corrected Hedge's g Statistics	0.462	0.374	
95% CI	(-0.66, 1.58)	(-0.54, 1.29)	
Week 52			
m	5	8	15
n	5	7	14
Baseline Mean (SD)	6.04 (0.78)	5.91 (1.18)	5.59 (0.97)
Analysis Visit Mean (SD)	6.10 (0.51)	5.40 (0.95)	5.46 (0.97)
LS Mean of Change from Baseline (SE)	0.32 (0.38)	-0.27 (0.35)	-0.03 (0.29)
95% CI	(-0.46, 1.10)	(-0.99, 0.46)	(-0.64, 0.57)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.35 (0.40)	-0.23 (0.35)	
95% CI	(-0.47, 1.18)	(-0.96, 0.49)	
p-value	0.3798	0.5109	
Corrected Hedge's g Statistics	0.327	-0.215	
95% CI	(-0.70, 1.35)	(-1.12, 0.69)	
Subgroup*Treatment Interaction p-value	0.3251	0.5520	

AMNOG Table SE18.5.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Worry			
Week 24			
m	5	8	16
n	4	7	14
Baseline Mean (SD)	6.43 (0.63)	6.79 (0.25)	6.73 (0.34)
Analysis Visit Mean (SD)	6.60 (0.49)	6.44 (0.90)	6.77 (0.55)
LS Mean of Change from Baseline (SE)	0.18 (0.32)	-0.22 (0.26)	0.14 (0.22)
95% CI	(-0.49, 0.86)	(-0.77, 0.32)	(-0.32, 0.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.04 (0.34)	-0.37 (0.27)	
95% CI	(-0.66, 0.75)	(-0.93, 0.20)	
p-value	0.9025	0.1907	
Corrected Hedge's g Statistics	0.050	-0.445	
95% CI	(-1.06, 1.16)	(-1.36, 0.47)	
Week 52			
m	5	8	15
n	5	7	14
Baseline Mean (SD)	6.32 (0.59)	6.79 (0.25)	6.73 (0.34)
Analysis Visit Mean (SD)	6.68 (0.28)	6.30 (0.96)	6.76 (0.35)
LS Mean of Change from Baseline (SE)	0.28 (0.31)	-0.33 (0.26)	0.14 (0.22)
95% CI	(-0.36, 0.92)	(-0.87, 0.20)	(-0.31, 0.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.14 (0.32)	-0.48 (0.26)	
95% CI	(-0.52, 0.80)	(-1.02, 0.07)	
p-value	0.6682	0.0826	
Corrected Hedge's g Statistics	0.168	-0.589	
95% CI	(-0.85, 1.19)	(-1.51, 0.34)	
Subgroup*Treatment Interaction p-value	0.6543	0.2920	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE18.5.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi-square Test. For this unadjusted analysis, only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.

AMNOG Table SE18.5.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (9.1)
No	4 (100)	6 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	1.86	
95% CI of the inverse odds ratio	(0.04, 37.98)	(0.07, 52.76)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	1.75	
95% CI of the inverse risk ratio	(0.06, 25.76)	(0.08, 37.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-5.36	
95% CI of the absolute risk difference	(-34.77, 29.77)	(-32.08, 21.37)	
p-value	0.8841	0.7136	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (25.0)	0	4 (36.4)
No	3 (75.0)	6 (100)	7 (63.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.71	7.80	
95% CI of the inverse odds ratio	(0.13, 22.51)	(0.35, 173.98)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.45	5.25	
95% CI of the inverse risk ratio	(0.22, 9.43)	(0.33, 83.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.36	-30.36	
95% CI of the absolute risk difference	(-62.44, 39.71)	(-63.74, 3.02)	
p-value	0.6797	0.1472	
p-value of Breslow-Day Test for Homogeneity [3]	0.7051	0.2434	

AMNOG Table SE18.5.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (16.7)	1 (9.1)
No	4 (100)	5 (83.3)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	0.50	
95% CI of the inverse odds ratio	(0.04, 37.98)	(0.03, 9.77)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	0.55	
95% CI of the inverse risk ratio	(0.06, 25.76)	(0.04, 7.25)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	7.58	
95% CI of the absolute risk difference	(-34.77, 29.77)	(-26.74, 41.90)	
p-value	0.8841	0.6431	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.3774	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (16.7)	1 (9.1)
No	4 (100)	5 (83.3)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	0.50	
95% CI of the inverse odds ratio	(0.04, 37.98)	(0.03, 9.77)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	0.55	
95% CI of the inverse risk ratio	(0.06, 25.76)	(0.04, 7.25)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	7.58	
95% CI of the absolute risk difference	(-34.77, 29.77)	(-26.74, 41.90)	
p-value	0.8841	0.6431	
p-value of Breslow-Day Test for Homogeneity [3]	0.5249	0.1607	

AMNOG Table SE18.5.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (25.0)	0	1 (9.1)
No	3 (75.0)	6 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.30	1.86	
95% CI of the inverse odds ratio	(0.01, 6.38)	(0.07, 52.76)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.36	1.75	
95% CI of the inverse risk ratio	(0.03, 4.54)	(0.08, 37.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	15.91	-5.36	
95% CI of the absolute risk difference	(-29.80, 61.62)	(-32.08, 21.37)	
p-value	0.4228	0.7136	
p-value of Breslow-Day Test for Homogeneity [3]	0.1794	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (25.0)	0	2 (18.2)
No	3 (75.0)	6 (100)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	3.42	
95% CI of the inverse odds ratio	(0.04, 10.25)	(0.14, 83.60)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	2.92	
95% CI of the inverse risk ratio	(0.09, 6.00)	(0.16, 52.47)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.82	-13.69	
95% CI of the absolute risk difference	(-41.35, 54.99)	(-43.56, 16.18)	
p-value	0.7703	0.4299	
p-value of Breslow-Day Test for Homogeneity [3]	0.6205	0.5408	

AMNOG Table SE18.5.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (18.2)
No	4 (100)	6 (100)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.37	3.42	
95% CI of the inverse odds ratio	(0.09, 60.29)	(0.14, 83.60)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.08	2.92	
95% CI of the inverse risk ratio	(0.12, 36.07)	(0.16, 52.47)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.83	-13.69	
95% CI of the absolute risk difference	(-45.75, 24.09)	(-43.56, 16.18)	
p-value	0.5934	0.4299	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (16.7)	3 (27.3)
No	4 (100)	5 (83.3)	8 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.71	1.88	
95% CI of the inverse odds ratio	(0.15, 88.75)	(0.15, 23.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.92	1.64	
95% CI of the inverse risk ratio	(0.18, 46.71)	(0.21, 12.49)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-19.17	-10.61	
95% CI of the absolute risk difference	(-55.95, 17.61)	(-50.38, 29.17)	
p-value	0.3959	0.6223	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.4052	

AMNOG Table SE18.5.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (25.0)	0	3 (27.3)
No	3 (75.0)	6 (100)	8 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	5.35	
95% CI of the inverse odds ratio	(0.08, 15.51)	(0.23, 122.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	4.08	
95% CI of the inverse risk ratio	(0.15, 7.69)	(0.25, 68.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.27	-22.02	
95% CI of the absolute risk difference	(-52.21, 47.66)	(-54.04, 10.00)	
p-value	0.9299	0.2560	
p-value of Breslow-Day Test for Homogeneity [3]	0.3797	0.1673	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (50.0)	1 (16.7)	3 (27.3)
No	2 (50.0)	5 (83.3)	8 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.38	1.88	
95% CI of the inverse odds ratio	(0.04, 4.00)	(0.15, 23.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.55	1.64	
95% CI of the inverse risk ratio	(0.14, 2.16)	(0.21, 12.49)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	22.73	-10.61	
95% CI of the absolute risk difference	(-32.89, 78.35)	(-50.38, 29.17)	
p-value	0.4090	0.6223	
p-value of Breslow-Day Test for Homogeneity [3]	0.3822	0.8757	

AMNOG Table SE18.5.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (18.2)
No	4 (100)	6 (100)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.37	3.42	
95% CI of the inverse odds ratio	(0.09, 60.29)	(0.14, 83.60)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.08	2.92	
95% CI of the inverse risk ratio	(0.12, 36.07)	(0.16, 52.47)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.83	-13.69	
95% CI of the absolute risk difference	(-45.75, 24.09)	(-43.56, 16.18)	
p-value	0.5934	0.4299	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.2222	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	4 (36.4)
No	4 (100)	6 (100)	7 (63.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.40	7.80	
95% CI of the inverse odds ratio	(0.23, 125.61)	(0.35, 173.98)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.75	5.25	
95% CI of the inverse risk ratio	(0.24, 57.45)	(0.33, 83.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-27.50	-30.36	
95% CI of the absolute risk difference	(-65.47, 10.47)	(-63.74, 3.02)	
p-value	0.2569	0.1472	
p-value of Breslow-Day Test for Homogeneity [3]	0.0748	0.2434	

AMNOG Table SE18.5.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	3 (27.3)
No	4 (100)	6 (100)	8 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.71	5.35	
95% CI of the inverse odds ratio	(0.15, 88.75)	(0.23, 122.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.92	4.08	
95% CI of the inverse risk ratio	(0.18, 46.71)	(0.25, 68.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-19.17	-22.02	
95% CI of the absolute risk difference	(-55.95, 17.61)	(-54.04, 10.00)	
p-value	0.3959	0.2560	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (25.0)	0	4 (36.4)
No	3 (75.0)	6 (100)	7 (63.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.71	7.80	
95% CI of the inverse odds ratio	(0.13, 22.51)	(0.35, 173.98)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.45	5.25	
95% CI of the inverse risk ratio	(0.22, 9.43)	(0.33, 83.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.36	-30.36	
95% CI of the absolute risk difference	(-62.44, 39.71)	(-63.74, 3.02)	
p-value	0.6797	0.1472	
p-value of Breslow-Day Test for Homogeneity [3]	0.0373	NE	

AMNOG Table SE18.5.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	9 (100)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (20.0)	1 (11.1)	3 (17.6)
No	4 (80.0)	8 (88.9)	14 (82.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	1.71	
95% CI of the inverse odds ratio	(0.07, 10.67)	(0.15, 19.36)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	1.59	
95% CI of the inverse risk ratio	(0.12, 6.73)	(0.19, 13.15)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.35	-6.54	
95% CI of the absolute risk difference	(-37.11, 41.82)	(-33.92, 20.85)	
p-value	0.9046	0.6603	
p-value of Breslow-Day Test for Homogeneity [3]	0.7051	0.2434	

AMNOG Table SE18.5.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (5.9)
No	5 (100)	9 (100)	16 (94.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	1.73	
95% CI of the inverse odds ratio	(0.04, 28.30)	(0.06, 46.77)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	1.67	
95% CI of the inverse risk ratio	(0.05, 21.42)	(0.07, 37.21)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	-3.33	
95% CI of the absolute risk difference	(-25.54, 25.54)	(-21.92, 15.25)	
p-value	>0.9999	0.7428	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.3774	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (20.0)	0	3 (17.6)
No	4 (80.0)	9 (100)	14 (82.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	4.59	
95% CI of the inverse odds ratio	(0.07, 10.67)	(0.21, 99.20)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	3.89	
95% CI of the inverse risk ratio	(0.12, 6.73)	(0.22, 67.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.35	-14.44	
95% CI of the absolute risk difference	(-37.11, 41.82)	(-37.18, 8.29)	
p-value	0.9046	0.2953	
p-value of Breslow-Day Test for Homogeneity [3]	0.5249	0.1607	

AMNOG Table SE18.5.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	3 (17.6)
No	5 (100)	9 (100)	14 (82.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.66	4.59	
95% CI of the inverse odds ratio	(0.12, 60.22)	(0.21, 99.20)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.33	3.89	
95% CI of the inverse risk ratio	(0.14, 38.97)	(0.22, 67.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.11	-14.44	
95% CI of the absolute risk difference	(-39.81, 17.58)	(-37.18, 8.29)	
p-value	0.5271	0.2953	
p-value of Breslow-Day Test for Homogeneity [3]	0.1794	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (20.0)	1 (11.1)	5 (29.4)
No	4 (80.0)	8 (88.9)	12 (70.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	3.33	
95% CI of the inverse odds ratio	(0.15, 18.87)	(0.33, 34.12)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.47	2.65	
95% CI of the inverse risk ratio	(0.22, 9.85)	(0.36, 19.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.41	-18.30	
95% CI of the absolute risk difference	(-50.62, 31.80)	(-48.15, 11.54)	
p-value	0.6779	0.2920	
p-value of Breslow-Day Test for Homogeneity [3]	0.6205	0.5408	

AMNOG Table SE18.5.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	9 (100)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (22.2)	2 (11.8)
No	5 (100)	7 (77.8)	15 (88.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.77	0.47	
95% CI of the inverse odds ratio	(0.07, 43.02)	(0.05, 4.03)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	0.53	
95% CI of the inverse risk ratio	(0.09, 30.06)	(0.09, 3.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.56	10.46	
95% CI of the absolute risk difference	(-32.84, 21.73)	(-20.72, 41.64)	
p-value	0.7216	0.4820	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.4052	

AMNOG Table SE18.5.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	2 (22.2)	3 (17.6)
No	5 (100)	7 (77.8)	14 (82.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.66	0.75	
95% CI of the inverse odds ratio	(0.12, 60.22)	(0.10, 5.58)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.33	0.79	
95% CI of the inverse risk ratio	(0.14, 38.97)	(0.16, 3.92)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.11	4.58	
95% CI of the absolute risk difference	(-39.81, 17.58)	(-28.08, 37.23)	
p-value	0.5271	0.7782	
p-value of Breslow-Day Test for Homogeneity [3]	0.3797	0.1673	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (20.0)	2 (22.2)	5 (29.4)
No	4 (80.0)	7 (77.8)	12 (70.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	1.46	
95% CI of the inverse odds ratio	(0.15, 18.87)	(0.22, 9.62)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.47	1.32	
95% CI of the inverse risk ratio	(0.22, 9.85)	(0.32, 5.51)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.41	-7.19	
95% CI of the absolute risk difference	(-50.62, 31.80)	(-41.93, 27.55)	
p-value	0.6779	0.6942	
p-value of Breslow-Day Test for Homogeneity [3]	0.3822	0.8757	

AMNOG Table SE18.5.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (11.1)	1 (5.9)
No	5 (100)	8 (88.9)	16 (94.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	0.50	
95% CI of the inverse odds ratio	(0.04, 28.30)	(0.03, 9.08)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	0.53	
95% CI of the inverse risk ratio	(0.05, 21.42)	(0.04, 7.50)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	5.23	
95% CI of the absolute risk difference	(-25.54, 25.54)	(-18.15, 28.61)	
p-value	>0.9999	0.6341	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.2222	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (40.0)	1 (11.1)	3 (17.6)
No	3 (60.0)	8 (88.9)	14 (82.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.32	1.71	
95% CI of the inverse odds ratio	(0.04, 2.85)	(0.15, 19.36)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.44	1.59	
95% CI of the inverse risk ratio	(0.10, 1.95)	(0.19, 13.15)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	22.35	-6.54	
95% CI of the absolute risk difference	(-24.25, 68.96)	(-33.92, 20.85)	
p-value	0.2944	0.6603	
p-value of Breslow-Day Test for Homogeneity [3]	0.0748	0.2434	

AMNOG Table SE18.5.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	9 (100)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (60.0)	0	1 (5.9)
No	2 (40.0)	9 (100)	16 (94.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.04	1.73	
95% CI of the inverse odds ratio	(0.00, 0.62)	(0.06, 46.77)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.10	1.67	
95% CI of the inverse risk ratio	(0.01, 0.75)	(0.07, 37.21)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	54.12	-3.33	
95% CI of the absolute risk difference	(9.74, 98.49)	(-21.92, 15.25)	
p-value	0.0058	0.7428	
p-value of Breslow-Day Test for Homogeneity [3]	0.0373	NE	

Program: t-se18-02-04-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE18.6.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Visit Statistic	Visit Result DB MGL-3196 80 mg (N=2)	 DB MGL-3196 100 mg (N=15)	 DB Placebo (N=24)	Change from Baseline DB MGL-3196 80 mg (N=2)	 DB MGL-3196 100 mg (N=15)	 DB Placebo (N=24)
CLDQ-NASH						
Baseline						
m	2	15	24			
n	2	14	21			
Mean (SD)	5.40 (1.98)	5.88 (0.66)	5.72 (0.80)			
Median	5.40	6.10	5.70			
IQR: Q1, Q3	4.00, 6.80	5.80, 6.20	5.20, 6.40			
Min, Max	4.0, 6.8	4.3, 6.8	4.2, 6.9			
Week 24						
m	2	12	23			
n	2	11	21	2	11	20
Mean (SD/SE)	5.70 (1.27)	5.77 (0.62)	5.58 (1.04)	0.30 (0.50)	-0.24 (0.23)	-0.11 (0.16)
Median	5.70	5.50	5.60	0.30	0	0
IQR: Q1, Q3	4.80, 6.60	5.30, 6.30	4.70, 6.60	-0.20, 0.80	-0.60, 0.30	-0.35, 0.10
Min, Max	4.8, 6.6	4.8, 6.7	3.8, 7.0	-0.2, 0.8	-2.0, 0.6	-2.2, 1.9
Week 52						
m	2	12	22			
n	1	10	20	1	10	19
Mean (SD/SE)	7.00 (N/A)	5.61 (0.54)	5.94 (0.84)	0.20 (N/A)	-0.49 (0.25)	0.17 (0.10)
Median	7.00	5.60	6.00	0.20	-0.35	0.20
IQR: Q1, Q3	7.00, 7.00	5.20, 6.10	5.45, 6.70	0.20, 0.20	-0.80, 0.00	-0.10, 0.40
Min, Max	7.0, 7.0	4.5, 6.2	4.5, 7.0	0.2, 0.2	-2.3, 0.6	-0.6, 1.3

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.6.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=24)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=24)
Abdominal Symptoms						
Baseline						
m	2	15	24			
n	2	14	21			
Mean (SD)	5.65 (1.91)	6.06 (0.92)	5.81 (1.16)			
Median	5.65	6.35	6.00			
IQR: Q1, Q3	4.30, 7.00	5.00, 6.70	5.00, 7.00			
Min, Max	4.3, 7.0	4.3, 7.0	3.7, 7.0			
Week 24						
m	2	12	23			
n	2	11	21	2	11	20
Mean (SD/SE)	6.35 (0.92)	6.06 (0.87)	5.57 (1.42)	0.70 (0.70)	-0.35 (0.29)	-0.07 (0.24)
Median	6.35	6.00	5.30	0.70	0	0
IQR: Q1, Q3	5.70, 7.00	5.70, 7.00	4.70, 7.00	0.00, 1.40	-1.30, 0.30	-0.15, 0.15
Min, Max	5.7, 7.0	4.3, 7.0	3.3, 7.0	0.0, 1.4	-1.7, 1.0	-2.7, 2.0
Week 52						
m	2	12	22			
n	1	10	20	1	10	19
Mean (SD/SE)	7.00 (N/A)	5.91 (0.61)	5.94 (1.15)	0.00 (N/A)	-0.57 (0.28)	0.13 (0.10)
Median	7.00	5.70	6.20	0	-0.65	0
IQR: Q1, Q3	7.00, 7.00	5.70, 6.30	5.00, 7.00	0.00, 0.00	-1.30, 0.00	0.00, 0.30
Min, Max	7.0, 7.0	5.0, 7.0	4.0, 7.0	0.0, 0.0	-1.7, 1.0	-1.0, 1.0

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.6.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter / Visit / Statistic	Visit Result: DB MGL-3196 80 mg (N=2)	Visit Result: DB MGL-3196 100 mg (N=15)	Visit Result: DB Placebo (N=24)	Change from Baseline: DB MGL-3196 80 mg (N=2)	Change from Baseline: DB MGL-3196 100 mg (N=15)	Change from Baseline: DB Placebo (N=24)
Activity						
Baseline						
m	2	15	24			
n	2	14	21			
Mean (SD)	5.20 (2.55)	5.80 (1.02)	5.63 (1.04)			
Median	5.20	5.90	5.60			
IQR: Q1, Q3	3.40, 7.00	5.40, 6.60	5.00, 6.60			
Min, Max	3.4, 7.0	3.6, 7.0	3.2, 7.0			
Week 24						
m	2	12	23			
n	2	11	21	2	11	20
Mean (SD/SE)	5.80 (1.41)	5.45 (1.01)	5.40 (1.49)	0.60 (0.80)	-0.55 (0.35)	-0.23 (0.29)
Median	5.80	5.20	5.80	0.60	0	0.10
IQR: Q1, Q3	4.80, 6.80	4.40, 6.60	4.40, 6.40	-0.20, 1.40	-1.60, 0.20	-1.20, 0.50
Min, Max	4.8, 6.8	4.4, 7.0	1.8, 7.0	-0.2, 1.4	-2.6, 0.8	-3.8, 2.6
Week 52						
m	2	12	22			
n	1	10	20	1	10	19
Mean (SD/SE)	7.00 (N/A)	5.30 (0.83)	5.94 (1.11)	0.00 (N/A)	-0.78 (0.32)	0.31 (0.21)
Median	7.00	5.00	6.30	0	-0.80	0
IQR: Q1, Q3	7.00, 7.00	4.60, 6.00	4.90, 7.00	0.00, 0.00	-1.20, 0.00	-0.20, 0.40
Min, Max	7.0, 7.0	4.2, 6.6	3.6, 7.0	0.0, 0.0	-2.4, 0.8	-1.0, 2.2

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.6.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=24)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=24)
Emotional Health						
Baseline						
m	2	15	24			
n	2	14	21			
Mean (SD)	5.95 (1.06)	5.90 (0.87)	5.93 (0.84)			
Median	5.95	6.05	5.90			
IQR: Q1, Q3	5.20, 6.70	5.20, 6.60	5.60, 6.70			
Min, Max	5.2, 6.7	3.8, 6.9	4.1, 7.0			
Week 24						
m	2	12	23			
n	2	11	21	2	11	20
Mean (SD/SE)	6.70 (0.14)	5.75 (0.90)	5.82 (1.06)	0.75 (0.65)	-0.17 (0.31)	-0.06 (0.14)
Median	6.70	5.80	6.10	0.75	0.10	0
IQR: Q1, Q3	6.60, 6.80	5.00, 6.60	4.80, 6.70	0.10, 1.40	-0.60, 0.70	-0.35, 0.30
Min, Max	6.6, 6.8	4.3, 6.9	3.7, 7.0	0.1, 1.4	-2.3, 0.9	-1.5, 1.2
Week 52						
m	2	12	22			
n	1	10	20	1	10	19
Mean (SD/SE)	7.00 (N/A)	5.69 (0.57)	6.07 (1.02)	0.30 (N/A)	-0.31 (0.29)	0.10 (0.12)
Median	7.00	5.85	6.35	0.30	-0.15	0
IQR: Q1, Q3	7.00, 7.00	5.30, 6.00	5.85, 6.85	0.30, 0.30	-0.60, 0.40	-0.30, 0.40
Min, Max	7.0, 7.0	4.7, 6.4	3.4, 7.0	0.3, 0.3	-1.9, 0.9	-0.7, 1.3

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.6.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=24)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=24)
Fatigue						
Baseline						
m	2	15	24			
n	2	14	21			
Mean (SD)	3.60 (3.68)	5.36 (1.07)	4.91 (1.55)			
Median	3.60	5.35	5.50			
IQR: Q1, Q3	1.00, 6.20	4.50, 6.30	4.00, 6.00			
Min, Max	1.0, 6.2	3.5, 7.0	1.5, 7.0			
Week 24						
m	2	12	23			
n	2	11	21	2	11	20
Mean (SD/SE)	3.25 (3.18)	4.96 (1.06)	4.92 (1.50)	-0.35 (0.35)	-0.25 (0.29)	-0.08 (0.30)
Median	3.25	4.70	4.50	-0.35	0.20	0
IQR: Q1, Q3	1.00, 5.50	4.30, 6.20	4.00, 6.30	-0.70, 0.00	-0.70, 0.40	-0.75, 0.60
Min, Max	1.0, 5.5	3.5, 6.8	2.2, 6.8	-0.7, 0.0	-2.2, 0.5	-3.3, 3.0
Week 52						
m	2	12	22			
n	1	10	20	1	10	19
Mean (SD/SE)	7.00 (N/A)	5.02 (0.74)	5.26 (1.25)	0.80 (N/A)	-0.23 (0.39)	0.17 (0.22)
Median	7.00	5.30	4.90	0.80	-0.25	0.20
IQR: Q1, Q3	7.00, 7.00	4.30, 5.50	4.25, 6.30	0.80, 0.80	-1.20, 0.80	-0.50, 1.10
Min, Max	7.0, 7.0	4.0, 6.0	2.8, 7.0	0.8, 0.8	-2.3, 1.8	-1.5, 1.7

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.6.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=2)	(N=15)	(N=24)	(N=2)	(N=15)	(N=24)
Systemic Symptoms						
Baseline						
m	2	15	24			
n	2	14	21			
Mean (SD)	5.65 (1.91)	5.67 (1.27)	5.59 (0.93)			
Median	5.65	5.95	5.50			
IQR: Q1, Q3	4.30, 7.00	5.00, 6.80	5.20, 6.50			
Min, Max	4.3, 7.0	2.7, 7.0	3.8, 7.0			
Week 24						
m	2	12	23			
n	2	11	21	2	11	20
Mean (SD/SE)	5.35 (1.91)	5.89 (0.74)	5.40 (1.22)	-0.30 (0.00)	-0.01 (0.26)	-0.14 (0.21)
Median	5.35	6.00	5.20	-0.30	0	0
IQR: Q1, Q3	4.00, 6.70	5.30, 6.50	4.70, 6.70	-0.30, -0.30	-0.80, 0.60	-0.40, 0.25
Min, Max	4.0, 6.7	4.5, 7.0	3.2, 7.0	-0.3, -0.3	-1.5, 1.5	-2.1, 1.6
Week 52						
m	2	12	22			
n	1	10	20	1	10	19
Mean (SD/SE)	7.00 (N/A)	5.47 (0.80)	5.70 (1.03)	0.00 (N/A)	-0.54 (0.34)	0.10 (0.16)
Median	7.00	5.40	5.65	0	-0.55	0
IQR: Q1, Q3	7.00, 7.00	4.80, 6.00	4.80, 6.65	0.00, 0.00	-0.90, -0.20	-0.30, 0.50
Min, Max	7.0, 7.0	4.2, 7.0	3.5, 7.0	0.0, 0.0	-2.8, 1.6	-1.2, 1.5

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.6.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=24)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=24)
Worry						
Baseline						
m	2	15	24			
n	2	14	21			
Mean (SD)	6.45 (0.78)	6.44 (0.63)	6.50 (0.54)			
Median	6.45	6.70	6.70			
IQR: Q1, Q3	5.90, 7.00	5.90, 6.90	6.30, 7.00			
Min, Max	5.9, 7.0	5.1, 7.0	5.4, 7.0			
Week 24						
m	2	12	23			
n	2	11	21	2	11	20
Mean (SD/SE)	7.00 (0.00)	6.43 (0.80)	6.30 (1.02)	0.55 (0.55)	-0.15 (0.22)	-0.20 (0.17)
Median	7.00	6.90	6.90	0.55	0.10	0
IQR: Q1, Q3	7.00, 7.00	5.60, 7.00	5.90, 7.00	0.00, 1.10	0.00, 0.20	-0.45, 0.15
Min, Max	7.0, 7.0	4.9, 7.0	3.7, 7.0	0.0, 1.1	-2.1, 0.5	-1.9, 0.9
Week 52						
m	2	12	22			
n	1	10	20	1	10	19
Mean (SD/SE)	7.00 (N/A)	6.29 (0.92)	6.65 (0.45)	0.00 (N/A)	-0.44 (0.27)	0.12 (0.10)
Median	7.00	6.70	6.90	0	-0.10	0
IQR: Q1, Q3	7.00, 7.00	6.10, 7.00	6.30, 7.00	0.00, 0.00	-0.80, 0.00	-0.10, 0.10
Min, Max	7.0, 7.0	4.3, 7.0	5.6, 7.0	0.0, 0.0	-2.7, 0.2	-0.3, 1.6

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.6.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result: DB MGL-3196 80 mg (N=7)	Visit Result: DB MGL-3196 100 mg (N=0)	Visit Result: DB Placebo (N=4)	Change from Baseline: DB MGL-3196 80 mg (N=7)	Change from Baseline: DB MGL-3196 100 mg (N=0)	Change from Baseline: DB Placebo (N=4)
CLDQ-NASH						
Baseline						
m	7	0	4			
n	7	0	4			
Mean (SD)	5.37 (1.59)	N/A	6.03 (0.83)			
Median	6.10	N/A	6.35			
IQR: Q1, Q3	4.70, 6.50	N/A	5.50, 6.55			
Min, Max	2.2, 6.6	N/A	4.8, 6.6			
Week 24						
m	6	0	4			
n	5	0	4	5	0	4
Mean (SD/SE)	5.62 (1.14)	N/A	6.05 (0.87)	0.26 (0.35)	N/A	0.03 (0.13)
Median	6.30	N/A	6.20	0	N/A	0.05
IQR: Q1, Q3	5.20, 6.30	N/A	5.40, 6.70	-0.20, 0.20	N/A	-0.15, 0.20
Min, Max	3.8, 6.5	N/A	4.9, 6.9	-0.3, 1.6	N/A	-0.3, 0.3
Week 52						
m	6	0	4			
n	6	0	4	6	0	4
Mean (SD/SE)	5.53 (1.49)	N/A	5.15 (1.66)	0.05 (0.13)	N/A	-0.88 (0.76)
Median	6.05	N/A	5.30	-0.05	N/A	-0.35
IQR: Q1, Q3	5.50, 6.40	N/A	3.85, 6.45	-0.20, 0.40	N/A	-1.80, 0.05
Min, Max	2.6, 6.6	N/A	3.1, 6.9	-0.3, 0.5	N/A	-3.1, 0.3

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.6.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=4)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=4)
Abdominal Symptoms						
Baseline						
m	7	0	4			
n	7	0	4			
Mean (SD)	5.67 (2.17)	N/A	6.08 (1.85)			
Median	6.70	N/A	7.00			
IQR: Q1, Q3	5.00, 7.00	N/A	5.15, 7.00			
Min, Max	1.0, 7.0	N/A	3.3, 7.0			
Week 24						
m	6	0	4			
n	5	0	4	5	0	4
Mean (SD/SE)	5.32 (1.95)	N/A	6.10 (1.41)	0.04 (0.29)	N/A	0.03 (0.24)
Median	6.00	N/A	6.70	0	N/A	-0.15
IQR: Q1, Q3	5.30, 6.30	N/A	5.35, 6.85	-0.40, 0.30	N/A	-0.30, 0.35
Min, Max	2.0, 7.0	N/A	4.0, 7.0	-0.7, 1.0	N/A	-0.3, 0.7
Week 52						
m	6	0	4			
n	6	0	4	6	0	4
Mean (SD/SE)	5.38 (2.19)	N/A	4.58 (2.32)	-0.07 (0.17)	N/A	-1.50 (1.19)
Median	6.15	N/A	4.65	-0.15	N/A	-0.50
IQR: Q1, Q3	5.70, 6.30	N/A	2.65, 6.50	-0.40, 0.00	N/A	-3.00, 0.00
Min, Max	1.0, 7.0	N/A	2.0, 7.0	-0.4, 0.7	N/A	-5.0, 0.0

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.6.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=4)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=4)
Activity						
Baseline						
m	7	0	4			
n	7	0	4			
Mean (SD)	5.49 (1.73)	N/A	6.30 (0.62)			
Median	6.20	N/A	6.30			
IQR: Q1, Q3	4.80, 6.80	N/A	5.80, 6.80			
Min, Max	2.0, 6.8	N/A	5.6, 7.0			
Week 24						
m	6	0	4			
n	5	0	4	5	0	4
Mean (SD/SE)	5.60 (0.68)	N/A	6.05 (1.12)	0.32 (0.63)	N/A	-0.25 (0.28)
Median	5.80	N/A	6.20	-0.40	N/A	-0.30
IQR: Q1, Q3	5.00, 6.00	N/A	5.10, 7.00	-0.40, 0.20	N/A	-0.70, 0.20
Min, Max	4.8, 6.4	N/A	4.8, 7.0	-0.6, 2.8	N/A	-0.8, 0.4
Week 52						
m	6	0	4			
n	6	0	4	6	0	4
Mean (SD/SE)	5.60 (1.18)	N/A	5.65 (1.66)	0.07 (0.36)	N/A	-0.65 (0.66)
Median	5.70	N/A	6.10	-0.10	N/A	-0.10
IQR: Q1, Q3	5.60, 6.40	N/A	4.40, 6.90	-0.60, 0.80	N/A	-1.40, 0.10
Min, Max	3.4, 6.8	N/A	3.4, 7.0	-1.0, 1.4	N/A	-2.6, 0.2

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.6.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=4)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=4)
Emotional Health						
Baseline						
m	7	0	4			
n	7	0	4			
Mean (SD)	5.70 (1.44)	N/A	5.85 (0.85)			
Median	6.20	N/A	6.00			
IQR: Q1, Q3	4.30, 6.90	N/A	5.25, 6.45			
Min, Max	3.3, 7.0	N/A	4.7, 6.7			
Week 24						
m	6	0	4			
n	5	0	4	5	0	4
Mean (SD/SE)	5.88 (1.14)	N/A	6.10 (0.86)	0.00 (0.27)	N/A	0.25 (0.12)
Median	6.30	N/A	6.15	-0.10	N/A	0.35
IQR: Q1, Q3	5.10, 6.80	N/A	5.40, 6.80	-0.30, 0.00	N/A	0.10, 0.40
Min, Max	4.3, 6.9	N/A	5.1, 7.0	-0.6, 1.0	N/A	-0.1, 0.4
Week 52						
m	6	0	4			
n	6	0	4	6	0	4
Mean (SD/SE)	5.62 (1.35)	N/A	5.10 (1.58)	-0.32 (0.14)	N/A	-0.75 (0.60)
Median	5.75	N/A	5.10	-0.15	N/A	-0.35
IQR: Q1, Q3	5.30, 6.80	N/A	3.85, 6.35	-0.60, -0.10	N/A	-1.45, -0.05
Min, Max	3.2, 6.9	N/A	3.3, 6.9	-0.9, 0.0	N/A	-2.5, 0.2

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.6.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=7)	(N=0)	(N=4)	(N=7)	(N=0)	(N=4)
Fatigue						
Baseline						
m	7	0	4			
n	7	0	4			
Mean (SD)	4.87 (1.45)	N/A	5.95 (0.73)			
Median	5.30	N/A	5.75			
IQR: Q1, Q3	4.50, 5.80	N/A	5.50, 6.40			
Min, Max	1.8, 6.0	N/A	5.3, 7.0			
Week 24						
m	6	0	4			
n	5	0	4	5	0	4
Mean (SD/SE)	5.04 (1.08)	N/A	5.63 (0.90)	0.28 (0.36)	N/A	-0.33 (0.14)
Median	5.80	N/A	5.50	0	N/A	-0.35
IQR: Q1, Q3	4.30, 5.80	N/A	4.95, 6.30	-0.20, 0.10	N/A	-0.55, -0.10
Min, Max	3.5, 5.8	N/A	4.7, 6.8	-0.2, 1.7	N/A	-0.6, 0.0
Week 52						
m	6	0	4			
n	6	0	4	6	0	4
Mean (SD/SE)	5.00 (1.27)	N/A	4.65 (1.81)	0.15 (0.20)	N/A	-1.30 (0.62)
Median	5.40	N/A	4.40	0.10	N/A	-1.15
IQR: Q1, Q3	4.50, 5.70	N/A	3.30, 6.00	-0.30, 0.50	N/A	-2.20, -0.40
Min, Max	2.7, 6.3	N/A	2.8, 7.0	-0.4, 0.9	N/A	-2.9, 0.0

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.6.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=4)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=4)
Systemic Symptoms						
Baseline						
m	7	0	4			
n	7	0	4			
Mean (SD)	5.50 (1.13)	N/A	5.98 (0.24)			
Median	5.80	N/A	5.90			
IQR: Q1, Q3	4.30, 6.50	N/A	5.80, 6.15			
Min, Max	4.0, 6.8	N/A	5.8, 6.3			
Week 24						
m	6	0	4			
n	5	0	4	5	0	4
Mean (SD/SE)	5.88 (0.95)	N/A	5.88 (0.64)	0.20 (0.20)	N/A	-0.10 (0.22)
Median	6.30	N/A	5.70	0.50	N/A	-0.20
IQR: Q1, Q3	5.30, 6.50	N/A	5.50, 6.25	0.00, 0.50	N/A	-0.40, 0.20
Min, Max	4.5, 6.8	N/A	5.3, 6.8	-0.5, 0.5	N/A	-0.5, 0.5
Week 52						
m	6	0	4			
n	6	0	4	6	0	4
Mean (SD/SE)	5.63 (1.23)	N/A	5.25 (1.51)	-0.07 (0.19)	N/A	-0.73 (0.67)
Median	6.25	N/A	5.50	-0.15	N/A	-0.40
IQR: Q1, Q3	5.20, 6.30	N/A	4.25, 6.25	-0.30, 0.40	N/A	-1.65, 0.20
Min, Max	3.3, 6.5	N/A	3.2, 6.8	-0.7, 0.5	N/A	-2.6, 0.5

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE18.6.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result: DB MGL-3196 80 mg (N=7)	Visit Result: DB MGL-3196 100 mg (N=0)	Visit Result: DB Placebo (N=4)	Change from Baseline: DB MGL-3196 80 mg (N=7)	Change from Baseline: DB MGL-3196 100 mg (N=0)	Change from Baseline: DB Placebo (N=4)
Worry						
Baseline						
m	7	0	4			
n	7	0	4			
Mean (SD)	5.03 (2.30)	N/A	6.00 (1.37)			
Median	5.90	N/A	6.45			
IQR: Q1, Q3	2.60, 6.90	N/A	5.00, 7.00			
Min, Max	1.0, 7.0	N/A	4.1, 7.0			
Week 24						
m	6	0	4			
n	5	0	4	5	0	4
Mean (SD/SE)	6.00 (1.41)	N/A	6.60 (0.80)	0.66 (0.49)	N/A	0.60 (0.35)
Median	6.40	N/A	7.00	0.30	N/A	0.55
IQR: Q1, Q3	6.00, 7.00	N/A	6.20, 7.00	0.10, 0.30	N/A	0.00, 1.20
Min, Max	3.6, 7.0	N/A	5.4, 7.0	0.0, 2.6	N/A	0.0, 1.3
Week 52						
m	6	0	4			
n	6	0	4	6	0	4
Mean (SD/SE)	5.85 (2.05)	N/A	5.78 (1.46)	0.42 (0.15)	N/A	-0.23 (0.92)
Median	6.60	N/A	6.00	0.45	N/A	0.45
IQR: Q1, Q3	6.30, 6.90	N/A	4.55, 7.00	0.00, 0.70	N/A	-1.45, 1.00
Min, Max	1.7, 7.0	N/A	4.1, 7.0	0.0, 0.9	N/A	-2.9, 1.1

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.6.2
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of CLDQ-NASH - MMRM Model
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

AMNOG Table SE18.6.2
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of CLDQ-NASH - MMRM Model
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
CLDQ-NASH			
Week 24			
m	2	12	23
n	2	11	20
Baseline Mean (SD)	5.40 (1.98)	6.01 (0.54)	5.74 (0.81)
Analysis Visit Mean (SD)	5.70 (1.27)	5.77 (0.62)	5.63 (1.04)
LS Mean of Change from Baseline (SE)	0.37 (0.56)	-0.05 (0.28)	0.04 (0.25)
95% CI	(-0.77, 1.51)	(-0.61, 0.52)	(-0.47, 0.55)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.33 (0.54)	-0.08 (0.28)	
95% CI	(-0.78, 1.45)	(-0.66, 0.49)	
p-value	0.5431	0.7683	
Corrected Hedge's g Statistics	0.292	-0.077	
95% CI	(-1.16, 1.75)	(-0.81, 0.66)	
Week 52			
m	2	12	22
n	1	10	19
Baseline Mean (SD)	6.80 (N/A)	6.10 (0.47)	5.76 (0.82)
Analysis Visit Mean (SD)	7.00 (N/A)	5.61 (0.54)	5.94 (0.86)
LS Mean of Change from Baseline (SE)	0.73 (0.60)	-0.26 (0.25)	0.31 (0.23)
95% CI	(-0.49, 1.96)	(-0.77, 0.24)	(-0.15, 0.78)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.42 (0.57)	-0.57 (0.23)	
95% CI	(-0.74, 1.59)	(-1.04, -0.11)	
p-value	0.4654	0.0166	
Corrected Hedge's g Statistics	0.406	-0.602	
95% CI	(-1.61, 2.42)	(-1.38, 0.18)	
Subgroup*Treatment Interaction p-value	0.7886	NE	

AMNOG Table SE18.6.2
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of CLDQ-NASH - MMRM Model
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
CLDQ-NASH			
Week 24			
m	6	0	4
n	5	0	4
Baseline Mean (SD)	5.36 (1.89)	N/A	6.03 (0.83)
Analysis Visit Mean (SD)	5.62 (1.14)	N/A	6.05 (0.87)
LS Mean of Change from Baseline (SE)	0.10 (0.23)	NE	0.03 (0.43)
95% CI	(-0.45, 0.65)	NE	(-1.01, 1.07)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.06 (0.34)	NE	
95% CI	(-0.77, 0.90)	NE	
p-value	0.8580	NE	
Corrected Hedge's g Statistics	0.084	NE	
95% CI	(-1.23, 1.40)	NE	
Week 52			
m	6	0	4
n	6	0	4
Baseline Mean (SD)	5.48 (1.72)	N/A	6.03 (0.83)
Analysis Visit Mean (SD)	5.53 (1.49)	N/A	5.15 (1.66)
LS Mean of Change from Baseline (SE)	-0.03 (0.46)	NE	-0.94 (0.65)
95% CI	(-1.17, 1.10)	NE	(-2.52, 0.65)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.90 (0.71)	NE	
95% CI	(-0.83, 2.63)	NE	
p-value	0.2492	NE	
Corrected Hedge's g Statistics	0.680	NE	
95% CI	(-0.62, 1.98)	NE	
Subgroup*Treatment Interaction p-value	0.7886	NE	

AMNOG Table SE18.6.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

AMNOG Table SE18.6.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Abdominal Symptoms			
Week 24			
m	2	12	23
n	2	11	20
Baseline Mean (SD)	5.65 (1.91)	6.41 (0.65)	5.75 (1.16)
Analysis Visit Mean (SD)	6.35 (0.92)	6.06 (0.87)	5.69 (1.35)
LS Mean of Change from Baseline (SE)	0.84 (0.73)	-0.01 (0.36)	0.10 (0.31)
95% CI	(-0.66, 2.33)	(-0.74, 0.72)	(-0.53, 0.73)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.74 (0.73)	-0.11 (0.39)	
95% CI	(-0.75, 2.22)	(-0.90, 0.68)	
p-value	0.3175	0.7812	
Corrected Hedge's g Statistics	0.523	-0.081	
95% CI	(-0.94, 1.99)	(-0.82, 0.66)	
Week 52			
m	2	12	22
n	1	10	19
Baseline Mean (SD)	7.00 (N/A)	6.48 (0.64)	5.86 (1.08)
Analysis Visit Mean (SD)	7.00 (N/A)	5.91 (0.61)	5.98 (1.16)
LS Mean of Change from Baseline (SE)	0.57 (0.69)	-0.27 (0.28)	0.36 (0.26)
95% CI	(-0.83, 1.98)	(-0.85, 0.31)	(-0.16, 0.89)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.21 (0.66)	-0.64 (0.26)	
95% CI	(-1.13, 1.55)	(-1.17, -0.10)	
p-value	0.7491	0.0224	
Corrected Hedge's g Statistics	0.181	-0.588	
95% CI	(-1.83, 2.19)	(-1.37, 0.19)	
Subgroup*Treatment Interaction p-value	0.7660	NE	

AMNOG Table SE18.6.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Activity			
Week 24			
m	2	12	23
n	2	11	20
Baseline Mean (SD)	5.20 (2.55)	6.00 (0.90)	5.59 (1.05)
Analysis Visit Mean (SD)	5.80 (1.41)	5.45 (1.01)	5.36 (1.52)
LS Mean of Change from Baseline (SE)	0.54 (0.90)	-0.34 (0.45)	-0.14 (0.39)
95% CI	(-1.30, 2.38)	(-1.26, 0.57)	(-0.94, 0.67)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.68 (0.89)	-0.21 (0.46)	
95% CI	(-1.13, 2.50)	(-1.14, 0.73)	
p-value	0.4495	0.6557	
Corrected Hedge's g Statistics	0.377	-0.120	
95% CI	(-1.08, 1.83)	(-0.86, 0.62)	
Week 52			
m	2	12	22
n	1	10	19
Baseline Mean (SD)	7.00 (N/A)	6.08 (0.91)	5.58 (1.07)
Analysis Visit Mean (SD)	7.00 (N/A)	5.30 (0.83)	5.88 (1.11)
LS Mean of Change from Baseline (SE)	0.83 (0.97)	-0.51 (0.39)	0.37 (0.35)
95% CI	(-1.15, 2.81)	(-1.30, 0.28)	(-0.35, 1.09)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.46 (0.92)	-0.88 (0.36)	
95% CI	(-1.43, 2.34)	(-1.60, -0.15)	
p-value	0.6231	0.0197	
Corrected Hedge's g Statistics	0.285	-0.593	
95% CI	(-1.73, 2.30)	(-1.37, 0.19)	
Subgroup*Treatment Interaction p-value	0.9949	NE	

AMNOG Table SE18.6.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Emotional Health			
Week 24			
m	2	12	23
n	2	11	20
Baseline Mean (SD)	5.95 (1.06)	5.92 (0.61)	5.95 (0.86)
Analysis Visit Mean (SD)	6.70 (0.14)	5.75 (0.90)	5.89 (1.03)
LS Mean of Change from Baseline (SE)	1.02 (0.57)	0.03 (0.29)	0.22 (0.27)
95% CI	(-0.15, 2.19)	(-0.56, 0.62)	(-0.33, 0.77)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.80 (0.55)	-0.19 (0.28)	
95% CI	(-0.32, 1.93)	(-0.76, 0.39)	
p-value	0.1551	0.5075	
Corrected Hedge's g Statistics	0.655	-0.164	
95% CI	(-0.81, 2.12)	(-0.90, 0.57)	
Week 52			
m	2	12	22
n	1	10	19
Baseline Mean (SD)	6.70 (N/A)	6.00 (0.57)	5.95 (0.88)
Analysis Visit Mean (SD)	7.00 (N/A)	5.69 (0.57)	6.05 (1.05)
LS Mean of Change from Baseline (SE)	1.01 (0.71)	-0.07 (0.28)	0.39 (0.26)
95% CI	(-0.45, 2.47)	(-0.65, 0.50)	(-0.15, 0.93)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.62 (0.69)	-0.46 (0.27)	
95% CI	(-0.79, 2.02)	(-1.02, 0.09)	
p-value	0.3772	0.0963	
Corrected Hedge's g Statistics	0.515	-0.422	
95% CI	(-1.50, 2.53)	(-1.20, 0.35)	
Subgroup*Treatment Interaction p-value	0.0900	NE	

AMNOG Table SE18.6.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Fatigue			
Week 24			
m	2	12	23
n	2	11	20
Baseline Mean (SD)	3.60 (3.68)	5.21 (1.12)	5.08 (1.37)
Analysis Visit Mean (SD)	3.25 (3.18)	4.96 (1.06)	5.01 (1.48)
LS Mean of Change from Baseline (SE)	-0.59 (0.90)	0.01 (0.43)	0.15 (0.39)
95% CI	(-2.43, 1.25)	(-0.87, 0.89)	(-0.65, 0.95)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.74 (0.88)	-0.14 (0.44)	
95% CI	(-2.54, 1.06)	(-1.03, 0.76)	
p-value	0.4073	0.7557	
Corrected Hedge's g Statistics	-0.414	-0.081	
95% CI	(-1.87, 1.04)	(-0.82, 0.65)	
Week 52			
m	2	12	22
n	1	10	19
Baseline Mean (SD)	6.20 (N/A)	5.25 (1.17)	5.11 (1.41)
Analysis Visit Mean (SD)	7.00 (N/A)	5.02 (0.74)	5.28 (1.28)
LS Mean of Change from Baseline (SE)	1.32 (0.92)	0.07 (0.37)	0.37 (0.36)
95% CI	(-0.55, 3.20)	(-0.70, 0.83)	(-0.36, 1.10)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.95 (0.87)	-0.30 (0.35)	
95% CI	(-0.83, 2.74)	(-1.01, 0.41)	
p-value	0.2834	0.3906	
Corrected Hedge's g Statistics	0.588	-0.204	
95% CI	(-1.43, 2.61)	(-0.97, 0.56)	
Subgroup*Treatment Interaction p-value	0.2374	NE	

AMNOG Table SE18.6.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Systemic Symptoms			
Week 24			
m	2	12	23
n	2	11	20
Baseline Mean (SD)	5.65 (1.91)	5.90 (0.99)	5.60 (0.95)
Analysis Visit Mean (SD)	5.35 (1.91)	5.89 (0.74)	5.46 (1.22)
LS Mean of Change from Baseline (SE)	-0.28 (0.69)	0.08 (0.36)	-0.15 (0.33)
95% CI	(-1.69, 1.13)	(-0.66, 0.82)	(-0.84, 0.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.13 (0.65)	0.23 (0.34)	
95% CI	(-1.46, 1.21)	(-0.46, 0.92)	
p-value	0.8486	0.4978	
Corrected Hedge's g Statistics	-0.082	0.161	
95% CI	(-1.54, 1.37)	(-0.58, 0.90)	
Week 52			
m	2	12	22
n	1	10	19
Baseline Mean (SD)	7.00 (N/A)	6.01 (0.97)	5.62 (0.97)
Analysis Visit Mean (SD)	7.00 (N/A)	5.47 (0.80)	5.72 (1.05)
LS Mean of Change from Baseline (SE)	0.22 (0.83)	-0.44 (0.35)	0.04 (0.33)
95% CI	(-1.48, 1.91)	(-1.17, 0.28)	(-0.63, 0.71)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.18 (0.78)	-0.48 (0.32)	
95% CI	(-1.42, 1.78)	(-1.13, 0.17)	
p-value	0.8203	0.1391	
Corrected Hedge's g Statistics	0.120	-0.353	
95% CI	(-1.89, 2.13)	(-1.12, 0.42)	
Subgroup*Treatment Interaction p-value	0.2886	NE	

AMNOG Table SE18.6.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Worry			
Week 24			
m	2	12	23
n	2	11	20
Baseline Mean (SD)	6.45 (0.78)	6.58 (0.60)	6.52 (0.55)
Analysis Visit Mean (SD)	7.00 (0.00)	6.43 (0.80)	6.32 (1.05)
LS Mean of Change from Baseline (SE)	0.61 (0.59)	-0.11 (0.30)	-0.13 (0.28)
95% CI	(-0.60, 1.82)	(-0.72, 0.50)	(-0.69, 0.44)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.74 (0.57)	0.01 (0.29)	
95% CI	(-0.44, 1.91)	(-0.59, 0.61)	
p-value	0.2094	0.9702	
Corrected Hedge's g Statistics	0.581	0.009	
95% CI	(-0.88, 2.04)	(-0.73, 0.75)	
Week 52			
m	2	12	22
n	1	10	19
Baseline Mean (SD)	7.00 (N/A)	6.73 (0.36)	6.53 (0.56)
Analysis Visit Mean (SD)	7.00 (N/A)	6.29 (0.92)	6.65 (0.46)
LS Mean of Change from Baseline (SE)	0.61 (0.61)	-0.28 (0.27)	0.13 (0.26)
95% CI	(-0.64, 1.85)	(-0.83, 0.27)	(-0.40, 0.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.48 (0.57)	-0.41 (0.25)	
95% CI	(-0.70, 1.65)	(-0.91, 0.09)	
p-value	0.4144	0.1030	
Corrected Hedge's g Statistics	0.405	-0.385	
95% CI	(-1.61, 2.42)	(-1.16, 0.39)	
Subgroup*Treatment Interaction p-value	0.6639	NE	

AMNOG Table SE18.6.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Abdominal Symptoms			
Week 24			
m	6	0	4
n	5	0	4
Baseline Mean (SD)	5.28 (2.52)	N/A	6.08 (1.85)
Analysis Visit Mean (SD)	5.32 (1.95)	N/A	6.10 (1.41)
LS Mean of Change from Baseline (SE)	0.06 (0.07)	NE	0.56 (0.11)
95% CI	(-0.10, 0.23)	NE	(0.28, 0.84)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.49 (0.11)	NE	
95% CI	(-0.76, -0.23)	NE	
p-value	0.0038	NE	
Corrected Hedge's g Statistics	-2.319	NE	
95% CI	(-4.02, -0.62)	NE	
Week 52			
m	6	0	4
n	6	0	4
Baseline Mean (SD)	5.45 (2.29)	N/A	6.08 (1.85)
Analysis Visit Mean (SD)	5.38 (2.19)	N/A	4.58 (2.32)
LS Mean of Change from Baseline (SE)	0.07 (0.62)	NE	-0.99 (0.76)
95% CI	(-1.44, 1.57)	NE	(-2.85, 0.87)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.05 (0.98)	NE	
95% CI	(-1.35, 3.45)	NE	
p-value	0.3243	NE	
Corrected Hedge's g Statistics	0.628	NE	
95% CI	(-0.67, 1.92)	NE	
Subgroup*Treatment Interaction p-value	0.7660	NE	

AMNOG Table SE18.6.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Activity			
Week 24			
m	6	0	4
n	5	0	4
Baseline Mean (SD)	5.28 (1.99)	N/A	6.30 (0.62)
Analysis Visit Mean (SD)	5.60 (0.68)	N/A	6.05 (1.12)
LS Mean of Change from Baseline (SE)	-0.17 (0.47)	NE	-0.27 (0.85)
95% CI	(-1.32, 0.98)	NE	(-2.35, 1.81)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.10 (0.70)	NE	
95% CI	(-1.60, 1.80)	NE	
p-value	0.8888	NE	
Corrected Hedge's g Statistics	0.066	NE	
95% CI	(-1.25, 1.38)	NE	
Week 52			
m	6	0	4
n	6	0	4
Baseline Mean (SD)	5.53 (1.89)	N/A	6.30 (0.62)
Analysis Visit Mean (SD)	5.60 (1.18)	N/A	5.65 (1.66)
LS Mean of Change from Baseline (SE)	-0.17 (0.59)	NE	-0.81 (0.93)
95% CI	(-1.61, 1.28)	NE	(-3.10, 1.47)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.64 (0.83)	NE	
95% CI	(-1.38, 2.67)	NE	
p-value	0.4667	NE	
Corrected Hedge's g Statistics	0.359	NE	
95% CI	(-0.92, 1.63)	NE	
Subgroup*Treatment Interaction p-value	0.9949	NE	

AMNOG Table SE18.6.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Emotional Health			
Week 24			
m	6	0	4
n	5	0	4
Baseline Mean (SD)	5.88 (1.58)	N/A	5.85 (0.85)
Analysis Visit Mean (SD)	5.88 (1.14)	N/A	6.10 (0.86)
LS Mean of Change from Baseline (SE)	0.06 (0.27)	NE	0.34 (0.46)
95% CI	(-0.59, 0.72)	NE	(-0.79, 1.47)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.28 (0.36)	NE	
95% CI	(-1.16, 0.60)	NE	
p-value	0.4635	NE	
Corrected Hedge's g Statistics	-0.331	NE	
95% CI	(-1.65, 0.99)	NE	
Week 52			
m	6	0	4
n	6	0	4
Baseline Mean (SD)	5.93 (1.42)	N/A	5.85 (0.85)
Analysis Visit Mean (SD)	5.62 (1.35)	N/A	5.10 (1.58)
LS Mean of Change from Baseline (SE)	-0.24 (0.42)	NE	-0.65 (0.60)
95% CI	(-1.26, 0.79)	NE	(-2.11, 0.81)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.41 (0.59)	NE	
95% CI	(-1.04, 1.86)	NE	
p-value	0.5126	NE	
Corrected Hedge's g Statistics	0.340	NE	
95% CI	(-0.93, 1.61)	NE	
Subgroup*Treatment Interaction p-value	0.0900	NE	

AMNOG Table SE18.6.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Fatigue			
Week 24			
m	6	0	4
n	5	0	4
Baseline Mean (SD)	4.76 (1.76)	N/A	5.95 (0.73)
Analysis Visit Mean (SD)	5.04 (1.08)	N/A	5.63 (0.90)
LS Mean of Change from Baseline (SE)	-0.04 (0.28)	NE	-0.55 (0.56)
95% CI	(-0.72, 0.64)	NE	(-1.93, 0.82)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.51 (0.47)	NE	
95% CI	(-0.63, 1.65)	NE	
p-value	0.3127	NE	
Corrected Hedge's g Statistics	0.522	NE	
95% CI	(-0.81, 1.86)	NE	
Week 52			
m	6	0	4
n	6	0	4
Baseline Mean (SD)	4.85 (1.59)	N/A	5.95 (0.73)
Analysis Visit Mean (SD)	5.00 (1.27)	N/A	4.65 (1.81)
LS Mean of Change from Baseline (SE)	-0.06 (0.44)	NE	-1.70 (0.69)
95% CI	(-1.14, 1.01)	NE	(-3.39, -0.02)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.64 (0.69)	NE	
95% CI	(-0.05, 3.33)	NE	
p-value	0.0549	NE	
Corrected Hedge's g Statistics	1.238	NE	
95% CI	(-0.14, 2.61)	NE	
Subgroup*Treatment Interaction p-value	0.2374	NE	

AMNOG Table SE18.6.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Systemic Symptoms			
Week 24			
m	6	0	4
n	5	0	4
Baseline Mean (SD)	5.68 (1.22)	N/A	5.98 (0.24)
Analysis Visit Mean (SD)	5.88 (0.95)	N/A	5.88 (0.64)
LS Mean of Change from Baseline (SE)	0.00 (0.22)	NE	-0.41 (0.40)
95% CI	(-0.55, 0.55)	NE	(-1.38, 0.57)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.41 (0.32)	NE	
95% CI	(-0.37, 1.19)	NE	
p-value	0.2503	NE	
Corrected Hedge's g Statistics	0.560	NE	
95% CI	(-0.78, 1.90)	NE	
Week 52			
m	6	0	4
n	6	0	4
Baseline Mean (SD)	5.70 (1.09)	N/A	5.98 (0.24)
Analysis Visit Mean (SD)	5.63 (1.23)	N/A	5.25 (1.51)
LS Mean of Change from Baseline (SE)	-0.27 (0.43)	NE	-1.09 (0.59)
95% CI	(-1.32, 0.78)	NE	(-2.54, 0.36)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.82 (0.64)	NE	
95% CI	(-0.75, 2.39)	NE	
p-value	0.2491	NE	
Corrected Hedge's g Statistics	0.674	NE	
95% CI	(-0.62, 1.97)	NE	
Subgroup*Treatment Interaction p-value	0.2886	NE	

AMNOG Table SE18.6.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Worry			
Week 24			
m	6	0	4
n	5	0	4
Baseline Mean (SD)	5.34 (2.49)	N/A	6.00 (1.37)
Analysis Visit Mean (SD)	6.00 (1.41)	N/A	6.60 (0.80)
LS Mean of Change from Baseline (SE)	0.47 (0.17)	NE	0.61 (0.32)
95% CI	(0.05, 0.90)	NE	(-0.18, 1.40)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.13 (0.26)	NE	
95% CI	(-0.77, 0.50)	NE	
p-value	0.6239	NE	
Corrected Hedge's g Statistics	-0.233	NE	
95% CI	(-1.55, 1.09)	NE	
Week 52			
m	6	0	4
n	6	0	4
Baseline Mean (SD)	5.43 (2.24)	N/A	6.00 (1.37)
Analysis Visit Mean (SD)	5.85 (2.05)	N/A	5.78 (1.46)
LS Mean of Change from Baseline (SE)	0.30 (0.50)	NE	-0.29 (0.66)
95% CI	(-0.93, 1.53)	NE	(-1.90, 1.32)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.59 (0.78)	NE	
95% CI	(-1.33, 2.51)	NE	
p-value	0.4797	NE	
Corrected Hedge's g Statistics	0.421	NE	
95% CI	(-0.86, 1.70)	NE	
Subgroup*Treatment Interaction p-value	0.6639	NE	

AMNOG Table SE18.6.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi-square Test. For this unadjusted analysis, only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.

AMNOG Table SE18.6.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (4.2)
No	2 (100)	15 (100)	23 (95.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.17	-4.17	
95% CI of the absolute risk difference	(-12.16, 3.83)	(-12.16, 3.83)	
p-value	0.7685	0.4232	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (6.7)	6 (25.0)
No	2 (100)	14 (93.3)	18 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.76	4.67	
95% CI of the inverse odds ratio	(0.07, 41.62)	(0.50, 43.37)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.56	3.75	
95% CI of the inverse risk ratio	(0.11, 21.33)	(0.50, 28.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.33	-18.33	
95% CI of the absolute risk difference	(-54.88, 36.21)	(-39.77, 3.10)	
p-value	0.7243	0.1467	
p-value of Breslow-Day Test for Homogeneity [3]	0.4244	NE	

AMNOG Table SE18.6.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (6.7)	2 (8.3)
No	2 (100)	14 (93.3)	22 (91.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	1.27	
95% CI of the inverse odds ratio	(0.02, 15.15)	(0.11, 15.38)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	1.25	
95% CI of the inverse risk ratio	(0.04, 9.77)	(0.12, 12.62)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.67	-1.67	
95% CI of the absolute risk difference	(-37.11, 50.45)	(-18.45, 15.11)	
p-value	0.7243	0.8493	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (6.7)	4 (16.7)
No	2 (100)	14 (93.3)	20 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.10	2.80	
95% CI of the inverse odds ratio	(0.04, 27.01)	(0.28, 27.80)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.08	2.50	
95% CI of the inverse risk ratio	(0.08, 15.52)	(0.31, 20.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.33	-10.00	
95% CI of the absolute risk difference	(-46.11, 43.45)	(-29.54, 9.54)	
p-value	0.9546	0.3635	
p-value of Breslow-Day Test for Homogeneity [3]	0.3171	NE	

AMNOG Table SE18.6.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	4 (16.7)
No	2 (100)	15 (100)	20 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.10	6.80	
95% CI of the inverse odds ratio	(0.04, 27.01)	(0.34, 136.04)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.08	5.76	
95% CI of the inverse risk ratio	(0.08, 15.52)	(0.33, 99.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.33	-14.88	
95% CI of the absolute risk difference	(-46.11, 43.45)	(-32.18, 2.43)	
p-value	0.9546	0.1557	
p-value of Breslow-Day Test for Homogeneity [3]	0.3171	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (6.7)	7 (29.2)
No	2 (100)	14 (93.3)	17 (70.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.14	5.76	
95% CI of the inverse odds ratio	(0.09, 50.23)	(0.63, 52.63)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.80	4.38	
95% CI of the inverse risk ratio	(0.13, 24.24)	(0.60, 32.12)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-13.33	-22.50	
95% CI of the absolute risk difference	(-59.17, 32.50)	(-44.64, -0.36)	
p-value	0.6291	0.0905	
p-value of Breslow-Day Test for Homogeneity [3]	0.1440	NE	

AMNOG Table SE18.6.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (8.3)
No	2 (100)	15 (100)	22 (91.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	3.44	
95% CI of the inverse odds ratio	(0.02, 15.15)	(0.15, 76.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	3.20	
95% CI of the inverse risk ratio	(0.04, 9.77)	(0.16, 62.43)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.67	-6.88	
95% CI of the absolute risk difference	(-37.11, 50.45)	(-21.40, 7.65)	
p-value	0.7243	0.4096	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	3 (20.0)	5 (20.8)
No	2 (100)	12 (80.0)	19 (79.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.41	1.05	
95% CI of the inverse odds ratio	(0.06, 33.93)	(0.21, 5.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.32	1.04	
95% CI of the inverse risk ratio	(0.09, 18.42)	(0.29, 3.74)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.33	-0.83	
95% CI of the absolute risk difference	(-50.52, 39.86)	(-26.79, 25.12)	
p-value	0.8315	0.9500	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE18.6.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	2 (13.3)	6 (25.0)
No	2 (100)	13 (86.7)	18 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.76	2.17	
95% CI of the inverse odds ratio	(0.07, 41.62)	(0.38, 12.49)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.56	1.88	
95% CI of the inverse risk ratio	(0.11, 21.33)	(0.43, 8.11)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.33	-11.67	
95% CI of the absolute risk difference	(-54.88, 36.21)	(-36.08, 12.75)	
p-value	0.7243	0.3800	
p-value of Breslow-Day Test for Homogeneity [3]	0.2542	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (50.0)	3 (20.0)	8 (33.3)
No	1 (50.0)	12 (80.0)	16 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	2.00	
95% CI of the inverse odds ratio	(0.03, 9.08)	(0.44, 9.18)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	1.67	
95% CI of the inverse risk ratio	(0.15, 2.98)	(0.52, 5.31)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.67	-13.33	
95% CI of the absolute risk difference	(-55.15, 88.48)	(-41.00, 14.33)	
p-value	0.6341	0.3680	
p-value of Breslow-Day Test for Homogeneity [3]	0.4208	NE	

AMNOG Table SE18.6.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (6.7)	3 (12.5)
No	2 (100)	14 (93.3)	21 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	2.00	
95% CI of the inverse odds ratio	(0.03, 20.78)	(0.19, 21.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	1.88	
95% CI of the inverse risk ratio	(0.06, 12.63)	(0.21, 16.41)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.67	-5.83	
95% CI of the absolute risk difference	(-41.64, 46.98)	(-24.12, 12.45)	
p-value	0.9007	0.5591	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (6.7)	6 (25.0)
No	2 (100)	14 (93.3)	18 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.76	4.67	
95% CI of the inverse odds ratio	(0.07, 41.62)	(0.50, 43.37)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.56	3.75	
95% CI of the inverse risk ratio	(0.11, 21.33)	(0.50, 28.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.33	-18.33	
95% CI of the absolute risk difference	(-54.88, 36.21)	(-39.77, 3.10)	
p-value	0.7243	0.1467	
p-value of Breslow-Day Test for Homogeneity [3]	0.4244	NE	

AMNOG Table SE18.6.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (4.2)
No	2 (100)	15 (100)	23 (95.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.17	-4.17	
95% CI of the absolute risk difference	(-12.16, 3.83)	(-12.16, 3.83)	
p-value	0.7685	0.4232	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	3 (12.5)
No	2 (100)	15 (100)	21 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	5.05	
95% CI of the inverse odds ratio	(0.03, 20.78)	(0.24, 104.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	4.48	
95% CI of the inverse risk ratio	(0.06, 12.63)	(0.25, 81.09)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.67	-10.88	
95% CI of the absolute risk difference	(-41.64, 46.98)	(-26.93, 5.18)	
p-value	0.9007	0.2523	
p-value of Breslow-Day Test for Homogeneity [3]	0.5576	NE	

AMNOG Table SE18.6.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (28.6)	0	1 (25.0)
No	5 (71.4)	0	3 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	NE	
95% CI of the inverse odds ratio	(0.05, 13.63)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	NE	
95% CI of the inverse risk ratio	(0.11, 6.88)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.57	NE	
95% CI of the absolute risk difference	(-50.47, 57.61)	NE	
p-value	0.8982	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4244	NE	

AMNOG Table SE18.6.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (14.3)	0	0
No	6 (85.7)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.48	NE	
95% CI of the inverse odds ratio	(0.02, 14.70)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.53	NE	
95% CI of the inverse risk ratio	(0.03, 10.70)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.75	NE	
95% CI of the absolute risk difference	(-28.97, 46.47)	NE	
p-value	0.6705	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3171	NE	

AMNOG Table SE18.6.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (14.3)	0	0
No	6 (85.7)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.48	NE	
95% CI of the inverse odds ratio	(0.02, 14.70)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.53	NE	
95% CI of the inverse risk ratio	(0.03, 10.70)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.75	NE	
95% CI of the absolute risk difference	(-28.97, 46.47)	NE	
p-value	0.6705	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3171	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (28.6)	0	0
No	5 (71.4)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.24	NE	
95% CI of the inverse odds ratio	(0.01, 6.51)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.32	NE	
95% CI of the inverse risk ratio	(0.02, 5.39)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	21.25	NE	
95% CI of the absolute risk difference	(-20.26, 62.76)	NE	
p-value	0.3763	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.1440	NE	

AMNOG Table SE18.6.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE18.6.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (14.3)	0	0
No	6 (85.7)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.48	NE	
95% CI of the inverse odds ratio	(0.02, 14.70)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.53	NE	
95% CI of the inverse risk ratio	(0.03, 10.70)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.75	NE	
95% CI of the absolute risk difference	(-28.97, 46.47)	NE	
p-value	0.6705	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2542	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (28.6)	0	0
No	5 (71.4)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.24	NE	
95% CI of the inverse odds ratio	(0.01, 6.51)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.32	NE	
95% CI of the inverse risk ratio	(0.02, 5.39)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	21.25	NE	
95% CI of the absolute risk difference	(-20.26, 62.76)	NE	
p-value	0.3763	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4208	NE	

AMNOG Table SE18.6.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (28.6)	0	1 (25.0)
No	5 (71.4)	0	3 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	NE	
95% CI of the inverse odds ratio	(0.05, 13.63)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	NE	
95% CI of the inverse risk ratio	(0.11, 6.88)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.57	NE	
95% CI of the absolute risk difference	(-50.47, 57.61)	NE	
p-value	0.8982	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4244	NE	

AMNOG Table SE18.6.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (50.0)
No	7 (100)	0	2 (50.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	15.00	NE	
95% CI of the inverse odds ratio	(0.52, 430.47)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	8.00	NE	
95% CI of the inverse risk ratio	(0.48, 134.66)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-43.75	NE	
95% CI of the absolute risk difference	(-90.68, 3.18)	NE	
p-value	0.0685	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (57.1)	0	2 (50.0)
No	3 (42.9)	0	2 (50.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	NE	
95% CI of the inverse odds ratio	(0.06, 8.83)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	NE	
95% CI of the inverse risk ratio	(0.27, 2.82)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.14	NE	
95% CI of the absolute risk difference	(-54.05, 68.34)	NE	
p-value	0.8190	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.5576	NE	

AMNOG Table SE18.7.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Visit Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=6)	Visit Result DB Placebo (N=19)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=6)	Change from Baseline DB Placebo (N=19)
CLDQ-NASH						
Baseline						
m	6	6	19			
n	6	6	17			
Mean (SD)	5.48 (1.78)	5.78 (0.95)	5.76 (0.81)			
Median	6.30	6.05	5.90			
IQR: Q1, Q3	4.70, 6.60	5.00, 6.50	5.40, 6.40			
Min, Max	2.2, 6.8	4.3, 6.8	4.2, 6.9			
Week 24						
m	5	5	18			
n	4	5	16	4	5	16
Mean (SD/SE)	5.75 (1.31)	5.62 (0.68)	5.61 (1.04)	0.23 (0.46)	-0.46 (0.41)	-0.18 (0.15)
Median	6.30	5.50	5.85	-0.20	-0.10	0
IQR: Q1, Q3	5.05, 6.45	5.30, 5.90	4.80, 6.55	-0.25, 0.70	-0.60, 0.10	-0.30, 0.10
Min, Max	3.8, 6.6	4.8, 6.6	3.8, 7.0	-0.3, 1.6	-2.0, 0.3	-2.2, 0.4
Week 52						
m	5	5	17			
n	5	5	16	5	5	16
Mean (SD/SE)	5.70 (1.78)	5.54 (0.72)	5.77 (1.10)	0.06 (0.11)	-0.54 (0.50)	-0.02 (0.23)
Median	6.40	5.60	6.05	0	-0.30	0.20
IQR: Q1, Q3	5.90, 6.60	5.20, 6.20	4.95, 6.75	-0.10, 0.20	-0.80, 0.10	-0.15, 0.40
Min, Max	2.6, 7.0	4.5, 6.2	3.1, 7.0	-0.2, 0.4	-2.3, 0.6	-3.1, 1.3

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.7.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=6)	(N=6)	(N=19)	(N=6)	(N=6)	(N=19)
Abdominal Symptoms						
Baseline						
m	6	6	19			
n	6	6	17			
Mean (SD)	5.78 (2.36)	6.35 (0.74)	6.05 (1.26)			
Median	6.70	6.70	7.00			
IQR: Q1, Q3	6.30, 7.00	6.00, 6.70	5.30, 7.00			
Min, Max	1.0, 7.0	5.0, 7.0	3.3, 7.0			
Week 24						
m	5	5	18			
n	4	5	16	4	5	16
Mean (SD/SE)	5.33 (2.26)	6.40 (0.83)	5.69 (1.49)	-0.03 (0.37)	-0.22 (0.48)	-0.30 (0.26)
Median	6.15	7.00	6.70	-0.20	0.30	0
IQR: Q1, Q3	4.00, 6.65	5.70, 7.00	4.00, 7.00	-0.55, 0.50	-1.30, 0.30	-0.30, 0.00
Min, Max	2.0, 7.0	5.3, 7.0	3.3, 7.0	-0.7, 1.0	-1.4, 1.0	-2.7, 1.0
Week 52						
m	5	5	17			
n	5	5	16	5	5	16
Mean (SD/SE)	5.32 (2.44)	5.80 (0.70)	5.74 (1.60)	-0.22 (0.09)	-0.82 (0.40)	-0.25 (0.34)
Median	6.30	5.70	6.50	-0.30	-1.30	0
IQR: Q1, Q3	6.00, 6.30	5.30, 6.30	4.80, 7.00	-0.40, 0.00	-1.40, 0.00	0.00, 0.00
Min, Max	1.0, 7.0	5.0, 6.7	2.0, 7.0	-0.4, 0.0	-1.7, 0.3	-5.0, 1.0

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.7.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=6)	(N=6)	(N=19)	(N=6)	(N=6)	(N=19)
Activity						
Baseline						
m	6	6	19			
n	6	6	17			
Mean (SD)	5.73 (1.94)	5.70 (1.46)	5.66 (1.07)			
Median	6.70	6.20	5.60			
IQR: Q1, Q3	5.20, 6.80	4.20, 7.00	5.00, 6.60			
Min, Max	2.0, 7.0	3.6, 7.0	3.2, 7.0			
Week 24						
m	5	5	18			
n	4	5	16	4	5	16
Mean (SD/SE)	6.00 (0.86)	4.92 (1.16)	5.28 (1.63)	0.40 (0.80)	-1.20 (0.55)	-0.34 (0.28)
Median	6.20	4.40	5.60	-0.30	-1.60	0.10
IQR: Q1, Q3	5.40, 6.60	4.40, 4.40	4.40, 6.60	-0.50, 1.30	-2.00, 0.00	-0.70, 0.30
Min, Max	4.8, 6.8	4.4, 7.0	1.8, 7.0	-0.6, 2.8	-2.6, 0.2	-3.8, 0.8
Week 52						
m	5	5	17			
n	5	5	16	5	5	16
Mean (SD/SE)	5.88 (1.46)	5.32 (0.76)	5.78 (1.29)	0.04 (0.39)	-0.80 (0.55)	0.16 (0.27)
Median	6.40	5.00	6.20	0	-1.20	0.10
IQR: Q1, Q3	5.80, 6.80	4.80, 5.80	4.70, 7.00	-0.20, 0.00	-1.20, 0.00	-0.20, 0.40
Min, Max	3.4, 7.0	4.6, 6.4	3.4, 7.0	-1.0, 1.4	-2.4, 0.8	-2.6, 2.0

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.7.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=6)	Visit Result DB Placebo (N=19)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=6)	Change from Baseline DB Placebo (N=19)
Emotional Health						
Baseline						
m	6	6	19			
n	6	6	17			
Mean (SD)	5.73 (1.56)	5.43 (1.01)	5.98 (0.75)			
Median	6.45	5.60	6.20			
IQR: Q1, Q3	4.30, 6.90	4.90, 6.10	5.70, 6.70			
Min, Max	3.3, 7.0	3.8, 6.6	4.4, 7.0			
Week 24						
m	5	5	18			
n	4	5	16	4	5	16
Mean (SD/SE)	6.08 (1.21)	5.38 (0.74)	5.81 (1.00)	0.10 (0.33)	-0.38 (0.53)	-0.19 (0.13)
Median	6.55	5.60	6.10	0	-0.20	-0.10
IQR: Q1, Q3	5.30, 6.85	5.00, 5.80	5.05, 6.60	-0.35, 0.55	-0.40, 0.10	-0.50, 0.30
Min, Max	4.3, 6.9	4.3, 6.2	3.7, 7.0	-0.6, 1.0	-2.3, 0.9	-1.5, 0.4
Week 52						
m	5	5	17			
n	5	5	16	5	5	16
Mean (SD/SE)	5.90 (1.61)	5.64 (0.66)	5.89 (1.14)	-0.12 (0.15)	-0.12 (0.48)	-0.11 (0.20)
Median	6.80	5.80	6.10	-0.10	0.10	-0.10
IQR: Q1, Q3	5.60, 6.90	5.30, 6.00	5.20, 6.85	-0.20, 0.00	-0.10, 0.40	-0.35, 0.20
Min, Max	3.2, 7.0	4.7, 6.4	3.3, 7.0	-0.6, 0.3	-1.9, 0.9	-2.5, 1.3

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.7.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=6)	(N=6)	(N=19)	(N=6)	(N=6)	(N=19)
Fatigue						
Baseline						
m	6	6	19			
n	6	6	17			
Mean (SD)	5.02 (1.64)	5.23 (1.31)	4.99 (1.54)			
Median	5.55	4.95	5.70			
IQR: Q1, Q3	5.00, 6.00	4.50, 6.50	4.20, 6.00			
Min, Max	1.8, 6.2	3.5, 7.0	1.5, 7.0			
Week 24						
m	5	5	18			
n	4	5	16	4	5	16
Mean (SD/SE)	5.15 (1.11)	4.72 (0.94)	5.02 (1.28)	0.20 (0.52)	-0.52 (0.45)	-0.19 (0.27)
Median	5.65	4.50	4.95	-0.10	0	-0.10
IQR: Q1, Q3	4.50, 5.80	4.30, 4.70	4.20, 6.05	-0.45, 0.85	-0.70, 0.00	-0.50, 0.35
Min, Max	3.5, 5.8	3.8, 6.3	2.2, 6.8	-0.7, 1.7	-2.2, 0.3	-3.3, 1.5
Week 52						
m	5	5	17			
n	5	5	16	5	5	16
Mean (SD/SE)	5.44 (1.64)	4.96 (0.65)	5.19 (1.33)	0.42 (0.22)	-0.28 (0.76)	-0.03 (0.31)
Median	5.70	5.30	5.00	0.50	-0.40	0.10
IQR: Q1, Q3	5.50, 6.30	4.30, 5.50	4.00, 6.25	0.20, 0.80	-1.50, 1.00	-0.65, 1.10
Min, Max	2.7, 7.0	4.2, 5.5	2.8, 7.0	-0.3, 0.9	-2.3, 1.8	-2.9, 1.7

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.7.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter / Visit / Statistic	Visit Result: DB MGL-3196 80 mg (N=6)	Visit Result: DB MGL-3196 100 mg (N=6)	Visit Result: DB Placebo (N=19)	Change from Baseline: DB MGL-3196 80 mg (N=6)	Change from Baseline: DB MGL-3196 100 mg (N=6)	Change from Baseline: DB Placebo (N=19)
Systemic Symptoms						
Baseline						
m	6	6	19			
n	6	6	17			
Mean (SD)	5.73 (1.30)	5.45 (1.86)	5.56 (0.93)			
Median	6.15	6.15	5.50			
IQR: Q1, Q3	4.30, 6.80	3.70, 7.00	5.30, 6.00			
Min, Max	4.0, 7.0	2.7, 7.0	3.8, 7.0			
Week 24						
m	5	5	18			
n	4	5	16	4	5	16
Mean (SD/SE)	6.00 (1.01)	5.94 (0.68)	5.49 (1.14)	-0.08 (0.22)	-0.06 (0.52)	-0.07 (0.20)
Median	6.40	6.00	5.70	-0.15	0	0
IQR: Q1, Q3	5.40, 6.60	5.50, 6.00	4.85, 6.50	-0.40, 0.25	-0.80, 0.50	-0.35, 0.40
Min, Max	4.5, 6.7	5.2, 7.0	3.2, 7.0	-0.5, 0.5	-1.5, 1.5	-2.1, 1.2
Week 52						
m	5	5	17			
n	5	5	16	5	5	16
Mean (SD/SE)	5.86 (1.46)	5.50 (1.11)	5.53 (1.20)	-0.16 (0.20)	-0.50 (0.71)	-0.04 (0.23)
Median	6.30	5.30	5.60	-0.30	-0.60	0
IQR: Q1, Q3	6.20, 6.50	4.80, 6.20	4.70, 6.65	-0.30, 0.00	-0.70, 0.00	-0.45, 0.50
Min, Max	3.3, 7.0	4.2, 7.0	3.2, 7.0	-0.7, 0.5	-2.8, 1.6	-2.6, 1.5

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.7.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=6)	(N=6)	(N=19)	(N=6)	(N=6)	(N=19)
Worry						
Baseline						
m	6	6	19			
n	6	6	17			
Mean (SD)	4.93 (2.52)	6.55 (0.62)	6.34 (0.83)			
Median	6.00	6.80	6.70			
IQR: Q1, Q3	2.60, 7.00	6.30, 7.00	5.90, 7.00			
Min, Max	1.0, 7.0	5.4, 7.0	4.1, 7.0			
Week 24						
m	5	5	18			
n	4	5	16	4	5	16
Mean (SD/SE)	6.00 (1.62)	6.24 (1.01)	6.33 (1.06)	0.73 (0.63)	-0.54 (0.44)	-0.03 (0.20)
Median	6.70	6.90	6.95	0.15	0	0
IQR: Q1, Q3	5.00, 7.00	5.40, 7.00	5.85, 7.00	0.00, 1.45	-0.90, 0.00	-0.05, 0.20
Min, Max	3.6, 7.0	4.9, 7.0	3.7, 7.0	0.0, 2.6	-2.1, 0.3	-1.9, 1.3
Week 52						
m	5	5	17			
n	5	5	16	5	5	16
Mean (SD/SE)	5.72 (2.27)	6.04 (1.05)	6.45 (0.87)	0.32 (0.14)	-0.74 (0.51)	0.10 (0.24)
Median	6.60	6.10	6.95	0.40	-0.20	0
IQR: Q1, Q3	6.30, 7.00	6.10, 6.70	6.15, 7.00	0.00, 0.50	-0.80, 0.00	-0.05, 0.60
Min, Max	1.7, 7.0	4.3, 7.0	4.1, 7.0	0.0, 0.7	-2.7, 0.0	-2.9, 1.6

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.7.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=3)	(N=9)	(N=9)	(N=3)	(N=9)	(N=9)
CLDQ-NASH						
Baseline						
m	3	9	9			
n	3	8	8			
Mean (SD)	5.17 (1.26)	5.95 (0.38)	5.78 (0.82)			
Median	5.00	6.10	5.45			
IQR: Q1, Q3	4.00, 6.50	5.85, 6.15	5.10, 6.70			
Min, Max	4.0, 6.5	5.1, 6.3	4.9, 6.8			
Week 24						
m	3	7	9			
n	3	6	9	3	6	8
Mean (SD/SE)	5.50 (0.89)	5.90 (0.61)	5.73 (1.01)	0.33 (0.24)	-0.05 (0.24)	0.10 (0.28)
Median	5.20	5.90	5.60	0.20	0.10	0
IQR: Q1, Q3	4.80, 6.50	5.30, 6.30	4.90, 6.70	0.00, 0.80	-0.60, 0.40	-0.35, 0.15
Min, Max	4.8, 6.5	5.3, 6.7	4.5, 6.9	0.0, 0.8	-0.9, 0.6	-0.7, 1.9
Week 52						
m	3	7	9			
n	2	5	8	2	5	7
Mean (SD/SE)	5.85 (0.49)	5.68 (0.34)	5.88 (0.88)	0.10 (0.40)	-0.44 (0.16)	0.01 (0.19)
Median	5.85	5.60	5.85	0.10	-0.40	0
IQR: Q1, Q3	5.50, 6.20	5.60, 5.90	5.25, 6.65	-0.30, 0.50	-0.50, -0.30	-0.50, 0.20
Min, Max	5.5, 6.2	5.2, 6.1	4.5, 7.0	-0.3, 0.5	-1.0, 0.0	-0.6, 0.9

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.7.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter / Visit / Statistic	Visit Result: DB MGL-3196 80 mg (N=3)	Visit Result: DB MGL-3196 100 mg (N=9)	Visit Result: DB Placebo (N=9)	Change from Baseline: DB MGL-3196 80 mg (N=3)	Change from Baseline: DB MGL-3196 100 mg (N=9)	Change from Baseline: DB Placebo (N=9)
Abdominal Symptoms						
Baseline						
m	3	9	9			
n	3	8	8			
Mean (SD)	5.43 (1.40)	5.84 (1.02)	5.43 (1.20)			
Median	5.00	5.85	5.00			
IQR: Q1, Q3	4.30, 7.00	5.00, 6.85	4.70, 6.65			
Min, Max	4.3, 7.0	4.3, 7.0	3.7, 7.0			
Week 24						
m	3	7	9			
n	3	6	9	3	6	8
Mean (SD/SE)	6.00 (0.89)	5.78 (0.87)	5.59 (1.30)	0.57 (0.43)	-0.45 (0.39)	0.45 (0.27)
Median	5.70	5.85	5.00	0.30	-0.50	0
IQR: Q1, Q3	5.30, 7.00	5.70, 6.00	5.00, 7.00	0.00, 1.40	-1.00, 0.00	0.00, 0.80
Min, Max	5.3, 7.0	4.3, 7.0	3.3, 7.0	0.0, 1.4	-1.7, 1.0	0.0, 2.0
Week 52						
m	3	7	9			
n	2	5	8	2	5	7
Mean (SD/SE)	6.35 (0.92)	6.02 (0.56)	5.64 (1.15)	0.35 (0.35)	-0.32 (0.40)	0.06 (0.20)
Median	6.35	5.70	5.35	0.35	-0.30	0
IQR: Q1, Q3	5.70, 7.00	5.70, 6.00	4.85, 6.85	0.00, 0.70	-1.00, 0.00	0.00, 0.40
Min, Max	5.7, 7.0	5.7, 7.0	4.0, 7.0	0.0, 0.7	-1.3, 1.0	-1.0, 0.7

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.7.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=3)	(N=9)	(N=9)	(N=3)	(N=9)	(N=9)
Activity						
Baseline						
m	3	9	9			
n	3	8	8			
Mean (SD)	4.80 (1.40)	5.88 (0.63)	5.90 (0.89)			
Median	4.80	5.70	5.80			
IQR: Q1, Q3	3.40, 6.20	5.40, 6.30	5.60, 6.60			
Min, Max	3.4, 6.2	5.2, 7.0	4.2, 7.0			
Week 24						
m	3	7	9			
n	3	6	9	3	6	8
Mean (SD/SE)	5.20 (0.53)	5.90 (0.65)	5.91 (0.96)	0.40 (0.53)	0.00 (0.34)	-0.03 (0.47)
Median	5.00	5.90	6.00	0.20	0.10	0
IQR: Q1, Q3	4.80, 5.80	5.20, 6.60	5.80, 6.80	-0.40, 1.40	-0.40, 0.80	-1.20, 0.50
Min, Max	4.8, 5.8	5.2, 6.6	4.4, 7.0	-0.4, 1.4	-1.4, 0.8	-1.4, 2.6
Week 52						
m	3	7	9			
n	2	5	8	2	5	7
Mean (SD/SE)	5.60 (0.00)	5.28 (1.00)	6.13 (0.95)	0.10 (0.70)	-0.76 (0.38)	0.09 (0.39)
Median	5.60	5.00	6.40	0.10	-0.40	0
IQR: Q1, Q3	5.60, 5.60	4.60, 6.00	5.30, 7.00	-0.60, 0.80	-1.20, -0.40	-0.60, 0.20
Min, Max	5.6, 5.6	4.2, 6.6	4.6, 7.0	-0.6, 0.8	-2.0, 0.2	-1.0, 2.2

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.7.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=3)	(N=9)	(N=9)	(N=3)	(N=9)	(N=9)
Emotional Health						
Baseline						
m	3	9	9			
n	3	8	8			
Mean (SD)	5.80 (0.87)	6.25 (0.60)	5.79 (0.99)			
Median	5.40	6.20	5.85			
IQR: Q1, Q3	5.20, 6.80	6.00, 6.80	5.10, 6.65			
Min, Max	5.2, 6.8	5.1, 6.9	4.1, 7.0			
Week 24						
m	3	7	9			
n	3	6	9	3	6	8
Mean (SD/SE)	6.17 (0.93)	6.05 (0.98)	5.96 (1.10)	0.37 (0.52)	0.00 (0.38)	0.36 (0.18)
Median	6.60	6.40	6.40	0	0.35	0.40
IQR: Q1, Q3	5.10, 6.80	5.40, 6.80	4.70, 6.90	-0.30, 1.40	-0.60, 0.70	0.00, 0.65
Min, Max	5.1, 6.8	4.4, 6.9	4.4, 7.0	-0.3, 1.4	-1.6, 0.8	-0.4, 1.2
Week 52						
m	3	7	9			
n	2	5	8	2	5	7
Mean (SD/SE)	5.60 (0.42)	5.74 (0.55)	5.94 (1.26)	-0.50 (0.40)	-0.50 (0.36)	0.10 (0.21)
Median	5.60	5.90	6.35	-0.50	-0.30	0
IQR: Q1, Q3	5.30, 5.90	5.40, 6.00	5.35, 6.85	-0.90, -0.10	-0.60, -0.20	-0.30, 0.40
Min, Max	5.3, 5.9	5.0, 6.4	3.4, 7.0	-0.9, -0.1	-1.8, 0.4	-0.7, 1.1

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.7.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=3)	(N=9)	(N=9)	(N=3)	(N=9)	(N=9)
Fatigue						
Baseline						
m	3	9	9			
n	3	8	8			
Mean (SD)	3.73 (2.44)	5.45 (0.94)	5.25 (1.47)			
Median	4.50	5.65	5.00			
IQR: Q1, Q3	1.00, 5.70	4.65, 6.15	4.15, 6.75			
Min, Max	1.0, 5.7	4.0, 6.7	3.2, 7.0			
Week 24						
m	3	7	9			
n	3	6	9	3	6	8
Mean (SD/SE)	3.70 (2.46)	5.17 (1.19)	5.06 (1.75)	-0.03 (0.09)	-0.02 (0.40)	0.04 (0.52)
Median	4.30	5.00	5.70	0	0.35	-0.10
IQR: Q1, Q3	1.00, 5.80	4.50, 6.20	3.20, 6.70	-0.20, 0.10	0.20, 0.50	-1.00, 0.60
Min, Max	1.0, 5.8	3.5, 6.8	2.8, 6.8	-0.2, 0.1	-2.0, 0.5	-1.7, 3.0
Week 52						
m	3	7	9			
n	2	5	8	2	5	7
Mean (SD/SE)	4.90 (0.57)	5.08 (0.89)	5.09 (1.41)	-0.20 (0.20)	-0.18 (0.32)	-0.23 (0.32)
Median	4.90	5.30	4.80	-0.20	-0.20	-0.20
IQR: Q1, Q3	4.50, 5.30	4.30, 5.80	4.25, 6.40	-0.40, 0.00	-0.30, 0.00	-1.00, 0.30
Min, Max	4.5, 5.3	4.0, 6.0	2.8, 7.0	-0.4, 0.0	-1.2, 0.8	-1.3, 1.1

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.7.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Visit Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=9)	Visit Result DB Placebo (N=9)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=9)	Change from Baseline DB Placebo (N=9)
Systemic Symptoms						
Baseline						
m	3	9	9			
n	3	8	8			
Mean (SD)	5.13 (1.04)	5.84 (0.68)	5.85 (0.72)			
Median	4.80	5.95	5.75			
IQR: Q1, Q3	4.30, 6.30	5.35, 6.25	5.20, 6.60			
Min, Max	4.3, 6.3	4.8, 6.8	5.0, 6.7			
Week 24						
m	3	7	9			
n	3	6	9	3	6	8
Mean (SD/SE)	5.37 (1.40)	5.85 (0.85)	5.44 (1.24)	0.23 (0.27)	0.03 (0.26)	-0.26 (0.35)
Median	5.30	6.00	5.20	0.50	0.05	-0.30
IQR: Q1, Q3	4.00, 6.80	5.30, 6.50	4.70, 6.70	-0.30, 0.50	-0.30, 0.60	-0.85, 0.15
Min, Max	4.0, 6.8	4.5, 6.8	3.5, 6.8	-0.3, 0.5	-1.0, 0.8	-1.7, 1.6
Week 52						
m	3	7	9			
n	2	5	8	2	5	7
Mean (SD/SE)	5.75 (0.78)	5.44 (0.46)	5.81 (0.87)	0.20 (0.20)	-0.58 (0.18)	-0.06 (0.26)
Median	5.75	5.50	5.75	0.20	-0.50	-0.20
IQR: Q1, Q3	5.20, 6.30	5.20, 5.70	5.05, 6.55	0.00, 0.40	-0.90, -0.20	-0.30, 0.30
Min, Max	5.2, 6.3	4.8, 6.0	4.8, 7.0	0.0, 0.4	-1.1, -0.2	-1.2, 1.1

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.7.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=3)	(N=9)	(N=9)	(N=3)	(N=9)	(N=9)
Worry						
Baseline						
m	3	9	9			
n	3	8	8			
Mean (SD)	6.17 (0.64)	6.35 (0.67)	6.59 (0.39)			
Median	5.90	6.55	6.55			
IQR: Q1, Q3	5.70, 6.90	5.90, 6.90	6.30, 7.00			
Min, Max	5.7, 6.9	5.1, 7.0	6.0, 7.0			
Week 24						
m	3	7	9			
n	3	6	9	3	6	8
Mean (SD/SE)	6.67 (0.58)	6.58 (0.62)	6.39 (0.88)	0.50 (0.31)	0.17 (0.07)	-0.14 (0.29)
Median	7.00	6.95	6.90	0.30	0.10	0
IQR: Q1, Q3	6.00, 7.00	6.00, 7.00	5.90, 7.00	0.10, 1.10	0.10, 0.20	-0.55, 0.45
Min, Max	6.0, 7.0	5.6, 7.0	4.7, 7.0	0.1, 1.1	0.0, 0.5	-1.6, 0.7
Week 52						
m	3	7	9			
n	2	5	8	2	5	7
Mean (SD/SE)	6.75 (0.21)	6.54 (0.81)	6.60 (0.45)	0.45 (0.45)	-0.14 (0.18)	-0.03 (0.06)
Median	6.75	6.90	6.75	0.45	0	0
IQR: Q1, Q3	6.60, 6.90	6.70, 7.00	6.20, 7.00	0.00, 0.90	-0.20, 0.10	-0.10, 0.00
Min, Max	6.6, 6.9	5.1, 7.0	5.9, 7.0	0.0, 0.9	-0.8, 0.2	-0.3, 0.2

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc. Page 1 of 3
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE18.7.2
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of CLDQ-NASH - MMRM Model
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable; T2D = Type 2 Diabetes.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE18.7.2
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of CLDQ-NASH - MMRM Model
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
CLDQ-NASH			
Week 24			
m	5	5	18
n	4	5	16
Baseline Mean (SD)	5.53 (2.22)	6.08 (0.68)	5.79 (0.83)
Analysis Visit Mean (SD)	5.75 (1.31)	5.62 (0.68)	5.61 (1.04)
LS Mean of Change from Baseline (SE)	0.19 (0.35)	-0.32 (0.33)	-0.10 (0.24)
95% CI	(-0.54, 0.92)	(-1.00, 0.36)	(-0.58, 0.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.29 (0.39)	-0.22 (0.35)	
95% CI	(-0.52, 1.09)	(-0.95, 0.51)	
p-value	0.4691	0.5375	
Corrected Hedge's g Statistics	0.301	-0.235	
95% CI	(-0.80, 1.40)	(-1.24, 0.77)	
Week 52			
m	5	5	17
n	5	5	16
Baseline Mean (SD)	5.64 (1.94)	6.08 (0.68)	5.79 (0.83)
Analysis Visit Mean (SD)	5.70 (1.78)	5.54 (0.72)	5.77 (1.10)
LS Mean of Change from Baseline (SE)	0.08 (0.40)	-0.41 (0.41)	0.07 (0.27)
95% CI	(-0.75, 0.92)	(-1.26, 0.43)	(-0.49, 0.63)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.02 (0.45)	-0.48 (0.45)	
95% CI	(-0.91, 0.94)	(-1.41, 0.45)	
p-value	0.9728	0.2936	
Corrected Hedge's g Statistics	0.014	-0.440	
95% CI	(-0.99, 1.02)	(-1.45, 0.57)	
Subgroup*Treatment Interaction p-value	0.8282	0.7351	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE18.7.2
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of CLDQ-NASH - MMRM Model
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
CLDQ-NASH			
Week 24			
m	3	7	9
n	3	6	8
Baseline Mean (SD)	5.17 (1.26)	5.95 (0.44)	5.78 (0.82)
Analysis Visit Mean (SD)	5.50 (0.89)	5.90 (0.61)	5.88 (0.99)
LS Mean of Change from Baseline (SE)	0.14 (0.41)	-0.01 (0.27)	0.09 (0.24)
95% CI	(-0.73, 1.02)	(-0.60, 0.57)	(-0.42, 0.59)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.06 (0.47)	-0.10 (0.36)	
95% CI	(-0.95, 1.06)	(-0.87, 0.67)	
p-value	0.9044	0.7872	
Corrected Hedge's g Statistics	0.078	-0.139	
95% CI	(-1.25, 1.41)	(-1.20, 0.92)	
Week 52			
m	3	7	9
n	2	5	7
Baseline Mean (SD)	5.75 (1.06)	6.12 (0.15)	5.86 (0.85)
Analysis Visit Mean (SD)	5.85 (0.49)	5.68 (0.34)	5.87 (0.95)
LS Mean of Change from Baseline (SE)	0.13 (0.30)	-0.40 (0.20)	-0.06 (0.17)
95% CI	(-0.51, 0.77)	(-0.83, 0.02)	(-0.42, 0.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.19 (0.34)	-0.34 (0.26)	
95% CI	(-0.53, 0.92)	(-0.89, 0.21)	
p-value	0.5812	0.2066	
Corrected Hedge's g Statistics	0.389	-0.713	
95% CI	(-1.19, 1.97)	(-1.90, 0.47)	
Subgroup*Treatment Interaction p-value	0.8282	0.7351	

AMNOG Table SE18.7.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable; T2D = Type 2 Diabetes.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

AMNOG Table SE18.7.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Abdominal Symptoms			
Week 24			
m	5	5	18
n	4	5	16
Baseline Mean (SD)	5.35 (2.90)	6.62 (0.37)	5.99 (1.27)
Analysis Visit Mean (SD)	5.33 (2.26)	6.40 (0.83)	5.69 (1.49)
LS Mean of Change from Baseline (SE)	-0.06 (0.51)	0.05 (0.47)	-0.11 (0.32)
95% CI	(-1.11, 0.98)	(-0.92, 1.03)	(-0.77, 0.56)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.04 (0.56)	0.16 (0.51)	
95% CI	(-1.12, 1.21)	(-0.89, 1.21)	
p-value	0.9388	0.7554	
Corrected Hedge's g Statistics	0.034	0.124	
95% CI	(-1.06, 1.13)	(-0.88, 1.13)	
Week 52			
m	5	5	17
n	5	5	16
Baseline Mean (SD)	5.54 (2.55)	6.62 (0.37)	5.99 (1.27)
Analysis Visit Mean (SD)	5.32 (2.44)	5.80 (0.70)	5.74 (1.60)
LS Mean of Change from Baseline (SE)	-0.18 (0.54)	-0.57 (0.55)	-0.06 (0.36)
95% CI	(-1.29, 0.93)	(-1.70, 0.56)	(-0.79, 0.68)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.12 (0.60)	-0.51 (0.60)	
95% CI	(-1.36, 1.12)	(-1.75, 0.73)	
p-value	0.8440	0.4016	
Corrected Hedge's g Statistics	-0.083	-0.356	
95% CI	(-1.09, 0.92)	(-1.37, 0.65)	
Subgroup*Treatment Interaction p-value	0.7638	0.5174	

AMNOG Table SE18.7.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Activity			
Week 24			
m	5	5	18
n	4	5	16
Baseline Mean (SD)	5.60 (2.41)	6.12 (1.15)	5.61 (1.08)
Analysis Visit Mean (SD)	6.00 (0.86)	4.92 (1.16)	5.28 (1.63)
LS Mean of Change from Baseline (SE)	0.35 (0.61)	-1.03 (0.57)	-0.32 (0.38)
95% CI	(-0.92, 1.61)	(-2.20, 0.14)	(-1.10, 0.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.67 (0.67)	-0.71 (0.62)	
95% CI	(-0.72, 2.06)	(-2.00, 0.58)	
p-value	0.3307	0.2651	
Corrected Hedge's g Statistics	0.437	-0.468	
95% CI	(-0.67, 1.54)	(-1.48, 0.55)	
Week 52			
m	5	5	17
n	5	5	16
Baseline Mean (SD)	5.84 (2.15)	6.12 (1.15)	5.61 (1.08)
Analysis Visit Mean (SD)	5.88 (1.46)	5.32 (0.76)	5.78 (1.29)
LS Mean of Change from Baseline (SE)	0.12 (0.46)	-0.61 (0.47)	0.17 (0.33)
95% CI	(-0.83, 1.07)	(-1.58, 0.36)	(-0.52, 0.86)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.05 (0.50)	-0.78 (0.50)	
95% CI	(-1.09, 0.98)	(-1.83, 0.26)	
p-value	0.9185	0.1339	
Corrected Hedge's g Statistics	-0.039	-0.589	
95% CI	(-1.04, 0.97)	(-1.61, 0.43)	
Subgroup*Treatment Interaction p-value	0.7349	0.6102	

AMNOG Table SE18.7.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Emotional Health			
Week 24			
m	5	5	18
n	4	5	16
Baseline Mean (SD)	5.98 (1.79)	5.76 (0.69)	6.00 (0.77)
Analysis Visit Mean (SD)	6.08 (1.21)	5.38 (0.74)	5.81 (1.00)
LS Mean of Change from Baseline (SE)	0.18 (0.36)	-0.32 (0.33)	-0.01 (0.24)
95% CI	(-0.57, 0.92)	(-1.01, 0.36)	(-0.51, 0.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.19 (0.39)	-0.31 (0.36)	
95% CI	(-0.62, 1.00)	(-1.06, 0.44)	
p-value	0.6342	0.4035	
Corrected Hedge's g Statistics	0.195	-0.322	
95% CI	(-0.90, 1.29)	(-1.33, 0.69)	
Week 52			
m	5	5	17
n	5	5	16
Baseline Mean (SD)	6.02 (1.55)	5.76 (0.69)	6.00 (0.77)
Analysis Visit Mean (SD)	5.90 (1.61)	5.64 (0.66)	5.89 (1.14)
LS Mean of Change from Baseline (SE)	0.00 (0.37)	-0.03 (0.37)	0.05 (0.26)
95% CI	(-0.77, 0.77)	(-0.80, 0.74)	(-0.48, 0.59)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.06 (0.41)	-0.08 (0.41)	
95% CI	(-0.90, 0.79)	(-0.94, 0.77)	
p-value	0.8925	0.8417	
Corrected Hedge's g Statistics	-0.054	-0.080	
95% CI	(-1.06, 0.95)	(-1.08, 0.92)	
Subgroup*Treatment Interaction p-value	0.3856	0.7015	

AMNOG Table SE18.7.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Fatigue			
Week 24			
m	5	5	18
n	4	5	16
Baseline Mean (SD)	4.95 (2.11)	5.24 (1.46)	5.21 (1.29)
Analysis Visit Mean (SD)	5.15 (1.11)	4.72 (0.94)	5.02 (1.28)
LS Mean of Change from Baseline (SE)	0.17 (0.47)	-0.41 (0.43)	-0.05 (0.31)
95% CI	(-0.80, 1.14)	(-1.30, 0.48)	(-0.69, 0.59)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.22 (0.51)	-0.35 (0.47)	
95% CI	(-0.83, 1.28)	(-1.32, 0.61)	
p-value	0.6647	0.4573	
Corrected Hedge's g Statistics	0.180	-0.286	
95% CI	(-0.92, 1.28)	(-1.29, 0.72)	
Week 52			
m	5	5	17
n	5	5	16
Baseline Mean (SD)	5.02 (1.83)	5.24 (1.46)	5.21 (1.29)
Analysis Visit Mean (SD)	5.44 (1.64)	4.96 (0.65)	5.19 (1.33)
LS Mean of Change from Baseline (SE)	0.43 (0.50)	-0.17 (0.50)	0.12 (0.34)
95% CI	(-0.61, 1.47)	(-1.21, 0.88)	(-0.59, 0.83)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.32 (0.56)	-0.28 (0.56)	
95% CI	(-0.84, 1.47)	(-1.43, 0.87)	
p-value	0.5781	0.6189	
Corrected Hedge's g Statistics	0.228	-0.204	
95% CI	(-0.78, 1.23)	(-1.21, 0.80)	
Subgroup*Treatment Interaction p-value	0.4157	0.5646	

AMNOG Table SE18.7.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Systemic Symptoms			
Week 24			
m	5	5	18
n	4	5	16
Baseline Mean (SD)	6.08 (1.40)	6.00 (1.43)	5.56 (0.96)
Analysis Visit Mean (SD)	6.00 (1.01)	5.94 (0.68)	5.49 (1.14)
LS Mean of Change from Baseline (SE)	0.10 (0.41)	0.04 (0.38)	-0.12 (0.28)
95% CI	(-0.76, 0.95)	(-0.76, 0.83)	(-0.71, 0.47)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.21 (0.44)	0.16 (0.41)	
95% CI	(-0.69, 1.12)	(-0.69, 1.00)	
p-value	0.6294	0.7055	
Corrected Hedge's g Statistics	0.189	0.138	
95% CI	(-0.91, 1.29)	(-0.87, 1.14)	
Week 52			
m	5	5	17
n	5	5	16
Baseline Mean (SD)	6.02 (1.22)	6.00 (1.43)	5.56 (0.96)
Analysis Visit Mean (SD)	5.86 (1.46)	5.50 (1.11)	5.53 (1.20)
LS Mean of Change from Baseline (SE)	-0.07 (0.48)	-0.42 (0.48)	-0.08 (0.32)
95% CI	(-1.06, 0.92)	(-1.40, 0.57)	(-0.75, 0.59)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.01 (0.52)	-0.33 (0.52)	
95% CI	(-1.07, 1.09)	(-1.41, 0.74)	
p-value	0.9822	0.5274	
Corrected Hedge's g Statistics	0.009	-0.256	
95% CI	(-1.00, 1.01)	(-1.26, 0.75)	
Subgroup*Treatment Interaction p-value	0.6642	0.9187	

AMNOG Table SE18.7.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Worry			
Week 24			
m	5	5	18
n	4	5	16
Baseline Mean (SD)	5.28 (2.88)	6.78 (0.29)	6.35 (0.85)
Analysis Visit Mean (SD)	6.00 (1.62)	6.24 (1.01)	6.33 (1.06)
LS Mean of Change from Baseline (SE)	0.42 (0.45)	-0.33 (0.40)	0.05 (0.28)
95% CI	(-0.51, 1.34)	(-1.16, 0.51)	(-0.54, 0.64)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.37 (0.49)	-0.37 (0.43)	
95% CI	(-0.65, 1.38)	(-1.27, 0.52)	
p-value	0.4620	0.3977	
Corrected Hedge's g Statistics	0.319	-0.328	
95% CI	(-0.78, 1.42)	(-1.34, 0.68)	
Week 52			
m	5	5	17
n	5	5	16
Baseline Mean (SD)	5.40 (2.51)	6.78 (0.29)	6.35 (0.85)
Analysis Visit Mean (SD)	5.72 (2.27)	6.04 (1.05)	6.45 (0.87)
LS Mean of Change from Baseline (SE)	0.12 (0.43)	-0.57 (0.42)	0.17 (0.29)
95% CI	(-0.77, 1.01)	(-1.45, 0.30)	(-0.44, 0.77)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.05 (0.48)	-0.74 (0.46)	
95% CI	(-1.03, 0.94)	(-1.68, 0.21)	
p-value	0.9200	0.1212	
Corrected Hedge's g Statistics	-0.041	-0.626	
95% CI	(-1.05, 0.96)	(-1.65, 0.40)	
Subgroup*Treatment Interaction p-value	0.5119	0.1831	

AMNOG Table SE18.7.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Abdominal Symptoms			
Week 24			
m	3	7	9
n	3	6	8
Baseline Mean (SD)	5.43 (1.40)	6.23 (0.81)	5.43 (1.20)
Analysis Visit Mean (SD)	6.00 (0.89)	5.78 (0.87)	5.88 (1.05)
LS Mean of Change from Baseline (SE)	0.41 (0.43)	-0.28 (0.31)	0.29 (0.27)
95% CI	(-0.51, 1.32)	(-0.94, 0.38)	(-0.29, 0.86)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.12 (0.50)	-0.57 (0.42)	
95% CI	(-0.94, 1.18)	(-1.47, 0.33)	
p-value	0.8124	0.1975	
Corrected Hedge's g Statistics	0.145	-0.701	
95% CI	(-1.18, 1.47)	(-1.79, 0.39)	
Week 52			
m	3	7	9
n	2	5	7
Baseline Mean (SD)	6.00 (1.41)	6.34 (0.85)	5.67 (1.06)
Analysis Visit Mean (SD)	6.35 (0.92)	6.02 (0.56)	5.73 (1.21)
LS Mean of Change from Baseline (SE)	0.50 (0.43)	-0.14 (0.29)	0.02 (0.24)
95% CI	(-0.42, 1.42)	(-0.76, 0.49)	(-0.49, 0.54)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.48 (0.49)	-0.16 (0.39)	
95% CI	(-0.58, 1.53)	(-0.99, 0.67)	
p-value	0.3499	0.6842	
Corrected Hedge's g Statistics	0.665	-0.230	
95% CI	(-0.94, 2.27)	(-1.38, 0.92)	
Subgroup*Treatment Interaction p-value	0.7638	0.5174	

AMNOG Table SE18.7.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Activity			
Week 24			
m	3	7	9
n	3	6	8
Baseline Mean (SD)	4.80 (1.40)	5.90 (0.73)	5.90 (0.89)
Analysis Visit Mean (SD)	5.20 (0.53)	5.90 (0.65)	5.88 (1.03)
LS Mean of Change from Baseline (SE)	-0.39 (0.55)	0.08 (0.35)	0.06 (0.30)
95% CI	(-1.56, 0.79)	(-0.66, 0.83)	(-0.59, 0.71)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.45 (0.64)	0.03 (0.46)	
95% CI	(-1.81, 0.91)	(-0.96, 1.01)	
p-value	0.4941	0.9576	
Corrected Hedge's g Statistics	-0.465	0.027	
95% CI	(-1.81, 0.88)	(-1.03, 1.09)	
Week 52			
m	3	7	9
n	2	5	7
Baseline Mean (SD)	5.50 (0.99)	6.04 (0.73)	5.91 (0.97)
Analysis Visit Mean (SD)	5.60 (0.00)	5.28 (1.00)	6.00 (0.95)
LS Mean of Change from Baseline (SE)	-0.08 (0.61)	-0.73 (0.39)	-0.01 (0.33)
95% CI	(-1.37, 1.21)	(-1.55, 0.09)	(-0.71, 0.68)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.06 (0.70)	-0.71 (0.50)	
95% CI	(-1.55, 1.42)	(-1.79, 0.36)	
p-value	0.9277	0.1758	
Corrected Hedge's g Statistics	-0.066	-0.762	
95% CI	(-1.64, 1.51)	(-1.95, 0.43)	
Subgroup*Treatment Interaction p-value	0.7349	0.6102	

AMNOG Table SE18.7.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Emotional Health			
Week 24			
m	3	7	9
n	3	6	8
Baseline Mean (SD)	5.80 (0.87)	6.05 (0.55)	5.79 (0.99)
Analysis Visit Mean (SD)	6.17 (0.93)	6.05 (0.98)	6.15 (1.00)
LS Mean of Change from Baseline (SE)	0.34 (0.43)	0.03 (0.31)	0.33 (0.27)
95% CI	(-0.58, 1.26)	(-0.63, 0.68)	(-0.23, 0.90)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.01 (0.51)	-0.31 (0.41)	
95% CI	(-1.07, 1.08)	(-1.18, 0.56)	
p-value	0.9894	0.4633	
Corrected Hedge's g Statistics	0.008	-0.383	
95% CI	(-1.32, 1.34)	(-1.45, 0.69)	
Week 52			
m	3	7	9
n	2	5	7
Baseline Mean (SD)	6.10 (0.99)	6.24 (0.33)	5.77 (1.07)
Analysis Visit Mean (SD)	5.60 (0.42)	5.74 (0.55)	5.87 (1.35)
LS Mean of Change from Baseline (SE)	-0.30 (0.48)	-0.46 (0.31)	0.09 (0.26)
95% CI	(-1.32, 0.71)	(-1.13, 0.21)	(-0.46, 0.65)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.40 (0.55)	-0.55 (0.41)	
95% CI	(-1.56, 0.77)	(-1.44, 0.33)	
p-value	0.4798	0.2003	
Corrected Hedge's g Statistics	-0.510	-0.736	
95% CI	(-2.10, 1.08)	(-1.92, 0.45)	
Subgroup*Treatment Interaction p-value	0.3856	0.7015	

AMNOG Table SE18.7.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Fatigue			
Week 24			
m	3	7	9
n	3	6	8
Baseline Mean (SD)	3.73 (2.44)	5.18 (0.90)	5.25 (1.47)
Analysis Visit Mean (SD)	3.70 (2.46)	5.17 (1.19)	5.29 (1.71)
LS Mean of Change from Baseline (SE)	-0.29 (0.76)	0.00 (0.50)	0.06 (0.43)
95% CI	(-1.91, 1.34)	(-1.06, 1.05)	(-0.85, 0.98)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.35 (0.89)	-0.07 (0.66)	
95% CI	(-2.24, 1.54)	(-1.46, 1.33)	
p-value	0.6967	0.9205	
Corrected Hedge's g Statistics	-0.259	-0.051	
95% CI	(-1.59, 1.07)	(-1.11, 1.01)	
Week 52			
m	3	7	9
n	2	5	7
Baseline Mean (SD)	5.10 (0.85)	5.26 (0.98)	5.36 (1.55)
Analysis Visit Mean (SD)	4.90 (0.57)	5.08 (0.89)	5.13 (1.52)
LS Mean of Change from Baseline (SE)	-0.33 (0.49)	-0.13 (0.32)	-0.34 (0.27)
95% CI	(-1.37, 0.72)	(-0.80, 0.55)	(-0.92, 0.24)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.02 (0.57)	0.22 (0.42)	
95% CI	(-1.19, 1.22)	(-0.67, 1.10)	
p-value	0.9784	0.6128	
Corrected Hedge's g Statistics	0.019	0.278	
95% CI	(-1.55, 1.59)	(-0.88, 1.43)	
Subgroup*Treatment Interaction p-value	0.4157	0.5646	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE18.7.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Systemic Symptoms			
Week 24			
m	3	7	9
n	3	6	8
Baseline Mean (SD)	5.13 (1.04)	5.82 (0.56)	5.85 (0.72)
Analysis Visit Mean (SD)	5.37 (1.40)	5.85 (0.85)	5.59 (1.24)
LS Mean of Change from Baseline (SE)	0.30 (0.53)	0.03 (0.35)	-0.27 (0.30)
95% CI	(-0.84, 1.44)	(-0.71, 0.77)	(-0.91, 0.38)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.57 (0.62)	0.30 (0.46)	
95% CI	(-0.75, 1.89)	(-0.68, 1.28)	
p-value	0.3750	0.5254	
Corrected Hedge's g Statistics	0.595	0.329	
95% CI	(-0.75, 1.95)	(-0.74, 1.39)	
Week 52			
m	3	7	9
n	2	5	7
Baseline Mean (SD)	5.55 (1.06)	6.02 (0.29)	5.94 (0.72)
Analysis Visit Mean (SD)	5.75 (0.78)	5.44 (0.46)	5.89 (0.92)
LS Mean of Change from Baseline (SE)	0.07 (0.41)	-0.63 (0.26)	-0.20 (0.23)
95% CI	(-0.80, 0.94)	(-1.19, -0.07)	(-0.68, 0.28)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.27 (0.47)	-0.43 (0.35)	
95% CI	(-0.73, 1.27)	(-1.17, 0.31)	
p-value	0.5728	0.2343	
Corrected Hedge's g Statistics	0.404	-0.665	
95% CI	(-1.18, 1.99)	(-1.84, 0.51)	
Subgroup*Treatment Interaction p-value	0.6642	0.9187	

AMNOG Table SE18.7.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Worry			
Week 24			
m	3	7	9
n	3	6	8
Baseline Mean (SD)	6.17 (0.64)	6.42 (0.76)	6.59 (0.39)
Analysis Visit Mean (SD)	6.67 (0.58)	6.58 (0.62)	6.45 (0.91)
LS Mean of Change from Baseline (SE)	0.44 (0.38)	0.15 (0.26)	-0.13 (0.22)
95% CI	(-0.37, 1.25)	(-0.41, 0.70)	(-0.60, 0.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.56 (0.45)	0.27 (0.35)	
95% CI	(-0.39, 1.51)	(-0.46, 1.01)	
p-value	0.2250	0.4396	
Corrected Hedge's g Statistics	0.805	0.404	
95% CI	(-0.56, 2.17)	(-0.67, 1.47)	
Week 52			
m	3	7	9
n	2	5	7
Baseline Mean (SD)	6.30 (0.85)	6.68 (0.45)	6.63 (0.40)
Analysis Visit Mean (SD)	6.75 (0.21)	6.54 (0.81)	6.60 (0.48)
LS Mean of Change from Baseline (SE)	0.53 (0.25)	-0.15 (0.16)	-0.09 (0.13)
95% CI	(0.00, 1.06)	(-0.49, 0.19)	(-0.37, 0.20)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.62 (0.29)	-0.06 (0.20)	
95% CI	(0.01, 1.23)	(-0.50, 0.37)	
p-value	0.0468	0.7608	
Corrected Hedge's g Statistics	1.555	-0.165	
95% CI	(-0.17, 3.28)	(-1.31, 0.98)	
Subgroup*Treatment Interaction p-value	0.5119	0.1831	

AMNOG Table SE18.7.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; T2D = Type 2 Diabetes.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi-square Test. For this unadjusted analysis, only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.

AMNOG Table SE18.7.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (5.3)
No	6 (100)	6 (100)	18 (94.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	1.05	
95% CI of the inverse odds ratio	(0.04, 29.24)	(0.04, 29.24)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	1.05	
95% CI of the inverse risk ratio	(0.05, 22.91)	(0.05, 22.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.36	-0.36	
95% CI of the absolute risk difference	(-22.66, 21.94)	(-22.66, 21.94)	
p-value	0.9752	0.9752	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (16.7)	1 (16.7)	6 (31.6)
No	5 (83.3)	5 (83.3)	13 (68.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.31	2.31	
95% CI of the inverse odds ratio	(0.22, 24.32)	(0.22, 24.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.89	1.89	
95% CI of the inverse risk ratio	(0.28, 12.77)	(0.28, 12.77)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-14.91	-14.91	
95% CI of the absolute risk difference	(-51.33, 21.50)	(-51.33, 21.50)	
p-value	0.4782	0.4782	
p-value of Breslow-Day Test for Homogeneity [3]	0.2478	0.5151	

AMNOG Table SE18.7.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (10.5)
No	6 (100)	6 (100)	17 (89.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.86	1.86	
95% CI of the inverse odds ratio	(0.08, 44.08)	(0.08, 44.08)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.75	1.75	
95% CI of the inverse risk ratio	(0.10, 32.18)	(0.10, 32.18)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.36	-5.36	
95% CI of the absolute risk difference	(-29.32, 18.60)	(-29.32, 18.60)	
p-value	0.6979	0.6979	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.1881	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	2 (10.5)
No	6 (100)	6 (100)	17 (89.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.86	1.86	
95% CI of the inverse odds ratio	(0.08, 44.08)	(0.08, 44.08)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.75	1.75	
95% CI of the inverse risk ratio	(0.10, 32.18)	(0.10, 32.18)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.36	-5.36	
95% CI of the absolute risk difference	(-29.32, 18.60)	(-29.32, 18.60)	
p-value	0.6979	0.6979	
p-value of Breslow-Day Test for Homogeneity [3]	0.3474	0.5799	

AMNOG Table SE18.7.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (16.7)	0	3 (15.8)
No	5 (83.3)	6 (100)	16 (84.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	2.76	
95% CI of the inverse odds ratio	(0.08, 11.15)	(0.12, 61.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	2.45	
95% CI of the inverse risk ratio	(0.12, 7.50)	(0.14, 41.74)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.88	-10.36	
95% CI of the absolute risk difference	(-33.15, 34.91)	(-35.68, 14.97)	
p-value	0.9592	0.5068	
p-value of Breslow-Day Test for Homogeneity [3]	0.5523	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (16.7)	1 (16.7)	6 (31.6)
No	5 (83.3)	5 (83.3)	13 (68.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.31	2.31	
95% CI of the inverse odds ratio	(0.22, 24.32)	(0.22, 24.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.89	1.89	
95% CI of the inverse risk ratio	(0.28, 12.77)	(0.28, 12.77)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-14.91	-14.91	
95% CI of the absolute risk difference	(-51.33, 21.50)	(-51.33, 21.50)	
p-value	0.4782	0.4782	
p-value of Breslow-Day Test for Homogeneity [3]	0.2478	0.5151	

AMNOG Table SE18.7.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (5.3)
No	6 (100)	6 (100)	18 (94.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	1.05	
95% CI of the inverse odds ratio	(0.04, 29.24)	(0.04, 29.24)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	1.05	
95% CI of the inverse risk ratio	(0.05, 22.91)	(0.05, 22.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.36	-0.36	
95% CI of the absolute risk difference	(-22.66, 21.94)	(-22.66, 21.94)	
p-value	0.9752	0.9752	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (33.3)	3 (15.8)
No	6 (100)	4 (66.7)	16 (84.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.76	0.38	
95% CI of the inverse odds ratio	(0.12, 61.16)	(0.05, 3.06)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.45	0.47	
95% CI of the inverse risk ratio	(0.14, 41.74)	(0.10, 2.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.36	17.54	
95% CI of the absolute risk difference	(-35.68, 14.97)	(-23.59, 58.67)	
p-value	0.5068	0.3490	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.2784	

AMNOG Table SE18.7.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (16.7)	2 (33.3)	5 (26.3)
No	5 (83.3)	4 (66.7)	14 (73.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.79	0.71	
95% CI of the inverse odds ratio	(0.17, 19.25)	(0.10, 5.18)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.58	0.79	
95% CI of the inverse risk ratio	(0.23, 11.00)	(0.20, 3.07)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.65	7.02	
95% CI of the absolute risk difference	(-45.44, 26.15)	(-35.58, 49.62)	
p-value	0.6295	0.7386	
p-value of Breslow-Day Test for Homogeneity [3]	0.6544	0.2830	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (50.0)	2 (33.3)	7 (36.8)
No	3 (50.0)	4 (66.7)	12 (63.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.58	1.17	
95% CI of the inverse odds ratio	(0.09, 3.72)	(0.17, 8.09)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	1.11	
95% CI of the inverse risk ratio	(0.27, 1.99)	(0.31, 3.96)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	13.16	-3.51	
95% CI of the absolute risk difference	(-32.35, 58.67)	(-47.02, 40.00)	
p-value	0.5663	0.8760	
p-value of Breslow-Day Test for Homogeneity [3]	0.4582	0.9316	

AMNOG Table SE18.7.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (16.7)	2 (10.5)
No	6 (100)	5 (83.3)	17 (89.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.86	0.59	
95% CI of the inverse odds ratio	(0.08, 44.08)	(0.04, 7.91)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.75	0.63	
95% CI of the inverse risk ratio	(0.10, 32.18)	(0.07, 5.80)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.36	6.14	
95% CI of the absolute risk difference	(-29.32, 18.60)	(-26.72, 39.00)	
p-value	0.6979	0.6866	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.2731	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (16.7)	1 (16.7)	6 (31.6)
No	5 (83.3)	5 (83.3)	13 (68.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.31	2.31	
95% CI of the inverse odds ratio	(0.22, 24.32)	(0.22, 24.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.89	1.89	
95% CI of the inverse risk ratio	(0.28, 12.77)	(0.28, 12.77)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-14.91	-14.91	
95% CI of the absolute risk difference	(-51.33, 21.50)	(-51.33, 21.50)	
p-value	0.4782	0.4782	
p-value of Breslow-Day Test for Homogeneity [3]	0.2478	0.5151	

AMNOG Table SE18.7.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	3 (15.8)
No	6 (100)	6 (100)	16 (84.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.76	2.76	
95% CI of the inverse odds ratio	(0.12, 61.16)	(0.12, 61.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.45	2.45	
95% CI of the inverse risk ratio	(0.14, 41.74)	(0.14, 41.74)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.36	-10.36	
95% CI of the absolute risk difference	(-35.68, 14.97)	(-35.68, 14.97)	
p-value	0.5068	0.5068	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (50.0)	0	5 (26.3)
No	3 (50.0)	6 (100)	14 (73.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.36	4.93	
95% CI of the inverse odds ratio	(0.05, 2.38)	(0.24, 103.01)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.53	3.85	
95% CI of the inverse risk ratio	(0.18, 1.58)	(0.24, 61.08)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	23.68	-20.36	
95% CI of the absolute risk difference	(-20.95, 68.32)	(-47.69, 6.97)	
p-value	0.2783	0.2648	
p-value of Breslow-Day Test for Homogeneity [3]	0.2913	NE	

AMNOG Table SE18.7.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	3 (100)	9 (100)	9 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (33.3)	0	1 (11.1)
No	2 (66.7)	9 (100)	8 (88.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.25	3.35	
95% CI of the inverse odds ratio	(0.01, 5.98)	(0.12, 93.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	3.00	
95% CI of the inverse risk ratio	(0.03, 3.84)	(0.14, 65.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	22.22	-10.00	
95% CI of the absolute risk difference	(-34.94, 79.38)	(-35.93, 15.93)	
p-value	0.3711	0.4561	
p-value of Breslow-Day Test for Homogeneity [3]	0.2478	0.5151	

AMNOG Table SE18.7.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (11.1)	0
No	3 (100)	8 (88.9)	9 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.30	
95% CI of the inverse odds ratio	NE	(0.01, 8.35)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.33	
95% CI of the inverse risk ratio	NE	(0.02, 7.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	10.00	
95% CI of the absolute risk difference	NE	(-15.93, 35.93)	
p-value	NE	0.4561	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.1881	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (33.3)	1 (11.1)	2 (22.2)
No	2 (66.7)	8 (88.9)	7 (77.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	2.29	
95% CI of the inverse odds ratio	(0.03, 10.07)	(0.17, 30.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	2.00	
95% CI of the inverse risk ratio	(0.09, 4.99)	(0.22, 18.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.11	-11.11	
95% CI of the absolute risk difference	(-48.75, 70.97)	(-45.16, 22.94)	
p-value	0.7003	0.5271	
p-value of Breslow-Day Test for Homogeneity [3]	0.3474	0.5799	

AMNOG Table SE18.7.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (11.1)
No	3 (100)	9 (100)	8 (88.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.24	3.35	
95% CI of the inverse odds ratio	(0.04, 38.30)	(0.12, 93.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	3.00	
95% CI of the inverse risk ratio	(0.06, 23.70)	(0.14, 65.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-10.00	
95% CI of the absolute risk difference	(-41.75, 36.75)	(-35.93, 15.93)	
p-value	0.9039	0.4561	
p-value of Breslow-Day Test for Homogeneity [3]	0.5523	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (33.3)	0	1 (11.1)
No	2 (66.7)	9 (100)	8 (88.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.25	3.35	
95% CI of the inverse odds ratio	(0.01, 5.98)	(0.12, 93.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	3.00	
95% CI of the inverse risk ratio	(0.03, 3.84)	(0.14, 65.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	22.22	-10.00	
95% CI of the absolute risk difference	(-34.94, 79.38)	(-35.93, 15.93)	
p-value	0.3711	0.4561	
p-value of Breslow-Day Test for Homogeneity [3]	0.2478	0.5151	

AMNOG Table SE18.7.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (11.1)
No	3 (100)	9 (100)	8 (88.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.24	3.35	
95% CI of the inverse odds ratio	(0.04, 38.30)	(0.12, 93.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	3.00	
95% CI of the inverse risk ratio	(0.06, 23.70)	(0.14, 65.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-10.00	
95% CI of the absolute risk difference	(-41.75, 36.75)	(-35.93, 15.93)	
p-value	0.9039	0.4561	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (11.1)	2 (22.2)
No	3 (100)	8 (88.9)	7 (77.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.33	2.29	
95% CI of the inverse odds ratio	(0.09, 62.68)	(0.17, 30.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	2.00	
95% CI of the inverse risk ratio	(0.12, 33.10)	(0.22, 18.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-12.50	-11.11	
95% CI of the absolute risk difference	(-54.58, 29.58)	(-45.16, 22.94)	
p-value	0.6066	0.5271	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.2784	

AMNOG Table SE18.7.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (11.1)
No	3 (100)	9 (100)	8 (88.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.24	3.35	
95% CI of the inverse odds ratio	(0.04, 38.30)	(0.12, 93.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	3.00	
95% CI of the inverse risk ratio	(0.06, 23.70)	(0.14, 65.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-10.00	
95% CI of the absolute risk difference	(-41.75, 36.75)	(-35.93, 15.93)	
p-value	0.9039	0.4561	
p-value of Breslow-Day Test for Homogeneity [3]	0.6544	0.2830	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (11.1)	1 (11.1)
No	3 (100)	8 (88.9)	8 (88.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.24	1.00	
95% CI of the inverse odds ratio	(0.04, 38.30)	(0.05, 18.91)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	1.00	
95% CI of the inverse risk ratio	(0.06, 23.70)	(0.07, 13.64)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	0.00	
95% CI of the absolute risk difference	(-41.75, 36.75)	(-29.04, 29.04)	
p-value	0.9039	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.4582	0.9316	

AMNOG Table SE18.7.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (11.1)
No	3 (100)	9 (100)	8 (88.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.24	3.35	
95% CI of the inverse odds ratio	(0.04, 38.30)	(0.12, 93.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	3.00	
95% CI of the inverse risk ratio	(0.06, 23.70)	(0.14, 65.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-10.00	
95% CI of the absolute risk difference	(-41.75, 36.75)	(-35.93, 15.93)	
p-value	0.9039	0.4561	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.2731	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (33.3)	0	1 (11.1)
No	2 (66.7)	9 (100)	8 (88.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.25	3.35	
95% CI of the inverse odds ratio	(0.01, 5.98)	(0.12, 93.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	3.00	
95% CI of the inverse risk ratio	(0.03, 3.84)	(0.14, 65.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	22.22	-10.00	
95% CI of the absolute risk difference	(-34.94, 79.38)	(-35.93, 15.93)	
p-value	0.3711	0.4561	
p-value of Breslow-Day Test for Homogeneity [3]	0.2478	0.5151	

AMNOG Table SE18.7.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	3 (100)	9 (100)	9 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (33.3)	0	0
No	2 (66.7)	9 (100)	9 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.09	NE	
95% CI of the inverse odds ratio	(0.00, 2.88)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.13	NE	
95% CI of the inverse risk ratio	(0.01, 2.63)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	32.50	NE	
95% CI of the absolute risk difference	(-16.83, 81.83)	NE	
p-value	0.1164	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2913	NE	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE18.8.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=2)	(N=7)	(N=1)	(N=2)	(N=7)
CLDQ-NASH						
Baseline						
m	1	2	7			
n	1	2	6			
Mean (SD)	4.70 (N/A)	5.75 (1.06)	5.47 (0.97)			
Median	4.70	5.75	5.40			
IQR: Q1, Q3	4.70, 4.70	5.00, 6.50	4.80, 6.40			
Min, Max	4.7, 4.7	5.0, 6.5	4.2, 6.6			
Week 24						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	5.95 (0.92)	5.43 (1.13)	N/A	0.20 (0.10)	-0.03 (0.09)
Median	N/A	5.95	5.35	N/A	0.20	-0.05
IQR: Q1, Q3	N/A	5.30, 6.60	4.70, 6.40	N/A	0.10, 0.30	-0.20, 0.10
Min, Max	N/A	5.3, 6.6	3.9, 6.9	N/A	0.1, 0.3	-0.3, 0.3
Week 52						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	5.90 (0.42)	5.72 (1.04)	N/A	0.15 (0.45)	0.25 (0.10)
Median	N/A	5.90	5.70	N/A	0.15	0.35
IQR: Q1, Q3	N/A	5.60, 6.20	4.60, 6.80	N/A	-0.30, 0.60	0.20, 0.40
Min, Max	N/A	5.6, 6.2	4.6, 6.9	N/A	-0.3, 0.6	-0.2, 0.4

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.8.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=2)	(N=7)	(N=1)	(N=2)	(N=7)
Abdominal Symptoms						
Baseline						
m	1	2	7			
n	1	2	6			
Mean (SD)	7.00 (N/A)	6.50 (0.71)	5.60 (1.66)			
Median	7.00	6.50	6.15			
IQR: Q1, Q3	7.00, 7.00	6.00, 7.00	4.00, 7.00			
Min, Max	7.0, 7.0	6.0, 7.0	3.3, 7.0			
Week 24						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	6.35 (0.92)	5.57 (1.46)	N/A	-0.15 (1.15)	-0.03 (0.16)
Median	N/A	6.35	6.00	N/A	-0.15	-0.15
IQR: Q1, Q3	N/A	5.70, 7.00	4.00, 6.70	N/A	-1.30, 1.00	-0.30, 0.00
Min, Max	N/A	5.7, 7.0	3.7, 7.0	N/A	-1.3, 1.0	-0.3, 0.7
Week 52						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	6.00 (0.42)	5.60 (1.66)	N/A	-0.50 (0.80)	0.00 (0.00)
Median	N/A	6.00	6.15	N/A	-0.50	0
IQR: Q1, Q3	N/A	5.70, 6.30	4.00, 7.00	N/A	-1.30, 0.30	0.00, 0.00
Min, Max	N/A	5.7, 6.3	3.3, 7.0	N/A	-1.3, 0.3	0.0, 0.0

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.8.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=2)	(N=7)	(N=1)	(N=2)	(N=7)
Activity						
Baseline						
m	1	2	7			
n	1	2	6			
Mean (SD)	5.20 (N/A)	5.60 (1.98)	5.17 (0.87)			
Median	5.20	5.60	5.10			
IQR: Q1, Q3	5.20, 5.20	4.20, 7.00	4.40, 5.60			
Min, Max	5.2, 5.2	4.2, 7.0	4.2, 6.6			
Week 24						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	5.70 (1.84)	4.93 (1.44)	N/A	0.10 (0.10)	-0.23 (0.32)
Median	N/A	5.70	5.10	N/A	0.10	-0.10
IQR: Q1, Q3	N/A	4.40, 7.00	4.00, 5.60	N/A	0.00, 0.20	-0.80, 0.40
Min, Max	N/A	4.4, 7.0	2.8, 7.0	N/A	0.0, 0.2	-1.4, 0.6
Week 52						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	5.40 (0.57)	5.87 (1.03)	N/A	-0.20 (1.00)	0.70 (0.39)
Median	N/A	5.40	5.90	N/A	-0.20	0.30
IQR: Q1, Q3	N/A	5.00, 5.80	5.40, 6.80	N/A	-1.20, 0.80	0.00, 1.80
Min, Max	N/A	5.0, 5.8	4.2, 7.0	N/A	-1.2, 0.8	-0.2, 2.0

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.8.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=2)	(N=7)	(N=1)	(N=2)	(N=7)
Emotional Health						
Baseline						
m	1	2	7			
n	1	2	6			
Mean (SD)	4.30 (N/A)	5.05 (0.21)	5.80 (1.07)			
Median	4.30	5.05	6.00			
IQR: Q1, Q3	4.30, 4.30	4.90, 5.20	4.70, 6.70			
Min, Max	4.3, 4.3	4.9, 5.2	4.4, 7.0			
Week 24						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	5.40 (0.57)	5.67 (1.14)	N/A	0.35 (0.55)	-0.13 (0.23)
Median	N/A	5.40	6.05	N/A	0.35	0.05
IQR: Q1, Q3	N/A	5.00, 5.80	5.10, 6.10	N/A	-0.20, 0.90	-0.70, 0.30
Min, Max	N/A	5.0, 5.8	3.7, 7.0	N/A	-0.2, 0.9	-0.9, 0.4
Week 52						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	5.55 (0.35)	5.75 (1.11)	N/A	0.50 (0.40)	-0.05 (0.09)
Median	N/A	5.55	6.00	N/A	0.50	-0.10
IQR: Q1, Q3	N/A	5.30, 5.80	4.40, 6.80	N/A	0.10, 0.90	-0.20, 0.20
Min, Max	N/A	5.3, 5.8	4.4, 6.9	N/A	0.1, 0.9	-0.3, 0.2

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.8.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=2)	(N=7)	(N=1)	(N=2)	(N=7)
Fatigue						
Baseline						
m	1	2	7			
n	1	2	6			
Mean (SD)	5.00 (N/A)	5.25 (2.47)	4.87 (1.50)			
Median	5.00	5.25	4.75			
IQR: Q1, Q3	5.00, 5.00	3.50, 7.00	4.20, 5.80			
Min, Max	5.0, 5.0	3.5, 7.0	2.7, 7.0			
Week 24						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	5.05 (1.77)	4.98 (1.26)	N/A	-0.20 (0.50)	0.12 (0.25)
Median	N/A	5.05	4.50	N/A	-0.20	-0.05
IQR: Q1, Q3	N/A	3.80, 6.30	4.00, 6.30	N/A	-0.70, 0.30	-0.20, 0.50
Min, Max	N/A	3.8, 6.3	3.8, 6.8	N/A	-0.7, 0.3	-0.6, 1.1
Week 52						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	5.40 (0.14)	5.05 (1.55)	N/A	0.15 (1.65)	0.18 (0.43)
Median	N/A	5.40	4.35	N/A	0.15	0.25
IQR: Q1, Q3	N/A	5.30, 5.50	3.80, 7.00	N/A	-1.50, 1.80	-0.40, 1.20
Min, Max	N/A	5.3, 5.5	3.8, 7.0	N/A	-1.5, 1.8	-1.5, 1.3

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.8.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=2)	(N=7)	(N=1)	(N=2)	(N=7)
Systemic Symptoms						
Baseline						
m	1	2	7			
n	1	2	6			
Mean (SD)	4.30 (N/A)	5.35 (2.33)	5.40 (1.13)			
Median	4.30	5.35	5.65			
IQR: Q1, Q3	4.30, 4.30	3.70, 7.00	4.30, 6.30			
Min, Max	4.3, 4.3	3.7, 7.0	3.8, 6.7			
Week 24						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	6.10 (1.27)	5.55 (1.05)	N/A	0.75 (0.75)	0.15 (0.16)
Median	N/A	6.10	5.70	N/A	0.75	0.10
IQR: Q1, Q3	N/A	5.20, 7.00	5.00, 6.30	N/A	0.00, 1.50	-0.10, 0.50
Min, Max	N/A	5.2, 7.0	3.8, 6.8	N/A	0.0, 1.5	-0.4, 0.7
Week 52						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	6.15 (1.20)	5.60 (0.95)	N/A	0.80 (0.80)	0.20 (0.25)
Median	N/A	6.15	5.75	N/A	0.80	0.45
IQR: Q1, Q3	N/A	5.30, 7.00	4.70, 6.30	N/A	0.00, 1.60	-0.10, 0.50
Min, Max	N/A	5.3, 7.0	4.3, 6.8	N/A	0.0, 1.6	-0.9, 0.8

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.8.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=1)	Visit Result DB MGL-3196 100 mg (N=2)	Visit Result DB Placebo (N=7)	Change from Baseline DB MGL-3196 80 mg (N=1)	Change from Baseline DB MGL-3196 100 mg (N=2)	Change from Baseline DB Placebo (N=7)
Worry						
Baseline						
m	1	2	7			
n	1	2	6			
Mean (SD)	2.60 (N/A)	6.85 (0.21)	5.95 (1.10)			
Median	2.60	6.85	6.10			
IQR: Q1, Q3	2.60, 2.60	6.70, 7.00	5.40, 7.00			
Min, Max	2.6, 2.6	6.7, 7.0	4.1, 7.0			
Week 24						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	7.00 (0.00)	5.97 (1.13)	N/A	0.15 (0.15)	0.02 (0.43)
Median	N/A	7.00	6.15	N/A	0.15	-0.05
IQR: Q1, Q3	N/A	7.00, 7.00	4.90, 7.00	N/A	0.00, 0.30	-0.80, 1.10
Min, Max	N/A	7.0, 7.0	4.6, 7.0	N/A	0.0, 0.3	-1.4, 1.3
Week 52						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	6.85 (0.21)	6.38 (0.80)	N/A	0.00 (0.00)	0.43 (0.20)
Median	N/A	6.85	6.65	N/A	0	0.30
IQR: Q1, Q3	N/A	6.70, 7.00	6.00, 7.00	N/A	0.00, 0.00	0.00, 0.90
Min, Max	N/A	6.7, 7.0	5.0, 7.0	N/A	0.0, 0.0	0.0, 1.1

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.8.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=8)	Visit Result DB MGL-3196 100 mg (N=13)	Visit Result DB Placebo (N=21)	Change from Baseline DB MGL-3196 80 mg (N=8)	Change from Baseline DB MGL-3196 100 mg (N=13)	Change from Baseline DB Placebo (N=21)
CLDQ-NASH						
Baseline						
m	8	13	21			
n	8	12	19			
Mean (SD)	5.46 (1.63)	5.90 (0.64)	5.86 (0.73)			
Median	6.30	6.10	5.90			
IQR: Q1, Q3	4.50, 6.55	5.85, 6.15	5.40, 6.50			
Min, Max	2.2, 6.8	4.3, 6.8	4.3, 6.9			
Week 24						
m	8	10	21			
n	7	9	19	7	9	18
Mean (SD/SE)	5.64 (1.07)	5.73 (0.61)	5.72 (1.00)	0.27 (0.26)	-0.33 (0.27)	-0.11 (0.18)
Median	6.30	5.50	5.90	0	-0.10	0
IQR: Q1, Q3	4.80, 6.50	5.30, 6.30	4.90, 6.60	-0.20, 0.80	-0.60, 0.20	-0.40, 0.10
Min, Max	3.8, 6.6	4.8, 6.7	3.8, 7.0	-0.3, 1.6	-2.0, 0.6	-2.2, 1.9
Week 52						
m	8	10	20			
n	7	8	18	7	8	17
Mean (SD/SE)	5.74 (1.47)	5.54 (0.56)	5.83 (1.03)	0.07 (0.11)	-0.65 (0.27)	-0.10 (0.22)
Median	6.20	5.60	5.95	0	-0.45	0
IQR: Q1, Q3	5.50, 6.60	5.20, 6.00	5.60, 6.70	-0.20, 0.40	-0.90, -0.15	-0.30, 0.20
Min, Max	2.6, 7.0	4.5, 6.2	3.1, 7.0	-0.3, 0.5	-2.3, 0.1	-3.1, 1.3

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.8.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=8)	(N=13)	(N=21)	(N=8)	(N=13)	(N=21)
Abdominal Symptoms						
Baseline						
m	8	13	21			
n	8	12	19			
Mean (SD)	5.50 (2.07)	5.98 (0.95)	5.93 (1.13)			
Median	6.50	6.35	6.00			
IQR: Q1, Q3	4.65, 6.85	5.00, 6.70	5.00, 7.00			
Min, Max	1.0, 7.0	4.3, 7.0	3.7, 7.0			
Week 24						
m	8	10	21			
n	7	9	19	7	9	18
Mean (SD/SE)	5.61 (1.71)	6.00 (0.91)	5.68 (1.42)	0.23 (0.28)	-0.39 (0.30)	-0.06 (0.27)
Median	6.00	6.00	6.30	0	0	0
IQR: Q1, Q3	5.30, 7.00	5.70, 7.00	4.70, 7.00	-0.40, 1.00	-1.00, 0.30	0.00, 0.30
Min, Max	2.0, 7.0	4.3, 7.0	3.3, 7.0	-0.7, 1.4	-1.7, 1.0	-2.7, 2.0
Week 52						
m	8	10	20			
n	7	8	18	7	8	17
Mean (SD/SE)	5.61 (2.09)	5.89 (0.67)	5.74 (1.41)	-0.06 (0.14)	-0.59 (0.32)	-0.21 (0.33)
Median	6.30	5.70	5.85	0	-0.65	0
IQR: Q1, Q3	5.70, 7.00	5.50, 6.35	5.00, 7.00	-0.40, 0.00	-1.35, 0.00	0.00, 0.30
Min, Max	1.0, 7.0	5.0, 7.0	2.0, 7.0	-0.4, 0.7	-1.7, 1.0	-5.0, 1.0

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.8.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=8)	Visit Result DB MGL-3196 100 mg (N=13)	Visit Result DB Placebo (N=21)	Change from Baseline DB MGL-3196 80 mg (N=8)	Change from Baseline DB MGL-3196 100 mg (N=13)	Change from Baseline DB Placebo (N=21)
Activity						
Baseline						
m	8	13	21			
n	8	12	19			
Mean (SD)	5.45 (1.87)	5.83 (0.93)	5.92 (0.99)			
Median	6.40	5.90	6.00			
IQR: Q1, Q3	4.10, 6.80	5.40, 6.50	5.60, 6.60			
Min, Max	2.0, 7.0	3.6, 7.0	3.2, 7.0			
Week 24						
m	8	10	21			
n	7	9	19	7	9	18
Mean (SD/SE)	5.66 (0.81)	5.40 (0.91)	5.68 (1.43)	0.40 (0.47)	-0.69 (0.42)	-0.23 (0.31)
Median	5.80	5.20	6.00	-0.20	-0.40	0
IQR: Q1, Q3	4.80, 6.40	4.40, 6.20	5.40, 6.80	-0.40, 1.40	-1.60, 0.20	-1.20, 0.40
Min, Max	4.8, 6.8	4.4, 6.6	1.8, 7.0	-0.6, 2.8	-2.6, 0.8	-3.8, 2.6
Week 52						
m	8	10	20			
n	7	8	18	7	8	17
Mean (SD/SE)	5.80 (1.20)	5.28 (0.92)	5.90 (1.25)	0.06 (0.31)	-0.93 (0.33)	-0.06 (0.24)
Median	5.80	4.90	6.40	0	-0.80	0
IQR: Q1, Q3	5.60, 6.80	4.60, 6.20	4.80, 7.00	-0.60, 0.80	-1.60, -0.20	-0.40, 0.20
Min, Max	3.4, 7.0	4.2, 6.6	3.4, 7.0	-1.0, 1.4	-2.4, 0.2	-2.6, 2.2

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.8.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=8)	(N=13)	(N=21)	(N=8)	(N=13)	(N=21)
Emotional Health						
Baseline						
m	8	13	21			
n	8	12	19			
Mean (SD)	5.94 (1.27)	6.04 (0.86)	5.96 (0.76)			
Median	6.45	6.15	5.90			
IQR: Q1, Q3	5.30, 6.85	6.00, 6.70	5.60, 6.70			
Min, Max	3.3, 7.0	3.8, 6.9	4.1, 7.0			
Week 24						
m	8	10	21			
n	7	9	19	7	9	18
Mean (SD/SE)	6.11 (1.01)	5.82 (0.97)	5.93 (1.00)	0.21 (0.27)	-0.29 (0.35)	0.04 (0.14)
Median	6.60	6.20	6.40	0	0.10	0
IQR: Q1, Q3	5.10, 6.80	5.40, 6.60	4.80, 6.80	-0.30, 1.00	-0.60, 0.40	-0.30, 0.40
Min, Max	4.3, 6.9	4.3, 6.9	4.1, 7.0	-0.6, 1.4	-2.3, 0.8	-1.5, 1.2
Week 52						
m	8	10	20			
n	7	8	18	7	8	17
Mean (SD/SE)	5.81 (1.34)	5.73 (0.63)	5.96 (1.19)	-0.23 (0.15)	-0.51 (0.32)	-0.05 (0.20)
Median	5.90	5.95	6.35	-0.10	-0.25	0
IQR: Q1, Q3	5.30, 6.90	5.20, 6.20	5.80, 6.90	-0.60, 0.00	-1.20, 0.15	-0.40, 0.40
Min, Max	3.2, 7.0	4.7, 6.4	3.3, 7.0	-0.9, 0.3	-1.9, 0.4	-2.5, 1.3

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.8.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=8)	Visit Result DB MGL-3196 100 mg (N=13)	Visit Result DB Placebo (N=21)	Change from Baseline DB MGL-3196 80 mg (N=8)	Change from Baseline DB MGL-3196 100 mg (N=13)	Change from Baseline DB Placebo (N=21)
Fatigue						
Baseline						
m	8	13	21			
n	8	12	19			
Mean (SD)	4.54 (2.02)	5.38 (0.89)	5.14 (1.52)			
Median	5.50	5.35	5.70			
IQR: Q1, Q3	3.15, 5.90	4.60, 6.15	4.00, 6.00			
Min, Max	1.0, 6.2	4.0, 6.7	1.5, 7.0			
Week 24						
m	8	10	21			
n	7	9	19	7	9	18
Mean (SD/SE)	4.53 (1.80)	4.94 (1.00)	5.05 (1.51)	0.10 (0.28)	-0.26 (0.35)	-0.19 (0.32)
Median	5.50	4.70	5.30	0	0.20	-0.10
IQR: Q1, Q3	3.50, 5.80	4.50, 5.20	4.20, 6.70	-0.20, 0.10	0.00, 0.40	-1.00, 0.20
Min, Max	1.0, 5.8	3.5, 6.8	2.2, 6.8	-0.7, 1.7	-2.2, 0.5	-3.3, 3.0
Week 52						
m	8	10	20			
n	7	8	18	7	8	17
Mean (SD/SE)	5.29 (1.38)	4.93 (0.81)	5.19 (1.29)	0.24 (0.19)	-0.33 (0.37)	-0.18 (0.28)
Median	5.50	4.80	5.00	0.20	-0.25	-0.20
IQR: Q1, Q3	4.50, 6.30	4.25, 5.65	4.30, 6.30	-0.30, 0.80	-0.80, 0.40	-0.80, 0.50
Min, Max	2.7, 7.0	4.0, 6.0	2.8, 7.0	-0.4, 0.9	-2.3, 1.0	-2.9, 1.7

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.8.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=8)	(N=13)	(N=21)	(N=8)	(N=13)	(N=21)
Systemic Symptoms						
Baseline						
m	8	13	21			
n	8	12	19			
Mean (SD)	5.69 (1.17)	5.73 (1.18)	5.73 (0.78)			
Median	6.05	5.95	5.50			
IQR: Q1, Q3	4.55, 6.65	5.25, 6.55	5.20, 6.50			
Min, Max	4.0, 7.0	2.7, 7.0	3.8, 7.0			
Week 24						
m	8	10	21			
n	7	9	19	7	9	18
Mean (SD/SE)	5.73 (1.13)	5.84 (0.68)	5.45 (1.21)	0.06 (0.17)	-0.18 (0.26)	-0.23 (0.22)
Median	6.30	6.00	5.30	0	0	-0.30
IQR: Q1, Q3	4.50, 6.70	5.50, 6.20	4.70, 6.70	-0.30, 0.50	-0.80, 0.50	-0.50, 0.20
Min, Max	4.0, 6.8	4.5, 6.8	3.2, 7.0	-0.5, 0.5	-1.5, 0.8	-2.1, 1.6
Week 52						
m	8	10	20			
n	7	8	18	7	8	17
Mean (SD/SE)	5.83 (1.24)	5.30 (0.68)	5.63 (1.16)	-0.06 (0.16)	-0.88 (0.30)	-0.13 (0.22)
Median	6.30	5.35	5.40	0	-0.65	-0.20
IQR: Q1, Q3	5.20, 6.50	4.80, 5.85	4.80, 6.80	-0.30, 0.40	-1.00, -0.35	-0.40, 0.20
Min, Max	3.3, 7.0	4.2, 6.2	3.2, 7.0	-0.7, 0.5	-2.8, -0.2	-2.6, 1.5

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.8.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=8)	(N=13)	(N=21)	(N=8)	(N=13)	(N=21)
Worry						
Baseline						
m	8	13	21			
n	8	12	19			
Mean (SD)	5.69 (1.97)	6.37 (0.66)	6.56 (0.51)			
Median	6.00	6.55	6.70			
IQR: Q1, Q3	5.80, 6.95	5.90, 6.90	6.30, 7.00			
Min, Max	1.0, 7.0	5.1, 7.0	5.4, 7.0			
Week 24						
m	8	10	21			
n	7	9	19	7	9	18
Mean (SD/SE)	6.29 (1.25)	6.30 (0.83)	6.47 (0.93)	0.63 (0.36)	-0.22 (0.27)	-0.09 (0.17)
Median	7.00	6.90	7.00	0.30	0.10	0
IQR: Q1, Q3	6.00, 7.00	5.60, 7.00	6.30, 7.00	0.00, 1.10	0.00, 0.10	0.00, 0.20
Min, Max	3.6, 7.0	4.9, 7.0	3.7, 7.0	0.0, 2.6	-2.1, 0.5	-1.9, 0.9
Week 52						
m	8	10	20			
n	7	8	18	7	8	17
Mean (SD/SE)	6.01 (1.92)	6.15 (0.99)	6.54 (0.75)	0.36 (0.14)	-0.55 (0.33)	-0.07 (0.21)
Median	6.60	6.40	6.90	0.40	-0.20	0
IQR: Q1, Q3	6.30, 7.00	5.60, 6.95	6.30, 7.00	0.00, 0.70	-0.80, 0.05	-0.10, 0.00
Min, Max	1.7, 7.0	4.3, 7.0	4.1, 7.0	0.0, 0.9	-2.7, 0.2	-2.9, 1.6

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.8.2
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of CLDQ-NASH - MMRM Model
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable; HbA1c = Hemoglobin A1C.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE18.8.2
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of CLDQ-NASH - MMRM Model
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
CLDQ-NASH			
Week 24			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	5.75 (1.06)	5.47 (0.97)
Analysis Visit Mean (SD)	N/A	5.95 (0.92)	5.43 (1.13)
LS Mean of Change from Baseline (SE)	NE	0.18 (0.14)	-0.03 (0.08)
95% CI	NE	(-0.17, 0.53)	(-0.23, 0.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	0.21 (0.16)	
95% CI	NE	(-0.20, 0.61)	
p-value	NE	0.2561	
Corrected Hedge's g Statistics	NE	0.897	
95% CI	NE	(-0.76, 2.56)	
Week 52			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	5.75 (1.06)	5.47 (0.97)
Analysis Visit Mean (SD)	N/A	5.90 (0.42)	5.72 (1.04)
LS Mean of Change from Baseline (SE)	NE	0.17 (0.26)	0.24 (0.15)
95% CI	NE	(-0.46, 0.79)	(-0.11, 0.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-0.08 (0.30)	
95% CI	NE	(-0.80, 0.65)	
p-value	NE	0.8032	
Corrected Hedge's g Statistics	NE	-0.186	
95% CI	NE	(-1.79, 1.42)	
Subgroup*Treatment Interaction p-value	NE	0.2726	

AMNOG Table SE18.8.2
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of CLDQ-NASH - MMRM Model
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
CLDQ-NASH			
Week 24			
m	8	10	21
n	7	9	18
Baseline Mean (SD)	5.37 (1.74)	6.07 (0.44)	5.89 (0.74)
Analysis Visit Mean (SD)	5.64 (1.07)	5.73 (0.61)	5.78 (0.99)
LS Mean of Change from Baseline (SE)	0.26 (0.30)	-0.17 (0.27)	0.09 (0.23)
95% CI	(-0.35, 0.86)	(-0.72, 0.38)	(-0.38, 0.57)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.16 (0.31)	-0.27 (0.29)	
95% CI	(-0.48, 0.80)	(-0.85, 0.32)	
p-value	0.6080	0.3580	
Corrected Hedge's g Statistics	0.167	-0.276	
95% CI	(-0.71, 1.04)	(-1.08, 0.53)	
Week 52			
m	8	10	20
n	7	8	17
Baseline Mean (SD)	5.67 (1.64)	6.19 (0.27)	5.93 (0.75)
Analysis Visit Mean (SD)	5.74 (1.47)	5.54 (0.56)	5.83 (1.07)
LS Mean of Change from Baseline (SE)	0.24 (0.33)	-0.48 (0.31)	0.10 (0.25)
95% CI	(-0.42, 0.91)	(-1.10, 0.15)	(-0.41, 0.61)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.14 (0.35)	-0.58 (0.33)	
95% CI	(-0.56, 0.85)	(-1.26, 0.10)	
p-value	0.6804	0.0922	
Corrected Hedge's g Statistics	0.140	-0.567	
95% CI	(-0.74, 1.02)	(-1.42, 0.29)	
Subgroup*Treatment Interaction p-value	NE	0.2726	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE18.8.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable; HbA1c = Hemoglobin A1C.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

AMNOG Table SE18.8.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Abdominal Symptoms			
Week 24			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	6.50 (0.71)	5.60 (1.66)
Analysis Visit Mean (SD)	N/A	6.35 (0.92)	5.57 (1.46)
LS Mean of Change from Baseline (SE)	NE	0.00 (0.54)	-0.08 (0.30)
95% CI	NE	(-1.32, 1.31)	(-0.83, 0.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	0.08 (0.63)	
95% CI	NE	(-1.45, 1.61)	
p-value	NE	0.9034	
Corrected Hedge's g Statistics	NE	0.092	
95% CI	NE	(-1.51, 1.69)	
Week 52			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	6.50 (0.71)	5.60 (1.66)
Analysis Visit Mean (SD)	N/A	6.00 (0.42)	5.60 (1.66)
LS Mean of Change from Baseline (SE)	NE	-0.46 (0.36)	-0.01 (0.21)
95% CI	NE	(-1.35, 0.42)	(-0.51, 0.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-0.45 (0.42)	
95% CI	NE	(-1.48, 0.58)	
p-value	NE	0.3283	
Corrected Hedge's g Statistics	NE	-0.776	
95% CI	NE	(-2.42, 0.87)	
Subgroup*Treatment Interaction p-value	NE	0.6024	

AMNOG Table SE18.8.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Activity			
Week 24			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	5.60 (1.98)	5.17 (0.87)
Analysis Visit Mean (SD)	N/A	5.70 (1.84)	4.93 (1.44)
LS Mean of Change from Baseline (SE)	NE	0.04 (0.53)	-0.21 (0.30)
95% CI	NE	(-1.26, 1.33)	(-0.95, 0.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	0.25 (0.61)	
95% CI	NE	(-1.25, 1.75)	
p-value	NE	0.6993	
Corrected Hedge's g Statistics	NE	0.291	
95% CI	NE	(-1.32, 1.90)	
Week 52			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	5.60 (1.98)	5.17 (0.87)
Analysis Visit Mean (SD)	N/A	5.40 (0.57)	5.87 (1.03)
LS Mean of Change from Baseline (SE)	NE	-0.02 (0.65)	0.64 (0.37)
95% CI	NE	(-1.62, 1.58)	(-0.27, 1.55)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-0.66 (0.76)	
95% CI	NE	(-2.51, 1.19)	
p-value	NE	0.4177	
Corrected Hedge's g Statistics	NE	-0.625	
95% CI	NE	(-2.25, 1.00)	
Subgroup*Treatment Interaction p-value	NE	0.5555	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE18.8.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Emotional Health			
Week 24			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	5.05 (0.21)	5.80 (1.07)
Analysis Visit Mean (SD)	N/A	5.40 (0.57)	5.67 (1.14)
LS Mean of Change from Baseline (SE)	NE	0.29 (0.49)	-0.11 (0.27)
95% CI	NE	(-0.89, 1.48)	(-0.78, 0.55)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	0.41 (0.57)	
95% CI	NE	(-0.99, 1.80)	
p-value	NE	0.4996	
Corrected Hedge's g Statistics	NE	0.533	
95% CI	NE	(-1.09, 2.15)	
Week 52			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	5.05 (0.21)	5.80 (1.07)
Analysis Visit Mean (SD)	N/A	5.55 (0.35)	5.75 (1.11)
LS Mean of Change from Baseline (SE)	NE	0.50 (0.25)	-0.05 (0.14)
95% CI	NE	(-0.10, 1.11)	(-0.39, 0.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	0.55 (0.29)	
95% CI	NE	(-0.16, 1.27)	
p-value	NE	0.1060	
Corrected Hedge's g Statistics	NE	1.412	
95% CI	NE	(-0.33, 3.16)	
Subgroup*Treatment Interaction p-value	NE	0.0726	

AMNOG Table SE18.8.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Fatigue			
Week 24			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	5.25 (2.47)	4.87 (1.50)
Analysis Visit Mean (SD)	N/A	5.05 (1.77)	4.98 (1.26)
LS Mean of Change from Baseline (SE)	NE	-0.13 (0.36)	0.09 (0.21)
95% CI	NE	(-1.00, 0.75)	(-0.41, 0.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-0.22 (0.41)	
95% CI	NE	(-1.23, 0.79)	
p-value	NE	0.6111	
Corrected Hedge's g Statistics	NE	-0.382	
95% CI	NE	(-1.99, 1.23)	
Week 52			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	5.25 (2.47)	4.87 (1.50)
Analysis Visit Mean (SD)	N/A	5.40 (0.14)	5.05 (1.55)
LS Mean of Change from Baseline (SE)	NE	0.29 (0.85)	0.14 (0.49)
95% CI	NE	(-1.79, 2.37)	(-1.06, 1.34)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	0.15 (0.98)	
95% CI	NE	(-2.26, 2.55)	
p-value	NE	0.8854	
Corrected Hedge's g Statistics	NE	0.107	
95% CI	NE	(-1.49, 1.71)	
Subgroup*Treatment Interaction p-value	NE	0.7802	

AMNOG Table SE18.8.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Systemic Symptoms			
Week 24			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	5.35 (2.33)	5.40 (1.13)
Analysis Visit Mean (SD)	N/A	6.10 (1.27)	5.55 (1.05)
LS Mean of Change from Baseline (SE)	NE	0.74 (0.32)	0.15 (0.18)
95% CI	NE	(-0.04, 1.51)	(-0.29, 0.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	0.59 (0.37)	
95% CI	NE	(-0.31, 1.48)	
p-value	NE	0.1605	
Corrected Hedge's g Statistics	NE	1.137	
95% CI	NE	(-0.56, 2.83)	
Week 52			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	5.35 (2.33)	5.40 (1.13)
Analysis Visit Mean (SD)	N/A	6.15 (1.20)	5.60 (0.95)
LS Mean of Change from Baseline (SE)	NE	0.79 (0.38)	0.20 (0.22)
95% CI	NE	(-0.13, 1.70)	(-0.33, 0.74)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	0.58 (0.43)	
95% CI	NE	(-0.48, 1.64)	
p-value	NE	0.2290	
Corrected Hedge's g Statistics	NE	0.951	
95% CI	NE	(-0.72, 2.62)	
Subgroup*Treatment Interaction p-value	NE	0.1875	

AMNOG Table SE18.8.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Worry			
Week 24			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	6.85 (0.21)	5.95 (1.10)
Analysis Visit Mean (SD)	N/A	7.00 (0.00)	5.97 (1.13)
LS Mean of Change from Baseline (SE)	NE	0.44 (0.71)	-0.08 (0.39)
95% CI	NE	(-1.29, 2.18)	(-1.04, 0.88)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	0.53 (0.84)	
95% CI	NE	(-1.53, 2.58)	
p-value	NE	0.5535	
Corrected Hedge's g Statistics	NE	0.472	
95% CI	NE	(-1.14, 2.09)	
Week 52			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	6.85 (0.21)	5.95 (1.10)
Analysis Visit Mean (SD)	N/A	6.85 (0.21)	6.38 (0.80)
LS Mean of Change from Baseline (SE)	NE	0.23 (0.25)	0.36 (0.14)
95% CI	NE	(-0.40, 0.85)	(0.01, 0.70)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-0.13 (0.30)	
95% CI	NE	(-0.87, 0.60)	
p-value	NE	0.6783	
Corrected Hedge's g Statistics	NE	-0.328	
95% CI	NE	(-1.94, 1.28)	
Subgroup*Treatment Interaction p-value	NE	0.4320	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE18.8.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Abdominal Symptoms			
Week 24			
m	8	10	21
n	7	9	18
Baseline Mean (SD)	5.39 (2.21)	6.39 (0.68)	5.87 (1.14)
Analysis Visit Mean (SD)	5.61 (1.71)	6.00 (0.91)	5.82 (1.33)
LS Mean of Change from Baseline (SE)	0.33 (0.39)	-0.11 (0.36)	0.24 (0.30)
95% CI	(-0.47, 1.14)	(-0.85, 0.63)	(-0.38, 0.85)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.10 (0.42)	-0.35 (0.39)	
95% CI	(-0.76, 0.96)	(-1.15, 0.45)	
p-value	0.8159	0.3812	
Corrected Hedge's g Statistics	0.078	-0.275	
95% CI	(-0.80, 0.95)	(-1.08, 0.53)	
Week 52			
m	8	10	20
n	7	8	17
Baseline Mean (SD)	5.67 (2.17)	6.48 (0.67)	6.00 (1.03)
Analysis Visit Mean (SD)	5.61 (2.09)	5.89 (0.67)	5.79 (1.44)
LS Mean of Change from Baseline (SE)	0.23 (0.45)	-0.30 (0.42)	0.13 (0.34)
95% CI	(-0.68, 1.14)	(-1.16, 0.57)	(-0.55, 0.82)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.10 (0.48)	-0.43 (0.47)	
95% CI	(-0.89, 1.08)	(-1.38, 0.52)	
p-value	0.8412	0.3653	
Corrected Hedge's g Statistics	0.071	-0.313	
95% CI	(-0.81, 0.95)	(-1.16, 0.53)	
Subgroup*Treatment Interaction p-value	NE	0.6024	

AMNOG Table SE18.8.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Activity			
Week 24			
m	8	10	21
n	7	9	18
Baseline Mean (SD)	5.26 (1.93)	6.09 (0.69)	5.89 (1.02)
Analysis Visit Mean (SD)	5.66 (0.81)	5.40 (0.91)	5.66 (1.47)
LS Mean of Change from Baseline (SE)	0.19 (0.47)	-0.49 (0.42)	-0.04 (0.35)
95% CI	(-0.77, 1.15)	(-1.36, 0.37)	(-0.76, 0.68)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.23 (0.51)	-0.45 (0.46)	
95% CI	(-0.81, 1.27)	(-1.40, 0.50)	
p-value	0.6531	0.3390	
Corrected Hedge's g Statistics	0.156	-0.306	
95% CI	(-0.72, 1.03)	(-1.11, 0.50)	
Week 52			
m	8	10	20
n	7	8	17
Baseline Mean (SD)	5.74 (1.81)	6.20 (0.65)	5.89 (1.05)
Analysis Visit Mean (SD)	5.80 (1.20)	5.28 (0.92)	5.84 (1.26)
LS Mean of Change from Baseline (SE)	0.22 (0.39)	-0.73 (0.37)	0.12 (0.32)
95% CI	(-0.59, 1.02)	(-1.48, 0.03)	(-0.53, 0.77)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.10 (0.40)	-0.85 (0.39)	
95% CI	(-0.72, 0.92)	(-1.64, -0.05)	
p-value	0.8083	0.0384	
Corrected Hedge's g Statistics	0.076	-0.657	
95% CI	(-0.80, 0.96)	(-1.52, 0.20)	
Subgroup*Treatment Interaction p-value	NE	0.5555	

AMNOG Table SE18.8.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Emotional Health			
Week 24			
m	8	10	21
n	7	9	18
Baseline Mean (SD)	5.90 (1.36)	6.11 (0.47)	5.97 (0.78)
Analysis Visit Mean (SD)	6.11 (1.01)	5.82 (0.97)	6.01 (0.96)
LS Mean of Change from Baseline (SE)	0.39 (0.30)	-0.14 (0.28)	0.28 (0.24)
95% CI	(-0.22, 1.01)	(-0.70, 0.42)	(-0.21, 0.77)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.11 (0.31)	-0.42 (0.29)	
95% CI	(-0.53, 0.76)	(-1.02, 0.18)	
p-value	0.7193	0.1619	
Corrected Hedge's g Statistics	0.114	-0.426	
95% CI	(-0.76, 0.99)	(-1.23, 0.38)	
Week 52			
m	8	10	20
n	7	8	17
Baseline Mean (SD)	6.04 (1.33)	6.24 (0.30)	5.98 (0.80)
Analysis Visit Mean (SD)	5.81 (1.34)	5.73 (0.63)	5.93 (1.22)
LS Mean of Change from Baseline (SE)	0.08 (0.34)	-0.36 (0.32)	0.22 (0.26)
95% CI	(-0.61, 0.77)	(-1.00, 0.29)	(-0.31, 0.75)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.14 (0.36)	-0.58 (0.35)	
95% CI	(-0.87, 0.60)	(-1.29, 0.14)	
p-value	0.7089	0.1087	
Corrected Hedge's g Statistics	-0.127	-0.546	
95% CI	(-1.01, 0.75)	(-1.40, 0.31)	
Subgroup*Treatment Interaction p-value	NE	0.0726	

AMNOG Table SE18.8.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Fatigue			
Week 24			
m	8	10	21
n	7	9	18
Baseline Mean (SD)	4.43 (2.15)	5.20 (0.90)	5.34 (1.28)
Analysis Visit Mean (SD)	4.53 (1.80)	4.94 (1.00)	5.15 (1.48)
LS Mean of Change from Baseline (SE)	0.03 (0.48)	-0.09 (0.43)	0.07 (0.37)
95% CI	(-0.96, 1.02)	(-0.96, 0.79)	(-0.68, 0.81)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.04 (0.52)	-0.15 (0.47)	
95% CI	(-1.10, 1.02)	(-1.11, 0.80)	
p-value	0.9408	0.7447	
Corrected Hedge's g Statistics	-0.025	-0.101	
95% CI	(-0.90, 0.85)	(-0.90, 0.70)	
Week 52			
m	8	10	20
n	7	8	17
Baseline Mean (SD)	5.04 (1.53)	5.25 (0.95)	5.39 (1.30)
Analysis Visit Mean (SD)	5.29 (1.38)	4.93 (0.81)	5.21 (1.33)
LS Mean of Change from Baseline (SE)	0.32 (0.42)	-0.12 (0.39)	0.06 (0.34)
95% CI	(-0.55, 1.19)	(-0.92, 0.68)	(-0.64, 0.76)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.26 (0.43)	-0.18 (0.42)	
95% CI	(-0.62, 1.15)	(-1.03, 0.67)	
p-value	0.5519	0.6679	
Corrected Hedge's g Statistics	0.188	-0.131	
95% CI	(-0.69, 1.07)	(-0.97, 0.71)	
Subgroup*Treatment Interaction p-value	NE	0.7802	

AMNOG Table SE18.8.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Systemic Symptoms			
Week 24			
m	8	10	21
n	7	9	18
Baseline Mean (SD)	5.67 (1.26)	6.02 (0.68)	5.74 (0.80)
Analysis Visit Mean (SD)	5.73 (1.13)	5.84 (0.68)	5.52 (1.21)
LS Mean of Change from Baseline (SE)	0.12 (0.37)	-0.14 (0.34)	-0.20 (0.30)
95% CI	(-0.63, 0.86)	(-0.85, 0.56)	(-0.81, 0.41)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.31 (0.37)	0.05 (0.36)	
95% CI	(-0.45, 1.08)	(-0.67, 0.78)	
p-value	0.4081	0.8786	
Corrected Hedge's g Statistics	0.254	0.044	
95% CI	(-0.62, 1.13)	(-0.76, 0.84)	
Week 52			
m	8	10	20
n	7	8	17
Baseline Mean (SD)	5.89 (1.11)	6.18 (0.53)	5.78 (0.81)
Analysis Visit Mean (SD)	5.83 (1.24)	5.30 (0.68)	5.65 (1.20)
LS Mean of Change from Baseline (SE)	-0.04 (0.37)	-0.87 (0.36)	-0.13 (0.30)
95% CI	(-0.80, 0.73)	(-1.61, -0.14)	(-0.74, 0.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.09 (0.38)	-0.75 (0.37)	
95% CI	(-0.68, 0.86)	(-1.51, 0.01)	
p-value	0.8161	0.0534	
Corrected Hedge's g Statistics	0.072	-0.611	
95% CI	(-0.81, 0.95)	(-1.47, 0.25)	
Subgroup*Treatment Interaction p-value	NE	0.1875	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE18.8.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Worry			
Week 24			
m	8	10	21
n	7	9	18
Baseline Mean (SD)	5.66 (2.13)	6.52 (0.65)	6.59 (0.51)
Analysis Visit Mean (SD)	6.29 (1.25)	6.30 (0.83)	6.50 (0.95)
LS Mean of Change from Baseline (SE)	0.45 (0.32)	-0.17 (0.28)	0.06 (0.25)
95% CI	(-0.21, 1.11)	(-0.75, 0.41)	(-0.45, 0.58)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.38 (0.34)	-0.23 (0.30)	
95% CI	(-0.32, 1.08)	(-0.85, 0.39)	
p-value	0.2733	0.4482	
Corrected Hedge's g Statistics	0.364	-0.225	
95% CI	(-0.51, 1.24)	(-1.03, 0.58)	
Week 52			
m	8	10	20
n	7	8	17
Baseline Mean (SD)	5.66 (2.13)	6.70 (0.40)	6.61 (0.52)
Analysis Visit Mean (SD)	6.01 (1.92)	6.15 (0.99)	6.54 (0.77)
LS Mean of Change from Baseline (SE)	0.35 (0.35)	-0.46 (0.31)	0.03 (0.27)
95% CI	(-0.36, 1.06)	(-1.10, 0.18)	(-0.51, 0.57)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.32 (0.37)	-0.49 (0.34)	
95% CI	(-0.44, 1.08)	(-1.18, 0.20)	
p-value	0.3940	0.1589	
Corrected Hedge's g Statistics	0.297	-0.457	
95% CI	(-0.59, 1.18)	(-1.31, 0.39)	
Subgroup*Treatment Interaction p-value	NE	0.4320	

AMNOG Table SE18.8.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; HbA1c = Hemoglobin A1C.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi-square Test. For this unadjusted analysis, only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.

AMNOG Table SE18.8.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	1 (100)	2 (100)	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (50.0)	4 (57.1)
No	1 (100)	1 (50.0)	3 (42.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.86	1.33	
95% CI of the inverse odds ratio	(0.12, 126.73)	(0.06, 31.12)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.25	1.14	
95% CI of the inverse risk ratio	(0.19, 26.79)	(0.25, 5.26)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-31.25	-7.14	
95% CI of the absolute risk difference	(-100.00, 37.91)	(-85.54, 71.25)	
p-value	0.4292	0.8577	
p-value of Breslow-Day Test for Homogeneity [3]	0.2079	0.2889	

AMNOG Table SE18.8.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	1 (100)	2 (100)	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	1 (100)	2 (100)	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE18.8.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (28.6)
No	1 (100)	2 (100)	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	2.27	
95% CI of the inverse odds ratio	(0.04, 46.65)	(0.08, 67.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	1.88	
95% CI of the inverse risk ratio	(0.09, 17.02)	(0.12, 28.78)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.25	-14.58	
95% CI of the absolute risk difference	(-74.32, 61.82)	(-67.59, 38.43)	
p-value	0.8630	0.6286	
p-value of Breslow-Day Test for Homogeneity [3]	0.5039	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (50.0)	3 (42.9)
No	1 (100)	1 (50.0)	4 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.33	0.75	
95% CI of the inverse odds ratio	(0.07, 76.67)	(0.03, 17.51)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.75	0.86	
95% CI of the inverse risk ratio	(0.14, 21.88)	(0.17, 4.37)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-18.75	7.14	
95% CI of the absolute risk difference	(-87.91, 50.41)	(-71.25, 85.54)	
p-value	0.6283	0.8577	
p-value of Breslow-Day Test for Homogeneity [3]	0.3669	0.1539	

AMNOG Table SE18.8.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	1 (100)	2 (100)	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (50.0)	0
No	1 (100)	1 (50.0)	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.07	
95% CI of the inverse odds ratio	NE	(0.00, 2.56)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.13	
95% CI of the inverse risk ratio	NE	(0.01, 2.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	43.75	
95% CI of the absolute risk difference	NE	(-15.26, 100.00)	
p-value	NE	0.0938	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.0410	

AMNOG Table SE18.8.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (50.0)	2 (28.6)
No	1 (100)	1 (50.0)	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	0.40	
95% CI of the inverse odds ratio	(0.04, 46.65)	(0.02, 10.02)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	0.57	
95% CI of the inverse risk ratio	(0.09, 17.02)	(0.09, 3.51)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.25	21.43	
95% CI of the absolute risk difference	(-74.32, 61.82)	(-55.52, 98.38)	
p-value	0.8630	0.5708	
p-value of Breslow-Day Test for Homogeneity [3]	0.6343	0.3179	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (50.0)	3 (42.9)
No	1 (100)	1 (50.0)	4 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.33	0.75	
95% CI of the inverse odds ratio	(0.07, 76.67)	(0.03, 17.51)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.75	0.86	
95% CI of the inverse risk ratio	(0.14, 21.88)	(0.17, 4.37)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-18.75	7.14	
95% CI of the absolute risk difference	(-87.91, 50.41)	(-71.25, 85.54)	
p-value	0.6283	0.8577	
p-value of Breslow-Day Test for Homogeneity [3]	0.3043	0.6525	

AMNOG Table SE18.8.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (50.0)	0
No	1 (100)	1 (50.0)	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.07	
95% CI of the inverse odds ratio	NE	(0.00, 2.56)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.13	
95% CI of the inverse risk ratio	NE	(0.01, 2.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	43.75	
95% CI of the absolute risk difference	NE	(-15.26, 100.00)	
p-value	NE	0.0938	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.0088	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (50.0)	4 (57.1)
No	1 (100)	1 (50.0)	3 (42.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.86	1.33	
95% CI of the inverse odds ratio	(0.12, 126.73)	(0.06, 31.12)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.25	1.14	
95% CI of the inverse risk ratio	(0.19, 26.79)	(0.25, 5.26)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-31.25	-7.14	
95% CI of the absolute risk difference	(-100.00, 37.91)	(-85.54, 71.25)	
p-value	0.4292	0.8577	
p-value of Breslow-Day Test for Homogeneity [3]	0.2079	0.2889	

AMNOG Table SE18.8.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (28.6)
No	1 (100)	2 (100)	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	2.27	
95% CI of the inverse odds ratio	(0.04, 46.65)	(0.08, 67.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	1.88	
95% CI of the inverse risk ratio	(0.09, 17.02)	(0.12, 28.78)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.25	-14.58	
95% CI of the absolute risk difference	(-74.32, 61.82)	(-67.59, 38.43)	
p-value	0.8630	0.6286	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	3 (42.9)
No	1 (100)	2 (100)	4 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.33	3.89	
95% CI of the inverse odds ratio	(0.07, 76.67)	(0.14, 109.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.75	2.63	
95% CI of the inverse risk ratio	(0.14, 21.88)	(0.19, 37.14)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-18.75	-27.08	
95% CI of the absolute risk difference	(-87.91, 50.41)	(-81.49, 27.32)	
p-value	0.6283	0.4056	
p-value of Breslow-Day Test for Homogeneity [3]	0.0825	NE	

AMNOG Table SE18.8.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (4.8)
No	8 (100)	13 (100)	20 (95.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.76	-4.76	
95% CI of the absolute risk difference	(-13.87, 4.35)	(-13.87, 4.35)	
p-value	0.5299	0.4245	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (25.0)	0	3 (14.3)
No	6 (75.0)	13 (100)	18 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	5.11	
95% CI of the inverse odds ratio	(0.07, 3.75)	(0.24, 107.33)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	4.45	
95% CI of the inverse risk ratio	(0.12, 2.81)	(0.25, 79.87)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	10.71	-12.34	
95% CI of the absolute risk difference	(-22.82, 44.25)	(-30.45, 5.78)	
p-value	0.4948	0.2508	
p-value of Breslow-Day Test for Homogeneity [3]	0.2079	0.2889	

AMNOG Table SE18.8.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (7.7)	2 (9.5)
No	8 (100)	12 (92.3)	19 (90.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.18	1.26	
95% CI of the inverse odds ratio	(0.09, 50.43)	(0.10, 15.49)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.05	1.24	
95% CI of the inverse risk ratio	(0.11, 38.52)	(0.12, 12.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.81	-1.83	
95% CI of the absolute risk difference	(-25.80, 14.19)	(-21.00, 17.34)	
p-value	0.6196	0.8548	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (12.5)	1 (7.7)	4 (19.0)
No	7 (87.5)	12 (92.3)	17 (81.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.65	2.82	
95% CI of the inverse odds ratio	(0.16, 17.47)	(0.28, 28.52)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.52	2.48	
95% CI of the inverse risk ratio	(0.20, 11.65)	(0.31, 19.81)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.55	-11.36	
95% CI of the absolute risk difference	(-34.96, 21.86)	(-33.53, 10.82)	
p-value	0.6765	0.3636	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE18.8.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (12.5)	0	2 (9.5)
No	7 (87.5)	13 (100)	19 (90.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	3.46	
95% CI of the inverse odds ratio	(0.06, 9.46)	(0.15, 77.97)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.76	3.18	
95% CI of the inverse risk ratio	(0.08, 7.29)	(0.16, 61.49)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.98	-7.79	
95% CI of the absolute risk difference	(-23.15, 29.11)	(-24.24, 8.65)	
p-value	0.8140	0.4096	
p-value of Breslow-Day Test for Homogeneity [3]	0.5039	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (25.0)	0	4 (19.0)
No	6 (75.0)	13 (100)	17 (81.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	6.94	
95% CI of the inverse odds ratio	(0.10, 4.89)	(0.34, 140.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.76	5.73	
95% CI of the inverse risk ratio	(0.17, 3.38)	(0.33, 98.41)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.95	-16.88	
95% CI of the absolute risk difference	(-28.43, 40.34)	(-36.34, 2.57)	
p-value	0.7236	0.1533	
p-value of Breslow-Day Test for Homogeneity [3]	0.3669	0.1539	

AMNOG Table SE18.8.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (9.5)
No	8 (100)	13 (100)	19 (90.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.18	3.46	
95% CI of the inverse odds ratio	(0.09, 50.43)	(0.15, 77.97)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.05	3.18	
95% CI of the inverse risk ratio	(0.11, 38.52)	(0.16, 61.49)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.81	-7.79	
95% CI of the absolute risk difference	(-25.80, 14.19)	(-24.24, 8.65)	
p-value	0.6196	0.4096	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (15.4)	5 (23.8)
No	8 (100)	11 (84.6)	16 (76.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.67	1.72	
95% CI of the inverse odds ratio	(0.28, 115.08)	(0.28, 10.51)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.50	1.55	
95% CI of the inverse risk ratio	(0.28, 73.21)	(0.35, 6.85)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-19.44	-8.42	
95% CI of the absolute risk difference	(-42.93, 4.04)	(-35.19, 18.34)	
p-value	0.2136	0.5549	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.0410	

AMNOG Table SE18.8.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (12.5)	1 (7.7)	4 (19.0)
No	7 (87.5)	12 (92.3)	17 (81.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.65	2.82	
95% CI of the inverse odds ratio	(0.16, 17.47)	(0.28, 28.52)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.52	2.48	
95% CI of the inverse risk ratio	(0.20, 11.65)	(0.31, 19.81)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.55	-11.36	
95% CI of the absolute risk difference	(-34.96, 21.86)	(-33.53, 10.82)	
p-value	0.6765	0.3636	
p-value of Breslow-Day Test for Homogeneity [3]	0.6343	0.3179	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (37.5)	2 (15.4)	5 (23.8)
No	5 (62.5)	11 (84.6)	16 (76.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.52	1.72	
95% CI of the inverse odds ratio	(0.09, 2.99)	(0.28, 10.51)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	1.55	
95% CI of the inverse risk ratio	(0.20, 2.06)	(0.35, 6.85)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	13.69	-8.42	
95% CI of the absolute risk difference	(-24.48, 51.86)	(-35.19, 18.34)	
p-value	0.4610	0.5549	
p-value of Breslow-Day Test for Homogeneity [3]	0.3043	0.6525	

AMNOG Table SE18.8.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	3 (14.3)
No	8 (100)	13 (100)	18 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.22	5.11	
95% CI of the inverse odds ratio	(0.15, 69.45)	(0.24, 107.33)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.86	4.45	
95% CI of the inverse risk ratio	(0.16, 50.00)	(0.25, 79.87)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.35	-12.34	
95% CI of the absolute risk difference	(-31.74, 11.04)	(-30.45, 5.78)	
p-value	0.4351	0.2508	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.0088	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (25.0)	0	3 (14.3)
No	6 (75.0)	13 (100)	18 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	5.11	
95% CI of the inverse odds ratio	(0.07, 3.75)	(0.24, 107.33)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	4.45	
95% CI of the inverse risk ratio	(0.12, 2.81)	(0.25, 79.87)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	10.71	-12.34	
95% CI of the absolute risk difference	(-22.82, 44.25)	(-30.45, 5.78)	
p-value	0.4948	0.2508	
p-value of Breslow-Day Test for Homogeneity [3]	0.2079	0.2889	

AMNOG Table SE18.8.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (4.8)
No	8 (100)	13 (100)	20 (95.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.76	-4.76	
95% CI of the absolute risk difference	(-13.87, 4.35)	(-13.87, 4.35)	
p-value	0.5299	0.4245	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (50.0)	0	2 (9.5)
No	4 (50.0)	13 (100)	19 (90.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.11	3.46	
95% CI of the inverse odds ratio	(0.01, 0.79)	(0.15, 77.97)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.19	3.18	
95% CI of the inverse risk ratio	(0.04, 0.84)	(0.16, 61.49)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	40.48	-7.79	
95% CI of the absolute risk difference	(3.62, 77.33)	(-24.24, 8.65)	
p-value	0.0162	0.4096	
p-value of Breslow-Day Test for Homogeneity [3]	0.0825	NE	

AMNOG Table SE18.9.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=8)	(N=10)	(N=20)	(N=8)	(N=10)	(N=20)
CLDQ-NASH						
Baseline						
m	8	10	20			
n	8	9	18			
Mean (SD)	5.46 (1.63)	5.81 (0.69)	6.02 (0.65)			
Median	6.30	6.10	6.10			
IQR: Q1, Q3	4.50, 6.55	5.80, 6.20	5.50, 6.60			
Min, Max	2.2, 6.8	4.3, 6.5	4.8, 6.9			
Week 24						
m	8	7	20			
n	7	6	18	7	6	17
Mean (SD/SE)	5.64 (1.07)	5.88 (0.58)	5.76 (1.01)	0.27 (0.26)	-0.13 (0.21)	-0.23 (0.14)
Median	6.30	5.90	5.90	0	0.05	0
IQR: Q1, Q3	4.80, 6.50	5.30, 6.30	4.90, 6.60	-0.20, 0.80	-0.60, 0.20	-0.30, 0.10
Min, Max	3.8, 6.6	5.3, 6.6	3.8, 7.0	-0.3, 1.6	-0.9, 0.4	-2.2, 0.4
Week 52						
m	8	7	19			
n	7	5	17	7	5	16
Mean (SD/SE)	5.74 (1.47)	5.70 (0.37)	5.97 (1.04)	0.07 (0.11)	-0.50 (0.13)	-0.13 (0.23)
Median	6.20	5.60	6.10	0	-0.40	0
IQR: Q1, Q3	5.50, 6.60	5.60, 5.90	5.60, 6.80	-0.20, 0.40	-0.50, -0.30	-0.25, 0.25
Min, Max	2.6, 7.0	5.2, 6.2	3.1, 7.0	-0.3, 0.5	-1.0, -0.3	-3.1, 1.3

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.9.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=8)	(N=10)	(N=20)	(N=8)	(N=10)	(N=20)
Abdominal Symptoms						
Baseline						
m	8	10	20			
n	8	9	18			
Mean (SD)	5.50 (2.07)	5.86 (0.95)	6.18 (1.19)			
Median	6.50	6.00	7.00			
IQR: Q1, Q3	4.65, 6.85	5.00, 6.70	6.00, 7.00			
Min, Max	1.0, 7.0	4.3, 7.0	3.3, 7.0			
Week 24						
m	8	7	20			
n	7	6	18	7	6	17
Mean (SD/SE)	5.61 (1.71)	5.95 (1.01)	5.82 (1.43)	0.23 (0.28)	-0.45 (0.39)	-0.17 (0.24)
Median	6.00	5.85	6.70	0	-0.50	0
IQR: Q1, Q3	5.30, 7.00	5.70, 7.00	4.70, 7.00	-0.40, 1.00	-1.00, 0.00	-0.30, 0.00
Min, Max	2.0, 7.0	4.3, 7.0	3.3, 7.0	-0.7, 1.4	-1.7, 1.0	-2.7, 1.3
Week 52						
m	8	7	19			
n	7	5	17	7	5	16
Mean (SD/SE)	5.61 (2.09)	6.08 (0.58)	6.00 (1.49)	-0.06 (0.14)	-0.46 (0.30)	-0.23 (0.34)
Median	6.30	5.70	7.00	0	-0.30	0
IQR: Q1, Q3	5.70, 7.00	5.70, 6.30	5.30, 7.00	-0.40, 0.00	-1.00, 0.00	0.00, 0.15
Min, Max	1.0, 7.0	5.7, 7.0	2.0, 7.0	-0.4, 0.7	-1.3, 0.3	-5.0, 1.0

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.9.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=8)	Visit Result DB MGL-3196 100 mg (N=10)	Visit Result DB Placebo (N=20)	Change from Baseline DB MGL-3196 80 mg (N=8)	Change from Baseline DB MGL-3196 100 mg (N=10)	Change from Baseline DB Placebo (N=20)
Activity						
Baseline						
m	8	10	20			
n	8	9	18			
Mean (SD)	5.45 (1.87)	5.76 (1.07)	5.93 (0.79)			
Median	6.40	5.60	5.80			
IQR: Q1, Q3	4.10, 6.80	5.40, 6.60	5.40, 6.60			
Min, Max	2.0, 7.0	3.6, 7.0	4.4, 7.0			
Week 24						
m	8	7	20			
n	7	6	18	7	6	17
Mean (SD/SE)	5.66 (0.81)	5.97 (0.75)	5.57 (1.15)	0.40 (0.47)	-0.13 (0.30)	-0.38 (0.27)
Median	5.80	5.90	5.70	-0.20	0	0
IQR: Q1, Q3	4.80, 6.40	5.20, 6.60	4.80, 6.20	-0.40, 1.40	-0.40, 0.20	-0.80, 0.20
Min, Max	4.8, 6.8	5.2, 7.0	2.8, 7.0	-0.6, 2.8	-1.4, 0.8	-3.8, 0.8
Week 52						
m	8	7	19			
n	7	5	17	7	5	16
Mean (SD/SE)	5.80 (1.20)	5.24 (0.96)	6.04 (1.14)	0.06 (0.31)	-1.04 (0.30)	0.06 (0.27)
Median	5.80	5.00	6.60	0	-1.20	0
IQR: Q1, Q3	5.60, 6.80	4.60, 5.80	5.40, 7.00	-0.60, 0.80	-1.20, -0.40	-0.20, 0.30
Min, Max	3.4, 7.0	4.2, 6.6	3.4, 7.0	-1.0, 1.4	-2.0, -0.4	-2.6, 2.0

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.9.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=8)	(N=10)	(N=20)	(N=8)	(N=10)	(N=20)
Emotional Health						
Baseline						
m	8	10	20			
n	8	9	18			
Mean (SD)	5.94 (1.27)	5.87 (1.02)	6.13 (0.68)			
Median	6.45	6.00	6.20			
IQR: Q1, Q3	5.30, 6.85	5.20, 6.80	5.70, 6.80			
Min, Max	3.3, 7.0	3.8, 6.9	4.7, 7.0			
Week 24						
m	8	7	20			
n	7	6	18	7	6	17
Mean (SD/SE)	6.11 (1.01)	5.73 (0.95)	5.97 (0.95)	0.21 (0.27)	-0.15 (0.35)	-0.09 (0.13)
Median	6.60	5.80	6.10	0	0.05	0
IQR: Q1, Q3	5.10, 6.80	5.00, 6.60	5.10, 6.80	-0.30, 1.00	-0.60, 0.40	-0.20, 0.30
Min, Max	4.3, 6.9	4.4, 6.8	4.1, 7.0	-0.6, 1.4	-1.6, 0.8	-1.5, 0.5
Week 52						
m	8	7	19			
n	7	5	17	7	5	16
Mean (SD/SE)	5.81 (1.34)	5.62 (0.57)	6.11 (1.07)	-0.23 (0.15)	-0.42 (0.38)	-0.09 (0.19)
Median	5.90	5.40	6.40	-0.10	-0.20	0
IQR: Q1, Q3	5.30, 6.90	5.30, 6.00	5.80, 6.90	-0.60, 0.00	-0.60, 0.10	-0.30, 0.20
Min, Max	3.2, 7.0	5.0, 6.4	3.3, 7.0	-0.9, 0.3	-1.8, 0.4	-2.5, 1.3

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.9.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Visit Statistic	Visit Result DB MGL-3196 80 mg (N=8)	Visit Result DB MGL-3196 100 mg (N=10)	Visit Result DB Placebo (N=20)	Change from Baseline DB MGL-3196 80 mg (N=8)	Change from Baseline DB MGL-3196 100 mg (N=10)	Change from Baseline DB Placebo (N=20)
Fatigue						
Baseline						
m	8	10	20			
n	8	9	18			
Mean (SD)	4.54 (2.02)	5.50 (0.99)	5.57 (1.34)			
Median	5.50	5.50	5.80			
IQR: Q1, Q3	3.15, 5.90	4.80, 6.00	5.30, 6.70			
Min, Max	1.0, 6.2	4.0, 7.0	1.5, 7.0			
Week 24						
m	8	7	20			
n	7	6	18	7	6	17
Mean (SD/SE)	4.53 (1.80)	5.08 (1.06)	5.20 (1.51)	0.10 (0.28)	-0.22 (0.40)	-0.49 (0.23)
Median	5.50	5.00	5.35	0	0.25	-0.20
IQR: Q1, Q3	3.50, 5.80	4.50, 6.20	4.30, 6.70	-0.20, 0.10	-0.70, 0.40	-0.60, 0.00
Min, Max	1.0, 5.8	3.5, 6.3	2.2, 6.8	-0.7, 1.7	-2.0, 0.5	-3.3, 0.7
Week 52						
m	8	7	19			
n	7	5	17	7	5	16
Mean (SD/SE)	5.29 (1.38)	4.98 (0.79)	5.41 (1.35)	0.24 (0.19)	-0.42 (0.42)	-0.45 (0.26)
Median	5.50	5.30	5.00	0.20	-0.20	-0.45
IQR: Q1, Q3	4.50, 6.30	4.30, 5.50	4.50, 6.50	-0.30, 0.80	-1.20, 0.00	-1.05, 0.20
Min, Max	2.7, 7.0	4.0, 5.8	2.8, 7.0	-0.4, 0.9	-1.5, 0.8	-2.9, 1.2

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.9.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=8)	(N=10)	(N=20)	(N=8)	(N=10)	(N=20)
Systemic Symptoms						
Baseline						
m	8	10	20			
n	8	9	18			
Mean (SD)	5.69 (1.17)	5.58 (1.31)	5.84 (0.76)			
Median	6.05	5.70	5.80			
IQR: Q1, Q3	4.55, 6.65	5.00, 6.30	5.50, 6.50			
Min, Max	4.0, 7.0	2.7, 7.0	3.8, 7.0			
Week 24						
m	8	7	20			
n	7	6	18	7	6	17
Mean (SD/SE)	5.73 (1.13)	5.88 (0.89)	5.39 (1.22)	0.06 (0.17)	-0.07 (0.24)	-0.41 (0.18)
Median	6.30	6.00	5.70	0	0	-0.30
IQR: Q1, Q3	4.50, 6.70	5.30, 6.50	4.30, 6.30	-0.30, 0.50	-0.30, 0.10	-0.50, 0.10
Min, Max	4.0, 6.8	4.5, 7.0	3.2, 7.0	-0.5, 0.5	-1.0, 0.8	-2.1, 0.5
Week 52						
m	8	7	19			
n	7	5	17	7	5	16
Mean (SD/SE)	5.83 (1.24)	5.64 (0.83)	5.71 (1.08)	-0.06 (0.16)	-0.54 (0.21)	-0.18 (0.23)
Median	6.30	5.50	5.70	0	-0.50	-0.05
IQR: Q1, Q3	5.20, 6.50	5.20, 5.70	5.30, 6.80	-0.30, 0.40	-0.90, -0.20	-0.60, 0.40
Min, Max	3.3, 7.0	4.8, 7.0	3.2, 7.0	-0.7, 0.5	-1.1, 0.0	-2.6, 1.5

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.9.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=8)	(N=10)	(N=20)	(N=8)	(N=10)	(N=20)
Worry						
Baseline						
m	8	10	20			
n	8	9	18			
Mean (SD)	5.69 (1.97)	6.26 (0.71)	6.46 (0.77)			
Median	6.00	6.40	6.85			
IQR: Q1, Q3	5.80, 6.95	5.90, 6.90	6.10, 7.00			
Min, Max	1.0, 7.0	5.1, 7.0	4.1, 7.0			
Week 24						
m	8	7	20			
n	7	6	18	7	6	17
Mean (SD/SE)	6.29 (1.25)	6.58 (0.62)	6.51 (0.76)	0.63 (0.36)	0.15 (0.08)	0.07 (0.18)
Median	7.00	6.95	6.95	0.30	0.10	0
IQR: Q1, Q3	6.00, 7.00	6.00, 7.00	6.30, 7.00	0.00, 1.10	0.00, 0.20	0.00, 0.30
Min, Max	3.6, 7.0	5.6, 7.0	4.7, 7.0	0.0, 2.6	0.0, 0.5	-1.6, 1.3
Week 52						
m	8	7	19			
n	7	5	17	7	5	16
Mean (SD/SE)	6.01 (1.92)	6.60 (0.84)	6.55 (0.83)	0.36 (0.14)	-0.10 (0.18)	0.06 (0.24)
Median	6.60	7.00	7.00	0.40	0	0
IQR: Q1, Q3	6.30, 7.00	6.90, 7.00	6.60, 7.00	0.00, 0.70	0.00, 0.10	-0.05, 0.30
Min, Max	1.7, 7.0	5.1, 7.0	4.1, 7.0	0.0, 0.9	-0.8, 0.2	-2.9, 1.6

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.9.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=1)	Visit Result DB MGL-3196 100 mg (N=5)	Visit Result DB Placebo (N=8)	Change from Baseline DB MGL-3196 80 mg (N=1)	Change from Baseline DB MGL-3196 100 mg (N=5)	Change from Baseline DB Placebo (N=8)
CLDQ-NASH						
Baseline						
m	1	5	8			
n	1	5	7			
Mean (SD)	4.70 (N/A)	6.00 (0.64)	5.13 (0.80)			
Median	4.70	6.10	5.00			
IQR: Q1, Q3	4.70, 4.70	6.00, 6.10	4.30, 5.60			
Min, Max	4.7, 4.7	5.0, 6.8	4.2, 6.5			
Week 24						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	5.64 (0.71)	5.39 (1.04)	N/A	-0.36 (0.46)	0.26 (0.29)
Median	N/A	5.50	5.20	N/A	-0.10	0.10
IQR: Q1, Q3	N/A	5.30, 5.90	4.60, 6.60	N/A	-0.60, 0.30	-0.30, 0.30
Min, Max	N/A	4.8, 6.7	3.9, 6.8	N/A	-2.0, 0.6	-0.4, 1.9
Week 52						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	5.52 (0.70)	5.40 (0.88)	N/A	-0.48 (0.51)	0.27 (0.16)
Median	N/A	5.60	5.60	N/A	0	0.20
IQR: Q1, Q3	N/A	5.20, 6.10	4.50, 6.10	N/A	-0.80, 0.10	0.20, 0.50
Min, Max	N/A	4.5, 6.2	4.5, 6.7	N/A	-2.3, 0.6	-0.5, 0.9

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.9.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=5)	(N=8)	(N=1)	(N=5)	(N=8)
Abdominal Symptoms						
Baseline						
m	1	5	8			
n	1	5	7			
Mean (SD)	7.00 (N/A)	6.42 (0.80)	5.00 (1.01)			
Median	7.00	6.70	5.00			
IQR: Q1, Q3	7.00, 7.00	6.70, 6.70	4.00, 5.30			
Min, Max	7.0, 7.0	5.0, 7.0	4.0, 7.0			
Week 24						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	6.20 (0.77)	5.24 (1.31)	N/A	-0.22 (0.48)	0.24 (0.39)
Median	N/A	6.00	5.00	N/A	0.30	0
IQR: Q1, Q3	N/A	5.70, 7.00	4.00, 7.00	N/A	-1.30, 0.30	-0.30, 1.00
Min, Max	N/A	5.3, 7.0	3.7, 7.0	N/A	-1.4, 1.0	-1.3, 2.0
Week 52						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	5.74 (0.66)	5.00 (1.09)	N/A	-0.68 (0.51)	0.00 (0.19)
Median	N/A	5.70	4.70	N/A	-1.30	0
IQR: Q1, Q3	N/A	5.30, 6.00	4.00, 5.70	N/A	-1.40, 0.00	0.00, 0.30
Min, Max	N/A	5.0, 6.7	4.0, 7.0	N/A	-1.7, 1.0	-1.0, 0.7

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.9.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=5)	(N=8)	(N=1)	(N=5)	(N=8)
Activity						
Baseline						
m	1	5	8			
n	1	5	7			
Mean (SD)	5.20 (N/A)	5.88 (1.04)	5.23 (1.36)			
Median	5.20	6.00	5.60			
IQR: Q1, Q3	5.20, 5.20	5.80, 6.40	4.20, 6.60			
Min, Max	5.2, 5.2	4.2, 7.0	3.2, 6.6			
Week 24						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	4.84 (0.98)	5.34 (2.12)	N/A	-1.04 (0.66)	0.11 (0.52)
Median	N/A	4.40	6.40	N/A	-1.60	0.20
IQR: Q1, Q3	N/A	4.40, 4.40	2.80, 6.80	N/A	-2.00, 0.20	-1.40, 0.60
Min, Max	N/A	4.4, 6.6	1.8, 6.8	N/A	-2.6, 0.8	-1.4, 2.6
Week 52						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	5.36 (0.79)	5.54 (1.28)	N/A	-0.52 (0.57)	0.31 (0.35)
Median	N/A	5.00	6.20	N/A	0	0.20
IQR: Q1, Q3	N/A	4.80, 6.00	4.20, 6.40	N/A	-1.20, 0.20	-0.40, 0.40
Min, Max	N/A	4.6, 6.4	3.6, 7.0	N/A	-2.4, 0.8	-0.6, 2.2

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.9.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=1)	Visit Result DB MGL-3196 100 mg (N=5)	Visit Result DB Placebo (N=8)	Change from Baseline DB MGL-3196 80 mg (N=1)	Change from Baseline DB MGL-3196 100 mg (N=5)	Change from Baseline DB Placebo (N=8)
Emotional Health						
Baseline						
m	1	5	8			
n	1	5	7			
Mean (SD)	4.30 (N/A)	5.96 (0.63)	5.37 (0.96)			
Median	4.30	6.10	5.20			
IQR: Q1, Q3	4.30, 4.30	6.00, 6.20	4.40, 6.30			
Min, Max	4.3, 4.3	4.9, 6.6	4.1, 6.7			
Week 24						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	5.76 (0.96)	5.59 (1.21)	N/A	-0.20 (0.57)	0.21 (0.25)
Median	N/A	5.80	5.90	N/A	0.10	0.30
IQR: Q1, Q3	N/A	5.60, 6.20	4.70, 6.60	N/A	-0.40, 0.70	-0.30, 0.70
Min, Max	N/A	4.3, 6.9	3.7, 7.0	N/A	-2.3, 0.9	-0.7, 1.2
Week 52						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	5.76 (0.63)	5.41 (1.28)	N/A	-0.20 (0.47)	0.04 (0.23)
Median	N/A	5.90	6.00	N/A	-0.10	0
IQR: Q1, Q3	N/A	5.80, 6.00	4.40, 6.40	N/A	-0.30, 0.40	-0.50, 0.50
Min, Max	N/A	4.7, 6.4	3.4, 6.8	N/A	-1.9, 0.9	-0.7, 1.1

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.9.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=5)	(N=8)	(N=1)	(N=5)	(N=8)
Fatigue						
Baseline						
m	1	5	8			
n	1	5	7			
Mean (SD)	5.00 (N/A)	5.10 (1.27)	3.80 (1.07)			
Median	5.00	4.70	3.80			
IQR: Q1, Q3	5.00, 5.00	4.50, 6.30	2.70, 4.50			
Min, Max	5.0, 5.0	3.5, 6.5	2.7, 5.7			
Week 24						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	4.82 (1.16)	4.60 (1.19)	N/A	-0.28 (0.49)	0.80 (0.50)
Median	N/A	4.50	4.20	N/A	0	1.10
IQR: Q1, Q3	N/A	4.30, 4.70	3.80, 5.70	N/A	0.00, 0.30	-0.40, 1.50
Min, Max	N/A	3.8, 6.8	2.8, 6.2	N/A	-2.2, 0.5	-1.0, 3.0
Week 52						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	5.06 (0.78)	4.54 (1.14)	N/A	-0.04 (0.70)	0.74 (0.34)
Median	N/A	5.30	4.30	N/A	-0.30	1.10
IQR: Q1, Q3	N/A	4.30, 5.50	4.00, 5.70	N/A	-0.40, 1.00	0.30, 1.30
Min, Max	N/A	4.2, 6.0	2.8, 6.2	N/A	-2.3, 1.8	-1.0, 1.7

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.9.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=5)	(N=8)	(N=1)	(N=5)	(N=8)
Systemic Symptoms						
Baseline						
m	1	5	8			
n	1	5	7			
Mean (SD)	4.30 (N/A)	5.84 (1.33)	5.16 (0.96)			
Median	4.30	6.20	5.20			
IQR: Q1, Q3	4.30, 4.30	5.50, 6.80	4.30, 5.50			
Min, Max	4.3, 4.3	3.7, 7.0	3.8, 6.8			
Week 24						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	5.90 (0.61)	5.70 (1.01)	N/A	0.06 (0.54)	0.54 (0.29)
Median	N/A	6.00	5.20	N/A	0.50	0.70
IQR: Q1, Q3	N/A	5.50, 6.00	4.70, 6.80	N/A	-0.80, 0.60	-0.30, 1.20
Min, Max	N/A	5.2, 6.8	4.7, 6.8	N/A	-1.5, 1.5	-0.3, 1.6
Week 52						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	5.30 (0.83)	5.41 (1.19)	N/A	-0.54 (0.70)	0.26 (0.22)
Median	N/A	5.30	5.30	N/A	-0.60	0
IQR: Q1, Q3	N/A	4.80, 6.00	4.70, 6.50	N/A	-0.70, -0.20	-0.20, 1.00
Min, Max	N/A	4.2, 6.2	3.5, 6.8	N/A	-2.8, 1.6	-0.3, 1.1

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.9.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=1)	Visit Result DB MGL-3196 100 mg (N=5)	Visit Result DB Placebo (N=8)	Change from Baseline DB MGL-3196 80 mg (N=1)	Change from Baseline DB MGL-3196 100 mg (N=5)	Change from Baseline DB Placebo (N=8)
Worry						
Baseline						
m	1	5	8			
n	1	5	7			
Mean (SD)	2.60 (N/A)	6.76 (0.28)	6.31 (0.60)			
Median	2.60	6.90	6.40			
IQR: Q1, Q3	2.60, 2.60	6.70, 6.90	5.60, 6.90			
Min, Max	2.6, 2.6	6.3, 7.0	5.4, 6.9			
Week 24						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	6.24 (1.01)	5.93 (1.39)	N/A	-0.52 (0.45)	-0.39 (0.34)
Median	N/A	6.90	6.90	N/A	0	0.10
IQR: Q1, Q3	N/A	5.40, 7.00	4.60, 7.00	N/A	-0.90, 0.10	-1.10, 0.20
Min, Max	N/A	4.9, 7.0	3.7, 7.0	N/A	-2.1, 0.3	-1.9, 0.7
Week 52						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	5.98 (0.99)	6.37 (0.52)	N/A	-0.78 (0.50)	0.06 (0.11)
Median	N/A	6.10	6.30	N/A	-0.20	0
IQR: Q1, Q3	N/A	6.10, 6.70	6.00, 6.90	N/A	-0.80, -0.20	-0.20, 0.20
Min, Max	N/A	4.3, 6.7	5.6, 7.0	N/A	-2.7, 0.0	-0.3, 0.6

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc. Page 1 of 3
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE18.9.2
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of CLDQ-NASH - MMRM Model
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE18.9.2
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of CLDQ-NASH - MMRM Model
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
CLDQ-NASH			
Week 24			
m	8	7	20
n	7	6	17
Baseline Mean (SD)	5.37 (1.74)	6.02 (0.49)	6.05 (0.66)
Analysis Visit Mean (SD)	5.64 (1.07)	5.88 (0.58)	5.82 (1.00)
LS Mean of Change from Baseline (SE)	0.06 (0.30)	-0.22 (0.36)	-0.33 (0.32)
95% CI	(-0.55, 0.67)	(-0.96, 0.53)	(-0.99, 0.32)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.39 (0.29)	0.12 (0.30)	
95% CI	(-0.21, 0.99)	(-0.50, 0.73)	
p-value	0.1923	0.7044	
Corrected Hedge's g Statistics	0.316	0.090	
95% CI	(-0.57, 1.20)	(-0.84, 1.02)	
Week 52			
m	8	7	19
n	7	5	16
Baseline Mean (SD)	5.67 (1.64)	6.20 (0.22)	6.11 (0.64)
Analysis Visit Mean (SD)	5.74 (1.47)	5.70 (0.37)	5.98 (1.08)
LS Mean of Change from Baseline (SE)	-0.04 (0.35)	-0.57 (0.43)	-0.25 (0.34)
95% CI	(-0.76, 0.67)	(-1.46, 0.32)	(-0.96, 0.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.21 (0.36)	-0.32 (0.40)	
95% CI	(-0.52, 0.94)	(-1.14, 0.49)	
p-value	0.5684	0.4240	
Corrected Hedge's g Statistics	0.157	-0.238	
95% CI	(-0.73, 1.05)	(-1.24, 0.77)	
Subgroup*Treatment Interaction p-value	NE	0.5561	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE18.9.2
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of CLDQ-NASH - MMRM Model
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
CLDQ-NASH			
Week 24			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	6.00 (0.64)	5.13 (0.80)
Analysis Visit Mean (SD)	N/A	5.64 (0.71)	5.39 (1.04)
LS Mean of Change from Baseline (SE)	NE	0.49 (0.53)	0.41 (0.37)
95% CI	NE	(-0.74, 1.71)	(-0.45, 1.26)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	0.08 (0.58)	
95% CI	NE	(-1.26, 1.42)	
p-value	NE	0.8943	
Corrected Hedge's g Statistics	NE	0.069	
95% CI	NE	(-1.08, 1.22)	
Week 52			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	6.00 (0.64)	5.13 (0.80)
Analysis Visit Mean (SD)	N/A	5.52 (0.70)	5.40 (0.88)
LS Mean of Change from Baseline (SE)	NE	0.39 (0.51)	0.40 (0.35)
95% CI	NE	(-0.78, 1.56)	(-0.40, 1.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-0.02 (0.54)	
95% CI	NE	(-1.25, 1.22)	
p-value	NE	0.9772	
Corrected Hedge's g Statistics	NE	-0.014	
95% CI	NE	(-1.16, 1.13)	
Subgroup*Treatment Interaction p-value	NE	0.5561	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE18.9.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

AMNOG Table SE18.9.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Abdominal Symptoms			
Week 24			
m	8	7	20
n	7	6	17
Baseline Mean (SD)	5.39 (2.21)	6.40 (0.57)	6.14 (1.21)
Analysis Visit Mean (SD)	5.61 (1.71)	5.95 (1.01)	5.96 (1.33)
LS Mean of Change from Baseline (SE)	0.01 (0.44)	-0.56 (0.54)	-0.20 (0.46)
95% CI	(-0.90, 0.92)	(-1.66, 0.54)	(-1.15, 0.74)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.21 (0.43)	-0.36 (0.46)	
95% CI	(-0.68, 1.11)	(-1.29, 0.58)	
p-value	0.6252	0.4408	
Corrected Hedge's g Statistics	0.120	-0.194	
95% CI	(-0.76, 1.00)	(-1.13, 0.74)	
Week 52			
m	8	7	19
n	7	5	16
Baseline Mean (SD)	5.67 (2.17)	6.54 (0.51)	6.29 (1.07)
Analysis Visit Mean (SD)	5.61 (2.09)	6.08 (0.58)	6.06 (1.51)
LS Mean of Change from Baseline (SE)	-0.14 (0.51)	-0.56 (0.64)	-0.22 (0.50)
95% CI	(-1.19, 0.91)	(-1.87, 0.74)	(-1.25, 0.80)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.09 (0.53)	-0.34 (0.59)	
95% CI	(-0.99, 1.17)	(-1.55, 0.88)	
p-value	0.8702	0.5735	
Corrected Hedge's g Statistics	0.046	-0.171	
95% CI	(-0.84, 0.93)	(-1.18, 0.83)	
Subgroup*Treatment Interaction p-value	NE	0.5633	

AMNOG Table SE18.9.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Activity			
Week 24			
m	8	7	20
n	7	6	17
Baseline Mean (SD)	5.26 (1.93)	6.10 (0.86)	5.91 (0.80)
Analysis Visit Mean (SD)	5.66 (0.81)	5.97 (0.75)	5.53 (1.18)
LS Mean of Change from Baseline (SE)	-0.06 (0.44)	-0.03 (0.54)	-0.55 (0.46)
95% CI	(-0.96, 0.85)	(-1.13, 1.07)	(-1.48, 0.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.49 (0.44)	0.52 (0.46)	
95% CI	(-0.41, 1.39)	(-0.42, 1.46)	
p-value	0.2728	0.2647	
Corrected Hedge's g Statistics	0.276	0.285	
95% CI	(-0.61, 1.16)	(-0.65, 1.22)	
Week 52			
m	8	7	19
n	7	5	16
Baseline Mean (SD)	5.74 (1.81)	6.28 (0.82)	5.91 (0.83)
Analysis Visit Mean (SD)	5.80 (1.20)	5.24 (0.96)	5.98 (1.15)
LS Mean of Change from Baseline (SE)	-0.14 (0.45)	-0.93 (0.57)	-0.14 (0.46)
95% CI	(-1.07, 0.78)	(-2.10, 0.23)	(-1.09, 0.81)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.01 (0.43)	-0.80 (0.50)	
95% CI	(-0.89, 0.88)	(-1.81, 0.22)	
p-value	0.9895	0.1205	
Corrected Hedge's g Statistics	-0.003	-0.438	
95% CI	(-0.89, 0.88)	(-1.45, 0.58)	
Subgroup*Treatment Interaction p-value	NE	0.9168	

AMNOG Table SE18.9.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Emotional Health			
Week 24			
m	8	7	20
n	7	6	17
Baseline Mean (SD)	5.90 (1.36)	5.88 (0.64)	6.16 (0.69)
Analysis Visit Mean (SD)	6.11 (1.01)	5.73 (0.95)	6.06 (0.89)
LS Mean of Change from Baseline (SE)	0.20 (0.32)	-0.21 (0.38)	-0.03 (0.34)
95% CI	(-0.45, 0.85)	(-1.00, 0.57)	(-0.72, 0.67)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.22 (0.31)	-0.19 (0.33)	
95% CI	(-0.40, 0.85)	(-0.86, 0.49)	
p-value	0.4704	0.5719	
Corrected Hedge's g Statistics	0.170	-0.139	
95% CI	(-0.71, 1.05)	(-1.07, 0.79)	
Week 52			
m	8	7	19
n	7	5	16
Baseline Mean (SD)	6.04 (1.33)	6.04 (0.57)	6.18 (0.71)
Analysis Visit Mean (SD)	5.81 (1.34)	5.62 (0.57)	6.09 (1.10)
LS Mean of Change from Baseline (SE)	-0.17 (0.36)	-0.43 (0.44)	-0.02 (0.36)
95% CI	(-0.91, 0.56)	(-1.33, 0.46)	(-0.76, 0.72)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.15 (0.35)	-0.41 (0.40)	
95% CI	(-0.87, 0.57)	(-1.24, 0.41)	
p-value	0.6707	0.3144	
Corrected Hedge's g Statistics	-0.111	-0.293	
95% CI	(-1.00, 0.78)	(-1.30, 0.71)	
Subgroup*Treatment Interaction p-value	NE	0.6539	

AMNOG Table SE18.9.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Fatigue			
Week 24			
m	8	7	20
n	7	6	17
Baseline Mean (SD)	4.43 (2.15)	5.30 (1.10)	5.81 (0.90)
Analysis Visit Mean (SD)	4.53 (1.80)	5.08 (1.06)	5.32 (1.47)
LS Mean of Change from Baseline (SE)	-0.15 (0.48)	-0.39 (0.57)	-0.66 (0.50)
95% CI	(-1.13, 0.84)	(-1.55, 0.78)	(-1.69, 0.37)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.52 (0.49)	0.28 (0.48)	
95% CI	(-0.49, 1.52)	(-0.72, 1.27)	
p-value	0.3013	0.5726	
Corrected Hedge's g Statistics	0.264	0.138	
95% CI	(-0.62, 1.15)	(-0.79, 1.07)	
Week 52			
m	8	7	19
n	7	5	16
Baseline Mean (SD)	5.04 (1.53)	5.40 (1.19)	5.89 (0.87)
Analysis Visit Mean (SD)	5.29 (1.38)	4.98 (0.79)	5.44 (1.38)
LS Mean of Change from Baseline (SE)	0.03 (0.48)	-0.55 (0.59)	-0.63 (0.51)
95% CI	(-0.95, 1.00)	(-1.76, 0.66)	(-1.69, 0.42)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.66 (0.47)	0.08 (0.52)	
95% CI	(-0.31, 1.63)	(-0.98, 1.15)	
p-value	0.1735	0.8728	
Corrected Hedge's g Statistics	0.342	0.042	
95% CI	(-0.55, 1.24)	(-0.96, 1.05)	
Subgroup*Treatment Interaction p-value	NE	0.5036	

AMNOG Table SE18.9.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Systemic Symptoms			
Week 24			
m	8	7	20
n	7	6	17
Baseline Mean (SD)	5.67 (1.26)	5.95 (0.74)	5.86 (0.78)
Analysis Visit Mean (SD)	5.73 (1.13)	5.88 (0.89)	5.45 (1.22)
LS Mean of Change from Baseline (SE)	-0.15 (0.35)	-0.34 (0.43)	-0.77 (0.38)
95% CI	(-0.87, 0.56)	(-1.23, 0.54)	(-1.55, 0.01)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.61 (0.32)	0.42 (0.35)	
95% CI	(-0.04, 1.27)	(-0.28, 1.13)	
p-value	0.0654	0.2298	
Corrected Hedge's g Statistics	0.417	0.280	
95% CI	(-0.47, 1.30)	(-0.65, 1.21)	
Week 52			
m	8	7	19
n	7	5	16
Baseline Mean (SD)	5.89 (1.11)	6.18 (0.54)	5.91 (0.79)
Analysis Visit Mean (SD)	5.83 (1.24)	5.64 (0.83)	5.73 (1.11)
LS Mean of Change from Baseline (SE)	-0.34 (0.39)	-0.83 (0.49)	-0.57 (0.40)
95% CI	(-1.15, 0.47)	(-1.84, 0.18)	(-1.39, 0.25)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.23 (0.38)	-0.26 (0.43)	
95% CI	(-0.54, 1.00)	(-1.15, 0.63)	
p-value	0.5489	0.5511	
Corrected Hedge's g Statistics	0.150	-0.166	
95% CI	(-0.74, 1.04)	(-1.17, 0.84)	
Subgroup*Treatment Interaction p-value	NE	0.2396	

AMNOG Table SE18.9.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Worry			
Week 24			
m	8	7	20
n	7	6	17
Baseline Mean (SD)	5.66 (2.13)	6.43 (0.77)	6.48 (0.79)
Analysis Visit Mean (SD)	6.29 (1.25)	6.58 (0.62)	6.55 (0.77)
LS Mean of Change from Baseline (SE)	0.32 (0.29)	0.19 (0.35)	0.07 (0.31)
95% CI	(-0.27, 0.91)	(-0.53, 0.90)	(-0.57, 0.71)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.25 (0.27)	0.12 (0.28)	
95% CI	(-0.30, 0.80)	(-0.46, 0.69)	
p-value	0.3618	0.6783	
Corrected Hedge's g Statistics	0.205	0.094	
95% CI	(-0.68, 1.09)	(-0.84, 1.03)	
Week 52			
m	8	7	19
n	7	5	16
Baseline Mean (SD)	5.66 (2.13)	6.70 (0.46)	6.49 (0.81)
Analysis Visit Mean (SD)	6.01 (1.92)	6.60 (0.84)	6.55 (0.86)
LS Mean of Change from Baseline (SE)	0.20 (0.36)	-0.05 (0.44)	-0.02 (0.34)
95% CI	(-0.54, 0.94)	(-0.95, 0.84)	(-0.73, 0.69)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.22 (0.37)	-0.03 (0.41)	
95% CI	(-0.54, 0.98)	(-0.87, 0.80)	
p-value	0.5569	0.9326	
Corrected Hedge's g Statistics	0.166	-0.025	
95% CI	(-0.72, 1.06)	(-1.03, 0.98)	
Subgroup*Treatment Interaction p-value	NE	0.5697	

AMNOG Table SE18.9.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Abdominal Symptoms			
Week 24			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	6.42 (0.80)	5.00 (1.01)
Analysis Visit Mean (SD)	N/A	6.20 (0.77)	5.24 (1.31)
LS Mean of Change from Baseline (SE)	NE	0.97 (0.56)	0.42 (0.40)
95% CI	NE	(-0.32, 2.25)	(-0.52, 1.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	0.55 (0.69)	
95% CI	NE	(-1.04, 2.14)	
p-value	NE	0.4502	
Corrected Hedge's g Statistics	NE	0.442	
95% CI	NE	(-0.72, 1.60)	
Week 52			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	6.42 (0.80)	5.00 (1.01)
Analysis Visit Mean (SD)	N/A	5.74 (0.66)	5.00 (1.09)
LS Mean of Change from Baseline (SE)	NE	0.48 (0.46)	0.19 (0.31)
95% CI	NE	(-0.57, 1.53)	(-0.52, 0.90)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	0.29 (0.51)	
95% CI	NE	(-0.88, 1.47)	
p-value	NE	0.5819	
Corrected Hedge's g Statistics	NE	0.300	
95% CI	NE	(-0.85, 1.45)	
Subgroup*Treatment Interaction p-value	NE	0.5633	

AMNOG Table SE18.9.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Activity			
Week 24			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	5.88 (1.04)	5.23 (1.36)
Analysis Visit Mean (SD)	N/A	4.84 (0.98)	5.34 (2.12)
LS Mean of Change from Baseline (SE)	NE	-0.34 (0.68)	0.43 (0.55)
95% CI	NE	(-1.92, 1.23)	(-0.84, 1.69)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-0.77 (0.76)	
95% CI	NE	(-2.53, 0.98)	
p-value	NE	0.3407	
Corrected Hedge's g Statistics	NE	-0.481	
95% CI	NE	(-1.64, 0.68)	
Week 52			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	5.88 (1.04)	5.23 (1.36)
Analysis Visit Mean (SD)	N/A	5.36 (0.79)	5.54 (1.28)
LS Mean of Change from Baseline (SE)	NE	0.30 (0.58)	0.54 (0.45)
95% CI	NE	(-1.03, 1.63)	(-0.51, 1.59)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-0.24 (0.59)	
95% CI	NE	(-1.59, 1.11)	
p-value	NE	0.6965	
Corrected Hedge's g Statistics	NE	-0.177	
95% CI	NE	(-1.33, 0.97)	
Subgroup*Treatment Interaction p-value	NE	0.9168	

AMNOG Table SE18.9.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Emotional Health			
Week 24			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	5.96 (0.63)	5.37 (0.96)
Analysis Visit Mean (SD)	N/A	5.76 (0.96)	5.59 (1.21)
LS Mean of Change from Baseline (SE)	NE	0.32 (0.54)	0.45 (0.44)
95% CI	NE	(-0.92, 1.57)	(-0.57, 1.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-0.12 (0.59)	
95% CI	NE	(-1.49, 1.25)	
p-value	NE	0.8415	
Corrected Hedge's g Statistics	NE	-0.096	
95% CI	NE	(-1.24, 1.05)	
Week 52			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	5.96 (0.63)	5.37 (0.96)
Analysis Visit Mean (SD)	N/A	5.76 (0.63)	5.41 (1.28)
LS Mean of Change from Baseline (SE)	NE	0.29 (0.52)	0.30 (0.43)
95% CI	NE	(-0.92, 1.50)	(-0.69, 1.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-0.01 (0.57)	
95% CI	NE	(-1.33, 1.30)	
p-value	NE	0.9831	
Corrected Hedge's g Statistics	NE	-0.010	
95% CI	NE	(-1.16, 1.14)	
Subgroup*Treatment Interaction p-value	NE	0.6539	

AMNOG Table SE18.9.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Fatigue			
Week 24			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	5.10 (1.27)	3.80 (1.07)
Analysis Visit Mean (SD)	N/A	4.82 (1.16)	4.60 (1.19)
LS Mean of Change from Baseline (SE)	NE	0.53 (0.76)	0.74 (0.55)
95% CI	NE	(-1.22, 2.27)	(-0.53, 2.02)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-0.22 (0.87)	
95% CI	NE	(-2.21, 1.78)	
p-value	NE	0.8099	
Corrected Hedge's g Statistics	NE	-0.128	
95% CI	NE	(-1.28, 1.02)	
Week 52			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	5.10 (1.27)	3.80 (1.07)
Analysis Visit Mean (SD)	N/A	5.06 (0.78)	4.54 (1.14)
LS Mean of Change from Baseline (SE)	NE	0.85 (0.69)	0.63 (0.49)
95% CI	NE	(-0.74, 2.43)	(-0.50, 1.75)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	0.22 (0.75)	
95% CI	NE	(-1.50, 1.94)	
p-value	NE	0.7762	
Corrected Hedge's g Statistics	NE	0.145	
95% CI	NE	(-1.00, 1.29)	
Subgroup*Treatment Interaction p-value	NE	0.5036	

AMNOG Table SE18.9.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Systemic Symptoms			
Week 24			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	5.84 (1.33)	5.16 (0.96)
Analysis Visit Mean (SD)	N/A	5.90 (0.61)	5.70 (1.01)
LS Mean of Change from Baseline (SE)	NE	0.46 (0.61)	0.48 (0.44)
95% CI	NE	(-0.95, 1.87)	(-0.53, 1.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-0.02 (0.57)	
95% CI	NE	(-1.33, 1.28)	
p-value	NE	0.9676	
Corrected Hedge's g Statistics	NE	-0.018	
95% CI	NE	(-1.17, 1.13)	
Week 52			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	5.84 (1.33)	5.16 (0.96)
Analysis Visit Mean (SD)	N/A	5.30 (0.83)	5.41 (1.19)
LS Mean of Change from Baseline (SE)	NE	-0.15 (0.66)	0.21 (0.48)
95% CI	NE	(-1.67, 1.36)	(-0.91, 1.32)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-0.36 (0.65)	
95% CI	NE	(-1.87, 1.15)	
p-value	NE	0.5964	
Corrected Hedge's g Statistics	NE	-0.244	
95% CI	NE	(-1.40, 0.91)	
Subgroup*Treatment Interaction p-value	NE	0.2396	

AMNOG Table SE18.9.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Worry			
Week 24			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	6.76 (0.28)	6.31 (0.60)
Analysis Visit Mean (SD)	N/A	6.24 (1.01)	5.93 (1.39)
LS Mean of Change from Baseline (SE)	NE	-0.39 (0.56)	0.00 (0.44)
95% CI	NE	(-1.68, 0.89)	(-1.02, 1.01)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-0.39 (0.64)	
95% CI	NE	(-1.88, 1.09)	
p-value	NE	0.5607	
Corrected Hedge's g Statistics	NE	-0.301	
95% CI	NE	(-1.46, 0.85)	
Week 52			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	6.76 (0.28)	6.31 (0.60)
Analysis Visit Mean (SD)	N/A	5.98 (0.99)	6.37 (0.52)
LS Mean of Change from Baseline (SE)	NE	-0.31 (0.49)	0.19 (0.38)
95% CI	NE	(-1.43, 0.82)	(-0.69, 1.07)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-0.50 (0.53)	
95% CI	NE	(-1.73, 0.73)	
p-value	NE	0.3756	
Corrected Hedge's g Statistics	NE	-0.442	
95% CI	NE	(-1.60, 0.72)	
Subgroup*Treatment Interaction p-value	NE	0.5697	

AMNOG Table SE18.9.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi-square Test. For this unadjusted analysis, only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.

AMNOG Table SE18.9.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (5.0)
No	8 (100)	10 (100)	19 (95.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.31	1.62	
95% CI of the inverse odds ratio	(0.05, 35.47)	(0.06, 43.25)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	1.57	
95% CI of the inverse risk ratio	(0.06, 28.65)	(0.07, 35.46)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.59	-2.60	
95% CI of the absolute risk difference	(-20.17, 16.99)	(-19.12, 13.92)	
p-value	0.8731	0.7731	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (25.0)	0	4 (20.0)
No	6 (75.0)	10 (100)	16 (80.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	5.73	
95% CI of the inverse odds ratio	(0.11, 5.22)	(0.28, 117.65)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	4.71	
95% CI of the inverse risk ratio	(0.18, 3.54)	(0.28, 79.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.00	-16.88	
95% CI of the absolute risk difference	(-29.75, 39.75)	(-38.32, 4.55)	
p-value	0.7708	0.2116	
p-value of Breslow-Day Test for Homogeneity [3]	0.4193	0.3455	

AMNOG Table SE18.9.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (10.0)
No	8 (100)	10 (100)	18 (90.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.30	2.84	
95% CI of the inverse odds ratio	(0.10, 53.24)	(0.12, 64.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.14	2.62	
95% CI of the inverse risk ratio	(0.11, 40.30)	(0.14, 49.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.35	-7.36	
95% CI of the absolute risk difference	(-26.74, 14.04)	(-25.89, 11.17)	
p-value	0.5953	0.4975	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.0910	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (12.5)	0	3 (15.0)
No	7 (87.5)	10 (100)	17 (85.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.24	4.20	
95% CI of the inverse odds ratio	(0.11, 14.01)	(0.20, 89.61)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	3.67	
95% CI of the inverse risk ratio	(0.15, 9.89)	(0.21, 64.80)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-12.12	
95% CI of the absolute risk difference	(-30.25, 25.25)	(-32.26, 8.02)	
p-value	0.8644	0.3248	
p-value of Breslow-Day Test for Homogeneity [3]	0.7376	0.1931	

AMNOG Table SE18.9.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (12.5)	0	3 (15.0)
No	7 (87.5)	10 (100)	17 (85.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.24	4.20	
95% CI of the inverse odds ratio	(0.11, 14.01)	(0.20, 89.61)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	3.67	
95% CI of the inverse risk ratio	(0.15, 9.89)	(0.21, 64.80)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-12.12	
95% CI of the absolute risk difference	(-30.25, 25.25)	(-32.26, 8.02)	
p-value	0.8644	0.3248	
p-value of Breslow-Day Test for Homogeneity [3]	0.7376	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (25.0)	0	4 (20.0)
No	6 (75.0)	10 (100)	16 (80.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	5.73	
95% CI of the inverse odds ratio	(0.11, 5.22)	(0.28, 117.65)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	4.71	
95% CI of the inverse risk ratio	(0.18, 3.54)	(0.28, 79.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.00	-16.88	
95% CI of the absolute risk difference	(-29.75, 39.75)	(-38.32, 4.55)	
p-value	0.7708	0.2116	
p-value of Breslow-Day Test for Homogeneity [3]	0.4193	0.3455	

AMNOG Table SE18.9.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (5.0)
No	8 (100)	10 (100)	19 (95.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.31	1.62	
95% CI of the inverse odds ratio	(0.05, 35.47)	(0.06, 43.25)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	1.57	
95% CI of the inverse risk ratio	(0.06, 28.65)	(0.07, 35.46)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.59	-2.60	
95% CI of the absolute risk difference	(-20.17, 16.99)	(-19.12, 13.92)	
p-value	0.8731	0.7731	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (10.0)	3 (15.0)
No	8 (100)	9 (90.0)	17 (85.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.40	1.59	
95% CI of the inverse odds ratio	(0.16, 73.57)	(0.14, 17.56)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	1.50	
95% CI of the inverse risk ratio	(0.17, 52.30)	(0.18, 12.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.11	-5.00	
95% CI of the absolute risk difference	(-32.97, 10.75)	(-29.30, 19.30)	
p-value	0.4120	0.7041	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.5013	

AMNOG Table SE18.9.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (12.5)	0	2 (10.0)
No	7 (87.5)	10 (100)	18 (90.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	2.84	
95% CI of the inverse odds ratio	(0.06, 10.00)	(0.12, 64.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	2.62	
95% CI of the inverse risk ratio	(0.08, 7.64)	(0.14, 49.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.50	-7.36	
95% CI of the absolute risk difference	(-23.92, 28.92)	(-25.89, 11.17)	
p-value	0.8468	0.4975	
p-value of Breslow-Day Test for Homogeneity [3]	0.3487	0.4203	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (37.5)	1 (10.0)	3 (15.0)
No	5 (62.5)	9 (90.0)	17 (85.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.29	1.59	
95% CI of the inverse odds ratio	(0.04, 1.94)	(0.14, 17.56)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.40	1.50	
95% CI of the inverse risk ratio	(0.10, 1.58)	(0.18, 12.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	22.50	-5.00	
95% CI of the absolute risk difference	(-14.52, 59.52)	(-29.30, 19.30)	
p-value	0.1899	0.7041	
p-value of Breslow-Day Test for Homogeneity [3]	0.0970	0.7885	

AMNOG Table SE18.9.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (5.0)
No	8 (100)	10 (100)	19 (95.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.31	1.62	
95% CI of the inverse odds ratio	(0.05, 35.47)	(0.06, 43.25)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	1.57	
95% CI of the inverse risk ratio	(0.06, 28.65)	(0.07, 35.46)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.59	-2.60	
95% CI of the absolute risk difference	(-20.17, 16.99)	(-19.12, 13.92)	
p-value	0.8731	0.7731	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.5524	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (25.0)	0	4 (20.0)
No	6 (75.0)	10 (100)	16 (80.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	5.73	
95% CI of the inverse odds ratio	(0.11, 5.22)	(0.28, 117.65)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	4.71	
95% CI of the inverse risk ratio	(0.18, 3.54)	(0.28, 79.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.00	-16.88	
95% CI of the absolute risk difference	(-29.75, 39.75)	(-38.32, 4.55)	
p-value	0.7708	0.2116	
p-value of Breslow-Day Test for Homogeneity [3]	0.4193	0.3455	

AMNOG Table SE18.9.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	3 (15.0)
No	8 (100)	10 (100)	17 (85.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.40	4.20	
95% CI of the inverse odds ratio	(0.16, 73.57)	(0.20, 89.61)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	3.67	
95% CI of the inverse risk ratio	(0.17, 52.30)	(0.21, 64.80)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.11	-12.12	
95% CI of the absolute risk difference	(-32.97, 10.75)	(-32.26, 8.02)	
p-value	0.4120	0.3248	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (50.0)	0	4 (20.0)
No	4 (50.0)	10 (100)	16 (80.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.25	5.73	
95% CI of the inverse odds ratio	(0.04, 1.46)	(0.28, 117.65)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.40	4.71	
95% CI of the inverse risk ratio	(0.13, 1.22)	(0.28, 79.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	30.00	-16.88	
95% CI of the absolute risk difference	(-8.83, 68.83)	(-38.32, 4.55)	
p-value	0.1124	0.2116	
p-value of Breslow-Day Test for Homogeneity [3]	0.4888	NE	

AMNOG Table SE18.9.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	1 (100)	5 (100)	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (20.0)	3 (37.5)
No	1 (100)	4 (80.0)	5 (62.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.91	2.40	
95% CI of the inverse odds ratio	(0.06, 61.34)	(0.18, 32.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.56	1.88	
95% CI of the inverse risk ratio	(0.12, 19.65)	(0.26, 13.42)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-13.89	-17.50	
95% CI of the absolute risk difference	(-81.83, 54.05)	(-66.03, 31.03)	
p-value	0.7119	0.5060	
p-value of Breslow-Day Test for Homogeneity [3]	0.4193	0.3455	

AMNOG Table SE18.9.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (20.0)	0
No	1 (100)	4 (80.0)	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.18	
95% CI of the inverse odds ratio	NE	(0.01, 5.28)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.22	
95% CI of the inverse risk ratio	NE	(0.01, 4.60)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	19.44	
95% CI of the absolute risk difference	NE	(-18.30, 57.19)	
p-value	NE	0.2778	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.0910	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (20.0)	1 (12.5)
No	1 (100)	4 (80.0)	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	0.57	
95% CI of the inverse odds ratio	(0.02, 23.07)	(0.03, 11.85)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	0.63	
95% CI of the inverse risk ratio	(0.04, 11.07)	(0.05, 7.90)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.33	7.50	
95% CI of the absolute risk difference	(-56.43, 73.10)	(-34.39, 49.39)	
p-value	0.7823	0.7154	
p-value of Breslow-Day Test for Homogeneity [3]	0.7376	0.1931	

AMNOG Table SE18.9.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (12.5)
No	1 (100)	5 (100)	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	2.20	
95% CI of the inverse odds ratio	(0.02, 23.07)	(0.07, 64.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	2.00	
95% CI of the inverse risk ratio	(0.04, 11.07)	(0.10, 41.37)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.33	-8.33	
95% CI of the absolute risk difference	(-56.43, 73.10)	(-41.23, 24.56)	
p-value	0.7823	0.6418	
p-value of Breslow-Day Test for Homogeneity [3]	0.7376	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (20.0)	3 (37.5)
No	1 (100)	4 (80.0)	5 (62.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.91	2.40	
95% CI of the inverse odds ratio	(0.06, 61.34)	(0.18, 32.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.56	1.88	
95% CI of the inverse risk ratio	(0.12, 19.65)	(0.26, 13.42)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-13.89	-17.50	
95% CI of the absolute risk difference	(-81.83, 54.05)	(-66.03, 31.03)	
p-value	0.7119	0.5060	
p-value of Breslow-Day Test for Homogeneity [3]	0.4193	0.3455	

AMNOG Table SE18.9.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (12.5)
No	1 (100)	5 (100)	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	2.20	
95% CI of the inverse odds ratio	(0.02, 23.07)	(0.07, 64.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	2.00	
95% CI of the inverse risk ratio	(0.04, 11.07)	(0.10, 41.37)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.33	-8.33	
95% CI of the absolute risk difference	(-56.43, 73.10)	(-41.23, 24.56)	
p-value	0.7823	0.6418	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (40.0)	2 (25.0)
No	1 (100)	3 (60.0)	6 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	0.50	
95% CI of the inverse odds ratio	(0.03, 38.88)	(0.05, 5.51)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	0.63	
95% CI of the inverse risk ratio	(0.08, 15.28)	(0.12, 3.13)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.78	15.00	
95% CI of the absolute risk difference	(-69.54, 63.99)	(-37.39, 67.39)	
p-value	0.9364	0.5686	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.5013	

AMNOG Table SE18.9.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	2 (40.0)	4 (50.0)
No	1 (100)	3 (60.0)	4 (50.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	1.50	
95% CI of the inverse odds ratio	(0.09, 95.17)	(0.16, 14.42)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	1.25	
95% CI of the inverse risk ratio	(0.17, 24.07)	(0.35, 4.49)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-25.00	-10.00	
95% CI of the absolute risk difference	(-93.33, 43.33)	(-65.18, 45.18)	
p-value	0.5207	0.7249	
p-value of Breslow-Day Test for Homogeneity [3]	0.3487	0.4203	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (40.0)	5 (62.5)
No	1 (100)	3 (60.0)	3 (37.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.71	2.50	
95% CI of the inverse odds ratio	(0.15, 151.48)	(0.25, 24.72)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.44	1.56	
95% CI of the inverse risk ratio	(0.21, 28.51)	(0.47, 5.19)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-36.11	-22.50	
95% CI of the absolute risk difference	(-100.00, 31.83)	(-76.99, 31.99)	
p-value	0.3536	0.4285	
p-value of Breslow-Day Test for Homogeneity [3]	0.0970	0.7885	

AMNOG Table SE18.9.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (20.0)	2 (25.0)
No	1 (100)	4 (80.0)	6 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	1.33	
95% CI of the inverse odds ratio	(0.03, 38.88)	(0.09, 20.11)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	1.25	
95% CI of the inverse risk ratio	(0.08, 15.28)	(0.15, 10.46)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.78	-5.00	
95% CI of the absolute risk difference	(-69.54, 63.99)	(-51.15, 41.15)	
p-value	0.9364	0.8351	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.5524	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (20.0)	3 (37.5)
No	1 (100)	4 (80.0)	5 (62.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.91	2.40	
95% CI of the inverse odds ratio	(0.06, 61.34)	(0.18, 32.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.56	1.88	
95% CI of the inverse risk ratio	(0.12, 19.65)	(0.26, 13.42)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-13.89	-17.50	
95% CI of the absolute risk difference	(-81.83, 54.05)	(-66.03, 31.03)	
p-value	0.7119	0.5060	
p-value of Breslow-Day Test for Homogeneity [3]	0.4193	0.3455	

AMNOG Table SE18.9.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	1 (100)	5 (100)	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	1 (12.5)
No	1 (100)	5 (100)	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	2.20	
95% CI of the inverse odds ratio	(0.02, 23.07)	(0.07, 64.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	2.00	
95% CI of the inverse risk ratio	(0.04, 11.07)	(0.10, 41.37)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.33	-8.33	
95% CI of the absolute risk difference	(-56.43, 73.10)	(-41.23, 24.56)	
p-value	0.7823	0.6418	
p-value of Breslow-Day Test for Homogeneity [3]	0.4888	NE	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE18.10.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=5)	Visit Result DB MGL-3196 100 mg (N=5)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=5)	Change from Baseline DB MGL-3196 100 mg (N=5)	Change from Baseline DB Placebo (N=17)
CLDQ-NASH						
Baseline						
m	5	5	17			
n	5	5	14			
Mean (SD)	4.90 (1.68)	5.58 (0.90)	5.91 (0.80)			
Median	5.00	6.00	6.05			
IQR: Q1, Q3	4.70, 6.10	5.00, 6.10	5.40, 6.50			
Min, Max	2.2, 6.5	4.3, 6.5	4.3, 6.9			
Week 24						
m	4	4	16			
n	3	4	14	3	4	13
Mean (SD/SE)	5.10 (1.25)	5.83 (0.57)	5.99 (0.89)	0.53 (0.55)	-0.08 (0.19)	0.14 (0.16)
Median	5.20	5.70	6.15	0.20	0	0
IQR: Q1, Q3	3.80, 6.30	5.40, 6.25	5.20, 6.80	-0.20, 1.60	-0.35, 0.20	-0.10, 0.10
Min, Max	3.8, 6.3	5.3, 6.6	4.6, 7.0	-0.2, 1.6	-0.6, 0.3	-0.4, 1.9
Week 52						
m	4	4	15			
n	4	4	14	4	4	13
Mean (SD/SE)	5.10 (1.71)	5.80 (0.49)	5.91 (1.07)	0.15 (0.18)	-0.10 (0.30)	-0.05 (0.27)
Median	5.70	5.90	6.05	0.15	-0.10	0.20
IQR: Q1, Q3	4.05, 6.15	5.40, 6.20	5.60, 6.80	-0.15, 0.45	-0.55, 0.35	0.00, 0.40
Min, Max	2.6, 6.4	5.2, 6.2	3.1, 7.0	-0.2, 0.5	-0.8, 0.6	-3.1, 0.9

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.10.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: Yes (Treated with Statins at baseline)

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=5)	(N=5)	(N=17)	(N=5)	(N=5)	(N=17)
Abdominal Symptoms						
Baseline						
m	5	5	17			
n	5	5	14			
Mean (SD)	5.20 (2.47)	6.28 (0.80)	6.33 (1.02)			
Median	6.30	6.70	7.00			
IQR: Q1, Q3	5.00, 6.70	6.00, 6.70	5.30, 7.00			
Min, Max	1.0, 7.0	5.0, 7.0	4.0, 7.0			
Week 24						
m	4	4	16			
n	3	4	14	3	4	13
Mean (SD/SE)	4.53 (2.25)	6.68 (0.65)	6.19 (1.26)	0.30 (0.40)	0.08 (0.49)	0.14 (0.22)
Median	5.30	7.00	6.85	0.30	0.30	0
IQR: Q1, Q3	2.00, 6.30	6.35, 7.00	5.30, 7.00	-0.40, 1.00	-0.50, 0.65	-0.30, 0.00
Min, Max	2.0, 6.3	5.7, 7.0	3.3, 7.0	-0.4, 1.0	-1.3, 1.0	-1.3, 2.0
Week 52						
m	4	4	15			
n	4	4	14	4	4	13
Mean (SD/SE)	4.75 (2.51)	6.00 (0.62)	5.90 (1.46)	0.00 (0.25)	-0.60 (0.44)	-0.31 (0.41)
Median	5.85	6.00	6.50	-0.15	-0.65	0
IQR: Q1, Q3	3.35, 6.15	5.50, 6.50	5.30, 7.00	-0.35, 0.35	-1.35, 0.15	0.00, 0.00
Min, Max	1.0, 6.3	5.3, 6.7	2.0, 7.0	-0.4, 0.7	-1.4, 0.3	-5.0, 1.0

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.10.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=5)	Visit Result DB MGL-3196 100 mg (N=5)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=5)	Change from Baseline DB MGL-3196 100 mg (N=5)	Change from Baseline DB Placebo (N=17)
Activity						
Baseline						
m	5	5	17			
n	5	5	14			
Mean (SD)	5.08 (1.93)	5.44 (1.47)	5.71 (1.21)			
Median	5.20	6.00	6.20			
IQR: Q1, Q3	4.80, 6.60	4.20, 6.40	5.00, 6.60			
Min, Max	2.0, 6.8	3.6, 7.0	3.2, 7.0			
Week 24						
m	4	4	16			
n	3	4	14	3	4	13
Mean (SD/SE)	5.27 (0.64)	5.05 (1.30)	5.86 (1.46)	0.80 (1.03)	-0.85 (0.56)	0.17 (0.25)
Median	5.00	4.40	6.30	0.20	-0.80	0.20
IQR: Q1, Q3	4.80, 6.00	4.40, 5.70	5.40, 7.00	-0.60, 2.80	-1.80, 0.10	-0.20, 0.40
Min, Max	4.8, 6.0	4.4, 7.0	1.8, 7.0	-0.6, 2.8	-2.0, 0.2	-1.4, 2.6
Week 52						
m	4	4	15			
n	4	4	14	4	4	13
Mean (SD/SE)	5.30 (1.31)	5.50 (0.74)	6.07 (1.27)	0.25 (0.53)	-0.40 (0.49)	0.34 (0.34)
Median	5.70	5.40	6.60	0.30	-0.60	0.20
IQR: Q1, Q3	4.50, 6.10	4.90, 6.10	5.60, 7.00	-0.60, 1.10	-1.20, 0.40	0.00, 0.40
Min, Max	3.4, 6.4	4.8, 6.4	3.4, 7.0	-1.0, 1.4	-1.2, 0.8	-2.6, 2.2

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.10.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=5)	Visit Result DB MGL-3196 100 mg (N=5)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=5)	Change from Baseline DB MGL-3196 100 mg (N=5)	Change from Baseline DB Placebo (N=17)
Emotional Health						
Baseline						
m	5	5	17			
n	5	5	14			
Mean (SD)	5.24 (1.47)	5.20 (0.94)	6.19 (0.53)			
Median	5.40	5.20	6.25			
IQR: Q1, Q3	4.30, 6.20	4.90, 6.00	5.80, 6.70			
Min, Max	3.3, 7.0	3.8, 6.1	5.1, 7.0			
Week 24						
m	4	4	16			
n	3	4	14	3	4	13
Mean (SD/SE)	5.43 (1.33)	5.65 (0.50)	6.17 (0.78)	0.20 (0.40)	0.10 (0.29)	0.08 (0.14)
Median	5.10	5.70	6.25	-0.10	-0.05	0.10
IQR: Q1, Q3	4.30, 6.90	5.30, 6.00	6.00, 6.70	-0.30, 1.00	-0.30, 0.50	-0.20, 0.30
Min, Max	4.3, 6.9	5.0, 6.2	4.4, 7.0	-0.3, 1.0	-0.4, 0.9	-0.9, 1.2
Week 52						
m	4	4	15			
n	4	4	14	4	4	13
Mean (SD/SE)	5.23 (1.50)	5.88 (0.46)	6.04 (1.01)	-0.25 (0.12)	0.33 (0.22)	-0.22 (0.21)
Median	5.45	5.90	6.25	-0.15	0.25	-0.20
IQR: Q1, Q3	4.25, 6.20	5.55, 6.20	5.80, 6.80	-0.40, -0.10	0.00, 0.65	-0.40, 0.20
Min, Max	3.2, 6.8	5.3, 6.4	3.3, 7.0	-0.6, -0.1	-0.1, 0.9	-2.5, 0.5

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.10.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter / Visit / Statistic	Visit Result: DB MGL-3196 80 mg (N=5)	Visit Result: DB MGL-3196 100 mg (N=5)	Visit Result: DB Placebo (N=17)	Change from Baseline: DB MGL-3196 80 mg (N=5)	Change from Baseline: DB MGL-3196 100 mg (N=5)	Change from Baseline: DB Placebo (N=17)
Fatigue						
Baseline						
m	5	5	17			
n	5	5	14			
Mean (SD)	4.52 (1.61)	4.98 (1.29)	4.96 (1.68)			
Median	5.00	4.70	5.70			
IQR: Q1, Q3	4.50, 5.30	4.50, 5.20	4.00, 6.00			
Min, Max	1.8, 6.0	3.5, 7.0	1.5, 7.0			
Week 24						
m	4	4	16			
n	3	4	14	3	4	13
Mean (SD/SE)	4.53 (1.17)	4.83 (1.06)	5.33 (1.19)	0.43 (0.63)	-0.10 (0.21)	0.27 (0.27)
Median	4.30	4.60	5.40	-0.20	0	0
IQR: Q1, Q3	3.50, 5.80	4.15, 5.50	4.20, 6.30	-0.20, 1.70	-0.35, 0.15	-0.20, 0.20
Min, Max	3.5, 5.8	3.8, 6.3	3.2, 6.8	-0.2, 1.7	-0.7, 0.3	-0.5, 3.0
Week 52						
m	4	4	15			
n	4	4	14	4	4	13
Mean (SD/SE)	4.60 (1.37)	5.15 (0.57)	5.22 (1.33)	0.20 (0.25)	0.23 (0.73)	0.03 (0.35)
Median	5.00	5.40	4.90	0.10	0.30	0.20
IQR: Q1, Q3	3.60, 5.60	4.80, 5.50	4.30, 6.30	-0.15, 0.55	-0.95, 1.40	-0.50, 1.10
Min, Max	2.7, 5.7	4.3, 5.5	2.8, 7.0	-0.3, 0.9	-1.5, 1.8	-2.9, 1.7

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.10.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Visit Statistic	Visit Result DB MGL-3196 80 mg (N=5)	Visit Result DB MGL-3196 100 mg (N=5)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=5)	Change from Baseline DB MGL-3196 100 mg (N=5)	Change from Baseline DB Placebo (N=17)
Systemic Symptoms						
Baseline						
m	5	5	17			
n	5	5	14			
Mean (SD)	5.14 (1.15)	5.14 (1.90)	5.70 (1.01)			
Median	4.80	5.50	5.65			
IQR: Q1, Q3	4.30, 5.80	3.70, 6.80	5.20, 6.70			
Min, Max	4.0, 6.8	2.7, 7.0	3.8, 7.0			
Week 24						
m	4	4	16			
n	3	4	14	3	4	13
Mean (SD/SE)	5.37 (0.90)	6.05 (0.74)	5.76 (1.16)	0.17 (0.33)	0.30 (0.48)	0.16 (0.21)
Median	5.30	6.00	6.00	0.50	0.25	0
IQR: Q1, Q3	4.50, 6.30	5.60, 6.50	4.70, 6.80	-0.50, 0.50	-0.40, 1.00	-0.30, 0.50
Min, Max	4.5, 6.3	5.2, 7.0	3.8, 7.0	-0.5, 0.5	-0.8, 1.5	-1.2, 1.6
Week 52						
m	4	4	15			
n	4	4	14	4	4	13
Mean (SD/SE)	5.33 (1.47)	5.83 (0.97)	5.63 (1.29)	-0.03 (0.29)	0.08 (0.53)	-0.06 (0.27)
Median	5.75	5.75	6.05	0.05	-0.30	0
IQR: Q1, Q3	4.25, 6.40	5.05, 6.60	4.70, 6.80	-0.50, 0.45	-0.65, 0.80	-0.50, 0.50
Min, Max	3.3, 6.5	4.8, 7.0	3.2, 7.0	-0.7, 0.5	-0.7, 1.6	-2.6, 1.1

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.10.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: Yes (Treated with Statins at baseline)

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=5)	Visit Result DB MGL-3196 100 mg (N=5)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=5)	Change from Baseline DB MGL-3196 100 mg (N=5)	Change from Baseline DB Placebo (N=17)
Worry						
Baseline						
m	5	5	17			
n	5	5	14			
Mean (SD)	4.26 (2.32)	6.46 (0.65)	6.64 (0.50)			
Median	5.70	6.70	6.95			
IQR: Q1, Q3	2.60, 5.90	6.30, 6.90	6.30, 7.00			
Min, Max	1.0, 6.1	5.4, 7.0	5.6, 7.0			
Week 24						
m	4	4	16			
n	3	4	14	3	4	13
Mean (SD/SE)	5.33 (1.51)	6.58 (0.78)	6.53 (1.02)	1.07 (0.77)	-0.15 (0.26)	-0.11 (0.21)
Median	6.00	6.95	7.00	0.30	0	0
IQR: Q1, Q3	3.60, 6.40	6.15, 7.00	6.90, 7.00	0.30, 2.60	-0.45, 0.15	0.00, 0.10
Min, Max	3.6, 6.4	5.4, 7.0	3.7, 7.0	0.3, 2.6	-0.9, 0.3	-1.9, 1.1
Week 52						
m	4	4	15			
n	4	4	14	4	4	13
Mean (SD/SE)	5.30 (2.40)	6.48 (0.45)	6.54 (0.81)	0.63 (0.11)	-0.25 (0.19)	-0.15 (0.25)
Median	6.45	6.40	6.95	0.60	-0.10	0
IQR: Q1, Q3	4.00, 6.60	6.10, 6.85	6.30, 7.00	0.45, 0.80	-0.50, 0.00	0.00, 0.00
Min, Max	1.7, 6.6	6.1, 7.0	4.1, 7.0	0.4, 0.9	-0.8, 0.0	-2.9, 1.1

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.10.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=10)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=10)	Change from Baseline DB Placebo (N=11)
CLDQ-NASH						
Baseline						
m	4	10	11			
n	4	9	11			
Mean (SD)	5.98 (1.32)	6.04 (0.45)	5.58 (0.78)			
Median	6.55	6.10	5.50			
IQR: Q1, Q3	5.25, 6.70	5.90, 6.20	5.00, 6.20			
Min, Max	4.0, 6.8	5.1, 6.8	4.2, 6.7			
Week 24						
m	4	8	11			
n	4	7	11	4	7	11
Mean (SD/SE)	6.05 (0.84)	5.74 (0.69)	5.23 (1.04)	0.08 (0.25)	-0.33 (0.34)	-0.35 (0.22)
Median	6.40	5.50	5.00	-0.10	0	-0.10
IQR: Q1, Q3	5.55, 6.55	5.30, 6.30	4.50, 6.60	-0.25, 0.40	-0.90, 0.40	-0.70, 0.10
Min, Max	4.8, 6.6	4.8, 6.7	3.8, 6.7	-0.3, 0.8	-2.0, 0.6	-2.2, 0.4
Week 52						
m	4	8	11			
n	3	6	10	3	6	10
Mean (SD/SE)	6.60 (0.40)	5.48 (0.57)	5.66 (0.96)	-0.03 (0.15)	-0.75 (0.34)	0.04 (0.17)
Median	6.60	5.60	5.75	0	-0.45	-0.05
IQR: Q1, Q3	6.20, 7.00	5.20, 5.90	4.60, 6.60	-0.30, 0.20	-1.00, -0.30	-0.20, 0.20
Min, Max	6.2, 7.0	4.5, 6.1	4.5, 7.0	-0.3, 0.2	-2.3, 0.0	-0.6, 1.3

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.10.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=4)	(N=10)	(N=11)	(N=4)	(N=10)	(N=11)
Abdominal Symptoms						
Baseline						
m	4	10	11			
n	4	9	11			
Mean (SD)	6.25 (1.31)	5.93 (0.99)	5.25 (1.30)			
Median	6.85	6.00	5.00			
IQR: Q1, Q3	5.50, 7.00	5.00, 6.70	4.00, 6.30			
Min, Max	4.3, 7.0	4.3, 7.0	3.3, 7.0			
Week 24						
m	4	8	11			
n	4	7	11	4	7	11
Mean (SD/SE)	6.43 (0.68)	5.71 (0.82)	4.97 (1.31)	0.18 (0.44)	-0.59 (0.36)	-0.27 (0.36)
Median	6.50	5.70	5.00	0	-1.00	0
IQR: Q1, Q3	5.85, 7.00	5.30, 6.00	3.70, 6.30	-0.35, 0.70	-1.40, 0.00	-0.30, 0.30
Min, Max	5.7, 7.0	4.3, 7.0	3.3, 7.0	-0.7, 1.4	-1.7, 1.0	-2.7, 1.3
Week 52						
m	4	8	11			
n	3	6	10	3	6	10
Mean (SD/SE)	6.77 (0.40)	5.85 (0.65)	5.44 (1.43)	-0.13 (0.13)	-0.55 (0.40)	0.04 (0.16)
Median	7.00	5.70	5.35	0	-0.65	0
IQR: Q1, Q3	6.30, 7.00	5.70, 6.00	4.00, 7.00	-0.40, 0.00	-1.30, 0.00	0.00, 0.30
Min, Max	6.3, 7.0	5.0, 7.0	3.3, 7.0	-0.4, 0.0	-1.7, 1.0	-1.0, 1.0

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.10.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=4)	(N=10)	(N=11)	(N=4)	(N=10)	(N=11)
Activity						
Baseline						
m	4	10	11			
n	4	9	11			
Mean (SD)	5.85 (1.67)	6.00 (0.70)	5.76 (0.71)			
Median	6.50	5.80	5.60			
IQR: Q1, Q3	4.80, 6.90	5.40, 6.60	5.60, 6.20			
Min, Max	3.4, 7.0	5.2, 7.0	4.2, 7.0			
Week 24						
m	4	8	11			
n	4	7	11	4	7	11
Mean (SD/SE)	5.95 (0.87)	5.69 (0.82)	5.05 (1.34)	0.10 (0.44)	-0.37 (0.47)	-0.71 (0.40)
Median	6.10	5.60	5.80	-0.30	0	-0.80
IQR: Q1, Q3	5.30, 6.60	5.20, 6.60	4.40, 6.00	-0.40, 0.60	-1.40, 0.80	-1.40, 0.40
Min, Max	4.8, 6.8	4.4, 6.6	2.8, 6.8	-0.4, 1.4	-2.6, 0.8	-3.8, 0.8
Week 52						
m	4	8	11			
n	3	6	10	3	6	10
Mean (SD/SE)	6.47 (0.76)	5.17 (0.93)	5.64 (1.05)	-0.20 (0.20)	-1.03 (0.41)	-0.12 (0.21)
Median	6.80	4.80	5.50	0	-0.80	-0.10
IQR: Q1, Q3	5.60, 7.00	4.60, 6.00	4.60, 6.60	-0.60, 0.00	-2.00, -0.40	-0.60, 0.00
Min, Max	5.6, 7.0	4.2, 6.6	4.2, 7.0	-0.6, 0.0	-2.4, 0.2	-1.0, 1.4

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.10.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Visit Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=10)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=10)	Change from Baseline DB Placebo (N=11)
Emotional Health						
Baseline						
m	4	10	11			
n	4	9	11			
Mean (SD)	6.40 (0.80)	6.29 (0.57)	5.57 (1.01)			
Median	6.75	6.20	5.60			
IQR: Q1, Q3	5.95, 6.85	6.00, 6.80	4.70, 6.80			
Min, Max	5.2, 6.9	5.1, 6.9	4.1, 7.0			
Week 24						
m	4	8	11			
n	4	7	11	4	7	11
Mean (SD/SE)	6.63 (0.24)	5.80 (1.11)	5.47 (1.18)	0.23 (0.42)	-0.33 (0.46)	-0.10 (0.20)
Median	6.70	6.20	5.10	0.05	0.30	0
IQR: Q1, Q3	6.45, 6.80	4.40, 6.80	4.60, 6.80	-0.30, 0.75	-1.60, 0.70	-0.70, 0.50
Min, Max	6.3, 6.8	4.3, 6.9	3.7, 7.0	-0.6, 1.4	-2.3, 0.8	-1.5, 0.7
Week 52						
m	4	8	11			
n	3	6	10	3	6	10
Mean (SD/SE)	6.60 (0.61)	5.57 (0.65)	5.71 (1.35)	-0.20 (0.36)	-0.73 (0.38)	0.17 (0.20)
Median	6.90	5.65	6.20	0	-0.45	0
IQR: Q1, Q3	5.90, 7.00	5.00, 6.00	4.40, 6.90	-0.90, 0.30	-1.80, -0.20	-0.30, 0.50
Min, Max	5.9, 7.0	4.7, 6.4	3.4, 7.0	-0.9, 0.3	-1.9, 0.4	-0.7, 1.3

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.10.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=10)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=10)	Change from Baseline DB Placebo (N=11)
Fatigue						
Baseline						
m	4	10	11			
n	4	9	11			
Mean (SD)	4.68 (2.46)	5.57 (0.94)	5.23 (1.27)			
Median	5.75	5.80	5.50			
IQR: Q1, Q3	3.35, 6.00	4.80, 6.30	4.50, 6.00			
Min, Max	1.0, 6.2	4.0, 6.7	2.7, 7.0			
Week 24						
m	4	8	11			
n	4	7	11	4	7	11
Mean (SD/SE)	4.53 (2.35)	5.04 (1.14)	4.65 (1.67)	-0.15 (0.18)	-0.33 (0.46)	-0.57 (0.40)
Median	5.65	4.80	4.50	0	0.30	-0.60
IQR: Q1, Q3	3.25, 5.80	4.30, 6.20	2.80, 6.70	-0.35, 0.05	-2.00, 0.50	-1.50, 0.70
Min, Max	1.0, 5.8	3.5, 6.8	2.2, 6.8	-0.7, 0.1	-2.2, 0.5	-3.3, 1.2
Week 52						
m	4	8	11			
n	3	6	10	3	6	10
Mean (SD/SE)	6.20 (0.85)	4.93 (0.88)	5.06 (1.39)	0.30 (0.36)	-0.53 (0.44)	-0.24 (0.30)
Median	6.30	4.80	4.90	0.50	-0.25	-0.35
IQR: Q1, Q3	5.30, 7.00	4.20, 5.80	4.00, 6.30	-0.40, 0.80	-1.20, 0.00	-1.00, 0.30
Min, Max	5.3, 7.0	4.0, 6.0	2.8, 7.0	-0.4, 0.8	-2.3, 0.8	-1.5, 1.3

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.10.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Visit Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=10)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=10)	Change from Baseline DB Placebo (N=11)
Systemic Symptoms						
Baseline						
m	4	10	11			
n	4	9	11			
Mean (SD)	6.03 (1.19)	5.97 (0.74)	5.59 (0.67)			
Median	6.40	6.20	5.50			
IQR: Q1, Q3	5.30, 6.75	5.70, 6.30	5.20, 6.00			
Min, Max	4.3, 7.0	4.8, 7.0	4.3, 6.7			
Week 24						
m	4	8	11			
n	4	7	11	4	7	11
Mean (SD/SE)	6.00 (1.34)	5.80 (0.78)	5.11 (1.08)	-0.03 (0.19)	-0.19 (0.31)	-0.48 (0.26)
Median	6.60	5.80	5.20	-0.15	0	-0.30
IQR: Q1, Q3	5.25, 6.75	5.30, 6.50	4.70, 6.00	-0.30, 0.25	-1.00, 0.60	-1.30, 0.20
Min, Max	4.0, 6.8	4.5, 6.8	3.2, 6.7	-0.3, 0.5	-1.5, 0.8	-2.1, 0.7
Week 52						
m	4	8	11			
n	3	6	10	3	6	10
Mean (SD/SE)	6.50 (0.44)	5.23 (0.65)	5.61 (0.82)	-0.10 (0.10)	-0.95 (0.40)	-0.02 (0.22)
Median	6.30	5.35	5.40	0	-0.70	-0.15
IQR: Q1, Q3	6.20, 7.00	4.80, 5.70	4.80, 6.20	-0.30, 0.00	-1.10, -0.20	-0.30, 0.20
Min, Max	6.2, 7.0	4.2, 6.0	4.7, 7.0	-0.3, 0.0	-2.8, -0.2	-1.2, 1.5

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.10.1
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=4)	(N=10)	(N=11)	(N=4)	(N=10)	(N=11)
Worry						
Baseline						
m	4	10	11			
n	4	9	11			
Mean (SD)	6.70 (0.54)	6.42 (0.66)	6.13 (0.87)			
Median	6.95	6.70	6.40			
IQR: Q1, Q3	6.40, 7.00	5.90, 6.90	5.40, 6.70			
Min, Max	5.9, 7.0	5.1, 7.0	4.1, 7.0			
Week 24						
m	4	8	11			
n	4	7	11	4	7	11
Mean (SD/SE)	7.00 (0.00)	6.34 (0.85)	6.12 (0.93)	0.30 (0.27)	-0.16 (0.33)	-0.01 (0.26)
Median	7.00	6.90	6.70	0.05	0.10	0
IQR: Q1, Q3	7.00, 7.00	5.60, 7.00	5.30, 6.90	0.00, 0.60	0.00, 0.20	-0.80, 0.70
Min, Max	7.0, 7.0	4.9, 7.0	4.6, 7.0	0.0, 1.1	-2.1, 0.5	-1.6, 1.3
Week 52						
m	4	8	11			
n	3	6	10	3	6	10
Mean (SD/SE)	6.97 (0.06)	6.17 (1.17)	6.45 (0.68)	0.00 (0.00)	-0.57 (0.45)	0.34 (0.19)
Median	7.00	6.80	6.75	0	-0.10	0.10
IQR: Q1, Q3	6.90, 7.00	5.10, 7.00	6.00, 7.00	0.00, 0.00	-0.80, 0.10	-0.10, 0.60
Min, Max	6.9, 7.0	4.3, 7.0	5.0, 7.0	0.0, 0.0	-2.7, 0.2	-0.3, 1.6

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE18.10.2
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of CLDQ-NASH - MMRM Model
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE18.10.2
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of CLDQ-NASH - MMRM Model
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
CLDQ-NASH			
Week 24			
m	4	4	16
n	3	4	13
Baseline Mean (SD)	4.57 (2.18)	5.90 (0.64)	5.95 (0.82)
Analysis Visit Mean (SD)	5.10 (1.25)	5.83 (0.57)	6.09 (0.83)
LS Mean of Change from Baseline (SE)	0.24 (0.30)	0.31 (0.30)	0.46 (0.23)
95% CI	(-0.39, 0.88)	(-0.32, 0.94)	(-0.03, 0.95)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.21 (0.37)	-0.15 (0.28)	
95% CI	(-0.99, 0.57)	(-0.73, 0.44)	
p-value	0.5702	0.6042	
Corrected Hedge's g Statistics	-0.253	-0.174	
95% CI	(-1.51, 1.01)	(-1.30, 0.95)	
Week 52			
m	4	4	15
n	4	4	13
Baseline Mean (SD)	4.95 (1.94)	5.90 (0.64)	5.95 (0.82)
Analysis Visit Mean (SD)	5.10 (1.71)	5.80 (0.49)	5.91 (1.12)
LS Mean of Change from Baseline (SE)	0.15 (0.44)	0.27 (0.45)	0.25 (0.30)
95% CI	(-0.79, 1.08)	(-0.68, 1.21)	(-0.38, 0.87)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.10 (0.51)	0.02 (0.47)	
95% CI	(-1.18, 0.98)	(-0.97, 1.02)	
p-value	0.8505	0.9652	
Corrected Hedge's g Statistics	-0.089	0.019	
95% CI	(-1.21, 1.03)	(-1.10, 1.14)	
Subgroup*Treatment Interaction p-value	0.2910	0.6873	

AMNOG Table SE18.10.2
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of CLDQ-NASH - MMRM Model
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
CLDQ-NASH			
Week 24			
m	4	8	11
n	4	7	11
Baseline Mean (SD)	5.98 (1.32)	6.07 (0.51)	5.58 (0.78)
Analysis Visit Mean (SD)	6.05 (0.84)	5.74 (0.69)	5.23 (1.04)
LS Mean of Change from Baseline (SE)	0.10 (0.34)	-0.39 (0.28)	-0.45 (0.22)
95% CI	(-0.62, 0.82)	(-0.98, 0.20)	(-0.91, 0.00)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.55 (0.41)	0.06 (0.36)	
95% CI	(-0.30, 1.41)	(-0.69, 0.81)	
p-value	0.1899	0.8629	
Corrected Hedge's g Statistics	0.738	0.082	
95% CI	(-0.44, 1.91)	(-0.87, 1.03)	
Week 52			
m	4	8	11
n	3	6	10
Baseline Mean (SD)	6.63 (0.15)	6.23 (0.31)	5.62 (0.81)
Analysis Visit Mean (SD)	6.60 (0.40)	5.48 (0.57)	5.66 (0.96)
LS Mean of Change from Baseline (SE)	0.17 (0.41)	-0.77 (0.29)	-0.04 (0.21)
95% CI	(-0.69, 1.04)	(-1.38, -0.17)	(-0.49, 0.41)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.21 (0.49)	-0.74 (0.37)	
95% CI	(-0.81, 1.23)	(-1.52, 0.04)	
p-value	0.6711	0.0630	
Corrected Hedge's g Statistics	0.286	-1.012	
95% CI	(-1.01, 1.58)	(-2.08, 0.06)	
Subgroup*Treatment Interaction p-value	0.2910	0.6873	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE18.10.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on CLDQ-NASH analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE18.10.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Abdominal Symptoms			
Week 24			
m	4	4	16
n	3	4	13
Baseline Mean (SD)	4.23 (2.93)	6.60 (0.42)	6.28 (1.04)
Analysis Visit Mean (SD)	4.53 (2.25)	6.68 (0.65)	6.42 (0.99)
LS Mean of Change from Baseline (SE)	-0.13 (0.46)	0.83 (0.45)	0.72 (0.34)
95% CI	(-1.10, 0.85)	(-0.12, 1.78)	(0.01, 1.43)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.85 (0.56)	0.10 (0.41)	
95% CI	(-2.04, 0.34)	(-0.75, 0.96)	
p-value	0.1486	0.7997	
Corrected Hedge's g Statistics	-0.693	0.086	
95% CI	(-1.97, 0.59)	(-1.04, 1.21)	
Week 52			
m	4	4	15
n	4	4	13
Baseline Mean (SD)	4.75 (2.60)	6.60 (0.42)	6.28 (1.04)
Analysis Visit Mean (SD)	4.75 (2.51)	6.00 (0.62)	5.97 (1.50)
LS Mean of Change from Baseline (SE)	-0.02 (0.69)	0.10 (0.68)	0.26 (0.44)
95% CI	(-1.47, 1.44)	(-1.34, 1.54)	(-0.67, 1.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.27 (0.79)	-0.16 (0.71)	
95% CI	(-1.94, 1.39)	(-1.66, 1.35)	
p-value	0.7355	0.8303	
Corrected Hedge's g Statistics	-0.166	-0.095	
95% CI	(-1.29, 0.96)	(-1.22, 1.03)	
Subgroup*Treatment Interaction p-value	0.0568	0.5866	

AMNOG Table SE18.10.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Activity			
Week 24			
m	4	4	16
n	3	4	13
Baseline Mean (SD)	4.47 (2.32)	5.90 (1.21)	5.66 (1.24)
Analysis Visit Mean (SD)	5.27 (0.64)	5.05 (1.30)	5.83 (1.52)
LS Mean of Change from Baseline (SE)	0.56 (0.63)	-0.36 (0.62)	0.47 (0.44)
95% CI	(-0.76, 1.89)	(-1.66, 0.94)	(-0.45, 1.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.10 (0.72)	-0.83 (0.60)	
95% CI	(-1.42, 1.61)	(-2.09, 0.43)	
p-value	0.8952	0.1836	
Corrected Hedge's g Statistics	0.060	-0.520	
95% CI	(-1.20, 1.32)	(-1.65, 0.61)	
Week 52			
m	4	4	15
n	4	4	13
Baseline Mean (SD)	5.05 (2.22)	5.90 (1.21)	5.66 (1.24)
Analysis Visit Mean (SD)	5.30 (1.31)	5.50 (0.74)	6.00 (1.29)
LS Mean of Change from Baseline (SE)	0.21 (0.53)	0.14 (0.59)	0.65 (0.43)
95% CI	(-0.91, 1.32)	(-1.10, 1.38)	(-0.25, 1.55)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.45 (0.58)	-0.51 (0.57)	
95% CI	(-1.67, 0.78)	(-1.71, 0.68)	
p-value	0.4532	0.3777	
Corrected Hedge's g Statistics	-0.291	-0.330	
95% CI	(-1.42, 0.83)	(-1.46, 0.80)	
Subgroup*Treatment Interaction p-value	0.3306	0.7082	

AMNOG Table SE18.10.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Emotional Health			
Week 24			
m	4	4	16
n	3	4	13
Baseline Mean (SD)	5.23 (1.86)	5.55 (0.59)	6.23 (0.53)
Analysis Visit Mean (SD)	5.43 (1.33)	5.65 (0.50)	6.31 (0.61)
LS Mean of Change from Baseline (SE)	0.03 (0.30)	0.24 (0.30)	0.46 (0.25)
95% CI	(-0.60, 0.66)	(-0.40, 0.87)	(-0.06, 0.97)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.43 (0.37)	-0.22 (0.31)	
95% CI	(-1.20, 0.34)	(-0.87, 0.44)	
p-value	0.2586	0.4901	
Corrected Hedge's g Statistics	-0.480	-0.248	
95% CI	(-1.75, 0.79)	(-1.37, 0.88)	
Week 52			
m	4	4	15
n	4	4	13
Baseline Mean (SD)	5.48 (1.59)	5.55 (0.59)	6.23 (0.53)
Analysis Visit Mean (SD)	5.23 (1.50)	5.88 (0.46)	6.02 (1.05)
LS Mean of Change from Baseline (SE)	-0.07 (0.35)	0.62 (0.38)	0.06 (0.27)
95% CI	(-0.81, 0.68)	(-0.18, 1.41)	(-0.52, 0.63)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.12 (0.41)	0.56 (0.41)	
95% CI	(-0.99, 0.74)	(-0.29, 1.42)	
p-value	0.7685	0.1830	
Corrected Hedge's g Statistics	-0.125	0.565	
95% CI	(-1.25, 1.00)	(-0.57, 1.70)	
Subgroup*Treatment Interaction p-value	0.2581	0.0917	

AMNOG Table SE18.10.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Fatigue			
Week 24			
m	4	4	16
n	3	4	13
Baseline Mean (SD)	4.10 (2.13)	4.93 (1.48)	5.22 (1.41)
Analysis Visit Mean (SD)	4.53 (1.17)	4.83 (1.06)	5.49 (1.06)
LS Mean of Change from Baseline (SE)	0.21 (0.38)	0.25 (0.39)	0.67 (0.29)
95% CI	(-0.59, 1.01)	(-0.57, 1.07)	(0.05, 1.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.46 (0.44)	-0.42 (0.37)	
95% CI	(-1.38, 0.46)	(-1.19, 0.36)	
p-value	0.3044	0.2712	
Corrected Hedge's g Statistics	-0.433	-0.395	
95% CI	(-1.70, 0.83)	(-1.52, 0.73)	
Week 52			
m	4	4	15
n	4	4	13
Baseline Mean (SD)	4.40 (1.84)	4.93 (1.48)	5.22 (1.41)
Analysis Visit Mean (SD)	4.60 (1.37)	5.15 (0.57)	5.25 (1.38)
LS Mean of Change from Baseline (SE)	0.13 (0.54)	0.57 (0.57)	0.44 (0.37)
95% CI	(-1.02, 1.28)	(-0.62, 1.77)	(-0.35, 1.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.31 (0.61)	0.14 (0.60)	
95% CI	(-1.60, 0.98)	(-1.12, 1.40)	
p-value	0.6231	0.8208	
Corrected Hedge's g Statistics	-0.225	0.100	
95% CI	(-1.35, 0.90)	(-1.02, 1.22)	
Subgroup*Treatment Interaction p-value	0.4735	0.8565	

AMNOG Table SE18.10.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Systemic Symptoms			
Week 24			
m	4	4	16
n	3	4	13
Baseline Mean (SD)	5.20 (1.44)	5.75 (1.52)	5.72 (1.05)
Analysis Visit Mean (SD)	5.37 (0.90)	6.05 (0.74)	5.88 (1.12)
LS Mean of Change from Baseline (SE)	0.21 (0.39)	0.60 (0.43)	0.31 (0.34)
95% CI	(-0.61, 1.03)	(-0.31, 1.51)	(-0.41, 1.02)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.10 (0.45)	0.29 (0.39)	
95% CI	(-1.04, 0.84)	(-0.53, 1.11)	
p-value	0.8242	0.4660	
Corrected Hedge's g Statistics	-0.082	0.237	
95% CI	(-1.34, 1.17)	(-0.89, 1.36)	
Week 52			
m	4	4	15
n	4	4	13
Baseline Mean (SD)	5.35 (1.22)	5.75 (1.52)	5.72 (1.05)
Analysis Visit Mean (SD)	5.33 (1.47)	5.83 (0.97)	5.65 (1.33)
LS Mean of Change from Baseline (SE)	0.03 (0.50)	0.36 (0.54)	0.08 (0.39)
95% CI	(-1.02, 1.08)	(-0.78, 1.50)	(-0.74, 0.89)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.05 (0.55)	0.28 (0.54)	
95% CI	(-1.21, 1.12)	(-0.85, 1.42)	
p-value	0.9333	0.6053	
Corrected Hedge's g Statistics	-0.034	0.202	
95% CI	(-1.15, 1.09)	(-0.92, 1.33)	
Subgroup*Treatment Interaction p-value	0.6979	0.5941	

AMNOG Table SE18.10.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Worry			
Week 24			
m	4	4	16
n	3	4	13
Baseline Mean (SD)	4.27 (2.84)	6.73 (0.31)	6.68 (0.49)
Analysis Visit Mean (SD)	5.33 (1.51)	6.58 (0.78)	6.58 (1.04)
LS Mean of Change from Baseline (SE)	0.47 (0.59)	0.09 (0.48)	0.07 (0.34)
95% CI	(-0.79, 1.72)	(-0.92, 1.11)	(-0.65, 0.80)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.39 (0.72)	0.02 (0.47)	
95% CI	(-1.12, 1.91)	(-0.96, 1.00)	
p-value	0.5910	0.9705	
Corrected Hedge's g Statistics	0.307	0.014	
95% CI	(-0.95, 1.57)	(-1.11, 1.13)	
Week 52			
m	4	4	15
n	4	4	13
Baseline Mean (SD)	4.68 (2.46)	6.73 (0.31)	6.68 (0.49)
Analysis Visit Mean (SD)	5.30 (2.40)	6.48 (0.45)	6.53 (0.85)
LS Mean of Change from Baseline (SE)	0.48 (0.49)	-0.09 (0.47)	-0.04 (0.33)
95% CI	(-0.55, 1.51)	(-1.07, 0.90)	(-0.75, 0.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.52 (0.58)	-0.04 (0.45)	
95% CI	(-0.69, 1.74)	(-1.00, 0.91)	
p-value	0.3772	0.9233	
Corrected Hedge's g Statistics	0.427	-0.036	
95% CI	(-0.70, 1.56)	(-1.16, 1.08)	
Subgroup*Treatment Interaction p-value	0.8430	0.5199	

AMNOG Table SE18.10.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Abdominal Symptoms			
Week 24			
m	4	8	11
n	4	7	11
Baseline Mean (SD)	6.25 (1.31)	6.30 (0.76)	5.25 (1.30)
Analysis Visit Mean (SD)	6.43 (0.68)	5.71 (0.82)	4.97 (1.31)
LS Mean of Change from Baseline (SE)	0.36 (0.43)	-0.58 (0.34)	-0.57 (0.27)
95% CI	(-0.54, 1.25)	(-1.30, 0.15)	(-1.15, 0.00)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.93 (0.52)	0.00 (0.46)	
95% CI	(-0.16, 2.02)	(-0.96, 0.95)	
p-value	0.0905	0.9954	
Corrected Hedge's g Statistics	0.975	-0.003	
95% CI	(-0.22, 2.17)	(-0.95, 0.94)	
Week 52			
m	4	8	11
n	3	6	10
Baseline Mean (SD)	6.90 (0.17)	6.40 (0.78)	5.40 (1.25)
Analysis Visit Mean (SD)	6.77 (0.40)	5.85 (0.65)	5.44 (1.43)
LS Mean of Change from Baseline (SE)	0.09 (0.45)	-0.66 (0.32)	-0.01 (0.24)
95% CI	(-0.86, 1.04)	(-1.33, 0.01)	(-0.51, 0.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.10 (0.54)	-0.65 (0.42)	
95% CI	(-1.02, 1.23)	(-1.52, 0.22)	
p-value	0.8494	0.1367	
Corrected Hedge's g Statistics	0.127	-0.799	
95% CI	(-1.16, 1.42)	(-1.85, 0.25)	
Subgroup*Treatment Interaction p-value	0.0568	0.5866	

AMNOG Table SE18.10.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Activity			
Week 24			
m	4	8	11
n	4	7	11
Baseline Mean (SD)	5.85 (1.67)	6.06 (0.79)	5.76 (0.71)
Analysis Visit Mean (SD)	5.95 (0.87)	5.69 (0.82)	5.05 (1.34)
LS Mean of Change from Baseline (SE)	0.04 (0.55)	-0.38 (0.43)	-0.83 (0.33)
95% CI	(-1.10, 1.18)	(-1.29, 0.53)	(-1.53, -0.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.87 (0.64)	0.45 (0.55)	
95% CI	(-0.46, 2.21)	(-0.69, 1.60)	
p-value	0.1869	0.4181	
Corrected Hedge's g Statistics	0.746	0.385	
95% CI	(-0.43, 1.92)	(-0.57, 1.34)	
Week 52			
m	4	8	11
n	3	6	10
Baseline Mean (SD)	6.67 (0.42)	6.20 (0.76)	5.76 (0.75)
Analysis Visit Mean (SD)	6.47 (0.76)	5.17 (0.93)	5.64 (1.05)
LS Mean of Change from Baseline (SE)	-0.11 (0.50)	-1.09 (0.35)	-0.16 (0.26)
95% CI	(-1.16, 0.93)	(-1.83, -0.34)	(-0.70, 0.38)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.04 (0.58)	-0.93 (0.45)	
95% CI	(-1.17, 1.26)	(-1.86, 0.01)	
p-value	0.9405	0.0513	
Corrected Hedge's g Statistics	0.049	-1.048	
95% CI	(-1.24, 1.34)	(-2.12, 0.03)	
Subgroup*Treatment Interaction p-value	0.3306	0.7082	

AMNOG Table SE18.10.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Emotional Health			
Week 24			
m	4	8	11
n	4	7	11
Baseline Mean (SD)	6.40 (0.80)	6.13 (0.54)	5.57 (1.01)
Analysis Visit Mean (SD)	6.63 (0.24)	5.80 (1.11)	5.47 (1.18)
LS Mean of Change from Baseline (SE)	0.34 (0.40)	-0.50 (0.31)	-0.22 (0.24)
95% CI	(-0.49, 1.18)	(-1.16, 0.16)	(-0.73, 0.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.57 (0.48)	-0.28 (0.40)	
95% CI	(-0.44, 1.57)	(-1.12, 0.57)	
p-value	0.2532	0.5013	
Corrected Hedge's g Statistics	0.662	-0.322	
95% CI	(-0.51, 1.83)	(-1.28, 0.63)	
Week 52			
m	4	8	11
n	3	6	10
Baseline Mean (SD)	6.80 (0.10)	6.30 (0.33)	5.54 (1.06)
Analysis Visit Mean (SD)	6.60 (0.61)	5.57 (0.65)	5.71 (1.35)
LS Mean of Change from Baseline (SE)	0.00 (0.53)	-0.91 (0.37)	0.17 (0.29)
95% CI	(-1.11, 1.11)	(-1.68, -0.13)	(-0.43, 0.76)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.17 (0.64)	-1.07 (0.49)	
95% CI	(-1.50, 1.17)	(-2.09, -0.06)	
p-value	0.7958	0.0393	
Corrected Hedge's g Statistics	-0.172	-1.124	
95% CI	(-1.46, 1.12)	(-2.21, -0.04)	
Subgroup*Treatment Interaction p-value	0.2581	0.0917	

AMNOG Table SE18.10.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Fatigue			
Week 24			
m	4	8	11
n	4	7	11
Baseline Mean (SD)	4.68 (2.46)	5.37 (0.96)	5.23 (1.27)
Analysis Visit Mean (SD)	4.53 (2.35)	5.04 (1.14)	4.65 (1.67)
LS Mean of Change from Baseline (SE)	-0.27 (0.62)	-0.30 (0.49)	-0.59 (0.37)
95% CI	(-1.57, 1.03)	(-1.33, 0.72)	(-1.36, 0.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.32 (0.72)	0.28 (0.61)	
95% CI	(-1.19, 1.83)	(-0.99, 1.55)	
p-value	0.6658	0.6492	
Corrected Hedge's g Statistics	0.243	0.214	
95% CI	(-0.91, 1.39)	(-0.74, 1.16)	
Week 52			
m	4	8	11
n	3	6	10
Baseline Mean (SD)	5.90 (0.26)	5.47 (1.01)	5.30 (1.31)
Analysis Visit Mean (SD)	6.20 (0.85)	4.93 (0.88)	5.06 (1.39)
LS Mean of Change from Baseline (SE)	0.38 (0.54)	-0.44 (0.41)	-0.29 (0.29)
95% CI	(-0.75, 1.51)	(-1.29, 0.40)	(-0.90, 0.33)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.67 (0.61)	-0.16 (0.50)	
95% CI	(-0.62, 1.95)	(-1.20, 0.88)	
p-value	0.2914	0.7539	
Corrected Hedge's g Statistics	0.669	-0.158	
95% CI	(-0.65, 1.98)	(-1.17, 0.86)	
Subgroup*Treatment Interaction p-value	0.4735	0.8565	

AMNOG Table SE18.10.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Systemic Symptoms			
Week 24			
m	4	8	11
n	4	7	11
Baseline Mean (SD)	6.03 (1.19)	5.99 (0.68)	5.59 (0.67)
Analysis Visit Mean (SD)	6.00 (1.34)	5.80 (0.78)	5.11 (1.08)
LS Mean of Change from Baseline (SE)	-0.01 (0.41)	-0.19 (0.33)	-0.52 (0.26)
95% CI	(-0.87, 0.86)	(-0.89, 0.51)	(-1.06, 0.02)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.51 (0.49)	0.33 (0.42)	
95% CI	(-0.52, 1.54)	(-0.56, 1.22)	
p-value	0.3137	0.4513	
Corrected Hedge's g Statistics	0.566	0.359	
95% CI	(-0.60, 1.73)	(-0.60, 1.31)	
Week 52			
m	4	8	11
n	3	6	10
Baseline Mean (SD)	6.60 (0.36)	6.18 (0.48)	5.63 (0.70)
Analysis Visit Mean (SD)	6.50 (0.44)	5.23 (0.65)	5.61 (0.82)
LS Mean of Change from Baseline (SE)	0.14 (0.45)	-0.86 (0.32)	-0.17 (0.24)
95% CI	(-0.81, 1.09)	(-1.53, -0.18)	(-0.67, 0.33)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.31 (0.54)	-0.69 (0.41)	
95% CI	(-0.82, 1.43)	(-1.55, 0.17)	
p-value	0.5736	0.1112	
Corrected Hedge's g Statistics	0.378	-0.852	
95% CI	(-0.92, 1.68)	(-1.91, 0.20)	
Subgroup*Treatment Interaction p-value	0.6979	0.5941	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE18.10.3
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Results - MMRM Model by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Worry			
Week 24			
m	4	8	11
n	4	7	11
Baseline Mean (SD)	6.70 (0.54)	6.50 (0.73)	6.13 (0.87)
Analysis Visit Mean (SD)	7.00 (0.00)	6.34 (0.85)	6.12 (0.93)
LS Mean of Change from Baseline (SE)	0.46 (0.38)	-0.20 (0.31)	-0.16 (0.23)
95% CI	(-0.33, 1.26)	(-0.85, 0.44)	(-0.66, 0.33)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.63 (0.46)	-0.04 (0.38)	
95% CI	(-0.33, 1.58)	(-0.84, 0.76)	
p-value	0.1856	0.9182	
Corrected Hedge's g Statistics	0.762	-0.048	
95% CI	(-0.41, 1.94)	(-1.00, 0.90)	
Week 52			
m	4	8	11
n	3	6	10
Baseline Mean (SD)	6.97 (0.06)	6.73 (0.42)	6.11 (0.91)
Analysis Visit Mean (SD)	6.97 (0.06)	6.17 (1.17)	6.45 (0.68)
LS Mean of Change from Baseline (SE)	0.39 (0.43)	-0.51 (0.33)	0.08 (0.25)
95% CI	(-0.50, 1.29)	(-1.19, 0.17)	(-0.44, 0.59)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.32 (0.51)	-0.59 (0.41)	
95% CI	(-0.75, 1.38)	(-1.44, 0.27)	
p-value	0.5418	0.1696	
Corrected Hedge's g Statistics	0.381	-0.705	
95% CI	(-0.92, 1.68)	(-1.75, 0.34)	
Subgroup*Treatment Interaction p-value	0.8430	0.5199	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE18.10.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi-square Test. For this unadjusted analysis, only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.

AMNOG Table SE18.10.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	5 (100)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (40.0)	1 (20.0)	5 (29.4)
No	3 (60.0)	4 (80.0)	12 (70.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	1.67	
95% CI of the inverse odds ratio	(0.08, 4.96)	(0.15, 18.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	1.47	
95% CI of the inverse risk ratio	(0.20, 2.70)	(0.22, 9.85)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	10.59	-9.41	
95% CI of the absolute risk difference	(-37.51, 58.68)	(-50.62, 31.80)	
p-value	0.6550	0.6779	
p-value of Breslow-Day Test for Homogeneity [3]	0.3027	0.3218	

AMNOG Table SE18.10.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (5.9)
No	5 (100)	5 (100)	16 (94.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	1.00	
95% CI of the inverse odds ratio	(0.04, 28.30)	(0.04, 28.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	1.00	
95% CI of the inverse risk ratio	(0.05, 21.42)	(0.05, 21.42)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	0.00	
95% CI of the absolute risk difference	(-25.54, 25.54)	(-25.54, 25.54)	
p-value	>0.9999	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.5791	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (20.0)	0	2 (11.8)
No	4 (80.0)	5 (100)	15 (88.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.53	1.77	
95% CI of the inverse odds ratio	(0.04, 7.49)	(0.07, 43.02)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	1.67	
95% CI of the inverse risk ratio	(0.07, 5.22)	(0.09, 30.06)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.24	-5.56	
95% CI of the absolute risk difference	(-30.02, 46.50)	(-32.84, 21.73)	
p-value	0.6371	0.7216	
p-value of Breslow-Day Test for Homogeneity [3]	0.2899	0.5698	

AMNOG Table SE18.10.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (20.0)	0	3 (17.6)
No	4 (80.0)	5 (100)	14 (82.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	2.66	
95% CI of the inverse odds ratio	(0.07, 10.67)	(0.12, 60.22)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	2.33	
95% CI of the inverse risk ratio	(0.12, 6.73)	(0.14, 38.97)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.35	-11.11	
95% CI of the absolute risk difference	(-37.11, 41.82)	(-39.81, 17.58)	
p-value	0.9046	0.5271	
p-value of Breslow-Day Test for Homogeneity [3]	0.5249	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (40.0)	1 (20.0)	6 (35.3)
No	3 (60.0)	4 (80.0)	11 (64.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	2.18	
95% CI of the inverse odds ratio	(0.11, 6.34)	(0.20, 24.21)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	1.76	
95% CI of the inverse risk ratio	(0.25, 3.08)	(0.27, 11.42)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.71	-15.29	
95% CI of the absolute risk difference	(-43.87, 53.29)	(-57.07, 26.48)	
p-value	0.8475	0.5186	
p-value of Breslow-Day Test for Homogeneity [3]	0.5104	0.5255	

AMNOG Table SE18.10.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	5 (100)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (40.0)	2 (11.8)
No	5 (100)	3 (60.0)	15 (88.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.77	0.20	
95% CI of the inverse odds ratio	(0.07, 43.02)	(0.02, 2.03)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	0.29	
95% CI of the inverse risk ratio	(0.09, 30.06)	(0.05, 1.59)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.56	28.24	
95% CI of the absolute risk difference	(-32.84, 21.73)	(-17.35, 73.83)	
p-value	0.7216	0.1502	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.0840	

AMNOG Table SE18.10.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (20.0)	2 (40.0)	4 (23.5)
No	4 (80.0)	3 (60.0)	13 (76.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.23	0.46	
95% CI of the inverse odds ratio	(0.11, 14.42)	(0.06, 3.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	0.59	
95% CI of the inverse risk ratio	(0.17, 8.28)	(0.15, 2.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.53	16.47	
95% CI of the absolute risk difference	(-43.98, 36.92)	(-30.97, 63.91)	
p-value	0.8685	0.4673	
p-value of Breslow-Day Test for Homogeneity [3]	0.4372	0.1111	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (20.0)	2 (40.0)	6 (35.3)
No	4 (80.0)	3 (60.0)	11 (64.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.18	0.82	
95% CI of the inverse odds ratio	(0.20, 24.21)	(0.11, 6.34)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.76	0.88	
95% CI of the inverse risk ratio	(0.27, 11.42)	(0.25, 3.08)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-15.29	4.71	
95% CI of the absolute risk difference	(-57.07, 26.48)	(-43.87, 53.29)	
p-value	0.5186	0.8475	
p-value of Breslow-Day Test for Homogeneity [3]	0.1825	0.5918	

AMNOG Table SE18.10.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (20.0)	2 (11.8)
No	5 (100)	4 (80.0)	15 (88.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.77	0.53	
95% CI of the inverse odds ratio	(0.07, 43.02)	(0.04, 7.49)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	0.59	
95% CI of the inverse risk ratio	(0.09, 30.06)	(0.07, 5.22)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.56	8.24	
95% CI of the absolute risk difference	(-32.84, 21.73)	(-30.02, 46.50)	
p-value	0.7216	0.6371	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.2766	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (40.0)	1 (20.0)	5 (29.4)
No	3 (60.0)	4 (80.0)	12 (70.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	1.67	
95% CI of the inverse odds ratio	(0.08, 4.96)	(0.15, 18.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	1.47	
95% CI of the inverse risk ratio	(0.20, 2.70)	(0.22, 9.85)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	10.59	-9.41	
95% CI of the absolute risk difference	(-37.51, 58.68)	(-50.62, 31.80)	
p-value	0.6550	0.6779	
p-value of Breslow-Day Test for Homogeneity [3]	0.3027	0.3218	

AMNOG Table SE18.10.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (5.9)
No	5 (100)	5 (100)	16 (94.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	1.00	
95% CI of the inverse odds ratio	(0.04, 28.30)	(0.04, 28.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	1.00	
95% CI of the inverse risk ratio	(0.05, 21.42)	(0.05, 21.42)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	0.00	
95% CI of the absolute risk difference	(-25.54, 25.54)	(-25.54, 25.54)	
p-value	>0.9999	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (80.0)	0	1 (5.9)
No	1 (20.0)	5 (100)	16 (94.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.02	1.00	
95% CI of the inverse odds ratio	(0.00, 0.31)	(0.04, 28.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.07	1.00	
95% CI of the inverse risk ratio	(0.01, 0.52)	(0.05, 21.42)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	74.12	0.00	
95% CI of the absolute risk difference	(37.32, 100.00)	(-25.54, 25.54)	
p-value	0.0005	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.0015	NE	

AMNOG Table SE18.10.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (9.1)
No	4 (100)	10 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	3.00	
95% CI of the inverse odds ratio	(0.04, 37.98)	(0.11, 82.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	2.75	
95% CI of the inverse risk ratio	(0.06, 25.76)	(0.12, 60.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-7.95	
95% CI of the absolute risk difference	(-34.77, 29.77)	(-30.35, 14.44)	
p-value	0.8841	0.4988	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	2 (18.2)
No	4 (100)	10 (100)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.37	5.53	
95% CI of the inverse odds ratio	(0.09, 60.29)	(0.23, 130.34)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.08	4.58	
95% CI of the inverse risk ratio	(0.12, 36.07)	(0.25, 85.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.83	-16.29	
95% CI of the absolute risk difference	(-45.75, 24.09)	(-42.36, 9.78)	
p-value	0.5934	0.2466	
p-value of Breslow-Day Test for Homogeneity [3]	0.3027	0.3218	

AMNOG Table SE18.10.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (10.0)	1 (9.1)
No	4 (100)	9 (90.0)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	0.90	
95% CI of the inverse odds ratio	(0.04, 37.98)	(0.05, 16.59)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	0.91	
95% CI of the inverse risk ratio	(0.06, 25.76)	(0.07, 12.69)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	0.91	
95% CI of the absolute risk difference	(-34.77, 29.77)	(-24.28, 26.10)	
p-value	0.8841	0.9435	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.5791	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (10.0)	2 (18.2)
No	4 (100)	9 (90.0)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.37	2.00	
95% CI of the inverse odds ratio	(0.09, 60.29)	(0.15, 26.19)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.08	1.82	
95% CI of the inverse risk ratio	(0.12, 36.07)	(0.19, 17.12)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.83	-8.18	
95% CI of the absolute risk difference	(-45.75, 24.09)	(-37.60, 21.23)	
p-value	0.5934	0.5926	
p-value of Breslow-Day Test for Homogeneity [3]	0.2899	0.5698	

AMNOG Table SE18.10.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (9.1)
No	4 (100)	10 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	3.00	
95% CI of the inverse odds ratio	(0.04, 37.98)	(0.11, 82.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	2.75	
95% CI of the inverse risk ratio	(0.06, 25.76)	(0.12, 60.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-7.95	
95% CI of the absolute risk difference	(-34.77, 29.77)	(-30.35, 14.44)	
p-value	0.8841	0.4988	
p-value of Breslow-Day Test for Homogeneity [3]	0.5249	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	1 (9.1)
No	4 (100)	10 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	3.00	
95% CI of the inverse odds ratio	(0.04, 37.98)	(0.11, 82.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	2.75	
95% CI of the inverse risk ratio	(0.06, 25.76)	(0.12, 60.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-7.95	
95% CI of the absolute risk difference	(-34.77, 29.77)	(-30.35, 14.44)	
p-value	0.8841	0.4988	
p-value of Breslow-Day Test for Homogeneity [3]	0.5104	0.5255	

AMNOG Table SE18.10.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (18.2)
No	4 (100)	10 (100)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.37	5.53	
95% CI of the inverse odds ratio	(0.09, 60.29)	(0.23, 130.34)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.08	4.58	
95% CI of the inverse risk ratio	(0.12, 36.07)	(0.25, 85.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.83	-16.29	
95% CI of the absolute risk difference	(-45.75, 24.09)	(-42.36, 9.78)	
p-value	0.5934	0.2466	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (10.0)	3 (27.3)
No	4 (100)	9 (90.0)	8 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.71	3.38	
95% CI of the inverse odds ratio	(0.15, 88.75)	(0.29, 39.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.92	2.73	
95% CI of the inverse risk ratio	(0.18, 46.71)	(0.34, 22.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-19.17	-17.27	
95% CI of the absolute risk difference	(-55.95, 17.61)	(-49.50, 14.95)	
p-value	0.3959	0.3141	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.0840	

AMNOG Table SE18.10.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (18.2)
No	4 (100)	10 (100)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.37	5.53	
95% CI of the inverse odds ratio	(0.09, 60.29)	(0.23, 130.34)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.08	4.58	
95% CI of the inverse risk ratio	(0.12, 36.07)	(0.25, 85.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.83	-16.29	
95% CI of the absolute risk difference	(-45.75, 24.09)	(-42.36, 9.78)	
p-value	0.5934	0.2466	
p-value of Breslow-Day Test for Homogeneity [3]	0.4372	0.1111	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (50.0)	1 (10.0)	2 (18.2)
No	2 (50.0)	9 (90.0)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.22	2.00	
95% CI of the inverse odds ratio	(0.02, 2.67)	(0.15, 26.19)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.36	1.82	
95% CI of the inverse risk ratio	(0.07, 1.79)	(0.19, 17.12)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	31.82	-8.18	
95% CI of the absolute risk difference	(-22.22, 85.86)	(-37.60, 21.23)	
p-value	0.2178	0.5926	
p-value of Breslow-Day Test for Homogeneity [3]	0.1825	0.5918	

AMNOG Table SE18.10.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (9.1)
No	4 (100)	10 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	3.00	
95% CI of the inverse odds ratio	(0.04, 37.98)	(0.11, 82.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	2.75	
95% CI of the inverse risk ratio	(0.06, 25.76)	(0.12, 60.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-7.95	
95% CI of the absolute risk difference	(-34.77, 29.77)	(-30.35, 14.44)	
p-value	0.8841	0.4988	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.2766	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	2 (18.2)
No	4 (100)	10 (100)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.37	5.53	
95% CI of the inverse odds ratio	(0.09, 60.29)	(0.23, 130.34)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.08	4.58	
95% CI of the inverse risk ratio	(0.12, 36.07)	(0.25, 85.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.83	-16.29	
95% CI of the absolute risk difference	(-45.75, 24.09)	(-42.36, 9.78)	
p-value	0.5934	0.2466	
p-value of Breslow-Day Test for Homogeneity [3]	0.3027	0.3218	

AMNOG Table SE18.10.4
Chronic Liver Disease Questionnaire-NASH (SE18): Summary of Response at Week 52 by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (18.2)
No	4 (100)	10 (100)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.37	5.53	
95% CI of the inverse odds ratio	(0.09, 60.29)	(0.23, 130.34)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.08	4.58	
95% CI of the inverse risk ratio	(0.12, 36.07)	(0.25, 85.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.83	-16.29	
95% CI of the absolute risk difference	(-45.75, 24.09)	(-42.36, 9.78)	
p-value	0.5934	0.2466	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	4 (36.4)
No	4 (100)	10 (100)	7 (63.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.40	12.60	
95% CI of the inverse odds ratio	(0.23, 125.61)	(0.59, 270.97)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.75	8.25	
95% CI of the inverse risk ratio	(0.24, 57.45)	(0.50, 136.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-27.50	-32.95	
95% CI of the absolute risk difference	(-65.47, 10.47)	(-62.98, -2.92)	
p-value	0.2569	0.0556	
p-value of Breslow-Day Test for Homogeneity [3]	0.0015	NE	

Madrigal Pharmaceuticals, Inc. Page 1 of 8
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE19.2.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=2)	(N=11)	(N=11)	(N=2)	(N=11)	(N=11)
Absenteeism						
Baseline						
m	2	11	11			
n	1	3	3			
Mean (SD)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 0.0	0.0, 0.0	0.0, 0.0			
Week 24						
m	2	8	11			
n	1	4	7	1	1	3
Mean (SD/SE)	0.00 (N/A)	2.75 (5.50)	0.31 (0.83)	0.00 (N/A)	0.00 (N/A)	0.73 (0.73)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 5.50	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 2.20
Min, Max	0.0, 0.0	0.0, 11.0	0.0, 2.2	0.0, 0.0	0.0, 0.0	0.0, 2.2
Week 52						
m	2	8	10			
n	0	4	7	0	2	3
Mean (SD/SE)	N/A	12.50 (25.00)	1.57 (4.16)	N/A	0.00 (0.00)	0.00 (0.00)
Median	N/A	0	0	N/A	0	0
IQR: Q1, Q3	N/A	0.00, 25.00	0.00, 0.00	N/A	0.00, 0.00	0.00, 0.00
Min, Max	N/A	0.0, 50.0	0.0, 11.0	N/A	0.0, 0.0	0.0, 0.0

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.2.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=2)	(N=11)	(N=11)	(N=2)	(N=11)	(N=11)
Presenteeism						
Baseline						
m	2	11	11			
n	1	3	3			
Mean (SD)	60.0 (N/A)	0.0 (0.0)	3.3 (5.8)			
Median	60.0	0	0			
IQR: Q1, Q3	60.0, 60.0	0.0, 0.0	0.0, 10.0			
Min, Max	60, 60	0, 0	0, 10			
Week 24						
m	2	8	11			
n	1	4	7	1	1	3
Mean (SD/SE)	0.0 (N/A)	20.0 (33.7)	4.3 (5.3)	-60.0 (N/A)	0.0 (N/A)	3.3 (3.3)
Median	0	5.0	0	-60.0	0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 40.0	0.0, 10.0	-60.0, -60.0	0.0, 0.0	0.0, 10.0
Min, Max	0, 0	0, 70	0, 10	-60, -60	0, 0	0, 10
Week 52						
m	2	8	10			
n	0	4	7	0	2	3
Mean (SD/SE)	N/A	17.5 (23.6)	11.4 (15.7)	N/A	0.0 (0.0)	10.0 (5.8)
Median	N/A	10.0	0	N/A	0	10.0
IQR: Q1, Q3	N/A	0.0, 35.0	0.0, 20.0	N/A	0.0, 0.0	0.0, 20.0
Min, Max	N/A	0, 50	0, 40	N/A	0, 0	0, 20

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.2.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=2)	(N=11)	(N=11)	(N=2)	(N=11)	(N=11)
Overall Work Impairment						
Baseline						
m	2	11	11			
n	1	3	3			
Mean (SD)	60.00 (N/A)	0.00 (0.00)	3.33 (5.77)			
Median	60.00	0	0			
IQR: Q1, Q3	60.00, 60.00	0.00, 0.00	0.00, 10.00			
Min, Max	60.0, 60.0	0.0, 0.0	0.0, 10.0			
Week 24						
m	2	8	11			
n	1	4	7	1	1	3
Mean (SD/SE)	0.00 (N/A)	22.75 (31.89)	4.57 (5.74)	-60.00 (N/A)	0.00 (N/A)	4.00 (3.06)
Median	0	10.50	0	-60.00	0	2.00
IQR: Q1, Q3	0.00, 0.00	5.00, 40.50	0.00, 10.00	-60.00, -60.00	0.00, 0.00	0.00, 10.00
Min, Max	0.0, 0.0	0.0, 70.0	0.0, 12.0	-60.0, -60.0	0.0, 0.0	0.0, 10.0
Week 52						
m	2	8	10			
n	0	4	7	0	2	3
Mean (SD/SE)	N/A	23.75 (35.44)	12.37 (17.80)	N/A	0.00 (0.00)	10.00 (5.77)
Median	N/A	10.00	0	N/A	0	10.00
IQR: Q1, Q3	N/A	0.00, 47.50	0.00, 20.00	N/A	0.00, 0.00	0.00, 20.00
Min, Max	N/A	0.0, 75.0	0.0, 46.6	N/A	0.0, 0.0	0.0, 20.0

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE19.2.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=11)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=11)	Change from Baseline DB Placebo (N=11)
Activity Impairment						
Baseline						
m	2	11	11			
n	2	4	5			
Mean (SD)	50.0 (70.7)	2.5 (5.0)	22.0 (24.9)			
Median	50.0	0	20.0			
IQR: Q1, Q3	0.0, 100.0	0.0, 5.0	0.0, 30.0			
Min, Max	0, 100	0, 10	0, 60			
Week 24						
m	2	8	11			
n	2	7	10	2	2	5
Mean (SD/SE)	5.0 (7.1)	18.6 (24.1)	17.0 (22.1)	-45.0 (45.0)	0.0 (0.0)	-10.0 (12.6)
Median	5.0	10.0	10.0	-45.0	0	0
IQR: Q1, Q3	0.0, 10.0	0.0, 20.0	0.0, 30.0	-90.0, 0.0	0.0, 0.0	0.0, 0.0
Min, Max	0, 10	0, 70	0, 70	-90, 0	0, 0	-60, 10
Week 52						
m	2	8	10			
n	1	6	8	1	3	4
Mean (SD/SE)	0.0 (N/A)	11.7 (20.4)	15.0 (21.4)	0.0 (N/A)	-3.3 (3.3)	0.0 (4.1)
Median	0	0	5.0	0	0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 20.0	0.0, 25.0	0.0, 0.0	-10.0, 0.0	-5.0, 5.0
Min, Max	0, 0	0, 50	0, 60	0, 0	-10, 0	-10, 10

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.2.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=4)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=4)	Change from Baseline DB Placebo (N=17)
Absenteeism						
Baseline						
m	7	4	17			
n	1	2	3			
Mean (SD)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 0.0	0.0, 0.0	0.0, 0.0			
Week 24						
m	6	4	16			
n	1	2	5	1	2	3
Mean (SD/SE)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 0.0	0.0, 0.0	0.0, 0.0	0.0, 0.0	0.0, 0.0	0.0, 0.0
Week 52						
m	6	4	16			
n	2	3	4	1	2	2
Mean (SD/SE)	0.00 (0.00)	0.00 (0.00)	12.50 (25.00)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 25.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 0.0	0.0, 0.0	0.0, 50.0	0.0, 0.0	0.0, 0.0	0.0, 0.0

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE19.2.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=7)	(N=4)	(N=17)	(N=7)	(N=4)	(N=17)
Presenteeism						
Baseline						
m	7	4	17			
n	1	2	3			
Mean (SD)	0.0 (N/A)	10.0 (14.1)	0.0 (0.0)			
Median	0	10.0	0			
IQR: Q1, Q3	0.0, 0.0	0.0, 20.0	0.0, 0.0			
Min, Max	0, 0	0, 20	0, 0			
Week 24						
m	6	4	16			
n	1	2	5	1	2	3
Mean (SD/SE)	0.0 (N/A)	5.0 (7.1)	4.0 (8.9)	0.0 (N/A)	-5.0 (5.0)	0.0 (0.0)
Median	0	5.0	0	0	-5.0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 10.0	0.0, 0.0	0.0, 0.0	-10.0, 0.0	0.0, 0.0
Min, Max	0, 0	0, 10	0, 20	0, 0	-10, 0	0, 0
Week 52						
m	6	4	16			
n	2	3	4	1	2	2
Mean (SD/SE)	0.0 (0.0)	0.0 (0.0)	17.5 (35.0)	0.0 (N/A)	-10.0 (10.0)	0.0 (0.0)
Median	0	0	0	0	-10.0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 0.0	0.0, 35.0	0.0, 0.0	-20.0, 0.0	0.0, 0.0
Min, Max	0, 0	0, 0	0, 70	0, 0	-20, 0	0, 0

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc. Page 7 of 8
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE19.2.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=7)	(N=4)	(N=17)	(N=7)	(N=4)	(N=17)
Overall Work Impairment						
Baseline						
m	7	4	17			
n	1	2	3			
Mean (SD)	0.00 (N/A)	10.00 (14.14)	0.00 (0.00)			
Median	0	10.00	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 20.00	0.00, 0.00			
Min, Max	0.0, 0.0	0.0, 20.0	0.0, 0.0			
Week 24						
m	6	4	16			
n	1	2	5	1	2	3
Mean (SD/SE)	0.00 (N/A)	5.00 (7.07)	4.00 (8.94)	0.00 (N/A)	-5.00 (5.00)	0.00 (0.00)
Median	0	5.00	0	0	-5.00	0
IQR: Q1, Q3	0.00, 0.00	0.00, 10.00	0.00, 0.00	0.00, 0.00	-10.00, 0.00	0.00, 0.00
Min, Max	0.0, 0.0	0.0, 10.0	0.0, 20.0	0.0, 0.0	-10.0, 0.0	0.0, 0.0
Week 52						
m	6	4	16			
n	2	3	4	1	2	2
Mean (SD/SE)	0.00 (0.00)	0.00 (0.00)	21.25 (42.50)	0.00 (N/A)	-10.00 (10.00)	0.00 (0.00)
Median	0	0	0	0	-10.00	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 42.50	0.00, 0.00	-20.00, 0.00	0.00, 0.00
Min, Max	0.0, 0.0	0.0, 0.0	0.0, 85.0	0.0, 0.0	-20.0, 0.0	0.0, 0.0

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE19.2.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=4)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=4)	Change from Baseline DB Placebo (N=17)
Activity Impairment						
Baseline						
m	7	4	17			
n	5	3	11			
Mean (SD)	16.0 (30.5)	6.7 (11.5)	14.5 (26.2)			
Median	0	0	10.0			
IQR: Q1, Q3	0.0, 10.0	0.0, 20.0	0.0, 20.0			
Min, Max	0, 70	0, 20	0, 90			
Week 24						
m	6	4	16			
n	5	3	16	4	3	11
Mean (SD/SE)	0.0 (0.0)	3.3 (5.8)	9.4 (18.1)	-20.0 (16.8)	-3.3 (3.3)	-8.2 (7.0)
Median	0	0	0	-5.0	0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 10.0	0.0, 15.0	-40.0, 0.0	-10.0, 0.0	-20.0, 10.0
Min, Max	0, 0	0, 10	0, 70	-70, 0	-10, 0	-70, 10
Week 52						
m	6	4	16			
n	6	4	16	4	3	11
Mean (SD/SE)	5.0 (8.4)	0.0 (0.0)	20.0 (24.5)	-12.5 (13.1)	-6.7 (6.7)	9.1 (6.1)
Median	0	0	10.0	-5.0	0	0
IQR: Q1, Q3	0.0, 10.0	0.0, 0.0	0.0, 40.0	-30.0, 5.0	-20.0, 0.0	0.0, 30.0
Min, Max	0, 20	0, 0	0, 70	-50, 10	-20, 0	-20, 40

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.2.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. If the MMRM for LS Means does not converge with unstructured covariance, compound symmetry is used. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

AMNOG Table SE19.2.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Absenteeism			
Week 24			
m	2	8	11
n	1	1	3
Baseline Mean (SD)	0.00 (N/A)	0.00 (N/A)	0.00 (0.00)
Analysis Visit Mean (SD)	0.00 (N/A)	0.00 (N/A)	0.73 (1.27)
LS Mean of Change from Baseline (SE)	0.28 (0.93)	0.28 (0.93)	0.64 (0.51)
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.37 (1.11)	-0.37 (1.10)	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	-0.239	-0.239	
95% CI	(-2.51, 2.03)	(-2.51, 2.03)	
Week 52			
m	2	8	10
n	0	2	3
Baseline Mean (SD)	N/A	0.00 (0.00)	0.00 (0.00)
Analysis Visit Mean (SD)	N/A	0.00 (0.00)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	NE	0.28 (0.71)	-0.09 (0.51)
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	0.37 (0.93)	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	0.289	
95% CI	NE	(-1.51, 2.09)	
Subgroup*Treatment Interaction p-value	0.9735	0.9582	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE19.2.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Presenteeism			
Week 24			
m	2	8	11
n	1	1	3
Baseline Mean (SD)	60.0 (N/A)	0.0 (N/A)	3.3 (5.8)
Analysis Visit Mean (SD)	0.0 (N/A)	0.0 (N/A)	6.7 (5.8)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	2	8	10
n	0	2	3
Baseline Mean (SD)	N/A	0.0 (0.0)	3.3 (5.8)
Analysis Visit Mean (SD)	N/A	0.0 (0.0)	13.3 (11.5)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.2525	0.6340	

AMNOG Table SE19.2.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Overall Work Impairment			
Week 24			
m	2	8	11
n	1	1	3
Baseline Mean (SD)	60.0 (N/A)	0.0 (N/A)	3.3 (5.8)
Analysis Visit Mean (SD)	0.0 (N/A)	0.0 (N/A)	7.3 (6.4)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	2	8	10
n	0	2	3
Baseline Mean (SD)	N/A	0.0 (0.0)	3.3 (5.8)
Analysis Visit Mean (SD)	N/A	0.0 (0.0)	13.3 (11.5)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.1892	0.5571	

AMNOG Table SE19.2.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Activity Impairment			
Week 24			
m	2	8	11
n	2	2	5
Baseline Mean (SD)	50.0 (70.7)	5.0 (7.1)	22.0 (24.9)
Analysis Visit Mean (SD)	5.0 (7.1)	5.0 (7.1)	12.0 (13.0)
LS Mean of Change from Baseline (SE)	-16.66 (8.56)	-13.31 (7.41)	-7.18 (4.71)
95% CI	(-125.41, 92.09)	(-107.48, 80.86)	(-67.05, 52.69)
LS Mean of Change from Baseline Compared to Placebo (SE)	-9.48 (9.52)	-6.13 (8.87)	
95% CI	(-130.49, 111.53)	(-118.80, 106.54)	
p-value	0.5013	0.6150	
Corrected Hedge's g Statistics	-0.735	-0.490	
95% CI	(-2.42, 0.95)	(-2.15, 1.17)	
Week 52			
m	2	8	10
n	1	3	4
Baseline Mean (SD)	0.0 (N/A)	3.3 (5.8)	22.5 (28.7)
Analysis Visit Mean (SD)	0.0 (N/A)	0.0 (0.0)	22.5 (26.3)
LS Mean of Change from Baseline (SE)	-4.44 (11.15)	-6.17 (6.85)	-0.10 (5.21)
95% CI	(-146.09, 137.21)	(-93.22, 80.87)	(-66.26, 66.05)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.34 (12.55)	-6.07 (8.89)	
95% CI	(-163.79, 155.11)	(-118.99, 106.85)	
p-value	0.7882	0.6185	
Corrected Hedge's g Statistics	-0.303	-0.464	
95% CI	(-2.50, 1.90)	(-1.98, 1.05)	
Subgroup*Treatment Interaction p-value	0.9168	0.8951	

AMNOG Table SE19.2.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Absenteeism			
Week 24			
m	6	4	16
n	1	2	3
Baseline Mean (SD)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)
Analysis Visit Mean (SD)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	6	4	16
n	1	2	2
Baseline Mean (SD)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)
Analysis Visit Mean (SD)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.9735	0.9582	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE19.2.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Presenteeism			
Week 24			
m	6	4	16
n	1	2	3
Baseline Mean (SD)	0.0 (N/A)	10.0 (14.1)	0.0 (0.0)
Analysis Visit Mean (SD)	0.0 (N/A)	5.0 (7.1)	0.0 (0.0)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	6	4	16
n	1	2	2
Baseline Mean (SD)	0.0 (N/A)	10.0 (14.1)	0.0 (0.0)
Analysis Visit Mean (SD)	0.0 (N/A)	0.0 (0.0)	0.0 (0.0)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.2525	0.6340	

AMNOG Table SE19.2.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Overall Work Impairment			
Week 24			
m	6	4	16
n	1	2	3
Baseline Mean (SD)	0.0 (N/A)	10.0 (14.1)	0.0 (0.0)
Analysis Visit Mean (SD)	0.0 (N/A)	5.0 (7.1)	0.0 (0.0)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	6	4	16
n	1	2	2
Baseline Mean (SD)	0.0 (N/A)	10.0 (14.1)	0.0 (0.0)
Analysis Visit Mean (SD)	0.0 (N/A)	0.0 (0.0)	0.0 (0.0)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.1892	0.5571	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE19.2.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Activity Impairment			
Week 24			
m	6	4	16
n	4	3	11
Baseline Mean (SD)	20.0 (33.7)	6.7 (11.5)	14.5 (26.2)
Analysis Visit Mean (SD)	0.0 (0.0)	3.3 (5.8)	6.4 (9.2)
LS Mean of Change from Baseline (SE)	-14.81 (8.67)	-9.78 (9.67)	-8.01 (6.21)
95% CI	(-33.71, 4.09)	(-30.86, 11.30)	(-21.54, 5.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.80 (8.55)	-1.77 (9.58)	
95% CI	(-25.43, 11.83)	(-22.64, 19.10)	
p-value	0.4416	0.8565	
Corrected Hedge's g Statistics	-0.322	-0.083	
95% CI	(-1.47, 0.83)	(-1.36, 1.19)	
Week 52			
m	6	4	16
n	4	3	11
Baseline Mean (SD)	20.0 (33.7)	6.7 (11.5)	14.5 (26.2)
Analysis Visit Mean (SD)	7.5 (9.6)	0.0 (0.0)	23.6 (27.3)
LS Mean of Change from Baseline (SE)	-9.74 (8.67)	-9.71 (9.67)	9.22 (6.21)
95% CI	(-28.64, 9.16)	(-30.79, 11.36)	(-4.31, 22.76)
LS Mean of Change from Baseline Compared to Placebo (SE)	-18.96 (8.55)	-18.94 (9.58)	
95% CI	(-37.59, -0.33)	(-39.81, 1.94)	
p-value	0.0467	0.0716	
Corrected Hedge's g Statistics	-0.897	-0.886	
95% CI	(-2.09, 0.29)	(-2.20, 0.43)	
Subgroup*Treatment Interaction p-value	0.9168	0.8951	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE19.2.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as a decrease of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.

AMNOG Table SE19.2.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	2 (100)	11 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	2 (100)	11 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.2.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	2 (100)	11 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	2 (100)	11 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.2.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	2 (100)	11 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	2 (100)	11 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.2.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	2 (100)	11 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (9.1)	1 (9.1)
No	2 (100)	10 (90.9)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	1.00	
95% CI of the inverse odds ratio	(0.02, 23.31)	(0.05, 18.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	1.00	
95% CI of the inverse risk ratio	(0.04, 14.19)	(0.07, 14.05)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.17	0.00	
95% CI of the absolute risk difference	(-41.97, 50.30)	(-24.03, 24.03)	
p-value	0.8494	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.4810	0.6480	

AMNOG Table SE19.2.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	7 (100)	4 (100)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	7 (100)	4 (100)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.2.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (25.0)	0
No	7 (100)	3 (75.0)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.07	
95% CI of the inverse odds ratio	NE	(0.00, 2.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.09	
95% CI of the inverse risk ratio	NE	(0.00, 1.94)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	27.22	
95% CI of the absolute risk difference	NE	(-13.66, 68.10)	
p-value	NE	0.0560	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (25.0)	0
No	7 (100)	3 (75.0)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.07	
95% CI of the inverse odds ratio	NE	(0.00, 2.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.09	
95% CI of the inverse risk ratio	NE	(0.00, 1.94)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	27.22	
95% CI of the absolute risk difference	NE	(-13.66, 68.10)	
p-value	NE	0.0560	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.2.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (25.0)	0
No	7 (100)	3 (75.0)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.07	
95% CI of the inverse odds ratio	NE	(0.00, 2.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.09	
95% CI of the inverse risk ratio	NE	(0.00, 1.94)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	27.22	
95% CI of the absolute risk difference	NE	(-13.66, 68.10)	
p-value	NE	0.0560	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (25.0)	0
No	7 (100)	3 (75.0)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.07	
95% CI of the inverse odds ratio	NE	(0.00, 2.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.09	
95% CI of the inverse risk ratio	NE	(0.00, 1.94)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	27.22	
95% CI of the absolute risk difference	NE	(-13.66, 68.10)	
p-value	NE	0.0560	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.2.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (14.3)	1 (25.0)	1 (5.9)
No	6 (85.7)	3 (75.0)	16 (94.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.38	0.19	
95% CI of the inverse odds ratio	(0.02, 7.00)	(0.01, 3.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.41	0.24	
95% CI of the inverse risk ratio	(0.03, 5.70)	(0.02, 3.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.40	19.12	
95% CI of the absolute risk difference	(-19.83, 36.64)	(-24.77, 63.00)	
p-value	0.4984	0.2412	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (28.6)	1 (25.0)	2 (11.8)
No	5 (71.4)	3 (75.0)	15 (88.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	0.40	
95% CI of the inverse odds ratio	(0.04, 3.03)	(0.03, 5.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.41	0.47	
95% CI of the inverse risk ratio	(0.07, 2.37)	(0.06, 4.00)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.81	13.24	
95% CI of the absolute risk difference	(-20.00, 53.61)	(-31.88, 58.35)	
p-value	0.3153	0.4961	
p-value of Breslow-Day Test for Homogeneity [3]	0.4810	0.6480	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE19.3.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=21)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=21)
Absenteeism						
Baseline						
m	6	15	21			
n	2	5	5			
Mean (SD)	0.00 (0.00)	0.00 (0.00)	0.00 (0.00)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 0.0	0.0, 0.0	0.0, 0.0			
Week 24						
m	6	12	20			
n	2	6	10	2	3	5
Mean (SD/SE)	0.00 (0.00)	1.83 (4.49)	0.22 (0.70)	0.00 (0.00)	0.00 (0.00)	0.44 (0.44)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 0.0	0.0, 11.0	0.0, 2.2	0.0, 0.0	0.0, 0.0	0.0, 2.2
Week 52						
m	6	12	19			
n	2	7	11	1	4	5
Mean (SD/SE)	0.00 (0.00)	7.14 (18.90)	5.55 (15.11)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 0.0	0.0, 50.0	0.0, 50.0	0.0, 0.0	0.0, 0.0	0.0, 0.0

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc. Page 2 of 8
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE19.3.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=6)	(N=15)	(N=21)	(N=6)	(N=15)	(N=21)
Presenteeism						
Baseline						
m	6	15	21			
n	2	5	5			
Mean (SD)	30.0 (42.4)	4.0 (8.9)	2.0 (4.5)			
Median	30.0	0	0			
IQR: Q1, Q3	0.0, 60.0	0.0, 0.0	0.0, 0.0			
Min, Max	0, 60	0, 20	0, 10			
Week 24						
m	6	12	20			
n	2	6	10	2	3	5
Mean (SD/SE)	0.0 (0.0)	15.0 (27.4)	3.0 (4.8)	-30.0 (30.0)	-3.3 (3.3)	2.0 (2.0)
Median	0	5.0	0	-30.0	0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 10.0	0.0, 10.0	-60.0, 0.0	-10.0, 0.0	0.0, 0.0
Min, Max	0, 0	0, 70	0, 10	-60, 0	-10, 0	0, 10
Week 52						
m	6	12	19			
n	2	7	11	1	4	5
Mean (SD/SE)	0.0 (0.0)	10.0 (19.1)	13.6 (22.9)	0.0 (N/A)	-5.0 (5.0)	6.0 (4.0)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 20.0	0.0, 20.0	0.0, 0.0	-10.0, 0.0	0.0, 10.0
Min, Max	0, 0	0, 50	0, 70	0, 0	-20, 0	0, 20

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.3.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=6)	(N=15)	(N=21)	(N=6)	(N=15)	(N=21)
Overall Work Impairment						
Baseline						
m	6	15	21			
n	2	5	5			
Mean (SD)	30.00 (42.43)	4.00 (8.94)	2.00 (4.47)			
Median	30.00	0	0			
IQR: Q1, Q3	0.00, 60.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 60.0	0.0, 20.0	0.0, 10.0			
Week 24						
m	6	12	20			
n	2	6	10	2	3	5
Mean (SD/SE)	0.00 (0.00)	16.83 (26.54)	3.20 (5.18)	-30.00 (30.00)	-3.33 (3.33)	2.40 (1.94)
Median	0	10.00	0	-30.00	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 11.00	0.00, 10.00	-60.00, 0.00	-10.00, 0.00	0.00, 2.00
Min, Max	0.0, 0.0	0.0, 70.0	0.0, 12.0	-60.0, 0.0	-10.0, 0.0	0.0, 10.0
Week 52						
m	6	12	19			
n	2	7	11	1	4	5
Mean (SD/SE)	0.00 (0.00)	13.57 (28.09)	15.60 (27.42)	0.00 (N/A)	-5.00 (5.00)	6.00 (4.00)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 20.00	0.00, 20.00	0.00, 0.00	-10.00, 0.00	0.00, 10.00
Min, Max	0.0, 0.0	0.0, 75.0	0.0, 85.0	0.0, 0.0	-20.0, 0.0	0.0, 20.0

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.3.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=21)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=21)
Activity Impairment						
Baseline						
m	6	15	21			
n	5	7	10			
Mean (SD)	36.0 (46.2)	4.3 (7.9)	23.0 (30.2)			
Median	10.0	0	15.0			
IQR: Q1, Q3	0.0, 70.0	0.0, 10.0	0.0, 30.0			
Min, Max	0, 100	0, 20	0, 90			
Week 24						
m	6	12	20			
n	5	10	19	5	5	10
Mean (SD/SE)	2.0 (4.5)	14.0 (21.2)	14.2 (22.2)	-34.0 (19.1)	-2.0 (2.0)	-15.0 (8.7)
Median	0	10.0	0	-10.0	0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 20.0	0.0, 20.0	-70.0, 0.0	0.0, 0.0	-20.0, 0.0
Min, Max	0, 10	0, 70	0, 70	-90, 0	-10, 0	-70, 10
Week 52						
m	6	12	19			
n	5	10	17	4	6	9
Mean (SD/SE)	4.0 (8.9)	7.0 (16.4)	21.2 (25.2)	-15.0 (11.9)	-5.0 (3.4)	6.7 (6.9)
Median	0	0	10.0	-5.0	0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 0.0	0.0, 40.0	-30.0, 0.0	-10.0, 0.0	0.0, 10.0
Min, Max	0, 20	0, 50	0, 70	-50, 0	-20, 0	-20, 40

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.3.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=3)	(N=0)	(N=7)	(N=3)	(N=0)	(N=7)
Absenteeism						
Baseline						
m	3	0	7			
n	0	0	1			
Mean (SD)	N/A	N/A	0.00 (N/A)			
Median	N/A	N/A	0			
IQR: Q1, Q3	N/A	N/A	0.00, 0.00			
Min, Max	N/A	N/A	0.0, 0.0			
Week 24						
m	2	0	7			
n	0	0	2	0	0	1
Mean (SD/SE)	N/A	N/A	0.00 (0.00)	N/A	N/A	0.00 (N/A)
Median	N/A	N/A	0	N/A	N/A	0
IQR: Q1, Q3	N/A	N/A	0.00, 0.00	N/A	N/A	0.00, 0.00
Min, Max	N/A	N/A	0.0, 0.0	N/A	N/A	0.0, 0.0
Week 52						
m	2	0	7			
n	0	0	0	0	0	0
Mean (SD/SE)	N/A	N/A	N/A	N/A	N/A	N/A
Median	N/A	N/A	N/A	N/A	N/A	N/A
IQR: Q1, Q3	N/A	N/A	N/A	N/A	N/A	N/A
Min, Max	N/A	N/A	N/A	N/A	N/A	N/A

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc. Page 6 of 8
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE19.3.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=3)	(N=0)	(N=7)	(N=3)	(N=0)	(N=7)
Presenteeism						
Baseline						
m	3	0	7			
n	0	0	1			
Mean (SD)	N/A	N/A	0.0 (N/A)			
Median	N/A	N/A	0			
IQR: Q1, Q3	N/A	N/A	0.0, 0.0			
Min, Max	N/A	N/A	0, 0			
Week 24						
m	2	0	7			
n	0	0	2	0	0	1
Mean (SD/SE)	N/A	N/A	10.0 (14.1)	N/A	N/A	0.0 (N/A)
Median	N/A	N/A	10.0	N/A	N/A	0
IQR: Q1, Q3	N/A	N/A	0.0, 20.0	N/A	N/A	0.0, 0.0
Min, Max	N/A	N/A	0, 20	N/A	N/A	0, 0
Week 52						
m	2	0	7			
n	0	0	0	0	0	0
Mean (SD/SE)	N/A	N/A	N/A	N/A	N/A	N/A
Median	N/A	N/A	N/A	N/A	N/A	N/A
IQR: Q1, Q3	N/A	N/A	N/A	N/A	N/A	N/A
Min, Max	N/A	N/A	N/A	N/A	N/A	N/A

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.3.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=3)	(N=0)	(N=7)	(N=3)	(N=0)	(N=7)
Overall Work Impairment						
Baseline						
m	3	0	7			
n	0	0	1			
Mean (SD)	N/A	N/A	0.00 (N/A)			
Median	N/A	N/A	0			
IQR: Q1, Q3	N/A	N/A	0.00, 0.00			
Min, Max	N/A	N/A	0.0, 0.0			
Week 24						
m	2	0	7			
n	0	0	2	0	0	1
Mean (SD/SE)	N/A	N/A	10.00 (14.14)	N/A	N/A	0.00 (N/A)
Median	N/A	N/A	10.00	N/A	N/A	0
IQR: Q1, Q3	N/A	N/A	0.00, 20.00	N/A	N/A	0.00, 0.00
Min, Max	N/A	N/A	0.0, 20.0	N/A	N/A	0.0, 0.0
Week 52						
m	2	0	7			
n	0	0	0	0	0	0
Mean (SD/SE)	N/A	N/A	N/A	N/A	N/A	N/A
Median	N/A	N/A	N/A	N/A	N/A	N/A
IQR: Q1, Q3	N/A	N/A	N/A	N/A	N/A	N/A
Min, Max	N/A	N/A	N/A	N/A	N/A	N/A

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.3.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=7)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=7)
Activity Impairment						
Baseline						
m	3	0	7			
n	2	0	6			
Mean (SD)	0.0 (0.0)	N/A	6.7 (8.2)			
Median	0	N/A	5.0			
IQR: Q1, Q3	0.0, 0.0	N/A	0.0, 10.0			
Min, Max	0, 0	N/A	0, 20			
Week 24						
m	2	0	7			
n	2	0	7	1	0	6
Mean (SD/SE)	0.0 (0.0)	N/A	7.1 (9.5)	0.0 (N/A)	N/A	1.7 (4.8)
Median	0	N/A	0	0	N/A	5.0
IQR: Q1, Q3	0.0, 0.0	N/A	0.0, 20.0	0.0, 0.0	N/A	0.0, 10.0
Min, Max	0, 0	N/A	0, 20	0, 0	N/A	-20, 10
Week 52						
m	2	0	7			
n	2	0	7	1	0	6
Mean (SD/SE)	5.0 (7.1)	N/A	11.4 (16.8)	10.0 (N/A)	N/A	6.7 (6.1)
Median	5.0	N/A	0	10.0	N/A	0
IQR: Q1, Q3	0.0, 10.0	N/A	0.0, 30.0	10.0, 10.0	N/A	0.0, 20.0
Min, Max	0, 10	N/A	0, 40	10, 10	N/A	-10, 30

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.3.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. If the MMRM for LS Means does not converge with unstructured covariance, compound symmetry is used. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

AMNOG Table SE19.3.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Absenteeism			
Week 24			
m	6	12	20
n	2	3	5
Baseline Mean (SD)	0.00 (0.00)	0.00 (0.00)	0.00 (0.00)
Analysis Visit Mean (SD)	0.00 (0.00)	0.00 (0.00)	0.44 (0.98)
LS Mean of Change from Baseline (SE)	-0.04 (0.48)	-0.03 (0.35)	0.36 (0.41)
95% CI	(-1.38, 1.30)	(-1.00, 0.94)	(-0.77, 1.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.40 (0.48)	-0.39 (0.46)	
95% CI	(-1.75, 0.95)	(-1.67, 0.88)	
p-value	0.4552	0.4383	
Corrected Hedge's g Statistics	-0.388	-0.418	
95% CI	(-2.04, 1.26)	(-1.86, 1.03)	
Week 52			
m	6	12	19
n	1	4	5
Baseline Mean (SD)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)
Analysis Visit Mean (SD)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	-0.10 (0.66)	-0.02 (0.31)	-0.08 (0.41)
95% CI	(-1.94, 1.75)	(-0.89, 0.85)	(-1.21, 1.05)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.02 (0.62)	0.06 (0.43)	
95% CI	(-1.75, 1.71)	(-1.13, 1.24)	
p-value	0.9770	0.8967	
Corrected Hedge's g Statistics	-0.017	0.065	
95% CI	(-2.16, 2.13)	(-1.25, 1.38)	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE19.3.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Presenteeism			
Week 24			
m	6	12	20
n	2	3	5
Baseline Mean (SD)	30.0 (42.4)	6.7 (11.5)	2.0 (4.5)
Analysis Visit Mean (SD)	0.0 (0.0)	3.3 (5.8)	4.0 (5.5)
LS Mean of Change from Baseline (SE)	-7.62 (8.40)	-2.58 (4.87)	-0.97 (6.61)
95% CI	(-34.36, 19.11)	(-18.08, 12.92)	(-22.02, 20.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.65 (8.22)	-1.61 (6.48)	
95% CI	(-32.80, 19.49)	(-22.24, 19.01)	
p-value	0.4774	0.8197	
Corrected Hedge's g Statistics	-0.393	-0.108	
95% CI	(-2.05, 1.26)	(-1.54, 1.32)	
Week 52			
m	6	12	19
n	1	4	5
Baseline Mean (SD)	0.0 (N/A)	5.0 (10.0)	2.0 (4.5)
Analysis Visit Mean (SD)	0.0 (N/A)	0.0 (0.0)	8.0 (11.0)
LS Mean of Change from Baseline (SE)	-6.94 (9.46)	-6.01 (4.65)	2.86 (6.93)
95% CI	(-37.06, 23.17)	(-20.79, 8.78)	(-19.18, 24.90)
LS Mean of Change from Baseline Compared to Placebo (SE)	-9.80 (8.46)	-8.87 (6.48)	
95% CI	(-36.73, 17.12)	(-29.48, 11.75)	
p-value	0.3304	0.2645	
Corrected Hedge's g Statistics	-0.506	-0.597	
95% CI	(-2.67, 1.66)	(-1.94, 0.75)	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE19.3.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Overall Work Impairment			
Week 24			
m	6	12	20
n	2	3	5
Baseline Mean (SD)	30.0 (42.4)	6.7 (11.5)	2.0 (4.5)
Analysis Visit Mean (SD)	0.0 (0.0)	3.3 (5.8)	4.4 (6.1)
LS Mean of Change from Baseline (SE)	-8.18 (8.78)	-2.85 (5.04)	-0.96 (6.95)
95% CI	(-36.14, 19.77)	(-18.88, 13.18)	(-23.07, 21.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	-7.22 (8.56)	-1.89 (6.73)	
95% CI	(-34.46, 20.02)	(-23.31, 19.52)	
p-value	0.4607	0.7969	
Corrected Hedge's g Statistics	-0.406	-0.121	
95% CI	(-2.06, 1.25)	(-1.55, 1.31)	
Week 52			
m	6	12	19
n	1	4	5
Baseline Mean (SD)	0.0 (N/A)	5.0 (10.0)	2.0 (4.5)
Analysis Visit Mean (SD)	0.0 (N/A)	0.0 (0.0)	8.0 (11.0)
LS Mean of Change from Baseline (SE)	-8.21 (9.65)	-6.20 (4.85)	2.14 (7.20)
95% CI	(-38.93, 22.51)	(-21.64, 9.23)	(-20.77, 25.04)
LS Mean of Change from Baseline Compared to Placebo (SE)	-10.35 (8.76)	-8.34 (6.73)	
95% CI	(-38.22, 17.53)	(-29.75, 13.06)	
p-value	0.3226	0.3030	
Corrected Hedge's g Statistics	-0.514	-0.540	
95% CI	(-2.68, 1.65)	(-1.88, 0.80)	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE19.3.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Activity Impairment			
Week 24			
m	6	12	20
n	5	5	10
Baseline Mean (SD)	36.0 (46.2)	6.0 (8.9)	23.0 (30.2)
Analysis Visit Mean (SD)	2.0 (4.5)	4.0 (5.5)	8.0 (11.4)
LS Mean of Change from Baseline (SE)	-18.27 (6.98)	-12.09 (6.19)	-10.75 (5.70)
95% CI	(-33.49, -3.06)	(-25.58, 1.40)	(-23.16, 1.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	-7.52 (6.66)	-1.34 (6.95)	
95% CI	(-22.04, 7.00)	(-16.47, 13.80)	
p-value	0.2812	0.8507	
Corrected Hedge's g Statistics	-0.409	-0.075	
95% CI	(-1.49, 0.67)	(-1.15, 1.00)	
Week 52			
m	6	12	19
n	4	6	9
Baseline Mean (SD)	20.0 (33.7)	5.0 (8.4)	23.3 (32.0)
Analysis Visit Mean (SD)	5.0 (10.0)	0.0 (0.0)	30.0 (29.6)
LS Mean of Change from Baseline (SE)	-12.81 (7.45)	-9.65 (5.98)	9.45 (5.88)
95% CI	(-29.03, 3.42)	(-22.67, 3.38)	(-3.35, 22.26)
LS Mean of Change from Baseline Compared to Placebo (SE)	-22.26 (7.19)	-19.10 (6.74)	
95% CI	(-37.92, -6.60)	(-33.78, -4.42)	
p-value	0.0092	0.0151	
Corrected Hedge's g Statistics	-1.223	-1.086	
95% CI	(-2.49, 0.05)	(-2.19, 0.02)	
Subgroup*Treatment Interaction p-value	0.2209	NE	

AMNOG Table SE19.3.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Absenteeism			
Week 24			
m	2	0	7
n	0	0	1
Baseline Mean (SD)	N/A	N/A	0.00 (N/A)
Analysis Visit Mean (SD)	N/A	N/A	0.00 (N/A)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	2	0	7
n	0	0	0
Baseline Mean (SD)	N/A	N/A	N/A
Analysis Visit Mean (SD)	N/A	N/A	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE19.3.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Presenteeism			
Week 24			
m	2	0	7
n	0	0	1
Baseline Mean (SD)	N/A	N/A	0.0 (N/A)
Analysis Visit Mean (SD)	N/A	N/A	0.0 (N/A)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	2	0	7
n	0	0	0
Baseline Mean (SD)	N/A	N/A	N/A
Analysis Visit Mean (SD)	N/A	N/A	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE19.3.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Overall Work Impairment			
Week 24			
m	2	0	7
n	0	0	1
Baseline Mean (SD)	N/A	N/A	0.0 (N/A)
Analysis Visit Mean (SD)	N/A	N/A	0.0 (N/A)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	2	0	7
n	0	0	0
Baseline Mean (SD)	N/A	N/A	N/A
Analysis Visit Mean (SD)	N/A	N/A	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE19.3.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Activity Impairment			
Week 24			
m	2	0	7
n	1	0	6
Baseline Mean (SD)	0.0 (N/A)	N/A	6.7 (8.2)
Analysis Visit Mean (SD)	0.0 (N/A)	N/A	8.3 (9.8)
LS Mean of Change from Baseline (SE)	-8.29 (21.23)	NE	-7.79 (13.23)
95% CI	(-75.84, 59.27)	NE	(-49.89, 34.31)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.50 (23.27)	NE	
95% CI	(-74.56, 73.56)	NE	
p-value	0.9842	NE	
Corrected Hedge's g Statistics	-0.013	NE	
95% CI	(-2.13, 2.10)	NE	
Week 52			
m	2	0	7
n	1	0	6
Baseline Mean (SD)	0.0 (N/A)	N/A	6.7 (8.2)
Analysis Visit Mean (SD)	10.0 (N/A)	N/A	13.3 (17.5)
LS Mean of Change from Baseline (SE)	6.86 (21.23)	NE	-3.64 (13.23)
95% CI	(-60.70, 74.41)	NE	(-45.74, 38.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	10.50 (23.27)	NE	
95% CI	(-63.56, 84.56)	NE	
p-value	0.6825	NE	
Corrected Hedge's g Statistics	0.273	NE	
95% CI	(-1.85, 2.39)	NE	
Subgroup*Treatment Interaction p-value	0.2209	NE	

AMNOG Table SE19.3.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as a decrease of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.

AMNOG Table SE19.3.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	6 (100)	15 (100)	21 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	6 (100)	15 (100)	21 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.3.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (6.7)	0
No	6 (100)	14 (93.3)	21 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.22	
95% CI of the inverse odds ratio	NE	(0.01, 5.91)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.24	
95% CI of the inverse risk ratio	NE	(0.01, 5.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	7.10	
95% CI of the absolute risk difference	NE	(-8.48, 22.68)	
p-value	NE	0.3330	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (6.7)	0
No	6 (100)	14 (93.3)	21 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.22	
95% CI of the inverse odds ratio	NE	(0.01, 5.91)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.24	
95% CI of the inverse risk ratio	NE	(0.01, 5.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	7.10	
95% CI of the absolute risk difference	NE	(-8.48, 22.68)	
p-value	NE	0.3330	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.3.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (6.7)	0
No	6 (100)	14 (93.3)	21 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.22	
95% CI of the inverse odds ratio	NE	(0.01, 5.91)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.24	
95% CI of the inverse risk ratio	NE	(0.01, 5.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	7.10	
95% CI of the absolute risk difference	NE	(-8.48, 22.68)	
p-value	NE	0.3330	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (6.7)	0
No	6 (100)	14 (93.3)	21 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.22	
95% CI of the inverse odds ratio	NE	(0.01, 5.91)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.24	
95% CI of the inverse risk ratio	NE	(0.01, 5.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	7.10	
95% CI of the absolute risk difference	NE	(-8.48, 22.68)	
p-value	NE	0.3330	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.3.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (16.7)	1 (6.7)	1 (4.8)
No	5 (83.3)	14 (93.3)	20 (95.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.25	0.70	
95% CI of the inverse odds ratio	(0.01, 4.73)	(0.04, 12.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.29	0.71	
95% CI of the inverse risk ratio	(0.02, 3.92)	(0.05, 10.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.90	1.90	
95% CI of the absolute risk difference	(-19.28, 43.08)	(-13.66, 17.47)	
p-value	0.3261	0.8057	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (33.3)	2 (13.3)	2 (9.5)
No	4 (66.7)	13 (86.7)	19 (90.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.21	0.68	
95% CI of the inverse odds ratio	(0.02, 1.97)	(0.09, 5.49)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.29	0.71	
95% CI of the inverse risk ratio	(0.05, 1.62)	(0.11, 4.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	23.81	3.81	
95% CI of the absolute risk difference	(-15.94, 63.56)	(-17.49, 25.11)	
p-value	0.1477	0.7199	
p-value of Breslow-Day Test for Homogeneity [3]	0.2320	NE	

AMNOG Table SE19.3.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	3 (100)	0	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	3 (100)	0	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.3.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	3 (100)	0	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	3 (100)	0	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.3.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	3 (100)	0	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	3 (100)	0	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.3.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	3 (100)	0	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	1 (14.3)
No	3 (100)	0	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.62	NE	
95% CI of the inverse odds ratio	(0.05, 51.11)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	NE	
95% CI of the inverse risk ratio	(0.08, 29.15)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.25	NE	
95% CI of the absolute risk difference	(-48.46, 35.96)	NE	
p-value	0.7842	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2320	NE	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE19.4.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=8)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=8)	Change from Baseline DB Placebo (N=14)
Absenteeism						
Baseline						
m	3	8	14			
n	1	5	4			
Mean (SD)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 0.0	0.0, 0.0	0.0, 0.0			
Week 24						
m	3	7	14			
n	1	4	6	1	3	4
Mean (SD/SE)	0.00 (N/A)	2.75 (5.50)	0.00 (0.00)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 5.50	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 0.0	0.0, 11.0	0.0, 0.0	0.0, 0.0	0.0, 0.0	0.0, 0.0
Week 52						
m	3	7	14			
n	2	4	6	1	4	3
Mean (SD/SE)	0.00 (0.00)	0.00 (0.00)	10.17 (20.00)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 11.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 0.0	0.0, 0.0	0.0, 50.0	0.0, 0.0	0.0, 0.0	0.0, 0.0

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.4.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=3)	(N=8)	(N=14)	(N=3)	(N=8)	(N=14)
Presenteeism						
Baseline						
m	3	8	14			
n	1	5	4			
Mean (SD)	0.0 (N/A)	4.0 (8.9)	0.0 (0.0)			
Median	0	0	0			
IQR: Q1, Q3	0.0, 0.0	0.0, 0.0	0.0, 0.0			
Min, Max	0, 0	0, 20	0, 0			
Week 24						
m	3	7	14			
n	1	4	6	1	3	4
Mean (SD/SE)	0.0 (N/A)	2.5 (5.0)	3.3 (5.2)	0.0 (N/A)	-3.3 (3.3)	2.5 (2.5)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 5.0	0.0, 10.0	0.0, 0.0	-10.0, 0.0	0.0, 5.0
Min, Max	0, 0	0, 10	0, 10	0, 0	-10, 0	0, 10
Week 52						
m	3	7	14			
n	2	4	6	1	4	3
Mean (SD/SE)	0.0 (0.0)	0.0 (0.0)	21.7 (28.6)	0.0 (N/A)	-5.0 (5.0)	6.7 (6.7)
Median	0	0	10.0	0	0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 0.0	0.0, 40.0	0.0, 0.0	-10.0, 0.0	0.0, 20.0
Min, Max	0, 0	0, 0	0, 70	0, 0	-20, 0	0, 20

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.4.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Visit Statistic	Visit Result DB MGL-3196 80 mg (N=3)	 DB MGL-3196 100 mg (N=8)	 DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=3)	 DB MGL-3196 100 mg (N=8)	 DB Placebo (N=14)
Overall Work Impairment						
Baseline						
m	3	8	14			
n	1	5	4			
Mean (SD)	0.00 (N/A)	4.00 (8.94)	0.00 (0.00)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 0.0	0.0, 20.0	0.0, 0.0			
Week 24						
m	3	7	14			
n	1	4	6	1	3	4
Mean (SD/SE)	0.00 (N/A)	5.25 (6.08)	3.33 (5.16)	0.00 (N/A)	-3.33 (3.33)	2.50 (2.50)
Median	0	5.00	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 10.50	0.00, 10.00	0.00, 0.00	-10.00, 0.00	0.00, 5.00
Min, Max	0.0, 0.0	0.0, 11.0	0.0, 10.0	0.0, 0.0	-10.0, 0.0	0.0, 10.0
Week 52						
m	3	7	14			
n	2	4	6	1	4	3
Mean (SD/SE)	0.00 (0.00)	0.00 (0.00)	25.27 (34.54)	0.00 (N/A)	-5.00 (5.00)	6.67 (6.67)
Median	0	0	10.00	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 46.60	0.00, 0.00	-10.00, 0.00	0.00, 20.00
Min, Max	0.0, 0.0	0.0, 0.0	0.0, 85.0	0.0, 0.0	-20.0, 0.0	0.0, 20.0

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc. Page 4 of 8
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE19.4.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=8)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=8)	Change from Baseline DB Placebo (N=14)
Activity Impairment						
Baseline						
m	3	8	14			
n	1	6	9			
Mean (SD)	0.0 (N/A)	5.0 (8.4)	13.3 (29.6)			
Median	0	0	0			
IQR: Q1, Q3	0.0, 0.0	0.0, 10.0	0.0, 10.0			
Min, Max	0, 0	0, 20	0, 90			
Week 24						
m	3	7	14			
n	2	6	13	1	4	9
Mean (SD/SE)	0.0 (0.0)	6.7 (8.2)	13.1 (19.7)	0.0 (N/A)	-2.5 (2.5)	-6.7 (8.5)
Median	0	5.0	10.0	0	0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 10.0	0.0, 20.0	0.0, 0.0	-5.0, 0.0	0.0, 10.0
Min, Max	0, 0	0, 20	0, 70	0, 0	-10, 0	-70, 10
Week 52						
m	3	7	14			
n	3	6	13	1	5	9
Mean (SD/SE)	0.0 (0.0)	3.3 (8.2)	14.6 (21.8)	0.0 (N/A)	-6.0 (4.0)	0.0 (3.7)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 0.0	0.0, 30.0	0.0, 0.0	-10.0, 0.0	0.0, 0.0
Min, Max	0, 0	0, 20	0, 70	0, 0	-20, 0	-20, 20

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.4.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=6)	(N=7)	(N=14)	(N=6)	(N=7)	(N=14)
Absenteeism						
Baseline						
m	6	7	14			
n	1	0	2			
Mean (SD)	0.00 (N/A)	N/A	0.00 (0.00)			
Median	0	N/A	0			
IQR: Q1, Q3	0.00, 0.00	N/A	0.00, 0.00			
Min, Max	0.0, 0.0	N/A	0.0, 0.0			
Week 24						
m	5	5	13			
n	1	2	6	1	0	2
Mean (SD/SE)	0.00 (N/A)	0.00 (0.00)	0.37 (0.90)	0.00 (N/A)	N/A	1.10 (1.10)
Median	0	0	0	0	N/A	1.10
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	N/A	0.00, 2.20
Min, Max	0.0, 0.0	0.0, 0.0	0.0, 2.2	0.0, 0.0	N/A	0.0, 2.2
Week 52						
m	5	5	12			
n	0	3	5	0	0	2
Mean (SD/SE)	N/A	16.67 (28.87)	0.00 (0.00)	N/A	N/A	0.00 (0.00)
Median	N/A	0	0	N/A	N/A	0
IQR: Q1, Q3	N/A	0.00, 50.00	0.00, 0.00	N/A	N/A	0.00, 0.00
Min, Max	N/A	0.0, 50.0	0.0, 0.0	N/A	N/A	0.0, 0.0

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.4.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=6)	(N=7)	(N=14)	(N=6)	(N=7)	(N=14)
Presenteeism						
Baseline						
m	6	7	14			
n	1	0	2			
Mean (SD)	60.0 (N/A)	N/A	5.0 (7.1)			
Median	60.0	N/A	5.0			
IQR: Q1, Q3	60.0, 60.0	N/A	0.0, 10.0			
Min, Max	60, 60	N/A	0, 10			
Week 24						
m	5	5	13			
n	1	2	6	1	0	2
Mean (SD/SE)	0.0 (N/A)	40.0 (42.4)	5.0 (8.4)	-60.0 (N/A)	N/A	0.0 (0.0)
Median	0	40.0	0	-60.0	N/A	0
IQR: Q1, Q3	0.0, 0.0	10.0, 70.0	0.0, 10.0	-60.0, -60.0	N/A	0.0, 0.0
Min, Max	0, 0	10, 70	0, 20	-60, -60	N/A	0, 0
Week 52						
m	5	5	12			
n	0	3	5	0	0	2
Mean (SD/SE)	N/A	23.3 (25.2)	4.0 (8.9)	N/A	N/A	5.0 (5.0)
Median	N/A	20.0	0	N/A	N/A	5.0
IQR: Q1, Q3	N/A	0.0, 50.0	0.0, 0.0	N/A	N/A	0.0, 10.0
Min, Max	N/A	0, 50	0, 20	N/A	N/A	0, 10

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.4.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Visit Statistic	Visit Result DB MGL-3196 80 mg (N=6)	 DB MGL-3196 100 mg (N=7)	 DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=6)	 DB MGL-3196 100 mg (N=7)	 DB Placebo (N=14)
Overall Work Impairment						
Baseline						
m	6	7	14			
n	1	0	2			
Mean (SD)	60.00 (N/A)	N/A	5.00 (7.07)			
Median	60.00	N/A	5.00			
IQR: Q1, Q3	60.00, 60.00	N/A	0.00, 10.00			
Min, Max	60.0, 60.0	N/A	0.0, 10.0			
Week 24						
m	5	5	13			
n	1	2	6	1	0	2
Mean (SD/SE)	0.00 (N/A)	40.00 (42.43)	5.33 (8.64)	-60.00 (N/A)	N/A	1.00 (1.00)
Median	0	40.00	0	-60.00	N/A	1.00
IQR: Q1, Q3	0.00, 0.00	10.00, 70.00	0.00, 12.00	-60.00, -60.00	N/A	0.00, 2.00
Min, Max	0.0, 0.0	10.0, 70.0	0.0, 20.0	-60.0, -60.0	N/A	0.0, 2.0
Week 52						
m	5	5	12			
n	0	3	5	0	0	2
Mean (SD/SE)	N/A	31.67 (38.84)	4.00 (8.94)	N/A	N/A	5.00 (5.00)
Median	N/A	20.00	0	N/A	N/A	5.00
IQR: Q1, Q3	N/A	0.00, 75.00	0.00, 0.00	N/A	N/A	0.00, 10.00
Min, Max	N/A	0.0, 75.0	0.0, 20.0	N/A	N/A	0.0, 10.0

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc. Page 8 of 8
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE19.4.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=7)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=7)	Change from Baseline DB Placebo (N=14)
Activity Impairment						
Baseline						
m	6	7	14			
n	6	1	7			
Mean (SD)	30.0 (43.8)	0.0 (N/A)	21.4 (19.5)			
Median	5.0	0	20.0			
IQR: Q1, Q3	0.0, 70.0	0.0, 0.0	10.0, 30.0			
Min, Max	0, 100	0, 0	0, 60			
Week 24						
m	5	5	13			
n	5	4	13	5	1	7
Mean (SD/SE)	2.0 (4.5)	25.0 (31.1)	11.5 (20.3)	-34.0 (19.1)	0.0 (N/A)	-11.4 (8.8)
Median	0	15.0	0	-10.0	0	0
IQR: Q1, Q3	0.0, 0.0	5.0, 45.0	0.0, 20.0	-70.0, 0.0	0.0, 0.0	-20.0, 0.0
Min, Max	0, 10	0, 70	0, 70	-90, 0	0, 0	-60, 10
Week 52						
m	5	5	12			
n	4	4	11	4	1	6
Mean (SD/SE)	7.5 (9.6)	12.5 (25.0)	22.7 (24.9)	-12.5 (13.1)	0.0 (N/A)	16.7 (9.2)
Median	5.0	0	10.0	-5.0	0	15.0
IQR: Q1, Q3	0.0, 15.0	0.0, 25.0	0.0, 50.0	-30.0, 5.0	0.0, 0.0	0.0, 40.0
Min, Max	0, 20	0, 50	0, 60	-50, 10	0, 0	-10, 40

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.4.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. If the MMRM for LS Means does not converge with unstructured covariance, compound symmetry is used. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

AMNOG Table SE19.4.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Absenteeism			
Week 24			
m	3	7	14
n	1	3	4
Baseline Mean (SD)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)
Analysis Visit Mean (SD)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	3	7	14
n	1	4	3
Baseline Mean (SD)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)
Analysis Visit Mean (SD)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.7279	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE19.4.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Presenteeism			
Week 24			
m	3	7	14
n	1	3	4
Baseline Mean (SD)	0.0 (N/A)	6.7 (11.5)	0.0 (0.0)
Analysis Visit Mean (SD)	0.0 (N/A)	3.3 (5.8)	2.5 (5.0)
LS Mean of Change from Baseline (SE)	9.16 (8.69)	-0.09 (3.45)	7.03 (5.48)
95% CI	(-101.27, 119.58)	(-43.90, 43.71)	(-62.61, 76.67)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.12 (6.66)	-7.12 (5.78)	
95% CI	(-82.45, 86.70)	(-80.53, 66.28)	
p-value	0.8033	0.4337	
Corrected Hedge's g Statistics	0.141	-0.646	
95% CI	(-2.05, 2.33)	(-2.18, 0.89)	
Week 52			
m	3	7	14
n	1	4	3
Baseline Mean (SD)	0.0 (N/A)	5.0 (10.0)	0.0 (0.0)
Analysis Visit Mean (SD)	0.0 (N/A)	0.0 (0.0)	6.7 (11.5)
LS Mean of Change from Baseline (SE)	7.91 (8.67)	-1.34 (3.20)	10.03 (5.78)
95% CI	(-102.24, 118.05)	(-42.05, 39.36)	(-63.43, 83.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.12 (6.66)	-11.37 (5.64)	
95% CI	(-86.70, 82.45)	(-83.00, 60.25)	
p-value	0.8033	0.2929	
Corrected Hedge's g Statistics	-0.121	-1.190	
95% CI	(-2.39, 2.14)	(-2.81, 0.43)	
Subgroup*Treatment Interaction p-value	0.2509	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE19.4.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Overall Work Impairment			
Week 24			
m	3	7	14
n	1	3	4
Baseline Mean (SD)	0.0 (N/A)	6.7 (11.5)	0.0 (0.0)
Analysis Visit Mean (SD)	0.0 (N/A)	3.3 (5.8)	2.5 (5.0)
LS Mean of Change from Baseline (SE)	9.16 (8.69)	-0.09 (3.45)	7.03 (5.48)
95% CI	(-101.27, 119.58)	(-43.90, 43.71)	(-62.61, 76.67)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.12 (6.66)	-7.12 (5.78)	
95% CI	(-82.45, 86.70)	(-80.53, 66.28)	
p-value	0.8033	0.4337	
Corrected Hedge's g Statistics	0.141	-0.646	
95% CI	(-2.05, 2.33)	(-2.18, 0.89)	
Week 52			
m	3	7	14
n	1	4	3
Baseline Mean (SD)	0.0 (N/A)	5.0 (10.0)	0.0 (0.0)
Analysis Visit Mean (SD)	0.0 (N/A)	0.0 (0.0)	6.7 (11.5)
LS Mean of Change from Baseline (SE)	7.91 (8.67)	-1.34 (3.20)	10.03 (5.78)
95% CI	(-102.24, 118.05)	(-42.05, 39.36)	(-63.43, 83.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.12 (6.66)	-11.37 (5.64)	
95% CI	(-86.70, 82.45)	(-83.00, 60.25)	
p-value	0.8033	0.2929	
Corrected Hedge's g Statistics	-0.121	-1.190	
95% CI	(-2.39, 2.14)	(-2.81, 0.43)	
Subgroup*Treatment Interaction p-value	0.1999	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE19.4.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Activity Impairment			
Week 24			
m	3	7	14
n	1	4	9
Baseline Mean (SD)	0.0 (N/A)	7.5 (9.6)	13.3 (29.6)
Analysis Visit Mean (SD)	0.0 (N/A)	5.0 (5.8)	6.7 (8.7)
LS Mean of Change from Baseline (SE)	-8.48 (9.29)	-4.38 (4.39)	-4.47 (3.98)
95% CI	(-29.91, 12.95)	(-14.50, 5.74)	(-13.64, 4.70)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.01 (8.63)	0.09 (4.72)	
95% CI	(-23.92, 15.90)	(-10.80, 10.97)	
p-value	0.6547	0.9857	
Corrected Hedge's g Statistics	-0.304	0.007	
95% CI	(-2.37, 1.77)	(-1.17, 1.19)	
Week 52			
m	3	7	14
n	1	5	9
Baseline Mean (SD)	0.0 (N/A)	6.0 (8.9)	13.3 (29.6)
Analysis Visit Mean (SD)	0.0 (N/A)	0.0 (0.0)	13.3 (23.5)
LS Mean of Change from Baseline (SE)	-3.01 (9.29)	-7.61 (4.15)	0.62 (3.98)
95% CI	(-24.45, 18.42)	(-17.19, 1.97)	(-8.55, 9.79)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.64 (8.64)	-8.23 (4.55)	
95% CI	(-23.55, 16.28)	(-18.73, 2.26)	
p-value	0.6849	0.1082	
Corrected Hedge's g Statistics	-0.275	-0.693	
95% CI	(-2.34, 1.79)	(-1.82, 0.43)	
Subgroup*Treatment Interaction p-value	0.2337	0.3367	

AMNOG Table SE19.4.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Absenteeism			
Week 24			
m	5	5	13
n	1	0	2
Baseline Mean (SD)	0.00 (N/A)	N/A	0.00 (0.00)
Analysis Visit Mean (SD)	0.00 (N/A)	N/A	1.10 (1.56)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	5	12
n	0	0	2
Baseline Mean (SD)	N/A	N/A	0.00 (0.00)
Analysis Visit Mean (SD)	N/A	N/A	0.00 (0.00)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.7279	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE19.4.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Presenteeism			
Week 24			
m	5	5	13
n	1	0	2
Baseline Mean (SD)	60.0 (N/A)	N/A	5.0 (7.1)
Analysis Visit Mean (SD)	0.0 (N/A)	N/A	5.0 (7.1)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	5	12
n	0	0	2
Baseline Mean (SD)	N/A	N/A	5.0 (7.1)
Analysis Visit Mean (SD)	N/A	N/A	10.0 (14.1)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.2509	NE	

AMNOG Table SE19.4.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Overall Work Impairment			
Week 24			
m	5	5	13
n	1	0	2
Baseline Mean (SD)	60.0 (N/A)	N/A	5.0 (7.1)
Analysis Visit Mean (SD)	0.0 (N/A)	N/A	6.0 (8.5)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	5	12
n	0	0	2
Baseline Mean (SD)	N/A	N/A	5.0 (7.1)
Analysis Visit Mean (SD)	N/A	N/A	10.0 (14.1)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.1999	NE	

AMNOG Table SE19.4.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Activity Impairment			
Week 24			
m	5	5	13
n	5	1	7
Baseline Mean (SD)	36.0 (46.2)	0.0 (N/A)	21.4 (19.5)
Analysis Visit Mean (SD)	2.0 (4.5)	0.0 (N/A)	10.0 (12.9)
LS Mean of Change from Baseline (SE)	-18.42 (7.74)	-14.64 (17.10)	-7.80 (8.22)
95% CI	(-38.31, 1.46)	(-58.58, 29.30)	(-28.92, 13.33)
LS Mean of Change from Baseline Compared to Placebo (SE)	-10.63 (9.47)	-6.84 (16.50)	
95% CI	(-34.97, 13.72)	(-49.26, 35.57)	
p-value	0.3127	0.6955	
Corrected Hedge's g Statistics	-0.489	-0.274	
95% CI	(-1.65, 0.68)	(-2.37, 1.83)	
Week 52			
m	5	5	12
n	4	1	6
Baseline Mean (SD)	20.0 (33.7)	0.0 (N/A)	21.7 (21.4)
Analysis Visit Mean (SD)	7.5 (9.6)	0.0 (N/A)	38.3 (24.0)
LS Mean of Change from Baseline (SE)	-11.02 (8.36)	-7.41 (17.53)	20.89 (8.68)
95% CI	(-32.51, 10.46)	(-52.48, 37.66)	(-1.43, 43.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	-31.91 (10.05)	-28.30 (16.90)	
95% CI	(-57.76, -6.07)	(-71.75, 15.15)	
p-value	0.0247	0.1550	
Corrected Hedge's g Statistics	-1.464	-1.121	
95% CI	(-2.88, -0.05)	(-3.32, 1.08)	
Subgroup*Treatment Interaction p-value	0.2337	0.3367	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE19.4.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as a decrease of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.

AMNOG Table SE19.4.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	3 (100)	8 (100)	14 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	3 (100)	8 (100)	14 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.4.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (12.5)	0
No	3 (100)	7 (87.5)	14 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.17	
95% CI of the inverse odds ratio	NE	(0.01, 4.77)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.20	
95% CI of the inverse risk ratio	NE	(0.01, 4.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	13.33	
95% CI of the absolute risk difference	NE	(-12.65, 39.32)	
p-value	NE	0.2526	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (12.5)	0
No	3 (100)	7 (87.5)	14 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.17	
95% CI of the inverse odds ratio	NE	(0.01, 4.77)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.20	
95% CI of the inverse risk ratio	NE	(0.01, 4.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	13.33	
95% CI of the absolute risk difference	NE	(-12.65, 39.32)	
p-value	NE	0.2526	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.4.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (12.5)	0
No	3 (100)	7 (87.5)	14 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.17	
95% CI of the inverse odds ratio	NE	(0.01, 4.77)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.20	
95% CI of the inverse risk ratio	NE	(0.01, 4.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	13.33	
95% CI of the absolute risk difference	NE	(-12.65, 39.32)	
p-value	NE	0.2526	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (12.5)	0
No	3 (100)	7 (87.5)	14 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.17	
95% CI of the inverse odds ratio	NE	(0.01, 4.77)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.20	
95% CI of the inverse risk ratio	NE	(0.01, 4.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	13.33	
95% CI of the absolute risk difference	NE	(-12.65, 39.32)	
p-value	NE	0.2526	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.4.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (12.5)	1 (7.1)
No	3 (100)	7 (87.5)	13 (92.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	0.54	
95% CI of the inverse odds ratio	(0.03, 23.53)	(0.03, 9.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	0.57	
95% CI of the inverse risk ratio	(0.04, 16.14)	(0.04, 7.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.50	5.36	
95% CI of the absolute risk difference	(-33.29, 38.29)	(-21.24, 31.95)	
p-value	0.8849	0.6742	
p-value of Breslow-Day Test for Homogeneity [3]	0.2175	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (25.0)	2 (14.3)
No	3 (100)	6 (75.0)	12 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	0.50	
95% CI of the inverse odds ratio	(0.05, 36.45)	(0.06, 4.47)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	0.57	
95% CI of the inverse risk ratio	(0.08, 22.57)	(0.10, 3.31)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.17	10.71	
95% CI of the absolute risk difference	(-41.66, 33.33)	(-24.45, 45.88)	
p-value	0.8391	0.5308	
p-value of Breslow-Day Test for Homogeneity [3]	0.1961	0.3621	

AMNOG Table SE19.4.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	6 (100)	7 (100)	14 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	6 (100)	7 (100)	14 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.4.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	6 (100)	7 (100)	14 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	6 (100)	7 (100)	14 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.4.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	6 (100)	7 (100)	14 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	6 (100)	7 (100)	14 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.4.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (16.7)	0	0
No	5 (83.3)	7 (100)	14 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.13	NE	
95% CI of the inverse odds ratio	(0.00, 3.60)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.16	NE	
95% CI of the inverse risk ratio	(0.01, 3.36)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	18.10	NE	
95% CI of the absolute risk difference	(-13.63, 49.82)	NE	
p-value	0.1691	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2175	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (33.3)	0	1 (7.1)
No	4 (66.7)	7 (100)	13 (92.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.15	1.67	
95% CI of the inverse odds ratio	(0.01, 2.18)	(0.06, 46.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.21	1.60	
95% CI of the inverse risk ratio	(0.02, 1.94)	(0.07, 34.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	26.19	-3.75	
95% CI of the absolute risk difference	(-13.87, 66.25)	(-26.37, 18.87)	
p-value	0.1328	0.7611	
p-value of Breslow-Day Test for Homogeneity [3]	0.1961	0.3621	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE19.5.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Visit Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=6)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=6)	Change from Baseline DB Placebo (N=11)
Absenteeism						
Baseline						
m	4	6	11			
n	2	3	2			
Mean (SD)	0.00 (0.00)	0.00 (0.00)	0.00 (0.00)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 0.0	0.0, 0.0	0.0, 0.0			
Week 24						
m	3	4	11			
n	2	3	3	2	1	2
Mean (SD/SE)	0.00 (0.00)	3.67 (6.35)	0.00 (0.00)	0.00 (0.00)	0.00 (N/A)	0.00 (0.00)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 11.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 0.0	0.0, 11.0	0.0, 0.0	0.0, 0.0	0.0, 0.0	0.0, 0.0
Week 52						
m	3	4	11			
n	1	3	4	1	2	1
Mean (SD/SE)	0.00 (N/A)	0.00 (0.00)	12.50 (25.00)	0.00 (N/A)	0.00 (0.00)	0.00 (N/A)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 25.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 0.0	0.0, 0.0	0.0, 50.0	0.0, 0.0	0.0, 0.0	0.0, 0.0

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.5.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=6)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=6)	Change from Baseline DB Placebo (N=11)
Presenteeism						
Baseline						
m	4	6	11			
n	2	3	2			
Mean (SD)	30.0 (42.4)	0.0 (0.0)	0.0 (0.0)			
Median	30.0	0	0			
IQR: Q1, Q3	0.0, 60.0	0.0, 0.0	0.0, 0.0			
Min, Max	0, 60	0, 0	0, 0			
Week 24						
m	3	4	11			
n	2	3	3	2	1	2
Mean (SD/SE)	0.0 (0.0)	3.3 (5.8)	0.0 (0.0)	-30.0 (30.0)	0.0 (N/A)	0.0 (0.0)
Median	0	0	0	-30.0	0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 10.0	0.0, 0.0	-60.0, 0.0	0.0, 0.0	0.0, 0.0
Min, Max	0, 0	0, 10	0, 0	-60, 0	0, 0	0, 0
Week 52						
m	3	4	11			
n	1	3	4	1	2	1
Mean (SD/SE)	0.0 (N/A)	6.7 (11.5)	17.5 (35.0)	0.0 (N/A)	0.0 (0.0)	0.0 (N/A)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 20.0	0.0, 35.0	0.0, 0.0	0.0, 0.0	0.0, 0.0
Min, Max	0, 0	0, 20	0, 70	0, 0	0, 0	0, 0

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.5.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=4)	(N=6)	(N=11)	(N=4)	(N=6)	(N=11)
Overall Work Impairment						
Baseline						
m	4	6	11			
n	2	3	2			
Mean (SD)	30.00 (42.43)	0.00 (0.00)	0.00 (0.00)			
Median	30.00	0	0			
IQR: Q1, Q3	0.00, 60.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 60.0	0.0, 0.0	0.0, 0.0			
Week 24						
m	3	4	11			
n	2	3	3	2	1	2
Mean (SD/SE)	0.00 (0.00)	7.00 (6.08)	0.00 (0.00)	-30.00 (30.00)	0.00 (N/A)	0.00 (0.00)
Median	0	10.00	0	-30.00	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 11.00	0.00, 0.00	-60.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 0.0	0.0, 11.0	0.0, 0.0	-60.0, 0.0	0.0, 0.0	0.0, 0.0
Week 52						
m	3	4	11			
n	1	3	4	1	2	1
Mean (SD/SE)	0.00 (N/A)	6.67 (11.55)	21.25 (42.50)	0.00 (N/A)	0.00 (0.00)	0.00 (N/A)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 20.00	0.00, 42.50	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 0.0	0.0, 20.0	0.0, 85.0	0.0, 0.0	0.0, 0.0	0.0, 0.0

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.5.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=6)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=6)	Change from Baseline DB Placebo (N=11)
Activity Impairment						
Baseline						
m	4	6	11			
n	4	3	6			
Mean (SD)	42.5 (50.6)	0.0 (0.0)	23.3 (33.9)			
Median	35.0	0	15.0			
IQR: Q1, Q3	0.0, 85.0	0.0, 0.0	0.0, 20.0			
Min, Max	0, 100	0, 0	0, 90			
Week 24						
m	3	4	11			
n	3	3	10	3	1	6
Mean (SD/SE)	3.3 (5.8)	3.3 (5.8)	12.0 (22.0)	-53.3 (27.3)	0.0 (N/A)	-16.7 (11.2)
Median	0	0	0	-70.0	0	-5.0
IQR: Q1, Q3	0.0, 10.0	0.0, 10.0	0.0, 20.0	-90.0, 0.0	0.0, 0.0	-20.0, 0.0
Min, Max	0, 10	0, 10	0, 70	-90, 0	0, 0	-70, 0
Week 52						
m	3	4	11			
n	2	3	9	2	2	5
Mean (SD/SE)	10.0 (14.1)	0.0 (0.0)	25.6 (29.2)	-25.0 (25.0)	0.0 (0.0)	12.0 (12.0)
Median	10.0	0	10.0	-25.0	0	0
IQR: Q1, Q3	0.0, 20.0	0.0, 0.0	0.0, 50.0	-50.0, 0.0	0.0, 0.0	0.0, 40.0
Min, Max	0, 20	0, 0	0, 70	-50, 0	0, 0	-20, 40

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.5.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=5)	(N=9)	(N=17)	(N=5)	(N=9)	(N=17)
Absenteeism						
Baseline						
m	5	9	17			
n	0	2	4			
Mean (SD)	N/A	0.00 (0.00)	0.00 (0.00)			
Median	N/A	0	0			
IQR: Q1, Q3	N/A	0.00, 0.00	0.00, 0.00			
Min, Max	N/A	0.0, 0.0	0.0, 0.0			
Week 24						
m	5	8	16			
n	0	3	9	0	2	4
Mean (SD/SE)	N/A	0.00 (0.00)	0.24 (0.73)	N/A	0.00 (0.00)	0.55 (0.55)
Median	N/A	0	0	N/A	0	0
IQR: Q1, Q3	N/A	0.00, 0.00	0.00, 0.00	N/A	0.00, 0.00	0.00, 1.10
Min, Max	N/A	0.0, 0.0	0.0, 2.2	N/A	0.0, 0.0	0.0, 2.2
Week 52						
m	5	8	15			
n	1	4	7	0	2	4
Mean (SD/SE)	0.00 (N/A)	12.50 (25.00)	1.57 (4.16)	N/A	0.00 (0.00)	0.00 (0.00)
Median	0	0	0	N/A	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 25.00	0.00, 0.00	N/A	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 0.0	0.0, 50.0	0.0, 11.0	N/A	0.0, 0.0	0.0, 0.0

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.5.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=5)	(N=9)	(N=17)	(N=5)	(N=9)	(N=17)
Presenteeism						
Baseline						
m	5	9	17			
n	0	2	4			
Mean (SD)	N/A	10.0 (14.1)	2.5 (5.0)			
Median	N/A	10.0	0			
IQR: Q1, Q3	N/A	0.0, 20.0	0.0, 5.0			
Min, Max	N/A	0, 20	0, 10			
Week 24						
m	5	8	16			
n	0	3	9	0	2	4
Mean (SD/SE)	N/A	26.7 (37.9)	5.6 (7.3)	N/A	-5.0 (5.0)	2.5 (2.5)
Median	N/A	10.0	0	N/A	-5.0	0
IQR: Q1, Q3	N/A	0.0, 70.0	0.0, 10.0	N/A	-10.0, 0.0	0.0, 5.0
Min, Max	N/A	0, 70	0, 20	N/A	-10, 0	0, 10
Week 52						
m	5	8	15			
n	1	4	7	0	2	4
Mean (SD/SE)	0.0 (N/A)	12.5 (25.0)	11.4 (15.7)	N/A	-10.0 (10.0)	7.5 (4.8)
Median	0	0	0	N/A	-10.0	5.0
IQR: Q1, Q3	0.0, 0.0	0.0, 25.0	0.0, 20.0	N/A	-20.0, 0.0	0.0, 15.0
Min, Max	0, 0	0, 50	0, 40	N/A	-20, 0	0, 20

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.5.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=5)	(N=9)	(N=17)	(N=5)	(N=9)	(N=17)
Overall Work Impairment						
Baseline						
m	5	9	17			
n	0	2	4			
Mean (SD)	N/A	10.00 (14.14)	2.50 (5.00)			
Median	N/A	10.00	0			
IQR: Q1, Q3	N/A	0.00, 20.00	0.00, 5.00			
Min, Max	N/A	0.0, 20.0	0.0, 10.0			
Week 24						
m	5	8	16			
n	0	3	9	0	2	4
Mean (SD/SE)	N/A	26.67 (37.86)	5.78 (7.45)	N/A	-5.00 (5.00)	3.00 (2.38)
Median	N/A	10.00	0	N/A	-5.00	1.00
IQR: Q1, Q3	N/A	0.00, 70.00	0.00, 10.00	N/A	-10.00, 0.00	0.00, 6.00
Min, Max	N/A	0.0, 70.0	0.0, 20.0	N/A	-10.0, 0.0	0.0, 10.0
Week 52						
m	5	8	15			
n	1	4	7	0	2	4
Mean (SD/SE)	0.00 (N/A)	18.75 (37.50)	12.37 (17.80)	N/A	-10.00 (10.00)	7.50 (4.79)
Median	0	0	0	N/A	-10.00	5.00
IQR: Q1, Q3	0.00, 0.00	0.00, 37.50	0.00, 20.00	N/A	-20.00, 0.00	0.00, 15.00
Min, Max	0.0, 0.0	0.0, 75.0	0.0, 46.6	N/A	-20.0, 0.0	0.0, 20.0

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.5.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=5)	(N=9)	(N=17)	(N=5)	(N=9)	(N=17)
Activity Impairment						
Baseline						
m	5	9	17			
n	3	4	10			
Mean (SD)	3.3 (5.8)	7.5 (9.6)	13.0 (19.5)			
Median	0	5.0	5.0			
IQR: Q1, Q3	0.0, 10.0	0.0, 15.0	0.0, 20.0			
Min, Max	0, 10	0, 20	0, 60			
Week 24						
m	5	8	16			
n	4	7	16	3	4	10
Mean (SD/SE)	0.0 (0.0)	18.6 (24.1)	12.5 (18.8)	-3.3 (3.3)	-2.5 (2.5)	-4.0 (6.9)
Median	0	10.0	5.0	0	0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 20.0	0.0, 20.0	-10.0, 0.0	-5.0, 0.0	0.0, 10.0
Min, Max	0, 0	0, 70	0, 70	-10, 0	-10, 0	-60, 10
Week 52						
m	5	8	15			
n	5	7	15	3	4	10
Mean (SD/SE)	2.0 (4.5)	10.0 (19.1)	14.0 (18.4)	0.0 (5.8)	-7.5 (4.8)	4.0 (4.0)
Median	0	0	10.0	0	-5.0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 20.0	0.0, 30.0	-10.0, 10.0	-15.0, 0.0	0.0, 10.0
Min, Max	0, 10	0, 50	0, 60	-10, 10	-20, 0	-10, 30

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.5.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. If the MMRM for LS Means does not converge with unstructured covariance, compound symmetry is used. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

AMNOG Table SE19.5.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Absenteeism			
Week 24			
m	3	4	11
n	2	1	2
Baseline Mean (SD)	0.00 (0.00)	0.00 (N/A)	0.00 (0.00)
Analysis Visit Mean (SD)	0.00 (0.00)	0.00 (N/A)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	3	4	11
n	1	2	1
Baseline Mean (SD)	0.00 (N/A)	0.00 (0.00)	0.00 (N/A)
Analysis Visit Mean (SD)	0.00 (N/A)	0.00 (0.00)	0.00 (N/A)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	0.4947	

AMNOG Table SE19.5.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Presenteeism			
Week 24			
m	3	4	11
n	2	1	2
Baseline Mean (SD)	30.0 (42.4)	0.0 (N/A)	0.0 (0.0)
Analysis Visit Mean (SD)	0.0 (0.0)	0.0 (N/A)	0.0 (0.0)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	3	4	11
n	1	2	1
Baseline Mean (SD)	0.0 (N/A)	0.0 (0.0)	0.0 (N/A)
Analysis Visit Mean (SD)	0.0 (N/A)	0.0 (0.0)	0.0 (N/A)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	0.1511	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE19.5.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Overall Work Impairment			
Week 24			
m	3	4	11
n	2	1	2
Baseline Mean (SD)	30.0 (42.4)	0.0 (N/A)	0.0 (0.0)
Analysis Visit Mean (SD)	0.0 (0.0)	0.0 (N/A)	0.0 (0.0)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	3	4	11
n	1	2	1
Baseline Mean (SD)	0.0 (N/A)	0.0 (0.0)	0.0 (N/A)
Analysis Visit Mean (SD)	0.0 (N/A)	0.0 (0.0)	0.0 (N/A)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	0.1215	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE19.5.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Activity Impairment			
Week 24			
m	3	4	11
n	3	1	6
Baseline Mean (SD)	56.7 (51.3)	0.0 (N/A)	23.3 (33.9)
Analysis Visit Mean (SD)	3.3 (5.8)	0.0 (N/A)	6.7 (10.3)
LS Mean of Change from Baseline (SE)	-27.41 (10.76)	-23.01 (17.61)	-19.19 (6.74)
95% CI	(-73.69, 18.87)	(-98.80, 52.77)	(-48.17, 9.79)
LS Mean of Change from Baseline Compared to Placebo (SE)	-8.22 (12.87)	-3.82 (18.75)	
95% CI	(-63.58, 47.14)	(-84.51, 76.86)	
p-value	0.5884	0.8573	
Corrected Hedge's g Statistics	-0.426	-0.195	
95% CI	(-1.83, 0.97)	(-2.31, 1.92)	
Week 52			
m	3	4	11
n	2	2	5
Baseline Mean (SD)	35.0 (49.5)	0.0 (0.0)	24.0 (37.8)
Analysis Visit Mean (SD)	10.0 (14.1)	0.0 (0.0)	36.0 (33.6)
LS Mean of Change from Baseline (SE)	-20.30 (12.47)	-12.79 (13.09)	11.21 (7.44)
95% CI	(-73.93, 33.34)	(-69.10, 43.51)	(-20.80, 43.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	-31.50 (14.27)	-24.00 (15.15)	
95% CI	(-92.92, 29.92)	(-89.20, 41.20)	
p-value	0.1581	0.2541	
Corrected Hedge's g Statistics	-1.576	-1.187	
95% CI	(-3.41, 0.26)	(-2.94, 0.57)	
Subgroup*Treatment Interaction p-value	0.3239	0.8150	

AMNOG Table SE19.5.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Absenteeism			
Week 24			
m	5	8	16
n	0	2	4
Baseline Mean (SD)	N/A	0.00 (0.00)	0.00 (0.00)
Analysis Visit Mean (SD)	N/A	0.00 (0.00)	0.55 (1.10)
LS Mean of Change from Baseline (SE)	NE	-0.18 (0.67)	0.46 (0.63)
95% CI	NE	(-2.32, 1.95)	(-1.54, 2.45)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-0.64 (0.84)	
95% CI	NE	(-3.32, 2.04)	
p-value	NE	0.5012	
Corrected Hedge's g Statistics	NE	-0.433	
95% CI	NE	(-2.15, 1.28)	
Week 52			
m	5	8	15
n	0	2	4
Baseline Mean (SD)	N/A	0.00 (0.00)	0.00 (0.00)
Analysis Visit Mean (SD)	N/A	0.00 (0.00)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	NE	-0.18 (0.67)	-0.09 (0.63)
95% CI	NE	(-2.32, 1.95)	(-2.09, 1.90)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-0.09 (0.84)	
95% CI	NE	(-2.77, 2.59)	
p-value	NE	0.9201	
Corrected Hedge's g Statistics	NE	-0.062	
95% CI	NE	(-1.76, 1.64)	
Subgroup*Treatment Interaction p-value	NE	0.4947	

AMNOG Table SE19.5.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Presenteeism			
Week 24			
m	5	8	16
n	0	2	4
Baseline Mean (SD)	N/A	10.0 (14.1)	2.5 (5.0)
Analysis Visit Mean (SD)	N/A	5.0 (7.1)	5.0 (5.8)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	8	15
n	0	2	4
Baseline Mean (SD)	N/A	10.0 (14.1)	2.5 (5.0)
Analysis Visit Mean (SD)	N/A	0.0 (0.0)	10.0 (11.5)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	0.1511	

AMNOG Table SE19.5.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Overall Work Impairment			
Week 24			
m	5	8	16
n	0	2	4
Baseline Mean (SD)	N/A	10.0 (14.1)	2.5 (5.0)
Analysis Visit Mean (SD)	N/A	5.0 (7.1)	5.5 (6.4)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	8	15
n	0	2	4
Baseline Mean (SD)	N/A	10.0 (14.1)	2.5 (5.0)
Analysis Visit Mean (SD)	N/A	0.0 (0.0)	10.0 (11.5)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	0.1215	

AMNOG Table SE19.5.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Activity Impairment			
Week 24			
m	5	8	16
n	3	4	10
Baseline Mean (SD)	3.3 (5.8)	7.5 (9.6)	13.0 (19.5)
Analysis Visit Mean (SD)	0.0 (0.0)	5.0 (5.8)	9.0 (11.0)
LS Mean of Change from Baseline (SE)	-9.78 (6.70)	-5.30 (6.69)	-1.77 (4.91)
95% CI	(-24.52, 4.97)	(-20.03, 9.42)	(-12.58, 9.03)
LS Mean of Change from Baseline Compared to Placebo (SE)	-8.00 (7.73)	-3.53 (6.72)	
95% CI	(-25.01, 9.00)	(-18.33, 11.27)	
p-value	0.3226	0.6100	
Corrected Hedge's g Statistics	-0.500	-0.220	
95% CI	(-1.80, 0.80)	(-1.38, 0.94)	
Week 52			
m	5	8	15
n	3	4	10
Baseline Mean (SD)	3.3 (5.8)	7.5 (9.6)	13.0 (19.5)
Analysis Visit Mean (SD)	3.3 (5.8)	0.0 (0.0)	17.0 (20.6)
LS Mean of Change from Baseline (SE)	-1.86 (6.70)	-8.59 (6.69)	4.17 (4.91)
95% CI	(-16.61, 12.88)	(-23.31, 6.14)	(-6.64, 14.97)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.03 (7.73)	-12.75 (6.72)	
95% CI	(-23.04, 10.98)	(-27.55, 2.05)	
p-value	0.4516	0.0844	
Corrected Hedge's g Statistics	-0.377	-0.795	
95% CI	(-1.68, 0.92)	(-1.99, 0.40)	
Subgroup*Treatment Interaction p-value	0.3239	0.8150	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE19.5.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as a decrease of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.

AMNOG Table SE19.5.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	4 (100)	6 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	4 (100)	6 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.5.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	4 (100)	6 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	4 (100)	6 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.5.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	4 (100)	6 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	4 (100)	6 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.5.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (25.0)	0	1 (9.1)
No	3 (75.0)	6 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.30	1.86	
95% CI of the inverse odds ratio	(0.01, 6.38)	(0.07, 52.76)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.36	1.75	
95% CI of the inverse risk ratio	(0.03, 4.54)	(0.08, 37.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	15.91	-5.36	
95% CI of the absolute risk difference	(-29.80, 61.62)	(-32.08, 21.37)	
p-value	0.4228	0.7136	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.1443	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (25.0)	0	1 (9.1)
No	3 (75.0)	6 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.30	1.86	
95% CI of the inverse odds ratio	(0.01, 6.38)	(0.07, 52.76)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.36	1.75	
95% CI of the inverse risk ratio	(0.03, 4.54)	(0.08, 37.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	15.91	-5.36	
95% CI of the absolute risk difference	(-29.80, 61.62)	(-32.08, 21.37)	
p-value	0.4228	0.7136	
p-value of Breslow-Day Test for Homogeneity [3]	0.7797	0.3287	

AMNOG Table SE19.5.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	9 (100)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	5 (100)	9 (100)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.5.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (11.1)	0
No	5 (100)	8 (88.9)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.16	
95% CI of the inverse odds ratio	NE	(0.01, 4.41)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.19	
95% CI of the inverse risk ratio	NE	(0.01, 4.13)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	12.22	
95% CI of the absolute risk difference	NE	(-11.17, 35.62)	
p-value	NE	0.2289	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (11.1)	0
No	5 (100)	8 (88.9)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.16	
95% CI of the inverse odds ratio	NE	(0.01, 4.41)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.19	
95% CI of the inverse risk ratio	NE	(0.01, 4.13)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	12.22	
95% CI of the absolute risk difference	NE	(-11.17, 35.62)	
p-value	NE	0.2289	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.5.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (11.1)	0
No	5 (100)	8 (88.9)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.16	
95% CI of the inverse odds ratio	NE	(0.01, 4.41)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.19	
95% CI of the inverse risk ratio	NE	(0.01, 4.13)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	12.22	
95% CI of the absolute risk difference	NE	(-11.17, 35.62)	
p-value	NE	0.2289	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (11.1)	0
No	5 (100)	8 (88.9)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.16	
95% CI of the inverse odds ratio	NE	(0.01, 4.41)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.19	
95% CI of the inverse risk ratio	NE	(0.01, 4.13)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	12.22	
95% CI of the absolute risk difference	NE	(-11.17, 35.62)	
p-value	NE	0.2289	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.5.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (11.1)	0
No	5 (100)	8 (88.9)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.16	
95% CI of the inverse odds ratio	NE	(0.01, 4.41)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.19	
95% CI of the inverse risk ratio	NE	(0.01, 4.13)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	12.22	
95% CI of the absolute risk difference	NE	(-11.17, 35.62)	
p-value	NE	0.2289	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.1443	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (20.0)	2 (22.2)	2 (11.8)
No	4 (80.0)	7 (77.8)	15 (88.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.53	0.47	
95% CI of the inverse odds ratio	(0.04, 7.49)	(0.05, 4.03)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	0.53	
95% CI of the inverse risk ratio	(0.07, 5.22)	(0.09, 3.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.24	10.46	
95% CI of the absolute risk difference	(-30.02, 46.50)	(-20.72, 41.64)	
p-value	0.6371	0.4820	
p-value of Breslow-Day Test for Homogeneity [3]	0.7797	0.3287	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE19.6.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=2)	(N=15)	(N=24)	(N=2)	(N=15)	(N=24)
Absenteeism						
Baseline						
m	2	15	24			
n	2	5	6			
Mean (SD)	0.00 (0.00)	0.00 (0.00)	0.00 (0.00)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 0.0	0.0, 0.0	0.0, 0.0			
Week 24						
m	2	12	23			
n	2	6	11	2	3	6
Mean (SD/SE)	0.00 (0.00)	1.83 (4.49)	0.20 (0.66)	0.00 (0.00)	0.00 (0.00)	0.37 (0.37)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 0.0	0.0, 11.0	0.0, 2.2	0.0, 0.0	0.0, 0.0	0.0, 2.2
Week 52						
m	2	12	22			
n	1	7	9	1	4	5
Mean (SD/SE)	0.00 (N/A)	7.14 (18.90)	6.78 (16.61)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 0.0	0.0, 50.0	0.0, 50.0	0.0, 0.0	0.0, 0.0	0.0, 0.0

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.6.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=2)	(N=15)	(N=24)	(N=2)	(N=15)	(N=24)
Presenteeism						
Baseline						
m	2	15	24			
n	2	5	6			
Mean (SD)	30.0 (42.4)	4.0 (8.9)	1.7 (4.1)			
Median	30.0	0	0			
IQR: Q1, Q3	0.0, 60.0	0.0, 0.0	0.0, 0.0			
Min, Max	0, 60	0, 20	0, 10			
Week 24						
m	2	12	23			
n	2	6	11	2	3	6
Mean (SD/SE)	0.0 (0.0)	15.0 (27.4)	4.5 (6.9)	-30.0 (30.0)	-3.3 (3.3)	1.7 (1.7)
Median	0	5.0	0	-30.0	0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 10.0	0.0, 10.0	-60.0, 0.0	-10.0, 0.0	0.0, 0.0
Min, Max	0, 0	0, 70	0, 20	-60, 0	-10, 0	0, 10
Week 52						
m	2	12	22			
n	1	7	9	1	4	5
Mean (SD/SE)	0.0 (N/A)	10.0 (19.1)	16.7 (24.5)	0.0 (N/A)	-5.0 (5.0)	6.0 (4.0)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 20.0	0.0, 20.0	0.0, 0.0	-10.0, 0.0	0.0, 10.0
Min, Max	0, 0	0, 50	0, 70	0, 0	-20, 0	0, 20

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.6.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=2)	(N=15)	(N=24)	(N=2)	(N=15)	(N=24)
Overall Work Impairment						
Baseline						
m	2	15	24			
n	2	5	6			
Mean (SD)	30.00 (42.43)	4.00 (8.94)	1.67 (4.08)			
Median	30.00	0	0			
IQR: Q1, Q3	0.00, 60.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 60.0	0.0, 20.0	0.0, 10.0			
Week 24						
m	2	12	23			
n	2	6	11	2	3	6
Mean (SD/SE)	0.00 (0.00)	16.83 (26.54)	4.73 (7.06)	-30.00 (30.00)	-3.33 (3.33)	2.00 (1.63)
Median	0	10.00	0	-30.00	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 11.00	0.00, 10.00	-60.00, 0.00	-10.00, 0.00	0.00, 2.00
Min, Max	0.0, 0.0	0.0, 70.0	0.0, 20.0	-60.0, 0.0	-10.0, 0.0	0.0, 10.0
Week 52						
m	2	12	22			
n	1	7	9	1	4	5
Mean (SD/SE)	0.00 (N/A)	13.57 (28.09)	19.07 (29.42)	0.00 (N/A)	-5.00 (5.00)	6.00 (4.00)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 20.00	0.00, 20.00	0.00, 0.00	-10.00, 0.00	0.00, 10.00
Min, Max	0.0, 0.0	0.0, 75.0	0.0, 85.0	0.0, 0.0	-20.0, 0.0	0.0, 20.0

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.6.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=24)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=24)
Activity Impairment						
Baseline						
m	2	15	24			
n	2	7	15			
Mean (SD)	50.0 (70.7)	4.3 (7.9)	16.7 (26.1)			
Median	50.0	0	10.0			
IQR: Q1, Q3	0.0, 100.0	0.0, 10.0	0.0, 20.0			
Min, Max	0, 100	0, 20	0, 90			
Week 24						
m	2	12	23			
n	2	10	22	2	5	15
Mean (SD/SE)	5.0 (7.1)	14.0 (21.2)	14.1 (20.9)	-45.0 (45.0)	-2.0 (2.0)	-8.0 (6.3)
Median	5.0	10.0	5.0	-45.0	0	0
IQR: Q1, Q3	0.0, 10.0	0.0, 20.0	0.0, 20.0	-90.0, 0.0	0.0, 0.0	-10.0, 10.0
Min, Max	0, 10	0, 70	0, 70	-90, 0	-10, 0	-70, 10
Week 52						
m	2	12	22			
n	1	10	20	1	6	14
Mean (SD/SE)	0.0 (N/A)	7.0 (16.4)	18.5 (22.8)	0.0 (N/A)	-5.0 (3.4)	4.3 (4.3)
Median	0	0	10.0	0	0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 0.0	0.0, 35.0	0.0, 0.0	-10.0, 0.0	0.0, 10.0
Min, Max	0, 0	0, 50	0, 70	0, 0	-20, 0	-20, 40

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.6.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=7)	(N=0)	(N=4)	(N=7)	(N=0)	(N=4)
Absenteeism						
Baseline						
m	7	0	4			
n	0	0	0			
Mean (SD)	N/A	N/A	N/A			
Median	N/A	N/A	N/A			
IQR: Q1, Q3	N/A	N/A	N/A			
Min, Max	N/A	N/A	N/A			
Week 24						
m	6	0	4			
n	0	0	1	0	0	0
Mean (SD/SE)	N/A	N/A	0.00 (N/A)	N/A	N/A	N/A
Median	N/A	N/A	0	N/A	N/A	N/A
IQR: Q1, Q3	N/A	N/A	0.00, 0.00	N/A	N/A	N/A
Min, Max	N/A	N/A	0.0, 0.0	N/A	N/A	N/A
Week 52						
m	6	0	4			
n	1	0	2	0	0	0
Mean (SD/SE)	0.00 (N/A)	N/A	0.00 (0.00)	N/A	N/A	N/A
Median	0	N/A	0	N/A	N/A	N/A
IQR: Q1, Q3	0.00, 0.00	N/A	0.00, 0.00	N/A	N/A	N/A
Min, Max	0.0, 0.0	N/A	0.0, 0.0	N/A	N/A	N/A

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.6.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=7)	(N=0)	(N=4)	(N=7)	(N=0)	(N=4)
Presenteeism						
Baseline						
m	7	0	4			
n	0	0	0			
Mean (SD)	N/A	N/A	N/A			
Median	N/A	N/A	N/A			
IQR: Q1, Q3	N/A	N/A	N/A			
Min, Max	N/A	N/A	N/A			
Week 24						
m	6	0	4			
n	0	0	1	0	0	0
Mean (SD/SE)	N/A	N/A	0.0 (N/A)	N/A	N/A	N/A
Median	N/A	N/A	0	N/A	N/A	N/A
IQR: Q1, Q3	N/A	N/A	0.0, 0.0	N/A	N/A	N/A
Min, Max	N/A	N/A	0, 0	N/A	N/A	N/A
Week 52						
m	6	0	4			
n	1	0	2	0	0	0
Mean (SD/SE)	0.0 (N/A)	N/A	0.0 (0.0)	N/A	N/A	N/A
Median	0	N/A	0	N/A	N/A	N/A
IQR: Q1, Q3	0.0, 0.0	N/A	0.0, 0.0	N/A	N/A	N/A
Min, Max	0, 0	N/A	0, 0	N/A	N/A	N/A

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.6.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=7)	(N=0)	(N=4)	(N=7)	(N=0)	(N=4)
Overall Work Impairment						
Baseline						
m	7	0	4			
n	0	0	0			
Mean (SD)	N/A	N/A	N/A			
Median	N/A	N/A	N/A			
IQR: Q1, Q3	N/A	N/A	N/A			
Min, Max	N/A	N/A	N/A			
Week 24						
m	6	0	4			
n	0	0	1	0	0	0
Mean (SD/SE)	N/A	N/A	0.00 (N/A)	N/A	N/A	N/A
Median	N/A	N/A	0	N/A	N/A	N/A
IQR: Q1, Q3	N/A	N/A	0.00, 0.00	N/A	N/A	N/A
Min, Max	N/A	N/A	0.0, 0.0	N/A	N/A	N/A
Week 52						
m	6	0	4			
n	1	0	2	0	0	0
Mean (SD/SE)	0.00 (N/A)	N/A	0.00 (0.00)	N/A	N/A	N/A
Median	0	N/A	0	N/A	N/A	N/A
IQR: Q1, Q3	0.00, 0.00	N/A	0.00, 0.00	N/A	N/A	N/A
Min, Max	0.0, 0.0	N/A	0.0, 0.0	N/A	N/A	N/A

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.6.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=7)	(N=0)	(N=4)	(N=7)	(N=0)	(N=4)
Activity Impairment						
Baseline						
m	7	0	4			
n	5	0	1			
Mean (SD)	16.0 (30.5)	N/A	20.0 (N/A)			
Median	0	N/A	20.0			
IQR: Q1, Q3	0.0, 10.0	N/A	20.0, 20.0			
Min, Max	0, 70	N/A	20, 20			
Week 24						
m	6	0	4			
n	5	0	4	4	0	1
Mean (SD/SE)	0.0 (0.0)	N/A	2.5 (5.0)	-20.0 (16.8)	N/A	-20.0 (N/A)
Median	0	N/A	0	-5.0	N/A	-20.0
IQR: Q1, Q3	0.0, 0.0	N/A	0.0, 5.0	-40.0, 0.0	N/A	-20.0, -20.0
Min, Max	0, 0	N/A	0, 10	-70, 0	N/A	-20, -20
Week 52						
m	6	0	4			
n	6	0	4	4	0	1
Mean (SD/SE)	5.0 (8.4)	N/A	17.5 (28.7)	-12.5 (13.1)	N/A	40.0 (N/A)
Median	0	N/A	5.0	-5.0	N/A	40.0
IQR: Q1, Q3	0.0, 10.0	N/A	0.0, 35.0	-30.0, 5.0	N/A	40.0, 40.0
Min, Max	0, 20	N/A	0, 60	-50, 10	N/A	40, 40

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.6.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. If the MMRM for LS Means does not converge with unstructured covariance, compound symmetry is used. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

AMNOG Table SE19.6.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Absenteeism			
Week 24			
m	2	12	23
n	2	3	6
Baseline Mean (SD)	0.00 (0.00)	0.00 (0.00)	0.00 (0.00)
Analysis Visit Mean (SD)	0.00 (0.00)	0.00 (0.00)	0.37 (0.90)
LS Mean of Change from Baseline (SE)	-0.06 (0.47)	-0.05 (0.34)	0.28 (0.36)
95% CI	(-1.35, 1.23)	(-0.98, 0.88)	(-0.71, 1.26)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.33 (0.45)	-0.33 (0.42)	
95% CI	(-1.59, 0.92)	(-1.50, 0.85)	
p-value	0.5001	0.4841	
Corrected Hedge's g Statistics	-0.346	-0.363	
95% CI	(-1.96, 1.26)	(-1.76, 1.03)	
Week 52			
m	2	12	22
n	1	4	5
Baseline Mean (SD)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)
Analysis Visit Mean (SD)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	-0.15 (0.64)	-0.03 (0.30)	-0.12 (0.38)
95% CI	(-1.92, 1.62)	(-0.87, 0.81)	(-1.19, 0.94)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.03 (0.60)	0.09 (0.41)	
95% CI	(-1.70, 1.65)	(-1.04, 1.22)	
p-value	0.9681	0.8338	
Corrected Hedge's g Statistics	-0.024	0.107	
95% CI	(-2.17, 2.12)	(-1.21, 1.42)	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE19.6.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Presenteeism			
Week 24			
m	2	12	23
n	2	3	6
Baseline Mean (SD)	30.0 (42.4)	6.7 (11.5)	1.7 (4.1)
Analysis Visit Mean (SD)	0.0 (0.0)	3.3 (5.8)	3.3 (5.2)
LS Mean of Change from Baseline (SE)	-8.22 (7.99)	-2.63 (4.67)	-2.41 (5.75)
95% CI	(-33.64, 17.20)	(-17.48, 12.22)	(-20.72, 15.89)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.81 (7.80)	-0.21 (5.85)	
95% CI	(-30.64, 19.02)	(-18.84, 18.41)	
p-value	0.5107	0.9731	
Corrected Hedge's g Statistics	-0.370	-0.015	
95% CI	(-1.98, 1.24)	(-1.40, 1.37)	
Week 52			
m	2	12	22
n	1	4	5
Baseline Mean (SD)	0.0 (N/A)	5.0 (10.0)	2.0 (4.5)
Analysis Visit Mean (SD)	0.0 (N/A)	0.0 (0.0)	8.0 (11.0)
LS Mean of Change from Baseline (SE)	-7.70 (8.95)	-5.98 (4.44)	1.59 (6.15)
95% CI	(-36.20, 20.79)	(-20.11, 8.15)	(-17.99, 21.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	-9.29 (8.13)	-7.56 (5.88)	
95% CI	(-35.15, 16.57)	(-26.27, 11.15)	
p-value	0.3359	0.2886	
Corrected Hedge's g Statistics	-0.540	-0.564	
95% CI	(-2.71, 1.63)	(-1.90, 0.78)	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE19.6.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Overall Work Impairment			
Week 24			
m	2	12	23
n	2	3	6
Baseline Mean (SD)	30.0 (42.4)	6.7 (11.5)	1.7 (4.1)
Analysis Visit Mean (SD)	0.0 (0.0)	3.3 (5.8)	3.7 (5.7)
LS Mean of Change from Baseline (SE)	-8.76 (8.29)	-2.87 (4.80)	-2.37 (6.00)
95% CI	(-35.15, 17.62)	(-18.13, 12.39)	(-21.46, 16.72)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.39 (8.07)	-0.50 (6.02)	
95% CI	(-32.06, 19.29)	(-19.65, 18.65)	
p-value	0.4862	0.9389	
Corrected Hedge's g Statistics	-0.390	-0.034	
95% CI	(-2.00, 1.22)	(-1.42, 1.35)	
Week 52			
m	2	12	22
n	1	4	5
Baseline Mean (SD)	0.0 (N/A)	5.0 (10.0)	2.0 (4.5)
Analysis Visit Mean (SD)	0.0 (N/A)	0.0 (0.0)	8.0 (11.0)
LS Mean of Change from Baseline (SE)	-8.85 (9.09)	-6.14 (4.60)	0.89 (6.33)
95% CI	(-37.78, 20.08)	(-20.80, 8.51)	(-19.24, 21.02)
LS Mean of Change from Baseline Compared to Placebo (SE)	-9.74 (8.34)	-7.04 (6.04)	
95% CI	(-36.28, 16.79)	(-26.24, 12.17)	
p-value	0.3270	0.3279	
Corrected Hedge's g Statistics	-0.551	-0.510	
95% CI	(-2.72, 1.62)	(-1.85, 0.83)	
Subgroup*Treatment Interaction p-value	NE	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE19.6.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Activity Impairment			
Week 24			
m	2	12	23
n	2	5	15
Baseline Mean (SD)	50.0 (70.7)	6.0 (8.9)	16.7 (26.1)
Analysis Visit Mean (SD)	5.0 (7.1)	4.0 (5.5)	8.7 (10.6)
LS Mean of Change from Baseline (SE)	-16.03 (9.28)	-10.22 (5.78)	-7.68 (4.28)
95% CI	(-35.94, 3.87)	(-22.61, 2.16)	(-16.86, 1.50)
LS Mean of Change from Baseline Compared to Placebo (SE)	-8.36 (9.17)	-2.55 (6.04)	
95% CI	(-28.03, 11.32)	(-15.51, 10.41)	
p-value	0.3779	0.6798	
Corrected Hedge's g Statistics	-0.484	-0.154	
95% CI	(-1.97, 1.00)	(-1.17, 0.86)	
Week 52			
m	2	12	22
n	1	6	14
Baseline Mean (SD)	0.0 (N/A)	5.0 (8.4)	16.4 (27.1)
Analysis Visit Mean (SD)	0.0 (N/A)	0.0 (0.0)	20.7 (25.0)
LS Mean of Change from Baseline (SE)	-5.27 (12.33)	-8.70 (5.46)	3.68 (4.38)
95% CI	(-31.70, 21.17)	(-20.42, 3.02)	(-5.71, 13.06)
LS Mean of Change from Baseline Compared to Placebo (SE)	-8.94 (12.05)	-12.38 (5.76)	
95% CI	(-34.79, 16.90)	(-24.74, -0.01)	
p-value	0.4703	0.0498	
Corrected Hedge's g Statistics	-0.514	-0.760	
95% CI	(-2.55, 1.52)	(-1.74, 0.23)	
Subgroup*Treatment Interaction p-value	0.2261	NE	

AMNOG Table SE19.6.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Absenteeism			
Week 24			
m	6	0	4
n	0	0	0
Baseline Mean (SD)	N/A	N/A	N/A
Analysis Visit Mean (SD)	N/A	N/A	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	6	0	4
n	0	0	0
Baseline Mean (SD)	N/A	N/A	N/A
Analysis Visit Mean (SD)	N/A	N/A	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE19.6.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Presenteeism			
Week 24			
m	6	0	4
n	0	0	0
Baseline Mean (SD)	N/A	N/A	N/A
Analysis Visit Mean (SD)	N/A	N/A	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	6	0	4
n	0	0	0
Baseline Mean (SD)	N/A	N/A	N/A
Analysis Visit Mean (SD)	N/A	N/A	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE19.6.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Overall Work Impairment			
Week 24			
m	6	0	4
n	0	0	0
Baseline Mean (SD)	N/A	N/A	N/A
Analysis Visit Mean (SD)	N/A	N/A	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	6	0	4
n	0	0	0
Baseline Mean (SD)	N/A	N/A	N/A
Analysis Visit Mean (SD)	N/A	N/A	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE19.6.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Activity Impairment			
Week 24			
m	6	0	4
n	4	0	1
Baseline Mean (SD)	20.0 (33.7)	N/A	20.0 (N/A)
Analysis Visit Mean (SD)	0.0 (0.0)	N/A	0.0 (N/A)
LS Mean of Change from Baseline (SE)	-17.92 (3.70)	NE	-15.83 (7.40)
95% CI	(-64.91, 29.07)	NE	(-109.82, 78.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.08 (6.30)	NE	
95% CI	(-82.15, 77.98)	NE	
p-value	0.7967	NE	
Corrected Hedge's g Statistics	-0.205	NE	
95% CI	(-2.40, 1.99)	NE	
Week 52			
m	6	0	4
n	4	0	1
Baseline Mean (SD)	20.0 (33.7)	N/A	20.0 (N/A)
Analysis Visit Mean (SD)	7.5 (9.6)	N/A	60.0 (N/A)
LS Mean of Change from Baseline (SE)	-10.42 (3.70)	NE	44.17 (7.40)
95% CI	(-57.41, 36.57)	NE	(-49.82, 138.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	-54.58 (6.30)	NE	
95% CI	(-134.65, 25.48)	NE	
p-value	0.0732	NE	
Corrected Hedge's g Statistics	-5.367	NE	
95% CI	(-9.35, -1.38)	NE	
Subgroup*Treatment Interaction p-value	0.2261	NE	

AMNOG Table SE19.6.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as a decrease of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.

AMNOG Table SE19.6.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	2 (100)	15 (100)	24 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	2 (100)	15 (100)	24 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.6.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (6.7)	0
No	2 (100)	14 (93.3)	24 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.20	
95% CI of the inverse odds ratio	NE	(0.01, 5.17)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.21	
95% CI of the inverse risk ratio	NE	(0.01, 4.92)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	7.38	
95% CI of the absolute risk difference	NE	(-7.93, 22.68)	
p-value	NE	0.2849	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (6.7)	0
No	2 (100)	14 (93.3)	24 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.20	
95% CI of the inverse odds ratio	NE	(0.01, 5.17)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.21	
95% CI of the inverse risk ratio	NE	(0.01, 4.92)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	7.38	
95% CI of the absolute risk difference	NE	(-7.93, 22.68)	
p-value	NE	0.2849	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.6.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (6.7)	0
No	2 (100)	14 (93.3)	24 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.20	
95% CI of the inverse odds ratio	NE	(0.01, 5.17)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.21	
95% CI of the inverse risk ratio	NE	(0.01, 4.92)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	7.38	
95% CI of the absolute risk difference	NE	(-7.93, 22.68)	
p-value	NE	0.2849	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (6.7)	0
No	2 (100)	14 (93.3)	24 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.20	
95% CI of the inverse odds ratio	NE	(0.01, 5.17)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.21	
95% CI of the inverse risk ratio	NE	(0.01, 4.92)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	7.38	
95% CI of the absolute risk difference	NE	(-7.93, 22.68)	
p-value	NE	0.2849	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.6.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (6.7)	1 (4.2)
No	2 (100)	14 (93.3)	23 (95.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.61	
95% CI of the inverse odds ratio	NE	(0.04, 10.53)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.63	
95% CI of the inverse risk ratio	NE	(0.04, 9.26)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.17	2.50	
95% CI of the absolute risk difference	(-12.16, 3.83)	(-12.44, 17.44)	
p-value	0.7685	0.7306	
p-value of Breslow-Day Test for Homogeneity [3]	0.4642	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (13.3)	3 (12.5)
No	2 (100)	13 (86.7)	21 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	0.93	
95% CI of the inverse odds ratio	(0.03, 20.78)	(0.14, 6.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	0.94	
95% CI of the inverse risk ratio	(0.06, 12.63)	(0.18, 4.97)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.67	0.83	
95% CI of the absolute risk difference	(-41.64, 46.98)	(-20.87, 22.54)	
p-value	0.9007	0.9396	
p-value of Breslow-Day Test for Homogeneity [3]	0.2470	NE	

AMNOG Table SE19.6.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.6.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.6.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.6.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (14.3)	0	0
No	6 (85.7)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.48	NE	
95% CI of the inverse odds ratio	(0.02, 14.70)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.53	NE	
95% CI of the inverse risk ratio	(0.03, 10.70)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.75	NE	
95% CI of the absolute risk difference	(-28.97, 46.47)	NE	
p-value	0.6705	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4642	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (28.6)	0	0
No	5 (71.4)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.24	NE	
95% CI of the inverse odds ratio	(0.01, 6.51)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.32	NE	
95% CI of the inverse risk ratio	(0.02, 5.39)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	21.25	NE	
95% CI of the absolute risk difference	(-20.26, 62.76)	NE	
p-value	0.3763	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2470	NE	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE19.7.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=6)	Visit Result DB Placebo (N=19)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=6)	Change from Baseline DB Placebo (N=19)
Absenteeism						
Baseline						
m	6	6	19			
n	1	2	4			
Mean (SD)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 0.0	0.0, 0.0	0.0, 0.0			
Week 24						
m	5	5	18			
n	1	3	7	1	2	4
Mean (SD/SE)	0.00 (N/A)	0.00 (0.00)	0.31 (0.83)	0.00 (N/A)	0.00 (0.00)	0.55 (0.55)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 1.10
Min, Max	0.0, 0.0	0.0, 0.0	0.0, 2.2	0.0, 0.0	0.0, 0.0	0.0, 2.2
Week 52						
m	5	5	17			
n	2	3	8	1	2	4
Mean (SD/SE)	0.00 (0.00)	16.67 (28.87)	6.25 (17.68)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 50.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 0.0	0.0, 50.0	0.0, 50.0	0.0, 0.0	0.0, 0.0	0.0, 0.0

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.7.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=6)	(N=6)	(N=19)	(N=6)	(N=6)	(N=19)
Presenteeism						
Baseline						
m	6	6	19			
n	1	2	4			
Mean (SD)	0.0 (N/A)	10.0 (14.1)	2.5 (5.0)			
Median	0	10.0	0			
IQR: Q1, Q3	0.0, 0.0	0.0, 20.0	0.0, 5.0			
Min, Max	0, 0	0, 20	0, 10			
Week 24						
m	5	5	18			
n	1	3	7	1	2	4
Mean (SD/SE)	0.0 (N/A)	26.7 (37.9)	4.3 (7.9)	0.0 (N/A)	-5.0 (5.0)	0.0 (0.0)
Median	0	10.0	0	0	-5.0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 70.0	0.0, 10.0	0.0, 0.0	-10.0, 0.0	0.0, 0.0
Min, Max	0, 0	0, 70	0, 20	0, 0	-10, 0	0, 0
Week 52						
m	5	5	17			
n	2	3	8	1	2	4
Mean (SD/SE)	0.0 (0.0)	16.7 (28.9)	11.3 (24.7)	0.0 (N/A)	-10.0 (10.0)	2.5 (2.5)
Median	0	0	0	0	-10.0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 50.0	0.0, 10.0	0.0, 0.0	-20.0, 0.0	0.0, 5.0
Min, Max	0, 0	0, 50	0, 70	0, 0	-20, 0	0, 10

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.7.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=6)	(N=6)	(N=19)	(N=6)	(N=6)	(N=19)
Overall Work Impairment						
Baseline						
m	6	6	19			
n	1	2	4			
Mean (SD)	0.00 (N/A)	10.00 (14.14)	2.50 (5.00)			
Median	0	10.00	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 20.00	0.00, 5.00			
Min, Max	0.0, 0.0	0.0, 20.0	0.0, 10.0			
Week 24						
m	5	5	18			
n	1	3	7	1	2	4
Mean (SD/SE)	0.00 (N/A)	26.67 (37.86)	4.57 (8.14)	0.00 (N/A)	-5.00 (5.00)	0.50 (0.50)
Median	0	10.00	0	0	-5.00	0
IQR: Q1, Q3	0.00, 0.00	0.00, 70.00	0.00, 12.00	0.00, 0.00	-10.00, 0.00	0.00, 1.00
Min, Max	0.0, 0.0	0.0, 70.0	0.0, 20.0	0.0, 0.0	-10.0, 0.0	0.0, 2.0
Week 52						
m	5	5	17			
n	2	3	8	1	2	4
Mean (SD/SE)	0.00 (0.00)	25.00 (43.30)	13.13 (29.87)	0.00 (N/A)	-10.00 (10.00)	2.50 (2.50)
Median	0	0	0	0	-10.00	0
IQR: Q1, Q3	0.00, 0.00	0.00, 75.00	0.00, 10.00	0.00, 0.00	-20.00, 0.00	0.00, 5.00
Min, Max	0.0, 0.0	0.0, 75.0	0.0, 85.0	0.0, 0.0	-20.0, 0.0	0.0, 10.0

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.7.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=6)	(N=6)	(N=19)	(N=6)	(N=6)	(N=19)
Activity Impairment						
Baseline						
m	6	6	19			
n	5	4	11			
Mean (SD)	16.0 (30.5)	7.5 (9.6)	16.4 (26.6)			
Median	0	5.0	10.0			
IQR: Q1, Q3	0.0, 10.0	0.0, 15.0	0.0, 20.0			
Min, Max	0, 70	0, 20	0, 90			
Week 24						
m	5	5	18			
n	4	5	17	4	4	11
Mean (SD/SE)	0.0 (0.0)	18.0 (29.5)	14.7 (22.9)	-20.0 (16.8)	-2.5 (2.5)	-7.3 (7.0)
Median	0	10.0	0	-5.0	0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 10.0	0.0, 20.0	-40.0, 0.0	-5.0, 0.0	-20.0, 10.0
Min, Max	0, 0	0, 70	0, 70	-70, 0	-10, 0	-70, 10
Week 52						
m	5	5	17			
n	5	5	16	4	4	11
Mean (SD/SE)	6.0 (8.9)	10.0 (22.4)	17.5 (23.5)	-12.5 (13.1)	-7.5 (4.8)	4.5 (5.5)
Median	0	0	5.0	-5.0	-5.0	0
IQR: Q1, Q3	0.0, 10.0	0.0, 0.0	0.0, 35.0	-30.0, 5.0	-15.0, 0.0	-10.0, 20.0
Min, Max	0, 20	0, 50	0, 70	-50, 10	-20, 0	-20, 40

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.7.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=3)	(N=9)	(N=9)	(N=3)	(N=9)	(N=9)
Absenteeism						
Baseline						
m	3	9	9			
n	1	3	2			
Mean (SD)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 0.0	0.0, 0.0	0.0, 0.0			
Week 24						
m	3	7	9			
n	1	3	5	1	1	2
Mean (SD/SE)	0.00 (N/A)	3.67 (6.35)	0.00 (0.00)	0.00 (N/A)	0.00 (N/A)	0.00 (0.00)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 11.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 0.0	0.0, 11.0	0.0, 0.0	0.0, 0.0	0.0, 0.0	0.0, 0.0
Week 52						
m	3	7	9			
n	0	4	3	0	2	1
Mean (SD/SE)	N/A	0.00 (0.00)	3.67 (6.35)	N/A	0.00 (0.00)	0.00 (N/A)
Median	N/A	0	0	N/A	0	0
IQR: Q1, Q3	N/A	0.00, 0.00	0.00, 11.00	N/A	0.00, 0.00	0.00, 0.00
Min, Max	N/A	0.0, 0.0	0.0, 11.0	N/A	0.0, 0.0	0.0, 0.0

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE19.7.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=9)	Visit Result DB Placebo (N=9)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=9)	Change from Baseline DB Placebo (N=9)
Presenteeism						
Baseline						
m	3	9	9			
n	1	3	2			
Mean (SD)	60.0 (N/A)	0.0 (0.0)	0.0 (0.0)			
Median	60.0	0	0			
IQR: Q1, Q3	60.0, 60.0	0.0, 0.0	0.0, 0.0			
Min, Max	60, 60	0, 0	0, 0			
Week 24						
m	3	7	9			
n	1	3	5	1	1	2
Mean (SD/SE)	0.0 (N/A)	3.3 (5.8)	4.0 (5.5)	-60.0 (N/A)	0.0 (N/A)	5.0 (5.0)
Median	0	0	0	-60.0	0	5.0
IQR: Q1, Q3	0.0, 0.0	0.0, 10.0	0.0, 10.0	-60.0, -60.0	0.0, 0.0	0.0, 10.0
Min, Max	0, 0	0, 10	0, 10	-60, -60	0, 0	0, 10
Week 52						
m	3	7	9			
n	0	4	3	0	2	1
Mean (SD/SE)	N/A	5.0 (10.0)	20.0 (20.0)	N/A	0.0 (0.0)	20.0 (N/A)
Median	N/A	0	20.0	N/A	0	20.0
IQR: Q1, Q3	N/A	0.0, 10.0	0.0, 40.0	N/A	0.0, 0.0	20.0, 20.0
Min, Max	N/A	0, 20	0, 40	N/A	0, 0	20, 20

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.7.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=3)	(N=9)	(N=9)	(N=3)	(N=9)	(N=9)
Overall Work Impairment						
Baseline						
m	3	9	9			
n	1	3	2			
Mean (SD)	60.00 (N/A)	0.00 (0.00)	0.00 (0.00)			
Median	60.00	0	0			
IQR: Q1, Q3	60.00, 60.00	0.00, 0.00	0.00, 0.00			
Min, Max	60.0, 60.0	0.0, 0.0	0.0, 0.0			
Week 24						
m	3	7	9			
n	1	3	5	1	1	2
Mean (SD/SE)	0.00 (N/A)	7.00 (6.08)	4.00 (5.48)	-60.00 (N/A)	0.00 (N/A)	5.00 (5.00)
Median	0	10.00	0	-60.00	0	5.00
IQR: Q1, Q3	0.00, 0.00	0.00, 11.00	0.00, 10.00	-60.00, -60.00	0.00, 0.00	0.00, 10.00
Min, Max	0.0, 0.0	0.0, 11.0	0.0, 10.0	-60.0, -60.0	0.0, 0.0	0.0, 10.0
Week 52						
m	3	7	9			
n	0	4	3	0	2	1
Mean (SD/SE)	N/A	5.00 (10.00)	22.20 (23.38)	N/A	0.00 (0.00)	20.00 (N/A)
Median	N/A	0	20.00	N/A	0	20.00
IQR: Q1, Q3	N/A	0.00, 10.00	0.00, 46.60	N/A	0.00, 0.00	20.00, 20.00
Min, Max	N/A	0.0, 20.0	0.0, 46.6	N/A	0.0, 0.0	20.0, 20.0

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.7.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=3)	(N=9)	(N=9)	(N=3)	(N=9)	(N=9)
Activity Impairment						
Baseline						
m	3	9	9			
n	2	3	5			
Mean (SD)	50.0 (70.7)	0.0 (0.0)	18.0 (24.9)			
Median	50.0	0	10.0			
IQR: Q1, Q3	0.0, 100.0	0.0, 0.0	0.0, 20.0			
Min, Max	0, 100	0, 0	0, 60			
Week 24						
m	3	7	9			
n	3	5	9	2	1	5
Mean (SD/SE)	3.3 (5.8)	10.0 (10.0)	7.8 (10.9)	-45.0 (45.0)	0.0 (N/A)	-12.0 (12.4)
Median	0	10.0	0	-45.0	0	0
IQR: Q1, Q3	0.0, 10.0	0.0, 20.0	0.0, 10.0	-90.0, 0.0	0.0, 0.0	-10.0, 0.0
Min, Max	0, 10	0, 20	0, 30	-90, 0	0, 0	-60, 10
Week 52						
m	3	7	9			
n	2	5	8	1	2	4
Mean (SD/SE)	0.0 (0.0)	4.0 (8.9)	20.0 (23.9)	0.0 (N/A)	0.0 (0.0)	12.5 (9.5)
Median	0	0	10.0	0	0	5.0
IQR: Q1, Q3	0.0, 0.0	0.0, 0.0	0.0, 40.0	0.0, 0.0	0.0, 0.0	0.0, 25.0
Min, Max	0, 0	0, 20	0, 60	0, 0	0, 0	0, 40

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.7.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable; T2D = Type 2 Diabetes.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. If the MMRM for LS Means does not converge with unstructured covariance, compound symmetry is used. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE19.7.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Absenteeism			
Week 24			
m	5	5	18
n	1	2	4
Baseline Mean (SD)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)
Analysis Visit Mean (SD)	0.00 (N/A)	0.00 (0.00)	0.55 (1.10)
LS Mean of Change from Baseline (SE)	0.00 (0.83)	0.00 (0.51)	0.55 (0.53)
95% CI	(-3.55, 3.55)	(-2.21, 2.21)	(-1.74, 2.84)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.55 (0.81)	-0.55 (0.74)	
95% CI	(-4.05, 2.95)	(-3.74, 2.64)	
p-value	0.5687	0.5350	
Corrected Hedge's g Statistics	-0.376	-0.444	
95% CI	(-2.58, 1.83)	(-2.16, 1.27)	
Week 52			
m	5	5	17
n	1	2	4
Baseline Mean (SD)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)
Analysis Visit Mean (SD)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	0.00 (0.83)	0.00 (0.51)	0.00 (0.53)
95% CI	(-3.55, 3.55)	(-2.21, 2.21)	(-2.29, 2.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (0.81)	0.00 (0.74)	
95% CI	(-3.50, 3.50)	(-3.19, 3.19)	
p-value	>0.9999	>0.9999	
Corrected Hedge's g Statistics	0.000	0.000	
95% CI	(-2.19, 2.19)	(-1.70, 1.70)	
Subgroup*Treatment Interaction p-value	0.7627	0.6473	

AMNOG Table SE19.7.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Presenteeism			
Week 24			
m	5	5	18
n	1	2	4
Baseline Mean (SD)	0.0 (N/A)	10.0 (14.1)	2.5 (5.0)
Analysis Visit Mean (SD)	0.0 (N/A)	5.0 (7.1)	2.5 (5.0)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	5	17
n	1	2	4
Baseline Mean (SD)	0.0 (N/A)	10.0 (14.1)	2.5 (5.0)
Analysis Visit Mean (SD)	0.0 (N/A)	0.0 (0.0)	5.0 (10.0)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.1210	NE	

AMNOG Table SE19.7.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Overall Work Impairment			
Week 24			
m	5	5	18
n	1	2	4
Baseline Mean (SD)	0.0 (N/A)	10.0 (14.1)	2.5 (5.0)
Analysis Visit Mean (SD)	0.0 (N/A)	5.0 (7.1)	3.0 (6.0)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	5	17
n	1	2	4
Baseline Mean (SD)	0.0 (N/A)	10.0 (14.1)	2.5 (5.0)
Analysis Visit Mean (SD)	0.0 (N/A)	0.0 (0.0)	5.0 (10.0)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.0866	0.1244	

AMNOG Table SE19.7.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Activity Impairment			
Week 24			
m	5	5	18
n	4	4	11
Baseline Mean (SD)	20.0 (33.7)	7.5 (9.6)	16.4 (26.6)
Analysis Visit Mean (SD)	0.0 (0.0)	5.0 (5.8)	9.1 (11.4)
LS Mean of Change from Baseline (SE)	-16.04 (6.61)	-9.17 (6.74)	-6.45 (4.71)
95% CI	(-30.31, -1.77)	(-23.73, 5.38)	(-16.62, 3.72)
LS Mean of Change from Baseline Compared to Placebo (SE)	-9.59 (7.58)	-2.72 (7.60)	
95% CI	(-25.96, 6.78)	(-19.14, 13.69)	
p-value	0.2278	0.7257	
Corrected Hedge's g Statistics	-0.598	-0.169	
95% CI	(-1.76, 0.57)	(-1.32, 0.98)	
Week 52			
m	5	5	17
n	4	4	11
Baseline Mean (SD)	20.0 (33.7)	7.5 (9.6)	16.4 (26.6)
Analysis Visit Mean (SD)	7.5 (9.6)	0.0 (0.0)	20.9 (25.9)
LS Mean of Change from Baseline (SE)	-10.49 (6.61)	-10.97 (6.74)	4.92 (4.71)
95% CI	(-24.76, 3.78)	(-25.53, 3.58)	(-5.25, 15.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	-15.41 (7.58)	-15.89 (7.60)	
95% CI	(-31.77, 0.96)	(-32.30, 0.52)	
p-value	0.0629	0.0567	
Corrected Hedge's g Statistics	-0.961	-0.988	
95% CI	(-2.16, 0.23)	(-2.19, 0.21)	
Subgroup*Treatment Interaction p-value	0.9465	0.9417	

AMNOG Table SE19.7.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Absenteeism			
Week 24			
m	3	7	9
n	1	1	2
Baseline Mean (SD)	0.00 (N/A)	0.00 (N/A)	0.00 (0.00)
Analysis Visit Mean (SD)	0.00 (N/A)	0.00 (N/A)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	3	7	9
n	0	2	1
Baseline Mean (SD)	N/A	0.00 (0.00)	0.00 (N/A)
Analysis Visit Mean (SD)	N/A	0.00 (0.00)	0.00 (N/A)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.7627	0.6473	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE19.7.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Presenteeism			
Week 24			
m	3	7	9
n	1	1	2
Baseline Mean (SD)	60.0 (N/A)	0.0 (N/A)	0.0 (0.0)
Analysis Visit Mean (SD)	0.0 (N/A)	0.0 (N/A)	5.0 (7.1)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-5.00 (5.09)	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	3	7	9
n	0	2	1
Baseline Mean (SD)	N/A	0.0 (0.0)	0.0 (N/A)
Analysis Visit Mean (SD)	N/A	0.0 (0.0)	20.0 (N/A)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-15.19 (5.09)	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.1210	NE	

AMNOG Table SE19.7.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Overall Work Impairment			
Week 24			
m	3	7	9
n	1	1	2
Baseline Mean (SD)	60.0 (N/A)	0.0 (N/A)	0.0 (0.0)
Analysis Visit Mean (SD)	0.0 (N/A)	0.0 (N/A)	5.0 (7.1)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-5.00 (5.09)	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	3	7	9
n	0	2	1
Baseline Mean (SD)	N/A	0.0 (0.0)	0.0 (N/A)
Analysis Visit Mean (SD)	N/A	0.0 (0.0)	20.0 (N/A)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-15.19 (5.09)	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.0866	0.1244	

AMNOG Table SE19.7.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Activity Impairment			
Week 24			
m	3	7	9
n	2	1	5
Baseline Mean (SD)	50.0 (70.7)	0.0 (N/A)	18.0 (24.9)
Analysis Visit Mean (SD)	5.0 (7.1)	0.0 (N/A)	6.0 (8.9)
LS Mean of Change from Baseline (SE)	-13.91 (11.07)	-16.50 (14.05)	-11.37 (6.18)
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.54 (12.63)	-5.13 (15.37)	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	-0.151	-0.297	
95% CI	(-1.79, 1.49)	(-2.45, 1.86)	
Week 52			
m	3	7	9
n	1	2	4
Baseline Mean (SD)	0.0 (N/A)	0.0 (0.0)	17.5 (28.7)
Analysis Visit Mean (SD)	0.0 (N/A)	0.0 (0.0)	30.0 (29.4)
LS Mean of Change from Baseline (SE)	-3.74 (14.60)	-3.51 (10.88)	12.23 (6.90)
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	-15.96 (16.16)	-15.74 (12.90)	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	-0.842	-0.886	
95% CI	(-3.09, 1.41)	(-2.66, 0.88)	
Subgroup*Treatment Interaction p-value	0.9465	0.9417	

AMNOG Table SE19.7.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; T2D = Type 2 Diabetes.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as a decrease of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.

AMNOG Table SE19.7.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	6 (100)	6 (100)	19 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	6 (100)	6 (100)	19 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.7.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (16.7)	0
No	6 (100)	5 (83.3)	19 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.09	
95% CI of the inverse odds ratio	NE	(0.00, 2.65)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.12	
95% CI of the inverse risk ratio	NE	(0.01, 2.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	18.93	
95% CI of the absolute risk difference	NE	(-12.23, 50.09)	
p-value	NE	0.0998	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (16.7)	0
No	6 (100)	5 (83.3)	19 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.09	
95% CI of the inverse odds ratio	NE	(0.00, 2.65)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.12	
95% CI of the inverse risk ratio	NE	(0.01, 2.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	18.93	
95% CI of the absolute risk difference	NE	(-12.23, 50.09)	
p-value	NE	0.0998	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.7.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (16.7)	0
No	6 (100)	5 (83.3)	19 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.09	
95% CI of the inverse odds ratio	NE	(0.00, 2.65)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.12	
95% CI of the inverse risk ratio	NE	(0.01, 2.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	18.93	
95% CI of the absolute risk difference	NE	(-12.23, 50.09)	
p-value	NE	0.0998	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (16.7)	0
No	6 (100)	5 (83.3)	19 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.09	
95% CI of the inverse odds ratio	NE	(0.00, 2.65)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.12	
95% CI of the inverse risk ratio	NE	(0.01, 2.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	18.93	
95% CI of the absolute risk difference	NE	(-12.23, 50.09)	
p-value	NE	0.0998	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.7.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (16.7)	1 (16.7)	1 (5.3)
No	5 (83.3)	5 (83.3)	18 (94.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.28	0.28	
95% CI of the inverse odds ratio	(0.01, 5.27)	(0.01, 5.27)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.32	0.32	
95% CI of the inverse risk ratio	(0.02, 4.32)	(0.02, 4.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.40	11.40	
95% CI of the absolute risk difference	(-20.06, 42.87)	(-20.06, 42.87)	
p-value	0.3694	0.3694	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (33.3)	2 (33.3)	3 (15.8)
No	4 (66.7)	4 (66.7)	16 (84.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.38	0.38	
95% CI of the inverse odds ratio	(0.05, 3.06)	(0.05, 3.06)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.47	0.47	
95% CI of the inverse risk ratio	(0.10, 2.20)	(0.10, 2.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	17.54	17.54	
95% CI of the absolute risk difference	(-23.59, 58.67)	(-23.59, 58.67)	
p-value	0.3490	0.3490	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.7.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	3 (100)	9 (100)	9 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	3 (100)	9 (100)	9 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.7.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	3 (100)	9 (100)	9 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	3 (100)	9 (100)	9 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.7.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	3 (100)	9 (100)	9 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	3 (100)	9 (100)	9 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.7.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	3 (100)	9 (100)	9 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	3 (100)	9 (100)	9 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE19.8.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=2)	(N=7)	(N=1)	(N=2)	(N=7)
Absenteeism						
Baseline						
m	1	2	7			
n	0	1	2			
Mean (SD)	N/A	0.00 (N/A)	0.00 (0.00)			
Median	N/A	0	0			
IQR: Q1, Q3	N/A	0.00, 0.00	0.00, 0.00			
Min, Max	N/A	0.0, 0.0	0.0, 0.0			
Week 24						
m	0	2	6			
n	0	1	2	0	1	2
Mean (SD/SE)	N/A	0.00 (N/A)	1.10 (1.56)	N/A	0.00 (N/A)	1.10 (1.10)
Median	N/A	0	1.10	N/A	0	1.10
IQR: Q1, Q3	N/A	0.00, 0.00	0.00, 2.20	N/A	0.00, 0.00	0.00, 2.20
Min, Max	N/A	0.0, 0.0	0.0, 2.2	N/A	0.0, 0.0	0.0, 2.2
Week 52						
m	0	2	6			
n	0	1	3	0	1	2
Mean (SD/SE)	N/A	0.00 (N/A)	0.00 (0.00)	N/A	0.00 (N/A)	0.00 (0.00)
Median	N/A	0	0	N/A	0	0
IQR: Q1, Q3	N/A	0.00, 0.00	0.00, 0.00	N/A	0.00, 0.00	0.00, 0.00
Min, Max	N/A	0.0, 0.0	0.0, 0.0	N/A	0.0, 0.0	0.0, 0.0

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.8.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=2)	(N=7)	(N=1)	(N=2)	(N=7)
Presenteeism						
Baseline						
m	1	2	7			
n	0	1	2			
Mean (SD)	N/A	20.0 (N/A)	5.0 (7.1)			
Median	N/A	20.0	5.0			
IQR: Q1, Q3	N/A	20.0, 20.0	0.0, 10.0			
Min, Max	N/A	20, 20	0, 10			
Week 24						
m	0	2	6			
n	0	1	2	0	1	2
Mean (SD/SE)	N/A	10.0 (N/A)	5.0 (7.1)	N/A	-10.0 (N/A)	0.0 (0.0)
Median	N/A	10.0	5.0	N/A	-10.0	0
IQR: Q1, Q3	N/A	10.0, 10.0	0.0, 10.0	N/A	-10.0, -10.0	0.0, 0.0
Min, Max	N/A	10, 10	0, 10	N/A	-10, -10	0, 0
Week 52						
m	0	2	6			
n	0	1	3	0	1	2
Mean (SD/SE)	N/A	0.0 (N/A)	6.7 (11.5)	N/A	-20.0 (N/A)	5.0 (5.0)
Median	N/A	0	0	N/A	-20.0	5.0
IQR: Q1, Q3	N/A	0.0, 0.0	0.0, 20.0	N/A	-20.0, -20.0	0.0, 10.0
Min, Max	N/A	0, 0	0, 20	N/A	-20, -20	0, 10

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.8.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=2)	(N=7)	(N=1)	(N=2)	(N=7)
Overall Work Impairment						
Baseline						
m	1	2	7			
n	0	1	2			
Mean (SD)	N/A	20.00 (N/A)	5.00 (7.07)			
Median	N/A	20.00	5.00			
IQR: Q1, Q3	N/A	20.00, 20.00	0.00, 10.00			
Min, Max	N/A	20.0, 20.0	0.0, 10.0			
Week 24						
m	0	2	6			
n	0	1	2	0	1	2
Mean (SD/SE)	N/A	10.00 (N/A)	6.00 (8.49)	N/A	-10.00 (N/A)	1.00 (1.00)
Median	N/A	10.00	6.00	N/A	-10.00	1.00
IQR: Q1, Q3	N/A	10.00, 10.00	0.00, 12.00	N/A	-10.00, -10.00	0.00, 2.00
Min, Max	N/A	10.0, 10.0	0.0, 12.0	N/A	-10.0, -10.0	0.0, 2.0
Week 52						
m	0	2	6			
n	0	1	3	0	1	2
Mean (SD/SE)	N/A	0.00 (N/A)	6.67 (11.55)	N/A	-20.00 (N/A)	5.00 (5.00)
Median	N/A	0	0	N/A	-20.00	5.00
IQR: Q1, Q3	N/A	0.00, 0.00	0.00, 20.00	N/A	-20.00, -20.00	0.00, 10.00
Min, Max	N/A	0.0, 0.0	0.0, 20.0	N/A	-20.0, -20.0	0.0, 10.0

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.8.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=2)	(N=7)	(N=1)	(N=2)	(N=7)
Activity Impairment						
Baseline						
m	1	2	7			
n	1	2	3			
Mean (SD)	0.0 (N/A)	10.0 (14.1)	10.0 (17.3)			
Median	0	10.0	0			
IQR: Q1, Q3	0.0, 0.0	0.0, 20.0	0.0, 30.0			
Min, Max	0, 0	0, 20	0, 30			
Week 24						
m	0	2	6			
n	0	2	6	0	2	3
Mean (SD/SE)	N/A	5.0 (7.1)	20.0 (26.8)	N/A	-5.0 (5.0)	3.3 (3.3)
Median	N/A	5.0	10.0	N/A	-5.0	0
IQR: Q1, Q3	N/A	0.0, 10.0	0.0, 30.0	N/A	-10.0, 0.0	0.0, 10.0
Min, Max	N/A	0, 10	0, 70	N/A	-10, 0	0, 10
Week 52						
m	0	2	6			
n	0	2	6	0	2	3
Mean (SD/SE)	N/A	0.0 (0.0)	11.7 (16.0)	N/A	-10.0 (10.0)	-3.3 (3.3)
Median	N/A	0	5.0	N/A	-10.0	0
IQR: Q1, Q3	N/A	0.0, 0.0	0.0, 20.0	N/A	-20.0, 0.0	-10.0, 0.0
Min, Max	N/A	0, 0	0, 40	N/A	-20, 0	-10, 0

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.8.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=8)	(N=13)	(N=21)	(N=8)	(N=13)	(N=21)
Absenteeism						
Baseline						
m	8	13	21			
n	2	4	4			
Mean (SD)	0.00 (0.00)	0.00 (0.00)	0.00 (0.00)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 0.0	0.0, 0.0	0.0, 0.0			
Week 24						
m	8	10	21			
n	2	5	10	2	2	4
Mean (SD/SE)	0.00 (0.00)	2.20 (4.92)	0.00 (0.00)	0.00 (0.00)	0.00 (0.00)	0.00 (0.00)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 0.0	0.0, 11.0	0.0, 0.0	0.0, 0.0	0.0, 0.0	0.0, 0.0
Week 52						
m	8	10	20			
n	2	6	8	1	3	3
Mean (SD/SE)	0.00 (0.00)	8.33 (20.41)	7.63 (17.55)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 5.50	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 0.0	0.0, 50.0	0.0, 50.0	0.0, 0.0	0.0, 0.0	0.0, 0.0

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE19.8.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=8)	(N=13)	(N=21)	(N=8)	(N=13)	(N=21)
Presenteeism						
Baseline						
m	8	13	21			
n	2	4	4			
Mean (SD)	30.0 (42.4)	0.0 (0.0)	0.0 (0.0)			
Median	30.0	0	0			
IQR: Q1, Q3	0.0, 60.0	0.0, 0.0	0.0, 0.0			
Min, Max	0, 60	0, 0	0, 0			
Week 24						
m	8	10	21			
n	2	5	10	2	2	4
Mean (SD/SE)	0.0 (0.0)	16.0 (30.5)	4.0 (7.0)	-30.0 (30.0)	0.0 (0.0)	2.5 (2.5)
Median	0	0	0	-30.0	0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 10.0	0.0, 10.0	-60.0, 0.0	0.0, 0.0	0.0, 5.0
Min, Max	0, 0	0, 70	0, 20	-60, 0	0, 0	0, 10
Week 52						
m	8	10	20			
n	2	6	8	1	3	3
Mean (SD/SE)	0.0 (0.0)	11.7 (20.4)	16.3 (26.2)	0.0 (N/A)	0.0 (0.0)	6.7 (6.7)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 20.0	0.0, 30.0	0.0, 0.0	0.0, 0.0	0.0, 20.0
Min, Max	0, 0	0, 50	0, 70	0, 0	0, 0	0, 20

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE19.8.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=8)	(N=13)	(N=21)	(N=8)	(N=13)	(N=21)
Overall Work Impairment						
Baseline						
m	8	13	21			
n	2	4	4			
Mean (SD)	30.00 (42.43)	0.00 (0.00)	0.00 (0.00)			
Median	30.00	0	0			
IQR: Q1, Q3	0.00, 60.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 60.0	0.0, 0.0	0.0, 0.0			
Week 24						
m	8	10	21			
n	2	5	10	2	2	4
Mean (SD/SE)	0.00 (0.00)	18.20 (29.43)	4.00 (6.99)	-30.00 (30.00)	0.00 (0.00)	2.50 (2.50)
Median	0	10.00	0	-30.00	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 11.00	0.00, 10.00	-60.00, 0.00	0.00, 0.00	0.00, 5.00
Min, Max	0.0, 0.0	0.0, 70.0	0.0, 20.0	-60.0, 0.0	0.0, 0.0	0.0, 10.0
Week 52						
m	8	10	20			
n	2	6	8	1	3	3
Mean (SD/SE)	0.00 (0.00)	15.83 (30.07)	18.95 (31.45)	0.00 (N/A)	0.00 (0.00)	6.67 (6.67)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 20.00	0.00, 33.30	0.00, 0.00	0.00, 0.00	0.00, 20.00
Min, Max	0.0, 0.0	0.0, 75.0	0.0, 85.0	0.0, 0.0	0.0, 0.0	0.0, 20.0

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.8.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=8)	(N=13)	(N=21)	(N=8)	(N=13)	(N=21)
Activity Impairment						
Baseline						
m	8	13	21			
n	6	5	13			
Mean (SD)	30.0 (43.8)	2.0 (4.5)	18.5 (27.0)			
Median	5.0	0	10.0			
IQR: Q1, Q3	0.0, 70.0	0.0, 0.0	0.0, 20.0			
Min, Max	0, 100	0, 10	0, 90			
Week 24						
m	8	10	21			
n	7	8	20	6	3	13
Mean (SD/SE)	1.4 (3.8)	16.3 (23.3)	10.0 (17.2)	-28.3 (16.6)	0.0 (0.0)	-11.5 (7.1)
Median	0	10.0	0	-5.0	0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 20.0	0.0, 20.0	-70.0, 0.0	0.0, 0.0	-20.0, 0.0
Min, Max	0, 10	0, 70	0, 70	-90, 0	0, 0	-70, 10
Week 52						
m	8	10	20			
n	7	8	18	5	4	12
Mean (SD/SE)	4.3 (7.9)	8.8 (18.1)	20.6 (25.1)	-10.0 (10.5)	-2.5 (2.5)	9.2 (5.6)
Median	0	0	10.0	0	0	0
IQR: Q1, Q3	0.0, 10.0	0.0, 10.0	0.0, 40.0	-10.0, 0.0	-5.0, 0.0	0.0, 25.0
Min, Max	0, 20	0, 50	0, 70	-50, 10	-10, 0	-20, 40

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.8.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable; HbA1c = Hemoglobin A1C.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. If the MMRM for LS Means does not converge with unstructured covariance, compound symmetry is used. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE19.8.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Absenteeism			
Week 24			
m	0	2	6
n	0	1	2
Baseline Mean (SD)	N/A	0.00 (N/A)	0.00 (0.00)
Analysis Visit Mean (SD)	N/A	0.00 (N/A)	1.10 (1.56)
LS Mean of Change from Baseline (SE)	NE	0.00 (1.10)	1.10 (0.78)
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-1.10 (1.35)	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	0.000	
95% CI	NE	(-2.40, 2.40)	
Week 52			
m	0	2	6
n	0	1	2
Baseline Mean (SD)	N/A	0.00 (N/A)	0.00 (0.00)
Analysis Visit Mean (SD)	N/A	0.00 (N/A)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	NE	0.00 (1.10)	0.00 (0.78)
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	0.00 (1.35)	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	0.000	
95% CI	NE	(-2.40, 2.40)	
Subgroup*Treatment Interaction p-value	NE	0.4274	

AMNOG Table SE19.8.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Presenteeism			
Week 24			
m	0	2	6
n	0	1	2
Baseline Mean (SD)	N/A	20.0 (N/A)	5.0 (7.1)
Analysis Visit Mean (SD)	N/A	10.0 (N/A)	5.0 (7.1)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	0	2	6
n	0	1	2
Baseline Mean (SD)	N/A	20.0 (N/A)	5.0 (7.1)
Analysis Visit Mean (SD)	N/A	0.0 (N/A)	10.0 (14.1)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	0.2706	

AMNOG Table SE19.8.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Overall Work Impairment			
Week 24			
m	0	2	6
n	0	1	2
Baseline Mean (SD)	N/A	20.0 (N/A)	5.0 (7.1)
Analysis Visit Mean (SD)	N/A	10.0 (N/A)	6.0 (8.5)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	0	2	6
n	0	1	2
Baseline Mean (SD)	N/A	20.0 (N/A)	5.0 (7.1)
Analysis Visit Mean (SD)	N/A	0.0 (N/A)	10.0 (14.1)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	0.2327	

AMNOG Table SE19.8.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Activity Impairment			
Week 24			
m	0	2	6
n	0	2	3
Baseline Mean (SD)	N/A	10.0 (14.1)	10.0 (17.3)
Analysis Visit Mean (SD)	N/A	5.0 (7.1)	13.3 (15.3)
LS Mean of Change from Baseline (SE)	NE	-5.00 (4.08)	3.33 (3.33)
95% CI	NE	(-56.87, 46.87)	(-39.02, 45.69)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-8.33 (5.27)	
95% CI	NE	(-75.30, 58.63)	
p-value	NE	0.3590	
Corrected Hedge's g Statistics	NE	-1.050	
95% CI	NE	(-2.95, 0.85)	
Week 52			
m	0	2	6
n	0	2	3
Baseline Mean (SD)	N/A	10.0 (14.1)	10.0 (17.3)
Analysis Visit Mean (SD)	N/A	0.0 (0.0)	6.7 (11.5)
LS Mean of Change from Baseline (SE)	NE	-10.00 (4.08)	-3.33 (3.33)
95% CI	NE	(-61.87, 41.87)	(-45.69, 39.02)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-6.67 (5.27)	
95% CI	NE	(-73.63, 60.30)	
p-value	NE	0.4259	
Corrected Hedge's g Statistics	NE	-0.840	
95% CI	NE	(-2.70, 1.02)	
Subgroup*Treatment Interaction p-value	NE	0.9860	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE19.8.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Absenteeism			
Week 24			
m	8	10	21
n	2	2	4
Baseline Mean (SD)	0.00 (0.00)	0.00 (0.00)	0.00 (0.00)
Analysis Visit Mean (SD)	0.00 (0.00)	0.00 (0.00)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	8	10	20
n	1	3	3
Baseline Mean (SD)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)
Analysis Visit Mean (SD)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	0.4274	

AMNOG Table SE19.8.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Presenteeism			
Week 24			
m	8	10	21
n	2	2	4
Baseline Mean (SD)	30.0 (42.4)	0.0 (0.0)	0.0 (0.0)
Analysis Visit Mean (SD)	0.0 (0.0)	0.0 (0.0)	2.5 (5.0)
LS Mean of Change from Baseline (SE)	4.63 (7.67)	-4.62 (3.74)	2.51 (4.73)
95% CI	(-92.79, 102.06)	(-52.16, 42.93)	(-57.54, 62.56)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.12 (6.66)	-7.12 (5.78)	
95% CI	(-82.45, 86.70)	(-80.53, 66.28)	
p-value	0.8033	0.4337	
Corrected Hedge's g Statistics	0.173	-0.663	
95% CI	(-1.53, 1.87)	(-2.40, 1.08)	
Week 52			
m	8	10	20
n	1	3	3
Baseline Mean (SD)	0.0 (N/A)	0.0 (0.0)	0.0 (0.0)
Analysis Visit Mean (SD)	0.0 (N/A)	0.0 (0.0)	6.7 (11.5)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.12 (6.66)	-11.37 (5.64)	
95% CI	(-86.70, 82.45)	(-83.00, 60.25)	
p-value	0.8033	0.2929	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	0.2706	

AMNOG Table SE19.8.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Overall Work Impairment			
Week 24			
m	8	10	21
n	2	2	4
Baseline Mean (SD)	30.0 (42.4)	0.0 (0.0)	0.0 (0.0)
Analysis Visit Mean (SD)	0.0 (0.0)	0.0 (0.0)	2.5 (5.0)
LS Mean of Change from Baseline (SE)	4.63 (7.67)	-4.62 (3.74)	2.51 (4.73)
95% CI	(-92.79, 102.06)	(-52.16, 42.93)	(-57.54, 62.56)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.12 (6.66)	-7.12 (5.78)	
95% CI	(-82.45, 86.70)	(-80.53, 66.28)	
p-value	0.8033	0.4337	
Corrected Hedge's g Statistics	0.173	-0.663	
95% CI	(-1.53, 1.87)	(-2.40, 1.08)	
Week 52			
m	8	10	20
n	1	3	3
Baseline Mean (SD)	0.0 (N/A)	0.0 (0.0)	0.0 (0.0)
Analysis Visit Mean (SD)	0.0 (N/A)	0.0 (0.0)	6.7 (11.5)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.12 (6.66)	-11.37 (5.64)	
95% CI	(-86.70, 82.45)	(-83.00, 60.25)	
p-value	0.8033	0.2929	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	0.2327	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE19.8.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Activity Impairment			
Week 24			
m	8	10	21
n	6	3	13
Baseline Mean (SD)	30.0 (43.8)	3.3 (5.8)	18.5 (27.0)
Analysis Visit Mean (SD)	1.7 (4.1)	3.3 (5.8)	6.9 (9.5)
LS Mean of Change from Baseline (SE)	-16.88 (5.85)	-12.66 (7.60)	-10.82 (4.67)
95% CI	(-29.43, -4.33)	(-28.96, 3.65)	(-20.83, -0.82)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.05 (6.40)	-1.83 (8.32)	
95% CI	(-19.78, 7.67)	(-19.69, 16.02)	
p-value	0.3602	0.8288	
Corrected Hedge's g Statistics	-0.359	-0.106	
95% CI	(-1.33, 0.62)	(-1.36, 1.15)	
Week 52			
m	8	10	20
n	5	4	12
Baseline Mean (SD)	16.0 (30.5)	2.5 (5.0)	18.3 (28.2)
Analysis Visit Mean (SD)	6.0 (8.9)	0.0 (0.0)	27.5 (27.3)
LS Mean of Change from Baseline (SE)	-10.46 (6.30)	-8.92 (6.86)	9.48 (4.81)
95% CI	(-23.96, 3.05)	(-23.62, 5.78)	(-0.83, 19.79)
LS Mean of Change from Baseline Compared to Placebo (SE)	-19.94 (6.79)	-18.40 (7.63)	
95% CI	(-34.50, -5.38)	(-34.76, -2.04)	
p-value	0.0108	0.0302	
Corrected Hedge's g Statistics	-1.183	-1.083	
95% CI	(-2.30, -0.07)	(-2.28, 0.11)	
Subgroup*Treatment Interaction p-value	NE	0.9860	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE19.8.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; HbA1c = Hemoglobin A1C.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as a decrease of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.

AMNOG Table SE19.8.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	1 (100)	2 (100)	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	1 (100)	2 (100)	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.8.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (50.0)	0
No	1 (100)	1 (50.0)	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.07	
95% CI of the inverse odds ratio	NE	(0.00, 2.56)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.13	
95% CI of the inverse risk ratio	NE	(0.01, 2.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	43.75	
95% CI of the absolute risk difference	NE	(-15.26, 100.00)	
p-value	NE	0.0938	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (50.0)	0
No	1 (100)	1 (50.0)	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.07	
95% CI of the inverse odds ratio	NE	(0.00, 2.56)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.13	
95% CI of the inverse risk ratio	NE	(0.01, 2.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	43.75	
95% CI of the absolute risk difference	NE	(-15.26, 100.00)	
p-value	NE	0.0938	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.8.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (50.0)	0
No	1 (100)	1 (50.0)	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.07	
95% CI of the inverse odds ratio	NE	(0.00, 2.56)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.13	
95% CI of the inverse risk ratio	NE	(0.01, 2.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	43.75	
95% CI of the absolute risk difference	NE	(-15.26, 100.00)	
p-value	NE	0.0938	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (50.0)	0
No	1 (100)	1 (50.0)	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.07	
95% CI of the inverse odds ratio	NE	(0.00, 2.56)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.13	
95% CI of the inverse risk ratio	NE	(0.01, 2.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	43.75	
95% CI of the absolute risk difference	NE	(-15.26, 100.00)	
p-value	NE	0.0938	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.8.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (50.0)	0
No	1 (100)	1 (50.0)	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.07	
95% CI of the inverse odds ratio	NE	(0.00, 2.56)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.13	
95% CI of the inverse risk ratio	NE	(0.01, 2.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	43.75	
95% CI of the absolute risk difference	NE	(-15.26, 100.00)	
p-value	NE	0.0938	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.0620	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (50.0)	1 (14.3)
No	1 (100)	1 (50.0)	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	0.17	
95% CI of the inverse odds ratio	(0.02, 26.90)	(0.01, 5.45)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	0.29	
95% CI of the inverse risk ratio	(0.05, 12.34)	(0.03, 2.80)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.25	35.71	
95% CI of the absolute risk difference	(-59.57, 72.07)	(-38.27, 100.00)	
p-value	0.8433	0.2840	
p-value of Breslow-Day Test for Homogeneity [3]	0.5094	0.3410	

AMNOG Table SE19.8.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	8 (100)	13 (100)	21 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	8 (100)	13 (100)	21 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.8.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	8 (100)	13 (100)	21 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	8 (100)	13 (100)	21 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.8.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	8 (100)	13 (100)	21 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	8 (100)	13 (100)	21 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.8.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (12.5)	0	1 (4.8)
No	7 (87.5)	13 (100)	20 (95.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.35	NE	
95% CI of the inverse odds ratio	(0.02, 6.38)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.38	NE	
95% CI of the inverse risk ratio	(0.03, 5.39)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.74	-4.76	
95% CI of the absolute risk difference	(-16.92, 32.40)	(-13.87, 4.35)	
p-value	0.4623	0.4245	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.0620	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (25.0)	1 (7.7)	2 (9.5)
No	6 (75.0)	12 (92.3)	19 (90.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.32	1.26	
95% CI of the inverse odds ratio	(0.04, 2.75)	(0.10, 15.49)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.38	1.24	
95% CI of the inverse risk ratio	(0.06, 2.27)	(0.12, 12.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	15.48	-1.83	
95% CI of the absolute risk difference	(-17.05, 48.00)	(-21.00, 17.34)	
p-value	0.2800	0.8548	
p-value of Breslow-Day Test for Homogeneity [3]	0.5094	0.3410	

Madrigal Pharmaceuticals, Inc. Page 1 of 8
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE19.9.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=8)	(N=10)	(N=20)	(N=8)	(N=10)	(N=20)
Absenteeism						
Baseline						
m	8	10	20			
n	2	2	5			
Mean (SD)	0.00 (0.00)	0.00 (0.00)	0.00 (0.00)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 0.0	0.0, 0.0	0.0, 0.0			
Week 24						
m	8	7	20			
n	2	2	9	2	0	5
Mean (SD/SE)	0.00 (0.00)	5.50 (7.78)	0.24 (0.73)	0.00 (0.00)	N/A	0.44 (0.44)
Median	0	5.50	0	0	N/A	0
IQR: Q1, Q3	0.00, 0.00	0.00, 11.00	0.00, 0.00	0.00, 0.00	N/A	0.00, 0.00
Min, Max	0.0, 0.0	0.0, 11.0	0.0, 2.2	0.0, 0.0	N/A	0.0, 2.2
Week 52						
m	8	7	19			
n	2	3	9	1	1	4
Mean (SD/SE)	0.00 (0.00)	0.00 (0.00)	6.78 (16.61)	0.00 (N/A)	0.00 (N/A)	0.00 (0.00)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 0.0	0.0, 0.0	0.0, 50.0	0.0, 0.0	0.0, 0.0	0.0, 0.0

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.9.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=8)	(N=10)	(N=20)	(N=8)	(N=10)	(N=20)
Presenteeism						
Baseline						
m	8	10	20			
n	2	2	5			
Mean (SD)	30.0 (42.4)	0.0 (0.0)	2.0 (4.5)			
Median	30.0	0	0			
IQR: Q1, Q3	0.0, 60.0	0.0, 0.0	0.0, 0.0			
Min, Max	0, 60	0, 0	0, 10			
Week 24						
m	8	7	20			
n	2	2	9	2	0	5
Mean (SD/SE)	0.0 (0.0)	5.0 (7.1)	4.4 (7.3)	-30.0 (30.0)	N/A	0.0 (0.0)
Median	0	5.0	0	-30.0	N/A	0
IQR: Q1, Q3	0.0, 0.0	0.0, 10.0	0.0, 10.0	-60.0, 0.0	N/A	0.0, 0.0
Min, Max	0, 0	0, 10	0, 20	-60, 0	N/A	0, 0
Week 52						
m	8	7	19			
n	2	3	9	1	1	4
Mean (SD/SE)	0.0 (0.0)	6.7 (11.5)	14.4 (25.1)	0.0 (N/A)	0.0 (N/A)	2.5 (2.5)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 20.0	0.0, 20.0	0.0, 0.0	0.0, 0.0	0.0, 5.0
Min, Max	0, 0	0, 20	0, 70	0, 0	0, 0	0, 10

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.9.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=8)	(N=10)	(N=20)	(N=8)	(N=10)	(N=20)
Overall Work Impairment						
Baseline						
m	8	10	20			
n	2	2	5			
Mean (SD)	30.00 (42.43)	0.00 (0.00)	2.00 (4.47)			
Median	30.00	0	0			
IQR: Q1, Q3	0.00, 60.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 60.0	0.0, 0.0	0.0, 10.0			
Week 24						
m	8	7	20			
n	2	2	9	2	0	5
Mean (SD/SE)	0.00 (0.00)	10.50 (0.71)	4.67 (7.48)	-30.00 (30.00)	N/A	0.40 (0.40)
Median	0	10.50	0	-30.00	N/A	0
IQR: Q1, Q3	0.00, 0.00	10.00, 11.00	0.00, 10.00	-60.00, 0.00	N/A	0.00, 0.00
Min, Max	0.0, 0.0	10.0, 11.0	0.0, 20.0	-60.0, 0.0	N/A	0.0, 2.0
Week 52						
m	8	7	19			
n	2	3	9	1	1	4
Mean (SD/SE)	0.00 (0.00)	6.67 (11.55)	16.84 (30.09)	0.00 (N/A)	0.00 (N/A)	2.50 (2.50)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 20.00	0.00, 20.00	0.00, 0.00	0.00, 0.00	0.00, 5.00
Min, Max	0.0, 0.0	0.0, 20.0	0.0, 85.0	0.0, 0.0	0.0, 0.0	0.0, 10.0

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.9.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=8)	(N=10)	(N=20)	(N=8)	(N=10)	(N=20)
Activity Impairment						
Baseline						
m	8	10	20			
n	6	3	11			
Mean (SD)	30.0 (43.8)	0.0 (0.0)	17.3 (26.5)			
Median	5.0	0	10.0			
IQR: Q1, Q3	0.0, 70.0	0.0, 0.0	0.0, 20.0			
Min, Max	0, 100	0, 0	0, 90			
Week 24						
m	8	7	20			
n	7	5	19	6	1	11
Mean (SD/SE)	1.4 (3.8)	10.0 (10.0)	11.6 (17.7)	-28.3 (16.6)	0.0 (N/A)	-8.2 (6.9)
Median	0	10.0	0	-5.0	0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 20.0	0.0, 20.0	-70.0, 0.0	0.0, 0.0	-20.0, 0.0
Min, Max	0, 10	0, 20	0, 70	-90, 0	0, 0	-70, 10
Week 52						
m	8	7	19			
n	7	5	17	5	2	10
Mean (SD/SE)	4.3 (7.9)	4.0 (8.9)	14.7 (22.4)	-10.0 (10.5)	0.0 (0.0)	3.0 (5.8)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.0, 10.0	0.0, 0.0	0.0, 20.0	-10.0, 0.0	0.0, 0.0	-10.0, 0.0
Min, Max	0, 20	0, 20	0, 70	-50, 10	0, 0	-20, 40

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.9.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=5)	(N=8)	(N=1)	(N=5)	(N=8)
Absenteeism						
Baseline						
m	1	5	8			
n	0	3	1			
Mean (SD)	N/A	0.00 (0.00)	0.00 (N/A)			
Median	N/A	0	0			
IQR: Q1, Q3	N/A	0.00, 0.00	0.00, 0.00			
Min, Max	N/A	0.0, 0.0	0.0, 0.0			
Week 24						
m	0	5	7			
n	0	4	3	0	3	1
Mean (SD/SE)	N/A	0.00 (0.00)	0.00 (0.00)	N/A	0.00 (0.00)	0.00 (N/A)
Median	N/A	0	0	N/A	0	0
IQR: Q1, Q3	N/A	0.00, 0.00	0.00, 0.00	N/A	0.00, 0.00	0.00, 0.00
Min, Max	N/A	0.0, 0.0	0.0, 0.0	N/A	0.0, 0.0	0.0, 0.0
Week 52						
m	0	5	7			
n	0	4	2	0	3	1
Mean (SD/SE)	N/A	12.50 (25.00)	0.00 (0.00)	N/A	0.00 (0.00)	0.00 (N/A)
Median	N/A	0	0	N/A	0	0
IQR: Q1, Q3	N/A	0.00, 25.00	0.00, 0.00	N/A	0.00, 0.00	0.00, 0.00
Min, Max	N/A	0.0, 50.0	0.0, 0.0	N/A	0.0, 0.0	0.0, 0.0

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.9.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=5)	(N=8)	(N=1)	(N=5)	(N=8)
Presenteeism						
Baseline						
m	1	5	8			
n	0	3	1			
Mean (SD)	N/A	6.7 (11.5)	0.0 (N/A)			
Median	N/A	0	0			
IQR: Q1, Q3	N/A	0.0, 20.0	0.0, 0.0			
Min, Max	N/A	0, 20	0, 0			
Week 24						
m	0	5	7			
n	0	4	3	0	3	1
Mean (SD/SE)	N/A	20.0 (33.7)	3.3 (5.8)	N/A	-3.3 (3.3)	10.0 (N/A)
Median	N/A	5.0	0	N/A	0	10.0
IQR: Q1, Q3	N/A	0.0, 40.0	0.0, 10.0	N/A	-10.0, 0.0	10.0, 10.0
Min, Max	N/A	0, 70	0, 10	N/A	-10, 0	10, 10
Week 52						
m	0	5	7			
n	0	4	2	0	3	1
Mean (SD/SE)	N/A	12.5 (25.0)	10.0 (14.1)	N/A	-6.7 (6.7)	20.0 (N/A)
Median	N/A	0	10.0	N/A	0	20.0
IQR: Q1, Q3	N/A	0.0, 25.0	0.0, 20.0	N/A	-20.0, 0.0	20.0, 20.0
Min, Max	N/A	0, 50	0, 20	N/A	-20, 0	20, 20

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.9.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=5)	(N=8)	(N=1)	(N=5)	(N=8)
Overall Work Impairment						
Baseline						
m	1	5	8			
n	0	3	1			
Mean (SD)	N/A	6.67 (11.55)	0.00 (N/A)			
Median	N/A	0	0			
IQR: Q1, Q3	N/A	0.00, 20.00	0.00, 0.00			
Min, Max	N/A	0.0, 20.0	0.0, 0.0			
Week 24						
m	0	5	7			
n	0	4	3	0	3	1
Mean (SD/SE)	N/A	20.00 (33.67)	3.33 (5.77)	N/A	-3.33 (3.33)	10.00 (N/A)
Median	N/A	5.00	0	N/A	0	10.00
IQR: Q1, Q3	N/A	0.00, 40.00	0.00, 10.00	N/A	-10.00, 0.00	10.00, 10.00
Min, Max	N/A	0.0, 70.0	0.0, 10.0	N/A	-10.0, 0.0	10.0, 10.0
Week 52						
m	0	5	7			
n	0	4	2	0	3	1
Mean (SD/SE)	N/A	18.75 (37.50)	10.00 (14.14)	N/A	-6.67 (6.67)	20.00 (N/A)
Median	N/A	0	10.00	N/A	0	20.00
IQR: Q1, Q3	N/A	0.00, 37.50	0.00, 20.00	N/A	-20.00, 0.00	20.00, 20.00
Min, Max	N/A	0.0, 75.0	0.0, 20.0	N/A	-20.0, 0.0	20.0, 20.0

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.9.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=5)	(N=8)	(N=1)	(N=5)	(N=8)
Activity Impairment						
Baseline						
m	1	5	8			
n	1	4	5			
Mean (SD)	0.0 (N/A)	7.5 (9.6)	16.0 (25.1)			
Median	0	5.0	10.0			
IQR: Q1, Q3	0.0, 0.0	0.0, 15.0	0.0, 10.0			
Min, Max	0, 0	0, 20	0, 60			
Week 24						
m	0	5	7			
n	0	5	7	0	4	5
Mean (SD/SE)	N/A	18.0 (29.5)	14.3 (25.7)	N/A	-2.5 (2.5)	-10.0 (13.0)
Median	N/A	10.0	0	N/A	0	0
IQR: Q1, Q3	N/A	0.0, 10.0	0.0, 20.0	N/A	-5.0, 0.0	-10.0, 10.0
Min, Max	N/A	0, 70	0, 70	N/A	-10, 0	-60, 10
Week 52						
m	0	5	7			
n	0	5	7	0	4	5
Mean (SD/SE)	N/A	10.0 (22.4)	27.1 (24.3)	N/A	-7.5 (4.8)	14.0 (7.5)
Median	N/A	0	30.0	N/A	-5.0	10.0
IQR: Q1, Q3	N/A	0.0, 0.0	0.0, 50.0	N/A	-15.0, 0.0	0.0, 20.0
Min, Max	N/A	0, 50	0, 60	N/A	-20, 0	0, 40

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.9.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. If the MMRM for LS Means does not converge with unstructured covariance, compound symmetry is used. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

AMNOG Table SE19.9.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Absenteeism			
Week 24			
m	8	7	20
n	2	0	5
Baseline Mean (SD)	0.00 (0.00)	N/A	0.00 (0.00)
Analysis Visit Mean (SD)	0.00 (0.00)	N/A	0.44 (0.98)
LS Mean of Change from Baseline (SE)	0.00 (0.52)	NE	0.34 (0.38)
95% CI	(-6.55, 6.55)	NE	(-4.47, 5.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.34 (0.64)	NE	
95% CI	(-8.47, 7.79)	NE	
p-value	0.6902	NE	
Corrected Hedge's g Statistics	-0.346	NE	
95% CI	(-2.00, 1.30)	NE	
Week 52			
m	8	7	19
n	1	1	4
Baseline Mean (SD)	0.00 (N/A)	0.00 (N/A)	0.00 (0.00)
Analysis Visit Mean (SD)	0.00 (N/A)	0.00 (N/A)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	-0.17 (0.80)	0.17 (0.80)	-0.17 (0.49)
95% CI	(-10.29, 9.95)	(-9.95, 10.29)	(-6.33, 5.99)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (0.82)	0.34 (1.04)	
95% CI	(-10.36, 10.36)	(-12.83, 13.51)	
p-value	>0.9999	0.7990	
Corrected Hedge's g Statistics	0.000	0.254	
95% CI	(-2.19, 2.19)	(-1.94, 2.45)	
Subgroup*Treatment Interaction p-value	NE	0.9178	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE19.9.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Presenteeism			
Week 24			
m	8	7	20
n	2	0	5
Baseline Mean (SD)	30.0 (42.4)	N/A	2.0 (4.5)
Analysis Visit Mean (SD)	0.0 (0.0)	N/A	2.0 (4.5)
LS Mean of Change from Baseline (SE)	-8.45 (3.51)	NE	-4.84 (1.89)
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.61 (3.84)	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	-0.696	NE	
95% CI	(-2.38, 0.98)	NE	
Week 52			
m	8	7	19
n	1	1	4
Baseline Mean (SD)	0.0 (N/A)	0.0 (N/A)	2.5 (5.0)
Analysis Visit Mean (SD)	0.0 (N/A)	0.0 (N/A)	5.0 (10.0)
LS Mean of Change from Baseline (SE)	4.35 (4.82)	7.96 (4.82)	4.35 (3.04)
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (4.17)	3.61 (5.66)	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	0.000	0.432	
95% CI	(-2.19, 2.19)	(-1.78, 2.64)	
Subgroup*Treatment Interaction p-value	NE	0.3042	

AMNOG Table SE19.9.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Overall Work Impairment			
Week 24			
m	8	7	20
n	2	0	5
Baseline Mean (SD)	30.0 (42.4)	N/A	2.0 (4.5)
Analysis Visit Mean (SD)	0.0 (0.0)	N/A	2.4 (5.4)
LS Mean of Change from Baseline (SE)	-8.91 (4.21)	NE	-4.57 (2.26)
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.34 (4.61)	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	-0.696	NE	
95% CI	(-2.38, 0.98)	NE	
Week 52			
m	8	7	19
n	1	1	4
Baseline Mean (SD)	0.0 (N/A)	0.0 (N/A)	2.5 (5.0)
Analysis Visit Mean (SD)	0.0 (N/A)	0.0 (N/A)	5.0 (10.0)
LS Mean of Change from Baseline (SE)	3.99 (5.79)	8.32 (5.79)	3.99 (3.65)
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (5.00)	4.34 (6.80)	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	0.000	0.432	
95% CI	(-2.19, 2.19)	(-1.78, 2.64)	
Subgroup*Treatment Interaction p-value	NE	0.3212	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE19.9.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Activity Impairment			
Week 24			
m	8	7	20
n	6	1	11
Baseline Mean (SD)	30.0 (43.8)	0.0 (N/A)	17.3 (26.5)
Analysis Visit Mean (SD)	1.7 (4.1)	0.0 (N/A)	9.1 (11.4)
LS Mean of Change from Baseline (SE)	-14.30 (6.75)	-9.35 (14.83)	-3.02 (7.53)
95% CI	(-29.34, 0.74)	(-42.39, 23.68)	(-19.81, 13.77)
LS Mean of Change from Baseline Compared to Placebo (SE)	-11.28 (7.18)	-6.33 (13.66)	
95% CI	(-27.28, 4.73)	(-36.77, 24.11)	
p-value	0.1475	0.6530	
Corrected Hedge's g Statistics	-0.475	-0.234	
95% CI	(-1.48, 0.53)	(-2.28, 1.82)	
Week 52			
m	8	7	19
n	5	2	10
Baseline Mean (SD)	16.0 (30.5)	0.0 (0.0)	17.0 (27.9)
Analysis Visit Mean (SD)	6.0 (8.9)	0.0 (0.0)	20.0 (27.1)
LS Mean of Change from Baseline (SE)	-7.31 (7.19)	-1.91 (11.29)	8.49 (7.82)
95% CI	(-23.32, 8.70)	(-27.06, 23.23)	(-8.94, 25.91)
LS Mean of Change from Baseline Compared to Placebo (SE)	-15.80 (7.55)	-10.40 (10.54)	
95% CI	(-32.61, 1.02)	(-33.88, 13.08)	
p-value	0.0628	0.3469	
Corrected Hedge's g Statistics	-0.663	-0.400	
95% CI	(-1.76, 0.44)	(-1.93, 1.13)	
Subgroup*Treatment Interaction p-value	NE	0.5898	

AMNOG Table SE19.9.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Absenteeism			
Week 24			
m	0	5	7
n	0	3	1
Baseline Mean (SD)	N/A	0.00 (0.00)	0.00 (N/A)
Analysis Visit Mean (SD)	N/A	0.00 (0.00)	0.00 (N/A)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	0	5	7
n	0	3	1
Baseline Mean (SD)	N/A	0.00 (0.00)	0.00 (N/A)
Analysis Visit Mean (SD)	N/A	0.00 (0.00)	0.00 (N/A)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	0.9178	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE19.9.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Presenteeism			
Week 24			
m	0	5	7
n	0	3	1
Baseline Mean (SD)	N/A	6.7 (11.5)	0.0 (N/A)
Analysis Visit Mean (SD)	N/A	3.3 (5.8)	10.0 (N/A)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	0	5	7
n	0	3	1
Baseline Mean (SD)	N/A	6.7 (11.5)	0.0 (N/A)
Analysis Visit Mean (SD)	N/A	0.0 (0.0)	20.0 (N/A)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	0.3042	

AMNOG Table SE19.9.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Overall Work Impairment			
Week 24			
m	0	5	7
n	0	3	1
Baseline Mean (SD)	N/A	6.7 (11.5)	0.0 (N/A)
Analysis Visit Mean (SD)	N/A	3.3 (5.8)	10.0 (N/A)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	0	5	7
n	0	3	1
Baseline Mean (SD)	N/A	6.7 (11.5)	0.0 (N/A)
Analysis Visit Mean (SD)	N/A	0.0 (0.0)	20.0 (N/A)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	0.3212	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE19.9.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Activity Impairment			
Week 24			
m	0	5	7
n	0	4	5
Baseline Mean (SD)	N/A	7.5 (9.6)	16.0 (25.1)
Analysis Visit Mean (SD)	N/A	5.0 (5.8)	6.0 (8.9)
LS Mean of Change from Baseline (SE)	NE	-10.96 (6.48)	-8.69 (5.44)
95% CI	NE	(-27.63, 5.71)	(-22.66, 5.28)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-2.27 (8.07)	
95% CI	NE	(-23.03, 18.49)	
p-value	NE	0.7898	
Corrected Hedge's g Statistics	NE	-0.161	
95% CI	NE	(-1.48, 1.16)	
Week 52			
m	0	5	7
n	0	4	5
Baseline Mean (SD)	N/A	7.5 (9.6)	16.0 (25.1)
Analysis Visit Mean (SD)	N/A	0.0 (0.0)	30.0 (25.5)
LS Mean of Change from Baseline (SE)	NE	-12.36 (6.48)	12.43 (5.44)
95% CI	NE	(-29.03, 4.31)	(-1.54, 26.40)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-24.79 (8.07)	
95% CI	NE	(-45.55, -4.04)	
p-value	NE	0.0278	
Corrected Hedge's g Statistics	NE	-1.762	
95% CI	NE	(-3.31, -0.22)	
Subgroup*Treatment Interaction p-value	NE	0.5898	

AMNOG Table SE19.9.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as a decrease of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.

AMNOG Table SE19.9.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	8 (100)	10 (100)	20 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	8 (100)	10 (100)	20 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.9.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	8 (100)	10 (100)	20 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	8 (100)	10 (100)	20 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.9.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	8 (100)	10 (100)	20 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	8 (100)	10 (100)	20 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.9.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (12.5)	0	1 (5.0)
No	7 (87.5)	10 (100)	19 (95.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.37	1.62	
95% CI of the inverse odds ratio	(0.02, 6.72)	(0.06, 43.25)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.40	1.57	
95% CI of the inverse risk ratio	(0.03, 5.65)	(0.07, 35.46)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.50	-2.60	
95% CI of the absolute risk difference	(-17.33, 32.33)	(-19.12, 13.92)	
p-value	0.4863	0.7731	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.1648	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (25.0)	0	3 (15.0)
No	6 (75.0)	10 (100)	17 (85.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.53	4.20	
95% CI of the inverse odds ratio	(0.07, 3.98)	(0.20, 89.61)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	3.67	
95% CI of the inverse risk ratio	(0.12, 2.94)	(0.21, 64.80)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	10.00	-12.12	
95% CI of the absolute risk difference	(-23.84, 43.84)	(-32.26, 8.02)	
p-value	0.5325	0.3248	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.0224	

AMNOG Table SE19.9.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	1 (100)	5 (100)	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	1 (100)	5 (100)	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.9.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (20.0)	0
No	1 (100)	4 (80.0)	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.18	
95% CI of the inverse odds ratio	NE	(0.01, 5.28)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.22	
95% CI of the inverse risk ratio	NE	(0.01, 4.60)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	19.44	
95% CI of the absolute risk difference	NE	(-18.30, 57.19)	
p-value	NE	0.2778	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (20.0)	0
No	1 (100)	4 (80.0)	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.18	
95% CI of the inverse odds ratio	NE	(0.01, 5.28)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.22	
95% CI of the inverse risk ratio	NE	(0.01, 4.60)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	19.44	
95% CI of the absolute risk difference	NE	(-18.30, 57.19)	
p-value	NE	0.2778	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.9.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (20.0)	0
No	1 (100)	4 (80.0)	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.18	
95% CI of the inverse odds ratio	NE	(0.01, 5.28)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.22	
95% CI of the inverse risk ratio	NE	(0.01, 4.60)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	19.44	
95% CI of the absolute risk difference	NE	(-18.30, 57.19)	
p-value	NE	0.2778	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (20.0)	0
No	1 (100)	4 (80.0)	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.18	
95% CI of the inverse odds ratio	NE	(0.01, 5.28)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.22	
95% CI of the inverse risk ratio	NE	(0.01, 4.60)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	19.44	
95% CI of the absolute risk difference	NE	(-18.30, 57.19)	
p-value	NE	0.2778	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.9.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (20.0)	0
No	1 (100)	4 (80.0)	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.18	
95% CI of the inverse odds ratio	NE	(0.01, 5.28)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.22	
95% CI of the inverse risk ratio	NE	(0.01, 4.60)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	19.44	
95% CI of the absolute risk difference	NE	(-18.30, 57.19)	
p-value	NE	0.2778	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.1648	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (40.0)	0
No	1 (100)	3 (60.0)	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.08	
95% CI of the inverse odds ratio	NE	(0.00, 2.19)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.13	
95% CI of the inverse risk ratio	NE	(0.01, 2.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	36.11	
95% CI of the absolute risk difference	NE	(-6.08, 78.30)	
p-value	NE	0.0867	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.0224	

Program: t-se18-02-04-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.10.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=5)	(N=5)	(N=17)	(N=5)	(N=5)	(N=17)
Absenteeism						
Baseline						
m	5	5	17			
n	0	2	4			
Mean (SD)	N/A	0.00 (0.00)	0.00 (0.00)			
Median	N/A	0	0			
IQR: Q1, Q3	N/A	0.00, 0.00	0.00, 0.00			
Min, Max	N/A	0.0, 0.0	0.0, 0.0			
Week 24						
m	4	4	16			
n	0	2	9	0	2	4
Mean (SD/SE)	N/A	0.00 (0.00)	0.24 (0.73)	N/A	0.00 (0.00)	0.55 (0.55)
Median	N/A	0	0	N/A	0	0
IQR: Q1, Q3	N/A	0.00, 0.00	0.00, 0.00	N/A	0.00, 0.00	0.00, 1.10
Min, Max	N/A	0.0, 0.0	0.0, 2.2	N/A	0.0, 0.0	0.0, 2.2
Week 52						
m	4	4	15			
n	1	2	7	0	2	3
Mean (SD/SE)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)	N/A	0.00 (0.00)	0.00 (0.00)
Median	0	0	0	N/A	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	N/A	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 0.0	0.0, 0.0	0.0, 0.0	N/A	0.0, 0.0	0.0, 0.0

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.10.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=5)	(N=5)	(N=17)	(N=5)	(N=5)	(N=17)
Presenteeism						
Baseline						
m	5	5	17			
n	0	2	4			
Mean (SD)	N/A	10.0 (14.1)	2.5 (5.0)			
Median	N/A	10.0	0			
IQR: Q1, Q3	N/A	0.0, 20.0	0.0, 5.0			
Min, Max	N/A	0, 20	0, 10			
Week 24						
m	4	4	16			
n	0	2	9	0	2	4
Mean (SD/SE)	N/A	5.0 (7.1)	3.3 (7.1)	N/A	-5.0 (5.0)	0.0 (0.0)
Median	N/A	5.0	0	N/A	-5.0	0
IQR: Q1, Q3	N/A	0.0, 10.0	0.0, 0.0	N/A	-10.0, 0.0	0.0, 0.0
Min, Max	N/A	0, 10	0, 20	N/A	-10, 0	0, 0
Week 52						
m	4	4	15			
n	1	2	7	0	2	3
Mean (SD/SE)	0.0 (N/A)	0.0 (0.0)	2.9 (7.6)	N/A	-10.0 (10.0)	3.3 (3.3)
Median	0	0	0	N/A	-10.0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 0.0	0.0, 0.0	N/A	-20.0, 0.0	0.0, 10.0
Min, Max	0, 0	0, 0	0, 20	N/A	-20, 0	0, 10

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.10.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=5)	(N=5)	(N=17)	(N=5)	(N=5)	(N=17)
Overall Work Impairment						
Baseline						
m	5	5	17			
n	0	2	4			
Mean (SD)	N/A	10.00 (14.14)	2.50 (5.00)			
Median	N/A	10.00	0			
IQR: Q1, Q3	N/A	0.00, 20.00	0.00, 5.00			
Min, Max	N/A	0.0, 20.0	0.0, 10.0			
Week 24						
m	4	4	16			
n	0	2	9	0	2	4
Mean (SD/SE)	N/A	5.00 (7.07)	3.56 (7.33)	N/A	-5.00 (5.00)	0.50 (0.50)
Median	N/A	5.00	0	N/A	-5.00	0
IQR: Q1, Q3	N/A	0.00, 10.00	0.00, 0.00	N/A	-10.00, 0.00	0.00, 1.00
Min, Max	N/A	0.0, 10.0	0.0, 20.0	N/A	-10.0, 0.0	0.0, 2.0
Week 52						
m	4	4	15			
n	1	2	7	0	2	3
Mean (SD/SE)	0.00 (N/A)	0.00 (0.00)	2.86 (7.56)	N/A	-10.00 (10.00)	3.33 (3.33)
Median	0	0	0	N/A	-10.00	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	N/A	-20.00, 0.00	0.00, 10.00
Min, Max	0.0, 0.0	0.0, 0.0	0.0, 20.0	N/A	-20.0, 0.0	0.0, 10.0

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.10.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=5)	(N=5)	(N=17)	(N=5)	(N=5)	(N=17)
Activity Impairment						
Baseline						
m	5	5	17			
n	4	4	10			
Mean (SD)	17.5 (35.0)	7.5 (9.6)	13.0 (19.5)			
Median	0	5.0	5.0			
IQR: Q1, Q3	0.0, 35.0	0.0, 15.0	0.0, 20.0			
Min, Max	0, 70	0, 20	0, 60			
Week 24						
m	4	4	16			
n	3	4	15	3	4	10
Mean (SD/SE)	0.0 (0.0)	5.0 (5.8)	12.0 (19.7)	-23.3 (23.3)	-2.5 (2.5)	-5.0 (6.7)
Median	0	5.0	0	0	0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 10.0	0.0, 20.0	-70.0, 0.0	-5.0, 0.0	0.0, 10.0
Min, Max	0, 0	0, 10	0, 70	-70, 0	-10, 0	-60, 10
Week 52						
m	4	4	15			
n	4	4	14	3	4	10
Mean (SD/SE)	7.5 (9.6)	0.0 (0.0)	15.0 (23.1)	-13.3 (18.6)	-7.5 (4.8)	8.0 (5.1)
Median	5.0	0	0	0	-5.0	0
IQR: Q1, Q3	0.0, 15.0	0.0, 0.0	0.0, 30.0	-50.0, 10.0	-15.0, 0.0	0.0, 20.0
Min, Max	0, 20	0, 0	0, 60	-50, 10	-20, 0	-10, 40

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE19.10.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter	Visit Result			Change from Baseline		
	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Absenteeism						
Baseline						
m	4	10	11			
n	2	3	2			
Mean (SD)	0.00 (0.00)	0.00 (0.00)	0.00 (0.00)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 0.0	0.0, 0.0	0.0, 0.0			
Week 24						
m	4	8	11			
n	2	4	3	2	1	2
Mean (SD/SE)	0.00 (0.00)	2.75 (5.50)	0.00 (0.00)	0.00 (0.00)	0.00 (N/A)	0.00 (0.00)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 5.50	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 0.0	0.0, 11.0	0.0, 0.0	0.0, 0.0	0.0, 0.0	0.0, 0.0
Week 52						
m	4	8	11			
n	1	5	4	1	2	2
Mean (SD/SE)	0.00 (N/A)	10.00 (22.36)	15.25 (23.74)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)
Median	0	0	5.50	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 30.50	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 0.0	0.0, 50.0	0.0, 50.0	0.0, 0.0	0.0, 0.0	0.0, 0.0

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.10.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=10)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=10)	Change from Baseline DB Placebo (N=11)
Presenteeism						
Baseline						
m	4	10	11			
n	2	3	2			
Mean (SD)	30.0 (42.4)	0.0 (0.0)	0.0 (0.0)			
Median	30.0	0	0			
IQR: Q1, Q3	0.0, 60.0	0.0, 0.0	0.0, 0.0			
Min, Max	0, 60	0, 0	0, 0			
Week 24						
m	4	8	11			
n	2	4	3	2	1	2
Mean (SD/SE)	0.0 (0.0)	20.0 (33.7)	6.7 (5.8)	-30.0 (30.0)	0.0 (N/A)	5.0 (5.0)
Median	0	5.0	10.0	-30.0	0	5.0
IQR: Q1, Q3	0.0, 0.0	0.0, 40.0	0.0, 10.0	-60.0, 0.0	0.0, 0.0	0.0, 10.0
Min, Max	0, 0	0, 70	0, 10	-60, 0	0, 0	0, 10
Week 52						
m	4	8	11			
n	1	5	4	1	2	2
Mean (SD/SE)	0.0 (N/A)	14.0 (21.9)	32.5 (29.9)	0.0 (N/A)	0.0 (0.0)	10.0 (10.0)
Median	0	0	30.0	0	0	10.0
IQR: Q1, Q3	0.0, 0.0	0.0, 20.0	10.0, 55.0	0.0, 0.0	0.0, 0.0	0.0, 20.0
Min, Max	0, 0	0, 50	0, 70	0, 0	0, 0	0, 20

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.10.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Visit Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=10)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=10)	Change from Baseline DB Placebo (N=11)
Overall Work Impairment						
Baseline						
m	4	10	11			
n	2	3	2			
Mean (SD)	30.00 (42.43)	0.00 (0.00)	0.00 (0.00)			
Median	30.00	0	0			
IQR: Q1, Q3	0.00, 60.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 60.0	0.0, 0.0	0.0, 0.0			
Week 24						
m	4	8	11			
n	2	4	3	2	1	2
Mean (SD/SE)	0.00 (0.00)	22.75 (31.89)	6.67 (5.77)	-30.00 (30.00)	0.00 (N/A)	5.00 (5.00)
Median	0	10.50	10.00	-30.00	0	5.00
IQR: Q1, Q3	0.00, 0.00	5.00, 40.50	0.00, 10.00	-60.00, 0.00	0.00, 0.00	0.00, 10.00
Min, Max	0.0, 0.0	0.0, 70.0	0.0, 10.0	-60.0, 0.0	0.0, 0.0	0.0, 10.0
Week 52						
m	4	8	11			
n	1	5	4	1	2	2
Mean (SD/SE)	0.00 (N/A)	19.00 (32.48)	37.90 (36.75)	0.00 (N/A)	0.00 (0.00)	10.00 (10.00)
Median	0	0	33.30	0	0	10.00
IQR: Q1, Q3	0.00, 0.00	0.00, 20.00	10.00, 65.80	0.00, 0.00	0.00, 0.00	0.00, 20.00
Min, Max	0.0, 0.0	0.0, 75.0	0.0, 85.0	0.0, 0.0	0.0, 0.0	0.0, 20.0

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.10.1
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=10)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=10)	Change from Baseline DB Placebo (N=11)
Activity Impairment						
Baseline						
m	4	10	11			
n	3	3	6			
Mean (SD)	36.7 (55.1)	0.0 (0.0)	23.3 (33.9)			
Median	10.0	0	15.0			
IQR: Q1, Q3	0.0, 100.0	0.0, 0.0	0.0, 20.0			
Min, Max	0, 100	0, 0	0, 90			
Week 24						
m	4	8	11			
n	4	6	11	3	1	6
Mean (SD/SE)	2.5 (5.0)	20.0 (26.1)	12.7 (20.5)	-33.3 (28.5)	0.0 (N/A)	-15.0 (11.8)
Median	0	15.0	10.0	-10.0	0	-5.0
IQR: Q1, Q3	0.0, 5.0	0.0, 20.0	0.0, 20.0	-90.0, 0.0	0.0, 0.0	-20.0, 0.0
Min, Max	0, 10	0, 70	0, 70	-90, 0	0, 0	-70, 10
Week 52						
m	4	8	11			
n	3	6	10	2	2	5
Mean (SD/SE)	0.0 (0.0)	11.7 (20.4)	23.0 (23.6)	-5.0 (5.0)	0.0 (0.0)	4.0 (10.3)
Median	0	0	10.0	-5.0	0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 20.0	10.0, 40.0	-10.0, 0.0	0.0, 0.0	-10.0, 10.0
Min, Max	0, 0	0, 50	0, 70	-10, 0	0, 0	-20, 40

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE19.10.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on WPAI-NASH analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. If the MMRM for LS Means does not converge with unstructured covariance, compound symmetry is used. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

AMNOG Table SE19.10.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Absenteeism			
Week 24			
m	4	4	16
n	0	2	4
Baseline Mean (SD)	N/A	0.00 (0.00)	0.00 (0.00)
Analysis Visit Mean (SD)	N/A	0.00 (0.00)	0.55 (1.10)
LS Mean of Change from Baseline (SE)	NE	-0.37 (0.75)	0.37 (0.65)
95% CI	NE	(-3.59, 2.85)	(-2.44, 3.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-0.73 (0.87)	
95% CI	NE	(-4.49, 3.02)	
p-value	NE	0.4892	
Corrected Hedge's g Statistics	NE	-0.470	
95% CI	NE	(-2.19, 1.25)	
Week 52			
m	4	4	15
n	0	2	3
Baseline Mean (SD)	N/A	0.00 (0.00)	0.00 (0.00)
Analysis Visit Mean (SD)	N/A	0.00 (0.00)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	NE	-0.37 (0.75)	-0.37 (0.78)
95% CI	NE	(-3.59, 2.85)	(-3.71, 2.98)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	0.00 (0.87)	
95% CI	NE	(-3.76, 3.76)	
p-value	NE	>0.9999	
Corrected Hedge's g Statistics	NE	0.000	
95% CI	NE	(-1.79, 1.79)	
Subgroup*Treatment Interaction p-value	NE	0.6068	

AMNOG Table SE19.10.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Presenteeism			
Week 24			
m	4	4	16
n	0	2	4
Baseline Mean (SD)	N/A	10.0 (14.1)	2.5 (5.0)
Analysis Visit Mean (SD)	N/A	5.0 (7.1)	2.5 (5.0)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	4	4	15
n	0	2	3
Baseline Mean (SD)	N/A	10.0 (14.1)	3.3 (5.8)
Analysis Visit Mean (SD)	N/A	0.0 (0.0)	6.7 (11.5)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	0.1799	

AMNOG Table SE19.10.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Overall Work Impairment			
Week 24			
m	4	4	16
n	0	2	4
Baseline Mean (SD)	N/A	10.0 (14.1)	2.5 (5.0)
Analysis Visit Mean (SD)	N/A	5.0 (7.1)	3.0 (6.0)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	4	4	15
n	0	2	3
Baseline Mean (SD)	N/A	10.0 (14.1)	3.3 (5.8)
Analysis Visit Mean (SD)	N/A	0.0 (0.0)	6.7 (11.5)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	0.1452	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE19.10.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Activity Impairment			
Week 24			
m	4	4	16
n	3	4	10
Baseline Mean (SD)	23.3 (40.4)	7.5 (9.6)	13.0 (19.5)
Analysis Visit Mean (SD)	0.0 (0.0)	5.0 (5.8)	8.0 (11.4)
LS Mean of Change from Baseline (SE)	-15.03 (8.42)	-10.68 (8.38)	-7.54 (6.00)
95% CI	(-33.57, 3.50)	(-29.12, 7.76)	(-20.75, 5.67)
LS Mean of Change from Baseline Compared to Placebo (SE)	-7.49 (9.73)	-3.14 (8.47)	
95% CI	(-28.90, 13.92)	(-21.77, 15.50)	
p-value	0.4576	0.7181	
Corrected Hedge's g Statistics	-0.381	-0.159	
95% CI	(-1.68, 0.92)	(-1.32, 1.00)	
Week 52			
m	4	4	15
n	3	4	10
Baseline Mean (SD)	23.3 (40.4)	7.5 (9.6)	13.0 (19.5)
Analysis Visit Mean (SD)	10.0 (10.0)	0.0 (0.0)	21.0 (25.1)
LS Mean of Change from Baseline (SE)	-10.19 (8.42)	-12.51 (8.38)	5.73 (6.00)
95% CI	(-28.73, 8.34)	(-30.94, 5.93)	(-7.47, 18.94)
LS Mean of Change from Baseline Compared to Placebo (SE)	-15.93 (9.73)	-18.24 (8.47)	
95% CI	(-37.34, 5.48)	(-36.88, 0.39)	
p-value	0.1298	0.0542	
Corrected Hedge's g Statistics	-0.812	-0.926	
95% CI	(-2.14, 0.52)	(-2.13, 0.28)	
Subgroup*Treatment Interaction p-value	0.7953	0.9493	

AMNOG Table SE19.10.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Absenteeism			
Week 24			
m	4	8	11
n	2	1	2
Baseline Mean (SD)	0.00 (0.00)	0.00 (N/A)	0.00 (0.00)
Analysis Visit Mean (SD)	0.00 (0.00)	0.00 (N/A)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	4	8	11
n	1	2	2
Baseline Mean (SD)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)
Analysis Visit Mean (SD)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	0.6068	

AMNOG Table SE19.10.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Presenteeism			
Week 24			
m	4	8	11
n	2	1	2
Baseline Mean (SD)	30.0 (42.4)	0.0 (N/A)	0.0 (0.0)
Analysis Visit Mean (SD)	0.0 (0.0)	0.0 (N/A)	5.0 (7.1)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	4	8	11
n	1	2	2
Baseline Mean (SD)	0.0 (N/A)	0.0 (0.0)	0.0 (0.0)
Analysis Visit Mean (SD)	0.0 (N/A)	0.0 (0.0)	10.0 (14.1)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	0.1799	

AMNOG Table SE19.10.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Overall Work Impairment			
Week 24			
m	4	8	11
n	2	1	2
Baseline Mean (SD)	30.0 (42.4)	0.0 (N/A)	0.0 (0.0)
Analysis Visit Mean (SD)	0.0 (0.0)	0.0 (N/A)	5.0 (7.1)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	4	8	11
n	1	2	2
Baseline Mean (SD)	0.0 (N/A)	0.0 (0.0)	0.0 (0.0)
Analysis Visit Mean (SD)	0.0 (N/A)	0.0 (0.0)	10.0 (14.1)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	0.1452	

AMNOG Table SE19.10.2
Work Productivity and Activity Impairment-NASH (SE19): Summary of Results - MMRM Model by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Activity Impairment			
Week 24			
m	4	8	11
n	3	1	6
Baseline Mean (SD)	36.7 (55.1)	0.0 (N/A)	23.3 (33.9)
Analysis Visit Mean (SD)	3.3 (5.8)	0.0 (N/A)	8.3 (9.8)
LS Mean of Change from Baseline (SE)	-16.16 (6.70)	-24.91 (10.68)	-12.04 (4.54)
95% CI	(-44.98, 12.66)	(-70.86, 21.04)	(-31.60, 7.51)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.12 (8.02)	-12.87 (11.67)	
95% CI	(-38.62, 30.38)	(-63.09, 37.35)	
p-value	0.6588	0.3852	
Corrected Hedge's g Statistics	-0.325	-0.973	
95% CI	(-1.72, 1.07)	(-3.15, 1.20)	
Week 52			
m	4	8	11
n	2	2	5
Baseline Mean (SD)	5.0 (7.1)	0.0 (0.0)	24.0 (37.8)
Analysis Visit Mean (SD)	0.0 (0.0)	0.0 (0.0)	28.0 (30.3)
LS Mean of Change from Baseline (SE)	2.33 (8.62)	-10.75 (8.39)	5.60 (4.89)
95% CI	(-34.76, 39.41)	(-46.84, 25.35)	(-15.42, 26.62)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.27 (9.77)	-16.35 (9.92)	
95% CI	(-45.30, 38.77)	(-59.02, 26.32)	
p-value	0.7698	0.2411	
Corrected Hedge's g Statistics	-0.246	-1.238	
95% CI	(-1.89, 1.40)	(-3.00, 0.53)	
Subgroup*Treatment Interaction p-value	0.7953	0.9493	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE19.10.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as a decrease of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.

AMNOG Table SE19.10.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	5 (100)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	5 (100)	5 (100)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.10.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (20.0)	0
No	5 (100)	4 (80.0)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.09	
95% CI of the inverse odds ratio	NE	(0.00, 2.48)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.11	
95% CI of the inverse risk ratio	NE	(0.01, 2.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	22.22	
95% CI of the absolute risk difference	NE	(-13.25, 57.69)	
p-value	NE	0.0881	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (20.0)	0
No	5 (100)	4 (80.0)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.09	
95% CI of the inverse odds ratio	NE	(0.00, 2.48)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.11	
95% CI of the inverse risk ratio	NE	(0.01, 2.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	22.22	
95% CI of the absolute risk difference	NE	(-13.25, 57.69)	
p-value	NE	0.0881	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.10.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (20.0)	0
No	5 (100)	4 (80.0)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.09	
95% CI of the inverse odds ratio	NE	(0.00, 2.48)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.11	
95% CI of the inverse risk ratio	NE	(0.01, 2.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	22.22	
95% CI of the absolute risk difference	NE	(-13.25, 57.69)	
p-value	NE	0.0881	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (20.0)	0
No	5 (100)	4 (80.0)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.09	
95% CI of the inverse odds ratio	NE	(0.00, 2.48)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.11	
95% CI of the inverse risk ratio	NE	(0.01, 2.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	22.22	
95% CI of the absolute risk difference	NE	(-13.25, 57.69)	
p-value	NE	0.0881	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.10.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (20.0)	1 (20.0)	0
No	4 (80.0)	4 (80.0)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.09	0.09	
95% CI of the inverse odds ratio	(0.00, 2.48)	(0.00, 2.48)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.11	0.11	
95% CI of the inverse risk ratio	(0.01, 2.38)	(0.01, 2.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	22.22	22.22	
95% CI of the absolute risk difference	(-13.25, 57.69)	(-13.25, 57.69)	
p-value	0.0881	0.0881	
p-value of Breslow-Day Test for Homogeneity [3]	0.1219	0.0516	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (20.0)	2 (40.0)	1 (5.9)
No	4 (80.0)	3 (60.0)	16 (94.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.25	0.09	
95% CI of the inverse odds ratio	(0.01, 4.92)	(0.01, 1.39)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.29	0.15	
95% CI of the inverse risk ratio	(0.02, 3.91)	(0.02, 1.31)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	14.12	34.12	
95% CI of the absolute risk difference	(-22.68, 50.92)	(-10.26, 78.49)	
p-value	0.3344	0.0507	
p-value of Breslow-Day Test for Homogeneity [3]	0.6316	0.0205	

AMNOG Table SE19.10.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	4 (100)	10 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	4 (100)	10 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.10.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	4 (100)	10 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	4 (100)	10 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.10.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	4 (100)	10 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	4 (100)	10 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE19.10.3
Work Productivity and Activity Impairment-NASH (SE19): Summary of Response at Week 52 by Domain
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (9.1)
No	4 (100)	10 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	3.00	
95% CI of the inverse odds ratio	(0.04, 37.98)	(0.11, 82.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	2.75	
95% CI of the inverse risk ratio	(0.06, 25.76)	(0.12, 60.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-7.95	
95% CI of the absolute risk difference	(-34.77, 29.77)	(-30.35, 14.44)	
p-value	0.8841	0.4988	
p-value of Breslow-Day Test for Homogeneity [3]	0.1219	0.0516	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (25.0)	0	2 (18.2)
No	3 (75.0)	10 (100)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	5.53	
95% CI of the inverse odds ratio	(0.04, 10.25)	(0.23, 130.34)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	4.58	
95% CI of the inverse risk ratio	(0.09, 6.00)	(0.25, 85.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.82	-16.29	
95% CI of the absolute risk difference	(-41.35, 54.99)	(-42.36, 9.78)	
p-value	0.7703	0.2466	
p-value of Breslow-Day Test for Homogeneity [3]	0.6316	0.0205	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.2.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=11)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=11)	Change from Baseline DB Placebo (N=11)
Total LDQOL						
Baseline						
m	2	11	11			
n	2	10	9			
Mean (SD)	68.60 (5.37)	88.25 (5.71)	84.82 (6.70)			
Median	68.60	89.05	82.80			
IQR: Q1, Q3	64.80, 72.40	86.80, 92.80	80.40, 87.80			
Min, Max	64.8, 72.4	75.2, 94.8	76.3, 97.8			
Week 24						
m	2	8	11			
n	2	7	9	2	7	8
Mean (SD/SE)	73.75 (0.64)	84.23 (9.24)	84.00 (10.33)	5.15 (3.35)	-5.71 (3.20)	-0.70 (2.91)
Median	73.75	79.00	81.70	5.15	-5.40	-1.15
IQR: Q1, Q3	73.30, 74.20	77.40, 93.10	80.00, 93.70	1.80, 8.50	-10.60, -0.40	-7.15, 4.45
Min, Max	73.3, 74.2	75.0, 98.9	68.1, 98.1	1.8, 8.5	-19.8, 6.1	-11.2, 13.3
Week 52						
m	2	8	10			
n	1	6	8	1	6	7
Mean (SD/SE)	79.60 (N/A)	84.32 (6.51)	82.30 (11.19)	7.20 (N/A)	-5.68 (2.29)	-3.26 (3.09)
Median	79.60	84.35	81.85	7.20	-4.85	-2.90
IQR: Q1, Q3	79.60, 79.60	79.20, 88.70	73.45, 91.05	7.20, 7.20	-7.60, -1.30	-9.00, 6.80
Min, Max	79.6, 79.6	75.6, 93.7	67.6, 98.1	7.2, 7.2	-15.6, 0.1	-14.5, 7.2

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.2.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=2)	(N=11)	(N=11)	(N=2)	(N=11)	(N=11)
Symptoms of Liver Disease						
Baseline						
m	2	11	11			
n	2	10	9			
Mean (SD)	66.65 (18.88)	84.67 (12.19)	76.29 (15.78)			
Median	66.65	85.00	70.00			
IQR: Q1, Q3	53.30, 80.00	80.00, 93.30	63.30, 90.00			
Min, Max	53.3, 80.0	56.7, 100.0	53.3, 100.0			
Week 24						
m	2	8	11			
n	2	7	9	2	7	8
Mean (SD/SE)	66.65 (4.74)	87.14 (10.43)	81.47 (16.43)	0.00 (16.70)	-1.43 (6.20)	8.75 (5.63)
Median	66.65	90.00	83.30	0	3.30	8.35
IQR: Q1, Q3	63.30, 70.00	83.30, 93.30	70.00, 93.30	-16.70, 16.70	-6.70, 6.70	-3.35, 15.00
Min, Max	63.3, 70.0	66.7, 100.0	53.3, 100.0	-16.7, 16.7	-33.3, 20.0	-10.0, 40.0
Week 52						
m	2	8	10			
n	1	6	8	1	6	7
Mean (SD/SE)	76.70 (N/A)	80.55 (10.18)	80.00 (15.00)	-3.30 (N/A)	-6.12 (5.66)	5.73 (4.75)
Median	76.70	80.00	80.00	-3.30	-5.00	6.70
IQR: Q1, Q3	76.70, 76.70	73.30, 90.00	70.00, 91.65	-3.30, -3.30	-20.00, 3.30	-6.60, 10.00
Min, Max	76.7, 76.7	66.7, 93.3	56.7, 100.0	-3.3, -3.3	-23.3, 13.3	-6.7, 30.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.2.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=2)	(N=11)	(N=11)	(N=2)	(N=11)	(N=11)
Effects of Liver Disease						
Baseline						
m	2	11	11			
n	2	10	9			
Mean (SD)	56.65 (33.02)	83.34 (7.21)	83.70 (8.24)			
Median	56.65	80.00	80.00			
IQR: Q1, Q3	33.30, 80.00	80.00, 86.70	80.00, 86.70			
Min, Max	33.3, 80.0	73.3, 100.0	73.3, 100.0			
Week 24						
m	2	8	11			
n	2	7	9	2	7	8
Mean (SD/SE)	80.00 (0.00)	83.80 (11.47)	80.74 (10.78)	23.35 (23.35)	-0.01 (5.04)	-4.16 (6.16)
Median	80.00	80.00	80.00	23.35	0	0
IQR: Q1, Q3	80.00, 80.00	73.30, 100.00	80.00, 86.70	0.00, 46.70	-6.70, 13.30	-10.00, 3.35
Min, Max	80.0, 80.0	73.3, 100.0	60.0, 100.0	0.0, 46.7	-20.0, 20.0	-40.0, 20.0
Week 52						
m	2	8	10			
n	1	6	8	1	6	7
Mean (SD/SE)	80.00 (N/A)	82.22 (9.11)	82.50 (7.93)	0.00 (N/A)	-2.23 (4.44)	-0.96 (5.13)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	80.00, 80.00	80.00, 80.00	80.00, 83.35	0.00, 0.00	-6.70, 0.00	0.00, 0.00
Min, Max	80.0, 80.0	73.3, 100.0	73.3, 100.0	0.0, 0.0	-20.0, 13.3	-26.7, 20.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.2.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=11)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=11)	Change from Baseline DB Placebo (N=11)
Concentration/Memory						
Baseline						
m	2	11	11			
n	2	10	9			
Mean (SD)	81.25 (26.52)	90.64 (15.66)	88.90 (12.00)			
Median	81.25	96.90	87.50			
IQR: Q1, Q3	62.50, 100.00	87.50, 100.00	81.30, 100.00			
Min, Max	62.5, 100.0	50.0, 100.0	68.8, 100.0			
Week 24						
m	2	8	11			
n	2	7	9	2	7	8
Mean (SD/SE)	62.50 (17.68)	90.20 (9.43)	90.30 (12.91)	-18.75 (6.25)	-5.36 (2.86)	5.48 (3.82)
Median	62.50	87.50	93.80	-18.75	0	3.15
IQR: Q1, Q3	50.00, 75.00	81.30, 100.00	87.50, 100.00	-25.00, -12.50	-12.50, 0.00	0.00, 15.60
Min, Max	50.0, 75.0	81.3, 100.0	68.8, 100.0	-25.0, -12.5	-18.7, 0.0	-12.5, 18.8
Week 52						
m	2	8	10			
n	1	6	8	1	6	7
Mean (SD/SE)	68.80 (N/A)	91.67 (10.21)	86.75 (11.77)	6.30 (N/A)	-6.27 (4.56)	-1.77 (4.86)
Median	68.80	93.75	87.55	6.30	-3.15	0
IQR: Q1, Q3	68.80, 68.80	87.50, 100.00	78.15, 96.90	6.30, 6.30	-12.50, 0.00	-6.20, 12.50
Min, Max	68.8, 68.8	75.0, 100.0	68.8, 100.0	6.3, 6.3	-25.0, 6.2	-25.0, 12.5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.2.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=11)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=11)	Change from Baseline DB Placebo (N=11)
Health Distress						
Baseline						
m	2	11	11			
n	2	10	9			
Mean (SD)	81.25 (8.84)	95.00 (6.45)	93.06 (11.02)			
Median	81.25	100.00	100.00			
IQR: Q1, Q3	75.00, 87.50	87.50, 100.00	87.50, 100.00			
Min, Max	75.0, 87.5	87.5, 100.0	75.0, 100.0			
Week 24						
m	2	8	11			
n	2	7	9	2	7	8
Mean (SD/SE)	93.75 (8.84)	94.64 (9.83)	94.44 (12.67)	12.50 (12.50)	0.00 (4.72)	1.56 (4.38)
Median	93.75	100.00	100.00	12.50	0	0
IQR: Q1, Q3	87.50, 100.00	87.50, 100.00	100.00, 100.00	0.00, 25.00	0.00, 12.50	-6.25, 6.25
Min, Max	87.5, 100.0	75.0, 100.0	62.5, 100.0	0.0, 25.0	-25.0, 12.5	-12.5, 25.0
Week 52						
m	2	8	10			
n	1	6	8	1	6	7
Mean (SD/SE)	100.00 (N/A)	95.83 (10.21)	95.31 (6.47)	12.50 (N/A)	2.08 (5.97)	0.00 (3.86)
Median	100.00	100.00	100.00	12.50	6.25	0
IQR: Q1, Q3	100.00, 100.00	100.00, 100.00	87.50, 100.00	12.50, 12.50	0.00, 12.50	-12.50, 12.50
Min, Max	100.0, 100.0	75.0, 100.0	87.5, 100.0	12.5, 12.5	-25.0, 12.5	-12.5, 12.5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.2.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=11)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=11)	Change from Baseline DB Placebo (N=11)
Sexual Function						
Baseline						
m	2	11	11			
n	1	5	5			
Mean (SD)	83.30 (N/A)	97.00 (6.71)	84.66 (14.51)			
Median	83.30	100.00	78.30			
IQR: Q1, Q3	83.30, 83.30	100.00, 100.00	76.70, 100.00			
Min, Max	83.3, 83.3	85.0, 100.0	68.3, 100.0			
Week 24						
m	2	8	11			
n	0	4	4	0	4	4
Mean (SD/SE)	N/A	88.33 (19.15)	82.50 (25.13)	N/A	-7.93 (5.91)	-6.25 (8.59)
Median	N/A	96.65	91.65	N/A	-3.35	0
IQR: Q1, Q3	N/A	76.65, 100.00	65.00, 100.00	N/A	-15.85, 0.00	-15.80, 3.30
Min, Max	N/A	60.0, 100.0	46.7, 100.0	N/A	-25.0, 0.0	-31.6, 6.6
Week 52						
m	2	8	10			
n	0	3	5	0	3	3
Mean (SD/SE)	N/A	97.77 (3.87)	67.66 (44.38)	N/A	-2.23 (2.23)	-21.10 (21.10)
Median	N/A	100.00	100.00	N/A	0	0
IQR: Q1, Q3	N/A	93.30, 100.00	23.30, 100.00	N/A	-6.70, 0.00	-63.30, 0.00
Min, Max	N/A	93.3, 100.0	15.0, 100.0	N/A	-6.7, 0.0	-63.3, 0.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc. Page 7 of 20
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.2.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=2)	(N=11)	(N=11)	(N=2)	(N=11)	(N=11)
Sleep						
Baseline						
m	2	11	11			
n	2	10	9			
Mean (SD)	25.0 (35.4)	73.5 (9.7)	62.8 (26.9)			
Median	25.0	75.0	70.0			
IQR: Q1, Q3	0.0, 50.0	65.0, 80.0	40.0, 80.0			
Min, Max	0, 50	60, 90	30, 100			
Week 24						
m	2	8	11			
n	2	7	9	2	7	8
Mean (SD/SE)	27.5 (38.9)	67.9 (12.5)	67.2 (17.3)	2.5 (2.5)	-2.9 (3.6)	1.9 (5.7)
Median	27.5	65.0	70.0	2.5	0	0
IQR: Q1, Q3	0.0, 55.0	60.0, 80.0	60.0, 80.0	0.0, 5.0	-15.0, 5.0	-10.0, 12.5
Min, Max	0, 55	55, 90	35, 85	0, 5	-15, 10	-20, 30
Week 52						
m	2	8	10			
n	1	6	8	1	6	7
Mean (SD/SE)	55.0 (N/A)	62.5 (12.5)	66.9 (16.7)	5.0 (N/A)	-9.2 (4.5)	-4.3 (5.8)
Median	55.0	60.0	65.0	5.0	-10.0	0
IQR: Q1, Q3	55.0, 55.0	50.0, 75.0	57.5, 77.5	5.0, 5.0	-15.0, 0.0	-20.0, 5.0
Min, Max	55, 55	50, 80	40, 95	5, 5	-25, 5	-25, 20

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc. Page 8 of 20
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.2.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=11)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=11)	Change from Baseline DB Placebo (N=11)
Loneliness						
Baseline						
m	2	11	11			
n	2	10	9			
Mean (SD)	75.0 (21.2)	91.0 (15.8)	95.0 (11.5)			
Median	75.0	97.5	100.0			
IQR: Q1, Q3	60.0, 90.0	90.0, 100.0	95.0, 100.0			
Min, Max	60, 90	50, 100	65, 100			
Week 24						
m	2	8	11			
n	2	7	9	2	7	8
Mean (SD/SE)	90.0 (7.1)	82.1 (20.0)	88.3 (16.2)	15.0 (10.0)	-16.4 (8.0)	-7.5 (4.6)
Median	90.0	90.0	100.0	15.0	-5.0	0
IQR: Q1, Q3	85.0, 95.0	60.0, 100.0	80.0, 100.0	5.0, 25.0	-40.0, 0.0	-12.5, 0.0
Min, Max	85, 95	50, 100	60, 100	5, 25	-50, 5	-35, 0
Week 52						
m	2	8	10			
n	1	6	8	1	6	7
Mean (SD/SE)	75.0 (N/A)	87.5 (22.3)	86.3 (16.6)	15.0 (N/A)	-11.7 (9.4)	-9.3 (4.4)
Median	75.0	100.0	92.5	15.0	0	-5.0
IQR: Q1, Q3	75.0, 75.0	80.0, 100.0	72.5, 100.0	15.0, 15.0	-20.0, 0.0	-20.0, 0.0
Min, Max	75, 75	45, 100	60, 100	15, 15	-55, 5	-30, 0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.2.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=11)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=11)	Change from Baseline DB Placebo (N=11)
Hopelessness						
Baseline						
m	2	11	11			
n	2	10	9			
Mean (SD)	79.20 (17.68)	94.17 (13.07)	92.60 (16.37)			
Median	79.20	100.00	100.00			
IQR: Q1, Q3	66.70, 91.70	91.70, 100.00	91.70, 100.00			
Min, Max	66.7, 91.7	58.3, 100.0	50.0, 100.0			
Week 24						
m	2	8	11			
n	2	7	9	2	7	8
Mean (SD/SE)	79.20 (17.68)	84.51 (21.75)	86.12 (19.97)	0.00 (25.00)	-8.34 (7.04)	-5.20 (3.12)
Median	79.20	100.00	91.70	0	0	0
IQR: Q1, Q3	66.70, 91.70	58.30, 100.00	83.30, 100.00	-25.00, 25.00	-8.40, 0.00	-8.30, 0.00
Min, Max	66.7, 91.7	50.0, 100.0	41.7, 100.0	-25.0, 25.0	-50.0, 0.0	-25.0, 0.0
Week 52						
m	2	8	10			
n	1	6	8	1	6	7
Mean (SD/SE)	100.00 (N/A)	90.28 (13.34)	86.46 (18.33)	33.30 (N/A)	-1.38 (7.58)	-5.96 (3.95)
Median	100.00	95.85	95.85	33.30	0	0
IQR: Q1, Q3	100.00, 100.00	83.30, 100.00	75.00, 100.00	33.30, 33.30	0.00, 0.00	-16.70, 0.00
Min, Max	100.0, 100.0	66.7, 100.0	50.0, 100.0	33.3, 33.3	-33.3, 25.0	-25.0, 0.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.2.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=2)	(N=11)	(N=11)	(N=2)	(N=11)	(N=11)
Stigma of Liver Disease						
Baseline						
m	2	11	11			
n	2	10	9			
Mean (SD)	78.15 (4.45)	90.02 (10.69)	85.43 (12.88)			
Median	78.15	90.65	81.30			
IQR: Q1, Q3	75.00, 81.30	81.30, 100.00	81.30, 100.00			
Min, Max	75.0, 81.3	75.0, 100.0	62.5, 100.0			
Week 24						
m	2	8	11			
n	2	7	9	2	7	8
Mean (SD/SE)	90.65 (13.22)	83.04 (20.00)	84.03 (17.97)	12.50 (12.50)	-8.04 (7.31)	-4.70 (5.24)
Median	90.65	87.50	87.50	12.50	0	-3.15
IQR: Q1, Q3	81.30, 100.00	62.50, 100.00	75.00, 100.00	0.00, 25.00	-12.50, 0.00	-12.50, 3.10
Min, Max	81.3, 100.0	50.0, 100.0	43.8, 100.0	0.0, 25.0	-50.0, 6.2	-31.2, 18.7
Week 52						
m	2	8	10			
n	1	6	8	1	6	7
Mean (SD/SE)	81.30 (N/A)	78.13 (20.06)	85.18 (18.56)	0.00 (N/A)	-11.47 (8.30)	-3.57 (4.69)
Median	81.30	78.15	87.50	0	0	0
IQR: Q1, Q3	81.30, 81.30	62.50, 100.00	81.30, 100.00	0.00, 0.00	-18.80, 0.00	0.00, 0.00
Min, Max	81.3, 81.3	50.0, 100.0	43.8, 100.0	0.0, 0.0	-50.0, 0.0	-31.2, 6.2

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.2.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Visit Statistic	Visit Result DB MGL-3196 80 mg (N=7)	 DB MGL-3196 100 mg (N=4)	 DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=7)	 DB MGL-3196 100 mg (N=4)	 DB Placebo (N=17)
Total LDQOL						
Baseline						
m	7	4	17			
n	7	4	17			
Mean (SD)	84.90 (13.60)	83.93 (6.87)	87.16 (8.68)			
Median	91.30	84.00	90.90			
IQR: Q1, Q3	76.50, 93.90	78.00, 89.85	85.00, 93.50			
Min, Max	57.3, 94.0	77.4, 90.3	64.4, 97.0			
Week 24						
m	6	4	16			
n	5	4	16	5	4	16
Mean (SD/SE)	85.64 (12.82)	85.58 (7.77)	84.30 (11.89)	-0.16 (1.60)	1.65 (3.19)	-2.59 (1.77)
Median	90.30	82.45	85.25	-0.90	3.70	-0.80
IQR: Q1, Q3	90.10, 92.00	81.05, 90.10	82.50, 94.10	-2.20, 0.70	-2.35, 5.65	-7.70, 1.30
Min, Max	62.8, 93.0	80.3, 97.1	52.0, 97.1	-3.9, 5.5	-7.6, 6.8	-17.6, 8.5
Week 52						
m	6	4	16			
n	6	4	16	6	4	16
Mean (SD/SE)	82.73 (21.09)	84.98 (4.10)	83.94 (12.65)	-3.57 (2.84)	1.05 (2.64)	-2.96 (2.79)
Median	90.25	86.30	86.80	-0.85	-0.80	-0.35
IQR: Q1, Q3	88.30, 92.80	82.55, 87.40	80.60, 93.60	-4.00, 0.70	-2.45, 4.55	-4.35, 2.55
Min, Max	40.0, 94.8	79.0, 88.3	51.7, 95.5	-17.3, 0.9	-2.9, 8.7	-40.4, 6.9

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.2.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=7)	(N=4)	(N=17)	(N=7)	(N=4)	(N=17)
Symptoms of Liver Disease						
Baseline						
m	7	4	17			
n	7	4	17			
Mean (SD)	91.44 (7.89)	79.98 (18.26)	86.86 (13.62)			
Median	93.30	86.65	90.00			
IQR: Q1, Q3	86.70, 96.70	68.30, 91.65	83.30, 96.70			
Min, Max	76.7, 100.0	53.3, 93.3	50.0, 100.0			
Week 24						
m	6	4	16			
n	5	4	16	5	4	16
Mean (SD/SE)	93.34 (8.50)	91.68 (5.76)	82.92 (15.39)	1.32 (0.81)	11.70 (8.44)	-3.54 (4.78)
Median	96.70	90.00	85.00	0	5.05	0
IQR: Q1, Q3	90.00, 100.00	88.35, 95.00	76.65, 95.00	0.00, 3.30	1.70, 21.70	-10.00, 5.05
Min, Max	80.0, 100.0	86.7, 100.0	36.7, 100.0	0.0, 3.3	0.0, 36.7	-60.0, 23.3
Week 52						
m	6	4	16			
n	6	4	16	6	4	16
Mean (SD/SE)	87.22 (15.10)	84.18 (19.69)	87.70 (11.73)	-5.02 (3.30)	4.20 (4.80)	1.24 (3.16)
Median	93.30	90.00	93.30	-3.35	3.40	3.30
IQR: Q1, Q3	90.00, 93.30	70.00, 98.35	78.35, 96.70	-6.70, 0.00	-1.65, 10.05	0.00, 6.70
Min, Max	56.7, 96.7	56.7, 100.0	63.3, 100.0	-20.0, 3.3	-6.7, 16.7	-36.7, 20.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.2.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=7)	(N=4)	(N=17)	(N=7)	(N=4)	(N=17)
Effects of Liver Disease						
Baseline						
m	7	4	17			
n	7	4	17			
Mean (SD)	77.16 (16.70)	91.68 (9.99)	80.01 (4.72)			
Median	80.00	93.35	80.00			
IQR: Q1, Q3	66.70, 86.70	83.35, 100.00	80.00, 80.00			
Min, Max	46.7, 100.0	80.0, 100.0	66.7, 86.7			
Week 24						
m	6	4	16			
n	5	4	16	5	4	16
Mean (SD/SE)	80.00 (0.00)	83.33 (6.65)	78.34 (6.67)	2.66 (8.58)	-8.35 (4.19)	-1.67 (1.14)
Median	80.00	80.00	80.00	0	-6.70	0
IQR: Q1, Q3	80.00, 80.00	80.00, 86.65	80.00, 80.00	0.00, 0.00	-13.35, -3.35	-3.35, 0.00
Min, Max	80.0, 80.0	80.0, 93.3	60.0, 86.7	-20.0, 33.3	-20.0, 0.0	-13.3, 6.7
Week 52						
m	6	4	16			
n	6	4	16	6	4	16
Mean (SD/SE)	72.22 (26.13)	81.68 (3.35)	80.01 (6.43)	-6.68 (5.96)	-10.00 (5.77)	0.00 (1.92)
Median	80.00	80.00	80.00	-3.35	-10.00	0
IQR: Q1, Q3	80.00, 80.00	80.00, 83.35	80.00, 80.00	-20.00, 0.00	-20.00, 0.00	0.00, 0.00
Min, Max	20.0, 93.3	80.0, 86.7	66.7, 93.3	-26.7, 13.3	-20.0, 0.0	-20.0, 13.3

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.2.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=4)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=4)	Change from Baseline DB Placebo (N=17)
Concentration/Memory						
Baseline						
m	7	4	17			
n	7	4	17			
Mean (SD)	82.16 (22.92)	65.65 (24.18)	89.72 (15.46)			
Median	87.50	59.40	93.80			
IQR: Q1, Q3	56.30, 100.00	50.05, 81.25	87.50, 100.00			
Min, Max	43.8, 100.0	43.8, 100.0	37.5, 100.0			
Week 24						
m	6	4	16			
n	5	4	16	5	4	16
Mean (SD/SE)	86.28 (23.95)	76.58 (24.15)	85.95 (13.97)	0.02 (1.98)	10.93 (6.95)	-3.51 (4.38)
Median	93.80	78.15	87.50	0	6.20	0
IQR: Q1, Q3	93.80, 100.00	56.25, 96.90	75.05, 100.00	0.00, 0.00	3.10, 18.75	-12.50, 6.25
Min, Max	43.8, 100.0	50.0, 100.0	62.5, 100.0	-6.2, 6.3	0.0, 31.3	-37.5, 31.3
Week 52						
m	6	4	16			
n	6	4	16	6	4	16
Mean (SD/SE)	75.00 (37.91)	75.03 (23.37)	81.66 (21.94)	-11.47 (6.93)	9.38 (5.98)	-7.80 (4.54)
Median	87.50	78.15	93.80	-6.25	6.25	-3.10
IQR: Q1, Q3	75.00, 100.00	59.40, 90.65	62.50, 100.00	-12.50, 0.00	0.00, 18.75	-12.50, 3.10
Min, Max	0.0, 100.0	43.8, 100.0	43.8, 100.0	-43.8, 0.0	0.0, 25.0	-50.0, 12.5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.2.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=7)	(N=4)	(N=17)	(N=7)	(N=4)	(N=17)
Health Distress						
Baseline						
m	7	4	17			
n	7	4	17			
Mean (SD)	76.79 (37.10)	100.00 (0.00)	95.59 (13.21)			
Median	100.00	100.00	100.00			
IQR: Q1, Q3	62.50, 100.00	100.00, 100.00	100.00, 100.00			
Min, Max	0.0, 100.0	100.0, 100.0	50.0, 100.0			
Week 24						
m	6	4	16			
n	5	4	16	5	4	16
Mean (SD/SE)	77.50 (43.66)	96.88 (6.25)	90.63 (14.79)	2.50 (2.50)	-3.13 (3.13)	-4.69 (3.20)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	87.50, 100.00	93.75, 100.00	81.25, 100.00	0.00, 0.00	-6.25, 0.00	-12.50, 0.00
Min, Max	0.0, 100.0	87.5, 100.0	50.0, 100.0	0.0, 12.5	-12.5, 0.0	-25.0, 25.0
Week 52						
m	6	4	16			
n	6	4	16	6	4	16
Mean (SD/SE)	81.25 (40.12)	93.75 (12.50)	88.28 (19.62)	2.08 (2.08)	-6.25 (6.25)	-7.03 (4.70)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	87.50, 100.00	87.50, 100.00	81.25, 100.00	0.00, 0.00	-12.50, 0.00	-12.50, 0.00
Min, Max	0.0, 100.0	75.0, 100.0	37.5, 100.0	0.0, 12.5	-25.0, 0.0	-62.5, 25.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.2.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=4)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=4)	Change from Baseline DB Placebo (N=17)
Sexual Function						
Baseline						
m	7	4	17			
n	3	1	8			
Mean (SD)	95.00 (4.40)	85.00 (N/A)	93.54 (6.26)			
Median	93.30	85.00	93.30			
IQR: Q1, Q3	91.70, 100.00	85.00, 85.00	88.35, 100.00			
Min, Max	91.7, 100.0	85.0, 85.0	85.0, 100.0			
Week 24						
m	6	4	16			
n	2	1	6	2	1	5
Mean (SD/SE)	80.85 (15.34)	85.00 (N/A)	95.27 (6.01)	-15.80 (7.50)	0.00 (N/A)	1.66 (1.30)
Median	80.85	85.00	96.65	-15.80	0	0
IQR: Q1, Q3	70.00, 91.70	85.00, 85.00	93.30, 100.00	-23.30, -8.30	0.00, 0.00	0.00, 1.60
Min, Max	70.0, 91.7	85.0, 85.0	85.0, 100.0	-23.3, -8.3	0.0, 0.0	0.0, 6.7
Week 52						
m	6	4	16			
n	2	1	6	2	1	5
Mean (SD/SE)	92.50 (10.61)	93.30 (N/A)	88.60 (13.57)	-4.15 (4.15)	8.30 (N/A)	-3.66 (4.04)
Median	92.50	93.30	92.50	-4.15	8.30	0
IQR: Q1, Q3	85.00, 100.00	93.30, 93.30	78.30, 100.00	-8.30, 0.00	8.30, 8.30	-8.30, 0.00
Min, Max	85.0, 100.0	93.3, 93.3	68.3, 100.0	-8.3, 0.0	8.3, 8.3	-16.7, 6.7

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.2.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=4)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=4)	Change from Baseline DB Placebo (N=17)
Sleep						
Baseline						
m	7	4	17			
n	7	4	17			
Mean (SD)	70.7 (15.7)	70.0 (10.8)	70.9 (18.7)			
Median	75.0	67.5	70.0			
IQR: Q1, Q3	65.0, 80.0	62.5, 77.5	55.0, 85.0			
Min, Max	40, 90	60, 85	40, 100			
Week 24						
m	6	4	16			
n	5	4	16	5	4	16
Mean (SD/SE)	72.0 (6.7)	63.8 (21.4)	71.3 (16.7)	2.0 (5.6)	-6.3 (6.6)	0.6 (3.1)
Median	75.0	62.5	65.0	0	-2.5	2.5
IQR: Q1, Q3	75.0, 75.0	47.5, 80.0	60.0, 87.5	0.0, 5.0	-15.0, 2.5	-5.0, 5.0
Min, Max	60, 75	40, 90	45, 100	-15, 20	-25, 5	-30, 20
Week 52						
m	6	4	16			
n	6	4	16	6	4	16
Mean (SD/SE)	66.7 (19.7)	67.5 (6.5)	70.0 (19.8)	-5.0 (2.2)	-2.5 (3.2)	-0.6 (4.7)
Median	70.0	67.5	72.5	-5.0	-2.5	0
IQR: Q1, Q3	65.0, 80.0	62.5, 72.5	55.0, 85.0	-10.0, -5.0	-7.5, 2.5	-10.0, 12.5
Min, Max	30, 85	60, 75	35, 95	-10, 5	-10, 5	-35, 35

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.2.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=4)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=4)	Change from Baseline DB Placebo (N=17)
Loneliness						
Baseline						
m	7	4	17			
n	7	4	17			
Mean (SD)	93.6 (8.0)	97.5 (2.9)	92.6 (9.7)			
Median	100.0	97.5	100.0			
IQR: Q1, Q3	85.0, 100.0	95.0, 100.0	85.0, 100.0			
Min, Max	85, 100	95, 100	75, 100			
Week 24						
m	6	4	16			
n	5	4	16	5	4	16
Mean (SD/SE)	91.0 (12.4)	96.3 (4.8)	86.9 (18.7)	-3.0 (2.0)	-1.3 (1.3)	-5.3 (3.7)
Median	100.0	97.5	100.0	0	0	0
IQR: Q1, Q3	80.0, 100.0	92.5, 100.0	77.5, 100.0	-5.0, 0.0	-2.5, 0.0	-7.5, 0.0
Min, Max	75, 100	90, 100	35, 100	-10, 0	-5, 0	-45, 10
Week 52						
m	6	4	16			
n	6	4	16	6	4	16
Mean (SD/SE)	96.7 (8.2)	93.8 (9.5)	89.1 (16.1)	1.7 (2.8)	-3.8 (5.5)	-3.1 (3.4)
Median	100.0	97.5	97.5	0	0	0
IQR: Q1, Q3	100.0, 100.0	87.5, 100.0	80.0, 100.0	0.0, 0.0	-10.0, 2.5	-7.5, 0.0
Min, Max	80, 100	80, 100	45, 100	-5, 15	-20, 5	-35, 20

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.2.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=4)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=4)	Change from Baseline DB Placebo (N=17)
Hopelessness						
Baseline						
m	7	4	17			
n	7	4	17			
Mean (SD)	90.49 (11.21)	89.60 (15.76)	85.79 (20.15)			
Median	91.70	95.85	91.70			
IQR: Q1, Q3	75.00, 100.00	79.20, 100.00	83.30, 100.00			
Min, Max	75.0, 100.0	66.7, 100.0	33.3, 100.0			
Week 24						
m	6	4	16			
n	5	4	16	5	4	16
Mean (SD/SE)	96.66 (7.47)	87.50 (19.86)	86.98 (24.15)	-0.02 (2.64)	-2.10 (2.10)	2.08 (3.09)
Median	100.00	95.85	100.00	0	0	0
IQR: Q1, Q3	100.00, 100.00	75.00, 100.00	83.35, 100.00	0.00, 0.00	-4.20, 0.00	-4.15, 8.30
Min, Max	83.3, 100.0	58.3, 100.0	25.0, 100.0	-8.4, 8.3	-8.4, 0.0	-16.7, 25.0
Week 52						
m	6	4	16			
n	6	4	16	6	4	16
Mean (SD/SE)	93.05 (8.21)	91.68 (16.65)	88.02 (18.51)	-0.02 (2.16)	2.08 (2.08)	3.12 (3.80)
Median	95.85	100.00	100.00	0	0	0
IQR: Q1, Q3	83.30, 100.00	83.35, 100.00	83.30, 100.00	0.00, 0.00	0.00, 4.15	0.00, 16.70
Min, Max	83.3, 100.0	66.7, 100.0	50.0, 100.0	-8.4, 8.3	0.0, 8.3	-33.4, 25.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.2.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=7)	(N=4)	(N=17)	(N=7)	(N=4)	(N=17)
Stigma of Liver Disease						
Baseline						
m	7	4	17			
n	7	4	17			
Mean (SD)	93.76 (9.55)	75.03 (18.42)	93.03 (13.23)			
Median	100.00	78.15	100.00			
IQR: Q1, Q3	87.50, 100.00	62.50, 87.55	93.80, 100.00			
Min, Max	75.0, 100.0	50.0, 93.8	50.0, 100.0			
Week 24						
m	6	4	16			
n	5	4	16	5	4	16
Mean (SD/SE)	92.52 (10.27)	87.50 (14.43)	87.51 (25.62)	-1.24 (1.24)	12.48 (14.66)	-6.25 (3.28)
Median	93.80	87.50	100.00	0	9.35	0
IQR: Q1, Q3	93.80, 100.00	75.00, 100.00	84.40, 100.00	0.00, 0.00	-9.40, 34.35	-9.35, 0.00
Min, Max	75.0, 100.0	75.0, 100.0	0.0, 100.0	-6.2, 0.0	-18.8, 50.0	-50.0, 0.0
Week 52						
m	6	4	16			
n	6	4	16	6	4	16
Mean (SD/SE)	89.60 (19.64)	90.65 (10.83)	87.53 (18.54)	-3.12 (5.04)	15.63 (10.37)	-6.24 (4.34)
Median	96.90	93.80	93.80	0	9.35	0
IQR: Q1, Q3	93.80, 100.00	84.40, 96.90	87.55, 100.00	-6.20, 0.00	0.00, 31.25	-6.20, 0.00
Min, Max	50.0, 100.0	75.0, 100.0	43.8, 100.0	-25.0, 12.5	0.0, 43.8	-56.2, 12.5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc. Page 1 of 3
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.2.2
Liver Disease Quality of Life (SE20): Summary of Total LDQOL - MMRM Model
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.2.2
Liver Disease Quality of Life (SE20): Summary of Total LDQOL - MMRM Model
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Total LDQOL			
Week 24			
m	2	8	11
n	2	7	8
Baseline Mean (SD)	68.60 (5.37)	89.94 (4.12)	85.15 (7.09)
Analysis Visit Mean (SD)	73.75 (0.64)	84.23 (9.24)	84.45 (10.95)
LS Mean of Change from Baseline (SE)	5.14 (9.39)	-6.48 (4.25)	-0.65 (3.07)
95% CI	(-14.99, 25.28)	(-15.59, 2.63)	(-7.22, 5.92)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.79 (9.62)	-5.83 (5.41)	
95% CI	(-14.85, 26.43)	(-17.44, 5.78)	
p-value	0.5567	0.2998	
Corrected Hedge's g Statistics	0.558	-0.552	
95% CI	(-1.01, 2.13)	(-1.59, 0.48)	
Week 52			
m	2	8	10
n	1	6	7
Baseline Mean (SD)	72.40 (N/A)	90.00 (4.51)	86.09 (7.10)
Analysis Visit Mean (SD)	79.60 (N/A)	84.32 (6.51)	82.83 (11.98)
LS Mean of Change from Baseline (SE)	11.27 (8.13)	-7.53 (3.76)	-2.99 (2.60)
95% CI	(-6.18, 28.71)	(-15.60, 0.53)	(-8.57, 2.58)
LS Mean of Change from Baseline Compared to Placebo (SE)	14.26 (8.38)	-4.54 (4.73)	
95% CI	(-3.72, 32.24)	(-14.68, 5.59)	
p-value	0.1111	0.3529	
Corrected Hedge's g Statistics	1.803	-0.526	
95% CI	(-0.47, 4.08)	(-1.64, 0.58)	
Subgroup*Treatment Interaction p-value	0.5814	0.1418	

AMNOG Table SE20.2.2
Liver Disease Quality of Life (SE20): Summary of Total LDQOL - MMRM Model
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Total LDQOL			
Week 24			
m	6	4	16
n	5	4	16
Baseline Mean (SD)	85.80 (15.97)	83.93 (6.87)	86.89 (8.89)
Analysis Visit Mean (SD)	85.64 (12.82)	85.58 (7.77)	84.30 (11.89)
LS Mean of Change from Baseline (SE)	0.96 (3.49)	2.25 (3.66)	-1.57 (2.79)
95% CI	(-6.28, 8.21)	(-5.35, 9.85)	(-7.35, 4.20)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.54 (3.48)	3.83 (3.90)	
95% CI	(-4.68, 9.76)	(-4.27, 11.92)	
p-value	0.4738	0.3374	
Corrected Hedge's g Statistics	0.231	0.346	
95% CI	(-0.78, 1.24)	(-0.76, 1.45)	
Week 52			
m	6	4	16
n	6	4	16
Baseline Mean (SD)	86.30 (14.34)	83.93 (6.87)	86.89 (8.89)
Analysis Visit Mean (SD)	82.73 (21.09)	84.98 (4.10)	83.94 (12.65)
LS Mean of Change from Baseline (SE)	-2.46 (4.57)	1.87 (5.26)	-2.00 (3.36)
95% CI	(-11.95, 7.02)	(-9.05, 12.79)	(-8.97, 4.98)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.47 (4.86)	3.87 (5.75)	
95% CI	(-10.55, 9.62)	(-8.07, 15.80)	
p-value	0.9246	0.5086	
Corrected Hedge's g Statistics	-0.035	0.285	
95% CI	(-0.97, 0.90)	(-0.81, 1.38)	
Subgroup*Treatment Interaction p-value	0.5814	0.1418	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.2.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

AMNOG Table SE20.2.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Symptoms of Liver Disease			
Week 24			
m	2	8	11
n	2	7	8
Baseline Mean (SD)	66.65 (18.88)	88.57 (8.58)	74.99 (16.34)
Analysis Visit Mean (SD)	66.65 (4.74)	87.14 (10.43)	83.74 (15.99)
LS Mean of Change from Baseline (SE)	-11.74 (10.95)	3.96 (6.28)	5.01 (5.22)
95% CI	(-35.23, 11.74)	(-9.50, 17.43)	(-6.20, 16.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	-16.75 (11.79)	-1.04 (8.68)	
95% CI	(-42.04, 8.54)	(-19.66, 17.57)	
p-value	0.1774	0.9060	
Corrected Hedge's g Statistics	-1.018	-0.063	
95% CI	(-2.63, 0.59)	(-1.08, 0.95)	
Week 52			
m	2	8	10
n	1	6	7
Baseline Mean (SD)	80.00 (N/A)	86.67 (7.60)	75.70 (17.52)
Analysis Visit Mean (SD)	76.70 (N/A)	80.55 (10.18)	81.43 (15.61)
LS Mean of Change from Baseline (SE)	-0.44 (10.96)	-5.77 (5.66)	3.01 (4.71)
95% CI	(-23.95, 23.07)	(-17.91, 6.37)	(-7.10, 13.11)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.45 (11.87)	-8.78 (7.86)	
95% CI	(-28.90, 22.01)	(-25.62, 8.07)	
p-value	0.7757	0.2826	
Corrected Hedge's g Statistics	-0.241	-0.622	
95% CI	(-2.34, 1.86)	(-1.74, 0.49)	
Subgroup*Treatment Interaction p-value	0.2357	0.3100	

AMNOG Table SE20.2.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Effects of Liver Disease			
Week 24			
m	2	8	11
n	2	7	8
Baseline Mean (SD)	56.65 (33.02)	83.81 (8.49)	85.00 (7.76)
Analysis Visit Mean (SD)	80.00 (0.00)	83.80 (11.47)	80.84 (11.52)
LS Mean of Change from Baseline (SE)	-3.39 (10.71)	2.95 (4.44)	-1.12 (4.08)
95% CI	(-26.36, 19.59)	(-6.56, 12.47)	(-9.87, 7.63)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.27 (11.85)	4.07 (5.99)	
95% CI	(-27.68, 23.15)	(-8.77, 16.91)	
p-value	0.8509	0.5074	
Corrected Hedge's g Statistics	-0.170	0.330	
95% CI	(-1.72, 1.38)	(-0.69, 1.35)	
Week 52			
m	2	8	10
n	1	6	7
Baseline Mean (SD)	80.00 (N/A)	84.45 (9.12)	83.81 (7.56)
Analysis Visit Mean (SD)	80.00 (N/A)	82.22 (9.11)	82.86 (8.49)
LS Mean of Change from Baseline (SE)	-1.35 (8.55)	-0.37 (3.53)	0.19 (3.18)
95% CI	(-19.69, 17.00)	(-7.93, 7.19)	(-6.63, 7.01)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.54 (9.36)	-0.56 (4.73)	
95% CI	(-21.61, 18.53)	(-10.71, 9.58)	
p-value	0.8718	0.9066	
Corrected Hedge's g Statistics	-0.159	-0.062	
95% CI	(-2.26, 1.94)	(-1.15, 1.03)	
Subgroup*Treatment Interaction p-value	0.8468	0.6402	

AMNOG Table SE20.2.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Concentration/Memory			
Week 24			
m	2	8	11
n	2	7	8
Baseline Mean (SD)	81.25 (26.52)	95.56 (6.93)	87.51 (12.03)
Analysis Visit Mean (SD)	62.50 (17.68)	90.20 (9.43)	92.99 (10.78)
LS Mean of Change from Baseline (SE)	-20.60 (6.50)	-1.98 (3.60)	4.07 (3.07)
95% CI	(-34.54, -6.66)	(-9.70, 5.73)	(-2.51, 10.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	-24.67 (7.09)	-6.06 (4.89)	
95% CI	(-39.88, -9.46)	(-16.56, 4.44)	
p-value	0.0037	0.2362	
Corrected Hedge's g Statistics	-2.547	-0.628	
95% CI	(-4.46, -0.64)	(-1.67, 0.41)	
Week 52			
m	2	8	10
n	1	6	7
Baseline Mean (SD)	62.50 (N/A)	97.93 (3.20)	89.30 (11.79)
Analysis Visit Mean (SD)	68.80 (N/A)	91.67 (10.21)	87.53 (12.49)
LS Mean of Change from Baseline (SE)	-9.85 (13.98)	-0.18 (5.22)	-2.22 (4.11)
95% CI	(-39.84, 20.15)	(-11.38, 11.02)	(-11.04, 6.59)
LS Mean of Change from Baseline Compared to Placebo (SE)	-7.62 (14.31)	2.04 (6.88)	
95% CI	(-38.32, 23.07)	(-12.70, 16.79)	
p-value	0.6026	0.7708	
Corrected Hedge's g Statistics	-0.609	0.161	
95% CI	(-2.73, 1.51)	(-0.93, 1.25)	
Subgroup*Treatment Interaction p-value	0.0515	0.5517	

AMNOG Table SE20.2.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Health Distress			
Week 24			
m	2	8	11
n	2	7	8
Baseline Mean (SD)	81.25 (8.84)	94.64 (6.68)	92.19 (11.45)
Analysis Visit Mean (SD)	93.75 (8.84)	94.64 (9.83)	93.75 (13.36)
LS Mean of Change from Baseline (SE)	6.47 (9.22)	2.38 (4.61)	1.16 (4.12)
95% CI	(-13.30, 26.24)	(-7.51, 12.26)	(-7.67, 9.99)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.31 (10.03)	1.22 (6.21)	
95% CI	(-16.21, 26.83)	(-12.09, 14.53)	
p-value	0.6050	0.8474	
Corrected Hedge's g Statistics	0.406	0.096	
95% CI	(-1.15, 1.97)	(-0.92, 1.11)	
Week 52			
m	2	8	10
n	1	6	7
Baseline Mean (SD)	87.50 (N/A)	93.75 (6.85)	94.64 (9.83)
Analysis Visit Mean (SD)	100.00 (N/A)	95.83 (10.21)	94.64 (6.68)
LS Mean of Change from Baseline (SE)	12.74 (10.06)	2.57 (4.22)	0.20 (3.82)
95% CI	(-8.83, 34.31)	(-6.47, 11.62)	(-8.00, 8.40)
LS Mean of Change from Baseline Compared to Placebo (SE)	12.54 (10.88)	2.37 (5.69)	
95% CI	(-10.79, 35.87)	(-9.84, 14.58)	
p-value	0.2683	0.6832	
Corrected Hedge's g Statistics	1.078	0.216	
95% CI	(-1.08, 3.24)	(-0.88, 1.31)	
Subgroup*Treatment Interaction p-value	0.5776	0.6238	

AMNOG Table SE20.2.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Sexual Function			
Week 24			
m	2	8	11
n	0	4	4
Baseline Mean (SD)	N/A	96.25 (7.50)	88.75 (13.01)
Analysis Visit Mean (SD)	N/A	88.33 (19.15)	82.50 (25.13)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	2	8	10
n	0	3	3
Baseline Mean (SD)	N/A	100.00 (0.00)	92.77 (12.53)
Analysis Visit Mean (SD)	N/A	97.77 (3.87)	71.67 (49.07)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	0.0010	

AMNOG Table SE20.2.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Sleep			
Week 24			
m	2	8	11
n	2	7	8
Baseline Mean (SD)	25.0 (35.4)	70.7 (7.3)	66.3 (26.6)
Analysis Visit Mean (SD)	27.5 (38.9)	67.9 (12.5)	68.1 (18.3)
LS Mean of Change from Baseline (SE)	-10.62 (10.42)	-2.12 (4.91)	1.86 (4.22)
95% CI	(-32.96, 11.73)	(-12.64, 8.41)	(-7.18, 10.91)
LS Mean of Change from Baseline Compared to Placebo (SE)	-12.48 (11.24)	-3.98 (6.47)	
95% CI	(-36.58, 11.62)	(-17.86, 9.90)	
p-value	0.2854	0.5486	
Corrected Hedge's g Statistics	-0.915	-0.301	
95% CI	(-2.52, 0.69)	(-1.32, 0.72)	
Week 52			
m	2	8	10
n	1	6	7
Baseline Mean (SD)	50.0 (N/A)	71.7 (7.5)	71.4 (23.9)
Analysis Visit Mean (SD)	55.0 (N/A)	62.5 (12.5)	67.1 (18.0)
LS Mean of Change from Baseline (SE)	-7.76 (11.71)	-7.93 (5.18)	-2.45 (4.51)
95% CI	(-32.87, 17.35)	(-19.05, 3.18)	(-12.13, 7.23)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.31 (12.69)	-5.49 (6.79)	
95% CI	(-32.53, 21.90)	(-20.04, 9.07)	
p-value	0.6817	0.4324	
Corrected Hedge's g Statistics	-0.387	-0.415	
95% CI	(-2.49, 1.72)	(-1.52, 0.69)	
Subgroup*Treatment Interaction p-value	0.1712	0.9100	

AMNOG Table SE20.2.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Loneliness			
Week 24			
m	2	8	11
n	2	7	8
Baseline Mean (SD)	75.0 (21.2)	98.6 (2.4)	94.4 (12.1)
Analysis Visit Mean (SD)	90.0 (7.1)	82.1 (20.0)	86.9 (16.7)
LS Mean of Change from Baseline (SE)	8.59 (15.58)	-13.29 (7.64)	-7.20 (6.37)
95% CI	(-24.83, 42.01)	(-29.67, 3.08)	(-20.87, 6.48)
LS Mean of Change from Baseline Compared to Placebo (SE)	15.78 (16.98)	-6.10 (9.85)	
95% CI	(-20.64, 52.21)	(-27.23, 15.04)	
p-value	0.3684	0.5460	
Corrected Hedge's g Statistics	0.767	-0.301	
95% CI	(-0.82, 2.35)	(-1.32, 0.72)	
Week 52			
m	2	8	10
n	1	6	7
Baseline Mean (SD)	60.0 (N/A)	99.2 (2.0)	93.6 (12.8)
Analysis Visit Mean (SD)	75.0 (N/A)	87.5 (22.3)	84.3 (16.9)
LS Mean of Change from Baseline (SE)	6.21 (21.70)	-8.30 (7.98)	-8.46 (6.53)
95% CI	(-40.33, 52.75)	(-25.41, 8.81)	(-22.47, 5.55)
LS Mean of Change from Baseline Compared to Placebo (SE)	14.67 (22.68)	0.16 (10.34)	
95% CI	(-33.98, 63.32)	(-22.01, 22.33)	
p-value	0.5283	0.9879	
Corrected Hedge's g Statistics	0.738	0.008	
95% CI	(-1.39, 2.86)	(-1.08, 1.10)	
Subgroup*Treatment Interaction p-value	0.2027	0.6105	

AMNOG Table SE20.2.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Hopelessness			
Week 24			
m	2	8	11
n	2	7	8
Baseline Mean (SD)	79.20 (17.68)	92.86 (15.55)	91.68 (17.25)
Analysis Visit Mean (SD)	79.20 (17.68)	84.51 (21.75)	86.48 (21.32)
LS Mean of Change from Baseline (SE)	-3.87 (13.09)	-9.03 (6.93)	-4.99 (6.16)
95% CI	(-31.95, 24.20)	(-23.90, 5.85)	(-18.19, 8.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.11 (14.53)	-4.04 (9.20)	
95% CI	(-30.04, 32.27)	(-23.78, 15.70)	
p-value	0.9400	0.6674	
Corrected Hedge's g Statistics	0.057	-0.213	
95% CI	(-1.49, 1.61)	(-1.23, 0.80)	
Week 52			
m	2	8	10
n	1	6	7
Baseline Mean (SD)	66.70 (N/A)	91.67 (16.68)	90.49 (18.28)
Analysis Visit Mean (SD)	100.00 (N/A)	90.28 (13.34)	84.53 (18.90)
LS Mean of Change from Baseline (SE)	2.66 (12.23)	-0.49 (6.02)	-5.00 (5.28)
95% CI	(-23.56, 28.89)	(-13.40, 12.42)	(-16.33, 6.33)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.66 (13.39)	4.51 (7.99)	
95% CI	(-21.06, 36.39)	(-12.62, 21.65)	
p-value	0.5763	0.5811	
Corrected Hedge's g Statistics	0.477	0.293	
95% CI	(-1.63, 2.59)	(-0.80, 1.39)	
Subgroup*Treatment Interaction p-value	0.6340	0.6977	

AMNOG Table SE20.2.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Stigma of Liver Disease			
Week 24			
m	2	8	11
n	2	7	8
Baseline Mean (SD)	78.15 (4.45)	91.09 (11.31)	88.30 (10.25)
Analysis Visit Mean (SD)	90.65 (13.22)	83.04 (20.00)	83.60 (19.16)
LS Mean of Change from Baseline (SE)	9.25 (14.27)	-8.49 (7.29)	-4.70 (6.42)
95% CI	(-21.36, 39.85)	(-24.12, 7.15)	(-18.47, 9.06)
LS Mean of Change from Baseline Compared to Placebo (SE)	13.95 (15.64)	-3.78 (9.71)	
95% CI	(-19.60, 47.50)	(-24.62, 17.05)	
p-value	0.3876	0.7028	
Corrected Hedge's g Statistics	0.684	-0.191	
95% CI	(-0.89, 2.26)	(-1.21, 0.83)	
Week 52			
m	2	8	10
n	1	6	7
Baseline Mean (SD)	81.30 (N/A)	89.60 (11.62)	88.41 (11.06)
Analysis Visit Mean (SD)	81.30 (N/A)	78.13 (20.06)	84.84 (20.02)
LS Mean of Change from Baseline (SE)	7.81 (14.95)	-11.10 (6.97)	-4.39 (6.15)
95% CI	(-24.25, 39.88)	(-26.06, 3.85)	(-17.59, 8.80)
LS Mean of Change from Baseline Compared to Placebo (SE)	12.20 (16.20)	-6.71 (9.33)	
95% CI	(-22.55, 46.96)	(-26.72, 13.30)	
p-value	0.4638	0.4838	
Corrected Hedge's g Statistics	0.652	-0.375	
95% CI	(-1.47, 2.77)	(-1.48, 0.72)	
Subgroup*Treatment Interaction p-value	0.1062	0.0513	

AMNOG Table SE20.2.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Symptoms of Liver Disease			
Week 24			
m	6	4	16
n	5	4	16
Baseline Mean (SD)	92.02 (9.30)	79.98 (18.26)	86.46 (13.96)
Analysis Visit Mean (SD)	93.34 (8.50)	91.68 (5.76)	82.92 (15.39)
LS Mean of Change from Baseline (SE)	8.83 (6.50)	8.59 (6.89)	-0.51 (4.53)
95% CI	(-4.65, 22.31)	(-5.70, 22.88)	(-9.91, 8.88)
LS Mean of Change from Baseline Compared to Placebo (SE)	9.34 (6.74)	9.10 (7.50)	
95% CI	(-4.64, 23.33)	(-6.46, 24.66)	
p-value	0.1799	0.2379	
Corrected Hedge's g Statistics	0.515	0.499	
95% CI	(-0.50, 1.53)	(-0.61, 1.61)	
Week 52			
m	6	4	16
n	6	4	16
Baseline Mean (SD)	92.23 (8.34)	79.98 (18.26)	86.46 (13.96)
Analysis Visit Mean (SD)	87.22 (15.10)	84.18 (19.69)	87.70 (11.73)
LS Mean of Change from Baseline (SE)	0.13 (5.53)	4.04 (6.00)	4.36 (4.21)
95% CI	(-11.33, 11.60)	(-8.40, 16.48)	(-4.38, 13.10)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.23 (5.45)	-0.32 (6.48)	
95% CI	(-15.54, 7.08)	(-13.77, 13.13)	
p-value	0.4462	0.9608	
Corrected Hedge's g Statistics	-0.253	-0.019	
95% CI	(-1.19, 0.69)	(-1.11, 1.08)	
Subgroup*Treatment Interaction p-value	0.2357	0.3100	

AMNOG Table SE20.2.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Effects of Liver Disease			
Week 24			
m	6	4	16
n	5	4	16
Baseline Mean (SD)	77.34 (19.19)	91.68 (9.99)	80.01 (4.87)
Analysis Visit Mean (SD)	80.00 (0.00)	83.33 (6.65)	78.34 (6.67)
LS Mean of Change from Baseline (SE)	1.58 (3.02)	1.53 (3.49)	-0.14 (2.19)
95% CI	(-4.68, 7.84)	(-5.71, 8.76)	(-4.68, 4.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.72 (3.14)	1.67 (3.79)	
95% CI	(-4.80, 8.24)	(-6.19, 9.53)	
p-value	0.5893	0.6638	
Corrected Hedge's g Statistics	0.198	0.189	
95% CI	(-0.81, 1.20)	(-0.91, 1.29)	
Week 52			
m	6	4	16
n	6	4	16
Baseline Mean (SD)	78.90 (17.59)	91.68 (9.99)	80.01 (4.87)
Analysis Visit Mean (SD)	72.22 (26.13)	81.68 (3.35)	80.01 (6.43)
LS Mean of Change from Baseline (SE)	-4.53 (4.24)	-7.04 (5.41)	2.50 (2.91)
95% CI	(-13.32, 4.27)	(-18.26, 4.18)	(-3.53, 8.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	-7.03 (4.67)	-9.54 (6.00)	
95% CI	(-16.72, 2.66)	(-21.97, 2.90)	
p-value	0.1468	0.1259	
Corrected Hedge's g Statistics	-0.597	-0.794	
95% CI	(-1.55, 0.36)	(-1.92, 0.33)	
Subgroup*Treatment Interaction p-value	0.8468	0.6402	

AMNOG Table SE20.2.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Concentration/Memory			
Week 24			
m	6	4	16
n	5	4	16
Baseline Mean (SD)	86.26 (24.35)	65.65 (24.18)	89.46 (15.93)
Analysis Visit Mean (SD)	86.28 (23.95)	76.58 (24.15)	85.95 (13.97)
LS Mean of Change from Baseline (SE)	5.83 (7.09)	6.27 (7.82)	4.97 (5.71)
95% CI	(-8.88, 20.54)	(-9.94, 22.49)	(-6.86, 16.81)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.85 (7.17)	1.30 (9.01)	
95% CI	(-14.01, 15.72)	(-17.39, 19.99)	
p-value	0.9061	0.8865	
Corrected Hedge's g Statistics	0.038	0.057	
95% CI	(-0.97, 1.04)	(-1.04, 1.15)	
Week 52			
m	6	4	16
n	6	4	16
Baseline Mean (SD)	86.47 (21.78)	65.65 (24.18)	89.46 (15.93)
Analysis Visit Mean (SD)	75.00 (37.91)	75.03 (23.37)	81.66 (21.94)
LS Mean of Change from Baseline (SE)	-5.75 (8.07)	13.92 (9.69)	-1.40 (6.30)
95% CI	(-22.48, 10.98)	(-6.17, 34.02)	(-14.46, 11.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.35 (8.40)	15.32 (11.11)	
95% CI	(-21.76, 13.07)	(-7.71, 38.36)	
p-value	0.6098	0.1816	
Corrected Hedge's g Statistics	-0.175	0.603	
95% CI	(-1.11, 0.77)	(-0.51, 1.71)	
Subgroup*Treatment Interaction p-value	0.0515	0.5517	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.2.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Health Distress			
Week 24			
m	6	4	16
n	5	4	16
Baseline Mean (SD)	75.00 (43.30)	100.00 (0.00)	95.31 (13.60)
Analysis Visit Mean (SD)	77.50 (43.66)	96.88 (6.25)	90.63 (14.79)
LS Mean of Change from Baseline (SE)	2.80 (6.06)	-0.45 (6.36)	-2.01 (4.67)
95% CI	(-9.77, 15.37)	(-13.65, 12.75)	(-11.70, 7.68)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.81 (6.32)	1.56 (6.58)	
95% CI	(-8.29, 17.91)	(-12.10, 15.21)	
p-value	0.4545	0.8150	
Corrected Hedge's g Statistics	0.260	0.084	
95% CI	(-0.75, 1.27)	(-1.01, 1.18)	
Week 52			
m	6	4	16
n	6	4	16
Baseline Mean (SD)	79.17 (40.05)	100.00 (0.00)	95.31 (13.60)
Analysis Visit Mean (SD)	81.25 (40.12)	93.75 (12.50)	88.28 (19.62)
LS Mean of Change from Baseline (SE)	2.81 (7.57)	-3.46 (8.59)	-4.31 (5.48)
95% CI	(-12.89, 18.51)	(-21.27, 14.34)	(-15.68, 7.06)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.12 (8.20)	0.84 (9.19)	
95% CI	(-9.88, 24.11)	(-18.22, 19.90)	
p-value	0.3945	0.9277	
Corrected Hedge's g Statistics	0.324	0.038	
95% CI	(-0.62, 1.27)	(-1.06, 1.13)	
Subgroup*Treatment Interaction p-value	0.5776	0.6238	

AMNOG Table SE20.2.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Sexual Function			
Week 24			
m	6	4	16
n	2	1	5
Baseline Mean (SD)	96.65 (4.74)	85.00 (N/A)	94.00 (6.30)
Analysis Visit Mean (SD)	80.85 (15.34)	85.00 (N/A)	95.66 (6.63)
LS Mean of Change from Baseline (SE)	-16.92 (4.13)	0.79 (6.91)	-0.22 (2.46)
95% CI	(-26.69, -7.14)	(-15.56, 17.14)	(-6.03, 5.59)
LS Mean of Change from Baseline Compared to Placebo (SE)	-16.70 (4.80)	1.01 (7.24)	
95% CI	(-28.04, -5.36)	(-16.12, 18.13)	
p-value	0.0102	0.8934	
Corrected Hedge's g Statistics	-2.525	0.146	
95% CI	(-4.63, -0.42)	(-2.00, 2.30)	
Week 52			
m	6	4	16
n	2	1	5
Baseline Mean (SD)	96.65 (4.74)	85.00 (N/A)	94.32 (6.19)
Analysis Visit Mean (SD)	92.50 (10.61)	93.30 (N/A)	90.66 (14.09)
LS Mean of Change from Baseline (SE)	-6.45 (4.68)	12.48 (8.00)	-3.76 (2.75)
95% CI	(-17.52, 4.62)	(-6.44, 31.40)	(-10.27, 2.75)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.69 (5.39)	16.24 (8.48)	
95% CI	(-15.44, 10.07)	(-3.81, 36.30)	
p-value	0.6337	0.0970	
Corrected Hedge's g Statistics	-0.362	2.111	
95% CI	(-2.01, 1.29)	(-0.35, 4.57)	
Subgroup*Treatment Interaction p-value	NE	0.0010	

AMNOG Table SE20.2.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Sleep			
Week 24			
m	6	4	16
n	5	4	16
Baseline Mean (SD)	70.0 (18.4)	70.0 (10.8)	70.6 (19.3)
Analysis Visit Mean (SD)	72.0 (6.7)	63.8 (21.4)	71.3 (16.7)
LS Mean of Change from Baseline (SE)	2.68 (5.68)	-5.97 (6.02)	0.47 (4.50)
95% CI	(-9.10, 14.45)	(-18.47, 6.52)	(-8.87, 9.81)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.20 (5.63)	-6.45 (6.32)	
95% CI	(-9.47, 13.87)	(-19.56, 6.66)	
p-value	0.6993	0.3188	
Corrected Hedge's g Statistics	0.124	-0.360	
95% CI	(-0.88, 1.13)	(-1.46, 0.74)	
Week 52			
m	6	4	16
n	6	4	16
Baseline Mean (SD)	71.7 (16.9)	70.0 (10.8)	70.6 (19.3)
Analysis Visit Mean (SD)	66.7 (19.7)	67.5 (6.5)	70.0 (19.8)
LS Mean of Change from Baseline (SE)	-3.89 (6.95)	-2.22 (7.91)	-0.78 (5.18)
95% CI	(-18.29, 10.52)	(-18.63, 14.19)	(-11.53, 9.97)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.11 (7.27)	-1.44 (8.54)	
95% CI	(-18.20, 11.98)	(-19.15, 16.26)	
p-value	0.6733	0.8675	
Corrected Hedge's g Statistics	-0.151	-0.069	
95% CI	(-1.09, 0.79)	(-1.16, 1.03)	
Subgroup*Treatment Interaction p-value	0.1712	0.9100	

AMNOG Table SE20.2.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Loneliness			
Week 24			
m	6	4	16
n	5	4	16
Baseline Mean (SD)	94.0 (8.2)	97.5 (2.9)	92.2 (9.8)
Analysis Visit Mean (SD)	91.0 (12.4)	96.3 (4.8)	86.9 (18.7)
LS Mean of Change from Baseline (SE)	-1.37 (6.67)	-0.57 (7.31)	-3.03 (5.14)
95% CI	(-15.21, 12.46)	(-15.74, 14.60)	(-13.68, 7.62)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.66 (6.53)	2.47 (7.53)	
95% CI	(-11.88, 15.19)	(-13.15, 18.08)	
p-value	0.8019	0.7465	
Corrected Hedge's g Statistics	0.082	0.120	
95% CI	(-0.92, 1.09)	(-0.98, 1.22)	
Week 52			
m	6	4	16
n	6	4	16
Baseline Mean (SD)	95.0 (7.7)	97.5 (2.9)	92.2 (9.8)
Analysis Visit Mean (SD)	96.7 (8.2)	93.8 (9.5)	89.1 (16.1)
LS Mean of Change from Baseline (SE)	3.85 (6.48)	-1.41 (7.22)	-1.40 (5.11)
95% CI	(-9.59, 17.28)	(-16.39, 13.56)	(-11.99, 9.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.25 (6.24)	-0.01 (7.42)	
95% CI	(-7.68, 18.18)	(-15.40, 15.38)	
p-value	0.4090	0.9989	
Corrected Hedge's g Statistics	0.260	-0.001	
95% CI	(-0.68, 1.20)	(-1.10, 1.10)	
Subgroup*Treatment Interaction p-value	0.2027	0.6105	

AMNOG Table SE20.2.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Hopelessness			
Week 24			
m	6	4	16
n	5	4	16
Baseline Mean (SD)	96.68 (4.55)	89.60 (15.76)	84.90 (20.47)
Analysis Visit Mean (SD)	96.66 (7.47)	87.50 (19.86)	86.98 (24.15)
LS Mean of Change from Baseline (SE)	3.76 (5.75)	0.60 (6.00)	5.55 (4.35)
95% CI	(-8.17, 15.68)	(-11.84, 13.04)	(-3.47, 14.57)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.79 (5.70)	-4.94 (6.31)	
95% CI	(-13.60, 10.03)	(-18.04, 8.15)	
p-value	0.7567	0.4422	
Corrected Hedge's g Statistics	-0.104	-0.285	
95% CI	(-1.11, 0.90)	(-1.38, 0.81)	
Week 52			
m	6	4	16
n	6	4	16
Baseline Mean (SD)	93.07 (9.74)	89.60 (15.76)	84.90 (20.47)
Analysis Visit Mean (SD)	93.05 (8.21)	91.68 (16.65)	88.02 (18.51)
LS Mean of Change from Baseline (SE)	5.52 (5.62)	5.44 (6.07)	5.56 (4.37)
95% CI	(-6.14, 17.17)	(-7.15, 18.03)	(-3.51, 14.63)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.04 (5.52)	-0.12 (6.40)	
95% CI	(-11.50, 11.41)	(-13.39, 13.15)	
p-value	0.9936	0.9854	
Corrected Hedge's g Statistics	-0.003	-0.007	
95% CI	(-0.94, 0.94)	(-1.10, 1.09)	
Subgroup*Treatment Interaction p-value	0.6340	0.6977	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.2.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Stigma of Liver Disease			
Week 24			
m	6	4	16
n	5	4	16
Baseline Mean (SD)	93.76 (10.83)	75.03 (18.42)	93.76 (13.30)
Analysis Visit Mean (SD)	92.52 (10.27)	87.50 (14.43)	87.51 (25.62)
LS Mean of Change from Baseline (SE)	-6.69 (7.73)	12.85 (8.45)	-13.97 (6.15)
95% CI	(-22.73, 9.34)	(-4.68, 30.38)	(-26.73, -1.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.28 (7.62)	26.82 (9.87)	
95% CI	(-8.53, 23.09)	(6.37, 47.28)	
p-value	0.3498	0.0125	
Corrected Hedge's g Statistics	0.301	1.094	
95% CI	(-0.71, 1.31)	(-0.05, 2.24)	
Week 52			
m	6	4	16
n	6	4	16
Baseline Mean (SD)	92.72 (10.01)	75.03 (18.42)	93.76 (13.30)
Analysis Visit Mean (SD)	89.60 (19.64)	90.65 (10.83)	87.53 (18.54)
LS Mean of Change from Baseline (SE)	-8.36 (8.23)	6.95 (9.72)	-12.19 (6.54)
95% CI	(-25.42, 8.70)	(-13.21, 27.12)	(-25.75, 1.36)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.84 (8.29)	19.15 (11.28)	
95% CI	(-13.37, 21.04)	(-4.25, 42.55)	
p-value	0.6483	0.1038	
Corrected Hedge's g Statistics	0.149	0.729	
95% CI	(-0.79, 1.09)	(-0.39, 1.85)	
Subgroup*Treatment Interaction p-value	0.1062	0.0513	

AMNOG Table SE20.2.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis, only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.

AMNOG Table SE20.2.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	2 (100)	11 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (50.0)	0	2 (18.2)
No	1 (50.0)	11 (100)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.22	6.05	
95% CI of the inverse odds ratio	(0.01, 5.28)	(0.26, 142.04)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.36	5.00	
95% CI of the inverse risk ratio	(0.06, 2.36)	(0.27, 93.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	31.82	-16.67	
95% CI of the absolute risk difference	(-41.13, 100.00)	(-42.28, 8.94)	
p-value	0.3259	0.2170	
p-value of Breslow-Day Test for Homogeneity [3]	0.1047	0.1574	

AMNOG Table SE20.2.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (9.1)
No	2 (100)	11 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	3.29	
95% CI of the inverse odds ratio	(0.02, 23.31)	(0.12, 89.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	3.00	
95% CI of the inverse risk ratio	(0.04, 14.19)	(0.14, 66.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.17	-8.33	
95% CI of the absolute risk difference	(-41.97, 50.30)	(-30.20, 13.53)	
p-value	0.8494	0.4602	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.2165	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (9.1)	4 (36.4)
No	2 (100)	10 (90.9)	7 (63.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	5.71	
95% CI of the inverse odds ratio	(0.12, 77.64)	(0.52, 62.66)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.25	4.00	
95% CI of the inverse risk ratio	(0.16, 31.33)	(0.53, 30.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-20.83	-27.27	
95% CI of the absolute risk difference	(-71.12, 29.45)	(-60.39, 5.84)	
p-value	0.4936	0.1269	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.4711	

AMNOG Table SE20.2.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (9.1)
No	2 (100)	11 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	3.29	
95% CI of the inverse odds ratio	(0.02, 23.31)	(0.12, 89.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	3.00	
95% CI of the inverse risk ratio	(0.04, 14.19)	(0.14, 66.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.17	-8.33	
95% CI of the absolute risk difference	(-41.97, 50.30)	(-30.20, 13.53)	
p-value	0.8494	0.4602	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (9.1)	1 (9.1)
No	2 (100)	10 (90.9)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	1.00	
95% CI of the inverse odds ratio	(0.02, 23.31)	(0.05, 18.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	1.00	
95% CI of the inverse risk ratio	(0.04, 14.19)	(0.07, 14.05)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.17	0.00	
95% CI of the absolute risk difference	(-41.97, 50.30)	(-24.03, 24.03)	
p-value	0.8494	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.6982	0.4063	

AMNOG Table SE20.2.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	2 (100)	11 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (50.0)	1 (9.1)	2 (18.2)
No	1 (50.0)	10 (90.9)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.22	2.22	
95% CI of the inverse odds ratio	(0.01, 5.28)	(0.17, 28.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.36	2.00	
95% CI of the inverse risk ratio	(0.06, 2.36)	(0.21, 18.98)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	31.82	-9.09	
95% CI of the absolute risk difference	(-41.13, 100.00)	(-37.52, 19.34)	
p-value	0.3259	0.5344	
p-value of Breslow-Day Test for Homogeneity [3]	0.0677	0.2441	

AMNOG Table SE20.2.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	2 (100)	11 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (50.0)	3 (27.3)	2 (18.2)
No	1 (50.0)	8 (72.7)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.22	0.59	
95% CI of the inverse odds ratio	(0.01, 5.28)	(0.08, 4.50)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.36	0.67	
95% CI of the inverse risk ratio	(0.06, 2.36)	(0.14, 3.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	31.82	9.09	
95% CI of the absolute risk difference	(-41.13, 100.00)	(-25.73, 43.91)	
p-value	0.3259	0.6109	
p-value of Breslow-Day Test for Homogeneity [3]	0.8116	0.5381	

AMNOG Table SE20.2.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	2 (100)	11 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	2 (100)	11 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE20.2.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (9.1)
No	2 (100)	11 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	3.29	
95% CI of the inverse odds ratio	(0.02, 23.31)	(0.12, 89.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	3.00	
95% CI of the inverse risk ratio	(0.04, 14.19)	(0.14, 66.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.17	-8.33	
95% CI of the absolute risk difference	(-41.97, 50.30)	(-30.20, 13.53)	
p-value	0.8494	0.4602	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (50.0)	1 (9.1)	2 (18.2)
No	1 (50.0)	10 (90.9)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.22	2.22	
95% CI of the inverse odds ratio	(0.01, 5.28)	(0.17, 28.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.36	2.00	
95% CI of the inverse risk ratio	(0.06, 2.36)	(0.21, 18.98)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	31.82	-9.09	
95% CI of the absolute risk difference	(-41.13, 100.00)	(-37.52, 19.34)	
p-value	0.3259	0.5344	
p-value of Breslow-Day Test for Homogeneity [3]	0.1084	0.9751	

AMNOG Table SE20.2.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (50.0)	0	0
No	1 (50.0)	11 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.04	NE	
95% CI of the inverse odds ratio	(0.00, 1.63)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.08	NE	
95% CI of the inverse risk ratio	(0.00, 1.58)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	45.83	NE	
95% CI of the absolute risk difference	(-11.86, 100.00)	NE	
p-value	0.0367	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.0914	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (50.0)	1 (9.1)	0
No	1 (50.0)	10 (90.9)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.04	0.30	
95% CI of the inverse odds ratio	(0.00, 1.63)	(0.01, 8.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.08	0.33	
95% CI of the inverse risk ratio	(0.00, 1.58)	(0.02, 7.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	45.83	8.33	
95% CI of the absolute risk difference	(-11.86, 100.00)	(-13.53, 30.20)	
p-value	0.0367	0.4602	
p-value of Breslow-Day Test for Homogeneity [3]	0.0461	0.4460	

AMNOG Table SE20.2.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (50.0)	1 (9.1)	0
No	1 (50.0)	10 (90.9)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.04	0.30	
95% CI of the inverse odds ratio	(0.00, 1.63)	(0.01, 8.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.08	0.33	
95% CI of the inverse risk ratio	(0.00, 1.58)	(0.02, 7.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	45.83	8.33	
95% CI of the absolute risk difference	(-11.86, 100.00)	(-13.53, 30.20)	
p-value	0.0367	0.4602	
p-value of Breslow-Day Test for Homogeneity [3]	0.0008	0.0956	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (50.0)	1 (9.1)	0
No	1 (50.0)	10 (90.9)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.04	0.30	
95% CI of the inverse odds ratio	(0.00, 1.63)	(0.01, 8.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.08	0.33	
95% CI of the inverse risk ratio	(0.00, 1.58)	(0.02, 7.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	45.83	8.33	
95% CI of the absolute risk difference	(-11.86, 100.00)	(-13.53, 30.20)	
p-value	0.0367	0.4602	
p-value of Breslow-Day Test for Homogeneity [3]	0.0060	0.2788	

AMNOG Table SE20.2.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	2 (100)	11 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	1 (9.1)
No	2 (100)	11 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	3.29	
95% CI of the inverse odds ratio	(0.02, 23.31)	(0.12, 89.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	3.00	
95% CI of the inverse risk ratio	(0.04, 14.19)	(0.14, 66.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.17	-8.33	
95% CI of the absolute risk difference	(-41.97, 50.30)	(-30.20, 13.53)	
p-value	0.8494	0.4602	
p-value of Breslow-Day Test for Homogeneity [3]	0.6314	0.0730	

AMNOG Table SE20.2.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	7 (100)	4 (100)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (25.0)	3 (17.6)
No	7 (100)	3 (75.0)	14 (82.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.62	0.64	
95% CI of the inverse odds ratio	(0.16, 79.69)	(0.05, 8.52)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.11	0.71	
95% CI of the inverse risk ratio	(0.18, 53.45)	(0.10, 5.13)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-13.19	7.35	
95% CI of the absolute risk difference	(-38.01, 11.62)	(-38.79, 53.49)	
p-value	0.3894	0.7362	
p-value of Breslow-Day Test for Homogeneity [3]	0.1047	0.1574	

AMNOG Table SE20.2.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (25.0)	2 (11.8)
No	7 (100)	3 (75.0)	15 (88.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.42	0.40	
95% CI of the inverse odds ratio	(0.10, 56.97)	(0.03, 5.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.22	0.47	
95% CI of the inverse risk ratio	(0.12, 41.20)	(0.06, 4.00)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.64	13.24	
95% CI of the absolute risk difference	(-30.80, 15.53)	(-31.88, 58.35)	
p-value	0.5736	0.4961	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.2165	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (25.0)	6 (35.3)
No	7 (100)	3 (75.0)	11 (64.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	8.48	1.64	
95% CI of the inverse odds ratio	(0.41, 173.72)	(0.14, 19.39)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.78	1.41	
95% CI of the inverse risk ratio	(0.37, 90.67)	(0.23, 8.67)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-29.86	-10.29	
95% CI of the absolute risk difference	(-57.68, -2.05)	(-58.43, 37.84)	
p-value	0.1131	0.6944	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.4711	

AMNOG Table SE20.2.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	7 (100)	4 (100)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (14.3)	0	3 (17.6)
No	6 (85.7)	4 (100)	14 (82.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	2.17	
95% CI of the inverse odds ratio	(0.11, 15.00)	(0.09, 50.51)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.24	1.94	
95% CI of the inverse risk ratio	(0.15, 9.94)	(0.12, 31.74)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.36	-9.44	
95% CI of the absolute risk difference	(-34.99, 28.27)	(-41.47, 22.58)	
p-value	0.8408	0.6221	
p-value of Breslow-Day Test for Homogeneity [3]	0.6982	0.4063	

AMNOG Table SE20.2.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (25.0)	0
No	7 (100)	3 (75.0)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.07	
95% CI of the inverse odds ratio	NE	(0.00, 2.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.09	
95% CI of the inverse risk ratio	NE	(0.00, 1.94)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	27.22	
95% CI of the absolute risk difference	NE	(-13.66, 68.10)	
p-value	NE	0.0560	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (50.0)	4 (23.5)
No	7 (100)	2 (50.0)	13 (76.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.00	0.31	
95% CI of the inverse odds ratio	(0.24, 106.11)	(0.03, 2.94)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.00	0.47	
95% CI of the inverse risk ratio	(0.24, 65.81)	(0.13, 1.73)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-18.75	26.47	
95% CI of the absolute risk difference	(-44.86, 7.36)	(-26.52, 79.46)	
p-value	0.2629	0.2917	
p-value of Breslow-Day Test for Homogeneity [3]	0.0677	0.2441	

AMNOG Table SE20.2.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (5.9)
No	7 (100)	4 (100)	16 (94.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	0.82	
95% CI of the inverse odds ratio	(0.05, 37.53)	(0.03, 23.70)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	0.83	
95% CI of the inverse risk ratio	(0.06, 29.31)	(0.04, 17.48)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.08	1.67	
95% CI of the absolute risk difference	(-23.16, 19.00)	(-27.56, 30.90)	
p-value	0.8540	0.9069	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (14.3)	0	1 (5.9)
No	6 (85.7)	4 (100)	16 (94.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.38	0.82	
95% CI of the inverse odds ratio	(0.02, 7.00)	(0.03, 23.70)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.41	0.83	
95% CI of the inverse risk ratio	(0.03, 5.70)	(0.04, 17.48)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.40	1.67	
95% CI of the absolute risk difference	(-19.83, 36.64)	(-27.56, 30.90)	
p-value	0.4984	0.9069	
p-value of Breslow-Day Test for Homogeneity [3]	0.8116	0.5381	

AMNOG Table SE20.2.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	7 (100)	4 (100)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (25.0)	1 (5.9)
No	7 (100)	3 (75.0)	16 (94.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	0.19	
95% CI of the inverse odds ratio	(0.05, 37.53)	(0.01, 3.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	0.24	
95% CI of the inverse risk ratio	(0.06, 29.31)	(0.02, 3.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.08	19.12	
95% CI of the absolute risk difference	(-23.16, 19.00)	(-24.77, 63.00)	
p-value	0.8540	0.2412	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

Program: t-se18-02-04-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.2.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	4 (23.5)
No	7 (100)	4 (100)	13 (76.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.00	3.00	
95% CI of the inverse odds ratio	(0.24, 106.11)	(0.13, 67.29)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.00	2.50	
95% CI of the inverse risk ratio	(0.24, 65.81)	(0.16, 39.05)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-18.75	-15.00	
95% CI of the absolute risk difference	(-44.86, 7.36)	(-48.04, 18.04)	
p-value	0.2629	0.4719	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (14.3)	1 (25.0)	7 (41.2)
No	6 (85.7)	3 (75.0)	10 (58.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.20	2.10	
95% CI of the inverse odds ratio	(0.41, 43.04)	(0.18, 24.60)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.88	1.65	
95% CI of the inverse risk ratio	(0.43, 19.30)	(0.28, 9.86)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-26.89	-16.18	
95% CI of the absolute risk difference	(-61.81, 8.03)	(-64.63, 32.28)	
p-value	0.2040	0.5489	
p-value of Breslow-Day Test for Homogeneity [3]	0.1084	0.9751	

AMNOG Table SE20.2.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (14.3)	0	2 (11.8)
No	6 (85.7)	4 (100)	15 (88.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	1.45	
95% CI of the inverse odds ratio	(0.06, 10.56)	(0.06, 36.06)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	1.39	
95% CI of the inverse risk ratio	(0.09, 7.68)	(0.08, 24.50)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.52	-3.89	
95% CI of the absolute risk difference	(-27.59, 32.63)	(-34.66, 26.88)	
p-value	0.8652	0.8193	
p-value of Breslow-Day Test for Homogeneity [3]	0.0914	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (14.3)	1 (25.0)	3 (17.6)
No	6 (85.7)	3 (75.0)	14 (82.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	0.64	
95% CI of the inverse odds ratio	(0.11, 15.00)	(0.05, 8.52)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.24	0.71	
95% CI of the inverse risk ratio	(0.15, 9.94)	(0.10, 5.13)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.36	7.35	
95% CI of the absolute risk difference	(-34.99, 28.27)	(-38.79, 53.49)	
p-value	0.8408	0.7362	
p-value of Breslow-Day Test for Homogeneity [3]	0.0461	0.4460	

AMNOG Table SE20.2.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	5 (29.4)
No	7 (100)	4 (100)	12 (70.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	6.60	3.96	
95% CI of the inverse odds ratio	(0.32, 137.05)	(0.18, 86.95)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.89	3.06	
95% CI of the inverse risk ratio	(0.31, 78.23)	(0.20, 46.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-24.31	-20.56	
95% CI of the absolute risk difference	(-51.40, 2.79)	(-54.38, 13.27)	
p-value	0.1746	0.3544	
p-value of Breslow-Day Test for Homogeneity [3]	0.0008	0.0956	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (14.3)	1 (25.0)	6 (35.3)
No	6 (85.7)	3 (75.0)	11 (64.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.27	1.64	
95% CI of the inverse odds ratio	(0.32, 33.94)	(0.14, 19.39)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.47	1.41	
95% CI of the inverse risk ratio	(0.36, 16.94)	(0.23, 8.67)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-21.01	-10.29	
95% CI of the absolute risk difference	(-55.48, 13.46)	(-58.43, 37.84)	
p-value	0.3034	0.6944	
p-value of Breslow-Day Test for Homogeneity [3]	0.0060	0.2788	

AMNOG Table SE20.2.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	2 (50.0)	0
No	7 (100)	2 (50.0)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.03	
95% CI of the inverse odds ratio	NE	(0.00, 0.78)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.06	
95% CI of the inverse risk ratio	NE	(0.00, 0.98)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	47.22	
95% CI of the absolute risk difference	NE	(2.74, 91.70)	
p-value	NE	0.0055	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (14.3)	2 (50.0)	2 (11.8)
No	6 (85.7)	2 (50.0)	15 (88.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	0.13	
95% CI of the inverse odds ratio	(0.06, 10.56)	(0.01, 1.55)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	0.24	
95% CI of the inverse risk ratio	(0.09, 7.68)	(0.05, 1.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.52	38.24	
95% CI of the absolute risk difference	(-27.59, 32.63)	(-13.10, 89.57)	
p-value	0.8652	0.0797	
p-value of Breslow-Day Test for Homogeneity [3]	0.6314	0.0730	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.3.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=21)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=21)
Total LDQOL						
Baseline						
m	6	15	21			
n	6	14	19			
Mean (SD)	78.53 (15.86)	87.01 (6.13)	85.09 (8.41)			
Median	80.60	89.05	85.40			
IQR: Q1, Q3	64.80, 93.90	83.20, 90.30	78.60, 92.10			
Min, Max	57.3, 94.0	75.2, 94.8	64.4, 97.8			
Week 24						
m	6	12	20			
n	5	11	18	5	11	17
Mean (SD/SE)	78.68 (12.62)	84.72 (8.35)	81.90 (12.15)	2.20 (2.21)	-3.04 (2.51)	-2.89 (1.99)
Median	74.20	81.80	82.50	1.80	-0.50	-1.60
IQR: Q1, Q3	73.30, 90.10	77.80, 93.10	75.90, 93.70	-0.90, 5.50	-9.40, 4.50	-9.60, 1.60
Min, Max	62.8, 93.0	75.0, 98.9	52.0, 98.1	-3.9, 8.5	-19.8, 6.8	-17.6, 13.3
Week 52						
m	6	12	19			
n	5	10	17	5	10	16
Mean (SD/SE)	79.10 (22.63)	84.58 (5.41)	81.18 (13.08)	-2.18 (4.06)	-2.99 (1.97)	-3.93 (2.91)
Median	88.30	85.80	84.90	-0.50	-2.45	-0.85
IQR: Q1, Q3	79.60, 92.80	79.20, 88.30	78.60, 87.50	-1.20, 0.90	-5.60, 0.10	-8.45, 4.00
Min, Max	40.0, 94.8	75.6, 93.7	51.7, 98.1	-17.3, 7.2	-15.6, 8.7	-40.4, 7.2

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.3.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=21)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=21)
Symptoms of Liver Disease						
Baseline						
m	6	15	21			
n	6	14	19			
Mean (SD)	81.67 (15.89)	83.33 (13.59)	82.81 (15.01)			
Median	85.00	85.00	86.70			
IQR: Q1, Q3	76.70, 93.30	80.00, 93.30	70.00, 96.70			
Min, Max	53.3, 96.7	53.3, 100.0	53.3, 100.0			
Week 24						
m	6	12	20			
n	5	11	18	5	11	17
Mean (SD/SE)	80.00 (13.76)	88.79 (8.97)	80.55 (16.73)	0.66 (5.32)	3.35 (5.14)	-0.39 (5.20)
Median	80.00	90.00	83.30	0	3.30	0
IQR: Q1, Q3	70.00, 90.00	86.70, 93.30	70.00, 93.30	0.00, 3.30	-3.30, 6.70	-10.00, 10.00
Min, Max	63.3, 96.7	66.7, 100.0	36.7, 100.0	-16.7, 16.7	-33.3, 36.7	-60.0, 40.0
Week 52						
m	6	12	19			
n	5	10	17	5	10	16
Mean (SD/SE)	82.00 (15.71)	82.00 (13.80)	82.94 (13.48)	-5.34 (4.03)	-1.99 (4.07)	1.04 (3.56)
Median	90.00	83.30	83.30	-3.30	0	1.65
IQR: Q1, Q3	76.70, 93.30	73.30, 93.30	73.30, 93.30	-6.70, 0.00	-6.70, 3.40	-5.00, 6.70
Min, Max	56.7, 93.3	56.7, 100.0	56.7, 100.0	-20.0, 3.3	-23.3, 16.7	-36.7, 30.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.3.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=21)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=21)
Effects of Liver Disease						
Baseline						
m	6	15	21			
n	6	14	19			
Mean (SD)	67.78 (22.09)	85.72 (8.62)	81.41 (7.23)			
Median	80.00	83.35	80.00			
IQR: Q1, Q3	46.70, 80.00	80.00, 86.70	80.00, 86.70			
Min, Max	33.3, 86.7	73.3, 100.0	66.7, 100.0			
Week 24						
m	6	12	20			
n	5	11	18	5	11	17
Mean (SD/SE)	80.00 (0.00)	83.63 (9.60)	78.89 (9.50)	16.00 (10.02)	-3.05 (3.64)	-3.14 (2.92)
Median	80.00	80.00	80.00	0	-6.70	0
IQR: Q1, Q3	80.00, 80.00	80.00, 93.30	80.00, 80.00	0.00, 33.30	-6.70, 0.00	-6.70, 0.00
Min, Max	80.0, 80.0	73.3, 100.0	60.0, 100.0	0.0, 46.7	-20.0, 20.0	-40.0, 20.0
Week 52						
m	6	12	19			
n	5	10	17	5	10	16
Mean (SD/SE)	68.00 (26.83)	82.00 (7.07)	81.18 (8.24)	-6.68 (5.17)	-5.34 (3.55)	0.00 (2.85)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	80.00, 80.00	80.00, 80.00	80.00, 86.70	-6.70, 0.00	-20.00, 0.00	0.00, 3.35
Min, Max	20.0, 80.0	73.3, 100.0	66.7, 100.0	-26.7, 0.0	-20.0, 13.3	-26.7, 20.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.3.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=6)	(N=15)	(N=21)	(N=6)	(N=15)	(N=21)
Concentration/Memory						
Baseline						
m	6	15	21			
n	6	14	19			
Mean (SD)	82.30 (23.84)	83.50 (21.02)	88.83 (15.67)			
Median	93.75	93.80	93.80			
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	81.30, 100.00			
Min, Max	43.8, 100.0	43.8, 100.0	37.5, 100.0			
Week 24						
m	6	12	20			
n	5	11	18	5	11	17
Mean (SD/SE)	72.52 (25.23)	85.25 (16.60)	88.21 (14.03)	-8.74 (4.68)	0.56 (3.81)	1.47 (4.14)
Median	75.00	87.50	93.80	-6.20	0	0
IQR: Q1, Q3	50.00, 93.80	81.30, 100.00	68.80, 100.00	-12.50, 0.00	-6.30, 6.20	0.00, 12.50
Min, Max	43.8, 100.0	50.0, 100.0	62.5, 100.0	-25.0, 0.0	-18.7, 31.3	-37.5, 31.3
Week 52						
m	6	12	19			
n	5	10	17	5	10	16
Mean (SD/SE)	66.26 (38.93)	85.01 (17.71)	83.85 (17.26)	-12.50 (8.63)	-0.01 (4.27)	-4.68 (3.97)
Median	75.00	87.50	87.50	-12.50	0	0
IQR: Q1, Q3	68.80, 87.50	75.00, 100.00	75.00, 100.00	-12.50, 0.00	-6.30, 6.20	-6.25, 3.10
Min, Max	0.0, 100.0	43.8, 100.0	43.8, 100.0	-43.8, 6.3	-25.0, 25.0	-50.0, 12.5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc. Page 5 of 20
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.3.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=6)	(N=15)	(N=21)	(N=6)	(N=15)	(N=21)
Health Distress						
Baseline						
m	6	15	21			
n	6	14	19			
Mean (SD)	77.08 (39.06)	96.43 (5.86)	92.76 (14.02)			
Median	93.75	100.00	100.00			
IQR: Q1, Q3	75.00, 100.00	87.50, 100.00	87.50, 100.00			
Min, Max	0.0, 100.0	87.5, 100.0	50.0, 100.0			
Week 24						
m	6	12	20			
n	5	11	18	5	11	17
Mean (SD/SE)	77.50 (43.66)	95.45 (8.43)	89.58 (15.61)	5.00 (5.00)	-1.14 (3.13)	-2.94 (3.64)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	87.50, 100.00	87.50, 100.00	75.00, 100.00	0.00, 0.00	0.00, 0.00	-12.50, 0.00
Min, Max	0.0, 100.0	75.0, 100.0	50.0, 100.0	0.0, 25.0	-25.0, 12.5	-25.0, 25.0
Week 52						
m	6	12	19			
n	5	10	17	5	10	16
Mean (SD/SE)	80.00 (44.72)	95.00 (10.54)	87.50 (18.75)	2.50 (2.50)	-1.25 (4.35)	-6.25 (4.97)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	100.00, 100.00	100.00, 100.00	87.50, 100.00	0.00, 0.00	0.00, 12.50	-12.50, 0.00
Min, Max	0.0, 100.0	75.0, 100.0	37.5, 100.0	0.0, 12.5	-25.0, 12.5	-62.5, 25.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.3.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=21)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=21)
Sexual Function						
Baseline						
m	6	15	21			
n	2	6	11			
Mean (SD)	91.65 (11.81)	95.00 (7.75)	89.69 (11.11)			
Median	91.65	100.00	93.30			
IQR: Q1, Q3	83.30, 100.00	85.00, 100.00	78.30, 100.00			
Min, Max	83.3, 100.0	85.0, 100.0	68.3, 100.0			
Week 24						
m	6	12	20			
n	1	5	8	1	5	8
Mean (SD/SE)	91.70 (N/A)	87.66 (16.65)	88.54 (18.28)	-8.30 (N/A)	-6.34 (4.84)	-2.09 (4.34)
Median	91.70	93.30	96.65	-8.30	0	0
IQR: Q1, Q3	91.70, 91.70	85.00, 100.00	84.15, 100.00	-8.30, -8.30	-6.70, 0.00	0.00, 4.10
Min, Max	91.7, 91.7	60.0, 100.0	46.7, 100.0	-8.3, -8.3	-25.0, 0.0	-31.6, 6.7
Week 52						
m	6	12	19			
n	1	4	8	1	4	6
Mean (SD/SE)	100.00 (N/A)	96.65 (3.87)	77.91 (36.70)	0.00 (N/A)	0.40 (3.07)	-10.82 (10.67)
Median	100.00	96.65	100.00	0	0	0
IQR: Q1, Q3	100.00, 100.00	93.30, 100.00	54.15, 100.00	0.00, 0.00	-3.35, 4.15	-8.30, 0.00
Min, Max	100.0, 100.0	93.3, 100.0	15.0, 100.0	0.0, 0.0	-6.7, 8.3	-63.3, 6.7

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.3.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=21)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=21)
Sleep						
Baseline						
m	6	15	21			
n	6	14	19			
Mean (SD)	55.8 (33.2)	72.5 (9.8)	66.1 (22.1)			
Median	62.5	72.5	70.0			
IQR: Q1, Q3	40.0, 80.0	65.0, 80.0	40.0, 85.0			
Min, Max	0, 90	60, 90	30, 100			
Week 24						
m	6	12	20			
n	5	11	18	5	11	17
Mean (SD/SE)	53.0 (30.9)	66.4 (15.3)	67.5 (16.7)	2.0 (5.6)	-4.1 (3.1)	0.6 (3.5)
Median	60.0	65.0	67.5	0	0	0
IQR: Q1, Q3	55.0, 75.0	55.0, 80.0	60.0, 80.0	0.0, 5.0	-15.0, 5.0	-10.0, 5.0
Min, Max	0, 75	40, 90	35, 100	-15, 20	-25, 10	-30, 30
Week 52						
m	6	12	19			
n	5	10	17	5	10	16
Mean (SD/SE)	65.0 (22.6)	64.5 (10.4)	66.5 (18.4)	-2.0 (3.0)	-6.5 (3.1)	-3.1 (4.1)
Median	75.0	62.5	65.0	-5.0	-5.0	0
IQR: Q1, Q3	55.0, 80.0	60.0, 75.0	60.0, 80.0	-5.0, 5.0	-15.0, 0.0	-15.0, 7.5
Min, Max	30, 85	50, 80	35, 95	-10, 5	-25, 5	-35, 20

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.3.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=21)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=21)
Loneliness						
Baseline						
m	6	15	21			
n	6	14	19			
Mean (SD)	86.7 (14.7)	92.9 (13.5)	92.9 (10.6)			
Median	87.5	97.5	100.0			
IQR: Q1, Q3	85.0, 100.0	95.0, 100.0	85.0, 100.0			
Min, Max	60, 100	50, 100	65, 100			
Week 24						
m	6	12	20			
n	5	11	18	5	11	17
Mean (SD/SE)	87.0 (10.4)	87.3 (17.2)	83.3 (18.9)	3.0 (6.0)	-10.9 (5.5)	-9.7 (3.6)
Median	85.0	95.0	85.0	0	-5.0	0
IQR: Q1, Q3	80.0, 95.0	80.0, 100.0	70.0, 100.0	-5.0, 5.0	-20.0, 0.0	-20.0, 0.0
Min, Max	75, 100	50, 100	35, 100	-10, 25	-50, 5	-45, 5
Week 52						
m	6	12	19			
n	5	10	17	5	10	16
Mean (SD/SE)	91.0 (12.4)	90.0 (17.8)	84.7 (17.5)	5.0 (4.2)	-8.5 (5.9)	-7.8 (3.5)
Median	100.0	100.0	90.0	0	0	-2.5
IQR: Q1, Q3	80.0, 100.0	80.0, 100.0	75.0, 100.0	0.0, 15.0	-20.0, 0.0	-15.0, 0.0
Min, Max	75, 100	45, 100	45, 100	-5, 15	-55, 5	-35, 15

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.3.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=21)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=21)
Hopelessness						
Baseline						
m	6	15	21			
n	6	14	19			
Mean (SD)	87.52 (13.69)	92.86 (13.42)	85.53 (21.31)			
Median	91.70	100.00	91.70			
IQR: Q1, Q3	75.00, 100.00	91.70, 100.00	75.00, 100.00			
Min, Max	66.7, 100.0	58.3, 100.0	33.3, 100.0			
Week 24						
m	6	12	20			
n	5	11	18	5	11	17
Mean (SD/SE)	88.34 (13.94)	85.60 (20.11)	82.88 (24.83)	-1.68 (8.08)	-6.07 (4.51)	-0.98 (3.27)
Median	91.70	100.00	91.70	0	0	0
IQR: Q1, Q3	83.30, 100.00	58.30, 100.00	75.00, 100.00	-8.40, 0.00	-8.40, 0.00	-8.30, 0.00
Min, Max	66.7, 100.0	50.0, 100.0	25.0, 100.0	-25.0, 25.0	-50.0, 0.0	-25.0, 25.0
Week 52						
m	6	12	19			
n	5	10	17	5	10	16
Mean (SD/SE)	93.32 (9.15)	90.84 (13.85)	84.31 (20.39)	6.64 (7.17)	0.00 (4.48)	0.51 (4.06)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	83.30, 100.00	83.30, 100.00	75.00, 100.00	0.00, 8.30	0.00, 0.00	-4.20, 12.50
Min, Max	83.3, 100.0	66.7, 100.0	50.0, 100.0	-8.4, 33.3	-33.3, 25.0	-33.4, 25.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.3.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

	Visit Result			Change from Baseline		
Parameter	DB	DB	DB	DB	DB	DB
Visit	MGL-3196 80 mg	MGL-3196 100 mg	Placebo	MGL-3196 80 mg	MGL-3196 100 mg	Placebo
Statistic	(N=6)	(N=15)	(N=21)	(N=6)	(N=15)	(N=21)
Stigma of Liver Disease						
Baseline						
m	6	15	21			
n	6	14	19			
Mean (SD)	86.47 (11.46)	85.74 (14.38)	87.19 (14.35)			
Median	84.40	81.30	87.50			
IQR: Q1, Q3	75.00, 100.00	81.30, 100.00	81.30, 100.00			
Min, Max	75.0, 100.0	50.0, 100.0	50.0, 100.0			
Week 24						
m	6	12	20			
n	5	11	18	5	11	17
Mean (SD/SE)	91.26 (12.17)	84.66 (17.54)	81.61 (25.49)	5.00 (5.00)	-0.58 (7.32)	-7.73 (3.77)
Median	100.00	87.50	87.50	0	0	0
IQR: Q1, Q3	81.30, 100.00	75.00, 100.00	75.00, 100.00	0.00, 0.00	-12.50, 6.20	-12.50, 0.00
Min, Max	75.0, 100.0	50.0, 100.0	0.0, 100.0	0.0, 25.0	-50.0, 50.0	-50.0, 18.7
Week 52						
m	6	12	19			
n	5	10	17	5	10	16
Mean (SD/SE)	86.26 (21.83)	83.14 (17.45)	82.38 (20.03)	-2.50 (6.12)	-0.63 (7.54)	-7.03 (4.70)
Median	100.00	87.55	87.50	0	0	0
IQR: Q1, Q3	81.30, 100.00	75.00, 100.00	81.30, 100.00	0.00, 0.00	0.00, 0.00	-9.35, 0.00
Min, Max	50.0, 100.0	50.0, 100.0	43.8, 100.0	-25.0, 12.5	-50.0, 43.8	-56.2, 12.5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.3.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=7)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=7)
Total LDQOL						
Baseline						
m	3	0	7			
n	3	0	7			
Mean (SD)	86.77 (8.91)	N/A	89.79 (5.92)			
Median	91.30	N/A	90.90			
IQR: Q1, Q3	76.50, 92.50	N/A	85.40, 94.30			
Min, Max	76.5, 92.5	N/A	80.2, 97.0			
Week 24						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	91.15 (1.20)	N/A	90.09 (4.64)	-0.75 (1.45)	N/A	0.30 (1.66)
Median	91.15	N/A	88.80	-0.75	N/A	-0.20
IQR: Q1, Q3	90.30, 92.00	N/A	85.10, 94.70	-2.20, 0.70	N/A	-1.80, 2.00
Min, Max	90.3, 92.0	N/A	84.0, 95.2	-2.2, 0.7	N/A	-5.8, 8.5
Week 52						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	90.25 (2.47)	N/A	88.76 (6.74)	-1.65 (2.35)	N/A	-1.03 (2.11)
Median	90.25	N/A	92.50	-1.65	N/A	-0.80
IQR: Q1, Q3	88.50, 92.00	N/A	79.40, 93.70	-4.00, 0.70	N/A	-2.30, 2.60
Min, Max	88.5, 92.0	N/A	79.4, 94.7	-4.0, 0.7	N/A	-11.5, 6.9

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.3.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=7)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=7)
Symptoms of Liver Disease						
Baseline						
m	3	0	7			
n	3	0	7			
Mean (SD)	94.47 (6.93)	N/A	84.29 (16.07)			
Median	96.70	N/A	90.00			
IQR: Q1, Q3	86.70, 100.00	N/A	80.00, 93.30			
Min, Max	86.7, 100.0	N/A	50.0, 96.7			
Week 24						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	100.00 (0.00)	N/A	87.14 (11.15)	1.65 (1.65)	N/A	2.86 (3.94)
Median	100.00	N/A	86.70	1.65	N/A	3.30
IQR: Q1, Q3	100.00, 100.00	N/A	73.30, 96.70	0.00, 3.30	N/A	-6.60, 6.70
Min, Max	100.0, 100.0	N/A	73.3, 100.0	0.0, 3.3	N/A	-6.7, 23.3
Week 52						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	95.00 (2.40)	N/A	90.47 (11.29)	-3.35 (0.05)	N/A	6.19 (2.57)
Median	95.00	N/A	93.30	-3.35	N/A	6.60
IQR: Q1, Q3	93.30, 96.70	N/A	80.00, 100.00	-3.40, -3.30	N/A	0.00, 6.70
Min, Max	93.3, 96.7	N/A	70.0, 100.0	-3.4, -3.3	N/A	0.0, 20.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.3.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=7)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=7)
Effects of Liver Disease						
Baseline						
m	3	0	7			
n	3	0	7			
Mean (SD)	82.23 (16.76)	N/A	80.96 (2.53)			
Median	80.00	N/A	80.00			
IQR: Q1, Q3	66.70, 100.00	N/A	80.00, 80.00			
Min, Max	66.7, 100.0	N/A	80.0, 86.7			
Week 24						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	80.00 (0.00)	N/A	80.00 (3.87)	-10.00 (10.00)	N/A	-0.96 (1.75)
Median	80.00	N/A	80.00	-10.00	N/A	0
IQR: Q1, Q3	80.00, 80.00	N/A	80.00, 80.00	-20.00, 0.00	N/A	-6.70, 0.00
Min, Max	80.0, 80.0	N/A	73.3, 86.7	-20.0, 0.0	N/A	-6.7, 6.7
Week 52						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	86.65 (9.40)	N/A	80.00 (0.00)	-3.35 (16.65)	N/A	-0.96 (0.96)
Median	86.65	N/A	80.00	-3.35	N/A	0
IQR: Q1, Q3	80.00, 93.30	N/A	80.00, 80.00	-20.00, 13.30	N/A	0.00, 0.00
Min, Max	80.0, 93.3	N/A	80.0, 80.0	-20.0, 13.3	N/A	-6.7, 0.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.3.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=7)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=7)
Concentration/Memory						
Baseline						
m	3	0	7			
n	3	0	7			
Mean (SD)	81.27 (22.51)	N/A	91.07 (9.45)			
Median	87.50	N/A	87.50			
IQR: Q1, Q3	56.30, 100.00	N/A	87.50, 100.00			
Min, Max	56.3, 100.0	N/A	75.0, 100.0			
Week 24						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	96.90 (4.38)	N/A	85.73 (12.86)	3.15 (3.15)	N/A	-5.34 (4.81)
Median	96.90	N/A	87.50	3.15	N/A	-6.20
IQR: Q1, Q3	93.80, 100.00	N/A	81.30, 100.00	0.00, 6.30	N/A	-12.50, 6.30
Min, Max	93.8, 100.0	N/A	62.5, 100.0	0.0, 6.3	N/A	-25.0, 12.5
Week 52						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	93.75 (8.84)	N/A	82.17 (24.32)	0.00 (0.00)	N/A	-8.90 (7.32)
Median	93.75	N/A	93.80	0	N/A	-6.20
IQR: Q1, Q3	87.50, 100.00	N/A	50.00, 100.00	0.00, 0.00	N/A	-25.00, 6.30
Min, Max	87.5, 100.0	N/A	43.8, 100.0	0.0, 0.0	N/A	-43.7, 12.5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.3.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=3)	(N=0)	(N=7)	(N=3)	(N=0)	(N=7)
Health Distress						
Baseline						
m	3	0	7			
n	3	0	7			
Mean (SD)	79.17 (19.09)	N/A	100.00 (0.00)			
Median	75.00	N/A	100.00			
IQR: Q1, Q3	62.50, 100.00	N/A	100.00, 100.00			
Min, Max	62.5, 100.0	N/A	100.0, 100.0			
Week 24						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	93.75 (8.84)	N/A	98.21 (4.72)	6.25 (6.25)	N/A	-1.79 (1.79)
Median	93.75	N/A	100.00	6.25	N/A	0
IQR: Q1, Q3	87.50, 100.00	N/A	100.00, 100.00	0.00, 12.50	N/A	0.00, 0.00
Min, Max	87.5, 100.0	N/A	87.5, 100.0	0.0, 12.5	N/A	-12.5, 0.0
Week 52						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	93.75 (8.84)	N/A	98.21 (4.72)	6.25 (6.25)	N/A	-1.79 (1.79)
Median	93.75	N/A	100.00	6.25	N/A	0
IQR: Q1, Q3	87.50, 100.00	N/A	100.00, 100.00	0.00, 12.50	N/A	0.00, 0.00
Min, Max	87.5, 100.0	N/A	87.5, 100.0	0.0, 12.5	N/A	-12.5, 0.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.3.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=7)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=7)
Sexual Function						
Baseline						
m	3	0	7			
n	2	0	2			
Mean (SD)	92.50 (1.13)	N/A	92.50 (10.61)			
Median	92.50	N/A	92.50			
IQR: Q1, Q3	91.70, 93.30	N/A	85.00, 100.00			
Min, Max	91.7, 93.3	N/A	85.0, 100.0			
Week 24						
m	2	0	7			
n	1	0	2	1	0	1
Mean (SD/SE)	70.00 (N/A)	N/A	96.65 (4.74)	-23.30 (N/A)	N/A	0.00 (N/A)
Median	70.00	N/A	96.65	-23.30	N/A	0
IQR: Q1, Q3	70.00, 70.00	N/A	93.30, 100.00	-23.30, -23.30	N/A	0.00, 0.00
Min, Max	70.0, 70.0	N/A	93.3, 100.0	-23.3, -23.3	N/A	0.0, 0.0
Week 52						
m	2	0	7			
n	1	0	3	1	0	2
Mean (SD/SE)	85.00 (N/A)	N/A	82.20 (16.21)	-8.30 (N/A)	N/A	-8.35 (8.35)
Median	85.00	N/A	78.30	-8.30	N/A	-8.35
IQR: Q1, Q3	85.00, 85.00	N/A	68.30, 100.00	-8.30, -8.30	N/A	-16.70, 0.00
Min, Max	85.0, 85.0	N/A	68.3, 100.0	-8.3, -8.3	N/A	-16.7, 0.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.3.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=7)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=7)
Sleep						
Baseline						
m	3	0	7			
n	3	0	7			
Mean (SD)	70.0 (5.0)	N/A	73.6 (21.4)			
Median	70.0	N/A	80.0			
IQR: Q1, Q3	65.0, 75.0	N/A	50.0, 90.0			
Min, Max	65, 75	N/A	50, 100			
Week 24						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	75.0 (0.0)	N/A	75.7 (16.2)	2.5 (2.5)	N/A	2.1 (4.5)
Median	75.0	N/A	75.0	2.5	N/A	5.0
IQR: Q1, Q3	75.0, 75.0	N/A	60.0, 90.0	0.0, 5.0	N/A	-10.0, 10.0
Min, Max	75, 75	N/A	55, 95	0, 5	N/A	-15, 20
Week 52						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	65.0 (0.0)	N/A	75.0 (18.7)	-7.5 (2.5)	N/A	1.4 (7.8)
Median	65.0	N/A	85.0	-7.5	N/A	0
IQR: Q1, Q3	65.0, 65.0	N/A	50.0, 90.0	-10.0, -5.0	N/A	-15.0, 15.0
Min, Max	65, 65	N/A	50, 95	-10, -5	N/A	-30, 35

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.3.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=7)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=7)
Loneliness						
Baseline						
m	3	0	7			
n	3	0	7			
Mean (SD)	95.0 (8.7)	N/A	95.0 (9.6)			
Median	100.0	N/A	100.0			
IQR: Q1, Q3	85.0, 100.0	N/A	90.0, 100.0			
Min, Max	85, 100	N/A	75, 100			
Week 24						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	100.0 (0.0)	N/A	97.9 (5.7)	0.0 (0.0)	N/A	2.9 (1.8)
Median	100.0	N/A	100.0	0	N/A	0
IQR: Q1, Q3	100.0, 100.0	N/A	100.0, 100.0	0.0, 0.0	N/A	0.0, 10.0
Min, Max	100, 100	N/A	85, 100	0, 0	N/A	0, 10
Week 52						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	100.0 (0.0)	N/A	96.4 (7.5)	0.0 (0.0)	N/A	1.4 (3.4)
Median	100.0	N/A	100.0	0	N/A	0
IQR: Q1, Q3	100.0, 100.0	N/A	95.0, 100.0	0.0, 0.0	N/A	0.0, 0.0
Min, Max	100, 100	N/A	80, 100	0, 0	N/A	-10, 20

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.3.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=7)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=7)
Hopelessness						
Baseline						
m	3	0	7			
n	3	0	7			
Mean (SD)	88.90 (12.73)	N/A	95.24 (6.56)			
Median	91.70	N/A	100.00			
IQR: Q1, Q3	75.00, 100.00	N/A	91.70, 100.00			
Min, Max	75.0, 100.0	N/A	83.3, 100.0			
Week 24						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	100.00 (0.00)	N/A	96.43 (9.45)	4.15 (4.15)	N/A	1.19 (2.16)
Median	100.00	N/A	100.00	4.15	N/A	0
IQR: Q1, Q3	100.00, 100.00	N/A	100.00, 100.00	0.00, 8.30	N/A	0.00, 8.30
Min, Max	100.0, 100.0	N/A	75.0, 100.0	0.0, 8.3	N/A	-8.3, 8.3
Week 52						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	95.85 (5.87)	N/A	95.24 (6.56)	0.00 (0.00)	N/A	0.00 (3.64)
Median	95.85	N/A	100.00	0	N/A	0
IQR: Q1, Q3	91.70, 100.00	N/A	91.70, 100.00	0.00, 0.00	N/A	0.00, 0.00
Min, Max	91.7, 100.0	N/A	83.3, 100.0	0.0, 0.0	N/A	-16.7, 16.7

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.3.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=3)	(N=0)	(N=7)	(N=3)	(N=0)	(N=7)
Stigma of Liver Disease						
Baseline						
m	3	0	7			
n	3	0	7			
Mean (SD)	97.93 (3.58)	N/A	99.11 (2.34)			
Median	100.00	N/A	100.00			
IQR: Q1, Q3	93.80, 100.00	N/A	100.00, 100.00			
Min, Max	93.8, 100.0	N/A	93.8, 100.0			
Week 24						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	93.80 (0.00)	N/A	98.23 (3.03)	-3.10 (3.10)	N/A	-0.89 (0.89)
Median	93.80	N/A	100.00	-3.10	N/A	0
IQR: Q1, Q3	93.80, 93.80	N/A	93.80, 100.00	-6.20, 0.00	N/A	0.00, 0.00
Min, Max	93.8, 93.8	N/A	93.8, 100.0	-6.2, 0.0	N/A	-6.2, 0.0
Week 52						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	93.80 (0.00)	N/A	97.34 (3.31)	-3.10 (3.10)	N/A	-1.77 (1.14)
Median	93.80	N/A	100.00	-3.10	N/A	0
IQR: Q1, Q3	93.80, 93.80	N/A	93.80, 100.00	-6.20, 0.00	N/A	-6.20, 0.00
Min, Max	93.8, 93.8	N/A	93.8, 100.0	-6.2, 0.0	N/A	-6.2, 0.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc. Page 1 of 3
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.3.2Liver Disease Quality of Life (SE20): Summary of Total LDQOL - MMRM Model
by Age
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 2 of 3
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.3.2Liver Disease Quality of Life (SE20): Summary of Total LDQOL - MMRM Model
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Total LDQOL			
Week 24			
m	6	12	20
n	5	11	17
Baseline Mean (SD)	76.48 (16.82)	87.75 (5.79)	84.88 (8.74)
Analysis Visit Mean (SD)	78.68 (12.62)	84.72 (8.35)	81.99 (12.52)
LS Mean of Change from Baseline (SE)	0.69 (5.60)	-3.65 (4.11)	-3.57 (4.60)
95% CI	(-10.75, 12.13)	(-12.05, 4.75)	(-12.96, 5.82)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.27 (4.21)	-0.08 (3.31)	
95% CI	(-4.33, 12.86)	(-6.84, 6.68)	
p-value	0.3189	0.9817	
Corrected Hedge's g Statistics	0.230	-0.004	
95% CI	(-0.77, 1.23)	(-0.76, 0.75)	
Week 52			
m	6	12	19
n	5	10	16
Baseline Mean (SD)	81.28 (16.06)	87.57 (6.07)	85.28 (8.87)
Analysis Visit Mean (SD)	79.10 (22.63)	84.58 (5.41)	81.34 (13.49)
LS Mean of Change from Baseline (SE)	-2.26 (6.21)	-4.18 (4.59)	-4.41 (4.88)
95% CI	(-14.95, 10.43)	(-13.55, 5.20)	(-14.37, 5.54)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.16 (5.19)	0.24 (4.21)	
95% CI	(-8.44, 12.76)	(-8.36, 8.83)	
p-value	0.6809	0.9556	
Corrected Hedge's g Statistics	0.112	0.013	
95% CI	(-0.89, 1.12)	(-0.78, 0.80)	
Subgroup*Treatment Interaction p-value	0.3311	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 3 of 3
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.3.2Liver Disease Quality of Life (SE20): Summary of Total LDQOL - MMRM Model
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Total LDQOL			
Week 24			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	91.90 (0.85)	N/A	89.79 (5.92)
Analysis Visit Mean (SD)	91.15 (1.20)	N/A	90.09 (4.64)
LS Mean of Change from Baseline (SE)	0.22 (2.77)	NE	2.37 (2.23)
95% CI	(-6.91, 7.36)	NE	(-3.37, 8.11)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.15 (3.50)	NE	
95% CI	(-11.15, 6.86)	NE	
p-value	0.5667	NE	
Corrected Hedge's g Statistics	-0.337	NE	
95% CI	(-1.92, 1.24)	NE	
Week 52			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	91.90 (0.85)	N/A	89.79 (5.92)
Analysis Visit Mean (SD)	90.25 (2.47)	N/A	88.76 (6.74)
LS Mean of Change from Baseline (SE)	-0.95 (3.54)	NE	1.12 (2.52)
95% CI	(-10.06, 8.16)	NE	(-5.36, 7.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.07 (4.31)	NE	
95% CI	(-13.14, 9.01)	NE	
p-value	0.6520	NE	
Corrected Hedge's g Statistics	-0.284	NE	
95% CI	(-1.86, 1.29)	NE	
Subgroup*Treatment Interaction p-value	0.3311	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.3.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

AMNOG Table SE20.3.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Symptoms of Liver Disease			
Week 24			
m	6	12	20
n	5	11	17
Baseline Mean (SD)	79.34 (16.59)	85.45 (12.77)	81.96 (15.65)
Analysis Visit Mean (SD)	80.00 (13.76)	88.79 (8.97)	81.56 (16.67)
LS Mean of Change from Baseline (SE)	-2.09 (8.79)	5.00 (6.44)	-1.62 (6.93)
95% CI	(-20.04, 15.87)	(-8.16, 18.16)	(-15.78, 12.54)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.47 (7.35)	6.62 (5.88)	
95% CI	(-15.48, 14.55)	(-5.39, 18.63)	
p-value	0.9498	0.2691	
Corrected Hedge's g Statistics	-0.017	0.247	
95% CI	(-1.01, 0.98)	(-0.51, 1.01)	
Week 52			
m	6	12	19
n	5	10	16
Baseline Mean (SD)	87.34 (8.62)	83.99 (12.46)	82.71 (15.85)
Analysis Visit Mean (SD)	82.00 (15.71)	82.00 (13.80)	83.74 (13.49)
LS Mean of Change from Baseline (SE)	-3.96 (8.16)	-2.55 (6.02)	0.69 (6.72)
95% CI	(-20.62, 12.70)	(-14.85, 9.75)	(-13.03, 14.41)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.65 (6.21)	-3.24 (5.13)	
95% CI	(-17.34, 8.03)	(-13.71, 7.23)	
p-value	0.4597	0.5318	
Corrected Hedge's g Statistics	-0.177	-0.130	
95% CI	(-1.18, 0.83)	(-0.92, 0.66)	
Subgroup*Treatment Interaction p-value	0.9933	NE	

AMNOG Table SE20.3.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Effects of Liver Disease			
Week 24			
m	6	12	20
n	5	11	17
Baseline Mean (SD)	64.00 (22.42)	86.67 (9.43)	81.96 (7.36)
Analysis Visit Mean (SD)	80.00 (0.00)	83.63 (9.60)	78.83 (9.79)
LS Mean of Change from Baseline (SE)	-0.33 (7.07)	1.47 (4.73)	-3.00 (5.30)
95% CI	(-14.78, 14.11)	(-8.18, 11.13)	(-13.83, 7.83)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.67 (5.44)	4.48 (3.93)	
95% CI	(-8.44, 13.78)	(-3.56, 12.51)	
p-value	0.6275	0.2642	
Corrected Hedge's g Statistics	0.123	0.220	
95% CI	(-0.87, 1.12)	(-0.54, 0.98)	
Week 52			
m	6	12	19
n	5	10	16
Baseline Mean (SD)	74.68 (15.91)	87.34 (9.67)	81.26 (6.98)
Analysis Visit Mean (SD)	68.00 (26.83)	82.00 (7.07)	81.26 (8.50)
LS Mean of Change from Baseline (SE)	-9.14 (7.32)	-4.14 (5.21)	-0.38 (5.56)
95% CI	(-24.10, 5.82)	(-14.78, 6.49)	(-11.74, 10.97)
LS Mean of Change from Baseline Compared to Placebo (SE)	-8.76 (5.94)	-3.76 (4.85)	
95% CI	(-20.89, 3.37)	(-13.66, 6.14)	
p-value	0.1506	0.4443	
Corrected Hedge's g Statistics	-0.398	-0.180	
95% CI	(-1.41, 0.61)	(-0.97, 0.61)	
Subgroup*Treatment Interaction p-value	0.8779	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.3.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Concentration/Memory			
Week 24			
m	6	12	20
n	5	11	17
Baseline Mean (SD)	81.26 (26.50)	84.68 (20.78)	87.88 (16.30)
Analysis Visit Mean (SD)	72.52 (25.23)	85.25 (16.60)	89.35 (13.57)
LS Mean of Change from Baseline (SE)	-8.78 (8.20)	1.90 (6.10)	4.18 (6.79)
95% CI	(-25.52, 7.97)	(-10.56, 14.37)	(-9.68, 18.05)
LS Mean of Change from Baseline Compared to Placebo (SE)	-12.96 (6.50)	-2.28 (5.15)	
95% CI	(-26.23, 0.31)	(-12.79, 8.23)	
p-value	0.0552	0.6611	
Corrected Hedge's g Statistics	-0.473	-0.087	
95% CI	(-1.48, 0.53)	(-0.85, 0.67)	
Week 52			
m	6	12	19
n	5	10	16
Baseline Mean (SD)	78.76 (24.83)	85.02 (21.88)	88.69 (16.49)
Analysis Visit Mean (SD)	66.26 (38.93)	85.01 (17.71)	84.01 (17.81)
LS Mean of Change from Baseline (SE)	-12.82 (9.39)	1.52 (6.86)	-2.16 (7.27)
95% CI	(-31.99, 6.35)	(-12.50, 15.53)	(-17.01, 12.69)
LS Mean of Change from Baseline Compared to Placebo (SE)	-10.66 (8.24)	3.68 (6.58)	
95% CI	(-27.48, 6.17)	(-9.76, 17.12)	
p-value	0.2057	0.5804	
Corrected Hedge's g Statistics	-0.371	0.134	
95% CI	(-1.38, 0.64)	(-0.66, 0.93)	
Subgroup*Treatment Interaction p-value	0.2144	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.3.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Health Distress			
Week 24			
m	6	12	20
n	5	11	17
Baseline Mean (SD)	72.50 (41.83)	96.59 (5.84)	91.91 (14.62)
Analysis Visit Mean (SD)	77.50 (43.66)	95.45 (8.43)	88.97 (15.86)
LS Mean of Change from Baseline (SE)	-4.14 (9.06)	-5.72 (6.72)	-8.70 (7.49)
95% CI	(-22.65, 14.37)	(-19.44, 8.01)	(-23.99, 6.58)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.56 (6.96)	2.99 (5.35)	
95% CI	(-9.66, 18.78)	(-7.93, 13.90)	
p-value	0.5177	0.5803	
Corrected Hedge's g Statistics	0.151	0.104	
95% CI	(-0.85, 1.15)	(-0.65, 0.86)	
Week 52			
m	6	12	19
n	5	10	16
Baseline Mean (SD)	77.50 (43.66)	96.25 (6.04)	92.97 (14.41)
Analysis Visit Mean (SD)	80.00 (44.72)	95.00 (10.54)	86.72 (19.08)
LS Mean of Change from Baseline (SE)	-3.20 (10.09)	-7.05 (7.44)	-12.19 (7.92)
95% CI	(-23.81, 17.41)	(-22.24, 8.14)	(-28.36, 3.97)
LS Mean of Change from Baseline Compared to Placebo (SE)	8.99 (8.54)	5.14 (6.73)	
95% CI	(-8.46, 26.43)	(-8.59, 18.88)	
p-value	0.3010	0.4505	
Corrected Hedge's g Statistics	0.288	0.172	
95% CI	(-0.72, 1.30)	(-0.62, 0.96)	
Subgroup*Treatment Interaction p-value	0.7318	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.3.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Sexual Function			
Week 24			
m	6	12	20
n	1	5	8
Baseline Mean (SD)	100.00 (N/A)	94.00 (8.22)	90.63 (9.63)
Analysis Visit Mean (SD)	91.70 (N/A)	87.66 (16.65)	88.54 (18.28)
LS Mean of Change from Baseline (SE)	-10.78 (11.43)	-7.03 (5.05)	-0.55 (3.87)
95% CI	(-35.68, 14.11)	(-18.04, 3.98)	(-8.97, 7.87)
LS Mean of Change from Baseline Compared to Placebo (SE)	-10.23 (12.24)	-6.48 (6.40)	
95% CI	(-36.90, 16.44)	(-20.42, 7.46)	
p-value	0.4195	0.3310	
Corrected Hedge's g Statistics	-0.832	-0.545	
95% CI	(-2.95, 1.28)	(-1.68, 0.59)	
Week 52			
m	6	12	19
n	1	4	6
Baseline Mean (SD)	100.00 (N/A)	96.25 (7.50)	94.15 (8.43)
Analysis Visit Mean (SD)	100.00 (N/A)	96.65 (3.87)	83.33 (34.01)
LS Mean of Change from Baseline (SE)	-5.63 (21.04)	-9.08 (9.30)	-3.47 (7.18)
95% CI	(-51.47, 40.21)	(-29.35, 11.20)	(-19.10, 12.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.16 (22.57)	-5.61 (11.78)	
95% CI	(-51.34, 47.02)	(-31.27, 20.05)	
p-value	0.9253	0.6425	
Corrected Hedge's g Statistics	-0.103	-0.282	
95% CI	(-2.22, 2.01)	(-1.55, 0.99)	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE20.3.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Sleep			
Week 24			
m	6	12	20
n	5	11	17
Baseline Mean (SD)	51.0 (34.7)	70.5 (8.2)	67.4 (21.9)
Analysis Visit Mean (SD)	53.0 (30.9)	66.4 (15.3)	67.9 (17.1)
LS Mean of Change from Baseline (SE)	-9.66 (8.00)	-9.65 (5.74)	-6.83 (6.50)
95% CI	(-26.00, 6.68)	(-21.38, 2.07)	(-20.11, 6.45)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.83 (5.87)	-2.83 (4.66)	
95% CI	(-14.81, 9.15)	(-12.34, 6.68)	
p-value	0.6326	0.5482	
Corrected Hedge's g Statistics	-0.108	-0.114	
95% CI	(-1.11, 0.89)	(-0.87, 0.65)	
Week 52			
m	6	12	19
n	5	10	16
Baseline Mean (SD)	67.0 (21.1)	71.0 (8.4)	69.7 (20.4)
Analysis Visit Mean (SD)	65.0 (22.6)	64.5 (10.4)	66.6 (19.0)
LS Mean of Change from Baseline (SE)	-11.32 (8.43)	-11.78 (6.17)	-9.78 (6.75)
95% CI	(-28.55, 5.90)	(-24.39, 0.82)	(-23.57, 4.00)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.54 (6.68)	-2.00 (5.48)	
95% CI	(-15.19, 12.11)	(-13.20, 9.19)	
p-value	0.8193	0.7176	
Corrected Hedge's g Statistics	-0.058	-0.079	
95% CI	(-1.06, 0.95)	(-0.87, 0.71)	
Subgroup*Treatment Interaction p-value	0.9058	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.3.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Loneliness			
Week 24			
m	6	12	20
n	5	11	17
Baseline Mean (SD)	84.0 (14.7)	98.2 (2.5)	92.1 (10.9)
Analysis Visit Mean (SD)	87.0 (10.4)	87.3 (17.2)	82.4 (19.0)
LS Mean of Change from Baseline (SE)	5.93 (11.09)	-5.36 (8.09)	-4.55 (8.97)
95% CI	(-16.72, 28.59)	(-21.88, 11.17)	(-22.88, 13.78)
LS Mean of Change from Baseline Compared to Placebo (SE)	10.48 (8.38)	-0.81 (6.99)	
95% CI	(-6.63, 27.60)	(-15.07, 13.46)	
p-value	0.2205	0.9089	
Corrected Hedge's g Statistics	0.289	-0.023	
95% CI	(-0.71, 1.29)	(-0.78, 0.74)	
Week 52			
m	6	12	19
n	5	10	16
Baseline Mean (SD)	86.0 (16.4)	98.5 (2.4)	91.6 (11.1)
Analysis Visit Mean (SD)	91.0 (12.4)	90.0 (17.8)	83.8 (17.6)
LS Mean of Change from Baseline (SE)	9.51 (10.82)	-2.78 (7.90)	-2.27 (8.92)
95% CI	(-12.58, 31.61)	(-18.92, 13.36)	(-20.48, 15.95)
LS Mean of Change from Baseline Compared to Placebo (SE)	11.78 (7.75)	-0.51 (6.74)	
95% CI	(-4.05, 27.61)	(-14.27, 13.25)	
p-value	0.1391	0.9402	
Corrected Hedge's g Statistics	0.337	-0.015	
95% CI	(-0.67, 1.35)	(-0.81, 0.77)	
Subgroup*Treatment Interaction p-value	0.3417	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.3.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Hopelessness			
Week 24			
m	6	12	20
n	5	11	17
Baseline Mean (SD)	90.02 (13.68)	91.67 (14.91)	83.83 (21.95)
Analysis Visit Mean (SD)	88.34 (13.94)	85.60 (20.11)	82.85 (25.60)
LS Mean of Change from Baseline (SE)	5.54 (9.71)	-1.03 (7.44)	5.55 (8.29)
95% CI	(-14.30, 25.37)	(-16.23, 14.17)	(-11.37, 22.48)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.02 (7.21)	-6.58 (6.13)	
95% CI	(-14.73, 14.70)	(-19.10, 5.94)	
p-value	0.9983	0.2914	
Corrected Hedge's g Statistics	0.000	-0.207	
95% CI	(-1.00, 1.00)	(-0.97, 0.55)	
Week 52			
m	6	12	19
n	5	10	16
Baseline Mean (SD)	86.68 (15.13)	90.84 (15.44)	82.82 (22.25)
Analysis Visit Mean (SD)	93.32 (9.15)	90.84 (13.85)	83.33 (20.64)
LS Mean of Change from Baseline (SE)	9.89 (9.42)	6.92 (7.22)	5.81 (8.18)
95% CI	(-9.34, 29.13)	(-7.82, 21.67)	(-10.89, 22.51)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.09 (6.59)	1.11 (5.70)	
95% CI	(-9.37, 17.54)	(-10.53, 12.76)	
p-value	0.5399	0.8463	
Corrected Hedge's g Statistics	0.128	0.037	
95% CI	(-0.88, 1.13)	(-0.75, 0.83)	
Subgroup*Treatment Interaction p-value	0.9628	NE	

AMNOG Table SE20.3.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Stigma of Liver Disease			
Week 24			
m	6	12	20
n	5	11	17
Baseline Mean (SD)	86.26 (12.80)	85.25 (15.63)	88.99 (13.71)
Analysis Visit Mean (SD)	91.26 (12.17)	84.66 (17.54)	81.26 (26.23)
LS Mean of Change from Baseline (SE)	2.15 (12.49)	-3.93 (9.36)	-11.65 (10.53)
95% CI	(-23.35, 27.65)	(-23.05, 15.19)	(-33.14, 9.85)
LS Mean of Change from Baseline Compared to Placebo (SE)	13.80 (9.51)	7.72 (7.79)	
95% CI	(-5.62, 33.22)	(-8.19, 23.62)	
p-value	0.1572	0.3297	
Corrected Hedge's g Statistics	0.325	0.192	
95% CI	(-0.68, 1.33)	(-0.57, 0.95)	
Week 52			
m	6	12	19
n	5	10	16
Baseline Mean (SD)	88.76 (11.17)	83.77 (15.65)	89.08 (14.15)
Analysis Visit Mean (SD)	86.26 (21.83)	83.14 (17.45)	82.06 (20.64)
LS Mean of Change from Baseline (SE)	-4.05 (12.75)	-5.41 (9.49)	-10.45 (10.64)
95% CI	(-30.09, 21.98)	(-24.80, 13.98)	(-32.17, 11.28)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.39 (9.68)	5.03 (8.16)	
95% CI	(-13.38, 26.17)	(-11.64, 21.70)	
p-value	0.5140	0.5420	
Corrected Hedge's g Statistics	0.153	0.127	
95% CI	(-0.85, 1.16)	(-0.66, 0.92)	
Subgroup*Treatment Interaction p-value	0.2758	NE	

AMNOG Table SE20.3.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Symptoms of Liver Disease			
Week 24			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	98.35 (2.33)	N/A	84.29 (16.07)
Analysis Visit Mean (SD)	100.00 (0.00)	N/A	87.14 (11.15)
LS Mean of Change from Baseline (SE)	6.76 (5.81)	NE	1.87 (3.48)
95% CI	(-8.17, 21.70)	NE	(-7.07, 10.81)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.89 (6.76)	NE	
95% CI	(-12.48, 22.27)	NE	
p-value	0.5016	NE	
Corrected Hedge's g Statistics	0.480	NE	
95% CI	(-1.11, 2.07)	NE	
Week 52			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	98.35 (2.33)	N/A	84.29 (16.07)
Analysis Visit Mean (SD)	95.00 (2.40)	N/A	90.47 (11.29)
LS Mean of Change from Baseline (SE)	0.33 (3.39)	NE	5.61 (2.52)
95% CI	(-8.38, 9.04)	NE	(-0.86, 12.07)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.28 (4.00)	NE	
95% CI	(-15.55, 4.99)	NE	
p-value	0.2439	NE	
Corrected Hedge's g Statistics	-0.730	NE	
95% CI	(-2.34, 0.88)	NE	
Subgroup*Treatment Interaction p-value	0.9933	NE	

AMNOG Table SE20.3.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Effects of Liver Disease			
Week 24			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	90.00 (14.14)	N/A	80.96 (2.53)
Analysis Visit Mean (SD)	80.00 (0.00)	N/A	80.00 (3.87)
LS Mean of Change from Baseline (SE)	-3.24 (3.65)	NE	-3.05 (1.97)
95% CI	(-12.63, 6.15)	NE	(-8.11, 2.00)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.19 (4.50)	NE	
95% CI	(-11.75, 11.38)	NE	
p-value	0.9687	NE	
Corrected Hedge's g Statistics	-0.032	NE	
95% CI	(-1.60, 1.54)	NE	
Week 52			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	90.00 (14.14)	N/A	80.96 (2.53)
Analysis Visit Mean (SD)	86.65 (9.40)	N/A	80.00 (0.00)
LS Mean of Change from Baseline (SE)	7.33 (1.55)	NE	-4.17 (1.18)
95% CI	(3.35, 11.32)	NE	(-7.21, -1.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	11.51 (2.23)	NE	
95% CI	(5.77, 17.25)	NE	
p-value	0.0036	NE	
Corrected Hedge's g Statistics	3.403	NE	
95% CI	(1.18, 5.63)	NE	
Subgroup*Treatment Interaction p-value	0.8779	NE	

AMNOG Table SE20.3.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Concentration/Memory			
Week 24			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	93.75 (8.84)	N/A	91.07 (9.45)
Analysis Visit Mean (SD)	96.90 (4.38)	N/A	85.73 (12.86)
LS Mean of Change from Baseline (SE)	4.90 (7.27)	NE	4.50 (6.31)
95% CI	(-13.78, 23.58)	NE	(-11.72, 20.73)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.40 (9.45)	NE	
95% CI	(-23.89, 24.69)	NE	
p-value	0.9678	NE	
Corrected Hedge's g Statistics	0.022	NE	
95% CI	(-1.55, 1.59)	NE	
Week 52			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	93.75 (8.84)	N/A	91.07 (9.45)
Analysis Visit Mean (SD)	93.75 (8.84)	N/A	82.17 (24.32)
LS Mean of Change from Baseline (SE)	-0.54 (12.03)	NE	1.60 (8.12)
95% CI	(-31.48, 30.39)	NE	(-19.26, 22.47)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.15 (14.42)	NE	
95% CI	(-39.22, 34.93)	NE	
p-value	0.8875	NE	
Corrected Hedge's g Statistics	-0.091	NE	
95% CI	(-1.66, 1.48)	NE	
Subgroup*Treatment Interaction p-value	0.2144	NE	

AMNOG Table SE20.3.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Health Distress			
Week 24			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	87.50 (17.68)	N/A	100.00 (0.00)
Analysis Visit Mean (SD)	93.75 (8.84)	N/A	98.21 (4.72)
LS Mean of Change from Baseline (SE)	1.39 (4.53)	NE	1.39 (2.39)
95% CI	(-10.25, 13.03)	NE	(-4.76, 7.54)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (5.43)	NE	
95% CI	(-13.97, 13.97)	NE	
p-value	>0.9999	NE	
Corrected Hedge's g Statistics	0.000	NE	
95% CI	(-1.57, 1.57)	NE	
Week 52			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	87.50 (17.68)	N/A	100.00 (0.00)
Analysis Visit Mean (SD)	93.75 (8.84)	N/A	98.21 (4.72)
LS Mean of Change from Baseline (SE)	1.39 (4.53)	NE	1.39 (2.39)
95% CI	(-10.25, 13.03)	NE	(-4.76, 7.54)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (5.43)	NE	
95% CI	(-13.97, 13.97)	NE	
p-value	>0.9999	NE	
Corrected Hedge's g Statistics	0.000	NE	
95% CI	(-1.57, 1.57)	NE	
Subgroup*Treatment Interaction p-value	0.7318	NE	

AMNOG Table SE20.3.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Sexual Function			
Week 24			
m	2	0	7
n	1	0	1
Baseline Mean (SD)	93.30 (N/A)	N/A	100.00 (N/A)
Analysis Visit Mean (SD)	70.00 (N/A)	N/A	100.00 (N/A)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	2	0	7
n	1	0	2
Baseline Mean (SD)	93.30 (N/A)	N/A	92.50 (10.61)
Analysis Visit Mean (SD)	85.00 (N/A)	N/A	84.15 (22.42)
LS Mean of Change from Baseline (SE)	-7.16 (0.00)	NE	-6.32 (0.00)
95% CI	(-7.17, -7.16)	NE	(-6.33, -6.32)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.84 (0.00)	NE	
95% CI	(-0.84, -0.84)	NE	
p-value	0.0002	NE	
Corrected Hedge's g Statistics	0.000	NE	
95% CI	(-2.40, 2.40)	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE20.3.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Sleep			
Week 24			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	72.5 (3.5)	N/A	73.6 (21.4)
Analysis Visit Mean (SD)	75.0 (0.0)	N/A	75.7 (16.2)
LS Mean of Change from Baseline (SE)	2.16 (9.00)	NE	-6.34 (6.32)
95% CI	(-20.98, 25.31)	NE	(-22.57, 9.90)
LS Mean of Change from Baseline Compared to Placebo (SE)	8.50 (11.01)	NE	
95% CI	(-19.80, 36.80)	NE	
p-value	0.4750	NE	
Corrected Hedge's g Statistics	0.466	NE	
95% CI	(-1.12, 2.05)	NE	
Week 52			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	72.5 (3.5)	N/A	73.6 (21.4)
Analysis Visit Mean (SD)	65.0 (0.0)	N/A	75.0 (18.7)
LS Mean of Change from Baseline (SE)	-8.02 (15.89)	NE	-7.00 (9.43)
95% CI	(-48.88, 32.84)	NE	(-31.23, 17.24)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.02 (18.49)	NE	
95% CI	(-48.55, 46.50)	NE	
p-value	0.9580	NE	
Corrected Hedge's g Statistics	-0.037	NE	
95% CI	(-1.61, 1.53)	NE	
Subgroup*Treatment Interaction p-value	0.9058	NE	

AMNOG Table SE20.3.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Loneliness			
Week 24			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	100.0 (0.0)	N/A	95.0 (9.6)
Analysis Visit Mean (SD)	100.0 (0.0)	N/A	97.9 (5.7)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	100.0 (0.0)	N/A	95.0 (9.6)
Analysis Visit Mean (SD)	100.0 (0.0)	N/A	96.4 (7.5)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.3417	NE	

AMNOG Table SE20.3.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Hopelessness			
Week 24			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	95.85 (5.87)	N/A	95.24 (6.56)
Analysis Visit Mean (SD)	100.00 (0.00)	N/A	96.43 (9.45)
LS Mean of Change from Baseline (SE)	4.23 (2.85)	NE	-2.31 (2.19)
95% CI	(-3.09, 11.56)	NE	(-7.93, 3.32)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.54 (3.61)	NE	
95% CI	(-2.73, 15.81)	NE	
p-value	0.1294	NE	
Corrected Hedge's g Statistics	1.043	NE	
95% CI	(-0.60, 2.69)	NE	
Week 52			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	95.85 (5.87)	N/A	95.24 (6.56)
Analysis Visit Mean (SD)	95.85 (5.87)	N/A	95.24 (6.56)
LS Mean of Change from Baseline (SE)	0.54 (6.86)	NE	-3.62 (3.99)
95% CI	(-17.10, 18.19)	NE	(-13.88, 6.63)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.17 (7.95)	NE	
95% CI	(-16.26, 24.59)	NE	
p-value	0.6225	NE	
Corrected Hedge's g Statistics	0.355	NE	
95% CI	(-1.23, 1.93)	NE	
Subgroup*Treatment Interaction p-value	0.9628	NE	

AMNOG Table SE20.3.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Stigma of Liver Disease			
Week 24			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	96.90 (4.38)	N/A	99.11 (2.34)
Analysis Visit Mean (SD)	93.80 (0.00)	N/A	98.23 (3.03)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	96.90 (4.38)	N/A	99.11 (2.34)
Analysis Visit Mean (SD)	93.80 (0.00)	N/A	97.34 (3.31)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.2758	NE	

AMNOG Table SE20.3.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis, only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.

AMNOG Table SE20.3.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	6 (100)	15 (100)	21 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (16.7)	1 (6.7)	4 (19.0)
No	5 (83.3)	14 (93.3)	17 (81.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	3.29	
95% CI of the inverse odds ratio	(0.11, 13.07)	(0.33, 32.94)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	2.86	
95% CI of the inverse risk ratio	(0.16, 8.40)	(0.35, 23.07)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.38	-12.38	
95% CI of the absolute risk difference	(-36.61, 31.84)	(-33.39, 8.63)	
p-value	0.8947	0.2896	
p-value of Breslow-Day Test for Homogeneity [3]	0.5418	NE	

AMNOG Table SE20.3.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (6.7)	2 (9.5)
No	6 (100)	14 (93.3)	19 (90.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	1.47	
95% CI of the inverse odds ratio	(0.07, 39.42)	(0.12, 17.91)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.59	1.43	
95% CI of the inverse risk ratio	(0.09, 29.34)	(0.14, 14.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.22	-2.86	
95% CI of the absolute risk difference	(-27.46, 19.01)	(-20.66, 14.95)	
p-value	0.7494	0.7598	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (13.3)	6 (28.6)
No	6 (100)	13 (86.7)	15 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.45	2.60	
95% CI of the inverse odds ratio	(0.27, 111.57)	(0.45, 15.18)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.14	2.14	
95% CI of the inverse risk ratio	(0.27, 64.56)	(0.50, 9.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-22.40	-15.24	
95% CI of the absolute risk difference	(-49.37, 4.57)	(-41.11, 10.63)	
p-value	0.2277	0.2783	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE20.3.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (4.8)
No	6 (100)	15 (100)	20 (95.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.76	-4.76	
95% CI of the absolute risk difference	(-13.87, 4.35)	(-13.87, 4.35)	
p-value	0.5860	0.3914	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (6.7)	4 (19.0)
No	6 (100)	14 (93.3)	17 (81.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.34	3.29	
95% CI of the inverse odds ratio	(0.16, 71.10)	(0.33, 32.94)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.86	2.86	
95% CI of the inverse risk ratio	(0.17, 46.87)	(0.35, 23.07)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-13.31	-12.38	
95% CI of the absolute risk difference	(-38.77, 12.15)	(-33.39, 8.63)	
p-value	0.4167	0.2896	
p-value of Breslow-Day Test for Homogeneity [3]	0.0391	NE	

AMNOG Table SE20.3.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (6.7)	0
No	6 (100)	14 (93.3)	21 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.22	
95% CI of the inverse odds ratio	NE	(0.01, 5.91)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.24	
95% CI of the inverse risk ratio	NE	(0.01, 5.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	7.10	
95% CI of the absolute risk difference	NE	(-8.48, 22.68)	
p-value	NE	0.3330	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (16.7)	3 (20.0)	4 (19.0)
No	5 (83.3)	12 (80.0)	17 (81.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	0.94	
95% CI of the inverse odds ratio	(0.11, 13.07)	(0.18, 5.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	0.95	
95% CI of the inverse risk ratio	(0.16, 8.40)	(0.25, 3.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.38	0.95	
95% CI of the absolute risk difference	(-36.61, 31.84)	(-25.35, 27.25)	
p-value	0.8947	0.9433	
p-value of Breslow-Day Test for Homogeneity [3]	0.3781	NE	

AMNOG Table SE20.3.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (4.8)
No	6 (100)	15 (100)	20 (95.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.76	-4.76	
95% CI of the absolute risk difference	(-13.87, 4.35)	(-13.87, 4.35)	
p-value	0.5860	0.3914	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (16.7)	3 (20.0)	3 (14.3)
No	5 (83.3)	12 (80.0)	18 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	0.67	
95% CI of the inverse odds ratio	(0.07, 9.86)	(0.11, 3.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	0.71	
95% CI of the inverse risk ratio	(0.11, 6.82)	(0.17, 3.07)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.38	5.71	
95% CI of the absolute risk difference	(-30.98, 35.75)	(-19.46, 30.89)	
p-value	0.8849	0.6501	
p-value of Breslow-Day Test for Homogeneity [3]	0.2164	NE	

AMNOG Table SE20.3.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	6 (100)	15 (100)	21 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (6.7)	1 (4.8)
No	6 (100)	14 (93.3)	20 (95.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.70	
95% CI of the inverse odds ratio	NE	(0.04, 12.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.71	
95% CI of the inverse risk ratio	NE	(0.05, 10.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.76	1.90	
95% CI of the absolute risk difference	(-13.87, 4.35)	(-13.66, 17.47)	
p-value	0.5860	0.8057	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE20.3.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	3 (14.3)
No	6 (100)	15 (100)	18 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.46	5.86	
95% CI of the inverse odds ratio	(0.11, 54.32)	(0.28, 122.49)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.23	5.09	
95% CI of the inverse risk ratio	(0.13, 38.06)	(0.28, 91.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.77	-12.78	
95% CI of the absolute risk difference	(-33.21, 15.68)	(-30.28, 4.72)	
p-value	0.5580	0.2049	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (33.3)	2 (13.3)	6 (28.6)
No	4 (66.7)	13 (86.7)	15 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	2.60	
95% CI of the inverse odds ratio	(0.11, 5.59)	(0.45, 15.18)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	2.14	
95% CI of the inverse risk ratio	(0.23, 3.20)	(0.50, 9.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.76	-15.24	
95% CI of the absolute risk difference	(-37.62, 47.14)	(-41.11, 10.63)	
p-value	0.8218	0.2783	
p-value of Breslow-Day Test for Homogeneity [3]	0.1873	NE	

AMNOG Table SE20.3.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (33.3)	0	1 (4.8)
No	4 (66.7)	15 (100)	20 (95.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.10	NE	
95% CI of the inverse odds ratio	(0.01, 1.39)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.14	NE	
95% CI of the inverse risk ratio	(0.02, 1.32)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	28.57	-4.76	
95% CI of the absolute risk difference	(-10.23, 67.38)	(-13.87, 4.35)	
p-value	0.0495	0.3914	
p-value of Breslow-Day Test for Homogeneity [3]	0.1446	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (33.3)	2 (13.3)	2 (9.5)
No	4 (66.7)	13 (86.7)	19 (90.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.21	0.68	
95% CI of the inverse odds ratio	(0.02, 1.97)	(0.09, 5.49)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.29	0.71	
95% CI of the inverse risk ratio	(0.05, 1.62)	(0.11, 4.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	23.81	3.81	
95% CI of the absolute risk difference	(-15.94, 63.56)	(-17.49, 25.11)	
p-value	0.1477	0.7199	
p-value of Breslow-Day Test for Homogeneity [3]	0.2320	NE	

AMNOG Table SE20.3.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (16.7)	1 (6.7)	4 (19.0)
No	5 (83.3)	14 (93.3)	17 (81.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	3.29	
95% CI of the inverse odds ratio	(0.11, 13.07)	(0.33, 32.94)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	2.86	
95% CI of the inverse risk ratio	(0.16, 8.40)	(0.35, 23.07)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.38	-12.38	
95% CI of the absolute risk difference	(-36.61, 31.84)	(-33.39, 8.63)	
p-value	0.8947	0.2896	
p-value of Breslow-Day Test for Homogeneity [3]	0.5418	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (33.3)	2 (13.3)	5 (23.8)
No	4 (66.7)	13 (86.7)	16 (76.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	2.03	
95% CI of the inverse odds ratio	(0.09, 4.49)	(0.34, 12.24)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	1.79	
95% CI of the inverse risk ratio	(0.18, 2.80)	(0.40, 8.00)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	9.52	-10.48	
95% CI of the absolute risk difference	(-32.36, 51.41)	(-35.53, 14.58)	
p-value	0.6387	0.4336	
p-value of Breslow-Day Test for Homogeneity [3]	0.4192	NE	

AMNOG Table SE20.3.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	2 (13.3)	0
No	6 (100)	13 (86.7)	21 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.13	
95% CI of the inverse odds ratio	NE	(0.01, 2.82)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.15	
95% CI of the inverse risk ratio	NE	(0.01, 2.83)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	13.35	
95% CI of the absolute risk difference	NE	(-5.50, 32.20)	
p-value	NE	0.1318	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (16.7)	2 (13.3)	3 (14.3)
No	5 (83.3)	13 (86.7)	18 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	1.08	
95% CI of the inverse odds ratio	(0.07, 9.86)	(0.16, 7.44)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	1.07	
95% CI of the inverse risk ratio	(0.11, 6.82)	(0.20, 5.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.38	-0.95	
95% CI of the absolute risk difference	(-30.98, 35.75)	(-23.75, 21.85)	
p-value	0.8849	0.9351	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE20.3.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	3 (100)	0	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	1 (14.3)
No	3 (100)	0	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.62	NE	
95% CI of the inverse odds ratio	(0.05, 51.11)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	NE	
95% CI of the inverse risk ratio	(0.08, 29.15)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.25	NE	
95% CI of the absolute risk difference	(-48.46, 35.96)	NE	
p-value	0.7842	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.5418	NE	

AMNOG Table SE20.3.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (14.3)
No	3 (100)	0	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.62	NE	
95% CI of the inverse odds ratio	(0.05, 51.11)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	NE	
95% CI of the inverse risk ratio	(0.08, 29.15)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.25	NE	
95% CI of the absolute risk difference	(-48.46, 35.96)	NE	
p-value	0.7842	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	4 (57.1)
No	3 (100)	0	3 (42.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	9.00	NE	
95% CI of the inverse odds ratio	(0.34, 238.21)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.50	NE	
95% CI of the inverse risk ratio	(0.31, 64.58)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-43.75	NE	
95% CI of the absolute risk difference	(-91.00, 3.50)	NE	
p-value	0.1473	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE20.3.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	3 (100)	0	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (33.3)	0	0
No	2 (66.7)	0	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.11	NE	
95% CI of the inverse odds ratio	(0.00, 3.70)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.17	NE	
95% CI of the inverse risk ratio	(0.01, 3.24)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	31.25	NE	
95% CI of the absolute risk difference	(-19.07, 81.57)	NE	
p-value	0.1709	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.0391	NE	

AMNOG Table SE20.3.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	3 (100)	0	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	2 (28.6)
No	3 (100)	0	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.18	NE	
95% CI of the inverse odds ratio	(0.12, 87.92)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.50	NE	
95% CI of the inverse risk ratio	(0.15, 40.67)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-18.75	NE	
95% CI of the absolute risk difference	(-64.38, 26.88)	NE	
p-value	0.4795	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3781	NE	

AMNOG Table SE20.3.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	3 (100)	0	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (33.3)	0	0
No	2 (66.7)	0	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.11	NE	
95% CI of the inverse odds ratio	(0.00, 3.70)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.17	NE	
95% CI of the inverse risk ratio	(0.01, 3.24)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	31.25	NE	
95% CI of the absolute risk difference	(-19.07, 81.57)	NE	
p-value	0.1709	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2164	NE	

AMNOG Table SE20.3.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	3 (100)	0	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	3 (100)	0	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE20.3.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (28.6)
No	3 (100)	0	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.18	NE	
95% CI of the inverse odds ratio	(0.12, 87.92)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.50	NE	
95% CI of the inverse risk ratio	(0.15, 40.67)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-18.75	NE	
95% CI of the absolute risk difference	(-64.38, 26.88)	NE	
p-value	0.4795	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	3 (42.9)
No	3 (100)	0	4 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.44	NE	
95% CI of the inverse odds ratio	(0.21, 144.10)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.50	NE	
95% CI of the inverse risk ratio	(0.23, 52.56)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-31.25	NE	
95% CI of the absolute risk difference	(-78.50, 16.00)	NE	
p-value	0.2790	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.1873	NE	

AMNOG Table SE20.3.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (14.3)
No	3 (100)	0	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.62	NE	
95% CI of the inverse odds ratio	(0.05, 51.11)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	NE	
95% CI of the inverse risk ratio	(0.08, 29.15)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.25	NE	
95% CI of the absolute risk difference	(-48.46, 35.96)	NE	
p-value	0.7842	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.1446	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	1 (14.3)
No	3 (100)	0	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.62	NE	
95% CI of the inverse odds ratio	(0.05, 51.11)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	NE	
95% CI of the inverse risk ratio	(0.08, 29.15)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.25	NE	
95% CI of the absolute risk difference	(-48.46, 35.96)	NE	
p-value	0.7842	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2320	NE	

AMNOG Table SE20.3.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (14.3)
No	3 (100)	0	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.62	NE	
95% CI of the inverse odds ratio	(0.05, 51.11)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	NE	
95% CI of the inverse risk ratio	(0.08, 29.15)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.25	NE	
95% CI of the absolute risk difference	(-48.46, 35.96)	NE	
p-value	0.7842	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.5418	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	1 (14.3)
No	3 (100)	0	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.62	NE	
95% CI of the inverse odds ratio	(0.05, 51.11)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	NE	
95% CI of the inverse risk ratio	(0.08, 29.15)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.25	NE	
95% CI of the absolute risk difference	(-48.46, 35.96)	NE	
p-value	0.7842	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4192	NE	

AMNOG Table SE20.3.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	3 (100)	0	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	3 (100)	0	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

Madrigal Pharmaceuticals, Inc. Page 1 of 20
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.4.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=8)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=8)	Change from Baseline DB Placebo (N=14)
Total LDQOL						
Baseline						
m	3	8	14			
n	3	8	12			
Mean (SD)	91.77 (2.68)	88.01 (5.30)	85.73 (10.15)			
Median	92.50	89.35	86.10			
IQR: Q1, Q3	88.80, 94.00	86.00, 91.20	78.45, 94.10			
Min, Max	88.8, 94.0	77.4, 93.6	64.4, 97.8			
Week 24						
m	3	7	14			
n	2	7	13	2	7	12
Mean (SD/SE)	90.20 (0.14)	85.61 (8.04)	82.36 (14.04)	-3.05 (0.85)	-2.21 (2.24)	-3.20 (1.87)
Median	90.20	81.80	88.70	-3.05	-0.50	-1.60
IQR: Q1, Q3	90.10, 90.30	79.00, 93.10	71.60, 94.10	-3.90, -2.20	-7.60, 2.90	-9.70, 0.90
Min, Max	90.1, 90.3	77.8, 98.9	52.0, 95.2	-3.9, -2.2	-10.6, 6.1	-12.4, 8.5
Week 52						
m	3	7	14			
n	3	6	13	3	6	12
Mean (SD/SE)	89.87 (2.54)	85.63 (6.03)	83.47 (12.39)	-1.90 (1.07)	-1.90 (2.37)	-1.85 (1.71)
Median	88.50	86.30	88.00	-1.20	-3.50	-1.10
IQR: Q1, Q3	88.30, 92.80	83.20, 88.70	78.60, 93.60	-4.00, -0.50	-5.60, 0.10	-4.65, 1.55
Min, Max	88.3, 92.8	75.6, 93.7	58.0, 94.9	-4.0, -0.5	-7.6, 8.7	-14.5, 6.9

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.4.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=8)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=8)	Change from Baseline DB Placebo (N=14)
Symptoms of Liver Disease						
Baseline						
m	3	8	14			
n	3	8	12			
Mean (SD)	95.57 (1.96)	86.25 (7.00)	85.83 (15.05)			
Median	96.70	85.00	90.00			
IQR: Q1, Q3	93.30, 96.70	80.00, 90.00	83.35, 95.00			
Min, Max	93.3, 96.7	80.0, 100.0	50.0, 100.0			
Week 24						
m	3	7	14			
n	2	7	13	2	7	12
Mean (SD/SE)	98.35 (2.33)	86.67 (10.35)	84.62 (12.30)	1.65 (1.65)	0.49 (6.14)	0.56 (3.15)
Median	98.35	86.70	86.70	1.65	3.30	1.65
IQR: Q1, Q3	96.70, 100.00	83.30, 93.30	73.30, 96.70	0.00, 3.30	0.00, 6.70	-6.65, 6.70
Min, Max	96.7, 100.0	66.7, 100.0	63.3, 100.0	0.0, 3.3	-33.3, 20.0	-16.7, 23.3
Week 52						
m	3	7	14			
n	3	6	13	3	6	12
Mean (SD/SE)	92.20 (1.91)	83.32 (12.28)	87.17 (12.69)	-3.37 (1.93)	-0.57 (6.05)	2.77 (2.36)
Median	93.30	83.30	93.30	-3.40	-1.70	3.30
IQR: Q1, Q3	90.00, 93.30	73.30, 93.30	73.30, 100.00	-6.70, 0.00	-6.70, 13.30	0.00, 6.70
Min, Max	90.0, 93.3	66.7, 100.0	70.0, 100.0	-6.7, 0.0	-23.3, 16.7	-13.4, 20.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.4.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=8)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=8)	Change from Baseline DB Placebo (N=14)
Effects of Liver Disease						
Baseline						
m	3	8	14			
n	3	8	12			
Mean (SD)	88.90 (10.18)	85.00 (9.93)	79.45 (5.29)			
Median	86.70	80.00	80.00			
IQR: Q1, Q3	80.00, 100.00	80.00, 93.35	80.00, 80.00			
Min, Max	80.0, 100.0	73.3, 100.0	66.7, 86.7			
Week 24						
m	3	7	14			
n	2	7	13	2	7	12
Mean (SD/SE)	80.00 (0.00)	80.94 (8.98)	77.95 (7.89)	-10.00 (10.00)	-3.81 (5.22)	-1.67 (1.67)
Median	80.00	80.00	80.00	-10.00	0	0
IQR: Q1, Q3	80.00, 80.00	73.30, 80.00	73.30, 80.00	-20.00, 0.00	-20.00, 0.00	-6.70, 0.00
Min, Max	80.0, 80.0	73.3, 100.0	60.0, 86.7	-20.0, 0.0	-20.0, 20.0	-13.3, 6.7
Week 52						
m	3	7	14			
n	3	6	13	3	6	12
Mean (SD/SE)	80.00 (0.00)	78.88 (2.74)	79.49 (4.27)	-8.90 (5.88)	-6.67 (4.22)	0.00 (1.42)
Median	80.00	80.00	80.00	-6.70	0	0
IQR: Q1, Q3	80.00, 80.00	80.00, 80.00	80.00, 80.00	-20.00, 0.00	-20.00, 0.00	0.00, 0.00
Min, Max	80.0, 80.0	73.3, 80.0	66.7, 86.7	-20.0, 0.0	-20.0, 0.0	-6.7, 13.3

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.4.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=8)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=8)	Change from Baseline DB Placebo (N=14)
Concentration/Memory						
Baseline						
m	3	8	14			
n	3	8	12			
Mean (SD)	91.67 (7.22)	89.09 (14.83)	88.03 (19.30)			
Median	87.50	93.80	100.00			
IQR: Q1, Q3	87.50, 100.00	84.40, 100.00	81.25, 100.00			
Min, Max	87.5, 100.0	56.3, 100.0	37.5, 100.0			
Week 24						
m	3	7	14			
n	2	7	13	2	7	12
Mean (SD/SE)	93.80 (0.00)	87.51 (13.97)	84.15 (13.63)	0.05 (6.25)	-1.80 (2.25)	-2.59 (4.77)
Median	93.80	87.50	87.50	0.05	0	0
IQR: Q1, Q3	93.80, 93.80	81.30, 100.00	68.80, 100.00	-6.20, 6.30	-6.30, 0.00	-12.50, 3.15
Min, Max	93.8, 93.8	62.5, 100.0	62.5, 100.0	-6.2, 6.3	-12.5, 6.2	-37.5, 31.3
Week 52						
m	3	7	14			
n	3	6	13	3	6	12
Mean (SD/SE)	83.33 (7.22)	90.63 (11.00)	84.16 (17.98)	-8.33 (4.17)	-0.02 (6.65)	-3.63 (3.48)
Median	87.50	93.75	93.80	-12.50	0	-3.10
IQR: Q1, Q3	75.00, 87.50	81.30, 100.00	75.00, 93.80	-12.50, 0.00	-6.30, 6.20	-6.20, 3.15
Min, Max	75.0, 87.5	75.0, 100.0	50.0, 100.0	-12.5, 0.0	-25.0, 25.0	-25.0, 12.5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.4.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=8)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=8)	Change from Baseline DB Placebo (N=14)
Health Distress						
Baseline						
m	3	8	14			
n	3	8	12			
Mean (SD)	100.00 (0.00)	96.88 (5.79)	97.92 (7.22)			
Median	100.00	100.00	100.00			
IQR: Q1, Q3	100.00, 100.00	93.75, 100.00	100.00, 100.00			
Min, Max	100.0, 100.0	87.5, 100.0	75.0, 100.0			
Week 24						
m	3	7	14			
n	2	7	13	2	7	12
Mean (SD/SE)	100.00 (0.00)	94.64 (9.83)	93.27 (14.98)	0.00 (0.00)	-1.79 (5.05)	-5.21 (2.86)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	100.00, 100.00	87.50, 100.00	100.00, 100.00	0.00, 0.00	-12.50, 12.50	-6.25, 0.00
Min, Max	100.0, 100.0	75.0, 100.0	50.0, 100.0	0.0, 0.0	-25.0, 12.5	-25.0, 0.0
Week 52						
m	3	7	14			
n	3	6	13	3	6	12
Mean (SD/SE)	100.00 (0.00)	91.67 (12.91)	95.19 (14.01)	0.00 (0.00)	-4.17 (6.97)	-3.13 (2.24)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	100.00, 100.00	75.00, 100.00	100.00, 100.00	0.00, 0.00	-25.00, 12.50	0.00, 0.00
Min, Max	100.0, 100.0	75.0, 100.0	50.0, 100.0	0.0, 0.0	-25.0, 12.5	-25.0, 0.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.4.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=3)	(N=8)	(N=14)	(N=3)	(N=8)	(N=14)
Sexual Function						
Baseline						
m	3	8	14			
n	1	6	7			
Mean (SD)	93.30 (N/A)	95.00 (7.75)	89.27 (12.52)			
Median	93.30	100.00	93.30			
IQR: Q1, Q3	93.30, 93.30	85.00, 100.00	78.30, 100.00			
Min, Max	93.3, 93.3	85.0, 100.0	68.3, 100.0			
Week 24						
m	3	7	14			
n	1	5	6	1	5	5
Mean (SD/SE)	70.00 (N/A)	87.66 (16.65)	90.00 (21.38)	-23.30 (N/A)	-6.34 (4.84)	-4.98 (6.78)
Median	70.00	93.30	100.00	-23.30	0	0
IQR: Q1, Q3	70.00, 70.00	85.00, 100.00	93.30, 100.00	-23.30, -23.30	-6.70, 0.00	0.00, 0.00
Min, Max	70.0, 70.0	60.0, 100.0	46.7, 100.0	-23.3, -23.3	-25.0, 0.0	-31.6, 6.7
Week 52						
m	3	7	14			
n	1	4	8	1	4	6
Mean (SD/SE)	85.00 (N/A)	96.65 (3.87)	73.11 (35.46)	-8.30 (N/A)	0.40 (3.07)	-12.22 (10.70)
Median	85.00	96.65	89.15	-8.30	0	0
IQR: Q1, Q3	85.00, 85.00	93.30, 100.00	45.80, 100.00	-8.30, -8.30	-3.35, 4.15	-16.70, 0.00
Min, Max	85.0, 85.0	93.3, 100.0	15.0, 100.0	-8.3, -8.3	-6.7, 8.3	-63.3, 6.7

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.4.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=8)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=8)	Change from Baseline DB Placebo (N=14)
Sleep						
Baseline						
m	3	8	14			
n	3	8	12			
Mean (SD)	80.0 (10.0)	71.9 (10.0)	70.0 (23.1)			
Median	80.0	70.0	70.0			
IQR: Q1, Q3	70.0, 90.0	65.0, 77.5	50.0, 90.0			
Min, Max	70, 90	60, 90	40, 100			
Week 24						
m	3	7	14			
n	2	7	13	2	7	12
Mean (SD/SE)	75.0 (0.0)	65.0 (16.3)	70.8 (18.6)	-5.0 (10.0)	-4.3 (4.6)	1.7 (3.4)
Median	75.0	65.0	75.0	-5.0	0	2.5
IQR: Q1, Q3	75.0, 75.0	55.0, 80.0	60.0, 85.0	-15.0, 5.0	-15.0, 5.0	-7.5, 7.5
Min, Max	75, 75	40, 90	35, 95	-15, 5	-25, 10	-20, 20
Week 52						
m	3	7	14			
n	3	6	13	3	6	12
Mean (SD/SE)	75.0 (10.0)	63.3 (12.5)	70.4 (19.7)	-5.0 (0.0)	-6.7 (4.8)	0.8 (4.9)
Median	75.0	62.5	80.0	-5.0	-5.0	0
IQR: Q1, Q3	65.0, 85.0	50.0, 75.0	55.0, 85.0	-5.0, -5.0	-15.0, 5.0	-10.0, 10.0
Min, Max	65, 85	50, 80	35, 95	-5, -5	-25, 5	-25, 35

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.4.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=8)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=8)	Change from Baseline DB Placebo (N=14)
Loneliness						
Baseline						
m	3	8	14			
n	3	8	12			
Mean (SD)	95.0 (8.7)	95.0 (6.5)	90.4 (12.3)			
Median	100.0	95.0	97.5			
IQR: Q1, Q3	85.0, 100.0	95.0, 100.0	80.0, 100.0			
Min, Max	85, 100	80, 100	65, 100			
Week 24						
m	3	7	14			
n	2	7	13	2	7	12
Mean (SD/SE)	87.5 (17.7)	90.0 (13.8)	85.0 (20.7)	-5.0 (5.0)	-7.1 (5.7)	-6.7 (5.0)
Median	87.5	95.0	100.0	-5.0	-5.0	0
IQR: Q1, Q3	75.0, 100.0	90.0, 100.0	80.0, 100.0	-10.0, 0.0	-5.0, 0.0	-10.0, 0.0
Min, Max	75, 100	60, 100	35, 100	-10, 0	-40, 5	-45, 10
Week 52						
m	3	7	14			
n	3	6	13	3	6	12
Mean (SD/SE)	100.0 (0.0)	90.0 (22.1)	86.5 (19.0)	5.0 (5.0)	-7.5 (9.6)	-5.0 (4.2)
Median	100.0	100.0	100.0	0	0	0
IQR: Q1, Q3	100.0, 100.0	95.0, 100.0	80.0, 100.0	0.0, 15.0	0.0, 5.0	-7.5, 0.0
Min, Max	100, 100	45, 100	45, 100	0, 15	-55, 5	-35, 20

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.4.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=3)	(N=8)	(N=14)	(N=3)	(N=8)	(N=14)
Hopelessness						
Baseline						
m	3	8	14			
n	3	8	12			
Mean (SD)	88.90 (12.73)	88.55 (16.63)	81.95 (25.09)			
Median	91.70	95.85	91.70			
IQR: Q1, Q3	75.00, 100.00	79.20, 100.00	66.65, 100.00			
Min, Max	75.0, 100.0	58.3, 100.0	33.3, 100.0			
Week 24						
m	3	7	14			
n	2	7	13	2	7	12
Mean (SD/SE)	100.00 (0.00)	86.90 (19.77)	78.21 (27.96)	4.15 (4.15)	-1.20 (1.20)	-4.17 (2.81)
Median	100.00	100.00	91.70	4.15	0	0
IQR: Q1, Q3	100.00, 100.00	58.30, 100.00	66.70, 100.00	0.00, 8.30	0.00, 0.00	-8.30, 0.00
Min, Max	100.0, 100.0	58.3, 100.0	25.0, 100.0	0.0, 8.3	-8.4, 0.0	-25.0, 8.3
Week 52						
m	3	7	14			
n	3	6	13	3	6	12
Mean (SD/SE)	91.67 (8.35)	91.67 (13.94)	83.98 (20.82)	2.77 (2.77)	5.55 (4.12)	0.69 (2.99)
Median	91.70	100.00	91.70	0	0	0
IQR: Q1, Q3	83.30, 100.00	83.30, 100.00	75.00, 100.00	0.00, 8.30	0.00, 8.30	0.00, 4.15
Min, Max	83.3, 100.0	66.7, 100.0	50.0, 100.0	0.0, 8.3	0.0, 25.0	-16.7, 16.7

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.4.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=3)	(N=8)	(N=14)	(N=3)	(N=8)	(N=14)
Stigma of Liver Disease						
Baseline						
m	3	8	14			
n	3	8	12			
Mean (SD)	93.77 (6.25)	85.96 (16.95)	91.68 (15.61)			
Median	93.80	87.55	100.00			
IQR: Q1, Q3	87.50, 100.00	81.30, 100.00	87.55, 100.00			
Min, Max	87.5, 100.0	50.0, 100.0	50.0, 100.0			
Week 24						
m	3	7	14			
n	2	7	13	2	7	12
Mean (SD/SE)	96.90 (4.38)	91.97 (10.64)	82.22 (30.06)	0.00 (0.00)	5.34 (8.01)	-9.89 (4.64)
Median	96.90	100.00	93.80	0	0	0
IQR: Q1, Q3	93.80, 100.00	81.30, 100.00	87.50, 100.00	0.00, 0.00	0.00, 6.20	-15.65, 0.00
Min, Max	93.8, 100.0	75.0, 100.0	0.0, 100.0	0.0, 0.0	-18.8, 50.0	-50.0, 0.0
Week 52						
m	3	7	14			
n	3	6	13	3	6	12
Mean (SD/SE)	97.93 (3.58)	88.57 (14.48)	89.44 (19.32)	4.17 (4.17)	4.17 (8.50)	-2.08 (2.91)
Median	100.00	93.80	100.00	0	0	0
IQR: Q1, Q3	93.80, 100.00	81.30, 100.00	93.80, 100.00	0.00, 12.50	0.00, 0.00	0.00, 0.00
Min, Max	93.8, 100.0	62.5, 100.0	43.8, 100.0	0.0, 12.5	-18.8, 43.8	-31.2, 12.5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.4.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter		Visit Result			Change from Baseline		
		DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Total LDQOL							
Baseline							
	m	6	7	14			
	n	6	6	14			
	Mean (SD)	76.03 (14.44)	85.68 (7.39)	86.89 (5.91)			
	Median	74.45	87.60	87.20			
	IQR: Q1, Q3	64.80, 91.30	78.60, 90.30	82.20, 91.50			
	Min, Max	57.3, 93.9	75.2, 94.8	76.1, 95.5			
Week 24							
	m	5	5	13			
	n	5	4	12	5	4	12
	Mean (SD/SE)	79.06 (13.07)	83.15 (9.90)	86.18 (6.88)	3.12 (1.71)	-4.48 (6.24)	-0.73 (2.38)
	Median	74.20	80.25	84.45	1.80	-2.45	0.90
	IQR: Q1, Q3	73.30, 92.00	76.20, 90.10	82.10, 91.00	0.70, 5.50	-14.60, 5.65	-5.95, 4.05
	Min, Max	62.8, 93.0	75.0, 97.1	75.9, 98.1	-0.9, 8.5	-19.8, 6.8	-17.6, 13.3
Week 52							
	m	5	5	12			
	n	4	4	11	4	4	11
	Mean (SD/SE)	76.60 (25.28)	83.00 (4.65)	83.30 (12.05)	-2.13 (5.28)	-4.63 (3.69)	-4.35 (4.09)
	Median	85.80	82.35	85.30	0.80	-1.65	0
	IQR: Q1, Q3	59.80, 93.40	79.10, 86.90	79.40, 87.50	-8.30, 4.05	-8.80, -0.45	-9.00, 5.70
	Min, Max	40.0, 94.8	79.0, 88.3	51.7, 98.1	-17.3, 7.2	-15.6, 0.4	-40.4, 7.2

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.4.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=6)	(N=7)	(N=14)	(N=6)	(N=7)	(N=14)
Symptoms of Liver Disease						
Baseline						
m	6	7	14			
n	6	6	14			
Mean (SD)	81.12 (15.88)	79.43 (19.48)	80.95 (15.11)			
Median	83.35	88.30	85.00			
IQR: Q1, Q3	76.70, 90.00	56.70, 93.30	70.00, 93.30			
Min, Max	53.3, 100.0	53.3, 96.7	53.3, 100.0			
Week 24						
m	5	5	13			
n	5	4	12	5	4	12
Mean (SD/SE)	80.66 (14.80)	92.50 (5.00)	79.99 (18.53)	0.66 (5.32)	8.35 (9.87)	0.55 (7.15)
Median	80.00	90.00	81.65	0	1.70	1.65
IQR: Q1, Q3	70.00, 90.00	90.00, 95.00	76.65, 93.30	0.00, 3.30	-5.00, 21.70	-8.35, 15.00
Min, Max	63.3, 100.0	90.0, 100.0	36.7, 100.0	-16.7, 16.7	-6.7, 36.7	-60.0, 40.0
Week 52						
m	5	5	12			
n	4	4	11	4	4	11
Mean (SD/SE)	80.85 (18.32)	80.03 (17.63)	82.73 (13.80)	-5.83 (4.97)	-4.13 (5.52)	2.43 (4.97)
Median	85.00	83.35	83.30	-3.30	0.05	3.30
IQR: Q1, Q3	66.70, 95.00	66.70, 93.35	76.70, 93.30	-11.65, 0.00	-11.65, 3.40	-3.40, 10.00
Min, Max	56.7, 96.7	56.7, 96.7	56.7, 100.0	-20.0, 3.3	-20.0, 3.4	-36.7, 30.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.4.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=6)	(N=7)	(N=14)	(N=6)	(N=7)	(N=14)
Effects of Liver Disease						
Baseline						
m	6	7	14			
n	6	6	14			
Mean (SD)	64.45 (20.08)	86.68 (7.30)	82.86 (6.78)			
Median	73.35	86.70	80.00			
IQR: Q1, Q3	46.70, 80.00	80.00, 86.70	80.00, 86.70			
Min, Max	33.3, 80.0	80.0, 100.0	73.3, 100.0			
Week 24						
m	5	5	13			
n	5	4	12	5	4	12
Mean (SD/SE)	80.00 (0.00)	88.33 (9.99)	80.56 (8.74)	16.00 (10.02)	-1.70 (5.00)	-3.33 (3.98)
Median	80.00	86.65	80.00	0	-6.70	0
IQR: Q1, Q3	80.00, 80.00	80.00, 96.65	80.00, 80.00	0.00, 33.30	-6.70, 3.30	-3.35, 0.00
Min, Max	80.0, 80.0	80.0, 100.0	60.0, 100.0	0.0, 46.7	-6.7, 13.3	-40.0, 20.0
Week 52						
m	5	5	12			
n	4	4	11	4	4	11
Mean (SD/SE)	68.33 (32.82)	86.68 (9.43)	82.43 (9.08)	-3.35 (8.39)	-3.35 (6.93)	-0.61 (3.97)
Median	80.00	83.35	80.00	0	-3.35	0
IQR: Q1, Q3	50.00, 86.65	80.00, 93.35	80.00, 86.70	-13.35, 6.65	-13.35, 6.65	0.00, 6.70
Min, Max	20.0, 93.3	80.0, 100.0	66.7, 100.0	-26.7, 13.3	-20.0, 13.3	-26.7, 20.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.4.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter		Visit Result			Change from Baseline		
		DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Concentration/Memory							
Baseline							
	m	6	7	14			
	n	6	6	14			
	Mean (SD)	77.10 (25.80)	76.05 (26.92)	90.64 (8.03)			
	Median	81.25	81.25	90.65			
	IQR: Q1, Q3	56.30, 100.00	50.00, 100.00	87.50, 100.00			
	Min, Max	43.8, 100.0	43.8, 100.0	75.0, 100.0			
Week 24							
	m	5	5	13			
	n	5	4	12	5	4	12
	Mean (SD/SE)	73.76 (26.65)	81.28 (22.25)	91.16 (12.90)	-7.50 (5.00)	4.70 (10.33)	1.56 (4.56)
	Median	75.00	87.55	96.90	0	3.10	6.20
	IQR: Q1, Q3	50.00, 100.00	65.65, 96.90	87.50, 100.00	-12.50, 0.00	-9.35, 18.75	-3.15, 12.50
	Min, Max	43.8, 100.0	50.0, 100.0	62.5, 100.0	-25.0, 0.0	-18.7, 31.3	-31.2, 18.8
Week 52							
	m	5	5	12			
	n	4	4	11	4	4	11
	Mean (SD/SE)	67.20 (47.15)	76.58 (24.12)	82.41 (21.05)	-9.38 (11.57)	0.00 (5.10)	-8.52 (6.32)
	Median	84.40	81.25	87.50	0	0	0
	IQR: Q1, Q3	34.40, 100.00	59.40, 93.75	75.00, 100.00	-21.90, 3.15	-6.25, 6.25	-18.70, 6.20
	Min, Max	0.0, 100.0	43.8, 100.0	43.8, 100.0	-43.8, 6.3	-12.5, 12.5	-50.0, 12.5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.4.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=7)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=7)	Change from Baseline DB Placebo (N=14)
Health Distress						
Baseline						
m	6	7	14			
n	6	6	14			
Mean (SD)	66.67 (35.06)	95.83 (6.45)	91.96 (15.20)			
Median	75.00	100.00	100.00			
IQR: Q1, Q3	62.50, 87.50	87.50, 100.00	87.50, 100.00			
Min, Max	0.0, 100.0	87.5, 100.0	50.0, 100.0			
Week 24						
m	5	5	13			
n	5	4	12	5	4	12
Mean (SD/SE)	75.00 (42.39)	96.88 (6.25)	90.63 (13.19)	7.50 (5.00)	0.00 (0.00)	0.00 (4.35)
Median	87.50	100.00	100.00	0	0	0
IQR: Q1, Q3	87.50, 100.00	93.75, 100.00	81.25, 100.00	0.00, 12.50	0.00, 0.00	-12.50, 6.25
Min, Max	0.0, 100.0	87.5, 100.0	62.5, 100.0	0.0, 25.0	0.0, 0.0	-25.0, 25.0
Week 52						
m	5	5	12			
n	4	4	11	4	4	11
Mean (SD/SE)	71.88 (48.28)	100.00 (0.00)	85.23 (18.39)	6.25 (3.61)	3.13 (3.13)	-6.82 (7.02)
Median	93.75	100.00	87.50	6.25	0	0
IQR: Q1, Q3	43.75, 100.00	100.00, 100.00	75.00, 100.00	0.00, 12.50	0.00, 6.25	-12.50, 12.50
Min, Max	0.0, 100.0	100.0, 100.0	37.5, 100.0	0.0, 12.5	0.0, 12.5	-62.5, 25.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.4.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=7)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=7)	Change from Baseline DB Placebo (N=14)
Sexual Function						
Baseline						
m	6	7	14			
n	3	0	6			
Mean (SD)	91.67 (8.35)	N/A	91.12 (9.04)			
Median	91.70	N/A	92.50			
IQR: Q1, Q3	83.30, 100.00	N/A	85.00, 100.00			
Min, Max	83.3, 100.0	N/A	76.7, 100.0			
Week 24						
m	5	5	13			
n	1	0	4	1	0	4
Mean (SD/SE)	91.70 (N/A)	N/A	90.40 (7.75)	-8.30 (N/A)	N/A	2.05 (1.56)
Median	91.70	N/A	89.15	-8.30	N/A	0.80
IQR: Q1, Q3	91.70, 91.70	N/A	84.15, 96.65	-8.30, -8.30	N/A	0.00, 4.10
Min, Max	91.7, 91.7	N/A	83.3, 100.0	-8.3, -8.3	N/A	0.0, 6.6
Week 52						
m	5	5	12			
n	1	0	3	1	0	2
Mean (SD/SE)	100.00 (N/A)	N/A	95.00 (8.66)	0.00 (N/A)	N/A	-4.15 (4.15)
Median	100.00	N/A	100.00	0	N/A	-4.15
IQR: Q1, Q3	100.00, 100.00	N/A	85.00, 100.00	0.00, 0.00	N/A	-8.30, 0.00
Min, Max	100.0, 100.0	N/A	85.0, 100.0	0.0, 0.0	N/A	-8.3, 0.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.4.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=7)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=7)	Change from Baseline DB Placebo (N=14)
Sleep						
Baseline						
m	6	7	14			
n	6	6	14			
Mean (SD)	50.8 (28.5)	73.3 (10.3)	66.4 (21.3)			
Median	57.5	72.5	70.0			
IQR: Q1, Q3	40.0, 75.0	65.0, 85.0	55.0, 80.0			
Min, Max	0, 75	60, 85	30, 100			
Week 24						
m	5	5	13			
n	5	4	12	5	4	12
Mean (SD/SE)	53.0 (30.9)	68.8 (15.5)	68.8 (15.1)	5.0 (3.9)	-3.8 (4.3)	0.4 (4.5)
Median	60.0	65.0	65.0	0	-2.5	2.5
IQR: Q1, Q3	55.0, 75.0	57.5, 80.0	60.0, 80.0	0.0, 5.0	-10.0, 2.5	-10.0, 7.5
Min, Max	0, 75	55, 90	45, 100	0, 20	-15, 5	-30, 30
Week 52						
m	5	5	12			
n	4	4	11	4	4	11
Mean (SD/SE)	57.5 (21.0)	66.3 (7.5)	67.3 (17.8)	-2.5 (4.3)	-6.3 (3.8)	-4.5 (5.6)
Median	60.0	65.0	65.0	-2.5	-5.0	0
IQR: Q1, Q3	42.5, 72.5	60.0, 72.5	60.0, 75.0	-10.0, 5.0	-12.5, 0.0	-25.0, 10.0
Min, Max	30, 80	60, 75	35, 95	-10, 5	-15, 0	-35, 20

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc. Page 18 of 20
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.4.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=7)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=7)	Change from Baseline DB Placebo (N=14)
Loneliness						
Baseline						
m	6	7	14			
n	6	6	14			
Mean (SD)	86.7 (14.7)	90.0 (20.0)	96.1 (7.4)			
Median	87.5	100.0	100.0			
IQR: Q1, Q3	85.0, 100.0	90.0, 100.0	95.0, 100.0			
Min, Max	60, 100	50, 100	75, 100			
Week 24						
m	5	5	13			
n	5	4	12	5	4	12
Mean (SD/SE)	92.0 (9.1)	82.5 (23.6)	90.0 (13.7)	5.0 (5.2)	-17.5 (11.8)	-5.4 (3.0)
Median	95.0	90.0	100.0	0	-10.0	0
IQR: Q1, Q3	85.0, 100.0	65.0, 100.0	77.5, 100.0	0.0, 5.0	-35.0, 0.0	-10.0, 0.0
Min, Max	80, 100	50, 100	65, 100	-5, 25	-50, 0	-30, 5
Week 52						
m	5	5	12			
n	4	4	11	4	4	11
Mean (SD/SE)	88.8 (13.1)	90.0 (11.5)	90.0 (12.2)	2.5 (4.3)	-10.0 (5.8)	-5.0 (3.7)
Median	90.0	90.0	95.0	0	-10.0	0
IQR: Q1, Q3	77.5, 100.0	80.0, 100.0	80.0, 100.0	-2.5, 7.5	-20.0, 0.0	-10.0, 0.0
Min, Max	75, 100	80, 100	65, 100	-5, 15	-20, 0	-30, 15

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.4.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=7)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=7)	Change from Baseline DB Placebo (N=14)
Hopelessness						
Baseline						
m	6	7	14			
n	6	6	14			
Mean (SD)	87.52 (13.69)	98.62 (3.39)	93.46 (9.35)			
Median	91.70	100.00	100.00			
IQR: Q1, Q3	75.00, 100.00	100.00, 100.00	91.70, 100.00			
Min, Max	66.7, 100.0	91.7, 100.0	75.0, 100.0			
Week 24						
m	5	5	13			
n	5	4	12	5	4	12
Mean (SD/SE)	88.34 (13.94)	83.33 (23.57)	95.84 (7.53)	-1.68 (8.08)	-14.60 (11.96)	3.48 (3.62)
Median	91.70	91.65	100.00	0	-4.20	0
IQR: Q1, Q3	83.30, 100.00	66.65, 100.00	91.70, 100.00	-8.40, 0.00	-29.20, 0.00	0.00, 8.35
Min, Max	66.7, 100.0	50.0, 100.0	75.0, 100.0	-25.0, 25.0	-50.0, 0.0	-16.7, 25.0
Week 52						
m	5	5	12			
n	4	4	11	4	4	11
Mean (SD/SE)	95.83 (8.35)	89.60 (15.76)	91.66 (13.95)	6.23 (9.24)	-8.33 (8.33)	-0.01 (5.51)
Median	100.00	95.85	100.00	0	0	0
IQR: Q1, Q3	91.65, 100.00	79.20, 100.00	83.30, 100.00	-4.20, 16.65	-16.65, 0.00	-8.40, 16.70
Min, Max	83.3, 100.0	66.7, 100.0	58.3, 100.0	-8.4, 33.3	-33.3, 0.0	-33.4, 25.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.4.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=7)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=7)	Change from Baseline DB Placebo (N=14)
Stigma of Liver Disease						
Baseline						
m	6	7	14			
n	6	6	14			
Mean (SD)	88.55 (12.75)	85.43 (11.63)	89.31 (11.60)			
Median	90.65	81.30	90.65			
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	81.30, 100.00			
Min, Max	75.0, 100.0	75.0, 100.0	62.5, 100.0			
Week 24						
m	5	5	13			
n	5	4	12	5	4	12
Mean (SD/SE)	90.02 (11.35)	71.88 (21.35)	90.63 (10.48)	3.76 (5.44)	-10.95 (14.51)	-1.58 (2.56)
Median	93.80	68.75	93.75	0	-6.25	0
IQR: Q1, Q3	81.30, 100.00	56.25, 87.50	81.30, 100.00	0.00, 0.00	-31.25, 9.35	-9.40, 0.00
Min, Max	75.0, 100.0	50.0, 100.0	75.0, 100.0	-6.2, 25.0	-50.0, 18.7	-12.5, 18.7
Week 52						
m	5	5	12			
n	4	4	11	4	4	11
Mean (SD/SE)	81.28 (22.25)	75.00 (20.41)	83.55 (17.06)	-7.80 (5.92)	-7.83 (14.73)	-9.08 (6.09)
Median	87.55	75.00	87.50	-3.10	0	0
IQR: Q1, Q3	65.65, 96.90	62.50, 87.50	81.30, 93.80	-15.60, 0.00	-25.00, 9.35	-12.50, 0.00
Min, Max	50.0, 100.0	50.0, 100.0	43.8, 100.0	-25.0, 0.0	-50.0, 18.7	-56.2, 12.5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc. Page 1 of 3
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.4.2Liver Disease Quality of Life (SE20): Summary of Total LDQOL - MMRM Model
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.4.2Liver Disease Quality of Life (SE20): Summary of Total LDQOL - MMRM Model
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Total LDQOL			
Week 24			
m	3	7	14
n	2	7	12
Baseline Mean (SD)	93.25 (1.06)	87.83 (5.70)	85.73 (10.15)
Analysis Visit Mean (SD)	90.20 (0.14)	85.61 (8.04)	82.53 (14.65)
LS Mean of Change from Baseline (SE)	-4.96 (4.62)	-2.02 (2.58)	-3.45 (2.38)
95% CI	(-14.68, 4.75)	(-7.44, 3.39)	(-8.46, 1.55)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.51 (4.58)	1.43 (2.90)	
95% CI	(-11.14, 8.11)	(-4.66, 7.52)	
p-value	0.7450	0.6277	
Corrected Hedge's g Statistics	-0.174	0.176	
95% CI	(-1.67, 1.32)	(-0.76, 1.11)	
Week 52			
m	3	7	14
n	3	6	12
Baseline Mean (SD)	91.77 (2.68)	87.53 (6.18)	85.73 (10.15)
Analysis Visit Mean (SD)	89.87 (2.54)	85.63 (6.03)	83.88 (12.85)
LS Mean of Change from Baseline (SE)	-3.02 (3.65)	-2.27 (2.40)	-2.44 (2.21)
95% CI	(-10.68, 4.64)	(-7.31, 2.76)	(-7.08, 2.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.58 (3.42)	0.17 (2.59)	
95% CI	(-7.76, 6.60)	(-5.27, 5.61)	
p-value	0.8677	0.9496	
Corrected Hedge's g Statistics	-0.073	0.022	
95% CI	(-1.34, 1.19)	(-0.96, 1.00)	
Subgroup*Treatment Interaction p-value	0.9021	0.5990	

Madrigal Pharmaceuticals, Inc. Page 3 of 3
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.4.2Liver Disease Quality of Life (SE20): Summary of Total LDQOL - MMRM Model
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Total LDQOL			
Week 24			
m	5	5	13
n	5	4	12
Baseline Mean (SD)	75.94 (16.14)	87.63 (6.85)	86.90 (6.11)
Analysis Visit Mean (SD)	79.06 (13.07)	83.15 (9.90)	86.18 (6.88)
LS Mean of Change from Baseline (SE)	1.67 (4.57)	0.03 (6.39)	4.07 (5.51)
95% CI	(-7.98, 11.32)	(-13.44, 13.50)	(-7.56, 15.70)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.40 (5.53)	-4.04 (4.56)	
95% CI	(-14.07, 9.28)	(-13.66, 5.59)	
p-value	0.6702	0.3885	
Corrected Hedge's g Statistics	-0.132	-0.213	
95% CI	(-1.18, 0.91)	(-1.35, 0.92)	
Week 52			
m	5	5	12
n	4	4	11
Baseline Mean (SD)	78.73 (17.20)	87.63 (6.85)	87.65 (5.80)
Analysis Visit Mean (SD)	76.60 (25.28)	83.00 (4.65)	83.30 (12.05)
LS Mean of Change from Baseline (SE)	-0.15 (6.63)	-0.96 (7.84)	-0.16 (6.21)
95% CI	(-14.15, 13.85)	(-17.49, 15.58)	(-13.25, 12.94)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.01 (8.00)	-0.80 (6.97)	
95% CI	(-16.87, 16.89)	(-15.51, 13.91)	
p-value	0.9989	0.9101	
Corrected Hedge's g Statistics	0.001	-0.038	
95% CI	(-1.14, 1.14)	(-1.18, 1.11)	
Subgroup*Treatment Interaction p-value	0.9021	0.5990	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.4.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

AMNOG Table SE20.4.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Symptoms of Liver Disease			
Week 24			
m	3	7	14
n	2	7	12
Baseline Mean (SD)	96.70 (0.00)	86.19 (7.56)	85.83 (15.05)
Analysis Visit Mean (SD)	98.35 (2.33)	86.67 (10.35)	86.39 (10.97)
LS Mean of Change from Baseline (SE)	11.05 (7.98)	1.69 (4.58)	1.40 (4.43)
95% CI	(-5.72, 27.82)	(-7.92, 11.30)	(-7.91, 10.72)
LS Mean of Change from Baseline Compared to Placebo (SE)	9.65 (7.53)	0.29 (4.94)	
95% CI	(-6.18, 25.47)	(-10.09, 10.66)	
p-value	0.2167	0.9545	
Corrected Hedge's g Statistics	0.600	0.019	
95% CI	(-0.91, 2.11)	(-0.91, 0.95)	
Week 52			
m	3	7	14
n	3	6	12
Baseline Mean (SD)	95.57 (1.96)	83.88 (4.91)	85.83 (15.05)
Analysis Visit Mean (SD)	92.20 (1.91)	83.32 (12.28)	88.60 (12.10)
LS Mean of Change from Baseline (SE)	3.09 (7.60)	-3.22 (4.87)	3.77 (4.52)
95% CI	(-12.88, 19.06)	(-13.46, 7.01)	(-5.73, 13.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.68 (7.12)	-7.00 (5.30)	
95% CI	(-15.65, 14.28)	(-18.13, 4.13)	
p-value	0.9244	0.2031	
Corrected Hedge's g Statistics	-0.042	-0.456	
95% CI	(-1.31, 1.22)	(-1.45, 0.53)	
Subgroup*Treatment Interaction p-value	0.3331	0.5172	

AMNOG Table SE20.4.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Effects of Liver Disease			
Week 24			
m	3	7	14
n	2	7	12
Baseline Mean (SD)	90.00 (14.14)	84.76 (10.70)	79.45 (5.29)
Analysis Visit Mean (SD)	80.00 (0.00)	80.94 (8.98)	77.78 (8.22)
LS Mean of Change from Baseline (SE)	-3.36 (5.84)	-1.51 (3.26)	-2.89 (2.77)
95% CI	(-15.63, 8.90)	(-8.36, 5.34)	(-8.71, 2.92)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.47 (6.31)	1.38 (4.06)	
95% CI	(-13.73, 12.79)	(-7.15, 9.92)	
p-value	0.9414	0.7371	
Corrected Hedge's g Statistics	-0.046	0.143	
95% CI	(-1.54, 1.45)	(-0.79, 1.08)	
Week 52			
m	3	7	14
n	3	6	12
Baseline Mean (SD)	88.90 (10.18)	85.55 (11.49)	79.45 (5.29)
Analysis Visit Mean (SD)	80.00 (0.00)	78.88 (2.74)	79.45 (4.45)
LS Mean of Change from Baseline (SE)	-2.64 (2.75)	-3.77 (1.79)	-1.54 (1.73)
95% CI	(-8.42, 3.13)	(-7.54, -0.01)	(-5.18, 2.10)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.11 (2.63)	-2.24 (1.98)	
95% CI	(-6.64, 4.42)	(-6.39, 1.91)	
p-value	0.6791	0.2726	
Corrected Hedge's g Statistics	-0.179	-0.384	
95% CI	(-1.45, 1.09)	(-1.37, 0.60)	
Subgroup*Treatment Interaction p-value	0.6361	0.3047	

AMNOG Table SE20.4.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Concentration/Memory			
Week 24			
m	3	7	14
n	2	7	12
Baseline Mean (SD)	93.75 (8.84)	89.31 (16.01)	88.03 (19.30)
Analysis Visit Mean (SD)	93.80 (0.00)	87.51 (13.97)	85.43 (13.40)
LS Mean of Change from Baseline (SE)	9.34 (7.26)	2.70 (4.05)	2.24 (3.65)
95% CI	(-5.92, 24.61)	(-5.81, 11.22)	(-5.42, 9.91)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.10 (7.36)	0.46 (4.66)	
95% CI	(-8.35, 22.55)	(-9.33, 10.25)	
p-value	0.3471	0.9226	
Corrected Hedge's g Statistics	0.534	0.037	
95% CI	(-0.98, 2.04)	(-0.90, 0.97)	
Week 52			
m	3	7	14
n	3	6	12
Baseline Mean (SD)	91.67 (7.22)	90.65 (17.10)	88.03 (19.30)
Analysis Visit Mean (SD)	83.33 (7.22)	90.63 (11.00)	84.40 (18.76)
LS Mean of Change from Baseline (SE)	-0.86 (7.12)	4.82 (4.92)	1.38 (4.03)
95% CI	(-15.82, 14.10)	(-5.51, 15.15)	(-7.08, 9.84)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.24 (7.32)	3.44 (5.68)	
95% CI	(-17.62, 13.14)	(-8.50, 15.38)	
p-value	0.7634	0.5526	
Corrected Hedge's g Statistics	-0.154	0.245	
95% CI	(-1.42, 1.11)	(-0.74, 1.23)	
Subgroup*Treatment Interaction p-value	0.1173	0.7037	

AMNOG Table SE20.4.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Health Distress			
Week 24			
m	3	7	14
n	2	7	12
Baseline Mean (SD)	100.00 (0.00)	96.43 (6.10)	97.92 (7.22)
Analysis Visit Mean (SD)	100.00 (0.00)	94.64 (9.83)	92.71 (15.50)
LS Mean of Change from Baseline (SE)	-2.20 (8.71)	-3.20 (5.18)	-6.43 (5.09)
95% CI	(-20.50, 16.11)	(-14.08, 7.67)	(-17.12, 4.26)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.23 (8.12)	3.23 (5.60)	
95% CI	(-12.83, 21.30)	(-8.54, 14.99)	
p-value	0.6086	0.5717	
Corrected Hedge's g Statistics	0.230	0.188	
95% CI	(-1.27, 1.73)	(-0.75, 1.12)	
Week 52			
m	3	7	14
n	3	6	12
Baseline Mean (SD)	100.00 (0.00)	95.83 (6.45)	97.92 (7.22)
Analysis Visit Mean (SD)	100.00 (0.00)	91.67 (12.91)	94.79 (14.56)
LS Mean of Change from Baseline (SE)	-1.77 (8.57)	-8.48 (5.65)	-4.32 (5.27)
95% CI	(-19.76, 16.23)	(-20.35, 3.39)	(-15.39, 6.76)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.55 (8.00)	-4.16 (6.21)	
95% CI	(-14.26, 19.36)	(-17.21, 8.88)	
p-value	0.7537	0.5112	
Corrected Hedge's g Statistics	0.135	-0.233	
95% CI	(-1.13, 1.40)	(-1.22, 0.75)	
Subgroup*Treatment Interaction p-value	0.9784	0.5619	

AMNOG Table SE20.4.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Sexual Function			
Week 24			
m	3	7	14
n	1	5	5
Baseline Mean (SD)	93.30 (N/A)	94.00 (8.22)	94.32 (9.41)
Analysis Visit Mean (SD)	70.00 (N/A)	87.66 (16.65)	89.34 (23.84)
LS Mean of Change from Baseline (SE)	-22.15 (9.20)	-6.04 (4.16)	-4.24 (3.76)
95% CI	(-42.97, -1.32)	(-15.44, 3.36)	(-12.75, 4.26)
LS Mean of Change from Baseline Compared to Placebo (SE)	-17.90 (9.96)	-1.80 (5.63)	
95% CI	(-40.43, 4.62)	(-14.53, 10.93)	
p-value	0.1056	0.7565	
Corrected Hedge's g Statistics	-1.704	-0.183	
95% CI	(-4.06, 0.65)	(-1.43, 1.06)	
Week 52			
m	3	7	14
n	1	4	6
Baseline Mean (SD)	93.30 (N/A)	96.25 (7.50)	92.77 (9.24)
Analysis Visit Mean (SD)	85.00 (N/A)	96.65 (3.87)	80.55 (34.53)
LS Mean of Change from Baseline (SE)	-6.46 (17.86)	-8.00 (8.09)	-9.72 (7.32)
95% CI	(-46.87, 33.95)	(-26.29, 10.30)	(-26.29, 6.84)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.27 (19.28)	1.73 (10.92)	
95% CI	(-40.36, 46.89)	(-22.96, 26.42)	
p-value	0.8693	0.8776	
Corrected Hedge's g Statistics	0.153	0.090	
95% CI	(-1.97, 2.27)	(-1.18, 1.36)	
Subgroup*Treatment Interaction p-value	NE	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.4.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Sleep			
Week 24			
m	3	7	14
n	2	7	12
Baseline Mean (SD)	80.0 (14.1)	69.3 (7.3)	70.0 (23.1)
Analysis Visit Mean (SD)	75.0 (0.0)	65.0 (16.3)	71.7 (19.1)
LS Mean of Change from Baseline (SE)	-5.31 (8.89)	-6.55 (5.38)	-1.11 (5.25)
95% CI	(-24.00, 13.38)	(-17.85, 4.76)	(-12.14, 9.92)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.20 (8.45)	-5.44 (5.68)	
95% CI	(-21.94, 13.54)	(-17.36, 6.49)	
p-value	0.6249	0.3508	
Corrected Hedge's g Statistics	-0.221	-0.307	
95% CI	(-1.72, 1.28)	(-1.24, 0.63)	
Week 52			
m	3	7	14
n	3	6	12
Baseline Mean (SD)	80.0 (10.0)	70.0 (7.7)	70.0 (23.1)
Analysis Visit Mean (SD)	75.0 (10.0)	63.3 (12.5)	70.8 (20.5)
LS Mean of Change from Baseline (SE)	-4.61 (9.51)	-8.44 (6.43)	-2.04 (5.77)
95% CI	(-24.60, 15.38)	(-21.96, 5.08)	(-14.16, 10.07)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.57 (9.33)	-6.40 (7.10)	
95% CI	(-22.16, 17.02)	(-21.32, 8.52)	
p-value	0.7860	0.3794	
Corrected Hedge's g Statistics	-0.124	-0.325	
95% CI	(-1.39, 1.14)	(-1.31, 0.66)	
Subgroup*Treatment Interaction p-value	0.8901	0.6646	

AMNOG Table SE20.4.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Loneliness			
Week 24			
m	3	7	14
n	2	7	12
Baseline Mean (SD)	92.5 (10.6)	97.1 (2.7)	90.4 (12.3)
Analysis Visit Mean (SD)	87.5 (17.7)	90.0 (13.8)	83.8 (21.1)
LS Mean of Change from Baseline (SE)	-5.01 (12.82)	-4.72 (8.24)	-5.64 (7.73)
95% CI	(-31.94, 21.92)	(-22.02, 12.59)	(-21.89, 10.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.63 (11.94)	0.93 (8.80)	
95% CI	(-24.45, 25.72)	(-17.56, 19.42)	
p-value	0.9582	0.9172	
Corrected Hedge's g Statistics	0.023	0.035	
95% CI	(-1.47, 1.52)	(-0.90, 0.97)	
Week 52			
m	3	7	14
n	3	6	12
Baseline Mean (SD)	95.0 (8.7)	97.5 (2.7)	90.4 (12.3)
Analysis Visit Mean (SD)	100.0 (0.0)	90.0 (22.1)	85.4 (19.4)
LS Mean of Change from Baseline (SE)	6.91 (12.35)	-4.48 (8.41)	-4.19 (7.76)
95% CI	(-19.04, 32.86)	(-22.14, 13.19)	(-20.50, 12.12)
LS Mean of Change from Baseline Compared to Placebo (SE)	11.10 (11.41)	-0.29 (9.00)	
95% CI	(-12.88, 35.08)	(-19.20, 18.62)	
p-value	0.3438	0.9749	
Corrected Hedge's g Statistics	0.400	-0.011	
95% CI	(-0.87, 1.67)	(-0.99, 0.97)	
Subgroup*Treatment Interaction p-value	0.7960	0.5463	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.4.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Hopelessness			
Week 24			
m	3	7	14
n	2	7	12
Baseline Mean (SD)	95.85 (5.87)	88.10 (17.91)	81.95 (25.09)
Analysis Visit Mean (SD)	100.00 (0.00)	86.90 (19.77)	77.78 (29.16)
LS Mean of Change from Baseline (SE)	6.16 (6.53)	0.48 (3.72)	-1.83 (3.46)
95% CI	(-7.56, 19.88)	(-7.34, 8.30)	(-9.10, 5.43)
LS Mean of Change from Baseline Compared to Placebo (SE)	8.00 (6.44)	2.31 (4.16)	
95% CI	(-5.53, 21.53)	(-6.42, 11.05)	
p-value	0.2303	0.5847	
Corrected Hedge's g Statistics	0.636	0.196	
95% CI	(-0.88, 2.15)	(-0.74, 1.13)	
Week 52			
m	3	7	14
n	3	6	12
Baseline Mean (SD)	88.90 (12.73)	86.12 (18.76)	81.95 (25.09)
Analysis Visit Mean (SD)	91.67 (8.35)	91.67 (13.94)	82.64 (21.16)
LS Mean of Change from Baseline (SE)	6.39 (5.36)	7.79 (3.63)	2.04 (3.31)
95% CI	(-4.87, 17.65)	(0.17, 15.41)	(-4.92, 9.00)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.35 (5.07)	5.75 (3.95)	
95% CI	(-6.30, 15.00)	(-2.55, 14.05)	
p-value	0.4020	0.1629	
Corrected Hedge's g Statistics	0.366	0.510	
95% CI	(-0.91, 1.64)	(-0.48, 1.50)	
Subgroup*Treatment Interaction p-value	0.2867	0.0962	

AMNOG Table SE20.4.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Stigma of Liver Disease			
Week 24			
m	3	7	14
n	2	7	12
Baseline Mean (SD)	96.90 (4.38)	86.63 (18.19)	91.68 (15.61)
Analysis Visit Mean (SD)	96.90 (4.38)	91.97 (10.64)	81.78 (31.36)
LS Mean of Change from Baseline (SE)	-3.41 (13.15)	4.70 (7.58)	-14.94 (7.07)
95% CI	(-31.03, 24.21)	(-11.24, 20.63)	(-29.80, -0.09)
LS Mean of Change from Baseline Compared to Placebo (SE)	11.54 (12.87)	19.64 (8.81)	
95% CI	(-15.51, 38.58)	(1.13, 38.15)	
p-value	0.3820	0.0388	
Corrected Hedge's g Statistics	0.449	0.815	
95% CI	(-1.06, 1.96)	(-0.15, 1.78)	
Week 52			
m	3	7	14
n	3	6	12
Baseline Mean (SD)	93.77 (6.25)	84.40 (18.86)	91.68 (15.61)
Analysis Visit Mean (SD)	97.93 (3.58)	88.57 (14.48)	89.60 (20.17)
LS Mean of Change from Baseline (SE)	-0.49 (9.40)	0.70 (6.08)	-6.53 (6.09)
95% CI	(-20.23, 19.25)	(-12.06, 13.47)	(-19.34, 6.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.04 (8.28)	7.23 (6.69)	
95% CI	(-11.35, 23.43)	(-6.82, 21.29)	
p-value	0.4749	0.2936	
Corrected Hedge's g Statistics	0.278	0.355	
95% CI	(-0.99, 1.55)	(-0.63, 1.34)	
Subgroup*Treatment Interaction p-value	0.9476	0.1970	

AMNOG Table SE20.4.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Symptoms of Liver Disease			
Week 24			
m	5	5	13
n	5	4	12
Baseline Mean (SD)	80.00 (17.49)	84.15 (20.63)	79.44 (15.83)
Analysis Visit Mean (SD)	80.66 (14.80)	92.50 (5.00)	79.99 (18.53)
LS Mean of Change from Baseline (SE)	4.99 (8.43)	19.14 (10.80)	8.10 (8.46)
95% CI	(-12.79, 22.77)	(-3.66, 41.93)	(-9.75, 25.94)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.11 (9.14)	11.04 (9.58)	
95% CI	(-22.38, 16.17)	(-9.17, 31.26)	
p-value	0.7380	0.2651	
Corrected Hedge's g Statistics	-0.110	0.375	
95% CI	(-1.15, 0.93)	(-0.76, 1.51)	
Week 52			
m	5	5	12
n	4	4	11
Baseline Mean (SD)	86.68 (10.53)	84.15 (20.63)	80.30 (16.31)
Analysis Visit Mean (SD)	80.85 (18.32)	80.03 (17.63)	82.73 (13.80)
LS Mean of Change from Baseline (SE)	1.51 (7.66)	5.51 (9.59)	11.43 (8.11)
95% CI	(-14.65, 17.67)	(-14.73, 25.75)	(-5.67, 28.54)
LS Mean of Change from Baseline Compared to Placebo (SE)	-9.92 (8.23)	-5.92 (7.77)	
95% CI	(-27.28, 7.44)	(-22.32, 10.47)	
p-value	0.2444	0.4563	
Corrected Hedge's g Statistics	-0.378	-0.220	
95% CI	(-1.53, 0.77)	(-1.37, 0.93)	
Subgroup*Treatment Interaction p-value	0.3331	0.5172	

AMNOG Table SE20.4.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Effects of Liver Disease			
Week 24			
m	5	5	13
n	5	4	12
Baseline Mean (SD)	64.00 (22.42)	90.03 (6.65)	83.89 (6.64)
Analysis Visit Mean (SD)	80.00 (0.00)	88.33 (9.99)	80.56 (8.74)
LS Mean of Change from Baseline (SE)	-5.02 (5.11)	7.77 (6.90)	-1.95 (5.68)
95% CI	(-15.80, 5.75)	(-6.80, 22.33)	(-13.94, 10.03)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.07 (6.23)	9.72 (4.91)	
95% CI	(-16.21, 10.07)	(-0.64, 20.08)	
p-value	0.6288	0.0642	
Corrected Hedge's g Statistics	-0.163	0.495	
95% CI	(-1.21, 0.88)	(-0.65, 1.64)	
Week 52			
m	5	5	12
n	4	4	11
Baseline Mean (SD)	71.68 (16.65)	90.03 (6.65)	83.04 (6.23)
Analysis Visit Mean (SD)	68.33 (32.82)	86.68 (9.43)	82.43 (9.08)
LS Mean of Change from Baseline (SE)	-5.58 (8.99)	-4.33 (10.01)	-2.24 (6.94)
95% CI	(-24.55, 13.38)	(-25.44, 16.78)	(-16.89, 12.41)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.35 (10.70)	-2.10 (9.41)	
95% CI	(-25.91, 19.22)	(-21.94, 17.75)	
p-value	0.7583	0.8264	
Corrected Hedge's g Statistics	-0.143	-0.088	
95% CI	(-1.29, 1.00)	(-1.23, 1.06)	
Subgroup*Treatment Interaction p-value	0.6361	0.3047	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.4.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Concentration/Memory			
Week 24			
m	5	5	13
n	5	4	12
Baseline Mean (SD)	81.26 (26.50)	76.58 (28.11)	89.60 (8.14)
Analysis Visit Mean (SD)	73.76 (26.65)	81.28 (22.25)	91.16 (12.90)
LS Mean of Change from Baseline (SE)	-3.55 (8.58)	10.31 (11.35)	12.67 (10.17)
95% CI	(-21.65, 14.55)	(-13.63, 34.25)	(-8.80, 34.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	-16.22 (9.15)	-2.36 (9.20)	
95% CI	(-35.52, 3.09)	(-21.77, 17.05)	
p-value	0.0942	0.8008	
Corrected Hedge's g Statistics	-0.485	-0.068	
95% CI	(-1.54, 0.57)	(-1.20, 1.06)	
Week 52			
m	5	5	12
n	4	4	11
Baseline Mean (SD)	76.58 (28.11)	76.58 (28.11)	90.93 (7.04)
Analysis Visit Mean (SD)	67.20 (47.15)	76.58 (24.12)	82.41 (21.05)
LS Mean of Change from Baseline (SE)	-5.77 (11.44)	9.16 (13.43)	1.37 (11.22)
95% CI	(-29.90, 18.36)	(-19.18, 37.50)	(-22.30, 25.04)
LS Mean of Change from Baseline Compared to Placebo (SE)	-7.14 (13.16)	7.79 (12.76)	
95% CI	(-34.91, 20.63)	(-19.13, 34.72)	
p-value	0.5946	0.5496	
Corrected Hedge's g Statistics	-0.195	0.209	
95% CI	(-1.34, 0.95)	(-0.94, 1.36)	
Subgroup*Treatment Interaction p-value	0.1173	0.7037	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.4.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Health Distress			
Week 24			
m	5	5	13
n	5	4	12
Baseline Mean (SD)	67.50 (39.13)	96.88 (6.25)	90.63 (16.10)
Analysis Visit Mean (SD)	75.00 (42.39)	96.88 (6.25)	90.63 (13.19)
LS Mean of Change from Baseline (SE)	7.13 (7.94)	6.19 (10.35)	5.59 (8.84)
95% CI	(-9.62, 23.89)	(-15.66, 28.04)	(-13.07, 24.24)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.55 (8.65)	0.61 (7.88)	
95% CI	(-16.70, 19.79)	(-16.03, 17.24)	
p-value	0.8602	0.9396	
Corrected Hedge's g Statistics	0.053	0.020	
95% CI	(-0.99, 1.10)	(-1.11, 1.15)	
Week 52			
m	5	5	12
n	4	4	11
Baseline Mean (SD)	65.63 (44.92)	96.88 (6.25)	92.05 (16.08)
Analysis Visit Mean (SD)	71.88 (48.28)	100.00 (0.00)	85.23 (18.39)
LS Mean of Change from Baseline (SE)	8.20 (10.99)	9.71 (12.43)	-1.77 (9.83)
95% CI	(-14.99, 31.40)	(-16.51, 35.93)	(-22.50, 18.97)
LS Mean of Change from Baseline Compared to Placebo (SE)	9.97 (12.58)	11.48 (11.16)	
95% CI	(-16.56, 36.50)	(-12.07, 35.03)	
p-value	0.4388	0.3182	
Corrected Hedge's g Statistics	0.308	0.349	
95% CI	(-0.84, 1.46)	(-0.80, 1.50)	
Subgroup*Treatment Interaction p-value	0.9784	0.5619	

AMNOG Table SE20.4.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Sexual Function			
Week 24			
m	5	5	13
n	1	0	4
Baseline Mean (SD)	100.00 (N/A)	N/A	88.35 (9.90)
Analysis Visit Mean (SD)	91.70 (N/A)	N/A	90.40 (7.75)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	5	12
n	1	0	2
Baseline Mean (SD)	100.00 (N/A)	N/A	96.65 (4.74)
Analysis Visit Mean (SD)	100.00 (N/A)	N/A	92.50 (10.61)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE20.4.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Sleep			
Week 24			
m	5	5	13
n	5	4	12
Baseline Mean (SD)	48.0 (30.9)	72.5 (10.4)	68.3 (20.8)
Analysis Visit Mean (SD)	53.0 (30.9)	68.8 (15.5)	68.8 (15.1)
LS Mean of Change from Baseline (SE)	2.86 (7.29)	-1.11 (9.51)	3.47 (7.94)
95% CI	(-12.53, 18.24)	(-21.17, 18.96)	(-13.29, 20.23)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.62 (8.08)	-4.58 (7.36)	
95% CI	(-17.65, 16.42)	(-20.10, 10.95)	
p-value	0.9401	0.5422	
Corrected Hedge's g Statistics	-0.023	-0.167	
95% CI	(-1.07, 1.02)	(-1.30, 0.97)	
Week 52			
m	5	5	12
n	4	4	11
Baseline Mean (SD)	60.0 (17.8)	72.5 (10.4)	71.8 (17.8)
Analysis Visit Mean (SD)	57.5 (21.0)	66.3 (7.5)	67.3 (17.8)
LS Mean of Change from Baseline (SE)	-4.18 (8.13)	-3.63 (10.12)	-0.25 (8.35)
95% CI	(-21.33, 12.97)	(-24.98, 17.71)	(-17.86, 17.36)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.93 (9.30)	-3.38 (8.36)	
95% CI	(-23.56, 15.70)	(-21.02, 14.25)	
p-value	0.6782	0.6907	
Corrected Hedge's g Statistics	-0.145	-0.122	
95% CI	(-1.29, 1.00)	(-1.27, 1.02)	
Subgroup*Treatment Interaction p-value	0.8901	0.6646	

AMNOG Table SE20.4.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Loneliness			
Week 24			
m	5	5	13
n	5	4	12
Baseline Mean (SD)	87.0 (16.4)	100.0 (0.0)	95.4 (7.8)
Analysis Visit Mean (SD)	92.0 (9.1)	82.5 (23.6)	90.0 (13.7)
LS Mean of Change from Baseline (SE)	4.13 (7.55)	-13.98 (10.15)	-2.74 (7.92)
95% CI	(-11.80, 20.06)	(-35.38, 7.43)	(-19.44, 13.96)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.87 (8.67)	-11.24 (8.31)	
95% CI	(-11.42, 25.16)	(-28.77, 6.29)	
p-value	0.4390	0.1940	
Corrected Hedge's g Statistics	0.260	-0.408	
95% CI	(-0.79, 1.31)	(-1.55, 0.73)	
Week 52			
m	5	5	12
n	4	4	11
Baseline Mean (SD)	86.3 (18.9)	100.0 (0.0)	95.0 (8.1)
Analysis Visit Mean (SD)	88.8 (13.1)	90.0 (11.5)	90.0 (12.2)
LS Mean of Change from Baseline (SE)	1.12 (6.89)	-6.06 (9.30)	-2.02 (7.65)
95% CI	(-13.42, 15.66)	(-25.69, 13.57)	(-18.16, 14.12)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.14 (8.04)	-4.04 (7.02)	
95% CI	(-13.82, 20.11)	(-18.85, 10.78)	
p-value	0.7008	0.5730	
Corrected Hedge's g Statistics	0.127	-0.158	
95% CI	(-1.02, 1.27)	(-1.30, 0.99)	
Subgroup*Treatment Interaction p-value	0.7960	0.5463	

AMNOG Table SE20.4.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Hopelessness			
Week 24			
m	5	5	13
n	5	4	12
Baseline Mean (SD)	90.02 (13.68)	97.93 (4.15)	92.37 (9.71)
Analysis Visit Mean (SD)	88.34 (13.94)	83.33 (23.57)	95.84 (7.53)
LS Mean of Change from Baseline (SE)	1.20 (7.78)	-0.96 (10.91)	12.41 (9.06)
95% CI	(-15.20, 17.61)	(-23.98, 22.06)	(-6.70, 31.52)
LS Mean of Change from Baseline Compared to Placebo (SE)	-11.21 (8.08)	-13.37 (8.22)	
95% CI	(-28.25, 5.83)	(-30.71, 3.96)	
p-value	0.1832	0.1220	
Corrected Hedge's g Statistics	-0.375	-0.427	
95% CI	(-1.43, 0.68)	(-1.57, 0.71)	
Week 52			
m	5	5	12
n	4	4	11
Baseline Mean (SD)	89.60 (15.76)	97.93 (4.15)	91.67 (9.86)
Analysis Visit Mean (SD)	95.83 (8.35)	89.60 (15.76)	91.66 (13.95)
LS Mean of Change from Baseline (SE)	3.01 (8.14)	6.33 (11.15)	8.40 (9.17)
95% CI	(-14.18, 20.19)	(-17.19, 29.85)	(-10.94, 27.74)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.40 (8.57)	-2.07 (8.66)	
95% CI	(-23.48, 12.69)	(-20.34, 16.20)	
p-value	0.5375	0.8137	
Corrected Hedge's g Statistics	-0.183	-0.068	
95% CI	(-1.33, 0.96)	(-1.21, 1.08)	
Subgroup*Treatment Interaction p-value	0.2867	0.0962	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.4.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Stigma of Liver Disease			
Week 24			
m	5	5	13
n	5	4	12
Baseline Mean (SD)	86.26 (12.80)	82.83 (11.83)	92.21 (8.87)
Analysis Visit Mean (SD)	90.02 (11.35)	71.88 (21.35)	90.63 (10.48)
LS Mean of Change from Baseline (SE)	2.08 (7.98)	-14.87 (10.59)	1.49 (9.71)
95% CI	(-14.75, 18.91)	(-37.21, 7.47)	(-18.99, 21.97)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.59 (8.68)	-16.36 (8.69)	
95% CI	(-17.72, 18.90)	(-34.70, 1.98)	
p-value	0.9467	0.0771	
Corrected Hedge's g Statistics	0.018	-0.493	
95% CI	(-1.02, 1.06)	(-1.64, 0.65)	
Week 52			
m	5	5	12
n	4	4	11
Baseline Mean (SD)	89.08 (12.87)	82.83 (11.83)	92.64 (9.17)
Analysis Visit Mean (SD)	81.28 (22.25)	75.00 (20.41)	83.55 (17.06)
LS Mean of Change from Baseline (SE)	-4.72 (10.81)	-13.31 (12.99)	-6.04 (10.72)
95% CI	(-27.53, 18.10)	(-40.71, 14.09)	(-28.65, 16.58)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.32 (12.24)	-7.28 (12.55)	
95% CI	(-24.50, 27.14)	(-33.77, 19.21)	
p-value	0.9155	0.5697	
Corrected Hedge's g Statistics	0.038	-0.204	
95% CI	(-1.11, 1.18)	(-1.35, 0.94)	
Subgroup*Treatment Interaction p-value	0.9476	0.1970	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.4.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis, only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.

AMNOG Table SE20.4.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	3 (100)	8 (100)	14 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (12.5)	2 (14.3)
No	3 (100)	7 (87.5)	12 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	1.17	
95% CI of the inverse odds ratio	(0.05, 36.45)	(0.09, 15.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	1.14	
95% CI of the inverse risk ratio	(0.08, 22.57)	(0.12, 10.71)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.17	-1.79	
95% CI of the absolute risk difference	(-41.66, 33.33)	(-31.13, 27.56)	
p-value	0.8391	0.9065	
p-value of Breslow-Day Test for Homogeneity [3]	0.5603	0.2794	

Program: t-se18-02-04-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.4.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (12.5)	1 (7.1)
No	3 (100)	7 (87.5)	13 (92.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	0.54	
95% CI of the inverse odds ratio	(0.03, 23.53)	(0.03, 9.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	0.57	
95% CI of the inverse risk ratio	(0.04, 16.14)	(0.04, 7.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.50	5.36	
95% CI of the absolute risk difference	(-33.29, 38.29)	(-21.24, 31.95)	
p-value	0.8849	0.6742	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.2534	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (25.0)	5 (35.7)
No	3 (100)	6 (75.0)	9 (64.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.05	1.67	
95% CI of the inverse odds ratio	(0.17, 93.99)	(0.24, 11.58)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.93	1.43	
95% CI of the inverse risk ratio	(0.20, 42.64)	(0.36, 5.74)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-24.17	-10.71	
95% CI of the absolute risk difference	(-64.73, 16.39)	(-49.83, 28.41)	
p-value	0.3555	0.6037	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.1946	

AMNOG Table SE20.4.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	3 (100)	8 (100)	14 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	1 (7.1)
No	3 (100)	8 (100)	13 (92.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	1.89	
95% CI of the inverse odds ratio	(0.03, 23.53)	(0.07, 51.92)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	1.80	
95% CI of the inverse risk ratio	(0.04, 16.14)	(0.08, 39.64)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.50	-4.44	
95% CI of the absolute risk difference	(-33.29, 38.29)	(-25.76, 16.87)	
p-value	0.8849	0.7029	
p-value of Breslow-Day Test for Homogeneity [3]	0.6857	0.5593	

AMNOG Table SE20.4.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (12.5)	0
No	3 (100)	7 (87.5)	14 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.17	
95% CI of the inverse odds ratio	NE	(0.01, 4.77)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.20	
95% CI of the inverse risk ratio	NE	(0.01, 4.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	13.33	
95% CI of the absolute risk difference	NE	(-12.65, 39.32)	
p-value	NE	0.2526	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (25.0)	3 (21.4)
No	3 (100)	6 (75.0)	11 (78.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.13	0.82	
95% CI of the inverse odds ratio	(0.09, 52.04)	(0.11, 6.34)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.87	0.86	
95% CI of the inverse risk ratio	(0.12, 29.21)	(0.18, 4.10)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.83	3.57	
95% CI of the absolute risk difference	(-49.67, 28.01)	(-33.34, 40.48)	
p-value	0.6368	0.8475	
p-value of Breslow-Day Test for Homogeneity [3]	0.4685	0.6709	

AMNOG Table SE20.4.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	3 (100)	8 (100)	14 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (25.0)	0
No	3 (100)	6 (75.0)	14 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.09	
95% CI of the inverse odds ratio	NE	(0.00, 2.14)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.12	
95% CI of the inverse risk ratio	NE	(0.01, 2.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	24.44	
95% CI of the absolute risk difference	NE	(-6.20, 55.08)	
p-value	NE	0.0796	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.0824	

AMNOG Table SE20.4.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	3 (100)	8 (100)	14 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (12.5)	1 (7.1)
No	3 (100)	7 (87.5)	13 (92.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	0.54	
95% CI of the inverse odds ratio	(0.03, 23.53)	(0.03, 9.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	0.57	
95% CI of the inverse risk ratio	(0.04, 16.14)	(0.04, 7.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.50	5.36	
95% CI of the absolute risk difference	(-33.29, 38.29)	(-21.24, 31.95)	
p-value	0.8849	0.6742	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE20.4.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	3 (21.4)
No	3 (100)	8 (100)	11 (78.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.13	5.17	
95% CI of the inverse odds ratio	(0.09, 52.04)	(0.23, 114.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.87	4.20	
95% CI of the inverse risk ratio	(0.12, 29.21)	(0.24, 72.29)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.83	-17.78	
95% CI of the absolute risk difference	(-49.67, 28.01)	(-43.89, 8.34)	
p-value	0.6368	0.2579	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (25.0)	4 (28.6)
No	3 (100)	6 (75.0)	10 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	1.20	
95% CI of the inverse odds ratio	(0.13, 70.87)	(0.17, 8.66)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.40	1.14	
95% CI of the inverse risk ratio	(0.16, 35.91)	(0.27, 4.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-17.50	-3.57	
95% CI of the absolute risk difference	(-57.35, 22.35)	(-41.79, 34.64)	
p-value	0.4800	0.8564	
p-value of Breslow-Day Test for Homogeneity [3]	0.3463	0.1472	

AMNOG Table SE20.4.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (33.3)	0	1 (7.1)
No	2 (66.7)	8 (100)	13 (92.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.15	1.89	
95% CI of the inverse odds ratio	(0.01, 3.58)	(0.07, 51.92)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.21	1.80	
95% CI of the inverse risk ratio	(0.02, 2.55)	(0.08, 39.64)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	26.19	-4.44	
95% CI of the absolute risk difference	(-28.83, 81.21)	(-25.76, 16.87)	
p-value	0.2014	0.7029	
p-value of Breslow-Day Test for Homogeneity [3]	0.6748	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (33.3)	2 (25.0)	1 (7.1)
No	2 (66.7)	6 (75.0)	13 (92.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.15	0.23	
95% CI of the inverse odds ratio	(0.01, 3.58)	(0.02, 3.07)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.21	0.29	
95% CI of the inverse risk ratio	(0.02, 2.55)	(0.03, 2.68)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	26.19	17.86	
95% CI of the absolute risk difference	(-28.83, 81.21)	(-15.04, 50.76)	
p-value	0.2014	0.2404	
p-value of Breslow-Day Test for Homogeneity [3]	0.4062	0.1279	

AMNOG Table SE20.4.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (12.5)	2 (14.3)
No	3 (100)	7 (87.5)	12 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	1.17	
95% CI of the inverse odds ratio	(0.05, 36.45)	(0.09, 15.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	1.14	
95% CI of the inverse risk ratio	(0.08, 22.57)	(0.12, 10.71)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.17	-1.79	
95% CI of the absolute risk difference	(-41.66, 33.33)	(-31.13, 27.56)	
p-value	0.8391	0.9065	
p-value of Breslow-Day Test for Homogeneity [3]	0.5603	0.2794	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (33.3)	2 (25.0)	3 (21.4)
No	2 (66.7)	6 (75.0)	11 (78.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.55	0.82	
95% CI of the inverse odds ratio	(0.04, 8.27)	(0.11, 6.34)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.64	0.86	
95% CI of the inverse risk ratio	(0.10, 4.25)	(0.18, 4.10)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.90	3.57	
95% CI of the absolute risk difference	(-45.61, 69.42)	(-33.34, 40.48)	
p-value	0.6591	0.8475	
p-value of Breslow-Day Test for Homogeneity [3]	0.6240	0.2048	

AMNOG Table SE20.4.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (12.5)	0
No	3 (100)	7 (87.5)	14 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.17	
95% CI of the inverse odds ratio	NE	(0.01, 4.77)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.20	
95% CI of the inverse risk ratio	NE	(0.01, 4.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	13.33	
95% CI of the absolute risk difference	NE	(-12.65, 39.32)	
p-value	NE	0.2526	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (33.3)	1 (12.5)	1 (7.1)
No	2 (66.7)	7 (87.5)	13 (92.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.15	0.54	
95% CI of the inverse odds ratio	(0.01, 3.58)	(0.03, 9.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.21	0.57	
95% CI of the inverse risk ratio	(0.02, 2.55)	(0.04, 7.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	26.19	5.36	
95% CI of the absolute risk difference	(-28.83, 81.21)	(-21.24, 31.95)	
p-value	0.2014	0.6742	
p-value of Breslow-Day Test for Homogeneity [3]	0.1128	0.7553	

AMNOG Table SE20.4.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	6 (100)	7 (100)	14 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (16.7)	0	3 (21.4)
No	5 (83.3)	7 (100)	11 (78.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	4.57	
95% CI of the inverse odds ratio	(0.11, 16.58)	(0.21, 101.61)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	3.73	
95% CI of the inverse risk ratio	(0.17, 10.00)	(0.22, 63.66)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.76	-17.08	
95% CI of the absolute risk difference	(-41.52, 32.00)	(-44.28, 10.11)	
p-value	0.8073	0.3033	
p-value of Breslow-Day Test for Homogeneity [3]	0.5603	0.2794	

AMNOG Table SE20.4.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (14.3)
No	6 (100)	7 (100)	12 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.60	3.00	
95% CI of the inverse odds ratio	(0.11, 62.57)	(0.13, 71.31)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.33	2.67	
95% CI of the inverse risk ratio	(0.13, 42.44)	(0.14, 49.08)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.52	-10.42	
95% CI of the absolute risk difference	(-36.35, 17.30)	(-35.66, 14.82)	
p-value	0.5443	0.4799	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.2534	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	5 (35.7)
No	6 (100)	7 (100)	9 (64.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	7.53	8.68	
95% CI of the inverse odds ratio	(0.35, 160.86)	(0.41, 183.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.13	5.87	
95% CI of the inverse risk ratio	(0.33, 80.50)	(0.37, 93.15)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-29.52	-30.42	
95% CI of the absolute risk difference	(-60.49, 1.44)	(-60.02, -0.82)	
p-value	0.1475	0.1136	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.1946	

AMNOG Table SE20.4.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (7.1)
No	6 (100)	7 (100)	13 (92.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.44	1.67	
95% CI of the inverse odds ratio	(0.05, 40.54)	(0.06, 46.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	1.60	
95% CI of the inverse risk ratio	(0.06, 30.23)	(0.07, 34.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.86	-3.75	
95% CI of the absolute risk difference	(-27.24, 21.52)	(-26.37, 18.87)	
p-value	0.8281	0.7611	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (16.7)	1 (14.3)	3 (21.4)
No	5 (83.3)	6 (85.7)	11 (78.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	1.64	
95% CI of the inverse odds ratio	(0.11, 16.58)	(0.14, 19.39)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	1.50	
95% CI of the inverse risk ratio	(0.17, 10.00)	(0.19, 11.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.76	-7.14	
95% CI of the absolute risk difference	(-41.52, 32.00)	(-40.82, 26.53)	
p-value	0.8073	0.6944	
p-value of Breslow-Day Test for Homogeneity [3]	0.6857	0.5593	

AMNOG Table SE20.4.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	6 (100)	7 (100)	14 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (16.7)	1 (14.3)	3 (21.4)
No	5 (83.3)	6 (85.7)	11 (78.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	1.64	
95% CI of the inverse odds ratio	(0.11, 16.58)	(0.14, 19.39)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	1.50	
95% CI of the inverse risk ratio	(0.17, 10.00)	(0.19, 11.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.76	-7.14	
95% CI of the absolute risk difference	(-41.52, 32.00)	(-40.82, 26.53)	
p-value	0.8073	0.6944	
p-value of Breslow-Day Test for Homogeneity [3]	0.4685	0.6709	

AMNOG Table SE20.4.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (7.1)
No	6 (100)	7 (100)	13 (92.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.44	1.67	
95% CI of the inverse odds ratio	(0.05, 40.54)	(0.06, 46.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	1.60	
95% CI of the inverse risk ratio	(0.06, 30.23)	(0.07, 34.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.86	-3.75	
95% CI of the absolute risk difference	(-27.24, 21.52)	(-26.37, 18.87)	
p-value	0.8281	0.7611	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (33.3)	1 (14.3)	3 (21.4)
No	4 (66.7)	6 (85.7)	11 (78.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.55	1.64	
95% CI of the inverse odds ratio	(0.07, 4.56)	(0.14, 19.39)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.64	1.50	
95% CI of the inverse risk ratio	(0.14, 2.92)	(0.19, 11.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.90	-7.14	
95% CI of the absolute risk difference	(-31.51, 55.32)	(-40.82, 26.53)	
p-value	0.5731	0.6944	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.0824	

AMNOG Table SE20.4.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	6 (100)	7 (100)	14 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	6 (100)	7 (100)	14 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE20.4.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (14.3)
No	6 (100)	7 (100)	12 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.60	3.00	
95% CI of the inverse odds ratio	(0.11, 62.57)	(0.13, 71.31)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.33	2.67	
95% CI of the inverse risk ratio	(0.13, 42.44)	(0.14, 49.08)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.52	-10.42	
95% CI of the absolute risk difference	(-36.35, 17.30)	(-35.66, 14.82)	
p-value	0.5443	0.4799	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (33.3)	0	5 (35.7)
No	4 (66.7)	7 (100)	9 (64.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	8.68	
95% CI of the inverse odds ratio	(0.15, 8.37)	(0.41, 183.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	5.87	
95% CI of the inverse risk ratio	(0.28, 4.06)	(0.37, 93.15)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.38	-30.42	
95% CI of the absolute risk difference	(-47.69, 42.93)	(-60.02, -0.82)	
p-value	0.9185	0.1136	
p-value of Breslow-Day Test for Homogeneity [3]	0.3463	0.1472	

AMNOG Table SE20.4.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (16.7)	0	1 (7.1)
No	5 (83.3)	7 (100)	13 (92.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.38	1.67	
95% CI of the inverse odds ratio	(0.02, 7.40)	(0.06, 46.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.43	1.60	
95% CI of the inverse risk ratio	(0.03, 5.78)	(0.07, 34.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	9.52	-3.75	
95% CI of the absolute risk difference	(-23.21, 42.25)	(-26.37, 18.87)	
p-value	0.5153	0.7611	
p-value of Breslow-Day Test for Homogeneity [3]	0.6748	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (16.7)	0	2 (14.3)
No	5 (83.3)	7 (100)	12 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	3.00	
95% CI of the inverse odds ratio	(0.06, 11.42)	(0.13, 71.31)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	2.67	
95% CI of the inverse risk ratio	(0.09, 7.75)	(0.14, 49.08)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.38	-10.42	
95% CI of the absolute risk difference	(-32.62, 37.38)	(-35.66, 14.82)	
p-value	0.8913	0.4799	
p-value of Breslow-Day Test for Homogeneity [3]	0.4062	0.1279	

AMNOG Table SE20.4.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (16.7)	0	3 (21.4)
No	5 (83.3)	7 (100)	11 (78.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	4.57	
95% CI of the inverse odds ratio	(0.11, 16.58)	(0.21, 101.61)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	3.73	
95% CI of the inverse risk ratio	(0.17, 10.00)	(0.22, 63.66)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.76	-17.08	
95% CI of the absolute risk difference	(-41.52, 32.00)	(-44.28, 10.11)	
p-value	0.8073	0.3033	
p-value of Breslow-Day Test for Homogeneity [3]	0.5603	0.2794	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (16.7)	0	3 (21.4)
No	5 (83.3)	7 (100)	11 (78.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	4.57	
95% CI of the inverse odds ratio	(0.11, 16.58)	(0.21, 101.61)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	3.73	
95% CI of the inverse risk ratio	(0.17, 10.00)	(0.22, 63.66)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.76	-17.08	
95% CI of the absolute risk difference	(-41.52, 32.00)	(-44.28, 10.11)	
p-value	0.8073	0.3033	
p-value of Breslow-Day Test for Homogeneity [3]	0.6240	0.2048	

AMNOG Table SE20.4.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (14.3)	0
No	6 (100)	6 (85.7)	14 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.15	
95% CI of the inverse odds ratio	NE	(0.01, 4.18)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.18	
95% CI of the inverse risk ratio	NE	(0.01, 3.88)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	15.42	
95% CI of the absolute risk difference	NE	(-13.11, 43.95)	
p-value	NE	0.2114	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (14.3)	2 (14.3)
No	6 (100)	6 (85.7)	12 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.60	1.00	
95% CI of the inverse odds ratio	(0.11, 62.57)	(0.07, 13.37)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.33	1.00	
95% CI of the inverse risk ratio	(0.13, 42.44)	(0.11, 9.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.52	0.00	
95% CI of the absolute risk difference	(-36.35, 17.30)	(-31.75, 31.75)	
p-value	0.5443	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.1128	0.7553	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.5.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Visit Statistic	Visit Result DB MGL-3196 80 mg (N=4)	 DB MGL-3196 100 mg (N=6)	 DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	 DB MGL-3196 100 mg (N=6)	 DB Placebo (N=11)
Total LDQOL						
Baseline						
m	4	6	11			
n	4	5	10			
Mean (SD)	73.15 (15.99)	90.42 (2.78)	84.09 (10.18)			
Median	70.65	89.60	85.20			
IQR: Q1, Q3	61.05, 85.25	89.30, 92.80	76.70, 92.10			
Min, Max	57.3, 94.0	86.8, 93.6	64.4, 97.8			
Week 24						
m	3	4	11			
n	3	4	10	3	4	10
Mean (SD/SE)	75.40 (13.77)	87.10 (10.57)	81.80 (14.06)	3.37 (3.74)	-3.60 (3.94)	-2.29 (2.22)
Median	73.30	86.05	83.15	5.50	-4.95	-0.60
IQR: Q1, Q3	62.80, 90.10	78.20, 96.00	80.00, 94.10	-3.90, 8.50	-10.00, 2.80	-9.60, 1.40
Min, Max	62.8, 90.1	77.4, 98.9	52.0, 98.1	-3.9, 8.5	-10.6, 6.1	-12.4, 7.2
Week 52						
m	3	4	11			
n	2	3	9	2	3	9
Mean (SD/SE)	66.40 (37.34)	89.30 (4.13)	81.42 (16.10)	-9.25 (8.05)	-1.77 (1.23)	-3.28 (4.87)
Median	66.40	88.70	86.10	-9.25	-1.30	0.70
IQR: Q1, Q3	40.00, 92.80	85.50, 93.70	81.80, 92.50	-17.30, -1.20	-4.10, 0.10	-2.90, 5.50
Min, Max	40.0, 92.8	85.5, 93.7	51.7, 98.1	-17.3, -1.2	-4.1, 0.1	-40.4, 7.2

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.5.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=6)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=6)	Change from Baseline DB Placebo (N=11)
Symptoms of Liver Disease						
Baseline						
m	4	6	11			
n	4	5	10			
Mean (SD)	78.35 (18.59)	88.00 (8.69)	87.67 (13.53)			
Median	81.70	86.70	90.00			
IQR: Q1, Q3	65.00, 91.70	80.00, 93.30	83.30, 100.00			
Min, Max	53.3, 96.7	80.0, 100.0	60.0, 100.0			
Week 24						
m	3	4	11			
n	3	4	10	3	4	10
Mean (SD/SE)	82.23 (13.49)	85.00 (14.00)	87.33 (10.52)	6.67 (5.11)	-3.33 (11.13)	-0.34 (4.05)
Median	80.00	86.65	85.00	3.30	0	1.65
IQR: Q1, Q3	70.00, 96.70	75.00, 95.00	80.00, 100.00	0.00, 16.70	-18.30, 11.65	-13.30, 10.00
Min, Max	70.0, 96.7	66.7, 100.0	70.0, 100.0	0.0, 16.7	-33.3, 20.0	-20.0, 20.0
Week 52						
m	3	4	11			
n	2	3	9	2	3	9
Mean (SD/SE)	73.35 (23.55)	88.87 (5.10)	88.51 (13.96)	-13.35 (6.65)	4.43 (4.83)	-1.12 (5.22)
Median	73.35	90.00	93.30	-13.35	3.30	3.30
IQR: Q1, Q3	56.70, 90.00	83.30, 93.30	76.70, 100.00	-20.00, -6.70	-3.30, 13.30	0.00, 6.70
Min, Max	56.7, 90.0	83.3, 93.3	63.3, 100.0	-20.0, -6.7	-3.3, 13.3	-36.7, 16.7

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.5.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=4)	(N=6)	(N=11)	(N=4)	(N=6)	(N=11)
Effects of Liver Disease						
Baseline						
m	4	6	11			
n	4	5	10			
Mean (SD)	56.68 (20.74)	86.68 (8.16)	80.67 (7.33)			
Median	56.70	86.70	80.00			
IQR: Q1, Q3	40.00, 73.35	80.00, 86.70	80.00, 86.70			
Min, Max	33.3, 80.0	80.0, 100.0	66.7, 93.3			
Week 24						
m	3	4	11			
n	3	4	10	3	4	10
Mean (SD/SE)	80.00 (0.00)	83.33 (11.56)	80.68 (11.09)	26.67 (13.88)	-3.35 (8.39)	0.01 (3.14)
Median	80.00	80.00	80.00	33.30	-6.70	0
IQR: Q1, Q3	80.00, 80.00	76.65, 90.00	80.00, 86.70	0.00, 46.70	-13.35, 6.65	-6.70, 6.70
Min, Max	80.0, 80.0	73.3, 100.0	60.0, 100.0	0.0, 46.7	-20.0, 20.0	-13.3, 20.0
Week 52						
m	3	4	11			
n	2	3	9	2	3	9
Mean (SD/SE)	50.00 (42.43)	80.00 (0.00)	80.76 (10.24)	-13.35 (13.35)	-8.90 (5.88)	1.49 (3.81)
Median	50.00	80.00	80.00	-13.35	-6.70	0
IQR: Q1, Q3	20.00, 80.00	80.00, 80.00	80.00, 86.70	-26.70, 0.00	-20.00, 0.00	0.00, 6.70
Min, Max	20.0, 80.0	80.0, 80.0	66.7, 100.0	-26.7, 0.0	-20.0, 0.0	-20.0, 20.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.5.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=6)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=6)	Change from Baseline DB Placebo (N=11)
Concentration/Memory						
Baseline						
m	4	6	11			
n	4	5	10			
Mean (SD)	75.03 (29.29)	93.76 (8.82)	86.89 (19.42)			
Median	78.15	100.00	93.80			
IQR: Q1, Q3	50.05, 100.00	87.50, 100.00	81.30, 100.00			
Min, Max	43.8, 100.0	81.3, 100.0	37.5, 100.0			
Week 24						
m	3	4	11			
n	3	4	10	3	4	10
Mean (SD/SE)	70.87 (25.25)	90.65 (10.80)	88.76 (13.43)	-10.40 (7.52)	-4.68 (4.68)	1.87 (5.90)
Median	75.00	90.65	90.65	-6.20	0	3.10
IQR: Q1, Q3	43.80, 93.80	81.30, 100.00	87.50, 100.00	-25.00, 0.00	-9.35, 0.00	-6.30, 12.50
Min, Max	43.8, 93.8	81.3, 100.0	62.5, 100.0	-25.0, 0.0	-18.7, 0.0	-37.5, 31.3
Week 52						
m	3	4	11			
n	2	3	9	2	3	9
Mean (SD/SE)	43.75 (61.87)	87.50 (12.50)	84.73 (22.98)	-28.15 (15.65)	-12.50 (7.22)	-3.48 (6.26)
Median	43.75	87.50	100.00	-28.15	-12.50	0
IQR: Q1, Q3	0.00, 87.50	75.00, 100.00	75.00, 100.00	-43.80, -12.50	-25.00, 0.00	-6.20, 6.20
Min, Max	0.0, 87.5	75.0, 100.0	43.8, 100.0	-43.8, -12.5	-25.0, 0.0	-50.0, 12.5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.5.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Visit Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=6)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=6)	Change from Baseline DB Placebo (N=11)
Health Distress						
Baseline						
m	4	6	11			
n	4	5	10			
Mean (SD)	59.38 (42.54)	95.00 (6.85)	87.50 (17.68)			
Median	68.75	100.00	100.00			
IQR: Q1, Q3	31.25, 87.50	87.50, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	87.5, 100.0	50.0, 100.0			
Week 24						
m	3	4	11			
n	3	4	10	3	4	10
Mean (SD/SE)	66.67 (57.74)	90.63 (11.97)	82.50 (17.87)	8.33 (8.33)	-3.13 (7.86)	-5.00 (5.95)
Median	100.00	93.75	81.25	0	0	-6.25
IQR: Q1, Q3	0.00, 100.00	81.25, 100.00	75.00, 100.00	0.00, 25.00	-12.50, 6.25	-25.00, 0.00
Min, Max	0.0, 100.0	75.0, 100.0	50.0, 100.0	0.0, 25.0	-25.0, 12.5	-25.0, 25.0
Week 52						
m	3	4	11			
n	2	3	9	2	3	9
Mean (SD/SE)	50.00 (70.71)	91.67 (14.43)	80.56 (23.48)	0.00 (0.00)	0.00 (12.50)	-8.33 (8.59)
Median	50.00	100.00	87.50	0	12.50	0
IQR: Q1, Q3	0.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 0.00	-25.00, 12.50	-25.00, 0.00
Min, Max	0.0, 100.0	75.0, 100.0	37.5, 100.0	0.0, 0.0	-25.0, 12.5	-62.5, 25.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.5.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=6)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=6)	Change from Baseline DB Placebo (N=11)
Sexual Function						
Baseline						
m	4	6	11			
n	1	4	7			
Mean (SD)	91.70 (N/A)	96.25 (7.50)	90.24 (8.57)			
Median	91.70	100.00	91.70			
IQR: Q1, Q3	91.70, 91.70	92.50, 100.00	85.00, 100.00			
Min, Max	91.7, 91.7	85.0, 100.0	76.7, 100.0			
Week 24						
m	3	4	11			
n	0	3	5	0	3	5
Mean (SD/SE)	N/A	86.67 (23.09)	92.32 (7.97)	N/A	-8.33 (8.33)	1.64 (1.28)
Median	N/A	100.00	93.30	N/A	0	0
IQR: Q1, Q3	N/A	60.00, 100.00	85.00, 100.00	N/A	-25.00, 0.00	0.00, 1.60
Min, Max	N/A	60.0, 100.0	83.3, 100.0	N/A	-25.0, 0.0	0.0, 6.6
Week 52						
m	3	4	11			
n	0	2	5	0	2	4
Mean (SD/SE)	N/A	100.00 (0.00)	90.66 (14.09)	N/A	0.00 (0.00)	-6.25 (4.00)
Median	N/A	100.00	100.00	N/A	0	-4.15
IQR: Q1, Q3	N/A	100.00, 100.00	85.00, 100.00	N/A	0.00, 0.00	-12.50, 0.00
Min, Max	N/A	100.0, 100.0	68.3, 100.0	N/A	0.0, 0.0	-16.7, 0.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.5.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=6)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=6)	Change from Baseline DB Placebo (N=11)
Sleep						
Baseline						
m	4	6	11			
n	4	5	10			
Mean (SD)	48.8 (38.4)	74.0 (11.9)	66.0 (23.1)			
Median	52.5	75.0	60.0			
IQR: Q1, Q3	20.0, 77.5	65.0, 80.0	55.0, 90.0			
Min, Max	0, 90	60, 90	30, 100			
Week 24						
m	3	4	11			
n	3	4	10	3	4	10
Mean (SD/SE)	45.0 (39.7)	72.5 (15.5)	67.0 (16.0)	1.7 (10.1)	2.5 (3.2)	1.0 (3.8)
Median	60.0	72.5	62.5	0	2.5	2.5
IQR: Q1, Q3	0.0, 75.0	60.0, 85.0	60.0, 80.0	-15.0, 20.0	-2.5, 7.5	-10.0, 5.0
Min, Max	0, 75	55, 90	45, 90	-15, 20	-5, 10	-20, 20
Week 52						
m	3	4	11			
n	2	3	9	2	3	9
Mean (SD/SE)	57.5 (38.9)	71.7 (10.4)	68.9 (21.8)	-7.5 (2.5)	0.0 (2.9)	-1.1 (5.8)
Median	57.5	75.0	75.0	-7.5	0	0
IQR: Q1, Q3	30.0, 85.0	60.0, 80.0	60.0, 80.0	-10.0, -5.0	-5.0, 5.0	-5.0, 10.0
Min, Max	30, 85	60, 80	35, 95	-10, -5	-5, 5	-35, 20

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.5.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=6)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=6)	Change from Baseline DB Placebo (N=11)
Loneliness						
Baseline						
m	4	6	11			
n	4	5	10			
Mean (SD)	86.3 (2.5)	94.0 (8.2)	91.5 (10.3)			
Median	85.0	95.0	97.5			
IQR: Q1, Q3	85.0, 87.5	95.0, 100.0	80.0, 100.0			
Min, Max	85, 90	80, 100	75, 100			
Week 24						
m	3	4	11			
n	3	4	10	3	4	10
Mean (SD/SE)	83.3 (10.4)	91.3 (8.5)	81.0 (20.9)	-3.3 (4.4)	-6.3 (5.2)	-10.5 (5.2)
Median	80.0	92.5	80.0	-5.0	-5.0	0
IQR: Q1, Q3	75.0, 95.0	85.0, 97.5	70.0, 100.0	-10.0, 5.0	-12.5, 0.0	-20.0, 0.0
Min, Max	75, 95	80, 100	35, 100	-10, 5	-20, 5	-45, 5
Week 52						
m	3	4	11			
n	2	3	9	2	3	9
Mean (SD/SE)	90.0 (14.1)	100.0 (0.0)	83.9 (19.5)	5.0 (10.0)	1.7 (1.7)	-6.7 (5.3)
Median	90.0	100.0	90.0	5.0	0	0
IQR: Q1, Q3	80.0, 100.0	100.0, 100.0	75.0, 100.0	-5.0, 15.0	0.0, 5.0	-10.0, 0.0
Min, Max	80, 100	100, 100	45, 100	-5, 15	0, 5	-35, 15

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.5.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=4)	(N=6)	(N=11)	(N=4)	(N=6)	(N=11)
Hopelessness						
Baseline						
m	4	6	11			
n	4	5	10			
Mean (SD)	89.60 (10.49)	96.68 (4.55)	80.00 (24.60)			
Median	91.70	100.00	87.50			
IQR: Q1, Q3	83.35, 95.85	91.70, 100.00	75.00, 100.00			
Min, Max	75.0, 100.0	91.7, 100.0	33.3, 100.0			
Week 24						
m	3	4	11			
n	3	4	10	3	4	10
Mean (SD/SE)	83.33 (16.65)	95.83 (8.35)	83.33 (29.66)	-11.13 (7.35)	-2.10 (2.10)	3.33 (4.69)
Median	83.30	100.00	100.00	-8.40	0	0
IQR: Q1, Q3	66.70, 100.00	91.65, 100.00	75.00, 100.00	-25.00, 0.00	-4.20, 0.00	0.00, 16.70
Min, Max	66.7, 100.0	83.3, 100.0	25.0, 100.0	-25.0, 0.0	-8.4, 0.0	-16.7, 25.0
Week 52						
m	3	4	11			
n	2	3	9	2	3	9
Mean (SD/SE)	91.65 (11.81)	97.23 (4.79)	84.26 (23.74)	-4.20 (4.20)	0.00 (0.00)	6.48 (6.03)
Median	91.65	100.00	100.00	-4.20	0	8.30
IQR: Q1, Q3	83.30, 100.00	91.70, 100.00	58.30, 100.00	-8.40, 0.00	0.00, 0.00	0.00, 16.70
Min, Max	83.3, 100.0	91.7, 100.0	50.0, 100.0	-8.4, 0.0	0.0, 0.0	-33.4, 25.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.5.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=4)	(N=6)	(N=11)	(N=4)	(N=6)	(N=11)
Stigma of Liver Disease						
Baseline						
m	4	6	11			
n	4	5	10			
Mean (SD)	87.50 (14.43)	91.26 (12.17)	88.77 (15.53)			
Median	87.50	100.00	93.80			
IQR: Q1, Q3	75.00, 100.00	81.30, 100.00	81.30, 100.00			
Min, Max	75.0, 100.0	75.0, 100.0	50.0, 100.0			
Week 24						
m	3	4	11			
n	3	4	10	3	4	10
Mean (SD/SE)	91.67 (14.43)	90.63 (18.75)	78.14 (30.09)	8.33 (8.33)	-3.13 (3.13)	-10.63 (4.94)
Median	100.00	100.00	84.40	0	0	-6.25
IQR: Q1, Q3	75.00, 100.00	81.25, 100.00	75.00, 100.00	0.00, 25.00	-6.25, 0.00	-12.50, 0.00
Min, Max	75.0, 100.0	62.5, 100.0	0.0, 100.0	0.0, 25.0	-12.5, 0.0	-50.0, 0.0
Week 52						
m	3	4	11			
n	2	3	9	2	3	9
Mean (SD/SE)	75.00 (35.36)	91.67 (14.43)	79.89 (22.05)	-12.50 (12.50)	0.00 (0.00)	-9.02 (7.73)
Median	75.00	100.00	93.80	-12.50	0	0
IQR: Q1, Q3	50.00, 100.00	75.00, 100.00	62.50, 93.80	-25.00, 0.00	0.00, 0.00	-12.50, 0.00
Min, Max	50.0, 100.0	75.0, 100.0	43.8, 100.0	-25.0, 0.0	0.0, 0.0	-56.2, 12.5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.5.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=5)	Visit Result DB MGL-3196 100 mg (N=9)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=5)	Change from Baseline DB MGL-3196 100 mg (N=9)	Change from Baseline DB Placebo (N=17)
Total LDQOL						
Baseline						
m	5	9	17			
n	5	9	16			
Mean (SD)	87.78 (8.80)	85.12 (6.78)	87.77 (6.21)			
Median	91.30	88.40	87.30			
IQR: Q1, Q3	88.80, 92.50	78.60, 89.40	82.50, 93.30			
Min, Max	72.4, 93.9	75.2, 94.8	76.3, 97.0			
Week 24						
m	5	8	16			
n	4	7	15	4	7	14
Mean (SD/SE)	87.38 (8.85)	83.36 (7.38)	85.79 (8.87)	-0.15 (0.88)	-2.71 (3.46)	-1.73 (2.09)
Median	91.15	81.80	88.30	-0.10	-0.40	-0.80
IQR: Q1, Q3	82.25, 92.50	77.80, 88.40	80.40, 94.10	-1.55, 1.25	-7.60, 4.50	-6.10, 1.70
Min, Max	74.2, 93.0	75.0, 97.1	68.1, 97.1	-2.2, 1.8	-19.8, 6.8	-17.6, 13.3
Week 52						
m	5	8	15			
n	5	7	15	5	7	14
Mean (SD/SE)	88.64 (5.72)	82.56 (4.72)	84.57 (9.11)	0.86 (1.81)	-3.51 (2.82)	-2.90 (1.75)
Median	88.50	83.20	85.30	0.70	-2.90	-1.25
IQR: Q1, Q3	88.30, 92.00	79.00, 86.50	78.80, 93.60	-0.50, 0.90	-7.60, 0.40	-8.70, 0.50
Min, Max	79.6, 94.8	75.6, 88.3	67.6, 95.5	-4.0, 7.2	-15.6, 8.7	-14.5, 6.9

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.5.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=5)	(N=9)	(N=17)	(N=5)	(N=9)	(N=17)
Symptoms of Liver Disease						
Baseline						
m	5	9	17			
n	5	9	16			
Mean (SD)	92.00 (7.68)	80.73 (15.53)	80.41 (15.59)			
Median	93.30	83.30	86.70			
IQR: Q1, Q3	90.00, 96.70	80.00, 90.00	66.65, 93.30			
Min, Max	80.0, 100.0	53.3, 96.7	50.0, 96.7			
Week 24						
m	5	8	16			
n	4	7	15	4	7	14
Mean (SD/SE)	88.33 (17.34)	90.96 (4.59)	79.11 (17.58)	-3.35 (4.52)	7.16 (5.22)	1.19 (6.01)
Median	95.00	90.00	83.30	0	3.40	1.70
IQR: Q1, Q3	76.65, 100.00	86.70, 93.30	70.00, 93.30	-8.35, 1.65	0.00, 6.70	-6.70, 10.00
Min, Max	63.3, 100.0	86.7, 100.0	36.7, 96.7	-16.7, 3.3	-6.7, 36.7	-60.0, 40.0
Week 52						
m	5	8	15			
n	5	7	15	5	7	14
Mean (SD/SE)	90.66 (7.94)	79.06 (15.59)	83.11 (12.62)	-1.34 (1.33)	-4.74 (5.29)	5.00 (2.66)
Median	93.30	76.70	83.30	-3.30	-6.70	4.95
IQR: Q1, Q3	93.30, 93.30	66.70, 96.70	70.00, 93.30	-3.30, 0.00	-20.00, 3.40	0.00, 6.70
Min, Max	76.7, 96.7	56.7, 100.0	56.7, 100.0	-3.4, 3.3	-23.3, 16.7	-6.7, 30.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.5.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=5)	(N=9)	(N=17)	(N=5)	(N=9)	(N=17)
Effects of Liver Disease						
Baseline						
m	5	9	17			
n	5	9	16			
Mean (SD)	85.34 (8.69)	85.19 (9.30)	81.67 (5.72)			
Median	80.00	80.00	80.00			
IQR: Q1, Q3	80.00, 86.70	80.00, 86.70	80.00, 80.00			
Min, Max	80.0, 100.0	73.3, 100.0	73.3, 100.0			
Week 24						
m	5	8	16			
n	4	7	15	4	7	14
Mean (SD/SE)	80.00 (0.00)	83.80 (9.32)	78.22 (5.90)	-5.00 (5.00)	-2.87 (3.81)	-4.29 (2.85)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	80.00, 80.00	80.00, 93.30	80.00, 80.00	-10.00, 0.00	-6.70, 0.00	-6.70, 0.00
Min, Max	80.0, 80.0	73.3, 100.0	60.0, 86.7	-20.0, 0.0	-20.0, 13.3	-40.0, 0.0
Week 52						
m	5	8	15			
n	5	7	15	5	7	14
Mean (SD/SE)	82.66 (5.95)	82.86 (8.49)	80.89 (4.27)	-2.68 (5.41)	-3.81 (4.56)	-1.44 (2.23)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	80.00, 80.00	80.00, 86.70	80.00, 80.00	-6.70, 0.00	-20.00, 0.00	0.00, 0.00
Min, Max	80.0, 93.3	73.3, 100.0	73.3, 93.3	-20.0, 13.3	-20.0, 13.3	-26.7, 13.3

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.5.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=5)	Visit Result DB MGL-3196 100 mg (N=9)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=5)	Change from Baseline DB MGL-3196 100 mg (N=9)	Change from Baseline DB Placebo (N=17)
Concentration/Memory						
Baseline						
m	5	9	17			
n	5	9	16			
Mean (SD)	87.50 (15.31)	77.80 (24.02)	91.03 (9.93)			
Median	87.50	93.80	90.65			
IQR: Q1, Q3	87.50, 100.00	56.30, 100.00	87.50, 100.00			
Min, Max	62.5, 100.0	43.8, 100.0	68.8, 100.0			
Week 24						
m	5	8	16			
n	4	7	15	4	7	14
Mean (SD/SE)	85.95 (24.14)	82.16 (19.24)	86.69 (13.93)	-1.55 (3.94)	3.56 (5.26)	-2.22 (3.80)
Median	96.90	87.50	87.50	0	0	0
IQR: Q1, Q3	71.90, 100.00	62.50, 100.00	68.80, 100.00	-6.25, 3.15	-6.30, 6.20	-12.50, 6.30
Min, Max	50.0, 100.0	50.0, 100.0	62.5, 100.0	-12.5, 6.3	-12.5, 31.3	-31.2, 18.7
Week 52						
m	5	8	15			
n	5	7	15	5	7	14
Mean (SD/SE)	86.26 (14.24)	83.94 (20.35)	82.53 (17.07)	-1.24 (3.07)	5.34 (3.96)	-7.56 (4.20)
Median	87.50	87.50	87.50	0	0	-6.20
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 93.80	0.00, 0.00	0.00, 12.50	-18.70, 0.00
Min, Max	68.8, 100.0	43.8, 100.0	43.8, 100.0	-12.5, 6.3	-6.3, 25.0	-43.7, 12.5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.5.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=5)	Visit Result DB MGL-3196 100 mg (N=9)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=5)	Change from Baseline DB MGL-3196 100 mg (N=9)	Change from Baseline DB Placebo (N=17)
Health Distress						
Baseline						
m	5	9	17			
n	5	9	16			
Mean (SD)	92.50 (11.18)	97.22 (5.51)	99.22 (3.13)			
Median	100.00	100.00	100.00			
IQR: Q1, Q3	87.50, 100.00	100.00, 100.00	100.00, 100.00			
Min, Max	75.0, 100.0	87.5, 100.0	87.5, 100.0			
Week 24						
m	5	8	16			
n	4	7	15	4	7	14
Mean (SD/SE)	93.75 (7.22)	98.21 (4.72)	98.33 (4.40)	3.13 (3.13)	0.00 (2.73)	-0.89 (1.59)
Median	93.75	100.00	100.00	0	0	0
IQR: Q1, Q3	87.50, 100.00	100.00, 100.00	100.00, 100.00	0.00, 6.25	0.00, 0.00	0.00, 0.00
Min, Max	87.5, 100.0	87.5, 100.0	87.5, 100.0	0.0, 12.5	-12.5, 12.5	-12.5, 12.5
Week 52						
m	5	8	15			
n	5	7	15	5	7	14
Mean (SD/SE)	97.50 (5.59)	96.43 (9.45)	96.67 (5.72)	5.00 (3.06)	-1.79 (4.25)	-2.68 (1.93)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	100.00, 100.00	100.00, 100.00	87.50, 100.00	0.00, 12.50	0.00, 0.00	-12.50, 0.00
Min, Max	87.5, 100.0	75.0, 100.0	87.5, 100.0	0.0, 12.5	-25.0, 12.5	-12.5, 12.5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.5.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=5)	Visit Result DB MGL-3196 100 mg (N=9)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=5)	Change from Baseline DB MGL-3196 100 mg (N=9)	Change from Baseline DB Placebo (N=17)
Sexual Function						
Baseline						
m	5	9	17			
n	3	2	6			
Mean (SD)	92.20 (8.40)	92.50 (10.61)	89.98 (13.55)			
Median	93.30	92.50	96.65			
IQR: Q1, Q3	83.30, 100.00	85.00, 100.00	78.30, 100.00			
Min, Max	83.3, 100.0	85.0, 100.0	68.3, 100.0			
Week 24						
m	5	8	16			
n	2	2	5	2	2	4
Mean (SD/SE)	80.85 (15.34)	89.15 (5.87)	88.00 (23.27)	-15.80 (7.50)	-3.35 (3.35)	-6.23 (8.60)
Median	80.85	89.15	100.00	-15.80	-3.35	0
IQR: Q1, Q3	70.00, 91.70	85.00, 93.30	93.30, 100.00	-23.30, -8.30	-6.70, 0.00	-15.80, 3.35
Min, Max	70.0, 91.7	85.0, 93.3	46.7, 100.0	-23.3, -8.3	-6.7, 0.0	-31.6, 6.7
Week 52						
m	5	8	15			
n	2	2	6	2	2	4
Mean (SD/SE)	92.50 (10.61)	93.30 (0.00)	69.43 (39.93)	-4.15 (4.15)	0.80 (7.50)	-14.15 (16.46)
Median	92.50	93.30	89.15	-4.15	0.80	0
IQR: Q1, Q3	85.00, 100.00	93.30, 93.30	23.30, 100.00	-8.30, 0.00	-6.70, 8.30	-31.65, 3.35
Min, Max	85.0, 100.0	93.3, 93.3	15.0, 100.0	-8.3, 0.0	-6.7, 8.3	-63.3, 6.7

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.5.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=5)	(N=9)	(N=17)	(N=5)	(N=9)	(N=17)
Sleep						
Baseline						
m	5	9	17			
n	5	9	16			
Mean (SD)	70.0 (11.7)	71.7 (9.0)	69.4 (21.5)			
Median	75.0	70.0	75.0			
IQR: Q1, Q3	70.0, 75.0	65.0, 75.0	50.0, 85.0			
Min, Max	50, 80	60, 85	35, 100			
Week 24						
m	5	8	16			
n	4	7	15	4	7	14
Mean (SD/SE)	70.0 (10.0)	62.9 (15.2)	71.7 (17.4)	2.5 (1.4)	-7.9 (4.1)	1.1 (4.0)
Median	75.0	60.0	70.0	2.5	-5.0	2.5
IQR: Q1, Q3	65.0, 75.0	55.0, 70.0	60.0, 85.0	0.0, 5.0	-15.0, 0.0	-10.0, 10.0
Min, Max	55, 75	40, 90	35, 100	0, 5	-25, 5	-30, 30
Week 52						
m	5	8	15			
n	5	7	15	5	7	14
Mean (SD/SE)	68.0 (9.7)	61.4 (9.4)	69.0 (17.1)	-2.0 (3.0)	-9.3 (3.8)	-2.1 (4.9)
Median	65.0	60.0	65.0	-5.0	-10.0	0
IQR: Q1, Q3	65.0, 75.0	50.0, 70.0	55.0, 85.0	-5.0, 5.0	-15.0, 0.0	-15.0, 5.0
Min, Max	55, 80	50, 75	40, 95	-10, 5	-25, 5	-30, 35

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.5.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=5)	Visit Result DB MGL-3196 100 mg (N=9)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=5)	Change from Baseline DB MGL-3196 100 mg (N=9)	Change from Baseline DB Placebo (N=17)
Loneliness						
Baseline						
m	5	9	17			
n	5	9	16			
Mean (SD)	92.0 (17.9)	92.2 (16.2)	94.7 (10.2)			
Median	100.0	100.0	100.0			
IQR: Q1, Q3	100.0, 100.0	95.0, 100.0	95.0, 100.0			
Min, Max	60, 100	50, 100	65, 100			
Week 24						
m	5	8	16			
n	4	7	15	4	7	14
Mean (SD/SE)	96.3 (7.5)	85.0 (21.0)	91.7 (14.0)	6.3 (6.3)	-13.6 (8.2)	-2.9 (3.1)
Median	100.0	95.0	100.0	0	0	0
IQR: Q1, Q3	92.5, 100.0	60.0, 100.0	85.0, 100.0	0.0, 12.5	-40.0, 0.0	0.0, 0.0
Min, Max	85, 100	50, 100	60, 100	0, 25	-50, 0	-35, 10
Week 52						
m	5	8	15			
n	5	7	15	5	7	14
Mean (SD/SE)	95.0 (11.2)	85.7 (20.1)	90.7 (13.6)	3.0 (3.0)	-12.9 (8.0)	-3.9 (3.1)
Median	100.0	95.0	100.0	0	0	0
IQR: Q1, Q3	100.0, 100.0	80.0, 100.0	80.0, 100.0	0.0, 0.0	-20.0, 0.0	-10.0, 0.0
Min, Max	75, 100	45, 100	60, 100	0, 15	-55, 5	-30, 20

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.5.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=5)	Visit Result DB MGL-3196 100 mg (N=9)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=5)	Change from Baseline DB MGL-3196 100 mg (N=9)	Change from Baseline DB Placebo (N=17)
Hopelessness						
Baseline						
m	5	9	17			
n	5	9	16			
Mean (SD)	86.68 (15.13)	90.74 (16.38)	93.24 (12.63)			
Median	91.70	100.00	100.00			
IQR: Q1, Q3	75.00, 100.00	91.70, 100.00	91.70, 100.00			
Min, Max	66.7, 100.0	58.3, 100.0	50.0, 100.0			
Week 24						
m	5	8	16			
n	4	7	15	4	7	14
Mean (SD/SE)	97.93 (4.15)	79.76 (23.02)	88.90 (16.56)	8.33 (5.89)	-8.34 (7.04)	-2.97 (2.24)
Median	100.00	91.70	91.70	4.15	0	0
IQR: Q1, Q3	95.85, 100.00	58.30, 100.00	83.30, 100.00	0.00, 16.65	-8.40, 0.00	-8.30, 0.00
Min, Max	91.7, 100.0	50.0, 100.0	41.7, 100.0	0.0, 25.0	-50.0, 0.0	-25.0, 8.3
Week 52						
m	5	8	15			
n	5	7	15	5	7	14
Mean (SD/SE)	95.00 (7.46)	88.10 (15.84)	89.45 (14.25)	8.32 (6.45)	0.00 (6.55)	-3.58 (2.73)
Median	100.00	100.00	91.70	0	0	0
IQR: Q1, Q3	91.70, 100.00	66.70, 100.00	83.30, 100.00	0.00, 8.30	0.00, 8.30	-8.40, 0.00
Min, Max	83.3, 100.0	66.7, 100.0	50.0, 100.0	0.0, 33.3	-33.3, 25.0	-25.0, 16.7

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.5.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=5)	Visit Result DB MGL-3196 100 mg (N=9)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=5)	Change from Baseline DB MGL-3196 100 mg (N=9)	Change from Baseline DB Placebo (N=17)
Stigma of Liver Disease						
Baseline						
m	5	9	17			
n	5	9	16			
Mean (SD)	92.52 (8.13)	82.67 (15.24)	91.42 (12.25)			
Median	93.80	81.30	100.00			
IQR: Q1, Q3	87.50, 100.00	81.30, 93.80	81.30, 100.00			
Min, Max	81.3, 100.0	50.0, 100.0	62.5, 100.0			
Week 24						
m	5	8	16			
n	4	7	15	4	7	14
Mean (SD/SE)	92.23 (7.85)	81.26 (17.31)	91.67 (15.24)	-1.55 (1.55)	0.87 (11.69)	-2.24 (2.90)
Median	93.80	81.30	100.00	0	0	0
IQR: Q1, Q3	87.55, 96.90	75.00, 100.00	87.50, 100.00	-3.10, 0.00	-18.80, 18.70	-6.20, 0.00
Min, Max	81.3, 100.0	50.0, 100.0	43.8, 100.0	-6.2, 0.0	-50.0, 50.0	-31.2, 18.7
Week 52						
m	5	8	15			
n	5	7	15	5	7	14
Mean (SD/SE)	93.78 (7.63)	79.49 (18.31)	90.85 (14.71)	1.26 (3.06)	-0.90 (11.04)	-3.11 (2.33)
Median	93.80	81.30	93.80	0	0	0
IQR: Q1, Q3	93.80, 100.00	62.50, 93.80	87.50, 100.00	0.00, 0.00	-18.80, 18.70	-6.20, 0.00
Min, Max	81.3, 100.0	50.0, 100.0	43.8, 100.0	-6.2, 12.5	-50.0, 43.8	-31.2, 6.2

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc. Page 1 of 3
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.5.2Liver Disease Quality of Life (SE20): Summary of Total LDQOL - MMRM Model
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.5.2Liver Disease Quality of Life (SE20): Summary of Total LDQOL - MMRM Model
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Total LDQOL			
Week 24			
m	3	4	11
n	3	4	10
Baseline Mean (SD)	72.03 (19.39)	90.70 (3.12)	84.09 (10.18)
Analysis Visit Mean (SD)	75.40 (13.77)	87.10 (10.57)	81.80 (14.06)
LS Mean of Change from Baseline (SE)	4.41 (4.84)	-6.05 (4.46)	-1.37 (2.49)
95% CI	(-5.97, 14.78)	(-15.62, 3.52)	(-6.72, 3.98)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.78 (5.32)	-4.67 (5.48)	
95% CI	(-5.63, 17.18)	(-16.42, 7.07)	
p-value	0.2955	0.4077	
Corrected Hedge's g Statistics	0.674	-0.536	
95% CI	(-0.64, 1.99)	(-1.71, 0.64)	
Week 52			
m	3	4	11
n	2	3	9
Baseline Mean (SD)	75.65 (25.95)	91.07 (3.72)	84.70 (10.61)
Analysis Visit Mean (SD)	66.40 (37.34)	89.30 (4.13)	81.42 (16.10)
LS Mean of Change from Baseline (SE)	-6.48 (9.97)	-5.23 (8.35)	-1.95 (4.61)
95% CI	(-27.87, 14.90)	(-23.13, 12.68)	(-11.85, 7.94)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.53 (10.91)	-3.27 (9.72)	
95% CI	(-27.93, 18.88)	(-24.12, 17.57)	
p-value	0.6845	0.7413	
Corrected Hedge's g Statistics	-0.298	-0.216	
95% CI	(-1.84, 1.24)	(-1.53, 1.09)	
Subgroup*Treatment Interaction p-value	0.7542	0.9455	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.5.2Liver Disease Quality of Life (SE20): Summary of Total LDQOL - MMRM Model
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Total LDQOL			
Week 24			
m	5	8	16
n	4	7	14
Baseline Mean (SD)	87.53 (10.14)	86.07 (6.48)	87.90 (6.41)
Analysis Visit Mean (SD)	87.38 (8.85)	83.36 (7.38)	86.17 (9.08)
LS Mean of Change from Baseline (SE)	0.69 (3.85)	-2.18 (3.41)	-0.07 (2.79)
95% CI	(-7.30, 8.67)	(-9.25, 4.89)	(-5.86, 5.71)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.76 (4.21)	-2.11 (3.62)	
95% CI	(-7.98, 9.50)	(-9.62, 5.40)	
p-value	0.8586	0.5665	
Corrected Hedge's g Statistics	0.073	-0.202	
95% CI	(-1.04, 1.18)	(-1.11, 0.71)	
Week 52			
m	5	8	15
n	5	7	14
Baseline Mean (SD)	87.78 (8.80)	86.07 (6.48)	87.90 (6.41)
Analysis Visit Mean (SD)	88.64 (5.72)	82.56 (4.72)	85.00 (9.30)
LS Mean of Change from Baseline (SE)	2.01 (3.10)	-2.92 (2.95)	-1.27 (2.52)
95% CI	(-4.42, 8.45)	(-9.04, 3.20)	(-6.49, 3.95)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.29 (3.32)	-1.65 (2.96)	
95% CI	(-3.60, 10.18)	(-7.78, 4.49)	
p-value	0.3333	0.5833	
Corrected Hedge's g Statistics	0.353	-0.177	
95% CI	(-0.67, 1.38)	(-1.09, 0.73)	
Subgroup*Treatment Interaction p-value	0.7542	0.9455	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.5.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

AMNOG Table SE20.5.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Symptoms of Liver Disease			
Week 24			
m	3	4	11
n	3	4	10
Baseline Mean (SD)	75.57 (21.72)	88.33 (9.99)	87.67 (13.53)
Analysis Visit Mean (SD)	82.23 (13.49)	85.00 (14.00)	87.33 (10.52)
LS Mean of Change from Baseline (SE)	-1.35 (7.66)	-2.00 (7.18)	0.20 (4.04)
95% CI	(-17.77, 15.08)	(-17.40, 13.39)	(-8.45, 8.86)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.55 (8.31)	-2.21 (8.92)	
95% CI	(-19.37, 16.27)	(-21.33, 16.92)	
p-value	0.8545	0.8082	
Corrected Hedge's g Statistics	-0.112	-0.157	
95% CI	(-1.40, 1.18)	(-1.32, 1.00)	
Week 52			
m	3	4	11
n	2	3	9
Baseline Mean (SD)	86.70 (14.14)	84.43 (7.68)	89.63 (12.74)
Analysis Visit Mean (SD)	73.35 (23.55)	88.87 (5.10)	88.51 (13.96)
LS Mean of Change from Baseline (SE)	-16.48 (9.85)	-4.33 (8.81)	0.20 (5.04)
95% CI	(-37.60, 4.64)	(-23.22, 14.57)	(-10.60, 11.01)
LS Mean of Change from Baseline Compared to Placebo (SE)	-16.69 (10.81)	-4.53 (10.72)	
95% CI	(-39.88, 6.51)	(-27.52, 18.46)	
p-value	0.1451	0.6789	
Corrected Hedge's g Statistics	-1.018	-0.276	
95% CI	(-2.61, 0.57)	(-1.59, 1.04)	
Subgroup*Treatment Interaction p-value	0.3076	0.8614	

AMNOG Table SE20.5.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Effects of Liver Disease			
Week 24			
m	3	4	11
n	3	4	10
Baseline Mean (SD)	53.33 (24.05)	86.68 (9.43)	80.67 (7.33)
Analysis Visit Mean (SD)	80.00 (0.00)	83.33 (11.56)	80.68 (11.09)
LS Mean of Change from Baseline (SE)	5.92 (9.03)	2.93 (6.76)	2.65 (3.71)
95% CI	(-13.45, 25.30)	(-11.57, 17.43)	(-5.31, 10.61)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.28 (9.97)	0.28 (8.02)	
95% CI	(-18.11, 24.67)	(-16.92, 17.49)	
p-value	0.7474	0.9724	
Corrected Hedge's g Statistics	0.243	0.022	
95% CI	(-1.05, 1.54)	(-1.14, 1.18)	
Week 52			
m	3	4	11
n	2	3	9
Baseline Mean (SD)	63.35 (23.55)	88.90 (10.18)	79.27 (6.19)
Analysis Visit Mean (SD)	50.00 (42.43)	80.00 (0.00)	80.76 (10.24)
LS Mean of Change from Baseline (SE)	-12.41 (10.92)	-10.88 (8.87)	1.93 (4.51)
95% CI	(-35.84, 11.01)	(-29.90, 8.14)	(-7.74, 11.59)
LS Mean of Change from Baseline Compared to Placebo (SE)	-14.34 (11.77)	-12.81 (10.21)	
95% CI	(-39.58, 10.89)	(-34.71, 9.10)	
p-value	0.2431	0.2305	
Corrected Hedge's g Statistics	-0.954	-0.850	
95% CI	(-2.54, 0.63)	(-2.20, 0.50)	
Subgroup*Treatment Interaction p-value	0.4012	0.3829	

AMNOG Table SE20.5.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Concentration/Memory			
Week 24			
m	3	4	11
n	3	4	10
Baseline Mean (SD)	81.27 (32.45)	95.33 (9.35)	86.89 (19.42)
Analysis Visit Mean (SD)	70.87 (25.25)	90.65 (10.80)	88.76 (13.43)
LS Mean of Change from Baseline (SE)	-14.10 (7.63)	-0.81 (7.39)	1.22 (4.33)
95% CI	(-30.46, 2.25)	(-16.67, 15.05)	(-8.07, 10.51)
LS Mean of Change from Baseline Compared to Placebo (SE)	-15.32 (8.59)	-2.03 (9.13)	
95% CI	(-33.74, 3.09)	(-21.61, 17.55)	
p-value	0.0960	0.8272	
Corrected Hedge's g Statistics	-1.048	-0.136	
95% CI	(-2.40, 0.30)	(-1.30, 1.02)	
Week 52			
m	3	4	11
n	2	3	9
Baseline Mean (SD)	71.90 (39.74)	100.00 (0.00)	88.21 (20.12)
Analysis Visit Mean (SD)	43.75 (61.87)	87.50 (12.50)	84.73 (22.98)
LS Mean of Change from Baseline (SE)	-28.42 (14.63)	-12.48 (12.03)	-3.38 (6.70)
95% CI	(-59.80, 2.96)	(-38.29, 13.33)	(-17.76, 10.99)
LS Mean of Change from Baseline Compared to Placebo (SE)	-25.04 (15.73)	-9.09 (14.23)	
95% CI	(-58.77, 8.69)	(-39.61, 21.43)	
p-value	0.1337	0.5331	
Corrected Hedge's g Statistics	-1.135	-0.414	
95% CI	(-2.74, 0.47)	(-1.73, 0.90)	
Subgroup*Treatment Interaction p-value	0.1004	0.4533	

AMNOG Table SE20.5.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Health Distress			
Week 24			
m	3	4	11
n	3	4	10
Baseline Mean (SD)	58.33 (52.04)	93.75 (7.22)	87.50 (17.68)
Analysis Visit Mean (SD)	66.67 (57.74)	90.63 (11.97)	82.50 (17.87)
LS Mean of Change from Baseline (SE)	4.64 (11.82)	-4.52 (10.67)	-3.02 (6.29)
95% CI	(-20.71, 29.98)	(-27.40, 18.35)	(-16.52, 10.48)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.66 (13.52)	-1.50 (13.18)	
95% CI	(-21.35, 36.66)	(-29.77, 26.76)	
p-value	0.5802	0.9108	
Corrected Hedge's g Statistics	0.356	-0.069	
95% CI	(-0.94, 1.65)	(-1.23, 1.09)	
Week 52			
m	3	4	11
n	2	3	9
Baseline Mean (SD)	50.00 (70.71)	91.67 (7.22)	88.89 (18.16)
Analysis Visit Mean (SD)	50.00 (70.71)	91.67 (14.43)	80.56 (23.48)
LS Mean of Change from Baseline (SE)	-1.37 (18.81)	-4.94 (14.61)	-6.09 (8.45)
95% CI	(-41.70, 38.97)	(-36.27, 26.39)	(-24.22, 12.04)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.72 (20.85)	1.15 (17.51)	
95% CI	(-40.00, 49.45)	(-36.41, 38.70)	
p-value	0.8241	0.9487	
Corrected Hedge's g Statistics	0.169	0.042	
95% CI	(-1.36, 1.70)	(-1.26, 1.35)	
Subgroup*Treatment Interaction p-value	0.5871	0.6640	

AMNOG Table SE20.5.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Sexual Function			
Week 24			
m	3	4	11
n	0	3	5
Baseline Mean (SD)	N/A	95.00 (8.66)	90.68 (10.03)
Analysis Visit Mean (SD)	N/A	86.67 (23.09)	92.32 (7.97)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	3	4	11
n	0	2	4
Baseline Mean (SD)	N/A	100.00 (0.00)	94.58 (7.12)
Analysis Visit Mean (SD)	N/A	100.00 (0.00)	88.33 (15.11)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE20.5.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Sleep			
Week 24			
m	3	4	11
n	3	4	10
Baseline Mean (SD)	43.3 (45.1)	70.0 (9.1)	66.0 (23.1)
Analysis Visit Mean (SD)	45.0 (39.7)	72.5 (15.5)	67.0 (16.0)
LS Mean of Change from Baseline (SE)	-4.48 (6.99)	3.58 (6.45)	1.01 (3.63)
95% CI	(-19.47, 10.51)	(-10.25, 17.41)	(-6.77, 8.80)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.49 (7.48)	2.57 (8.04)	
95% CI	(-21.55, 10.56)	(-14.68, 19.82)	
p-value	0.4750	0.7540	
Corrected Hedge's g Statistics	-0.441	0.203	
95% CI	(-1.74, 0.86)	(-0.96, 1.37)	
Week 52			
m	3	4	11
n	2	3	9
Baseline Mean (SD)	65.0 (35.4)	71.7 (10.4)	70.0 (20.5)
Analysis Visit Mean (SD)	57.5 (38.9)	71.7 (10.4)	68.9 (21.8)
LS Mean of Change from Baseline (SE)	-12.94 (10.96)	-0.70 (9.45)	-0.49 (5.40)
95% CI	(-36.44, 10.56)	(-20.98, 19.58)	(-12.07, 11.09)
LS Mean of Change from Baseline Compared to Placebo (SE)	-12.45 (11.93)	-0.21 (11.29)	
95% CI	(-38.03, 13.13)	(-24.43, 24.01)	
p-value	0.3142	0.9852	
Corrected Hedge's g Statistics	-0.706	-0.012	
95% CI	(-2.27, 0.85)	(-1.32, 1.29)	
Subgroup*Treatment Interaction p-value	0.4451	0.2687	

AMNOG Table SE20.5.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Loneliness			
Week 24			
m	3	4	11
n	3	4	10
Baseline Mean (SD)	86.7 (2.9)	97.5 (2.9)	91.5 (10.3)
Analysis Visit Mean (SD)	83.3 (10.4)	91.3 (8.5)	81.0 (20.9)
LS Mean of Change from Baseline (SE)	-1.45 (8.96)	-10.56 (8.75)	-9.06 (5.02)
95% CI	(-20.68, 17.78)	(-29.33, 8.22)	(-19.83, 1.71)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.61 (10.10)	-1.50 (10.75)	
95% CI	(-14.05, 29.27)	(-24.55, 21.56)	
p-value	0.4634	0.8913	
Corrected Hedge's g Statistics	0.448	-0.086	
95% CI	(-0.85, 1.75)	(-1.25, 1.07)	
Week 52			
m	3	4	11
n	2	3	9
Baseline Mean (SD)	85.0 (0.0)	98.3 (2.9)	90.6 (10.4)
Analysis Visit Mean (SD)	90.0 (14.1)	100.0 (0.0)	83.9 (19.5)
LS Mean of Change from Baseline (SE)	10.15 (9.64)	-1.83 (9.04)	-4.27 (5.06)
95% CI	(-10.53, 30.83)	(-21.23, 17.57)	(-15.12, 6.58)
LS Mean of Change from Baseline Compared to Placebo (SE)	14.42 (10.52)	2.44 (11.13)	
95% CI	(-8.14, 36.98)	(-21.42, 26.31)	
p-value	0.1920	0.8294	
Corrected Hedge's g Statistics	0.878	0.148	
95% CI	(-0.70, 2.45)	(-1.16, 1.46)	
Subgroup*Treatment Interaction p-value	0.8539	0.0686	

AMNOG Table SE20.5.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Hopelessness			
Week 24			
m	3	4	11
n	3	4	10
Baseline Mean (SD)	94.47 (4.79)	97.93 (4.15)	80.00 (24.60)
Analysis Visit Mean (SD)	83.33 (16.65)	95.83 (8.35)	83.33 (29.66)
LS Mean of Change from Baseline (SE)	-11.79 (8.41)	-2.90 (8.20)	3.71 (4.75)
95% CI	(-29.82, 6.24)	(-20.49, 14.69)	(-6.48, 13.90)
LS Mean of Change from Baseline Compared to Placebo (SE)	-15.50 (9.56)	-6.61 (10.26)	
95% CI	(-36.00, 5.00)	(-28.62, 15.41)	
p-value	0.1272	0.5300	
Corrected Hedge's g Statistics	-0.965	-0.402	
95% CI	(-2.31, 0.38)	(-1.57, 0.77)	
Week 52			
m	3	4	11
n	2	3	9
Baseline Mean (SD)	95.85 (5.87)	97.23 (4.79)	77.78 (25.00)
Analysis Visit Mean (SD)	91.65 (11.81)	97.23 (4.79)	84.26 (23.74)
LS Mean of Change from Baseline (SE)	-7.57 (9.26)	4.20 (8.75)	3.50 (5.06)
95% CI	(-27.44, 12.29)	(-14.56, 22.97)	(-7.35, 14.36)
LS Mean of Change from Baseline Compared to Placebo (SE)	-11.08 (10.48)	0.70 (10.91)	
95% CI	(-33.55, 11.40)	(-22.69, 24.10)	
p-value	0.3083	0.9497	
Corrected Hedge's g Statistics	-0.677	0.043	
95% CI	(-2.23, 0.88)	(-1.26, 1.35)	
Subgroup*Treatment Interaction p-value	0.0275	0.6845	

AMNOG Table SE20.5.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Stigma of Liver Disease			
Week 24			
m	3	4	11
n	3	4	10
Baseline Mean (SD)	83.33 (14.43)	93.75 (12.50)	88.77 (15.53)
Analysis Visit Mean (SD)	91.67 (14.43)	90.63 (18.75)	78.14 (30.09)
LS Mean of Change from Baseline (SE)	12.93 (6.38)	-9.08 (6.28)	-9.16 (3.63)
95% CI	(-0.75, 26.61)	(-22.54, 4.38)	(-16.94, -1.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	22.09 (7.16)	0.08 (7.78)	
95% CI	(6.75, 37.44)	(-16.61, 16.77)	
p-value	0.0080	0.9920	
Corrected Hedge's g Statistics	1.804	0.006	
95% CI	(0.34, 3.27)	(-1.15, 1.17)	
Week 52			
m	3	4	11
n	2	3	9
Baseline Mean (SD)	87.50 (17.68)	91.67 (14.43)	88.91 (16.47)
Analysis Visit Mean (SD)	75.00 (35.36)	91.67 (14.43)	79.89 (22.05)
LS Mean of Change from Baseline (SE)	-5.55 (15.22)	-2.20 (12.76)	-7.69 (7.31)
95% CI	(-38.18, 27.09)	(-29.56, 25.16)	(-23.36, 7.99)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.14 (16.69)	5.49 (15.03)	
95% CI	(-33.67, 37.94)	(-26.74, 37.72)	
p-value	0.8999	0.7204	
Corrected Hedge's g Statistics	0.089	0.231	
95% CI	(-1.44, 1.62)	(-1.08, 1.54)	
Subgroup*Treatment Interaction p-value	0.1483	0.2878	

AMNOG Table SE20.5.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Symptoms of Liver Disease			
Week 24			
m	5	8	16
n	4	7	14
Baseline Mean (SD)	91.68 (8.83)	83.80 (14.60)	79.04 (16.21)
Analysis Visit Mean (SD)	88.33 (17.34)	90.96 (4.59)	80.24 (17.67)
LS Mean of Change from Baseline (SE)	5.48 (8.04)	9.55 (6.28)	0.02 (4.93)
95% CI	(-11.19, 22.16)	(-3.48, 22.58)	(-10.21, 10.25)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.47 (9.06)	9.53 (7.14)	
95% CI	(-13.32, 24.25)	(-5.29, 24.35)	
p-value	0.5525	0.1959	
Corrected Hedge's g Statistics	0.289	0.511	
95% CI	(-0.83, 1.40)	(-0.41, 1.43)	
Week 52			
m	5	8	15
n	5	7	14
Baseline Mean (SD)	92.00 (7.68)	83.80 (14.60)	79.04 (16.21)
Analysis Visit Mean (SD)	90.66 (7.94)	79.06 (15.59)	84.04 (12.55)
LS Mean of Change from Baseline (SE)	3.64 (4.88)	-2.85 (4.33)	5.32 (3.69)
95% CI	(-6.47, 13.76)	(-11.84, 6.13)	(-2.33, 12.98)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.68 (5.25)	-8.17 (4.41)	
95% CI	(-12.56, 9.20)	(-17.31, 0.96)	
p-value	0.7520	0.0770	
Corrected Hedge's g Statistics	-0.122	-0.598	
95% CI	(-1.14, 0.90)	(-1.52, 0.33)	
Subgroup*Treatment Interaction p-value	0.3076	0.8614	

AMNOG Table SE20.5.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Effects of Liver Disease			
Week 24			
m	5	8	16
n	4	7	14
Baseline Mean (SD)	85.00 (10.00)	86.67 (10.19)	82.39 (5.62)
Analysis Visit Mean (SD)	80.00 (0.00)	83.80 (9.32)	78.09 (6.10)
LS Mean of Change from Baseline (SE)	-4.03 (3.63)	0.43 (3.17)	-5.20 (2.78)
95% CI	(-11.55, 3.48)	(-6.15, 7.01)	(-10.95, 0.56)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.16 (4.04)	5.63 (3.45)	
95% CI	(-7.21, 9.54)	(-1.52, 12.77)	
p-value	0.7758	0.1168	
Corrected Hedge's g Statistics	0.112	0.551	
95% CI	(-1.00, 1.22)	(-0.37, 1.47)	
Week 52			
m	5	8	15
n	5	7	14
Baseline Mean (SD)	85.34 (8.69)	86.67 (10.19)	82.39 (5.62)
Analysis Visit Mean (SD)	82.66 (5.95)	82.86 (8.49)	80.95 (4.42)
LS Mean of Change from Baseline (SE)	-0.79 (3.10)	-0.37 (2.90)	-2.43 (2.62)
95% CI	(-7.22, 5.64)	(-6.38, 5.64)	(-7.87, 3.00)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.64 (3.41)	2.06 (3.05)	
95% CI	(-5.42, 8.71)	(-4.26, 8.39)	
p-value	0.6344	0.5057	
Corrected Hedge's g Statistics	0.170	0.216	
95% CI	(-0.85, 1.19)	(-0.69, 1.13)	
Subgroup*Treatment Interaction p-value	0.4012	0.3829	

AMNOG Table SE20.5.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Concentration/Memory			
Week 24			
m	5	8	16
n	4	7	14
Baseline Mean (SD)	87.50 (17.68)	78.60 (23.61)	90.19 (10.31)
Analysis Visit Mean (SD)	85.95 (24.14)	82.16 (19.24)	87.96 (13.52)
LS Mean of Change from Baseline (SE)	0.23 (6.67)	5.22 (5.95)	3.73 (5.01)
95% CI	(-13.60, 14.06)	(-7.13, 17.57)	(-6.67, 14.12)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.50 (7.33)	1.49 (6.46)	
95% CI	(-18.69, 11.70)	(-11.90, 14.88)	
p-value	0.6377	0.8193	
Corrected Hedge's g Statistics	-0.186	0.080	
95% CI	(-1.30, 0.93)	(-0.83, 0.99)	
Week 52			
m	5	8	15
n	5	7	14
Baseline Mean (SD)	87.50 (15.31)	78.60 (23.61)	90.19 (10.31)
Analysis Visit Mean (SD)	86.26 (14.24)	83.94 (20.35)	82.62 (17.71)
LS Mean of Change from Baseline (SE)	2.33 (6.39)	7.66 (6.02)	-1.92 (5.05)
95% CI	(-10.91, 15.58)	(-4.82, 20.14)	(-12.39, 8.55)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.25 (6.97)	9.58 (6.55)	
95% CI	(-10.20, 18.70)	(-4.00, 23.16)	
p-value	0.5481	0.1577	
Corrected Hedge's g Statistics	0.227	0.511	
95% CI	(-0.80, 1.25)	(-0.41, 1.43)	
Subgroup*Treatment Interaction p-value	0.1004	0.4533	

AMNOG Table SE20.5.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Health Distress			
Week 24			
m	5	8	16
n	4	7	14
Baseline Mean (SD)	90.63 (11.97)	98.21 (4.72)	99.11 (3.34)
Analysis Visit Mean (SD)	93.75 (7.22)	98.21 (4.72)	98.21 (4.54)
LS Mean of Change from Baseline (SE)	-3.82 (2.94)	-1.19 (2.22)	-1.88 (1.89)
95% CI	(-9.91, 2.28)	(-5.79, 3.42)	(-5.80, 2.03)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.93 (3.03)	0.70 (2.21)	
95% CI	(-8.22, 4.36)	(-3.89, 5.29)	
p-value	0.5305	0.7555	
Corrected Hedge's g Statistics	-0.268	0.100	
95% CI	(-1.38, 0.85)	(-0.81, 1.01)	
Week 52			
m	5	8	15
n	5	7	14
Baseline Mean (SD)	92.50 (11.18)	98.21 (4.72)	99.11 (3.34)
Analysis Visit Mean (SD)	97.50 (5.59)	96.43 (9.45)	96.43 (5.86)
LS Mean of Change from Baseline (SE)	-1.19 (3.38)	-2.90 (2.73)	-3.51 (2.20)
95% CI	(-8.21, 5.82)	(-8.56, 2.76)	(-8.08, 1.06)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.31 (3.63)	0.60 (2.95)	
95% CI	(-5.22, 9.84)	(-5.51, 6.72)	
p-value	0.5306	0.8396	
Corrected Hedge's g Statistics	0.273	0.073	
95% CI	(-0.75, 1.30)	(-0.83, 0.98)	
Subgroup*Treatment Interaction p-value	0.5871	0.6640	

AMNOG Table SE20.5.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Sexual Function			
Week 24			
m	5	8	16
n	2	2	4
Baseline Mean (SD)	96.65 (4.74)	92.50 (10.61)	92.90 (10.23)
Analysis Visit Mean (SD)	80.85 (15.34)	89.15 (5.87)	86.68 (26.65)
LS Mean of Change from Baseline (SE)	-19.12 (3.93)	-1.94 (3.87)	-2.09 (2.74)
95% CI	(-29.22, -9.01)	(-11.89, 8.01)	(-9.14, 4.95)
LS Mean of Change from Baseline Compared to Placebo (SE)	-17.03 (4.83)	0.15 (4.73)	
95% CI	(-29.43, -4.62)	(-12.00, 12.31)	
p-value	0.0168	0.9756	
Corrected Hedge's g Statistics	-2.476	0.022	
95% CI	(-4.68, -0.28)	(-1.68, 1.72)	
Week 52			
m	5	8	15
n	2	2	4
Baseline Mean (SD)	96.65 (4.74)	92.50 (10.61)	92.90 (10.23)
Analysis Visit Mean (SD)	92.50 (10.61)	93.30 (0.00)	78.75 (42.50)
LS Mean of Change from Baseline (SE)	-9.92 (11.90)	3.25 (11.72)	-9.31 (8.29)
95% CI	(-40.51, 20.67)	(-26.88, 33.38)	(-30.61, 11.99)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.61 (14.60)	12.56 (14.31)	
95% CI	(-38.15, 36.93)	(-24.22, 49.35)	
p-value	0.9683	0.4201	
Corrected Hedge's g Statistics	-0.029	0.606	
95% CI	(-1.73, 1.67)	(-1.13, 2.34)	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE20.5.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Sleep			
Week 24			
m	5	8	16
n	4	7	14
Baseline Mean (SD)	67.5 (11.9)	70.7 (8.4)	71.4 (20.9)
Analysis Visit Mean (SD)	70.0 (10.0)	62.9 (15.2)	72.5 (17.7)
LS Mean of Change from Baseline (SE)	1.26 (6.22)	-8.70 (5.54)	0.51 (4.72)
95% CI	(-11.65, 14.16)	(-20.18, 2.79)	(-9.28, 10.30)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.75 (6.76)	-9.21 (5.62)	
95% CI	(-13.28, 14.78)	(-20.87, 2.45)	
p-value	0.9129	0.1158	
Corrected Hedge's g Statistics	0.042	-0.527	
95% CI	(-1.07, 1.15)	(-1.45, 0.39)	
Week 52			
m	5	8	15
n	5	7	14
Baseline Mean (SD)	70.0 (11.7)	70.7 (8.4)	71.4 (20.9)
Analysis Visit Mean (SD)	68.0 (9.7)	61.4 (9.4)	69.3 (17.7)
LS Mean of Change from Baseline (SE)	-2.95 (6.26)	-10.14 (5.79)	-2.59 (4.87)
95% CI	(-15.94, 10.04)	(-22.15, 1.87)	(-12.69, 7.51)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.36 (6.79)	-7.55 (5.99)	
95% CI	(-14.45, 13.73)	(-19.98, 4.88)	
p-value	0.9579	0.2210	
Corrected Hedge's g Statistics	-0.020	-0.418	
95% CI	(-1.04, 1.00)	(-1.33, 0.50)	
Subgroup*Treatment Interaction p-value	0.4451	0.2687	

AMNOG Table SE20.5.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Loneliness			
Week 24			
m	5	8	16
n	4	7	14
Baseline Mean (SD)	90.0 (20.0)	98.6 (2.4)	93.9 (10.8)
Analysis Visit Mean (SD)	96.3 (7.5)	85.0 (21.0)	91.1 (14.3)
LS Mean of Change from Baseline (SE)	4.17 (7.67)	-12.36 (6.65)	-3.18 (5.43)
95% CI	(-11.74, 20.08)	(-26.14, 1.42)	(-14.43, 8.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.35 (8.40)	-9.18 (7.07)	
95% CI	(-10.07, 24.76)	(-23.84, 5.47)	
p-value	0.3912	0.2072	
Corrected Hedge's g Statistics	0.359	-0.452	
95% CI	(-0.76, 1.48)	(-1.37, 0.47)	
Week 52			
m	5	8	15
n	5	7	14
Baseline Mean (SD)	92.0 (17.9)	98.6 (2.4)	93.9 (10.8)
Analysis Visit Mean (SD)	95.0 (11.2)	85.7 (20.1)	90.0 (13.9)
LS Mean of Change from Baseline (SE)	1.76 (6.31)	-11.87 (5.93)	-4.20 (5.02)
95% CI	(-11.33, 14.85)	(-24.18, 0.44)	(-14.61, 6.20)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.96 (6.78)	-7.67 (6.05)	
95% CI	(-8.11, 20.03)	(-20.21, 4.88)	
p-value	0.3889	0.2184	
Corrected Hedge's g Statistics	0.320	-0.412	
95% CI	(-0.71, 1.35)	(-1.33, 0.50)	
Subgroup*Treatment Interaction p-value	0.8539	0.0686	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.5.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Hopelessness			
Week 24			
m	5	8	16
n	4	7	14
Baseline Mean (SD)	89.60 (15.76)	88.10 (17.91)	92.27 (13.26)
Analysis Visit Mean (SD)	97.93 (4.15)	79.76 (23.02)	89.30 (17.11)
LS Mean of Change from Baseline (SE)	10.25 (6.71)	-4.28 (5.91)	1.73 (4.88)
95% CI	(-3.67, 24.16)	(-16.55, 7.98)	(-8.39, 11.85)
LS Mean of Change from Baseline Compared to Placebo (SE)	8.52 (7.34)	-6.01 (6.25)	
95% CI	(-6.69, 23.73)	(-18.96, 6.94)	
p-value	0.2578	0.3462	
Corrected Hedge's g Statistics	0.465	-0.330	
95% CI	(-0.66, 1.59)	(-1.24, 0.58)	
Week 52			
m	5	8	15
n	5	7	14
Baseline Mean (SD)	86.68 (15.13)	88.10 (17.91)	92.27 (13.26)
Analysis Visit Mean (SD)	95.00 (7.46)	88.10 (15.84)	88.69 (14.48)
LS Mean of Change from Baseline (SE)	9.95 (5.63)	3.30 (5.28)	1.76 (4.50)
95% CI	(-1.71, 21.62)	(-7.66, 14.25)	(-7.58, 11.10)
LS Mean of Change from Baseline Compared to Placebo (SE)	8.20 (6.04)	1.54 (5.32)	
95% CI	(-4.32, 20.71)	(-9.49, 12.57)	
p-value	0.1882	0.7748	
Corrected Hedge's g Statistics	0.491	0.092	
95% CI	(-0.54, 1.52)	(-0.82, 1.00)	
Subgroup*Treatment Interaction p-value	0.0275	0.6845	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.5.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Stigma of Liver Disease			
Week 24			
m	5	8	16
n	4	7	14
Baseline Mean (SD)	93.78 (8.82)	80.39 (15.91)	94.21 (9.62)
Analysis Visit Mean (SD)	92.23 (7.85)	81.26 (17.31)	91.97 (15.77)
LS Mean of Change from Baseline (SE)	2.91 (8.02)	-10.03 (7.56)	0.59 (6.48)
95% CI	(-13.72, 19.55)	(-25.70, 5.65)	(-12.84, 14.02)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.33 (8.57)	-10.62 (8.59)	
95% CI	(-15.45, 20.10)	(-28.43, 7.20)	
p-value	0.7887	0.2295	
Corrected Hedge's g Statistics	0.097	-0.444	
95% CI	(-1.02, 1.21)	(-1.36, 0.47)	
Week 52			
m	5	8	15
n	5	7	14
Baseline Mean (SD)	92.52 (8.13)	80.39 (15.91)	94.21 (9.62)
Analysis Visit Mean (SD)	93.78 (7.63)	79.49 (18.31)	91.09 (15.24)
LS Mean of Change from Baseline (SE)	2.32 (7.51)	-9.89 (7.27)	-1.07 (6.33)
95% CI	(-13.25, 17.90)	(-24.95, 5.18)	(-14.20, 12.07)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.39 (7.97)	-8.82 (8.18)	
95% CI	(-13.13, 19.91)	(-25.79, 8.15)	
p-value	0.6745	0.2929	
Corrected Hedge's g Statistics	0.146	-0.378	
95% CI	(-0.88, 1.17)	(-1.29, 0.54)	
Subgroup*Treatment Interaction p-value	0.1483	0.2878	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.5.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis, only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.

AMNOG Table SE20.5.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	4 (100)	6 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	3 (27.3)
No	4 (100)	6 (100)	8 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.71	5.35	
95% CI of the inverse odds ratio	(0.15, 88.75)	(0.23, 122.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.92	4.08	
95% CI of the inverse risk ratio	(0.18, 46.71)	(0.25, 68.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-19.17	-22.02	
95% CI of the absolute risk difference	(-55.95, 17.61)	(-54.04, 10.00)	
p-value	0.3959	0.2560	
p-value of Breslow-Day Test for Homogeneity [3]	0.1996	0.2398	

AMNOG Table SE20.5.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (9.1)
No	4 (100)	6 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	1.86	
95% CI of the inverse odds ratio	(0.04, 37.98)	(0.07, 52.76)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	1.75	
95% CI of the inverse risk ratio	(0.06, 25.76)	(0.08, 37.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-5.36	
95% CI of the absolute risk difference	(-34.77, 29.77)	(-32.08, 21.37)	
p-value	0.8841	0.7136	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.4910	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (16.7)	3 (27.3)
No	4 (100)	5 (83.3)	8 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.71	1.88	
95% CI of the inverse odds ratio	(0.15, 88.75)	(0.15, 23.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.92	1.64	
95% CI of the inverse risk ratio	(0.18, 46.71)	(0.21, 12.49)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-19.17	-10.61	
95% CI of the absolute risk difference	(-55.95, 17.61)	(-50.38, 29.17)	
p-value	0.3959	0.6223	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.5244	

AMNOG Table SE20.5.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (9.1)
No	4 (100)	6 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	1.86	
95% CI of the inverse odds ratio	(0.04, 37.98)	(0.07, 52.76)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	1.75	
95% CI of the inverse risk ratio	(0.06, 25.76)	(0.08, 37.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-5.36	
95% CI of the absolute risk difference	(-34.77, 29.77)	(-32.08, 21.37)	
p-value	0.8841	0.7136	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	3 (27.3)
No	4 (100)	6 (100)	8 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.71	5.35	
95% CI of the inverse odds ratio	(0.15, 88.75)	(0.23, 122.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.92	4.08	
95% CI of the inverse risk ratio	(0.18, 46.71)	(0.25, 68.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-19.17	-22.02	
95% CI of the absolute risk difference	(-55.95, 17.61)	(-54.04, 10.00)	
p-value	0.3959	0.2560	
p-value of Breslow-Day Test for Homogeneity [3]	0.1137	0.1432	

AMNOG Table SE20.5.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	4 (100)	6 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	3 (27.3)
No	4 (100)	6 (100)	8 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.71	5.35	
95% CI of the inverse odds ratio	(0.15, 88.75)	(0.23, 122.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.92	4.08	
95% CI of the inverse risk ratio	(0.18, 46.71)	(0.25, 68.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-19.17	-22.02	
95% CI of the absolute risk difference	(-55.95, 17.61)	(-54.04, 10.00)	
p-value	0.3959	0.2560	
p-value of Breslow-Day Test for Homogeneity [3]	0.2730	0.0922	

AMNOG Table SE20.5.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (9.1)
No	4 (100)	6 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	1.86	
95% CI of the inverse odds ratio	(0.04, 37.98)	(0.07, 52.76)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	1.75	
95% CI of the inverse risk ratio	(0.06, 25.76)	(0.08, 37.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-5.36	
95% CI of the absolute risk difference	(-34.77, 29.77)	(-32.08, 21.37)	
p-value	0.8841	0.7136	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (33.3)	2 (18.2)
No	4 (100)	4 (66.7)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.37	0.44	
95% CI of the inverse odds ratio	(0.09, 60.29)	(0.05, 4.37)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.08	0.55	
95% CI of the inverse risk ratio	(0.12, 36.07)	(0.10, 2.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.83	15.15	
95% CI of the absolute risk difference	(-45.75, 24.09)	(-28.92, 59.22)	
p-value	0.5934	0.4816	
p-value of Breslow-Day Test for Homogeneity [3]	0.0747	0.9501	

AMNOG Table SE20.5.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	4 (100)	6 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	4 (100)	6 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE20.5.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (18.2)
No	4 (100)	6 (100)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.37	3.42	
95% CI of the inverse odds ratio	(0.09, 60.29)	(0.14, 83.60)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.08	2.92	
95% CI of the inverse risk ratio	(0.12, 36.07)	(0.16, 52.47)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.83	-13.69	
95% CI of the absolute risk difference	(-45.75, 24.09)	(-43.56, 16.18)	
p-value	0.5934	0.4299	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (16.7)	4 (36.4)
No	4 (100)	5 (83.3)	7 (63.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.40	2.86	
95% CI of the inverse odds ratio	(0.23, 125.61)	(0.24, 33.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.75	2.18	
95% CI of the inverse risk ratio	(0.24, 57.45)	(0.31, 15.37)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-27.50	-19.70	
95% CI of the absolute risk difference	(-65.47, 10.47)	(-60.90, 21.50)	
p-value	0.2569	0.3943	
p-value of Breslow-Day Test for Homogeneity [3]	0.1438	0.9290	

AMNOG Table SE20.5.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (25.0)	0	1 (9.1)
No	3 (75.0)	6 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.30	1.86	
95% CI of the inverse odds ratio	(0.01, 6.38)	(0.07, 52.76)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.36	1.75	
95% CI of the inverse risk ratio	(0.03, 4.54)	(0.08, 37.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	15.91	-5.36	
95% CI of the absolute risk difference	(-29.80, 61.62)	(-32.08, 21.37)	
p-value	0.4228	0.7136	
p-value of Breslow-Day Test for Homogeneity [3]	0.9333	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (25.0)	1 (16.7)	1 (9.1)
No	3 (75.0)	5 (83.3)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.30	0.50	
95% CI of the inverse odds ratio	(0.01, 6.38)	(0.03, 9.77)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.36	0.55	
95% CI of the inverse risk ratio	(0.03, 4.54)	(0.04, 7.25)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	15.91	7.58	
95% CI of the absolute risk difference	(-29.80, 61.62)	(-26.74, 41.90)	
p-value	0.4228	0.6431	
p-value of Breslow-Day Test for Homogeneity [3]	0.7797	0.7032	

AMNOG Table SE20.5.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	4 (36.4)
No	4 (100)	6 (100)	7 (63.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.40	7.80	
95% CI of the inverse odds ratio	(0.23, 125.61)	(0.35, 173.98)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.75	5.25	
95% CI of the inverse risk ratio	(0.24, 57.45)	(0.33, 83.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-27.50	-30.36	
95% CI of the absolute risk difference	(-65.47, 10.47)	(-63.74, 3.02)	
p-value	0.2569	0.1472	
p-value of Breslow-Day Test for Homogeneity [3]	0.0713	0.0938	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	5 (45.5)
No	4 (100)	6 (100)	6 (54.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	7.62	11.00	
95% CI of the inverse odds ratio	(0.33, 175.01)	(0.50, 242.34)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.58	6.42	
95% CI of the inverse risk ratio	(0.31, 68.24)	(0.41, 99.46)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-35.83	-38.69	
95% CI of the absolute risk difference	(-74.38, 2.72)	(-72.73, -4.65)	
p-value	0.1589	0.0801	
p-value of Breslow-Day Test for Homogeneity [3]	0.0104	0.0182	

AMNOG Table SE20.5.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	4 (100)	6 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	2 (18.2)
No	4 (100)	6 (100)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.37	3.42	
95% CI of the inverse odds ratio	(0.09, 60.29)	(0.14, 83.60)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.08	2.92	
95% CI of the inverse risk ratio	(0.12, 36.07)	(0.16, 52.47)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.83	-13.69	
95% CI of the absolute risk difference	(-45.75, 24.09)	(-43.56, 16.18)	
p-value	0.5934	0.4299	
p-value of Breslow-Day Test for Homogeneity [3]	0.1847	0.1074	

AMNOG Table SE20.5.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	9 (100)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (20.0)	1 (11.1)	2 (11.8)
No	4 (80.0)	8 (88.9)	15 (88.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.53	1.07	
95% CI of the inverse odds ratio	(0.04, 7.49)	(0.08, 13.65)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	1.06	
95% CI of the inverse risk ratio	(0.07, 5.22)	(0.11, 10.15)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.24	-0.65	
95% CI of the absolute risk difference	(-30.02, 46.50)	(-26.27, 24.96)	
p-value	0.6371	0.9604	
p-value of Breslow-Day Test for Homogeneity [3]	0.1996	0.2398	

AMNOG Table SE20.5.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (11.1)	2 (11.8)
No	5 (100)	8 (88.9)	15 (88.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.77	1.07	
95% CI of the inverse odds ratio	(0.07, 43.02)	(0.08, 13.65)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	1.06	
95% CI of the inverse risk ratio	(0.09, 30.06)	(0.11, 10.15)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.56	-0.65	
95% CI of the absolute risk difference	(-32.84, 21.73)	(-26.27, 24.96)	
p-value	0.7216	0.9604	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.4910	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (11.1)	7 (41.2)
No	5 (100)	8 (88.9)	10 (58.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	7.86	5.60	
95% CI of the inverse odds ratio	(0.37, 164.74)	(0.57, 55.43)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.00	3.71	
95% CI of the inverse risk ratio	(0.33, 75.11)	(0.54, 25.61)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-33.33	-30.07	
95% CI of the absolute risk difference	(-65.08, -1.59)	(-61.19, 1.06)	
p-value	0.1336	0.1141	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.5244	

AMNOG Table SE20.5.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	9 (100)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (20.0)	1 (11.1)	1 (5.9)
No	4 (80.0)	8 (88.9)	16 (94.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.25	0.50	
95% CI of the inverse odds ratio	(0.01, 4.92)	(0.03, 9.08)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.29	0.53	
95% CI of the inverse risk ratio	(0.02, 3.91)	(0.04, 7.50)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	14.12	5.23	
95% CI of the absolute risk difference	(-22.68, 50.92)	(-18.15, 28.61)	
p-value	0.3344	0.6341	
p-value of Breslow-Day Test for Homogeneity [3]	0.1137	0.1432	

Program: t-se18-02-04-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.5.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (11.1)	0
No	5 (100)	8 (88.9)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.16	
95% CI of the inverse odds ratio	NE	(0.01, 4.41)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.19	
95% CI of the inverse risk ratio	NE	(0.01, 4.13)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	12.22	
95% CI of the absolute risk difference	NE	(-11.17, 35.62)	
p-value	NE	0.2289	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (20.0)	3 (33.3)	3 (17.6)
No	4 (80.0)	6 (66.7)	14 (82.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	0.43	
95% CI of the inverse odds ratio	(0.07, 10.67)	(0.07, 2.76)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	0.53	
95% CI of the inverse risk ratio	(0.12, 6.73)	(0.13, 2.11)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.35	15.69	
95% CI of the absolute risk difference	(-37.11, 41.82)	(-20.05, 51.42)	
p-value	0.9046	0.3664	
p-value of Breslow-Day Test for Homogeneity [3]	0.2730	0.0922	

AMNOG Table SE20.5.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	9 (100)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (40.0)	1 (11.1)	1 (5.9)
No	3 (60.0)	8 (88.9)	16 (94.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.09	0.50	
95% CI of the inverse odds ratio	(0.01, 1.39)	(0.03, 9.08)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.15	0.53	
95% CI of the inverse risk ratio	(0.02, 1.31)	(0.04, 7.50)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	34.12	5.23	
95% CI of the absolute risk difference	(-10.26, 78.49)	(-18.15, 28.61)	
p-value	0.0507	0.6341	
p-value of Breslow-Day Test for Homogeneity [3]	0.0747	0.9501	

AMNOG Table SE20.5.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	9 (100)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (11.1)	1 (5.9)
No	5 (100)	8 (88.9)	16 (94.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	0.50	
95% CI of the inverse odds ratio	(0.04, 28.30)	(0.03, 9.08)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	0.53	
95% CI of the inverse risk ratio	(0.05, 21.42)	(0.04, 7.50)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	5.23	
95% CI of the absolute risk difference	(-25.54, 25.54)	(-18.15, 28.61)	
p-value	>0.9999	0.6341	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

Program: t-se18-02-04-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.5.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	3 (17.6)
No	5 (100)	9 (100)	14 (82.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.66	4.59	
95% CI of the inverse odds ratio	(0.12, 60.22)	(0.21, 99.20)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.33	3.89	
95% CI of the inverse risk ratio	(0.14, 38.97)	(0.22, 67.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.11	-14.44	
95% CI of the absolute risk difference	(-39.81, 17.58)	(-37.18, 8.29)	
p-value	0.5271	0.2953	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (40.0)	1 (11.1)	5 (29.4)
No	3 (60.0)	8 (88.9)	12 (70.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	3.33	
95% CI of the inverse odds ratio	(0.08, 4.96)	(0.33, 34.12)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	2.65	
95% CI of the inverse risk ratio	(0.20, 2.70)	(0.36, 19.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	10.59	-18.30	
95% CI of the absolute risk difference	(-37.51, 58.68)	(-48.15, 11.54)	
p-value	0.6550	0.2920	
p-value of Breslow-Day Test for Homogeneity [3]	0.1438	0.9290	

AMNOG Table SE20.5.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (20.0)	0	1 (5.9)
No	4 (80.0)	9 (100)	16 (94.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.25	1.73	
95% CI of the inverse odds ratio	(0.01, 4.92)	(0.06, 46.77)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.29	1.67	
95% CI of the inverse risk ratio	(0.02, 3.91)	(0.07, 37.21)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	14.12	-3.33	
95% CI of the absolute risk difference	(-22.68, 50.92)	(-21.92, 15.25)	
p-value	0.3344	0.7428	
p-value of Breslow-Day Test for Homogeneity [3]	0.9333	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (20.0)	1 (11.1)	2 (11.8)
No	4 (80.0)	8 (88.9)	15 (88.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.53	1.07	
95% CI of the inverse odds ratio	(0.04, 7.49)	(0.08, 13.65)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	1.06	
95% CI of the inverse risk ratio	(0.07, 5.22)	(0.11, 10.15)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.24	-0.65	
95% CI of the absolute risk difference	(-30.02, 46.50)	(-26.27, 24.96)	
p-value	0.6371	0.9604	
p-value of Breslow-Day Test for Homogeneity [3]	0.7797	0.7032	

AMNOG Table SE20.5.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (20.0)	1 (11.1)	1 (5.9)
No	4 (80.0)	8 (88.9)	16 (94.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.25	0.50	
95% CI of the inverse odds ratio	(0.01, 4.92)	(0.03, 9.08)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.29	0.53	
95% CI of the inverse risk ratio	(0.02, 3.91)	(0.04, 7.50)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	14.12	5.23	
95% CI of the absolute risk difference	(-22.68, 50.92)	(-18.15, 28.61)	
p-value	0.3344	0.6341	
p-value of Breslow-Day Test for Homogeneity [3]	0.0713	0.0938	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (40.0)	2 (22.2)	1 (5.9)
No	3 (60.0)	7 (77.8)	16 (94.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.09	0.22	
95% CI of the inverse odds ratio	(0.01, 1.39)	(0.02, 2.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.15	0.26	
95% CI of the inverse risk ratio	(0.02, 1.31)	(0.03, 2.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	34.12	16.34	
95% CI of the absolute risk difference	(-10.26, 78.49)	(-13.03, 45.71)	
p-value	0.0507	0.2147	
p-value of Breslow-Day Test for Homogeneity [3]	0.0104	0.0182	

AMNOG Table SE20.5.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	2 (22.2)	0
No	5 (100)	7 (77.8)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.09	
95% CI of the inverse odds ratio	NE	(0.00, 2.01)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.11	
95% CI of the inverse risk ratio	NE	(0.01, 2.09)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	22.22	
95% CI of the absolute risk difference	NE	(-5.67, 50.11)	
p-value	NE	0.0685	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (20.0)	2 (22.2)	1 (5.9)
No	4 (80.0)	7 (77.8)	16 (94.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.25	0.22	
95% CI of the inverse odds ratio	(0.01, 4.92)	(0.02, 2.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.29	0.26	
95% CI of the inverse risk ratio	(0.02, 3.91)	(0.03, 2.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	14.12	16.34	
95% CI of the absolute risk difference	(-22.68, 50.92)	(-13.03, 45.71)	
p-value	0.3344	0.2147	
p-value of Breslow-Day Test for Homogeneity [3]	0.1847	0.1074	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.6.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=2)	(N=15)	(N=24)	(N=2)	(N=15)	(N=24)
Total LDQOL						
Baseline						
m	2	15	24			
n	2	14	22			
Mean (SD)	79.40 (20.65)	87.01 (6.13)	86.34 (8.27)			
Median	79.40	89.05	86.10			
IQR: Q1, Q3	64.80, 94.00	83.20, 90.30	80.40, 93.50			
Min, Max	64.8, 94.0	75.2, 94.8	64.4, 97.8			
Week 24						
m	2	12	23			
n	2	11	21	2	11	20
Mean (SD/SE)	81.70 (11.88)	84.72 (8.35)	83.50 (11.73)	2.30 (6.20)	-3.04 (2.51)	-2.64 (1.63)
Median	81.70	81.80	85.10	2.30	-0.50	-1.50
IQR: Q1, Q3	73.30, 90.10	77.80, 93.10	80.00, 94.10	-3.90, 8.50	-9.40, 4.50	-7.15, 1.20
Min, Max	73.3, 90.1	75.0, 98.9	52.0, 97.1	-3.9, 8.5	-19.8, 6.8	-17.6, 13.3
Week 52						
m	2	12	22			
n	1	10	20	1	10	19
Mean (SD/SE)	92.80 (N/A)	84.58 (5.41)	84.25 (10.39)	-1.20 (N/A)	-2.99 (1.97)	-2.15 (1.40)
Median	92.80	85.80	86.65	-1.20	-2.45	-0.80
IQR: Q1, Q3	92.80, 92.80	79.20, 88.30	79.10, 93.60	-1.20, -1.20	-5.60, 0.10	-8.20, 2.50
Min, Max	92.8, 92.8	75.6, 93.7	58.0, 95.5	-1.2, -1.2	-15.6, 8.7	-14.5, 6.9

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.6.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=24)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=24)
Symptoms of Liver Disease						
Baseline						
m	2	15	24			
n	2	14	22			
Mean (SD)	75.00 (30.69)	83.33 (13.59)	82.42 (15.51)			
Median	75.00	85.00	86.70			
IQR: Q1, Q3	53.30, 96.70	80.00, 93.30	70.00, 93.30			
Min, Max	53.3, 96.7	53.3, 100.0	50.0, 100.0			
Week 24						
m	2	12	23			
n	2	11	21	2	11	20
Mean (SD/SE)	83.35 (18.88)	88.79 (8.97)	80.79 (16.09)	8.35 (8.35)	3.35 (5.14)	0.00 (4.34)
Median	83.35	90.00	83.30	8.35	3.30	0
IQR: Q1, Q3	70.00, 96.70	86.70, 93.30	73.30, 93.30	0.00, 16.70	-3.30, 6.70	-6.70, 8.35
Min, Max	70.0, 96.7	66.7, 100.0	36.7, 100.0	0.0, 16.7	-33.3, 36.7	-60.0, 40.0
Week 52						
m	2	12	22			
n	1	10	20	1	10	19
Mean (SD/SE)	90.00 (N/A)	82.00 (13.80)	85.50 (12.81)	-6.70 (N/A)	-1.99 (4.07)	4.03 (2.29)
Median	90.00	83.30	86.65	-6.70	0	3.30
IQR: Q1, Q3	90.00, 90.00	73.30, 93.30	75.00, 96.70	-6.70, -6.70	-6.70, 3.40	0.00, 6.70
Min, Max	90.0, 90.0	56.7, 100.0	56.7, 100.0	-6.7, -6.7	-23.3, 16.7	-13.4, 30.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc. Page 3 of 20
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.6.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

	Visit Result			Change from Baseline		
Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Effects of Liver Disease						
Baseline						
m	2	15	24			
n	2	14	22			
Mean (SD)	56.65 (33.02)	85.72 (8.62)	81.21 (6.71)			
Median	56.65	83.35	80.00			
IQR: Q1, Q3	33.30, 80.00	80.00, 86.70	80.00, 80.00			
Min, Max	33.3, 80.0	73.3, 100.0	66.7, 100.0			
Week 24						
m	2	12	23			
n	2	11	21	2	11	20
Mean (SD/SE)	80.00 (0.00)	83.63 (9.60)	78.10 (7.65)	23.35 (23.35)	-3.05 (3.64)	-3.67 (2.24)
Median	80.00	80.00	80.00	23.35	-6.70	0
IQR: Q1, Q3	80.00, 80.00	80.00, 93.30	80.00, 80.00	0.00, 46.70	-6.70, 0.00	-6.70, 0.00
Min, Max	80.0, 80.0	73.3, 100.0	60.0, 86.7	0.0, 46.7	-20.0, 20.0	-40.0, 6.7
Week 52						
m	2	12	22			
n	1	10	20	1	10	19
Mean (SD/SE)	80.00 (N/A)	82.00 (7.07)	80.67 (5.25)	0.00 (N/A)	-5.34 (3.55)	-0.35 (1.87)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	80.00, 80.00	80.00, 80.00	80.00, 80.00	0.00, 0.00	-20.00, 0.00	0.00, 0.00
Min, Max	80.0, 80.0	73.3, 100.0	66.7, 93.3	0.0, 0.0	-20.0, 13.3	-26.7, 13.3

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc. Page 4 of 20
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.6.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=24)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=24)
Concentration/Memory						
Baseline						
m	2	15	24			
n	2	14	22			
Mean (SD)	100.00 (0.00)	83.50 (21.02)	89.21 (15.08)			
Median	100.00	93.80	93.80			
IQR: Q1, Q3	100.00, 100.00	62.50, 100.00	87.50, 100.00			
Min, Max	100.0, 100.0	43.8, 100.0	37.5, 100.0			
Week 24						
m	2	12	23			
n	2	11	21	2	11	20
Mean (SD/SE)	84.40 (13.29)	85.25 (16.60)	85.73 (13.84)	-15.60 (9.40)	0.56 (3.81)	-1.87 (3.82)
Median	84.40	87.50	87.50	-15.60	0	0
IQR: Q1, Q3	75.00, 93.80	81.30, 100.00	68.80, 100.00	-25.00, -6.20	-6.30, 6.20	-12.50, 9.40
Min, Max	75.0, 93.8	50.0, 100.0	62.5, 100.0	-25.0, -6.2	-18.7, 31.3	-37.5, 31.3
Week 52						
m	2	12	22			
n	1	10	20	1	10	19
Mean (SD/SE)	87.50 (N/A)	85.01 (17.71)	84.09 (17.96)	-12.50 (N/A)	-0.01 (4.27)	-4.92 (3.33)
Median	87.50	87.50	93.80	-12.50	0	0
IQR: Q1, Q3	87.50, 87.50	75.00, 100.00	78.15, 96.90	-12.50, -12.50	-6.30, 6.20	-6.20, 6.20
Min, Max	87.5, 87.5	43.8, 100.0	43.8, 100.0	-12.5, -12.5	-25.0, 25.0	-43.7, 12.5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.6.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=2)	(N=15)	(N=24)	(N=2)	(N=15)	(N=24)
Health Distress						
Baseline						
m	2	15	24			
n	2	14	22			
Mean (SD)	87.50 (17.68)	96.43 (5.86)	97.16 (7.65)			
Median	87.50	100.00	100.00			
IQR: Q1, Q3	75.00, 100.00	87.50, 100.00	100.00, 100.00			
Min, Max	75.0, 100.0	87.5, 100.0	75.0, 100.0			
Week 24						
m	2	12	23			
n	2	11	21	2	11	20
Mean (SD/SE)	100.00 (0.00)	95.45 (8.43)	91.67 (14.43)	12.50 (12.50)	-1.14 (3.13)	-5.63 (2.31)
Median	100.00	100.00	100.00	12.50	0	0
IQR: Q1, Q3	100.00, 100.00	87.50, 100.00	87.50, 100.00	0.00, 25.00	0.00, 0.00	-12.50, 0.00
Min, Max	100.0, 100.0	75.0, 100.0	50.0, 100.0	0.0, 25.0	-25.0, 12.5	-25.0, 12.5
Week 52						
m	2	12	22			
n	1	10	20	1	10	19
Mean (SD/SE)	100.00 (N/A)	95.00 (10.54)	93.75 (12.50)	0.00 (N/A)	-1.25 (4.35)	-4.61 (2.18)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	100.00, 100.00	100.00, 100.00	87.50, 100.00	0.00, 0.00	0.00, 12.50	-12.50, 0.00
Min, Max	100.0, 100.0	75.0, 100.0	50.0, 100.0	0.0, 0.0	-25.0, 12.5	-25.0, 12.5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.6.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=24)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=24)
Sexual Function						
Baseline						
m	2	15	24			
n	0	6	12			
Mean (SD)	N/A	95.00 (7.75)	90.55 (11.00)			
Median	N/A	100.00	93.30			
IQR: Q1, Q3	N/A	85.00, 100.00	81.65, 100.00			
Min, Max	N/A	85.0, 100.0	68.3, 100.0			
Week 24						
m	2	12	23			
n	0	5	9	0	5	8
Mean (SD/SE)	N/A	87.66 (16.65)	90.73 (17.45)	N/A	-6.34 (4.84)	-2.09 (4.34)
Median	N/A	93.30	100.00	N/A	0	0
IQR: Q1, Q3	N/A	85.00, 100.00	93.30, 100.00	N/A	-6.70, 0.00	0.00, 4.10
Min, Max	N/A	60.0, 100.0	46.7, 100.0	N/A	-25.0, 0.0	-31.6, 6.7
Week 52						
m	2	12	22			
n	0	4	10	0	4	8
Mean (SD/SE)	N/A	96.65 (3.87)	76.99 (32.51)	N/A	0.40 (3.07)	-10.20 (7.98)
Median	N/A	96.65	92.50	N/A	0	0
IQR: Q1, Q3	N/A	93.30, 100.00	68.30, 100.00	N/A	-3.35, 4.15	-12.50, 0.00
Min, Max	N/A	93.3, 100.0	15.0, 100.0	N/A	-6.7, 8.3	-63.3, 6.7

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.6.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Visit Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=24)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=24)
Sleep						
Baseline						
m	2	15	24			
n	2	14	22			
Mean (SD)	45.0 (63.6)	72.5 (9.8)	67.0 (22.7)			
Median	45.0	72.5	65.0			
IQR: Q1, Q3	0.0, 90.0	65.0, 80.0	50.0, 85.0			
Min, Max	0, 90	60, 90	30, 100			
Week 24						
m	2	12	23			
n	2	11	21	2	11	20
Mean (SD/SE)	37.5 (53.0)	66.4 (15.3)	69.5 (17.5)	-7.5 (7.5)	-4.1 (3.1)	1.8 (3.2)
Median	37.5	65.0	70.0	-7.5	0	2.5
IQR: Q1, Q3	0.0, 75.0	55.0, 80.0	60.0, 80.0	-15.0, 0.0	-15.0, 5.0	-7.5, 10.0
Min, Max	0, 75	40, 90	35, 100	-15, 0	-25, 10	-30, 30
Week 52						
m	2	12	22			
n	1	10	20	1	10	19
Mean (SD/SE)	85.0 (N/A)	64.5 (10.4)	70.0 (17.7)	-5.0 (N/A)	-6.5 (3.1)	0.0 (4.0)
Median	85.0	62.5	72.5	-5.0	-5.0	0
IQR: Q1, Q3	85.0, 85.0	60.0, 75.0	57.5, 85.0	-5.0, -5.0	-15.0, 0.0	-15.0, 15.0
Min, Max	85, 85	50, 80	35, 95	-5, -5	-25, 5	-30, 35

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.6.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=24)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=24)
Loneliness						
Baseline						
m	2	15	24			
n	2	14	22			
Mean (SD)	87.5 (3.5)	92.9 (13.5)	93.9 (10.2)			
Median	87.5	97.5	100.0			
IQR: Q1, Q3	85.0, 90.0	95.0, 100.0	90.0, 100.0			
Min, Max	85, 90	50, 100	65, 100			
Week 24						
m	2	12	23			
n	2	11	21	2	11	20
Mean (SD/SE)	85.0 (14.1)	87.3 (17.2)	88.1 (18.2)	-2.5 (7.5)	-10.9 (5.5)	-5.8 (3.2)
Median	85.0	95.0	100.0	-2.5	-5.0	0
IQR: Q1, Q3	75.0, 95.0	80.0, 100.0	80.0, 100.0	-10.0, 5.0	-20.0, 0.0	-7.5, 0.0
Min, Max	75, 95	50, 100	35, 100	-10, 5	-50, 5	-45, 10
Week 52						
m	2	12	22			
n	1	10	20	1	10	19
Mean (SD/SE)	100.0 (N/A)	90.0 (17.8)	88.8 (16.5)	15.0 (N/A)	-8.5 (5.9)	-4.7 (2.8)
Median	100.0	100.0	100.0	15.0	0	0
IQR: Q1, Q3	100.0, 100.0	80.0, 100.0	80.0, 100.0	15.0, 15.0	-20.0, 0.0	-10.0, 0.0
Min, Max	100, 100	45, 100	45, 100	15, 15	-55, 5	-35, 20

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc. Page 9 of 20
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.6.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter / Visit / Statistic	Visit Result: DB MGL-3196 80 mg (N=2)	Visit Result: DB MGL-3196 100 mg (N=15)	Visit Result: DB Placebo (N=24)	Change from Baseline: DB MGL-3196 80 mg (N=2)	Change from Baseline: DB MGL-3196 100 mg (N=15)	Change from Baseline: DB Placebo (N=24)
Hopelessness						
Baseline						
m	2	15	24			
n	2	14	22			
Mean (SD)	95.85 (5.87)	92.86 (13.42)	87.88 (20.21)			
Median	95.85	100.00	100.00			
IQR: Q1, Q3	91.70, 100.00	91.70, 100.00	83.30, 100.00			
Min, Max	91.7, 100.0	58.3, 100.0	33.3, 100.0			
Week 24						
m	2	12	23			
n	2	11	21	2	11	20
Mean (SD/SE)	83.35 (23.55)	85.60 (20.11)	85.72 (23.88)	-12.50 (12.50)	-6.07 (4.51)	-0.83 (2.41)
Median	83.35	100.00	100.00	-12.50	0	0
IQR: Q1, Q3	66.70, 100.00	58.30, 100.00	83.30, 100.00	-25.00, 0.00	-8.40, 0.00	-8.30, 0.00
Min, Max	66.7, 100.0	50.0, 100.0	25.0, 100.0	-25.0, 0.0	-50.0, 0.0	-25.0, 25.0
Week 52						
m	2	12	22			
n	1	10	20	1	10	19
Mean (SD/SE)	100.00 (N/A)	90.84 (13.85)	87.50 (18.24)	0.00 (N/A)	0.00 (4.48)	0.87 (2.85)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	100.00, 100.00	83.30, 100.00	79.15, 100.00	0.00, 0.00	0.00, 0.00	0.00, 8.30
Min, Max	100.0, 100.0	66.7, 100.0	50.0, 100.0	0.0, 0.0	-33.3, 25.0	-25.0, 25.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc. Page 10 of 20
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.6.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

	Visit Result			Change from Baseline		
Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Stigma of Liver Disease						
Baseline						
m	2	15	24			
n	2	14	22			
Mean (SD)	87.50 (17.68)	85.74 (14.38)	89.79 (14.11)			
Median	87.50	81.30	100.00			
IQR: Q1, Q3	75.00, 100.00	81.30, 100.00	81.30, 100.00			
Min, Max	75.0, 100.0	50.0, 100.0	50.0, 100.0			
Week 24						
m	2	12	23			
n	2	11	21	2	11	20
Mean (SD/SE)	100.00 (0.00)	84.66 (17.54)	85.72 (24.46)	12.50 (12.50)	-0.58 (7.32)	-5.94 (3.25)
Median	100.00	87.50	93.80	12.50	0	0
IQR: Q1, Q3	100.00, 100.00	75.00, 100.00	87.50, 100.00	0.00, 25.00	-12.50, 6.20	-12.50, 0.00
Min, Max	100.0, 100.0	50.0, 100.0	0.0, 100.0	0.0, 25.0	-50.0, 50.0	-50.0, 18.7
Week 52						
m	2	12	22			
n	1	10	20	1	10	19
Mean (SD/SE)	100.00 (N/A)	83.14 (17.45)	88.77 (16.91)	0.00 (N/A)	-0.63 (7.54)	-2.95 (2.80)
Median	100.00	87.55	93.80	0	0	0
IQR: Q1, Q3	100.00, 100.00	75.00, 100.00	87.50, 100.00	0.00, 0.00	0.00, 0.00	-6.20, 0.00
Min, Max	100.0, 100.0	50.0, 100.0	43.8, 100.0	0.0, 0.0	-50.0, 43.8	-37.5, 12.5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.6.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=4)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=4)
Total LDQOL						
Baseline						
m	7	0	4			
n	7	0	4			
Mean (SD)	81.81 (13.64)	N/A	86.43 (7.28)			
Median	88.80	N/A	88.75			
IQR: Q1, Q3	72.40, 92.50	N/A	81.35, 91.50			
Min, Max	57.3, 93.9	N/A	76.1, 92.1			
Week 24						
m	6	0	4			
n	5	0	4	5	0	4
Mean (SD/SE)	82.46 (13.40)	N/A	87.85 (7.36)	0.98 (1.32)	N/A	1.43 (3.87)
Median	90.30	N/A	85.40	0.70	N/A	4.05
IQR: Q1, Q3	74.20, 92.00	N/A	82.50, 93.20	-0.90, 1.80	N/A	-3.95, 6.80
Min, Max	62.8, 93.0	N/A	82.5, 98.1	-2.2, 5.5	N/A	-9.6, 7.2
Week 52						
m	6	0	4			
n	6	0	4	6	0	4
Mean (SD/SE)	80.53 (20.51)	N/A	79.13 (19.60)	-2.17 (3.37)	N/A	-7.30 (11.20)
Median	88.40	N/A	83.35	0.10	N/A	2.00
IQR: Q1, Q3	79.60, 92.00	N/A	66.75, 91.50	-4.00, 0.90	N/A	-21.05, 6.45
Min, Max	40.0, 94.8	N/A	51.7, 98.1	-17.3, 7.2	N/A	-40.4, 7.2

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.6.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=4)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=4)
Symptoms of Liver Disease						
Baseline						
m	7	0	4			
n	7	0	4			
Mean (SD)	89.06 (8.54)	N/A	87.50 (12.58)			
Median	90.00	N/A	90.00			
IQR: Q1, Q3	80.00, 96.70	N/A	80.00, 95.00			
Min, Max	76.7, 100.0	N/A	70.0, 100.0			
Week 24						
m	6	0	4			
n	5	0	4	5	0	4
Mean (SD/SE)	86.66 (15.47)	N/A	90.83 (8.33)	-2.02 (3.74)	N/A	3.33 (8.50)
Median	90.00	N/A	91.65	0	N/A	6.65
IQR: Q1, Q3	80.00, 100.00	N/A	85.00, 96.65	0.00, 3.30	N/A	-8.35, 15.00
Min, Max	63.3, 100.0	N/A	80.0, 100.0	-16.7, 3.3	N/A	-20.0, 20.0
Week 52						
m	6	0	4			
n	6	0	4	6	0	4
Mean (SD/SE)	85.00 (15.58)	N/A	83.33 (16.56)	-4.45 (3.29)	N/A	-4.18 (10.93)
Median	93.30	N/A	85.00	-3.30	N/A	5.00
IQR: Q1, Q3	76.70, 93.30	N/A	70.00, 96.65	-3.40, 0.00	N/A	-16.70, 8.35
Min, Max	56.7, 96.7	N/A	63.3, 100.0	-20.0, 3.3	N/A	-36.7, 10.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.6.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result: DB MGL-3196 80 mg (N=7)	Visit Result: DB MGL-3196 100 mg (N=0)	Visit Result: DB Placebo (N=4)	Change from Baseline: DB MGL-3196 80 mg (N=7)	Change from Baseline: DB MGL-3196 100 mg (N=0)	Change from Baseline: DB Placebo (N=4)
Effects of Liver Disease						
Baseline						
m	7	0	4			
n	7	0	4			
Mean (SD)	77.16 (16.70)	N/A	81.68 (3.35)			
Median	80.00	N/A	80.00			
IQR: Q1, Q3	66.70, 86.70	N/A	80.00, 83.35			
Min, Max	46.7, 100.0	N/A	80.0, 86.7			
Week 24						
m	6	0	4			
n	5	0	4	5	0	4
Mean (SD/SE)	80.00 (0.00)	N/A	85.00 (10.00)	2.66 (8.58)	N/A	3.33 (5.78)
Median	80.00	N/A	80.00	0	N/A	0
IQR: Q1, Q3	80.00, 80.00	N/A	80.00, 90.00	0.00, 0.00	N/A	-3.35, 10.00
Min, Max	80.0, 80.0	N/A	80.0, 100.0	-20.0, 33.3	N/A	-6.7, 20.0
Week 52						
m	6	0	4			
n	6	0	4	6	0	4
Mean (SD/SE)	72.22 (26.13)	N/A	81.68 (13.73)	-6.68 (5.96)	N/A	0.00 (8.16)
Median	80.00	N/A	80.00	-3.35	N/A	0
IQR: Q1, Q3	80.00, 80.00	N/A	73.35, 90.00	-20.00, 0.00	N/A	-10.00, 10.00
Min, Max	20.0, 93.3	N/A	66.7, 100.0	-26.7, 13.3	N/A	-20.0, 20.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.6.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=4)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=4)
Concentration/Memory						
Baseline						
m	7	0	4			
n	7	0	4			
Mean (SD)	76.80 (22.43)	N/A	90.65 (8.06)			
Median	87.50	N/A	90.65			
IQR: Q1, Q3	56.30, 100.00	N/A	84.40, 96.90			
Min, Max	43.8, 100.0	N/A	81.3, 100.0			
Week 24						
m	6	0	4			
n	5	0	4	5	0	4
Mean (SD/SE)	77.52 (28.15)	N/A	96.88 (6.25)	-1.24 (3.07)	N/A	6.23 (2.55)
Median	93.80	N/A	100.00	0	N/A	6.20
IQR: Q1, Q3	50.00, 100.00	N/A	93.75, 100.00	0.00, 0.00	N/A	3.10, 9.35
Min, Max	43.8, 100.0	N/A	87.5, 100.0	-12.5, 6.3	N/A	0.0, 12.5
Week 52						
m	6	0	4			
n	6	0	4	6	0	4
Mean (SD/SE)	71.88 (37.45)	N/A	79.70 (26.68)	-8.33 (7.52)	N/A	-10.95 (13.59)
Median	81.25	N/A	87.50	0	N/A	-3.15
IQR: Q1, Q3	68.80, 100.00	N/A	59.40, 100.00	-12.50, 0.00	N/A	-28.15, 6.25
Min, Max	0.0, 100.0	N/A	43.8, 100.0	-43.8, 6.3	N/A	-50.0, 12.5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.6.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter	Visit Result			Change from Baseline		
	DB	DB	DB	DB	DB	DB
Visit	MGL-3196 80 mg	MGL-3196 100 mg	Placebo	MGL-3196 80 mg	MGL-3196 100 mg	Placebo
Statistic	(N=7)	(N=0)	(N=4)	(N=7)	(N=0)	(N=4)
Health Distress						
Baseline						
m	7	0	4			
n	7	0	4			
Mean (SD)	75.00 (36.08)	N/A	81.25 (23.94)			
Median	87.50	N/A	87.50			
IQR: Q1, Q3	62.50, 100.00	N/A	62.50, 100.00			
Min, Max	0.0, 100.0	N/A	50.0, 100.0			
Week 24						
m	6	0	4			
n	5	0	4	5	0	4
Mean (SD/SE)	75.00 (42.39)	N/A	93.75 (12.50)	2.50 (2.50)	N/A	12.50 (7.22)
Median	87.50	N/A	100.00	0	N/A	12.50
IQR: Q1, Q3	87.50, 100.00	N/A	87.50, 100.00	0.00, 0.00	N/A	0.00, 25.00
Min, Max	0.0, 100.0	N/A	75.0, 100.0	0.0, 12.5	N/A	0.0, 25.0
Week 52						
m	6	0	4			
n	6	0	4	6	0	4
Mean (SD/SE)	81.25 (40.12)	N/A	75.00 (27.00)	4.17 (2.64)	N/A	-6.25 (19.43)
Median	100.00	N/A	81.25	0	N/A	6.25
IQR: Q1, Q3	87.50, 100.00	N/A	56.25, 93.75	0.00, 12.50	N/A	-31.25, 18.75
Min, Max	0.0, 100.0	N/A	37.5, 100.0	0.0, 12.5	N/A	-62.5, 25.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.6.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=7)	(N=0)	(N=4)	(N=7)	(N=0)	(N=4)
Sexual Function						
Baseline						
m	7	0	4			
n	4	0	1			
Mean (SD)	92.08 (6.87)	N/A	85.00 (N/A)			
Median	92.50	N/A	85.00			
IQR: Q1, Q3	87.50, 96.65	N/A	85.00, 85.00			
Min, Max	83.3, 100.0	N/A	85.0, 85.0			
Week 24						
m	6	0	4			
n	2	0	1	2	0	1
Mean (SD/SE)	80.85 (15.34)	N/A	85.00 (N/A)	-15.80 (7.50)	N/A	0.00 (N/A)
Median	80.85	N/A	85.00	-15.80	N/A	0
IQR: Q1, Q3	70.00, 91.70	N/A	85.00, 85.00	-23.30, -8.30	N/A	0.00, 0.00
Min, Max	70.0, 91.7	N/A	85.0, 85.0	-23.3, -8.3	N/A	0.0, 0.0
Week 52						
m	6	0	4			
n	2	0	1	2	0	0
Mean (SD/SE)	92.50 (10.61)	N/A	100.00 (N/A)	-4.15 (4.15)	N/A	N/A
Median	92.50	N/A	100.00	-4.15	N/A	N/A
IQR: Q1, Q3	85.00, 100.00	N/A	100.00, 100.00	-8.30, 0.00	N/A	N/A
Min, Max	85.0, 100.0	N/A	100.0, 100.0	-8.3, 0.0	N/A	N/A

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc. Page 17 of 20
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.6.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=4)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=4)
Sleep						
Baseline						
m	7	0	4			
n	7	0	4			
Mean (SD)	65.0 (14.7)	N/A	73.8 (16.5)			
Median	70.0	N/A	72.5			
IQR: Q1, Q3	50.0, 75.0	N/A	62.5, 85.0			
Min, Max	40, 80	N/A	55, 95			
Week 24						
m	6	0	4			
n	5	0	4	5	0	4
Mean (SD/SE)	68.0 (9.7)	N/A	71.3 (13.1)	6.0 (3.7)	N/A	-2.5 (4.3)
Median	75.0	N/A	70.0	5.0	N/A	-2.5
IQR: Q1, Q3	60.0, 75.0	N/A	60.0, 82.5	0.0, 5.0	N/A	-10.0, 5.0
Min, Max	55, 75	N/A	60, 85	0, 20	N/A	-10, 5
Week 52						
m	6	0	4			
n	6	0	4	6	0	4
Mean (SD/SE)	61.7 (17.8)	N/A	63.8 (24.6)	-3.3 (2.8)	N/A	-10.0 (8.9)
Median	65.0	N/A	62.5	-5.0	N/A	-5.0
IQR: Q1, Q3	55.0, 75.0	N/A	47.5, 80.0	-10.0, 5.0	N/A	-22.5, 2.5
Min, Max	30, 80	N/A	35, 95	-10, 5	N/A	-35, 5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.6.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=4)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=4)
Loneliness						
Baseline						
m	7	0	4			
n	7	0	4			
Mean (SD)	90.0 (15.0)	N/A	91.3 (11.1)			
Median	100.0	N/A	95.0			
IQR: Q1, Q3	85.0, 100.0	N/A	85.0, 97.5			
Min, Max	60, 100	N/A	75, 100			
Week 24						
m	6	0	4			
n	5	0	4	5	0	4
Mean (SD/SE)	93.0 (9.7)	N/A	83.8 (14.9)	4.0 (5.3)	N/A	-7.5 (7.8)
Median	100.0	N/A	85.0	0	N/A	-2.5
IQR: Q1, Q3	85.0, 100.0	N/A	72.5, 95.0	0.0, 0.0	N/A	-17.5, 2.5
Min, Max	80, 100	N/A	65, 100	-5, 25	N/A	-30, 5
Week 52						
m	6	0	4			
n	6	0	4	6	0	4
Mean (SD/SE)	92.5 (11.7)	N/A	85.0 (14.7)	1.7 (2.8)	N/A	-6.3 (9.4)
Median	100.0	N/A	87.5	0	N/A	-5.0
IQR: Q1, Q3	80.0, 100.0	N/A	75.0, 95.0	0.0, 0.0	N/A	-20.0, 7.5
Min, Max	75, 100	N/A	65, 100	-5, 15	N/A	-30, 15

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc. Page 19 of 20
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.6.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=7)	(N=0)	(N=4)	(N=7)	(N=0)	(N=4)
Hopelessness						
Baseline						
m	7	0	4			
n	7	0	4			
Mean (SD)	85.73 (13.36)	N/A	89.60 (10.49)			
Median	91.70	N/A	91.70			
IQR: Q1, Q3	75.00, 100.00	N/A	83.35, 95.85			
Min, Max	66.7, 100.0	N/A	75.0, 100.0			
Week 24						
m	6	0	4			
n	5	0	4	5	0	4
Mean (SD/SE)	95.00 (7.46)	N/A	91.68 (11.79)	4.98 (5.66)	N/A	2.08 (8.60)
Median	100.00	N/A	95.85	0	N/A	0
IQR: Q1, Q3	91.70, 100.00	N/A	83.35, 100.00	0.00, 8.30	N/A	-8.35, 12.50
Min, Max	83.3, 100.0	N/A	75.0, 100.0	-8.4, 25.0	N/A	-16.7, 25.0
Week 52						
m	6	0	4			
n	6	0	4	6	0	4
Mean (SD/SE)	93.05 (8.21)	N/A	87.50 (19.86)	5.53 (5.96)	N/A	-2.10 (11.98)
Median	95.85	N/A	95.85	0	N/A	0
IQR: Q1, Q3	83.30, 100.00	N/A	75.00, 100.00	0.00, 8.30	N/A	-16.70, 12.50
Min, Max	83.3, 100.0	N/A	58.3, 100.0	-8.4, 33.3	N/A	-33.4, 25.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.6.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=4)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=4)
Stigma of Liver Disease						
Baseline						
m	7	0	4			
n	7	0	4			
Mean (SD)	91.09 (10.11)	N/A	93.78 (8.82)			
Median	93.80	N/A	96.90			
IQR: Q1, Q3	81.30, 100.00	N/A	87.55, 100.00			
Min, Max	75.0, 100.0	N/A	81.3, 100.0			
Week 24						
m	6	0	4			
n	5	0	4	5	0	4
Mean (SD/SE)	88.78 (10.27)	N/A	89.08 (12.87)	-1.24 (1.24)	N/A	-4.70 (2.99)
Median	93.80	N/A	90.65	0	N/A	-3.15
IQR: Q1, Q3	81.30, 93.80	N/A	78.15, 100.00	0.00, 0.00	N/A	-9.40, 0.00
Min, Max	75.0, 100.0	N/A	75.0, 100.0	-6.2, 0.0	N/A	-12.5, 0.0
Week 52						
m	6	0	4			
n	6	0	4	6	0	4
Mean (SD/SE)	86.48 (19.13)	N/A	76.60 (23.58)	-3.12 (5.04)	N/A	-17.18 (13.34)
Median	93.80	N/A	81.30	0	N/A	-6.25
IQR: Q1, Q3	81.30, 100.00	N/A	62.55, 90.65	-6.20, 0.00	N/A	-34.35, 0.00
Min, Max	50.0, 100.0	N/A	43.8, 100.0	-25.0, 12.5	N/A	-56.2, 0.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc. Page 1 of 3
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.6.2Liver Disease Quality of Life (SE20): Summary of Total LDQOL - MMRM Model by Weight
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.6.2Liver Disease Quality of Life (SE20): Summary of Total LDQOL - MMRM Model by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Total LDQOL			
Week 24			
m	2	12	23
n	2	11	20
Baseline Mean (SD)	79.40 (20.65)	87.75 (5.79)	86.29 (8.56)
Analysis Visit Mean (SD)	81.70 (11.88)	84.72 (8.35)	83.65 (12.01)
LS Mean of Change from Baseline (SE)	4.20 (6.21)	-0.99 (3.05)	-0.34 (2.80)
95% CI	(-8.50, 16.89)	(-7.23, 5.25)	(-6.07, 5.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.54 (6.01)	-0.65 (3.02)	
95% CI	(-7.75, 16.82)	(-6.84, 5.53)	
p-value	0.4563	0.8304	
Corrected Hedge's g Statistics	0.353	-0.054	
95% CI	(-1.10, 1.81)	(-0.79, 0.68)	
Week 52			
m	2	12	22
n	1	10	19
Baseline Mean (SD)	94.00 (N/A)	87.57 (6.07)	86.69 (8.60)
Analysis Visit Mean (SD)	92.80 (N/A)	84.58 (5.41)	84.54 (10.59)
LS Mean of Change from Baseline (SE)	5.47 (6.19)	-1.26 (2.70)	0.28 (2.59)
95% CI	(-7.19, 18.12)	(-6.77, 4.26)	(-5.02, 5.58)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.19 (5.83)	-1.53 (2.44)	
95% CI	(-6.73, 17.11)	(-6.53, 3.46)	
p-value	0.3804	0.5352	
Corrected Hedge's g Statistics	0.440	-0.142	
95% CI	(-1.58, 2.46)	(-0.91, 0.62)	
Subgroup*Treatment Interaction p-value	0.4023	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 3 of 3
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.6.2Liver Disease Quality of Life (SE20): Summary of Total LDQOL - MMRM Model
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Total LDQOL			
Week 24			
m	6	0	4
n	5	0	4
Baseline Mean (SD)	81.48 (16.12)	N/A	86.43 (7.28)
Analysis Visit Mean (SD)	82.46 (13.40)	N/A	87.85 (7.36)
LS Mean of Change from Baseline (SE)	-0.10 (2.60)	NE	-0.44 (4.15)
95% CI	(-6.45, 6.25)	NE	(-10.60, 9.73)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.34 (3.90)	NE	
95% CI	(-9.21, 9.89)	NE	
p-value	0.9332	NE	
Corrected Hedge's g Statistics	0.043	NE	
95% CI	(-1.27, 1.36)	NE	
Week 52			
m	6	0	4
n	6	0	4
Baseline Mean (SD)	82.70 (14.72)	N/A	86.43 (7.28)
Analysis Visit Mean (SD)	80.53 (20.51)	N/A	79.13 (19.60)
LS Mean of Change from Baseline (SE)	-2.93 (7.06)	NE	-9.86 (9.04)
95% CI	(-20.19, 14.34)	NE	(-31.97, 12.26)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.93 (11.06)	NE	
95% CI	(-20.14, 33.99)	NE	
p-value	0.5541	NE	
Corrected Hedge's g Statistics	0.356	NE	
95% CI	(-0.92, 1.63)	NE	
Subgroup*Treatment Interaction p-value	0.4023	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.6.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

AMNOG Table SE20.6.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Symptoms of Liver Disease			
Week 24			
m	2	12	23
n	2	11	20
Baseline Mean (SD)	75.00 (30.69)	85.45 (12.77)	81.67 (16.07)
Analysis Visit Mean (SD)	83.35 (18.88)	88.79 (8.97)	81.67 (15.99)
LS Mean of Change from Baseline (SE)	4.69 (10.55)	7.21 (5.12)	1.48 (4.52)
95% CI	(-16.89, 26.27)	(-3.26, 17.69)	(-7.76, 10.73)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.21 (10.43)	5.73 (5.33)	
95% CI	(-18.13, 24.54)	(-5.17, 16.64)	
p-value	0.7607	0.2911	
Corrected Hedge's g Statistics	0.154	0.291	
95% CI	(-1.30, 1.61)	(-0.45, 1.03)	
Week 52			
m	2	12	22
n	1	10	19
Baseline Mean (SD)	96.70 (N/A)	83.99 (12.46)	82.28 (16.27)
Analysis Visit Mean (SD)	90.00 (N/A)	82.00 (13.80)	86.31 (12.61)
LS Mean of Change from Baseline (SE)	-0.23 (10.33)	-0.30 (4.18)	6.28 (3.96)
95% CI	(-21.36, 20.91)	(-8.85, 8.24)	(-1.81, 14.38)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.51 (9.80)	-6.59 (3.84)	
95% CI	(-26.56, 13.54)	(-14.45, 1.27)	
p-value	0.5119	0.0973	
Corrected Hedge's g Statistics	-0.362	-0.400	
95% CI	(-2.38, 1.65)	(-1.17, 0.37)	
Subgroup*Treatment Interaction p-value	0.9855	NE	

AMNOG Table SE20.6.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Effects of Liver Disease			
Week 24			
m	2	12	23
n	2	11	20
Baseline Mean (SD)	56.65 (33.02)	86.67 (9.43)	81.67 (6.80)
Analysis Visit Mean (SD)	80.00 (0.00)	83.63 (9.60)	78.01 (7.84)
LS Mean of Change from Baseline (SE)	0.16 (7.92)	0.66 (3.24)	-4.23 (2.94)
95% CI	(-16.03, 16.35)	(-5.97, 7.29)	(-10.25, 1.78)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.39 (7.56)	4.89 (3.37)	
95% CI	(-11.07, 19.85)	(-2.00, 11.79)	
p-value	0.5660	0.1575	
Corrected Hedge's g Statistics	0.324	0.385	
95% CI	(-1.13, 1.78)	(-0.36, 1.13)	
Week 52			
m	2	12	22
n	1	10	19
Baseline Mean (SD)	80.00 (N/A)	87.34 (9.67)	81.06 (6.39)
Analysis Visit Mean (SD)	80.00 (N/A)	82.00 (7.07)	80.71 (5.39)
LS Mean of Change from Baseline (SE)	-0.78 (6.57)	-1.32 (2.71)	-1.46 (2.66)
95% CI	(-14.23, 12.66)	(-6.86, 4.22)	(-6.89, 3.98)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.68 (6.07)	0.14 (2.60)	
95% CI	(-11.74, 13.10)	(-5.18, 5.46)	
p-value	0.9121	0.9583	
Corrected Hedge's g Statistics	0.056	0.013	
95% CI	(-1.96, 2.07)	(-0.75, 0.78)	
Subgroup*Treatment Interaction p-value	0.2502	NE	

AMNOG Table SE20.6.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Concentration/Memory			
Week 24			
m	2	12	23
n	2	11	20
Baseline Mean (SD)	100.00 (0.00)	84.68 (20.78)	88.45 (15.61)
Analysis Visit Mean (SD)	84.40 (13.29)	85.25 (16.60)	86.58 (13.63)
LS Mean of Change from Baseline (SE)	-2.54 (9.99)	3.70 (5.01)	4.12 (4.72)
95% CI	(-22.97, 17.88)	(-6.55, 13.94)	(-5.53, 13.77)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.66 (9.48)	-0.42 (4.82)	
95% CI	(-26.05, 12.72)	(-10.27, 9.43)	
p-value	0.4877	0.9306	
Corrected Hedge's g Statistics	-0.308	-0.021	
95% CI	(-1.76, 1.15)	(-0.76, 0.71)	
Week 52			
m	2	12	22
n	1	10	19
Baseline Mean (SD)	100.00 (N/A)	85.02 (21.88)	89.15 (15.70)
Analysis Visit Mean (SD)	87.50 (N/A)	85.01 (17.71)	84.24 (18.44)
LS Mean of Change from Baseline (SE)	-5.50 (13.80)	3.91 (5.29)	1.46 (4.87)
95% CI	(-33.72, 22.71)	(-6.92, 14.73)	(-8.51, 11.43)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.97 (13.34)	2.45 (5.26)	
95% CI	(-34.26, 20.32)	(-8.31, 13.20)	
p-value	0.6056	0.6452	
Corrected Hedge's g Statistics	-0.314	0.120	
95% CI	(-2.33, 1.70)	(-0.65, 0.89)	
Subgroup*Treatment Interaction p-value	0.6866	NE	

AMNOG Table SE20.6.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Health Distress			
Week 24			
m	2	12	23
n	2	11	20
Baseline Mean (SD)	87.50 (17.68)	96.59 (5.84)	96.88 (7.98)
Analysis Visit Mean (SD)	100.00 (0.00)	95.45 (8.43)	91.25 (14.68)
LS Mean of Change from Baseline (SE)	11.52 (8.75)	-2.33 (4.44)	-6.04 (4.25)
95% CI	(-6.37, 29.42)	(-11.42, 6.75)	(-14.73, 2.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	17.56 (8.25)	3.71 (4.06)	
95% CI	(0.70, 34.43)	(-4.59, 12.01)	
p-value	0.0418	0.3686	
Corrected Hedge's g Statistics	0.902	0.204	
95% CI	(-0.58, 2.38)	(-0.53, 0.94)	
Week 52			
m	2	12	22
n	1	10	19
Baseline Mean (SD)	100.00 (N/A)	96.25 (6.04)	98.03 (6.27)
Analysis Visit Mean (SD)	100.00 (N/A)	95.00 (10.54)	93.42 (12.75)
LS Mean of Change from Baseline (SE)	9.22 (11.21)	-4.13 (4.71)	-4.99 (4.41)
95% CI	(-13.70, 32.13)	(-13.77, 5.50)	(-14.02, 4.03)
LS Mean of Change from Baseline Compared to Placebo (SE)	14.21 (10.78)	0.86 (4.52)	
95% CI	(-7.84, 36.26)	(-8.39, 10.11)	
p-value	0.1978	0.8504	
Corrected Hedge's g Statistics	0.707	0.047	
95% CI	(-1.32, 2.73)	(-0.72, 0.81)	
Subgroup*Treatment Interaction p-value	0.0052	NE	

AMNOG Table SE20.6.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Sexual Function			
Week 24			
m	2	12	23
n	0	5	8
Baseline Mean (SD)	N/A	94.00 (8.22)	92.50 (9.84)
Analysis Visit Mean (SD)	N/A	87.66 (16.65)	90.41 (18.63)
LS Mean of Change from Baseline (SE)	NE	-6.85 (4.72)	-1.77 (3.37)
95% CI	NE	(-17.13, 3.44)	(-9.12, 5.59)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-5.08 (5.78)	
95% CI	NE	(-17.67, 7.52)	
p-value	NE	0.3969	
Corrected Hedge's g Statistics	NE	-0.476	
95% CI	NE	(-1.61, 0.66)	
Week 52			
m	2	12	22
n	0	4	8
Baseline Mean (SD)	N/A	96.25 (7.50)	93.74 (8.21)
Analysis Visit Mean (SD)	N/A	96.65 (3.87)	83.54 (29.97)
LS Mean of Change from Baseline (SE)	NE	-8.94 (8.75)	-5.21 (6.27)
95% CI	NE	(-28.00, 10.12)	(-18.87, 8.45)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-3.74 (10.74)	
95% CI	NE	(-27.13, 19.66)	
p-value	NE	0.7339	
Corrected Hedge's g Statistics	NE	-0.195	
95% CI	NE	(-1.40, 1.01)	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE20.6.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Sleep			
Week 24			
m	2	12	23
n	2	11	20
Baseline Mean (SD)	45.0 (63.6)	70.5 (8.2)	68.3 (22.6)
Analysis Visit Mean (SD)	37.5 (53.0)	66.4 (15.3)	70.0 (17.8)
LS Mean of Change from Baseline (SE)	-15.09 (9.95)	-4.42 (5.00)	1.04 (4.86)
95% CI	(-35.43, 5.25)	(-14.65, 5.81)	(-8.90, 10.99)
LS Mean of Change from Baseline Compared to Placebo (SE)	-16.13 (9.10)	-5.46 (4.53)	
95% CI	(-34.74, 2.48)	(-14.72, 3.79)	
p-value	0.0868	0.2370	
Corrected Hedge's g Statistics	-0.724	-0.264	
95% CI	(-2.19, 0.75)	(-1.00, 0.47)	
Week 52			
m	2	12	22
n	1	10	19
Baseline Mean (SD)	90.0 (N/A)	71.0 (8.4)	70.3 (21.3)
Analysis Visit Mean (SD)	85.0 (N/A)	64.5 (10.4)	70.3 (18.1)
LS Mean of Change from Baseline (SE)	-0.44 (12.88)	-6.20 (5.38)	0.12 (5.06)
95% CI	(-26.77, 25.89)	(-17.20, 4.80)	(-10.23, 10.47)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.56 (12.32)	-6.33 (5.14)	
95% CI	(-25.76, 24.63)	(-16.84, 4.18)	
p-value	0.9640	0.2283	
Corrected Hedge's g Statistics	-0.024	-0.300	
95% CI	(-2.04, 1.99)	(-1.07, 0.47)	
Subgroup*Treatment Interaction p-value	0.0654	NE	

AMNOG Table SE20.6.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Loneliness			
Week 24			
m	2	12	23
n	2	11	20
Baseline Mean (SD)	87.5 (3.5)	98.2 (2.5)	93.3 (10.5)
Analysis Visit Mean (SD)	85.0 (14.1)	87.3 (17.2)	87.5 (18.5)
LS Mean of Change from Baseline (SE)	1.51 (12.84)	-7.96 (6.72)	-2.54 (6.18)
95% CI	(-24.76, 27.78)	(-21.69, 5.78)	(-15.18, 10.10)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.05 (12.20)	-5.42 (6.38)	
95% CI	(-20.90, 29.01)	(-18.47, 7.64)	
p-value	0.7421	0.4031	
Corrected Hedge's g Statistics	0.143	-0.204	
95% CI	(-1.31, 1.60)	(-0.94, 0.53)	
Week 52			
m	2	12	22
n	1	10	19
Baseline Mean (SD)	85.0 (N/A)	98.5 (2.4)	92.9 (10.7)
Analysis Visit Mean (SD)	100.0 (N/A)	90.0 (17.8)	88.2 (16.8)
LS Mean of Change from Baseline (SE)	22.81 (14.46)	-4.95 (6.51)	-1.47 (6.06)
95% CI	(-6.78, 52.39)	(-18.27, 8.37)	(-13.86, 10.92)
LS Mean of Change from Baseline Compared to Placebo (SE)	24.28 (13.70)	-3.48 (6.05)	
95% CI	(-3.75, 52.30)	(-15.86, 8.91)	
p-value	0.0869	0.5703	
Corrected Hedge's g Statistics	0.881	-0.137	
95% CI	(-1.15, 2.91)	(-0.90, 0.63)	
Subgroup*Treatment Interaction p-value	0.8358	NE	

AMNOG Table SE20.6.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Hopelessness			
Week 24			
m	2	12	23
n	2	11	20
Baseline Mean (SD)	95.85 (5.87)	91.67 (14.91)	86.67 (20.84)
Analysis Visit Mean (SD)	83.35 (23.55)	85.60 (20.11)	85.84 (24.50)
LS Mean of Change from Baseline (SE)	-5.32 (10.49)	-0.34 (5.29)	6.39 (4.88)
95% CI	(-26.78, 16.13)	(-11.15, 10.47)	(-3.59, 16.37)
LS Mean of Change from Baseline Compared to Placebo (SE)	-11.71 (10.16)	-6.73 (5.20)	
95% CI	(-32.50, 9.07)	(-17.36, 3.89)	
p-value	0.2585	0.2052	
Corrected Hedge's g Statistics	-0.524	-0.321	
95% CI	(-1.99, 0.94)	(-1.06, 0.42)	
Week 52			
m	2	12	22
n	1	10	19
Baseline Mean (SD)	100.00 (N/A)	90.84 (15.44)	85.97 (21.17)
Analysis Visit Mean (SD)	100.00 (N/A)	90.84 (13.85)	86.84 (18.49)
LS Mean of Change from Baseline (SE)	4.35 (10.02)	7.01 (4.69)	7.26 (4.54)
95% CI	(-16.14, 24.85)	(-2.59, 16.61)	(-2.02, 16.54)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.91 (9.40)	-0.25 (4.22)	
95% CI	(-22.13, 16.32)	(-8.89, 8.39)	
p-value	0.7595	0.9528	
Corrected Hedge's g Statistics	-0.141	-0.013	
95% CI	(-2.15, 1.87)	(-0.78, 0.75)	
Subgroup*Treatment Interaction p-value	0.2750	NE	

AMNOG Table SE20.6.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Stigma of Liver Disease			
Week 24			
m	2	12	23
n	2	11	20
Baseline Mean (SD)	87.50 (17.68)	85.25 (15.63)	91.58 (13.18)
Analysis Visit Mean (SD)	100.00 (0.00)	84.66 (17.54)	85.64 (25.09)
LS Mean of Change from Baseline (SE)	13.40 (15.02)	0.10 (7.62)	-5.17 (7.21)
95% CI	(-17.32, 44.12)	(-15.48, 15.67)	(-19.92, 9.57)
LS Mean of Change from Baseline Compared to Placebo (SE)	18.58 (14.49)	5.27 (7.59)	
95% CI	(-11.06, 48.21)	(-10.26, 20.80)	
p-value	0.2100	0.4931	
Corrected Hedge's g Statistics	0.562	0.171	
95% CI	(-0.90, 2.03)	(-0.57, 0.91)	
Week 52			
m	2	12	22
n	1	10	19
Baseline Mean (SD)	100.00 (N/A)	83.77 (15.65)	91.79 (13.50)
Analysis Visit Mean (SD)	100.00 (N/A)	83.14 (17.45)	88.84 (17.37)
LS Mean of Change from Baseline (SE)	11.97 (15.24)	-2.19 (6.84)	-1.48 (6.79)
95% CI	(-19.21, 43.14)	(-16.19, 11.81)	(-15.38, 12.41)
LS Mean of Change from Baseline Compared to Placebo (SE)	13.45 (14.18)	-0.71 (6.40)	
95% CI	(-15.56, 42.46)	(-13.79, 12.38)	
p-value	0.3508	0.9129	
Corrected Hedge's g Statistics	0.435	-0.025	
95% CI	(-1.58, 2.45)	(-0.79, 0.74)	
Subgroup*Treatment Interaction p-value	0.4785	NE	

AMNOG Table SE20.6.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Symptoms of Liver Disease			
Week 24			
m	6	0	4
n	5	0	4
Baseline Mean (SD)	88.68 (10.16)	N/A	87.50 (12.58)
Analysis Visit Mean (SD)	86.66 (15.47)	N/A	90.83 (8.33)
LS Mean of Change from Baseline (SE)	0.15 (8.66)	NE	3.31 (14.01)
95% CI	(-21.05, 21.34)	NE	(-30.98, 37.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.17 (10.86)	NE	
95% CI	(-29.73, 23.40)	NE	
p-value	0.7804	NE	
Corrected Hedge's g Statistics	-0.120	NE	
95% CI	(-1.44, 1.20)	NE	
Week 52			
m	6	0	4
n	6	0	4
Baseline Mean (SD)	89.45 (9.28)	N/A	87.50 (12.58)
Analysis Visit Mean (SD)	85.00 (15.58)	N/A	83.33 (16.56)
LS Mean of Change from Baseline (SE)	-2.72 (9.94)	NE	-4.07 (15.03)
95% CI	(-27.04, 21.60)	NE	(-40.84, 32.69)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.35 (12.54)	NE	
95% CI	(-29.33, 32.03)	NE	
p-value	0.9177	NE	
Corrected Hedge's g Statistics	0.046	NE	
95% CI	(-1.22, 1.31)	NE	
Subgroup*Treatment Interaction p-value	0.9855	NE	

AMNOG Table SE20.6.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Effects of Liver Disease			
Week 24			
m	6	0	4
n	5	0	4
Baseline Mean (SD)	77.34 (19.19)	N/A	81.68 (3.35)
Analysis Visit Mean (SD)	80.00 (0.00)	N/A	85.00 (10.00)
LS Mean of Change from Baseline (SE)	0.05 (5.23)	NE	5.71 (10.35)
95% CI	(-12.75, 12.85)	NE	(-19.62, 31.04)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.66 (8.13)	NE	
95% CI	(-25.56, 14.24)	NE	
p-value	0.5127	NE	
Corrected Hedge's g Statistics	-0.311	NE	
95% CI	(-1.63, 1.01)	NE	
Week 52			
m	6	0	4
n	6	0	4
Baseline Mean (SD)	78.90 (17.59)	N/A	81.68 (3.35)
Analysis Visit Mean (SD)	72.22 (26.13)	N/A	81.68 (13.73)
LS Mean of Change from Baseline (SE)	-6.64 (8.38)	NE	-0.03 (12.79)
95% CI	(-27.14, 13.87)	NE	(-31.31, 31.26)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.61 (12.23)	NE	
95% CI	(-36.53, 23.31)	NE	
p-value	0.6082	NE	
Corrected Hedge's g Statistics	-0.265	NE	
95% CI	(-1.54, 1.01)	NE	
Subgroup*Treatment Interaction p-value	0.2502	NE	

AMNOG Table SE20.6.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Concentration/Memory			
Week 24			
m	6	0	4
n	5	0	4
Baseline Mean (SD)	78.76 (24.83)	N/A	90.65 (8.06)
Analysis Visit Mean (SD)	77.52 (28.15)	N/A	96.88 (6.25)
LS Mean of Change from Baseline (SE)	-0.92 (4.59)	NE	5.68 (8.43)
95% CI	(-12.16, 10.32)	NE	(-14.94, 26.30)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.60 (7.15)	NE	
95% CI	(-24.09, 10.88)	NE	
p-value	0.3912	NE	
Corrected Hedge's g Statistics	-0.435	NE	
95% CI	(-1.77, 0.90)	NE	
Week 52			
m	6	0	4
n	6	0	4
Baseline Mean (SD)	80.22 (22.49)	N/A	90.65 (8.06)
Analysis Visit Mean (SD)	71.88 (37.45)	N/A	79.70 (26.68)
LS Mean of Change from Baseline (SE)	-6.56 (9.92)	NE	-14.01 (13.58)
95% CI	(-30.84, 17.72)	NE	(-47.25, 19.23)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.45 (15.44)	NE	
95% CI	(-30.34, 45.24)	NE	
p-value	0.6465	NE	
Corrected Hedge's g Statistics	0.265	NE	
95% CI	(-1.01, 1.54)	NE	
Subgroup*Treatment Interaction p-value	0.6866	NE	

AMNOG Table SE20.6.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Health Distress			
Week 24			
m	6	0	4
n	5	0	4
Baseline Mean (SD)	72.50 (41.83)	N/A	81.25 (23.94)
Analysis Visit Mean (SD)	75.00 (42.39)	N/A	93.75 (12.50)
LS Mean of Change from Baseline (SE)	6.88 (6.27)	NE	21.98 (11.27)
95% CI	(-8.47, 22.24)	NE	(-5.59, 49.54)
LS Mean of Change from Baseline Compared to Placebo (SE)	-15.09 (9.13)	NE	
95% CI	(-37.44, 7.25)	NE	
p-value	0.1494	NE	
Corrected Hedge's g Statistics	-0.738	NE	
95% CI	(-2.10, 0.62)	NE	
Week 52			
m	6	0	4
n	6	0	4
Baseline Mean (SD)	77.08 (39.06)	N/A	81.25 (23.94)
Analysis Visit Mean (SD)	81.25 (40.12)	N/A	75.00 (27.00)
LS Mean of Change from Baseline (SE)	9.53 (11.49)	NE	3.57 (16.06)
95% CI	(-18.58, 37.64)	NE	(-35.73, 42.86)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.96 (17.03)	NE	
95% CI	(-35.72, 47.64)	NE	
p-value	0.7383	NE	
Corrected Hedge's g Statistics	0.181	NE	
95% CI	(-1.09, 1.45)	NE	
Subgroup*Treatment Interaction p-value	0.0052	NE	

AMNOG Table SE20.6.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Sexual Function			
Week 24			
m	6	0	4
n	2	0	1
Baseline Mean (SD)	96.65 (4.74)	N/A	85.00 (N/A)
Analysis Visit Mean (SD)	80.85 (15.34)	N/A	85.00 (N/A)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	6	0	4
n	2	0	0
Baseline Mean (SD)	96.65 (4.74)	N/A	N/A
Analysis Visit Mean (SD)	92.50 (10.61)	N/A	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE20.6.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Sleep			
Week 24			
m	6	0	4
n	5	0	4
Baseline Mean (SD)	62.0 (16.0)	N/A	73.8 (16.5)
Analysis Visit Mean (SD)	68.0 (9.7)	N/A	71.3 (13.1)
LS Mean of Change from Baseline (SE)	2.34 (4.15)	NE	-3.44 (7.39)
95% CI	(-7.81, 12.49)	NE	(-21.52, 14.63)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.78 (6.23)	NE	
95% CI	(-9.47, 21.04)	NE	
p-value	0.3893	NE	
Corrected Hedge's g Statistics	0.430	NE	
95% CI	(-0.90, 1.76)	NE	
Week 52			
m	6	0	4
n	6	0	4
Baseline Mean (SD)	65.0 (16.1)	N/A	73.8 (16.5)
Analysis Visit Mean (SD)	61.7 (17.8)	N/A	63.8 (24.6)
LS Mean of Change from Baseline (SE)	-4.87 (6.54)	NE	-13.32 (9.46)
95% CI	(-20.87, 11.14)	NE	(-36.47, 9.83)
LS Mean of Change from Baseline Compared to Placebo (SE)	8.45 (9.65)	NE	
95% CI	(-15.16, 32.07)	NE	
p-value	0.4148	NE	
Corrected Hedge's g Statistics	0.445	NE	
95% CI	(-0.84, 1.72)	NE	
Subgroup*Treatment Interaction p-value	0.0654	NE	

AMNOG Table SE20.6.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Loneliness			
Week 24			
m	6	0	4
n	5	0	4
Baseline Mean (SD)	89.0 (17.5)	N/A	91.3 (11.1)
Analysis Visit Mean (SD)	93.0 (9.7)	N/A	83.8 (14.9)
LS Mean of Change from Baseline (SE)	5.88 (7.47)	NE	-2.14 (12.13)
95% CI	(-12.41, 24.17)	NE	(-31.82, 27.55)
LS Mean of Change from Baseline Compared to Placebo (SE)	8.02 (9.57)	NE	
95% CI	(-15.41, 31.44)	NE	
p-value	0.4345	NE	
Corrected Hedge's g Statistics	0.351	NE	
95% CI	(-0.97, 1.68)	NE	
Week 52			
m	6	0	4
n	6	0	4
Baseline Mean (SD)	90.8 (16.3)	N/A	91.3 (11.1)
Analysis Visit Mean (SD)	92.5 (11.7)	N/A	85.0 (14.7)
LS Mean of Change from Baseline (SE)	4.15 (7.76)	NE	-0.94 (12.36)
95% CI	(-14.85, 23.14)	NE	(-31.18, 29.30)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.09 (9.92)	NE	
95% CI	(-19.19, 29.37)	NE	
p-value	0.6264	NE	
Corrected Hedge's g Statistics	0.215	NE	
95% CI	(-1.05, 1.48)	NE	
Subgroup*Treatment Interaction p-value	0.8358	NE	

AMNOG Table SE20.6.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Hopelessness			
Week 24			
m	6	0	4
n	5	0	4
Baseline Mean (SD)	90.02 (13.68)	N/A	89.60 (10.49)
Analysis Visit Mean (SD)	95.00 (7.46)	N/A	91.68 (11.79)
LS Mean of Change from Baseline (SE)	8.59 (5.95)	NE	12.33 (9.64)
95% CI	(-5.97, 23.15)	NE	(-11.26, 35.92)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.74 (8.13)	NE	
95% CI	(-23.64, 16.16)	NE	
p-value	0.6617	NE	
Corrected Hedge's g Statistics	-0.206	NE	
95% CI	(-1.52, 1.11)	NE	
Week 52			
m	6	0	4
n	6	0	4
Baseline Mean (SD)	87.52 (13.69)	N/A	89.60 (10.49)
Analysis Visit Mean (SD)	93.05 (8.21)	N/A	87.50 (19.86)
LS Mean of Change from Baseline (SE)	8.58 (7.60)	NE	8.27 (11.13)
95% CI	(-10.02, 27.18)	NE	(-18.97, 35.52)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.31 (10.71)	NE	
95% CI	(-25.90, 26.52)	NE	
p-value	0.9780	NE	
Corrected Hedge's g Statistics	0.014	NE	
95% CI	(-1.25, 1.28)	NE	
Subgroup*Treatment Interaction p-value	0.2750	NE	

AMNOG Table SE20.6.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Stigma of Liver Disease			
Week 24			
m	6	0	4
n	5	0	4
Baseline Mean (SD)	90.02 (11.35)	N/A	93.78 (8.82)
Analysis Visit Mean (SD)	88.78 (10.27)	N/A	89.08 (12.87)
LS Mean of Change from Baseline (SE)	-3.16 (2.79)	NE	-7.94 (4.88)
95% CI	(-9.99, 3.66)	NE	(-19.88, 4.00)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.78 (4.11)	NE	
95% CI	(-5.28, 14.84)	NE	
p-value	0.2890	NE	
Corrected Hedge's g Statistics	0.535	NE	
95% CI	(-0.80, 1.87)	NE	
Week 52			
m	6	0	4
n	6	0	4
Baseline Mean (SD)	89.60 (10.20)	N/A	93.78 (8.82)
Analysis Visit Mean (SD)	86.48 (19.13)	N/A	76.60 (23.58)
LS Mean of Change from Baseline (SE)	-5.23 (8.73)	NE	-20.13 (11.21)
95% CI	(-26.60, 16.13)	NE	(-47.56, 7.30)
LS Mean of Change from Baseline Compared to Placebo (SE)	14.90 (13.73)	NE	
95% CI	(-18.70, 48.50)	NE	
p-value	0.3196	NE	
Corrected Hedge's g Statistics	0.618	NE	
95% CI	(-0.68, 1.91)	NE	
Subgroup*Treatment Interaction p-value	0.4785	NE	

AMNOG Table SE20.6.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis, only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.

AMNOG Table SE20.6.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	2 (100)	15 (100)	24 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (6.7)	3 (12.5)
No	2 (100)	14 (93.3)	21 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	2.00	
95% CI of the inverse odds ratio	(0.03, 20.78)	(0.19, 21.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	1.88	
95% CI of the inverse risk ratio	(0.06, 12.63)	(0.21, 16.41)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.67	-5.83	
95% CI of the absolute risk difference	(-41.64, 46.98)	(-24.12, 12.45)	
p-value	0.9007	0.5591	
p-value of Breslow-Day Test for Homogeneity [3]	0.8124	NE	

AMNOG Table SE20.6.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (6.7)	3 (12.5)
No	2 (100)	14 (93.3)	21 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	2.00	
95% CI of the inverse odds ratio	(0.03, 20.78)	(0.19, 21.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	1.88	
95% CI of the inverse risk ratio	(0.06, 12.63)	(0.21, 16.41)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.67	-5.83	
95% CI of the absolute risk difference	(-41.64, 46.98)	(-24.12, 12.45)	
p-value	0.9007	0.5591	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (13.3)	8 (33.3)
No	2 (100)	13 (86.7)	16 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.58	3.25	
95% CI of the inverse odds ratio	(0.11, 59.93)	(0.59, 18.03)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.04	2.50	
95% CI of the inverse risk ratio	(0.15, 27.15)	(0.61, 10.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-17.33	-20.00	
95% CI of the absolute risk difference	(-63.41, 28.75)	(-45.53, 5.53)	
p-value	0.5436	0.1640	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE20.6.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	2 (100)	15 (100)	24 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (6.7)	3 (12.5)
No	2 (100)	14 (93.3)	21 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	2.00	
95% CI of the inverse odds ratio	(0.03, 20.78)	(0.19, 21.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	1.88	
95% CI of the inverse risk ratio	(0.06, 12.63)	(0.21, 16.41)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.67	-5.83	
95% CI of the absolute risk difference	(-41.64, 46.98)	(-24.12, 12.45)	
p-value	0.9007	0.5591	
p-value of Breslow-Day Test for Homogeneity [3]	0.6983	NE	

AMNOG Table SE20.6.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (6.7)	0
No	2 (100)	14 (93.3)	24 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.20	
95% CI of the inverse odds ratio	NE	(0.01, 5.17)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.21	
95% CI of the inverse risk ratio	NE	(0.01, 4.92)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	7.38	
95% CI of the absolute risk difference	NE	(-7.93, 22.68)	
p-value	NE	0.2849	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	3 (20.0)	5 (20.8)
No	2 (100)	12 (80.0)	19 (79.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.41	1.05	
95% CI of the inverse odds ratio	(0.06, 33.93)	(0.21, 5.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.32	1.04	
95% CI of the inverse risk ratio	(0.09, 18.42)	(0.29, 3.74)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.33	-0.83	
95% CI of the absolute risk difference	(-50.52, 39.86)	(-26.79, 25.12)	
p-value	0.8315	0.9500	
p-value of Breslow-Day Test for Homogeneity [3]	0.6038	NE	

AMNOG Table SE20.6.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	2 (100)	15 (100)	24 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	3 (20.0)	1 (4.2)
No	2 (100)	12 (80.0)	23 (95.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.17	
95% CI of the inverse odds ratio	NE	(0.02, 1.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.21	
95% CI of the inverse risk ratio	NE	(0.02, 1.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.17	15.83	
95% CI of the absolute risk difference	(-12.16, 3.83)	(-5.93, 37.60)	
p-value	0.7685	0.1128	
p-value of Breslow-Day Test for Homogeneity [3]	0.8497	NE	

Program: t-se18-02-04-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.6.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	2 (100)	15 (100)	24 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (6.7)	1 (4.2)
No	2 (100)	14 (93.3)	23 (95.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.61	
95% CI of the inverse odds ratio	NE	(0.04, 10.53)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.63	
95% CI of the inverse risk ratio	NE	(0.04, 9.26)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.17	2.50	
95% CI of the absolute risk difference	(-12.16, 3.83)	(-12.44, 17.44)	
p-value	0.7685	0.7306	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE20.6.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	5 (20.8)
No	2 (100)	15 (100)	19 (79.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.41	8.74	
95% CI of the inverse odds ratio	(0.06, 33.93)	(0.45, 170.58)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.32	7.04	
95% CI of the inverse risk ratio	(0.09, 18.42)	(0.42, 118.85)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.33	-18.88	
95% CI of the absolute risk difference	(-50.52, 39.86)	(-37.22, -0.53)	
p-value	0.8315	0.0953	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (13.3)	8 (33.3)
No	2 (100)	13 (86.7)	16 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.58	3.25	
95% CI of the inverse odds ratio	(0.11, 59.93)	(0.59, 18.03)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.04	2.50	
95% CI of the inverse risk ratio	(0.15, 27.15)	(0.61, 10.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-17.33	-20.00	
95% CI of the absolute risk difference	(-63.41, 28.75)	(-45.53, 5.53)	
p-value	0.5436	0.1640	
p-value of Breslow-Day Test for Homogeneity [3]	0.3504	NE	

AMNOG Table SE20.6.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (50.0)	0	1 (4.2)
No	1 (50.0)	15 (100)	23 (95.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.04	NE	
95% CI of the inverse odds ratio	(0.00, 1.33)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.08	NE	
95% CI of the inverse risk ratio	(0.01, 0.89)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	45.83	-4.17	
95% CI of the absolute risk difference	(-23.92, 100.00)	(-12.16, 3.83)	
p-value	0.0194	0.4232	
p-value of Breslow-Day Test for Homogeneity [3]	0.0619	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (50.0)	2 (13.3)	2 (8.3)
No	1 (50.0)	13 (86.7)	22 (91.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.09	0.59	
95% CI of the inverse odds ratio	(0.00, 2.07)	(0.07, 4.71)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.17	0.63	
95% CI of the inverse risk ratio	(0.02, 1.14)	(0.10, 3.98)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	41.67	5.00	
95% CI of the absolute risk difference	(-28.51, 100.00)	(-15.45, 25.45)	
p-value	0.0764	0.6166	
p-value of Breslow-Day Test for Homogeneity [3]	0.1340	NE	

AMNOG Table SE20.6.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (6.7)	4 (16.7)
No	2 (100)	14 (93.3)	20 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.10	2.80	
95% CI of the inverse odds ratio	(0.04, 27.01)	(0.28, 27.80)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.08	2.50	
95% CI of the inverse risk ratio	(0.08, 15.52)	(0.31, 20.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.33	-10.00	
95% CI of the absolute risk difference	(-46.11, 43.45)	(-29.54, 9.54)	
p-value	0.9546	0.3635	
p-value of Breslow-Day Test for Homogeneity [3]	0.6481	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (13.3)	5 (20.8)
No	2 (100)	13 (86.7)	19 (79.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.41	1.71	
95% CI of the inverse odds ratio	(0.06, 33.93)	(0.29, 10.20)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.32	1.56	
95% CI of the inverse risk ratio	(0.09, 18.42)	(0.35, 7.06)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.33	-7.50	
95% CI of the absolute risk difference	(-50.52, 39.86)	(-31.16, 16.16)	
p-value	0.8315	0.5527	
p-value of Breslow-Day Test for Homogeneity [3]	0.4683	NE	

AMNOG Table SE20.6.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	2 (13.3)	0
No	2 (100)	13 (86.7)	24 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.11	
95% CI of the inverse odds ratio	NE	(0.00, 2.47)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.13	
95% CI of the inverse risk ratio	NE	(0.01, 2.50)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	13.63	
95% CI of the absolute risk difference	NE	(-4.99, 32.24)	
p-value	NE	0.1022	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (13.3)	3 (12.5)
No	2 (100)	13 (86.7)	21 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	0.93	
95% CI of the inverse odds ratio	(0.03, 20.78)	(0.14, 6.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	0.94	
95% CI of the inverse risk ratio	(0.06, 12.63)	(0.18, 4.97)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.67	0.83	
95% CI of the absolute risk difference	(-41.64, 46.98)	(-20.87, 22.54)	
p-value	0.9007	0.9396	
p-value of Breslow-Day Test for Homogeneity [3]	0.3567	NE	

AMNOG Table SE20.6.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (14.3)	0	2 (50.0)
No	6 (85.7)	0	2 (50.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	6.00	NE	
95% CI of the inverse odds ratio	(0.34, 107.42)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.50	NE	
95% CI of the inverse risk ratio	(0.45, 27.52)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-35.71	NE	
95% CI of the absolute risk difference	(-91.15, 19.72)	NE	
p-value	0.2008	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.8124	NE	

AMNOG Table SE20.6.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	2 (50.0)
No	7 (100)	0	2 (50.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	15.00	NE	
95% CI of the inverse odds ratio	(0.52, 430.47)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	8.00	NE	
95% CI of the inverse risk ratio	(0.48, 134.66)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-43.75	NE	
95% CI of the absolute risk difference	(-90.68, 3.18)	NE	
p-value	0.0685	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE20.6.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (25.0)
No	7 (100)	0	3 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	6.43	NE	
95% CI of the inverse odds ratio	(0.21, 201.07)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.80	NE	
95% CI of the inverse risk ratio	(0.24, 96.34)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-23.75	NE	
95% CI of the absolute risk difference	(-67.28, 19.78)	NE	
p-value	0.2482	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (14.3)	0	1 (25.0)
No	6 (85.7)	0	3 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	NE	
95% CI of the inverse odds ratio	(0.09, 44.35)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.75	NE	
95% CI of the inverse risk ratio	(0.15, 21.00)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.71	NE	
95% CI of the absolute risk difference	(-60.44, 39.01)	NE	
p-value	0.6576	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.6983	NE	

AMNOG Table SE20.6.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (14.3)	0	1 (25.0)
No	6 (85.7)	0	3 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	NE	
95% CI of the inverse odds ratio	(0.09, 44.35)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.75	NE	
95% CI of the inverse risk ratio	(0.15, 21.00)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.71	NE	
95% CI of the absolute risk difference	(-60.44, 39.01)	NE	
p-value	0.6576	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.6038	NE	

AMNOG Table SE20.6.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (25.0)
No	7 (100)	0	3 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	6.43	NE	
95% CI of the inverse odds ratio	(0.21, 201.07)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.80	NE	
95% CI of the inverse risk ratio	(0.24, 96.34)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-23.75	NE	
95% CI of the absolute risk difference	(-67.28, 19.78)	NE	
p-value	0.2482	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (28.6)	0	2 (50.0)
No	5 (71.4)	0	2 (50.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.50	NE	
95% CI of the inverse odds ratio	(0.19, 32.19)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.75	NE	
95% CI of the inverse risk ratio	(0.38, 8.06)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-21.43	NE	
95% CI of the absolute risk difference	(-80.77, 37.91)	NE	
p-value	0.4773	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.8497	NE	

AMNOG Table SE20.6.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE20.6.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (28.6)	0	1 (25.0)
No	5 (71.4)	0	3 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	NE	
95% CI of the inverse odds ratio	(0.05, 13.63)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	NE	
95% CI of the inverse risk ratio	(0.11, 6.88)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.57	NE	
95% CI of the absolute risk difference	(-50.47, 57.61)	NE	
p-value	0.8982	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3504	NE	

AMNOG Table SE20.6.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (14.3)	0	1 (25.0)
No	6 (85.7)	0	3 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	NE	
95% CI of the inverse odds ratio	(0.09, 44.35)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.75	NE	
95% CI of the inverse risk ratio	(0.15, 21.00)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.71	NE	
95% CI of the absolute risk difference	(-60.44, 39.01)	NE	
p-value	0.6576	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.0619	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (14.3)	0	1 (25.0)
No	6 (85.7)	0	3 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	NE	
95% CI of the inverse odds ratio	(0.09, 44.35)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.75	NE	
95% CI of the inverse risk ratio	(0.15, 21.00)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.71	NE	
95% CI of the absolute risk difference	(-60.44, 39.01)	NE	
p-value	0.6576	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.1340	NE	

AMNOG Table SE20.6.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (14.3)	0	1 (25.0)
No	6 (85.7)	0	3 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	NE	
95% CI of the inverse odds ratio	(0.09, 44.35)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.75	NE	
95% CI of the inverse risk ratio	(0.15, 21.00)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.71	NE	
95% CI of the absolute risk difference	(-60.44, 39.01)	NE	
p-value	0.6576	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.6481	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (28.6)	0	1 (25.0)
No	5 (71.4)	0	3 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	NE	
95% CI of the inverse odds ratio	(0.05, 13.63)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	NE	
95% CI of the inverse risk ratio	(0.11, 6.88)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.57	NE	
95% CI of the absolute risk difference	(-50.47, 57.61)	NE	
p-value	0.8982	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4683	NE	

AMNOG Table SE20.6.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (14.3)	0	0
No	6 (85.7)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.48	NE	
95% CI of the inverse odds ratio	(0.02, 14.70)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.53	NE	
95% CI of the inverse risk ratio	(0.03, 10.70)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.75	NE	
95% CI of the absolute risk difference	(-28.97, 46.47)	NE	
p-value	0.6705	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3567	NE	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.7.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Visit Statistic	Visit Result DB MGL-3196 80 mg (N=6)	 DB MGL-3196 100 mg (N=6)	 DB Placebo (N=19)	Change from Baseline DB MGL-3196 80 mg (N=6)	 DB MGL-3196 100 mg (N=6)	 DB Placebo (N=19)
Total LDQOL						
Baseline						
m	6	6	19			
n	6	6	18			
Mean (SD)	83.63 (14.44)	85.98 (7.82)	86.41 (8.16)			
Median	90.05	89.10	87.30			
IQR: Q1, Q3	76.50, 93.90	77.40, 90.30	82.20, 92.10			
Min, Max	57.3, 94.0	75.2, 94.8	64.4, 97.8			
Week 24						
m	5	5	18			
n	4	5	16	4	5	16
Mean (SD/SE)	84.48 (14.50)	84.52 (8.50)	83.76 (11.65)	0.35 (1.96)	-3.62 (4.69)	-2.59 (1.88)
Median	91.05	81.80	85.25	-0.10	-0.40	-0.80
IQR: Q1, Q3	76.45, 92.50	80.30, 88.40	82.10, 91.45	-2.40, 3.10	-7.60, 2.90	-7.85, 1.85
Min, Max	62.8, 93.0	75.0, 97.1	52.0, 98.1	-3.9, 5.5	-19.8, 6.8	-17.6, 8.5
Week 52						
m	5	5	17			
n	5	5	16	5	5	16
Mean (SD/SE)	81.58 (23.36)	84.66 (3.56)	83.18 (12.68)	-3.48 (3.48)	-3.48 (3.89)	-3.17 (2.87)
Median	92.00	86.10	85.10	-0.50	-2.90	-0.75
IQR: Q1, Q3	88.30, 92.80	83.20, 86.50	79.40, 93.60	-1.20, 0.70	-5.60, -2.00	-7.30, 4.05
Min, Max	40.0, 94.8	79.2, 88.3	51.7, 98.1	-17.3, 0.9	-15.6, 8.7	-40.4, 7.2

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.7.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=6)	(N=6)	(N=19)	(N=6)	(N=6)	(N=19)
Symptoms of Liver Disease						
Baseline						
m	6	6	19			
n	6	6	18			
Mean (SD)	90.57 (8.27)	85.00 (14.56)	84.26 (14.59)			
Median	91.65	90.00	88.35			
IQR: Q1, Q3	86.70, 96.70	83.30, 93.30	80.00, 93.30			
Min, Max	76.7, 100.0	56.7, 96.7	50.0, 100.0			
Week 24						
m	5	5	18			
n	4	5	16	4	5	16
Mean (SD/SE)	91.68 (8.83)	92.00 (5.04)	81.46 (17.39)	0.83 (0.83)	1.34 (2.27)	-2.09 (5.06)
Median	93.35	90.00	85.00	0	3.30	1.65
IQR: Q1, Q3	85.00, 98.35	90.00, 93.30	73.30, 95.00	0.00, 1.65	0.00, 3.40	-11.65, 10.00
Min, Max	80.0, 100.0	86.7, 100.0	36.7, 100.0	0.0, 3.3	-6.7, 6.7	-60.0, 23.3
Week 52						
m	5	5	17			
n	5	5	16	5	5	16
Mean (SD/SE)	86.00 (16.55)	84.68 (13.86)	85.00 (14.40)	-5.34 (4.03)	-5.98 (7.41)	1.46 (3.24)
Median	93.30	83.30	88.30	-3.30	-6.70	3.30
IQR: Q1, Q3	90.00, 93.30	76.70, 96.70	75.00, 98.35	-6.70, 0.00	-20.00, 3.40	0.00, 6.70
Min, Max	56.7, 96.7	66.7, 100.0	56.7, 100.0	-20.0, 3.3	-23.3, 16.7	-36.7, 20.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.7.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=6)	(N=6)	(N=19)	(N=6)	(N=6)	(N=19)
Effects of Liver Disease						
Baseline						
m	6	6	19			
n	6	6	18			
Mean (SD)	73.35 (14.60)	87.78 (9.81)	80.74 (6.82)			
Median	80.00	83.35	80.00			
IQR: Q1, Q3	66.70, 80.00	80.00, 100.00	80.00, 80.00			
Min, Max	46.7, 86.7	80.0, 100.0	66.7, 100.0			
Week 24						
m	5	5	18			
n	4	5	16	4	5	16
Mean (SD/SE)	80.00 (0.00)	86.66 (9.42)	78.34 (9.89)	8.33 (8.33)	-2.68 (5.41)	-2.92 (3.04)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	80.00, 80.00	80.00, 93.30	76.65, 80.00	0.00, 16.65	-6.70, 0.00	-6.70, 0.00
Min, Max	80.0, 80.0	80.0, 100.0	60.0, 100.0	0.0, 33.3	-20.0, 13.3	-40.0, 20.0
Week 52						
m	5	5	17			
n	5	5	16	5	5	16
Mean (SD/SE)	70.66 (28.90)	84.00 (8.94)	79.59 (7.49)	-4.02 (6.53)	-5.34 (6.46)	-1.67 (2.69)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	80.00, 80.00	80.00, 80.00	80.00, 80.00	-6.70, 0.00	-20.00, 0.00	-3.30, 0.00
Min, Max	20.0, 93.3	80.0, 100.0	66.7, 100.0	-26.7, 13.3	-20.0, 13.3	-26.7, 20.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.7.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=6)	(N=6)	(N=19)	(N=6)	(N=6)	(N=19)
Concentration/Memory						
Baseline						
m	6	6	19			
n	6	6	18			
Mean (SD)	81.27 (24.98)	77.10 (23.27)	89.94 (15.18)			
Median	93.75	78.15	93.80			
IQR: Q1, Q3	56.30, 100.00	56.30, 100.00	87.50, 100.00			
Min, Max	43.8, 100.0	50.0, 100.0	37.5, 100.0			
Week 24						
m	5	5	18			
n	4	5	16	4	5	16
Mean (SD/SE)	84.40 (27.22)	88.76 (15.57)	87.13 (14.51)	-1.55 (1.55)	6.24 (6.57)	-1.94 (4.37)
Median	96.90	93.80	90.65	0	0	0
IQR: Q1, Q3	68.80, 100.00	87.50, 100.00	75.05, 100.00	-3.10, 0.00	0.00, 6.20	-9.35, 6.30
Min, Max	43.8, 100.0	62.5, 100.0	62.5, 100.0	-6.2, 0.0	-6.3, 31.3	-37.5, 31.3
Week 52						
m	5	5	17			
n	5	5	16	5	5	16
Mean (SD/SE)	72.50 (41.83)	88.76 (11.17)	81.28 (21.89)	-13.76 (8.01)	6.24 (5.60)	-7.79 (4.62)
Median	87.50	87.50	93.80	-12.50	0	-6.20
IQR: Q1, Q3	75.00, 100.00	81.30, 100.00	62.50, 100.00	-12.50, 0.00	0.00, 12.50	-12.50, 3.15
Min, Max	0.0, 100.0	75.0, 100.0	43.8, 100.0	-43.8, 0.0	-6.3, 25.0	-50.0, 12.5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.7.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=6)	(N=6)	(N=19)	(N=6)	(N=6)	(N=19)
Health Distress						
Baseline						
m	6	6	19			
n	6	6	18			
Mean (SD)	72.92 (39.06)	100.00 (0.00)	94.44 (13.71)			
Median	87.50	100.00	100.00			
IQR: Q1, Q3	62.50, 100.00	100.00, 100.00	100.00, 100.00			
Min, Max	0.0, 100.0	100.0, 100.0	50.0, 100.0			
Week 24						
m	5	5	18			
n	4	5	16	4	5	16
Mean (SD/SE)	71.88 (48.28)	97.50 (5.59)	90.63 (14.79)	3.13 (3.13)	-2.50 (2.50)	-3.13 (3.70)
Median	93.75	100.00	100.00	0	0	0
IQR: Q1, Q3	43.75, 100.00	100.00, 100.00	81.25, 100.00	0.00, 6.25	0.00, 0.00	-12.50, 0.00
Min, Max	0.0, 100.0	87.5, 100.0	50.0, 100.0	0.0, 12.5	-12.5, 0.0	-25.0, 25.0
Week 52						
m	5	5	17			
n	5	5	16	5	5	16
Mean (SD/SE)	77.50 (43.66)	95.00 (11.18)	86.72 (19.08)	2.50 (2.50)	-5.00 (5.00)	-7.03 (4.84)
Median	100.00	100.00	93.75	0	0	0
IQR: Q1, Q3	87.50, 100.00	100.00, 100.00	81.25, 100.00	0.00, 0.00	0.00, 0.00	-12.50, 0.00
Min, Max	0.0, 100.0	75.0, 100.0	37.5, 100.0	0.0, 12.5	-25.0, 0.0	-62.5, 25.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.7.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=6)	(N=6)	(N=19)	(N=6)	(N=6)	(N=19)
Sexual Function						
Baseline						
m	6	6	19			
n	2	1	6			
Mean (SD)	95.85 (5.87)	85.00 (N/A)	95.27 (6.01)			
Median	95.85	85.00	96.65			
IQR: Q1, Q3	91.70, 100.00	85.00, 85.00	93.30, 100.00			
Min, Max	91.7, 100.0	85.0, 85.0	85.0, 100.0			
Week 24						
m	5	5	18			
n	1	1	5	1	1	4
Mean (SD/SE)	91.70 (N/A)	85.00 (N/A)	95.66 (6.63)	-8.30 (N/A)	0.00 (N/A)	1.68 (1.68)
Median	91.70	85.00	100.00	-8.30	0	0
IQR: Q1, Q3	91.70, 91.70	85.00, 85.00	93.30, 100.00	-8.30, -8.30	0.00, 0.00	0.00, 3.35
Min, Max	91.7, 91.7	85.0, 85.0	85.0, 100.0	-8.3, -8.3	0.0, 0.0	0.0, 6.7
Week 52						
m	5	5	17			
n	1	1	6	1	1	4
Mean (SD/SE)	100.00 (N/A)	93.30 (N/A)	93.88 (9.71)	0.00 (N/A)	8.30 (N/A)	-0.40 (3.07)
Median	100.00	93.30	100.00	0	8.30	0
IQR: Q1, Q3	100.00, 100.00	93.30, 93.30	85.00, 100.00	0.00, 0.00	8.30, 8.30	-4.15, 3.35
Min, Max	100.0, 100.0	93.3, 93.3	78.3, 100.0	0.0, 0.0	8.3, 8.3	-8.3, 6.7

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.7.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter		Visit Result			Change from Baseline		
		DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Sleep							
	Baseline						
	m	6	6	19			
	n	6	6	18			
	Mean (SD)	70.8 (17.2)	69.2 (9.2)	68.3 (18.9)			
	Median	75.0	65.0	70.0			
	IQR: Q1, Q3	65.0, 80.0	65.0, 75.0	55.0, 85.0			
	Min, Max	40, 90	60, 85	35, 100			
	Week 24						
	m	5	5	18			
	n	4	5	16	4	5	16
	Mean (SD/SE)	71.3 (7.5)	62.0 (18.2)	70.0 (14.1)	1.3 (7.2)	-8.0 (5.4)	0.0 (3.4)
	Median	75.0	60.0	70.0	0	-5.0	5.0
	IQR: Q1, Q3	67.5, 75.0	55.0, 65.0	60.0, 80.0	-7.5, 10.0	-15.0, 0.0	-10.0, 7.5
	Min, Max	60, 75	40, 90	45, 95	-15, 20	-25, 5	-30, 20
	Week 52						
	m	5	5	17			
	n	5	5	16	5	5	16
	Mean (SD/SE)	67.0 (22.0)	62.0 (9.1)	68.1 (18.9)	-5.0 (2.7)	-8.0 (3.7)	-1.9 (4.7)
	Median	75.0	60.0	70.0	-5.0	-10.0	0
	IQR: Q1, Q3	65.0, 80.0	60.0, 65.0	55.0, 82.5	-10.0, -5.0	-15.0, -5.0	-15.0, 7.5
	Min, Max	30, 85	50, 75	35, 95	-10, 5	-15, 5	-35, 35

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.7.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=6)	Visit Result DB Placebo (N=19)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=6)	Change from Baseline DB Placebo (N=19)
Loneliness						
Baseline						
m	6	6	19			
n	6	6	18			
Mean (SD)	92.5 (8.2)	90.0 (19.7)	93.6 (9.4)			
Median	92.5	97.5	100.0			
IQR: Q1, Q3	85.0, 100.0	95.0, 100.0	90.0, 100.0			
Min, Max	85, 100	50, 100	75, 100			
Week 24						
m	5	5	18			
n	4	5	16	4	5	16
Mean (SD/SE)	88.8 (13.1)	87.0 (21.1)	86.9 (18.0)	-3.8 (2.4)	-11.0 (9.8)	-5.9 (3.8)
Median	90.0	95.0	95.0	-2.5	0	0
IQR: Q1, Q3	77.5, 100.0	90.0, 100.0	80.0, 100.0	-7.5, 0.0	-5.0, 0.0	-12.5, 0.0
Min, Max	75, 100	50, 100	35, 100	-10, 0	-50, 0	-45, 10
Week 52						
m	5	5	17			
n	5	5	16	5	5	16
Mean (SD/SE)	96.0 (8.9)	91.0 (10.2)	90.0 (15.9)	2.0 (3.4)	-7.0 (5.4)	-2.8 (3.4)
Median	100.0	95.0	100.0	0	0	0
IQR: Q1, Q3	100.0, 100.0	80.0, 100.0	82.5, 100.0	0.0, 0.0	-20.0, 0.0	-5.0, 0.0
Min, Max	80, 100	80, 100	45, 100	-5, 15	-20, 5	-35, 20

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.7.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=6)	Visit Result DB Placebo (N=19)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=6)	Change from Baseline DB Placebo (N=19)
Hopelessness						
Baseline						
m	6	6	19			
n	6	6	18			
Mean (SD)	90.28 (12.27)	93.07 (13.34)	87.51 (19.65)			
Median	95.85	100.00	91.70			
IQR: Q1, Q3	75.00, 100.00	91.70, 100.00	83.30, 100.00			
Min, Max	75.0, 100.0	66.7, 100.0	33.3, 100.0			
Week 24						
m	5	5	18			
n	4	5	16	4	5	16
Mean (SD/SE)	95.83 (8.35)	80.00 (24.02)	85.94 (23.72)	-2.10 (2.10)	-11.68 (9.72)	0.00 (2.74)
Median	100.00	91.70	95.85	0	0	0
IQR: Q1, Q3	91.65, 100.00	58.30, 100.00	83.35, 100.00	-4.20, 0.00	-8.40, 0.00	-8.30, 4.15
Min, Max	83.3, 100.0	50.0, 100.0	25.0, 100.0	-8.4, 0.0	-50.0, 0.0	-16.7, 25.0
Week 52						
m	5	5	17			
n	5	5	16	5	5	16
Mean (SD/SE)	93.32 (9.15)	86.68 (18.24)	85.94 (18.19)	-0.02 (2.64)	-5.00 (7.26)	-0.01 (3.88)
Median	100.00	100.00	91.70	0	0	0
IQR: Q1, Q3	83.30, 100.00	66.70, 100.00	79.15, 100.00	0.00, 0.00	0.00, 0.00	-4.20, 12.50
Min, Max	83.3, 100.0	66.7, 100.0	50.0, 100.0	-8.4, 8.3	-33.3, 8.3	-33.4, 25.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.7.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=6)	(N=6)	(N=19)	(N=6)	(N=6)	(N=19)
Stigma of Liver Disease						
Baseline						
m	6	6	19			
n	6	6	18			
Mean (SD)	93.75 (10.46)	84.40 (18.86)	89.60 (14.84)			
Median	100.00	87.55	100.00			
IQR: Q1, Q3	87.50, 100.00	81.30, 100.00	81.30, 100.00			
Min, Max	75.0, 100.0	50.0, 100.0	50.0, 100.0			
Week 24						
m	5	5	18			
n	4	5	16	4	5	16
Mean (SD/SE)	92.20 (11.83)	81.26 (20.73)	86.34 (25.74)	-1.55 (1.55)	-0.02 (16.89)	-5.48 (3.32)
Median	96.90	81.30	100.00	0	0	0
IQR: Q1, Q3	84.40, 100.00	75.00, 100.00	81.30, 100.00	-3.10, 0.00	-18.80, 18.70	-6.25, 0.00
Min, Max	75.0, 100.0	50.0, 100.0	0.0, 100.0	-6.2, 0.0	-50.0, 50.0	-50.0, 6.2
Week 52						
m	5	5	17			
n	5	5	16	5	5	16
Mean (SD/SE)	88.76 (21.83)	83.78 (20.07)	87.92 (17.44)	-3.74 (6.12)	2.50 (15.39)	-3.89 (3.82)
Median	100.00	93.80	93.80	0	0	0
IQR: Q1, Q3	93.80, 100.00	81.30, 93.80	81.30, 100.00	-6.20, 0.00	0.00, 18.70	-6.20, 0.00
Min, Max	50.0, 100.0	50.0, 100.0	43.8, 100.0	-25.0, 12.5	-50.0, 43.8	-56.2, 12.5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.7.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter		Visit Result			Change from Baseline		
Visit	Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Total LDQOL							
Baseline							
	m	3	9	9			
	n	3	8	8			
	Mean (SD)	76.57 (14.31)	87.79 (4.95)	86.24 (8.14)			
	Median	72.40	88.85	84.10			
	IQR: Q1, Q3	64.80, 92.50	85.00, 91.20	79.50, 94.70			
	Min, Max	64.8, 92.5	78.6, 93.6	76.3, 97.0			
Week 24							
	m	3	7	9			
	n	3	6	9	3	6	8
	Mean (SD/SE)	79.27 (9.57)	84.88 (9.03)	84.96 (10.80)	2.70 (3.12)	-2.55 (2.88)	-0.71 (2.59)
	Median	74.20	81.05	83.80	1.80	-2.95	-0.40
	IQR: Q1, Q3	73.30, 90.30	77.80, 93.10	80.00, 94.70	-2.20, 8.50	-9.40, 4.50	-5.00, 1.50
	Min, Max	73.3, 90.3	77.4, 98.9	68.1, 97.1	-2.2, 8.5	-10.6, 6.1	-11.2, 13.3
Week 52							
	m	3	7	9			
	n	2	5	8	2	5	7
	Mean (SD/SE)	84.05 (6.29)	84.50 (7.29)	83.81 (11.20)	1.60 (5.60)	-2.50 (1.50)	-2.77 (2.61)
	Median	84.05	85.50	86.65	1.60	-1.30	-1.40
	IQR: Q1, Q3	79.60, 88.50	79.00, 88.70	73.45, 93.60	-4.00, 7.20	-4.10, 0.10	-8.70, 0.70
	Min, Max	79.6, 88.5	75.6, 93.7	67.6, 95.5	-4.0, 7.2	-7.6, 0.4	-14.5, 6.8

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.7.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=3)	(N=9)	(N=9)	(N=3)	(N=9)	(N=9)
Symptoms of Liver Disease						
Baseline						
m	3	9	9			
n	3	8	8			
Mean (SD)	76.67 (21.89)	82.08 (13.69)	80.83 (16.61)			
Median	80.00	81.65	86.65			
IQR: Q1, Q3	53.30, 96.70	80.00, 90.00	66.65, 95.00			
Min, Max	53.3, 96.7	53.3, 100.0	53.3, 96.7			
Week 24						
m	3	7	9			
n	3	6	9	3	6	8
Mean (SD/SE)	77.77 (19.54)	86.12 (11.03)	84.07 (12.00)	1.10 (9.70)	5.02 (9.61)	5.84 (5.30)
Median	70.00	88.35	83.30	3.30	5.00	1.65
IQR: Q1, Q3	63.30, 100.00	83.30, 90.00	80.00, 93.30	-16.70, 16.70	-3.30, 20.00	-3.30, 8.35
Min, Max	63.3, 100.0	66.7, 100.0	63.3, 100.0	-16.7, 16.7	-33.3, 36.7	-6.7, 40.0
Week 52						
m	3	7	9			
n	2	5	8	2	5	7
Mean (SD/SE)	85.00 (11.74)	79.32 (14.78)	85.40 (10.97)	-3.35 (0.05)	2.00 (3.43)	5.23 (4.54)
Median	85.00	83.30	86.65	-3.35	3.30	3.30
IQR: Q1, Q3	76.70, 93.30	73.30, 90.00	76.65, 93.30	-3.40, -3.30	-3.30, 3.40	-3.40, 6.70
Min, Max	76.7, 93.3	56.7, 93.3	70.0, 100.0	-3.4, -3.3	-6.7, 13.3	-6.7, 30.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.7.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=3)	(N=9)	(N=9)	(N=3)	(N=9)	(N=9)
Effects of Liver Disease						
Baseline						
m	3	9	9			
n	3	8	8			
Mean (SD)	71.10 (34.23)	84.18 (7.93)	82.50 (4.95)			
Median	80.00	83.35	80.00			
IQR: Q1, Q3	33.30, 100.00	80.00, 86.70	80.00, 83.35			
Min, Max	33.3, 100.0	73.3, 100.0	80.0, 93.3			
Week 24						
m	3	7	9			
n	3	6	9	3	6	8
Mean (SD/SE)	80.00 (0.00)	81.10 (9.82)	80.74 (4.03)	8.90 (19.76)	-3.35 (5.38)	-1.66 (2.09)
Median	80.00	80.00	80.00	0	-6.70	0
IQR: Q1, Q3	80.00, 80.00	73.30, 80.00	80.00, 80.00	-20.00, 46.70	-6.70, 0.00	-3.35, 0.00
Min, Max	80.0, 80.0	73.3, 100.0	73.3, 86.7	-20.0, 46.7	-20.0, 20.0	-13.3, 6.7
Week 52						
m	3	7	9			
n	2	5	8	2	5	7
Mean (SD/SE)	80.00 (0.00)	80.00 (4.74)	83.34 (5.04)	-10.00 (10.00)	-5.34 (3.89)	2.86 (1.98)
Median	80.00	80.00	80.00	-10.00	0	0
IQR: Q1, Q3	80.00, 80.00	80.00, 80.00	80.00, 86.70	-20.00, 0.00	-6.70, 0.00	0.00, 6.70
Min, Max	80.0, 80.0	73.3, 86.7	80.0, 93.3	-20.0, 0.0	-20.0, 0.0	0.0, 13.3

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.7.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=3)	(N=9)	(N=9)	(N=3)	(N=9)	(N=9)
Concentration/Memory						
Baseline						
m	3	9	9			
n	3	8	8			
Mean (SD)	83.33 (19.09)	88.30 (19.30)	88.30 (12.23)			
Median	87.50	96.90	90.65			
IQR: Q1, Q3	62.50, 100.00	84.40, 100.00	78.15, 100.00			
Min, Max	62.5, 100.0	43.8, 100.0	68.8, 100.0			
Week 24						
m	3	7	9			
n	3	6	9	3	6	8
Mean (SD/SE)	72.93 (21.97)	82.32 (18.29)	88.21 (12.26)	-10.40 (9.10)	-4.17 (3.83)	2.34 (4.57)
Median	75.00	81.30	87.50	-12.50	0	0
IQR: Q1, Q3	50.00, 93.80	81.30, 100.00	87.50, 100.00	-25.00, 6.30	-12.50, 0.00	-9.40, 15.60
Min, Max	50.0, 93.8	50.0, 100.0	68.8, 100.0	-25.0, 6.3	-18.7, 6.2	-12.5, 18.8
Week 52						
m	3	7	9			
n	2	5	8	2	5	7
Mean (SD/SE)	78.15 (13.22)	81.26 (23.37)	87.53 (11.57)	3.15 (3.15)	-6.26 (5.58)	-1.79 (4.46)
Median	78.15	87.50	90.65	3.15	0	0
IQR: Q1, Q3	68.80, 87.50	75.00, 100.00	78.15, 96.90	0.00, 6.30	-12.50, 0.00	-6.20, 6.20
Min, Max	68.8, 87.5	43.8, 100.0	68.8, 100.0	0.0, 6.3	-25.0, 6.2	-25.0, 12.5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.7.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=3)	(N=9)	(N=9)	(N=3)	(N=9)	(N=9)
Health Distress						
Baseline						
m	3	9	9			
n	3	8	8			
Mean (SD)	87.50 (12.50)	93.75 (6.68)	95.31 (9.30)			
Median	87.50	93.75	100.00			
IQR: Q1, Q3	75.00, 100.00	87.50, 100.00	93.75, 100.00			
Min, Max	75.0, 100.0	87.5, 100.0	75.0, 100.0			
Week 24						
m	3	7	9			
n	3	6	9	3	6	8
Mean (SD/SE)	95.83 (7.22)	93.75 (10.46)	94.44 (12.67)	8.33 (8.33)	0.00 (5.59)	-1.56 (2.83)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	87.50, 100.00	87.50, 100.00	100.00, 100.00	0.00, 25.00	0.00, 12.50	-6.25, 0.00
Min, Max	87.5, 100.0	75.0, 100.0	62.5, 100.0	0.0, 25.0	-25.0, 12.5	-12.5, 12.5
Week 52						
m	3	7	9			
n	2	5	8	2	5	7
Mean (SD/SE)	100.00 (0.00)	95.00 (11.18)	98.44 (4.42)	6.25 (6.25)	2.50 (7.29)	0.00 (2.73)
Median	100.00	100.00	100.00	6.25	12.50	0
IQR: Q1, Q3	100.00, 100.00	100.00, 100.00	100.00, 100.00	0.00, 12.50	0.00, 12.50	0.00, 0.00
Min, Max	100.0, 100.0	75.0, 100.0	87.5, 100.0	0.0, 12.5	-25.0, 12.5	-12.5, 12.5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.7.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=9)	Visit Result DB Placebo (N=9)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=9)	Change from Baseline DB Placebo (N=9)
Sexual Function						
Baseline						
m	3	9	9			
n	2	5	7			
Mean (SD)	88.30 (7.07)	97.00 (6.71)	85.71 (12.14)			
Median	88.30	100.00	85.00			
IQR: Q1, Q3	83.30, 93.30	100.00, 100.00	76.70, 100.00			
Min, Max	83.3, 93.3	85.0, 100.0	68.3, 100.0			
Week 24						
m	3	7	9			
n	1	4	5	1	4	5
Mean (SD/SE)	70.00 (N/A)	88.33 (19.15)	84.66 (22.29)	-23.30 (N/A)	-7.93 (5.91)	-4.68 (6.84)
Median	70.00	96.65	93.30	-23.30	-3.35	0
IQR: Q1, Q3	70.00, 70.00	76.65, 100.00	83.30, 100.00	-23.30, -23.30	-15.85, 0.00	0.00, 1.60
Min, Max	70.0, 70.0	60.0, 100.0	46.7, 100.0	-23.3, -23.3	-25.0, 0.0	-31.6, 6.6
Week 52						
m	3	7	9			
n	1	3	5	1	3	4
Mean (SD/SE)	85.00 (N/A)	97.77 (3.87)	61.32 (40.72)	-8.30 (N/A)	-2.23 (2.23)	-20.00 (14.96)
Median	85.00	100.00	68.30	-8.30	0	-8.35
IQR: Q1, Q3	85.00, 85.00	93.30, 100.00	23.30, 100.00	-8.30, -8.30	-6.70, 0.00	-40.00, 0.00
Min, Max	85.0, 85.0	93.3, 100.0	15.0, 100.0	-8.3, -8.3	-6.7, 0.0	-63.3, 0.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.7.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=3)	(N=9)	(N=9)	(N=3)	(N=9)	(N=9)
Sleep						
Baseline						
m	3	9	9			
n	3	8	8			
Mean (SD)	40.0 (36.1)	75.0 (10.0)	67.5 (28.7)			
Median	50.0	75.0	70.0			
IQR: Q1, Q3	0.0, 70.0	67.5, 82.5	40.0, 95.0			
Min, Max	0, 70	60, 90	30, 100			
Week 24						
m	3	7	9			
n	3	6	9	3	6	8
Mean (SD/SE)	43.3 (38.8)	70.0 (13.0)	69.4 (21.4)	3.3 (1.7)	-0.8 (3.5)	3.1 (4.8)
Median	55.0	67.5	70.0	5.0	0	0
IQR: Q1, Q3	0.0, 75.0	60.0, 80.0	60.0, 90.0	0.0, 5.0	-5.0, 5.0	-7.5, 10.0
Min, Max	0, 75	55, 90	35, 100	0, 5	-15, 10	-10, 30
Week 52						
m	3	7	9			
n	2	5	8	2	5	7
Mean (SD/SE)	60.0 (7.1)	67.0 (12.0)	70.6 (19.0)	0.0 (5.0)	-5.0 (5.2)	-1.4 (5.9)
Median	60.0	70.0	70.0	0	0	0
IQR: Q1, Q3	55.0, 65.0	60.0, 75.0	57.5, 87.5	-5.0, 5.0	-5.0, 0.0	-15.0, 15.0
Min, Max	55, 65	50, 80	40, 95	-5, 5	-25, 5	-25, 20

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.7.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=3)	(N=9)	(N=9)	(N=3)	(N=9)	(N=9)
Loneliness						
Baseline						
m	3	9	9			
n	3	8	8			
Mean (SD)	83.3 (20.8)	95.0 (7.1)	93.1 (12.5)			
Median	90.0	97.5	100.0			
IQR: Q1, Q3	60.0, 100.0	92.5, 100.0	90.0, 100.0			
Min, Max	60, 100	80, 100	65, 100			
Week 24						
m	3	7	9			
n	3	6	9	3	6	8
Mean (SD/SE)	93.3 (7.6)	87.5 (15.4)	88.3 (17.7)	10.0 (7.6)	-10.8 (6.8)	-6.3 (4.5)
Median	95.0	92.5	100.0	5.0	-5.0	0
IQR: Q1, Q3	85.0, 100.0	80.0, 100.0	70.0, 100.0	0.0, 25.0	-20.0, 0.0	-7.5, 0.0
Min, Max	85, 100	60, 100	60, 100	0, 25	-40, 5	-35, 0
Week 52						
m	3	7	9			
n	2	5	8	2	5	7
Mean (SD/SE)	87.5 (17.7)	89.0 (24.6)	84.4 (16.6)	7.5 (7.5)	-10.0 (11.3)	-10.0 (4.2)
Median	87.5	100.0	87.5	7.5	0	-5.0
IQR: Q1, Q3	75.0, 100.0	100.0, 100.0	70.0, 100.0	0.0, 15.0	0.0, 0.0	-20.0, 0.0
Min, Max	75, 100	45, 100	60, 100	0, 15	-55, 5	-30, 0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.7.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=3)	(N=9)	(N=9)	(N=3)	(N=9)	(N=9)
Hopelessness						
Baseline						
m	3	9	9			
n	3	8	8			
Mean (SD)	83.37 (14.43)	92.71 (14.40)	89.59 (18.23)			
Median	91.70	100.00	100.00			
IQR: Q1, Q3	66.70, 91.70	91.70, 100.00	83.35, 100.00			
Min, Max	66.7, 91.7	58.3, 100.0	50.0, 100.0			
Week 24						
m	3	7	9			
n	3	6	9	3	6	8
Mean (SD/SE)	86.13 (17.33)	90.27 (17.03)	87.97 (20.87)	2.77 (14.70)	-1.40 (1.40)	-1.04 (4.84)
Median	91.70	100.00	100.00	8.30	0	0
IQR: Q1, Q3	66.70, 100.00	83.30, 100.00	83.30, 100.00	-25.00, 25.00	0.00, 0.00	-4.15, 0.00
Min, Max	66.7, 100.0	58.3, 100.0	41.7, 100.0	-25.0, 25.0	-8.4, 0.0	-25.0, 25.0
Week 52						
m	3	7	9			
n	2	5	8	2	5	7
Mean (SD/SE)	95.85 (5.87)	95.00 (7.46)	90.63 (18.60)	16.65 (16.65)	5.00 (5.00)	1.19 (4.61)
Median	95.85	100.00	100.00	16.65	0	0
IQR: Q1, Q3	91.70, 100.00	91.70, 100.00	87.50, 100.00	0.00, 33.30	0.00, 0.00	0.00, 0.00
Min, Max	91.7, 100.0	83.3, 100.0	50.0, 100.0	0.0, 33.3	0.0, 25.0	-16.7, 25.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.7.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=9)	Visit Result DB Placebo (N=9)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=9)	Change from Baseline DB Placebo (N=9)
Stigma of Liver Disease						
Baseline						
m	3	9	9			
n	3	8	8			
Mean (SD)	83.37 (9.57)	86.74 (11.29)	92.20 (9.88)			
Median	81.30	81.30	96.90			
IQR: Q1, Q3	75.00, 93.80	78.15, 100.00	84.40, 100.00			
Min, Max	75.0, 93.8	75.0, 100.0	75.0, 100.0			
Week 24						
m	3	7	9			
n	3	6	9	3	6	8
Mean (SD/SE)	91.70 (9.53)	87.50 (15.81)	86.12 (17.88)	8.33 (8.33)	-1.05 (2.50)	-6.25 (5.14)
Median	93.80	93.75	87.50	0	0	-6.25
IQR: Q1, Q3	81.30, 100.00	75.00, 100.00	87.50, 100.00	0.00, 25.00	0.00, 0.00	-12.50, 0.00
Min, Max	81.3, 100.0	62.5, 100.0	43.8, 100.0	0.0, 25.0	-12.5, 6.2	-31.2, 18.7
Week 52						
m	3	7	9			
n	2	5	8	2	5	7
Mean (SD/SE)	87.55 (8.84)	82.50 (16.77)	84.39 (20.58)	0.00 (0.00)	-3.76 (3.76)	-8.93 (6.65)
Median	87.55	75.00	90.65	0	0	0
IQR: Q1, Q3	81.30, 93.80	75.00, 100.00	75.00, 100.00	0.00, 0.00	0.00, 0.00	-31.20, 0.00
Min, Max	81.3, 93.8	62.5, 100.0	43.8, 100.0	0.0, 0.0	-18.8, 0.0	-37.5, 6.2

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc. Page 1 of 3
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.7.2Liver Disease Quality of Life (SE20): Summary of Total LDQOL - MMRM Model
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable; T2D = Type 2 Diabetes.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.7.2Liver Disease Quality of Life (SE20): Summary of Total LDQOL - MMRM Model
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Total LDQOL			
Week 24			
m	5	5	18
n	4	5	16
Baseline Mean (SD)	84.13 (17.93)	88.14 (6.45)	86.35 (8.52)
Analysis Visit Mean (SD)	84.48 (14.50)	84.52 (8.50)	83.76 (11.65)
LS Mean of Change from Baseline (SE)	0.84 (4.12)	-2.76 (3.88)	-1.70 (2.91)
95% CI	(-7.68, 9.37)	(-10.78, 5.26)	(-7.71, 4.31)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.54 (4.49)	-1.06 (4.15)	
95% CI	(-6.74, 11.82)	(-9.65, 7.52)	
p-value	0.5769	0.8000	
Corrected Hedge's g Statistics	0.219	-0.092	
95% CI	(-0.88, 1.32)	(-1.10, 0.91)	
Week 52			
m	5	5	17
n	5	5	16
Baseline Mean (SD)	85.06 (15.67)	88.14 (6.45)	86.35 (8.52)
Analysis Visit Mean (SD)	81.58 (23.36)	84.66 (3.56)	83.18 (12.68)
LS Mean of Change from Baseline (SE)	-2.91 (5.01)	-2.81 (5.03)	-2.27 (3.41)
95% CI	(-13.28, 7.46)	(-13.22, 7.61)	(-9.33, 4.79)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.64 (5.55)	-0.53 (5.55)	
95% CI	(-12.11, 10.84)	(-12.01, 10.94)	
p-value	0.9097	0.9240	
Corrected Hedge's g Statistics	-0.046	-0.039	
95% CI	(-1.05, 0.96)	(-1.04, 0.97)	
Subgroup*Treatment Interaction p-value	0.8031	0.9133	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.7.2Liver Disease Quality of Life (SE20): Summary of Total LDQOL - MMRM Model
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Total LDQOL			
Week 24			
m	3	7	9
n	3	6	8
Baseline Mean (SD)	76.57 (14.31)	87.43 (5.79)	86.24 (8.14)
Analysis Visit Mean (SD)	79.27 (9.57)	84.88 (9.03)	85.53 (11.40)
LS Mean of Change from Baseline (SE)	1.72 (4.62)	-2.36 (2.96)	-0.65 (2.54)
95% CI	(-8.12, 11.56)	(-8.67, 3.95)	(-6.07, 4.77)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.37 (5.32)	-1.71 (3.89)	
95% CI	(-8.97, 13.71)	(-10.00, 6.58)	
p-value	0.6623	0.6668	
Corrected Hedge's g Statistics	0.294	-0.222	
95% CI	(-1.04, 1.63)	(-1.28, 0.84)	
Week 52			
m	3	7	9
n	2	5	7
Baseline Mean (SD)	82.45 (14.21)	87.00 (6.37)	87.33 (8.14)
Analysis Visit Mean (SD)	84.05 (6.29)	84.50 (7.29)	84.56 (11.88)
LS Mean of Change from Baseline (SE)	2.62 (4.17)	-3.32 (2.65)	-2.44 (2.26)
95% CI	(-6.27, 11.51)	(-8.96, 2.33)	(-7.26, 2.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.06 (4.80)	-0.88 (3.46)	
95% CI	(-5.16, 15.28)	(-8.26, 6.50)	
p-value	0.3082	0.8030	
Corrected Hedge's g Statistics	0.752	-0.136	
95% CI	(-0.86, 2.36)	(-1.29, 1.01)	
Subgroup*Treatment Interaction p-value	0.8031	0.9133	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.7.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable; T2D = Type 2 Diabetes.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

AMNOG Table SE20.7.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Symptoms of Liver Disease			
Week 24			
m	5	5	18
n	4	5	16
Baseline Mean (SD)	90.85 (10.31)	90.66 (4.96)	83.54 (15.33)
Analysis Visit Mean (SD)	91.68 (8.83)	92.00 (5.04)	81.46 (17.39)
LS Mean of Change from Baseline (SE)	6.18 (7.56)	6.11 (6.97)	-1.52 (4.75)
95% CI	(-9.47, 21.82)	(-8.31, 20.53)	(-11.36, 8.31)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.70 (8.30)	7.64 (7.68)	
95% CI	(-9.47, 24.88)	(-8.26, 23.54)	
p-value	0.3633	0.3305	
Corrected Hedge's g Statistics	0.400	0.400	
95% CI	(-0.70, 1.50)	(-0.61, 1.41)	
Week 52			
m	5	5	17
n	5	5	16
Baseline Mean (SD)	91.34 (9.00)	90.66 (4.96)	83.54 (15.33)
Analysis Visit Mean (SD)	86.00 (16.55)	84.68 (13.86)	85.00 (14.40)
LS Mean of Change from Baseline (SE)	-1.64 (6.13)	-2.55 (6.10)	2.86 (4.36)
95% CI	(-14.32, 11.03)	(-15.17, 10.07)	(-6.17, 11.88)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.50 (6.64)	-5.41 (6.62)	
95% CI	(-18.25, 9.24)	(-19.10, 8.28)	
p-value	0.5048	0.4219	
Corrected Hedge's g Statistics	-0.258	-0.311	
95% CI	(-1.27, 0.75)	(-1.32, 0.70)	
Subgroup*Treatment Interaction p-value	0.5533	0.5480	

AMNOG Table SE20.7.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Effects of Liver Disease			
Week 24			
m	5	5	18
n	4	5	16
Baseline Mean (SD)	71.68 (16.65)	89.34 (10.11)	81.26 (6.98)
Analysis Visit Mean (SD)	80.00 (0.00)	86.66 (9.42)	78.34 (9.89)
LS Mean of Change from Baseline (SE)	-0.68 (5.30)	5.25 (4.85)	-2.57 (3.42)
95% CI	(-11.65, 10.29)	(-4.78, 15.27)	(-9.64, 4.50)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.88 (5.65)	7.81 (5.23)	
95% CI	(-9.81, 13.58)	(-3.01, 18.63)	
p-value	0.7419	0.1489	
Corrected Hedge's g Statistics	0.137	0.572	
95% CI	(-0.96, 1.23)	(-0.45, 1.59)	
Week 52			
m	5	5	17
n	5	5	16
Baseline Mean (SD)	74.68 (15.91)	89.34 (10.11)	81.26 (6.98)
Analysis Visit Mean (SD)	70.66 (28.90)	84.00 (8.94)	79.59 (7.49)
LS Mean of Change from Baseline (SE)	-5.32 (6.04)	-3.03 (6.08)	-1.18 (3.93)
95% CI	(-17.82, 7.18)	(-15.61, 9.55)	(-9.32, 6.95)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.14 (6.56)	-1.85 (6.70)	
95% CI	(-17.71, 9.44)	(-15.71, 12.02)	
p-value	0.5345	0.7851	
Corrected Hedge's g Statistics	-0.260	-0.116	
95% CI	(-1.27, 0.75)	(-1.12, 0.89)	
Subgroup*Treatment Interaction p-value	0.6370	0.1095	

AMNOG Table SE20.7.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Concentration/Memory			
Week 24			
m	5	5	18
n	4	5	16
Baseline Mean (SD)	85.95 (28.10)	82.52 (21.37)	89.07 (15.89)
Analysis Visit Mean (SD)	84.40 (27.22)	88.76 (15.57)	87.13 (14.51)
LS Mean of Change from Baseline (SE)	0.60 (6.96)	7.02 (6.46)	3.42 (4.88)
95% CI	(-13.79, 15.00)	(-6.34, 20.39)	(-6.68, 13.52)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.82 (7.61)	3.60 (7.08)	
95% CI	(-18.55, 12.92)	(-11.04, 18.25)	
p-value	0.7146	0.6156	
Corrected Hedge's g Statistics	-0.144	0.186	
95% CI	(-1.24, 0.95)	(-0.82, 1.19)	
Week 52			
m	5	5	17
n	5	5	16
Baseline Mean (SD)	86.26 (24.35)	82.52 (21.37)	89.07 (15.89)
Analysis Visit Mean (SD)	72.50 (41.83)	88.76 (11.17)	81.28 (21.89)
LS Mean of Change from Baseline (SE)	-10.74 (8.23)	9.04 (8.25)	-3.20 (5.66)
95% CI	(-27.77, 6.30)	(-8.04, 26.12)	(-14.90, 8.51)
LS Mean of Change from Baseline Compared to Placebo (SE)	-7.54 (9.13)	12.24 (9.22)	
95% CI	(-26.43, 11.35)	(-6.84, 31.31)	
p-value	0.4173	0.1974	
Corrected Hedge's g Statistics	-0.332	0.538	
95% CI	(-1.34, 0.68)	(-0.48, 1.56)	
Subgroup*Treatment Interaction p-value	0.6385	0.1202	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.7.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Health Distress			
Week 24			
m	5	5	18
n	4	5	16
Baseline Mean (SD)	68.75 (47.32)	100.00 (0.00)	93.75 (14.43)
Analysis Visit Mean (SD)	71.88 (48.28)	97.50 (5.59)	90.63 (14.79)
LS Mean of Change from Baseline (SE)	0.17 (7.03)	-0.85 (6.27)	-2.27 (4.65)
95% CI	(-14.38, 14.71)	(-13.82, 12.11)	(-11.89, 7.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.44 (7.75)	1.42 (6.65)	
95% CI	(-13.59, 18.47)	(-12.33, 15.16)	
p-value	0.7557	0.8330	
Corrected Hedge's g Statistics	0.130	0.077	
95% CI	(-0.97, 1.23)	(-0.93, 1.08)	
Week 52			
m	5	5	17
n	5	5	16
Baseline Mean (SD)	75.00 (43.30)	100.00 (0.00)	93.75 (14.43)
Analysis Visit Mean (SD)	77.50 (43.66)	95.00 (11.18)	86.72 (19.08)
LS Mean of Change from Baseline (SE)	0.31 (8.23)	-3.31 (7.96)	-6.16 (5.38)
95% CI	(-16.71, 17.33)	(-19.78, 13.16)	(-17.30, 4.97)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.48 (9.16)	2.85 (8.68)	
95% CI	(-12.46, 25.42)	(-15.11, 20.81)	
p-value	0.4864	0.7454	
Corrected Hedge's g Statistics	0.297	0.132	
95% CI	(-0.71, 1.31)	(-0.87, 1.14)	
Subgroup*Treatment Interaction p-value	0.4868	0.6256	

AMNOG Table SE20.7.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Sexual Function			
Week 24			
m	5	5	18
n	1	1	4
Baseline Mean (SD)	100.00 (N/A)	85.00 (N/A)	94.58 (7.12)
Analysis Visit Mean (SD)	91.70 (N/A)	85.00 (N/A)	96.25 (7.50)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	5	17
n	1	1	4
Baseline Mean (SD)	100.00 (N/A)	85.00 (N/A)	96.65 (3.87)
Analysis Visit Mean (SD)	100.00 (N/A)	93.30 (N/A)	96.25 (7.50)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	0.0001	

AMNOG Table SE20.7.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Sleep			
Week 24			
m	5	5	18
n	4	5	16
Baseline Mean (SD)	70.0 (21.2)	70.0 (10.0)	70.0 (18.0)
Analysis Visit Mean (SD)	71.3 (7.5)	62.0 (18.2)	70.0 (14.1)
LS Mean of Change from Baseline (SE)	0.42 (5.72)	-9.23 (5.39)	-1.75 (4.12)
95% CI	(-11.41, 12.25)	(-20.39, 1.93)	(-10.26, 6.77)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.17 (6.20)	-7.48 (5.78)	
95% CI	(-10.66, 14.99)	(-19.44, 4.48)	
p-value	0.7300	0.2085	
Corrected Hedge's g Statistics	0.132	-0.459	
95% CI	(-0.96, 1.23)	(-1.47, 0.55)	
Week 52			
m	5	5	17
n	5	5	16
Baseline Mean (SD)	72.0 (18.9)	70.0 (10.0)	70.0 (18.0)
Analysis Visit Mean (SD)	67.0 (22.0)	62.0 (9.1)	68.1 (18.9)
LS Mean of Change from Baseline (SE)	-5.47 (7.17)	-9.21 (7.18)	-3.60 (4.89)
95% CI	(-20.30, 9.36)	(-24.05, 5.64)	(-13.72, 6.52)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.87 (7.94)	-5.61 (7.92)	
95% CI	(-18.29, 14.55)	(-22.00, 10.79)	
p-value	0.8160	0.4865	
Corrected Hedge's g Statistics	-0.095	-0.285	
95% CI	(-1.10, 0.91)	(-1.29, 0.72)	
Subgroup*Treatment Interaction p-value	0.3783	0.6303	

AMNOG Table SE20.7.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Loneliness			
Week 24			
m	5	5	18
n	4	5	16
Baseline Mean (SD)	92.5 (8.7)	98.0 (2.7)	92.8 (9.7)
Analysis Visit Mean (SD)	88.8 (13.1)	87.0 (21.1)	86.9 (18.0)
LS Mean of Change from Baseline (SE)	-2.04 (7.99)	-9.09 (7.76)	-3.24 (5.29)
95% CI	(-18.58, 14.50)	(-25.15, 6.97)	(-14.18, 7.69)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.20 (8.70)	-5.84 (8.47)	
95% CI	(-16.80, 19.20)	(-23.36, 11.67)	
p-value	0.8912	0.4970	
Corrected Hedge's g Statistics	0.057	-0.275	
95% CI	(-1.04, 1.15)	(-1.28, 0.73)	
Week 52			
m	5	5	17
n	5	5	16
Baseline Mean (SD)	94.0 (8.2)	98.0 (2.7)	92.8 (9.7)
Analysis Visit Mean (SD)	96.0 (8.9)	91.0 (10.2)	90.0 (15.9)
LS Mean of Change from Baseline (SE)	3.88 (6.22)	-4.01 (6.42)	-0.41 (4.72)
95% CI	(-8.99, 16.75)	(-17.30, 9.28)	(-10.17, 9.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.29 (6.67)	-3.60 (6.82)	
95% CI	(-9.50, 18.08)	(-17.72, 10.52)	
p-value	0.5263	0.6030	
Corrected Hedge's g Statistics	0.230	-0.192	
95% CI	(-0.78, 1.24)	(-1.20, 0.81)	
Subgroup*Treatment Interaction p-value	0.3067	0.7223	

AMNOG Table SE20.7.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Hopelessness			
Week 24			
m	5	5	18
n	4	5	16
Baseline Mean (SD)	97.93 (4.15)	91.68 (14.42)	85.94 (20.35)
Analysis Visit Mean (SD)	95.83 (8.35)	80.00 (24.02)	85.94 (23.72)
LS Mean of Change from Baseline (SE)	0.71 (6.88)	-9.04 (6.53)	3.85 (4.80)
95% CI	(-13.53, 14.95)	(-22.55, 4.47)	(-6.08, 13.78)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.14 (7.50)	-12.89 (7.11)	
95% CI	(-18.66, 12.38)	(-27.61, 1.82)	
p-value	0.6795	0.0829	
Corrected Hedge's g Statistics	-0.163	-0.675	
95% CI	(-1.26, 0.93)	(-1.70, 0.35)	
Week 52			
m	5	5	17
n	5	5	16
Baseline Mean (SD)	93.34 (10.86)	91.68 (14.42)	85.94 (20.35)
Analysis Visit Mean (SD)	93.32 (9.15)	86.68 (18.24)	85.94 (18.19)
LS Mean of Change from Baseline (SE)	4.39 (6.15)	-1.23 (6.13)	2.77 (4.63)
95% CI	(-8.34, 17.12)	(-13.91, 11.45)	(-6.80, 12.34)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.62 (6.65)	-4.00 (6.62)	
95% CI	(-12.15, 15.38)	(-17.69, 9.69)	
p-value	0.8103	0.5513	
Corrected Hedge's g Statistics	0.088	-0.218	
95% CI	(-0.92, 1.09)	(-1.22, 0.79)	
Subgroup*Treatment Interaction p-value	0.8396	0.2559	

AMNOG Table SE20.7.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Stigma of Liver Disease			
Week 24			
m	5	5	18
n	4	5	16
Baseline Mean (SD)	93.75 (12.50)	81.28 (19.27)	91.81 (13.82)
Analysis Visit Mean (SD)	92.20 (11.83)	81.26 (20.73)	86.34 (25.74)
LS Mean of Change from Baseline (SE)	1.03 (10.35)	-1.10 (9.78)	-5.20 (7.11)
95% CI	(-20.39, 22.44)	(-21.33, 19.13)	(-19.90, 9.50)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.23 (11.12)	4.10 (11.01)	
95% CI	(-16.78, 29.23)	(-18.67, 26.87)	
p-value	0.5811	0.7130	
Corrected Hedge's g Statistics	0.218	0.145	
95% CI	(-0.88, 1.32)	(-0.86, 1.15)	
Week 52			
m	5	5	17
n	5	5	16
Baseline Mean (SD)	92.50 (11.18)	81.28 (19.27)	91.81 (13.82)
Analysis Visit Mean (SD)	88.76 (21.83)	83.78 (20.07)	87.92 (17.44)
LS Mean of Change from Baseline (SE)	-2.21 (9.03)	-2.63 (9.05)	-2.76 (6.82)
95% CI	(-20.88, 16.47)	(-21.34, 16.08)	(-16.87, 11.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.55 (9.62)	0.13 (10.15)	
95% CI	(-19.35, 20.45)	(-20.87, 21.13)	
p-value	0.9550	0.9901	
Corrected Hedge's g Statistics	0.020	0.005	
95% CI	(-0.98, 1.02)	(-1.00, 1.01)	
Subgroup*Treatment Interaction p-value	0.1547	0.9687	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.7.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Symptoms of Liver Disease			
Week 24			
m	3	7	9
n	3	6	8
Baseline Mean (SD)	76.67 (21.89)	81.10 (16.02)	80.83 (16.61)
Analysis Visit Mean (SD)	77.77 (19.54)	86.12 (11.03)	86.66 (9.76)
LS Mean of Change from Baseline (SE)	-2.34 (7.09)	5.32 (4.98)	5.90 (4.32)
95% CI	(-17.45, 12.77)	(-5.31, 15.94)	(-3.30, 15.10)
LS Mean of Change from Baseline Compared to Placebo (SE)	-8.25 (8.30)	-0.59 (6.59)	
95% CI	(-25.94, 9.45)	(-14.64, 13.46)	
p-value	0.3364	0.9300	
Corrected Hedge's g Statistics	-0.617	-0.045	
95% CI	(-1.97, 0.73)	(-1.10, 1.01)	
Week 52			
m	3	7	9
n	2	5	7
Baseline Mean (SD)	88.35 (11.81)	77.32 (14.61)	82.37 (17.31)
Analysis Visit Mean (SD)	85.00 (11.74)	79.32 (14.78)	87.60 (9.76)
LS Mean of Change from Baseline (SE)	-0.70 (5.48)	-1.35 (3.55)	5.69 (3.01)
95% CI	(-12.39, 10.99)	(-8.92, 6.22)	(-0.73, 12.10)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.38 (6.23)	-7.04 (4.67)	
95% CI	(-19.66, 6.89)	(-17.00, 2.92)	
p-value	0.3214	0.1528	
Corrected Hedge's g Statistics	-0.715	-0.817	
95% CI	(-2.32, 0.89)	(-2.01, 0.38)	
Subgroup*Treatment Interaction p-value	0.5533	0.5480	

AMNOG Table SE20.7.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Effects of Liver Disease			
Week 24			
m	3	7	9
n	3	6	8
Baseline Mean (SD)	71.10 (34.23)	84.45 (9.12)	82.50 (4.95)
Analysis Visit Mean (SD)	80.00 (0.00)	81.10 (9.82)	80.84 (4.29)
LS Mean of Change from Baseline (SE)	-2.20 (4.21)	-1.30 (2.81)	-1.53 (2.42)
95% CI	(-11.17, 6.77)	(-7.29, 4.69)	(-6.70, 3.63)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.67 (4.86)	0.23 (3.71)	
95% CI	(-11.03, 9.69)	(-7.68, 8.14)	
p-value	0.8926	0.9507	
Corrected Hedge's g Statistics	-0.088	0.032	
95% CI	(-1.42, 1.24)	(-1.03, 1.09)	
Week 52			
m	3	7	9
n	2	5	7
Baseline Mean (SD)	90.00 (14.14)	85.34 (9.90)	80.96 (2.53)
Analysis Visit Mean (SD)	80.00 (0.00)	80.00 (4.74)	83.81 (5.24)
LS Mean of Change from Baseline (SE)	-3.65 (3.71)	-3.06 (2.24)	1.67 (1.85)
95% CI	(-11.56, 4.26)	(-7.82, 1.71)	(-2.27, 5.61)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.33 (4.24)	-4.73 (2.95)	
95% CI	(-14.36, 3.71)	(-11.03, 1.56)	
p-value	0.2283	0.1298	
Corrected Hedge's g Statistics	-0.958	-0.885	
95% CI	(-2.59, 0.67)	(-2.09, 0.32)	
Subgroup*Treatment Interaction p-value	0.6370	0.1095	

AMNOG Table SE20.7.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Concentration/Memory			
Week 24			
m	3	7	9
n	3	6	8
Baseline Mean (SD)	83.33 (19.09)	86.48 (22.14)	88.30 (12.23)
Analysis Visit Mean (SD)	72.93 (21.97)	82.32 (18.29)	90.64 (10.55)
LS Mean of Change from Baseline (SE)	-11.63 (6.44)	-4.31 (4.53)	2.82 (3.93)
95% CI	(-25.36, 2.09)	(-13.98, 5.35)	(-5.57, 11.20)
LS Mean of Change from Baseline Compared to Placebo (SE)	-14.45 (7.56)	-7.13 (6.00)	
95% CI	(-30.57, 1.67)	(-19.93, 5.67)	
p-value	0.0754	0.2534	
Corrected Hedge's g Statistics	-1.187	-0.601	
95% CI	(-2.60, 0.23)	(-1.68, 0.48)	
Week 52			
m	3	7	9
n	2	5	7
Baseline Mean (SD)	75.00 (17.68)	87.52 (24.59)	90.20 (11.87)
Analysis Visit Mean (SD)	78.15 (13.22)	81.26 (23.37)	88.41 (12.19)
LS Mean of Change from Baseline (SE)	-0.96 (8.16)	-6.00 (4.99)	-0.56 (4.26)
95% CI	(-18.35, 16.43)	(-16.63, 4.63)	(-9.64, 8.52)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.41 (9.35)	-5.44 (6.55)	
95% CI	(-20.33, 19.52)	(-19.40, 8.52)	
p-value	0.9660	0.4189	
Corrected Hedge's g Statistics	-0.032	-0.448	
95% CI	(-1.60, 1.54)	(-1.61, 0.71)	
Subgroup*Treatment Interaction p-value	0.6385	0.1202	

AMNOG Table SE20.7.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Health Distress			
Week 24			
m	3	7	9
n	3	6	8
Baseline Mean (SD)	87.50 (12.50)	93.75 (6.85)	95.31 (9.30)
Analysis Visit Mean (SD)	95.83 (7.22)	93.75 (10.46)	93.75 (13.36)
LS Mean of Change from Baseline (SE)	5.20 (6.70)	-0.28 (4.48)	-1.12 (3.89)
95% CI	(-9.09, 19.49)	(-9.82, 9.27)	(-9.41, 7.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.32 (7.84)	0.85 (5.94)	
95% CI	(-10.39, 23.03)	(-11.82, 13.51)	
p-value	0.4326	0.8885	
Corrected Hedge's g Statistics	0.519	0.072	
95% CI	(-0.83, 1.86)	(-0.99, 1.13)	
Week 52			
m	3	7	9
n	2	5	7
Baseline Mean (SD)	93.75 (8.84)	92.50 (6.85)	98.21 (4.72)
Analysis Visit Mean (SD)	100.00 (0.00)	95.00 (11.18)	98.21 (4.72)
LS Mean of Change from Baseline (SE)	4.90 (5.14)	-0.03 (3.32)	6.17 (3.08)
95% CI	(-6.05, 15.86)	(-7.10, 7.04)	(-0.39, 12.74)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.27 (6.04)	-6.21 (4.73)	
95% CI	(-14.15, 11.61)	(-16.28, 3.87)	
p-value	0.8363	0.2092	
Corrected Hedge's g Statistics	-0.141	-0.728	
95% CI	(-1.71, 1.43)	(-1.91, 0.46)	
Subgroup*Treatment Interaction p-value	0.4868	0.6256	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.7.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Sexual Function			
Week 24			
m	3	7	9
n	1	4	5
Baseline Mean (SD)	93.30 (N/A)	96.25 (7.50)	89.34 (11.34)
Analysis Visit Mean (SD)	70.00 (N/A)	88.33 (19.15)	84.66 (22.29)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	3	7	9
n	1	3	4
Baseline Mean (SD)	93.30 (N/A)	100.00 (0.00)	90.83 (10.94)
Analysis Visit Mean (SD)	85.00 (N/A)	97.77 (3.87)	70.83 (40.10)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	0.0001	

AMNOG Table SE20.7.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Sleep			
Week 24			
m	3	7	9
n	3	6	8
Baseline Mean (SD)	40.0 (36.1)	70.8 (7.4)	67.5 (28.7)
Analysis Visit Mean (SD)	43.3 (38.8)	70.0 (13.0)	70.6 (22.6)
LS Mean of Change from Baseline (SE)	-1.15 (6.81)	-0.19 (4.33)	3.22 (3.73)
95% CI	(-15.67, 13.38)	(-9.41, 9.04)	(-4.73, 11.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.36 (7.79)	-3.40 (5.71)	
95% CI	(-20.98, 12.25)	(-15.57, 8.76)	
p-value	0.5838	0.5598	
Corrected Hedge's g Statistics	-0.368	-0.301	
95% CI	(-1.70, 0.97)	(-1.37, 0.76)	
Week 52			
m	3	7	9
n	2	5	7
Baseline Mean (SD)	60.0 (14.1)	72.0 (7.6)	72.9 (26.3)
Analysis Visit Mean (SD)	60.0 (7.1)	67.0 (12.0)	71.4 (20.4)
LS Mean of Change from Baseline (SE)	-6.23 (7.81)	-3.38 (4.96)	1.14 (4.26)
95% CI	(-22.88, 10.42)	(-13.95, 7.19)	(-7.94, 10.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	-7.37 (8.97)	-4.51 (6.47)	
95% CI	(-26.49, 11.76)	(-18.31, 9.28)	
p-value	0.4245	0.4962	
Corrected Hedge's g Statistics	-0.583	-0.372	
95% CI	(-2.18, 1.01)	(-1.53, 0.79)	
Subgroup*Treatment Interaction p-value	0.3783	0.6303	

AMNOG Table SE20.7.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Loneliness			
Week 24			
m	3	7	9
n	3	6	8
Baseline Mean (SD)	83.3 (20.8)	98.3 (2.6)	93.1 (12.5)
Analysis Visit Mean (SD)	93.3 (7.6)	87.5 (15.4)	86.9 (18.3)
LS Mean of Change from Baseline (SE)	7.07 (8.85)	-9.24 (6.10)	-6.23 (5.07)
95% CI	(-11.81, 25.94)	(-22.24, 3.75)	(-17.05, 4.58)
LS Mean of Change from Baseline Compared to Placebo (SE)	13.30 (10.21)	-3.01 (7.93)	
95% CI	(-8.47, 35.06)	(-19.91, 13.88)	
p-value	0.2124	0.7092	
Corrected Hedge's g Statistics	0.834	-0.193	
95% CI	(-0.54, 2.21)	(-1.25, 0.87)	
Week 52			
m	3	7	9
n	2	5	7
Baseline Mean (SD)	80.0 (28.3)	99.0 (2.2)	92.1 (13.2)
Analysis Visit Mean (SD)	87.5 (17.7)	89.0 (24.6)	82.1 (16.5)
LS Mean of Change from Baseline (SE)	3.06 (11.52)	-7.72 (7.49)	-9.11 (6.16)
95% CI	(-21.49, 27.61)	(-23.69, 8.25)	(-22.24, 4.02)
LS Mean of Change from Baseline Compared to Placebo (SE)	12.17 (13.01)	1.39 (9.73)	
95% CI	(-15.56, 39.91)	(-19.35, 22.13)	
p-value	0.3644	0.8880	
Corrected Hedge's g Statistics	0.664	0.078	
95% CI	(-0.94, 2.27)	(-1.07, 1.23)	
Subgroup*Treatment Interaction p-value	0.3067	0.7223	

AMNOG Table SE20.7.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Hopelessness			
Week 24			
m	3	7	9
n	3	6	8
Baseline Mean (SD)	83.37 (14.43)	91.67 (16.68)	89.59 (18.23)
Analysis Visit Mean (SD)	86.13 (17.33)	90.27 (17.03)	88.55 (22.23)
LS Mean of Change from Baseline (SE)	1.97 (8.18)	-0.90 (5.78)	-0.86 (4.97)
95% CI	(-15.47, 19.42)	(-13.21, 11.41)	(-11.46, 9.74)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.83 (9.60)	-0.04 (7.60)	
95% CI	(-17.64, 23.31)	(-16.23, 16.16)	
p-value	0.7720	0.9961	
Corrected Hedge's g Statistics	0.184	-0.003	
95% CI	(-1.15, 1.51)	(-1.06, 1.06)	
Week 52			
m	3	7	9
n	2	5	7
Baseline Mean (SD)	79.20 (17.68)	90.00 (18.08)	88.10 (19.16)
Analysis Visit Mean (SD)	95.85 (5.87)	95.00 (7.46)	89.29 (19.67)
LS Mean of Change from Baseline (SE)	1.16 (7.73)	6.19 (5.32)	1.34 (4.57)
95% CI	(-15.33, 17.64)	(-5.15, 17.54)	(-8.39, 11.07)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.18 (9.00)	4.85 (7.00)	
95% CI	(-19.36, 19.00)	(-10.06, 19.77)	
p-value	0.9843	0.4983	
Corrected Hedge's g Statistics	-0.013	0.373	
95% CI	(-1.58, 1.56)	(-0.78, 1.53)	
Subgroup*Treatment Interaction p-value	0.8396	0.2559	

AMNOG Table SE20.7.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Stigma of Liver Disease			
Week 24			
m	3	7	9
n	3	6	8
Baseline Mean (SD)	83.37 (9.57)	88.55 (12.75)	92.20 (9.88)
Analysis Visit Mean (SD)	91.70 (9.53)	87.50 (15.81)	85.95 (19.11)
LS Mean of Change from Baseline (SE)	8.74 (7.54)	-0.98 (5.17)	-6.43 (4.54)
95% CI	(-7.33, 24.82)	(-12.00, 10.03)	(-16.11, 3.26)
LS Mean of Change from Baseline Compared to Placebo (SE)	15.17 (8.98)	5.44 (6.92)	
95% CI	(-3.97, 34.31)	(-9.30, 20.19)	
p-value	0.1118	0.4437	
Corrected Hedge's g Statistics	1.075	0.399	
95% CI	(-0.33, 2.48)	(-0.67, 1.47)	
Week 52			
m	3	7	9
n	2	5	7
Baseline Mean (SD)	87.55 (8.84)	86.26 (12.80)	92.87 (10.47)
Analysis Visit Mean (SD)	87.55 (8.84)	82.50 (16.77)	83.94 (22.19)
LS Mean of Change from Baseline (SE)	5.89 (9.74)	-3.27 (6.37)	-9.95 (5.48)
95% CI	(-14.87, 26.65)	(-16.84, 10.31)	(-21.62, 1.73)
LS Mean of Change from Baseline Compared to Placebo (SE)	15.84 (11.29)	6.68 (8.54)	
95% CI	(-8.24, 39.91)	(-11.53, 24.89)	
p-value	0.1812	0.4463	
Corrected Hedge's g Statistics	0.978	0.429	
95% CI	(-0.66, 2.61)	(-0.73, 1.59)	
Subgroup*Treatment Interaction p-value	0.1547	0.9687	

AMNOG Table SE20.7.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; T2D = Type 2 Diabetes.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis, only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.

AMNOG Table SE20.7.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	6 (100)	6 (100)	19 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (16.7)	4 (21.1)
No	6 (100)	5 (83.3)	15 (78.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.77	1.33	
95% CI of the inverse odds ratio	(0.18, 80.65)	(0.12, 14.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.15	1.26	
95% CI of the inverse risk ratio	(0.19, 51.39)	(0.17, 9.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-15.36	-4.39	
95% CI of the absolute risk difference	(-41.79, 11.08)	(-39.39, 30.62)	
p-value	0.3680	0.8149	
p-value of Breslow-Day Test for Homogeneity [3]	0.1078	0.4153	

AMNOG Table SE20.7.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (16.7)	2 (10.5)
No	6 (100)	5 (83.3)	17 (89.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.86	0.59	
95% CI of the inverse odds ratio	(0.08, 44.08)	(0.04, 7.91)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.75	0.63	
95% CI of the inverse risk ratio	(0.10, 32.18)	(0.07, 5.80)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.36	6.14	
95% CI of the absolute risk difference	(-29.32, 18.60)	(-26.72, 39.00)	
p-value	0.6979	0.6866	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.2731	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (16.7)	7 (36.8)
No	6 (100)	5 (83.3)	12 (63.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	7.80	2.92	
95% CI of the inverse odds ratio	(0.38, 159.12)	(0.28, 30.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.25	2.21	
95% CI of the inverse risk ratio	(0.34, 80.52)	(0.34, 14.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-30.36	-20.18	
95% CI of the absolute risk difference	(-58.89, -1.82)	(-57.05, 16.70)	
p-value	0.1301	0.3557	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.8563	

AMNOG Table SE20.7.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (5.3)
No	6 (100)	6 (100)	18 (94.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	1.05	
95% CI of the inverse odds ratio	(0.04, 29.24)	(0.04, 29.24)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	1.05	
95% CI of the inverse risk ratio	(0.05, 22.91)	(0.05, 22.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.36	-0.36	
95% CI of the absolute risk difference	(-22.66, 21.94)	(-22.66, 21.94)	
p-value	0.9752	0.9752	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (16.7)	1 (16.7)	2 (10.5)
No	5 (83.3)	5 (83.3)	17 (89.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	0.59	
95% CI of the inverse odds ratio	(0.04, 7.91)	(0.04, 7.91)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	0.63	
95% CI of the inverse risk ratio	(0.07, 5.80)	(0.07, 5.80)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.14	6.14	
95% CI of the absolute risk difference	(-26.72, 39.00)	(-26.72, 39.00)	
p-value	0.6866	0.6866	
p-value of Breslow-Day Test for Homogeneity [3]	0.3158	0.1420	

AMNOG Table SE20.7.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (16.7)	0
No	6 (100)	5 (83.3)	19 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.09	
95% CI of the inverse odds ratio	NE	(0.00, 2.65)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.12	
95% CI of the inverse risk ratio	NE	(0.01, 2.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	18.93	
95% CI of the absolute risk difference	NE	(-12.23, 50.09)	
p-value	NE	0.0998	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (33.3)	4 (21.1)
No	6 (100)	4 (66.7)	15 (78.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.77	0.53	
95% CI of the inverse odds ratio	(0.18, 80.65)	(0.07, 4.04)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.15	0.63	
95% CI of the inverse risk ratio	(0.19, 51.39)	(0.15, 2.63)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-15.36	12.28	
95% CI of the absolute risk difference	(-41.79, 11.08)	(-29.66, 54.22)	
p-value	0.3680	0.5392	
p-value of Breslow-Day Test for Homogeneity [3]	0.1993	0.3799	

AMNOG Table SE20.7.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (5.3)
No	6 (100)	6 (100)	18 (94.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	1.05	
95% CI of the inverse odds ratio	(0.04, 29.24)	(0.04, 29.24)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	1.05	
95% CI of the inverse risk ratio	(0.05, 22.91)	(0.05, 22.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.36	-0.36	
95% CI of the absolute risk difference	(-22.66, 21.94)	(-22.66, 21.94)	
p-value	0.9752	0.9752	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (16.7)	0	2 (10.5)
No	5 (83.3)	6 (100)	17 (89.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	1.86	
95% CI of the inverse odds ratio	(0.04, 7.91)	(0.08, 44.08)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	1.75	
95% CI of the inverse risk ratio	(0.07, 5.80)	(0.10, 32.18)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.14	-5.36	
95% CI of the absolute risk difference	(-26.72, 39.00)	(-29.32, 18.60)	
p-value	0.6866	0.6979	
p-value of Breslow-Day Test for Homogeneity [3]	0.6813	0.2051	

AMNOG Table SE20.7.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	6 (100)	6 (100)	19 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (16.7)	1 (5.3)
No	6 (100)	5 (83.3)	18 (94.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	0.28	
95% CI of the inverse odds ratio	(0.04, 29.24)	(0.01, 5.27)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	0.32	
95% CI of the inverse risk ratio	(0.05, 22.91)	(0.02, 4.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.36	11.40	
95% CI of the absolute risk difference	(-22.66, 21.94)	(-20.06, 42.87)	
p-value	0.9752	0.3694	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE20.7.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	3 (15.8)
No	6 (100)	6 (100)	16 (84.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.76	2.76	
95% CI of the inverse odds ratio	(0.12, 61.16)	(0.12, 61.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.45	2.45	
95% CI of the inverse risk ratio	(0.14, 41.74)	(0.14, 41.74)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.36	-10.36	
95% CI of the absolute risk difference	(-35.68, 14.97)	(-35.68, 14.97)	
p-value	0.5068	0.5068	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (16.7)	1 (16.7)	7 (36.8)
No	5 (83.3)	5 (83.3)	12 (63.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.92	2.92	
95% CI of the inverse odds ratio	(0.28, 30.30)	(0.28, 30.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.21	2.21	
95% CI of the inverse risk ratio	(0.34, 14.54)	(0.34, 14.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-20.18	-20.18	
95% CI of the absolute risk difference	(-57.05, 16.70)	(-57.05, 16.70)	
p-value	0.3557	0.3557	
p-value of Breslow-Day Test for Homogeneity [3]	0.3765	0.8913	

AMNOG Table SE20.7.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (16.7)	0	2 (10.5)
No	5 (83.3)	6 (100)	17 (89.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	1.86	
95% CI of the inverse odds ratio	(0.04, 7.91)	(0.08, 44.08)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	1.75	
95% CI of the inverse risk ratio	(0.07, 5.80)	(0.10, 32.18)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.14	-5.36	
95% CI of the absolute risk difference	(-26.72, 39.00)	(-29.32, 18.60)	
p-value	0.6866	0.6979	
p-value of Breslow-Day Test for Homogeneity [3]	0.2361	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (16.7)	1 (16.7)	3 (15.8)
No	5 (83.3)	5 (83.3)	16 (84.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	0.94	
95% CI of the inverse odds ratio	(0.08, 11.15)	(0.08, 11.15)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	0.95	
95% CI of the inverse risk ratio	(0.12, 7.50)	(0.12, 7.50)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.88	0.88	
95% CI of the absolute risk difference	(-33.15, 34.91)	(-33.15, 34.91)	
p-value	0.9592	0.9592	
p-value of Breslow-Day Test for Homogeneity [3]	0.1608	0.3751	

AMNOG Table SE20.7.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	4 (21.1)
No	6 (100)	6 (100)	15 (78.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.77	3.77	
95% CI of the inverse odds ratio	(0.18, 80.65)	(0.18, 80.65)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.15	3.15	
95% CI of the inverse risk ratio	(0.19, 51.39)	(0.19, 51.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-15.36	-15.36	
95% CI of the absolute risk difference	(-41.79, 11.08)	(-41.79, 11.08)	
p-value	0.3680	0.3680	
p-value of Breslow-Day Test for Homogeneity [3]	0.1078	0.2861	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (16.7)	1 (16.7)	5 (26.3)
No	5 (83.3)	5 (83.3)	14 (73.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.79	1.79	
95% CI of the inverse odds ratio	(0.17, 19.25)	(0.17, 19.25)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.58	1.58	
95% CI of the inverse risk ratio	(0.23, 11.00)	(0.23, 11.00)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.65	-9.65	
95% CI of the absolute risk difference	(-45.44, 26.15)	(-45.44, 26.15)	
p-value	0.6295	0.6295	
p-value of Breslow-Day Test for Homogeneity [3]	0.3140	0.7628	

AMNOG Table SE20.7.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	2 (33.3)	0
No	6 (100)	4 (66.7)	19 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.05	
95% CI of the inverse odds ratio	NE	(0.00, 1.14)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.07	
95% CI of the inverse risk ratio	NE	(0.00, 1.29)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	33.21	
95% CI of the absolute risk difference	NE	(-2.94, 69.36)	
p-value	NE	0.0161	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (16.7)	2 (33.3)	2 (10.5)
No	5 (83.3)	4 (66.7)	17 (89.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	0.24	
95% CI of the inverse odds ratio	(0.04, 7.91)	(0.02, 2.22)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	0.32	
95% CI of the inverse risk ratio	(0.07, 5.80)	(0.06, 1.78)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.14	22.81	
95% CI of the absolute risk difference	(-26.72, 39.00)	(-17.36, 62.97)	
p-value	0.6866	0.1840	
p-value of Breslow-Day Test for Homogeneity [3]	0.4727	0.1208	

AMNOG Table SE20.7.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	3 (100)	9 (100)	9 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (33.3)	0	1 (11.1)
No	2 (66.7)	9 (100)	8 (88.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.25	3.35	
95% CI of the inverse odds ratio	(0.01, 5.98)	(0.12, 93.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	3.00	
95% CI of the inverse risk ratio	(0.03, 3.84)	(0.14, 65.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	22.22	-10.00	
95% CI of the absolute risk difference	(-34.94, 79.38)	(-35.93, 15.93)	
p-value	0.3711	0.4561	
p-value of Breslow-Day Test for Homogeneity [3]	0.1078	0.4153	

AMNOG Table SE20.7.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (11.1)
No	3 (100)	9 (100)	8 (88.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.24	3.35	
95% CI of the inverse odds ratio	(0.04, 38.30)	(0.12, 93.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	3.00	
95% CI of the inverse risk ratio	(0.06, 23.70)	(0.14, 65.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-10.00	
95% CI of the absolute risk difference	(-41.75, 36.75)	(-35.93, 15.93)	
p-value	0.9039	0.4561	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.2731	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (11.1)	3 (33.3)
No	3 (100)	8 (88.9)	6 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.77	4.00	
95% CI of the inverse odds ratio	(0.15, 95.82)	(0.33, 48.66)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.80	3.00	
95% CI of the inverse risk ratio	(0.18, 42.80)	(0.38, 23.68)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-22.50	-22.22	
95% CI of the absolute risk difference	(-66.37, 21.37)	(-59.24, 14.79)	
p-value	0.3999	0.2568	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.8563	

AMNOG Table SE20.7.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	3 (100)	9 (100)	9 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	2 (22.2)
No	3 (100)	9 (100)	7 (77.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.33	6.33	
95% CI of the inverse odds ratio	(0.09, 62.68)	(0.26, 152.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	5.00	
95% CI of the inverse risk ratio	(0.12, 33.10)	(0.27, 91.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-12.50	-20.00	
95% CI of the absolute risk difference	(-54.58, 29.58)	(-50.05, 10.05)	
p-value	0.6066	0.2104	
p-value of Breslow-Day Test for Homogeneity [3]	0.3158	0.1420	

AMNOG Table SE20.7.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	3 (100)	9 (100)	9 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (33.3)	1 (11.1)	2 (22.2)
No	2 (66.7)	8 (88.9)	7 (77.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	2.29	
95% CI of the inverse odds ratio	(0.03, 10.07)	(0.17, 30.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	2.00	
95% CI of the inverse risk ratio	(0.09, 4.99)	(0.22, 18.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.11	-11.11	
95% CI of the absolute risk difference	(-48.75, 70.97)	(-45.16, 22.94)	
p-value	0.7003	0.5271	
p-value of Breslow-Day Test for Homogeneity [3]	0.1993	0.3799	

AMNOG Table SE20.7.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	3 (100)	9 (100)	9 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (33.3)	3 (33.3)	1 (11.1)
No	2 (66.7)	6 (66.7)	8 (88.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.25	0.25	
95% CI of the inverse odds ratio	(0.01, 5.98)	(0.02, 3.04)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	0.33	
95% CI of the inverse risk ratio	(0.03, 3.84)	(0.04, 2.63)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	22.22	22.22	
95% CI of the absolute risk difference	(-34.94, 79.38)	(-14.79, 59.24)	
p-value	0.3711	0.2568	
p-value of Breslow-Day Test for Homogeneity [3]	0.6813	0.2051	

AMNOG Table SE20.7.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	3 (100)	9 (100)	9 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	3 (100)	9 (100)	9 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE20.7.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (22.2)
No	3 (100)	9 (100)	7 (77.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.33	6.33	
95% CI of the inverse odds ratio	(0.09, 62.68)	(0.26, 152.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	5.00	
95% CI of the inverse risk ratio	(0.12, 33.10)	(0.27, 91.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-12.50	-20.00	
95% CI of the absolute risk difference	(-54.58, 29.58)	(-50.05, 10.05)	
p-value	0.6066	0.2104	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (33.3)	1 (11.1)	2 (22.2)
No	2 (66.7)	8 (88.9)	7 (77.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	2.29	
95% CI of the inverse odds ratio	(0.03, 10.07)	(0.17, 30.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	2.00	
95% CI of the inverse risk ratio	(0.09, 4.99)	(0.22, 18.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.11	-11.11	
95% CI of the absolute risk difference	(-48.75, 70.97)	(-45.16, 22.94)	
p-value	0.7003	0.5271	
p-value of Breslow-Day Test for Homogeneity [3]	0.3765	0.8913	

AMNOG Table SE20.7.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (33.3)	0	0
No	2 (66.7)	9 (100)	9 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.09	NE	
95% CI of the inverse odds ratio	(0.00, 2.88)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.13	NE	
95% CI of the inverse risk ratio	(0.01, 2.63)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	32.50	NE	
95% CI of the absolute risk difference	(-16.83, 81.83)	NE	
p-value	0.1164	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2361	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (33.3)	1 (11.1)	0
No	2 (66.7)	8 (88.9)	9 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.09	0.30	
95% CI of the inverse odds ratio	(0.00, 2.88)	(0.01, 8.35)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.13	0.33	
95% CI of the inverse risk ratio	(0.01, 2.63)	(0.02, 7.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	32.50	10.00	
95% CI of the absolute risk difference	(-16.83, 81.83)	(-15.93, 35.93)	
p-value	0.1164	0.4561	
p-value of Breslow-Day Test for Homogeneity [3]	0.1608	0.3751	

AMNOG Table SE20.7.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (33.3)	1 (11.1)	1 (11.1)
No	2 (66.7)	8 (88.9)	8 (88.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.25	1.00	
95% CI of the inverse odds ratio	(0.01, 5.98)	(0.05, 18.91)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	1.00	
95% CI of the inverse risk ratio	(0.03, 3.84)	(0.07, 13.64)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	22.22	0.00	
95% CI of the absolute risk difference	(-34.94, 79.38)	(-29.04, 29.04)	
p-value	0.3711	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.1078	0.2861	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (33.3)	1 (11.1)	1 (11.1)
No	2 (66.7)	8 (88.9)	8 (88.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.25	1.00	
95% CI of the inverse odds ratio	(0.01, 5.98)	(0.05, 18.91)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	1.00	
95% CI of the inverse risk ratio	(0.03, 3.84)	(0.07, 13.64)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	22.22	0.00	
95% CI of the absolute risk difference	(-34.94, 79.38)	(-29.04, 29.04)	
p-value	0.3711	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.3140	0.7628	

Program: t-se18-02-04-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.7.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	3 (100)	9 (100)	9 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	1 (11.1)
No	3 (100)	9 (100)	8 (88.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.24	3.35	
95% CI of the inverse odds ratio	(0.04, 38.30)	(0.12, 93.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	3.00	
95% CI of the inverse risk ratio	(0.06, 23.70)	(0.14, 65.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-10.00	
95% CI of the absolute risk difference	(-41.75, 36.75)	(-35.93, 15.93)	
p-value	0.9039	0.4561	
p-value of Breslow-Day Test for Homogeneity [3]	0.4727	0.1208	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.8.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=2)	(N=7)	(N=1)	(N=2)	(N=7)
Total LDQOL						
Baseline						
m	1	2	7			
n	1	2	7			
Mean (SD)	76.50 (N/A)	83.85 (9.12)	84.17 (10.40)			
Median	76.50	83.85	87.80			
IQR: Q1, Q3	76.50, 76.50	77.40, 90.30	76.10, 91.50			
Min, Max	76.5, 76.5	77.4, 90.3	64.4, 93.1			
Week 24						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	88.70 (11.88)	82.07 (16.19)	N/A	4.85 (1.95)	-0.88 (3.07)
Median	N/A	88.70	83.25	N/A	4.85	-0.20
IQR: Q1, Q3	N/A	80.30, 97.10	81.70, 94.10	N/A	2.90, 6.80	-6.10, 6.40
Min, Max	N/A	80.3, 97.1	52.0, 98.1	N/A	2.9, 6.8	-12.4, 7.2
Week 52						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	87.20 (1.56)	83.05 (14.21)	N/A	3.35 (5.35)	0.10 (2.67)
Median	N/A	87.20	84.90	N/A	3.35	1.55
IQR: Q1, Q3	N/A	86.10, 88.30	78.80, 93.60	N/A	-2.00, 8.70	-6.40, 5.70
Min, Max	N/A	86.1, 88.3	58.0, 98.1	N/A	-2.0, 8.7	-9.0, 7.2

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.8.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=2)	(N=7)	(N=1)	(N=2)	(N=7)
Symptoms of Liver Disease						
Baseline						
m	1	2	7			
n	1	2	7			
Mean (SD)	86.70 (N/A)	88.30 (7.07)	84.29 (10.14)			
Median	86.70	88.30	86.70			
IQR: Q1, Q3	86.70, 86.70	83.30, 93.30	80.00, 90.00			
Min, Max	86.7, 86.7	83.3, 93.3	63.3, 93.3			
Week 24						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	93.35 (9.40)	81.65 (17.23)	N/A	5.05 (1.65)	-1.13 (4.45)
Median	N/A	93.35	86.65	N/A	5.05	-0.05
IQR: Q1, Q3	N/A	86.70, 100.00	70.00, 93.30	N/A	3.40, 6.70	-10.00, 10.00
Min, Max	N/A	86.7, 100.0	53.3, 100.0	N/A	3.4, 6.7	-16.7, 10.0
Week 52						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	98.35 (2.33)	83.32 (16.04)	N/A	10.05 (6.65)	0.53 (3.59)
Median	N/A	98.35	88.30	N/A	10.05	3.30
IQR: Q1, Q3	N/A	96.70, 100.00	73.30, 93.30	N/A	3.40, 16.70	-6.60, 6.60
Min, Max	N/A	96.7, 100.0	56.7, 100.0	N/A	3.4, 16.7	-13.4, 10.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.8.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter / Visit / Statistic	Visit Result: DB MGL-3196 80 mg (N=1)	Visit Result: DB MGL-3196 100 mg (N=2)	Visit Result: DB Placebo (N=7)	Change from Baseline: DB MGL-3196 80 mg (N=1)	Change from Baseline: DB MGL-3196 100 mg (N=2)	Change from Baseline: DB Placebo (N=7)
Effects of Liver Disease						
Baseline						
m	1	2	7			
n	1	2	7			
Mean (SD)	66.70 (N/A)	100.00 (0.00)	81.90 (8.36)			
Median	66.70	100.00	80.00			
IQR: Q1, Q3	66.70, 66.70	100.00, 100.00	80.00, 80.00			
Min, Max	66.7, 66.7	100.0, 100.0	73.3, 100.0			
Week 24						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	86.65 (9.40)	75.55 (15.01)	N/A	-13.35 (6.65)	-6.67 (8.07)
Median	N/A	86.65	76.65	N/A	-13.35	-3.35
IQR: Q1, Q3	N/A	80.00, 93.30	60.00, 80.00	N/A	-20.00, -6.70	-13.30, 0.00
Min, Max	N/A	80.0, 93.3	60.0, 100.0	N/A	-20.0, -6.7	-40.0, 20.0
Week 52						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	80.00 (0.00)	80.00 (11.15)	N/A	-20.00 (0.00)	-2.22 (6.13)
Median	N/A	80.00	80.00	N/A	-20.00	0
IQR: Q1, Q3	N/A	80.00, 80.00	73.30, 80.00	N/A	-20.00, -20.00	-6.60, 0.00
Min, Max	N/A	80.0, 80.0	66.7, 100.0	N/A	-20.0, -20.0	-26.7, 20.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.8.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=2)	(N=7)	(N=1)	(N=2)	(N=7)
Concentration/Memory						
Baseline						
m	1	2	7			
n	1	2	7			
Mean (SD)	56.30 (N/A)	59.40 (4.38)	83.94 (21.61)			
Median	56.30	59.40	87.50			
IQR: Q1, Q3	56.30, 56.30	56.30, 62.50	81.30, 100.00			
Min, Max	56.3, 56.3	56.3, 62.5	37.5, 100.0			
Week 24						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	78.15 (22.13)	89.60 (11.62)	N/A	18.75 (12.55)	7.30 (5.92)
Median	N/A	78.15	90.65	N/A	18.75	6.25
IQR: Q1, Q3	N/A	62.50, 93.80	87.50, 100.00	N/A	6.20, 31.30	0.00, 12.50
Min, Max	N/A	62.5, 93.8	68.8, 100.0	N/A	6.2, 31.3	-12.5, 31.3
Week 52						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	78.15 (4.45)	82.32 (18.31)	N/A	18.75 (6.25)	0.02 (3.95)
Median	N/A	78.15	87.55	N/A	18.75	-6.20
IQR: Q1, Q3	N/A	75.00, 81.30	75.00, 93.80	N/A	12.50, 25.00	-6.20, 12.50
Min, Max	N/A	75.0, 81.3	50.0, 100.0	N/A	12.5, 25.0	-6.3, 12.5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.8.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=2)	(N=7)	(N=1)	(N=2)	(N=7)
Health Distress						
Baseline						
m	1	2	7			
n	1	2	7			
Mean (SD)	62.50 (N/A)	100.00 (0.00)	85.71 (19.67)			
Median	62.50	100.00	100.00			
IQR: Q1, Q3	62.50, 62.50	100.00, 100.00	75.00, 100.00			
Min, Max	62.5, 62.5	100.0, 100.0	50.0, 100.0			
Week 24						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	100.00 (0.00)	83.33 (18.82)	N/A	0.00 (0.00)	0.00 (8.54)
Median	N/A	100.00	87.50	N/A	0	-6.25
IQR: Q1, Q3	N/A	100.00, 100.00	75.00, 100.00	N/A	0.00, 0.00	-12.50, 25.00
Min, Max	N/A	100.0, 100.0	50.0, 100.0	N/A	0.0, 0.0	-25.0, 25.0
Week 52						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	100.00 (0.00)	83.33 (18.82)	N/A	0.00 (0.00)	0.00 (7.22)
Median	N/A	100.00	87.50	N/A	0	0
IQR: Q1, Q3	N/A	100.00, 100.00	75.00, 100.00	N/A	0.00, 0.00	-12.50, 12.50
Min, Max	N/A	100.0, 100.0	50.0, 100.0	N/A	0.0, 0.0	-25.0, 25.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.8.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=2)	(N=7)	(N=1)	(N=2)	(N=7)
Sexual Function						
Baseline						
m	1	2	7			
n	1	1	3			
Mean (SD)	91.70 (N/A)	85.00 (N/A)	92.77 (7.51)			
Median	91.70	85.00	93.30			
IQR: Q1, Q3	91.70, 91.70	85.00, 85.00	85.00, 100.00			
Min, Max	91.7, 91.7	85.0, 85.0	85.0, 100.0			
Week 24						
m	0	2	6			
n	0	1	2	0	1	2
Mean (SD/SE)	N/A	85.00 (N/A)	92.50 (10.61)	N/A	0.00 (N/A)	3.35 (3.35)
Median	N/A	85.00	92.50	N/A	0	3.35
IQR: Q1, Q3	N/A	85.00, 85.00	85.00, 100.00	N/A	0.00, 0.00	0.00, 6.70
Min, Max	N/A	85.0, 85.0	85.0, 100.0	N/A	0.0, 0.0	0.0, 6.7
Week 52						
m	0	2	6			
n	0	1	2	0	1	1
Mean (SD/SE)	N/A	93.30 (N/A)	100.00 (0.00)	N/A	8.30 (N/A)	6.70 (N/A)
Median	N/A	93.30	100.00	N/A	8.30	6.70
IQR: Q1, Q3	N/A	93.30, 93.30	100.00, 100.00	N/A	8.30, 8.30	6.70, 6.70
Min, Max	N/A	93.3, 93.3	100.0, 100.0	N/A	8.3, 8.3	6.7, 6.7

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.8.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Visit Statistic	Visit Result DB MGL-3196 80 mg (N=1)	 DB MGL-3196 100 mg (N=2)	 DB Placebo (N=7)	Change from Baseline DB MGL-3196 80 mg (N=1)	 DB MGL-3196 100 mg (N=2)	 DB Placebo (N=7)
Sleep						
Baseline						
m	1	2	7			
n	1	2	7			
Mean (SD)	65.0 (N/A)	72.5 (17.7)	67.1 (19.8)			
Median	65.0	72.5	70.0			
IQR: Q1, Q3	65.0, 65.0	60.0, 85.0	50.0, 85.0			
Min, Max	65, 65	60, 85	40, 95			
Week 24						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	72.5 (24.7)	68.3 (17.2)	N/A	0.0 (5.0)	2.5 (2.8)
Median	N/A	72.5	70.0	N/A	0	5.0
IQR: Q1, Q3	N/A	55.0, 90.0	55.0, 85.0	N/A	-5.0, 5.0	0.0, 5.0
Min, Max	N/A	55, 90	45, 85	N/A	-5, 5	-10, 10
Week 52						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	70.0 (7.1)	66.7 (22.5)	N/A	-2.5 (7.5)	0.8 (1.5)
Median	N/A	70.0	67.5	N/A	-2.5	0
IQR: Q1, Q3	N/A	65.0, 75.0	50.0, 85.0	N/A	-10.0, 5.0	0.0, 5.0
Min, Max	N/A	65, 75	35, 95	N/A	-10, 5	-5, 5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.8.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=2)	(N=7)	(N=1)	(N=2)	(N=7)
Loneliness						
Baseline						
m	1	2	7			
n	1	2	7			
Mean (SD)	85.0 (N/A)	97.5 (3.5)	90.0 (12.6)			
Median	85.0	97.5	100.0			
IQR: Q1, Q3	85.0, 85.0	95.0, 100.0	75.0, 100.0			
Min, Max	85, 85	95, 100	75, 100			
Week 24						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	97.5 (3.5)	83.3 (25.2)	N/A	0.0 (0.0)	-5.0 (8.2)
Median	N/A	97.5	92.5	N/A	0	0
IQR: Q1, Q3	N/A	95.0, 100.0	80.0, 100.0	N/A	0.0, 0.0	0.0, 5.0
Min, Max	N/A	95, 100	35, 100	N/A	0, 0	-45, 10
Week 52						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	87.5 (10.6)	88.3 (21.6)	N/A	-10.0 (10.0)	0.0 (7.9)
Median	N/A	87.5	97.5	N/A	-10.0	0
IQR: Q1, Q3	N/A	80.0, 95.0	90.0, 100.0	N/A	-20.0, 0.0	0.0, 15.0
Min, Max	N/A	80, 95	45, 100	N/A	-20, 0	-35, 20

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.8.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=1)	Visit Result DB MGL-3196 100 mg (N=2)	Visit Result DB Placebo (N=7)	Change from Baseline DB MGL-3196 80 mg (N=1)	Change from Baseline DB MGL-3196 100 mg (N=2)	Change from Baseline DB Placebo (N=7)
Hopelessness						
Baseline						
m	1	2	7			
n	1	2	7			
Mean (SD)	75.00 (N/A)	83.35 (23.55)	86.91 (21.96)			
Median	75.00	83.35	100.00			
IQR: Q1, Q3	75.00, 75.00	66.70, 100.00	75.00, 100.00			
Min, Max	75.0, 75.0	66.7, 100.0	41.7, 100.0			
Week 24						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	79.15 (29.49)	84.73 (29.54)	N/A	-4.20 (4.20)	0.00 (6.08)
Median	N/A	79.15	95.85	N/A	-4.20	-4.15
IQR: Q1, Q3	N/A	58.30, 100.00	91.70, 100.00	N/A	-8.40, 0.00	-8.30, 8.30
Min, Max	N/A	58.3, 100.0	25.0, 100.0	N/A	-8.4, 0.0	-16.7, 25.0
Week 52						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	83.35 (23.55)	86.12 (20.19)	N/A	0.00 (0.00)	1.38 (6.60)
Median	N/A	83.35	95.85	N/A	0	0
IQR: Q1, Q3	N/A	66.70, 100.00	75.00, 100.00	N/A	0.00, 0.00	0.00, 8.30
Min, Max	N/A	66.7, 100.0	50.0, 100.0	N/A	0.0, 0.0	-25.0, 25.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.8.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=2)	(N=7)	(N=1)	(N=2)	(N=7)
Stigma of Liver Disease						
Baseline						
m	1	2	7			
n	1	2	7			
Mean (SD)	100.00 (N/A)	65.65 (22.13)	91.10 (9.43)			
Median	100.00	65.65	93.80			
IQR: Q1, Q3	100.00, 100.00	50.00, 81.30	81.30, 100.00			
Min, Max	100.0, 100.0	50.0, 81.3	81.3, 100.0			
Week 24						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	100.00 (0.00)	88.55 (15.00)	N/A	34.35 (15.65)	-4.18 (3.84)
Median	N/A	100.00	93.75	N/A	34.35	0
IQR: Q1, Q3	N/A	100.00, 100.00	81.30, 100.00	N/A	18.70, 50.00	-12.50, 0.00
Min, Max	N/A	100.0, 100.0	62.5, 100.0	N/A	18.7, 50.0	-18.8, 6.2
Week 52						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	96.90 (4.38)	92.73 (9.18)	N/A	31.25 (12.55)	0.00 (3.23)
Median	N/A	96.90	96.90	N/A	31.25	0
IQR: Q1, Q3	N/A	93.80, 100.00	81.30, 100.00	N/A	18.70, 43.80	0.00, 0.00
Min, Max	N/A	93.8, 100.0	81.3, 100.0	N/A	18.7, 43.8	-12.5, 12.5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.8.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=8)	Visit Result DB MGL-3196 100 mg (N=13)	Visit Result DB Placebo (N=21)	Change from Baseline DB MGL-3196 80 mg (N=8)	Change from Baseline DB MGL-3196 100 mg (N=13)	Change from Baseline DB Placebo (N=21)
Total LDQOL						
Baseline						
m	8	13	21			
n	8	12	19			
Mean (SD)	81.88 (14.77)	87.54 (5.89)	87.16 (7.08)			
Median	90.05	89.05	86.60			
IQR: Q1, Q3	68.60, 93.20	85.00, 91.20	80.40, 93.90			
Min, Max	57.3, 94.0	75.2, 94.8	76.3, 97.8			
Week 24						
m	8	10	21			
n	7	9	19	7	9	18
Mean (SD/SE)	82.24 (11.97)	83.83 (8.04)	84.86 (9.52)	1.36 (1.65)	-4.79 (2.72)	-2.32 (1.76)
Median	90.10	81.80	85.40	0.70	-5.40	-0.90
IQR: Q1, Q3	73.30, 92.00	77.80, 88.40	80.00, 94.10	-2.20, 5.50	-9.40, -0.40	-8.20, 1.60
Min, Max	62.8, 93.0	75.0, 98.9	64.9, 97.1	-3.9, 8.5	-19.8, 6.1	-17.6, 13.3
Week 52						
m	8	10	20			
n	7	8	18	7	8	17
Mean (SD/SE)	82.29 (19.29)	83.93 (5.90)	83.51 (11.59)	-2.03 (2.85)	-4.58 (1.85)	-4.16 (2.69)
Median	88.50	84.35	85.70	-0.50	-3.50	-1.40
IQR: Q1, Q3	79.60, 92.80	79.10, 87.60	79.40, 93.60	-4.00, 0.90	-6.60, -0.60	-8.20, 0.70
Min, Max	40.0, 94.8	75.6, 93.7	51.7, 95.5	-17.3, 7.2	-15.6, 0.4	-40.4, 6.9

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.8.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=8)	(N=13)	(N=21)	(N=8)	(N=13)	(N=21)
Symptoms of Liver Disease						
Baseline						
m	8	13	21			
n	8	12	19			
Mean (SD)	85.84 (15.52)	82.50 (14.44)	82.81 (16.65)			
Median	91.65	85.00	90.00			
IQR: Q1, Q3	78.35, 96.70	80.00, 91.65	70.00, 96.70			
Min, Max	53.3, 100.0	53.3, 100.0	50.0, 100.0			
Week 24						
m	8	10	21			
n	7	9	19	7	9	18
Mean (SD/SE)	85.71 (14.88)	87.78 (9.12)	82.63 (15.34)	0.94 (3.69)	2.97 (6.35)	1.12 (4.93)
Median	90.00	90.00	83.30	0	3.30	1.65
IQR: Q1, Q3	70.00, 100.00	86.70, 90.00	73.30, 96.70	0.00, 3.30	-3.30, 6.70	-6.70, 10.00
Min, Max	63.3, 100.0	66.7, 100.0	36.7, 100.0	-16.7, 16.7	-33.3, 36.7	-60.0, 40.0
Week 52						
m	8	10	20			
n	7	8	18	7	8	17
Mean (SD/SE)	85.71 (14.35)	77.91 (12.19)	85.74 (12.46)	-4.77 (2.80)	-5.00 (4.32)	3.34 (3.34)
Median	93.30	80.00	86.65	-3.30	-5.00	3.30
IQR: Q1, Q3	76.70, 93.30	70.00, 86.65	76.70, 96.70	-6.70, 0.00	-13.35, 3.35	0.00, 6.70
Min, Max	56.7, 96.7	56.7, 93.3	63.3, 100.0	-20.0, 3.3	-23.3, 13.3	-36.7, 30.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.8.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=8)	(N=13)	(N=21)	(N=8)	(N=13)	(N=21)
Effects of Liver Disease						
Baseline						
m	8	13	21			
n	8	12	19			
Mean (SD)	73.34 (21.97)	83.34 (6.68)	81.06 (5.56)			
Median	80.00	80.00	80.00			
IQR: Q1, Q3	63.35, 83.35	80.00, 86.70	80.00, 86.70			
Min, Max	33.3, 100.0	73.3, 100.0	66.7, 93.3			
Week 24						
m	8	10	21			
n	7	9	19	7	9	18
Mean (SD/SE)	80.00 (0.00)	82.96 (10.07)	80.36 (4.71)	8.57 (8.70)	-0.76 (3.92)	-1.11 (1.11)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	80.00, 80.00	80.00, 80.00	80.00, 80.00	0.00, 33.30	-6.70, 0.00	0.00, 0.00
Min, Max	80.0, 80.0	73.3, 100.0	66.7, 86.7	-20.0, 46.7	-20.0, 20.0	-13.3, 6.7
Week 52						
m	8	10	20			
n	7	8	18	7	8	17
Mean (SD/SE)	73.33 (24.03)	82.50 (7.93)	81.12 (5.24)	-5.73 (5.13)	-1.68 (3.27)	0.39 (1.76)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	80.00, 80.00	80.00, 83.35	80.00, 80.00	-20.00, 0.00	-3.35, 0.00	0.00, 0.00
Min, Max	20.0, 93.3	73.3, 100.0	66.7, 93.3	-26.7, 13.3	-20.0, 13.3	-20.0, 13.3

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.8.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=8)	(N=13)	(N=21)	(N=8)	(N=13)	(N=21)
Concentration/Memory						
Baseline						
m	8	13	21			
n	8	12	19			
Mean (SD)	85.16 (21.10)	87.52 (19.93)	91.46 (10.24)			
Median	93.75	96.90	93.80			
IQR: Q1, Q3	75.00, 100.00	84.40, 100.00	87.50, 100.00			
Min, Max	43.8, 100.0	43.8, 100.0	68.8, 100.0			
Week 24						
m	8	10	21			
n	7	9	19	7	9	18
Mean (SD/SE)	79.49 (23.86)	86.82 (16.36)	86.86 (14.26)	-5.34 (3.96)	-3.48 (2.57)	-3.12 (3.75)
Median	93.80	87.50	87.50	0	0	0
IQR: Q1, Q3	50.00, 100.00	81.30, 100.00	68.80, 100.00	-12.50, 0.00	-6.30, 0.00	-12.50, 6.30
Min, Max	43.8, 100.0	50.0, 100.0	62.5, 100.0	-25.0, 6.3	-18.7, 6.2	-37.5, 18.8
Week 52						
m	8	10	20			
n	7	8	18	7	8	17
Mean (SD/SE)	74.11 (34.69)	86.73 (19.59)	83.71 (19.77)	-8.93 (6.39)	-4.70 (3.49)	-8.08 (4.44)
Median	87.50	93.75	93.80	0	0	0
IQR: Q1, Q3	68.80, 100.00	81.25, 100.00	75.00, 100.00	-12.50, 0.00	-9.40, 0.00	-18.70, 0.00
Min, Max	0.0, 100.0	43.8, 100.0	43.8, 100.0	-43.8, 6.3	-25.0, 6.2	-50.0, 12.5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.8.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=8)	Visit Result DB MGL-3196 100 mg (N=13)	Visit Result DB Placebo (N=21)	Change from Baseline DB MGL-3196 80 mg (N=8)	Change from Baseline DB MGL-3196 100 mg (N=13)	Change from Baseline DB Placebo (N=21)
Health Distress						
Baseline						
m	8	13	21			
n	8	12	19			
Mean (SD)	79.69 (34.03)	95.83 (6.15)	98.03 (6.27)			
Median	93.75	100.00	100.00			
IQR: Q1, Q3	75.00, 100.00	87.50, 100.00	100.00, 100.00			
Min, Max	0.0, 100.0	87.5, 100.0	75.0, 100.0			
Week 24						
m	8	10	21			
n	7	9	19	7	9	18
Mean (SD/SE)	82.14 (36.70)	94.44 (9.08)	94.74 (11.27)	5.36 (3.72)	-1.39 (3.87)	-3.47 (2.22)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	87.50, 100.00	87.50, 100.00	100.00, 100.00	0.00, 12.50	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 100.0	75.0, 100.0	62.5, 100.0	0.0, 25.0	-25.0, 12.5	-25.0, 12.5
Week 52						
m	8	10	20			
n	7	8	18	7	8	17
Mean (SD/SE)	83.93 (37.30)	93.75 (11.57)	93.06 (15.59)	3.57 (2.31)	-1.56 (5.51)	-6.62 (4.03)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	87.50, 100.00	87.50, 100.00	87.50, 100.00	0.00, 12.50	-12.50, 12.50	-12.50, 0.00
Min, Max	0.0, 100.0	75.0, 100.0	37.5, 100.0	0.0, 12.5	-25.0, 12.5	-62.5, 12.5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.8.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=8)	(N=13)	(N=21)	(N=8)	(N=13)	(N=21)
Sexual Function						
Baseline						
m	8	13	21			
n	3	5	10			
Mean (SD)	92.20 (8.40)	97.00 (6.71)	89.33 (11.64)			
Median	93.30	100.00	92.50			
IQR: Q1, Q3	83.30, 100.00	100.00, 100.00	78.30, 100.00			
Min, Max	83.3, 100.0	85.0, 100.0	68.3, 100.0			
Week 24						
m	8	10	21			
n	2	4	8	2	4	7
Mean (SD/SE)	80.85 (15.34)	88.33 (19.15)	89.58 (18.28)	-15.80 (7.50)	-7.93 (5.91)	-3.34 (4.80)
Median	80.85	96.65	96.65	-15.80	-3.35	0
IQR: Q1, Q3	70.00, 91.70	76.65, 100.00	88.30, 100.00	-23.30, -8.30	-15.85, 0.00	0.00, 1.60
Min, Max	70.0, 91.7	60.0, 100.0	46.7, 100.0	-23.3, -8.3	-25.0, 0.0	-31.6, 6.6
Week 52						
m	8	10	20			
n	2	3	9	2	3	7
Mean (SD/SE)	92.50 (10.61)	97.77 (3.87)	74.43 (33.40)	-4.15 (4.15)	-2.23 (2.23)	-12.61 (8.78)
Median	92.50	100.00	85.00	-4.15	0	0
IQR: Q1, Q3	85.00, 100.00	93.30, 100.00	68.30, 100.00	-8.30, 0.00	-6.70, 0.00	-16.70, 0.00
Min, Max	85.0, 100.0	93.3, 100.0	15.0, 100.0	-8.3, 0.0	-6.7, 0.0	-63.3, 0.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.8.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=8)	(N=13)	(N=21)	(N=8)	(N=13)	(N=21)
Sleep						
Baseline						
m	8	13	21			
n	8	12	19			
Mean (SD)	60.0 (29.2)	72.5 (9.2)	68.4 (22.9)			
Median	72.5	72.5	70.0			
IQR: Q1, Q3	45.0, 77.5	65.0, 77.5	50.0, 90.0			
Min, Max	0, 90	60, 90	30, 100			
Week 24						
m	8	10	21			
n	7	9	19	7	9	18
Mean (SD/SE)	59.3 (27.5)	65.0 (14.4)	70.3 (17.0)	2.1 (3.9)	-5.0 (3.7)	0.6 (3.6)
Median	75.0	65.0	70.0	0	0	0
IQR: Q1, Q3	55.0, 75.0	60.0, 70.0	60.0, 80.0	0.0, 5.0	-15.0, 0.0	-10.0, 10.0
Min, Max	0, 75	40, 90	35, 100	-15, 20	-25, 10	-30, 30
Week 52						
m	8	10	20			
n	7	8	18	7	8	17
Mean (SD/SE)	65.0 (18.5)	63.1 (11.0)	69.7 (17.7)	-3.6 (2.4)	-7.5 (3.5)	-2.6 (4.9)
Median	65.0	60.0	70.0	-5.0	-5.0	0
IQR: Q1, Q3	55.0, 80.0	55.0, 72.5	60.0, 85.0	-10.0, 5.0	-15.0, 0.0	-20.0, 15.0
Min, Max	30, 85	50, 80	35, 95	-10, 5	-25, 5	-35, 35

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.8.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=8)	(N=13)	(N=21)	(N=8)	(N=13)	(N=21)
Loneliness						
Baseline						
m	8	13	21			
n	8	12	19			
Mean (SD)	90.0 (13.9)	92.1 (14.5)	94.7 (9.2)			
Median	95.0	97.5	100.0			
IQR: Q1, Q3	85.0, 100.0	92.5, 100.0	95.0, 100.0			
Min, Max	60, 100	50, 100	65, 100			
Week 24						
m	8	10	21			
n	7	9	19	7	9	18
Mean (SD/SE)	90.7 (10.6)	85.0 (18.4)	88.7 (15.0)	2.1 (4.2)	-13.3 (6.5)	-6.4 (2.9)
Median	95.0	90.0	100.0	0	-5.0	0
IQR: Q1, Q3	80.0, 100.0	80.0, 100.0	75.0, 100.0	-5.0, 5.0	-20.0, 0.0	-15.0, 0.0
Min, Max	75, 100	50, 100	60, 100	-10, 25	-50, 5	-35, 10
Week 52						
m	8	10	20			
n	7	8	18	7	8	17
Mean (SD/SE)	93.6 (11.1)	90.6 (19.7)	88.1 (14.5)	3.6 (3.0)	-8.1 (7.3)	-6.8 (2.6)
Median	100.0	100.0	97.5	0	0	0
IQR: Q1, Q3	80.0, 100.0	90.0, 100.0	80.0, 100.0	0.0, 15.0	-10.0, 2.5	-10.0, 0.0
Min, Max	75, 100	45, 100	60, 100	-5, 15	-55, 5	-30, 5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.8.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=8)	Visit Result DB MGL-3196 100 mg (N=13)	Visit Result DB Placebo (N=21)	Change from Baseline DB MGL-3196 80 mg (N=8)	Change from Baseline DB MGL-3196 100 mg (N=13)	Change from Baseline DB Placebo (N=21)
Hopelessness						
Baseline						
m	8	13	21			
n	8	12	19			
Mean (SD)	89.60 (12.39)	94.45 (11.97)	88.60 (18.27)			
Median	91.70	100.00	91.70			
IQR: Q1, Q3	83.35, 100.00	91.70, 100.00	83.30, 100.00			
Min, Max	66.7, 100.0	58.3, 100.0	33.3, 100.0			
Week 24						
m	8	10	21			
n	7	9	19	7	9	18
Mean (SD/SE)	91.67 (12.72)	87.03 (19.60)	87.28 (20.48)	-0.01 (5.75)	-6.49 (5.52)	-0.46 (2.56)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	83.30, 100.00	83.30, 100.00	75.00, 100.00	-8.40, 8.30	0.00, 0.00	0.00, 0.00
Min, Max	66.7, 100.0	50.0, 100.0	33.3, 100.0	-25.0, 25.0	-50.0, 0.0	-25.0, 25.0
Week 52						
m	8	10	20			
n	7	8	18	7	8	17
Mean (SD/SE)	94.04 (7.94)	92.71 (12.14)	87.96 (17.91)	4.74 (5.10)	0.00 (5.67)	-0.01 (3.43)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	83.30, 100.00	87.50, 100.00	83.30, 100.00	0.00, 8.30	0.00, 4.15	0.00, 0.00
Min, Max	83.3, 100.0	66.7, 100.0	50.0, 100.0	-8.4, 33.3	-33.3, 25.0	-33.4, 25.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.8.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

	Visit Result			Change from Baseline		
Parameter	DB	DB	DB	DB	DB	DB
Visit	MGL-3196 80 mg	MGL-3196 100 mg	Placebo	MGL-3196 80 mg	MGL-3196 100 mg	Placebo
Statistic	(N=8)	(N=13)	(N=21)	(N=8)	(N=13)	(N=21)
Stigma of Liver Disease						
Baseline						
m	8	13	21			
n	8	12	19			
Mean (SD)	89.08 (10.95)	89.08 (10.69)	90.14 (14.77)			
Median	90.65	87.55	100.00			
IQR: Q1, Q3	78.15, 100.00	81.30, 100.00	81.30, 100.00			
Min, Max	75.0, 100.0	75.0, 100.0	50.0, 100.0			
Week 24						
m	8	10	21			
n	7	9	19	7	9	18
Mean (SD/SE)	91.99 (10.02)	81.26 (17.68)	85.54 (25.09)	2.69 (3.82)	-8.34 (5.80)	-6.25 (3.46)
Median	93.80	81.30	93.80	0	0	0
IQR: Q1, Q3	81.30, 100.00	75.00, 100.00	81.30, 100.00	0.00, 0.00	-12.50, 0.00	-12.50, 0.00
Min, Max	75.0, 100.0	50.0, 100.0	0.0, 100.0	-6.2, 25.0	-50.0, 6.2	-50.0, 18.7
Week 52						
m	8	10	20			
n	7	8	18	7	8	17
Mean (SD/SE)	88.41 (18.20)	79.70 (17.92)	84.74 (20.13)	-2.67 (4.28)	-8.60 (6.36)	-7.34 (4.26)
Median	93.80	78.15	93.80	0	0	0
IQR: Q1, Q3	81.30, 100.00	68.75, 96.90	81.30, 100.00	-6.20, 0.00	-9.40, 0.00	-6.20, 0.00
Min, Max	50.0, 100.0	50.0, 100.0	43.8, 100.0	-25.0, 12.5	-50.0, 0.0	-56.2, 12.5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc. Page 1 of 3
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.8.2Liver Disease Quality of Life (SE20): Summary of Total LDQOL - MMRM Model
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable; HbA1c = Hemoglobin A1C.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 2 of 3
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.8.2Liver Disease Quality of Life (SE20): Summary of Total LDQOL - MMRM Model
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Total LDQOL			
Week 24			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	83.85 (9.12)	82.95 (10.83)
Analysis Visit Mean (SD)	N/A	88.70 (11.88)	82.07 (16.19)
LS Mean of Change from Baseline (SE)	NE	4.60 (4.47)	-0.80 (2.58)
95% CI	NE	(-6.34, 15.54)	(-7.11, 5.51)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	5.40 (5.16)	
95% CI	NE	(-7.23, 18.04)	
p-value	NE	0.3356	
Corrected Hedge's g Statistics	NE	0.744	
95% CI	NE	(-0.90, 2.38)	
Week 52			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	83.85 (9.12)	82.95 (10.83)
Analysis Visit Mean (SD)	N/A	87.20 (1.56)	83.05 (14.21)
LS Mean of Change from Baseline (SE)	NE	3.31 (5.19)	0.11 (2.99)
95% CI	NE	(-9.38, 16.00)	(-7.21, 7.44)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	3.20 (5.99)	
95% CI	NE	(-11.45, 17.86)	
p-value	NE	0.6121	
Corrected Hedge's g Statistics	NE	0.380	
95% CI	NE	(-1.23, 1.99)	
Subgroup*Treatment Interaction p-value	NE	0.2143	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 3 of 3
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.8.2Liver Disease Quality of Life (SE20): Summary of Total LDQOL - MMRM Model
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Total LDQOL			
Week 24			
m	8	10	21
n	7	9	18
Baseline Mean (SD)	80.89 (15.66)	88.62 (5.19)	87.43 (7.18)
Analysis Visit Mean (SD)	82.24 (11.97)	83.83 (8.04)	85.11 (9.73)
LS Mean of Change from Baseline (SE)	2.24 (3.14)	-3.31 (2.81)	0.06 (2.51)
95% CI	(-4.17, 8.65)	(-9.05, 2.42)	(-5.06, 5.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.18 (3.23)	-3.37 (2.92)	
95% CI	(-4.40, 8.76)	(-9.33, 2.59)	
p-value	0.5044	0.2572	
Corrected Hedge's g Statistics	0.209	-0.327	
95% CI	(-0.67, 1.08)	(-1.13, 0.48)	
Week 52			
m	8	10	20
n	7	8	17
Baseline Mean (SD)	84.31 (14.10)	88.50 (5.53)	87.95 (7.04)
Analysis Visit Mean (SD)	82.29 (19.29)	83.93 (5.90)	83.79 (11.88)
LS Mean of Change from Baseline (SE)	0.65 (3.86)	-3.79 (3.56)	-1.79 (2.92)
95% CI	(-7.21, 8.52)	(-11.06, 3.48)	(-7.75, 4.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.44 (4.15)	-2.00 (3.94)	
95% CI	(-6.03, 10.91)	(-10.04, 6.03)	
p-value	0.5612	0.6151	
Corrected Hedge's g Statistics	0.204	-0.168	
95% CI	(-0.68, 1.09)	(-1.01, 0.67)	
Subgroup*Treatment Interaction p-value	NE	0.2143	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.8.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable; HbA1c = Hemoglobin A1C.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

AMNOG Table SE20.8.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Symptoms of Liver Disease			
Week 24			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	88.30 (7.07)	82.78 (10.22)
Analysis Visit Mean (SD)	N/A	93.35 (9.40)	81.65 (17.23)
LS Mean of Change from Baseline (SE)	NE	3.60 (7.49)	-0.65 (4.24)
95% CI	NE	(-14.72, 21.91)	(-11.02, 9.72)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	4.25 (8.72)	
95% CI	NE	(-17.10, 25.59)	
p-value	NE	0.6436	
Corrected Hedge's g Statistics	NE	0.355	
95% CI	NE	(-1.26, 1.96)	
Week 52			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	88.30 (7.07)	82.78 (10.22)
Analysis Visit Mean (SD)	N/A	98.35 (2.33)	83.32 (16.04)
LS Mean of Change from Baseline (SE)	NE	9.17 (6.90)	0.83 (3.91)
95% CI	NE	(-7.72, 26.05)	(-8.73, 10.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	8.34 (8.04)	
95% CI	NE	(-11.34, 28.01)	
p-value	NE	0.3397	
Corrected Hedge's g Statistics	NE	0.755	
95% CI	NE	(-0.89, 2.40)	
Subgroup*Treatment Interaction p-value	NE	0.0323	

AMNOG Table SE20.8.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Effects of Liver Disease			
Week 24			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	100.00 (0.00)	82.22 (9.11)
Analysis Visit Mean (SD)	N/A	86.65 (9.40)	75.55 (15.01)
LS Mean of Change from Baseline (SE)	NE	6.63 (14.37)	-13.33 (6.90)
95% CI	NE	(-28.52, 41.78)	(-30.21, 3.56)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	19.95 (17.82)	
95% CI	NE	(-23.64, 63.55)	
p-value	NE	0.3056	
Corrected Hedge's g Statistics	NE	0.990	
95% CI	NE	(-0.68, 2.66)	
Week 52			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	100.00 (0.00)	82.22 (9.11)
Analysis Visit Mean (SD)	N/A	80.00 (0.00)	80.00 (11.15)
LS Mean of Change from Baseline (SE)	NE	-5.22 (10.70)	-7.14 (5.14)
95% CI	NE	(-31.41, 20.97)	(-19.72, 5.44)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	1.92 (13.27)	
95% CI	NE	(-30.56, 34.40)	
p-value	NE	0.8896	
Corrected Hedge's g Statistics	NE	0.128	
95% CI	NE	(-1.47, 1.73)	
Subgroup*Treatment Interaction p-value	NE	0.9879	

AMNOG Table SE20.8.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Concentration/Memory			
Week 24			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	59.40 (4.38)	82.30 (23.19)
Analysis Visit Mean (SD)	N/A	78.15 (22.13)	89.60 (11.62)
LS Mean of Change from Baseline (SE)	NE	9.53 (8.44)	10.37 (4.57)
95% CI	NE	(-11.12, 30.18)	(-0.81, 21.56)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-0.85 (10.03)	
95% CI	NE	(-25.39, 23.70)	
p-value	NE	0.9355	
Corrected Hedge's g Statistics	NE	-0.065	
95% CI	NE	(-1.67, 1.54)	
Week 52			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	59.40 (4.38)	82.30 (23.19)
Analysis Visit Mean (SD)	N/A	78.15 (4.45)	82.32 (18.31)
LS Mean of Change from Baseline (SE)	NE	13.81 (6.26)	1.66 (3.39)
95% CI	NE	(-1.50, 29.12)	(-6.63, 9.96)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	12.14 (7.44)	
95% CI	NE	(-6.05, 30.34)	
p-value	NE	0.1536	
Corrected Hedge's g Statistics	NE	1.258	
95% CI	NE	(-0.46, 2.97)	
Subgroup*Treatment Interaction p-value	NE	0.3896	

AMNOG Table SE20.8.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Health Distress			
Week 24			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	100.00 (0.00)	83.33 (20.41)
Analysis Visit Mean (SD)	N/A	100.00 (0.00)	83.33 (18.82)
LS Mean of Change from Baseline (SE)	NE	7.50 (12.86)	-2.50 (7.09)
95% CI	NE	(-23.96, 38.96)	(-19.86, 14.86)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	10.00 (15.17)	
95% CI	NE	(-27.11, 47.11)	
p-value	NE	0.5341	
Corrected Hedge's g Statistics	NE	0.497	
95% CI	NE	(-1.12, 2.12)	
Week 52			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	100.00 (0.00)	83.33 (20.41)
Analysis Visit Mean (SD)	N/A	100.00 (0.00)	83.33 (18.82)
LS Mean of Change from Baseline (SE)	NE	5.63 (11.45)	-1.88 (6.32)
95% CI	NE	(-22.40, 33.65)	(-17.34, 13.59)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	7.50 (13.51)	
95% CI	NE	(-25.56, 40.56)	
p-value	NE	0.5988	
Corrected Hedge's g Statistics	NE	0.418	
95% CI	NE	(-1.20, 2.03)	
Subgroup*Treatment Interaction p-value	NE	0.4967	

AMNOG Table SE20.8.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Sexual Function			
Week 24			
m	0	2	6
n	0	1	2
Baseline Mean (SD)	N/A	85.00 (N/A)	89.15 (5.87)
Analysis Visit Mean (SD)	N/A	85.00 (N/A)	92.50 (10.61)
LS Mean of Change from Baseline (SE)	NE	2.68 (0.00)	2.68 (0.00)
95% CI	NE	(2.68, 2.68)	(2.68, 2.68)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	0.00 (0.00)	
95% CI	NE	(0.00, 0.00)	
p-value	NE	>0.9999	
Corrected Hedge's g Statistics	NE	0.000	
95% CI	NE	(-2.40, 2.40)	
Week 52			
m	0	2	6
n	0	1	1
Baseline Mean (SD)	N/A	85.00 (N/A)	93.30 (N/A)
Analysis Visit Mean (SD)	N/A	93.30 (N/A)	100.00 (N/A)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	0.0029	

AMNOG Table SE20.8.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Sleep			
Week 24			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	72.5 (17.7)	65.8 (21.3)
Analysis Visit Mean (SD)	N/A	72.5 (24.7)	68.3 (17.2)
LS Mean of Change from Baseline (SE)	NE	0.75 (4.84)	2.25 (2.77)
95% CI	NE	(-11.08, 12.58)	(-4.54, 9.04)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-1.50 (5.60)	
95% CI	NE	(-15.21, 12.21)	
p-value	NE	0.7978	
Corrected Hedge's g Statistics	NE	-0.192	
95% CI	NE	(-1.79, 1.41)	
Week 52			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	72.5 (17.7)	65.8 (21.3)
Analysis Visit Mean (SD)	N/A	70.0 (7.1)	66.7 (22.5)
LS Mean of Change from Baseline (SE)	NE	-2.32 (4.28)	0.77 (2.46)
95% CI	NE	(-12.81, 8.16)	(-5.24, 6.79)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-3.10 (4.96)	
95% CI	NE	(-15.24, 9.05)	
p-value	NE	0.5556	
Corrected Hedge's g Statistics	NE	-0.447	
95% CI	NE	(-2.06, 1.17)	
Subgroup*Treatment Interaction p-value	NE	0.5387	

AMNOG Table SE20.8.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Loneliness			
Week 24			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	97.5 (3.5)	88.3 (12.9)
Analysis Visit Mean (SD)	N/A	97.5 (3.5)	83.3 (25.2)
LS Mean of Change from Baseline (SE)	NE	-1.42 (14.78)	-4.53 (8.24)
95% CI	NE	(-37.58, 34.73)	(-24.69, 15.64)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	3.10 (17.35)	
95% CI	NE	(-39.34, 45.55)	
p-value	NE	0.8639	
Corrected Hedge's g Statistics	NE	0.133	
95% CI	NE	(-1.47, 1.73)	
Week 52			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	97.5 (3.5)	88.3 (12.9)
Analysis Visit Mean (SD)	N/A	87.5 (10.6)	88.3 (21.6)
LS Mean of Change from Baseline (SE)	NE	-8.17 (14.87)	-0.61 (8.30)
95% CI	NE	(-44.57, 28.23)	(-20.91, 19.69)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-7.56 (17.46)	
95% CI	NE	(-50.29, 35.16)	
p-value	NE	0.6801	
Corrected Hedge's g Statistics	NE	-0.322	
95% CI	NE	(-1.93, 1.29)	
Subgroup*Treatment Interaction p-value	NE	0.9470	

AMNOG Table SE20.8.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Hopelessness			
Week 24			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	83.35 (23.55)	84.73 (23.21)
Analysis Visit Mean (SD)	N/A	79.15 (29.49)	84.73 (29.54)
LS Mean of Change from Baseline (SE)	NE	-4.07 (10.45)	-0.04 (6.03)
95% CI	NE	(-29.64, 21.51)	(-14.81, 14.72)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-4.02 (12.07)	
95% CI	NE	(-33.56, 25.51)	
p-value	NE	0.7503	
Corrected Hedge's g Statistics	NE	-0.237	
95% CI	NE	(-1.84, 1.37)	
Week 52			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	83.35 (23.55)	84.73 (23.21)
Analysis Visit Mean (SD)	N/A	83.35 (23.55)	86.12 (20.19)
LS Mean of Change from Baseline (SE)	NE	-0.31 (10.06)	1.49 (5.80)
95% CI	NE	(-24.92, 24.29)	(-12.71, 15.69)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-1.80 (11.61)	
95% CI	NE	(-30.22, 26.61)	
p-value	NE	0.8818	
Corrected Hedge's g Statistics	NE	-0.110	
95% CI	NE	(-1.71, 1.49)	
Subgroup*Treatment Interaction p-value	NE	0.9660	

AMNOG Table SE20.8.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Stigma of Liver Disease			
Week 24			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	65.65 (22.13)	92.73 (9.18)
Analysis Visit Mean (SD)	N/A	100.00 (0.00)	88.55 (15.00)
LS Mean of Change from Baseline (SE)	NE	26.34 (12.28)	-1.51 (5.86)
95% CI	NE	(-3.71, 56.39)	(-15.85, 12.83)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	27.86 (15.26)	
95% CI	NE	(-9.49, 65.20)	
p-value	NE	0.1178	
Corrected Hedge's g Statistics	NE	1.626	
95% CI	NE	(-0.16, 3.41)	
Week 52			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	65.65 (22.13)	92.73 (9.18)
Analysis Visit Mean (SD)	N/A	96.90 (4.38)	92.73 (9.18)
LS Mean of Change from Baseline (SE)	NE	19.01 (7.52)	4.08 (3.59)
95% CI	NE	(0.61, 37.40)	(-4.70, 12.86)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	14.92 (9.34)	
95% CI	NE	(-7.94, 37.79)	
p-value	NE	0.1613	
Corrected Hedge's g Statistics	NE	1.423	
95% CI	NE	(-0.32, 3.17)	
Subgroup*Treatment Interaction p-value	NE	0.0058	

AMNOG Table SE20.8.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Symptoms of Liver Disease			
Week 24			
m	8	10	21
n	7	9	18
Baseline Mean (SD)	84.77 (16.44)	84.81 (13.97)	82.59 (17.10)
Analysis Visit Mean (SD)	85.71 (14.88)	87.78 (9.12)	83.71 (15.03)
LS Mean of Change from Baseline (SE)	5.51 (5.57)	6.36 (5.02)	4.18 (4.13)
95% CI	(-5.84, 16.86)	(-3.87, 16.60)	(-4.25, 12.61)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.33 (6.04)	2.19 (5.62)	
95% CI	(-11.00, 13.66)	(-9.28, 13.65)	
p-value	0.8272	0.7002	
Corrected Hedge's g Statistics	0.076	0.126	
95% CI	(-0.80, 0.95)	(-0.67, 0.93)	
Week 52			
m	8	10	20
n	7	8	17
Baseline Mean (SD)	90.49 (8.91)	82.91 (13.63)	83.33 (17.33)
Analysis Visit Mean (SD)	85.71 (14.35)	77.91 (12.19)	86.66 (12.19)
LS Mean of Change from Baseline (SE)	2.24 (4.50)	-3.28 (4.06)	7.35 (3.56)
95% CI	(-6.95, 11.42)	(-11.56, 5.00)	(0.09, 14.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.11 (4.51)	-10.63 (4.32)	
95% CI	(-14.32, 4.10)	(-19.44, -1.82)	
p-value	0.2663	0.0197	
Corrected Hedge's g Statistics	-0.353	-0.746	
95% CI	(-1.24, 0.53)	(-1.61, 0.12)	
Subgroup*Treatment Interaction p-value	NE	0.0323	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.8.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Effects of Liver Disease			
Week 24			
m	8	10	21
n	7	9	18
Baseline Mean (SD)	71.43 (23.01)	83.71 (7.55)	81.49 (5.39)
Analysis Visit Mean (SD)	80.00 (0.00)	82.96 (10.07)	80.38 (4.84)
LS Mean of Change from Baseline (SE)	0.34 (2.92)	2.51 (2.56)	-0.04 (2.25)
95% CI	(-5.60, 6.29)	(-2.71, 7.72)	(-4.63, 4.56)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.38 (3.06)	2.54 (2.70)	
95% CI	(-5.86, 6.62)	(-2.96, 8.05)	
p-value	0.9021	0.3530	
Corrected Hedge's g Statistics	0.040	0.274	
95% CI	(-0.83, 0.91)	(-0.53, 1.08)	
Week 52			
m	8	10	20
n	7	8	17
Baseline Mean (SD)	79.06 (16.06)	84.18 (7.93)	80.79 (4.65)
Analysis Visit Mean (SD)	73.33 (24.03)	82.50 (7.93)	81.18 (5.39)
LS Mean of Change from Baseline (SE)	-5.72 (3.91)	-1.12 (3.68)	0.64 (2.85)
95% CI	(-13.70, 2.25)	(-8.62, 6.38)	(-5.18, 6.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.36 (4.31)	-1.76 (4.17)	
95% CI	(-15.14, 2.42)	(-10.27, 6.75)	
p-value	0.1494	0.6759	
Corrected Hedge's g Statistics	-0.539	-0.150	
95% CI	(-1.43, 0.35)	(-0.99, 0.69)	
Subgroup*Treatment Interaction p-value	NE	0.9879	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.8.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Concentration/Memory			
Week 24			
m	8	10	21
n	7	9	18
Baseline Mean (SD)	84.83 (22.77)	90.30 (18.50)	90.98 (10.32)
Analysis Visit Mean (SD)	79.49 (23.86)	86.82 (16.36)	87.86 (13.96)
LS Mean of Change from Baseline (SE)	-0.74 (5.38)	1.49 (4.87)	4.39 (4.26)
95% CI	(-11.71, 10.22)	(-8.43, 11.41)	(-4.31, 13.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.13 (5.67)	-2.90 (5.21)	
95% CI	(-16.69, 6.43)	(-13.52, 7.73)	
p-value	0.3722	0.5819	
Corrected Hedge's g Statistics	-0.289	-0.165	
95% CI	(-1.17, 0.59)	(-0.97, 0.64)	
Week 52			
m	8	10	20
n	7	8	17
Baseline Mean (SD)	83.04 (21.85)	91.43 (19.45)	91.92 (9.81)
Analysis Visit Mean (SD)	74.11 (34.69)	86.73 (19.59)	83.85 (20.37)
LS Mean of Change from Baseline (SE)	-1.77 (6.56)	-0.01 (6.00)	-0.83 (4.88)
95% CI	(-15.16, 11.61)	(-12.24, 12.23)	(-10.79, 9.13)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.94 (7.17)	0.82 (6.71)	
95% CI	(-15.57, 13.69)	(-12.86, 14.51)	
p-value	0.8964	0.9031	
Corrected Hedge's g Statistics	-0.047	0.041	
95% CI	(-0.93, 0.83)	(-0.80, 0.88)	
Subgroup*Treatment Interaction p-value	NE	0.3896	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.8.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Health Distress			
Week 24			
m	8	10	21
n	7	9	18
Baseline Mean (SD)	76.79 (35.67)	95.83 (6.25)	97.92 (6.43)
Analysis Visit Mean (SD)	82.14 (36.70)	94.44 (9.08)	94.44 (11.52)
LS Mean of Change from Baseline (SE)	5.79 (4.86)	-1.29 (4.13)	-1.87 (3.75)
95% CI	(-4.11, 15.69)	(-9.72, 7.13)	(-9.52, 5.78)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.66 (5.14)	0.58 (4.32)	
95% CI	(-2.83, 18.15)	(-8.23, 9.38)	
p-value	0.1464	0.8945	
Corrected Hedge's g Statistics	0.488	0.038	
95% CI	(-0.40, 1.37)	(-0.76, 0.84)	
Week 52			
m	8	10	20
n	7	8	17
Baseline Mean (SD)	80.36 (36.70)	95.31 (6.47)	99.26 (3.03)
Analysis Visit Mean (SD)	83.93 (37.30)	93.75 (11.57)	92.65 (15.97)
LS Mean of Change from Baseline (SE)	5.66 (6.44)	-2.68 (5.65)	-4.92 (4.63)
95% CI	(-7.47, 18.78)	(-14.20, 8.83)	(-14.37, 4.52)
LS Mean of Change from Baseline Compared to Placebo (SE)	10.58 (7.25)	2.24 (6.38)	
95% CI	(-4.20, 25.36)	(-10.78, 15.26)	
p-value	0.1543	0.7282	
Corrected Hedge's g Statistics	0.551	0.119	
95% CI	(-0.34, 1.44)	(-0.72, 0.96)	
Subgroup*Treatment Interaction p-value	NE	0.4967	

AMNOG Table SE20.8.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Sexual Function			
Week 24			
m	8	10	21
n	2	4	7
Baseline Mean (SD)	96.65 (4.74)	96.25 (7.50)	92.39 (10.62)
Analysis Visit Mean (SD)	80.85 (15.34)	88.33 (19.15)	89.04 (19.68)
LS Mean of Change from Baseline (SE)	-16.98 (7.90)	-10.14 (6.78)	0.16 (4.05)
95% CI	(-34.20, 0.24)	(-24.92, 4.64)	(-8.67, 8.99)
LS Mean of Change from Baseline Compared to Placebo (SE)	-17.14 (8.94)	-10.30 (7.65)	
95% CI	(-36.62, 2.34)	(-26.96, 6.37)	
p-value	0.0794	0.2032	
Corrected Hedge's g Statistics	-1.412	-0.801	
95% CI	(-3.11, 0.29)	(-2.07, 0.47)	
Week 52			
m	8	10	20
n	2	3	7
Baseline Mean (SD)	96.65 (4.74)	100.00 (0.00)	93.80 (8.87)
Analysis Visit Mean (SD)	92.50 (10.61)	97.77 (3.87)	81.19 (31.56)
LS Mean of Change from Baseline (SE)	-7.67 (7.20)	-16.69 (6.68)	-7.83 (3.67)
95% CI	(-23.37, 8.02)	(-31.25, -2.14)	(-15.82, 0.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.16 (8.13)	-8.87 (7.39)	
95% CI	(-17.56, 17.88)	(-24.96, 7.23)	
p-value	0.9849	0.2533	
Corrected Hedge's g Statistics	0.014	-0.785	
95% CI	(-1.56, 1.59)	(-2.18, 0.61)	
Subgroup*Treatment Interaction p-value	NE	0.0029	

AMNOG Table SE20.8.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Sleep			
Week 24			
m	8	10	21
n	7	9	18
Baseline Mean (SD)	57.1 (30.3)	70.0 (6.6)	70.3 (22.1)
Analysis Visit Mean (SD)	59.3 (27.5)	65.0 (14.4)	70.8 (17.3)
LS Mean of Change from Baseline (SE)	-0.28 (5.59)	-5.00 (4.92)	1.43 (4.47)
95% CI	(-11.69, 11.12)	(-15.03, 5.03)	(-7.69, 10.54)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.71 (5.53)	-6.43 (5.12)	
95% CI	(-12.98, 9.56)	(-16.86, 4.01)	
p-value	0.7589	0.2186	
Corrected Hedge's g Statistics	-0.092	-0.352	
95% CI	(-0.97, 0.78)	(-1.16, 0.45)	
Week 52			
m	8	10	20
n	7	8	17
Baseline Mean (SD)	68.6 (17.5)	70.6 (6.8)	72.6 (20.2)
Analysis Visit Mean (SD)	65.0 (18.5)	63.1 (11.0)	70.0 (18.2)
LS Mean of Change from Baseline (SE)	-4.78 (6.29)	-6.88 (5.74)	-0.71 (4.90)
95% CI	(-17.61, 8.06)	(-18.59, 4.83)	(-10.70, 9.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.07 (6.51)	-6.17 (6.26)	
95% CI	(-17.34, 9.20)	(-18.93, 6.59)	
p-value	0.5362	0.3314	
Corrected Hedge's g Statistics	-0.204	-0.313	
95% CI	(-1.09, 0.68)	(-1.16, 0.53)	
Subgroup*Treatment Interaction p-value	NE	0.5387	

AMNOG Table SE20.8.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Loneliness			
Week 24			
m	8	10	21
n	7	9	18
Baseline Mean (SD)	88.6 (14.4)	98.3 (2.5)	94.4 (9.4)
Analysis Visit Mean (SD)	90.7 (10.6)	85.0 (18.4)	88.1 (15.2)
LS Mean of Change from Baseline (SE)	2.76 (6.22)	-9.35 (5.76)	-3.09 (4.95)
95% CI	(-9.93, 15.45)	(-21.11, 2.40)	(-13.18, 7.01)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.85 (6.42)	-6.27 (6.03)	
95% CI	(-7.23, 18.93)	(-18.57, 6.04)	
p-value	0.3688	0.3071	
Corrected Hedge's g Statistics	0.284	-0.306	
95% CI	(-0.59, 1.16)	(-1.11, 0.50)	
Week 52			
m	8	10	20
n	7	8	17
Baseline Mean (SD)	90.0 (15.0)	98.8 (2.3)	94.1 (9.6)
Analysis Visit Mean (SD)	93.6 (11.1)	90.6 (19.7)	87.4 (14.6)
LS Mean of Change from Baseline (SE)	5.81 (6.03)	-4.09 (5.69)	-3.25 (4.88)
95% CI	(-6.48, 18.11)	(-15.69, 7.50)	(-13.21, 6.71)
LS Mean of Change from Baseline Compared to Placebo (SE)	9.06 (6.08)	-0.84 (5.94)	
95% CI	(-3.35, 21.47)	(-12.96, 11.27)	
p-value	0.1464	0.8882	
Corrected Hedge's g Statistics	0.458	-0.043	
95% CI	(-0.43, 1.35)	(-0.88, 0.80)	
Subgroup*Treatment Interaction p-value	NE	0.9470	

AMNOG Table SE20.8.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Hopelessness			
Week 24			
m	8	10	21
n	7	9	18
Baseline Mean (SD)	91.69 (11.77)	93.52 (13.69)	87.97 (18.58)
Analysis Visit Mean (SD)	91.67 (12.72)	87.03 (19.60)	87.51 (21.05)
LS Mean of Change from Baseline (SE)	4.93 (5.87)	-2.85 (5.45)	4.43 (4.81)
95% CI	(-7.04, 16.91)	(-13.97, 8.27)	(-5.37, 14.23)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.50 (5.97)	-7.28 (5.81)	
95% CI	(-11.68, 12.69)	(-19.13, 4.58)	
p-value	0.9336	0.2200	
Corrected Hedge's g Statistics	0.025	-0.368	
95% CI	(-0.85, 0.90)	(-1.17, 0.44)	
Week 52			
m	8	10	20
n	7	8	17
Baseline Mean (SD)	89.30 (13.36)	92.71 (14.40)	87.26 (18.90)
Analysis Visit Mean (SD)	94.04 (7.94)	92.71 (12.14)	87.25 (18.20)
LS Mean of Change from Baseline (SE)	6.86 (5.43)	5.23 (5.07)	4.14 (4.59)
95% CI	(-4.21, 17.93)	(-5.11, 15.58)	(-5.23, 13.51)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.72 (5.33)	1.09 (5.27)	
95% CI	(-8.15, 13.58)	(-9.67, 11.85)	
p-value	0.6135	0.8374	
Corrected Hedge's g Statistics	0.147	0.060	
95% CI	(-0.73, 1.03)	(-0.78, 0.90)	
Subgroup*Treatment Interaction p-value	NE	0.9660	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.8.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Stigma of Liver Disease			
Week 24			
m	8	10	21
n	7	9	18
Baseline Mean (SD)	89.30 (11.81)	89.60 (11.26)	91.68 (13.55)
Analysis Visit Mean (SD)	91.99 (10.02)	81.26 (17.68)	85.43 (25.81)
LS Mean of Change from Baseline (SE)	3.73 (6.24)	-9.69 (5.71)	-6.96 (5.20)
95% CI	(-9.00, 16.46)	(-21.34, 1.96)	(-17.56, 3.63)
LS Mean of Change from Baseline Compared to Placebo (SE)	10.70 (6.36)	-2.72 (5.99)	
95% CI	(-2.27, 23.66)	(-14.94, 9.49)	
p-value	0.1025	0.6524	
Corrected Hedge's g Statistics	0.499	-0.128	
95% CI	(-0.39, 1.38)	(-0.93, 0.67)	
Week 52			
m	8	10	20
n	7	8	17
Baseline Mean (SD)	91.09 (10.11)	88.30 (11.29)	91.92 (13.93)
Analysis Visit Mean (SD)	88.41 (18.20)	79.70 (17.92)	84.58 (20.74)
LS Mean of Change from Baseline (SE)	-0.13 (7.34)	-10.22 (6.81)	-7.64 (5.77)
95% CI	(-15.09, 14.83)	(-24.10, 3.66)	(-19.40, 4.13)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.51 (7.72)	-2.59 (7.51)	
95% CI	(-8.24, 23.26)	(-17.91, 12.74)	
p-value	0.3384	0.7330	
Corrected Hedge's g Statistics	0.320	-0.111	
95% CI	(-0.57, 1.20)	(-0.95, 0.73)	
Subgroup*Treatment Interaction p-value	NE	0.0058	

AMNOG Table SE20.8.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; HbA1c = Hemoglobin A1C.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis, only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.

AMNOG Table SE20.8.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	1 (100)	2 (100)	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (50.0)	2 (28.6)
No	1 (100)	1 (50.0)	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	0.40	
95% CI of the inverse odds ratio	(0.04, 46.65)	(0.02, 10.02)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	0.57	
95% CI of the inverse risk ratio	(0.09, 17.02)	(0.09, 3.51)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.25	21.43	
95% CI of the absolute risk difference	(-74.32, 61.82)	(-55.52, 98.38)	
p-value	0.8630	0.5708	
p-value of Breslow-Day Test for Homogeneity [3]	0.5802	0.1309	

AMNOG Table SE20.8.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (50.0)	0
No	1 (100)	1 (50.0)	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.07	
95% CI of the inverse odds ratio	NE	(0.00, 2.56)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.13	
95% CI of the inverse risk ratio	NE	(0.01, 2.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	43.75	
95% CI of the absolute risk difference	NE	(-15.26, 100.00)	
p-value	NE	0.0938	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.0088	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (50.0)	2 (28.6)
No	1 (100)	1 (50.0)	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	0.40	
95% CI of the inverse odds ratio	(0.04, 46.65)	(0.02, 10.02)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	0.57	
95% CI of the inverse risk ratio	(0.09, 17.02)	(0.09, 3.51)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.25	21.43	
95% CI of the absolute risk difference	(-74.32, 61.82)	(-55.52, 98.38)	
p-value	0.8630	0.5708	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.1110	

AMNOG Table SE20.8.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (14.3)
No	1 (100)	2 (100)	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	1.15	
95% CI of the inverse odds ratio	(0.02, 26.90)	(0.03, 38.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	1.13	
95% CI of the inverse risk ratio	(0.05, 12.34)	(0.06, 20.71)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.25	-2.08	
95% CI of the absolute risk difference	(-59.57, 72.07)	(-52.18, 48.02)	
p-value	0.8433	0.9364	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	1 (14.3)
No	1 (100)	2 (100)	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	1.15	
95% CI of the inverse odds ratio	(0.02, 26.90)	(0.03, 38.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	1.13	
95% CI of the inverse risk ratio	(0.05, 12.34)	(0.06, 20.71)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.25	-2.08	
95% CI of the absolute risk difference	(-59.57, 72.07)	(-52.18, 48.02)	
p-value	0.8433	0.9364	
p-value of Breslow-Day Test for Homogeneity [3]	0.7114	0.6881	

AMNOG Table SE20.8.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (50.0)	0
No	1 (100)	1 (50.0)	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.07	
95% CI of the inverse odds ratio	NE	(0.00, 2.56)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.13	
95% CI of the inverse risk ratio	NE	(0.01, 2.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	43.75	
95% CI of the absolute risk difference	NE	(-15.26, 100.00)	
p-value	NE	0.0938	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (100)	2 (28.6)
No	1 (100)	0	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	NE	
95% CI of the inverse odds ratio	(0.04, 46.65)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	0.29	
95% CI of the inverse risk ratio	(0.09, 17.02)	(0.09, 0.92)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.25	71.43	
95% CI of the absolute risk difference	(-74.32, 61.82)	(37.96, 100.00)	
p-value	0.8630	0.0730	
p-value of Breslow-Day Test for Homogeneity [3]	0.6343	0.0462	

AMNOG Table SE20.8.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (14.3)
No	1 (100)	2 (100)	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	1.15	
95% CI of the inverse odds ratio	(0.02, 26.90)	(0.03, 38.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	1.13	
95% CI of the inverse risk ratio	(0.05, 12.34)	(0.06, 20.71)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.25	-2.08	
95% CI of the absolute risk difference	(-59.57, 72.07)	(-52.18, 48.02)	
p-value	0.8433	0.9364	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	2 (28.6)
No	1 (100)	2 (100)	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	2.27	
95% CI of the inverse odds ratio	(0.04, 46.65)	(0.08, 67.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	1.88	
95% CI of the inverse risk ratio	(0.09, 17.02)	(0.12, 28.78)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.25	-14.58	
95% CI of the absolute risk difference	(-74.32, 61.82)	(-67.59, 38.43)	
p-value	0.8630	0.6286	
p-value of Breslow-Day Test for Homogeneity [3]	0.2357	0.1420	

AMNOG Table SE20.8.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	1 (100)	2 (100)	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (50.0)	1 (14.3)
No	1 (100)	1 (50.0)	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	0.17	
95% CI of the inverse odds ratio	(0.02, 26.90)	(0.01, 5.45)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	0.29	
95% CI of the inverse risk ratio	(0.05, 12.34)	(0.03, 2.80)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.25	35.71	
95% CI of the absolute risk difference	(-59.57, 72.07)	(-38.27, 100.00)	
p-value	0.8433	0.2840	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE20.8.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	1 (100)	2 (100)	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (50.0)	2 (28.6)
No	1 (100)	1 (50.0)	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	0.40	
95% CI of the inverse odds ratio	(0.04, 46.65)	(0.02, 10.02)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	0.57	
95% CI of the inverse risk ratio	(0.09, 17.02)	(0.09, 3.51)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.25	21.43	
95% CI of the absolute risk difference	(-74.32, 61.82)	(-55.52, 98.38)	
p-value	0.8630	0.5708	
p-value of Breslow-Day Test for Homogeneity [3]	0.6162	0.1447	

AMNOG Table SE20.8.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (28.6)
No	1 (100)	2 (100)	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	2.27	
95% CI of the inverse odds ratio	(0.04, 46.65)	(0.08, 67.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	1.88	
95% CI of the inverse risk ratio	(0.09, 17.02)	(0.12, 28.78)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.25	-14.58	
95% CI of the absolute risk difference	(-74.32, 61.82)	(-67.59, 38.43)	
p-value	0.8630	0.6286	
p-value of Breslow-Day Test for Homogeneity [3]	0.0879	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	2 (28.6)
No	1 (100)	2 (100)	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	2.27	
95% CI of the inverse odds ratio	(0.04, 46.65)	(0.08, 67.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	1.88	
95% CI of the inverse risk ratio	(0.09, 17.02)	(0.12, 28.78)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.25	-14.58	
95% CI of the absolute risk difference	(-74.32, 61.82)	(-67.59, 38.43)	
p-value	0.8630	0.6286	
p-value of Breslow-Day Test for Homogeneity [3]	0.2357	0.2135	

AMNOG Table SE20.8.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (14.3)
No	1 (100)	2 (100)	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	1.15	
95% CI of the inverse odds ratio	(0.02, 26.90)	(0.03, 38.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	1.13	
95% CI of the inverse risk ratio	(0.05, 12.34)	(0.06, 20.71)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.25	-2.08	
95% CI of the absolute risk difference	(-59.57, 72.07)	(-52.18, 48.02)	
p-value	0.8433	0.9364	
p-value of Breslow-Day Test for Homogeneity [3]	0.7529	0.7326	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	2 (28.6)
No	1 (100)	2 (100)	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	2.27	
95% CI of the inverse odds ratio	(0.04, 46.65)	(0.08, 67.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	1.88	
95% CI of the inverse risk ratio	(0.09, 17.02)	(0.12, 28.78)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.25	-14.58	
95% CI of the absolute risk difference	(-74.32, 61.82)	(-67.59, 38.43)	
p-value	0.8630	0.6286	
p-value of Breslow-Day Test for Homogeneity [3]	0.4867	0.4631	

AMNOG Table SE20.8.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	2 (100)	0
No	1 (100)	0	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.01	
95% CI of the inverse odds ratio	NE	(0.00, 0.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.08	
95% CI of the inverse risk ratio	NE	(0.00, 1.15)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	77.08	
95% CI of the absolute risk difference	NE	(31.70, 100.00)	
p-value	NE	0.0106	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (100)	1 (14.3)
No	1 (100)	0	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	NE	
95% CI of the inverse odds ratio	(0.02, 26.90)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	0.14	
95% CI of the inverse risk ratio	(0.05, 12.34)	(0.02, 0.88)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.25	85.71	
95% CI of the absolute risk difference	(-59.57, 72.07)	(59.79, 100.00)	
p-value	0.8433	0.0233	
p-value of Breslow-Day Test for Homogeneity [3]	0.6492	0.0169	

AMNOG Table SE20.8.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	8 (100)	13 (100)	21 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (12.5)	0	3 (14.3)
No	7 (87.5)	13 (100)	18 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	5.11	
95% CI of the inverse odds ratio	(0.10, 13.20)	(0.24, 107.33)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	4.45	
95% CI of the inverse risk ratio	(0.14, 9.44)	(0.25, 79.87)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.79	-12.34	
95% CI of the absolute risk difference	(-29.16, 25.59)	(-30.45, 5.78)	
p-value	0.9008	0.2508	
p-value of Breslow-Day Test for Homogeneity [3]	0.5802	0.1309	

AMNOG Table SE20.8.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	3 (14.3)
No	8 (100)	13 (100)	18 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.22	5.11	
95% CI of the inverse odds ratio	(0.15, 69.45)	(0.24, 107.33)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.86	4.45	
95% CI of the inverse risk ratio	(0.16, 50.00)	(0.25, 79.87)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.35	-12.34	
95% CI of the absolute risk difference	(-31.74, 11.04)	(-30.45, 5.78)	
p-value	0.4351	0.2508	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.0088	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (7.7)	8 (38.1)
No	8 (100)	12 (92.3)	13 (61.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	10.70	7.38	
95% CI of the inverse odds ratio	(0.54, 210.41)	(0.80, 68.13)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	6.95	4.95	
95% CI of the inverse risk ratio	(0.45, 108.21)	(0.70, 35.17)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-33.08	-30.40	
95% CI of the absolute risk difference	(-58.34, -7.82)	(-55.73, -5.08)	
p-value	0.0655	0.0509	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.1110	

AMNOG Table SE20.8.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	8 (100)	13 (100)	21 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (12.5)	1 (7.7)	3 (14.3)
No	7 (87.5)	12 (92.3)	18 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	2.00	
95% CI of the inverse odds ratio	(0.10, 13.20)	(0.19, 21.57)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	1.86	
95% CI of the inverse risk ratio	(0.14, 9.44)	(0.22, 16.02)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.79	-6.59	
95% CI of the absolute risk difference	(-29.16, 25.59)	(-27.42, 14.23)	
p-value	0.9008	0.5620	
p-value of Breslow-Day Test for Homogeneity [3]	0.7114	0.6881	

AMNOG Table SE20.8.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	8 (100)	13 (100)	21 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (12.5)	1 (7.7)	4 (19.0)
No	7 (87.5)	12 (92.3)	17 (81.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.65	2.82	
95% CI of the inverse odds ratio	(0.16, 17.47)	(0.28, 28.52)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.52	2.48	
95% CI of the inverse risk ratio	(0.20, 11.65)	(0.31, 19.81)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.55	-11.36	
95% CI of the absolute risk difference	(-34.96, 21.86)	(-33.53, 10.82)	
p-value	0.6765	0.3636	
p-value of Breslow-Day Test for Homogeneity [3]	0.6343	0.0462	

AMNOG Table SE20.8.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	8 (100)	13 (100)	21 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (25.0)	3 (23.1)	1 (4.8)
No	6 (75.0)	10 (76.9)	20 (95.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.15	0.17	
95% CI of the inverse odds ratio	(0.01, 1.96)	(0.02, 1.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.19	0.21	
95% CI of the inverse risk ratio	(0.02, 1.82)	(0.02, 1.78)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	20.24	18.32	
95% CI of the absolute risk difference	(-11.12, 51.60)	(-6.33, 42.96)	
p-value	0.1097	0.1072	
p-value of Breslow-Day Test for Homogeneity [3]	0.2357	0.1420	

AMNOG Table SE20.8.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	8 (100)	13 (100)	21 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	8 (100)	13 (100)	21 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE20.8.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	5 (23.8)
No	8 (100)	13 (100)	16 (76.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.67	9.00	
95% CI of the inverse odds ratio	(0.28, 115.08)	(0.46, 177.74)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.50	7.00	
95% CI of the inverse risk ratio	(0.28, 73.21)	(0.42, 117.02)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-19.44	-21.43	
95% CI of the absolute risk difference	(-42.93, 4.04)	(-41.97, -0.89)	
p-value	0.2136	0.0926	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (25.0)	1 (7.7)	7 (33.3)
No	6 (75.0)	12 (92.3)	14 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	6.00	
95% CI of the inverse odds ratio	(0.24, 9.44)	(0.64, 55.95)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	4.33	
95% CI of the inverse risk ratio	(0.35, 5.11)	(0.60, 31.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.33	-25.64	
95% CI of the absolute risk difference	(-44.48, 27.82)	(-50.47, -0.82)	
p-value	0.6646	0.0867	
p-value of Breslow-Day Test for Homogeneity [3]	0.6162	0.1447	

AMNOG Table SE20.8.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (25.0)	0	0
No	6 (75.0)	13 (100)	21 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.06	NE	
95% CI of the inverse odds ratio	(0.00, 1.43)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.08	NE	
95% CI of the inverse risk ratio	(0.00, 1.54)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	25.51	NE	
95% CI of the absolute risk difference	(-4.41, 55.42)	NE	
p-value	0.0292	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.0879	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (25.0)	2 (15.4)	1 (4.8)
No	6 (75.0)	11 (84.6)	20 (95.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.15	0.28	
95% CI of the inverse odds ratio	(0.01, 1.96)	(0.02, 3.39)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.19	0.31	
95% CI of the inverse risk ratio	(0.02, 1.82)	(0.03, 3.08)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	20.24	10.62	
95% CI of the absolute risk difference	(-11.12, 51.60)	(-11.00, 32.25)	
p-value	0.1097	0.2886	
p-value of Breslow-Day Test for Homogeneity [3]	0.2357	0.2135	

AMNOG Table SE20.8.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (12.5)	1 (7.7)	4 (19.0)
No	7 (87.5)	12 (92.3)	17 (81.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.65	2.82	
95% CI of the inverse odds ratio	(0.16, 17.47)	(0.28, 28.52)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.52	2.48	
95% CI of the inverse risk ratio	(0.20, 11.65)	(0.31, 19.81)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.55	-11.36	
95% CI of the absolute risk difference	(-34.96, 21.86)	(-33.53, 10.82)	
p-value	0.6765	0.3636	
p-value of Breslow-Day Test for Homogeneity [3]	0.7529	0.7326	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (25.0)	2 (15.4)	4 (19.0)
No	6 (75.0)	11 (84.6)	17 (81.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	1.29	
95% CI of the inverse odds ratio	(0.10, 4.89)	(0.20, 8.31)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.76	1.24	
95% CI of the inverse risk ratio	(0.17, 3.38)	(0.26, 5.83)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.95	-3.66	
95% CI of the absolute risk difference	(-28.43, 40.34)	(-29.48, 22.16)	
p-value	0.7236	0.7854	
p-value of Breslow-Day Test for Homogeneity [3]	0.4867	0.4631	

AMNOG Table SE20.8.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	8 (100)	13 (100)	21 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (12.5)	0	2 (9.5)
No	7 (87.5)	13 (100)	19 (90.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	3.46	
95% CI of the inverse odds ratio	(0.06, 9.46)	(0.15, 77.97)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.76	3.18	
95% CI of the inverse risk ratio	(0.08, 7.29)	(0.16, 61.49)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.98	-7.79	
95% CI of the absolute risk difference	(-23.15, 29.11)	(-24.24, 8.65)	
p-value	0.8140	0.4096	
p-value of Breslow-Day Test for Homogeneity [3]	0.6492	0.0169	

Program: t-se18-02-04-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.9.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=8)	Visit Result DB MGL-3196 100 mg (N=10)	Visit Result DB Placebo (N=20)	Change from Baseline DB MGL-3196 80 mg (N=8)	Change from Baseline DB MGL-3196 100 mg (N=10)	Change from Baseline DB Placebo (N=20)
Total LDQOL						
Baseline						
m	8	10	20			
n	8	9	18			
Mean (SD)	81.88 (14.77)	86.11 (5.98)	88.62 (6.94)			
Median	90.05	88.40	90.90			
IQR: Q1, Q3	68.60, 93.20	83.20, 89.60	82.80, 93.90			
Min, Max	57.3, 94.0	75.2, 93.6	76.1, 97.8			
Week 24						
m	8	7	20			
n	7	6	18	7	6	17
Mean (SD/SE)	82.24 (11.97)	84.58 (8.49)	85.79 (9.40)	1.36 (1.65)	-2.43 (2.95)	-2.89 (1.62)
Median	90.10	81.05	84.55	0.70	-2.95	-1.40
IQR: Q1, Q3	73.30, 92.00	77.80, 93.10	80.40, 94.10	-2.20, 5.50	-9.40, 4.50	-6.10, 1.40
Min, Max	62.8, 93.0	77.4, 97.1	64.9, 98.1	-3.9, 8.5	-10.6, 6.8	-17.6, 7.2
Week 52						
m	8	7	19			
n	7	5	17	7	5	16
Mean (SD/SE)	82.29 (19.29)	84.42 (7.24)	84.82 (11.73)	-2.03 (2.85)	-2.08 (1.45)	-4.44 (2.85)
Median	88.50	85.50	85.30	-0.50	-1.30	-1.55
IQR: Q1, Q3	79.60, 92.80	79.00, 88.30	79.40, 93.60	-4.00, 0.90	-2.00, 0.10	-8.60, 1.55
Min, Max	40.0, 94.8	75.6, 93.7	51.7, 98.1	-17.3, 7.2	-7.6, 0.4	-40.4, 7.2

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.9.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=8)	(N=10)	(N=20)	(N=8)	(N=10)	(N=20)
Symptoms of Liver Disease						
Baseline						
m	8	10	20			
n	8	9	18			
Mean (SD)	85.84 (15.52)	80.73 (16.05)	87.78 (11.09)			
Median	91.65	83.30	90.00			
IQR: Q1, Q3	78.35, 96.70	80.00, 93.30	80.00, 96.70			
Min, Max	53.3, 100.0	53.3, 100.0	63.3, 100.0			
Week 24						
m	8	7	20			
n	7	6	18	7	6	17
Mean (SD/SE)	85.71 (14.88)	86.12 (11.03)	82.96 (17.15)	0.94 (3.69)	2.80 (9.17)	-3.73 (4.27)
Median	90.00	88.35	86.70	0	5.00	0
IQR: Q1, Q3	70.00, 100.00	83.30, 90.00	80.00, 96.70	0.00, 3.30	-3.30, 6.70	-6.70, 6.70
Min, Max	63.3, 100.0	66.7, 100.0	36.7, 100.0	-16.7, 16.7	-33.3, 36.7	-60.0, 20.0
Week 52						
m	8	7	19			
n	7	5	17	7	5	16
Mean (SD/SE)	85.71 (14.35)	80.00 (15.63)	87.05 (13.63)	-4.77 (2.80)	0.02 (2.12)	-0.84 (2.66)
Median	93.30	83.30	93.30	-3.30	3.30	0
IQR: Q1, Q3	76.70, 93.30	73.30, 90.00	80.00, 96.70	-6.70, 0.00	-3.30, 3.40	-1.70, 4.95
Min, Max	56.7, 96.7	56.7, 96.7	56.7, 100.0	-20.0, 3.3	-6.7, 3.4	-36.7, 10.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.9.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=8)	Visit Result DB MGL-3196 100 mg (N=10)	Visit Result DB Placebo (N=20)	Change from Baseline DB MGL-3196 80 mg (N=8)	Change from Baseline DB MGL-3196 100 mg (N=10)	Change from Baseline DB Placebo (N=20)
Effects of Liver Disease						
Baseline						
m	8	10	20			
n	8	9	18			
Mean (SD)	73.34 (21.97)	85.93 (9.10)	81.86 (7.16)			
Median	80.00	86.70	80.00			
IQR: Q1, Q3	63.35, 83.35	80.00, 86.70	80.00, 86.70			
Min, Max	33.3, 100.0	73.3, 100.0	66.7, 100.0			
Week 24						
m	8	7	20			
n	7	6	18	7	6	17
Mean (SD/SE)	80.00 (0.00)	79.98 (7.30)	80.01 (8.25)	8.57 (8.70)	-7.80 (2.67)	-2.35 (2.91)
Median	80.00	80.00	80.00	0	-6.70	0
IQR: Q1, Q3	80.00, 80.00	73.30, 80.00	80.00, 80.00	0.00, 33.30	-6.70, -6.70	-6.70, 0.00
Min, Max	80.0, 80.0	73.3, 93.3	60.0, 100.0	-20.0, 46.7	-20.0, 0.0	-40.0, 20.0
Week 52						
m	8	7	19			
n	7	5	17	7	5	16
Mean (SD/SE)	73.33 (24.03)	80.00 (4.74)	81.18 (7.16)	-5.73 (5.13)	-9.34 (4.52)	-0.43 (2.82)
Median	80.00	80.00	80.00	0	-6.70	0
IQR: Q1, Q3	80.00, 80.00	80.00, 80.00	80.00, 80.00	-20.00, 0.00	-20.00, 0.00	0.00, 0.00
Min, Max	20.0, 93.3	73.3, 86.7	66.7, 100.0	-26.7, 13.3	-20.0, 0.0	-26.7, 20.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.9.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=8)	Visit Result DB MGL-3196 100 mg (N=10)	Visit Result DB Placebo (N=20)	Change from Baseline DB MGL-3196 80 mg (N=8)	Change from Baseline DB MGL-3196 100 mg (N=10)	Change from Baseline DB Placebo (N=20)
Concentration/Memory						
Baseline						
m	8	10	20			
n	8	9	18			
Mean (SD)	85.16 (21.10)	79.88 (22.26)	93.76 (8.02)			
Median	93.75	87.50	100.00			
IQR: Q1, Q3	75.00, 100.00	62.50, 100.00	87.50, 100.00			
Min, Max	43.8, 100.0	43.8, 100.0	75.0, 100.0			
Week 24						
m	8	7	20			
n	7	6	18	7	6	17
Mean (SD/SE)	79.49 (23.86)	81.28 (17.24)	87.86 (13.63)	-5.34 (3.96)	1.05 (7.11)	-4.41 (3.82)
Median	93.80	81.30	90.65	0	0	0
IQR: Q1, Q3	50.00, 100.00	81.30, 93.80	81.30, 100.00	-12.50, 0.00	-12.50, 6.20	-12.50, 6.20
Min, Max	43.8, 100.0	50.0, 100.0	62.5, 100.0	-25.0, 6.3	-18.7, 31.3	-37.5, 18.8
Week 52						
m	8	7	19			
n	7	5	17	7	5	16
Mean (SD/SE)	74.11 (34.69)	81.26 (23.37)	84.59 (17.55)	-8.93 (6.39)	1.24 (4.14)	-9.74 (4.23)
Median	87.50	87.50	93.80	0	0	-6.20
IQR: Q1, Q3	68.80, 100.00	75.00, 100.00	81.30, 93.80	-12.50, 0.00	0.00, 6.20	-12.50, 0.00
Min, Max	0.0, 100.0	43.8, 100.0	43.8, 100.0	-43.8, 6.3	-12.5, 12.5	-50.0, 12.5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.9.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter / Visit / Statistic	Visit Result: DB MGL-3196 80 mg (N=8)	Visit Result: DB MGL-3196 100 mg (N=10)	Visit Result: DB Placebo (N=20)	Change from Baseline: DB MGL-3196 80 mg (N=8)	Change from Baseline: DB MGL-3196 100 mg (N=10)	Change from Baseline: DB Placebo (N=20)
Health Distress						
Baseline						
m	8	10	20			
n	8	9	18			
Mean (SD)	79.69 (34.03)	94.44 (6.59)	94.44 (13.71)			
Median	93.75	100.00	100.00			
IQR: Q1, Q3	75.00, 100.00	87.50, 100.00	100.00, 100.00			
Min, Max	0.0, 100.0	87.5, 100.0	50.0, 100.0			
Week 24						
m	8	7	20			
n	7	6	18	7	6	17
Mean (SD/SE)	82.14 (36.70)	93.75 (10.46)	93.75 (11.54)	5.36 (3.72)	0.00 (5.59)	-0.74 (2.93)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	87.50, 100.00	87.50, 100.00	87.50, 100.00	0.00, 12.50	0.00, 12.50	0.00, 0.00
Min, Max	0.0, 100.0	75.0, 100.0	62.5, 100.0	0.0, 25.0	-25.0, 12.5	-25.0, 25.0
Week 52						
m	8	7	19			
n	7	5	17	7	5	16
Mean (SD/SE)	83.93 (37.30)	100.00 (0.00)	91.18 (15.79)	3.57 (2.31)	7.50 (3.06)	-4.69 (4.55)
Median	100.00	100.00	100.00	0	12.50	0
IQR: Q1, Q3	87.50, 100.00	100.00, 100.00	87.50, 100.00	0.00, 12.50	0.00, 12.50	-12.50, 0.00
Min, Max	0.0, 100.0	100.0, 100.0	37.5, 100.0	0.0, 12.5	0.0, 12.5	-62.5, 25.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.9.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=8)	(N=10)	(N=20)	(N=8)	(N=10)	(N=20)
Sexual Function						
Baseline						
m	8	10	20			
n	3	4	8			
Mean (SD)	92.20 (8.40)	96.25 (7.50)	88.54 (11.90)			
Median	93.30	100.00	89.15			
IQR: Q1, Q3	83.30, 100.00	92.50, 100.00	80.85, 100.00			
Min, Max	83.3, 100.0	85.0, 100.0	68.3, 100.0			
Week 24						
m	8	7	20			
n	2	3	6	2	3	6
Mean (SD/SE)	80.85 (15.34)	84.43 (21.42)	94.72 (8.20)	-15.80 (7.50)	-10.57 (7.47)	2.22 (1.40)
Median	80.85	93.30	100.00	-15.80	-6.70	0
IQR: Q1, Q3	70.00, 91.70	60.00, 100.00	85.00, 100.00	-23.30, -8.30	-25.00, 0.00	0.00, 6.60
Min, Max	70.0, 91.7	60.0, 100.0	83.3, 100.0	-23.3, -8.3	-25.0, 0.0	0.0, 6.7
Week 52						
m	8	7	19			
n	2	2	7	2	2	5
Mean (SD/SE)	92.50 (10.61)	96.65 (4.74)	84.51 (29.47)	-4.15 (4.15)	-3.35 (3.35)	-2.00 (3.90)
Median	92.50	96.65	100.00	-4.15	-3.35	0
IQR: Q1, Q3	85.00, 100.00	93.30, 100.00	68.30, 100.00	-8.30, 0.00	-6.70, 0.00	0.00, 0.00
Min, Max	85.0, 100.0	93.3, 100.0	23.3, 100.0	-8.3, 0.0	-6.7, 0.0	-16.7, 6.7

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.9.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Visit Statistic	Visit Result DB MGL-3196 80 mg (N=8)	 DB MGL-3196 100 mg (N=10)	 DB Placebo (N=20)	Change from Baseline DB MGL-3196 80 mg (N=8)	 DB MGL-3196 100 mg (N=10)	 DB Placebo (N=20)
Sleep						
Baseline						
m	8	10	20			
n	8	9	18			
Mean (SD)	60.0 (29.2)	74.4 (10.4)	75.0 (21.6)			
Median	72.5	75.0	80.0			
IQR: Q1, Q3	45.0, 77.5	65.0, 85.0	60.0, 90.0			
Min, Max	0, 90	60, 90	30, 100			
Week 24						
m	8	7	20			
n	7	6	18	7	6	17
Mean (SD/SE)	59.3 (27.5)	70.0 (13.0)	74.2 (15.8)	2.1 (3.9)	-1.7 (3.1)	-2.4 (3.1)
Median	75.0	67.5	80.0	0	0	0
IQR: Q1, Q3	55.0, 75.0	60.0, 80.0	60.0, 85.0	0.0, 5.0	-5.0, 5.0	-10.0, 5.0
Min, Max	0, 75	55, 90	45, 100	-15, 20	-15, 5	-30, 20
Week 52						
m	8	7	19			
n	7	5	17	7	5	16
Mean (SD/SE)	65.0 (18.5)	67.0 (12.0)	71.8 (18.4)	-3.6 (2.4)	-6.0 (5.3)	-8.1 (3.8)
Median	65.0	70.0	75.0	-5.0	0	-2.5
IQR: Q1, Q3	55.0, 80.0	60.0, 75.0	60.0, 85.0	-10.0, 5.0	-10.0, 0.0	-22.5, 2.5
Min, Max	30, 85	50, 80	35, 95	-10, 5	-25, 5	-35, 20

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.9.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=8)	(N=10)	(N=20)	(N=8)	(N=10)	(N=20)
Loneliness						
Baseline						
m	8	10	20			
n	8	9	18			
Mean (SD)	90.0 (13.9)	90.6 (16.7)	95.0 (8.7)			
Median	95.0	100.0	100.0			
IQR: Q1, Q3	85.0, 100.0	90.0, 100.0	95.0, 100.0			
Min, Max	60, 100	50, 100	75, 100			
Week 24						
m	8	7	20			
n	7	6	18	7	6	17
Mean (SD/SE)	90.7 (10.6)	87.5 (15.4)	89.7 (13.4)	2.1 (4.2)	-11.7 (6.4)	-5.6 (3.1)
Median	95.0	92.5	100.0	0	-5.0	0
IQR: Q1, Q3	80.0, 100.0	80.0, 100.0	80.0, 100.0	-5.0, 5.0	-20.0, 0.0	-5.0, 0.0
Min, Max	75, 100	60, 100	60, 100	-10, 25	-40, 0	-35, 10
Week 52						
m	8	7	19			
n	7	5	17	7	5	16
Mean (SD/SE)	93.6 (11.1)	85.0 (24.0)	92.6 (12.0)	3.6 (3.0)	-15.0 (10.7)	-2.2 (3.2)
Median	100.0	100.0	100.0	0	0	0
IQR: Q1, Q3	80.0, 100.0	80.0, 100.0	90.0, 100.0	0.0, 15.0	-20.0, 0.0	-2.5, 0.0
Min, Max	75, 100	45, 100	65, 100	-5, 15	-55, 0	-30, 20

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.9.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=8)	(N=10)	(N=20)	(N=8)	(N=10)	(N=20)
Hopelessness						
Baseline						
m	8	10	20			
n	8	9	18			
Mean (SD)	89.60 (12.39)	93.52 (13.69)	90.28 (19.02)			
Median	91.70	100.00	100.00			
IQR: Q1, Q3	83.35, 100.00	91.70, 100.00	91.70, 100.00			
Min, Max	66.7, 100.0	58.3, 100.0	33.3, 100.0			
Week 24						
m	8	7	20			
n	7	6	18	7	6	17
Mean (SD/SE)	91.67 (12.72)	90.27 (17.03)	88.89 (20.01)	-0.01 (5.75)	-1.40 (1.40)	-0.49 (2.08)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	83.30, 100.00	83.30, 100.00	91.70, 100.00	-8.40, 8.30	0.00, 0.00	0.00, 0.00
Min, Max	66.7, 100.0	58.3, 100.0	33.3, 100.0	-25.0, 25.0	-8.4, 0.0	-16.7, 25.0
Week 52						
m	8	7	19			
n	7	5	17	7	5	16
Mean (SD/SE)	94.04 (7.94)	95.00 (7.46)	87.25 (18.20)	4.74 (5.10)	5.00 (5.00)	-2.61 (3.47)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	83.30, 100.00	91.70, 100.00	83.30, 100.00	0.00, 8.30	0.00, 0.00	-4.20, 0.00
Min, Max	83.3, 100.0	83.3, 100.0	50.0, 100.0	-8.4, 33.3	0.0, 25.0	-33.4, 25.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.9.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

	Visit Result			Change from Baseline		
Parameter	DB	DB	DB	DB	DB	DB
Visit	MGL-3196 80 mg	MGL-3196 100 mg	Placebo	MGL-3196 80 mg	MGL-3196 100 mg	Placebo
Statistic	(N=8)	(N=10)	(N=20)	(N=8)	(N=10)	(N=20)
Stigma of Liver Disease						
Baseline						
m	8	10	20			
n	8	9	18			
Mean (SD)	89.08 (10.95)	86.13 (10.71)	90.29 (14.88)			
Median	90.65	81.30	100.00			
IQR: Q1, Q3	78.15, 100.00	81.30, 100.00	81.30, 100.00			
Min, Max	75.0, 100.0	75.0, 100.0	50.0, 100.0			
Week 24						
m	8	7	20			
n	7	6	18	7	6	17
Mean (SD/SE)	91.99 (10.02)	87.50 (15.81)	85.77 (25.97)	2.69 (3.82)	2.07 (4.16)	-6.25 (3.43)
Median	93.80	93.75	100.00	0	0	0
IQR: Q1, Q3	81.30, 100.00	75.00, 100.00	81.30, 100.00	0.00, 0.00	0.00, 6.20	-6.30, 0.00
Min, Max	75.0, 100.0	62.5, 100.0	0.0, 100.0	-6.2, 25.0	-12.5, 18.7	-50.0, 6.2
Week 52						
m	8	7	19			
n	7	5	17	7	5	16
Mean (SD/SE)	88.41 (18.20)	82.50 (16.77)	85.32 (20.11)	-2.67 (4.28)	-0.02 (5.93)	-7.02 (3.86)
Median	93.80	75.00	93.80	0	0	0
IQR: Q1, Q3	81.30, 100.00	75.00, 100.00	81.30, 100.00	-6.20, 0.00	0.00, 0.00	-6.20, 0.00
Min, Max	50.0, 100.0	62.5, 100.0	43.8, 100.0	-25.0, 12.5	-18.8, 18.7	-56.2, 0.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.9.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=5)	(N=8)	(N=1)	(N=5)	(N=8)
Total LDQOL						
Baseline						
m	1	5	8			
n	1	5	8			
Mean (SD)	76.50 (N/A)	88.64 (6.75)	81.25 (8.26)			
Median	76.50	89.40	82.70			
IQR: Q1, Q3	76.50, 76.50	88.80, 92.80	78.25, 86.10			
Min, Max	76.5, 76.5	77.4, 94.8	64.4, 91.5			
Week 24						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	84.88 (9.18)	80.07 (14.78)	N/A	-3.76 (4.61)	0.29 (3.37)
Median	N/A	81.80	85.40	N/A	-0.40	0.40
IQR: Q1, Q3	N/A	80.30, 88.40	68.10, 88.80	N/A	-7.60, 2.90	-8.20, 8.50
Min, Max	N/A	75.0, 98.9	52.0, 93.7	N/A	-19.8, 6.1	-12.4, 13.3
Week 52						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	84.74 (3.66)	79.93 (12.72)	N/A	-3.90 (3.87)	0.14 (2.28)
Median	N/A	86.10	86.10	N/A	-4.10	0.70
IQR: Q1, Q3	N/A	83.20, 86.50	67.60, 87.50	N/A	-5.60, -2.90	-6.40, 6.80
Min, Max	N/A	79.2, 88.7	58.0, 93.7	N/A	-15.6, 8.7	-8.7, 6.9

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.9.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=5)	(N=8)	(N=1)	(N=5)	(N=8)
Symptoms of Liver Disease						
Baseline						
m	1	5	8			
n	1	5	8			
Mean (SD)	86.70 (N/A)	88.00 (6.51)	72.90 (18.12)			
Median	86.70	90.00	73.30			
IQR: Q1, Q3	86.70, 86.70	83.30, 90.00	56.65, 90.00			
Min, Max	86.7, 86.7	80.0, 96.7	50.0, 93.3			
Week 24						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	92.00 (5.04)	80.94 (10.84)	N/A	4.00 (4.40)	10.96 (6.97)
Median	N/A	90.00	80.00	N/A	3.30	6.70
IQR: Q1, Q3	N/A	90.00, 93.30	70.00, 93.30	N/A	0.00, 3.40	0.00, 23.30
Min, Max	N/A	86.7, 100.0	70.0, 96.7	N/A	-6.7, 20.0	-16.7, 40.0
Week 52						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	84.00 (13.19)	80.47 (11.29)	N/A	-4.00 (8.26)	10.49 (5.17)
Median	N/A	83.30	76.70	N/A	-6.70	6.70
IQR: Q1, Q3	N/A	76.70, 93.30	70.00, 90.00	N/A	-20.00, 13.30	6.70, 20.00
Min, Max	N/A	66.7, 100.0	70.0, 100.0	N/A	-23.3, 16.7	-13.4, 30.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.9.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=1)	Visit Result DB MGL-3196 100 mg (N=5)	Visit Result DB Placebo (N=8)	Change from Baseline DB MGL-3196 80 mg (N=1)	Change from Baseline DB MGL-3196 100 mg (N=5)	Change from Baseline DB Placebo (N=8)
Effects of Liver Disease						
Baseline						
m	1	5	8			
n	1	5	8			
Mean (SD)	66.70 (N/A)	85.34 (8.69)	80.00 (3.58)			
Median	66.70	80.00	80.00			
IQR: Q1, Q3	66.70, 66.70	80.00, 86.70	80.00, 80.00			
Min, Max	66.7, 66.7	80.0, 100.0	73.3, 86.7			
Week 24						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	88.00 (10.95)	77.14 (8.49)	N/A	2.66 (6.86)	-2.86 (1.98)
Median	N/A	80.00	80.00	N/A	0	0
IQR: Q1, Q3	N/A	80.00, 100.00	73.30, 80.00	N/A	0.00, 13.30	-6.70, 0.00
Min, Max	N/A	80.0, 100.0	60.0, 86.7	N/A	-20.0, 20.0	-13.3, 0.0
Week 52						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	84.00 (8.94)	80.01 (6.67)	N/A	-1.34 (5.33)	0.01 (1.45)
Median	N/A	80.00	80.00	N/A	0	0
IQR: Q1, Q3	N/A	80.00, 80.00	80.00, 86.70	N/A	0.00, 0.00	0.00, 0.00
Min, Max	N/A	80.0, 100.0	66.7, 86.7	N/A	-20.0, 13.3	-6.6, 6.7

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.9.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=1)	Visit Result DB MGL-3196 100 mg (N=5)	Visit Result DB Placebo (N=8)	Change from Baseline DB MGL-3196 80 mg (N=1)	Change from Baseline DB MGL-3196 100 mg (N=5)	Change from Baseline DB Placebo (N=8)
Concentration/Memory						
Baseline						
m	1	5	8			
n	1	5	8			
Mean (SD)	56.30 (N/A)	90.02 (19.04)	79.71 (19.98)			
Median	56.30	100.00	84.40			
IQR: Q1, Q3	56.30, 56.30	93.80, 100.00	71.90, 93.80			
Min, Max	56.3, 56.3	56.3, 100.0	37.5, 100.0			
Week 24						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	90.00 (16.30)	86.63 (14.15)	N/A	-0.02 (1.98)	8.93 (4.90)
Median	N/A	100.00	87.50	N/A	0	6.30
IQR: Q1, Q3	N/A	87.50, 100.00	68.80, 100.00	N/A	0.00, 0.00	0.00, 18.70
Min, Max	N/A	62.5, 100.0	68.8, 100.0	N/A	-6.3, 6.2	-6.3, 31.3
Week 52						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	88.76 (11.17)	80.37 (23.51)	N/A	-1.26 (8.01)	2.67 (5.08)
Median	N/A	87.50	93.80	N/A	0	6.20
IQR: Q1, Q3	N/A	81.30, 100.00	50.00, 100.00	N/A	-6.30, 0.00	0.00, 12.50
Min, Max	N/A	75.0, 100.0	50.0, 100.0	N/A	-25.0, 25.0	-25.0, 12.5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.9.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

	Visit Result			Change from Baseline		
Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Health Distress						
Baseline						
m	1	5	8			
n	1	5	8			
Mean (SD)	62.50 (N/A)	100.00 (0.00)	95.31 (9.30)			
Median	62.50	100.00	100.00			
IQR: Q1, Q3	62.50, 62.50	100.00, 100.00	93.75, 100.00			
Min, Max	62.5, 62.5	100.0, 100.0	75.0, 100.0			
Week 24						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	97.50 (5.59)	87.50 (19.09)	N/A	-2.50 (2.50)	-7.14 (5.36)
Median	N/A	100.00	100.00	N/A	0	0
IQR: Q1, Q3	N/A	100.00, 100.00	75.00, 100.00	N/A	0.00, 0.00	-25.00, 0.00
Min, Max	N/A	87.5, 100.0	50.0, 100.0	N/A	-12.5, 0.0	-25.0, 12.5
Week 52						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	90.00 (13.69)	89.29 (19.67)	N/A	-10.00 (6.12)	-5.36 (5.36)
Median	N/A	100.00	100.00	N/A	0	0
IQR: Q1, Q3	N/A	75.00, 100.00	75.00, 100.00	N/A	-25.00, 0.00	-25.00, 0.00
Min, Max	N/A	75.0, 100.0	50.0, 100.0	N/A	-25.0, 0.0	-25.0, 12.5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.9.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter / Visit / Statistic	Visit Result: DB MGL-3196 80 mg (N=1)	Visit Result: DB MGL-3196 100 mg (N=5)	Visit Result: DB Placebo (N=8)	Change from Baseline: DB MGL-3196 80 mg (N=1)	Change from Baseline: DB MGL-3196 100 mg (N=5)	Change from Baseline: DB Placebo (N=8)
Sexual Function						
Baseline						
m	1	5	8			
n	1	2	5			
Mean (SD)	91.70 (N/A)	92.50 (10.61)	92.66 (8.88)			
Median	91.70	92.50	93.30			
IQR: Q1, Q3	91.70, 91.70	85.00, 100.00	91.70, 100.00			
Min, Max	91.7, 91.7	85.0, 100.0	78.3, 100.0			
Week 24						
m	0	5	7			
n	0	2	4	0	2	3
Mean (SD/SE)	N/A	92.50 (10.61)	83.33 (24.62)	N/A	0.00 (0.00)	-10.00 (10.81)
Median	N/A	92.50	93.30	N/A	0	0
IQR: Q1, Q3	N/A	85.00, 100.00	70.00, 96.65	N/A	0.00, 0.00	-31.60, 1.60
Min, Max	N/A	85.0, 100.0	46.7, 100.0	N/A	0.0, 0.0	-31.6, 1.6
Week 52						
m	0	5	7			
n	0	2	4	0	2	3
Mean (SD/SE)	N/A	96.65 (4.74)	69.58 (37.50)	N/A	4.15 (4.15)	-23.87 (19.86)
Median	N/A	96.65	81.65	N/A	4.15	-8.30
IQR: Q1, Q3	N/A	93.30, 100.00	46.65, 92.50	N/A	0.00, 8.30	-63.30, 0.00
Min, Max	N/A	93.3, 100.0	15.0, 100.0	N/A	0.0, 8.3	-63.3, 0.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.9.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=1)	Visit Result DB MGL-3196 100 mg (N=5)	Visit Result DB Placebo (N=8)	Change from Baseline DB MGL-3196 80 mg (N=1)	Change from Baseline DB MGL-3196 100 mg (N=5)	Change from Baseline DB Placebo (N=8)
Sleep						
Baseline						
m	1	5	8			
n	1	5	8			
Mean (SD)	65.0 (N/A)	69.0 (8.2)	52.5 (12.5)			
Median	65.0	65.0	52.5			
IQR: Q1, Q3	65.0, 65.0	65.0, 75.0	40.0, 60.0			
Min, Max	65, 65	60, 80	40, 75			
Week 24						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	62.0 (18.2)	58.6 (14.1)	N/A	-7.0 (6.0)	9.3 (4.6)
Median	N/A	60.0	60.0	N/A	-5.0	5.0
IQR: Q1, Q3	N/A	55.0, 65.0	45.0, 70.0	N/A	-15.0, 0.0	0.0, 20.0
Min, Max	N/A	40, 90	35, 75	N/A	-25, 10	-5, 30
Week 52						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	62.0 (9.1)	62.1 (18.5)	N/A	-7.0 (3.7)	12.9 (5.0)
Median	N/A	60.0	70.0	N/A	-5.0	15.0
IQR: Q1, Q3	N/A	60.0, 65.0	40.0, 75.0	N/A	-15.0, -5.0	0.0, 20.0
Min, Max	N/A	50, 75	35, 85	N/A	-15, 5	-5, 35

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.9.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=1)	Visit Result DB MGL-3196 100 mg (N=5)	Visit Result DB Placebo (N=8)	Change from Baseline DB MGL-3196 80 mg (N=1)	Change from Baseline DB MGL-3196 100 mg (N=5)	Change from Baseline DB Placebo (N=8)
Loneliness						
Baseline						
m	1	5	8			
n	1	5	8			
Mean (SD)	85.0 (N/A)	97.0 (2.7)	90.0 (12.8)			
Median	85.0	95.0	95.0			
IQR: Q1, Q3	85.0, 85.0	95.0, 100.0	82.5, 100.0			
Min, Max	85, 85	95, 100	65, 100			
Week 24						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	87.0 (21.1)	81.4 (25.6)	N/A	-10.0 (10.1)	-7.1 (6.9)
Median	N/A	95.0	100.0	N/A	0	0
IQR: Q1, Q3	N/A	90.0, 100.0	65.0, 100.0	N/A	-5.0, 0.0	-15.0, 0.0
Min, Max	N/A	50, 100	35, 100	N/A	-50, 5	-45, 10
Week 52						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	95.0 (8.7)	77.1 (20.0)	N/A	-2.0 (4.6)	-11.4 (4.7)
Median	N/A	100.0	80.0	N/A	0	-10.0
IQR: Q1, Q3	N/A	95.0, 100.0	60.0, 100.0	N/A	0.0, 5.0	-20.0, 0.0
Min, Max	N/A	80, 100	45, 100	N/A	-20, 5	-35, 0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.9.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=5)	(N=8)	(N=1)	(N=5)	(N=8)
Hopelessness						
Baseline						
m	1	5	8			
n	1	5	8			
Mean (SD)	75.00 (N/A)	91.68 (14.42)	83.34 (18.89)			
Median	75.00	100.00	87.50			
IQR: Q1, Q3	75.00, 75.00	91.70, 100.00	79.15, 95.85			
Min, Max	75.0, 75.0	66.7, 100.0	41.7, 100.0			
Week 24						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	80.00 (24.02)	80.96 (28.34)	N/A	-11.68 (9.72)	0.00 (6.81)
Median	N/A	91.70	100.00	N/A	0	0
IQR: Q1, Q3	N/A	58.30, 100.00	66.70, 100.00	N/A	-8.40, 0.00	-16.70, 16.70
Min, Max	N/A	50.0, 100.0	25.0, 100.0	N/A	-50.0, 0.0	-25.0, 25.0
Week 52						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	86.68 (18.24)	88.10 (19.16)	N/A	-5.00 (7.26)	7.14 (5.29)
Median	N/A	100.00	100.00	N/A	0	8.30
IQR: Q1, Q3	N/A	66.70, 100.00	75.00, 100.00	N/A	0.00, 0.00	0.00, 16.70
Min, Max	N/A	66.7, 100.0	50.0, 100.0	N/A	-33.3, 8.3	-16.7, 25.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.9.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=1)	Visit Result DB MGL-3196 100 mg (N=5)	Visit Result DB Placebo (N=8)	Change from Baseline DB MGL-3196 80 mg (N=1)	Change from Baseline DB MGL-3196 100 mg (N=5)	Change from Baseline DB Placebo (N=8)
Stigma of Liver Disease						
Baseline						
m	1	5	8			
n	1	5	8			
Mean (SD)	100.00 (N/A)	85.02 (21.01)	90.65 (10.00)			
Median	100.00	93.80	90.65			
IQR: Q1, Q3	100.00, 100.00	81.30, 100.00	81.30, 100.00			
Min, Max	100.0, 100.0	50.0, 100.0	81.3, 100.0			
Week 24						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	81.26 (20.73)	87.51 (13.01)	N/A	-3.76 (16.25)	-4.47 (4.67)
Median	N/A	81.30	87.50	N/A	0	-6.20
IQR: Q1, Q3	N/A	75.00, 100.00	81.30, 100.00	N/A	-18.80, 0.00	-12.50, 0.00
Min, Max	N/A	50.0, 100.0	62.5, 100.0	N/A	-50.0, 50.0	-18.8, 18.7
Week 52						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	83.78 (20.07)	90.20 (12.95)	N/A	-1.24 (14.85)	-1.79 (6.50)
Median	N/A	93.80	93.80	N/A	0	0
IQR: Q1, Q3	N/A	81.30, 93.80	87.50, 100.00	N/A	0.00, 0.00	-6.20, 12.50
Min, Max	N/A	50.0, 100.0	62.5, 100.0	N/A	-50.0, 43.8	-37.5, 12.5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc. Page 1 of 3
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.9.2Liver Disease Quality of Life (SE20): Summary of Total LDQOL - MMRM Model
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.9.2Liver Disease Quality of Life (SE20): Summary of Total LDQOL - MMRM Model
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Total LDQOL			
Week 24			
m	8	7	20
n	7	6	17
Baseline Mean (SD)	80.89 (15.66)	87.02 (5.41)	89.00 (6.96)
Analysis Visit Mean (SD)	82.24 (11.97)	84.58 (8.49)	86.11 (9.59)
LS Mean of Change from Baseline (SE)	0.85 (3.54)	-1.74 (4.38)	-1.84 (4.02)
95% CI	(-6.40, 8.11)	(-10.72, 7.25)	(-10.08, 6.40)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.69 (3.32)	0.11 (3.39)	
95% CI	(-4.12, 9.51)	(-6.85, 7.06)	
p-value	0.4243	0.9751	
Corrected Hedge's g Statistics	0.174	0.007	
95% CI	(-0.71, 1.06)	(-0.92, 0.94)	
Week 52			
m	8	7	19
n	7	5	16
Baseline Mean (SD)	84.31 (14.10)	86.50 (5.88)	89.65 (6.63)
Analysis Visit Mean (SD)	82.29 (19.29)	84.42 (7.24)	85.21 (12.01)
LS Mean of Change from Baseline (SE)	-1.02 (4.60)	-2.35 (5.60)	-3.65 (4.48)
95% CI	(-10.46, 8.43)	(-13.85, 9.15)	(-12.85, 5.55)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.63 (4.78)	1.29 (5.28)	
95% CI	(-7.17, 12.43)	(-9.54, 12.12)	
p-value	0.5862	0.8085	
Corrected Hedge's g Statistics	0.154	0.073	
95% CI	(-0.74, 1.04)	(-0.93, 1.08)	
Subgroup*Treatment Interaction p-value	NE	0.6116	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 3 of 3
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.9.2Liver Disease Quality of Life (SE20): Summary of Total LDQOL - MMRM Model
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Total LDQOL			
Week 24			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	88.64 (6.75)	79.79 (7.72)
Analysis Visit Mean (SD)	N/A	84.88 (9.18)	80.07 (14.78)
LS Mean of Change from Baseline (SE)	NE	-2.10 (6.81)	3.03 (5.08)
95% CI	NE	(-17.81, 13.62)	(-8.67, 14.74)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-5.13 (8.09)	
95% CI	NE	(-23.78, 13.52)	
p-value	NE	0.5436	
Corrected Hedge's g Statistics	NE	-0.334	
95% CI	NE	(-1.49, 0.82)	
Week 52			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	88.64 (6.75)	79.79 (7.72)
Analysis Visit Mean (SD)	N/A	84.74 (3.66)	79.93 (12.72)
LS Mean of Change from Baseline (SE)	NE	-1.09 (5.68)	2.08 (4.03)
95% CI	NE	(-14.20, 12.01)	(-7.22, 11.37)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-3.17 (6.15)	
95% CI	NE	(-17.34, 11.00)	
p-value	NE	0.6200	
Corrected Hedge's g Statistics	NE	-0.254	
95% CI	NE	(-1.41, 0.90)	
Subgroup*Treatment Interaction p-value	NE	0.6116	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.9.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

AMNOG Table SE20.9.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Symptoms of Liver Disease			
Week 24			
m	8	7	20
n	7	6	17
Baseline Mean (SD)	84.77 (16.44)	83.32 (16.74)	87.85 (11.43)
Analysis Visit Mean (SD)	85.71 (14.88)	86.12 (11.03)	84.12 (16.94)
LS Mean of Change from Baseline (SE)	1.43 (6.86)	2.78 (8.00)	-1.09 (6.47)
95% CI	(-12.64, 15.50)	(-13.63, 19.19)	(-14.37, 12.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.52 (6.99)	3.87 (7.56)	
95% CI	(-11.81, 16.86)	(-11.64, 19.39)	
p-value	0.7208	0.6128	
Corrected Hedge's g Statistics	0.099	0.148	
95% CI	(-0.78, 0.98)	(-0.78, 1.08)	
Week 52			
m	8	7	19
n	7	5	16
Baseline Mean (SD)	90.49 (8.91)	79.98 (16.33)	88.96 (10.81)
Analysis Visit Mean (SD)	85.71 (14.35)	80.00 (15.63)	88.12 (13.33)
LS Mean of Change from Baseline (SE)	-3.07 (5.42)	0.50 (6.63)	1.45 (5.92)
95% CI	(-14.18, 8.05)	(-13.10, 14.11)	(-10.69, 13.59)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.51 (4.61)	-0.95 (5.61)	
95% CI	(-13.98, 4.95)	(-12.46, 10.56)	
p-value	0.3366	0.8672	
Corrected Hedge's g Statistics	-0.203	-0.041	
95% CI	(-1.09, 0.69)	(-1.05, 0.96)	
Subgroup*Treatment Interaction p-value	NE	0.6841	

AMNOG Table SE20.9.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Effects of Liver Disease			
Week 24			
m	8	7	20
n	7	6	17
Baseline Mean (SD)	71.43 (23.01)	87.78 (10.69)	82.36 (7.04)
Analysis Visit Mean (SD)	80.00 (0.00)	79.98 (7.30)	80.01 (8.50)
LS Mean of Change from Baseline (SE)	1.14 (4.14)	1.11 (5.07)	1.99 (4.44)
95% CI	(-7.36, 9.63)	(-9.30, 11.52)	(-7.11, 11.09)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.86 (3.91)	-0.88 (4.05)	
95% CI	(-8.89, 7.18)	(-9.20, 7.43)	
p-value	0.8287	0.8291	
Corrected Hedge's g Statistics	-0.050	-0.050	
95% CI	(-0.93, 0.83)	(-0.98, 0.88)	
Week 52			
m	8	7	19
n	7	5	16
Baseline Mean (SD)	79.06 (16.06)	89.34 (11.16)	81.68 (6.67)
Analysis Visit Mean (SD)	73.33 (24.03)	80.00 (4.74)	81.25 (7.39)
LS Mean of Change from Baseline (SE)	-3.86 (5.12)	-4.35 (6.45)	3.25 (4.89)
95% CI	(-14.37, 6.65)	(-17.59, 8.90)	(-6.80, 13.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	-7.10 (5.17)	-7.59 (6.07)	
95% CI	(-17.71, 3.50)	(-20.05, 4.86)	
p-value	0.1807	0.2217	
Corrected Hedge's g Statistics	-0.379	-0.392	
95% CI	(-1.27, 0.52)	(-1.40, 0.62)	
Subgroup*Treatment Interaction p-value	NE	0.1258	

AMNOG Table SE20.9.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Concentration/Memory			
Week 24			
m	8	7	20
n	7	6	17
Baseline Mean (SD)	84.83 (22.77)	80.23 (22.84)	93.39 (8.11)
Analysis Visit Mean (SD)	79.49 (23.86)	81.28 (17.24)	88.98 (13.17)
LS Mean of Change from Baseline (SE)	-2.61 (7.33)	3.34 (8.88)	3.82 (8.11)
95% CI	(-17.65, 12.43)	(-14.87, 21.56)	(-12.82, 20.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.43 (6.96)	-0.48 (7.73)	
95% CI	(-20.71, 7.84)	(-16.34, 15.39)	
p-value	0.3635	0.9513	
Corrected Hedge's g Statistics	-0.205	-0.015	
95% CI	(-1.09, 0.68)	(-0.95, 0.92)	
Week 52			
m	8	7	19
n	7	5	16
Baseline Mean (SD)	83.04 (21.85)	80.02 (25.53)	94.54 (6.79)
Analysis Visit Mean (SD)	74.11 (34.69)	81.26 (23.37)	84.79 (18.10)
LS Mean of Change from Baseline (SE)	-4.47 (8.05)	7.84 (9.90)	-3.46 (8.52)
95% CI	(-21.00, 12.05)	(-12.47, 28.15)	(-20.93, 14.01)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.01 (8.07)	11.30 (9.35)	
95% CI	(-17.57, 15.54)	(-7.88, 30.47)	
p-value	0.9009	0.2371	
Corrected Hedge's g Statistics	-0.032	0.340	
95% CI	(-0.92, 0.86)	(-0.67, 1.35)	
Subgroup*Treatment Interaction p-value	NE	0.7769	

AMNOG Table SE20.9.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Health Distress			
Week 24			
m	8	7	20
n	7	6	17
Baseline Mean (SD)	76.79 (35.67)	93.75 (6.85)	94.12 (14.06)
Analysis Visit Mean (SD)	82.14 (36.70)	93.75 (10.46)	93.38 (11.79)
LS Mean of Change from Baseline (SE)	6.25 (6.34)	4.25 (7.50)	5.03 (6.68)
95% CI	(-6.77, 19.27)	(-11.13, 19.63)	(-8.67, 18.73)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.22 (5.90)	-0.78 (6.10)	
95% CI	(-10.90, 13.33)	(-13.30, 11.75)	
p-value	0.8379	0.8993	
Corrected Hedge's g Statistics	0.047	-0.029	
95% CI	(-0.83, 0.93)	(-0.96, 0.90)	
Week 52			
m	8	7	19
n	7	5	16
Baseline Mean (SD)	80.36 (36.70)	92.50 (6.85)	95.31 (13.60)
Analysis Visit Mean (SD)	83.93 (37.30)	100.00 (0.00)	90.63 (16.14)
LS Mean of Change from Baseline (SE)	6.61 (7.23)	9.54 (8.67)	0.97 (7.10)
95% CI	(-8.23, 21.45)	(-8.25, 27.33)	(-13.59, 15.54)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.63 (7.12)	8.57 (7.87)	
95% CI	(-8.98, 20.25)	(-7.58, 24.71)	
p-value	0.4360	0.2858	
Corrected Hedge's g Statistics	0.208	0.307	
95% CI	(-0.68, 1.10)	(-0.70, 1.32)	
Subgroup*Treatment Interaction p-value	NE	0.6329	

AMNOG Table SE20.9.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Sexual Function			
Week 24			
m	8	7	20
n	2	3	6
Baseline Mean (SD)	96.65 (4.74)	95.00 (8.66)	92.50 (9.75)
Analysis Visit Mean (SD)	80.85 (15.34)	84.43 (21.42)	94.72 (8.20)
LS Mean of Change from Baseline (SE)	-16.57 (8.42)	-11.14 (7.01)	0.20 (4.83)
95% CI	(-35.62, 2.48)	(-27.00, 4.71)	(-10.73, 11.13)
LS Mean of Change from Baseline Compared to Placebo (SE)	-16.77 (9.82)	-11.34 (8.57)	
95% CI	(-38.99, 5.46)	(-30.72, 8.03)	
p-value	0.1221	0.2181	
Corrected Hedge's g Statistics	-1.231	-0.846	
95% CI	(-2.94, 0.48)	(-2.29, 0.59)	
Week 52			
m	8	7	19
n	2	2	5
Baseline Mean (SD)	96.65 (4.74)	100.00 (0.00)	95.66 (6.63)
Analysis Visit Mean (SD)	92.50 (10.61)	96.65 (4.74)	93.66 (14.18)
LS Mean of Change from Baseline (SE)	-4.33 (6.56)	-8.15 (5.59)	1.49 (3.78)
95% CI	(-19.17, 10.51)	(-20.80, 4.50)	(-7.05, 10.03)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.82 (7.66)	-9.64 (6.82)	
95% CI	(-23.14, 11.50)	(-25.07, 5.79)	
p-value	0.4668	0.1911	
Corrected Hedge's g Statistics	-0.569	-0.974	
95% CI	(-2.24, 1.10)	(-2.69, 0.74)	
Subgroup*Treatment Interaction p-value	NE	0.3339	

AMNOG Table SE20.9.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Sleep			
Week 24			
m	8	7	20
n	7	6	17
Baseline Mean (SD)	57.1 (30.3)	71.7 (8.8)	77.4 (19.7)
Analysis Visit Mean (SD)	59.3 (27.5)	70.0 (13.0)	75.0 (15.9)
LS Mean of Change from Baseline (SE)	-1.79 (5.89)	-1.01 (7.19)	-1.02 (6.56)
95% CI	(-13.88, 10.31)	(-15.75, 13.74)	(-14.48, 12.44)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.76 (5.32)	0.02 (5.55)	
95% CI	(-11.69, 10.16)	(-11.36, 11.40)	
p-value	0.8868	0.9976	
Corrected Hedge's g Statistics	-0.030	0.001	
95% CI	(-0.91, 0.85)	(-0.93, 0.93)	
Week 52			
m	8	7	19
n	7	5	16
Baseline Mean (SD)	68.6 (17.5)	73.0 (9.1)	80.3 (16.0)
Analysis Visit Mean (SD)	65.0 (18.5)	67.0 (12.0)	72.2 (18.9)
LS Mean of Change from Baseline (SE)	-5.89 (6.76)	-4.87 (8.19)	-7.05 (6.96)
95% CI	(-19.77, 7.99)	(-21.68, 11.94)	(-21.32, 7.23)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.16 (6.60)	2.18 (7.20)	
95% CI	(-12.38, 14.70)	(-12.59, 16.94)	
p-value	0.8622	0.7644	
Corrected Hedge's g Statistics	0.044	0.080	
95% CI	(-0.84, 0.93)	(-0.92, 1.08)	
Subgroup*Treatment Interaction p-value	NE	0.4109	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.9.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Loneliness			
Week 24			
m	8	7	20
n	7	6	17
Baseline Mean (SD)	88.6 (14.4)	99.2 (2.0)	94.7 (8.9)
Analysis Visit Mean (SD)	90.7 (10.6)	87.5 (15.4)	89.1 (13.6)
LS Mean of Change from Baseline (SE)	0.72 (6.85)	-8.23 (8.77)	-3.94 (7.69)
95% CI	(-13.33, 14.77)	(-26.22, 9.76)	(-19.72, 11.84)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.65 (6.20)	-4.30 (6.70)	
95% CI	(-8.07, 17.38)	(-18.05, 9.46)	
p-value	0.4596	0.5270	
Corrected Hedge's g Statistics	0.157	-0.140	
95% CI	(-0.72, 1.04)	(-1.07, 0.79)	
Week 52			
m	8	7	19
n	7	5	16
Baseline Mean (SD)	90.0 (15.0)	100.0 (0.0)	94.4 (9.1)
Analysis Visit Mean (SD)	93.6 (11.1)	85.0 (24.0)	92.2 (12.2)
LS Mean of Change from Baseline (SE)	2.94 (7.25)	-10.28 (9.29)	-0.31 (7.85)
95% CI	(-11.93, 17.81)	(-29.34, 8.78)	(-16.41, 15.79)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.25 (6.63)	-9.97 (7.55)	
95% CI	(-10.35, 16.85)	(-25.47, 5.53)	
p-value	0.6275	0.1980	
Corrected Hedge's g Statistics	0.110	-0.325	
95% CI	(-0.78, 1.00)	(-1.33, 0.68)	
Subgroup*Treatment Interaction p-value	NE	0.1732	

AMNOG Table SE20.9.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Hopelessness			
Week 24			
m	8	7	20
n	7	6	17
Baseline Mean (SD)	91.69 (11.77)	91.67 (16.68)	89.71 (19.45)
Analysis Visit Mean (SD)	91.67 (12.72)	90.27 (17.03)	89.22 (20.58)
LS Mean of Change from Baseline (SE)	0.49 (5.56)	-0.73 (6.90)	-0.23 (6.24)
95% CI	(-10.92, 11.91)	(-14.88, 13.42)	(-13.03, 12.57)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.73 (4.68)	-0.49 (5.32)	
95% CI	(-8.88, 10.33)	(-11.41, 10.42)	
p-value	0.8777	0.9267	
Corrected Hedge's g Statistics	0.030	-0.020	
95% CI	(-0.85, 0.91)	(-0.95, 0.91)	
Week 52			
m	8	7	19
n	7	5	16
Baseline Mean (SD)	89.30 (13.36)	90.00 (18.08)	89.07 (19.90)
Analysis Visit Mean (SD)	94.04 (7.94)	95.00 (7.46)	86.46 (18.48)
LS Mean of Change from Baseline (SE)	1.09 (6.16)	5.97 (7.56)	-2.61 (6.47)
95% CI	(-11.55, 13.72)	(-9.53, 21.47)	(-15.89, 10.67)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.70 (5.55)	8.58 (6.39)	
95% CI	(-7.69, 15.09)	(-4.53, 21.69)	
p-value	0.5107	0.1903	
Corrected Hedge's g Statistics	0.151	0.339	
95% CI	(-0.74, 1.04)	(-0.67, 1.35)	
Subgroup*Treatment Interaction p-value	NE	0.1786	

AMNOG Table SE20.9.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Stigma of Liver Disease			
Week 24			
m	8	7	20
n	7	6	17
Baseline Mean (SD)	89.30 (11.81)	85.43 (11.63)	91.92 (13.58)
Analysis Visit Mean (SD)	91.99 (10.02)	87.50 (15.81)	85.67 (26.77)
LS Mean of Change from Baseline (SE)	-2.05 (5.71)	-2.21 (6.94)	-15.08 (6.25)
95% CI	(-13.77, 9.68)	(-16.44, 12.02)	(-27.90, -2.25)
LS Mean of Change from Baseline Compared to Placebo (SE)	13.03 (5.22)	12.87 (5.72)	
95% CI	(2.32, 23.73)	(1.13, 24.61)	
p-value	0.0189	0.0329	
Corrected Hedge's g Statistics	0.539	0.517	
95% CI	(-0.35, 1.43)	(-0.43, 1.46)	
Week 52			
m	8	7	19
n	7	5	16
Baseline Mean (SD)	91.09 (10.11)	82.52 (10.27)	92.20 (13.97)
Analysis Visit Mean (SD)	88.41 (18.20)	82.50 (16.77)	85.18 (20.76)
LS Mean of Change from Baseline (SE)	-7.08 (6.96)	-7.12 (8.59)	-15.11 (6.81)
95% CI	(-21.37, 7.21)	(-24.74, 10.51)	(-29.09, -1.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	8.03 (6.90)	8.00 (8.21)	
95% CI	(-6.13, 22.19)	(-8.85, 24.84)	
p-value	0.2546	0.3387	
Corrected Hedge's g Statistics	0.309	0.298	
95% CI	(-0.58, 1.20)	(-0.71, 1.31)	
Subgroup*Treatment Interaction p-value	NE	0.4684	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.9.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Symptoms of Liver Disease			
Week 24			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	88.00 (6.51)	69.99 (17.43)
Analysis Visit Mean (SD)	N/A	92.00 (5.04)	80.94 (10.84)
LS Mean of Change from Baseline (SE)	NE	19.94 (5.82)	8.16 (4.33)
95% CI	NE	(6.51, 33.37)	(-1.83, 18.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	11.78 (6.47)	
95% CI	NE	(-3.15, 26.72)	
p-value	NE	0.1062	
Corrected Hedge's g Statistics	NE	0.899	
95% CI	NE	(-0.30, 2.10)	
Week 52			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	88.00 (6.51)	69.99 (17.43)
Analysis Visit Mean (SD)	N/A	84.00 (13.19)	80.47 (11.29)
LS Mean of Change from Baseline (SE)	NE	10.38 (6.92)	8.80 (5.30)
95% CI	NE	(-5.58, 26.34)	(-3.42, 21.02)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	1.58 (8.34)	
95% CI	NE	(-17.65, 20.82)	
p-value	NE	0.8544	
Corrected Hedge's g Statistics	NE	0.100	
95% CI	NE	(-1.05, 1.25)	
Subgroup*Treatment Interaction p-value	NE	0.6841	

AMNOG Table SE20.9.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Effects of Liver Disease			
Week 24			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	85.34 (8.69)	80.00 (3.87)
Analysis Visit Mean (SD)	N/A	88.00 (10.95)	77.14 (8.49)
LS Mean of Change from Baseline (SE)	NE	5.51 (5.66)	-4.38 (5.12)
95% CI	NE	(-7.55, 18.58)	(-16.20, 7.44)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	9.89 (6.79)	
95% CI	NE	(-5.76, 25.55)	
p-value	NE	0.1832	
Corrected Hedge's g Statistics	NE	0.692	
95% CI	NE	(-0.49, 1.87)	
Week 52			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	85.34 (8.69)	80.00 (3.87)
Analysis Visit Mean (SD)	N/A	84.00 (8.94)	80.01 (6.67)
LS Mean of Change from Baseline (SE)	NE	1.02 (4.91)	-1.16 (4.56)
95% CI	NE	(-10.30, 12.35)	(-11.66, 9.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	2.18 (5.60)	
95% CI	NE	(-10.74, 15.10)	
p-value	NE	0.7075	
Corrected Hedge's g Statistics	NE	0.173	
95% CI	NE	(-0.98, 1.32)	
Subgroup*Treatment Interaction p-value	NE	0.1258	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.9.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Concentration/Memory			
Week 24			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	90.02 (19.04)	77.70 (20.69)
Analysis Visit Mean (SD)	N/A	90.00 (16.30)	86.63 (14.15)
LS Mean of Change from Baseline (SE)	NE	4.81 (5.10)	9.56 (3.96)
95% CI	NE	(-6.95, 16.57)	(0.42, 18.69)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-4.75 (5.39)	
95% CI	NE	(-17.17, 7.68)	
p-value	NE	0.4039	
Corrected Hedge's g Statistics	NE	-0.403	
95% CI	NE	(-1.56, 0.76)	
Week 52			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	90.02 (19.04)	77.70 (20.69)
Analysis Visit Mean (SD)	N/A	88.76 (11.17)	80.37 (23.51)
LS Mean of Change from Baseline (SE)	NE	3.33 (7.48)	3.47 (6.06)
95% CI	NE	(-13.93, 20.59)	(-10.51, 17.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-0.15 (9.09)	
95% CI	NE	(-21.12, 20.83)	
p-value	NE	0.9876	
Corrected Hedge's g Statistics	NE	-0.008	
95% CI	NE	(-1.16, 1.14)	
Subgroup*Treatment Interaction p-value	NE	0.7769	

AMNOG Table SE20.9.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Health Distress			
Week 24			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	100.00 (0.00)	94.64 (9.83)
Analysis Visit Mean (SD)	N/A	97.50 (5.59)	87.50 (19.09)
LS Mean of Change from Baseline (SE)	NE	0.39 (7.51)	-5.09 (5.98)
95% CI	NE	(-16.93, 17.71)	(-18.89, 8.72)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	5.47 (7.97)	
95% CI	NE	(-12.90, 23.84)	
p-value	NE	0.5114	
Corrected Hedge's g Statistics	NE	0.311	
95% CI	NE	(-0.84, 1.47)	
Week 52			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	100.00 (0.00)	94.64 (9.83)
Analysis Visit Mean (SD)	N/A	90.00 (13.69)	89.29 (19.67)
LS Mean of Change from Baseline (SE)	NE	-7.47 (8.73)	-3.04 (7.05)
95% CI	NE	(-27.61, 12.67)	(-19.30, 13.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-4.43 (9.97)	
95% CI	NE	(-27.42, 18.56)	
p-value	NE	0.6686	
Corrected Hedge's g Statistics	NE	-0.215	
95% CI	NE	(-1.37, 0.94)	
Subgroup*Treatment Interaction p-value	NE	0.6329	

AMNOG Table SE20.9.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Sexual Function			
Week 24			
m	0	5	7
n	0	2	3
Baseline Mean (SD)	N/A	92.50 (10.61)	90.00 (10.95)
Analysis Visit Mean (SD)	N/A	92.50 (10.61)	80.00 (29.03)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	0	5	7
n	0	2	3
Baseline Mean (SD)	N/A	92.50 (10.61)	90.53 (11.11)
Analysis Visit Mean (SD)	N/A	96.65 (4.74)	66.67 (45.37)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	0.3339	

AMNOG Table SE20.9.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Sleep			
Week 24			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	69.0 (8.2)	49.3 (9.3)
Analysis Visit Mean (SD)	N/A	62.0 (18.2)	58.6 (14.1)
LS Mean of Change from Baseline (SE)	NE	-4.02 (10.27)	14.08 (8.33)
95% CI	NE	(-27.69, 19.66)	(-5.12, 33.28)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-18.10 (14.49)	
95% CI	NE	(-51.51, 15.31)	
p-value	NE	0.2468	
Corrected Hedge's g Statistics	NE	-0.746	
95% CI	NE	(-1.93, 0.44)	
Week 52			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	69.0 (8.2)	49.3 (9.3)
Analysis Visit Mean (SD)	N/A	62.0 (9.1)	62.1 (18.5)
LS Mean of Change from Baseline (SE)	NE	-5.00 (8.05)	18.36 (6.64)
95% CI	NE	(-23.57, 13.56)	(3.04, 33.67)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-23.36 (10.85)	
95% CI	NE	(-48.38, 1.65)	
p-value	NE	0.0634	
Corrected Hedge's g Statistics	NE	-1.215	
95% CI	NE	(-2.46, 0.03)	
Subgroup*Treatment Interaction p-value	NE	0.4109	

AMNOG Table SE20.9.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Loneliness			
Week 24			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	97.0 (2.7)	88.6 (13.1)
Analysis Visit Mean (SD)	N/A	87.0 (21.1)	81.4 (25.6)
LS Mean of Change from Baseline (SE)	NE	-5.82 (10.72)	-1.11 (8.97)
95% CI	NE	(-30.55, 18.91)	(-21.80, 19.57)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-4.71 (13.58)	
95% CI	NE	(-36.03, 26.61)	
p-value	NE	0.7376	
Corrected Hedge's g Statistics	NE	-0.182	
95% CI	NE	(-1.33, 0.97)	
Week 52			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	97.0 (2.7)	88.6 (13.1)
Analysis Visit Mean (SD)	N/A	95.0 (8.7)	77.1 (20.0)
LS Mean of Change from Baseline (SE)	NE	2.98 (6.93)	-5.97 (5.84)
95% CI	NE	(-13.02, 18.97)	(-19.43, 7.50)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	8.94 (7.84)	
95% CI	NE	(-9.13, 27.02)	
p-value	NE	0.2869	
Corrected Hedge's g Statistics	NE	0.534	
95% CI	NE	(-0.63, 1.70)	
Subgroup*Treatment Interaction p-value	NE	0.1732	

AMNOG Table SE20.9.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Hopelessness			
Week 24			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	91.68 (14.42)	80.96 (19.07)
Analysis Visit Mean (SD)	N/A	80.00 (24.02)	80.96 (28.34)
LS Mean of Change from Baseline (SE)	NE	-1.05 (11.82)	11.01 (9.71)
95% CI	NE	(-28.31, 26.20)	(-11.37, 33.40)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-12.07 (14.92)	
95% CI	NE	(-46.46, 22.33)	
p-value	NE	0.4420	
Corrected Hedge's g Statistics	NE	-0.429	
95% CI	NE	(-1.59, 0.73)	
Week 52			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	91.68 (14.42)	80.96 (19.07)
Analysis Visit Mean (SD)	N/A	86.68 (18.24)	88.10 (19.16)
LS Mean of Change from Baseline (SE)	NE	7.69 (8.31)	16.68 (6.69)
95% CI	NE	(-11.48, 26.86)	(1.27, 32.10)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-8.99 (9.81)	
95% CI	NE	(-31.61, 13.63)	
p-value	NE	0.3861	
Corrected Hedge's g Statistics	NE	-0.460	
95% CI	NE	(-1.62, 0.70)	
Subgroup*Treatment Interaction p-value	NE	0.1786	

AMNOG Table SE20.9.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Stigma of Liver Disease			
Week 24			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	85.02 (21.01)	91.99 (10.00)
Analysis Visit Mean (SD)	N/A	81.26 (20.73)	87.51 (13.01)
LS Mean of Change from Baseline (SE)	NE	-1.02 (9.08)	6.22 (8.20)
95% CI	NE	(-21.96, 19.93)	(-12.69, 25.13)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-7.23 (10.00)	
95% CI	NE	(-30.30, 15.83)	
p-value	NE	0.4901	
Corrected Hedge's g Statistics	NE	-0.316	
95% CI	NE	(-1.47, 0.84)	
Week 52			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	85.02 (21.01)	91.99 (10.00)
Analysis Visit Mean (SD)	N/A	83.78 (20.07)	90.20 (12.95)
LS Mean of Change from Baseline (SE)	NE	1.41 (9.31)	8.97 (8.38)
95% CI	NE	(-20.06, 22.89)	(-10.36, 28.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-7.55 (10.37)	
95% CI	NE	(-31.46, 16.35)	
p-value	NE	0.4869	
Corrected Hedge's g Statistics	NE	-0.322	
95% CI	NE	(-1.48, 0.83)	
Subgroup*Treatment Interaction p-value	NE	0.4684	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.9.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis, only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.

AMNOG Table SE20.9.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	8 (100)	10 (100)	20 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (12.5)	0	3 (15.0)
No	7 (87.5)	10 (100)	17 (85.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.24	4.20	
95% CI of the inverse odds ratio	(0.11, 14.01)	(0.20, 89.61)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	3.67	
95% CI of the inverse risk ratio	(0.15, 9.89)	(0.21, 64.80)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-12.12	
95% CI of the absolute risk difference	(-30.25, 25.25)	(-32.26, 8.02)	
p-value	0.8644	0.3248	
p-value of Breslow-Day Test for Homogeneity [3]	0.6182	0.3151	

AMNOG Table SE20.9.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	8 (100)	10 (100)	20 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	4 (20.0)
No	8 (100)	10 (100)	16 (80.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.64	5.73	
95% CI of the inverse odds ratio	(0.22, 96.60)	(0.28, 117.65)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.86	4.71	
95% CI of the inverse risk ratio	(0.23, 64.42)	(0.28, 79.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-15.87	-16.88	
95% CI of the absolute risk difference	(-38.94, 7.19)	(-38.32, 4.55)	
p-value	0.2850	0.2116	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.4430	

AMNOG Table SE20.9.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (5.0)
No	8 (100)	10 (100)	19 (95.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.31	1.62	
95% CI of the inverse odds ratio	(0.05, 35.47)	(0.06, 43.25)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	1.57	
95% CI of the inverse risk ratio	(0.06, 28.65)	(0.07, 35.46)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.59	-2.60	
95% CI of the absolute risk difference	(-20.17, 16.99)	(-19.12, 13.92)	
p-value	0.8731	0.7731	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (12.5)	0	3 (15.0)
No	7 (87.5)	10 (100)	17 (85.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.24	4.20	
95% CI of the inverse odds ratio	(0.11, 14.01)	(0.20, 89.61)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	3.67	
95% CI of the inverse risk ratio	(0.15, 9.89)	(0.21, 64.80)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-12.12	
95% CI of the absolute risk difference	(-30.25, 25.25)	(-32.26, 8.02)	
p-value	0.8644	0.3248	
p-value of Breslow-Day Test for Homogeneity [3]	0.7376	0.1931	

AMNOG Table SE20.9.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	8 (100)	10 (100)	20 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (12.5)	2 (20.0)	2 (10.0)
No	7 (87.5)	8 (80.0)	18 (90.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	0.44	
95% CI of the inverse odds ratio	(0.06, 10.00)	(0.05, 3.74)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	0.50	
95% CI of the inverse risk ratio	(0.08, 7.64)	(0.08, 3.05)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.50	10.00	
95% CI of the absolute risk difference	(-23.92, 28.92)	(-18.06, 38.06)	
p-value	0.8468	0.4475	
p-value of Breslow-Day Test for Homogeneity [3]	0.3487	0.1867	

AMNOG Table SE20.9.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (5.0)
No	8 (100)	10 (100)	19 (95.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.31	1.62	
95% CI of the inverse odds ratio	(0.05, 35.47)	(0.06, 43.25)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	1.57	
95% CI of the inverse risk ratio	(0.06, 28.65)	(0.07, 35.46)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.59	-2.60	
95% CI of the absolute risk difference	(-20.17, 16.99)	(-19.12, 13.92)	
p-value	0.8731	0.7731	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (25.0)	3 (30.0)	2 (10.0)
No	6 (75.0)	7 (70.0)	18 (90.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	0.26	
95% CI of the inverse odds ratio	(0.04, 2.91)	(0.04, 1.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.40	0.33	
95% CI of the inverse risk ratio	(0.07, 2.37)	(0.07, 1.68)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	15.00	20.00	
95% CI of the absolute risk difference	(-17.76, 47.76)	(-11.30, 51.30)	
p-value	0.3055	0.1659	
p-value of Breslow-Day Test for Homogeneity [3]	0.5453	0.1910	

AMNOG Table SE20.9.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	8 (100)	10 (100)	20 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	1 (5.0)
No	8 (100)	10 (100)	19 (95.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.31	1.62	
95% CI of the inverse odds ratio	(0.05, 35.47)	(0.06, 43.25)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	1.57	
95% CI of the inverse risk ratio	(0.06, 28.65)	(0.07, 35.46)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.59	-2.60	
95% CI of the absolute risk difference	(-20.17, 16.99)	(-19.12, 13.92)	
p-value	0.8731	0.7731	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.1648	

AMNOG Table SE20.9.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (5.0)
No	8 (100)	10 (100)	19 (95.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.31	1.62	
95% CI of the inverse odds ratio	(0.05, 35.47)	(0.06, 43.25)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	1.57	
95% CI of the inverse risk ratio	(0.06, 28.65)	(0.07, 35.46)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.59	-2.60	
95% CI of the absolute risk difference	(-20.17, 16.99)	(-19.12, 13.92)	
p-value	0.8731	0.7731	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (25.0)	1 (10.0)	4 (20.0)
No	6 (75.0)	9 (90.0)	16 (80.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	2.25	
95% CI of the inverse odds ratio	(0.11, 5.22)	(0.22, 23.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	2.00	
95% CI of the inverse risk ratio	(0.18, 3.54)	(0.26, 15.62)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.00	-10.00	
95% CI of the absolute risk difference	(-29.75, 39.75)	(-35.55, 15.55)	
p-value	0.7708	0.4884	
p-value of Breslow-Day Test for Homogeneity [3]	0.2326	0.5412	

AMNOG Table SE20.9.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (25.0)	0	2 (10.0)
No	6 (75.0)	10 (100)	18 (90.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	2.84	
95% CI of the inverse odds ratio	(0.04, 2.91)	(0.12, 64.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.40	2.62	
95% CI of the inverse risk ratio	(0.07, 2.37)	(0.14, 49.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	15.00	-7.36	
95% CI of the absolute risk difference	(-17.76, 47.76)	(-25.89, 11.17)	
p-value	0.3055	0.4975	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (25.0)	0	3 (15.0)
No	6 (75.0)	10 (100)	17 (85.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.53	4.20	
95% CI of the inverse odds ratio	(0.07, 3.98)	(0.20, 89.61)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	3.67	
95% CI of the inverse risk ratio	(0.12, 2.94)	(0.21, 64.80)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	10.00	-12.12	
95% CI of the absolute risk difference	(-23.84, 43.84)	(-32.26, 8.02)	
p-value	0.5325	0.3248	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.0224	

AMNOG Table SE20.9.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (12.5)	1 (10.0)	2 (10.0)
No	7 (87.5)	9 (90.0)	18 (90.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	1.00	
95% CI of the inverse odds ratio	(0.06, 10.00)	(0.08, 12.56)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	1.00	
95% CI of the inverse risk ratio	(0.08, 7.64)	(0.10, 9.75)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.50	0.00	
95% CI of the absolute risk difference	(-23.92, 28.92)	(-22.77, 22.77)	
p-value	0.8468	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.4395	0.1916	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (25.0)	1 (10.0)	2 (10.0)
No	6 (75.0)	9 (90.0)	18 (90.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	1.00	
95% CI of the inverse odds ratio	(0.04, 2.91)	(0.08, 12.56)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.40	1.00	
95% CI of the inverse risk ratio	(0.07, 2.37)	(0.10, 9.75)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	15.00	0.00	
95% CI of the absolute risk difference	(-17.76, 47.76)	(-22.77, 22.77)	
p-value	0.3055	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.1929	0.4472	

AMNOG Table SE20.9.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (10.0)	0
No	8 (100)	9 (90.0)	20 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.15	
95% CI of the inverse odds ratio	NE	(0.01, 4.15)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.17	
95% CI of the inverse risk ratio	NE	(0.01, 3.94)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	11.26	
95% CI of the absolute risk difference	NE	(-10.05, 32.56)	
p-value	NE	0.2116	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (12.5)	1 (10.0)	0
No	7 (87.5)	9 (90.0)	20 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.12	0.15	
95% CI of the inverse odds ratio	(0.00, 3.33)	(0.01, 4.15)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.14	0.17	
95% CI of the inverse risk ratio	(0.01, 3.18)	(0.01, 3.94)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	14.29	11.26	
95% CI of the absolute risk difference	(-10.92, 39.49)	(-10.05, 32.56)	
p-value	0.1506	0.2116	
p-value of Breslow-Day Test for Homogeneity [3]	0.1231	0.1201	

AMNOG Table SE20.9.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	1 (100)	5 (100)	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (20.0)	2 (25.0)
No	1 (100)	4 (80.0)	6 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	1.33	
95% CI of the inverse odds ratio	(0.03, 38.88)	(0.09, 20.11)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	1.25	
95% CI of the inverse risk ratio	(0.08, 15.28)	(0.15, 10.46)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.78	-5.00	
95% CI of the absolute risk difference	(-69.54, 63.99)	(-51.15, 41.15)	
p-value	0.9364	0.8351	
p-value of Breslow-Day Test for Homogeneity [3]	0.6182	0.3151	

AMNOG Table SE20.9.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (20.0)	3 (37.5)
No	1 (100)	4 (80.0)	5 (62.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.91	2.40	
95% CI of the inverse odds ratio	(0.06, 61.34)	(0.18, 32.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.56	1.88	
95% CI of the inverse risk ratio	(0.12, 19.65)	(0.26, 13.42)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-13.89	-17.50	
95% CI of the absolute risk difference	(-81.83, 54.05)	(-66.03, 31.03)	
p-value	0.7119	0.5060	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (40.0)	6 (75.0)
No	1 (100)	3 (60.0)	2 (25.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	7.80	4.50	
95% CI of the inverse odds ratio	(0.23, 262.81)	(0.41, 49.63)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.89	1.88	
95% CI of the inverse risk ratio	(0.25, 32.96)	(0.60, 5.90)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-47.22	-35.00	
95% CI of the absolute risk difference	(-100.00, 19.54)	(-87.39, 17.39)	
p-value	0.2092	0.2070	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.4430	

AMNOG Table SE20.9.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	1 (100)	5 (100)	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (20.0)	1 (12.5)
No	1 (100)	4 (80.0)	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	0.57	
95% CI of the inverse odds ratio	(0.02, 23.07)	(0.03, 11.85)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	0.63	
95% CI of the inverse risk ratio	(0.04, 11.07)	(0.05, 7.90)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.33	7.50	
95% CI of the absolute risk difference	(-56.43, 73.10)	(-34.39, 49.39)	
p-value	0.7823	0.7154	
p-value of Breslow-Day Test for Homogeneity [3]	0.7376	0.1931	

AMNOG Table SE20.9.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (20.0)	0
No	1 (100)	4 (80.0)	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.18	
95% CI of the inverse odds ratio	NE	(0.01, 5.28)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.22	
95% CI of the inverse risk ratio	NE	(0.01, 4.60)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	19.44	
95% CI of the absolute risk difference	NE	(-18.30, 57.19)	
p-value	NE	0.2778	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (20.0)	4 (50.0)
No	1 (100)	4 (80.0)	4 (50.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	4.00	
95% CI of the inverse odds ratio	(0.09, 95.17)	(0.30, 53.47)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	2.50	
95% CI of the inverse risk ratio	(0.17, 24.07)	(0.38, 16.47)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-25.00	-30.00	
95% CI of the absolute risk difference	(-93.33, 43.33)	(-79.29, 19.29)	
p-value	0.5207	0.2794	
p-value of Breslow-Day Test for Homogeneity [3]	0.3487	0.1867	

AMNOG Table SE20.9.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	1 (100)	5 (100)	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	1 (12.5)
No	1 (100)	5 (100)	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	2.20	
95% CI of the inverse odds ratio	(0.02, 23.07)	(0.07, 64.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	2.00	
95% CI of the inverse risk ratio	(0.04, 11.07)	(0.10, 41.37)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.33	-8.33	
95% CI of the absolute risk difference	(-56.43, 73.10)	(-41.23, 24.56)	
p-value	0.7823	0.6418	
p-value of Breslow-Day Test for Homogeneity [3]	0.5453	0.1910	

AMNOG Table SE20.9.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	1 (100)	5 (100)	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (20.0)	0
No	1 (100)	4 (80.0)	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.18	
95% CI of the inverse odds ratio	NE	(0.01, 5.28)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.22	
95% CI of the inverse risk ratio	NE	(0.01, 4.60)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	19.44	
95% CI of the absolute risk difference	NE	(-18.30, 57.19)	
p-value	NE	0.2778	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.1648	

AMNOG Table SE20.9.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	4 (50.0)
No	1 (100)	5 (100)	4 (50.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	11.00	
95% CI of the inverse odds ratio	(0.09, 95.17)	(0.46, 263.53)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	6.00	
95% CI of the inverse risk ratio	(0.17, 24.07)	(0.39, 92.28)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-25.00	-41.67	
95% CI of the absolute risk difference	(-93.33, 43.33)	(-81.11, -2.22)	
p-value	0.5207	0.0935	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (20.0)	5 (62.5)
No	1 (100)	4 (80.0)	3 (37.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.71	6.67	
95% CI of the inverse odds ratio	(0.15, 151.48)	(0.49, 91.33)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.44	3.13	
95% CI of the inverse risk ratio	(0.21, 28.51)	(0.50, 19.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-36.11	-42.50	
95% CI of the absolute risk difference	(-100.00, 31.83)	(-91.03, 6.03)	
p-value	0.3536	0.1348	
p-value of Breslow-Day Test for Homogeneity [3]	0.2326	0.5412	

AMNOG Table SE20.9.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	1 (100)	5 (100)	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (40.0)	0
No	1 (100)	3 (60.0)	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.08	
95% CI of the inverse odds ratio	NE	(0.00, 2.19)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.13	
95% CI of the inverse risk ratio	NE	(0.01, 2.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	36.11	
95% CI of the absolute risk difference	NE	(-6.08, 78.30)	
p-value	NE	0.0867	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.0224	

AMNOG Table SE20.9.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	3 (37.5)
No	1 (100)	5 (100)	5 (62.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.91	7.00	
95% CI of the inverse odds ratio	(0.06, 61.34)	(0.29, 170.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.56	4.67	
95% CI of the inverse risk ratio	(0.12, 19.65)	(0.29, 75.02)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-13.89	-30.56	
95% CI of the absolute risk difference	(-81.83, 54.05)	(-69.33, 8.22)	
p-value	0.7119	0.1899	
p-value of Breslow-Day Test for Homogeneity [3]	0.4395	0.1916	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (20.0)	4 (50.0)
No	1 (100)	4 (80.0)	4 (50.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	4.00	
95% CI of the inverse odds ratio	(0.09, 95.17)	(0.30, 53.47)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	2.50	
95% CI of the inverse risk ratio	(0.17, 24.07)	(0.38, 16.47)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-25.00	-30.00	
95% CI of the absolute risk difference	(-93.33, 43.33)	(-79.29, 19.29)	
p-value	0.5207	0.2794	
p-value of Breslow-Day Test for Homogeneity [3]	0.1929	0.4472	

AMNOG Table SE20.9.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (20.0)	0
No	1 (100)	4 (80.0)	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.18	
95% CI of the inverse odds ratio	NE	(0.01, 5.28)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.22	
95% CI of the inverse risk ratio	NE	(0.01, 4.60)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	19.44	
95% CI of the absolute risk difference	NE	(-18.30, 57.19)	
p-value	NE	0.2778	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (20.0)	3 (37.5)
No	1 (100)	4 (80.0)	5 (62.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.91	2.40	
95% CI of the inverse odds ratio	(0.06, 61.34)	(0.18, 32.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.56	1.88	
95% CI of the inverse risk ratio	(0.12, 19.65)	(0.26, 13.42)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-13.89	-17.50	
95% CI of the absolute risk difference	(-81.83, 54.05)	(-66.03, 31.03)	
p-value	0.7119	0.5060	
p-value of Breslow-Day Test for Homogeneity [3]	0.1231	0.1201	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.10.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=5)	(N=5)	(N=17)	(N=5)	(N=5)	(N=17)
Total LDQOL						
Baseline						
m	5	5	17			
n	5	5	15			
Mean (SD)	77.26 (13.72)	84.22 (7.29)	88.31 (5.16)			
Median	76.50	88.80	87.80			
IQR: Q1, Q3	72.40, 88.80	77.40, 89.40	85.00, 92.10			
Min, Max	57.3, 91.3	75.2, 90.3	80.2, 97.8			
Week 24						
m	4	4	16			
n	3	4	14	3	4	13
Mean (SD/SE)	76.33 (14.72)	86.90 (7.66)	88.54 (5.61)	2.67 (1.45)	0.43 (3.05)	0.64 (1.76)
Median	74.20	85.10	88.50	1.80	1.25	0.80
IQR: Q1, Q3	62.80, 92.00	81.05, 92.75	84.00, 94.10	0.70, 5.50	-4.00, 4.85	-3.70, 2.00
Min, Max	62.8, 92.0	80.3, 97.1	80.4, 98.1	0.7, 5.5	-7.6, 6.8	-9.6, 13.3
Week 52						
m	4	4	15			
n	4	4	14	4	4	13
Mean (SD/SE)	74.98 (23.89)	86.03 (2.11)	84.88 (11.59)	-2.48 (5.22)	-0.45 (3.14)	-3.17 (3.48)
Median	83.95	86.30	87.35	0.10	-2.45	-0.80
IQR: Q1, Q3	59.80, 90.15	84.65, 87.40	79.40, 93.60	-8.90, 3.95	-4.25, 3.35	-2.90, 2.60
Min, Max	40.0, 92.0	83.2, 88.3	51.7, 98.1	-17.3, 7.2	-5.6, 8.7	-40.4, 7.2

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.10.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=5)	(N=5)	(N=17)	(N=5)	(N=5)	(N=17)
Symptoms of Liver Disease						
Baseline						
m	5	5	17			
n	5	5	15			
Mean (SD)	87.34 (9.53)	82.66 (14.96)	80.22 (16.93)			
Median	86.70	90.00	86.70			
IQR: Q1, Q3	80.00, 93.30	83.30, 90.00	63.30, 93.30			
Min, Max	76.7, 100.0	56.7, 93.3	50.0, 100.0			
Week 24						
m	4	4	16			
n	3	4	14	3	4	13
Mean (SD/SE)	81.10 (18.37)	92.50 (5.68)	84.04 (14.47)	-4.47 (6.19)	3.35 (1.37)	6.92 (4.46)
Median	80.00	91.65	86.65	0	3.35	3.40
IQR: Q1, Q3	63.30, 100.00	88.35, 96.65	73.30, 96.70	-16.70, 3.30	1.65, 5.05	-3.40, 20.00
Min, Max	63.3, 100.0	86.7, 100.0	53.3, 100.0	-16.7, 3.3	0.0, 6.7	-20.0, 40.0
Week 52						
m	4	4	15			
n	4	4	14	4	4	13
Mean (SD/SE)	80.85 (18.32)	86.68 (15.15)	82.38 (14.58)	-6.65 (4.52)	-2.48 (8.43)	4.62 (4.35)
Median	85.00	90.00	81.65	-3.30	-1.65	6.60
IQR: Q1, Q3	66.70, 95.00	75.00, 98.35	70.00, 100.00	-11.65, -1.65	-15.00, 10.05	0.00, 10.00
Min, Max	56.7, 96.7	66.7, 100.0	56.7, 100.0	-20.0, 0.0	-23.3, 16.7	-36.7, 30.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.10.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=5)	(N=5)	(N=17)	(N=5)	(N=5)	(N=17)
Effects of Liver Disease						
Baseline						
m	5	5	17			
n	5	5	15			
Mean (SD)	72.02 (15.91)	88.00 (10.95)	81.78 (5.90)			
Median	80.00	80.00	80.00			
IQR: Q1, Q3	66.70, 80.00	80.00, 100.00	80.00, 80.00			
Min, Max	46.7, 86.7	80.0, 100.0	73.3, 100.0			
Week 24						
m	4	4	16			
n	3	4	14	3	4	13
Mean (SD/SE)	80.00 (0.00)	83.33 (6.65)	80.96 (8.62)	11.10 (11.10)	-6.68 (4.71)	-1.54 (3.71)
Median	80.00	80.00	80.00	0	-3.35	0
IQR: Q1, Q3	80.00, 80.00	80.00, 86.65	80.00, 86.70	0.00, 33.30	-13.35, 0.00	0.00, 0.00
Min, Max	80.0, 80.0	80.0, 93.3	60.0, 100.0	0.0, 33.3	-20.0, 0.0	-40.0, 20.0
Week 52						
m	4	4	15			
n	4	4	14	4	4	13
Mean (SD/SE)	68.33 (32.82)	80.00 (0.00)	80.48 (7.14)	-5.03 (8.34)	-10.00 (5.77)	-2.05 (3.06)
Median	80.00	80.00	80.00	-3.35	-10.00	0
IQR: Q1, Q3	50.00, 86.65	80.00, 80.00	80.00, 80.00	-16.70, 6.65	-20.00, 0.00	0.00, 0.00
Min, Max	20.0, 93.3	80.0, 80.0	66.7, 100.0	-26.7, 13.3	-20.0, 0.0	-26.7, 20.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.10.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=5)	(N=5)	(N=17)	(N=5)	(N=5)	(N=17)
Concentration/Memory						
Baseline						
m	5	5	17			
n	5	5	15			
Mean (SD)	70.02 (23.11)	72.52 (22.80)	92.93 (8.13)			
Median	62.50	62.50	93.80			
IQR: Q1, Q3	56.30, 87.50	56.30, 93.80	87.50, 100.00			
Min, Max	43.8, 100.0	50.0, 100.0	75.0, 100.0			
Week 24						
m	4	4	16			
n	3	4	14	3	4	13
Mean (SD/SE)	64.60 (30.81)	85.95 (16.45)	91.53 (12.64)	-4.17 (4.17)	7.80 (8.24)	0.96 (3.31)
Median	50.00	90.65	100.00	0	3.10	0
IQR: Q1, Q3	43.80, 100.00	75.00, 96.90	87.50, 100.00	-12.50, 0.00	-3.15, 18.75	0.00, 6.30
Min, Max	43.8, 100.0	62.5, 100.0	62.5, 100.0	-12.5, 0.0	-6.3, 31.3	-25.0, 18.7
Week 52						
m	4	4	15			
n	4	4	14	4	4	13
Mean (SD/SE)	60.95 (42.81)	85.95 (10.67)	83.96 (21.60)	-12.50 (11.14)	7.80 (6.94)	-8.15 (5.54)
Median	71.90	84.40	93.80	-6.25	6.25	-6.20
IQR: Q1, Q3	34.40, 87.50	78.15, 93.75	81.30, 100.00	-28.15, 3.15	-3.15, 18.75	-6.20, 0.00
Min, Max	0.0, 100.0	75.0, 100.0	43.8, 100.0	-43.8, 6.3	-6.3, 25.0	-50.0, 12.5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.10.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=5)	(N=5)	(N=17)	(N=5)	(N=5)	(N=17)
Health Distress						
Baseline						
m	5	5	17			
n	5	5	15			
Mean (SD)	65.00 (38.93)	100.00 (0.00)	97.50 (7.01)			
Median	75.00	100.00	100.00			
IQR: Q1, Q3	62.50, 87.50	100.00, 100.00	100.00, 100.00			
Min, Max	0.0, 100.0	100.0, 100.0	75.0, 100.0			
Week 24						
m	4	4	16			
n	3	4	14	3	4	13
Mean (SD/SE)	58.33 (50.52)	96.88 (6.25)	96.43 (7.64)	4.17 (4.17)	-3.13 (3.13)	-0.96 (3.31)
Median	87.50	100.00	100.00	0	0	0
IQR: Q1, Q3	0.00, 87.50	93.75, 100.00	100.00, 100.00	0.00, 12.50	-6.25, 0.00	0.00, 0.00
Min, Max	0.0, 87.5	87.5, 100.0	75.0, 100.0	0.0, 12.5	-12.5, 0.0	-25.0, 25.0
Week 52						
m	4	4	15			
n	4	4	14	4	4	13
Mean (SD/SE)	71.88 (48.28)	93.75 (12.50)	91.07 (17.28)	6.25 (3.61)	-6.25 (6.25)	-6.73 (5.41)
Median	93.75	100.00	100.00	6.25	0	0
IQR: Q1, Q3	43.75, 100.00	87.50, 100.00	87.50, 100.00	0.00, 12.50	-12.50, 0.00	-12.50, 0.00
Min, Max	0.0, 100.0	75.0, 100.0	37.5, 100.0	0.0, 12.5	-25.0, 0.0	-62.5, 12.5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.10.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=5)	(N=5)	(N=17)	(N=5)	(N=5)	(N=17)
Sexual Function						
Baseline						
m	5	5	17			
n	2	1	6			
Mean (SD)	87.50 (5.94)	85.00 (N/A)	95.27 (6.01)			
Median	87.50	85.00	96.65			
IQR: Q1, Q3	83.30, 91.70	85.00, 85.00	93.30, 100.00			
Min, Max	83.3, 91.7	85.0, 85.0	85.0, 100.0			
Week 24						
m	4	4	16			
n	0	1	4	0	1	3
Mean (SD/SE)	N/A	85.00 (N/A)	98.33 (3.35)	N/A	0.00 (N/A)	2.23 (2.23)
Median	N/A	85.00	100.00	N/A	0	0
IQR: Q1, Q3	N/A	85.00, 85.00	96.65, 100.00	N/A	0.00, 0.00	0.00, 6.70
Min, Max	N/A	85.0, 85.0	93.3, 100.0	N/A	0.0, 0.0	0.0, 6.7
Week 52						
m	4	4	15			
n	0	1	8	0	1	5
Mean (SD/SE)	N/A	93.30 (N/A)	81.86 (26.60)	N/A	8.30 (N/A)	-3.66 (4.04)
Median	N/A	93.30	92.50	N/A	8.30	0
IQR: Q1, Q3	N/A	93.30, 93.30	73.30, 100.00	N/A	8.30, 8.30	-8.30, 0.00
Min, Max	N/A	93.3, 93.3	23.3, 100.0	N/A	8.3, 8.3	-16.7, 6.7

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.10.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=5)	(N=5)	(N=17)	(N=5)	(N=5)	(N=17)
Sleep						
Baseline						
m	5	5	17			
n	5	5	15			
Mean (SD)	62.0 (16.8)	68.0 (9.7)	68.7 (19.9)			
Median	65.0	65.0	70.0			
IQR: Q1, Q3	50.0, 75.0	65.0, 65.0	50.0, 85.0			
Min, Max	40, 80	60, 85	35, 100			
Week 24						
m	4	4	16			
n	3	4	14	3	4	13
Mean (SD/SE)	63.3 (10.4)	62.5 (21.0)	71.8 (11.7)	8.3 (6.0)	-6.3 (6.6)	1.9 (3.9)
Median	60.0	60.0	72.5	5.0	-2.5	0
IQR: Q1, Q3	55.0, 75.0	47.5, 77.5	60.0, 80.0	0.0, 20.0	-15.0, 2.5	-10.0, 10.0
Min, Max	55, 75	40, 90	55, 90	0, 20	-25, 5	-20, 30
Week 52						
m	4	4	15			
n	4	4	14	4	4	13
Mean (SD/SE)	56.3 (19.3)	62.5 (10.4)	69.6 (17.0)	-5.0 (3.5)	-6.3 (4.3)	-0.8 (5.4)
Median	60.0	62.5	70.0	-7.5	-7.5	0
IQR: Q1, Q3	42.5, 70.0	55.0, 70.0	60.0, 85.0	-10.0, 0.0	-12.5, 0.0	-10.0, 10.0
Min, Max	30, 75	50, 75	35, 95	-10, 5	-15, 5	-35, 35

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.10.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=5)	(N=5)	(N=17)	(N=5)	(N=5)	(N=17)
Loneliness						
Baseline						
m	5	5	17			
n	5	5	15			
Mean (SD)	86.0 (16.4)	88.0 (21.4)	97.0 (6.8)			
Median	85.0	95.0	100.0			
IQR: Q1, Q3	85.0, 100.0	95.0, 100.0	95.0, 100.0			
Min, Max	60, 100	50, 100	75, 100			
Week 24						
m	4	4	16			
n	3	4	14	3	4	13
Mean (SD/SE)	88.3 (10.4)	96.3 (4.8)	94.3 (10.7)	6.7 (9.3)	-1.3 (1.3)	-2.7 (3.0)
Median	85.0	97.5	100.0	0	0	0
IQR: Q1, Q3	80.0, 100.0	92.5, 100.0	90.0, 100.0	-5.0, 25.0	-2.5, 0.0	0.0, 0.0
Min, Max	80, 100	90, 100	65, 100	-5, 25	-5, 0	-30, 10
Week 52						
m	4	4	15			
n	4	4	14	4	4	13
Mean (SD/SE)	88.8 (13.1)	93.8 (9.5)	93.2 (11.2)	2.5 (4.3)	-3.8 (5.5)	-3.8 (3.3)
Median	90.0	97.5	100.0	0	0	0
IQR: Q1, Q3	77.5, 100.0	87.5, 100.0	85.0, 100.0	-2.5, 7.5	-10.0, 2.5	-10.0, 0.0
Min, Max	75, 100	80, 100	65, 100	-5, 15	-20, 5	-30, 20

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.10.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=5)	(N=5)	(N=17)	(N=5)	(N=5)	(N=17)
Hopelessness						
Baseline						
m	5	5	17			
n	5	5	15			
Mean (SD)	81.68 (13.69)	91.68 (14.42)	95.56 (6.20)			
Median	75.00	100.00	100.00			
IQR: Q1, Q3	75.00, 91.70	91.70, 100.00	91.70, 100.00			
Min, Max	66.7, 100.0	66.7, 100.0	83.3, 100.0			
Week 24						
m	4	4	16			
n	3	4	14	3	4	13
Mean (SD/SE)	91.67 (8.35)	87.50 (19.86)	93.46 (9.35)	5.53 (10.03)	-2.10 (2.10)	-0.64 (2.40)
Median	91.70	95.85	100.00	0	0	0
IQR: Q1, Q3	83.30, 100.00	75.00, 100.00	91.70, 100.00	-8.40, 25.00	-4.20, 0.00	-8.30, 0.00
Min, Max	83.3, 100.0	58.3, 100.0	75.0, 100.0	-8.4, 25.0	-8.4, 0.0	-16.7, 16.7
Week 52						
m	4	4	15			
n	4	4	14	4	4	13
Mean (SD/SE)	91.65 (9.64)	91.68 (16.65)	93.46 (12.31)	8.30 (9.00)	2.08 (2.08)	-1.92 (3.80)
Median	91.65	100.00	100.00	4.15	0	0
IQR: Q1, Q3	83.30, 100.00	83.35, 100.00	91.70, 100.00	-4.20, 20.80	0.00, 4.15	0.00, 0.00
Min, Max	83.3, 100.0	66.7, 100.0	58.3, 100.0	-8.4, 33.3	0.0, 8.3	-33.4, 16.7

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.10.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

	Visit Result			Change from Baseline		
Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Stigma of Liver Disease						
Baseline						
m	5	5	17			
n	5	5	15			
Mean (SD)	88.76 (11.17)	81.28 (19.27)	90.85 (11.77)			
Median	87.50	81.30	100.00			
IQR: Q1, Q3	81.30, 100.00	81.30, 93.80	81.30, 100.00			
Min, Max	75.0, 100.0	50.0, 100.0	62.5, 100.0			
Week 24						
m	4	4	16			
n	3	4	14	3	4	13
Mean (SD/SE)	83.37 (9.57)	89.08 (12.87)	94.21 (8.29)	-2.07 (2.07)	12.48 (14.66)	0.95 (1.71)
Median	81.30	90.65	100.00	0	9.35	0
IQR: Q1, Q3	75.00, 93.80	78.15, 100.00	87.50, 100.00	-6.20, 0.00	-9.40, 34.35	0.00, 0.00
Min, Max	75.0, 93.8	75.0, 100.0	75.0, 100.0	-6.2, 0.0	-18.8, 50.0	-6.3, 18.7
Week 52						
m	4	4	15			
n	4	4	14	4	4	13
Mean (SD/SE)	81.28 (22.25)	92.23 (7.85)	89.76 (14.82)	-4.68 (7.81)	15.63 (10.37)	-3.84 (4.56)
Median	87.55	93.80	93.80	-3.10	9.35	0
IQR: Q1, Q3	65.65, 96.90	87.55, 96.90	87.50, 100.00	-15.60, 6.25	0.00, 31.25	0.00, 0.00
Min, Max	50.0, 100.0	81.3, 100.0	43.8, 100.0	-25.0, 12.5	0.0, 43.8	-56.2, 12.5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.10.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=4)	(N=10)	(N=11)	(N=4)	(N=10)	(N=11)
Total LDQOL						
Baseline						
m	4	10	11			
n	4	9	11			
Mean (SD)	86.30 (14.35)	88.57 (5.18)	83.69 (10.43)			
Median	93.20	89.30	82.80			
IQR: Q1, Q3	78.65, 93.95	86.80, 92.80	76.30, 94.30			
Min, Max	64.8, 94.0	78.6, 94.8	64.4, 97.0			
Week 24						
m	4	8	11			
n	4	7	11	4	7	11
Mean (SD/SE)	86.68 (9.01)	83.47 (9.05)	78.65 (14.01)	0.38 (2.78)	-5.01 (3.46)	-5.04 (2.27)
Median	90.20	79.00	80.00	-1.55	-5.40	-1.80
IQR: Q1, Q3	81.70, 91.65	77.40, 93.10	68.10, 94.10	-3.05, 3.80	-10.60, 4.50	-11.80, 1.40
Min, Max	73.3, 93.0	75.0, 98.9	52.0, 97.1	-3.9, 8.5	-19.8, 6.1	-17.6, 6.4
Week 52						
m	4	8	11			
n	3	6	10	3	6	10
Mean (SD/SE)	92.03 (3.22)	83.62 (6.87)	81.31 (12.79)	-1.43 (1.42)	-4.68 (2.50)	-2.89 (2.05)
Median	92.80	82.35	83.75	-1.20	-2.70	-1.50
IQR: Q1, Q3	88.50, 94.80	79.00, 88.70	68.30, 93.60	-4.00, 0.90	-7.60, 0.10	-8.20, 0.70
Min, Max	88.5, 94.8	75.6, 93.7	58.0, 95.5	-4.0, 0.9	-15.6, 0.4	-14.5, 5.7

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.10.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=4)	(N=10)	(N=11)	(N=4)	(N=10)	(N=11)
Symptoms of Liver Disease						
Baseline						
m	4	10	11			
n	4	9	11			
Mean (SD)	84.18 (20.82)	83.70 (13.70)	87.27 (11.35)			
Median	93.35	83.30	90.00			
IQR: Q1, Q3	71.65, 96.70	80.00, 93.30	83.30, 96.70			
Min, Max	53.3, 96.7	53.3, 100.0	63.3, 100.0			
Week 24						
m	4	8	11			
n	4	7	11	4	7	11
Mean (SD/SE)	89.18 (13.44)	86.67 (10.17)	80.31 (17.09)	5.00 (3.98)	3.34 (8.29)	-6.96 (5.89)
Median	93.35	90.00	83.30	1.65	3.30	0
IQR: Q1, Q3	80.00, 98.35	83.30, 90.00	70.00, 93.30	0.00, 10.00	-6.70, 20.00	-13.30, 6.70
Min, Max	70.0, 100.0	66.7, 100.0	36.7, 96.7	0.0, 16.7	-33.3, 36.7	-60.0, 10.0
Week 52						
m	4	8	11			
n	3	6	10	3	6	10
Mean (SD/SE)	92.20 (1.91)	78.88 (13.26)	88.99 (10.20)	-2.27 (2.94)	-1.67 (4.61)	-0.01 (2.06)
Median	93.30	80.00	93.30	-3.40	0	0
IQR: Q1, Q3	90.00, 93.30	73.30, 90.00	83.30, 96.70	-6.70, 3.30	-6.70, 3.40	-3.40, 6.70
Min, Max	90.0, 93.3	56.7, 93.3	70.0, 100.0	-6.7, 3.3	-20.0, 13.3	-13.4, 6.7

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.10.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=4)	(N=10)	(N=11)	(N=4)	(N=10)	(N=11)
Effects of Liver Disease						
Baseline						
m	4	10	11			
n	4	9	11			
Mean (SD)	73.33 (28.30)	84.46 (7.46)	80.61 (6.96)			
Median	80.00	86.70	80.00			
IQR: Q1, Q3	56.65, 90.00	80.00, 86.70	80.00, 86.70			
Min, Max	33.3, 100.0	73.3, 100.0	66.7, 93.3			
Week 24						
m	4	8	11			
n	4	7	11	4	7	11
Mean (SD/SE)	80.00 (0.00)	83.80 (11.47)	76.97 (7.52)	6.68 (14.15)	-0.97 (5.13)	-3.64 (1.65)
Median	80.00	80.00	80.00	0	-6.70	0
IQR: Q1, Q3	80.00, 80.00	73.30, 100.00	73.30, 80.00	-10.00, 23.35	-6.70, 13.30	-6.70, 0.00
Min, Max	80.0, 80.0	73.3, 100.0	60.0, 86.7	-20.0, 46.7	-20.0, 20.0	-13.3, 0.0
Week 52						
m	4	8	11			
n	3	6	10	3	6	10
Mean (SD/SE)	80.00 (0.00)	83.33 (9.20)	81.34 (6.88)	-6.67 (6.67)	-2.23 (4.44)	2.00 (2.23)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	80.00, 80.00	80.00, 86.70	80.00, 86.70	-20.00, 0.00	-6.70, 0.00	0.00, 6.70
Min, Max	80.0, 80.0	73.3, 100.0	66.7, 93.3	-20.0, 0.0	-20.0, 13.3	-6.7, 13.3

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.10.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=4)	(N=10)	(N=11)	(N=4)	(N=10)	(N=11)
Concentration/Memory						
Baseline						
m	4	10	11			
n	4	9	11			
Mean (SD)	96.88 (6.25)	89.60 (18.47)	84.67 (19.03)			
Median	100.00	100.00	87.50			
IQR: Q1, Q3	93.75, 100.00	87.50, 100.00	75.00, 100.00			
Min, Max	87.5, 100.0	43.8, 100.0	37.5, 100.0			
Week 24						
m	4	8	11			
n	4	7	11	4	7	11
Mean (SD/SE)	90.65 (10.83)	84.84 (17.99)	82.41 (13.34)	-6.23 (6.76)	-3.57 (3.29)	-2.26 (6.09)
Median	93.80	81.30	87.50	-3.10	0	0
IQR: Q1, Q3	84.40, 96.90	81.30, 100.00	68.80, 93.80	-15.60, 3.15	-12.50, 0.00	-12.50, 12.50
Min, Max	75.0, 100.0	50.0, 100.0	62.5, 100.0	-25.0, 6.3	-18.7, 6.2	-37.5, 31.3
Week 52						
m	4	8	11			
n	3	6	10	3	6	10
Mean (SD/SE)	91.67 (7.22)	84.38 (22.25)	82.52 (15.81)	-4.17 (4.17)	-5.22 (4.68)	-3.12 (3.64)
Median	87.50	93.75	84.40	0	0	0
IQR: Q1, Q3	87.50, 100.00	75.00, 100.00	75.00, 93.80	-12.50, 0.00	-12.50, 0.00	-6.30, 6.20
Min, Max	87.5, 100.0	43.8, 100.0	50.0, 100.0	-12.5, 0.0	-25.0, 6.2	-25.0, 12.5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.10.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=4)	(N=10)	(N=11)	(N=4)	(N=10)	(N=11)
Health Distress						
Baseline						
m	4	10	11			
n	4	9	11			
Mean (SD)	93.75 (12.50)	94.44 (6.59)	90.91 (16.85)			
Median	100.00	100.00	100.00			
IQR: Q1, Q3	87.50, 100.00	87.50, 100.00	75.00, 100.00			
Min, Max	75.0, 100.0	87.5, 100.0	50.0, 100.0			
Week 24						
m	4	8	11			
n	4	7	11	4	7	11
Mean (SD/SE)	100.00 (0.00)	94.64 (9.83)	86.36 (18.07)	6.25 (6.25)	0.00 (4.72)	-4.55 (4.22)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	100.00, 100.00	87.50, 100.00	75.00, 100.00	0.00, 12.50	0.00, 12.50	-12.50, 0.00
Min, Max	100.0, 100.0	75.0, 100.0	50.0, 100.0	0.0, 25.0	-25.0, 12.5	-25.0, 25.0
Week 52						
m	4	8	11			
n	3	6	10	3	6	10
Mean (SD/SE)	100.00 (0.00)	95.83 (10.21)	90.00 (16.46)	0.00 (0.00)	2.08 (5.97)	-2.50 (4.08)
Median	100.00	100.00	100.00	0	6.25	0
IQR: Q1, Q3	100.00, 100.00	100.00, 100.00	87.50, 100.00	0.00, 0.00	0.00, 12.50	-12.50, 0.00
Min, Max	100.0, 100.0	75.0, 100.0	50.0, 100.0	0.0, 0.0	-25.0, 12.5	-25.0, 25.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.10.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=4)	(N=10)	(N=11)	(N=4)	(N=10)	(N=11)
Sexual Function						
Baseline						
m	4	10	11			
n	2	5	7			
Mean (SD)	96.65 (4.74)	97.00 (6.71)	85.71 (12.14)			
Median	96.65	100.00	85.00			
IQR: Q1, Q3	93.30, 100.00	100.00, 100.00	76.70, 100.00			
Min, Max	93.3, 100.0	85.0, 100.0	68.3, 100.0			
Week 24						
m	4	8	11			
n	2	4	6	2	4	6
Mean (SD/SE)	80.85 (15.34)	88.33 (19.15)	84.72 (19.94)	-15.80 (7.50)	-7.93 (5.91)	-3.90 (5.64)
Median	80.85	96.65	89.15	-15.80	-3.35	0
IQR: Q1, Q3	70.00, 91.70	76.65, 100.00	83.30, 100.00	-23.30, -8.30	-15.85, 0.00	0.00, 1.60
Min, Max	70.0, 91.7	60.0, 100.0	46.7, 100.0	-23.3, -8.3	-25.0, 0.0	-31.6, 6.6
Week 52						
m	4	8	11			
n	2	3	3	2	3	3
Mean (SD/SE)	92.50 (10.61)	97.77 (3.87)	71.67 (49.07)	-4.15 (4.15)	-2.23 (2.23)	-21.10 (21.10)
Median	92.50	100.00	100.00	-4.15	0	0
IQR: Q1, Q3	85.00, 100.00	93.30, 100.00	15.00, 100.00	-8.30, 0.00	-6.70, 0.00	-63.30, 0.00
Min, Max	85.0, 100.0	93.3, 100.0	15.0, 100.0	-8.3, 0.0	-6.7, 0.0	-63.3, 0.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.10.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=4)	(N=10)	(N=11)	(N=4)	(N=10)	(N=11)
Sleep						
Baseline						
m	4	10	11			
n	4	9	11			
Mean (SD)	58.8 (40.1)	75.0 (9.4)	67.3 (25.0)			
Median	72.5	75.0	60.0			
IQR: Q1, Q3	35.0, 82.5	70.0, 80.0	40.0, 90.0			
Min, Max	0, 90	60, 90	30, 100			
Week 24						
m	4	8	11			
n	4	7	11	4	7	11
Mean (SD/SE)	56.3 (37.5)	68.6 (12.5)	67.3 (21.8)	-2.5 (4.3)	-2.9 (3.6)	0.0 (4.1)
Median	75.0	65.0	65.0	0	0	5.0
IQR: Q1, Q3	37.5, 75.0	60.0, 80.0	45.0, 90.0	-7.5, 2.5	-15.0, 5.0	-10.0, 5.0
Min, Max	0, 75	55, 90	35, 100	-15, 5	-15, 10	-30, 20
Week 52						
m	4	8	11			
n	3	6	10	3	6	10
Mean (SD/SE)	76.7 (10.4)	65.8 (11.1)	68.0 (21.4)	-1.7 (3.3)	-6.7 (4.6)	-3.0 (4.8)
Median	80.0	65.0	67.5	-5.0	-2.5	-2.5
IQR: Q1, Q3	65.0, 85.0	60.0, 75.0	55.0, 85.0	-5.0, 5.0	-15.0, 0.0	-15.0, 5.0
Min, Max	65, 85	50, 80	35, 95	-5, 5	-25, 5	-25, 20

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.10.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=4)	(N=10)	(N=11)	(N=4)	(N=10)	(N=11)
Loneliness						
Baseline						
m	4	10	11			
n	4	9	11			
Mean (SD)	93.8 (7.5)	95.6 (6.8)	88.6 (12.3)			
Median	95.0	100.0	95.0			
IQR: Q1, Q3	87.5, 100.0	95.0, 100.0	80.0, 100.0			
Min, Max	85, 100	80, 100	65, 100			
Week 24						
m	4	8	11			
n	4	7	11	4	7	11
Mean (SD/SE)	92.5 (11.9)	82.1 (20.0)	78.6 (20.9)	-1.3 (3.1)	-16.4 (8.0)	-10.0 (5.0)
Median	97.5	90.0	80.0	0	-5.0	0
IQR: Q1, Q3	85.0, 100.0	60.0, 100.0	65.0, 100.0	-5.0, 2.5	-40.0, 0.0	-20.0, 0.0
Min, Max	75, 100	50, 100	35, 100	-10, 5	-50, 5	-45, 5
Week 52						
m	4	8	11			
n	3	6	10	3	6	10
Mean (SD/SE)	100.0 (0.0)	87.5 (22.3)	81.0 (19.4)	5.0 (5.0)	-11.7 (9.4)	-6.5 (4.8)
Median	100.0	100.0	85.0	0	0	-2.5
IQR: Q1, Q3	100.0, 100.0	80.0, 100.0	65.0, 100.0	0.0, 15.0	-20.0, 0.0	-10.0, 0.0
Min, Max	100, 100	45, 100	45, 100	0, 15	-55, 5	-35, 15

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.10.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=10)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=10)	Change from Baseline DB Placebo (N=11)
Hopelessness						
Baseline						
m	4	10	11			
n	4	9	11			
Mean (SD)	95.85 (4.79)	93.52 (13.69)	78.04 (25.36)			
Median	95.85	100.00	91.70			
IQR: Q1, Q3	91.70, 100.00	91.70, 100.00	50.00, 100.00			
Min, Max	91.7, 100.0	58.3, 100.0	33.3, 100.0			
Week 24						
m	4	8	11			
n	4	7	11	4	7	11
Mean (SD/SE)	91.68 (16.65)	84.51 (21.75)	78.04 (30.57)	-4.18 (7.21)	-8.34 (7.04)	0.00 (4.50)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	83.35, 100.00	58.30, 100.00	41.70, 100.00	-12.50, 4.15	-8.40, 0.00	-8.30, 0.00
Min, Max	66.7, 100.0	50.0, 100.0	25.0, 100.0	-25.0, 8.3	-50.0, 0.0	-25.0, 25.0
Week 52						
m	4	8	11			
n	3	6	10	3	6	10
Mean (SD/SE)	97.23 (4.79)	90.28 (13.34)	79.16 (21.96)	0.00 (0.00)	-1.38 (7.58)	3.32 (4.85)
Median	100.00	95.85	83.30	0	0	0
IQR: Q1, Q3	91.70, 100.00	83.30, 100.00	50.00, 100.00	0.00, 0.00	0.00, 0.00	-8.40, 16.70
Min, Max	91.7, 100.0	66.7, 100.0	50.0, 100.0	0.0, 0.0	-33.3, 25.0	-16.7, 25.0

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE20.10.1
Liver Disease Quality of Life (SE20): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

	Visit Result			Change from Baseline		
Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Stigma of Liver Disease						
Baseline						
m	4	10	11			
n	4	9	11			
Mean (SD)	92.20 (11.83)	88.21 (11.45)	89.78 (15.88)			
Median	96.90	81.30	100.00			
IQR: Q1, Q3	84.40, 100.00	81.30, 100.00	81.30, 100.00			
Min, Max	75.0, 100.0	75.0, 100.0	50.0, 100.0			
Week 24						
m	4	8	11			
n	4	7	11	4	7	11
Mean (SD/SE)	98.45 (3.10)	82.14 (20.23)	76.15 (30.97)	6.25 (6.25)	-8.04 (7.31)	-13.64 (4.68)
Median	100.00	87.50	87.50	0	0	-12.50
IQR: Q1, Q3	96.90, 100.00	62.50, 100.00	62.50, 100.00	0.00, 12.50	-12.50, 0.00	-18.80, 0.00
Min, Max	93.8, 100.0	50.0, 100.0	0.0, 100.0	0.0, 25.0	-50.0, 6.2	-50.0, 0.0
Week 52						
m	4	8	11			
n	3	6	10	3	6	10
Mean (SD/SE)	97.93 (3.58)	77.08 (20.03)	82.52 (22.20)	0.00 (0.00)	-11.47 (8.30)	-7.49 (4.91)
Median	100.00	75.00	93.80	0	0	0
IQR: Q1, Q3	93.80, 100.00	62.50, 100.00	62.50, 100.00	0.00, 0.00	-18.80, 0.00	-12.50, 0.00
Min, Max	93.8, 100.0	50.0, 100.0	43.8, 100.0	0.0, 0.0	-50.0, 0.0	-37.5, 12.5

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE20.10.2Liver Disease Quality of Life (SE20): Summary of Total LDQOL - MMRM Model
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

AMNOG Table SE20.10.2Liver Disease Quality of Life (SE20): Summary of Total LDQOL - MMRM Model
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Total LDQOL			
Week 24			
m	4	4	16
n	3	4	13
Baseline Mean (SD)	73.67 (17.04)	86.48 (6.08)	88.53 (5.20)
Analysis Visit Mean (SD)	76.33 (14.72)	86.90 (7.66)	89.17 (5.31)
LS Mean of Change from Baseline (SE)	-0.12 (3.75)	2.28 (3.59)	2.29 (2.88)
95% CI	(-8.04, 7.79)	(-5.29, 9.85)	(-3.78, 8.37)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.41 (4.62)	-0.01 (3.35)	
95% CI	(-12.17, 7.34)	(-7.07, 7.05)	
p-value	0.6082	0.9979	
Corrected Hedge's g Statistics	-0.230	-0.001	
95% CI	(-1.49, 1.03)	(-1.12, 1.12)	
Week 52			
m	4	4	15
n	4	4	13
Baseline Mean (SD)	77.45 (15.83)	86.48 (6.08)	88.53 (5.20)
Analysis Visit Mean (SD)	74.98 (23.89)	86.03 (2.11)	85.36 (11.92)
LS Mean of Change from Baseline (SE)	-1.75 (6.62)	1.26 (6.23)	-2.25 (4.08)
95% CI	(-15.71, 12.22)	(-11.89, 14.41)	(-10.85, 6.34)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.51 (7.73)	3.51 (6.74)	
95% CI	(-15.80, 16.81)	(-10.71, 17.74)	
p-value	0.9484	0.6091	
Corrected Hedge's g Statistics	0.033	0.234	
95% CI	(-1.09, 1.15)	(-0.89, 1.36)	
Subgroup*Treatment Interaction p-value	0.2351	0.5979	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.10.2Liver Disease Quality of Life (SE20): Summary of Total LDQOL - MMRM Model
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Total LDQOL			
Week 24			
m	4	8	11
n	4	7	11
Baseline Mean (SD)	86.30 (14.35)	88.49 (5.98)	83.69 (10.43)
Analysis Visit Mean (SD)	86.68 (9.01)	83.47 (9.05)	78.65 (14.01)
LS Mean of Change from Baseline (SE)	0.38 (3.87)	-5.59 (3.15)	-5.37 (2.38)
95% CI	(-7.72, 8.47)	(-12.18, 1.00)	(-10.35, -0.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.75 (4.54)	-0.22 (3.96)	
95% CI	(-3.76, 15.25)	(-8.51, 8.07)	
p-value	0.2210	0.9565	
Corrected Hedge's g Statistics	0.689	-0.026	
95% CI	(-0.48, 1.86)	(-0.97, 0.92)	
Week 52			
m	4	8	11
n	3	6	10
Baseline Mean (SD)	93.47 (0.84)	88.30 (6.53)	84.20 (10.85)
Analysis Visit Mean (SD)	92.03 (3.22)	83.62 (6.87)	81.31 (12.79)
LS Mean of Change from Baseline (SE)	0.85 (3.68)	-5.64 (2.78)	-2.91 (2.04)
95% CI	(-6.85, 8.54)	(-11.46, 0.17)	(-7.18, 1.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.76 (4.28)	-2.73 (3.46)	
95% CI	(-5.19, 12.71)	(-9.98, 4.51)	
p-value	0.3903	0.4400	
Corrected Hedge's g Statistics	0.544	-0.393	
95% CI	(-0.76, 1.85)	(-1.41, 0.63)	
Subgroup*Treatment Interaction p-value	0.2351	0.5979	

AMNOG Table SE20.10.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on LDQOL analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, and history of documented atherosclerotic cardiovascular disease as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

AMNOG Table SE20.10.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Symptoms of Liver Disease			
Week 24			
m	4	4	16
n	3	4	13
Baseline Mean (SD)	85.57 (12.61)	89.15 (4.20)	78.72 (17.73)
Analysis Visit Mean (SD)	81.10 (18.37)	92.50 (5.68)	85.63 (13.71)
LS Mean of Change from Baseline (SE)	1.80 (7.03)	12.13 (7.50)	10.09 (5.42)
95% CI	(-13.04, 16.64)	(-3.69, 27.95)	(-1.36, 21.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	-8.29 (7.67)	2.04 (7.12)	
95% CI	(-24.47, 7.90)	(-12.97, 17.06)	
p-value	0.2951	0.7774	
Corrected Hedge's g Statistics	-0.419	0.104	
95% CI	(-1.68, 0.84)	(-1.02, 1.22)	
Week 52			
m	4	4	15
n	4	4	13
Baseline Mean (SD)	87.50 (11.00)	89.15 (4.20)	78.72 (17.73)
Analysis Visit Mean (SD)	80.85 (18.32)	86.68 (15.15)	83.33 (14.71)
LS Mean of Change from Baseline (SE)	-0.72 (7.43)	5.86 (8.18)	8.00 (5.73)
95% CI	(-16.40, 14.97)	(-11.39, 23.12)	(-4.09, 20.09)
LS Mean of Change from Baseline Compared to Placebo (SE)	-8.72 (8.04)	-2.14 (8.08)	
95% CI	(-25.67, 8.24)	(-19.18, 14.91)	
p-value	0.2933	0.7947	
Corrected Hedge's g Statistics	-0.421	-0.102	
95% CI	(-1.55, 0.71)	(-1.22, 1.02)	
Subgroup*Treatment Interaction p-value	0.1555	0.6132	

AMNOG Table SE20.10.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Effects of Liver Disease			
Week 24			
m	4	4	16
n	3	4	13
Baseline Mean (SD)	68.90 (19.23)	90.00 (11.55)	82.57 (5.80)
Analysis Visit Mean (SD)	80.00 (0.00)	83.33 (6.65)	81.03 (8.97)
LS Mean of Change from Baseline (SE)	-3.59 (5.71)	4.19 (5.71)	0.37 (4.05)
95% CI	(-15.64, 8.46)	(-7.84, 16.23)	(-8.17, 8.92)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.97 (6.26)	3.82 (5.30)	
95% CI	(-17.18, 9.25)	(-7.36, 15.01)	
p-value	0.5350	0.4808	
Corrected Hedge's g Statistics	-0.267	0.259	
95% CI	(-1.53, 0.99)	(-0.87, 1.38)	
Week 52			
m	4	4	15
n	4	4	13
Baseline Mean (SD)	73.35 (18.05)	90.00 (11.55)	82.57 (5.80)
Analysis Visit Mean (SD)	68.33 (32.82)	80.00 (0.00)	80.52 (7.43)
LS Mean of Change from Baseline (SE)	-5.49 (7.17)	-7.09 (7.47)	-0.60 (4.79)
95% CI	(-20.62, 9.64)	(-22.84, 8.67)	(-10.70, 9.51)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.90 (7.78)	-6.49 (7.64)	
95% CI	(-21.31, 11.52)	(-22.61, 9.63)	
p-value	0.5374	0.4075	
Corrected Hedge's g Statistics	-0.278	-0.366	
95% CI	(-1.40, 0.85)	(-1.49, 0.76)	
Subgroup*Treatment Interaction p-value	0.5323	0.7220	

AMNOG Table SE20.10.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Concentration/Memory			
Week 24			
m	4	4	16
n	3	4	13
Baseline Mean (SD)	68.77 (28.62)	78.15 (21.94)	92.32 (8.52)
Analysis Visit Mean (SD)	64.60 (30.81)	85.95 (16.45)	93.28 (11.25)
LS Mean of Change from Baseline (SE)	-8.91 (7.64)	8.81 (7.53)	10.00 (6.36)
95% CI	(-25.04, 7.21)	(-7.08, 24.70)	(-3.41, 23.41)
LS Mean of Change from Baseline Compared to Placebo (SE)	-18.91 (9.80)	-1.19 (7.92)	
95% CI	(-39.58, 1.76)	(-17.89, 15.52)	
p-value	0.0704	0.8826	
Corrected Hedge's g Statistics	-0.820	-0.052	
95% CI	(-2.11, 0.47)	(-1.17, 1.07)	
Week 52			
m	4	4	15
n	4	4	13
Baseline Mean (SD)	73.45 (25.17)	78.15 (21.94)	92.32 (8.52)
Analysis Visit Mean (SD)	60.95 (42.81)	85.95 (10.67)	84.16 (22.47)
LS Mean of Change from Baseline (SE)	-8.99 (10.89)	12.07 (11.09)	-1.75 (7.80)
95% CI	(-31.98, 13.99)	(-11.33, 35.48)	(-18.21, 14.70)
LS Mean of Change from Baseline Compared to Placebo (SE)	-7.24 (13.06)	13.83 (12.43)	
95% CI	(-34.80, 20.32)	(-12.40, 40.05)	
p-value	0.5867	0.2815	
Corrected Hedge's g Statistics	-0.255	0.485	
95% CI	(-1.38, 0.87)	(-0.65, 1.62)	
Subgroup*Treatment Interaction p-value	0.0407	0.6875	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.10.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Health Distress			
Week 24			
m	4	4	16
n	3	4	13
Baseline Mean (SD)	54.17 (47.32)	100.00 (0.00)	97.12 (7.49)
Analysis Visit Mean (SD)	58.33 (50.52)	96.88 (6.25)	96.15 (7.88)
LS Mean of Change from Baseline (SE)	-0.30 (8.28)	2.91 (7.52)	3.85 (5.72)
95% CI	(-17.76, 17.16)	(-12.95, 18.78)	(-8.21, 15.92)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.16 (10.26)	-0.94 (6.55)	
95% CI	(-25.79, 17.48)	(-14.76, 12.87)	
p-value	0.6904	0.8873	
Corrected Hedge's g Statistics	-0.198	-0.046	
95% CI	(-1.46, 1.06)	(-1.17, 1.08)	
Week 52			
m	4	4	15
n	4	4	13
Baseline Mean (SD)	65.63 (44.92)	100.00 (0.00)	97.12 (7.49)
Analysis Visit Mean (SD)	71.88 (48.28)	93.75 (12.50)	90.38 (17.79)
LS Mean of Change from Baseline (SE)	7.05 (10.47)	-1.00 (10.00)	-2.44 (6.76)
95% CI	(-15.05, 29.15)	(-22.11, 20.10)	(-16.69, 11.82)
LS Mean of Change from Baseline Compared to Placebo (SE)	9.49 (12.13)	1.44 (10.02)	
95% CI	(-16.11, 35.09)	(-19.70, 22.57)	
p-value	0.4451	0.8878	
Corrected Hedge's g Statistics	0.380	0.058	
95% CI	(-0.75, 1.51)	(-1.06, 1.18)	
Subgroup*Treatment Interaction p-value	0.1562	0.7397	

AMNOG Table SE20.10.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Sexual Function			
Week 24			
m	4	4	16
n	0	1	3
Baseline Mean (SD)	N/A	85.00 (N/A)	97.77 (3.87)
Analysis Visit Mean (SD)	N/A	85.00 (N/A)	100.00 (0.00)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	4	4	15
n	0	1	5
Baseline Mean (SD)	N/A	85.00 (N/A)	94.32 (6.19)
Analysis Visit Mean (SD)	N/A	93.30 (N/A)	90.66 (14.09)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	0.0010	

AMNOG Table SE20.10.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Sleep			
Week 24			
m	4	4	16
n	3	4	13
Baseline Mean (SD)	55.0 (18.0)	68.8 (11.1)	70.8 (18.9)
Analysis Visit Mean (SD)	63.3 (10.4)	62.5 (21.0)	72.7 (11.7)
LS Mean of Change from Baseline (SE)	3.45 (6.63)	-4.03 (6.66)	3.53 (4.95)
95% CI	(-10.53, 17.42)	(-18.08, 10.03)	(-6.91, 13.97)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.09 (7.20)	-7.56 (6.21)	
95% CI	(-15.29, 15.11)	(-20.66, 5.54)	
p-value	0.9906	0.2400	
Corrected Hedge's g Statistics	-0.005	-0.421	
95% CI	(-1.26, 1.25)	(-1.55, 0.71)	
Week 52			
m	4	4	15
n	4	4	13
Baseline Mean (SD)	61.3 (19.3)	68.8 (11.1)	70.8 (18.9)
Analysis Visit Mean (SD)	56.3 (19.3)	62.5 (10.4)	70.0 (17.7)
LS Mean of Change from Baseline (SE)	-7.72 (8.23)	-4.02 (8.61)	0.85 (5.80)
95% CI	(-25.09, 9.64)	(-22.20, 14.15)	(-11.40, 13.09)
LS Mean of Change from Baseline Compared to Placebo (SE)	-8.57 (8.98)	-4.87 (8.81)	
95% CI	(-27.51, 10.37)	(-23.47, 13.73)	
p-value	0.3533	0.5878	
Corrected Hedge's g Statistics	-0.404	-0.228	
95% CI	(-1.53, 0.72)	(-1.35, 0.89)	
Subgroup*Treatment Interaction p-value	0.5925	0.7133	

AMNOG Table SE20.10.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Loneliness			
Week 24			
m	4	4	16
n	3	4	13
Baseline Mean (SD)	81.7 (20.2)	97.5 (2.9)	96.5 (7.2)
Analysis Visit Mean (SD)	88.3 (10.4)	96.3 (4.8)	93.8 (11.0)
LS Mean of Change from Baseline (SE)	1.27 (6.64)	2.83 (6.05)	1.10 (4.45)
95% CI	(-12.74, 15.28)	(-9.95, 15.60)	(-8.28, 10.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.17 (7.46)	1.72 (5.77)	
95% CI	(-15.58, 15.91)	(-10.45, 13.90)	
p-value	0.9825	0.7689	
Corrected Hedge's g Statistics	0.010	0.107	
95% CI	(-1.25, 1.27)	(-1.01, 1.23)	
Week 52			
m	4	4	15
n	4	4	13
Baseline Mean (SD)	86.3 (18.9)	97.5 (2.9)	96.5 (7.2)
Analysis Visit Mean (SD)	88.8 (13.1)	93.8 (9.5)	92.7 (11.5)
LS Mean of Change from Baseline (SE)	0.18 (6.37)	0.08 (6.48)	-0.22 (4.62)
95% CI	(-13.27, 13.63)	(-13.60, 13.75)	(-9.95, 9.52)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.39 (6.99)	0.29 (6.37)	
95% CI	(-14.35, 15.13)	(-13.15, 13.73)	
p-value	0.9557	0.9638	
Corrected Hedge's g Statistics	0.023	0.017	
95% CI	(-1.10, 1.14)	(-1.10, 1.14)	
Subgroup*Treatment Interaction p-value	0.4308	0.6122	

AMNOG Table SE20.10.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Hopelessness			
Week 24			
m	4	4	16
n	3	4	13
Baseline Mean (SD)	86.13 (17.33)	89.60 (15.76)	94.88 (6.40)
Analysis Visit Mean (SD)	91.67 (8.35)	87.50 (19.86)	94.24 (9.24)
LS Mean of Change from Baseline (SE)	4.66 (5.63)	0.80 (5.95)	1.95 (4.48)
95% CI	(-7.22, 16.54)	(-11.76, 13.35)	(-7.50, 11.41)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.70 (6.28)	-1.16 (5.61)	
95% CI	(-10.55, 15.95)	(-13.00, 10.68)	
p-value	0.6723	0.8390	
Corrected Hedge's g Statistics	0.166	-0.071	
95% CI	(-1.09, 1.42)	(-1.19, 1.05)	
Week 52			
m	4	4	15
n	4	4	13
Baseline Mean (SD)	83.35 (15.21)	89.60 (15.76)	94.88 (6.40)
Analysis Visit Mean (SD)	91.65 (9.64)	91.68 (16.65)	92.95 (12.67)
LS Mean of Change from Baseline (SE)	5.19 (7.16)	4.23 (7.31)	1.50 (5.10)
95% CI	(-9.92, 20.29)	(-11.20, 19.66)	(-9.26, 12.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.69 (8.04)	2.73 (7.48)	
95% CI	(-13.27, 20.64)	(-13.06, 18.52)	
p-value	0.6524	0.7197	
Corrected Hedge's g Statistics	0.198	0.146	
95% CI	(-0.92, 1.32)	(-0.98, 1.27)	
Subgroup*Treatment Interaction p-value	0.5473	0.7122	

AMNOG Table SE20.10.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Stigma of Liver Disease			
Week 24			
m	4	4	16
n	3	4	13
Baseline Mean (SD)	85.43 (13.00)	76.60 (18.69)	93.77 (8.82)
Analysis Visit Mean (SD)	83.37 (9.57)	89.08 (12.87)	94.72 (8.40)
LS Mean of Change from Baseline (SE)	-4.09 (5.93)	2.92 (6.74)	3.12 (5.18)
95% CI	(-16.61, 8.43)	(-11.30, 17.14)	(-7.80, 14.04)
LS Mean of Change from Baseline Compared to Placebo (SE)	-7.21 (7.10)	-0.20 (7.57)	
95% CI	(-22.18, 7.77)	(-16.17, 15.78)	
p-value	0.3243	0.9795	
Corrected Hedge's g Statistics	-0.385	-0.011	
95% CI	(-1.65, 0.88)	(-1.13, 1.11)	
Week 52			
m	4	4	15
n	4	4	13
Baseline Mean (SD)	85.95 (10.67)	76.60 (18.69)	93.77 (8.82)
Analysis Visit Mean (SD)	81.28 (22.25)	92.23 (7.85)	89.93 (15.41)
LS Mean of Change from Baseline (SE)	-7.18 (8.59)	8.15 (9.97)	-2.46 (6.44)
95% CI	(-25.29, 10.94)	(-12.89, 29.19)	(-16.04, 11.12)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.71 (9.98)	10.62 (11.60)	
95% CI	(-25.77, 16.35)	(-13.85, 35.08)	
p-value	0.6429	0.3726	
Corrected Hedge's g Statistics	-0.202	0.446	
95% CI	(-1.32, 0.92)	(-0.68, 1.58)	
Subgroup*Treatment Interaction p-value	0.0646	0.1213	

AMNOG Table SE20.10.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Symptoms of Liver Disease			
Week 24			
m	4	8	11
n	4	7	11
Baseline Mean (SD)	84.18 (20.82)	83.33 (15.76)	87.27 (11.35)
Analysis Visit Mean (SD)	89.18 (13.44)	86.67 (10.17)	80.31 (17.09)
LS Mean of Change from Baseline (SE)	3.32 (7.45)	-0.01 (5.79)	-6.28 (4.50)
95% CI	(-12.28, 18.92)	(-12.13, 12.11)	(-15.69, 3.13)
LS Mean of Change from Baseline Compared to Placebo (SE)	9.60 (8.72)	6.27 (7.31)	
95% CI	(-8.65, 27.85)	(-9.04, 21.58)	
p-value	0.2847	0.4022	
Corrected Hedge's g Statistics	0.606	0.396	
95% CI	(-0.56, 1.77)	(-0.56, 1.35)	
Week 52			
m	4	8	11
n	3	6	10
Baseline Mean (SD)	94.47 (3.87)	80.55 (15.28)	89.00 (10.32)
Analysis Visit Mean (SD)	92.20 (1.91)	78.88 (13.26)	88.99 (10.20)
LS Mean of Change from Baseline (SE)	-0.01 (4.57)	-4.59 (3.38)	0.77 (2.45)
95% CI	(-9.57, 9.56)	(-11.66, 2.47)	(-4.35, 5.90)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.78 (5.08)	-5.37 (4.23)	
95% CI	(-11.40, 9.85)	(-14.22, 3.48)	
p-value	0.8796	0.2196	
Corrected Hedge's g Statistics	-0.093	-0.640	
95% CI	(-1.38, 1.20)	(-1.68, 0.40)	
Subgroup*Treatment Interaction p-value	0.1555	0.6132	

AMNOG Table SE20.10.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Effects of Liver Disease			
Week 24			
m	4	8	11
n	4	7	11
Baseline Mean (SD)	73.33 (28.30)	84.77 (8.37)	80.61 (6.96)
Analysis Visit Mean (SD)	80.00 (0.00)	83.80 (11.47)	76.97 (7.52)
LS Mean of Change from Baseline (SE)	-0.42 (4.51)	1.77 (3.54)	-4.40 (2.62)
95% CI	(-9.85, 9.02)	(-5.64, 9.18)	(-9.89, 1.09)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.99 (5.18)	6.17 (4.38)	
95% CI	(-6.86, 14.84)	(-2.99, 15.33)	
p-value	0.4514	0.1745	
Corrected Hedge's g Statistics	0.428	0.656	
95% CI	(-0.73, 1.58)	(-0.32, 1.63)	
Week 52			
m	4	8	11
n	3	6	10
Baseline Mean (SD)	86.67 (11.55)	85.57 (8.87)	79.34 (5.84)
Analysis Visit Mean (SD)	80.00 (0.00)	83.33 (9.20)	81.34 (6.88)
LS Mean of Change from Baseline (SE)	-1.21 (4.21)	0.22 (3.20)	0.24 (2.33)
95% CI	(-10.02, 7.60)	(-6.48, 6.93)	(-4.63, 5.11)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.45 (4.89)	-0.02 (3.99)	
95% CI	(-11.68, 8.77)	(-8.37, 8.33)	
p-value	0.7694	0.9962	
Corrected Hedge's g Statistics	-0.184	-0.002	
95% CI	(-1.48, 1.11)	(-1.01, 1.01)	
Subgroup*Treatment Interaction p-value	0.5323	0.7220	

AMNOG Table SE20.10.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Concentration/Memory			
Week 24			
m	4	8	11
n	4	7	11
Baseline Mean (SD)	96.88 (6.25)	88.41 (20.84)	84.67 (19.03)
Analysis Visit Mean (SD)	90.65 (10.83)	84.84 (17.99)	82.41 (13.34)
LS Mean of Change from Baseline (SE)	-1.24 (6.65)	-3.43 (5.14)	-4.35 (3.97)
95% CI	(-15.15, 12.68)	(-14.18, 7.32)	(-12.65, 3.96)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.11 (7.85)	0.91 (6.45)	
95% CI	(-13.32, 19.53)	(-12.58, 14.41)	
p-value	0.6964	0.8887	
Corrected Hedge's g Statistics	0.222	0.065	
95% CI	(-0.93, 1.37)	(-0.88, 1.01)	
Week 52			
m	4	8	11
n	3	6	10
Baseline Mean (SD)	95.83 (7.22)	89.60 (22.57)	85.64 (19.77)
Analysis Visit Mean (SD)	91.67 (7.22)	84.38 (22.25)	82.52 (15.81)
LS Mean of Change from Baseline (SE)	-2.89 (6.02)	-4.81 (4.42)	-3.63 (3.26)
95% CI	(-15.50, 9.71)	(-14.07, 4.44)	(-10.46, 3.20)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.73 (6.90)	-1.19 (5.50)	
95% CI	(-13.72, 15.18)	(-12.69, 10.32)	
p-value	0.9165	0.8316	
Corrected Hedge's g Statistics	0.066	-0.107	
95% CI	(-1.22, 1.36)	(-1.12, 0.91)	
Subgroup*Treatment Interaction p-value	0.0407	0.6875	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.10.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Health Distress			
Week 24			
m	4	8	11
n	4	7	11
Baseline Mean (SD)	93.75 (12.50)	94.64 (6.68)	90.91 (16.85)
Analysis Visit Mean (SD)	100.00 (0.00)	94.64 (9.83)	86.36 (18.07)
LS Mean of Change from Baseline (SE)	6.45 (6.17)	-0.79 (5.02)	-5.78 (3.76)
95% CI	(-6.45, 19.36)	(-11.30, 9.72)	(-13.65, 2.09)
LS Mean of Change from Baseline Compared to Placebo (SE)	12.24 (7.23)	4.99 (6.21)	
95% CI	(-2.89, 27.37)	(-8.01, 18.00)	
p-value	0.1068	0.4314	
Corrected Hedge's g Statistics	0.926	0.372	
95% CI	(-0.27, 2.12)	(-0.58, 1.33)	
Week 52			
m	4	8	11
n	3	6	10
Baseline Mean (SD)	100.00 (0.00)	93.75 (6.85)	92.50 (16.87)
Analysis Visit Mean (SD)	100.00 (0.00)	95.83 (10.21)	90.00 (16.46)
LS Mean of Change from Baseline (SE)	5.54 (6.96)	-1.22 (5.24)	-3.86 (3.86)
95% CI	(-9.04, 20.11)	(-12.19, 9.74)	(-11.94, 4.23)
LS Mean of Change from Baseline Compared to Placebo (SE)	9.39 (8.00)	2.63 (6.47)	
95% CI	(-7.36, 26.14)	(-10.90, 16.17)	
p-value	0.2550	0.6884	
Corrected Hedge's g Statistics	0.717	0.200	
95% CI	(-0.60, 2.04)	(-0.81, 1.21)	
Subgroup*Treatment Interaction p-value	0.1562	0.7397	

AMNOG Table SE20.10.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Sexual Function			
Week 24			
m	4	8	11
n	2	4	6
Baseline Mean (SD)	96.65 (4.74)	96.25 (7.50)	88.62 (10.30)
Analysis Visit Mean (SD)	80.85 (15.34)	88.33 (19.15)	84.72 (19.94)
LS Mean of Change from Baseline (SE)	-17.95 (8.73)	-11.82 (6.97)	-0.01 (5.60)
95% CI	(-37.70, 1.79)	(-27.59, 3.95)	(-12.68, 12.65)
LS Mean of Change from Baseline Compared to Placebo (SE)	-17.94 (10.63)	-11.81 (9.04)	
95% CI	(-42.00, 6.11)	(-32.25, 8.63)	
p-value	0.1258	0.2237	
Corrected Hedge's g Statistics	-1.156	-0.773	
95% CI	(-2.85, 0.54)	(-2.08, 0.54)	
Week 52			
m	4	8	11
n	2	3	3
Baseline Mean (SD)	96.65 (4.74)	100.00 (0.00)	92.77 (12.53)
Analysis Visit Mean (SD)	92.50 (10.61)	97.77 (3.87)	71.67 (49.07)
LS Mean of Change from Baseline (SE)	-10.97 (4.53)	-20.91 (5.32)	-14.73 (3.37)
95% CI	(-21.22, -0.72)	(-32.95, -8.88)	(-22.36, -7.09)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.76 (5.70)	-6.19 (6.02)	
95% CI	(-9.14, 16.67)	(-19.81, 7.44)	
p-value	0.5262	0.3311	
Corrected Hedge's g Statistics	0.453	-0.641	
95% CI	(-1.36, 2.26)	(-2.28, 1.00)	
Subgroup*Treatment Interaction p-value	NE	0.0010	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE20.10.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Sleep			
Week 24			
m	4	8	11
n	4	7	11
Baseline Mean (SD)	58.8 (40.1)	71.4 (6.9)	67.3 (25.0)
Analysis Visit Mean (SD)	56.3 (37.5)	68.6 (12.5)	67.3 (21.8)
LS Mean of Change from Baseline (SE)	-4.41 (5.86)	-2.88 (4.75)	-0.46 (3.47)
95% CI	(-16.66, 7.85)	(-12.83, 7.08)	(-7.72, 6.81)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.95 (6.77)	-2.42 (5.83)	
95% CI	(-18.12, 10.22)	(-14.63, 9.79)	
p-value	0.5664	0.6829	
Corrected Hedge's g Statistics	-0.322	-0.193	
95% CI	(-1.47, 0.83)	(-1.14, 0.76)	
Week 52			
m	4	8	11
n	3	6	10
Baseline Mean (SD)	78.3 (10.4)	72.5 (6.9)	71.0 (22.9)
Analysis Visit Mean (SD)	76.7 (10.4)	65.8 (11.1)	68.0 (21.4)
LS Mean of Change from Baseline (SE)	-1.69 (6.80)	-6.04 (5.25)	-1.98 (3.86)
95% CI	(-15.93, 12.54)	(-17.04, 4.95)	(-10.05, 6.09)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.29 (7.78)	-4.06 (6.47)	
95% CI	(-16.00, 16.57)	(-17.60, 9.48)	
p-value	0.9708	0.5374	
Corrected Hedge's g Statistics	0.022	-0.309	
95% CI	(-1.27, 1.31)	(-1.33, 0.71)	
Subgroup*Treatment Interaction p-value	0.5925	0.7133	

AMNOG Table SE20.10.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Loneliness			
Week 24			
m	4	8	11
n	4	7	11
Baseline Mean (SD)	93.8 (7.5)	98.6 (2.4)	88.6 (12.3)
Analysis Visit Mean (SD)	92.5 (11.9)	82.1 (20.0)	78.6 (20.9)
LS Mean of Change from Baseline (SE)	-1.13 (8.66)	-18.27 (7.41)	-10.70 (5.50)
95% CI	(-19.26, 16.99)	(-33.78, -2.77)	(-22.21, 0.82)
LS Mean of Change from Baseline Compared to Placebo (SE)	9.56 (10.34)	-7.58 (9.51)	
95% CI	(-12.09, 31.21)	(-27.48, 12.32)	
p-value	0.3669	0.4353	
Corrected Hedge's g Statistics	0.499	-0.385	
95% CI	(-0.66, 1.66)	(-1.34, 0.57)	
Week 52			
m	4	8	11
n	3	6	10
Baseline Mean (SD)	95.0 (8.7)	99.2 (2.0)	87.5 (12.3)
Analysis Visit Mean (SD)	100.0 (0.0)	87.5 (22.3)	81.0 (19.4)
LS Mean of Change from Baseline (SE)	7.29 (9.82)	-11.25 (8.06)	-6.90 (6.01)
95% CI	(-13.27, 27.85)	(-28.12, 5.62)	(-19.48, 5.68)
LS Mean of Change from Baseline Compared to Placebo (SE)	14.19 (11.68)	-4.35 (10.49)	
95% CI	(-10.26, 38.64)	(-26.31, 17.61)	
p-value	0.2393	0.6831	
Corrected Hedge's g Statistics	0.707	-0.213	
95% CI	(-0.61, 2.03)	(-1.23, 0.80)	
Subgroup*Treatment Interaction p-value	0.4308	0.6122	

AMNOG Table SE20.10.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Hopelessness			
Week 24			
m	4	8	11
n	4	7	11
Baseline Mean (SD)	95.85 (4.79)	92.86 (15.55)	78.04 (25.36)
Analysis Visit Mean (SD)	91.68 (16.65)	84.51 (21.75)	78.04 (30.57)
LS Mean of Change from Baseline (SE)	-4.02 (8.54)	-10.20 (6.73)	-0.35 (5.20)
95% CI	(-21.89, 13.85)	(-24.29, 3.90)	(-11.23, 10.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.67 (10.27)	-9.85 (8.62)	
95% CI	(-25.16, 17.82)	(-27.89, 8.20)	
p-value	0.7247	0.2677	
Corrected Hedge's g Statistics	-0.201	-0.537	
95% CI	(-1.35, 0.95)	(-1.50, 0.43)	
Week 52			
m	4	8	11
n	3	6	10
Baseline Mean (SD)	97.23 (4.79)	91.67 (16.68)	75.84 (25.60)
Analysis Visit Mean (SD)	97.23 (4.79)	90.28 (13.34)	79.16 (21.96)
LS Mean of Change from Baseline (SE)	0.19 (6.94)	0.33 (5.50)	-0.62 (4.15)
95% CI	(-14.33, 14.71)	(-11.17, 11.83)	(-9.30, 8.06)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.81 (8.33)	0.96 (6.95)	
95% CI	(-16.62, 18.24)	(-13.60, 15.51)	
p-value	0.9235	0.8921	
Corrected Hedge's g Statistics	0.058	0.068	
95% CI	(-1.23, 1.35)	(-0.94, 1.08)	
Subgroup*Treatment Interaction p-value	0.5473	0.7122	

AMNOG Table SE20.10.3
Liver Disease Quality of Life (SE20): Summary of Results - MMRM Model by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Stigma of Liver Disease			
Week 24			
m	4	8	11
n	4	7	11
Baseline Mean (SD)	92.20 (11.83)	90.19 (12.42)	89.78 (15.88)
Analysis Visit Mean (SD)	98.45 (3.10)	82.14 (20.23)	76.15 (30.97)
LS Mean of Change from Baseline (SE)	5.58 (7.18)	-12.52 (5.90)	-13.91 (4.34)
95% CI	(-9.44, 20.61)	(-24.88, -0.16)	(-22.98, -4.84)
LS Mean of Change from Baseline Compared to Placebo (SE)	19.49 (8.39)	1.39 (7.23)	
95% CI	(1.93, 37.06)	(-13.74, 16.52)	
p-value	0.0314	0.8494	
Corrected Hedge's g Statistics	1.277	0.089	
95% CI	(0.04, 2.51)	(-0.86, 1.04)	
Week 52			
m	4	8	11
n	3	6	10
Baseline Mean (SD)	97.93 (3.58)	88.55 (12.75)	90.01 (16.72)
Analysis Visit Mean (SD)	97.93 (3.58)	77.08 (20.03)	82.52 (22.20)
LS Mean of Change from Baseline (SE)	9.52 (9.86)	-16.09 (7.42)	-7.96 (5.52)
95% CI	(-11.13, 30.17)	(-31.63, -0.56)	(-19.51, 3.59)
LS Mean of Change from Baseline Compared to Placebo (SE)	17.48 (11.33)	-8.13 (9.18)	
95% CI	(-6.24, 41.20)	(-27.35, 11.08)	
p-value	0.1394	0.3868	
Corrected Hedge's g Statistics	0.935	-0.434	
95% CI	(-0.40, 2.27)	(-1.46, 0.59)	
Subgroup*Treatment Interaction p-value	0.0646	0.1213	

AMNOG Table SE20.10.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; LDQOL = Liver Disease Quality of Life; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis, only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.

AMNOG Table SE20.10.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	5 (100)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (20.0)	1 (20.0)	3 (17.6)
No	4 (80.0)	4 (80.0)	14 (82.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	0.86	
95% CI of the inverse odds ratio	(0.07, 10.67)	(0.07, 10.67)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	0.88	
95% CI of the inverse risk ratio	(0.12, 6.73)	(0.12, 6.73)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.35	2.35	
95% CI of the absolute risk difference	(-37.11, 41.82)	(-37.11, 41.82)	
p-value	0.9046	0.9046	
p-value of Breslow-Day Test for Homogeneity [3]	0.3715	0.2110	

AMNOG Table SE20.10.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (20.0)	3 (17.6)
No	5 (100)	4 (80.0)	14 (82.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.66	0.86	
95% CI of the inverse odds ratio	(0.12, 60.22)	(0.07, 10.67)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.33	0.88	
95% CI of the inverse risk ratio	(0.14, 38.97)	(0.12, 6.73)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.11	2.35	
95% CI of the absolute risk difference	(-39.81, 17.58)	(-37.11, 41.82)	
p-value	0.5271	0.9046	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (20.0)	7 (41.2)
No	5 (100)	4 (80.0)	10 (58.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	7.86	2.80	
95% CI of the inverse odds ratio	(0.37, 164.74)	(0.26, 30.70)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.00	2.06	
95% CI of the inverse risk ratio	(0.33, 75.11)	(0.33, 13.00)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-33.33	-21.18	
95% CI of the absolute risk difference	(-65.08, -1.59)	(-63.33, 20.97)	
p-value	0.1336	0.3869	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.9150	

AMNOG Table SE20.10.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (5.9)
No	5 (100)	5 (100)	16 (94.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	1.00	
95% CI of the inverse odds ratio	(0.04, 28.30)	(0.04, 28.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	1.00	
95% CI of the inverse risk ratio	(0.05, 21.42)	(0.05, 21.42)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	0.00	
95% CI of the absolute risk difference	(-25.54, 25.54)	(-25.54, 25.54)	
p-value	>0.9999	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (20.0)	0	1 (5.9)
No	4 (80.0)	5 (100)	16 (94.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.25	1.00	
95% CI of the inverse odds ratio	(0.01, 4.92)	(0.04, 28.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.29	1.00	
95% CI of the inverse risk ratio	(0.02, 3.91)	(0.05, 21.42)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	14.12	0.00	
95% CI of the absolute risk difference	(-22.68, 50.92)	(-25.54, 25.54)	
p-value	0.3344	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.1137	0.7573	

AMNOG Table SE20.10.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (20.0)	0
No	5 (100)	4 (80.0)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.09	
95% CI of the inverse odds ratio	NE	(0.00, 2.48)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.11	
95% CI of the inverse risk ratio	NE	(0.01, 2.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	22.22	
95% CI of the absolute risk difference	NE	(-13.25, 57.69)	
p-value	NE	0.0881	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (20.0)	2 (40.0)	3 (17.6)
No	4 (80.0)	3 (60.0)	14 (82.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	0.32	
95% CI of the inverse odds ratio	(0.07, 10.67)	(0.04, 2.85)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	0.44	
95% CI of the inverse risk ratio	(0.12, 6.73)	(0.10, 1.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.35	22.35	
95% CI of the absolute risk difference	(-37.11, 41.82)	(-24.25, 68.96)	
p-value	0.9046	0.2944	
p-value of Breslow-Day Test for Homogeneity [3]	0.2730	0.1453	

AMNOG Table SE20.10.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	5 (100)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (40.0)	0	2 (11.8)
No	3 (60.0)	5 (100)	15 (88.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.20	1.77	
95% CI of the inverse odds ratio	(0.02, 2.03)	(0.07, 43.02)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.29	1.67	
95% CI of the inverse risk ratio	(0.05, 1.59)	(0.09, 30.06)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	28.24	-5.56	
95% CI of the absolute risk difference	(-17.35, 73.83)	(-32.84, 21.73)	
p-value	0.1502	0.7216	
p-value of Breslow-Day Test for Homogeneity [3]	0.2591	0.2029	

AMNOG Table SE20.10.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	5 (100)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (20.0)	1 (5.9)
No	5 (100)	4 (80.0)	16 (94.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	0.25	
95% CI of the inverse odds ratio	(0.04, 28.30)	(0.01, 4.92)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	0.29	
95% CI of the inverse risk ratio	(0.05, 21.42)	(0.02, 3.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	14.12	
95% CI of the absolute risk difference	(-25.54, 25.54)	(-22.68, 50.92)	
p-value	>0.9999	0.3344	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE20.10.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	3 (17.6)
No	5 (100)	5 (100)	14 (82.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.66	2.66	
95% CI of the inverse odds ratio	(0.12, 60.22)	(0.12, 60.22)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.33	2.33	
95% CI of the inverse risk ratio	(0.14, 38.97)	(0.14, 38.97)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.11	-11.11	
95% CI of the absolute risk difference	(-39.81, 17.58)	(-39.81, 17.58)	
p-value	0.5271	0.5271	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (20.0)	1 (20.0)	5 (29.4)
No	4 (80.0)	4 (80.0)	12 (70.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	1.67	
95% CI of the inverse odds ratio	(0.15, 18.87)	(0.15, 18.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.47	1.47	
95% CI of the inverse risk ratio	(0.22, 9.85)	(0.22, 9.85)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.41	-9.41	
95% CI of the absolute risk difference	(-50.62, 31.80)	(-50.62, 31.80)	
p-value	0.6779	0.6779	
p-value of Breslow-Day Test for Homogeneity [3]	0.9875	0.5139	

AMNOG Table SE20.10.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (20.0)	0	1 (5.9)
No	4 (80.0)	5 (100)	16 (94.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.25	1.00	
95% CI of the inverse odds ratio	(0.01, 4.92)	(0.04, 28.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.29	1.00	
95% CI of the inverse risk ratio	(0.02, 3.91)	(0.05, 21.42)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	14.12	0.00	
95% CI of the absolute risk difference	(-22.68, 50.92)	(-25.54, 25.54)	
p-value	0.3344	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.9333	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (20.0)	1 (20.0)	1 (5.9)
No	4 (80.0)	4 (80.0)	16 (94.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.25	0.25	
95% CI of the inverse odds ratio	(0.01, 4.92)	(0.01, 4.92)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.29	0.29	
95% CI of the inverse risk ratio	(0.02, 3.91)	(0.02, 3.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	14.12	14.12	
95% CI of the absolute risk difference	(-22.68, 50.92)	(-22.68, 50.92)	
p-value	0.3344	0.3344	
p-value of Breslow-Day Test for Homogeneity [3]	0.6316	0.2805	

AMNOG Table SE20.10.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (20.0)	0	2 (11.8)
No	4 (80.0)	5 (100)	15 (88.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.53	1.77	
95% CI of the inverse odds ratio	(0.04, 7.49)	(0.07, 43.02)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	1.67	
95% CI of the inverse risk ratio	(0.07, 5.22)	(0.09, 30.06)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.24	-5.56	
95% CI of the absolute risk difference	(-30.02, 46.50)	(-32.84, 21.73)	
p-value	0.6371	0.7216	
p-value of Breslow-Day Test for Homogeneity [3]	0.1996	0.6513	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (40.0)	1 (20.0)	2 (11.8)
No	3 (60.0)	4 (80.0)	15 (88.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.20	0.53	
95% CI of the inverse odds ratio	(0.02, 2.03)	(0.04, 7.49)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.29	0.59	
95% CI of the inverse risk ratio	(0.05, 1.59)	(0.07, 5.22)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	28.24	8.24	
95% CI of the absolute risk difference	(-17.35, 73.83)	(-30.02, 46.50)	
p-value	0.1502	0.6371	
p-value of Breslow-Day Test for Homogeneity [3]	0.0446	0.1919	

AMNOG Table SE20.10.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	2 (40.0)	0
No	5 (100)	3 (60.0)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.04	
95% CI of the inverse odds ratio	NE	(0.00, 1.03)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.07	
95% CI of the inverse risk ratio	NE	(0.00, 1.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	38.89	
95% CI of the absolute risk difference	NE	(-1.28, 79.06)	
p-value	NE	0.0126	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (20.0)	2 (40.0)	2 (11.8)
No	4 (80.0)	3 (60.0)	15 (88.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.53	0.20	
95% CI of the inverse odds ratio	(0.04, 7.49)	(0.02, 2.03)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	0.29	
95% CI of the inverse risk ratio	(0.07, 5.22)	(0.05, 1.59)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.24	28.24	
95% CI of the absolute risk difference	(-30.02, 46.50)	(-17.35, 73.83)	
p-value	0.6371	0.1502	
p-value of Breslow-Day Test for Homogeneity [3]	0.4426	0.1179	

AMNOG Table SE20.10.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	4 (100)	10 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	2 (18.2)
No	4 (100)	10 (100)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.37	5.53	
95% CI of the inverse odds ratio	(0.09, 60.29)	(0.23, 130.34)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.08	4.58	
95% CI of the inverse risk ratio	(0.12, 36.07)	(0.25, 85.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.83	-16.29	
95% CI of the absolute risk difference	(-45.75, 24.09)	(-42.36, 9.78)	
p-value	0.5934	0.2466	
p-value of Breslow-Day Test for Homogeneity [3]	0.3715	0.2110	

AMNOG Table SE20.10.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	4 (100)	10 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (10.0)	3 (27.3)
No	4 (100)	9 (90.0)	8 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.71	3.38	
95% CI of the inverse odds ratio	(0.15, 88.75)	(0.29, 39.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.92	2.73	
95% CI of the inverse risk ratio	(0.18, 46.71)	(0.34, 22.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-19.17	-17.27	
95% CI of the absolute risk difference	(-55.95, 17.61)	(-49.50, 14.95)	
p-value	0.3959	0.3141	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.9150	

AMNOG Table SE20.10.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	4 (100)	10 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (10.0)	3 (27.3)
No	4 (100)	9 (90.0)	8 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.71	3.38	
95% CI of the inverse odds ratio	(0.15, 88.75)	(0.29, 39.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.92	2.73	
95% CI of the inverse risk ratio	(0.18, 46.71)	(0.34, 22.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-19.17	-17.27	
95% CI of the absolute risk difference	(-55.95, 17.61)	(-49.50, 14.95)	
p-value	0.3959	0.3141	
p-value of Breslow-Day Test for Homogeneity [3]	0.1137	0.7573	

AMNOG Table SE20.10.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	4 (100)	10 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (10.0)	3 (27.3)
No	4 (100)	9 (90.0)	8 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.71	3.38	
95% CI of the inverse odds ratio	(0.15, 88.75)	(0.29, 39.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.92	2.73	
95% CI of the inverse risk ratio	(0.18, 46.71)	(0.34, 22.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-19.17	-17.27	
95% CI of the absolute risk difference	(-55.95, 17.61)	(-49.50, 14.95)	
p-value	0.3959	0.3141	
p-value of Breslow-Day Test for Homogeneity [3]	0.2730	0.1453	

AMNOG Table SE20.10.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (9.1)
No	4 (100)	10 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	3.00	
95% CI of the inverse odds ratio	(0.04, 37.98)	(0.11, 82.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	2.75	
95% CI of the inverse risk ratio	(0.06, 25.76)	(0.12, 60.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-7.95	
95% CI of the absolute risk difference	(-34.77, 29.77)	(-30.35, 14.44)	
p-value	0.8841	0.4988	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	3 (30.0)	1 (9.1)
No	4 (100)	7 (70.0)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	0.23	
95% CI of the inverse odds ratio	(0.04, 37.98)	(0.02, 2.73)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	0.30	
95% CI of the inverse risk ratio	(0.06, 25.76)	(0.04, 2.46)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	20.91	
95% CI of the absolute risk difference	(-34.77, 29.77)	(-12.19, 54.00)	
p-value	0.8841	0.2230	
p-value of Breslow-Day Test for Homogeneity [3]	0.2591	0.2029	

AMNOG Table SE20.10.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	4 (100)	10 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	4 (100)	10 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE20.10.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (18.2)
No	4 (100)	10 (100)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.37	5.53	
95% CI of the inverse odds ratio	(0.09, 60.29)	(0.23, 130.34)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.08	4.58	
95% CI of the inverse risk ratio	(0.12, 36.07)	(0.25, 85.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.83	-16.29	
95% CI of the absolute risk difference	(-45.75, 24.09)	(-42.36, 9.78)	
p-value	0.5934	0.2466	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (25.0)	1 (10.0)	4 (36.4)
No	3 (75.0)	9 (90.0)	7 (63.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.71	5.14	
95% CI of the inverse odds ratio	(0.13, 22.51)	(0.46, 56.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.45	3.64	
95% CI of the inverse risk ratio	(0.22, 9.43)	(0.48, 27.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.36	-26.36	
95% CI of the absolute risk difference	(-62.44, 39.71)	(-60.33, 7.60)	
p-value	0.6797	0.1566	
p-value of Breslow-Day Test for Homogeneity [3]	0.9875	0.5139	

AMNOG Table SE20.10.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (25.0)	0	1 (9.1)
No	3 (75.0)	10 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.30	3.00	
95% CI of the inverse odds ratio	(0.01, 6.38)	(0.11, 82.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.36	2.75	
95% CI of the inverse risk ratio	(0.03, 4.54)	(0.12, 60.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	15.91	-7.95	
95% CI of the absolute risk difference	(-29.80, 61.62)	(-30.35, 14.44)	
p-value	0.4228	0.4988	
p-value of Breslow-Day Test for Homogeneity [3]	0.9333	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (25.0)	1 (10.0)	2 (18.2)
No	3 (75.0)	9 (90.0)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	2.00	
95% CI of the inverse odds ratio	(0.04, 10.25)	(0.15, 26.19)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	1.82	
95% CI of the inverse risk ratio	(0.09, 6.00)	(0.19, 17.12)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.82	-8.18	
95% CI of the absolute risk difference	(-41.35, 54.99)	(-37.60, 21.23)	
p-value	0.7703	0.5926	
p-value of Breslow-Day Test for Homogeneity [3]	0.6316	0.2805	

AMNOG Table SE20.10.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (10.0)	3 (27.3)
No	4 (100)	9 (90.0)	8 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.71	3.38	
95% CI of the inverse odds ratio	(0.15, 88.75)	(0.29, 39.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.92	2.73	
95% CI of the inverse risk ratio	(0.18, 46.71)	(0.34, 22.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-19.17	-17.27	
95% CI of the absolute risk difference	(-55.95, 17.61)	(-49.50, 14.95)	
p-value	0.3959	0.3141	
p-value of Breslow-Day Test for Homogeneity [3]	0.1996	0.6513	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (10.0)	4 (36.4)
No	4 (100)	9 (90.0)	7 (63.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.40	5.14	
95% CI of the inverse odds ratio	(0.23, 125.61)	(0.46, 56.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.75	3.64	
95% CI of the inverse risk ratio	(0.24, 57.45)	(0.48, 27.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-27.50	-26.36	
95% CI of the absolute risk difference	(-65.47, 10.47)	(-60.33, 7.60)	
p-value	0.2569	0.1566	
p-value of Breslow-Day Test for Homogeneity [3]	0.0446	0.1919	

AMNOG Table SE20.10.4
Liver Disease Quality of Life (SE20): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	4 (100)	10 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	1 (9.1)
No	4 (100)	10 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	3.00	
95% CI of the inverse odds ratio	(0.04, 37.98)	(0.11, 82.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	2.75	
95% CI of the inverse risk ratio	(0.06, 25.76)	(0.12, 60.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-7.95	
95% CI of the absolute risk difference	(-34.77, 29.77)	(-30.35, 14.44)	
p-value	0.8841	0.4988	
p-value of Breslow-Day Test for Homogeneity [3]	0.4426	0.1179	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.2.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=11)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=11)	Change from Baseline DB Placebo (N=11)
Physical Functioning						
Baseline						
m	2	11	11			
n	2	10	9			
Mean (SD)	47.50 (38.89)	82.50 (16.37)	82.78 (21.38)			
Median	47.50	87.50	90.00			
IQR: Q1, Q3	20.00, 75.00	70.00, 95.00	75.00, 95.00			
Min, Max	20.0, 75.0	50.0, 100.0	35.0, 100.0			
Week 24						
m	2	8	11			
n	2	7	9	2	7	8
Mean (SD/SE)	65.00 (28.28)	87.14 (11.13)	86.11 (13.87)	17.50 (7.50)	0.00 (2.18)	3.13 (5.08)
Median	65.00	90.00	85.00	17.50	0	0
IQR: Q1, Q3	45.00, 85.00	75.00, 95.00	75.00, 100.00	10.00, 25.00	-5.00, 5.00	-2.50, 5.00
Min, Max	45.0, 85.0	70.0, 100.0	70.0, 100.0	10.0, 25.0	-5.0, 10.0	-15.0, 35.0
Week 52						
m	2	8	10			
n	1	6	8	1	6	7
Mean (SD/SE)	70.00 (N/A)	74.17 (20.35)	89.38 (14.50)	-5.00 (N/A)	-12.50 (4.43)	2.14 (5.65)
Median	70.00	77.50	97.50	-5.00	-10.00	0
IQR: Q1, Q3	70.00, 70.00	50.00, 95.00	77.50, 100.00	-5.00, -5.00	-20.00, -5.00	-5.00, 5.00
Min, Max	70.0, 70.0	50.0, 95.0	65.0, 100.0	-5.0, -5.0	-30.0, 0.0	-20.0, 30.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.2.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=11)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=11)	Change from Baseline DB Placebo (N=11)
Role Physical						
Baseline						
m	2	11	11			
n	2	10	9			
Mean (SD)	71.90 (4.38)	91.27 (11.85)	85.42 (17.67)			
Median	71.90	96.90	87.50			
IQR: Q1, Q3	68.80, 75.00	81.30, 100.00	75.00, 100.00			
Min, Max	68.8, 75.0	68.8, 100.0	50.0, 100.0			
Week 24						
m	2	8	11			
n	2	7	9	2	7	8
Mean (SD/SE)	65.65 (13.22)	87.53 (17.66)	84.03 (20.52)	-6.25 (12.45)	-7.13 (6.30)	3.13 (5.54)
Median	65.65	93.80	100.00	-6.25	0	0
IQR: Q1, Q3	56.30, 75.00	68.80, 100.00	62.50, 100.00	-18.70, 6.20	-6.20, 0.00	0.00, 9.40
Min, Max	56.3, 75.0	56.3, 100.0	50.0, 100.0	-18.7, 6.2	-43.7, 6.2	-25.0, 31.2
Week 52						
m	2	8	10			
n	1	6	8	1	6	7
Mean (SD/SE)	75.00 (N/A)	75.02 (29.85)	87.50 (14.94)	6.20 (N/A)	-19.78 (10.63)	2.67 (7.94)
Median	75.00	87.55	93.75	6.20	-12.45	0
IQR: Q1, Q3	75.00, 75.00	37.50, 100.00	75.00, 100.00	6.20, 6.20	-37.50, 0.00	0.00, 25.00
Min, Max	75.0, 75.0	37.5, 100.0	62.5, 100.0	6.2, 6.2	-62.5, 6.2	-37.5, 25.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.2.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=11)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=11)	Change from Baseline DB Placebo (N=11)
Bodily Pain						
Baseline						
m	2	11	11			
n	2	10	9			
Mean (SD)	57.0 (7.1)	77.3 (17.7)	76.4 (19.4)			
Median	57.0	84.0	84.0			
IQR: Q1, Q3	52.0, 62.0	62.0, 84.0	62.0, 84.0			
Min, Max	52, 62	51, 100	41, 100			
Week 24						
m	2	8	11			
n	2	7	9	2	7	8
Mean (SD/SE)	73.0 (15.6)	74.3 (16.3)	71.6 (20.3)	16.0 (6.0)	-7.1 (6.0)	-4.3 (6.1)
Median	73.0	74.0	72.0	16.0	-10.0	0
IQR: Q1, Q3	62.0, 84.0	62.0, 84.0	62.0, 84.0	10.0, 22.0	-10.0, 0.0	-6.0, 5.0
Min, Max	62, 84	52, 100	41, 100	10, 22	-36, 16	-43, 11
Week 52						
m	2	8	10			
n	1	6	8	1	6	7
Mean (SD/SE)	62.0 (N/A)	70.0 (11.2)	77.3 (16.9)	10.0 (N/A)	-11.0 (4.6)	0.3 (4.5)
Median	62.0	74.0	74.0	10.0	-10.0	0
IQR: Q1, Q3	62.0, 62.0	62.0, 74.0	67.0, 92.0	10.0, 10.0	-22.0, 0.0	-10.0, 11.0
Min, Max	62, 62	52, 84	52, 100	10, 10	-26, 2	-10, 21

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.2.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=11)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=11)	Change from Baseline DB Placebo (N=11)
General Health						
Baseline						
m	2	11	11			
n	2	10	9			
Mean (SD)	51.00 (36.77)	67.30 (12.19)	73.78 (19.97)			
Median	51.00	69.50	72.00			
IQR: Q1, Q3	25.00, 77.00	62.00, 77.00	70.00, 87.00			
Min, Max	25.0, 77.0	47.0, 82.0	30.0, 97.0			
Week 24						
m	2	8	11			
n	2	7	9	2	7	8
Mean (SD/SE)	46.00 (29.70)	61.00 (15.72)	66.22 (16.29)	-5.00 (5.00)	-6.43 (6.12)	-10.00 (4.01)
Median	46.00	57.00	67.00	-5.00	-3.00	-10.00
IQR: Q1, Q3	25.00, 67.00	47.00, 77.00	62.00, 77.00	-10.00, 0.00	-25.00, 5.00	-15.00, -5.00
Min, Max	25.0, 67.0	45.0, 87.0	40.0, 87.0	-10.0, 0.0	-27.0, 15.0	-30.0, 10.0
Week 52						
m	2	8	10			
n	1	6	8	1	6	7
Mean (SD/SE)	77.00 (N/A)	59.17 (16.68)	69.56 (15.89)	0.00 (N/A)	-6.67 (4.48)	-8.50 (3.62)
Median	77.00	54.50	67.00	0	-5.00	-10.00
IQR: Q1, Q3	77.00, 77.00	45.00, 77.00	54.50, 87.00	0.00, 0.00	-8.00, 0.00	-20.00, 0.00
Min, Max	77.0, 77.0	42.0, 82.0	52.0, 87.5	0.0, 0.0	-27.0, 5.0	-20.0, 5.5

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.2.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=11)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=11)	Change from Baseline DB Placebo (N=11)
Vitality						
Baseline						
m	2	11	11			
n	2	10	9			
Mean (SD)	31.25 (44.19)	70.65 (12.54)	60.43 (14.99)			
Median	31.25	68.80	56.30			
IQR: Q1, Q3	0.00, 62.50	62.50, 81.30	50.00, 62.50			
Min, Max	0.0, 62.5	50.0, 93.8	43.8, 87.5			
Week 24						
m	2	8	11			
n	2	7	9	2	7	8
Mean (SD/SE)	28.15 (39.81)	67.00 (17.21)	60.43 (21.41)	-3.10 (3.10)	-3.56 (7.59)	0.78 (3.81)
Median	28.15	68.80	56.30	-3.10	0	3.10
IQR: Q1, Q3	0.00, 56.30	50.00, 81.30	43.80, 75.00	-6.20, 0.00	-18.70, 6.30	-6.30, 9.40
Min, Max	0.0, 56.3	43.8, 93.8	31.3, 87.5	-6.2, 0.0	-31.3, 31.3	-18.7, 12.5
Week 52						
m	2	8	10			
n	1	6	8	1	6	7
Mean (SD/SE)	56.30 (N/A)	58.37 (17.08)	63.30 (24.88)	-6.20 (N/A)	-10.40 (2.63)	-1.79 (7.31)
Median	56.30	59.40	71.90	-6.20	-12.50	0
IQR: Q1, Q3	56.30, 56.30	50.00, 68.80	40.65, 81.25	-6.20, -6.20	-12.50, -6.20	-18.80, 12.50
Min, Max	56.3, 56.3	31.3, 81.3	25.0, 93.8	-6.2, -6.2	-18.7, 0.0	-25.0, 25.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.2.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=11)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=11)	Change from Baseline DB Placebo (N=11)
Social Functioning						
Baseline						
m	2	11	11			
n	2	10	9			
Mean (SD)	68.75 (8.84)	92.50 (8.74)	94.44 (9.08)			
Median	68.75	93.75	100.00			
IQR: Q1, Q3	62.50, 75.00	87.50, 100.00	87.50, 100.00			
Min, Max	62.5, 75.0	75.0, 100.0	75.0, 100.0			
Week 24						
m	2	8	11			
n	2	7	9	2	7	8
Mean (SD/SE)	56.25 (8.84)	89.29 (11.25)	87.50 (17.68)	-12.50 (0.00)	-5.36 (4.61)	-6.25 (4.72)
Median	56.25	87.50	100.00	-12.50	0	0
IQR: Q1, Q3	50.00, 62.50	75.00, 100.00	75.00, 100.00	-12.50, -12.50	-12.50, 0.00	-6.25, 0.00
Min, Max	50.0, 62.5	75.0, 100.0	50.0, 100.0	-12.5, -12.5	-25.0, 12.5	-37.5, 0.0
Week 52						
m	2	8	10			
n	1	6	8	1	6	7
Mean (SD/SE)	62.50 (N/A)	91.67 (10.21)	96.88 (8.84)	-12.50 (N/A)	-4.17 (6.18)	1.79 (4.25)
Median	62.50	93.75	100.00	-12.50	-6.25	0
IQR: Q1, Q3	62.50, 62.50	87.50, 100.00	100.00, 100.00	-12.50, -12.50	-12.50, 12.50	0.00, 0.00
Min, Max	62.5, 62.5	75.0, 100.0	75.0, 100.0	-12.5, -12.5	-25.0, 12.5	-12.5, 25.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.2.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=11)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=11)	Change from Baseline DB Placebo (N=11)
Role Emotional						
Baseline						
m	2	11	11			
n	2	10	9			
Mean (SD)	95.85 (5.87)	97.50 (7.91)	95.37 (7.36)			
Median	95.85	100.00	100.00			
IQR: Q1, Q3	91.70, 100.00	100.00, 100.00	91.70, 100.00			
Min, Max	91.7, 100.0	75.0, 100.0	83.3, 100.0			
Week 24						
m	2	8	11			
n	2	7	9	2	7	8
Mean (SD/SE)	75.00 (11.74)	86.90 (19.16)	91.67 (13.17)	-20.85 (12.45)	-13.10 (7.24)	-2.09 (1.37)
Median	75.00	100.00	100.00	-20.85	0	0
IQR: Q1, Q3	66.70, 83.30	75.00, 100.00	83.30, 100.00	-33.30, -8.40	-25.00, 0.00	-4.15, 0.00
Min, Max	66.7, 83.3	50.0, 100.0	66.7, 100.0	-33.3, -8.4	-50.0, 0.0	-8.4, 0.0
Week 52						
m	2	8	10			
n	1	6	8	1	6	7
Mean (SD/SE)	83.30 (N/A)	87.50 (20.92)	88.54 (18.88)	-8.40 (N/A)	-12.50 (8.54)	-9.53 (5.29)
Median	83.30	100.00	100.00	-8.40	0	0
IQR: Q1, Q3	83.30, 83.30	75.00, 100.00	75.00, 100.00	-8.40, -8.40	-25.00, 0.00	-25.00, 0.00
Min, Max	83.3, 83.3	50.0, 100.0	58.3, 100.0	-8.4, -8.4	-50.0, 0.0	-33.4, 0.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.2.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=11)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=11)	Change from Baseline DB Placebo (N=11)
Mental Health						
Baseline						
m	2	11	11			
n	2	10	9			
Mean (SD)	72.5 (3.5)	86.0 (8.1)	85.0 (12.2)			
Median	72.5	85.0	85.0			
IQR: Q1, Q3	70.0, 75.0	85.0, 90.0	80.0, 95.0			
Min, Max	70, 75	70, 100	60, 100			
Week 24						
m	2	8	11			
n	2	7	9	2	7	8
Mean (SD/SE)	80.0 (14.1)	82.1 (14.1)	85.0 (15.0)	7.5 (7.5)	-5.0 (5.6)	-0.6 (2.6)
Median	80.0	85.0	90.0	7.5	0	0
IQR: Q1, Q3	70.0, 90.0	75.0, 95.0	85.0, 95.0	0.0, 15.0	-10.0, 5.0	-7.5, 5.0
Min, Max	70, 90	55, 95	55, 100	0, 15	-35, 10	-10, 10
Week 52						
m	2	8	10			
n	1	6	8	1	6	7
Mean (SD/SE)	80.0 (N/A)	77.5 (10.8)	83.1 (18.5)	5.0 (N/A)	-10.0 (3.4)	-3.6 (2.8)
Median	80.0	80.0	87.5	5.0	-5.0	-5.0
IQR: Q1, Q3	80.0, 80.0	70.0, 85.0	72.5, 97.5	5.0, 5.0	-15.0, -5.0	-10.0, 5.0
Min, Max	80, 80	60, 90	50, 100	5, 5	-25, -5	-15, 5

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.2.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=11)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=11)	Change from Baseline DB Placebo (N=11)
Mental Component Score						
Baseline						
m	2	11	11			
n	2	10	9			
Mean (SD)	51.30 (2.55)	57.16 (2.51)	55.78 (5.41)			
Median	51.30	57.00	56.70			
IQR: Q1, Q3	49.50, 53.10	55.40, 59.00	53.70, 59.70			
Min, Max	49.5, 53.1	53.3, 60.9	44.5, 62.9			
Week 24						
m	2	8	11			
n	2	7	9	2	7	8
Mean (SD/SE)	45.90 (8.49)	53.43 (7.04)	54.37 (7.43)	-5.40 (4.20)	-3.97 (3.08)	-1.30 (1.23)
Median	45.90	55.10	58.00	-5.40	-1.30	-0.60
IQR: Q1, Q3	39.90, 51.90	48.30, 59.60	51.40, 58.30	-9.60, -1.20	-6.90, 0.40	-4.50, 1.05
Min, Max	39.9, 51.9	40.8, 60.8	38.7, 61.0	-9.6, -1.2	-20.1, 5.4	-5.9, 3.6
Week 52						
m	2	8	10			
n	1	6	8	1	6	7
Mean (SD/SE)	50.60 (N/A)	53.50 (5.53)	53.99 (10.03)	-2.50 (N/A)	-3.98 (1.94)	-2.87 (2.03)
Median	50.60	53.15	57.20	-2.50	-2.40	-0.40
IQR: Q1, Q3	50.60, 50.60	52.60, 58.80	46.55, 60.60	-2.50, -2.50	-7.80, -1.60	-6.60, 1.20
Min, Max	50.6, 50.6	44.0, 59.3	37.9, 65.3	-2.5, -2.5	-11.4, 1.7	-12.8, 2.4

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.2.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=11)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=11)	Change from Baseline DB Placebo (N=11)
Physical Component Score						
Baseline						
m	2	11	11			
n	2	10	9			
Mean (SD)	39.15 (9.83)	50.61 (5.44)	50.72 (7.87)			
Median	39.15	53.05	51.40			
IQR: Q1, Q3	32.20, 46.10	44.40, 54.40	49.80, 57.10			
Min, Max	32.2, 46.1	41.8, 56.1	34.5, 59.3			
Week 24						
m	2	8	11			
n	2	7	9	2	7	8
Mean (SD/SE)	43.45 (5.73)	51.03 (5.31)	49.88 (8.12)	4.30 (2.90)	-0.96 (1.45)	-0.56 (2.04)
Median	43.45	50.90	52.60	4.30	0.50	0.50
IQR: Q1, Q3	39.40, 47.50	48.00, 55.50	41.40, 55.80	1.40, 7.20	-4.50, 1.90	-1.95, 2.20
Min, Max	39.4, 47.5	42.3, 58.0	37.3, 59.3	1.4, 7.2	-6.4, 4.2	-12.9, 6.9
Week 52						
m	2	8	10			
n	1	6	8	1	6	7
Mean (SD/SE)	47.50 (N/A)	46.93 (8.95)	52.46 (5.15)	1.40 (N/A)	-4.68 (2.47)	0.87 (1.67)
Median	47.50	49.05	52.70	1.40	-3.15	1.10
IQR: Q1, Q3	47.50, 47.50	39.60, 52.40	50.35, 56.10	1.40, 1.40	-8.40, -0.60	-0.40, 2.80
Min, Max	47.5, 47.5	33.4, 58.1	42.5, 58.9	1.4, 1.4	-14.8, 2.0	-6.9, 8.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.2.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=4)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=4)	Change from Baseline DB Placebo (N=17)
Physical Functioning						
Baseline						
m	7	4	17			
n	7	4	17			
Mean (SD)	81.43 (13.14)	71.25 (25.29)	79.12 (21.88)			
Median	85.00	72.50	80.00			
IQR: Q1, Q3	70.00, 90.00	52.50, 90.00	70.00, 95.00			
Min, Max	60.0, 100.0	40.0, 100.0	25.0, 100.0			
Week 24						
m	6	4	16			
n	5	4	16	5	4	16
Mean (SD/SE)	91.00 (13.42)	77.50 (23.27)	70.94 (27.82)	6.00 (8.28)	6.25 (4.73)	-8.75 (6.78)
Median	100.00	82.50	82.50	0	2.50	0
IQR: Q1, Q3	85.00, 100.00	62.50, 92.50	55.00, 92.50	-5.00, 20.00	0.00, 12.50	-12.50, 5.00
Min, Max	70.0, 100.0	45.0, 100.0	20.0, 100.0	-15.0, 30.0	0.0, 20.0	-75.0, 25.0
Week 52						
m	6	4	16			
n	6	4	16	6	4	16
Mean (SD/SE)	80.83 (16.86)	75.00 (25.50)	77.92 (24.91)	-4.17 (6.51)	3.75 (2.39)	-1.77 (4.80)
Median	82.50	80.00	87.50	-5.00	2.50	2.50
IQR: Q1, Q3	80.00, 90.00	57.50, 92.50	63.35, 97.50	-5.00, 0.00	0.00, 7.50	-7.50, 10.00
Min, Max	50.0, 100.0	40.0, 100.0	20.0, 100.0	-30.0, 20.0	0.0, 10.0	-60.0, 25.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.2.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=4)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=4)	Change from Baseline DB Placebo (N=17)
Role Physical						
Baseline						
m	7	4	17			
n	7	4	17			
Mean (SD)	83.93 (18.70)	84.38 (18.75)	76.48 (27.74)			
Median	87.50	87.50	81.30			
IQR: Q1, Q3	75.00, 100.00	68.75, 100.00	68.80, 100.00			
Min, Max	50.0, 100.0	62.5, 100.0	0.0, 100.0			
Week 24						
m	6	4	16			
n	5	4	16	5	4	16
Mean (SD/SE)	95.00 (11.18)	85.95 (17.95)	71.49 (34.68)	7.50 (5.00)	1.58 (1.58)	-3.91 (7.03)
Median	100.00	90.65	87.50	0	0	0
IQR: Q1, Q3	100.00, 100.00	71.90, 100.00	43.75, 100.00	0.00, 12.50	0.00, 3.15	0.00, 15.60
Min, Max	75.0, 100.0	62.5, 100.0	6.3, 100.0	0.0, 25.0	0.0, 6.3	-75.0, 25.0
Week 52						
m	6	4	16			
n	6	4	16	6	4	16
Mean (SD/SE)	85.42 (18.40)	78.13 (29.54)	72.28 (28.58)	-4.17 (6.97)	-6.25 (6.25)	-3.12 (5.32)
Median	93.75	87.50	75.00	-6.25	0	0
IQR: Q1, Q3	62.50, 100.00	56.25, 100.00	53.15, 100.00	-12.50, 0.00	-12.50, 0.00	-21.85, 12.50
Min, Max	62.5, 100.0	37.5, 100.0	25.0, 100.0	-25.0, 25.0	-25.0, 0.0	-43.8, 31.3

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.2.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=7)	(N=4)	(N=17)	(N=7)	(N=4)	(N=17)
Bodily Pain						
Baseline						
m	7	4	17			
n	7	4	17			
Mean (SD)	78.9 (25.4)	81.0 (21.9)	77.1 (22.4)			
Median	84.0	81.0	84.0			
IQR: Q1, Q3	62.0, 100.0	62.0, 100.0	62.0, 84.0			
Min, Max	32, 100	62, 100	12, 100			
Week 24						
m	6	4	16			
n	5	4	16	5	4	16
Mean (SD/SE)	90.2 (21.9)	85.5 (18.3)	75.6 (27.8)	12.2 (5.2)	4.5 (4.5)	-1.1 (4.2)
Median	100.0	90.0	84.0	16.0	0	0
IQR: Q1, Q3	100.0, 100.0	71.0, 100.0	63.0, 100.0	0.0, 19.0	0.0, 9.0	0.0, 11.0
Min, Max	51, 100	62, 100	12, 100	0, 26	0, 18	-53, 16
Week 52						
m	6	4	16			
n	6	4	16	6	4	16
Mean (SD/SE)	69.0 (27.3)	84.0 (19.1)	73.4 (22.1)	-12.7 (3.0)	3.0 (3.0)	-3.3 (4.1)
Median	73.0	87.0	74.0	-14.0	0	0
IQR: Q1, Q3	62.0, 84.0	68.0, 100.0	52.0, 92.0	-16.0, -10.0	0.0, 6.0	-15.5, 8.0
Min, Max	22, 100	62, 100	32, 100	-22, 0	0, 12	-28, 23

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.2.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=4)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=4)	Change from Baseline DB Placebo (N=17)
General Health						
Baseline						
m	7	4	17			
n	7	4	17			
Mean (SD)	72.71 (12.39)	68.25 (10.31)	67.71 (19.05)			
Median	77.00	67.00	72.00			
IQR: Q1, Q3	57.00, 82.00	62.00, 74.50	62.00, 82.00			
Min, Max	57.0, 87.0	57.0, 82.0	25.0, 92.0			
Week 24						
m	6	4	16			
n	5	4	16	5	4	16
Mean (SD/SE)	86.00 (9.62)	73.25 (11.09)	67.75 (21.11)	9.00 (2.45)	5.00 (3.54)	0.63 (3.92)
Median	87.00	72.00	74.50	10.00	7.50	2.50
IQR: Q1, Q3	82.00, 92.00	64.50, 82.00	45.00, 84.50	10.00, 10.00	0.00, 10.00	-2.50, 11.00
Min, Max	72.0, 97.0	62.0, 87.0	30.0, 92.0	0.0, 15.0	-5.0, 10.0	-35.0, 20.0
Week 52						
m	6	4	16			
n	6	4	16	6	4	16
Mean (SD/SE)	78.33 (14.65)	69.50 (11.90)	65.88 (21.73)	3.00 (3.16)	1.25 (3.15)	-1.25 (5.02)
Median	79.50	69.50	71.00	5.00	0	1.00
IQR: Q1, Q3	72.00, 92.00	59.50, 79.50	51.00, 79.50	-2.00, 10.00	-2.50, 5.00	-10.00, 12.50
Min, Max	55.0, 92.0	57.0, 82.0	15.0, 97.0	-10.0, 10.0	-5.0, 10.0	-57.0, 25.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.2.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=7)	(N=4)	(N=17)	(N=7)	(N=4)	(N=17)
Vitality						
Baseline						
m	7	4	17			
n	7	4	17			
Mean (SD)	64.33 (12.86)	60.98 (13.84)	69.14 (19.94)			
Median	68.80	62.55	75.00			
IQR: Q1, Q3	56.30, 75.00	50.05, 71.90	62.50, 81.30			
Min, Max	43.8, 81.3	43.8, 75.0	25.0, 100.0			
Week 24						
m	6	4	16			
n	5	4	16	5	4	16
Mean (SD/SE)	65.02 (23.65)	65.65 (10.80)	64.48 (21.01)	-2.52 (5.80)	4.68 (2.99)	-4.29 (4.76)
Median	75.00	65.65	68.75	0	3.10	-3.10
IQR: Q1, Q3	62.50, 81.30	56.30, 75.00	56.30, 78.15	-12.50, 6.20	0.00, 9.35	-9.40, 6.20
Min, Max	25.0, 81.3	56.3, 75.0	6.3, 93.8	-18.8, 12.5	0.0, 12.5	-50.0, 31.3
Week 52						
m	6	4	16			
n	6	4	16	6	4	16
Mean (SD/SE)	57.32 (23.52)	62.53 (15.28)	67.59 (21.20)	-8.35 (4.75)	1.55 (1.55)	-1.18 (4.16)
Median	68.80	65.65	65.65	-6.25	0	-3.10
IQR: Q1, Q3	37.50, 75.00	50.05, 75.00	62.50, 81.30	-18.80, 0.00	0.00, 3.10	-12.50, 12.50
Min, Max	18.8, 75.0	43.8, 75.0	25.0, 100.0	-25.0, 6.2	0.0, 6.2	-37.5, 31.2

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.2.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=7)	(N=4)	(N=17)	(N=7)	(N=4)	(N=17)
Social Functioning						
Baseline						
m	7	4	17			
n	7	4	17			
Mean (SD)	96.43 (9.45)	78.13 (27.72)	90.44 (20.02)			
Median	100.00	87.50	100.00			
IQR: Q1, Q3	100.00, 100.00	62.50, 93.75	87.50, 100.00			
Min, Max	75.0, 100.0	37.5, 100.0	25.0, 100.0			
Week 24						
m	6	4	16			
n	5	4	16	5	4	16
Mean (SD/SE)	95.00 (11.18)	93.75 (12.50)	86.72 (26.80)	-5.00 (5.00)	15.63 (16.44)	-3.91 (7.19)
Median	100.00	100.00	100.00	0	6.25	0
IQR: Q1, Q3	100.00, 100.00	87.50, 100.00	81.25, 100.00	0.00, 0.00	-6.25, 37.50	0.00, 0.00
Min, Max	75.0, 100.0	75.0, 100.0	0.0, 100.0	-25.0, 0.0	-12.5, 62.5	-100.0, 50.0
Week 52						
m	6	4	16			
n	6	4	16	6	4	16
Mean (SD/SE)	93.75 (15.31)	93.75 (12.50)	92.19 (15.05)	-6.25 (6.25)	15.63 (17.95)	1.56 (3.93)
Median	100.00	100.00	100.00	0	12.50	0
IQR: Q1, Q3	100.00, 100.00	87.50, 100.00	93.75, 100.00	0.00, 0.00	-6.25, 37.50	0.00, 0.00
Min, Max	62.5, 100.0	75.0, 100.0	62.5, 100.0	-37.5, 0.0	-25.0, 62.5	-37.5, 37.5

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.2.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=7)	(N=4)	(N=17)	(N=7)	(N=4)	(N=17)
Role Emotional						
Baseline						
m	7	4	17			
n	7	4	17			
Mean (SD)	90.49 (18.28)	93.75 (7.99)	87.26 (19.78)			
Median	100.00	95.85	100.00			
IQR: Q1, Q3	91.70, 100.00	87.50, 100.00	75.00, 100.00			
Min, Max	50.0, 100.0	83.3, 100.0	41.7, 100.0			
Week 24						
m	6	4	16			
n	5	4	16	5	4	16
Mean (SD/SE)	95.00 (11.18)	100.00 (0.00)	81.77 (22.60)	-1.68 (4.08)	6.25 (4.00)	-4.69 (3.65)
Median	100.00	100.00	91.65	0	4.15	0
IQR: Q1, Q3	100.00, 100.00	100.00, 100.00	62.50, 100.00	0.00, 0.00	0.00, 12.50	0.00, 0.00
Min, Max	75.0, 100.0	100.0, 100.0	41.7, 100.0	-16.7, 8.3	0.0, 16.7	-50.0, 8.3
Week 52						
m	6	4	16			
n	6	4	16	6	4	16
Mean (SD/SE)	91.67 (13.94)	95.83 (8.35)	84.89 (22.41)	-5.57 (5.12)	2.08 (2.08)	-1.57 (4.52)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	83.30, 100.00	91.65, 100.00	70.85, 100.00	-16.70, 0.00	0.00, 4.15	0.00, 0.00
Min, Max	66.7, 100.0	83.3, 100.0	25.0, 100.0	-25.0, 8.3	0.0, 8.3	-41.7, 33.3

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.2.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=7)	(N=4)	(N=17)	(N=7)	(N=4)	(N=17)
Mental Health						
Baseline						
m	7	4	17			
n	7	4	17			
Mean (SD)	83.6 (13.1)	85.0 (7.1)	82.1 (16.1)			
Median	90.0	87.5	85.0			
IQR: Q1, Q3	75.0, 90.0	80.0, 90.0	70.0, 95.0			
Min, Max	60, 100	75, 90	50, 100			
Week 24						
m	6	4	16			
n	5	4	16	5	4	16
Mean (SD/SE)	89.0 (11.4)	90.0 (7.1)	80.6 (18.6)	0.0 (2.7)	5.0 (6.8)	-1.3 (1.9)
Median	90.0	87.5	87.5	0	0	0
IQR: Q1, Q3	90.0, 95.0	85.0, 95.0	67.5, 95.0	-5.0, 0.0	-2.5, 12.5	-5.0, 2.5
Min, Max	70, 100	85, 100	45, 100	-5, 10	-5, 25	-20, 15
Week 52						
m	6	4	16			
n	6	4	16	6	4	16
Mean (SD/SE)	86.7 (9.8)	86.3 (7.5)	83.1 (19.7)	-0.8 (2.4)	1.3 (5.5)	1.3 (3.7)
Median	90.0	85.0	90.0	0	0	2.5
IQR: Q1, Q3	80.0, 95.0	80.0, 92.5	75.0, 97.5	-5.0, 5.0	-7.5, 10.0	-2.5, 5.0
Min, Max	70, 95	80, 95	30, 100	-10, 5	-10, 15	-40, 25

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.2.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=4)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=4)	Change from Baseline DB Placebo (N=17)
Mental Component Score						
Baseline						
m	7	4	17			
n	7	4	17			
Mean (SD)	55.29 (6.21)	54.70 (3.45)	54.86 (7.87)			
Median	57.00	54.95	58.00			
IQR: Q1, Q3	53.30, 59.70	51.75, 57.65	46.80, 61.60			
Min, Max	42.9, 61.1	51.1, 57.8	38.1, 63.2			
Week 24						
m	6	4	16			
n	5	4	16	5	4	16
Mean (SD/SE)	55.54 (8.35)	58.50 (2.16)	53.58 (8.45)	-2.52 (2.47)	3.80 (2.02)	-1.08 (1.08)
Median	60.20	58.40	57.25	-0.90	4.05	-0.90
IQR: Q1, Q3	55.50, 60.20	56.75, 60.25	46.35, 59.75	-1.50, 1.00	0.95, 6.65	-3.70, -0.20
Min, Max	41.1, 60.7	56.2, 61.0	37.1, 62.8	-12.2, 1.0	-1.3, 8.4	-8.1, 10.8
Week 52						
m	6	4	16			
n	6	4	16	6	4	16
Mean (SD/SE)	55.57 (6.39)	57.10 (1.89)	55.15 (8.83)	-1.78 (1.41)	2.40 (1.90)	0.49 (1.58)
Median	58.20	56.90	59.55	-0.85	3.25	1.50
IQR: Q1, Q3	47.70, 60.60	55.90, 58.30	49.20, 61.35	-5.90, 1.40	-0.35, 5.15	-1.20, 4.65
Min, Max	47.4, 61.3	55.0, 59.6	35.3, 65.5	-6.1, 1.6	-2.8, 5.9	-16.0, 8.7

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.2.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=4)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=4)	Change from Baseline DB Placebo (N=17)
Physical Component Score						
Baseline						
m	7	4	17			
n	7	4	17			
Mean (SD)	51.11 (5.54)	48.85 (10.04)	49.48 (9.27)			
Median	49.60	48.65	50.90			
IQR: Q1, Q3	45.20, 56.50	40.75, 56.95	45.80, 55.90			
Min, Max	44.1, 58.0	37.8, 60.3	21.6, 61.1			
Week 24						
m	6	4	16			
n	5	4	16	5	4	16
Mean (SD/SE)	56.10 (3.49)	50.13 (7.25)	47.89 (11.34)	4.64 (2.26)	1.28 (1.65)	-1.50 (2.41)
Median	57.40	50.80	51.80	1.00	1.25	0.50
IQR: Q1, Q3	54.80, 58.70	44.75, 55.50	41.35, 55.75	1.00, 9.60	-1.45, 4.00	-4.20, 3.00
Min, Max	50.6, 59.0	40.9, 58.0	24.6, 61.0	0.9, 10.7	-2.3, 4.9	-30.0, 11.8
Week 52						
m	6	4	16			
n	6	4	16	6	4	16
Mean (SD/SE)	50.07 (8.38)	48.88 (10.35)	48.11 (9.41)	-2.03 (1.72)	0.03 (1.28)	-1.28 (1.93)
Median	53.20	50.80	52.45	-1.30	-0.15	-1.55
IQR: Q1, Q3	44.50, 56.80	40.95, 56.80	38.95, 55.60	-5.10, 0.30	-2.10, 2.15	-7.75, 4.60
Min, Max	35.7, 57.0	35.3, 58.6	31.5, 58.7	-8.4, 3.6	-2.5, 2.9	-15.9, 10.1

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.2.2
Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

AMNOG Table SE21.2.2
Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Physical Functioning			
Week 24			
m	2	8	11
n	2	7	8
Baseline Mean (SD)	47.50 (38.89)	87.14 (9.94)	85.00 (21.71)
Analysis Visit Mean (SD)	65.00 (28.28)	87.14 (11.13)	88.13 (13.35)
LS Mean of Change from Baseline (SE)	5.71 (7.93)	2.24 (3.32)	3.74 (2.98)
95% CI	(-11.29, 22.71)	(-4.88, 9.35)	(-2.65, 10.13)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.97 (8.57)	-1.50 (4.45)	
95% CI	(-16.42, 20.36)	(-11.05, 8.04)	
p-value	0.8215	0.7405	
Corrected Hedge's g Statistics	0.202	-0.165	
95% CI	(-1.35, 1.75)	(-1.18, 0.85)	
Week 52			
m	2	8	10
n	1	6	7
Baseline Mean (SD)	75.00 (N/A)	86.67 (10.80)	86.43 (23.04)
Analysis Visit Mean (SD)	70.00 (N/A)	74.17 (20.35)	88.57 (15.47)
LS Mean of Change from Baseline (SE)	-8.40 (11.80)	-11.88 (4.96)	1.51 (4.53)
95% CI	(-33.72, 16.91)	(-22.53, -1.23)	(-8.20, 11.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	-9.91 (12.74)	-13.39 (6.67)	
95% CI	(-37.24, 17.42)	(-27.70, 0.92)	
p-value	0.4495	0.0645	
Corrected Hedge's g Statistics	-0.720	-1.033	
95% CI	(-2.84, 1.40)	(-2.19, 0.13)	
Subgroup*Treatment Interaction p-value	0.3683	0.1534	

AMNOG Table SE21.2.2
Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Role Physical			
Week 24			
m	2	8	11
n	2	7	8
Baseline Mean (SD)	71.90 (4.38)	94.66 (9.15)	85.16 (18.87)
Analysis Visit Mean (SD)	65.65 (13.22)	87.53 (17.66)	88.29 (17.17)
LS Mean of Change from Baseline (SE)	-18.89 (12.26)	-6.38 (6.22)	1.98 (5.37)
95% CI	(-45.19, 7.41)	(-19.72, 6.96)	(-9.53, 13.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	-20.87 (13.14)	-8.36 (8.37)	
95% CI	(-49.06, 7.32)	(-26.31, 9.59)	
p-value	0.1347	0.3348	
Corrected Hedge's g Statistics	-1.219	-0.499	
95% CI	(-2.86, 0.42)	(-1.53, 0.53)	
Week 52			
m	2	8	10
n	1	6	7
Baseline Mean (SD)	68.80 (N/A)	94.80 (10.01)	84.83 (20.36)
Analysis Visit Mean (SD)	75.00 (N/A)	75.02 (29.85)	87.50 (16.14)
LS Mean of Change from Baseline (SE)	-21.63 (22.88)	-16.95 (10.05)	-3.02 (8.84)
95% CI	(-70.71, 27.45)	(-38.51, 4.60)	(-21.99, 15.95)
LS Mean of Change from Baseline Compared to Placebo (SE)	-18.61 (24.15)	-13.93 (13.65)	
95% CI	(-70.40, 33.18)	(-43.21, 15.35)	
p-value	0.4536	0.3248	
Corrected Hedge's g Statistics	-0.692	-0.541	
95% CI	(-2.81, 1.43)	(-1.65, 0.57)	
Subgroup*Treatment Interaction p-value	0.2609	0.2169	

AMNOG Table SE21.2.2
Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Bodily Pain			
Week 24			
m	2	8	11
n	2	7	8
Baseline Mean (SD)	57.0 (7.1)	81.4 (11.8)	77.0 (20.6)
Analysis Visit Mean (SD)	73.0 (15.6)	74.3 (16.3)	72.8 (21.4)
LS Mean of Change from Baseline (SE)	14.69 (13.26)	-3.70 (6.54)	-4.09 (5.87)
95% CI	(-13.76, 43.14)	(-17.73, 10.33)	(-16.68, 8.51)
LS Mean of Change from Baseline Compared to Placebo (SE)	18.78 (14.56)	0.38 (8.77)	
95% CI	(-12.45, 50.01)	(-18.43, 19.20)	
p-value	0.2181	0.9657	
Corrected Hedge's g Statistics	1.004	0.021	
95% CI	(-0.61, 2.61)	(-0.99, 1.04)	
Week 52			
m	2	8	10
n	1	6	7
Baseline Mean (SD)	52.0 (N/A)	81.0 (12.9)	76.0 (22.1)
Analysis Visit Mean (SD)	62.0 (N/A)	70.0 (11.2)	76.3 (18.0)
LS Mean of Change from Baseline (SE)	9.38 (10.71)	-6.87 (4.63)	-2.94 (4.10)
95% CI	(-13.59, 32.35)	(-16.79, 3.05)	(-11.73, 5.85)
LS Mean of Change from Baseline Compared to Placebo (SE)	12.32 (11.53)	-3.93 (6.22)	
95% CI	(-12.42, 37.05)	(-17.26, 9.40)	
p-value	0.3035	0.5373	
Corrected Hedge's g Statistics	0.988	-0.330	
95% CI	(-1.16, 3.14)	(-1.43, 0.77)	
Subgroup*Treatment Interaction p-value	0.5522	0.1155	

AMNOG Table SE21.2.2
Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
General Health			
Week 24			
m	2	8	11
n	2	7	8
Baseline Mean (SD)	51.00 (36.77)	67.43 (14.65)	79.25 (12.15)
Analysis Visit Mean (SD)	46.00 (29.70)	61.00 (15.72)	69.25 (14.46)
LS Mean of Change from Baseline (SE)	-13.07 (10.51)	-8.56 (5.13)	-7.84 (4.81)
95% CI	(-35.62, 9.48)	(-19.55, 2.43)	(-18.15, 2.48)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.23 (12.11)	-0.72 (7.23)	
95% CI	(-31.20, 20.73)	(-16.23, 14.79)	
p-value	0.6722	0.9217	
Corrected Hedge's g Statistics	-0.343	-0.050	
95% CI	(-1.90, 1.21)	(-1.06, 0.96)	
Week 52			
m	2	8	10
n	1	6	7
Baseline Mean (SD)	77.00 (N/A)	65.83 (15.37)	80.57 (12.49)
Analysis Visit Mean (SD)	77.00 (N/A)	59.17 (16.68)	72.07 (15.36)
LS Mean of Change from Baseline (SE)	-2.07 (11.15)	-7.75 (4.79)	-8.97 (4.55)
95% CI	(-26.00, 21.85)	(-18.03, 2.53)	(-18.73, 0.80)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.89 (11.97)	1.22 (7.04)	
95% CI	(-18.78, 32.56)	(-13.89, 16.33)	
p-value	0.5739	0.8650	
Corrected Hedge's g Statistics	0.497	0.095	
95% CI	(-1.61, 2.61)	(-1.00, 1.19)	
Subgroup*Treatment Interaction p-value	0.3256	0.5206	

AMNOG Table SE21.2.2
Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Vitality			
Week 24			
m	2	8	11
n	2	7	8
Baseline Mean (SD)	31.25 (44.19)	70.56 (15.21)	61.74 (15.47)
Analysis Visit Mean (SD)	28.15 (39.81)	67.00 (17.21)	62.51 (21.89)
LS Mean of Change from Baseline (SE)	-7.35 (13.64)	-1.72 (6.58)	0.42 (5.68)
95% CI	(-36.60, 21.91)	(-15.82, 12.38)	(-11.75, 12.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	-7.77 (14.57)	-2.15 (8.79)	
95% CI	(-39.01, 23.47)	(-21.01, 16.71)	
p-value	0.6019	0.8106	
Corrected Hedge's g Statistics	-0.426	-0.121	
95% CI	(-1.99, 1.14)	(-1.14, 0.89)	
Week 52			
m	2	8	10
n	1	6	7
Baseline Mean (SD)	62.50 (N/A)	68.77 (15.84)	64.30 (14.76)
Analysis Visit Mean (SD)	56.30 (N/A)	58.37 (17.08)	62.51 (26.76)
LS Mean of Change from Baseline (SE)	-5.67 (15.22)	-11.19 (6.67)	-2.67 (5.77)
95% CI	(-38.31, 26.98)	(-25.49, 3.12)	(-15.06, 9.71)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.99 (16.30)	-8.51 (8.88)	
95% CI	(-37.94, 31.96)	(-27.57, 10.54)	
p-value	0.8570	0.3543	
Corrected Hedge's g Statistics	-0.170	-0.502	
95% CI	(-2.27, 1.93)	(-1.61, 0.61)	
Subgroup*Treatment Interaction p-value	0.7198	0.3528	

AMNOG Table SE21.2.2
Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Social Functioning			
Week 24			
m	2	8	11
n	2	7	8
Baseline Mean (SD)	68.75 (8.84)	94.64 (6.68)	95.31 (9.30)
Analysis Visit Mean (SD)	56.25 (8.84)	89.29 (11.25)	89.06 (18.22)
LS Mean of Change from Baseline (SE)	-11.04 (14.36)	-5.25 (5.15)	-6.36 (4.78)
95% CI	(-41.85, 19.76)	(-16.31, 5.80)	(-16.61, 3.89)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.69 (15.89)	1.11 (6.92)	
95% CI	(-38.76, 29.39)	(-13.74, 15.95)	
p-value	0.7724	0.8751	
Corrected Hedge's g Statistics	-0.291	0.077	
95% CI	(-1.85, 1.26)	(-0.94, 1.09)	
Week 52			
m	2	8	10
n	1	6	7
Baseline Mean (SD)	75.00 (N/A)	95.83 (6.45)	94.64 (9.83)
Analysis Visit Mean (SD)	62.50 (N/A)	91.67 (10.21)	96.43 (9.45)
LS Mean of Change from Baseline (SE)	-30.41 (11.53)	-0.19 (4.05)	4.27 (3.68)
95% CI	(-55.14, -5.68)	(-8.88, 8.49)	(-3.62, 12.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	-34.68 (12.64)	-4.47 (5.41)	
95% CI	(-61.79, -7.57)	(-16.08, 7.14)	
p-value	0.0158	0.4230	
Corrected Hedge's g Statistics	-3.097	-0.423	
95% CI	(-5.68, -0.51)	(-1.53, 0.68)	
Subgroup*Treatment Interaction p-value	0.0866	0.2570	

AMNOG Table SE21.2.2
Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Role Emotional			
Week 24			
m	2	8	11
n	2	7	8
Baseline Mean (SD)	95.85 (5.87)	100.00 (0.00)	96.88 (6.21)
Analysis Visit Mean (SD)	75.00 (11.74)	86.90 (19.16)	94.79 (9.90)
LS Mean of Change from Baseline (SE)	-24.72 (10.24)	-16.53 (5.88)	-1.51 (4.86)
95% CI	(-46.68, -2.76)	(-29.14, -3.92)	(-11.94, 8.92)
LS Mean of Change from Baseline Compared to Placebo (SE)	-23.21 (11.32)	-15.02 (7.89)	
95% CI	(-47.49, 1.07)	(-31.94, 1.90)	
p-value	0.0596	0.0777	
Corrected Hedge's g Statistics	-1.514	-0.967	
95% CI	(-3.20, 0.17)	(-2.04, 0.10)	
Week 52			
m	2	8	10
n	1	6	7
Baseline Mean (SD)	91.70 (N/A)	100.00 (0.00)	96.43 (6.56)
Analysis Visit Mean (SD)	83.30 (N/A)	87.50 (20.92)	86.90 (19.77)
LS Mean of Change from Baseline (SE)	-13.41 (15.96)	-16.93 (7.32)	-6.64 (6.29)
95% CI	(-47.65, 20.82)	(-32.64, -1.23)	(-20.12, 6.84)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.77 (16.87)	-10.29 (10.04)	
95% CI	(-42.94, 29.40)	(-31.83, 11.25)	
p-value	0.6942	0.3230	
Corrected Hedge's g Statistics	-0.354	-0.555	
95% CI	(-2.46, 1.75)	(-1.67, 0.56)	
Subgroup*Treatment Interaction p-value	0.1027	0.0588	

AMNOG Table SE21.2.2
Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Mental Health			
Week 24			
m	2	8	11
n	2	7	8
Baseline Mean (SD)	72.5 (3.5)	87.1 (3.9)	85.0 (13.1)
Analysis Visit Mean (SD)	80.0 (14.1)	82.1 (14.1)	84.4 (15.9)
LS Mean of Change from Baseline (SE)	7.62 (8.97)	-5.67 (4.50)	-0.63 (4.02)
95% CI	(-11.61, 26.86)	(-15.32, 3.98)	(-9.25, 8.00)
LS Mean of Change from Baseline Compared to Placebo (SE)	8.25 (9.83)	-5.04 (6.04)	
95% CI	(-12.84, 29.33)	(-17.99, 7.90)	
p-value	0.4156	0.4175	
Corrected Hedge's g Statistics	0.645	-0.408	
95% CI	(-0.93, 2.22)	(-1.43, 0.62)	
Week 52			
m	2	8	10
n	1	6	7
Baseline Mean (SD)	75.0 (N/A)	87.5 (4.2)	85.7 (14.0)
Analysis Visit Mean (SD)	80.0 (N/A)	77.5 (10.8)	82.1 (19.8)
LS Mean of Change from Baseline (SE)	9.40 (7.86)	-11.70 (3.27)	-3.83 (2.87)
95% CI	(-7.45, 26.25)	(-18.71, -4.69)	(-9.99, 2.32)
LS Mean of Change from Baseline Compared to Placebo (SE)	13.24 (8.42)	-7.87 (4.38)	
95% CI	(-4.83, 31.30)	(-17.26, 1.53)	
p-value	0.1384	0.0941	
Corrected Hedge's g Statistics	1.517	-0.940	
95% CI	(-0.71, 3.74)	(-2.09, 0.21)	
Subgroup*Treatment Interaction p-value	0.3885	0.1964	

AMNOG Table SE21.2.2
Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Mental Component Score			
Week 24			
m	2	8	11
n	2	7	8
Baseline Mean (SD)	51.30 (2.55)	57.40 (2.51)	56.04 (5.72)
Analysis Visit Mean (SD)	45.90 (8.49)	53.43 (7.04)	54.74 (7.85)
LS Mean of Change from Baseline (SE)	-5.63 (4.66)	-4.68 (2.48)	-1.26 (2.14)
95% CI	(-15.64, 4.37)	(-10.00, 0.65)	(-5.84, 3.33)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.38 (5.10)	-3.42 (3.30)	
95% CI	(-15.33, 6.57)	(-10.50, 3.66)	
p-value	0.4054	0.3174	
Corrected Hedge's g Statistics	-0.646	-0.512	
95% CI	(-2.22, 0.93)	(-1.54, 0.52)	
Week 52			
m	2	8	10
n	1	6	7
Baseline Mean (SD)	53.10 (N/A)	57.48 (2.73)	56.27 (6.14)
Analysis Visit Mean (SD)	50.60 (N/A)	53.50 (5.53)	53.40 (10.68)
LS Mean of Change from Baseline (SE)	-1.99 (5.09)	-5.13 (2.20)	-2.61 (1.89)
95% CI	(-12.91, 8.93)	(-9.85, -0.41)	(-6.66, 1.43)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.62 (5.46)	-2.52 (2.95)	
95% CI	(-11.08, 12.33)	(-8.84, 3.81)	
p-value	0.9108	0.4078	
Corrected Hedge's g Statistics	0.108	-0.452	
95% CI	(-1.99, 2.20)	(-1.56, 0.65)	
Subgroup*Treatment Interaction p-value	0.6985	0.0940	

AMNOG Table SE21.2.2
Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Physical Component Score			
Week 24			
m	2	8	11
n	2	7	8
Baseline Mean (SD)	39.15 (9.83)	51.99 (4.73)	51.66 (7.86)
Analysis Visit Mean (SD)	43.45 (5.73)	51.03 (5.31)	51.10 (7.75)
LS Mean of Change from Baseline (SE)	1.18 (4.48)	-0.56 (1.92)	-0.32 (1.73)
95% CI	(-8.43, 10.80)	(-4.68, 3.56)	(-4.02, 3.38)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.50 (4.89)	-0.24 (2.58)	
95% CI	(-9.00, 12.00)	(-5.77, 5.28)	
p-value	0.7635	0.9261	
Corrected Hedge's g Statistics	0.267	-0.046	
95% CI	(-1.29, 1.82)	(-1.06, 0.97)	
Week 52			
m	2	8	10
n	1	6	7
Baseline Mean (SD)	46.10 (N/A)	51.62 (5.07)	51.87 (8.46)
Analysis Visit Mean (SD)	47.50 (N/A)	46.93 (8.95)	52.74 (5.50)
LS Mean of Change from Baseline (SE)	1.41 (6.22)	-4.72 (2.59)	-0.73 (2.36)
95% CI	(-11.93, 14.74)	(-10.28, 0.84)	(-5.80, 4.34)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.14 (6.74)	-3.99 (3.49)	
95% CI	(-12.32, 16.59)	(-11.49, 3.50)	
p-value	0.7561	0.2726	
Corrected Hedge's g Statistics	0.297	-0.590	
95% CI	(-1.80, 2.40)	(-1.70, 0.52)	
Subgroup*Treatment Interaction p-value	0.4693	0.1937	

AMNOG Table SE21.2.2
Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Physical Functioning			
Week 24			
m	6	4	16
n	5	4	16
Baseline Mean (SD)	85.00 (11.18)	71.25 (25.29)	79.69 (22.47)
Analysis Visit Mean (SD)	91.00 (13.42)	77.50 (23.27)	70.94 (27.82)
LS Mean of Change from Baseline (SE)	9.11 (11.27)	3.34 (12.14)	-8.22 (8.03)
95% CI	(-14.26, 32.48)	(-21.84, 28.51)	(-24.88, 8.44)
LS Mean of Change from Baseline Compared to Placebo (SE)	17.33 (11.68)	11.56 (13.17)	
95% CI	(-6.89, 41.55)	(-15.76, 38.88)	
p-value	0.1520	0.3897	
Corrected Hedge's g Statistics	0.540	0.358	
95% CI	(-0.48, 1.56)	(-0.74, 1.46)	
Week 52			
m	6	4	16
n	6	4	16
Baseline Mean (SD)	85.00 (10.00)	71.25 (25.29)	79.69 (22.47)
Analysis Visit Mean (SD)	80.83 (16.86)	75.00 (25.50)	77.92 (24.91)
LS Mean of Change from Baseline (SE)	-2.16 (8.96)	2.70 (9.69)	-1.28 (7.18)
95% CI	(-20.74, 16.43)	(-17.39, 22.79)	(-16.17, 13.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.88 (8.64)	3.98 (10.34)	
95% CI	(-18.80, 17.05)	(-17.46, 25.43)	
p-value	0.9202	0.7038	
Corrected Hedge's g Statistics	-0.031	0.139	
95% CI	(-0.97, 0.91)	(-0.96, 1.24)	
Subgroup*Treatment Interaction p-value	0.3683	0.1534	

AMNOG Table SE21.2.2
Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Role Physical			
Week 24			
m	6	4	16
n	5	4	16
Baseline Mean (SD)	87.50 (12.50)	84.38 (18.75)	75.40 (28.27)
Analysis Visit Mean (SD)	95.00 (11.18)	85.95 (17.95)	71.49 (34.68)
LS Mean of Change from Baseline (SE)	10.42 (11.87)	3.84 (12.62)	-3.39 (8.24)
95% CI	(-14.20, 35.04)	(-22.34, 30.01)	(-20.48, 13.71)
LS Mean of Change from Baseline Compared to Placebo (SE)	13.80 (12.47)	7.22 (13.58)	
95% CI	(-12.06, 39.67)	(-20.95, 35.39)	
p-value	0.2802	0.6004	
Corrected Hedge's g Statistics	0.418	0.217	
95% CI	(-0.59, 1.43)	(-0.88, 1.32)	
Week 52			
m	6	4	16
n	6	4	16
Baseline Mean (SD)	89.58 (12.29)	84.38 (18.75)	75.40 (28.27)
Analysis Visit Mean (SD)	85.42 (18.40)	78.13 (29.54)	72.28 (28.58)
LS Mean of Change from Baseline (SE)	-0.50 (9.96)	-4.11 (10.79)	-2.49 (7.56)
95% CI	(-21.15, 20.16)	(-26.49, 18.26)	(-18.17, 13.20)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.99 (9.92)	-1.63 (11.42)	
95% CI	(-18.58, 22.55)	(-25.31, 22.06)	
p-value	0.8429	0.8880	
Corrected Hedge's g Statistics	0.066	-0.054	
95% CI	(-0.87, 1.00)	(-1.15, 1.04)	
Subgroup*Treatment Interaction p-value	0.2609	0.2169	

AMNOG Table SE21.2.2
Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Bodily Pain			
Week 24			
m	6	4	16
n	5	4	16
Baseline Mean (SD)	78.0 (28.0)	81.0 (21.9)	76.7 (23.1)
Analysis Visit Mean (SD)	90.2 (21.9)	85.5 (18.3)	75.6 (27.8)
LS Mean of Change from Baseline (SE)	15.40 (6.80)	7.65 (7.41)	1.72 (4.78)
95% CI	(1.30, 29.49)	(-7.71, 23.01)	(-8.20, 11.64)
LS Mean of Change from Baseline Compared to Placebo (SE)	13.68 (7.26)	5.93 (7.96)	
95% CI	(-1.37, 28.73)	(-10.57, 22.43)	
p-value	0.0728	0.4641	
Corrected Hedge's g Statistics	0.714	0.307	
95% CI	(-0.31, 1.74)	(-0.79, 1.41)	
Week 52			
m	6	4	16
n	6	4	16
Baseline Mean (SD)	81.7 (26.6)	81.0 (21.9)	76.7 (23.1)
Analysis Visit Mean (SD)	69.0 (27.3)	84.0 (19.1)	73.4 (22.1)
LS Mean of Change from Baseline (SE)	-8.25 (6.32)	6.36 (7.16)	-0.57 (4.69)
95% CI	(-21.36, 4.85)	(-8.48, 21.20)	(-10.30, 9.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	-7.69 (6.54)	6.93 (7.67)	
95% CI	(-21.25, 5.88)	(-8.98, 22.83)	
p-value	0.2525	0.3760	
Corrected Hedge's g Statistics	-0.411	0.366	
95% CI	(-1.36, 0.54)	(-0.74, 1.47)	
Subgroup*Treatment Interaction p-value	0.5522	0.1155	

AMNOG Table SE21.2.2
Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
General Health			
Week 24			
m	6	4	16
n	5	4	16
Baseline Mean (SD)	77.00 (11.73)	68.25 (10.31)	67.13 (19.52)
Analysis Visit Mean (SD)	86.00 (9.62)	73.25 (11.09)	67.75 (21.11)
LS Mean of Change from Baseline (SE)	14.17 (7.17)	7.03 (7.25)	2.59 (5.42)
95% CI	(-0.71, 29.04)	(-8.00, 22.06)	(-8.65, 13.83)
LS Mean of Change from Baseline Compared to Placebo (SE)	11.58 (6.89)	4.44 (7.58)	
95% CI	(-2.71, 25.86)	(-11.28, 20.16)	
p-value	0.1070	0.5640	
Corrected Hedge's g Statistics	0.539	0.206	
95% CI	(-0.48, 1.56)	(-0.89, 1.30)	
Week 52			
m	6	4	16
n	6	4	16
Baseline Mean (SD)	75.33 (11.25)	68.25 (10.31)	67.13 (19.52)
Analysis Visit Mean (SD)	78.33 (14.65)	69.50 (11.90)	65.88 (21.73)
LS Mean of Change from Baseline (SE)	8.60 (7.86)	3.18 (8.45)	0.49 (5.84)
95% CI	(-7.69, 24.90)	(-14.36, 20.71)	(-11.63, 12.61)
LS Mean of Change from Baseline Compared to Placebo (SE)	8.11 (7.84)	2.68 (9.01)	
95% CI	(-8.14, 24.36)	(-16.00, 21.37)	
p-value	0.3119	0.7685	
Corrected Hedge's g Statistics	0.348	0.115	
95% CI	(-0.60, 1.29)	(-0.98, 1.21)	
Subgroup*Treatment Interaction p-value	0.3256	0.5206	

AMNOG Table SE21.2.2
Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Vitality			
Week 24			
m	6	4	16
n	5	4	16
Baseline Mean (SD)	67.54 (14.25)	60.98 (13.84)	68.77 (20.54)
Analysis Visit Mean (SD)	65.02 (23.65)	65.65 (10.80)	64.48 (21.01)
LS Mean of Change from Baseline (SE)	-0.45 (7.91)	4.72 (8.42)	-1.33 (5.93)
95% CI	(-16.85, 15.95)	(-12.74, 22.18)	(-13.63, 10.97)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.88 (8.17)	6.05 (9.19)	
95% CI	(-16.07, 17.83)	(-13.01, 25.11)	
p-value	0.9152	0.5172	
Corrected Hedge's g Statistics	0.037	0.255	
95% CI	(-0.97, 1.04)	(-0.84, 1.35)	
Week 52			
m	6	4	16
n	6	4	16
Baseline Mean (SD)	65.67 (13.54)	60.98 (13.84)	68.77 (20.54)
Analysis Visit Mean (SD)	57.32 (23.52)	62.53 (15.28)	67.59 (21.20)
LS Mean of Change from Baseline (SE)	-5.81 (7.24)	2.46 (8.05)	1.54 (5.81)
95% CI	(-20.83, 9.21)	(-14.24, 19.17)	(-10.51, 13.58)
LS Mean of Change from Baseline Compared to Placebo (SE)	-7.35 (7.33)	0.92 (8.78)	
95% CI	(-22.54, 7.84)	(-17.28, 19.12)	
p-value	0.3268	0.9171	
Corrected Hedge's g Statistics	-0.321	0.040	
95% CI	(-1.26, 0.62)	(-1.06, 1.14)	
Subgroup*Treatment Interaction p-value	0.7198	0.3528	

AMNOG Table SE21.2.2
Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Social Functioning			
Week 24			
m	6	4	16
n	5	4	16
Baseline Mean (SD)	100.00 (0.00)	78.13 (27.72)	90.63 (20.67)
Analysis Visit Mean (SD)	95.00 (11.18)	93.75 (12.50)	86.72 (26.80)
LS Mean of Change from Baseline (SE)	4.03 (11.36)	7.06 (12.22)	-2.45 (7.28)
95% CI	(-19.53, 27.60)	(-18.28, 32.40)	(-17.56, 12.65)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.49 (12.12)	9.51 (13.45)	
95% CI	(-18.64, 31.62)	(-18.39, 37.42)	
p-value	0.5977	0.4869	
Corrected Hedge's g Statistics	0.219	0.321	
95% CI	(-0.79, 1.23)	(-0.78, 1.42)	
Week 52			
m	6	4	16
n	6	4	16
Baseline Mean (SD)	100.00 (0.00)	78.13 (27.72)	90.63 (20.67)
Analysis Visit Mean (SD)	93.75 (15.31)	93.75 (12.50)	92.19 (15.05)
LS Mean of Change from Baseline (SE)	2.31 (7.58)	7.57 (7.94)	3.02 (5.74)
95% CI	(-13.40, 18.02)	(-8.89, 24.03)	(-8.88, 14.92)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.70 (7.22)	4.55 (8.64)	
95% CI	(-15.68, 14.27)	(-13.37, 22.47)	
p-value	0.9231	0.6037	
Corrected Hedge's g Statistics	-0.031	0.199	
95% CI	(-0.97, 0.91)	(-0.90, 1.30)	
Subgroup*Treatment Interaction p-value	0.0866	0.2570	

AMNOG Table SE21.2.2
Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Role Emotional			
Week 24			
m	6	4	16
n	5	4	16
Baseline Mean (SD)	96.68 (4.55)	93.75 (7.99)	86.46 (20.15)
Analysis Visit Mean (SD)	95.00 (11.18)	100.00 (0.00)	81.77 (22.60)
LS Mean of Change from Baseline (SE)	2.35 (6.88)	9.85 (7.15)	-1.55 (5.17)
95% CI	(-11.92, 16.61)	(-4.98, 24.67)	(-12.27, 9.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.90 (6.83)	11.40 (7.50)	
95% CI	(-10.27, 18.07)	(-4.15, 26.94)	
p-value	0.5741	0.1427	
Corrected Hedge's g Statistics	0.190	0.552	
95% CI	(-0.82, 1.20)	(-0.56, 1.66)	
Week 52			
m	6	4	16
n	6	4	16
Baseline Mean (SD)	97.23 (4.29)	93.75 (7.99)	86.46 (20.15)
Analysis Visit Mean (SD)	91.67 (13.94)	95.83 (8.35)	84.89 (22.41)
LS Mean of Change from Baseline (SE)	0.46 (7.68)	6.11 (8.45)	1.19 (5.65)
95% CI	(-15.47, 16.39)	(-11.42, 23.64)	(-10.53, 12.91)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.73 (7.91)	4.92 (9.06)	
95% CI	(-17.13, 15.67)	(-13.87, 23.71)	
p-value	0.9275	0.5926	
Corrected Hedge's g Statistics	-0.032	0.217	
95% CI	(-0.97, 0.91)	(-0.88, 1.31)	
Subgroup*Treatment Interaction p-value	0.1027	0.0588	

AMNOG Table SE21.2.2
Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Mental Health			
Week 24			
m	6	4	16
n	5	4	16
Baseline Mean (SD)	89.0 (8.9)	85.0 (7.1)	81.9 (16.6)
Analysis Visit Mean (SD)	89.0 (11.4)	90.0 (7.1)	80.6 (18.6)
LS Mean of Change from Baseline (SE)	0.44 (4.90)	5.97 (5.00)	-0.31 (3.81)
95% CI	(-9.73, 10.60)	(-4.40, 16.35)	(-8.21, 7.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.74 (4.61)	6.28 (5.14)	
95% CI	(-8.82, 10.30)	(-4.38, 16.94)	
p-value	0.8737	0.2349	
Corrected Hedge's g Statistics	0.049	0.414	
95% CI	(-0.96, 1.05)	(-0.69, 1.52)	
Week 52			
m	6	4	16
n	6	4	16
Baseline Mean (SD)	87.5 (8.8)	85.0 (7.1)	81.9 (16.6)
Analysis Visit Mean (SD)	86.7 (9.8)	86.3 (7.5)	83.1 (19.7)
LS Mean of Change from Baseline (SE)	1.27 (6.09)	2.46 (6.77)	1.85 (4.45)
95% CI	(-11.36, 13.90)	(-11.59, 16.51)	(-7.38, 11.07)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.57 (6.25)	0.62 (7.25)	
95% CI	(-13.53, 12.39)	(-14.43, 15.66)	
p-value	0.9280	0.9331	
Corrected Hedge's g Statistics	-0.032	0.034	
95% CI	(-0.97, 0.91)	(-1.06, 1.13)	
Subgroup*Treatment Interaction p-value	0.3885	0.1964	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE21.2.2
Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Mental Component Score			
Week 24			
m	6	4	16
n	5	4	16
Baseline Mean (SD)	58.06 (3.04)	54.70 (3.45)	54.66 (8.09)
Analysis Visit Mean (SD)	55.54 (8.35)	58.50 (2.16)	53.58 (8.45)
LS Mean of Change from Baseline (SE)	-1.87 (2.52)	4.29 (2.55)	-0.48 (1.85)
95% CI	(-7.09, 3.35)	(-0.99, 9.57)	(-4.33, 3.36)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.39 (2.47)	4.77 (2.69)	
95% CI	(-6.51, 3.73)	(-0.81, 10.35)	
p-value	0.5799	0.0901	
Corrected Hedge's g Statistics	-0.188	0.645	
95% CI	(-1.19, 0.82)	(-0.47, 1.76)	
Week 52			
m	6	4	16
n	6	4	16
Baseline Mean (SD)	57.35 (3.23)	54.70 (3.45)	54.66 (8.09)
Analysis Visit Mean (SD)	55.57 (6.39)	57.10 (1.89)	55.15 (8.83)
LS Mean of Change from Baseline (SE)	-0.61 (2.72)	2.81 (2.97)	1.01 (2.01)
95% CI	(-6.26, 5.03)	(-3.35, 8.98)	(-3.15, 5.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.62 (2.75)	1.81 (3.19)	
95% CI	(-7.32, 4.08)	(-4.81, 8.42)	
p-value	0.5615	0.5766	
Corrected Hedge's g Statistics	-0.202	0.224	
95% CI	(-1.14, 0.74)	(-0.87, 1.32)	
Subgroup*Treatment Interaction p-value	0.6985	0.0940	

AMNOG Table SE21.2.2
Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Physical Component Score			
Week 24			
m	6	4	16
n	5	4	16
Baseline Mean (SD)	51.46 (5.73)	48.85 (10.04)	49.39 (9.57)
Analysis Visit Mean (SD)	56.10 (3.49)	50.13 (7.25)	47.89 (11.34)
LS Mean of Change from Baseline (SE)	5.96 (3.92)	1.50 (4.17)	-1.07 (2.76)
95% CI	(-2.17, 14.09)	(-7.16, 10.15)	(-6.80, 4.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.03 (4.09)	2.57 (4.50)	
95% CI	(-1.46, 15.52)	(-6.77, 11.91)	
p-value	0.1000	0.5743	
Corrected Hedge's g Statistics	0.636	0.231	
95% CI	(-0.39, 1.66)	(-0.87, 1.33)	
Week 52			
m	6	4	16
n	6	4	16
Baseline Mean (SD)	52.10 (5.36)	48.85 (10.04)	49.39 (9.57)
Analysis Visit Mean (SD)	50.07 (8.38)	48.88 (10.35)	48.11 (9.41)
LS Mean of Change from Baseline (SE)	-0.76 (3.28)	0.35 (3.57)	-0.80 (2.54)
95% CI	(-7.56, 6.05)	(-7.05, 7.75)	(-6.08, 4.47)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.05 (3.24)	1.16 (3.80)	
95% CI	(-6.68, 6.77)	(-6.73, 9.04)	
p-value	0.9886	0.7637	
Corrected Hedge's g Statistics	0.005	0.114	
95% CI	(-0.93, 0.94)	(-0.98, 1.21)	
Subgroup*Treatment Interaction p-value	0.4693	0.1937	

AMNOG Table SE21.2.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis, only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.

AMNOG Table SE21.2.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (9.1)
No	2 (100)	11 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	3.29	
95% CI of the inverse odds ratio	(0.02, 23.31)	(0.12, 89.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	3.00	
95% CI of the inverse risk ratio	(0.04, 14.19)	(0.14, 66.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.17	-8.33	
95% CI of the absolute risk difference	(-41.97, 50.30)	(-30.20, 13.53)	
p-value	0.8494	0.4602	
p-value of Breslow-Day Test for Homogeneity [3]	0.5147	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	3 (27.3)
No	2 (100)	11 (100)	8 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.06	9.47	
95% CI of the inverse odds ratio	(0.08, 54.80)	(0.43, 208.75)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.75	7.00	
95% CI of the inverse risk ratio	(0.12, 25.51)	(0.40, 121.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-12.50	-25.00	
95% CI of the absolute risk difference	(-61.89, 36.89)	(-53.09, 3.09)	
p-value	0.6615	0.1003	
p-value of Breslow-Day Test for Homogeneity [3]	0.7036	0.1157	

AMNOG Table SE21.2.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (18.2)
No	2 (100)	11 (100)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.32	6.05	
95% CI of the inverse odds ratio	(0.05, 37.16)	(0.26, 142.04)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	5.00	
95% CI of the inverse risk ratio	(0.08, 19.75)	(0.27, 93.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.17	-16.67	
95% CI of the absolute risk difference	(-52.19, 43.86)	(-42.28, 8.94)	
p-value	0.8718	0.2170	
p-value of Breslow-Day Test for Homogeneity [3]	0.5731	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (50.0)	1 (9.1)	3 (27.3)
No	1 (50.0)	10 (90.9)	8 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.38	3.75	
95% CI of the inverse odds ratio	(0.02, 8.10)	(0.32, 43.31)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.55	3.00	
95% CI of the inverse risk ratio	(0.10, 2.95)	(0.37, 24.58)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	22.73	-18.18	
95% CI of the absolute risk difference	(-51.40, 96.85)	(-49.51, 13.14)	
p-value	0.5218	0.2689	
p-value of Breslow-Day Test for Homogeneity [3]	0.2491	0.4551	

AMNOG Table SE21.2.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (9.1)
No	2 (100)	11 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	3.29	
95% CI of the inverse odds ratio	(0.02, 23.31)	(0.12, 89.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	3.00	
95% CI of the inverse risk ratio	(0.04, 14.19)	(0.14, 66.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.17	-8.33	
95% CI of the absolute risk difference	(-41.97, 50.30)	(-30.20, 13.53)	
p-value	0.8494	0.4602	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (50.0)	0	2 (18.2)
No	1 (50.0)	11 (100)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.22	6.05	
95% CI of the inverse odds ratio	(0.01, 5.28)	(0.26, 142.04)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.36	5.00	
95% CI of the inverse risk ratio	(0.06, 2.36)	(0.27, 93.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	31.82	-16.67	
95% CI of the absolute risk difference	(-41.13, 100.00)	(-42.28, 8.94)	
p-value	0.3259	0.2170	
p-value of Breslow-Day Test for Homogeneity [3]	0.0677	0.2084	

AMNOG Table SE21.2.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	2 (100)	11 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (9.1)	1 (9.1)
No	2 (100)	10 (90.9)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	1.00	
95% CI of the inverse odds ratio	(0.02, 23.31)	(0.05, 18.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	1.00	
95% CI of the inverse risk ratio	(0.04, 14.19)	(0.07, 14.05)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.17	0.00	
95% CI of the absolute risk difference	(-41.97, 50.30)	(-24.03, 24.03)	
p-value	0.8494	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.5565	0.7010	

AMNOG Table SE21.2.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (9.1)
No	2 (100)	11 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	3.29	
95% CI of the inverse odds ratio	(0.02, 23.31)	(0.12, 89.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	3.00	
95% CI of the inverse risk ratio	(0.04, 14.19)	(0.14, 66.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.17	-8.33	
95% CI of the absolute risk difference	(-41.97, 50.30)	(-30.20, 13.53)	
p-value	0.8494	0.4602	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	3 (27.3)
No	2 (100)	11 (100)	8 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.06	9.47	
95% CI of the inverse odds ratio	(0.08, 54.80)	(0.43, 208.75)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.75	7.00	
95% CI of the inverse risk ratio	(0.12, 25.51)	(0.40, 121.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-12.50	-25.00	
95% CI of the absolute risk difference	(-61.89, 36.89)	(-53.09, 3.09)	
p-value	0.6615	0.1003	
p-value of Breslow-Day Test for Homogeneity [3]	0.6353	0.2098	

AMNOG Table SE21.2.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (9.1)
No	2 (100)	11 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	3.29	
95% CI of the inverse odds ratio	(0.02, 23.31)	(0.12, 89.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	3.00	
95% CI of the inverse risk ratio	(0.04, 14.19)	(0.14, 66.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.17	-8.33	
95% CI of the absolute risk difference	(-41.97, 50.30)	(-30.20, 13.53)	
p-value	0.8494	0.4602	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.2165	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (18.2)	1 (9.1)
No	2 (100)	9 (81.8)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	0.45	
95% CI of the inverse odds ratio	(0.02, 23.31)	(0.03, 5.84)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	0.50	
95% CI of the inverse risk ratio	(0.04, 14.19)	(0.05, 4.75)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.17	9.09	
95% CI of the absolute risk difference	(-41.97, 50.30)	(-19.34, 37.52)	
p-value	0.8494	0.5344	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.3111	

AMNOG Table SE21.2.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	2 (100)	11 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	2 (100)	11 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE21.2.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	2 (100)	11 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (50.0)	0	2 (18.2)
No	1 (50.0)	11 (100)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.22	6.05	
95% CI of the inverse odds ratio	(0.01, 5.28)	(0.26, 142.04)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.36	5.00	
95% CI of the inverse risk ratio	(0.06, 2.36)	(0.27, 93.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	31.82	-16.67	
95% CI of the absolute risk difference	(-41.13, 100.00)	(-42.28, 8.94)	
p-value	0.3259	0.2170	
p-value of Breslow-Day Test for Homogeneity [3]	0.1940	0.1900	

AMNOG Table SE21.2.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	2 (100)	11 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	2 (100)	11 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE21.2.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: < Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	2 (100)	11 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	1 (9.1)
No	2 (100)	11 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	3.29	
95% CI of the inverse odds ratio	(0.02, 23.31)	(0.12, 89.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	3.00	
95% CI of the inverse risk ratio	(0.04, 14.19)	(0.14, 66.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.17	-8.33	
95% CI of the absolute risk difference	(-41.97, 50.30)	(-30.20, 13.53)	
p-value	0.8494	0.4602	
p-value of Breslow-Day Test for Homogeneity [3]	0.7433	NE	

AMNOG Table SE21.2.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (14.3)	0	1 (5.9)
No	6 (85.7)	4 (100)	16 (94.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.38	0.82	
95% CI of the inverse odds ratio	(0.02, 7.00)	(0.03, 23.70)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.41	0.83	
95% CI of the inverse risk ratio	(0.03, 5.70)	(0.04, 17.48)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.40	1.67	
95% CI of the absolute risk difference	(-19.83, 36.64)	(-27.56, 30.90)	
p-value	0.4984	0.9069	
p-value of Breslow-Day Test for Homogeneity [3]	0.5147	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (14.3)	2 (50.0)	8 (47.1)
No	6 (85.7)	2 (50.0)	9 (52.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.33	0.89	
95% CI of the inverse odds ratio	(0.52, 54.34)	(0.10, 7.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.29	0.94	
95% CI of the inverse risk ratio	(0.50, 21.66)	(0.31, 2.83)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-32.77	2.94	
95% CI of the absolute risk difference	(-67.91, 2.37)	(-51.50, 57.38)	
p-value	0.1317	0.9156	
p-value of Breslow-Day Test for Homogeneity [3]	0.7036	0.1157	

AMNOG Table SE21.2.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (14.3)	0	3 (17.6)
No	6 (85.7)	4 (100)	14 (82.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	2.17	
95% CI of the inverse odds ratio	(0.11, 15.00)	(0.09, 50.51)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.24	1.94	
95% CI of the inverse risk ratio	(0.15, 9.94)	(0.12, 31.74)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.36	-9.44	
95% CI of the absolute risk difference	(-34.99, 28.27)	(-41.47, 22.58)	
p-value	0.8408	0.6221	
p-value of Breslow-Day Test for Homogeneity [3]	0.5731	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (14.3)	0	6 (35.3)
No	6 (85.7)	4 (100)	11 (64.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.27	5.09	
95% CI of the inverse odds ratio	(0.32, 33.94)	(0.23, 110.24)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.47	3.61	
95% CI of the inverse risk ratio	(0.36, 16.94)	(0.24, 53.75)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-21.01	-26.11	
95% CI of the absolute risk difference	(-55.48, 13.46)	(-60.52, 8.30)	
p-value	0.3034	0.2616	
p-value of Breslow-Day Test for Homogeneity [3]	0.2491	0.4551	

AMNOG Table SE21.2.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	4 (23.5)
No	7 (100)	4 (100)	13 (76.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.00	3.00	
95% CI of the inverse odds ratio	(0.24, 106.11)	(0.13, 67.29)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.00	2.50	
95% CI of the inverse risk ratio	(0.24, 65.81)	(0.16, 39.05)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-18.75	-15.00	
95% CI of the absolute risk difference	(-44.86, 7.36)	(-48.04, 18.04)	
p-value	0.2629	0.4719	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (25.0)	4 (23.5)
No	7 (100)	3 (75.0)	13 (76.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.00	0.92	
95% CI of the inverse odds ratio	(0.24, 106.11)	(0.07, 11.54)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.00	0.94	
95% CI of the inverse risk ratio	(0.24, 65.81)	(0.14, 6.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-18.75	1.47	
95% CI of the absolute risk difference	(-44.86, 7.36)	(-45.51, 48.45)	
p-value	0.2629	0.9505	
p-value of Breslow-Day Test for Homogeneity [3]	0.0677	0.2084	

AMNOG Table SE21.2.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	4 (23.5)
No	7 (100)	4 (100)	13 (76.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.00	3.00	
95% CI of the inverse odds ratio	(0.24, 106.11)	(0.13, 67.29)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.00	2.50	
95% CI of the inverse risk ratio	(0.24, 65.81)	(0.16, 39.05)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-18.75	-15.00	
95% CI of the absolute risk difference	(-44.86, 7.36)	(-48.04, 18.04)	
p-value	0.2629	0.4719	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (57.1)	1 (25.0)	7 (41.2)
No	3 (42.9)	3 (75.0)	10 (58.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.53	2.10	
95% CI of the inverse odds ratio	(0.09, 3.12)	(0.18, 24.60)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.72	1.65	
95% CI of the inverse risk ratio	(0.31, 1.70)	(0.28, 9.86)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	15.97	-16.18	
95% CI of the absolute risk difference	(-27.52, 59.46)	(-64.63, 32.28)	
p-value	0.4755	0.5489	
p-value of Breslow-Day Test for Homogeneity [3]	0.5565	0.7010	

AMNOG Table SE21.2.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (11.8)
No	7 (100)	4 (100)	15 (88.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.42	1.45	
95% CI of the inverse odds ratio	(0.10, 56.97)	(0.06, 36.06)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.22	1.39	
95% CI of the inverse risk ratio	(0.12, 41.20)	(0.08, 24.50)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.64	-3.89	
95% CI of the absolute risk difference	(-30.80, 15.53)	(-34.66, 26.88)	
p-value	0.5736	0.8193	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (14.3)	1 (25.0)	6 (35.3)
No	6 (85.7)	3 (75.0)	11 (64.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.27	1.64	
95% CI of the inverse odds ratio	(0.32, 33.94)	(0.14, 19.39)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.47	1.41	
95% CI of the inverse risk ratio	(0.36, 16.94)	(0.23, 8.67)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-21.01	-10.29	
95% CI of the absolute risk difference	(-55.48, 13.46)	(-58.43, 37.84)	
p-value	0.3034	0.6944	
p-value of Breslow-Day Test for Homogeneity [3]	0.6353	0.2098	

AMNOG Table SE21.2.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (25.0)	2 (11.8)
No	7 (100)	3 (75.0)	15 (88.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.42	0.40	
95% CI of the inverse odds ratio	(0.10, 56.97)	(0.03, 5.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.22	0.47	
95% CI of the inverse risk ratio	(0.12, 41.20)	(0.06, 4.00)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.64	13.24	
95% CI of the absolute risk difference	(-30.80, 15.53)	(-31.88, 58.35)	
p-value	0.5736	0.4961	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.2165	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	3 (75.0)	3 (17.6)
No	7 (100)	1 (25.0)	14 (82.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.62	0.07	
95% CI of the inverse odds ratio	(0.16, 79.69)	(0.01, 0.95)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.11	0.24	
95% CI of the inverse risk ratio	(0.18, 53.45)	(0.07, 0.76)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-13.19	57.35	
95% CI of the absolute risk difference	(-38.01, 11.62)	(11.21, 100.00)	
p-value	0.3894	0.0223	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.3111	

AMNOG Table SE21.2.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (11.8)
No	7 (100)	4 (100)	15 (88.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.42	1.45	
95% CI of the inverse odds ratio	(0.10, 56.97)	(0.06, 36.06)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.22	1.39	
95% CI of the inverse risk ratio	(0.12, 41.20)	(0.08, 24.50)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.64	-3.89	
95% CI of the absolute risk difference	(-30.80, 15.53)	(-34.66, 26.88)	
p-value	0.5736	0.8193	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (14.3)	1 (25.0)	3 (17.6)
No	6 (85.7)	3 (75.0)	14 (82.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	0.64	
95% CI of the inverse odds ratio	(0.11, 15.00)	(0.05, 8.52)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.24	0.71	
95% CI of the inverse risk ratio	(0.15, 9.94)	(0.10, 5.13)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.36	7.35	
95% CI of the absolute risk difference	(-34.99, 28.27)	(-38.79, 53.49)	
p-value	0.8408	0.7362	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE21.2.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (25.0)	3 (17.6)
No	7 (100)	3 (75.0)	14 (82.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.62	0.64	
95% CI of the inverse odds ratio	(0.16, 79.69)	(0.05, 8.52)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.11	0.71	
95% CI of the inverse risk ratio	(0.18, 53.45)	(0.10, 5.13)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-13.19	7.35	
95% CI of the absolute risk difference	(-38.01, 11.62)	(-38.79, 53.49)	
p-value	0.3894	0.7362	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (28.6)	2 (50.0)	8 (47.1)
No	5 (71.4)	2 (50.0)	9 (52.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.22	0.89	
95% CI of the inverse odds ratio	(0.33, 14.80)	(0.10, 7.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.65	0.94	
95% CI of the inverse risk ratio	(0.46, 5.90)	(0.31, 2.83)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-18.49	2.94	
95% CI of the absolute risk difference	(-59.51, 22.54)	(-51.50, 57.38)	
p-value	0.4037	0.9156	
p-value of Breslow-Day Test for Homogeneity [3]	0.1940	0.1900	

AMNOG Table SE21.2.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	7 (100)	4 (100)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (50.0)	6 (35.3)
No	7 (100)	2 (50.0)	11 (64.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	8.48	0.55	
95% CI of the inverse odds ratio	(0.41, 173.72)	(0.06, 4.91)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.78	0.71	
95% CI of the inverse risk ratio	(0.37, 90.67)	(0.22, 2.28)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-29.86	14.71	
95% CI of the absolute risk difference	(-57.68, -2.05)	(-39.30, 68.71)	
p-value	0.1131	0.5858	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE21.2.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Age (Median)
(Label Population based on Modified Intent-to-Treat Population)

Age: >= Median

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (11.8)
No	7 (100)	4 (100)	15 (88.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.42	1.45	
95% CI of the inverse odds ratio	(0.10, 56.97)	(0.06, 36.06)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.22	1.39	
95% CI of the inverse risk ratio	(0.12, 41.20)	(0.08, 24.50)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.64	-3.89	
95% CI of the absolute risk difference	(-30.80, 15.53)	(-34.66, 26.88)	
p-value	0.5736	0.8193	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (14.3)	0	4 (23.5)
No	6 (85.7)	4 (100)	13 (76.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.85	3.00	
95% CI of the inverse odds ratio	(0.17, 20.26)	(0.13, 67.29)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.65	2.50	
95% CI of the inverse risk ratio	(0.22, 12.25)	(0.16, 39.05)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.24	-15.00	
95% CI of the absolute risk difference	(-42.09, 23.60)	(-48.04, 18.04)	
p-value	0.6123	0.4719	
p-value of Breslow-Day Test for Homogeneity [3]	0.7433	NE	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.3.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=21)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=21)
Physical Functioning						
Baseline						
m	6	15	21			
n	6	14	19			
Mean (SD)	71.67 (27.33)	79.29 (19.00)	84.74 (19.68)			
Median	77.50	82.50	95.00			
IQR: Q1, Q3	70.00, 85.00	65.00, 95.00	75.00, 100.00			
Min, Max	20.0, 100.0	40.0, 100.0	35.0, 100.0			
Week 24						
m	6	12	20			
n	5	11	18	5	11	17
Mean (SD/SE)	86.00 (23.82)	83.64 (16.14)	76.67 (25.61)	17.00 (5.39)	2.27 (2.27)	-9.71 (6.42)
Median	100.00	85.00	80.00	20.00	0	0
IQR: Q1, Q3	85.00, 100.00	75.00, 95.00	70.00, 100.00	10.00, 25.00	-5.00, 5.00	-15.00, 5.00
Min, Max	45.0, 100.0	45.0, 100.0	20.0, 100.0	0.0, 30.0	-5.0, 20.0	-75.0, 35.0
Week 52						
m	6	12	19			
n	5	10	17	5	10	16
Mean (SD/SE)	78.00 (19.24)	74.50 (21.14)	85.00 (22.36)	-4.00 (7.97)	-6.00 (3.79)	-3.13 (4.78)
Median	80.00	77.50	95.00	-5.00	-2.50	0
IQR: Q1, Q3	70.00, 90.00	50.00, 95.00	80.00, 100.00	-5.00, 0.00	-10.00, 0.00	-5.00, 5.00
Min, Max	50.0, 100.0	40.0, 100.0	20.0, 100.0	-30.0, 20.0	-30.0, 10.0	-60.0, 30.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.3.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=21)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=21)
Role Physical						
Baseline						
m	6	15	21			
n	6	14	19			
Mean (SD)	84.38 (13.54)	89.30 (13.74)	84.88 (20.23)			
Median	81.25	96.90	87.50			
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	68.8, 100.0	62.5, 100.0	25.0, 100.0			
Week 24						
m	6	12	20			
n	5	11	18	5	11	17
Mean (SD/SE)	86.26 (19.94)	86.95 (16.86)	75.35 (30.05)	5.00 (7.23)	-3.96 (4.15)	-7.36 (6.48)
Median	100.00	93.80	87.50	6.20	0	0
IQR: Q1, Q3	75.00, 100.00	68.80, 100.00	62.50, 100.00	0.00, 12.50	-6.20, 0.00	0.00, 0.00
Min, Max	56.3, 100.0	56.3, 100.0	12.5, 100.0	-18.7, 25.0	-43.7, 6.3	-75.0, 31.2
Week 52						
m	6	12	19			
n	5	10	17	5	10	16
Mean (SD/SE)	85.00 (16.30)	76.26 (28.08)	81.62 (24.94)	-1.26 (8.48)	-14.37 (6.91)	-2.74 (5.26)
Median	87.50	87.55	100.00	0	-3.10	0
IQR: Q1, Q3	75.00, 100.00	37.50, 100.00	75.00, 100.00	-12.50, 6.20	-25.00, 0.00	-12.50, 9.40
Min, Max	62.5, 100.0	37.5, 100.0	25.0, 100.0	-25.0, 25.0	-62.5, 6.2	-43.8, 25.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.3.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=21)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=21)
Bodily Pain						
Baseline						
m	6	15	21			
n	6	14	19			
Mean (SD)	71.7 (27.6)	78.4 (18.2)	80.6 (16.7)			
Median	73.0	84.0	84.0			
IQR: Q1, Q3	52.0, 100.0	62.0, 100.0	62.0, 100.0			
Min, Max	32, 100	51, 100	41, 100			
Week 24						
m	6	12	20			
n	5	11	18	5	11	17
Mean (SD/SE)	79.4 (22.2)	78.4 (17.1)	74.9 (23.1)	13.4 (3.9)	-2.9 (4.4)	-5.3 (4.5)
Median	84.0	80.0	74.0	16.0	0	0
IQR: Q1, Q3	62.0, 100.0	62.0, 100.0	62.0, 100.0	10.0, 19.0	-10.0, 0.0	-10.0, 0.0
Min, Max	51, 100	52, 100	31, 100	0, 22	-36, 18	-53, 16
Week 52						
m	6	12	19			
n	5	10	17	5	10	16
Mean (SD/SE)	62.8 (25.3)	75.6 (15.6)	77.0 (18.0)	-10.8 (5.5)	-5.4 (3.7)	-4.2 (2.9)
Median	62.0	74.0	74.0	-16.0	0	0
IQR: Q1, Q3	62.0, 84.0	62.0, 84.0	72.0, 84.0	-16.0, -10.0	-10.0, 0.0	-10.0, 0.0
Min, Max	22, 84	52, 100	41, 100	-22, 10	-26, 12	-28, 21

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.3.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=21)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=21)
General Health						
Baseline						
m	6	15	21			
n	6	14	19			
Mean (SD)	64.17 (21.17)	67.57 (11.30)	69.89 (18.78)			
Median	72.00	67.00	72.00			
IQR: Q1, Q3	57.00, 77.00	62.00, 77.00	62.00, 82.00			
Min, Max	25.0, 82.0	47.0, 82.0	25.0, 97.0			
Week 24						
m	6	12	20			
n	5	11	18	5	11	17
Mean (SD/SE)	68.60 (26.46)	65.45 (14.94)	63.50 (19.13)	5.00 (4.47)	-2.27 (4.32)	-7.06 (3.74)
Median	72.00	62.00	68.50	10.00	5.00	-5.00
IQR: Q1, Q3	67.00, 87.00	52.00, 77.00	42.00, 77.00	0.00, 10.00	-15.00, 10.00	-15.00, 10.00
Min, Max	25.0, 92.0	45.0, 87.0	30.0, 92.0	-10.0, 15.0	-27.0, 15.0	-35.0, 15.0
Week 52						
m	6	12	19			
n	5	10	17	5	10	16
Mean (SD/SE)	76.60 (14.43)	63.30 (15.17)	65.50 (21.12)	4.60 (2.48)	-3.50 (3.11)	-5.59 (4.91)
Median	77.00	59.50	62.00	5.00	-2.50	-2.50
IQR: Q1, Q3	72.00, 87.00	52.00, 77.00	52.00, 87.00	0.00, 10.00	-5.00, 0.00	-15.00, 7.75
Min, Max	55.0, 92.0	42.0, 82.0	15.0, 97.0	-2.0, 10.0	-27.0, 10.0	-57.0, 25.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.3.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=21)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=21)
Vitality						
Baseline						
m	6	15	21			
n	6	14	19			
Mean (SD)	51.07 (27.22)	67.89 (13.17)	67.12 (17.90)			
Median	59.40	68.80	62.50			
IQR: Q1, Q3	43.80, 68.80	62.50, 75.00	50.00, 81.30			
Min, Max	0.0, 75.0	43.8, 93.8	37.5, 100.0			
Week 24						
m	6	12	20			
n	5	11	18	5	11	17
Mean (SD/SE)	45.02 (32.31)	66.51 (14.60)	61.48 (23.40)	-5.00 (5.38)	-0.56 (4.95)	-5.15 (4.09)
Median	56.30	68.80	68.75	-6.20	0	0
IQR: Q1, Q3	25.00, 62.50	56.30, 75.00	43.80, 75.00	-12.50, 0.00	-12.50, 6.30	-6.30, 6.20
Min, Max	0.0, 81.3	43.8, 93.8	6.3, 93.8	-18.8, 12.5	-31.3, 31.3	-50.0, 12.5
Week 52						
m	6	12	19			
n	5	10	17	5	10	16
Mean (SD/SE)	51.28 (23.13)	60.03 (15.64)	65.82 (24.42)	-10.00 (5.45)	-5.62 (2.54)	-3.52 (4.27)
Median	56.30	59.40	68.80	-6.20	-3.10	0
IQR: Q1, Q3	37.50, 68.80	50.00, 75.00	43.80, 81.30	-18.80, -6.20	-12.50, 0.00	-18.75, 12.50
Min, Max	18.8, 75.0	31.3, 81.3	25.0, 100.0	-25.0, 6.2	-18.7, 6.2	-37.5, 25.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.3.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=21)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=21)
Social Functioning						
Baseline						
m	6	15	21			
n	6	14	19			
Mean (SD)	89.58 (16.61)	88.39 (16.60)	93.42 (11.31)			
Median	100.00	87.50	100.00			
IQR: Q1, Q3	75.00, 100.00	87.50, 100.00	87.50, 100.00			
Min, Max	62.5, 100.0	37.5, 100.0	62.5, 100.0			
Week 24						
m	6	12	20			
n	5	11	18	5	11	17
Mean (SD/SE)	77.50 (22.36)	90.91 (11.31)	84.03 (26.71)	-10.00 (4.68)	2.27 (6.91)	-9.56 (6.11)
Median	75.00	100.00	100.00	-12.50	0	0
IQR: Q1, Q3	62.50, 100.00	75.00, 100.00	75.00, 100.00	-12.50, 0.00	-12.50, 12.50	0.00, 0.00
Min, Max	50.0, 100.0	75.0, 100.0	0.0, 100.0	-25.0, 0.0	-25.0, 62.5	-100.0, 0.0
Week 52						
m	6	12	19			
n	5	10	17	5	10	16
Mean (SD/SE)	85.00 (20.54)	92.50 (10.54)	94.12 (13.34)	-10.00 (7.29)	3.75 (8.13)	0.00 (3.42)
Median	100.00	100.00	100.00	0	6.25	0
IQR: Q1, Q3	62.50, 100.00	87.50, 100.00	100.00, 100.00	-12.50, 0.00	-12.50, 12.50	0.00, 0.00
Min, Max	62.5, 100.0	75.0, 100.0	62.5, 100.0	-37.5, 0.0	-25.0, 62.5	-37.5, 25.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.3.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=6)	(N=15)	(N=21)	(N=6)	(N=15)	(N=21)
Role Emotional						
Baseline						
m	6	15	21			
n	6	14	19			
Mean (SD)	95.85 (4.55)	96.43 (7.82)	90.35 (16.25)			
Median	95.85	100.00	100.00			
IQR: Q1, Q3	91.70, 100.00	100.00, 100.00	83.30, 100.00			
Min, Max	91.7, 100.0	75.0, 100.0	41.7, 100.0			
Week 24						
m	6	12	20			
n	5	11	18	5	11	17
Mean (SD/SE)	85.00 (14.90)	91.66 (16.25)	82.87 (21.28)	-10.02 (7.16)	-6.06 (5.52)	-6.38 (3.24)
Median	83.30	100.00	91.65	-8.40	0	0
IQR: Q1, Q3	75.00, 100.00	83.30, 100.00	66.70, 100.00	-16.70, 0.00	-16.70, 0.00	-8.30, 0.00
Min, Max	66.7, 100.0	50.0, 100.0	41.7, 100.0	-33.3, 8.3	-50.0, 16.7	-50.0, 0.0
Week 52						
m	6	12	19			
n	5	10	17	5	10	16
Mean (SD/SE)	86.66 (13.94)	90.83 (16.88)	83.33 (22.64)	-8.36 (5.89)	-6.67 (5.53)	-7.30 (4.81)
Median	83.30	100.00	100.00	-8.40	0	0
IQR: Q1, Q3	83.30, 100.00	83.30, 100.00	66.70, 100.00	-16.70, 0.00	0.00, 0.00	-16.65, 0.00
Min, Max	66.7, 100.0	50.0, 100.0	25.0, 100.0	-25.0, 8.3	-50.0, 8.3	-41.7, 33.3

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.3.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=21)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=21)
Mental Health						
Baseline						
m	6	15	21			
n	6	14	19			
Mean (SD)	80.0 (8.4)	85.7 (7.6)	80.5 (15.5)			
Median	77.5	85.0	85.0			
IQR: Q1, Q3	75.0, 90.0	85.0, 90.0	65.0, 95.0			
Min, Max	70, 90	70, 100	50, 100			
Week 24						
m	6	12	20			
n	5	11	18	5	11	17
Mean (SD/SE)	84.0 (13.4)	85.0 (12.2)	78.9 (18.7)	4.0 (3.7)	-1.4 (4.4)	-1.8 (2.0)
Median	90.0	85.0	87.5	0	0	0
IQR: Q1, Q3	70.0, 90.0	80.0, 95.0	60.0, 95.0	0.0, 10.0	-5.0, 5.0	-5.0, 0.0
Min, Max	70, 100	55, 100	45, 100	-5, 15	-35, 25	-20, 15
Week 52						
m	6	12	19			
n	5	10	17	5	10	16
Mean (SD/SE)	83.0 (9.7)	81.0 (10.2)	79.4 (20.0)	1.0 (2.9)	-5.5 (3.4)	-1.3 (3.8)
Median	80.0	80.0	85.0	5.0	-5.0	0
IQR: Q1, Q3	80.0, 90.0	80.0, 90.0	70.0, 95.0	0.0, 5.0	-10.0, -5.0	-7.5, 5.0
Min, Max	70, 95	60, 95	30, 100	-10, 5	-25, 15	-40, 25

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.3.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=21)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=21)
Mental Component Score						
Baseline						
m	6	15	21			
n	6	14	19			
Mean (SD)	54.32 (3.38)	56.46 (2.90)	54.10 (7.04)			
Median	53.55	57.00	56.60			
IQR: Q1, Q3	53.10, 57.00	55.20, 57.80	46.80, 59.70			
Min, Max	49.5, 59.2	51.1, 60.9	38.1, 62.9			
Week 24						
m	6	12	20			
n	5	11	18	5	11	17
Mean (SD/SE)	49.72 (8.93)	55.27 (6.14)	52.09 (8.66)	-4.70 (2.60)	-1.15 (2.34)	-1.76 (0.86)
Median	51.90	57.30	55.35	-1.50	-0.30	-1.00
IQR: Q1, Q3	41.10, 55.50	52.10, 59.60	44.20, 58.40	-9.60, -1.20	-5.00, 4.90	-4.20, 0.80
Min, Max	39.9, 60.2	40.8, 61.0	37.1, 62.8	-12.2, 1.0	-20.1, 8.4	-8.1, 4.0
Week 52						
m	6	12	19			
n	5	10	17	5	10	16
Mean (SD/SE)	52.64 (5.86)	54.94 (4.65)	52.76 (9.46)	-2.64 (1.51)	-1.43 (1.68)	-1.43 (1.78)
Median	50.60	55.90	56.30	-2.50	-1.80	0.05
IQR: Q1, Q3	47.70, 56.90	53.10, 58.80	45.30, 60.30	-5.90, -0.10	-2.80, 2.10	-5.35, 3.70
Min, Max	47.4, 60.6	44.0, 59.6	35.3, 65.3	-6.1, 1.4	-11.4, 5.9	-16.0, 8.7

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.3.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=21)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=21)
Physical Component Score						
Baseline						
m	6	15	21			
n	6	14	19			
Mean (SD)	47.47 (9.18)	50.11 (6.66)	52.06 (6.85)			
Median	47.60	53.05	52.30			
IQR: Q1, Q3	44.10, 55.30	43.70, 54.40	49.80, 57.10			
Min, Max	32.2, 58.0	37.8, 60.3	34.5, 61.1			
Week 24						
m	6	12	20			
n	5	11	18	5	11	17
Mean (SD/SE)	51.88 (8.38)	50.70 (5.74)	48.79 (9.96)	5.98 (2.03)	-0.15 (1.10)	-3.34 (2.15)
Median	54.80	50.90	51.70	7.20	0.50	-0.10
IQR: Q1, Q3	47.50, 58.70	48.00, 55.50	40.10, 56.00	1.40, 9.60	-3.30, 3.10	-4.60, 1.20
Min, Max	39.4, 59.0	40.9, 58.0	25.9, 61.0	1.0, 10.7	-6.4, 4.9	-30.0, 6.9
Week 52						
m	6	12	19			
n	5	10	17	5	10	16
Mean (SD/SE)	49.32 (8.34)	47.71 (9.01)	51.38 (7.29)	-1.20 (2.02)	-2.80 (1.69)	-1.36 (1.48)
Median	52.70	49.05	52.80	-1.00	-2.00	-0.15
IQR: Q1, Q3	47.50, 53.70	39.60, 55.00	50.50, 54.90	-1.60, 1.40	-4.00, 1.40	-4.55, 1.75
Min, Max	35.7, 57.0	33.4, 58.6	34.3, 58.9	-8.4, 3.6	-14.8, 2.9	-15.9, 8.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.3.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=7)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=7)
Physical Functioning						
Baseline						
m	3	0	7			
n	3	0	7			
Mean (SD)	78.33 (16.07)	N/A	68.57 (22.68)			
Median	85.00	N/A	75.00			
IQR: Q1, Q3	60.00, 90.00	N/A	55.00, 80.00			
Min, Max	60.0, 90.0	N/A	25.0, 95.0			
Week 24						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	77.50 (10.61)	N/A	75.71 (23.53)	-10.00 (5.00)	N/A	7.14 (3.76)
Median	77.50	N/A	85.00	-10.00	N/A	5.00
IQR: Q1, Q3	70.00, 85.00	N/A	60.00, 90.00	-15.00, -5.00	N/A	0.00, 15.00
Min, Max	70.0, 85.0	N/A	30.0, 100.0	-15.0, -5.0	N/A	-5.0, 25.0
Week 52						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	82.50 (3.54)	N/A	73.81 (21.83)	-5.00 (0.00)	N/A	5.24 (5.16)
Median	82.50	N/A	80.00	-5.00	N/A	10.00
IQR: Q1, Q3	80.00, 85.00	N/A	60.00, 90.00	-5.00, -5.00	N/A	-10.00, 11.70
Min, Max	80.0, 85.0	N/A	35.0, 100.0	-5.0, -5.0	N/A	-15.0, 25.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.3.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=7)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=7)
Role Physical						
Baseline						
m	3	0	7			
n	3	0	7			
Mean (SD)	75.00 (25.00)	N/A	65.19 (31.43)			
Median	75.00	N/A	75.00			
IQR: Q1, Q3	50.00, 100.00	N/A	62.50, 81.30			
Min, Max	50.0, 100.0	N/A	0.0, 100.0			
Week 24						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	87.50 (17.68)	N/A	77.70 (34.00)	0.00 (0.00)	N/A	12.51 (3.34)
Median	87.50	N/A	93.80	0	N/A	12.50
IQR: Q1, Q3	75.00, 100.00	N/A	68.80, 100.00	0.00, 0.00	N/A	6.30, 18.80
Min, Max	75.0, 100.0	N/A	6.3, 100.0	0.0, 0.0	N/A	0.0, 25.0
Week 52						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	81.25 (26.52)	N/A	66.99 (25.93)	-6.25 (6.25)	N/A	1.80 (8.27)
Median	81.25	N/A	56.30	-6.25	N/A	0
IQR: Q1, Q3	62.50, 100.00	N/A	50.00, 100.00	-12.50, 0.00	N/A	-18.70, 25.00
Min, Max	62.5, 100.0	N/A	31.3, 100.0	-12.5, 0.0	N/A	-25.0, 31.3

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.3.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=7)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=7)
Bodily Pain						
Baseline						
m	3	0	7			
n	3	0	7			
Mean (SD)	78.7 (19.4)	N/A	66.7 (28.9)			
Median	74.0	N/A	74.0			
IQR: Q1, Q3	62.0, 100.0	N/A	51.0, 84.0			
Min, Max	62, 100	N/A	12, 100			
Week 24						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	100.0 (0.0)	N/A	72.3 (31.3)	13.0 (13.0)	N/A	5.6 (2.6)
Median	100.0	N/A	84.0	13.0	N/A	1.0
IQR: Q1, Q3	100.0, 100.0	N/A	52.0, 100.0	0.0, 26.0	N/A	0.0, 12.0
Min, Max	100, 100	N/A	12, 100	0, 26	N/A	0, 16
Week 52						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	81.0 (26.9)	N/A	69.1 (25.6)	-6.0 (6.0)	N/A	2.4 (8.0)
Median	81.0	N/A	74.0	-6.0	N/A	16.0
IQR: Q1, Q3	62.0, 100.0	N/A	52.0, 100.0	-12.0, 0.0	N/A	-22.0, 20.0
Min, Max	62, 100	N/A	32, 100	-12, 0	N/A	-26, 23

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.3.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=7)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=7)
General Health						
Baseline						
m	3	0	7			
n	3	0	7			
Mean (SD)	75.33 (16.07)	N/A	69.57 (21.86)			
Median	82.00	N/A	72.00			
IQR: Q1, Q3	57.00, 87.00	N/A	62.00, 82.00			
Min, Max	57.0, 87.0	N/A	25.0, 92.0			
Week 24						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	89.50 (10.61)	N/A	76.71 (16.95)	5.00 (5.00)	N/A	7.14 (3.06)
Median	89.50	N/A	82.00	5.00	N/A	5.00
IQR: Q1, Q3	82.00, 97.00	N/A	67.00, 92.00	0.00, 10.00	N/A	0.00, 15.00
Min, Max	82.0, 97.0	N/A	45.0, 92.0	0.0, 10.0	N/A	0.0, 20.0
Week 52						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	82.00 (14.14)	N/A	71.00 (16.54)	-2.50 (7.50)	N/A	1.43 (4.46)
Median	82.00	N/A	72.00	-2.50	N/A	0
IQR: Q1, Q3	72.00, 92.00	N/A	62.00, 82.00	-10.00, 5.00	N/A	-10.00, 15.00
Min, Max	72.0, 92.0	N/A	40.0, 92.0	-10.0, 5.0	N/A	-10.0, 15.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.3.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=7)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=7)
Vitality						
Baseline						
m	3	0	7			
n	3	0	7			
Mean (SD)	68.80 (12.50)	N/A	63.41 (21.47)			
Median	68.80	N/A	68.80			
IQR: Q1, Q3	56.30, 81.30	N/A	43.80, 75.00			
Min, Max	56.3, 81.3	N/A	25.0, 87.5			
Week 24						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	78.15 (4.45)	N/A	66.99 (12.36)	3.10 (3.10)	N/A	3.57 (5.93)
Median	78.15	N/A	62.50	3.10	N/A	6.20
IQR: Q1, Q3	75.00, 81.30	N/A	56.30, 81.30	0.00, 6.20	N/A	-12.50, 12.50
Min, Max	75.0, 81.3	N/A	50.0, 81.3	0.0, 6.2	N/A	-12.5, 31.3
Week 52						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	71.90 (4.38)	N/A	66.97 (16.43)	-3.15 (3.15)	N/A	3.56 (6.51)
Median	71.90	N/A	62.50	-3.15	N/A	-6.20
IQR: Q1, Q3	68.80, 75.00	N/A	62.50, 81.30	-6.30, 0.00	N/A	-12.50, 18.70
Min, Max	68.8, 75.0	N/A	37.5, 87.5	-6.3, 0.0	N/A	-12.5, 31.2

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.3.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=3)	(N=0)	(N=7)	(N=3)	(N=0)	(N=7)
Social Functioning						
Baseline						
m	3	0	7			
n	3	0	7			
Mean (SD)	91.67 (14.43)	N/A	87.50 (27.95)			
Median	100.00	N/A	100.00			
IQR: Q1, Q3	75.00, 100.00	N/A	87.50, 100.00			
Min, Max	75.0, 100.0	N/A	25.0, 100.0			
Week 24						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	100.00 (0.00)	N/A	94.64 (9.83)	0.00 (0.00)	N/A	7.14 (7.14)
Median	100.00	N/A	100.00	0	N/A	0
IQR: Q1, Q3	100.00, 100.00	N/A	87.50, 100.00	0.00, 0.00	N/A	0.00, 0.00
Min, Max	100.0, 100.0	N/A	75.0, 100.0	0.0, 0.0	N/A	0.0, 50.0
Week 52						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	100.00 (0.00)	N/A	92.86 (14.17)	0.00 (0.00)	N/A	5.36 (6.01)
Median	100.00	N/A	100.00	0	N/A	0
IQR: Q1, Q3	100.00, 100.00	N/A	87.50, 100.00	0.00, 0.00	N/A	0.00, 12.50
Min, Max	100.0, 100.0	N/A	62.5, 100.0	0.0, 0.0	N/A	-12.5, 37.5

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.3.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=3)	(N=0)	(N=7)	(N=3)	(N=0)	(N=7)
Role Emotional						
Baseline						
m	3	0	7			
n	3	0	7			
Mean (SD)	83.33 (28.87)	N/A	89.29 (19.67)			
Median	100.00	N/A	100.00			
IQR: Q1, Q3	50.00, 100.00	N/A	75.00, 100.00			
Min, Max	50.0, 100.0	N/A	50.0, 100.0			
Week 24						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	100.00 (0.00)	N/A	91.66 (15.97)	0.00 (0.00)	N/A	2.37 (1.53)
Median	100.00	N/A	100.00	0	N/A	0
IQR: Q1, Q3	100.00, 100.00	N/A	83.30, 100.00	0.00, 0.00	N/A	0.00, 8.30
Min, Max	100.0, 100.0	N/A	58.3, 100.0	0.0, 0.0	N/A	0.0, 8.3
Week 52						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	100.00 (0.00)	N/A	92.86 (15.55)	0.00 (0.00)	N/A	3.57 (2.48)
Median	100.00	N/A	100.00	0	N/A	0
IQR: Q1, Q3	100.00, 100.00	N/A	91.70, 100.00	0.00, 0.00	N/A	0.00, 8.30
Min, Max	100.0, 100.0	N/A	58.3, 100.0	0.0, 0.0	N/A	0.0, 16.7

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.3.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=3)	(N=0)	(N=7)	(N=3)	(N=0)	(N=7)
Mental Health						
Baseline						
m	3	0	7			
n	3	0	7			
Mean (SD)	83.3 (20.8)	N/A	90.0 (10.0)			
Median	90.0	N/A	95.0			
IQR: Q1, Q3	60.0, 100.0	N/A	85.0, 95.0			
Min, Max	60, 100	N/A	70, 100			
Week 24						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	92.5 (3.5)	N/A	90.7 (8.9)	-2.5 (2.5)	N/A	0.7 (1.7)
Median	92.5	N/A	90.0	-2.5	N/A	0
IQR: Q1, Q3	90.0, 95.0	N/A	85.0, 100.0	-5.0, 0.0	N/A	-5.0, 5.0
Min, Max	90, 95	N/A	75, 100	-5, 0	N/A	-5, 5
Week 52						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	92.5 (3.5)	N/A	92.1 (12.9)	-2.5 (2.5)	N/A	2.1 (1.5)
Median	92.5	N/A	100.0	-2.5	N/A	5.0
IQR: Q1, Q3	90.0, 95.0	N/A	90.0, 100.0	-5.0, 0.0	N/A	0.0, 5.0
Min, Max	90, 95	N/A	65, 100	-5, 0	N/A	-5, 5

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.3.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=7)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=7)
Mental Component Score						
Baseline						
m	3	0	7			
n	3	0	7			
Mean (SD)	54.57 (10.13)	N/A	58.10 (6.54)			
Median	59.70	N/A	59.60			
IQR: Q1, Q3	42.90, 61.10	N/A	56.90, 62.30			
Min, Max	42.9, 61.1	N/A	44.1, 63.2			
Week 24						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	60.45 (0.35)	N/A	58.43 (2.49)	0.05 (0.95)	N/A	0.33 (1.81)
Median	60.45	N/A	57.60	0.05	N/A	-0.70
IQR: Q1, Q3	60.20, 60.70	N/A	56.90, 60.40	-0.90, 1.00	N/A	-1.90, 0.00
Min, Max	60.2, 60.7	N/A	54.9, 62.5	-0.9, 1.0	N/A	-4.0, 10.8
Week 52						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	60.40 (1.27)	N/A	59.61 (6.00)	0.00 (1.60)	N/A	1.51 (0.81)
Median	60.40	N/A	61.20	0	N/A	2.00
IQR: Q1, Q3	59.50, 61.30	N/A	60.00, 61.60	-1.60, 1.60	N/A	-0.70, 3.20
Min, Max	59.5, 61.3	N/A	46.6, 65.5	-1.6, 1.6	N/A	-1.7, 4.3

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.3.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=3)	(N=0)	(N=7)	(N=3)	(N=0)	(N=7)
Physical Component Score						
Baseline						
m	3	0	7			
n	3	0	7			
Mean (SD)	50.43 (5.70)	N/A	44.09 (10.87)			
Median	49.60	N/A	46.60			
IQR: Q1, Q3	45.20, 56.50	N/A	41.50, 53.50			
Min, Max	45.2, 56.5	N/A	21.6, 53.6			
Week 24						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	54.00 (4.81)	N/A	48.13 (11.50)	0.95 (0.05)	N/A	4.04 (1.57)
Median	54.00	N/A	53.40	0.95	N/A	3.00
IQR: Q1, Q3	50.60, 57.40	N/A	44.50, 54.40	0.90, 1.00	N/A	0.80, 7.30
Min, Max	50.6, 57.4	N/A	24.6, 59.3	0.9, 1.0	N/A	-0.1, 11.8
Week 52						
m	2	0	7			
n	2	0	7	2	0	7
Mean (SD/SE)	50.65 (8.70)	N/A	45.14 (9.77)	-2.40 (2.70)	N/A	1.06 (3.39)
Median	50.65	N/A	42.80	-2.40	N/A	2.80
IQR: Q1, Q3	44.50, 56.80	N/A	37.90, 56.30	-5.10, 0.30	N/A	-8.70, 9.90
Min, Max	44.5, 56.8	N/A	31.5, 57.6	-5.1, 0.3	N/A	-10.8, 10.1

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.3.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Age
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

Madrigal Pharmaceuticals, Inc. Page 2 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.3.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Age

(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Physical Functioning			
Week 24			
m	6	12	20
n	5	11	17
Baseline Mean (SD)	69.00 (29.66)	81.36 (17.76)	86.76 (19.84)
Analysis Visit Mean (SD)	86.00 (23.82)	83.64 (16.14)	77.06 (26.34)
LS Mean of Change from Baseline (SE)	15.66 (12.42)	4.54 (9.07)	-4.72 (9.90)
95% CI	(-9.70, 41.01)	(-13.98, 23.06)	(-24.93, 15.50)
LS Mean of Change from Baseline Compared to Placebo (SE)	20.37 (10.22)	9.26 (7.91)	
95% CI	(-0.49, 41.24)	(-6.90, 25.41)	
p-value	0.0553	0.2512	
Corrected Hedge's g Statistics	0.508	0.243	
95% CI	(-0.50, 1.52)	(-0.52, 1.00)	
Week 52			
m	6	12	19
n	5	10	16
Baseline Mean (SD)	82.00 (11.51)	80.50 (18.48)	87.50 (20.25)
Analysis Visit Mean (SD)	78.00 (19.24)	74.50 (21.14)	84.38 (22.94)
LS Mean of Change from Baseline (SE)	-1.35 (11.58)	-3.82 (8.63)	1.64 (9.70)
95% CI	(-25.01, 22.30)	(-21.44, 13.80)	(-18.17, 21.45)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.99 (8.63)	-5.46 (7.18)	
95% CI	(-20.61, 14.63)	(-20.12, 9.20)	
p-value	0.7311	0.4527	
Corrected Hedge's g Statistics	-0.079	-0.151	
95% CI	(-1.08, 0.93)	(-0.94, 0.64)	
Subgroup*Treatment Interaction p-value	0.5673	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 3 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.3.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Age

(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Role Physical			
Week 24			
m	6	12	20
n	5	11	17
Baseline Mean (SD)	81.26 (12.49)	90.92 (13.51)	84.20 (21.32)
Analysis Visit Mean (SD)	86.26 (19.94)	86.95 (16.86)	76.84 (30.28)
LS Mean of Change from Baseline (SE)	11.41 (13.93)	3.45 (10.51)	0.53 (11.41)
95% CI	(-17.04, 39.87)	(-18.00, 24.91)	(-22.77, 23.84)
LS Mean of Change from Baseline Compared to Placebo (SE)	10.88 (11.02)	2.92 (8.91)	
95% CI	(-11.62, 33.37)	(-15.28, 21.12)	
p-value	0.3313	0.7454	
Corrected Hedge's g Statistics	0.236	0.066	
95% CI	(-0.76, 1.24)	(-0.69, 0.82)	
Week 52			
m	6	12	19
n	5	10	16
Baseline Mean (SD)	86.26 (14.24)	90.63 (14.21)	83.99 (22.00)
Analysis Visit Mean (SD)	85.00 (16.30)	76.26 (28.08)	81.26 (25.71)
LS Mean of Change from Baseline (SE)	5.53 (13.96)	-7.05 (10.49)	4.89 (11.45)
95% CI	(-22.97, 34.03)	(-28.47, 14.37)	(-18.49, 28.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.63 (10.78)	-11.94 (8.97)	
95% CI	(-21.39, 22.66)	(-30.26, 6.37)	
p-value	0.9536	0.1929	
Corrected Hedge's g Statistics	0.014	-0.279	
95% CI	(-0.99, 1.02)	(-1.07, 0.52)	
Subgroup*Treatment Interaction p-value	0.5533	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 4 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.3.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Age

(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Bodily Pain			
Week 24			
m	6	12	20
n	5	11	17
Baseline Mean (SD)	66.0 (26.7)	81.3 (15.1)	80.9 (17.6)
Analysis Visit Mean (SD)	79.4 (22.2)	78.4 (17.1)	75.6 (23.6)
LS Mean of Change from Baseline (SE)	14.96 (9.41)	1.45 (6.81)	-0.51 (7.10)
95% CI	(-4.26, 34.17)	(-12.46, 15.35)	(-15.02, 13.99)
LS Mean of Change from Baseline Compared to Placebo (SE)	15.47 (8.58)	1.96 (6.47)	
95% CI	(-2.05, 32.99)	(-11.26, 15.18)	
p-value	0.0813	0.7639	
Corrected Hedge's g Statistics	0.535	0.071	
95% CI	(-0.47, 1.54)	(-0.69, 0.83)	
Week 52			
m	6	12	19
n	5	10	16
Baseline Mean (SD)	73.6 (30.4)	81.0 (15.9)	80.8 (18.1)
Analysis Visit Mean (SD)	62.8 (25.3)	75.6 (15.6)	76.6 (18.5)
LS Mean of Change from Baseline (SE)	-7.68 (7.75)	-1.11 (5.82)	-0.01 (6.55)
95% CI	(-23.52, 8.15)	(-12.99, 10.77)	(-13.38, 13.37)
LS Mean of Change from Baseline Compared to Placebo (SE)	-7.68 (5.76)	-1.11 (4.72)	
95% CI	(-19.44, 4.09)	(-10.75, 8.54)	
p-value	0.1926	0.8165	
Corrected Hedge's g Statistics	-0.300	-0.045	
95% CI	(-1.31, 0.71)	(-0.84, 0.74)	
Subgroup*Treatment Interaction p-value	0.8539	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 5 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.3.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
General Health			
Week 24			
m	6	12	20
n	5	11	17
Baseline Mean (SD)	63.60 (23.62)	67.73 (12.68)	71.82 (17.03)
Analysis Visit Mean (SD)	68.60 (26.46)	65.45 (14.94)	64.76 (18.93)
LS Mean of Change from Baseline (SE)	6.27 (9.72)	-0.73 (7.29)	-3.96 (8.14)
95% CI	(-13.57, 26.12)	(-15.61, 14.15)	(-20.59, 12.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	10.24 (7.36)	3.24 (5.93)	
95% CI	(-4.80, 25.28)	(-8.88, 15.35)	
p-value	0.1747	0.5893	
Corrected Hedge's g Statistics	0.312	0.104	
95% CI	(-0.69, 1.31)	(-0.66, 0.86)	
Week 52			
m	6	12	19
n	5	10	16
Baseline Mean (SD)	72.00 (10.00)	66.80 (12.97)	71.94 (17.58)
Analysis Visit Mean (SD)	76.60 (14.43)	63.30 (15.17)	66.34 (21.51)
LS Mean of Change from Baseline (SE)	6.01 (10.14)	-2.75 (7.58)	-3.41 (8.33)
95% CI	(-14.69, 26.71)	(-18.23, 12.72)	(-20.42, 13.61)
LS Mean of Change from Baseline Compared to Placebo (SE)	9.41 (7.90)	0.65 (6.57)	
95% CI	(-6.72, 25.55)	(-12.77, 14.07)	
p-value	0.2428	0.9217	
Corrected Hedge's g Statistics	0.288	0.021	
95% CI	(-0.72, 1.30)	(-0.77, 0.81)	
Subgroup*Treatment Interaction p-value	0.4874	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 6 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.3.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Vitality			
Week 24			
m	6	12	20
n	5	11	17
Baseline Mean (SD)	50.02 (30.30)	67.07 (14.82)	67.66 (18.39)
Analysis Visit Mean (SD)	45.02 (32.31)	66.51 (14.60)	62.52 (23.69)
LS Mean of Change from Baseline (SE)	-6.58 (10.27)	1.27 (7.36)	-3.03 (7.93)
95% CI	(-27.55, 14.38)	(-13.76, 16.30)	(-19.22, 13.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.55 (8.77)	4.30 (6.58)	
95% CI	(-21.46, 14.35)	(-9.13, 17.74)	
p-value	0.6882	0.5180	
Corrected Hedge's g Statistics	-0.110	0.140	
95% CI	(-1.11, 0.89)	(-0.62, 0.90)	
Week 52			
m	6	12	19
n	5	10	16
Baseline Mean (SD)	61.28 (12.01)	65.65 (14.81)	69.16 (17.90)
Analysis Visit Mean (SD)	51.28 (23.13)	60.03 (15.64)	65.64 (25.21)
LS Mean of Change from Baseline (SE)	-8.23 (9.56)	-4.32 (7.05)	-2.08 (7.83)
95% CI	(-27.76, 11.30)	(-18.71, 10.07)	(-18.07, 13.90)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.15 (7.56)	-2.24 (6.11)	
95% CI	(-21.58, 9.29)	(-14.72, 10.24)	
p-value	0.4226	0.7168	
Corrected Hedge's g Statistics	-0.200	-0.077	
95% CI	(-1.21, 0.81)	(-0.87, 0.71)	
Subgroup*Treatment Interaction p-value	0.5248	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 7 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.3.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Age

(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Social Functioning			
Week 24			
m	6	12	20
n	5	11	17
Baseline Mean (SD)	87.50 (17.68)	88.64 (18.07)	94.12 (11.79)
Analysis Visit Mean (SD)	77.50 (22.36)	90.91 (11.31)	84.56 (27.43)
LS Mean of Change from Baseline (SE)	-11.13 (12.38)	1.09 (8.94)	-8.66 (9.17)
95% CI	(-36.42, 14.15)	(-17.18, 19.35)	(-27.39, 10.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.48 (11.45)	9.74 (8.96)	
95% CI	(-25.85, 20.90)	(-8.57, 28.05)	
p-value	0.8301	0.2858	
Corrected Hedge's g Statistics	-0.066	0.271	
95% CI	(-1.06, 0.93)	(-0.49, 1.03)	
Week 52			
m	6	12	19
n	5	10	16
Baseline Mean (SD)	95.00 (11.18)	88.75 (19.05)	93.75 (12.08)
Analysis Visit Mean (SD)	85.00 (20.54)	92.50 (10.54)	93.75 (13.69)
LS Mean of Change from Baseline (SE)	-8.76 (9.95)	1.48 (7.32)	1.32 (8.26)
95% CI	(-29.09, 11.56)	(-13.48, 16.44)	(-15.55, 18.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	-10.08 (7.32)	0.17 (6.15)	
95% CI	(-25.03, 4.86)	(-12.40, 12.73)	
p-value	0.1785	0.9786	
Corrected Hedge's g Statistics	-0.311	0.005	
95% CI	(-1.32, 0.70)	(-0.78, 0.80)	
Subgroup*Treatment Interaction p-value	0.2987	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 8 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.3.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Role Emotional			
Week 24			
m	6	12	20
n	5	11	17
Baseline Mean (SD)	95.02 (4.55)	97.73 (5.39)	90.20 (16.98)
Analysis Visit Mean (SD)	85.00 (14.90)	91.66 (16.25)	83.82 (21.53)
LS Mean of Change from Baseline (SE)	-5.91 (10.74)	-2.21 (8.16)	-2.47 (9.05)
95% CI	(-27.84, 16.02)	(-18.87, 14.46)	(-20.96, 16.01)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.44 (8.06)	0.27 (6.69)	
95% CI	(-19.90, 13.02)	(-13.40, 13.93)	
p-value	0.6727	0.9683	
Corrected Hedge's g Statistics	-0.094	0.008	
95% CI	(-1.09, 0.90)	(-0.75, 0.77)	
Week 52			
m	6	12	19
n	5	10	16
Baseline Mean (SD)	95.02 (4.55)	97.50 (5.63)	89.59 (17.34)
Analysis Visit Mean (SD)	86.66 (13.94)	90.83 (16.88)	82.29 (22.95)
LS Mean of Change from Baseline (SE)	-6.21 (11.55)	-1.85 (8.71)	-3.67 (9.40)
95% CI	(-29.81, 17.38)	(-19.63, 15.93)	(-22.87, 15.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.54 (9.32)	1.82 (7.84)	
95% CI	(-21.57, 16.49)	(-14.19, 17.83)	
p-value	0.7869	0.8181	
Corrected Hedge's g Statistics	-0.069	0.052	
95% CI	(-1.07, 0.94)	(-0.74, 0.84)	
Subgroup*Treatment Interaction p-value	0.7826	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 9 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.3.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Mental Health			
Week 24			
m	6	12	20
n	5	11	17
Baseline Mean (SD)	80.0 (9.4)	86.4 (5.0)	80.0 (16.4)
Analysis Visit Mean (SD)	84.0 (13.4)	85.0 (12.2)	78.2 (19.0)
LS Mean of Change from Baseline (SE)	7.17 (7.26)	1.45 (5.49)	2.26 (6.09)
95% CI	(-7.66, 22.01)	(-9.76, 12.67)	(-10.17, 14.69)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.92 (5.48)	-0.80 (4.55)	
95% CI	(-6.28, 16.11)	(-10.09, 8.48)	
p-value	0.3770	0.8609	
Corrected Hedge's g Statistics	0.200	-0.034	
95% CI	(-0.80, 1.20)	(-0.79, 0.72)	
Week 52			
m	6	12	19
n	5	10	16
Baseline Mean (SD)	82.0 (7.6)	86.5 (5.3)	80.0 (16.9)
Analysis Visit Mean (SD)	83.0 (9.7)	81.0 (10.2)	78.8 (20.5)
LS Mean of Change from Baseline (SE)	4.99 (8.10)	-1.63 (6.06)	2.69 (6.43)
95% CI	(-11.56, 21.53)	(-14.01, 10.76)	(-10.44, 15.82)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.30 (6.75)	-4.32 (5.65)	
95% CI	(-11.50, 16.09)	(-15.86, 7.23)	
p-value	0.7363	0.4510	
Corrected Hedge's g Statistics	0.091	-0.178	
95% CI	(-0.91, 1.10)	(-0.97, 0.61)	
Subgroup*Treatment Interaction p-value	0.1752	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE21.3.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Age

(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Mental Component Score			
Week 24			
m	6	12	20
n	5	11	17
Baseline Mean (SD)	54.42 (3.77)	56.42 (3.03)	53.89 (7.40)
Analysis Visit Mean (SD)	49.72 (8.93)	55.27 (6.14)	52.13 (8.93)
LS Mean of Change from Baseline (SE)	-4.10 (3.75)	-0.47 (2.81)	-0.95 (3.08)
95% CI	(-11.76, 3.56)	(-6.20, 5.26)	(-7.24, 5.34)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.15 (2.95)	0.48 (2.41)	
95% CI	(-9.18, 2.89)	(-4.44, 5.40)	
p-value	0.2951	0.8428	
Corrected Hedge's g Statistics	-0.253	0.041	
95% CI	(-1.25, 0.75)	(-0.72, 0.80)	
Week 52			
m	6	12	19
n	5	10	16
Baseline Mean (SD)	55.28 (2.70)	56.37 (3.19)	53.86 (7.64)
Analysis Visit Mean (SD)	52.64 (5.86)	54.94 (4.65)	52.43 (9.67)
LS Mean of Change from Baseline (SE)	-2.12 (3.94)	-0.47 (2.93)	-0.65 (3.16)
95% CI	(-10.17, 5.93)	(-6.46, 5.51)	(-7.11, 5.81)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.47 (3.20)	0.18 (2.66)	
95% CI	(-8.01, 5.07)	(-5.25, 5.61)	
p-value	0.6497	0.9475	
Corrected Hedge's g Statistics	-0.118	0.015	
95% CI	(-1.12, 0.89)	(-0.78, 0.80)	
Subgroup*Treatment Interaction p-value	0.5106	NE	

Madrigal Pharmaceuticals, Inc. Page 11 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.3.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Physical Component Score			
Week 24			
m	6	12	20
n	5	11	17
Baseline Mean (SD)	45.90 (9.32)	50.85 (6.79)	52.65 (6.89)
Analysis Visit Mean (SD)	51.88 (8.38)	50.70 (5.74)	49.31 (10.02)
LS Mean of Change from Baseline (SE)	6.64 (4.25)	1.31 (3.07)	-0.90 (3.32)
95% CI	(-2.05, 15.32)	(-4.97, 7.59)	(-7.68, 5.88)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.54 (3.69)	2.21 (2.80)	
95% CI	(-0.01, 15.08)	(-3.51, 7.93)	
p-value	0.0502	0.4364	
Corrected Hedge's g Statistics	0.559	0.172	
95% CI	(-0.45, 1.57)	(-0.59, 0.93)	
Week 52			
m	6	12	19
n	5	10	16
Baseline Mean (SD)	50.52 (5.95)	50.51 (7.06)	52.80 (7.08)
Analysis Visit Mean (SD)	49.32 (8.34)	47.71 (9.01)	51.44 (7.52)
LS Mean of Change from Baseline (SE)	0.72 (3.83)	-1.39 (2.84)	0.73 (3.21)
95% CI	(-7.10, 8.54)	(-7.19, 4.41)	(-5.82, 7.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.01 (2.90)	-2.12 (2.41)	
95% CI	(-5.93, 5.91)	(-7.03, 2.79)	
p-value	0.9965	0.3850	
Corrected Hedge's g Statistics	-0.001	-0.178	
95% CI	(-1.01, 1.00)	(-0.97, 0.61)	
Subgroup*Treatment Interaction p-value	0.5290	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 12 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.3.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Age

(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Physical Functioning			
Week 24			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	87.50 (3.54)	N/A	68.57 (22.68)
Analysis Visit Mean (SD)	77.50 (10.61)	N/A	75.71 (23.53)
LS Mean of Change from Baseline (SE)	-9.43 (9.43)	NE	6.71 (7.57)
95% CI	(-33.67, 14.81)	NE	(-12.75, 26.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	-16.13 (11.06)	NE	
95% CI	(-44.55, 12.29)	NE	
p-value	0.2043	NE	
Corrected Hedge's g Statistics	-0.746	NE	
95% CI	(-2.36, 0.86)	NE	
Week 52			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	87.50 (3.54)	N/A	68.57 (22.68)
Analysis Visit Mean (SD)	82.50 (3.54)	N/A	73.81 (21.83)
LS Mean of Change from Baseline (SE)	-1.96 (9.90)	NE	4.10 (7.72)
95% CI	(-27.41, 23.50)	NE	(-15.75, 23.95)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.06 (11.59)	NE	
95% CI	(-35.86, 23.74)	NE	
p-value	0.6236	NE	
Corrected Hedge's g Statistics	-0.274	NE	
95% CI	(-1.85, 1.30)	NE	
Subgroup*Treatment Interaction p-value	0.5673	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE21.3.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Role Physical			
Week 24			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	87.50 (17.68)	N/A	65.19 (31.43)
Analysis Visit Mean (SD)	87.50 (17.68)	N/A	77.70 (34.00)
LS Mean of Change from Baseline (SE)	0.22 (7.56)	NE	15.70 (5.96)
95% CI	(-19.22, 19.66)	NE	(0.37, 31.02)
LS Mean of Change from Baseline Compared to Placebo (SE)	-15.48 (9.10)	NE	
95% CI	(-38.88, 7.91)	NE	
p-value	0.1496	NE	
Corrected Hedge's g Statistics	-0.908	NE	
95% CI	(-2.53, 0.72)	NE	
Week 52			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	87.50 (17.68)	N/A	65.19 (31.43)
Analysis Visit Mean (SD)	81.25 (26.52)	N/A	66.99 (25.93)
LS Mean of Change from Baseline (SE)	0.91 (14.07)	NE	3.00 (8.56)
95% CI	(-35.27, 37.08)	NE	(-19.00, 25.00)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.10 (16.38)	NE	
95% CI	(-44.22, 40.02)	NE	
p-value	0.9031	NE	
Corrected Hedge's g Statistics	-0.084	NE	
95% CI	(-1.66, 1.49)	NE	
Subgroup*Treatment Interaction p-value	0.5533	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 14 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.3.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Bodily Pain			
Week 24			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	87.0 (18.4)	N/A	66.7 (28.9)
Analysis Visit Mean (SD)	100.0 (0.0)	N/A	72.3 (31.3)
LS Mean of Change from Baseline (SE)	12.24 (5.89)	NE	3.61 (4.21)
95% CI	(-2.90, 27.37)	NE	(-7.22, 14.44)
LS Mean of Change from Baseline Compared to Placebo (SE)	8.63 (6.86)	NE	
95% CI	(-9.00, 26.25)	NE	
p-value	0.2639	NE	
Corrected Hedge's g Statistics	0.711	NE	
95% CI	(-0.89, 2.32)	NE	
Week 52			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	87.0 (18.4)	N/A	66.7 (28.9)
Analysis Visit Mean (SD)	81.0 (26.9)	N/A	69.1 (25.6)
LS Mean of Change from Baseline (SE)	-1.86 (13.56)	NE	-0.93 (7.60)
95% CI	(-36.73, 33.00)	NE	(-20.47, 18.61)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.93 (15.61)	NE	
95% CI	(-41.05, 39.18)	NE	
p-value	0.9547	NE	
Corrected Hedge's g Statistics	-0.041	NE	
95% CI	(-1.61, 1.53)	NE	
Subgroup*Treatment Interaction p-value	0.8539	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 15 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.3.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Age

(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
General Health			
Week 24			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	84.50 (3.54)	N/A	69.57 (21.86)
Analysis Visit Mean (SD)	89.50 (10.61)	N/A	76.71 (16.95)
LS Mean of Change from Baseline (SE)	8.13 (5.83)	NE	6.58 (4.69)
95% CI	(-6.87, 23.13)	NE	(-5.48, 18.65)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.55 (7.29)	NE	
95% CI	(-17.20, 20.30)	NE	
p-value	0.8405	NE	
Corrected Hedge's g Statistics	0.115	NE	
95% CI	(-1.46, 1.69)	NE	
Week 52			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	84.50 (3.54)	N/A	69.57 (21.86)
Analysis Visit Mean (SD)	82.00 (14.14)	N/A	71.00 (16.54)
LS Mean of Change from Baseline (SE)	1.64 (8.05)	NE	0.58 (5.50)
95% CI	(-19.06, 22.33)	NE	(-13.57, 14.73)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.05 (9.68)	NE	
95% CI	(-23.84, 25.95)	NE	
p-value	0.9175	NE	
Corrected Hedge's g Statistics	0.066	NE	
95% CI	(-1.51, 1.64)	NE	
Subgroup*Treatment Interaction p-value	0.4874	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 16 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.3.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Age

(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Vitality			
Week 24			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	75.05 (8.84)	N/A	63.41 (21.47)
Analysis Visit Mean (SD)	78.15 (4.45)	N/A	66.99 (12.36)
LS Mean of Change from Baseline (SE)	9.33 (6.26)	NE	4.29 (5.09)
95% CI	(-6.77, 25.42)	NE	(-8.79, 17.37)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.04 (7.70)	NE	
95% CI	(-14.76, 24.83)	NE	
p-value	0.5420	NE	
Corrected Hedge's g Statistics	0.347	NE	
95% CI	(-1.23, 1.93)	NE	
Week 52			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	75.05 (8.84)	N/A	63.41 (21.47)
Analysis Visit Mean (SD)	71.90 (4.38)	N/A	66.97 (16.43)
LS Mean of Change from Baseline (SE)	2.45 (8.80)	NE	4.46 (6.03)
95% CI	(-20.17, 25.07)	NE	(-11.05, 19.96)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.01 (10.45)	NE	
95% CI	(-28.87, 24.85)	NE	
p-value	0.8552	NE	
Corrected Hedge's g Statistics	-0.115	NE	
95% CI	(-1.69, 1.46)	NE	
Subgroup*Treatment Interaction p-value	0.5248	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 17 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.3.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Social Functioning			
Week 24			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	100.00 (0.00)	N/A	87.50 (27.95)
Analysis Visit Mean (SD)	100.00 (0.00)	N/A	94.64 (9.83)
LS Mean of Change from Baseline (SE)	6.38 (2.77)	NE	4.06 (1.67)
95% CI	(-0.74, 13.50)	NE	(-0.24, 8.36)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.32 (3.24)	NE	
95% CI	(-6.00, 10.64)	NE	
p-value	0.5050	NE	
Corrected Hedge's g Statistics	0.474	NE	
95% CI	(-1.11, 2.06)	NE	
Week 52			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	100.00 (0.00)	N/A	87.50 (27.95)
Analysis Visit Mean (SD)	100.00 (0.00)	N/A	92.86 (14.17)
LS Mean of Change from Baseline (SE)	5.09 (3.35)	NE	2.64 (1.95)
95% CI	(-3.53, 13.70)	NE	(-2.36, 7.65)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.44 (3.89)	NE	
95% CI	(-7.55, 12.43)	NE	
p-value	0.5573	NE	
Corrected Hedge's g Statistics	0.426	NE	
95% CI	(-1.16, 2.01)	NE	
Subgroup*Treatment Interaction p-value	0.2987	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 18 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.3.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Age

(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Role Emotional			
Week 24			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	100.00 (0.00)	N/A	89.29 (19.67)
Analysis Visit Mean (SD)	100.00 (0.00)	N/A	91.66 (15.97)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	100.00 (0.00)	N/A	89.29 (19.67)
Analysis Visit Mean (SD)	100.00 (0.00)	N/A	92.86 (15.55)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.7826	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 19 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.3.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Age

(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Mental Health			
Week 24			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	95.0 (7.1)	N/A	90.0 (10.0)
Analysis Visit Mean (SD)	92.5 (3.5)	N/A	90.7 (8.9)
LS Mean of Change from Baseline (SE)	-1.46 (3.27)	NE	1.13 (2.70)
95% CI	(-9.86, 6.93)	NE	(-5.81, 8.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.60 (4.05)	NE	
95% CI	(-13.00, 7.80)	NE	
p-value	0.5490	NE	
Corrected Hedge's g Statistics	-0.337	NE	
95% CI	(-1.92, 1.24)	NE	
Week 52			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	95.0 (7.1)	N/A	90.0 (10.0)
Analysis Visit Mean (SD)	92.5 (3.5)	N/A	92.1 (12.9)
LS Mean of Change from Baseline (SE)	-3.11 (3.20)	NE	3.03 (2.68)
95% CI	(-11.34, 5.12)	NE	(-3.86, 9.92)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.14 (3.98)	NE	
95% CI	(-16.36, 4.08)	NE	
p-value	0.1830	NE	
Corrected Hedge's g Statistics	-0.805	NE	
95% CI	(-2.42, 0.81)	NE	
Subgroup*Treatment Interaction p-value	0.1752	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 20 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.3.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Age

(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Mental Component Score			
Week 24			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	60.40 (0.99)	N/A	58.10 (6.54)
Analysis Visit Mean (SD)	60.45 (0.35)	N/A	58.43 (2.49)
LS Mean of Change from Baseline (SE)	1.25 (1.30)	NE	-0.46 (0.96)
95% CI	(-2.09, 4.58)	NE	(-2.93, 2.00)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.71 (1.59)	NE	
95% CI	(-2.37, 5.80)	NE	
p-value	0.3302	NE	
Corrected Hedge's g Statistics	0.621	NE	
95% CI	(-0.98, 2.22)	NE	
Week 52			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	60.40 (0.99)	N/A	58.10 (6.54)
Analysis Visit Mean (SD)	60.40 (1.27)	N/A	59.61 (6.00)
LS Mean of Change from Baseline (SE)	0.20 (1.51)	NE	1.01 (1.04)
95% CI	(-3.67, 4.07)	NE	(-1.67, 3.69)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.81 (1.81)	NE	
95% CI	(-5.46, 3.85)	NE	
p-value	0.6742	NE	
Corrected Hedge's g Statistics	-0.268	NE	
95% CI	(-1.84, 1.31)	NE	
Subgroup*Treatment Interaction p-value	0.5106	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 21 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.3.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Age

(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Physical Component Score			
Week 24			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	53.05 (4.88)	N/A	44.09 (10.87)
Analysis Visit Mean (SD)	54.00 (4.81)	N/A	48.13 (11.50)
LS Mean of Change from Baseline (SE)	1.15 (3.73)	NE	4.20 (3.10)
95% CI	(-8.42, 10.73)	NE	(-3.77, 12.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.05 (4.39)	NE	
95% CI	(-14.32, 8.23)	NE	
p-value	0.5181	NE	
Corrected Hedge's g Statistics	-0.345	NE	
95% CI	(-1.92, 1.23)	NE	
Week 52			
m	2	0	7
n	2	0	7
Baseline Mean (SD)	53.05 (4.88)	N/A	44.09 (10.87)
Analysis Visit Mean (SD)	50.65 (8.70)	N/A	45.14 (9.77)
LS Mean of Change from Baseline (SE)	0.47 (6.02)	NE	0.45 (3.94)
95% CI	(-15.01, 15.96)	NE	(-9.66, 10.57)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.02 (7.00)	NE	
95% CI	(-17.98, 18.02)	NE	
p-value	0.9979	NE	
Corrected Hedge's g Statistics	0.002	NE	
95% CI	(-1.57, 1.57)	NE	
Subgroup*Treatment Interaction p-value	0.5290	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE21.3.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis, only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.

AMNOG Table SE21.3.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (16.7)	0	1 (4.8)
No	5 (83.3)	15 (100)	20 (95.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.25	NE	
95% CI of the inverse odds ratio	(0.01, 4.73)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.29	NE	
95% CI of the inverse risk ratio	(0.02, 3.92)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.90	-4.76	
95% CI of the absolute risk difference	(-19.28, 43.08)	(-13.87, 4.35)	
p-value	0.3261	0.3914	
p-value of Breslow-Day Test for Homogeneity [3]	0.2853	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (16.7)	2 (13.3)	6 (28.6)
No	5 (83.3)	13 (86.7)	15 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	2.60	
95% CI of the inverse odds ratio	(0.19, 20.90)	(0.45, 15.18)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.71	2.14	
95% CI of the inverse risk ratio	(0.25, 11.61)	(0.50, 9.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.90	-15.24	
95% CI of the absolute risk difference	(-47.44, 23.63)	(-41.11, 10.63)	
p-value	0.5573	0.2783	
p-value of Breslow-Day Test for Homogeneity [3]	0.1729	NE	

AMNOG Table SE21.3.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (16.7)	0	3 (14.3)
No	5 (83.3)	15 (100)	18 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	5.86	
95% CI of the inverse odds ratio	(0.07, 9.86)	(0.28, 122.49)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	5.09	
95% CI of the inverse risk ratio	(0.11, 6.82)	(0.28, 91.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.38	-12.78	
95% CI of the absolute risk difference	(-30.98, 35.75)	(-30.28, 4.72)	
p-value	0.8849	0.2049	
p-value of Breslow-Day Test for Homogeneity [3]	0.3170	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (33.3)	1 (6.7)	6 (28.6)
No	4 (66.7)	14 (93.3)	15 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	5.60	
95% CI of the inverse odds ratio	(0.11, 5.59)	(0.60, 52.54)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	4.29	
95% CI of the inverse risk ratio	(0.23, 3.20)	(0.57, 32.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.76	-21.90	
95% CI of the absolute risk difference	(-37.62, 47.14)	(-44.98, 1.17)	
p-value	0.8218	0.1016	
p-value of Breslow-Day Test for Homogeneity [3]	0.1873	NE	

AMNOG Table SE21.3.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (4.8)
No	6 (100)	15 (100)	20 (95.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.76	-4.76	
95% CI of the absolute risk difference	(-13.87, 4.35)	(-13.87, 4.35)	
p-value	0.5860	0.3914	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (16.7)	1 (6.7)	2 (9.5)
No	5 (83.3)	14 (93.3)	19 (90.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.53	1.47	
95% CI of the inverse odds ratio	(0.04, 7.05)	(0.12, 17.91)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	1.43	
95% CI of the inverse risk ratio	(0.06, 5.27)	(0.14, 14.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.14	-2.86	
95% CI of the absolute risk difference	(-25.21, 39.50)	(-20.66, 14.95)	
p-value	0.6234	0.7598	
p-value of Breslow-Day Test for Homogeneity [3]	0.0901	NE	

AMNOG Table SE21.3.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (9.5)
No	6 (100)	15 (100)	19 (90.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	3.97	
95% CI of the inverse odds ratio	(0.07, 39.42)	(0.18, 89.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.59	3.64	
95% CI of the inverse risk ratio	(0.09, 29.34)	(0.19, 70.69)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.22	-8.24	
95% CI of the absolute risk difference	(-27.46, 19.01)	(-24.00, 7.53)	
p-value	0.7494	0.3524	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (50.0)	2 (13.3)	5 (23.8)
No	3 (50.0)	13 (86.7)	16 (76.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.31	2.03	
95% CI of the inverse odds ratio	(0.05, 2.07)	(0.34, 12.24)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.48	1.79	
95% CI of the inverse risk ratio	(0.16, 1.44)	(0.40, 8.00)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	26.19	-10.48	
95% CI of the absolute risk difference	(-17.77, 70.15)	(-35.53, 14.58)	
p-value	0.2153	0.4336	
p-value of Breslow-Day Test for Homogeneity [3]	0.3590	NE	

AMNOG Table SE21.3.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (4.8)
No	6 (100)	15 (100)	20 (95.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.76	-4.76	
95% CI of the absolute risk difference	(-13.87, 4.35)	(-13.87, 4.35)	
p-value	0.5860	0.3914	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (16.7)	1 (6.7)	6 (28.6)
No	5 (83.3)	14 (93.3)	15 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	5.60	
95% CI of the inverse odds ratio	(0.19, 20.90)	(0.60, 52.54)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.71	4.29	
95% CI of the inverse risk ratio	(0.25, 11.61)	(0.57, 32.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.90	-21.90	
95% CI of the absolute risk difference	(-47.44, 23.63)	(-44.98, 1.17)	
p-value	0.5573	0.1016	
p-value of Breslow-Day Test for Homogeneity [3]	0.3586	NE	

AMNOG Table SE21.3.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (6.7)	2 (9.5)
No	6 (100)	14 (93.3)	19 (90.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	1.47	
95% CI of the inverse odds ratio	(0.07, 39.42)	(0.12, 17.91)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.59	1.43	
95% CI of the inverse risk ratio	(0.09, 29.34)	(0.14, 14.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.22	-2.86	
95% CI of the absolute risk difference	(-27.46, 19.01)	(-20.66, 14.95)	
p-value	0.7494	0.7598	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	5 (33.3)	2 (9.5)
No	6 (100)	10 (66.7)	19 (90.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	0.21	
95% CI of the inverse odds ratio	(0.07, 39.42)	(0.03, 1.29)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.59	0.29	
95% CI of the inverse risk ratio	(0.09, 29.34)	(0.06, 1.28)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.22	23.81	
95% CI of the absolute risk difference	(-27.46, 19.01)	(-3.15, 50.77)	
p-value	0.7494	0.0752	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE21.3.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (4.8)
No	6 (100)	15 (100)	20 (95.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.76	-4.76	
95% CI of the absolute risk difference	(-13.87, 4.35)	(-13.87, 4.35)	
p-value	0.5860	0.3914	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (16.7)	1 (6.7)	1 (4.8)
No	5 (83.3)	14 (93.3)	20 (95.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.25	0.70	
95% CI of the inverse odds ratio	(0.01, 4.73)	(0.04, 12.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.29	0.71	
95% CI of the inverse risk ratio	(0.02, 3.92)	(0.05, 10.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.90	1.90	
95% CI of the absolute risk difference	(-19.28, 43.08)	(-13.66, 17.47)	
p-value	0.3261	0.8057	
p-value of Breslow-Day Test for Homogeneity [3]	0.1496	NE	

AMNOG Table SE21.3.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (6.7)	3 (14.3)
No	6 (100)	14 (93.3)	18 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.46	2.33	
95% CI of the inverse odds ratio	(0.11, 54.32)	(0.22, 24.92)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.23	2.14	
95% CI of the inverse risk ratio	(0.13, 38.06)	(0.25, 18.66)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.77	-7.62	
95% CI of the absolute risk difference	(-33.21, 15.68)	(-27.20, 11.96)	
p-value	0.5580	0.4733	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (50.0)	2 (13.3)	6 (28.6)
No	3 (50.0)	13 (86.7)	15 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.40	2.60	
95% CI of the inverse odds ratio	(0.06, 2.57)	(0.45, 15.18)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	2.14	
95% CI of the inverse risk ratio	(0.20, 1.63)	(0.50, 9.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	21.43	-15.24	
95% CI of the absolute risk difference	(-23.00, 65.86)	(-41.11, 10.63)	
p-value	0.3261	0.2783	
p-value of Breslow-Day Test for Homogeneity [3]	0.0498	NE	

AMNOG Table SE21.3.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	6 (100)	15 (100)	21 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (13.3)	4 (19.0)
No	6 (100)	13 (86.7)	17 (81.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.34	1.53	
95% CI of the inverse odds ratio	(0.16, 71.10)	(0.24, 9.67)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.86	1.43	
95% CI of the inverse risk ratio	(0.17, 46.87)	(0.30, 6.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-13.31	-5.71	
95% CI of the absolute risk difference	(-38.77, 12.15)	(-29.76, 18.33)	
p-value	0.4167	0.6501	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE21.3.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: < 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	6 (100)	15 (100)	21 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (16.7)	0	2 (9.5)
No	5 (83.3)	15 (100)	19 (90.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.53	3.97	
95% CI of the inverse odds ratio	(0.04, 7.05)	(0.18, 89.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	3.64	
95% CI of the inverse risk ratio	(0.06, 5.27)	(0.19, 70.69)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.14	-8.24	
95% CI of the absolute risk difference	(-25.21, 39.50)	(-24.00, 7.53)	
p-value	0.6234	0.3524	
p-value of Breslow-Day Test for Homogeneity [3]	0.1503	NE	

AMNOG Table SE21.3.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (14.3)
No	3 (100)	0	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.62	NE	
95% CI of the inverse odds ratio	(0.05, 51.11)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	NE	
95% CI of the inverse risk ratio	(0.08, 29.15)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.25	NE	
95% CI of the absolute risk difference	(-48.46, 35.96)	NE	
p-value	0.7842	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2853	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	5 (71.4)
No	3 (100)	0	2 (28.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	15.40	NE	
95% CI of the inverse odds ratio	(0.56, 425.53)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.50	NE	
95% CI of the inverse risk ratio	(0.39, 76.65)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-56.25	NE	
95% CI of the absolute risk difference	(-100.00, -10.62)	NE	
p-value	0.0662	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.1729	NE	

AMNOG Table SE21.3.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (28.6)
No	3 (100)	0	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.18	NE	
95% CI of the inverse odds ratio	(0.12, 87.92)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.50	NE	
95% CI of the inverse risk ratio	(0.15, 40.67)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-18.75	NE	
95% CI of the absolute risk difference	(-64.38, 26.88)	NE	
p-value	0.4795	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3170	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	3 (42.9)
No	3 (100)	0	4 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.44	NE	
95% CI of the inverse odds ratio	(0.21, 144.10)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.50	NE	
95% CI of the inverse risk ratio	(0.23, 52.56)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-31.25	NE	
95% CI of the absolute risk difference	(-78.50, 16.00)	NE	
p-value	0.2790	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.1873	NE	

AMNOG Table SE21.3.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	4 (57.1)
No	3 (100)	0	3 (42.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	9.00	NE	
95% CI of the inverse odds ratio	(0.34, 238.21)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.50	NE	
95% CI of the inverse risk ratio	(0.31, 64.58)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-43.75	NE	
95% CI of the absolute risk difference	(-91.00, 3.50)	NE	
p-value	0.1473	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	4 (57.1)
No	3 (100)	0	3 (42.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	9.00	NE	
95% CI of the inverse odds ratio	(0.34, 238.21)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.50	NE	
95% CI of the inverse risk ratio	(0.31, 64.58)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-43.75	NE	
95% CI of the absolute risk difference	(-91.00, 3.50)	NE	
p-value	0.1473	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.0901	NE	

AMNOG Table SE21.3.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (28.6)
No	3 (100)	0	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.18	NE	
95% CI of the inverse odds ratio	(0.12, 87.92)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.50	NE	
95% CI of the inverse risk ratio	(0.15, 40.67)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-18.75	NE	
95% CI of the absolute risk difference	(-64.38, 26.88)	NE	
p-value	0.4795	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (33.3)	0	3 (42.9)
No	2 (66.7)	0	4 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	NE	
95% CI of the inverse odds ratio	(0.09, 25.39)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	NE	
95% CI of the inverse risk ratio	(0.21, 7.89)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.52	NE	
95% CI of the absolute risk difference	(-74.25, 55.20)	NE	
p-value	0.7782	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3590	NE	

AMNOG Table SE21.3.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (28.6)
No	3 (100)	0	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.18	NE	
95% CI of the inverse odds ratio	(0.12, 87.92)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.50	NE	
95% CI of the inverse risk ratio	(0.15, 40.67)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-18.75	NE	
95% CI of the absolute risk difference	(-64.38, 26.88)	NE	
p-value	0.4795	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	3 (42.9)
No	3 (100)	0	4 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.44	NE	
95% CI of the inverse odds ratio	(0.21, 144.10)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.50	NE	
95% CI of the inverse risk ratio	(0.23, 52.56)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-31.25	NE	
95% CI of the absolute risk difference	(-78.50, 16.00)	NE	
p-value	0.2790	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3586	NE	

AMNOG Table SE21.3.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (14.3)
No	3 (100)	0	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.62	NE	
95% CI of the inverse odds ratio	(0.05, 51.11)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	NE	
95% CI of the inverse risk ratio	(0.08, 29.15)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.25	NE	
95% CI of the absolute risk difference	(-48.46, 35.96)	NE	
p-value	0.7842	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	2 (28.6)
No	3 (100)	0	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.18	NE	
95% CI of the inverse odds ratio	(0.12, 87.92)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.50	NE	
95% CI of the inverse risk ratio	(0.15, 40.67)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-18.75	NE	
95% CI of the absolute risk difference	(-64.38, 26.88)	NE	
p-value	0.4795	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE21.3.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (14.3)
No	3 (100)	0	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.62	NE	
95% CI of the inverse odds ratio	(0.05, 51.11)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	NE	
95% CI of the inverse risk ratio	(0.08, 29.15)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.25	NE	
95% CI of the absolute risk difference	(-48.46, 35.96)	NE	
p-value	0.7842	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	2 (28.6)
No	3 (100)	0	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.18	NE	
95% CI of the inverse odds ratio	(0.12, 87.92)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.50	NE	
95% CI of the inverse risk ratio	(0.15, 40.67)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-18.75	NE	
95% CI of the absolute risk difference	(-64.38, 26.88)	NE	
p-value	0.4795	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.1496	NE	

AMNOG Table SE21.3.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	3 (100)	0	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	4 (57.1)
No	3 (100)	0	3 (42.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	9.00	NE	
95% CI of the inverse odds ratio	(0.34, 238.21)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.50	NE	
95% CI of the inverse risk ratio	(0.31, 64.58)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-43.75	NE	
95% CI of the absolute risk difference	(-91.00, 3.50)	NE	
p-value	0.1473	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.0498	NE	

AMNOG Table SE21.3.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	3 (100)	0	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	2 (28.6)
No	3 (100)	0	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.18	NE	
95% CI of the inverse odds ratio	(0.12, 87.92)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.50	NE	
95% CI of the inverse risk ratio	(0.15, 40.67)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-18.75	NE	
95% CI of the absolute risk difference	(-64.38, 26.88)	NE	
p-value	0.4795	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE21.3.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Age
(Label Population based on Modified Intent-to-Treat Population)

Age: >= 65 years

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (28.6)
No	3 (100)	0	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.18	NE	
95% CI of the inverse odds ratio	(0.12, 87.92)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.50	NE	
95% CI of the inverse risk ratio	(0.15, 40.67)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-18.75	NE	
95% CI of the absolute risk difference	(-64.38, 26.88)	NE	
p-value	0.4795	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	3 (42.9)
No	3 (100)	0	4 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.44	NE	
95% CI of the inverse odds ratio	(0.21, 144.10)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.50	NE	
95% CI of the inverse risk ratio	(0.23, 52.56)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-31.25	NE	
95% CI of the absolute risk difference	(-78.50, 16.00)	NE	
p-value	0.2790	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.1503	NE	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.4.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=8)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=8)	Change from Baseline DB Placebo (N=14)
Physical Functioning						
Baseline						
m	3	8	14			
n	3	8	12			
Mean (SD)	90.00 (8.66)	84.38 (12.08)	77.92 (23.40)			
Median	85.00	87.50	85.00			
IQR: Q1, Q3	85.00, 100.00	75.00, 92.50	72.50, 92.50			
Min, Max	85.0, 100.0	65.0, 100.0	25.0, 100.0			
Week 24						
m	3	7	14			
n	2	7	13	2	7	12
Mean (SD/SE)	85.00 (21.21)	86.43 (9.88)	75.77 (19.77)	-7.50 (7.50)	4.29 (3.17)	-1.67 (4.82)
Median	85.00	85.00	80.00	-7.50	0	0
IQR: Q1, Q3	70.00, 100.00	80.00, 95.00	70.00, 85.00	-15.00, 0.00	0.00, 10.00	-10.00, 7.50
Min, Max	70.0, 100.0	70.0, 100.0	30.0, 100.0	-15.0, 0.0	-5.0, 20.0	-40.0, 25.0
Week 52						
m	3	7	14			
n	3	6	13	3	6	12
Mean (SD/SE)	86.67 (11.55)	76.67 (15.06)	80.77 (21.20)	-3.33 (1.67)	-4.17 (4.55)	1.67 (3.66)
Median	80.00	77.50	85.00	-5.00	-5.00	2.50
IQR: Q1, Q3	80.00, 100.00	75.00, 85.00	70.00, 100.00	-5.00, 0.00	-10.00, 5.00	-7.50, 10.00
Min, Max	80.0, 100.0	50.0, 95.0	35.0, 100.0	-5.0, 0.0	-20.0, 10.0	-20.0, 25.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.4.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=3)	(N=8)	(N=14)	(N=3)	(N=8)	(N=14)
Role Physical						
Baseline						
m	3	8	14			
n	3	8	12			
Mean (SD)	91.67 (14.43)	92.20 (10.96)	73.44 (31.55)			
Median	100.00	96.90	78.15			
IQR: Q1, Q3	75.00, 100.00	84.40, 100.00	68.75, 100.00			
Min, Max	75.0, 100.0	75.0, 100.0	0.0, 100.0			
Week 24						
m	3	7	14			
n	2	7	13	2	7	12
Mean (SD/SE)	87.50 (17.68)	91.10 (11.87)	75.02 (31.24)	0.00 (0.00)	0.01 (1.92)	3.66 (4.52)
Median	87.50	93.80	87.50	0	0	3.15
IQR: Q1, Q3	75.00, 100.00	81.30, 100.00	62.50, 100.00	0.00, 0.00	-6.20, 6.20	0.00, 12.50
Min, Max	75.0, 100.0	68.8, 100.0	6.3, 100.0	0.0, 0.0	-6.2, 6.3	-37.5, 25.0
Week 52						
m	3	7	14			
n	3	6	13	3	6	12
Mean (SD/SE)	83.33 (19.09)	81.27 (23.72)	76.94 (26.67)	-8.33 (4.17)	-9.37 (6.60)	2.62 (6.08)
Median	87.50	87.55	87.50	-12.50	-3.10	3.15
IQR: Q1, Q3	62.50, 100.00	75.00, 100.00	56.30, 100.00	-12.50, 0.00	-18.70, 0.00	-9.35, 18.75
Min, Max	62.5, 100.0	37.5, 100.0	31.3, 100.0	-12.5, 0.0	-37.5, 6.2	-37.5, 31.3

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.4.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Visit Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=8)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=8)	Change from Baseline DB Placebo (N=14)
Bodily Pain						
Baseline						
m	3	8	14			
n	3	8	12			
Mean (SD)	91.3 (15.0)	81.0 (14.9)	74.8 (25.4)			
Median	100.0	84.0	84.0			
IQR: Q1, Q3	74.0, 100.0	67.0, 92.0	62.0, 92.0			
Min, Max	74, 100	62, 100	12, 100			
Week 24						
m	3	7	14			
n	2	7	13	2	7	12
Mean (SD/SE)	100.0 (0.0)	77.7 (19.3)	72.5 (26.7)	13.0 (13.0)	-0.6 (3.3)	-1.3 (2.8)
Median	100.0	84.0	74.0	13.0	0	0
IQR: Q1, Q3	100.0, 100.0	62.0, 100.0	62.0, 100.0	0.0, 26.0	-10.0, 0.0	-5.0, 0.5
Min, Max	100, 100	52, 100	12, 100	0, 26	-10, 16	-21, 16
Week 52						
m	3	7	14			
n	3	6	13	3	6	12
Mean (SD/SE)	76.7 (12.7)	76.3 (15.7)	73.6 (23.5)	-14.7 (1.3)	-1.0 (3.4)	-2.0 (5.0)
Median	84.0	74.0	74.0	-16.0	0	-5.0
IQR: Q1, Q3	62.0, 84.0	74.0, 84.0	52.0, 100.0	-16.0, -12.0	-10.0, 2.0	-15.5, 16.0
Min, Max	62, 84	52, 100	32, 100	-16, -12	-10, 12	-26, 23

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.4.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=8)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=8)	Change from Baseline DB Placebo (N=14)
General Health						
Baseline						
m	3	8	14			
n	3	8	12			
Mean (SD)	75.33 (7.64)	68.25 (11.88)	70.83 (18.37)			
Median	77.00	67.00	72.00			
IQR: Q1, Q3	67.00, 82.00	62.00, 79.50	62.00, 79.50			
Min, Max	67.0, 82.0	47.0, 82.0	25.0, 97.0			
Week 24						
m	3	7	14			
n	2	7	13	2	7	12
Mean (SD/SE)	84.50 (3.54)	67.71 (12.72)	70.15 (17.83)	5.00 (5.00)	-1.43 (5.42)	1.67 (4.14)
Median	84.50	62.00	72.00	5.00	5.00	2.50
IQR: Q1, Q3	82.00, 87.00	57.00, 77.00	67.00, 87.00	0.00, 10.00	-15.00, 10.00	-2.50, 10.00
Min, Max	82.0, 87.0	52.0, 87.0	42.0, 92.0	0.0, 10.0	-25.0, 15.0	-35.0, 20.0
Week 52						
m	3	7	14			
n	3	6	13	3	6	12
Mean (SD/SE)	77.00 (8.66)	67.83 (12.42)	66.69 (16.30)	1.67 (6.01)	0.00 (2.58)	-2.92 (4.06)
Median	72.00	69.50	70.00	5.00	-2.50	-2.50
IQR: Q1, Q3	72.00, 87.00	57.00, 77.00	52.00, 77.00	-10.00, 10.00	-5.00, 5.00	-10.00, 10.00
Min, Max	72.0, 87.0	52.0, 82.0	40.0, 92.0	-10.0, 10.0	-5.0, 10.0	-30.0, 15.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.4.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=8)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=8)	Change from Baseline DB Placebo (N=14)
Vitality						
Baseline						
m	3	8	14			
n	3	8	12			
Mean (SD)	66.70 (9.53)	67.21 (11.46)	65.13 (22.84)			
Median	68.80	65.65	68.80			
IQR: Q1, Q3	56.30, 75.00	59.40, 78.15	46.90, 84.40			
Min, Max	56.3, 75.0	50.0, 81.3	25.0, 100.0			
Week 24						
m	3	7	14			
n	2	7	13	2	7	12
Mean (SD/SE)	68.75 (8.84)	67.00 (17.94)	61.56 (18.55)	-3.15 (9.35)	0.01 (5.95)	-2.08 (4.95)
Median	68.75	68.80	62.50	-3.15	0	-3.10
IQR: Q1, Q3	62.50, 75.00	50.00, 81.30	50.00, 81.30	-12.50, 6.20	-12.50, 0.00	-9.40, 6.20
Min, Max	62.5, 75.0	43.8, 93.8	31.3, 87.5	-12.5, 6.2	-18.7, 31.3	-37.5, 31.3
Week 52						
m	3	7	14			
n	3	6	13	3	6	12
Mean (SD/SE)	58.37 (18.07)	57.32 (15.51)	66.84 (25.82)	-8.33 (5.53)	-7.28 (3.39)	1.55 (4.75)
Median	68.80	59.40	68.80	-6.20	-6.25	0
IQR: Q1, Q3	37.50, 68.80	50.00, 68.80	37.50, 87.50	-18.80, 0.00	-12.50, 0.00	-9.40, 12.50
Min, Max	37.5, 68.8	31.3, 75.0	25.0, 100.0	-18.8, 0.0	-18.7, 0.0	-25.0, 31.2

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.4.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=3)	(N=8)	(N=14)	(N=3)	(N=8)	(N=14)
Social Functioning						
Baseline						
m	3	8	14			
n	3	8	12			
Mean (SD)	100.00 (0.00)	85.94 (20.53)	89.58 (23.13)			
Median	100.00	87.50	100.00			
IQR: Q1, Q3	100.00, 100.00	87.50, 100.00	93.75, 100.00			
Min, Max	100.0, 100.0	37.5, 100.0	25.0, 100.0			
Week 24						
m	3	7	14			
n	2	7	13	2	7	12
Mean (SD/SE)	100.00 (0.00)	91.07 (11.89)	89.42 (17.56)	0.00 (0.00)	7.14 (9.78)	1.04 (5.43)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	100.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 0.00	-12.50, 12.50	0.00, 0.00
Min, Max	100.0, 100.0	75.0, 100.0	50.0, 100.0	0.0, 0.0	-12.5, 62.5	-37.5, 50.0
Week 52						
m	3	7	14			
n	3	6	13	3	6	12
Mean (SD/SE)	100.00 (0.00)	97.92 (5.10)	91.35 (14.78)	0.00 (0.00)	14.58 (10.42)	1.04 (3.59)
Median	100.00	100.00	100.00	0	12.50	0
IQR: Q1, Q3	100.00, 100.00	100.00, 100.00	87.50, 100.00	0.00, 0.00	0.00, 12.50	0.00, 0.00
Min, Max	100.0, 100.0	87.5, 100.0	62.5, 100.0	0.0, 0.0	-12.5, 62.5	-12.5, 37.5

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.4.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter		Visit Result			Change from Baseline		
Visit		DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic		(N=3)	(N=8)	(N=14)	(N=3)	(N=8)	(N=14)
Role Emotional							
Baseline							
	m	3	8	14			
	n	3	8	12			
	Mean (SD)	100.00 (0.00)	98.96 (2.93)	88.89 (20.82)			
	Median	100.00	100.00	100.00			
	IQR: Q1, Q3	100.00, 100.00	100.00, 100.00	87.50, 100.00			
	Min, Max	100.0, 100.0	91.7, 100.0	41.7, 100.0			
Week 24							
	m	3	7	14			
	n	2	7	13	2	7	12
	Mean (SD/SE)	100.00 (0.00)	97.61 (6.31)	82.69 (21.90)	0.00 (0.00)	-1.20 (2.84)	-4.87 (4.29)
	Median	100.00	100.00	100.00	0	0	0
	IQR: Q1, Q3	100.00, 100.00	100.00, 100.00	66.70, 100.00	0.00, 0.00	0.00, 0.00	-4.15, 0.00
	Min, Max	100.0, 100.0	83.3, 100.0	41.7, 100.0	0.0, 0.0	-16.7, 8.3	-50.0, 8.3
Week 52							
	m	3	7	14			
	n	3	6	13	3	6	12
	Mean (SD/SE)	94.43 (9.64)	95.83 (10.21)	88.45 (18.50)	-5.57 (5.57)	-2.78 (4.65)	-1.40 (4.68)
	Median	100.00	100.00	100.00	0	0	0
	IQR: Q1, Q3	83.30, 100.00	100.00, 100.00	75.00, 100.00	-16.70, 0.00	0.00, 0.00	0.00, 0.00
	Min, Max	83.3, 100.0	75.0, 100.0	58.3, 100.0	-16.7, 0.0	-25.0, 8.3	-33.4, 33.3

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.4.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Visit Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=8)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=8)	Change from Baseline DB Placebo (N=14)
Mental Health						
Baseline						
m	3	8	14			
n	3	8	12			
Mean (SD)	86.7 (5.8)	89.4 (5.6)	82.1 (18.0)			
Median	90.0	87.5	92.5			
IQR: Q1, Q3	80.0, 90.0	85.0, 92.5	65.0, 95.0			
Min, Max	80, 90	85, 100	50, 100			
Week 24						
m	3	7	14			
n	2	7	13	2	7	12
Mean (SD/SE)	90.0 (0.0)	88.6 (5.6)	80.4 (18.4)	0.0 (0.0)	0.7 (2.0)	-2.5 (1.4)
Median	90.0	90.0	90.0	0	0	-2.5
IQR: Q1, Q3	90.0, 90.0	85.0, 95.0	65.0, 95.0	0.0, 0.0	-5.0, 5.0	-5.0, 0.0
Min, Max	90, 90	80, 95	45, 100	0, 0	-5, 10	-10, 5
Week 52						
m	3	7	14			
n	3	6	13	3	6	12
Mean (SD/SE)	83.3 (11.5)	79.2 (12.8)	83.1 (18.9)	-3.3 (3.3)	-9.2 (4.2)	0.4 (2.6)
Median	90.0	80.0	90.0	0	-7.5	0
IQR: Q1, Q3	70.0, 90.0	70.0, 90.0	65.0, 100.0	-10.0, 0.0	-15.0, -5.0	-5.0, 5.0
Min, Max	70, 90	60, 95	50, 100	-10, 0	-25, 5	-15, 20

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.4.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=8)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=8)	Change from Baseline DB Placebo (N=14)
Mental Component Score						
Baseline						
m	3	8	14			
n	3	8	12			
Mean (SD)	56.83 (2.95)	56.83 (2.55)	54.92 (8.54)			
Median	57.00	57.00	59.30			
IQR: Q1, Q3	53.80, 59.70	55.40, 58.25	48.40, 61.70			
Min, Max	53.8, 59.7	52.4, 60.9	38.1, 63.2			
Week 24						
m	3	7	14			
n	2	7	13	2	7	12
Mean (SD/SE)	58.10 (3.68)	56.91 (2.87)	53.16 (8.81)	-0.25 (1.25)	0.40 (1.39)	-1.61 (1.37)
Median	58.10	57.30	57.60	-0.25	-0.30	-1.60
IQR: Q1, Q3	55.50, 60.70	55.10, 59.60	46.50, 59.10	-1.50, 1.00	-1.30, 4.90	-4.90, -0.60
Min, Max	55.5, 60.7	52.1, 60.8	37.1, 62.8	-1.5, 1.0	-5.0, 5.4	-8.1, 10.8
Week 52						
m	3	7	14			
n	3	6	13	3	6	12
Mean (SD/SE)	55.30 (6.94)	55.18 (6.06)	55.13 (9.32)	-1.53 (2.34)	-1.27 (2.29)	-0.03 (1.53)
Median	56.90	57.80	60.00	-0.10	0.05	0.65
IQR: Q1, Q3	47.70, 61.30	52.60, 59.30	46.60, 61.50	-6.10, 1.60	-2.80, 2.10	-1.20, 2.85
Min, Max	47.7, 61.3	44.0, 59.6	37.9, 65.5	-6.1, 1.6	-11.4, 4.4	-12.8, 7.2

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.4.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=3)	(N=8)	(N=14)	(N=3)	(N=8)	(N=14)
Physical Component Score						
Baseline						
m	3	8	14			
n	3	8	12			
Mean (SD)	54.30 (4.29)	51.09 (5.36)	48.78 (10.42)			
Median	55.30	53.30	51.05			
IQR: Q1, Q3	49.60, 58.00	47.50, 54.60	44.70, 55.35			
Min, Max	49.6, 58.0	41.8, 56.1	21.6, 59.8			
Week 24						
m	3	7	14			
n	2	7	13	2	7	12
Mean (SD/SE)	54.80 (5.94)	50.97 (5.18)	48.91 (9.84)	1.00 (0.00)	0.44 (1.34)	0.86 (1.47)
Median	54.80	50.90	53.20	1.00	0.50	0.40
IQR: Q1, Q3	50.60, 59.00	48.50, 55.50	44.50, 54.40	1.00, 1.00	-3.30, 4.20	-2.65, 3.00
Min, Max	50.6, 59.0	42.3, 58.0	24.6, 59.3	1.0, 1.0	-4.5, 4.9	-6.6, 11.8
Week 52						
m	3	7	14			
n	3	6	13	3	6	12
Mean (SD/SE)	51.73 (6.48)	49.08 (8.71)	49.00 (9.18)	-2.57 (1.28)	-0.83 (1.70)	0.09 (2.10)
Median	53.70	50.70	50.50	-1.60	0.40	0.85
IQR: Q1, Q3	44.50, 57.00	46.60, 55.00	42.80, 56.30	-5.10, -1.00	-2.30, 2.00	-7.00, 5.60
Min, Max	44.5, 57.0	33.4, 58.1	31.5, 58.9	-5.1, -1.0	-8.4, 2.9	-10.8, 10.1

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.4.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=7)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=7)	Change from Baseline DB Placebo (N=14)
Physical Functioning						
Baseline						
m	6	7	14			
n	6	6	14			
Mean (SD)	65.83 (24.58)	72.50 (25.25)	82.50 (20.07)			
Median	72.50	72.50	95.00			
IQR: Q1, Q3	60.00, 80.00	50.00, 100.00	70.00, 95.00			
Min, Max	20.0, 90.0	40.0, 100.0	35.0, 100.0			
Week 24						
m	5	5	13			
n	5	4	12	5	4	12
Mean (SD/SE)	83.00 (22.53)	78.75 (24.96)	77.08 (29.81)	16.00 (6.20)	-1.25 (2.39)	-7.92 (8.67)
Median	85.00	85.00	92.50	20.00	-2.50	0
IQR: Q1, Q3	85.00, 100.00	60.00, 97.50	65.00, 100.00	10.00, 25.00	-5.00, 2.50	-7.50, 5.00
Min, Max	45.0, 100.0	45.0, 100.0	20.0, 100.0	-5.0, 30.0	-5.0, 5.0	-75.0, 35.0
Week 52						
m	5	5	12			
n	4	4	11	4	4	11
Mean (SD/SE)	73.75 (17.97)	71.25 (30.65)	82.88 (24.62)	-5.00 (10.21)	-8.75 (7.18)	-3.03 (6.78)
Median	77.50	72.50	95.00	-5.00	-2.50	0
IQR: Q1, Q3	60.00, 87.50	45.00, 97.50	66.70, 100.00	-17.50, 7.50	-17.50, 0.00	-5.00, 5.00
Min, Max	50.0, 90.0	40.0, 100.0	20.0, 100.0	-30.0, 20.0	-30.0, 0.0	-60.0, 30.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.4.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=7)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=7)	Change from Baseline DB Placebo (N=14)
Role Physical						
Baseline						
m	6	7	14			
n	6	6	14			
Mean (SD)	76.05 (16.96)	85.43 (17.07)	84.84 (16.39)			
Median	75.00	90.65	87.50			
IQR: Q1, Q3	68.80, 87.50	68.80, 100.00	68.80, 100.00			
Min, Max	50.0, 100.0	62.5, 100.0	50.0, 100.0			
Week 24						
m	5	5	13			
n	5	4	12	5	4	12
Mean (SD/SE)	86.26 (19.94)	79.70 (23.58)	77.08 (31.00)	5.00 (7.23)	-10.93 (10.93)	-6.78 (8.92)
Median	100.00	81.25	93.75	6.20	0	0
IQR: Q1, Q3	75.00, 100.00	59.40, 100.00	62.50, 100.00	0.00, 12.50	-21.85, 0.00	-12.50, 12.50
Min, Max	56.3, 100.0	56.3, 100.0	12.5, 100.0	-18.7, 25.0	-43.7, 0.0	-75.0, 31.2
Week 52						
m	5	5	12			
n	4	4	11	4	4	11
Mean (SD/SE)	84.38 (18.75)	68.75 (36.08)	77.85 (25.52)	1.55 (10.32)	-21.88 (14.77)	-5.69 (6.27)
Median	87.50	68.75	75.00	3.10	-12.50	0
IQR: Q1, Q3	68.75, 100.00	37.50, 100.00	56.30, 100.00	-12.50, 15.60	-43.75, 0.00	-25.00, 6.20
Min, Max	62.5, 100.0	37.5, 100.0	25.0, 100.0	-25.0, 25.0	-62.5, 0.0	-43.8, 25.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.4.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=7)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=7)	Change from Baseline DB Placebo (N=14)
Bodily Pain						
Baseline						
m	6	7	14			
n	6	6	14			
Mean (SD)	65.3 (23.9)	74.8 (22.8)	78.7 (17.2)			
Median	62.0	73.0	84.0			
IQR: Q1, Q3	52.0, 84.0	52.0, 100.0	62.0, 84.0			
Min, Max	32, 100	51, 100	41, 100			
Week 24						
m	5	5	13			
n	5	4	12	5	4	12
Mean (SD/SE)	79.4 (22.2)	79.5 (15.2)	75.9 (24.0)	13.4 (3.9)	-7.0 (11.3)	-2.9 (6.3)
Median	84.0	77.0	79.0	16.0	-5.0	0
IQR: Q1, Q3	62.0, 100.0	69.0, 90.0	61.5, 100.0	10.0, 19.0	-23.0, 9.0	0.0, 11.5
Min, Max	51, 100	64, 100	31, 100	0, 22	-36, 18	-53, 16
Week 52						
m	5	5	12			
n	4	4	11	4	4	11
Mean (SD/SE)	61.5 (31.8)	74.5 (17.9)	76.0 (16.5)	-5.5 (6.8)	-12.0 (7.0)	-2.4 (3.8)
Median	62.0	68.0	74.0	-5.0	-11.0	0
IQR: Q1, Q3	42.0, 81.0	62.0, 87.0	62.0, 84.0	-16.0, 5.0	-24.0, 0.0	-10.0, 0.0
Min, Max	22, 100	62, 100	52, 100	-22, 10	-26, 0	-28, 21

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.4.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Visit Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=7)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=7)	Change from Baseline DB Placebo (N=14)
General Health						
Baseline						
m	6	7	14			
n	6	6	14			
Mean (SD)	64.17 (22.98)	66.67 (11.52)	68.93 (20.53)			
Median	67.00	69.50	74.50			
IQR: Q1, Q3	57.00, 82.00	57.00, 72.00	62.00, 82.00			
Min, Max	25.0, 87.0	50.0, 82.0	25.0, 92.0			
Week 24						
m	5	5	13			
n	5	4	12	5	4	12
Mean (SD/SE)	70.60 (28.50)	61.50 (19.69)	64.00 (20.83)	5.00 (4.47)	-3.75 (8.20)	-7.50 (4.28)
Median	72.00	57.00	72.00	10.00	1.00	-7.50
IQR: Q1, Q3	67.00, 92.00	46.00, 77.00	42.50, 79.50	0.00, 10.00	-15.00, 7.50	-17.50, 5.00
Min, Max	25.0, 97.0	45.0, 87.0	30.0, 92.0	-10.0, 15.0	-27.0, 10.0	-30.0, 15.0
Week 52						
m	5	5	12			
n	4	4	11	4	4	11
Mean (SD/SE)	79.00 (17.49)	56.50 (18.19)	67.59 (23.95)	3.25 (2.69)	-8.75 (6.37)	-4.05 (6.52)
Median	84.50	51.00	72.00	2.50	-4.00	0
IQR: Q1, Q3	66.00, 92.00	43.50, 69.50	52.00, 87.50	-1.00, 7.50	-17.50, 0.00	-10.00, 10.00
Min, Max	55.0, 92.0	42.0, 82.0	15.0, 97.0	-2.0, 10.0	-27.0, 0.0	-57.0, 25.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.4.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=7)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=7)	Change from Baseline DB Placebo (N=14)
Vitality						
Baseline						
m	6	7	14			
n	6	6	14			
Mean (SD)	52.12 (28.43)	68.78 (16.30)	66.98 (14.80)			
Median	59.40	68.80	62.50			
IQR: Q1, Q3	43.80, 68.80	62.50, 75.00	56.30, 75.00			
Min, Max	0.0, 81.3	43.8, 93.8	43.8, 93.8			
Week 24						
m	5	5	13			
n	5	4	12	5	4	12
Mean (SD/SE)	48.78 (35.77)	65.65 (8.06)	64.60 (23.73)	-2.50 (5.08)	-1.58 (10.02)	-3.13 (4.90)
Median	56.30	65.65	75.00	0	6.25	0
IQR: Q1, Q3	25.00, 81.30	59.40, 71.90	56.30, 75.00	-6.20, 0.00	-12.55, 9.40	-6.30, 9.40
Min, Max	0.0, 81.3	56.3, 75.0	6.3, 93.8	-18.8, 12.5	-31.3, 12.5	-50.0, 12.5
Week 52						
m	5	5	12			
n	4	4	11	4	4	11
Mean (SD/SE)	56.28 (26.49)	64.10 (17.20)	65.35 (17.76)	-7.83 (6.43)	-3.13 (4.02)	-4.55 (5.40)
Median	65.65	65.65	68.80	-6.25	-3.10	-6.20
IQR: Q1, Q3	37.55, 75.00	50.05, 78.15	62.50, 75.00	-15.65, 0.00	-9.35, 3.10	-18.70, 12.50
Min, Max	18.8, 75.0	43.8, 81.3	25.0, 87.5	-25.0, 6.2	-12.5, 6.2	-37.5, 25.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.4.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=7)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=7)	Change from Baseline DB Placebo (N=14)
Social Functioning						
Baseline						
m	6	7	14			
n	6	6	14			
Mean (SD)	85.42 (16.61)	91.67 (10.21)	93.75 (9.49)			
Median	87.50	93.75	100.00			
IQR: Q1, Q3	75.00, 100.00	87.50, 100.00	87.50, 100.00			
Min, Max	62.5, 100.0	75.0, 100.0	75.0, 100.0			
Week 24						
m	5	5	13			
n	5	4	12	5	4	12
Mean (SD/SE)	77.50 (22.36)	90.63 (11.97)	84.38 (29.25)	-10.00 (4.68)	-6.25 (8.07)	-10.42 (8.26)
Median	75.00	93.75	100.00	-12.50	-6.25	0
IQR: Q1, Q3	62.50, 100.00	81.25, 100.00	81.25, 100.00	-12.50, 0.00	-18.75, 6.25	-6.25, 0.00
Min, Max	50.0, 100.0	75.0, 100.0	0.0, 100.0	-25.0, 0.0	-25.0, 12.5	-100.0, 0.0
Week 52						
m	5	5	12			
n	4	4	11	4	4	11
Mean (SD/SE)	81.25 (21.65)	84.38 (11.97)	96.59 (11.31)	-12.50 (8.84)	-12.50 (8.84)	2.27 (5.01)
Median	81.25	81.25	100.00	-6.25	-18.75	0
IQR: Q1, Q3	62.50, 100.00	75.00, 93.75	100.00, 100.00	-25.00, 0.00	-25.00, 0.00	0.00, 12.50
Min, Max	62.5, 100.0	75.0, 100.0	62.5, 100.0	-37.5, 0.0	-25.0, 12.5	-37.5, 25.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.4.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=7)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=7)	Change from Baseline DB Placebo (N=14)
Role Emotional						
Baseline						
m	6	7	14			
n	6	6	14			
Mean (SD)	87.52 (18.82)	93.05 (11.08)	91.07 (13.26)			
Median	91.70	100.00	100.00			
IQR: Q1, Q3	91.70, 100.00	83.30, 100.00	83.30, 100.00			
Min, Max	50.0, 100.0	75.0, 100.0	66.7, 100.0			
Week 24						
m	5	5	13			
n	5	4	12	5	4	12
Mean (SD/SE)	85.00 (14.90)	81.25 (23.94)	88.19 (18.27)	-10.02 (7.16)	-14.58 (14.59)	-2.78 (2.58)
Median	83.30	87.50	100.00	-8.40	-12.50	0
IQR: Q1, Q3	75.00, 100.00	62.50, 100.00	83.30, 100.00	-16.70, 0.00	-37.50, 8.35	0.00, 0.00
Min, Max	66.7, 100.0	50.0, 100.0	41.7, 100.0	-33.3, 8.3	-50.0, 16.7	-25.0, 8.3
Week 52						
m	5	5	12			
n	4	4	11	4	4	11
Mean (SD/SE)	87.50 (15.95)	83.33 (23.57)	83.34 (24.16)	-6.28 (7.11)	-12.50 (12.50)	-6.82 (5.49)
Median	91.65	91.65	91.70	-4.20	0	0
IQR: Q1, Q3	75.00, 100.00	66.65, 100.00	66.70, 100.00	-16.70, 4.15	-25.00, 0.00	-8.30, 0.00
Min, Max	66.7, 100.0	50.0, 100.0	25.0, 100.0	-25.0, 8.3	-50.0, 0.0	-41.7, 16.7

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.4.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Visit Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=7)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=7)	Change from Baseline DB Placebo (N=14)
Mental Health						
Baseline						
m	6	7	14			
n	6	6	14			
Mean (SD)	78.3 (14.4)	80.8 (7.4)	83.9 (11.8)			
Median	75.0	82.5	85.0			
IQR: Q1, Q3	70.0, 90.0	75.0, 85.0	80.0, 95.0			
Min, Max	60, 100	70, 90	60, 100			
Week 24						
m	5	5	13			
n	5	4	12	5	4	12
Mean (SD/SE)	85.0 (14.1)	78.8 (18.9)	84.2 (16.4)	3.0 (4.1)	-5.0 (12.4)	0.4 (2.6)
Median	90.0	80.0	90.0	0	-5.0	0
IQR: Q1, Q3	70.0, 95.0	65.0, 92.5	80.0, 95.0	-5.0, 10.0	-22.5, 12.5	-2.5, 5.0
Min, Max	70, 100	55, 100	50, 100	-5, 15	-35, 25	-20, 15
Week 52						
m	5	5	12			
n	4	4	11	4	4	11
Mean (SD/SE)	87.5 (8.7)	83.8 (4.8)	83.2 (19.8)	2.5 (2.5)	0.0 (5.0)	-0.9 (5.0)
Median	87.5	82.5	85.0	5.0	-5.0	0
IQR: Q1, Q3	80.0, 95.0	80.0, 87.5	80.0, 95.0	0.0, 5.0	-5.0, 5.0	-5.0, 5.0
Min, Max	80, 95	80, 90	30, 100	-5, 5	-5, 15	-40, 25

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.4.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=7)	Visit Result DB Placebo (N=14)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=7)	Change from Baseline DB Placebo (N=14)
Mental Component Score						
Baseline						
m	6	7	14			
n	6	6	14			
Mean (SD)	53.18 (6.61)	55.97 (3.51)	55.40 (5.73)			
Median	53.20	56.35	56.80			
IQR: Q1, Q3	49.50, 59.20	53.30, 57.80	53.70, 59.20			
Min, Max	42.9, 61.1	51.1, 60.9	44.5, 62.9			
Week 24						
m	5	5	13			
n	5	4	12	5	4	12
Mean (SD/SE)	50.66 (9.88)	52.40 (9.59)	54.63 (7.20)	-4.58 (2.64)	-3.85 (6.28)	-0.70 (0.92)
Median	51.90	53.90	57.75	-1.20	-1.85	-0.20
IQR: Q1, Q3	41.10, 60.20	44.55, 60.25	50.85, 59.05	-9.60, -0.90	-13.50, 5.80	-3.30, 1.05
Min, Max	39.9, 60.2	40.8, 61.0	40.1, 61.7	-12.2, 1.0	-20.1, 8.4	-6.7, 4.0
Week 52						
m	5	5	12			
n	4	4	11	4	4	11
Mean (SD/SE)	54.53 (6.53)	54.58 (1.84)	54.33 (9.13)	-2.15 (1.50)	-1.68 (2.83)	-1.08 (2.16)
Median	55.05	54.10	56.30	-2.05	-2.40	-0.10
IQR: Q1, Q3	49.00, 60.05	53.15, 56.00	51.80, 60.90	-4.20, -0.10	-5.30, 1.95	-4.10, 4.30
Min, Max	47.4, 60.6	53.1, 57.0	35.3, 65.3	-5.9, 1.4	-7.8, 5.9	-16.0, 8.7

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.4.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=6)	(N=7)	(N=14)	(N=6)	(N=7)	(N=14)
Physical Component Score						
Baseline						
m	6	7	14			
n	6	6	14			
Mean (SD)	45.53 (7.92)	48.80 (8.47)	50.88 (7.11)			
Median	45.65	48.75	51.15			
IQR: Q1, Q3	44.10, 49.10	42.80, 54.40	45.80, 56.90			
Min, Max	32.2, 56.5	37.8, 60.3	34.5, 61.1			
Week 24						
m	5	5	13			
n	5	4	12	5	4	12
Mean (SD/SE)	51.56 (8.06)	50.23 (7.45)	48.28 (10.94)	5.96 (2.05)	-1.18 (2.06)	-3.23 (3.06)
Median	54.80	51.00	51.50	7.20	-0.70	0.70
IQR: Q1, Q3	47.50, 57.40	44.45, 56.00	39.35, 56.55	1.40, 9.60	-4.35, 2.00	-7.65, 2.85
Min, Max	39.4, 58.7	40.9, 58.0	25.9, 61.0	0.9, 10.7	-6.4, 3.1	-30.0, 6.9
Week 52						
m	5	5	12			
n	4	4	11	4	4	11
Mean (SD/SE)	48.18 (9.15)	45.65 (10.38)	50.23 (7.72)	-0.78 (2.63)	-5.75 (3.05)	-1.41 (1.99)
Median	50.10	44.35	52.80	0.85	-3.25	0.10
IQR: Q1, Q3	41.60, 54.75	37.45, 53.85	42.50, 54.90	-4.05, 2.50	-9.40, -2.10	-4.30, 1.40
Min, Max	35.7, 56.8	35.3, 58.6	34.3, 58.3	-8.4, 3.6	-14.8, -1.7	-15.9, 8.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.4.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Sex
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

Madrigal Pharmaceuticals, Inc. Page 2 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.4.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Sex

(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Physical Functioning			
Week 24			
m	3	7	14
n	2	7	12
Baseline Mean (SD)	92.50 (10.61)	82.14 (11.13)	77.92 (23.40)
Analysis Visit Mean (SD)	85.00 (21.21)	86.43 (9.88)	76.25 (20.57)
LS Mean of Change from Baseline (SE)	-4.64 (10.37)	4.21 (5.74)	-3.17 (5.31)
95% CI	(-26.43, 17.14)	(-7.85, 16.27)	(-14.34, 7.99)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.47 (10.17)	7.38 (6.41)	
95% CI	(-22.84, 19.90)	(-6.09, 20.85)	
p-value	0.8868	0.2646	
Corrected Hedge's g Statistics	-0.076	0.407	
95% CI	(-1.57, 1.42)	(-0.53, 1.35)	
Week 52			
m	3	7	14
n	3	6	12
Baseline Mean (SD)	90.00 (8.66)	80.83 (11.58)	77.92 (23.40)
Analysis Visit Mean (SD)	86.67 (11.55)	76.67 (15.06)	79.58 (21.69)
LS Mean of Change from Baseline (SE)	-2.18 (8.40)	-5.01 (5.49)	0.56 (5.02)
95% CI	(-19.83, 15.47)	(-16.55, 6.53)	(-9.99, 11.11)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.74 (7.83)	-5.57 (5.95)	
95% CI	(-19.19, 13.71)	(-18.07, 6.94)	
p-value	0.7306	0.3618	
Corrected Hedge's g Statistics	-0.152	-0.326	
95% CI	(-1.42, 1.11)	(-1.31, 0.66)	
Subgroup*Treatment Interaction p-value	0.8489	0.8620	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 3 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.4.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Role Physical			
Week 24			
m	3	7	14
n	2	7	12
Baseline Mean (SD)	87.50 (17.68)	91.09 (11.33)	73.44 (31.55)
Analysis Visit Mean (SD)	87.50 (17.68)	91.10 (11.87)	77.10 (31.67)
LS Mean of Change from Baseline (SE)	5.36 (9.66)	4.22 (5.65)	7.19 (5.15)
95% CI	(-14.93, 25.65)	(-7.64, 16.09)	(-3.62, 18.00)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.83 (9.45)	-2.97 (6.17)	
95% CI	(-21.69, 18.02)	(-15.93, 9.99)	
p-value	0.8483	0.6357	
Corrected Hedge's g Statistics	-0.098	-0.168	
95% CI	(-1.60, 1.40)	(-1.10, 0.77)	
Week 52			
m	3	7	14
n	3	6	12
Baseline Mean (SD)	91.67 (14.43)	90.63 (12.35)	73.44 (31.55)
Analysis Visit Mean (SD)	83.33 (19.09)	81.27 (23.72)	76.06 (27.65)
LS Mean of Change from Baseline (SE)	0.53 (11.83)	-3.45 (8.27)	5.03 (6.59)
95% CI	(-24.32, 25.39)	(-20.83, 13.92)	(-8.81, 18.88)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.50 (12.35)	-8.49 (9.69)	
95% CI	(-30.44, 21.43)	(-28.84, 11.87)	
p-value	0.7195	0.3927	
Corrected Hedge's g Statistics	-0.189	-0.366	
95% CI	(-1.46, 1.08)	(-1.35, 0.62)	
Subgroup*Treatment Interaction p-value	0.4089	0.7545	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 4 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.4.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Bodily Pain			
Week 24			
m	3	7	14
n	2	7	12
Baseline Mean (SD)	87.0 (18.4)	78.3 (13.8)	74.8 (25.4)
Analysis Visit Mean (SD)	100.0 (0.0)	77.7 (19.3)	73.4 (27.7)
LS Mean of Change from Baseline (SE)	14.50 (8.53)	-0.21 (4.80)	0.57 (4.67)
95% CI	(-3.41, 32.41)	(-10.29, 9.87)	(-9.24, 10.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	13.92 (7.85)	-0.79 (5.01)	
95% CI	(-2.58, 30.42)	(-11.30, 9.73)	
p-value	0.0932	0.8770	
Corrected Hedge's g Statistics	0.821	-0.050	
95% CI	(-0.71, 2.35)	(-0.98, 0.88)	
Week 52			
m	3	7	14
n	3	6	12
Baseline Mean (SD)	91.3 (15.0)	77.3 (14.8)	74.8 (25.4)
Analysis Visit Mean (SD)	76.7 (12.7)	76.3 (15.7)	72.8 (24.3)
LS Mean of Change from Baseline (SE)	-8.95 (9.69)	-0.44 (6.26)	-0.80 (5.41)
95% CI	(-29.30, 11.40)	(-13.59, 12.71)	(-12.17, 10.56)
LS Mean of Change from Baseline Compared to Placebo (SE)	-8.15 (9.39)	0.36 (6.99)	
95% CI	(-27.88, 11.58)	(-14.32, 15.05)	
p-value	0.3969	0.9593	
Corrected Hedge's g Statistics	-0.416	0.019	
95% CI	(-1.69, 0.86)	(-0.96, 1.00)	
Subgroup*Treatment Interaction p-value	0.8503	0.4523	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 5 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.4.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
General Health			
Week 24			
m	3	7	14
n	2	7	12
Baseline Mean (SD)	79.50 (3.54)	69.14 (12.54)	70.83 (18.37)
Analysis Visit Mean (SD)	84.50 (3.54)	67.71 (12.72)	72.50 (16.39)
LS Mean of Change from Baseline (SE)	8.94 (9.78)	-2.22 (5.57)	1.57 (5.23)
95% CI	(-11.61, 29.49)	(-13.92, 9.48)	(-9.42, 12.56)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.37 (9.53)	-3.79 (6.24)	
95% CI	(-12.65, 27.39)	(-16.91, 9.33)	
p-value	0.4492	0.5512	
Corrected Hedge's g Statistics	0.388	-0.213	
95% CI	(-1.12, 1.89)	(-1.15, 0.72)	
Week 52			
m	3	7	14
n	3	6	12
Baseline Mean (SD)	75.33 (7.64)	67.83 (13.20)	70.83 (18.37)
Analysis Visit Mean (SD)	77.00 (8.66)	67.83 (12.42)	67.92 (16.38)
LS Mean of Change from Baseline (SE)	3.23 (7.95)	-1.84 (5.30)	-3.01 (4.95)
95% CI	(-13.47, 19.92)	(-12.98, 9.29)	(-13.41, 7.38)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.24 (7.36)	1.17 (5.78)	
95% CI	(-9.23, 21.70)	(-10.97, 13.30)	
p-value	0.4081	0.8421	
Corrected Hedge's g Statistics	0.352	0.070	
95% CI	(-0.92, 1.62)	(-0.91, 1.05)	
Subgroup*Treatment Interaction p-value	0.7508	0.8916	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 6 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.4.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Vitality			
Week 24			
m	3	7	14
n	2	7	12
Baseline Mean (SD)	71.90 (4.38)	66.99 (12.36)	65.13 (22.84)
Analysis Visit Mean (SD)	68.75 (8.84)	67.00 (17.94)	63.04 (18.56)
LS Mean of Change from Baseline (SE)	-6.80 (11.88)	-0.97 (6.96)	-5.06 (6.62)
95% CI	(-31.77, 18.17)	(-15.60, 13.66)	(-18.97, 8.85)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.74 (11.41)	4.09 (7.61)	
95% CI	(-25.71, 22.24)	(-11.89, 20.07)	
p-value	0.8806	0.5976	
Corrected Hedge's g Statistics	-0.072	0.182	
95% CI	(-1.57, 1.42)	(-0.75, 1.12)	
Week 52			
m	3	7	14
n	3	6	12
Baseline Mean (SD)	66.70 (9.53)	64.60 (11.64)	65.13 (22.84)
Analysis Visit Mean (SD)	58.37 (18.07)	57.32 (15.51)	66.68 (26.97)
LS Mean of Change from Baseline (SE)	-11.45 (10.17)	-9.43 (6.81)	-1.16 (6.41)
95% CI	(-32.81, 9.91)	(-23.74, 4.89)	(-14.63, 12.31)
LS Mean of Change from Baseline Compared to Placebo (SE)	-10.29 (9.39)	-8.26 (7.31)	
95% CI	(-30.01, 9.43)	(-23.63, 7.11)	
p-value	0.2874	0.2736	
Corrected Hedge's g Statistics	-0.449	-0.381	
95% CI	(-1.72, 0.83)	(-1.37, 0.61)	
Subgroup*Treatment Interaction p-value	0.7482	0.6276	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 7 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.4.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Social Functioning			
Week 24			
m	3	7	14
n	2	7	12
Baseline Mean (SD)	100.00 (0.00)	83.93 (21.30)	89.58 (23.13)
Analysis Visit Mean (SD)	100.00 (0.00)	91.07 (11.89)	90.63 (17.78)
LS Mean of Change from Baseline (SE)	2.81 (10.70)	1.84 (6.09)	-2.37 (5.50)
95% CI	(-19.67, 25.30)	(-10.96, 14.64)	(-13.94, 9.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.19 (10.60)	4.21 (7.15)	
95% CI	(-17.07, 27.45)	(-10.81, 19.23)	
p-value	0.6303	0.5630	
Corrected Hedge's g Statistics	0.259	0.223	
95% CI	(-1.24, 1.76)	(-0.71, 1.16)	
Week 52			
m	3	7	14
n	3	6	12
Baseline Mean (SD)	100.00 (0.00)	83.33 (23.27)	89.58 (23.13)
Analysis Visit Mean (SD)	100.00 (0.00)	97.92 (5.10)	90.63 (15.19)
LS Mean of Change from Baseline (SE)	1.99 (7.17)	8.83 (4.50)	-2.42 (4.49)
95% CI	(-13.07, 17.05)	(-0.63, 18.28)	(-11.84, 7.01)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.41 (6.25)	11.24 (4.90)	
95% CI	(-8.72, 17.53)	(0.95, 21.53)	
p-value	0.4899	0.0339	
Corrected Hedge's g Statistics	0.275	0.750	
95% CI	(-0.99, 1.54)	(-0.26, 1.76)	
Subgroup*Treatment Interaction p-value	0.0831	0.0450	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 8 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.4.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Role Emotional			
Week 24			
m	3	7	14
n	2	7	12
Baseline Mean (SD)	100.00 (0.00)	98.81 (3.14)	88.89 (20.82)
Analysis Visit Mean (SD)	100.00 (0.00)	97.61 (6.31)	84.03 (22.32)
LS Mean of Change from Baseline (SE)	2.25 (10.17)	1.14 (5.77)	-5.12 (5.12)
95% CI	(-19.11, 23.62)	(-10.98, 13.25)	(-15.87, 5.64)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.37 (10.26)	6.25 (6.59)	
95% CI	(-14.19, 28.93)	(-7.58, 20.09)	
p-value	0.4819	0.3550	
Corrected Hedge's g Statistics	0.395	0.353	
95% CI	(-1.11, 1.90)	(-0.59, 1.29)	
Week 52			
m	3	7	14
n	3	6	12
Baseline Mean (SD)	100.00 (0.00)	98.62 (3.39)	88.89 (20.82)
Analysis Visit Mean (SD)	94.43 (9.64)	95.83 (10.21)	87.49 (18.98)
LS Mean of Change from Baseline (SE)	-2.16 (8.59)	0.32 (5.91)	-2.56 (5.03)
95% CI	(-20.20, 15.89)	(-12.11, 12.74)	(-13.12, 7.99)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.41 (8.50)	2.88 (6.64)	
95% CI	(-17.45, 18.26)	(-11.08, 16.84)	
p-value	0.9623	0.6697	
Corrected Hedge's g Statistics	0.022	0.166	
95% CI	(-1.24, 1.29)	(-0.82, 1.15)	
Subgroup*Treatment Interaction p-value	0.3500	0.2175	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 9 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.4.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Mental Health			
Week 24			
m	3	7	14
n	2	7	12
Baseline Mean (SD)	90.0 (0.0)	87.9 (3.9)	82.1 (18.0)
Analysis Visit Mean (SD)	90.0 (0.0)	88.6 (5.6)	79.6 (19.0)
LS Mean of Change from Baseline (SE)	2.92 (4.21)	2.77 (2.39)	-0.39 (2.22)
95% CI	(-5.92, 11.76)	(-2.26, 7.80)	(-5.06, 4.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.32 (4.13)	3.17 (2.63)	
95% CI	(-5.36, 12.00)	(-2.36, 8.69)	
p-value	0.4321	0.2440	
Corrected Hedge's g Statistics	0.411	0.418	
95% CI	(-1.09, 1.92)	(-0.52, 1.36)	
Week 52			
m	3	7	14
n	3	6	12
Baseline Mean (SD)	86.7 (5.8)	88.3 (4.1)	82.1 (18.0)
Analysis Visit Mean (SD)	83.3 (11.5)	79.2 (12.8)	82.5 (19.6)
LS Mean of Change from Baseline (SE)	-0.73 (5.42)	-7.41 (3.82)	2.56 (3.01)
95% CI	(-12.12, 10.67)	(-15.43, 0.61)	(-3.76, 8.88)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.28 (5.70)	-9.97 (4.49)	
95% CI	(-15.26, 8.69)	(-19.40, -0.54)	
p-value	0.5717	0.0394	
Corrected Hedge's g Statistics	-0.301	-0.940	
95% CI	(-1.57, 0.97)	(-1.97, 0.09)	
Subgroup*Treatment Interaction p-value	0.8135	0.6898	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 10 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.4.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Mental Component Score			
Week 24			
m	3	7	14
n	2	7	12
Baseline Mean (SD)	58.35 (1.91)	56.51 (2.59)	54.92 (8.54)
Analysis Visit Mean (SD)	58.10 (3.68)	56.91 (2.87)	53.31 (9.19)
LS Mean of Change from Baseline (SE)	-0.07 (3.57)	0.60 (1.98)	-2.48 (1.77)
95% CI	(-7.57, 7.44)	(-3.56, 4.76)	(-6.21, 1.25)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.41 (3.61)	3.08 (2.27)	
95% CI	(-5.17, 9.99)	(-1.68, 7.84)	
p-value	0.5123	0.1906	
Corrected Hedge's g Statistics	0.372	0.504	
95% CI	(-1.13, 1.88)	(-0.44, 1.45)	
Week 52			
m	3	7	14
n	3	6	12
Baseline Mean (SD)	56.83 (2.95)	56.45 (2.83)	54.92 (8.54)
Analysis Visit Mean (SD)	55.30 (6.94)	55.18 (6.06)	54.88 (9.69)
LS Mean of Change from Baseline (SE)	-2.38 (3.00)	-1.42 (2.07)	-0.83 (1.76)
95% CI	(-8.69, 3.92)	(-5.76, 2.92)	(-4.53, 2.86)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.55 (2.99)	-0.59 (2.33)	
95% CI	(-7.83, 4.73)	(-5.48, 4.31)	
p-value	0.6101	0.8043	
Corrected Hedge's g Statistics	-0.245	-0.096	
95% CI	(-1.51, 1.02)	(-1.08, 0.88)	
Subgroup*Treatment Interaction p-value	0.3119	0.4346	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 11 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.4.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Physical Component Score			
Week 24			
m	3	7	14
n	2	7	12
Baseline Mean (SD)	53.80 (5.94)	50.53 (5.53)	48.78 (10.42)
Analysis Visit Mean (SD)	54.80 (5.94)	50.97 (5.18)	49.64 (9.89)
LS Mean of Change from Baseline (SE)	2.02 (3.58)	0.47 (2.01)	1.00 (1.94)
95% CI	(-5.51, 9.56)	(-3.76, 4.70)	(-3.08, 5.07)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.03 (3.41)	-0.52 (2.17)	
95% CI	(-6.14, 8.20)	(-5.08, 4.03)	
p-value	0.7666	0.8119	
Corrected Hedge's g Statistics	0.146	-0.080	
95% CI	(-1.35, 1.64)	(-1.01, 0.85)	
Week 52			
m	3	7	14
n	3	6	12
Baseline Mean (SD)	54.30 (4.29)	49.92 (5.79)	48.78 (10.42)
Analysis Visit Mean (SD)	51.73 (6.48)	49.08 (8.71)	48.88 (9.57)
LS Mean of Change from Baseline (SE)	-1.10 (4.03)	-1.01 (2.68)	0.19 (2.27)
95% CI	(-9.57, 7.36)	(-6.64, 4.63)	(-4.59, 4.96)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.29 (4.01)	-1.19 (3.05)	
95% CI	(-9.72, 7.15)	(-7.59, 5.21)	
p-value	0.7520	0.7004	
Corrected Hedge's g Statistics	-0.157	-0.151	
95% CI	(-1.42, 1.11)	(-1.13, 0.83)	
Subgroup*Treatment Interaction p-value	0.4862	0.7859	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 12 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.4.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Physical Functioning			
Week 24			
m	5	5	13
n	5	4	12
Baseline Mean (SD)	67.00 (27.29)	80.00 (28.28)	85.00 (20.67)
Analysis Visit Mean (SD)	83.00 (22.53)	78.75 (24.96)	77.08 (29.81)
LS Mean of Change from Baseline (SE)	11.13 (13.33)	-2.08 (17.02)	-6.54 (14.31)
95% CI	(-17.00, 39.25)	(-37.99, 33.83)	(-36.74, 23.65)
LS Mean of Change from Baseline Compared to Placebo (SE)	17.67 (14.91)	4.46 (14.28)	
95% CI	(-13.79, 49.13)	(-25.66, 34.59)	
p-value	0.2523	0.7584	
Corrected Hedge's g Statistics	0.371	0.090	
95% CI	(-0.68, 1.42)	(-1.04, 1.22)	
Week 52			
m	5	5	12
n	4	4	11
Baseline Mean (SD)	78.75 (8.54)	80.00 (28.28)	85.91 (21.43)
Analysis Visit Mean (SD)	73.75 (17.97)	71.25 (30.65)	82.88 (24.62)
LS Mean of Change from Baseline (SE)	-6.34 (12.36)	-9.47 (15.89)	-1.41 (14.04)
95% CI	(-32.42, 19.75)	(-43.00, 24.06)	(-31.03, 28.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.93 (13.67)	-8.06 (12.57)	
95% CI	(-33.78, 23.93)	(-34.57, 18.46)	
p-value	0.7232	0.5301	
Corrected Hedge's g Statistics	-0.109	-0.174	
95% CI	(-1.25, 1.04)	(-1.32, 0.97)	
Subgroup*Treatment Interaction p-value	0.8489	0.8620	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 13 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.4.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Role Physical			
Week 24			
m	5	5	13
n	5	4	12
Baseline Mean (SD)	81.26 (12.49)	90.63 (18.75)	83.87 (17.56)
Analysis Visit Mean (SD)	86.26 (19.94)	79.70 (23.58)	77.08 (31.00)
LS Mean of Change from Baseline (SE)	5.40 (14.82)	-5.53 (19.81)	-4.02 (15.88)
95% CI	(-25.87, 36.67)	(-47.33, 36.28)	(-37.54, 29.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	9.42 (15.88)	-1.50 (16.39)	
95% CI	(-24.07, 42.92)	(-36.08, 33.08)	
p-value	0.5607	0.9280	
Corrected Hedge's g Statistics	0.178	-0.027	
95% CI	(-0.87, 1.22)	(-1.16, 1.10)	
Week 52			
m	5	5	12
n	4	4	11
Baseline Mean (SD)	82.83 (13.84)	90.63 (18.75)	83.54 (18.38)
Analysis Visit Mean (SD)	84.38 (18.75)	68.75 (36.08)	77.85 (25.52)
LS Mean of Change from Baseline (SE)	0.04 (14.15)	-17.98 (18.63)	-3.42 (15.61)
95% CI	(-29.81, 29.90)	(-57.29, 21.33)	(-36.35, 29.51)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.46 (15.27)	-14.56 (14.64)	
95% CI	(-28.76, 35.69)	(-45.44, 16.33)	
p-value	0.8232	0.3339	
Corrected Hedge's g Statistics	0.069	-0.281	
95% CI	(-1.08, 1.21)	(-1.43, 0.87)	
Subgroup*Treatment Interaction p-value	0.4089	0.7545	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 14 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.4.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Bodily Pain			
Week 24			
m	5	5	13
n	5	4	12
Baseline Mean (SD)	66.0 (26.7)	86.5 (18.0)	78.8 (18.6)
Analysis Visit Mean (SD)	79.4 (22.2)	79.5 (15.2)	75.9 (24.0)
LS Mean of Change from Baseline (SE)	12.62 (9.83)	4.54 (12.54)	4.94 (9.22)
95% CI	(-8.12, 33.37)	(-21.92, 31.00)	(-14.52, 24.40)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.69 (11.43)	-0.40 (11.49)	
95% CI	(-16.42, 31.80)	(-24.64, 23.85)	
p-value	0.5102	0.9729	
Corrected Hedge's g Statistics	0.246	-0.012	
95% CI	(-0.80, 1.29)	(-1.14, 1.12)	
Week 52			
m	5	5	12
n	4	4	11
Baseline Mean (SD)	67.0 (30.7)	86.5 (18.0)	78.4 (19.4)
Analysis Visit Mean (SD)	61.5 (31.8)	74.5 (17.9)	76.0 (16.5)
LS Mean of Change from Baseline (SE)	-5.15 (7.15)	-1.75 (9.80)	4.83 (8.22)
95% CI	(-20.24, 9.94)	(-22.42, 18.93)	(-12.50, 22.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	-9.98 (8.41)	-6.58 (7.35)	
95% CI	(-27.72, 7.76)	(-22.09, 8.94)	
p-value	0.2515	0.3837	
Corrected Hedge's g Statistics	-0.378	-0.241	
95% CI	(-1.53, 0.77)	(-1.39, 0.91)	
Subgroup*Treatment Interaction p-value	0.8503	0.4523	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 15 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.4.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
General Health			
Week 24			
m	5	5	13
n	5	4	12
Baseline Mean (SD)	65.60 (25.39)	65.25 (14.45)	71.50 (18.63)
Analysis Visit Mean (SD)	70.60 (28.50)	61.50 (19.69)	64.00 (20.83)
LS Mean of Change from Baseline (SE)	7.37 (8.66)	0.46 (11.55)	-2.39 (10.24)
95% CI	(-10.90, 25.63)	(-23.91, 24.82)	(-23.99, 19.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	9.75 (9.08)	2.84 (8.93)	
95% CI	(-9.40, 28.90)	(-16.01, 21.69)	
p-value	0.2977	0.7543	
Corrected Hedge's g Statistics	0.289	0.081	
95% CI	(-0.76, 1.34)	(-1.05, 1.21)	
Week 52			
m	5	5	12
n	4	4	11
Baseline Mean (SD)	75.75 (13.15)	65.25 (14.45)	71.64 (19.54)
Analysis Visit Mean (SD)	79.00 (17.49)	56.50 (18.19)	67.59 (23.95)
LS Mean of Change from Baseline (SE)	5.14 (10.62)	-4.87 (12.94)	-0.51 (10.86)
95% CI	(-17.27, 27.55)	(-32.16, 22.42)	(-23.42, 22.41)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.64 (11.51)	-4.36 (11.27)	
95% CI	(-18.64, 29.92)	(-28.15, 19.42)	
p-value	0.6303	0.7035	
Corrected Hedge's g Statistics	0.160	-0.121	
95% CI	(-0.99, 1.31)	(-1.27, 1.02)	
Subgroup*Treatment Interaction p-value	0.7508	0.8916	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 16 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.4.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Vitality			
Week 24			
m	5	5	13
n	5	4	12
Baseline Mean (SD)	51.28 (31.70)	67.23 (20.65)	67.73 (15.04)
Analysis Visit Mean (SD)	48.78 (35.77)	65.65 (8.06)	64.60 (23.73)
LS Mean of Change from Baseline (SE)	-0.40 (9.18)	2.77 (11.77)	2.10 (9.68)
95% CI	(-19.78, 18.98)	(-22.07, 27.60)	(-18.33, 22.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.50 (10.48)	0.67 (9.88)	
95% CI	(-24.60, 19.61)	(-20.17, 21.50)	
p-value	0.8144	0.9469	
Corrected Hedge's g Statistics	-0.077	0.020	
95% CI	(-1.12, 0.97)	(-1.11, 1.15)	
Week 52			
m	5	5	12
n	4	4	11
Baseline Mean (SD)	64.10 (15.63)	67.23 (20.65)	69.90 (13.65)
Analysis Visit Mean (SD)	56.28 (26.49)	64.10 (17.20)	65.35 (17.76)
LS Mean of Change from Baseline (SE)	-4.93 (9.26)	1.43 (11.55)	1.55 (9.91)
95% CI	(-24.46, 14.60)	(-22.94, 25.79)	(-19.36, 22.47)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.49 (10.58)	-0.13 (9.66)	
95% CI	(-28.81, 15.84)	(-20.50, 20.25)	
p-value	0.5480	0.9897	
Corrected Hedge's g Statistics	-0.202	-0.004	
95% CI	(-1.35, 0.94)	(-1.15, 1.14)	
Subgroup*Treatment Interaction p-value	0.7482	0.6276	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 17 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.4.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Social Functioning			
Week 24			
m	5	5	13
n	5	4	12
Baseline Mean (SD)	87.50 (17.68)	96.88 (6.25)	94.79 (9.91)
Analysis Visit Mean (SD)	77.50 (22.36)	90.63 (11.97)	84.38 (29.25)
LS Mean of Change from Baseline (SE)	-4.83 (12.27)	6.36 (14.67)	1.58 (10.64)
95% CI	(-30.73, 21.06)	(-24.59, 37.30)	(-20.87, 24.04)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.42 (14.11)	4.77 (14.33)	
95% CI	(-36.18, 23.35)	(-25.45, 35.00)	
p-value	0.6550	0.7431	
Corrected Hedge's g Statistics	-0.176	0.127	
95% CI	(-1.22, 0.87)	(-1.00, 1.26)	
Week 52			
m	5	5	12
n	4	4	11
Baseline Mean (SD)	93.75 (12.50)	96.88 (6.25)	94.32 (10.25)
Analysis Visit Mean (SD)	81.25 (21.65)	84.38 (11.97)	96.59 (11.31)
LS Mean of Change from Baseline (SE)	-7.02 (8.24)	2.22 (10.52)	14.40 (9.03)
95% CI	(-24.41, 10.37)	(-19.97, 24.42)	(-4.65, 33.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	-21.42 (9.03)	-12.18 (8.35)	
95% CI	(-40.48, -2.37)	(-29.81, 5.45)	
p-value	0.0298	0.1631	
Corrected Hedge's g Statistics	-0.735	-0.407	
95% CI	(-1.91, 0.44)	(-1.56, 0.75)	
Subgroup*Treatment Interaction p-value	0.0831	0.0450	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 18 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.4.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Role Emotional			
Week 24			
m	5	5	13
n	5	4	12
Baseline Mean (SD)	95.02 (4.55)	95.83 (8.35)	90.98 (13.96)
Analysis Visit Mean (SD)	85.00 (14.90)	81.25 (23.94)	88.19 (18.27)
LS Mean of Change from Baseline (SE)	-4.83 (9.70)	-6.58 (12.92)	5.00 (11.06)
95% CI	(-25.28, 15.63)	(-33.84, 20.68)	(-18.33, 28.32)
LS Mean of Change from Baseline Compared to Placebo (SE)	-9.83 (9.83)	-11.58 (9.92)	
95% CI	(-30.56, 10.91)	(-32.51, 9.35)	
p-value	0.3314	0.2593	
Corrected Hedge's g Statistics	-0.269	-0.304	
95% CI	(-1.32, 0.78)	(-1.44, 0.83)	
Week 52			
m	5	5	12
n	4	4	11
Baseline Mean (SD)	93.78 (4.15)	95.83 (8.35)	90.15 (14.34)
Analysis Visit Mean (SD)	87.50 (15.95)	83.33 (23.57)	83.34 (24.16)
LS Mean of Change from Baseline (SE)	-7.14 (11.22)	-4.89 (14.13)	1.49 (11.58)
95% CI	(-30.81, 16.54)	(-34.70, 24.93)	(-22.94, 25.92)
LS Mean of Change from Baseline Compared to Placebo (SE)	-8.62 (11.85)	-6.37 (12.00)	
95% CI	(-33.63, 16.39)	(-31.69, 18.94)	
p-value	0.4769	0.6021	
Corrected Hedge's g Statistics	-0.229	-0.165	
95% CI	(-1.38, 0.92)	(-1.31, 0.98)	
Subgroup*Treatment Interaction p-value	0.3500	0.2175	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 19 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.4.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Mental Health			
Week 24			
m	5	5	13
n	5	4	12
Baseline Mean (SD)	82.0 (12.5)	83.8 (6.3)	83.8 (12.8)
Analysis Visit Mean (SD)	85.0 (14.1)	78.8 (18.9)	84.2 (16.4)
LS Mean of Change from Baseline (SE)	2.00 (7.54)	-7.27 (10.14)	-1.01 (8.66)
95% CI	(-13.90, 17.90)	(-28.66, 14.11)	(-19.28, 17.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.01 (7.91)	-6.26 (7.86)	
95% CI	(-13.67, 19.69)	(-22.85, 10.32)	
p-value	0.7080	0.4365	
Corrected Hedge's g Statistics	0.105	-0.210	
95% CI	(-0.94, 1.15)	(-1.34, 0.92)	
Week 52			
m	5	5	12
n	4	4	11
Baseline Mean (SD)	85.0 (12.2)	83.8 (6.3)	84.1 (13.4)
Analysis Visit Mean (SD)	87.5 (8.7)	83.8 (4.8)	83.2 (19.8)
LS Mean of Change from Baseline (SE)	1.70 (8.29)	-2.27 (10.47)	-1.91 (8.90)
95% CI	(-15.80, 19.19)	(-24.36, 19.82)	(-20.69, 16.86)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.61 (8.93)	-0.36 (8.51)	
95% CI	(-15.23, 22.45)	(-18.30, 17.59)	
p-value	0.6909	0.9669	
Corrected Hedge's g Statistics	0.126	-0.012	
95% CI	(-1.02, 1.27)	(-1.16, 1.13)	
Subgroup*Treatment Interaction p-value	0.8135	0.6898	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 20 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.4.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Mental Component Score			
Week 24			
m	5	5	13
n	5	4	12
Baseline Mean (SD)	55.24 (4.78)	56.25 (4.15)	55.33 (6.16)
Analysis Visit Mean (SD)	50.66 (9.88)	52.40 (9.59)	54.63 (7.20)
LS Mean of Change from Baseline (SE)	-2.88 (3.57)	-1.38 (4.72)	2.14 (3.92)
95% CI	(-10.42, 4.65)	(-11.33, 8.57)	(-6.13, 10.42)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.03 (3.75)	-3.53 (3.82)	
95% CI	(-12.93, 2.88)	(-11.58, 4.53)	
p-value	0.1972	0.3685	
Corrected Hedge's g Statistics	-0.387	-0.260	
95% CI	(-1.44, 0.66)	(-1.40, 0.87)	
Week 52			
m	5	5	12
n	4	4	11
Baseline Mean (SD)	56.68 (4.09)	56.25 (4.15)	55.41 (6.45)
Analysis Visit Mean (SD)	54.53 (6.53)	54.58 (1.84)	54.33 (9.13)
LS Mean of Change from Baseline (SE)	-0.87 (3.81)	0.86 (4.75)	2.01 (3.99)
95% CI	(-8.91, 7.18)	(-9.17, 10.89)	(-6.41, 10.43)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.87 (4.10)	-1.15 (3.92)	
95% CI	(-11.52, 5.77)	(-9.42, 7.13)	
p-value	0.4927	0.7734	
Corrected Hedge's g Statistics	-0.222	-0.087	
95% CI	(-1.37, 0.93)	(-1.23, 1.06)	
Subgroup*Treatment Interaction p-value	0.3119	0.4346	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 21 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.4.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Sex

(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Physical Component Score			
Week 24			
m	5	5	13
n	5	4	12
Baseline Mean (SD)	45.60 (8.85)	51.40 (9.59)	51.52 (7.34)
Analysis Visit Mean (SD)	51.56 (8.06)	50.23 (7.45)	48.28 (10.94)
LS Mean of Change from Baseline (SE)	4.95 (4.60)	0.41 (5.81)	-1.56 (4.66)
95% CI	(-4.77, 14.66)	(-11.85, 12.68)	(-11.39, 8.28)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.51 (5.29)	1.97 (5.12)	
95% CI	(-4.65, 17.67)	(-8.83, 12.77)	
p-value	0.2354	0.7048	
Corrected Hedge's g Statistics	0.417	0.122	
95% CI	(-0.64, 1.47)	(-1.01, 1.25)	
Week 52			
m	5	5	12
n	4	4	11
Baseline Mean (SD)	48.95 (5.44)	51.40 (9.59)	51.64 (7.69)
Analysis Visit Mean (SD)	48.18 (9.15)	45.65 (10.38)	50.23 (7.72)
LS Mean of Change from Baseline (SE)	-0.66 (3.84)	-4.29 (5.01)	-0.11 (4.41)
95% CI	(-8.75, 7.44)	(-14.85, 6.27)	(-9.41, 9.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.55 (4.32)	-4.18 (3.88)	
95% CI	(-9.67, 8.57)	(-12.36, 4.00)	
p-value	0.9007	0.2959	
Corrected Hedge's g Statistics	-0.039	-0.287	
95% CI	(-1.18, 1.11)	(-1.44, 0.86)	
Subgroup*Treatment Interaction p-value	0.4862	0.7859	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE21.4.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component by Sex
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis, only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.

AMNOG Table SE21.4.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (7.1)
No	3 (100)	8 (100)	13 (92.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	1.89	
95% CI of the inverse odds ratio	(0.03, 23.53)	(0.07, 51.92)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	1.80	
95% CI of the inverse risk ratio	(0.04, 16.14)	(0.08, 39.64)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.50	-4.44	
95% CI of the absolute risk difference	(-33.29, 38.29)	(-25.76, 16.87)	
p-value	0.8849	0.7029	
p-value of Breslow-Day Test for Homogeneity [3]	0.4928	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (25.0)	6 (42.9)
No	3 (100)	6 (75.0)	8 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.35	2.25	
95% CI of the inverse odds ratio	(0.23, 122.96)	(0.33, 15.33)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.47	1.71	
95% CI of the inverse risk ratio	(0.24, 49.39)	(0.45, 6.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-30.83	-17.86	
95% CI of the absolute risk difference	(-71.81, 10.15)	(-57.51, 21.80)	
p-value	0.2560	0.4023	
p-value of Breslow-Day Test for Homogeneity [3]	0.4072	0.2438	

AMNOG Table SE21.4.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	3 (21.4)
No	3 (100)	8 (100)	11 (78.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.13	5.17	
95% CI of the inverse odds ratio	(0.09, 52.04)	(0.23, 114.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.87	4.20	
95% CI of the inverse risk ratio	(0.12, 29.21)	(0.24, 72.29)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.83	-17.78	
95% CI of the absolute risk difference	(-49.67, 28.01)	(-43.89, 8.34)	
p-value	0.6368	0.2579	
p-value of Breslow-Day Test for Homogeneity [3]	0.3808	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (12.5)	6 (42.9)
No	3 (100)	7 (87.5)	8 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.35	5.25	
95% CI of the inverse odds ratio	(0.23, 122.96)	(0.50, 54.91)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.47	3.43	
95% CI of the inverse risk ratio	(0.24, 49.39)	(0.50, 23.63)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-30.83	-30.36	
95% CI of the absolute risk difference	(-71.81, 10.15)	(-64.96, 4.24)	
p-value	0.2560	0.1414	
p-value of Breslow-Day Test for Homogeneity [3]	0.1296	0.5470	

AMNOG Table SE21.4.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	4 (28.6)
No	3 (100)	8 (100)	10 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	7.29	
95% CI of the inverse odds ratio	(0.13, 70.87)	(0.34, 155.15)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.40	5.40	
95% CI of the inverse risk ratio	(0.16, 35.91)	(0.33, 89.02)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-17.50	-24.44	
95% CI of the absolute risk difference	(-57.35, 22.35)	(-52.04, 3.16)	
p-value	0.4800	0.1534	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (12.5)	4 (28.6)
No	3 (100)	7 (87.5)	10 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	2.80	
95% CI of the inverse odds ratio	(0.13, 70.87)	(0.26, 30.70)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.40	2.29	
95% CI of the inverse risk ratio	(0.16, 35.91)	(0.31, 17.09)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-17.50	-16.07	
95% CI of the absolute risk difference	(-57.35, 22.35)	(-49.01, 16.87)	
p-value	0.4800	0.3869	
p-value of Breslow-Day Test for Homogeneity [3]	0.3086	0.5314	

AMNOG Table SE21.4.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (14.3)
No	3 (100)	8 (100)	12 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	3.40	
95% CI of the inverse odds ratio	(0.05, 36.45)	(0.14, 80.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	3.00	
95% CI of the inverse risk ratio	(0.08, 22.57)	(0.16, 55.72)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.17	-11.11	
95% CI of the absolute risk difference	(-41.66, 33.33)	(-35.19, 12.96)	
p-value	0.8391	0.4256	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (66.7)	2 (25.0)	4 (28.6)
No	1 (33.3)	6 (75.0)	10 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.20	1.20	
95% CI of the inverse odds ratio	(0.01, 2.88)	(0.17, 8.66)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.43	1.14	
95% CI of the inverse risk ratio	(0.14, 1.36)	(0.27, 4.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	38.10	-3.57	
95% CI of the absolute risk difference	(-20.26, 96.45)	(-41.79, 34.64)	
p-value	0.2102	0.8564	
p-value of Breslow-Day Test for Homogeneity [3]	0.4140	0.1982	

AMNOG Table SE21.4.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (14.3)
No	3 (100)	8 (100)	12 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	3.40	
95% CI of the inverse odds ratio	(0.05, 36.45)	(0.14, 80.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	3.00	
95% CI of the inverse risk ratio	(0.08, 22.57)	(0.16, 55.72)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.17	-11.11	
95% CI of the absolute risk difference	(-41.66, 33.33)	(-35.19, 12.96)	
p-value	0.8391	0.4256	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	5 (35.7)
No	3 (100)	8 (100)	9 (64.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.05	9.84	
95% CI of the inverse odds ratio	(0.17, 93.99)	(0.47, 205.62)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.93	6.60	
95% CI of the inverse risk ratio	(0.20, 42.64)	(0.41, 105.81)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-24.17	-31.11	
95% CI of the absolute risk difference	(-64.73, 16.39)	(-59.72, -2.50)	
p-value	0.3555	0.0884	
p-value of Breslow-Day Test for Homogeneity [3]	0.4027	0.2480	

AMNOG Table SE21.4.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (12.5)	1 (7.1)
No	3 (100)	7 (87.5)	13 (92.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	0.54	
95% CI of the inverse odds ratio	(0.03, 23.53)	(0.03, 9.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	0.57	
95% CI of the inverse risk ratio	(0.04, 16.14)	(0.04, 7.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.50	5.36	
95% CI of the absolute risk difference	(-33.29, 38.29)	(-21.24, 31.95)	
p-value	0.8849	0.6742	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.2534	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	4 (50.0)	1 (7.1)
No	3 (100)	4 (50.0)	13 (92.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	0.08	
95% CI of the inverse odds ratio	(0.03, 23.53)	(0.01, 0.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	0.14	
95% CI of the inverse risk ratio	(0.04, 16.14)	(0.02, 1.07)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.50	42.86	
95% CI of the absolute risk difference	(-33.29, 38.29)	(5.68, 80.04)	
p-value	0.8849	0.0210	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.0711	

AMNOG Table SE21.4.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (7.1)
No	3 (100)	8 (100)	13 (92.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	1.89	
95% CI of the inverse odds ratio	(0.03, 23.53)	(0.07, 51.92)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	1.80	
95% CI of the inverse risk ratio	(0.04, 16.14)	(0.08, 39.64)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.50	-4.44	
95% CI of the absolute risk difference	(-33.29, 38.29)	(-25.76, 16.87)	
p-value	0.8849	0.7029	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (12.5)	2 (14.3)
No	3 (100)	7 (87.5)	12 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	1.17	
95% CI of the inverse odds ratio	(0.05, 36.45)	(0.09, 15.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	1.14	
95% CI of the inverse risk ratio	(0.08, 22.57)	(0.12, 10.71)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.17	-1.79	
95% CI of the absolute risk difference	(-41.66, 33.33)	(-31.13, 27.56)	
p-value	0.8391	0.9065	
p-value of Breslow-Day Test for Homogeneity [3]	0.3487	0.5254	

AMNOG Table SE21.4.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (7.1)
No	3 (100)	8 (100)	13 (92.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	1.89	
95% CI of the inverse odds ratio	(0.03, 23.53)	(0.07, 51.92)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	1.80	
95% CI of the inverse risk ratio	(0.04, 16.14)	(0.08, 39.64)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.50	-4.44	
95% CI of the absolute risk difference	(-33.29, 38.29)	(-25.76, 16.87)	
p-value	0.8849	0.7029	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.4746	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (12.5)	5 (35.7)
No	3 (100)	7 (87.5)	9 (64.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.05	3.89	
95% CI of the inverse odds ratio	(0.17, 93.99)	(0.37, 41.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.93	2.86	
95% CI of the inverse risk ratio	(0.20, 42.64)	(0.40, 20.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-24.17	-23.21	
95% CI of the absolute risk difference	(-64.73, 16.39)	(-57.20, 10.77)	
p-value	0.3555	0.2396	
p-value of Breslow-Day Test for Homogeneity [3]	0.1671	0.9282	

AMNOG Table SE21.4.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	3 (100)	8 (100)	14 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (12.5)	3 (21.4)
No	3 (100)	7 (87.5)	11 (78.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.13	1.91	
95% CI of the inverse odds ratio	(0.09, 52.04)	(0.16, 22.20)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.87	1.71	
95% CI of the inverse risk ratio	(0.12, 29.21)	(0.21, 13.86)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.83	-8.93	
95% CI of the absolute risk difference	(-49.67, 28.01)	(-40.35, 22.49)	
p-value	0.6368	0.6014	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.9309	

AMNOG Table SE21.4.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Male

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (14.3)
No	3 (100)	8 (100)	12 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	3.40	
95% CI of the inverse odds ratio	(0.05, 36.45)	(0.14, 80.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	3.00	
95% CI of the inverse risk ratio	(0.08, 22.57)	(0.16, 55.72)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.17	-11.11	
95% CI of the absolute risk difference	(-41.66, 33.33)	(-35.19, 12.96)	
p-value	0.8391	0.4256	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	3 (21.4)
No	3 (100)	8 (100)	11 (78.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.13	5.17	
95% CI of the inverse odds ratio	(0.09, 52.04)	(0.23, 114.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.87	4.20	
95% CI of the inverse risk ratio	(0.12, 29.21)	(0.24, 72.29)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.83	-17.78	
95% CI of the absolute risk difference	(-49.67, 28.01)	(-43.89, 8.34)	
p-value	0.6368	0.2579	
p-value of Breslow-Day Test for Homogeneity [3]	0.3808	NE	

AMNOG Table SE21.4.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (16.7)	0	1 (7.1)
No	5 (83.3)	7 (100)	13 (92.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.38	1.67	
95% CI of the inverse odds ratio	(0.02, 7.40)	(0.06, 46.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.43	1.60	
95% CI of the inverse risk ratio	(0.03, 5.78)	(0.07, 34.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	9.52	-3.75	
95% CI of the absolute risk difference	(-23.21, 42.25)	(-26.37, 18.87)	
p-value	0.5153	0.7611	
p-value of Breslow-Day Test for Homogeneity [3]	0.4928	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (16.7)	0	5 (35.7)
No	5 (83.3)	7 (100)	9 (64.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.78	8.68	
95% CI of the inverse odds ratio	(0.25, 30.91)	(0.41, 183.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.14	5.87	
95% CI of the inverse risk ratio	(0.31, 14.65)	(0.37, 93.15)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-19.05	-30.42	
95% CI of the absolute risk difference	(-58.02, 19.93)	(-60.02, -0.82)	
p-value	0.3943	0.1136	
p-value of Breslow-Day Test for Homogeneity [3]	0.4072	0.2438	

AMNOG Table SE21.4.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (16.7)	0	2 (14.3)
No	5 (83.3)	7 (100)	12 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	3.00	
95% CI of the inverse odds ratio	(0.06, 11.42)	(0.13, 71.31)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	2.67	
95% CI of the inverse risk ratio	(0.09, 7.75)	(0.14, 49.08)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.38	-10.42	
95% CI of the absolute risk difference	(-32.62, 37.38)	(-35.66, 14.82)	
p-value	0.8913	0.4799	
p-value of Breslow-Day Test for Homogeneity [3]	0.3808	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (33.3)	0	3 (21.4)
No	4 (66.7)	7 (100)	11 (78.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.55	4.57	
95% CI of the inverse odds ratio	(0.07, 4.56)	(0.21, 101.61)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.64	3.73	
95% CI of the inverse risk ratio	(0.14, 2.92)	(0.22, 63.66)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.90	-17.08	
95% CI of the absolute risk difference	(-31.51, 55.32)	(-44.28, 10.11)	
p-value	0.5731	0.3033	
p-value of Breslow-Day Test for Homogeneity [3]	0.1296	0.5470	

AMNOG Table SE21.4.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (7.1)
No	6 (100)	7 (100)	13 (92.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.44	1.67	
95% CI of the inverse odds ratio	(0.05, 40.54)	(0.06, 46.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	1.60	
95% CI of the inverse risk ratio	(0.06, 30.23)	(0.07, 34.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.86	-3.75	
95% CI of the absolute risk difference	(-27.24, 21.52)	(-26.37, 18.87)	
p-value	0.8281	0.7611	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (16.7)	0	2 (14.3)
No	5 (83.3)	7 (100)	12 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	3.00	
95% CI of the inverse odds ratio	(0.06, 11.42)	(0.13, 71.31)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	2.67	
95% CI of the inverse risk ratio	(0.09, 7.75)	(0.14, 49.08)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.38	-10.42	
95% CI of the absolute risk difference	(-32.62, 37.38)	(-35.66, 14.82)	
p-value	0.8913	0.4799	
p-value of Breslow-Day Test for Homogeneity [3]	0.3086	0.5314	

AMNOG Table SE21.4.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (14.3)
No	6 (100)	7 (100)	12 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.60	3.00	
95% CI of the inverse odds ratio	(0.11, 62.57)	(0.13, 71.31)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.33	2.67	
95% CI of the inverse risk ratio	(0.13, 42.44)	(0.14, 49.08)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.52	-10.42	
95% CI of the absolute risk difference	(-36.35, 17.30)	(-35.66, 14.82)	
p-value	0.5443	0.4799	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (33.3)	0	4 (28.6)
No	4 (66.7)	7 (100)	10 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	6.43	
95% CI of the inverse odds ratio	(0.10, 6.25)	(0.30, 138.25)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	4.80	
95% CI of the inverse risk ratio	(0.21, 3.48)	(0.29, 78.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.76	-23.75	
95% CI of the absolute risk difference	(-39.77, 49.29)	(-52.37, 4.87)	
p-value	0.8314	0.1884	
p-value of Breslow-Day Test for Homogeneity [3]	0.4140	0.1982	

AMNOG Table SE21.4.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (7.1)
No	6 (100)	7 (100)	13 (92.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.44	1.67	
95% CI of the inverse odds ratio	(0.05, 40.54)	(0.06, 46.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	1.60	
95% CI of the inverse risk ratio	(0.06, 30.23)	(0.07, 34.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.86	-3.75	
95% CI of the absolute risk difference	(-27.24, 21.52)	(-26.37, 18.87)	
p-value	0.8281	0.7611	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (16.7)	1 (14.3)	4 (28.6)
No	5 (83.3)	6 (85.7)	10 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	2.40	
95% CI of the inverse odds ratio	(0.17, 22.95)	(0.21, 26.82)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.71	2.00	
95% CI of the inverse risk ratio	(0.24, 12.31)	(0.27, 14.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.90	-14.29	
95% CI of the absolute risk difference	(-49.97, 26.16)	(-49.38, 20.81)	
p-value	0.5731	0.4687	
p-value of Breslow-Day Test for Homogeneity [3]	0.4027	0.2480	

AMNOG Table SE21.4.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (14.3)
No	6 (100)	7 (100)	12 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.60	3.00	
95% CI of the inverse odds ratio	(0.11, 62.57)	(0.13, 71.31)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.33	2.67	
95% CI of the inverse risk ratio	(0.13, 42.44)	(0.14, 49.08)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.52	-10.42	
95% CI of the absolute risk difference	(-36.35, 17.30)	(-35.66, 14.82)	
p-value	0.5443	0.4799	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.2534	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (14.3)	3 (21.4)
No	6 (100)	6 (85.7)	11 (78.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.96	1.64	
95% CI of the inverse odds ratio	(0.18, 89.19)	(0.14, 19.39)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.27	1.50	
95% CI of the inverse risk ratio	(0.19, 55.03)	(0.19, 11.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-16.19	-7.14	
95% CI of the absolute risk difference	(-44.86, 12.48)	(-40.82, 26.53)	
p-value	0.3591	0.6944	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.0711	

AMNOG Table SE21.4.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (7.1)
No	6 (100)	7 (100)	13 (92.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.44	1.67	
95% CI of the inverse odds ratio	(0.05, 40.54)	(0.06, 46.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	1.60	
95% CI of the inverse risk ratio	(0.06, 30.23)	(0.07, 34.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.86	-3.75	
95% CI of the absolute risk difference	(-27.24, 21.52)	(-26.37, 18.87)	
p-value	0.8281	0.7611	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (16.7)	0	1 (7.1)
No	5 (83.3)	7 (100)	13 (92.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.38	1.67	
95% CI of the inverse odds ratio	(0.02, 7.40)	(0.06, 46.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.43	1.60	
95% CI of the inverse risk ratio	(0.03, 5.78)	(0.07, 34.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	9.52	-3.75	
95% CI of the absolute risk difference	(-23.21, 42.25)	(-26.37, 18.87)	
p-value	0.5153	0.7611	
p-value of Breslow-Day Test for Homogeneity [3]	0.3487	0.5254	

AMNOG Table SE21.4.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (14.3)	2 (14.3)
No	6 (100)	6 (85.7)	12 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.60	1.00	
95% CI of the inverse odds ratio	(0.11, 62.57)	(0.07, 13.37)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.33	1.00	
95% CI of the inverse risk ratio	(0.13, 42.44)	(0.11, 9.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.52	0.00	
95% CI of the absolute risk difference	(-36.35, 17.30)	(-31.75, 31.75)	
p-value	0.5443	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.4746	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (50.0)	1 (14.3)	5 (35.7)
No	3 (50.0)	6 (85.7)	9 (64.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	3.33	
95% CI of the inverse odds ratio	(0.08, 3.86)	(0.31, 36.11)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	2.50	
95% CI of the inverse risk ratio	(0.25, 2.07)	(0.36, 17.50)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	14.29	-21.43	
95% CI of the absolute risk difference	(-32.94, 61.51)	(-57.51, 14.65)	
p-value	0.5501	0.3055	
p-value of Breslow-Day Test for Homogeneity [3]	0.1671	0.9282	

AMNOG Table SE21.4.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	6 (100)	7 (100)	14 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (14.3)	3 (21.4)
No	6 (100)	6 (85.7)	11 (78.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.96	1.64	
95% CI of the inverse odds ratio	(0.18, 89.19)	(0.14, 19.39)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.27	1.50	
95% CI of the inverse risk ratio	(0.19, 55.03)	(0.19, 11.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-16.19	-7.14	
95% CI of the absolute risk difference	(-44.86, 12.48)	(-40.82, 26.53)	
p-value	0.3591	0.6944	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.9309	

AMNOG Table SE21.4.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sex
(Label Population based on Modified Intent-to-Treat Population)

Sex: Female

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	6 (100)	7 (100)	14 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (16.7)	0	2 (14.3)
No	5 (83.3)	7 (100)	12 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	3.00	
95% CI of the inverse odds ratio	(0.06, 11.42)	(0.13, 71.31)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	2.67	
95% CI of the inverse risk ratio	(0.09, 7.75)	(0.14, 49.08)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.38	-10.42	
95% CI of the absolute risk difference	(-32.62, 37.38)	(-35.66, 14.82)	
p-value	0.8913	0.4799	
p-value of Breslow-Day Test for Homogeneity [3]	0.3808	NE	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.5.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=6)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=6)	Change from Baseline DB Placebo (N=11)
Physical Functioning						
Baseline						
m	4	6	11			
n	4	5	10			
Mean (SD)	65.00 (34.16)	95.00 (5.00)	86.50 (19.59)			
Median	70.00	95.00	97.50			
IQR: Q1, Q3	40.00, 90.00	90.00, 100.00	75.00, 100.00			
Min, Max	20.0, 100.0	90.0, 100.0	40.0, 100.0			
Week 24						
m	3	4	11			
n	3	4	10	3	4	10
Mean (SD/SE)	81.67 (31.75)	93.75 (6.29)	78.50 (27.19)	15.00 (7.64)	0.00 (3.54)	-8.00 (7.75)
Median	100.00	95.00	92.50	20.00	-2.50	0
IQR: Q1, Q3	45.00, 100.00	90.00, 97.50	60.00, 100.00	0.00, 25.00	-5.00, 5.00	-10.00, 0.00
Min, Max	45.0, 100.0	85.0, 100.0	20.0, 100.0	0.0, 25.0	-5.0, 10.0	-60.0, 25.0
Week 52						
m	3	4	11			
n	2	3	9	2	3	9
Mean (SD/SE)	75.00 (35.36)	90.00 (8.66)	82.78 (28.84)	-15.00 (15.00)	-5.00 (2.89)	-5.00 (7.95)
Median	75.00	95.00	100.00	-15.00	-5.00	0
IQR: Q1, Q3	50.00, 100.00	80.00, 95.00	80.00, 100.00	-30.00, 0.00	-10.00, 0.00	-5.00, 5.00
Min, Max	50.0, 100.0	80.0, 95.0	20.0, 100.0	-30.0, 0.0	-10.0, 0.0	-60.0, 25.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.5.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=6)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=6)	Change from Baseline DB Placebo (N=11)
Role Physical						
Baseline						
m	4	6	11			
n	4	5	10			
Mean (SD)	78.13 (21.35)	97.52 (3.40)	82.51 (23.16)			
Median	81.25	100.00	87.50			
IQR: Q1, Q3	62.50, 93.75	93.80, 100.00	75.00, 100.00			
Min, Max	50.0, 100.0	93.8, 100.0	25.0, 100.0			
Week 24						
m	3	4	11			
n	3	4	10	3	4	10
Mean (SD/SE)	85.43 (25.23)	98.45 (3.10)	75.00 (33.33)	-2.07 (9.07)	1.55 (1.55)	-7.51 (7.90)
Median	100.00	100.00	93.75	0	0	0
IQR: Q1, Q3	56.30, 100.00	96.90, 100.00	62.50, 100.00	-18.70, 12.50	0.00, 3.10	-25.00, 0.00
Min, Max	56.3, 100.0	93.8, 100.0	12.5, 100.0	-18.7, 12.5	0.0, 6.2	-56.3, 25.0
Week 52						
m	3	4	11			
n	2	3	9	2	3	9
Mean (SD/SE)	81.25 (26.52)	93.77 (10.80)	76.40 (31.36)	-12.50 (12.50)	-4.17 (7.48)	-5.56 (7.69)
Median	81.25	100.00	100.00	-12.50	0	0
IQR: Q1, Q3	62.50, 100.00	81.30, 100.00	56.30, 100.00	-25.00, 0.00	-18.70, 6.20	-25.00, 6.30
Min, Max	62.5, 100.0	81.3, 100.0	25.0, 100.0	-25.0, 0.0	-18.7, 6.2	-43.8, 25.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.5.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=6)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=6)	Change from Baseline DB Placebo (N=11)
Bodily Pain						
Baseline						
m	4	6	11			
n	4	5	10			
Mean (SD)	64.0 (27.9)	87.2 (7.2)	86.0 (14.7)			
Median	62.0	84.0	84.0			
IQR: Q1, Q3	47.0, 81.0	84.0, 84.0	84.0, 100.0			
Min, Max	32, 100	84, 100	62, 100			
Week 24						
m	3	4	11			
n	3	4	10	3	4	10
Mean (SD/SE)	78.3 (25.0)	85.5 (10.8)	84.0 (24.3)	13.7 (6.9)	1.5 (5.4)	-2.0 (5.7)
Median	84.0	84.0	100.0	19.0	0	0
IQR: Q1, Q3	51.0, 100.0	79.0, 92.0	74.0, 100.0	0.0, 22.0	-5.0, 8.0	0.0, 12.0
Min, Max	51, 100	74, 100	41, 100	0, 22	-10, 16	-43, 16
Week 52						
m	3	4	11			
n	2	3	9	2	3	9
Mean (SD/SE)	53.0 (43.8)	73.3 (11.0)	84.6 (22.8)	-13.0 (3.0)	-10.7 (6.4)	-1.7 (3.3)
Median	53.0	74.0	100.0	-13.0	-10.0	0
IQR: Q1, Q3	22.0, 84.0	62.0, 84.0	84.0, 100.0	-16.0, -10.0	-22.0, 0.0	0.0, 0.0
Min, Max	22, 84	62, 84	41, 100	-16, -10	-22, 0	-21, 16

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.5.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter / Visit / Statistic	Visit Result: DB MGL-3196 80 mg (N=4)	Visit Result: DB MGL-3196 100 mg (N=6)	Visit Result: DB Placebo (N=11)	Change from Baseline: DB MGL-3196 80 mg (N=4)	Change from Baseline: DB MGL-3196 100 mg (N=6)	Change from Baseline: DB Placebo (N=11)
General Health						
Baseline						
m	4	6	11			
n	4	5	10			
Mean (SD)	54.00 (21.51)	66.60 (12.88)	69.90 (19.04)			
Median	57.00	62.00	72.00			
IQR: Q1, Q3	41.00, 67.00	62.00, 77.00	62.00, 82.00			
Min, Max	25.0, 77.0	50.0, 82.0	25.0, 97.0			
Week 24						
m	3	4	11			
n	3	4	10	3	4	10
Mean (SD/SE)	61.33 (32.35)	68.25 (17.50)	64.40 (21.61)	8.33 (4.41)	0.50 (6.34)	-5.50 (6.39)
Median	72.00	69.50	68.50	10.00	1.00	0
IQR: Q1, Q3	25.00, 87.00	54.50, 82.00	42.00, 87.00	0.00, 15.00	-9.00, 10.00	-27.00, 12.00
Min, Max	25.0, 87.0	47.0, 87.0	37.0, 92.0	0.0, 15.0	-15.0, 15.0	-35.0, 15.0
Week 52						
m	3	4	11			
n	2	3	9	2	3	9
Mean (SD/SE)	71.00 (22.63)	58.67 (17.56)	65.83 (26.06)	4.00 (6.00)	-6.00 (1.00)	-4.06 (8.50)
Median	71.00	57.00	70.00	4.00	-5.00	5.50
IQR: Q1, Q3	55.00, 87.00	42.00, 77.00	50.00, 87.00	-2.00, 10.00	-8.00, -5.00	-10.00, 10.00
Min, Max	55.0, 87.0	42.0, 77.0	15.0, 97.0	-2.0, 10.0	-8.0, -5.0	-57.0, 25.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.5.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=6)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=6)	Change from Baseline DB Placebo (N=11)
Vitality						
Baseline						
m	4	6	11			
n	4	5	10			
Mean (SD)	43.78 (31.88)	71.28 (9.50)	70.02 (19.27)			
Median	50.05	68.80	71.90			
IQR: Q1, Q3	21.90, 65.65	62.50, 81.30	62.50, 81.30			
Min, Max	0.0, 75.0	62.5, 81.3	37.5, 100.0			
Week 24						
m	3	4	11			
n	3	4	10	3	4	10
Mean (SD/SE)	29.17 (31.46)	78.18 (11.97)	67.51 (18.59)	-10.43 (5.52)	6.28 (9.21)	-2.51 (4.49)
Median	25.00	75.05	75.00	-12.50	3.15	0
IQR: Q1, Q3	0.00, 62.50	68.80, 87.55	56.30, 81.30	-18.80, 0.00	-6.25, 18.80	-6.30, 6.20
Min, Max	0.0, 62.5	68.8, 93.8	37.5, 87.5	-18.8, 0.0	-12.5, 31.3	-37.5, 12.5
Week 52						
m	3	4	11			
n	2	3	9	2	3	9
Mean (SD/SE)	43.80 (35.36)	62.53 (6.25)	70.84 (25.58)	-15.60 (9.40)	-6.23 (3.61)	-2.09 (5.80)
Median	43.80	62.50	75.00	-15.60	-6.20	0
IQR: Q1, Q3	18.80, 68.80	56.30, 68.80	62.50, 87.50	-25.00, -6.20	-12.50, 0.00	-6.20, 12.50
Min, Max	18.8, 68.8	56.3, 68.8	25.0, 100.0	-25.0, -6.2	-12.5, 0.0	-37.5, 18.7

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.5.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=6)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=6)	Change from Baseline DB Placebo (N=11)
Social Functioning						
Baseline						
m	4	6	11			
n	4	5	10			
Mean (SD)	84.38 (18.75)	97.50 (5.59)	93.75 (13.50)			
Median	87.50	100.00	100.00			
IQR: Q1, Q3	68.75, 100.00	100.00, 100.00	100.00, 100.00			
Min, Max	62.5, 100.0	87.5, 100.0	62.5, 100.0			
Week 24						
m	3	4	11			
n	3	4	10	3	4	10
Mean (SD/SE)	75.00 (25.00)	93.75 (7.22)	92.50 (15.81)	-12.50 (7.22)	-3.13 (3.13)	-1.25 (1.25)
Median	75.00	93.75	100.00	-12.50	0	0
IQR: Q1, Q3	50.00, 100.00	87.50, 100.00	100.00, 100.00	-25.00, 0.00	-6.25, 0.00	0.00, 0.00
Min, Max	50.0, 100.0	87.5, 100.0	62.5, 100.0	-25.0, 0.0	-12.5, 0.0	-12.5, 0.0
Week 52						
m	3	4	11			
n	2	3	9	2	3	9
Mean (SD/SE)	81.25 (26.52)	91.67 (7.22)	91.67 (16.54)	-18.75 (18.75)	-8.33 (4.17)	-1.39 (5.29)
Median	81.25	87.50	100.00	-18.75	-12.50	0
IQR: Q1, Q3	62.50, 100.00	87.50, 100.00	100.00, 100.00	-37.50, 0.00	-12.50, 0.00	0.00, 0.00
Min, Max	62.5, 100.0	87.5, 100.0	62.5, 100.0	-37.5, 0.0	-12.5, 0.0	-37.5, 25.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.5.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=6)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=6)	Change from Baseline DB Placebo (N=11)
Role Emotional						
Baseline						
m	4	6	11			
n	4	5	10			
Mean (SD)	85.43 (23.94)	100.00 (0.00)	87.51 (21.23)			
Median	95.85	100.00	100.00			
IQR: Q1, Q3	70.85, 100.00	100.00, 100.00	66.70, 100.00			
Min, Max	50.0, 100.0	100.0, 100.0	41.7, 100.0			
Week 24						
m	3	4	11			
n	3	4	10	3	4	10
Mean (SD/SE)	80.57 (17.33)	93.75 (12.50)	78.34 (25.81)	-16.67 (9.61)	-6.25 (6.25)	-9.17 (5.34)
Median	75.00	100.00	91.65	-16.70	0	0
IQR: Q1, Q3	66.70, 100.00	87.50, 100.00	50.00, 100.00	-33.30, 0.00	-12.50, 0.00	-16.70, 0.00
Min, Max	66.7, 100.0	75.0, 100.0	41.7, 100.0	-33.3, 0.0	-25.0, 0.0	-50.0, 0.0
Week 52						
m	3	4	11			
n	2	3	9	2	3	9
Mean (SD/SE)	83.35 (23.55)	91.67 (14.43)	80.56 (26.68)	-12.50 (12.50)	-8.33 (8.33)	-5.57 (7.74)
Median	83.35	100.00	100.00	-12.50	0	0
IQR: Q1, Q3	66.70, 100.00	75.00, 100.00	66.70, 100.00	-25.00, 0.00	-25.00, 0.00	0.00, 0.00
Min, Max	66.7, 100.0	75.0, 100.0	25.0, 100.0	-25.0, 0.0	-25.0, 0.0	-41.7, 33.3

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.5.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=6)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=6)	Change from Baseline DB Placebo (N=11)
Mental Health						
Baseline						
m	4	6	11			
n	4	5	10			
Mean (SD)	73.8 (12.5)	90.0 (7.1)	79.0 (17.9)			
Median	72.5	85.0	82.5			
IQR: Q1, Q3	65.0, 82.5	85.0, 95.0	60.0, 95.0			
Min, Max	60, 90	85, 100	50, 100			
Week 24						
m	3	4	11			
n	3	4	10	3	4	10
Mean (SD/SE)	76.7 (11.5)	88.8 (9.5)	77.0 (18.9)	-1.7 (1.7)	1.3 (4.3)	-2.0 (3.0)
Median	70.0	92.5	85.0	0	2.5	-2.5
IQR: Q1, Q3	70.0, 90.0	82.5, 95.0	60.0, 90.0	-5.0, 0.0	-5.0, 7.5	-5.0, 5.0
Min, Max	70, 90	75, 95	45, 100	-5, 0	-10, 10	-20, 15
Week 52						
m	3	4	11			
n	2	3	9	2	3	9
Mean (SD/SE)	85.0 (7.1)	76.7 (15.3)	78.9 (23.7)	2.5 (2.5)	-11.7 (6.7)	0.0 (6.4)
Median	85.0	80.0	85.0	2.5	-5.0	5.0
IQR: Q1, Q3	80.0, 90.0	60.0, 90.0	70.0, 95.0	0.0, 5.0	-25.0, -5.0	-5.0, 5.0
Min, Max	80, 90	60, 90	30, 100	0, 5	-25, -5	-40, 25

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.5.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=4)	(N=6)	(N=11)	(N=4)	(N=6)	(N=11)
Mental Component Score						
Baseline						
m	4	6	11			
n	4	5	10			
Mean (SD)	50.68 (6.02)	57.48 (2.44)	53.30 (7.88)			
Median	51.40	56.90	55.50			
IQR: Q1, Q3	46.20, 55.15	55.40, 59.00	46.50, 59.70			
Min, Max	42.9, 57.0	55.2, 60.9	38.1, 61.6			
Week 24						
m	3	4	11			
n	3	4	10	3	4	10
Mean (SD/SE)	45.50 (8.68)	56.50 (5.66)	51.86 (8.30)	-7.77 (3.22)	-0.60 (2.54)	-1.44 (1.18)
Median	41.10	58.45	55.40	-9.60	-0.45	-1.40
IQR: Q1, Q3	39.90, 55.50	52.80, 60.20	44.20, 58.30	-12.20, -1.50	-4.10, 2.90	-4.00, 1.30
Min, Max	39.9, 55.5	48.3, 60.8	37.1, 61.0	-12.2, -1.5	-6.9, 5.4	-8.1, 4.0
Week 52						
m	3	4	11			
n	2	3	9	2	3	9
Mean (SD/SE)	52.15 (6.72)	52.17 (7.70)	52.54 (9.74)	-3.00 (2.90)	-5.00 (3.20)	-0.63 (2.72)
Median	52.15	53.20	57.30	-3.00	-2.00	0.20
IQR: Q1, Q3	47.40, 56.90	44.00, 59.30	45.30, 60.30	-5.90, -0.10	-11.40, -1.60	-0.70, 5.00
Min, Max	47.4, 56.9	44.0, 59.3	35.3, 60.9	-5.9, -0.1	-11.4, -1.6	-16.0, 8.7

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.5.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=6)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=6)	Change from Baseline DB Placebo (N=11)
Physical Component Score						
Baseline						
m	4	6	11			
n	4	5	10			
Mean (SD)	44.88 (10.55)	53.94 (1.84)	53.18 (6.63)			
Median	44.65	54.20	53.55			
IQR: Q1, Q3	38.15, 51.60	53.10, 55.00	47.50, 59.30			
Min, Max	32.2, 58.0	51.3, 56.1	42.8, 61.1			
Week 24						
m	3	4	11			
n	3	4	10	3	4	10
Mean (SD/SE)	51.07 (10.32)	54.60 (2.97)	50.96 (10.05)	6.30 (2.84)	0.93 (1.57)	-2.22 (2.48)
Median	54.80	54.75	54.50	7.20	1.40	-1.25
IQR: Q1, Q3	39.40, 59.00	52.45, 56.75	38.20, 59.30	1.00, 10.70	-1.20, 3.05	-6.60, 2.20
Min, Max	39.4, 59.0	50.9, 58.0	36.0, 61.0	1.0, 10.7	-3.3, 4.2	-14.2, 11.8
Week 52						
m	3	4	11			
n	2	3	9	2	3	9
Mean (SD/SE)	46.35 (15.06)	52.07 (5.23)	51.73 (9.81)	-4.70 (3.70)	-1.43 (1.79)	-1.78 (2.61)
Median	46.35	49.10	57.20	-4.70	-2.30	-0.40
IQR: Q1, Q3	35.70, 57.00	49.00, 58.10	52.20, 58.30	-8.40, -1.00	-4.00, 2.00	-7.10, 0.30
Min, Max	35.7, 57.0	49.0, 58.1	34.3, 58.9	-8.4, -1.0	-4.0, 2.0	-15.9, 10.1

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.5.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=5)	(N=9)	(N=17)	(N=5)	(N=9)	(N=17)
Physical Functioning						
Baseline						
m	5	9	17			
n	5	9	16			
Mean (SD)	81.00 (8.22)	70.56 (18.28)	76.56 (22.11)			
Median	85.00	70.00	85.00			
IQR: Q1, Q3	75.00, 85.00	65.00, 80.00	67.50, 95.00			
Min, Max	70.0, 90.0	40.0, 100.0	25.0, 95.0			
Week 24						
m	5	8	16			
n	4	7	15	4	7	14
Mean (SD/SE)	85.00 (12.25)	77.86 (17.53)	75.00 (23.53)	5.00 (9.79)	3.57 (3.03)	-2.50 (6.48)
Median	85.00	80.00	80.00	2.50	0	5.00
IQR: Q1, Q3	77.50, 92.50	70.00, 90.00	70.00, 90.00	-10.00, 20.00	0.00, 5.00	-5.00, 5.00
Min, Max	70.0, 100.0	45.0, 100.0	20.0, 100.0	-15.0, 30.0	-5.0, 20.0	-75.0, 35.0
Week 52						
m	5	8	15			
n	5	7	15	5	7	14
Mean (SD/SE)	81.00 (7.42)	67.86 (21.77)	81.11 (18.53)	0.00 (5.00)	-6.43 (5.42)	2.26 (3.41)
Median	80.00	75.00	85.00	-5.00	0	5.00
IQR: Q1, Q3	80.00, 85.00	50.00, 85.00	66.70, 95.00	-5.00, -5.00	-20.00, 5.00	-5.00, 10.00
Min, Max	70.0, 90.0	40.0, 100.0	35.0, 100.0	-5.0, 20.0	-30.0, 10.0	-20.0, 30.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.5.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=5)	(N=9)	(N=17)	(N=5)	(N=9)	(N=17)
Role Physical						
Baseline						
m	5	9	17			
n	5	9	16			
Mean (SD)	83.76 (15.04)	84.73 (15.34)	77.74 (26.22)			
Median	75.00	81.30	84.40			
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	65.65, 100.00			
Min, Max	68.8, 100.0	62.5, 100.0	0.0, 100.0			
Week 24						
m	5	8	16			
n	4	7	15	4	7	14
Mean (SD/SE)	87.50 (14.43)	80.39 (18.19)	76.68 (29.64)	7.80 (5.92)	-7.11 (6.31)	2.69 (6.48)
Median	87.50	81.30	87.50	3.10	0	6.30
IQR: Q1, Q3	75.00, 100.00	62.50, 100.00	62.50, 100.00	0.00, 15.60	-6.20, 0.00	0.00, 12.50
Min, Max	75.0, 100.0	56.3, 100.0	6.3, 100.0	0.0, 25.0	-43.7, 6.3	-75.0, 31.2
Week 52						
m	5	8	15			
n	5	7	15	5	7	14
Mean (SD/SE)	85.00 (16.30)	68.76 (30.41)	77.93 (22.63)	1.24 (6.96)	-18.74 (9.15)	1.34 (5.29)
Median	87.50	75.00	75.00	0	-6.20	0
IQR: Q1, Q3	75.00, 100.00	37.50, 100.00	56.30, 100.00	-12.50, 6.20	-37.50, 0.00	-12.50, 12.50
Min, Max	62.5, 100.0	37.5, 100.0	31.3, 100.0	-12.5, 25.0	-62.5, 0.0	-37.5, 31.3

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.5.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=5)	(N=9)	(N=17)	(N=5)	(N=9)	(N=17)
Bodily Pain						
Baseline						
m	5	9	17			
n	5	9	16			
Mean (SD)	82.0 (20.1)	73.4 (20.8)	71.2 (22.7)			
Median	84.0	62.0	79.0			
IQR: Q1, Q3	74.0, 100.0	62.0, 100.0	61.5, 84.0			
Min, Max	52, 100	51, 100	12, 100			
Week 24						
m	5	8	16			
n	4	7	15	4	7	14
Mean (SD/SE)	90.5 (19.0)	74.3 (19.4)	67.6 (24.0)	13.0 (5.4)	-5.4 (6.2)	-2.2 (4.4)
Median	100.0	64.0	72.0	13.0	0	0
IQR: Q1, Q3	81.0, 100.0	62.0, 100.0	52.0, 84.0	5.0, 21.0	-10.0, 0.0	0.0, 10.0
Min, Max	62, 100	52, 100	12, 100	0, 26	-36, 18	-53, 12
Week 52						
m	5	8	15			
n	5	7	15	5	7	14
Mean (SD/SE)	74.0 (17.4)	76.6 (18.0)	68.8 (16.6)	-8.0 (5.8)	-3.1 (4.5)	-2.5 (4.7)
Median	62.0	74.0	74.0	-12.0	0	-10.0
IQR: Q1, Q3	62.0, 84.0	62.0, 100.0	52.0, 74.0	-16.0, 0.0	-10.0, 2.0	-10.0, 16.0
Min, Max	62, 100	52, 100	32, 100	-22, 10	-26, 12	-28, 23

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.5.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=5)	Visit Result DB MGL-3196 100 mg (N=9)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=5)	Change from Baseline DB MGL-3196 100 mg (N=9)	Change from Baseline DB Placebo (N=17)
General Health						
Baseline						
m	5	9	17			
n	5	9	16			
Mean (SD)	79.00 (7.58)	68.11 (11.12)	69.75 (19.92)			
Median	82.00	67.00	74.50			
IQR: Q1, Q3	77.00, 82.00	67.00, 72.00	62.00, 82.00			
Min, Max	67.0, 87.0	47.0, 82.0	25.0, 92.0			
Week 24						
m	5	8	16			
n	4	7	15	4	7	14
Mean (SD/SE)	84.50 (13.23)	63.86 (14.52)	69.07 (17.91)	2.50 (4.79)	-3.86 (6.03)	-1.07 (2.78)
Median	87.00	62.00	72.00	5.00	5.00	0
IQR: Q1, Q3	74.50, 94.50	52.00, 77.00	62.00, 82.00	-5.00, 10.00	-25.00, 10.00	-5.00, 5.00
Min, Max	67.0, 97.0	45.0, 87.0	30.0, 92.0	-10.0, 10.0	-27.0, 10.0	-20.0, 20.0
Week 52						
m	5	8	15			
n	5	7	15	5	7	14
Mean (SD/SE)	81.00 (10.25)	65.29 (15.07)	67.87 (15.74)	2.00 (3.39)	-2.43 (4.47)	-3.07 (3.01)
Median	77.00	62.00	72.00	5.00	0	-2.50
IQR: Q1, Q3	72.00, 92.00	52.00, 82.00	52.00, 77.00	0.00, 5.00	-5.00, 5.00	-10.00, 2.00
Min, Max	72.0, 92.0	45.0, 82.0	40.0, 92.0	-10.0, 10.0	-27.0, 10.0	-20.0, 15.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.5.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=5)	Visit Result DB MGL-3196 100 mg (N=9)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=5)	Change from Baseline DB MGL-3196 100 mg (N=9)	Change from Baseline DB Placebo (N=17)
Vitality						
Baseline						
m	5	9	17			
n	5	9	16			
Mean (SD)	67.54 (9.28)	66.00 (15.02)	63.69 (18.29)			
Median	68.80	68.80	62.50			
IQR: Q1, Q3	62.50, 68.80	56.30, 75.00	50.00, 75.00			
Min, Max	56.3, 81.3	43.8, 93.8	25.0, 93.8			
Week 24						
m	5	8	16			
n	4	7	15	4	7	14
Mean (SD/SE)	73.48 (11.83)	59.84 (11.87)	60.03 (22.26)	3.13 (4.02)	-4.47 (5.74)	-2.67 (5.02)
Median	78.15	56.30	62.50	3.10	0	-3.10
IQR: Q1, Q3	65.65, 81.30	50.00, 75.00	50.00, 75.00	-3.10, 9.35	-18.70, 6.20	-12.50, 6.30
Min, Max	56.3, 81.3	43.8, 75.0	6.3, 93.8	-6.2, 12.5	-31.3, 12.5	-50.0, 31.3
Week 52						
m	5	8	15			
n	5	7	15	5	7	14
Mean (SD/SE)	62.52 (15.93)	58.96 (18.69)	63.35 (20.03)	-5.02 (4.15)	-5.36 (3.45)	-0.90 (4.67)
Median	68.80	56.30	62.50	-6.20	0	-6.25
IQR: Q1, Q3	56.30, 75.00	43.80, 75.00	43.80, 75.00	-6.30, 0.00	-12.50, 0.00	-12.50, 12.50
Min, Max	37.5, 75.0	31.3, 81.3	25.0, 100.0	-18.8, 6.2	-18.7, 6.2	-25.0, 31.2

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.5.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=5)	(N=9)	(N=17)	(N=5)	(N=9)	(N=17)
Social Functioning						
Baseline						
m	5	9	17			
n	5	9	16			
Mean (SD)	95.00 (11.18)	83.33 (18.75)	90.63 (19.09)			
Median	100.00	87.50	100.00			
IQR: Q1, Q3	100.00, 100.00	87.50, 87.50	87.50, 100.00			
Min, Max	75.0, 100.0	37.5, 100.0	25.0, 100.0			
Week 24						
m	5	8	16			
n	4	7	15	4	7	14
Mean (SD/SE)	90.63 (18.75)	89.29 (13.36)	83.33 (27.41)	-3.13 (3.13)	5.36 (10.86)	-7.14 (8.56)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	81.25, 100.00	75.00, 100.00	75.00, 100.00	-6.25, 0.00	-12.50, 12.50	0.00, 0.00
Min, Max	62.5, 100.0	75.0, 100.0	0.0, 100.0	-12.5, 0.0	-25.0, 62.5	-100.0, 50.0
Week 52						
m	5	8	15			
n	5	7	15	5	7	14
Mean (SD/SE)	92.50 (16.77)	92.86 (12.20)	95.00 (11.38)	-2.50 (2.50)	8.93 (11.15)	3.57 (3.57)
Median	100.00	100.00	100.00	0	12.50	0
IQR: Q1, Q3	100.00, 100.00	75.00, 100.00	100.00, 100.00	0.00, 0.00	-25.00, 12.50	0.00, 0.00
Min, Max	62.5, 100.0	75.0, 100.0	62.5, 100.0	-12.5, 0.0	-25.0, 62.5	-12.5, 37.5

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.5.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=5)	Visit Result DB MGL-3196 100 mg (N=9)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=5)	Change from Baseline DB MGL-3196 100 mg (N=9)	Change from Baseline DB Placebo (N=17)
Role Emotional						
Baseline						
m	5	9	17			
n	5	9	16			
Mean (SD)	96.68 (4.55)	94.44 (9.32)	91.66 (13.95)			
Median	100.00	100.00	100.00			
IQR: Q1, Q3	91.70, 100.00	91.70, 100.00	83.30, 100.00			
Min, Max	91.7, 100.0	75.0, 100.0	50.0, 100.0			
Week 24						
m	5	8	16			
n	4	7	15	4	7	14
Mean (SD/SE)	95.83 (8.35)	90.47 (18.90)	89.99 (14.16)	-0.03 (3.41)	-5.96 (8.28)	-0.01 (1.23)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	91.65, 100.00	83.30, 100.00	83.30, 100.00	-4.20, 4.15	-16.70, 8.30	0.00, 0.00
Min, Max	83.3, 100.0	50.0, 100.0	58.3, 100.0	-8.4, 8.3	-50.0, 16.7	-8.4, 8.3
Week 52						
m	5	8	15			
n	5	7	15	5	7	14
Mean (SD/SE)	93.32 (9.15)	90.47 (18.90)	89.44 (16.82)	-3.36 (4.25)	-5.96 (7.43)	-2.98 (3.34)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	83.30, 100.00	83.30, 100.00	83.30, 100.00	-8.40, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	83.3, 100.0	50.0, 100.0	58.3, 100.0	-16.7, 8.3	-50.0, 8.3	-33.4, 16.7

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.5.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=5)	Visit Result DB MGL-3196 100 mg (N=9)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=5)	Change from Baseline DB MGL-3196 100 mg (N=9)	Change from Baseline DB Placebo (N=17)
Mental Health						
Baseline						
m	5	9	17			
n	5	9	16			
Mean (SD)	87.0 (9.7)	83.3 (7.1)	85.6 (12.2)			
Median	90.0	85.0	87.5			
IQR: Q1, Q3	80.0, 90.0	80.0, 90.0	80.0, 95.0			
Min, Max	75, 100	70, 90	60, 100			
Week 24						
m	5	8	16			
n	4	7	15	4	7	14
Mean (SD/SE)	93.8 (4.8)	82.9 (13.8)	85.7 (15.7)	5.0 (4.6)	-2.9 (6.6)	-0.4 (1.5)
Median	92.5	85.0	90.0	5.0	0	0
IQR: Q1, Q3	90.0, 97.5	80.0, 90.0	75.0, 95.0	-2.5, 12.5	-5.0, 0.0	-5.0, 5.0
Min, Max	90, 100	55, 100	55, 100	-5, 15	-35, 25	-10, 10
Week 52						
m	5	8	15			
n	5	7	15	5	7	14
Mean (SD/SE)	86.0 (10.8)	82.9 (8.1)	85.7 (15.7)	-1.0 (2.9)	-2.9 (3.8)	-0.4 (2.0)
Median	90.0	80.0	90.0	0	-5.0	0
IQR: Q1, Q3	80.0, 95.0	80.0, 90.0	80.0, 100.0	-5.0, 5.0	-10.0, 5.0	-5.0, 5.0
Min, Max	70, 95	70, 95	50, 100	-10, 5	-15, 15	-15, 15

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.5.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=5)	Visit Result DB MGL-3196 100 mg (N=9)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=5)	Change from Baseline DB MGL-3196 100 mg (N=9)	Change from Baseline DB Placebo (N=17)
Mental Component Score						
Baseline						
m	5	9	17			
n	5	9	16			
Mean (SD)	57.38 (3.66)	55.89 (3.11)	56.35 (6.40)			
Median	59.20	57.10	57.80			
IQR: Q1, Q3	53.80, 59.70	53.30, 57.50	53.05, 61.95			
Min, Max	53.1, 61.1	51.1, 60.9	44.1, 63.2			
Week 24						
m	5	8	16			
n	4	7	15	4	7	14
Mean (SD/SE)	58.25 (4.24)	54.57 (6.73)	55.20 (7.70)	-0.03 (0.59)	-1.46 (3.52)	-0.95 (1.14)
Median	60.20	56.20	57.60	0.05	-0.30	-0.60
IQR: Q1, Q3	56.05, 60.45	52.10, 59.50	51.40, 60.40	-1.05, 1.00	-5.00, 4.90	-3.20, 0.60
Min, Max	51.9, 60.7	40.8, 61.0	38.7, 62.8	-1.2, 1.0	-20.1, 8.4	-6.7, 10.8
Week 52						
m	5	8	15			
n	5	7	15	5	7	14
Mean (SD/SE)	55.94 (6.32)	56.13 (2.69)	56.09 (8.66)	-1.44 (1.42)	0.10 (1.81)	-0.47 (1.28)
Median	59.50	56.80	60.00	-1.60	1.70	0.65
IQR: Q1, Q3	50.60, 60.60	53.10, 58.80	51.80, 61.60	-2.50, 1.40	-2.80, 4.40	-1.70, 2.50
Min, Max	47.7, 61.3	52.6, 59.6	37.9, 65.5	-6.1, 1.6	-7.8, 5.9	-12.8, 5.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.5.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=5)	Visit Result DB MGL-3196 100 mg (N=9)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=5)	Change from Baseline DB MGL-3196 100 mg (N=9)	Change from Baseline DB Placebo (N=17)
Physical Component Score						
Baseline						
m	5	9	17			
n	5	9	16			
Mean (SD)	51.32 (4.41)	47.98 (7.50)	47.87 (9.35)			
Median	49.60	44.40	51.15			
IQR: Q1, Q3	49.10, 55.30	42.80, 53.60	43.75, 53.55			
Min, Max	46.1, 56.5	37.8, 60.3	21.6, 57.1			
Week 24						
m	5	8	16			
n	4	7	15	4	7	14
Mean (SD/SE)	53.55 (5.37)	48.47 (5.87)	47.04 (10.28)	3.23 (2.13)	-0.76 (1.52)	-0.45 (2.40)
Median	54.00	48.50	50.80	1.20	-0.60	1.10
IQR: Q1, Q3	49.05, 58.05	42.30, 53.00	41.40, 54.40	0.95, 5.50	-4.50, 3.10	-0.10, 3.00
Min, Max	47.5, 58.7	40.9, 58.0	24.6, 57.1	0.9, 9.6	-6.4, 4.9	-30.0, 7.3
Week 52						
m	5	8	15			
n	5	7	15	5	7	14
Mean (SD/SE)	51.04 (4.96)	45.84 (9.96)	48.26 (7.46)	-0.28 (1.47)	-3.39 (2.34)	0.11 (1.70)
Median	52.70	46.60	50.50	0.30	-1.70	1.25
IQR: Q1, Q3	47.50, 53.70	35.30, 55.00	42.50, 53.90	-1.60, 1.40	-8.40, 1.40	-4.30, 2.80
Min, Max	44.5, 56.8	33.4, 58.6	31.5, 56.3	-5.1, 3.6	-14.8, 2.9	-10.8, 9.9

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.5.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

Madrigal Pharmaceuticals, Inc. Page 2 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.5.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Physical Functioning			
Week 24			
m	3	4	11
n	3	4	10
Baseline Mean (SD)	66.67 (41.63)	93.75 (4.79)	86.50 (19.59)
Analysis Visit Mean (SD)	81.67 (31.75)	93.75 (6.29)	78.50 (27.19)
LS Mean of Change from Baseline (SE)	12.83 (13.25)	-4.37 (12.38)	-5.79 (6.86)
95% CI	(-15.60, 41.25)	(-30.92, 22.18)	(-20.50, 8.92)
LS Mean of Change from Baseline Compared to Placebo (SE)	18.62 (14.14)	1.42 (15.40)	
95% CI	(-11.71, 48.94)	(-31.61, 34.45)	
p-value	0.2091	0.9278	
Corrected Hedge's g Statistics	0.790	0.059	
95% CI	(-0.54, 2.12)	(-1.10, 1.22)	
Week 52			
m	3	4	11
n	2	3	9
Baseline Mean (SD)	90.00 (14.14)	95.00 (5.00)	87.78 (20.33)
Analysis Visit Mean (SD)	75.00 (35.36)	90.00 (8.66)	82.78 (28.84)
LS Mean of Change from Baseline (SE)	-11.98 (15.27)	-12.47 (13.81)	-2.03 (7.59)
95% CI	(-44.73, 20.77)	(-42.09, 17.14)	(-18.30, 14.23)
LS Mean of Change from Baseline Compared to Placebo (SE)	-9.95 (16.21)	-10.44 (16.93)	
95% CI	(-44.71, 24.82)	(-46.74, 25.86)	
p-value	0.5493	0.5473	
Corrected Hedge's g Statistics	-0.402	-0.419	
95% CI	(-1.94, 1.14)	(-1.74, 0.90)	
Subgroup*Treatment Interaction p-value	0.7080	0.6089	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 3 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.5.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Role Physical			
Week 24			
m	3	4	11
n	3	4	10
Baseline Mean (SD)	87.50 (12.50)	96.90 (3.58)	82.51 (23.16)
Analysis Visit Mean (SD)	85.43 (25.23)	98.45 (3.10)	75.00 (33.33)
LS Mean of Change from Baseline (SE)	-2.33 (13.18)	2.39 (13.41)	-7.85 (7.72)
95% CI	(-30.59, 25.93)	(-26.37, 31.14)	(-24.40, 8.71)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.52 (14.92)	10.23 (16.81)	
95% CI	(-26.49, 37.52)	(-25.83, 46.29)	
p-value	0.7172	0.5526	
Corrected Hedge's g Statistics	0.213	0.383	
95% CI	(-1.08, 1.51)	(-0.79, 1.55)	
Week 52			
m	3	4	11
n	2	3	9
Baseline Mean (SD)	93.75 (8.84)	97.93 (3.58)	81.96 (24.49)
Analysis Visit Mean (SD)	81.25 (26.52)	93.77 (10.80)	76.40 (31.36)
LS Mean of Change from Baseline (SE)	-17.35 (15.27)	-2.82 (14.20)	-7.45 (7.98)
95% CI	(-50.10, 15.40)	(-33.28, 27.64)	(-24.56, 9.67)
LS Mean of Change from Baseline Compared to Placebo (SE)	-9.90 (16.68)	4.63 (17.73)	
95% CI	(-45.68, 25.88)	(-33.39, 42.65)	
p-value	0.5623	0.7979	
Corrected Hedge's g Statistics	-0.382	0.177	
95% CI	(-1.92, 1.16)	(-1.13, 1.49)	
Subgroup*Treatment Interaction p-value	0.7715	0.2682	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 4 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.5.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Bodily Pain			
Week 24			
m	3	4	11
n	3	4	10
Baseline Mean (SD)	64.7 (34.1)	84.0 (0.0)	86.0 (14.7)
Analysis Visit Mean (SD)	78.3 (25.0)	85.5 (10.8)	84.0 (24.3)
LS Mean of Change from Baseline (SE)	12.23 (10.84)	0.75 (9.37)	-1.26 (5.63)
95% CI	(-11.02, 35.47)	(-19.36, 20.85)	(-13.33, 10.82)
LS Mean of Change from Baseline Compared to Placebo (SE)	13.48 (12.36)	2.00 (11.48)	
95% CI	(-13.02, 39.98)	(-22.61, 26.62)	
p-value	0.2936	0.8639	
Corrected Hedge's g Statistics	0.697	0.104	
95% CI	(-0.62, 2.02)	(-1.06, 1.26)	
Week 52			
m	3	4	11
n	2	3	9
Baseline Mean (SD)	66.0 (48.1)	84.0 (0.0)	86.2 (15.6)
Analysis Visit Mean (SD)	53.0 (43.8)	73.3 (11.0)	84.6 (22.8)
LS Mean of Change from Baseline (SE)	-7.57 (8.75)	-12.17 (7.75)	-4.92 (4.50)
95% CI	(-26.34, 11.19)	(-28.80, 4.46)	(-14.58, 4.74)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.65 (9.65)	-7.25 (9.73)	
95% CI	(-23.34, 18.03)	(-28.11, 13.61)	
p-value	0.7872	0.4683	
Corrected Hedge's g Statistics	-0.181	-0.496	
95% CI	(-1.72, 1.35)	(-1.82, 0.83)	
Subgroup*Treatment Interaction p-value	0.3215	0.5729	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 5 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.5.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
General Health			
Week 24			
m	3	4	11
n	3	4	10
Baseline Mean (SD)	53.00 (26.23)	67.75 (14.57)	69.90 (19.04)
Analysis Visit Mean (SD)	61.33 (32.35)	68.25 (17.50)	64.40 (21.61)
LS Mean of Change from Baseline (SE)	5.20 (11.38)	0.55 (10.69)	-4.91 (6.20)
95% CI	(-19.21, 29.60)	(-22.38, 23.49)	(-18.20, 8.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	10.10 (12.77)	5.46 (13.28)	
95% CI	(-17.28, 37.49)	(-23.02, 33.94)	
p-value	0.4420	0.6872	
Corrected Hedge's g Statistics	0.479	0.255	
95% CI	(-0.82, 1.78)	(-0.91, 1.42)	
Week 52			
m	3	4	11
n	2	3	9
Baseline Mean (SD)	67.00 (14.14)	64.67 (16.17)	69.89 (20.20)
Analysis Visit Mean (SD)	71.00 (22.63)	58.67 (17.56)	65.83 (26.06)
LS Mean of Change from Baseline (SE)	-3.15 (15.33)	-11.04 (13.59)	-6.10 (7.87)
95% CI	(-36.02, 29.73)	(-40.20, 18.11)	(-22.99, 10.79)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.95 (17.07)	-4.94 (16.47)	
95% CI	(-33.67, 39.57)	(-40.28, 30.39)	
p-value	0.8653	0.7685	
Corrected Hedge's g Statistics	0.115	-0.193	
95% CI	(-1.42, 1.65)	(-1.50, 1.12)	
Subgroup*Treatment Interaction p-value	0.8279	0.9382	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 6 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.5.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Vitality			
Week 24			
m	3	4	11
n	3	4	10
Baseline Mean (SD)	39.60 (37.68)	71.90 (10.85)	70.02 (19.27)
Analysis Visit Mean (SD)	29.17 (31.46)	78.18 (11.97)	67.51 (18.59)
LS Mean of Change from Baseline (SE)	-17.61 (10.20)	5.93 (8.60)	-1.13 (4.73)
95% CI	(-39.48, 4.27)	(-12.52, 24.38)	(-11.28, 9.03)
LS Mean of Change from Baseline Compared to Placebo (SE)	-16.48 (10.89)	7.06 (10.55)	
95% CI	(-39.84, 6.87)	(-15.56, 29.67)	
p-value	0.1524	0.5144	
Corrected Hedge's g Statistics	-0.989	0.425	
95% CI	(-2.33, 0.36)	(-0.75, 1.59)	
Week 52			
m	3	4	11
n	2	3	9
Baseline Mean (SD)	59.40 (22.06)	68.77 (10.85)	72.93 (17.96)
Analysis Visit Mean (SD)	43.80 (35.36)	62.53 (6.25)	70.84 (25.58)
LS Mean of Change from Baseline (SE)	-13.59 (12.35)	-11.39 (10.34)	-2.98 (5.90)
95% CI	(-40.08, 12.90)	(-33.58, 10.79)	(-15.64, 9.68)
LS Mean of Change from Baseline Compared to Placebo (SE)	-10.61 (13.36)	-8.41 (12.61)	
95% CI	(-39.25, 18.03)	(-35.46, 18.63)	
p-value	0.4402	0.5155	
Corrected Hedge's g Statistics	-0.549	-0.438	
95% CI	(-2.10, 1.00)	(-1.76, 0.88)	
Subgroup*Treatment Interaction p-value	0.1596	0.5094	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 7 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.5.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Social Functioning			
Week 24			
m	3	4	11
n	3	4	10
Baseline Mean (SD)	87.50 (21.65)	96.88 (6.25)	93.75 (13.50)
Analysis Visit Mean (SD)	75.00 (25.00)	93.75 (7.22)	92.50 (15.81)
LS Mean of Change from Baseline (SE)	-11.68 (4.07)	-4.20 (3.96)	-0.85 (2.29)
95% CI	(-20.42, -2.95)	(-12.70, 4.30)	(-5.76, 4.06)
LS Mean of Change from Baseline Compared to Placebo (SE)	-10.83 (4.53)	-3.35 (4.93)	
95% CI	(-20.54, -1.12)	(-13.93, 7.23)	
p-value	0.0313	0.5082	
Corrected Hedge's g Statistics	-1.398	-0.423	
95% CI	(-2.80, 0.00)	(-1.59, 0.75)	
Week 52			
m	3	4	11
n	2	3	9
Baseline Mean (SD)	100.00 (0.00)	100.00 (0.00)	93.06 (14.13)
Analysis Visit Mean (SD)	81.25 (26.52)	91.67 (7.22)	91.67 (16.54)
LS Mean of Change from Baseline (SE)	-14.91 (11.32)	-5.75 (9.47)	-1.56 (5.33)
95% CI	(-39.19, 9.37)	(-26.07, 14.56)	(-13.00, 9.87)
LS Mean of Change from Baseline Compared to Placebo (SE)	-13.35 (12.49)	-4.19 (11.13)	
95% CI	(-40.14, 13.45)	(-28.07, 19.68)	
p-value	0.3035	0.7122	
Corrected Hedge's g Statistics	-0.763	-0.241	
95% CI	(-2.33, 0.80)	(-1.55, 1.07)	
Subgroup*Treatment Interaction p-value	0.2205	0.7341	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 8 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.5.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Role Emotional			
Week 24			
m	3	4	11
n	3	4	10
Baseline Mean (SD)	97.23 (4.79)	100.00 (0.00)	87.51 (21.23)
Analysis Visit Mean (SD)	80.57 (17.33)	93.75 (12.50)	78.34 (25.81)
LS Mean of Change from Baseline (SE)	-15.54 (10.10)	-7.47 (9.97)	-8.72 (5.79)
95% CI	(-37.20, 6.11)	(-28.86, 13.92)	(-21.14, 3.70)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.82 (11.51)	1.25 (12.45)	
95% CI	(-31.50, 17.86)	(-25.46, 27.96)	
p-value	0.5627	0.9215	
Corrected Hedge's g Statistics	-0.349	0.062	
95% CI	(-1.65, 0.95)	(-1.10, 1.22)	
Week 52			
m	3	4	11
n	2	3	9
Baseline Mean (SD)	95.85 (5.87)	100.00 (0.00)	86.12 (22.03)
Analysis Visit Mean (SD)	83.35 (23.55)	91.67 (14.43)	80.56 (26.68)
LS Mean of Change from Baseline (SE)	-13.01 (15.71)	-7.01 (13.71)	-5.67 (7.85)
95% CI	(-46.71, 20.68)	(-36.41, 22.39)	(-22.50, 11.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	-7.34 (17.24)	-1.34 (16.83)	
95% CI	(-44.31, 29.62)	(-37.44, 34.76)	
p-value	0.6765	0.9377	
Corrected Hedge's g Statistics	-0.287	-0.052	
95% CI	(-1.82, 1.25)	(-1.36, 1.25)	
Subgroup*Treatment Interaction p-value	0.4956	0.6042	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 9 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.5.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Mental Health			
Week 24			
m	3	4	11
n	3	4	10
Baseline Mean (SD)	78.3 (10.4)	87.5 (5.0)	79.0 (17.9)
Analysis Visit Mean (SD)	76.7 (11.5)	88.8 (9.5)	77.0 (18.9)
LS Mean of Change from Baseline (SE)	-0.42 (4.96)	-2.57 (5.07)	-0.45 (2.88)
95% CI	(-11.07, 10.22)	(-13.44, 8.29)	(-6.63, 5.73)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.03 (5.55)	-2.12 (6.34)	
95% CI	(-11.88, 11.93)	(-15.71, 11.47)	
p-value	0.9965	0.7424	
Corrected Hedge's g Statistics	0.003	-0.212	
95% CI	(-1.29, 1.29)	(-1.37, 0.95)	
Week 52			
m	3	4	11
n	2	3	9
Baseline Mean (SD)	82.5 (10.6)	88.3 (5.8)	78.9 (19.0)
Analysis Visit Mean (SD)	85.0 (7.1)	76.7 (15.3)	78.9 (23.7)
LS Mean of Change from Baseline (SE)	5.09 (11.22)	-13.40 (9.77)	1.99 (5.53)
95% CI	(-18.96, 29.14)	(-34.35, 7.56)	(-9.87, 13.85)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.10 (12.41)	-15.38 (11.60)	
95% CI	(-23.52, 29.72)	(-40.27, 9.50)	
p-value	0.8063	0.2061	
Corrected Hedge's g Statistics	0.172	-0.852	
95% CI	(-1.36, 1.71)	(-2.20, 0.50)	
Subgroup*Treatment Interaction p-value	0.5977	0.9055	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 10 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.5.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Mental Component Score			
Week 24			
m	3	4	11
n	3	4	10
Baseline Mean (SD)	53.27 (3.75)	57.10 (2.64)	53.30 (7.88)
Analysis Visit Mean (SD)	45.50 (8.68)	56.50 (5.66)	51.86 (8.30)
LS Mean of Change from Baseline (SE)	-7.29 (2.68)	-2.02 (2.69)	-0.87 (1.54)
95% CI	(-13.03, -1.55)	(-7.78, 3.74)	(-4.19, 2.44)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.42 (3.00)	-1.15 (3.34)	
95% CI	(-12.86, 0.02)	(-8.31, 6.02)	
p-value	0.0508	0.7364	
Corrected Hedge's g Statistics	-1.234	-0.214	
95% CI	(-2.61, 0.14)	(-1.38, 0.95)	
Week 52			
m	3	4	11
n	2	3	9
Baseline Mean (SD)	55.15 (2.62)	57.17 (3.23)	53.18 (8.35)
Analysis Visit Mean (SD)	52.15 (6.72)	52.17 (7.70)	52.54 (9.74)
LS Mean of Change from Baseline (SE)	-1.67 (5.37)	-5.68 (4.55)	-0.05 (2.58)
95% CI	(-13.17, 9.84)	(-15.45, 4.08)	(-5.59, 5.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.62 (5.84)	-5.63 (5.45)	
95% CI	(-14.13, 10.90)	(-17.33, 6.06)	
p-value	0.7860	0.3190	
Corrected Hedge's g Statistics	-0.191	-0.669	
95% CI	(-1.73, 1.34)	(-2.00, 0.66)	
Subgroup*Treatment Interaction p-value	0.1017	0.9863	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 11 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.5.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Physical Component Score			
Week 24			
m	3	4	11
n	3	4	10
Baseline Mean (SD)	44.77 (12.91)	53.68 (2.01)	53.18 (6.63)
Analysis Visit Mean (SD)	51.07 (10.32)	54.60 (2.97)	50.96 (10.05)
LS Mean of Change from Baseline (SE)	5.37 (4.76)	0.71 (4.25)	-1.96 (2.40)
95% CI	(-4.84, 15.59)	(-8.41, 9.83)	(-7.12, 3.20)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.33 (5.20)	2.67 (5.24)	
95% CI	(-3.83, 18.49)	(-8.58, 13.91)	
p-value	0.1807	0.6191	
Corrected Hedge's g Statistics	0.883	0.318	
95% CI	(-0.45, 2.22)	(-0.85, 1.48)	
Week 52			
m	3	4	11
n	2	3	9
Baseline Mean (SD)	51.05 (9.83)	53.50 (2.42)	53.51 (6.94)
Analysis Visit Mean (SD)	46.35 (15.06)	52.07 (5.23)	51.73 (9.81)
LS Mean of Change from Baseline (SE)	-4.71 (5.37)	-3.12 (4.71)	-2.78 (2.66)
95% CI	(-16.24, 6.81)	(-13.22, 6.99)	(-8.49, 2.93)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.93 (5.83)	-0.34 (5.76)	
95% CI	(-14.45, 10.58)	(-12.68, 12.01)	
p-value	0.7455	0.9539	
Corrected Hedge's g Statistics	-0.222	-0.039	
95% CI	(-1.76, 1.31)	(-1.35, 1.27)	
Subgroup*Treatment Interaction p-value	0.7057	0.7160	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 12 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.5.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Physical Functioning			
Week 24			
m	5	8	16
n	4	7	14
Baseline Mean (SD)	80.00 (9.13)	74.29 (18.80)	77.86 (23.43)
Analysis Visit Mean (SD)	85.00 (12.25)	77.86 (17.53)	75.36 (24.37)
LS Mean of Change from Baseline (SE)	4.78 (9.65)	0.73 (7.84)	-3.68 (6.22)
95% CI	(-15.23, 24.78)	(-15.54, 17.00)	(-16.59, 9.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	8.46 (10.70)	4.41 (8.81)	
95% CI	(-13.72, 30.64)	(-13.86, 22.69)	
p-value	0.4374	0.6215	
Corrected Hedge's g Statistics	0.357	0.188	
95% CI	(-0.76, 1.47)	(-0.72, 1.10)	
Week 52			
m	5	8	15
n	5	7	14
Baseline Mean (SD)	81.00 (8.22)	74.29 (18.80)	77.86 (23.43)
Analysis Visit Mean (SD)	81.00 (7.42)	67.86 (21.77)	80.12 (18.81)
LS Mean of Change from Baseline (SE)	0.04 (6.00)	-8.79 (5.54)	1.00 (4.84)
95% CI	(-12.40, 12.47)	(-20.27, 2.69)	(-9.03, 11.03)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.96 (6.33)	-9.79 (5.60)	
95% CI	(-14.09, 12.17)	(-21.40, 1.82)	
p-value	0.8804	0.0943	
Corrected Hedge's g Statistics	-0.054	-0.550	
95% CI	(-1.08, 0.97)	(-1.47, 0.37)	
Subgroup*Treatment Interaction p-value	0.7080	0.6089	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 13 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.5.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Role Physical			
Week 24			
m	5	8	16
n	4	7	14
Baseline Mean (SD)	79.70 (13.85)	87.50 (16.14)	75.90 (27.61)
Analysis Visit Mean (SD)	87.50 (14.43)	80.39 (18.19)	78.59 (29.79)
LS Mean of Change from Baseline (SE)	9.51 (10.33)	-0.62 (8.99)	5.32 (7.13)
95% CI	(-11.92, 30.93)	(-19.27, 18.03)	(-9.46, 20.11)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.18 (11.50)	-5.94 (9.52)	
95% CI	(-19.67, 28.04)	(-25.68, 13.80)	
p-value	0.7196	0.5388	
Corrected Hedge's g Statistics	0.155	-0.221	
95% CI	(-0.96, 1.27)	(-1.13, 0.69)	
Week 52			
m	5	8	15
n	5	7	14
Baseline Mean (SD)	83.76 (15.04)	87.50 (16.14)	75.90 (27.61)
Analysis Visit Mean (SD)	85.00 (16.30)	68.76 (30.41)	77.24 (23.32)
LS Mean of Change from Baseline (SE)	5.47 (9.67)	-12.18 (9.00)	3.94 (7.16)
95% CI	(-14.58, 25.53)	(-30.85, 6.49)	(-10.92, 18.80)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.53 (10.63)	-16.12 (9.56)	
95% CI	(-20.51, 23.58)	(-35.94, 3.71)	
p-value	0.8867	0.1059	
Corrected Hedge's g Statistics	0.057	-0.597	
95% CI	(-0.96, 1.08)	(-1.52, 0.33)	
Subgroup*Treatment Interaction p-value	0.7715	0.2682	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 14 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.5.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Bodily Pain			
Week 24			
m	5	8	16
n	4	7	14
Baseline Mean (SD)	77.5 (20.1)	79.7 (19.3)	70.2 (24.1)
Analysis Visit Mean (SD)	90.5 (19.0)	74.3 (19.4)	68.0 (24.8)
LS Mean of Change from Baseline (SE)	15.98 (7.72)	-0.06 (6.46)	0.78 (4.97)
95% CI	(-0.03, 31.99)	(-13.46, 13.34)	(-9.53, 11.10)
LS Mean of Change from Baseline Compared to Placebo (SE)	15.20 (8.68)	-0.85 (7.10)	
95% CI	(-2.80, 33.19)	(-15.58, 13.88)	
p-value	0.0938	0.9063	
Corrected Hedge's g Statistics	0.802	-0.045	
95% CI	(-0.34, 1.94)	(-0.95, 0.86)	
Week 52			
m	5	8	15
n	5	7	14
Baseline Mean (SD)	82.0 (20.1)	79.7 (19.3)	70.2 (24.1)
Analysis Visit Mean (SD)	74.0 (17.4)	76.6 (18.0)	67.7 (16.6)
LS Mean of Change from Baseline (SE)	-1.25 (6.09)	3.32 (5.55)	-0.42 (4.41)
95% CI	(-13.89, 11.39)	(-8.20, 14.83)	(-9.57, 8.74)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.84 (6.59)	3.73 (5.83)	
95% CI	(-14.51, 12.84)	(-8.35, 15.82)	
p-value	0.9004	0.5284	
Corrected Hedge's g Statistics	-0.050	0.225	
95% CI	(-1.07, 0.97)	(-0.69, 1.13)	
Subgroup*Treatment Interaction p-value	0.3215	0.5729	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 15 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.5.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
General Health			
Week 24			
m	5	8	16
n	4	7	14
Baseline Mean (SD)	82.00 (4.08)	67.71 (12.72)	72.07 (18.07)
Analysis Visit Mean (SD)	84.50 (13.23)	63.86 (14.52)	71.00 (16.88)
LS Mean of Change from Baseline (SE)	6.28 (6.26)	-3.75 (5.12)	0.55 (4.19)
95% CI	(-6.70, 19.27)	(-14.37, 6.86)	(-8.14, 9.24)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.73 (6.84)	-4.31 (5.51)	
95% CI	(-8.45, 19.92)	(-15.73, 7.12)	
p-value	0.4110	0.4427	
Corrected Hedge's g Statistics	0.361	-0.275	
95% CI	(-0.76, 1.48)	(-1.19, 0.64)	
Week 52			
m	5	8	15
n	5	7	14
Baseline Mean (SD)	79.00 (7.58)	67.71 (12.72)	72.07 (18.07)
Analysis Visit Mean (SD)	81.00 (10.25)	65.29 (15.07)	69.00 (15.68)
LS Mean of Change from Baseline (SE)	5.18 (5.18)	-2.38 (4.65)	-1.45 (3.92)
95% CI	(-5.57, 15.92)	(-12.02, 7.27)	(-9.59, 6.68)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.63 (5.54)	-0.92 (4.87)	
95% CI	(-4.86, 18.12)	(-11.01, 9.17)	
p-value	0.2444	0.8512	
Corrected Hedge's g Statistics	0.452	-0.063	
95% CI	(-0.58, 1.48)	(-0.97, 0.84)	
Subgroup*Treatment Interaction p-value	0.8279	0.9382	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 16 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.5.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Vitality			
Week 24			
m	5	8	16
n	4	7	14
Baseline Mean (SD)	70.35 (7.88)	64.31 (16.82)	63.86 (19.02)
Analysis Visit Mean (SD)	73.48 (11.83)	59.84 (11.87)	61.19 (22.62)
LS Mean of Change from Baseline (SE)	3.18 (8.56)	-6.31 (7.08)	-4.41 (5.79)
95% CI	(-14.57, 20.93)	(-20.99, 8.38)	(-16.42, 7.59)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.60 (9.43)	-1.89 (7.61)	
95% CI	(-11.96, 27.15)	(-17.68, 13.89)	
p-value	0.4292	0.8057	
Corrected Hedge's g Statistics	0.346	-0.088	
95% CI	(-0.77, 1.46)	(-1.00, 0.82)	
Week 52			
m	5	8	15
n	5	7	14
Baseline Mean (SD)	67.54 (9.28)	64.31 (16.82)	63.86 (19.02)
Analysis Visit Mean (SD)	62.52 (15.93)	58.96 (18.69)	62.96 (20.73)
LS Mean of Change from Baseline (SE)	-5.46 (7.01)	-7.11 (6.41)	-2.49 (5.38)
95% CI	(-19.99, 9.07)	(-20.40, 6.18)	(-13.65, 8.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.96 (7.56)	-4.62 (6.66)	
95% CI	(-18.64, 12.71)	(-18.43, 9.19)	
p-value	0.6987	0.4951	
Corrected Hedge's g Statistics	-0.148	-0.231	
95% CI	(-1.17, 0.87)	(-1.14, 0.68)	
Subgroup*Treatment Interaction p-value	0.1596	0.5094	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 17 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.5.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Social Functioning			
Week 24			
m	5	8	16
n	4	7	14
Baseline Mean (SD)	93.75 (12.50)	83.93 (21.30)	91.07 (20.47)
Analysis Visit Mean (SD)	90.63 (18.75)	89.29 (13.36)	83.93 (28.35)
LS Mean of Change from Baseline (SE)	0.12 (12.61)	-1.44 (10.02)	-7.85 (7.58)
95% CI	(-26.02, 26.27)	(-22.23, 19.35)	(-23.57, 7.88)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.97 (14.07)	6.41 (11.70)	
95% CI	(-21.21, 37.15)	(-17.86, 30.68)	
p-value	0.5768	0.5892	
Corrected Hedge's g Statistics	0.273	0.221	
95% CI	(-0.84, 1.39)	(-0.69, 1.13)	
Week 52			
m	5	8	15
n	5	7	14
Baseline Mean (SD)	95.00 (11.18)	83.93 (21.30)	91.07 (20.47)
Analysis Visit Mean (SD)	92.50 (16.77)	92.86 (12.20)	94.64 (11.72)
LS Mean of Change from Baseline (SE)	-0.11 (5.97)	2.78 (5.49)	2.71 (4.81)
95% CI	(-12.48, 12.27)	(-8.61, 14.18)	(-7.26, 12.69)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.82 (6.28)	0.07 (5.60)	
95% CI	(-15.84, 10.20)	(-11.55, 11.69)	
p-value	0.6576	0.9904	
Corrected Hedge's g Statistics	-0.158	0.004	
95% CI	(-1.18, 0.86)	(-0.90, 0.91)	
Subgroup*Treatment Interaction p-value	0.2205	0.7341	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE21.5.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Role Emotional			
Week 24			
m	5	8	16
n	4	7	14
Baseline Mean (SD)	95.85 (4.79)	96.43 (6.56)	91.66 (14.62)
Analysis Visit Mean (SD)	95.83 (8.35)	90.47 (18.90)	91.66 (13.09)
LS Mean of Change from Baseline (SE)	0.70 (6.32)	-1.92 (5.91)	2.62 (5.00)
95% CI	(-12.41, 13.81)	(-14.18, 10.34)	(-7.74, 12.98)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.92 (6.81)	-4.54 (5.85)	
95% CI	(-16.04, 12.20)	(-16.67, 7.59)	
p-value	0.7809	0.4458	
Corrected Hedge's g Statistics	-0.103	-0.245	
95% CI	(-1.21, 1.01)	(-1.16, 0.67)	
Week 52			
m	5	8	15
n	5	7	14
Baseline Mean (SD)	96.68 (4.55)	96.43 (6.56)	91.66 (14.62)
Analysis Visit Mean (SD)	93.32 (9.15)	90.47 (18.90)	88.69 (17.19)
LS Mean of Change from Baseline (SE)	-0.20 (7.36)	-2.09 (6.77)	-0.22 (5.52)
95% CI	(-15.46, 15.07)	(-16.14, 11.96)	(-11.67, 11.23)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.02 (8.05)	-1.87 (7.14)	
95% CI	(-16.67, 16.72)	(-16.67, 12.93)	
p-value	0.9977	0.7958	
Corrected Hedge's g Statistics	0.001	-0.090	
95% CI	(-1.02, 1.02)	(-1.00, 0.82)	
Subgroup*Treatment Interaction p-value	0.4956	0.6042	

AMNOG Table SE21.5.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Mental Health			
Week 24			
m	5	8	16
n	4	7	14
Baseline Mean (SD)	88.8 (10.3)	85.7 (5.3)	85.7 (13.1)
Analysis Visit Mean (SD)	93.8 (4.8)	82.9 (13.8)	85.4 (16.2)
LS Mean of Change from Baseline (SE)	3.99 (5.91)	-3.28 (4.86)	-0.34 (3.90)
95% CI	(-8.26, 16.24)	(-13.37, 6.81)	(-8.42, 7.74)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.32 (6.53)	-2.94 (5.37)	
95% CI	(-9.21, 17.86)	(-14.08, 8.19)	
p-value	0.5146	0.5890	
Corrected Hedge's g Statistics	0.292	-0.201	
95% CI	(-0.82, 1.41)	(-1.11, 0.71)	
Week 52			
m	5	8	15
n	5	7	14
Baseline Mean (SD)	87.0 (9.7)	85.7 (5.3)	85.7 (13.1)
Analysis Visit Mean (SD)	86.0 (10.8)	82.9 (8.1)	85.4 (16.2)
LS Mean of Change from Baseline (SE)	-0.91 (3.94)	-3.25 (3.68)	-0.30 (3.18)
95% CI	(-9.09, 7.27)	(-10.88, 4.39)	(-6.90, 6.30)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.61 (4.20)	-2.94 (3.70)	
95% CI	(-9.31, 8.10)	(-10.62, 4.73)	
p-value	0.8866	0.4345	
Corrected Hedge's g Statistics	-0.051	-0.251	
95% CI	(-1.07, 0.97)	(-1.16, 0.66)	
Subgroup*Treatment Interaction p-value	0.5977	0.9055	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 20 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.5.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Mental Component Score			
Week 24			
m	5	8	16
n	4	7	14
Baseline Mean (SD)	58.28 (3.54)	56.03 (3.37)	56.42 (6.82)
Analysis Visit Mean (SD)	58.25 (4.24)	54.57 (6.73)	55.47 (7.91)
LS Mean of Change from Baseline (SE)	-0.91 (3.20)	-2.38 (2.66)	-1.51 (2.13)
95% CI	(-7.54, 5.73)	(-7.88, 3.13)	(-5.92, 2.91)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.60 (3.53)	-0.87 (2.93)	
95% CI	(-6.72, 7.92)	(-6.95, 5.21)	
p-value	0.8672	0.7694	
Corrected Hedge's g Statistics	0.074	-0.109	
95% CI	(-1.04, 1.19)	(-1.02, 0.80)	
Week 52			
m	5	8	15
n	5	7	14
Baseline Mean (SD)	57.38 (3.66)	56.03 (3.37)	56.42 (6.82)
Analysis Visit Mean (SD)	55.94 (6.32)	56.13 (2.69)	55.95 (8.97)
LS Mean of Change from Baseline (SE)	-1.82 (2.15)	-0.69 (2.00)	-1.00 (1.73)
95% CI	(-6.27, 2.63)	(-4.84, 3.46)	(-4.59, 2.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.82 (2.28)	0.30 (2.01)	
95% CI	(-5.55, 3.91)	(-3.87, 4.47)	
p-value	0.7223	0.8813	
Corrected Hedge's g Statistics	-0.128	0.048	
95% CI	(-1.15, 0.89)	(-0.86, 0.95)	
Subgroup*Treatment Interaction p-value	0.1017	0.9863	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 21 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.5.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Physical Component Score			
Week 24			
m	5	8	16
n	4	7	14
Baseline Mean (SD)	50.33 (4.40)	49.23 (8.15)	47.99 (9.92)
Analysis Visit Mean (SD)	53.55 (5.37)	48.47 (5.87)	47.54 (10.48)
LS Mean of Change from Baseline (SE)	4.04 (3.57)	-0.03 (2.93)	-0.18 (2.32)
95% CI	(-3.36, 11.45)	(-6.11, 6.04)	(-5.00, 4.63)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.23 (3.99)	0.15 (3.22)	
95% CI	(-4.04, 12.50)	(-6.53, 6.83)	
p-value	0.3007	0.9631	
Corrected Hedge's g Statistics	0.479	0.017	
95% CI	(-0.64, 1.60)	(-0.89, 0.92)	
Week 52			
m	5	8	15
n	5	7	14
Baseline Mean (SD)	51.32 (4.41)	49.23 (8.15)	47.99 (9.92)
Analysis Visit Mean (SD)	51.04 (4.96)	45.84 (9.96)	48.10 (7.71)
LS Mean of Change from Baseline (SE)	0.94 (2.72)	-2.68 (2.46)	0.42 (2.03)
95% CI	(-4.69, 6.57)	(-7.79, 2.43)	(-3.80, 4.63)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.52 (2.93)	-3.10 (2.57)	
95% CI	(-5.55, 6.59)	(-8.42, 2.23)	
p-value	0.8604	0.2411	
Corrected Hedge's g Statistics	0.068	-0.408	
95% CI	(-0.95, 1.09)	(-1.32, 0.51)	
Subgroup*Treatment Interaction p-value	0.7057	0.7160	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE21.5.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis, only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.

AMNOG Table SE21.5.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (9.1)
No	4 (100)	6 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	1.86	
95% CI of the inverse odds ratio	(0.04, 37.98)	(0.07, 52.76)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	1.75	
95% CI of the inverse risk ratio	(0.06, 25.76)	(0.08, 37.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-5.36	
95% CI of the absolute risk difference	(-34.77, 29.77)	(-32.08, 21.37)	
p-value	0.8841	0.7136	
p-value of Breslow-Day Test for Homogeneity [3]	0.3204	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	3 (27.3)
No	4 (100)	6 (100)	8 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.71	5.35	
95% CI of the inverse odds ratio	(0.15, 88.75)	(0.23, 122.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.92	4.08	
95% CI of the inverse risk ratio	(0.18, 46.71)	(0.25, 68.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-19.17	-22.02	
95% CI of the absolute risk difference	(-55.95, 17.61)	(-54.04, 10.00)	
p-value	0.3959	0.2560	
p-value of Breslow-Day Test for Homogeneity [3]	0.5268	0.4167	

AMNOG Table SE21.5.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (18.2)
No	4 (100)	6 (100)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.37	3.42	
95% CI of the inverse odds ratio	(0.09, 60.29)	(0.14, 83.60)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.08	2.92	
95% CI of the inverse risk ratio	(0.12, 36.07)	(0.16, 52.47)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.83	-13.69	
95% CI of the absolute risk difference	(-45.75, 24.09)	(-43.56, 16.18)	
p-value	0.5934	0.4299	
p-value of Breslow-Day Test for Homogeneity [3]	0.3715	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (16.7)	3 (27.3)
No	4 (100)	5 (83.3)	8 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.71	1.88	
95% CI of the inverse odds ratio	(0.15, 88.75)	(0.15, 23.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.92	1.64	
95% CI of the inverse risk ratio	(0.18, 46.71)	(0.21, 12.49)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-19.17	-10.61	
95% CI of the absolute risk difference	(-55.95, 17.61)	(-50.38, 29.17)	
p-value	0.3959	0.6223	
p-value of Breslow-Day Test for Homogeneity [3]	0.2517	0.1880	

AMNOG Table SE21.5.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (9.1)
No	4 (100)	6 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	1.86	
95% CI of the inverse odds ratio	(0.04, 37.98)	(0.07, 52.76)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	1.75	
95% CI of the inverse risk ratio	(0.06, 25.76)	(0.08, 37.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-5.36	
95% CI of the absolute risk difference	(-34.77, 29.77)	(-32.08, 21.37)	
p-value	0.8841	0.7136	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	1 (9.1)
No	4 (100)	6 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	1.86	
95% CI of the inverse odds ratio	(0.04, 37.98)	(0.07, 52.76)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	1.75	
95% CI of the inverse risk ratio	(0.06, 25.76)	(0.08, 37.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-5.36	
95% CI of the absolute risk difference	(-34.77, 29.77)	(-32.08, 21.37)	
p-value	0.8841	0.7136	
p-value of Breslow-Day Test for Homogeneity [3]	0.6335	0.6747	

AMNOG Table SE21.5.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (18.2)
No	4 (100)	6 (100)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.37	3.42	
95% CI of the inverse odds ratio	(0.09, 60.29)	(0.14, 83.60)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.08	2.92	
95% CI of the inverse risk ratio	(0.12, 36.07)	(0.16, 52.47)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.83	-13.69	
95% CI of the absolute risk difference	(-45.75, 24.09)	(-43.56, 16.18)	
p-value	0.5934	0.4299	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (25.0)	0	5 (45.5)
No	3 (75.0)	6 (100)	6 (54.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.50	11.00	
95% CI of the inverse odds ratio	(0.19, 32.19)	(0.50, 242.34)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.82	6.42	
95% CI of the inverse risk ratio	(0.30, 11.18)	(0.41, 99.46)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-20.45	-38.69	
95% CI of the absolute risk difference	(-72.09, 31.18)	(-72.73, -4.65)	
p-value	0.4745	0.0801	
p-value of Breslow-Day Test for Homogeneity [3]	0.0818	0.0718	

AMNOG Table SE21.5.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (9.1)
No	4 (100)	6 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	1.86	
95% CI of the inverse odds ratio	(0.04, 37.98)	(0.07, 52.76)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	1.75	
95% CI of the inverse risk ratio	(0.06, 25.76)	(0.08, 37.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-5.36	
95% CI of the absolute risk difference	(-34.77, 29.77)	(-32.08, 21.37)	
p-value	0.8841	0.7136	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	3 (27.3)
No	4 (100)	6 (100)	8 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.71	5.35	
95% CI of the inverse odds ratio	(0.15, 88.75)	(0.23, 122.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.92	4.08	
95% CI of the inverse risk ratio	(0.18, 46.71)	(0.25, 68.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-19.17	-22.02	
95% CI of the absolute risk difference	(-55.95, 17.61)	(-54.04, 10.00)	
p-value	0.3959	0.2560	
p-value of Breslow-Day Test for Homogeneity [3]	0.4405	0.4906	

AMNOG Table SE21.5.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (9.1)
No	4 (100)	6 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	1.86	
95% CI of the inverse odds ratio	(0.04, 37.98)	(0.07, 52.76)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	1.75	
95% CI of the inverse risk ratio	(0.06, 25.76)	(0.08, 37.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-5.36	
95% CI of the absolute risk difference	(-34.77, 29.77)	(-32.08, 21.37)	
p-value	0.8841	0.7136	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.4910	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	1 (9.1)
No	4 (100)	6 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	1.86	
95% CI of the inverse odds ratio	(0.04, 37.98)	(0.07, 52.76)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	1.75	
95% CI of the inverse risk ratio	(0.06, 25.76)	(0.08, 37.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-5.36	
95% CI of the absolute risk difference	(-34.77, 29.77)	(-32.08, 21.37)	
p-value	0.8841	0.7136	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.1414	

AMNOG Table SE21.5.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (9.1)
No	4 (100)	6 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	1.86	
95% CI of the inverse odds ratio	(0.04, 37.98)	(0.07, 52.76)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	1.75	
95% CI of the inverse risk ratio	(0.06, 25.76)	(0.08, 37.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-5.36	
95% CI of the absolute risk difference	(-34.77, 29.77)	(-32.08, 21.37)	
p-value	0.8841	0.7136	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	1 (9.1)
No	4 (100)	6 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	1.86	
95% CI of the inverse odds ratio	(0.04, 37.98)	(0.07, 52.76)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	1.75	
95% CI of the inverse risk ratio	(0.06, 25.76)	(0.08, 37.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-5.36	
95% CI of the absolute risk difference	(-34.77, 29.77)	(-32.08, 21.37)	
p-value	0.8841	0.7136	
p-value of Breslow-Day Test for Homogeneity [3]	0.4426	0.4910	

AMNOG Table SE21.5.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (18.2)
No	4 (100)	6 (100)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.37	3.42	
95% CI of the inverse odds ratio	(0.09, 60.29)	(0.14, 83.60)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.08	2.92	
95% CI of the inverse risk ratio	(0.12, 36.07)	(0.16, 52.47)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.83	-13.69	
95% CI of the absolute risk difference	(-45.75, 24.09)	(-43.56, 16.18)	
p-value	0.5934	0.4299	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.2222	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (25.0)	0	5 (45.5)
No	3 (75.0)	6 (100)	6 (54.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.50	11.00	
95% CI of the inverse odds ratio	(0.19, 32.19)	(0.50, 242.34)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.82	6.42	
95% CI of the inverse risk ratio	(0.30, 11.18)	(0.41, 99.46)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-20.45	-38.69	
95% CI of the absolute risk difference	(-72.09, 31.18)	(-72.73, -4.65)	
p-value	0.4745	0.0801	
p-value of Breslow-Day Test for Homogeneity [3]	0.4029	0.1418	

AMNOG Table SE21.5.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	4 (100)	6 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	3 (27.3)
No	4 (100)	6 (100)	8 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.71	5.35	
95% CI of the inverse odds ratio	(0.15, 88.75)	(0.23, 122.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.92	4.08	
95% CI of the inverse risk ratio	(0.18, 46.71)	(0.25, 68.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-19.17	-22.02	
95% CI of the absolute risk difference	(-55.95, 17.61)	(-54.04, 10.00)	
p-value	0.3959	0.2560	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.1673	

AMNOG Table SE21.5.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (9.1)
No	4 (100)	6 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	1.86	
95% CI of the inverse odds ratio	(0.04, 37.98)	(0.07, 52.76)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	1.75	
95% CI of the inverse risk ratio	(0.06, 25.76)	(0.08, 37.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-5.36	
95% CI of the absolute risk difference	(-34.77, 29.77)	(-32.08, 21.37)	
p-value	0.8841	0.7136	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	2 (18.2)
No	4 (100)	6 (100)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.37	3.42	
95% CI of the inverse odds ratio	(0.09, 60.29)	(0.14, 83.60)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.08	2.92	
95% CI of the inverse risk ratio	(0.12, 36.07)	(0.16, 52.47)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.83	-13.69	
95% CI of the absolute risk difference	(-45.75, 24.09)	(-43.56, 16.18)	
p-value	0.5934	0.4299	
p-value of Breslow-Day Test for Homogeneity [3]	0.3715	NE	

AMNOG Table SE21.5.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (20.0)	0	1 (5.9)
No	4 (80.0)	9 (100)	16 (94.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.25	1.73	
95% CI of the inverse odds ratio	(0.01, 4.92)	(0.06, 46.77)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.29	1.67	
95% CI of the inverse risk ratio	(0.02, 3.91)	(0.07, 37.21)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	14.12	-3.33	
95% CI of the absolute risk difference	(-22.68, 50.92)	(-21.92, 15.25)	
p-value	0.3344	0.7428	
p-value of Breslow-Day Test for Homogeneity [3]	0.3204	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (20.0)	2 (22.2)	8 (47.1)
No	4 (80.0)	7 (77.8)	9 (52.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.56	3.11	
95% CI of the inverse odds ratio	(0.33, 38.78)	(0.50, 19.54)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.35	2.12	
95% CI of the inverse risk ratio	(0.38, 14.58)	(0.56, 7.94)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-27.06	-24.84	
95% CI of the absolute risk difference	(-69.39, 15.28)	(-60.90, 11.23)	
p-value	0.2794	0.2156	
p-value of Breslow-Day Test for Homogeneity [3]	0.5268	0.4167	

AMNOG Table SE21.5.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (20.0)	0	3 (17.6)
No	4 (80.0)	9 (100)	14 (82.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	4.59	
95% CI of the inverse odds ratio	(0.07, 10.67)	(0.21, 99.20)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	3.89	
95% CI of the inverse risk ratio	(0.12, 6.73)	(0.22, 67.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.35	-14.44	
95% CI of the absolute risk difference	(-37.11, 41.82)	(-37.18, 8.29)	
p-value	0.9046	0.2953	
p-value of Breslow-Day Test for Homogeneity [3]	0.3715	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (40.0)	0	6 (35.3)
No	3 (60.0)	9 (100)	11 (64.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	10.74	
95% CI of the inverse odds ratio	(0.11, 6.34)	(0.53, 216.14)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	7.22	
95% CI of the inverse risk ratio	(0.25, 3.08)	(0.45, 115.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.71	-31.11	
95% CI of the absolute risk difference	(-43.87, 53.29)	(-57.09, -5.13)	
p-value	0.8475	0.0685	
p-value of Breslow-Day Test for Homogeneity [3]	0.2517	0.1880	

AMNOG Table SE21.5.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	4 (23.5)
No	5 (100)	9 (100)	13 (76.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.67	6.33	
95% CI of the inverse odds ratio	(0.17, 80.21)	(0.30, 132.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	5.00	
95% CI of the inverse risk ratio	(0.19, 47.96)	(0.30, 83.69)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-16.67	-20.00	
95% CI of the absolute risk difference	(-46.49, 13.15)	(-44.14, 4.14)	
p-value	0.3840	0.1855	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (20.0)	1 (11.1)	5 (29.4)
No	4 (80.0)	8 (88.9)	12 (70.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	3.33	
95% CI of the inverse odds ratio	(0.15, 18.87)	(0.33, 34.12)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.47	2.65	
95% CI of the inverse risk ratio	(0.22, 9.85)	(0.36, 19.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.41	-18.30	
95% CI of the absolute risk difference	(-50.62, 31.80)	(-48.15, 11.54)	
p-value	0.6779	0.2920	
p-value of Breslow-Day Test for Homogeneity [3]	0.6335	0.6747	

AMNOG Table SE21.5.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (11.8)
No	5 (100)	9 (100)	15 (88.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.77	3.06	
95% CI of the inverse odds ratio	(0.07, 43.02)	(0.13, 70.94)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	2.78	
95% CI of the inverse risk ratio	(0.09, 30.06)	(0.15, 52.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.56	-8.89	
95% CI of the absolute risk difference	(-32.84, 21.73)	(-29.81, 12.03)	
p-value	0.7216	0.4662	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (60.0)	2 (22.2)	3 (17.6)
No	2 (40.0)	7 (77.8)	14 (82.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.14	0.75	
95% CI of the inverse odds ratio	(0.02, 1.26)	(0.10, 5.58)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.29	0.79	
95% CI of the inverse risk ratio	(0.08, 1.03)	(0.16, 3.92)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	42.35	4.58	
95% CI of the absolute risk difference	(-4.25, 88.96)	(-28.08, 37.23)	
p-value	0.0616	0.7782	
p-value of Breslow-Day Test for Homogeneity [3]	0.0818	0.0718	

AMNOG Table SE21.5.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (11.8)
No	5 (100)	9 (100)	15 (88.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.77	3.06	
95% CI of the inverse odds ratio	(0.07, 43.02)	(0.13, 70.94)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	2.78	
95% CI of the inverse risk ratio	(0.09, 30.06)	(0.15, 52.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.56	-8.89	
95% CI of the absolute risk difference	(-32.84, 21.73)	(-29.81, 12.03)	
p-value	0.7216	0.4662	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (20.0)	1 (11.1)	6 (35.3)
No	4 (80.0)	8 (88.9)	11 (64.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.18	4.36	
95% CI of the inverse odds ratio	(0.20, 24.21)	(0.44, 43.72)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.76	3.18	
95% CI of the inverse risk ratio	(0.27, 11.42)	(0.45, 22.48)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-15.29	-24.18	
95% CI of the absolute risk difference	(-57.07, 26.48)	(-54.80, 6.44)	
p-value	0.5186	0.1860	
p-value of Breslow-Day Test for Homogeneity [3]	0.4405	0.4906	

AMNOG Table SE21.5.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (11.1)	2 (11.8)
No	5 (100)	8 (88.9)	15 (88.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.77	1.07	
95% CI of the inverse odds ratio	(0.07, 43.02)	(0.08, 13.65)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	1.06	
95% CI of the inverse risk ratio	(0.09, 30.06)	(0.11, 10.15)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.56	-0.65	
95% CI of the absolute risk difference	(-32.84, 21.73)	(-26.27, 24.96)	
p-value	0.7216	0.9604	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.4910	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	5 (55.6)	3 (17.6)
No	5 (100)	4 (44.4)	14 (82.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.66	0.17	
95% CI of the inverse odds ratio	(0.12, 60.22)	(0.03, 1.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.33	0.32	
95% CI of the inverse risk ratio	(0.14, 38.97)	(0.10, 1.04)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.11	37.91	
95% CI of the absolute risk difference	(-39.81, 17.58)	(0.73, 75.09)	
p-value	0.5271	0.0463	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.1414	

AMNOG Table SE21.5.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (5.9)
No	5 (100)	9 (100)	16 (94.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	1.73	
95% CI of the inverse odds ratio	(0.04, 28.30)	(0.06, 46.77)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	1.67	
95% CI of the inverse risk ratio	(0.05, 21.42)	(0.07, 37.21)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	-3.33	
95% CI of the absolute risk difference	(-25.54, 25.54)	(-21.92, 15.25)	
p-value	>0.9999	0.7428	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (20.0)	1 (11.1)	2 (11.8)
No	4 (80.0)	8 (88.9)	15 (88.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.53	1.07	
95% CI of the inverse odds ratio	(0.04, 7.49)	(0.08, 13.65)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	1.06	
95% CI of the inverse risk ratio	(0.07, 5.22)	(0.11, 10.15)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.24	-0.65	
95% CI of the absolute risk difference	(-30.02, 46.50)	(-26.27, 24.96)	
p-value	0.6371	0.9604	
p-value of Breslow-Day Test for Homogeneity [3]	0.4426	0.4910	

AMNOG Table SE21.5.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (11.1)	1 (5.9)
No	5 (100)	8 (88.9)	16 (94.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	0.50	
95% CI of the inverse odds ratio	(0.04, 28.30)	(0.03, 9.08)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	0.53	
95% CI of the inverse risk ratio	(0.05, 21.42)	(0.04, 7.50)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	5.23	
95% CI of the absolute risk difference	(-25.54, 25.54)	(-18.15, 28.61)	
p-value	>0.9999	0.6341	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.2222	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (40.0)	2 (22.2)	5 (29.4)
No	3 (60.0)	7 (77.8)	12 (70.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	1.46	
95% CI of the inverse odds ratio	(0.08, 4.96)	(0.22, 9.62)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	1.32	
95% CI of the inverse risk ratio	(0.20, 2.70)	(0.32, 5.51)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	10.59	-7.19	
95% CI of the absolute risk difference	(-37.51, 58.68)	(-41.93, 27.55)	
p-value	0.6550	0.6942	
p-value of Breslow-Day Test for Homogeneity [3]	0.4029	0.1418	

AMNOG Table SE21.5.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	9 (100)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (22.2)	3 (17.6)
No	5 (100)	7 (77.8)	14 (82.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.66	0.75	
95% CI of the inverse odds ratio	(0.12, 60.22)	(0.10, 5.58)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.33	0.79	
95% CI of the inverse risk ratio	(0.14, 38.97)	(0.16, 3.92)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.11	4.58	
95% CI of the absolute risk difference	(-39.81, 17.58)	(-28.08, 37.23)	
p-value	0.5271	0.7782	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.1673	

AMNOG Table SE21.5.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Non-Hispanic

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (5.9)
No	5 (100)	9 (100)	16 (94.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	1.73	
95% CI of the inverse odds ratio	(0.04, 28.30)	(0.06, 46.77)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	1.67	
95% CI of the inverse risk ratio	(0.05, 21.42)	(0.07, 37.21)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	-3.33	
95% CI of the absolute risk difference	(-25.54, 25.54)	(-21.92, 15.25)	
p-value	>0.9999	0.7428	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (20.0)	0	3 (17.6)
No	4 (80.0)	9 (100)	14 (82.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	4.59	
95% CI of the inverse odds ratio	(0.07, 10.67)	(0.21, 99.20)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	3.89	
95% CI of the inverse risk ratio	(0.12, 6.73)	(0.22, 67.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.35	-14.44	
95% CI of the absolute risk difference	(-37.11, 41.82)	(-37.18, 8.29)	
p-value	0.9046	0.2953	
p-value of Breslow-Day Test for Homogeneity [3]	0.3715	NE	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.6.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=24)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=24)
Physical Functioning						
Baseline						
m	2	15	24			
n	2	14	22			
Mean (SD)	60.00 (56.57)	79.29 (19.00)	77.95 (22.13)			
Median	60.00	82.50	85.00			
IQR: Q1, Q3	20.00, 100.00	65.00, 95.00	70.00, 95.00			
Min, Max	20.0, 100.0	40.0, 100.0	25.0, 100.0			
Week 24						
m	2	12	23			
n	2	11	21	2	11	20
Mean (SD/SE)	72.50 (38.89)	83.64 (16.14)	75.95 (22.17)	12.50 (12.50)	2.27 (2.27)	-2.75 (5.12)
Median	72.50	85.00	80.00	12.50	0	0
IQR: Q1, Q3	45.00, 100.00	75.00, 95.00	70.00, 90.00	0.00, 25.00	-5.00, 5.00	-7.50, 5.00
Min, Max	45.0, 100.0	45.0, 100.0	20.0, 100.0	0.0, 25.0	-5.0, 20.0	-75.0, 35.0
Week 52						
m	2	12	22			
n	1	10	20	1	10	19
Mean (SD/SE)	100.00 (N/A)	74.50 (21.14)	82.34 (18.94)	0.00 (N/A)	-6.00 (3.79)	2.46 (3.06)
Median	100.00	77.50	87.50	0	-2.50	5.00
IQR: Q1, Q3	100.00, 100.00	50.00, 95.00	68.35, 100.00	0.00, 0.00	-10.00, 0.00	-5.00, 10.00
Min, Max	100.0, 100.0	40.0, 100.0	35.0, 100.0	0.0, 0.0	-30.0, 10.0	-20.0, 30.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=24)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=24)
Role Physical						
Baseline						
m	2	15	24			
n	2	14	22			
Mean (SD)	87.50 (17.68)	89.30 (13.74)	77.28 (25.63)			
Median	87.50	96.90	84.40			
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	68.80, 100.00			
Min, Max	75.0, 100.0	62.5, 100.0	0.0, 100.0			
Week 24						
m	2	12	23			
n	2	11	21	2	11	20
Mean (SD/SE)	78.15 (30.90)	86.95 (16.86)	75.60 (28.77)	-9.35 (9.35)	-3.96 (4.15)	0.94 (5.31)
Median	78.15	93.80	87.50	-9.35	0	3.15
IQR: Q1, Q3	56.30, 100.00	68.80, 100.00	62.50, 100.00	-18.70, 0.00	-6.20, 0.00	0.00, 15.60
Min, Max	56.3, 100.0	56.3, 100.0	6.3, 100.0	-18.7, 0.0	-43.7, 6.3	-75.0, 31.2
Week 52						
m	2	12	22			
n	1	10	20	1	10	19
Mean (SD/SE)	100.00 (N/A)	76.26 (28.08)	77.83 (24.36)	0.00 (N/A)	-14.37 (6.91)	1.98 (4.53)
Median	100.00	87.55	81.25	0	-3.10	0
IQR: Q1, Q3	100.00, 100.00	37.50, 100.00	56.30, 100.00	0.00, 0.00	-25.00, 0.00	-12.50, 18.70
Min, Max	100.0, 100.0	37.5, 100.0	31.3, 100.0	0.0, 0.0	-62.5, 6.2	-37.5, 31.3

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=24)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=24)
Bodily Pain						
Baseline						
m	2	15	24			
n	2	14	22			
Mean (SD)	81.0 (26.9)	78.4 (18.2)	76.2 (21.3)			
Median	81.0	84.0	84.0			
IQR: Q1, Q3	62.0, 100.0	62.0, 100.0	62.0, 84.0			
Min, Max	62, 100	51, 100	12, 100			
Week 24						
m	2	12	23			
n	2	11	21	2	11	20
Mean (SD/SE)	92.0 (11.3)	78.4 (17.1)	71.8 (26.0)	11.0 (11.0)	-2.9 (4.4)	-3.7 (3.9)
Median	92.0	80.0	74.0	11.0	0	0
IQR: Q1, Q3	84.0, 100.0	62.0, 100.0	52.0, 100.0	0.0, 22.0	-10.0, 0.0	-5.0, 5.5
Min, Max	84, 100	52, 100	12, 100	0, 22	-36, 18	-53, 16
Week 52						
m	2	12	22			
n	1	10	20	1	10	19
Mean (SD/SE)	84.0 (N/A)	75.6 (15.6)	73.5 (19.9)	-16.0 (N/A)	-5.4 (3.7)	-2.7 (3.7)
Median	84.0	74.0	74.0	-16.0	0	0
IQR: Q1, Q3	84.0, 84.0	62.0, 84.0	57.0, 84.0	-16.0, -16.0	-10.0, 0.0	-10.0, 16.0
Min, Max	84, 84	52, 100	32, 100	-16, -16	-26, 12	-28, 23

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=24)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=24)
General Health						
Baseline						
m	2	15	24			
n	2	14	22			
Mean (SD)	51.00 (36.77)	67.57 (11.30)	69.41 (20.69)			
Median	51.00	67.00	74.50			
IQR: Q1, Q3	25.00, 77.00	62.00, 77.00	62.00, 82.00			
Min, Max	25.0, 77.0	47.0, 82.0	25.0, 97.0			
Week 24						
m	2	12	23			
n	2	11	21	2	11	20
Mean (SD/SE)	56.00 (43.84)	65.45 (14.94)	68.05 (20.24)	5.00 (5.00)	-2.27 (4.32)	-1.65 (3.27)
Median	56.00	62.00	72.00	5.00	5.00	0
IQR: Q1, Q3	25.00, 87.00	52.00, 77.00	45.00, 82.00	0.00, 10.00	-15.00, 10.00	-7.50, 10.00
Min, Max	25.0, 87.0	45.0, 87.0	30.0, 92.0	0.0, 10.0	-27.0, 15.0	-35.0, 20.0
Week 52						
m	2	12	22			
n	1	10	20	1	10	19
Mean (SD/SE)	87.00 (N/A)	63.30 (15.17)	69.45 (17.10)	10.00 (N/A)	-3.50 (3.11)	-0.68 (3.30)
Median	87.00	59.50	72.00	10.00	-2.50	0
IQR: Q1, Q3	87.00, 87.00	52.00, 77.00	52.00, 84.50	10.00, 10.00	-5.00, 0.00	-10.00, 10.00
Min, Max	87.0, 87.0	42.0, 82.0	40.0, 97.0	10.0, 10.0	-27.0, 10.0	-30.0, 25.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter / Visit / Statistic	Visit Result: DB MGL-3196 80 mg (N=2)	Visit Result: DB MGL-3196 100 mg (N=15)	Visit Result: DB Placebo (N=24)	Change from Baseline: DB MGL-3196 80 mg (N=2)	Change from Baseline: DB MGL-3196 100 mg (N=15)	Change from Baseline: DB Placebo (N=24)
Vitality						
Baseline						
m	2	15	24			
n	2	14	22			
Mean (SD)	37.50 (53.03)	67.89 (13.17)	64.79 (19.34)			
Median	37.50	68.80	65.65			
IQR: Q1, Q3	0.00, 75.00	62.50, 75.00	50.00, 75.00			
Min, Max	0.0, 75.0	43.8, 93.8	25.0, 100.0			
Week 24						
m	2	12	23			
n	2	11	21	2	11	20
Mean (SD/SE)	31.25 (44.19)	66.51 (14.60)	61.03 (21.64)	-6.25 (6.25)	-0.56 (4.95)	-3.13 (4.02)
Median	31.25	68.80	62.50	-6.25	0	0
IQR: Q1, Q3	0.00, 62.50	56.30, 75.00	50.00, 75.00	-12.50, 0.00	-12.50, 6.30	-9.40, 6.25
Min, Max	0.0, 62.5	43.8, 93.8	6.3, 93.8	-12.5, 0.0	-31.3, 31.3	-50.0, 31.3
Week 52						
m	2	12	22			
n	1	10	20	1	10	19
Mean (SD/SE)	68.80 (N/A)	60.03 (15.64)	68.45 (21.03)	-6.20 (N/A)	-5.62 (2.54)	2.29 (3.52)
Median	68.80	59.40	71.90	-6.20	-3.10	0
IQR: Q1, Q3	68.80, 68.80	50.00, 75.00	62.50, 81.30	-6.20, -6.20	-12.50, 0.00	-12.50, 12.50
Min, Max	68.8, 68.8	31.3, 81.3	25.0, 100.0	-6.2, -6.2	-18.7, 6.2	-25.0, 31.2

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=24)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=24)
Social Functioning						
Baseline						
m	2	15	24			
n	2	14	22			
Mean (SD)	81.25 (26.52)	88.39 (16.60)	91.48 (17.84)			
Median	81.25	87.50	100.00			
IQR: Q1, Q3	62.50, 100.00	87.50, 100.00	87.50, 100.00			
Min, Max	62.5, 100.0	37.5, 100.0	25.0, 100.0			
Week 24						
m	2	12	23			
n	2	11	21	2	11	20
Mean (SD/SE)	75.00 (35.36)	90.91 (11.31)	86.31 (24.66)	-6.25 (6.25)	2.27 (6.91)	-5.00 (5.97)
Median	75.00	100.00	100.00	-6.25	0	0
IQR: Q1, Q3	50.00, 100.00	75.00, 100.00	75.00, 100.00	-12.50, 0.00	-12.50, 12.50	0.00, 0.00
Min, Max	50.0, 100.0	75.0, 100.0	0.0, 100.0	-12.5, 0.0	-25.0, 62.5	-100.0, 50.0
Week 52						
m	2	12	22			
n	1	10	20	1	10	19
Mean (SD/SE)	100.00 (N/A)	92.50 (10.54)	94.38 (12.48)	0.00 (N/A)	3.75 (8.13)	2.63 (2.63)
Median	100.00	100.00	100.00	0	6.25	0
IQR: Q1, Q3	100.00, 100.00	87.50, 100.00	100.00, 100.00	0.00, 0.00	-12.50, 12.50	0.00, 0.00
Min, Max	100.0, 100.0	75.0, 100.0	62.5, 100.0	0.0, 0.0	-25.0, 62.5	-12.5, 37.5

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=2)	(N=15)	(N=24)	(N=2)	(N=15)	(N=24)
Role Emotional						
Baseline						
m	2	15	24			
n	2	14	22			
Mean (SD)	100.00 (0.00)	96.43 (7.82)	89.77 (17.23)			
Median	100.00	100.00	100.00			
IQR: Q1, Q3	100.00, 100.00	100.00, 100.00	83.30, 100.00			
Min, Max	100.0, 100.0	75.0, 100.0	41.7, 100.0			
Week 24						
m	2	12	23			
n	2	11	21	2	11	20
Mean (SD/SE)	83.35 (23.55)	91.66 (16.25)	86.11 (19.06)	-16.65 (16.65)	-6.06 (5.52)	-2.51 (2.64)
Median	83.35	100.00	100.00	-16.65	0	0
IQR: Q1, Q3	66.70, 100.00	83.30, 100.00	75.00, 100.00	-33.30, 0.00	-16.70, 0.00	0.00, 0.00
Min, Max	66.7, 100.0	50.0, 100.0	41.7, 100.0	-33.3, 0.0	-50.0, 16.7	-50.0, 8.3
Week 52						
m	2	12	22			
n	1	10	20	1	10	19
Mean (SD/SE)	100.00 (N/A)	90.83 (16.88)	89.17 (16.25)	0.00 (N/A)	-6.67 (5.53)	-0.44 (3.09)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	100.00, 100.00	83.30, 100.00	79.15, 100.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	100.0, 100.0	50.0, 100.0	58.3, 100.0	0.0, 0.0	-50.0, 8.3	-33.4, 33.3

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=24)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=24)
Mental Health						
Baseline						
m	2	15	24			
n	2	14	22			
Mean (SD)	80.0 (14.1)	85.7 (7.6)	82.7 (15.5)			
Median	80.0	85.0	85.0			
IQR: Q1, Q3	70.0, 90.0	85.0, 90.0	70.0, 95.0			
Min, Max	70, 90	70, 100	50, 100			
Week 24						
m	2	12	23			
n	2	11	21	2	11	20
Mean (SD/SE)	80.0 (14.1)	85.0 (12.2)	82.4 (16.9)	0.0 (0.0)	-1.4 (4.4)	-0.5 (1.5)
Median	80.0	85.0	90.0	0	0	0
IQR: Q1, Q3	70.0, 90.0	80.0, 95.0	75.0, 95.0	0.0, 0.0	-5.0, 5.0	-5.0, 5.0
Min, Max	70, 90	55, 100	45, 100	0, 0	-35, 25	-10, 15
Week 52						
m	2	12	22			
n	1	10	20	1	10	19
Mean (SD/SE)	90.0 (N/A)	81.0 (10.2)	85.5 (15.9)	0.0 (N/A)	-5.5 (3.4)	2.6 (2.2)
Median	90.0	80.0	90.0	0	-5.0	0
IQR: Q1, Q3	90.0, 90.0	80.0, 90.0	80.0, 97.5	0.0, 0.0	-10.0, -5.0	-5.0, 5.0
Min, Max	90, 90	60, 95	50, 100	0, 0	-25, 15	-15, 25

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=2)	Visit Result DB MGL-3196 100 mg (N=15)	Visit Result DB Placebo (N=24)	Change from Baseline DB MGL-3196 80 mg (N=2)	Change from Baseline DB MGL-3196 100 mg (N=15)	Change from Baseline DB Placebo (N=24)
Mental Component Score						
Baseline						
m	2	15	24			
n	2	14	22			
Mean (SD)	53.25 (5.30)	56.46 (2.90)	55.19 (7.33)			
Median	53.25	57.00	57.45			
IQR: Q1, Q3	49.50, 57.00	55.20, 57.80	52.30, 61.60			
Min, Max	49.5, 57.0	51.1, 60.9	38.1, 63.2			
Week 24						
m	2	12	23			
n	2	11	21	2	11	20
Mean (SD/SE)	47.70 (11.03)	55.27 (6.14)	53.90 (8.10)	-5.55 (4.05)	-1.15 (2.34)	-1.10 (0.95)
Median	47.70	57.30	57.60	-5.55	-0.30	-0.90
IQR: Q1, Q3	39.90, 55.50	52.10, 59.60	48.50, 59.10	-9.60, -1.50	-5.00, 4.90	-3.60, 0.40
Min, Max	39.9, 55.5	40.8, 61.0	37.1, 62.8	-9.6, -1.5	-20.1, 8.4	-8.1, 10.8
Week 52						
m	2	12	22			
n	1	10	20	1	10	19
Mean (SD/SE)	56.90 (N/A)	54.94 (4.65)	56.20 (8.01)	-0.10 (N/A)	-1.43 (1.68)	0.94 (1.11)
Median	56.90	55.90	59.55	-0.10	-1.80	1.00
IQR: Q1, Q3	56.90, 56.90	53.10, 58.80	52.50, 61.35	-0.10, -0.10	-2.80, 2.10	-0.70, 4.30
Min, Max	56.9, 56.9	44.0, 59.6	37.9, 65.5	-0.1, -0.1	-11.4, 5.9	-12.8, 8.7

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter / Visit / Statistic	Visit Result: DB MGL-3196 80 mg (N=2)	Visit Result: DB MGL-3196 100 mg (N=15)	Visit Result: DB Placebo (N=24)	Change from Baseline: DB MGL-3196 80 mg (N=2)	Change from Baseline: DB MGL-3196 100 mg (N=15)	Change from Baseline: DB Placebo (N=24)
Physical Component Score						
Baseline						
m	2	15	24			
n	2	14	22			
Mean (SD)	45.10 (18.24)	50.11 (6.66)	49.14 (9.12)			
Median	45.10	53.05	50.55			
IQR: Q1, Q3	32.20, 58.00	43.70, 54.40	44.30, 55.90			
Min, Max	32.2, 58.0	37.8, 60.3	21.6, 61.1			
Week 24						
m	2	12	23			
n	2	11	21	2	11	20
Mean (SD/SE)	49.20 (13.86)	50.70 (5.74)	48.18 (10.34)	4.10 (3.10)	-0.15 (1.10)	-0.77 (1.94)
Median	49.20	50.90	50.80	4.10	0.50	0.50
IQR: Q1, Q3	39.40, 59.00	48.00, 55.50	41.40, 55.60	1.00, 7.20	-3.30, 3.10	-2.65, 3.10
Min, Max	39.4, 59.0	40.9, 58.0	24.6, 61.0	1.0, 7.2	-6.4, 4.9	-30.0, 11.8
Week 52						
m	2	12	22			
n	1	10	20	1	10	19
Mean (SD/SE)	57.00 (N/A)	47.71 (9.01)	49.35 (8.07)	-1.00 (N/A)	-2.80 (1.69)	-0.02 (1.52)
Median	57.00	49.05	52.40	-1.00	-2.00	-0.40
IQR: Q1, Q3	57.00, 57.00	39.60, 55.00	42.65, 54.65	-1.00, -1.00	-4.00, 1.40	-6.90, 6.40
Min, Max	57.0, 57.0	33.4, 58.6	31.5, 58.9	-1.0, -1.0	-14.8, 2.9	-10.8, 10.1

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc. Page 11 of 20
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.6.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=4)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=4)
Physical Functioning						
Baseline						
m	7	0	4			
n	7	0	4			
Mean (SD)	77.86 (10.35)	N/A	93.75 (9.46)			
Median	80.00	N/A	97.50			
IQR: Q1, Q3	70.00, 85.00	N/A	87.50, 100.00			
Min, Max	60.0, 90.0	N/A	80.0, 100.0			
Week 24						
m	6	0	4			
n	5	0	4	5	0	4
Mean (SD/SE)	88.00 (12.55)	N/A	78.75 (39.24)	8.00 (8.15)	N/A	-15.00 (15.14)
Median	85.00	N/A	97.50	10.00	N/A	-2.50
IQR: Q1, Q3	85.00, 100.00	N/A	57.50, 100.00	-5.00, 20.00	N/A	-32.50, 2.50
Min, Max	70.0, 100.0	N/A	20.0, 100.0	-15.0, 30.0	N/A	-60.0, 5.0
Week 52						
m	6	0	4			
n	6	0	4	6	0	4
Mean (SD/SE)	75.83 (14.29)	N/A	78.75 (39.24)	-5.00 (6.45)	N/A	-15.00 (15.14)
Median	80.00	N/A	97.50	-5.00	N/A	-2.50
IQR: Q1, Q3	70.00, 85.00	N/A	57.50, 100.00	-5.00, -5.00	N/A	-32.50, 2.50
Min, Max	50.0, 90.0	N/A	20.0, 100.0	-30.0, 20.0	N/A	-60.0, 5.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=4)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=4)
Role Physical						
Baseline						
m	7	0	4			
n	7	0	4			
Mean (SD)	79.47 (17.93)	N/A	92.20 (15.60)			
Median	75.00	N/A	100.00			
IQR: Q1, Q3	68.80, 100.00	N/A	84.40, 100.00			
Min, Max	50.0, 100.0	N/A	68.8, 100.0			
Week 24						
m	6	0	4			
n	5	0	4	5	0	4
Mean (SD/SE)	90.00 (13.69)	N/A	78.13 (43.75)	8.74 (4.68)	N/A	-14.08 (14.08)
Median	100.00	N/A	100.00	6.20	N/A	0
IQR: Q1, Q3	75.00, 100.00	N/A	56.25, 100.00	0.00, 12.50	N/A	-28.15, 0.00
Min, Max	75.0, 100.0	N/A	12.5, 100.0	0.0, 25.0	N/A	-56.3, 0.0
Week 52						
m	6	0	4			
n	6	0	4	6	0	4
Mean (SD/SE)	81.25 (17.23)	N/A	75.00 (35.36)	-3.13 (7.17)	N/A	-17.20 (10.65)
Median	81.25	N/A	87.50	-6.25	N/A	-12.50
IQR: Q1, Q3	62.50, 100.00	N/A	50.00, 100.00	-12.50, 6.20	N/A	-34.40, 0.00
Min, Max	62.5, 100.0	N/A	25.0, 100.0	-25.0, 25.0	N/A	-43.8, 0.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=4)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=4)
Bodily Pain						
Baseline						
m	7	0	4			
n	7	0	4			
Mean (SD)	72.0 (25.2)	N/A	80.8 (22.2)			
Median	74.0	N/A	81.0			
IQR: Q1, Q3	52.0, 100.0	N/A	61.5, 100.0			
Min, Max	32, 100	N/A	61, 100			
Week 24						
m	6	0	4			
n	5	0	4	5	0	4
Mean (SD/SE)	82.6 (24.1)	N/A	86.5 (15.6)	14.2 (4.4)	N/A	5.8 (3.3)
Median	100.0	N/A	87.0	16.0	N/A	5.5
IQR: Q1, Q3	62.0, 100.0	N/A	73.0, 100.0	10.0, 19.0	N/A	0.0, 11.5
Min, Max	51, 100	N/A	72, 100	0, 26	N/A	0, 12
Week 52						
m	6	0	4			
n	6	0	4	6	0	4
Mean (SD/SE)	65.3 (26.3)	N/A	81.0 (23.4)	-8.3 (4.7)	N/A	0.3 (4.3)
Median	62.0	N/A	86.0	-11.0	N/A	0
IQR: Q1, Q3	62.0, 84.0	N/A	62.0, 100.0	-16.0, 0.0	N/A	-5.0, 5.5
Min, Max	22, 100	N/A	52, 100	-22, 10	N/A	-10, 11

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=4)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=4)
General Health						
Baseline						
m	7	0	4			
n	7	0	4			
Mean (SD)	72.71 (12.39)	N/A	72.00 (8.16)			
Median	77.00	N/A	72.00			
IQR: Q1, Q3	57.00, 82.00	N/A	67.00, 77.00			
Min, Max	57.0, 87.0	N/A	62.0, 82.0			
Week 24						
m	6	0	4			
n	5	0	4	5	0	4
Mean (SD/SE)	82.00 (12.75)	N/A	62.75 (13.38)	5.00 (4.47)	N/A	-9.25 (8.84)
Median	82.00	N/A	64.50	10.00	N/A	-12.50
IQR: Q1, Q3	72.00, 92.00	N/A	53.50, 72.00	0.00, 10.00	N/A	-21.00, 2.50
Min, Max	67.0, 97.0	N/A	45.0, 77.0	-10.0, 15.0	N/A	-27.0, 15.0
Week 52						
m	6	0	4			
n	6	0	4	6	0	4
Mean (SD/SE)	76.67 (14.02)	N/A	55.38 (30.05)	1.33 (2.85)	N/A	-16.63 (13.84)
Median	74.50	N/A	59.50	2.50	N/A	-7.50
IQR: Q1, Q3	72.00, 92.00	N/A	36.00, 74.75	-2.00, 5.00	N/A	-33.50, 0.25
Min, Max	55.0, 92.0	N/A	15.0, 87.5	-10.0, 10.0	N/A	-57.0, 5.5

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=4)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=4)
Vitality						
Baseline						
m	7	0	4			
n	7	0	4			
Mean (SD)	62.54 (11.97)	N/A	73.45 (12.89)			
Median	62.50	N/A	71.90			
IQR: Q1, Q3	56.30, 68.80	N/A	62.50, 84.40			
Min, Max	43.8, 81.3	N/A	62.5, 87.5			
Week 24						
m	6	0	4			
n	5	0	4	5	0	4
Mean (SD/SE)	63.78 (23.98)	N/A	73.45 (12.86)	-1.26 (5.38)	N/A	0.00 (4.42)
Median	75.00	N/A	75.00	0	N/A	-3.10
IQR: Q1, Q3	56.30, 81.30	N/A	65.65, 81.25	-6.20, 6.20	N/A	-6.25, 6.25
Min, Max	25.0, 81.3	N/A	56.3, 87.5	-18.8, 12.5	N/A	-6.3, 12.5
Week 52						
m	6	0	4			
n	6	0	4	6	0	4
Mean (SD/SE)	55.23 (22.84)	N/A	54.70 (26.69)	-8.35 (4.75)	N/A	-18.75 (7.65)
Median	62.55	N/A	53.15	-6.25	N/A	-18.75
IQR: Q1, Q3	37.50, 75.00	N/A	34.40, 75.00	-18.80, 0.00	N/A	-28.15, -9.35
Min, Max	18.8, 75.0	N/A	25.0, 87.5	-25.0, 6.2	N/A	-37.5, 0.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=4)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=4)
Social Functioning						
Baseline						
m	7	0	4			
n	7	0	4			
Mean (SD)	92.86 (12.20)	N/A	93.75 (12.50)			
Median	100.00	N/A	100.00			
IQR: Q1, Q3	75.00, 100.00	N/A	87.50, 100.00			
Min, Max	75.0, 100.0	N/A	75.0, 100.0			
Week 24						
m	6	0	4			
n	5	0	4	5	0	4
Mean (SD/SE)	87.50 (17.68)	N/A	90.63 (18.75)	-7.50 (5.00)	N/A	-3.13 (3.13)
Median	100.00	N/A	100.00	0	N/A	0
IQR: Q1, Q3	75.00, 100.00	N/A	81.25, 100.00	-12.50, 0.00	N/A	-6.25, 0.00
Min, Max	62.5, 100.0	N/A	62.5, 100.0	-25.0, 0.0	N/A	-12.5, 0.0
Week 52						
m	6	0	4			
n	6	0	4	6	0	4
Mean (SD/SE)	87.50 (19.36)	N/A	90.63 (18.75)	-8.33 (6.18)	N/A	-3.13 (12.88)
Median	100.00	N/A	100.00	0	N/A	0
IQR: Q1, Q3	62.50, 100.00	N/A	81.25, 100.00	-12.50, 0.00	N/A	-18.75, 12.50
Min, Max	62.5, 100.0	N/A	62.5, 100.0	-37.5, 0.0	N/A	-37.5, 25.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=4)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=4)
Role Emotional						
Baseline						
m	7	0	4			
n	7	0	4			
Mean (SD)	89.30 (17.82)	N/A	91.68 (16.65)			
Median	91.70	N/A	100.00			
IQR: Q1, Q3	91.70, 100.00	N/A	83.35, 100.00			
Min, Max	50.0, 100.0	N/A	66.7, 100.0			
Week 24						
m	6	0	4			
n	5	0	4	5	0	4
Mean (SD/SE)	91.66 (11.79)	N/A	81.25 (27.52)	-3.36 (4.25)	N/A	-10.43 (6.25)
Median	100.00	N/A	91.65	0	N/A	-8.35
IQR: Q1, Q3	83.30, 100.00	N/A	62.50, 100.00	-8.40, 0.00	N/A	-20.85, 0.00
Min, Max	75.0, 100.0	N/A	41.7, 100.0	-16.7, 8.3	N/A	-25.0, 0.0
Week 52						
m	6	0	4			
n	6	0	4	6	0	4
Mean (SD/SE)	88.88 (13.60)	N/A	70.83 (36.33)	-6.97 (5.01)	N/A	-20.85 (12.04)
Median	91.65	N/A	79.15	-4.20	N/A	-20.85
IQR: Q1, Q3	83.30, 100.00	N/A	41.65, 100.00	-16.70, 0.00	N/A	-41.70, 0.00
Min, Max	66.7, 100.0	N/A	25.0, 100.0	-25.0, 8.3	N/A	-41.7, 0.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=4)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=4)
Mental Health						
Baseline						
m	7	0	4			
n	7	0	4			
Mean (SD)	81.4 (13.1)	N/A	85.0 (10.8)			
Median	80.0	N/A	87.5			
IQR: Q1, Q3	75.0, 90.0	N/A	77.5, 92.5			
Min, Max	60, 100	N/A	70, 95			
Week 24						
m	6	0	4			
n	5	0	4	5	0	4
Mean (SD/SE)	89.0 (11.4)	N/A	81.3 (21.7)	3.0 (4.1)	N/A	-3.8 (5.5)
Median	90.0	N/A	87.5	0	N/A	0
IQR: Q1, Q3	90.0, 95.0	N/A	67.5, 95.0	-5.0, 10.0	N/A	-10.0, 2.5
Min, Max	70, 100	N/A	50, 100	-5, 15	N/A	-20, 5
Week 52						
m	6	0	4			
n	6	0	4	6	0	4
Mean (SD/SE)	85.0 (10.0)	N/A	71.3 (30.1)	0.0 (2.6)	N/A	-13.8 (9.7)
Median	85.0	N/A	77.5	2.5	N/A	-10.0
IQR: Q1, Q3	80.0, 95.0	N/A	50.0, 92.5	-5.0, 5.0	N/A	-27.5, 0.0
Min, Max	70, 95	N/A	30, 100	-10, 5	N/A	-40, 5

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=4)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=4)
Mental Component Score						
Baseline						
m	7	0	4			
n	7	0	4			
Mean (SD)	54.73 (6.20)	N/A	55.10 (5.88)			
Median	53.80	N/A	57.10			
IQR: Q1, Q3	53.10, 59.70	N/A	51.55, 58.65			
Min, Max	42.9, 61.1	N/A	46.5, 59.7			
Week 24						
m	6	0	4			
n	5	0	4	5	0	4
Mean (SD/SE)	54.82 (8.50)	N/A	53.68 (8.24)	-2.46 (2.48)	N/A	-1.43 (1.39)
Median	60.20	N/A	55.70	-0.90	N/A	-1.40
IQR: Q1, Q3	51.90, 60.20	N/A	47.75, 59.60	-1.20, 1.00	N/A	-3.80, 0.95
Min, Max	41.1, 60.7	N/A	42.3, 61.0	-12.2, 1.0	N/A	-4.2, 1.3
Week 52						
m	6	0	4			
n	6	0	4	6	0	4
Mean (SD/SE)	54.52 (6.64)	N/A	47.58 (11.72)	-2.18 (1.38)	N/A	-7.53 (3.80)
Median	55.05	N/A	47.05	-2.05	N/A	-7.65
IQR: Q1, Q3	47.70, 60.60	N/A	37.95, 57.20	-5.90, 1.40	N/A	-13.60, -1.45
Min, Max	47.4, 61.3	N/A	35.3, 60.9	-6.1, 1.6	N/A	-16.0, 1.2

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=7)	Visit Result DB MGL-3196 100 mg (N=0)	Visit Result DB Placebo (N=4)	Change from Baseline DB MGL-3196 80 mg (N=7)	Change from Baseline DB MGL-3196 100 mg (N=0)	Change from Baseline DB Placebo (N=4)
Physical Component Score						
Baseline						
m	7	0	4			
n	7	0	4			
Mean (SD)	49.41 (4.86)	N/A	54.18 (3.96)			
Median	49.10	N/A	54.15			
IQR: Q1, Q3	45.20, 55.30	N/A	50.80, 57.55			
Min, Max	44.1, 56.5	N/A	50.2, 58.2			
Week 24						
m	6	0	4			
n	5	0	4	5	0	4
Mean (SD/SE)	53.80 (4.69)	N/A	50.88 (10.27)	4.72 (2.23)	N/A	-3.30 (3.77)
Median	54.80	N/A	54.20	1.40	N/A	-0.60
IQR: Q1, Q3	50.60, 57.40	N/A	44.30, 57.45	1.00, 9.60	N/A	-8.30, 1.70
Min, Max	47.5, 58.7	N/A	36.0, 59.1	0.9, 10.7	N/A	-14.2, 2.2
Week 52						
m	6	0	4			
n	6	0	4	6	0	4
Mean (SD/SE)	48.48 (7.67)	N/A	50.65 (11.16)	-1.63 (1.81)	N/A	-3.53 (4.13)
Median	50.10	N/A	55.00	-0.65	N/A	0.20
IQR: Q1, Q3	44.50, 53.70	N/A	43.55, 57.75	-5.10, 1.40	N/A	-7.90, 0.85
Min, Max	35.7, 56.8	N/A	34.3, 58.3	-8.4, 3.6	N/A	-15.9, 1.4

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.6.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

Madrigal Pharmaceuticals, Inc. Page 2 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.6.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Physical Functioning			
Week 24			
m	2	12	23
n	2	11	20
Baseline Mean (SD)	60.00 (56.57)	81.36 (17.76)	79.00 (22.98)
Analysis Visit Mean (SD)	72.50 (38.89)	83.64 (16.14)	76.25 (22.70)
LS Mean of Change from Baseline (SE)	4.57 (12.86)	3.04 (6.16)	-2.71 (5.48)
95% CI	(-21.73, 30.88)	(-9.56, 15.64)	(-13.92, 8.50)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.28 (12.78)	5.75 (6.39)	
95% CI	(-18.85, 33.41)	(-7.32, 18.81)	
p-value	0.5731	0.3758	
Corrected Hedge's g Statistics	0.289	0.241	
95% CI	(-1.17, 1.75)	(-0.50, 0.98)	
Week 52			
m	2	12	22
n	1	10	19
Baseline Mean (SD)	100.00 (N/A)	80.50 (18.48)	79.21 (23.59)
Analysis Visit Mean (SD)	100.00 (N/A)	74.50 (21.14)	81.67 (19.22)
LS Mean of Change from Baseline (SE)	5.32 (13.10)	-5.77 (5.13)	2.67 (4.86)
95% CI	(-21.46, 32.10)	(-16.26, 4.72)	(-7.27, 12.62)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.65 (12.41)	-8.44 (4.76)	
95% CI	(-22.74, 28.03)	(-18.19, 1.30)	
p-value	0.8327	0.0869	
Corrected Hedge's g Statistics	0.120	-0.417	
95% CI	(-1.89, 2.13)	(-1.19, 0.36)	
Subgroup*Treatment Interaction p-value	0.5265	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE21.6.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Role Physical			
Week 24			
m	2	12	23
n	2	11	20
Baseline Mean (SD)	87.50 (17.68)	90.92 (13.51)	75.95 (26.54)
Analysis Visit Mean (SD)	78.15 (30.90)	86.95 (16.86)	76.89 (28.89)
LS Mean of Change from Baseline (SE)	-2.77 (15.09)	2.55 (7.83)	4.05 (6.99)
95% CI	(-33.63, 28.10)	(-13.45, 18.56)	(-10.24, 18.34)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.82 (14.61)	-1.50 (7.72)	
95% CI	(-36.69, 23.06)	(-17.28, 14.29)	
p-value	0.6442	0.8475	
Corrected Hedge's g Statistics	-0.213	-0.049	
95% CI	(-1.67, 1.24)	(-0.79, 0.69)	
Week 52			
m	2	12	22
n	1	10	19
Baseline Mean (SD)	100.00 (N/A)	90.63 (14.21)	75.34 (27.12)
Analysis Visit Mean (SD)	100.00 (N/A)	76.26 (28.08)	77.32 (24.91)
LS Mean of Change from Baseline (SE)	10.78 (21.80)	-7.71 (8.26)	4.87 (7.22)
95% CI	(-33.81, 55.36)	(-24.61, 9.19)	(-9.90, 19.63)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.91 (21.37)	-12.58 (8.39)	
95% CI	(-37.78, 49.61)	(-29.74, 4.59)	
p-value	0.7839	0.1448	
Corrected Hedge's g Statistics	0.180	-0.410	
95% CI	(-1.83, 2.19)	(-1.18, 0.36)	
Subgroup*Treatment Interaction p-value	0.2542	NE	

Madrigal Pharmaceuticals, Inc. Page 4 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.6.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Bodily Pain			
Week 24			
m	2	12	23
n	2	11	20
Baseline Mean (SD)	81.0 (26.9)	81.3 (15.1)	76.0 (22.3)
Analysis Visit Mean (SD)	92.0 (11.3)	78.4 (17.1)	72.3 (26.6)
LS Mean of Change from Baseline (SE)	13.56 (12.61)	-0.80 (6.36)	-1.97 (5.72)
95% CI	(-12.23, 39.36)	(-13.81, 12.21)	(-13.66, 9.72)
LS Mean of Change from Baseline Compared to Placebo (SE)	15.53 (12.23)	1.17 (6.26)	
95% CI	(-9.48, 40.55)	(-11.64, 13.97)	
p-value	0.2142	0.8534	
Corrected Hedge's g Statistics	0.592	0.047	
95% CI	(-0.87, 2.06)	(-0.69, 0.78)	
Week 52			
m	2	12	22
n	1	10	19
Baseline Mean (SD)	100.0 (N/A)	81.0 (15.9)	75.6 (22.8)
Analysis Visit Mean (SD)	84.0 (N/A)	75.6 (15.6)	72.9 (20.3)
LS Mean of Change from Baseline (SE)	-2.89 (15.11)	-2.65 (5.87)	-1.91 (5.40)
95% CI	(-33.79, 28.01)	(-14.66, 9.35)	(-12.95, 9.13)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.98 (14.34)	-0.75 (5.45)	
95% CI	(-30.31, 28.35)	(-11.89, 10.40)	
p-value	0.9459	0.8922	
Corrected Hedge's g Statistics	-0.040	-0.033	
95% CI	(-2.05, 1.97)	(-0.80, 0.73)	
Subgroup*Treatment Interaction p-value	0.5159	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 5 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.6.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
General Health			
Week 24			
m	2	12	23
n	2	11	20
Baseline Mean (SD)	51.00 (36.77)	67.73 (12.68)	71.00 (19.64)
Analysis Visit Mean (SD)	56.00 (43.84)	65.45 (14.94)	69.35 (19.84)
LS Mean of Change from Baseline (SE)	2.06 (11.26)	-1.55 (5.56)	0.24 (5.16)
95% CI	(-20.97, 25.08)	(-12.92, 9.82)	(-10.32, 10.80)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.82 (10.96)	-1.79 (5.44)	
95% CI	(-20.61, 24.24)	(-12.91, 9.33)	
p-value	0.8696	0.7441	
Corrected Hedge's g Statistics	0.077	-0.081	
95% CI	(-1.38, 1.53)	(-0.82, 0.66)	
Week 52			
m	2	12	22
n	1	10	19
Baseline Mean (SD)	77.00 (N/A)	66.80 (12.97)	71.05 (20.18)
Analysis Visit Mean (SD)	87.00 (N/A)	63.30 (15.17)	70.37 (17.06)
LS Mean of Change from Baseline (SE)	9.01 (12.21)	-3.69 (5.16)	0.68 (4.93)
95% CI	(-15.97, 33.98)	(-14.25, 6.86)	(-9.41, 10.76)
LS Mean of Change from Baseline Compared to Placebo (SE)	8.33 (11.61)	-4.37 (4.80)	
95% CI	(-15.42, 32.08)	(-14.18, 5.45)	
p-value	0.4789	0.3703	
Corrected Hedge's g Statistics	0.371	-0.213	
95% CI	(-1.64, 2.39)	(-0.98, 0.55)	
Subgroup*Treatment Interaction p-value	0.3305	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 6 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.6.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Vitality			
Week 24			
m	2	12	23
n	2	11	20
Baseline Mean (SD)	37.50 (53.03)	67.07 (14.82)	65.02 (19.91)
Analysis Visit Mean (SD)	31.25 (44.19)	66.51 (14.60)	61.90 (21.83)
LS Mean of Change from Baseline (SE)	-18.15 (13.39)	-1.83 (6.32)	-6.04 (5.68)
95% CI	(-45.54, 9.24)	(-14.76, 11.09)	(-17.67, 5.58)
LS Mean of Change from Baseline Compared to Placebo (SE)	-12.11 (13.24)	4.21 (6.42)	
95% CI	(-39.19, 14.98)	(-8.93, 17.35)	
p-value	0.3681	0.5175	
Corrected Hedge's g Statistics	-0.463	0.171	
95% CI	(-1.92, 1.00)	(-0.57, 0.91)	
Week 52			
m	2	12	22
n	1	10	19
Baseline Mean (SD)	75.00 (N/A)	65.65 (14.81)	66.14 (19.80)
Analysis Visit Mean (SD)	68.80 (N/A)	60.03 (15.64)	68.43 (21.60)
LS Mean of Change from Baseline (SE)	-11.04 (13.56)	-7.81 (5.46)	-0.71 (5.19)
95% CI	(-38.78, 16.69)	(-18.98, 3.36)	(-11.31, 9.90)
LS Mean of Change from Baseline Compared to Placebo (SE)	-10.34 (12.89)	-7.10 (5.06)	
95% CI	(-36.71, 16.03)	(-17.46, 3.25)	
p-value	0.4292	0.1713	
Corrected Hedge's g Statistics	-0.438	-0.329	
95% CI	(-2.45, 1.58)	(-1.10, 0.44)	
Subgroup*Treatment Interaction p-value	0.2589	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 7 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.6.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Social Functioning			
Week 24			
m	2	12	23
n	2	11	20
Baseline Mean (SD)	81.25 (26.52)	88.64 (18.07)	91.88 (18.71)
Analysis Visit Mean (SD)	75.00 (35.36)	90.91 (11.31)	86.88 (25.16)
LS Mean of Change from Baseline (SE)	-13.81 (16.24)	0.11 (7.46)	-5.55 (6.33)
95% CI	(-47.02, 19.40)	(-15.15, 15.38)	(-18.50, 7.40)
LS Mean of Change from Baseline Compared to Placebo (SE)	-8.26 (16.53)	5.66 (8.36)	
95% CI	(-42.07, 25.54)	(-11.43, 22.75)	
p-value	0.6209	0.5036	
Corrected Hedge's g Statistics	-0.283	0.203	
95% CI	(-1.74, 1.17)	(-0.53, 0.94)	
Week 52			
m	2	12	22
n	1	10	19
Baseline Mean (SD)	100.00 (N/A)	88.75 (19.05)	91.45 (19.12)
Analysis Visit Mean (SD)	100.00 (N/A)	92.50 (10.54)	94.08 (12.75)
LS Mean of Change from Baseline (SE)	0.96 (12.31)	1.51 (4.88)	1.79 (4.75)
95% CI	(-24.20, 26.13)	(-8.47, 11.50)	(-7.93, 11.51)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.83 (11.53)	-0.28 (4.50)	
95% CI	(-24.41, 22.75)	(-9.48, 8.92)	
p-value	0.9434	0.9510	
Corrected Hedge's g Statistics	-0.038	-0.014	
95% CI	(-2.05, 1.97)	(-0.78, 0.75)	
Subgroup*Treatment Interaction p-value	0.9819	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.6.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Role Emotional			
Week 24			
m	2	12	23
n	2	11	20
Baseline Mean (SD)	100.00 (0.00)	97.73 (5.39)	89.59 (17.90)
Analysis Visit Mean (SD)	83.35 (23.55)	91.66 (16.25)	87.08 (19.01)
LS Mean of Change from Baseline (SE)	-12.36 (11.83)	-2.67 (6.09)	-1.07 (5.51)
95% CI	(-36.56, 11.84)	(-15.12, 9.79)	(-12.34, 10.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	-11.29 (11.40)	-1.59 (5.91)	
95% CI	(-34.60, 12.02)	(-13.69, 10.50)	
p-value	0.3301	0.7897	
Corrected Hedge's g Statistics	-0.447	-0.067	
95% CI	(-1.91, 1.01)	(-0.80, 0.67)	
Week 52			
m	2	12	22
n	1	10	19
Baseline Mean (SD)	100.00 (N/A)	97.50 (5.63)	89.04 (18.22)
Analysis Visit Mean (SD)	100.00 (N/A)	90.83 (16.88)	88.59 (16.49)
LS Mean of Change from Baseline (SE)	-2.01 (14.45)	-2.37 (5.94)	0.36 (5.41)
95% CI	(-31.57, 27.55)	(-14.53, 9.78)	(-10.71, 11.43)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.37 (13.91)	-2.73 (5.68)	
95% CI	(-30.82, 26.08)	(-14.34, 8.88)	
p-value	0.8657	0.6337	
Corrected Hedge's g Statistics	-0.096	-0.120	
95% CI	(-2.11, 1.91)	(-0.89, 0.65)	
Subgroup*Treatment Interaction p-value	0.0780	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 9 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.6.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Mental Health			
Week 24			
m	2	12	23
n	2	11	20
Baseline Mean (SD)	80.0 (14.1)	86.4 (5.0)	82.5 (16.3)
Analysis Visit Mean (SD)	80.0 (14.1)	85.0 (12.2)	82.0 (17.2)
LS Mean of Change from Baseline (SE)	2.79 (7.85)	1.65 (3.97)	2.17 (3.60)
95% CI	(-13.27, 18.84)	(-6.47, 9.78)	(-5.19, 9.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.62 (7.63)	-0.51 (3.93)	
95% CI	(-14.98, 16.22)	(-8.54, 7.51)	
p-value	0.9361	0.8966	
Corrected Hedge's g Statistics	0.037	-0.033	
95% CI	(-1.42, 1.49)	(-0.77, 0.70)	
Week 52			
m	2	12	22
n	1	10	19
Baseline Mean (SD)	90.0 (N/A)	86.5 (5.3)	82.6 (16.7)
Analysis Visit Mean (SD)	90.0 (N/A)	81.0 (10.2)	85.3 (16.3)
LS Mean of Change from Baseline (SE)	4.03 (10.01)	-2.10 (3.89)	5.21 (3.53)
95% CI	(-16.44, 24.50)	(-10.05, 5.84)	(-2.01, 12.43)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.18 (9.68)	-7.31 (3.77)	
95% CI	(-20.98, 18.62)	(-15.02, 0.40)	
p-value	0.9038	0.0622	
Corrected Hedge's g Statistics	-0.073	-0.493	
95% CI	(-2.08, 1.94)	(-1.27, 0.28)	
Subgroup*Treatment Interaction p-value	0.5000	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE21.6.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Mental Component Score			
Week 24			
m	2	12	23
n	2	11	20
Baseline Mean (SD)	53.25 (5.30)	56.42 (3.03)	55.13 (7.67)
Analysis Visit Mean (SD)	47.70 (11.03)	55.27 (6.14)	54.03 (8.29)
LS Mean of Change from Baseline (SE)	-5.53 (4.58)	-0.51 (2.23)	-1.12 (1.97)
95% CI	(-14.91, 3.84)	(-5.07, 4.05)	(-5.14, 2.91)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.42 (4.54)	0.61 (2.32)	
95% CI	(-13.70, 4.87)	(-4.13, 5.34)	
p-value	0.3386	0.7952	
Corrected Hedge's g Statistics	-0.488	0.071	
95% CI	(-1.95, 0.97)	(-0.67, 0.81)	
Week 52			
m	2	12	22
n	1	10	19
Baseline Mean (SD)	57.00 (N/A)	56.37 (3.19)	55.16 (7.87)
Analysis Visit Mean (SD)	56.90 (N/A)	54.94 (4.65)	56.10 (8.22)
LS Mean of Change from Baseline (SE)	-1.65 (4.67)	-0.87 (1.86)	0.89 (1.74)
95% CI	(-11.19, 7.90)	(-4.68, 2.93)	(-2.68, 4.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.54 (4.45)	-1.76 (1.74)	
95% CI	(-11.65, 6.57)	(-5.32, 1.79)	
p-value	0.5734	0.3190	
Corrected Hedge's g Statistics	-0.319	-0.242	
95% CI	(-2.33, 1.69)	(-1.01, 0.53)	
Subgroup*Treatment Interaction p-value	0.2024	NE	

Madrigal Pharmaceuticals, Inc. Page 11 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.6.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Physical Component Score			
Week 24			
m	2	12	23
n	2	11	20
Baseline Mean (SD)	45.10 (18.24)	50.85 (6.79)	49.35 (9.48)
Analysis Visit Mean (SD)	49.20 (13.86)	50.70 (5.74)	48.58 (10.44)
LS Mean of Change from Baseline (SE)	2.89 (5.19)	0.33 (2.55)	-0.40 (2.30)
95% CI	(-7.71, 13.50)	(-4.89, 5.55)	(-5.09, 4.30)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.29 (5.10)	0.73 (2.59)	
95% CI	(-7.15, 13.73)	(-4.57, 6.02)	
p-value	0.5244	0.7812	
Corrected Hedge's g Statistics	0.312	0.073	
95% CI	(-1.14, 1.77)	(-0.66, 0.81)	
Week 52			
m	2	12	22
n	1	10	19
Baseline Mean (SD)	58.00 (N/A)	50.51 (7.06)	49.30 (9.74)
Analysis Visit Mean (SD)	57.00 (N/A)	47.71 (9.01)	49.28 (8.28)
LS Mean of Change from Baseline (SE)	2.80 (6.32)	-2.37 (2.37)	0.31 (2.18)
95% CI	(-10.12, 15.73)	(-7.22, 2.47)	(-4.15, 4.76)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.50 (6.08)	-2.68 (2.29)	
95% CI	(-9.93, 14.92)	(-7.37, 2.01)	
p-value	0.6842	0.2516	
Corrected Hedge's g Statistics	0.252	-0.294	
95% CI	(-1.76, 2.26)	(-1.06, 0.48)	
Subgroup*Treatment Interaction p-value	0.8212	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 12 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.6.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Physical Functioning			
Week 24			
m	6	0	4
n	5	0	4
Baseline Mean (SD)	80.00 (7.91)	N/A	93.75 (9.46)
Analysis Visit Mean (SD)	88.00 (12.55)	N/A	78.75 (39.24)
LS Mean of Change from Baseline (SE)	0.57 (14.22)	NE	-50.42 (28.40)
95% CI	(-34.22, 35.35)	NE	(-119.90, 19.07)
LS Mean of Change from Baseline Compared to Placebo (SE)	50.98 (26.07)	NE	
95% CI	(-12.82, 114.79)	NE	
p-value	0.0983	NE	
Corrected Hedge's g Statistics	1.024	NE	
95% CI	(-0.37, 2.42)	NE	
Week 52			
m	6	0	4
n	6	0	4
Baseline Mean (SD)	80.83 (7.36)	N/A	93.75 (9.46)
Analysis Visit Mean (SD)	75.83 (14.29)	N/A	78.75 (39.24)
LS Mean of Change from Baseline (SE)	-11.45 (15.45)	NE	-53.28 (29.05)
95% CI	(-49.24, 26.34)	NE	(-124.36, 17.79)
LS Mean of Change from Baseline Compared to Placebo (SE)	41.83 (26.90)	NE	
95% CI	(-23.99, 107.66)	NE	
p-value	0.1709	NE	
Corrected Hedge's g Statistics	0.813	NE	
95% CI	(-0.50, 2.13)	NE	
Subgroup*Treatment Interaction p-value	0.5265	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 13 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.6.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Role Physical			
Week 24			
m	6	0	4
n	5	0	4
Baseline Mean (SD)	81.26 (12.49)	N/A	92.20 (15.60)
Analysis Visit Mean (SD)	90.00 (13.69)	N/A	78.13 (43.75)
LS Mean of Change from Baseline (SE)	-5.62 (7.31)	NE	-56.21 (11.73)
95% CI	(-23.49, 12.26)	NE	(-84.90, -27.52)
LS Mean of Change from Baseline Compared to Placebo (SE)	50.60 (10.85)	NE	
95% CI	(24.04, 77.15)	NE	
p-value	0.0035	NE	
Corrected Hedge's g Statistics	2.283	NE	
95% CI	(0.60, 3.97)	NE	
Week 52			
m	6	0	4
n	6	0	4
Baseline Mean (SD)	84.38 (13.54)	N/A	92.20 (15.60)
Analysis Visit Mean (SD)	81.25 (17.23)	N/A	75.00 (35.36)
LS Mean of Change from Baseline (SE)	-23.40 (12.95)	NE	-55.43 (17.52)
95% CI	(-55.10, 8.29)	NE	(-98.29, -12.56)
LS Mean of Change from Baseline Compared to Placebo (SE)	32.02 (20.02)	NE	
95% CI	(-16.96, 81.01)	NE	
p-value	0.1608	NE	
Corrected Hedge's g Statistics	0.876	NE	
95% CI	(-0.45, 2.20)	NE	
Subgroup*Treatment Interaction p-value	0.2542	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 14 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.6.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Bodily Pain			
Week 24			
m	6	0	4
n	5	0	4
Baseline Mean (SD)	68.4 (26.8)	N/A	80.8 (22.2)
Analysis Visit Mean (SD)	82.6 (24.1)	N/A	86.5 (15.6)
LS Mean of Change from Baseline (SE)	14.83 (3.45)	NE	12.24 (5.07)
95% CI	(6.37, 23.28)	NE	(-0.17, 24.65)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.59 (5.61)	NE	
95% CI	(-11.15, 16.32)	NE	
p-value	0.6613	NE	
Corrected Hedge's g Statistics	0.260	NE	
95% CI	(-1.06, 1.58)	NE	
Week 52			
m	6	0	4
n	6	0	4
Baseline Mean (SD)	73.7 (27.2)	N/A	80.8 (22.2)
Analysis Visit Mean (SD)	65.3 (26.3)	N/A	81.0 (23.4)
LS Mean of Change from Baseline (SE)	-6.13 (4.36)	NE	6.06 (5.90)
95% CI	(-16.79, 4.53)	NE	(-8.37, 20.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	-12.19 (6.58)	NE	
95% CI	(-28.30, 3.91)	NE	
p-value	0.1133	NE	
Corrected Hedge's g Statistics	-0.992	NE	
95% CI	(-2.33, 0.35)	NE	
Subgroup*Treatment Interaction p-value	0.5159	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 15 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.6.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
General Health			
Week 24			
m	6	0	4
n	5	0	4
Baseline Mean (SD)	77.00 (11.73)	N/A	72.00 (8.16)
Analysis Visit Mean (SD)	82.00 (12.75)	N/A	62.75 (13.38)
LS Mean of Change from Baseline (SE)	8.56 (9.53)	NE	-12.05 (15.07)
95% CI	(-14.77, 31.89)	NE	(-48.92, 24.83)
LS Mean of Change from Baseline Compared to Placebo (SE)	20.61 (10.90)	NE	
95% CI	(-6.06, 47.27)	NE	
p-value	0.1075	NE	
Corrected Hedge's g Statistics	0.719	NE	
95% CI	(-0.64, 2.08)	NE	
Week 52			
m	6	0	4
n	6	0	4
Baseline Mean (SD)	75.33 (11.25)	N/A	72.00 (8.16)
Analysis Visit Mean (SD)	76.67 (14.02)	N/A	55.38 (30.05)
LS Mean of Change from Baseline (SE)	2.26 (11.52)	NE	-17.44 (16.87)
95% CI	(-25.93, 30.44)	NE	(-58.71, 23.84)
LS Mean of Change from Baseline Compared to Placebo (SE)	19.69 (14.36)	NE	
95% CI	(-15.44, 54.83)	NE	
p-value	0.2194	NE	
Corrected Hedge's g Statistics	0.585	NE	
95% CI	(-0.71, 1.88)	NE	
Subgroup*Treatment Interaction p-value	0.3305	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 16 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.6.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Vitality			
Week 24			
m	6	0	4
n	5	0	4
Baseline Mean (SD)	65.04 (13.70)	N/A	73.45 (12.89)
Analysis Visit Mean (SD)	63.78 (23.98)	N/A	73.45 (12.86)
LS Mean of Change from Baseline (SE)	-7.01 (6.77)	NE	-13.95 (11.43)
95% CI	(-23.57, 9.55)	NE	(-41.91, 14.01)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.94 (10.36)	NE	
95% CI	(-18.40, 32.28)	NE	
p-value	0.5277	NE	
Corrected Hedge's g Statistics	0.328	NE	
95% CI	(-1.00, 1.65)	NE	
Week 52			
m	6	0	4
n	6	0	4
Baseline Mean (SD)	63.58 (12.76)	N/A	73.45 (12.89)
Analysis Visit Mean (SD)	55.23 (22.84)	N/A	54.70 (26.69)
LS Mean of Change from Baseline (SE)	-10.55 (5.29)	NE	-35.11 (10.35)
95% CI	(-23.49, 2.39)	NE	(-60.43, -9.80)
LS Mean of Change from Baseline Compared to Placebo (SE)	24.56 (8.00)	NE	
95% CI	(4.98, 44.14)	NE	
p-value	0.0220	NE	
Corrected Hedge's g Statistics	1.362	NE	
95% CI	(-0.04, 2.76)	NE	
Subgroup*Treatment Interaction p-value	0.2589	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 17 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.6.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Social Functioning			
Week 24			
m	6	0	4
n	5	0	4
Baseline Mean (SD)	95.00 (11.18)	N/A	93.75 (12.50)
Analysis Visit Mean (SD)	87.50 (17.68)	N/A	90.63 (18.75)
LS Mean of Change from Baseline (SE)	-2.52 (5.30)	NE	8.62 (9.27)
95% CI	(-15.49, 10.45)	NE	(-14.06, 31.31)
LS Mean of Change from Baseline Compared to Placebo (SE)	-11.14 (7.53)	NE	
95% CI	(-29.56, 7.28)	NE	
p-value	0.1892	NE	
Corrected Hedge's g Statistics	-0.657	NE	
95% CI	(-2.01, 0.69)	NE	
Week 52			
m	6	0	4
n	6	0	4
Baseline Mean (SD)	95.83 (10.21)	N/A	93.75 (12.50)
Analysis Visit Mean (SD)	87.50 (19.36)	N/A	90.63 (18.75)
LS Mean of Change from Baseline (SE)	-2.32 (9.49)	NE	7.67 (13.24)
95% CI	(-25.54, 20.90)	NE	(-24.74, 40.07)
LS Mean of Change from Baseline Compared to Placebo (SE)	-9.99 (14.14)	NE	
95% CI	(-44.58, 24.61)	NE	
p-value	0.5066	NE	
Corrected Hedge's g Statistics	-0.368	NE	
95% CI	(-1.64, 0.91)	NE	
Subgroup*Treatment Interaction p-value	0.9819	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 18 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.6.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Role Emotional			
Week 24			
m	6	0	4
n	5	0	4
Baseline Mean (SD)	95.02 (4.55)	N/A	91.68 (16.65)
Analysis Visit Mean (SD)	91.66 (11.79)	N/A	81.25 (27.52)
LS Mean of Change from Baseline (SE)	-6.32 (5.27)	NE	-11.73 (8.08)
95% CI	(-19.21, 6.57)	NE	(-31.50, 8.03)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.42 (7.34)	NE	
95% CI	(-12.54, 23.37)	NE	
p-value	0.4884	NE	
Corrected Hedge's g Statistics	0.348	NE	
95% CI	(-0.98, 1.67)	NE	
Week 52			
m	6	0	4
n	6	0	4
Baseline Mean (SD)	95.85 (4.55)	N/A	91.68 (16.65)
Analysis Visit Mean (SD)	88.88 (13.60)	N/A	70.83 (36.33)
LS Mean of Change from Baseline (SE)	-9.57 (7.97)	NE	-21.67 (10.81)
95% CI	(-29.08, 9.94)	NE	(-48.12, 4.78)
LS Mean of Change from Baseline Compared to Placebo (SE)	12.10 (11.81)	NE	
95% CI	(-16.80, 40.99)	NE	
p-value	0.3452	NE	
Corrected Hedge's g Statistics	0.537	NE	
95% CI	(-0.75, 1.82)	NE	
Subgroup*Treatment Interaction p-value	0.0780	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 19 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.6.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Mental Health			
Week 24			
m	6	0	4
n	5	0	4
Baseline Mean (SD)	86.0 (10.8)	N/A	85.0 (10.8)
Analysis Visit Mean (SD)	89.0 (11.4)	N/A	81.3 (21.7)
LS Mean of Change from Baseline (SE)	-3.30 (6.06)	NE	-10.21 (9.76)
95% CI	(-18.13, 11.53)	NE	(-34.09, 13.67)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.91 (7.48)	NE	
95% CI	(-11.38, 25.21)	NE	
p-value	0.3907	NE	
Corrected Hedge's g Statistics	0.375	NE	
95% CI	(-0.95, 1.70)	NE	
Week 52			
m	6	0	4
n	6	0	4
Baseline Mean (SD)	85.0 (10.0)	N/A	85.0 (10.8)
Analysis Visit Mean (SD)	85.0 (10.0)	N/A	71.3 (30.1)
LS Mean of Change from Baseline (SE)	-5.06 (6.53)	NE	-20.13 (10.16)
95% CI	(-21.05, 10.93)	NE	(-45.00, 4.74)
LS Mean of Change from Baseline Compared to Placebo (SE)	15.06 (8.09)	NE	
95% CI	(-4.73, 34.86)	NE	
p-value	0.1119	NE	
Corrected Hedge's g Statistics	0.767	NE	
95% CI	(-0.54, 2.08)	NE	
Subgroup*Treatment Interaction p-value	0.5000	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 20 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.6.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Mental Component Score			
Week 24			
m	6	0	4
n	5	0	4
Baseline Mean (SD)	57.28 (3.79)	N/A	55.10 (5.88)
Analysis Visit Mean (SD)	54.82 (8.50)	N/A	53.68 (8.24)
LS Mean of Change from Baseline (SE)	-2.40 (2.40)	NE	2.07 (3.78)
95% CI	(-8.28, 3.49)	NE	(-7.18, 11.32)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.46 (3.07)	NE	
95% CI	(-11.97, 3.04)	NE	
p-value	0.1959	NE	
Corrected Hedge's g Statistics	-0.619	NE	
95% CI	(-1.96, 0.73)	NE	
Week 52			
m	6	0	4
n	6	0	4
Baseline Mean (SD)	56.70 (3.68)	N/A	55.10 (5.88)
Analysis Visit Mean (SD)	54.52 (6.64)	N/A	47.58 (11.72)
LS Mean of Change from Baseline (SE)	-1.43 (2.79)	NE	-3.97 (4.12)
95% CI	(-8.25, 5.39)	NE	(-14.05, 6.12)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.54 (3.61)	NE	
95% CI	(-6.29, 11.37)	NE	
p-value	0.5079	NE	
Corrected Hedge's g Statistics	0.311	NE	
95% CI	(-0.96, 1.58)	NE	
Subgroup*Treatment Interaction p-value	0.2024	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 21 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.6.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Visit Statistic	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Physical Component Score			
Week 24			
m	6	0	4
n	5	0	4
Baseline Mean (SD)	49.08 (4.72)	N/A	54.18 (3.96)
Analysis Visit Mean (SD)	53.80 (4.69)	N/A	50.88 (10.27)
LS Mean of Change from Baseline (SE)	2.24 (4.00)	NE	-7.75 (7.38)
95% CI	(-7.56, 12.03)	NE	(-25.82, 10.32)
LS Mean of Change from Baseline Compared to Placebo (SE)	9.98 (6.40)	NE	
95% CI	(-5.69, 25.65)	NE	
p-value	0.1700	NE	
Corrected Hedge's g Statistics	0.752	NE	
95% CI	(-0.61, 2.11)	NE	
Week 52			
m	6	0	4
n	6	0	4
Baseline Mean (SD)	50.12 (4.92)	N/A	54.18 (3.96)
Analysis Visit Mean (SD)	48.48 (7.67)	N/A	50.65 (11.16)
LS Mean of Change from Baseline (SE)	-2.95 (4.19)	NE	-9.63 (7.34)
95% CI	(-13.20, 7.30)	NE	(-27.60, 8.33)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.69 (6.06)	NE	
95% CI	(-8.14, 21.52)	NE	
p-value	0.3121	NE	
Corrected Hedge's g Statistics	0.499	NE	
95% CI	(-0.79, 1.78)	NE	
Subgroup*Treatment Interaction p-value	0.8212	NE	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE21.6.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis, only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.

AMNOG Table SE21.6.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (8.3)
No	2 (100)	15 (100)	22 (91.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	3.44	
95% CI of the inverse odds ratio	(0.02, 15.15)	(0.15, 76.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	3.20	
95% CI of the inverse risk ratio	(0.04, 9.77)	(0.16, 62.43)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.67	-6.88	
95% CI of the absolute risk difference	(-37.11, 50.45)	(-21.40, 7.65)	
p-value	0.7243	0.4096	
p-value of Breslow-Day Test for Homogeneity [3]	0.4045	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (13.3)	10 (41.7)
No	2 (100)	13 (86.7)	14 (58.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.62	4.64	
95% CI of the inverse odds ratio	(0.16, 83.53)	(0.85, 25.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.52	3.13	
95% CI of the inverse risk ratio	(0.19, 32.99)	(0.79, 12.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-25.33	-28.33	
95% CI of the absolute risk difference	(-71.73, 21.06)	(-54.51, -2.16)	
p-value	0.3959	0.0622	
p-value of Breslow-Day Test for Homogeneity [3]	0.4330	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	5 (20.8)
No	2 (100)	15 (100)	19 (79.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.41	8.74	
95% CI of the inverse odds ratio	(0.06, 33.93)	(0.45, 170.58)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.32	7.04	
95% CI of the inverse risk ratio	(0.09, 18.42)	(0.42, 118.85)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.33	-18.88	
95% CI of the absolute risk difference	(-50.52, 39.86)	(-37.22, -0.53)	
p-value	0.8315	0.0953	
p-value of Breslow-Day Test for Homogeneity [3]	0.2834	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (6.7)	9 (37.5)
No	2 (100)	14 (93.3)	15 (62.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.06	8.40	
95% CI of the inverse odds ratio	(0.13, 70.94)	(0.94, 75.10)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.28	5.63	
95% CI of the inverse risk ratio	(0.17, 30.07)	(0.79, 40.04)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-21.33	-30.83	
95% CI of the absolute risk difference	(-67.60, 24.93)	(-53.95, -7.71)	
p-value	0.4662	0.0319	
p-value of Breslow-Day Test for Homogeneity [3]	0.1110	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	5 (20.8)
No	2 (100)	15 (100)	19 (79.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.41	8.74	
95% CI of the inverse odds ratio	(0.06, 33.93)	(0.45, 170.58)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.32	7.04	
95% CI of the inverse risk ratio	(0.09, 18.42)	(0.42, 118.85)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.33	-18.88	
95% CI of the absolute risk difference	(-50.52, 39.86)	(-37.22, -0.53)	
p-value	0.8315	0.0953	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (6.7)	5 (20.8)
No	2 (100)	14 (93.3)	19 (79.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.41	3.68	
95% CI of the inverse odds ratio	(0.06, 33.93)	(0.39, 35.14)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.32	3.13	
95% CI of the inverse risk ratio	(0.09, 18.42)	(0.40, 24.22)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.33	-14.17	
95% CI of the absolute risk difference	(-50.52, 39.86)	(-34.74, 6.41)	
p-value	0.8315	0.2329	
p-value of Breslow-Day Test for Homogeneity [3]	0.6038	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	4 (16.7)
No	2 (100)	15 (100)	20 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.10	6.80	
95% CI of the inverse odds ratio	(0.04, 27.01)	(0.34, 136.04)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.08	5.76	
95% CI of the inverse risk ratio	(0.08, 15.52)	(0.33, 99.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.33	-14.88	
95% CI of the absolute risk difference	(-46.11, 43.45)	(-32.18, 2.43)	
p-value	0.9546	0.1557	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (50.0)	2 (13.3)	7 (29.2)
No	1 (50.0)	13 (86.7)	17 (70.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.41	2.68	
95% CI of the inverse odds ratio	(0.02, 7.55)	(0.47, 15.09)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.58	2.19	
95% CI of the inverse risk ratio	(0.13, 2.67)	(0.52, 9.17)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	20.83	-15.83	
95% CI of the absolute risk difference	(-50.81, 92.47)	(-40.87, 9.20)	
p-value	0.5397	0.2536	
p-value of Breslow-Day Test for Homogeneity [3]	0.9699	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	3 (12.5)
No	2 (100)	15 (100)	21 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	5.05	
95% CI of the inverse odds ratio	(0.03, 20.78)	(0.24, 104.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	4.48	
95% CI of the inverse risk ratio	(0.06, 12.63)	(0.25, 81.09)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.67	-10.88	
95% CI of the absolute risk difference	(-41.64, 46.98)	(-26.93, 5.18)	
p-value	0.9007	0.2523	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (6.7)	9 (37.5)
No	2 (100)	14 (93.3)	15 (62.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.06	8.40	
95% CI of the inverse odds ratio	(0.13, 70.94)	(0.94, 75.10)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.28	5.63	
95% CI of the inverse risk ratio	(0.17, 30.07)	(0.79, 40.04)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-21.33	-30.83	
95% CI of the absolute risk difference	(-67.60, 24.93)	(-53.95, -7.71)	
p-value	0.4662	0.0319	
p-value of Breslow-Day Test for Homogeneity [3]	0.1855	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (6.7)	2 (8.3)
No	2 (100)	14 (93.3)	22 (91.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	1.27	
95% CI of the inverse odds ratio	(0.02, 15.15)	(0.11, 15.38)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	1.25	
95% CI of the inverse risk ratio	(0.04, 9.77)	(0.12, 12.62)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.67	-1.67	
95% CI of the absolute risk difference	(-37.11, 50.45)	(-18.45, 15.11)	
p-value	0.7243	0.8493	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	5 (33.3)	3 (12.5)
No	2 (100)	10 (66.7)	21 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	0.29	
95% CI of the inverse odds ratio	(0.03, 20.78)	(0.06, 1.44)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	0.38	
95% CI of the inverse risk ratio	(0.06, 12.63)	(0.10, 1.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.67	20.83	
95% CI of the absolute risk difference	(-41.64, 46.98)	(-6.45, 48.11)	
p-value	0.9007	0.1170	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (8.3)
No	2 (100)	15 (100)	22 (91.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	3.44	
95% CI of the inverse odds ratio	(0.02, 15.15)	(0.15, 76.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	3.20	
95% CI of the inverse risk ratio	(0.04, 9.77)	(0.16, 62.43)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.67	-6.88	
95% CI of the absolute risk difference	(-37.11, 50.45)	(-21.40, 7.65)	
p-value	0.7243	0.4096	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (6.7)	3 (12.5)
No	2 (100)	14 (93.3)	21 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	2.00	
95% CI of the inverse odds ratio	(0.03, 20.78)	(0.19, 21.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	1.88	
95% CI of the inverse risk ratio	(0.06, 12.63)	(0.21, 16.41)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.67	-5.83	
95% CI of the absolute risk difference	(-41.64, 46.98)	(-24.12, 12.45)	
p-value	0.9007	0.5591	
p-value of Breslow-Day Test for Homogeneity [3]	0.3567	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (6.7)	3 (12.5)
No	2 (100)	14 (93.3)	21 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	2.00	
95% CI of the inverse odds ratio	(0.03, 20.78)	(0.19, 21.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	1.88	
95% CI of the inverse risk ratio	(0.06, 12.63)	(0.21, 16.41)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.67	-5.83	
95% CI of the absolute risk difference	(-41.64, 46.98)	(-24.12, 12.45)	
p-value	0.9007	0.5591	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (13.3)	9 (37.5)
No	2 (100)	13 (86.7)	15 (62.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.06	3.90	
95% CI of the inverse odds ratio	(0.13, 70.94)	(0.71, 21.41)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.28	2.81	
95% CI of the inverse risk ratio	(0.17, 30.07)	(0.70, 11.29)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-21.33	-24.17	
95% CI of the absolute risk difference	(-67.60, 24.93)	(-50.07, 1.74)	
p-value	0.4662	0.1028	
p-value of Breslow-Day Test for Homogeneity [3]	0.2184	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	2 (100)	15 (100)	24 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (13.3)	6 (25.0)
No	2 (100)	13 (86.7)	18 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.76	2.17	
95% CI of the inverse odds ratio	(0.07, 41.62)	(0.38, 12.49)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.56	1.88	
95% CI of the inverse risk ratio	(0.11, 21.33)	(0.43, 8.11)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.33	-11.67	
95% CI of the absolute risk difference	(-54.88, 36.21)	(-36.08, 12.75)	
p-value	0.7243	0.3800	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: >200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (8.3)
No	2 (100)	15 (100)	22 (91.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	3.44	
95% CI of the inverse odds ratio	(0.02, 15.15)	(0.15, 76.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	3.20	
95% CI of the inverse risk ratio	(0.04, 9.77)	(0.16, 62.43)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.67	-6.88	
95% CI of the absolute risk difference	(-37.11, 50.45)	(-21.40, 7.65)	
p-value	0.7243	0.4096	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	5 (20.8)
No	2 (100)	15 (100)	19 (79.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.41	8.74	
95% CI of the inverse odds ratio	(0.06, 33.93)	(0.45, 170.58)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.32	7.04	
95% CI of the inverse risk ratio	(0.09, 18.42)	(0.42, 118.85)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.33	-18.88	
95% CI of the absolute risk difference	(-50.52, 39.86)	(-37.22, -0.53)	
p-value	0.8315	0.0953	
p-value of Breslow-Day Test for Homogeneity [3]	0.2834	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (14.3)	0	0
No	6 (85.7)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.48	NE	
95% CI of the inverse odds ratio	(0.02, 14.70)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.53	NE	
95% CI of the inverse risk ratio	(0.03, 10.70)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.75	NE	
95% CI of the absolute risk difference	(-28.97, 46.47)	NE	
p-value	0.6705	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4045	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (14.3)	0	1 (25.0)
No	6 (85.7)	0	3 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	NE	
95% CI of the inverse odds ratio	(0.09, 44.35)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.75	NE	
95% CI of the inverse risk ratio	(0.15, 21.00)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.71	NE	
95% CI of the absolute risk difference	(-60.44, 39.01)	NE	
p-value	0.6576	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4330	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (14.3)	0	0
No	6 (85.7)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.48	NE	
95% CI of the inverse odds ratio	(0.02, 14.70)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.53	NE	
95% CI of the inverse risk ratio	(0.03, 10.70)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.75	NE	
95% CI of the absolute risk difference	(-28.97, 46.47)	NE	
p-value	0.6705	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2834	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (28.6)	0	0
No	5 (71.4)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.24	NE	
95% CI of the inverse odds ratio	(0.01, 6.51)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.32	NE	
95% CI of the inverse risk ratio	(0.02, 5.39)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	21.25	NE	
95% CI of the absolute risk difference	(-20.26, 62.76)	NE	
p-value	0.3763	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.1110	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (14.3)	0	1 (25.0)
No	6 (85.7)	0	3 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	NE	
95% CI of the inverse odds ratio	(0.09, 44.35)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.75	NE	
95% CI of the inverse risk ratio	(0.15, 21.00)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.71	NE	
95% CI of the absolute risk difference	(-60.44, 39.01)	NE	
p-value	0.6576	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.6038	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (42.9)	0	1 (25.0)
No	4 (57.1)	0	3 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.44	NE	
95% CI of the inverse odds ratio	(0.03, 6.70)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.58	NE	
95% CI of the inverse risk ratio	(0.09, 3.90)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	17.86	NE	
95% CI of the absolute risk difference	(-38.22, 73.93)	NE	
p-value	0.5537	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.9699	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (14.3)	0	0
No	6 (85.7)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.48	NE	
95% CI of the inverse odds ratio	(0.02, 14.70)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.53	NE	
95% CI of the inverse risk ratio	(0.03, 10.70)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.75	NE	
95% CI of the absolute risk difference	(-28.97, 46.47)	NE	
p-value	0.6705	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.1855	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (25.0)
No	7 (100)	0	3 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	6.43	NE	
95% CI of the inverse odds ratio	(0.21, 201.07)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.80	NE	
95% CI of the inverse risk ratio	(0.24, 96.34)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-23.75	NE	
95% CI of the absolute risk difference	(-67.28, 19.78)	NE	
p-value	0.2482	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	1 (25.0)
No	7 (100)	0	3 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	6.43	NE	
95% CI of the inverse odds ratio	(0.21, 201.07)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.80	NE	
95% CI of the inverse risk ratio	(0.24, 96.34)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-23.75	NE	
95% CI of the absolute risk difference	(-67.28, 19.78)	NE	
p-value	0.2482	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (14.3)	0	0
No	6 (85.7)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.48	NE	
95% CI of the inverse odds ratio	(0.02, 14.70)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.53	NE	
95% CI of the inverse risk ratio	(0.03, 10.70)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.75	NE	
95% CI of the absolute risk difference	(-28.97, 46.47)	NE	
p-value	0.6705	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3567	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (42.9)	0	1 (25.0)
No	4 (57.1)	0	3 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.44	NE	
95% CI of the inverse odds ratio	(0.03, 6.70)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.58	NE	
95% CI of the inverse risk ratio	(0.09, 3.90)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	17.86	NE	
95% CI of the absolute risk difference	(-38.22, 73.93)	NE	
p-value	0.5537	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2184	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Weight
(Label Population based on Modified Intent-to-Treat Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (14.3)	0	0
No	6 (85.7)	0	4 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.48	NE	
95% CI of the inverse odds ratio	(0.02, 14.70)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.53	NE	
95% CI of the inverse risk ratio	(0.03, 10.70)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.75	NE	
95% CI of the absolute risk difference	(-28.97, 46.47)	NE	
p-value	0.6705	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2834	NE	

AMNOG Table SE21.7.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=6)	(N=6)	(N=19)	(N=6)	(N=6)	(N=19)
Physical Functioning						
Baseline						
m	6	6	19			
n	6	6	18			
Mean (SD)	80.83 (14.29)	74.17 (16.86)	77.22 (24.45)			
Median	82.50	75.00	85.00			
IQR: Q1, Q3	70.00, 90.00	65.00, 80.00	65.00, 95.00			
Min, Max	60.0, 100.0	50.0, 100.0	25.0, 100.0			
Week 24						
m	5	5	18			
n	4	5	16	4	5	16
Mean (SD/SE)	96.25 (7.50)	82.00 (11.51)	70.94 (28.30)	11.25 (8.26)	3.00 (4.36)	-7.50 (7.03)
Median	100.00	80.00	80.00	10.00	0	0
IQR: Q1, Q3	92.50, 100.00	75.00, 85.00	55.00, 95.00	-2.50, 25.00	0.00, 0.00	-10.00, 5.00
Min, Max	85.0, 100.0	70.0, 100.0	20.0, 100.0	-5.0, 30.0	-5.0, 20.0	-75.0, 35.0
Week 52						
m	5	5	17			
n	5	5	16	5	5	16
Mean (SD/SE)	81.00 (18.84)	72.00 (21.97)	78.23 (25.95)	-4.00 (7.97)	-7.00 (7.68)	-0.21 (4.77)
Median	85.00	75.00	90.00	-5.00	0	2.50
IQR: Q1, Q3	80.00, 90.00	50.00, 85.00	62.50, 100.00	-5.00, 0.00	-20.00, 5.00	-5.00, 10.00
Min, Max	50.0, 100.0	50.0, 100.0	20.0, 100.0	-30.0, 20.0	-30.0, 10.0	-60.0, 30.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.7.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=6)	(N=6)	(N=19)	(N=6)	(N=6)	(N=19)
Role Physical						
Baseline						
m	6	6	19			
n	6	6	18			
Mean (SD)	85.42 (20.03)	88.55 (12.75)	76.40 (28.24)			
Median	93.75	90.65	84.40			
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	62.50, 100.00			
Min, Max	50.0, 100.0	75.0, 100.0	0.0, 100.0			
Week 24						
m	5	5	18			
n	4	5	16	4	5	16
Mean (SD/SE)	100.00 (0.00)	81.28 (19.24)	69.93 (34.47)	9.38 (5.98)	-8.72 (8.97)	-4.69 (6.86)
Median	100.00	81.30	81.25	6.25	0	0
IQR: Q1, Q3	100.00, 100.00	68.80, 100.00	43.75, 100.00	0.00, 18.75	-6.20, 0.00	0.00, 12.50
Min, Max	100.0, 100.0	56.3, 100.0	6.3, 100.0	0.0, 25.0	-43.7, 6.3	-75.0, 18.8
Week 52						
m	5	5	17			
n	5	5	16	5	5	16
Mean (SD/SE)	90.00 (16.30)	70.00 (31.37)	73.45 (28.26)	-2.50 (8.29)	-20.00 (12.87)	-1.17 (4.98)
Median	100.00	75.00	75.00	0	0	0
IQR: Q1, Q3	87.50, 100.00	37.50, 100.00	53.15, 100.00	-12.50, 0.00	-37.50, 0.00	-15.60, 12.50
Min, Max	62.5, 100.0	37.5, 100.0	25.0, 100.0	-25.0, 25.0	-62.5, 0.0	-43.8, 31.3

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.7.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=6)	Visit Result DB Placebo (N=19)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=6)	Change from Baseline DB Placebo (N=19)
Bodily Pain						
Baseline						
m	6	6	19			
n	6	6	18			
Mean (SD)	79.7 (27.7)	79.2 (23.2)	74.1 (24.1)			
Median	92.0	81.0	79.0			
IQR: Q1, Q3	62.0, 100.0	62.0, 100.0	62.0, 100.0			
Min, Max	32, 100	51, 100	12, 100			
Week 24						
m	5	5	18			
n	4	5	16	4	5	16
Mean (SD/SE)	87.8 (24.5)	75.6 (22.7)	71.8 (27.4)	8.8 (5.1)	-9.2 (7.0)	-1.8 (4.0)
Median	100.0	64.0	74.0	8.0	0	0
IQR: Q1, Q3	75.5, 100.0	62.0, 100.0	51.5, 100.0	0.0, 17.5	-10.0, 0.0	0.0, 10.0
Min, Max	51, 100	52, 100	12, 100	0, 19	-36, 0	-53, 12
Week 52						
m	5	5	17			
n	5	5	16	5	5	16
Mean (SD/SE)	70.4 (30.2)	80.0 (20.3)	72.1 (22.1)	-12.8 (3.7)	-4.8 (6.3)	-1.5 (3.7)
Median	84.0	74.0	74.0	-16.0	0	0
IQR: Q1, Q3	62.0, 84.0	74.0, 100.0	52.0, 92.0	-16.0, -10.0	-10.0, 0.0	-10.0, 5.5
Min, Max	22, 100	52, 100	32, 100	-22, 0	-26, 12	-26, 23

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.7.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=6)	Visit Result DB Placebo (N=19)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=6)	Change from Baseline DB Placebo (N=19)
General Health						
Baseline						
m	6	6	19			
n	6	6	18			
Mean (SD)	71.17 (12.81)	67.00 (11.40)	66.44 (21.49)			
Median	72.00	67.00	72.00			
IQR: Q1, Q3	57.00, 82.00	67.00, 72.00	60.00, 82.00			
Min, Max	57.0, 87.0	47.0, 82.0	25.0, 97.0			
Week 24						
m	5	5	18			
n	4	5	16	4	5	16
Mean (SD/SE)	87.00 (10.80)	64.60 (17.36)	64.31 (18.90)	11.25 (1.25)	-2.40 (6.62)	-3.75 (3.96)
Median	89.50	62.00	68.50	10.00	5.00	0
IQR: Q1, Q3	79.50, 94.50	52.00, 77.00	45.00, 77.00	10.00, 12.50	-5.00, 5.00	-15.00, 10.00
Min, Max	72.0, 97.0	45.0, 87.0	30.0, 92.0	10.0, 15.0	-27.0, 10.0	-35.0, 20.0
Week 52						
m	5	5	17			
n	5	5	16	5	5	16
Mean (SD/SE)	79.60 (16.01)	63.60 (15.82)	62.47 (18.75)	5.60 (2.20)	-3.40 (6.41)	-5.59 (4.91)
Median	87.00	62.00	66.00	5.00	0	-7.50
IQR: Q1, Q3	72.00, 92.00	52.00, 77.00	51.00, 74.50	5.00, 10.00	-5.00, 5.00	-10.00, 7.75
Min, Max	55.0, 92.0	45.0, 82.0	15.0, 87.5	-2.0, 10.0	-27.0, 10.0	-57.0, 25.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.7.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=6)	Visit Result DB Placebo (N=19)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=6)	Change from Baseline DB Placebo (N=19)
Vitality						
Baseline						
m	6	6	19			
n	6	6	18			
Mean (SD)	63.58 (13.92)	69.82 (15.53)	65.64 (19.44)			
Median	62.55	71.90	65.65			
IQR: Q1, Q3	56.30, 75.00	56.30, 75.00	50.00, 81.30			
Min, Max	43.8, 81.3	50.0, 93.8	25.0, 100.0			
Week 24						
m	5	5	18			
n	4	5	16	4	5	16
Mean (SD/SE)	62.53 (26.54)	63.76 (11.17)	62.91 (20.46)	-4.70 (6.94)	-5.02 (6.68)	-3.13 (4.84)
Median	71.90	62.50	62.50	-6.25	0	0
IQR: Q1, Q3	43.75, 81.30	56.30, 75.00	56.30, 75.00	-15.65, 6.25	0.00, 0.00	-9.40, 6.25
Min, Max	25.0, 81.3	50.0, 75.0	6.3, 87.5	-18.8, 12.5	-31.3, 6.2	-50.0, 31.3
Week 52						
m	5	5	17			
n	5	5	16	5	5	16
Mean (SD/SE)	55.02 (25.53)	63.78 (20.43)	66.41 (22.58)	-10.02 (5.45)	-5.00 (4.58)	0.38 (4.44)
Median	68.80	75.00	62.50	-6.30	0	0
IQR: Q1, Q3	37.50, 75.00	56.30, 75.00	53.15, 81.25	-18.80, -6.20	-12.50, 0.00	-12.50, 12.50
Min, Max	18.8, 75.0	31.3, 81.3	25.0, 100.0	-25.0, 6.2	-18.7, 6.2	-37.5, 31.2

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.7.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=6)	(N=6)	(N=19)	(N=6)	(N=6)	(N=19)
Social Functioning						
Baseline						
m	6	6	19			
n	6	6	18			
Mean (SD)	95.83 (10.21)	81.25 (22.01)	88.89 (19.60)			
Median	100.00	87.50	100.00			
IQR: Q1, Q3	100.00, 100.00	87.50, 87.50	87.50, 100.00			
Min, Max	75.0, 100.0	37.5, 100.0	25.0, 100.0			
Week 24						
m	5	5	18			
n	4	5	16	4	5	16
Mean (SD/SE)	93.75 (12.50)	85.00 (13.69)	85.16 (26.70)	-6.25 (6.25)	5.00 (15.61)	-3.91 (7.19)
Median	100.00	75.00	100.00	0	-12.50	0
IQR: Q1, Q3	87.50, 100.00	75.00, 100.00	75.00, 100.00	-12.50, 0.00	-12.50, 12.50	0.00, 0.00
Min, Max	75.0, 100.0	75.0, 100.0	0.0, 100.0	-25.0, 0.0	-25.0, 62.5	-100.0, 50.0
Week 52						
m	5	5	17			
n	5	5	16	5	5	16
Mean (SD/SE)	92.50 (16.77)	95.00 (11.18)	92.19 (15.05)	-7.50 (7.50)	15.00 (13.92)	3.13 (4.19)
Median	100.00	100.00	100.00	0	12.50	0
IQR: Q1, Q3	100.00, 100.00	100.00, 100.00	93.75, 100.00	0.00, 0.00	12.50, 12.50	0.00, 6.25
Min, Max	62.5, 100.0	75.0, 100.0	62.5, 100.0	-37.5, 0.0	-25.0, 62.5	-37.5, 37.5

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.7.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=6)	(N=6)	(N=19)	(N=6)	(N=6)	(N=19)
Role Emotional						
Baseline						
m	6	6	19			
n	6	6	18			
Mean (SD)	88.90 (19.49)	94.45 (10.09)	88.89 (18.74)			
Median	95.85	100.00	100.00			
IQR: Q1, Q3	91.70, 100.00	91.70, 100.00	83.30, 100.00			
Min, Max	50.0, 100.0	75.0, 100.0	41.7, 100.0			
Week 24						
m	5	5	18			
n	4	5	16	4	5	16
Mean (SD/SE)	93.75 (12.50)	86.66 (21.73)	83.85 (22.66)	-2.10 (5.25)	-11.68 (10.41)	-4.69 (3.65)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	87.50, 100.00	83.30, 100.00	70.80, 100.00	-8.35, 4.15	-16.70, 0.00	0.00, 0.00
Min, Max	75.0, 100.0	50.0, 100.0	41.7, 100.0	-16.7, 8.3	-50.0, 8.3	-50.0, 8.3
Week 52						
m	5	5	17			
n	5	5	16	5	5	16
Mean (SD/SE)	90.00 (14.90)	90.00 (22.36)	86.98 (22.15)	-6.68 (6.12)	-8.34 (10.54)	-1.57 (4.52)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	83.30, 100.00	100.00, 100.00	79.15, 100.00	-16.70, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	66.7, 100.0	50.0, 100.0	25.0, 100.0	-25.0, 8.3	-50.0, 8.3	-41.7, 33.3

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.7.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=6)	Visit Result DB Placebo (N=19)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=6)	Change from Baseline DB Placebo (N=19)
Mental Health						
Baseline						
m	6	6	19			
n	6	6	18			
Mean (SD)	82.5 (14.1)	83.3 (8.8)	83.6 (14.4)			
Median	85.0	87.5	87.5			
IQR: Q1, Q3	75.0, 90.0	75.0, 90.0	70.0, 95.0			
Min, Max	60, 100	70, 90	50, 100			
Week 24						
m	5	5	18			
n	4	5	16	4	5	16
Mean (SD/SE)	88.8 (13.1)	82.0 (16.8)	81.3 (18.4)	0.0 (3.5)	-4.0 (9.5)	-2.2 (1.7)
Median	92.5	85.0	90.0	-2.5	-5.0	0
IQR: Q1, Q3	80.0, 97.5	80.0, 90.0	67.5, 95.0	-5.0, 5.0	-5.0, 0.0	-5.0, 2.5
Min, Max	70, 100	55, 100	45, 100	-5, 10	-35, 25	-20, 5
Week 52						
m	5	5	17			
n	5	5	16	5	5	16
Mean (SD/SE)	86.0 (10.8)	86.0 (6.5)	83.1 (19.7)	-1.0 (2.9)	0.0 (4.5)	-0.3 (3.3)
Median	90.0	85.0	90.0	0	-5.0	2.5
IQR: Q1, Q3	80.0, 95.0	80.0, 90.0	75.0, 97.5	-5.0, 5.0	-5.0, 5.0	-5.0, 5.0
Min, Max	70, 95	80, 95	30, 100	-10, 5	-10, 15	-40, 20

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.7.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=6)	(N=6)	(N=19)	(N=6)	(N=6)	(N=19)
Mental Component Score						
Baseline						
m	6	6	19			
n	6	6	18			
Mean (SD)	54.55 (6.46)	55.38 (3.73)	55.29 (7.02)			
Median	55.40	55.20	57.80			
IQR: Q1, Q3	53.30, 59.20	52.40, 57.50	52.30, 59.70			
Min, Max	42.9, 61.1	51.1, 60.9	38.1, 62.9			
Week 24						
m	5	5	18			
n	4	5	16	4	5	16
Mean (SD/SE)	54.25 (9.04)	53.18 (7.42)	54.01 (8.23)	-3.40 (2.98)	-2.62 (4.95)	-1.21 (1.03)
Median	57.85	56.20	57.90	-1.20	-1.30	-1.20
IQR: Q1, Q3	48.30, 60.20	52.10, 57.30	48.70, 59.40	-6.85, 0.05	-5.00, 4.90	-3.30, 0.30
Min, Max	41.1, 60.2	40.8, 59.5	37.1, 62.8	-12.2, 1.0	-20.1, 8.4	-8.1, 10.8
Week 52						
m	5	5	17			
n	5	5	16	5	5	16
Mean (SD/SE)	54.42 (6.41)	57.06 (2.51)	55.40 (9.05)	-2.46 (1.52)	1.26 (2.39)	0.18 (1.51)
Median	56.90	57.00	59.55	-1.60	2.10	1.60
IQR: Q1, Q3	47.70, 59.50	56.80, 58.80	49.20, 61.40	-5.90, -0.10	1.70, 4.40	0.05, 3.75
Min, Max	47.4, 60.6	53.1, 59.6	35.3, 65.5	-6.1, 1.4	-7.8, 5.9	-16.0, 7.2

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.7.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=6)	Visit Result DB MGL-3196 100 mg (N=6)	Visit Result DB Placebo (N=19)	Change from Baseline DB MGL-3196 80 mg (N=6)	Change from Baseline DB MGL-3196 100 mg (N=6)	Change from Baseline DB Placebo (N=19)
Physical Component Score						
Baseline						
m	6	6	19			
n	6	6	18			
Mean (SD)	51.37 (6.03)	49.70 (7.43)	48.27 (9.63)			
Median	52.20	49.00	50.55			
IQR: Q1, Q3	45.20, 56.50	43.70, 54.40	43.20, 55.90			
Min, Max	44.1, 58.0	41.8, 60.3	21.6, 59.8			
Week 24						
m	5	5	18			
n	4	5	16	4	5	16
Mean (SD/SE)	57.48 (1.91)	49.98 (5.88)	46.54 (10.77)	5.55 (2.67)	-0.78 (1.84)	-1.88 (2.31)
Median	58.05	48.60	49.45	5.30	-0.60	1.00
IQR: Q1, Q3	56.10, 58.85	48.00, 53.00	39.80, 54.15	0.95, 10.15	-2.30, 0.50	-4.20, 3.00
Min, Max	54.8, 59.0	42.3, 58.0	24.6, 59.3	0.9, 10.7	-6.4, 4.9	-30.0, 7.3
Week 52						
m	5	5	17			
n	5	5	16	5	5	16
Mean (SD/SE)	51.18 (8.86)	46.64 (10.46)	47.55 (9.57)	-1.42 (1.96)	-4.12 (3.30)	-0.87 (1.81)
Median	53.70	46.60	51.05	-1.00	-1.70	-0.15
IQR: Q1, Q3	52.70, 56.80	39.60, 55.00	38.95, 55.80	-1.60, 0.30	-8.40, 1.40	-5.70, 4.25
Min, Max	35.7, 57.0	33.4, 58.6	31.5, 58.9	-8.4, 3.6	-14.8, 2.9	-15.9, 9.9

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.7.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=9)	Visit Result DB Placebo (N=9)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=9)	Change from Baseline DB Placebo (N=9)
Physical Functioning						
Baseline						
m	3	9	9			
n	3	8	8			
Mean (SD)	60.00 (35.00)	83.13 (20.69)	87.50 (9.64)			
Median	75.00	90.00	90.00			
IQR: Q1, Q3	20.00, 85.00	75.00, 97.50	77.50, 95.00			
Min, Max	20.0, 85.0	40.0, 100.0	75.0, 100.0			
Week 24						
m	3	7	9			
n	3	6	9	3	6	8
Mean (SD/SE)	66.67 (20.21)	85.00 (20.25)	86.11 (11.93)	6.67 (11.67)	1.67 (2.47)	0.63 (4.27)
Median	70.00	92.50	85.00	10.00	2.50	0
IQR: Q1, Q3	45.00, 85.00	85.00, 95.00	75.00, 100.00	-15.00, 25.00	-5.00, 5.00	-7.50, 5.00
Min, Max	45.0, 85.0	45.0, 100.0	70.0, 100.0	-15.0, 25.0	-5.0, 10.0	-15.0, 25.0
Week 52						
m	3	7	9			
n	2	5	8	2	5	7
Mean (SD/SE)	75.00 (7.07)	77.00 (22.53)	88.75 (10.61)	-5.00 (0.00)	-5.00 (2.24)	-1.43 (5.95)
Median	75.00	80.00	90.00	-5.00	-5.00	0
IQR: Q1, Q3	70.00, 80.00	75.00, 95.00	82.50, 97.50	-5.00, -5.00	-10.00, 0.00	-20.00, 5.00
Min, Max	70.0, 80.0	40.0, 95.0	70.0, 100.0	-5.0, -5.0	-10.0, 0.0	-20.0, 25.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.7.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=9)	Visit Result DB Placebo (N=9)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=9)	Change from Baseline DB Placebo (N=9)
Role Physical						
Baseline						
m	3	9	9			
n	3	8	8			
Mean (SD)	72.93 (3.58)	89.86 (15.28)	86.73 (12.68)			
Median	75.00	96.90	87.50			
IQR: Q1, Q3	68.80, 75.00	81.30, 100.00	75.00, 100.00			
Min, Max	68.8, 75.0	62.5, 100.0	68.8, 100.0			
Week 24						
m	3	7	9			
n	3	6	9	3	6	8
Mean (SD/SE)	68.77 (10.80)	91.68 (14.62)	86.81 (18.86)	-4.17 (7.48)	0.00 (1.60)	4.69 (6.11)
Median	75.00	96.90	100.00	0	0	0
IQR: Q1, Q3	56.30, 75.00	93.80, 100.00	81.30, 100.00	-18.70, 6.20	0.00, 0.00	0.00, 15.65
Min, Max	56.3, 75.0	62.5, 100.0	50.0, 100.0	-18.7, 6.2	-6.2, 6.2	-25.0, 31.2
Week 52						
m	3	7	9			
n	2	5	8	2	5	7
Mean (SD/SE)	68.75 (8.84)	82.52 (26.30)	85.16 (18.27)	-3.15 (9.35)	-8.74 (5.79)	-1.79 (9.32)
Median	68.75	93.80	93.75	-3.15	-6.20	0
IQR: Q1, Q3	62.50, 75.00	81.30, 100.00	68.75, 100.00	-12.50, 6.20	-18.70, 0.00	-31.20, 25.00
Min, Max	62.5, 75.0	37.5, 100.0	56.3, 100.0	-12.5, 6.2	-25.0, 6.2	-37.5, 25.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.7.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=9)	Visit Result DB Placebo (N=9)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=9)	Change from Baseline DB Placebo (N=9)
Bodily Pain						
Baseline						
m	3	9	9			
n	3	8	8			
Mean (SD)	62.7 (11.0)	77.8 (15.1)	83.3 (10.3)			
Median	62.0	84.0	84.0			
IQR: Q1, Q3	52.0, 74.0	67.0, 84.0	84.0, 84.0			
Min, Max	52, 74	52, 100	62, 100			
Week 24						
m	3	7	9			
n	3	6	9	3	6	8
Mean (SD/SE)	82.0 (19.1)	80.7 (12.6)	78.3 (20.7)	19.3 (4.8)	2.3 (5.0)	-2.9 (6.6)
Median	84.0	82.0	84.0	22.0	0	0
IQR: Q1, Q3	62.0, 100.0	74.0, 84.0	62.0, 100.0	10.0, 26.0	-10.0, 16.0	-6.0, 8.0
Min, Max	62, 100	62, 100	41, 100	10, 26	-10, 18	-43, 16
Week 52						
m	3	7	9			
n	2	5	8	2	5	7
Mean (SD/SE)	62.0 (0.0)	71.2 (9.3)	80.0 (15.8)	-1.0 (11.0)	-6.0 (4.5)	-3.7 (6.0)
Median	62.0	74.0	79.0	-1.0	0	-10.0
IQR: Q1, Q3	62.0, 62.0	62.0, 74.0	73.0, 92.0	-12.0, 10.0	-10.0, 0.0	-10.0, 16.0
Min, Max	62, 62	62, 84	52, 100	-12, 10	-22, 2	-28, 16

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.7.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=3)	(N=9)	(N=9)	(N=3)	(N=9)	(N=9)
General Health						
Baseline						
m	3	9	9			
n	3	8	8			
Mean (SD)	61.33 (31.56)	68.00 (11.99)	77.38 (9.98)			
Median	77.00	67.00	77.00			
IQR: Q1, Q3	25.00, 82.00	59.50, 79.50	71.00, 84.50			
Min, Max	25.0, 82.0	50.0, 82.0	62.0, 92.0			
Week 24						
m	3	7	9			
n	3	6	9	3	6	8
Mean (SD/SE)	58.00 (29.55)	66.17 (14.29)	72.33 (19.68)	-3.33 (3.33)	-2.17 (6.27)	-1.25 (4.98)
Median	67.00	64.50	77.00	0	1.00	-2.50
IQR: Q1, Q3	25.00, 82.00	57.00, 77.00	67.00, 87.00	-10.00, 0.00	-15.00, 10.00	-5.00, 10.00
Min, Max	25.0, 82.0	47.0, 87.0	40.0, 92.0	-10.0, 0.0	-25.0, 15.0	-30.0, 15.0
Week 52						
m	3	7	9			
n	2	5	8	2	5	7
Mean (SD/SE)	74.50 (3.54)	63.00 (16.36)	76.38 (19.35)	-5.00 (5.00)	-3.60 (1.57)	1.43 (4.46)
Median	74.50	57.00	84.50	-5.00	-5.00	0
IQR: Q1, Q3	72.00, 77.00	57.00, 77.00	54.50, 92.00	-10.00, 0.00	-5.00, 0.00	-5.00, 10.00
Min, Max	72.0, 77.0	42.0, 82.0	52.0, 97.0	-10.0, 0.0	-8.0, 0.0	-20.0, 15.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.7.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=9)	Visit Result DB Placebo (N=9)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=9)	Change from Baseline DB Placebo (N=9)
Vitality						
Baseline						
m	3	9	9			
n	3	8	8			
Mean (SD)	43.77 (38.03)	66.44 (12.02)	67.21 (17.60)			
Median	62.50	65.65	65.65			
IQR: Q1, Q3	0.00, 68.80	62.50, 75.05	53.15, 81.25			
Min, Max	0.0, 68.8	43.8, 81.3	43.8, 93.8			
Week 24						
m	3	7	9			
n	3	6	9	3	6	8
Mean (SD/SE)	43.77 (39.04)	68.80 (17.68)	63.22 (22.64)	0.00 (3.58)	3.15 (7.35)	-1.56 (3.69)
Median	56.30	68.80	75.00	0	3.15	-3.10
IQR: Q1, Q3	0.00, 75.00	56.30, 81.30	43.80, 81.30	-6.20, 6.20	-12.50, 12.50	-6.30, 6.25
Min, Max	0.0, 75.0	43.8, 93.8	31.3, 93.8	-6.2, 6.2	-18.7, 31.3	-18.7, 12.5
Week 52						
m	3	7	9			
n	2	5	8	2	5	7
Mean (SD/SE)	62.55 (8.84)	56.28 (9.88)	65.65 (22.42)	-3.10 (3.10)	-6.24 (2.80)	-5.36 (6.01)
Median	62.55	56.30	71.90	-3.10	-6.20	-6.20
IQR: Q1, Q3	56.30, 68.80	50.00, 62.50	53.15, 81.30	-6.20, 0.00	-12.50, 0.00	-18.80, 12.50
Min, Max	56.3, 68.8	43.8, 68.8	25.0, 87.5	-6.2, 0.0	-12.5, 0.0	-25.0, 18.7

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.7.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=9)	Visit Result DB Placebo (N=9)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=9)	Change from Baseline DB Placebo (N=9)
Social Functioning						
Baseline						
m	3	9	9			
n	3	8	8			
Mean (SD)	79.17 (19.09)	93.75 (9.45)	98.44 (4.42)			
Median	75.00	100.00	100.00			
IQR: Q1, Q3	62.50, 100.00	87.50, 100.00	100.00, 100.00			
Min, Max	62.5, 100.0	75.0, 100.0	87.5, 100.0			
Week 24						
m	3	7	9			
n	3	6	9	3	6	8
Mean (SD/SE)	70.83 (26.02)	95.83 (6.45)	90.28 (17.43)	-8.33 (4.17)	0.00 (3.23)	-6.25 (4.72)
Median	62.50	100.00	100.00	-12.50	0	0
IQR: Q1, Q3	50.00, 100.00	87.50, 100.00	87.50, 100.00	-12.50, 0.00	0.00, 0.00	-6.25, 0.00
Min, Max	50.0, 100.0	87.5, 100.0	50.0, 100.0	-12.5, 0.0	-12.5, 12.5	-37.5, 0.0
Week 52						
m	3	7	9			
n	2	5	8	2	5	7
Mean (SD/SE)	81.25 (26.52)	90.00 (10.46)	96.88 (8.84)	-6.25 (6.25)	-7.50 (6.37)	-1.79 (1.79)
Median	81.25	87.50	100.00	-6.25	-12.50	0
IQR: Q1, Q3	62.50, 100.00	87.50, 100.00	100.00, 100.00	-12.50, 0.00	-12.50, 0.00	0.00, 0.00
Min, Max	62.5, 100.0	75.0, 100.0	75.0, 100.0	-12.5, 0.0	-25.0, 12.5	-12.5, 0.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.7.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=9)	Visit Result DB Placebo (N=9)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=9)	Change from Baseline DB Placebo (N=9)
Role Emotional						
Baseline						
m	3	9	9			
n	3	8	8			
Mean (SD)	97.23 (4.79)	97.91 (5.90)	92.71 (12.14)			
Median	100.00	100.00	100.00			
IQR: Q1, Q3	91.70, 100.00	100.00, 100.00	87.50, 100.00			
Min, Max	91.7, 100.0	83.3, 100.0	66.7, 100.0			
Week 24						
m	3	7	9			
n	3	6	9	3	6	8
Mean (SD/SE)	83.33 (16.65)	95.83 (10.21)	87.97 (15.08)	-13.90 (10.00)	-1.38 (5.45)	-2.09 (1.37)
Median	83.30	100.00	100.00	-8.40	0	0
IQR: Q1, Q3	66.70, 100.00	100.00, 100.00	75.00, 100.00	-33.30, 0.00	0.00, 0.00	-4.15, 0.00
Min, Max	66.7, 100.0	75.0, 100.0	66.7, 100.0	-33.3, 0.0	-25.0, 16.7	-8.4, 0.0
Week 52						
m	3	7	9			
n	2	5	8	2	5	7
Mean (SD/SE)	91.65 (11.81)	91.66 (11.79)	84.38 (19.65)	-4.20 (4.20)	-5.00 (5.00)	-9.53 (5.29)
Median	91.65	100.00	95.85	-4.20	0	0
IQR: Q1, Q3	83.30, 100.00	83.30, 100.00	62.50, 100.00	-8.40, 0.00	0.00, 0.00	-25.00, 0.00
Min, Max	83.3, 100.0	75.0, 100.0	58.3, 100.0	-8.4, 0.0	-25.0, 0.0	-33.4, 0.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.7.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=9)	Visit Result DB Placebo (N=9)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=9)	Change from Baseline DB Placebo (N=9)
Mental Health						
Baseline						
m	3	9	9			
n	3	8	8			
Mean (SD)	78.3 (10.4)	87.5 (6.5)	81.9 (16.2)			
Median	75.0	85.0	82.5			
IQR: Q1, Q3	70.0, 90.0	85.0, 90.0	67.5, 97.5			
Min, Max	70, 90	80, 100	60, 100			
Week 24						
m	3	7	9			
n	3	6	9	3	6	8
Mean (SD/SE)	83.3 (11.5)	87.5 (7.6)	83.9 (15.8)	5.0 (5.0)	0.8 (2.7)	1.3 (3.0)
Median	90.0	87.5	90.0	0	0	0
IQR: Q1, Q3	70.0, 90.0	85.0, 95.0	75.0, 95.0	0.0, 15.0	0.0, 5.0	-5.0, 7.5
Min, Max	70, 90	75, 95	55, 100	0, 15	-10, 10	-10, 15
Week 52						
m	3	7	9			
n	2	5	8	2	5	7
Mean (SD/SE)	85.0 (7.1)	76.0 (11.4)	83.1 (18.5)	2.5 (2.5)	-11.0 (4.0)	0.0 (4.9)
Median	85.0	80.0	87.5	2.5	-5.0	0
IQR: Q1, Q3	80.0, 90.0	70.0, 80.0	72.5, 97.5	0.0, 5.0	-15.0, -5.0	-10.0, 5.0
Min, Max	80, 90	60, 90	50, 100	0, 5	-25, -5	-15, 25

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.7.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=3)	Visit Result DB MGL-3196 100 mg (N=9)	Visit Result DB Placebo (N=9)	Change from Baseline DB MGL-3196 80 mg (N=3)	Change from Baseline DB MGL-3196 100 mg (N=9)	Change from Baseline DB Placebo (N=9)
Mental Component Score						
Baseline						
m	3	9	9			
n	3	8	8			
Mean (SD)	54.10 (5.17)	57.26 (2.00)	54.93 (7.48)			
Median	53.10	57.20	55.55			
IQR: Q1, Q3	49.50, 59.70	55.40, 58.40	48.45, 61.85			
Min, Max	49.5, 59.7	55.2, 60.9	44.5, 63.2			
Week 24						
m	3	7	9			
n	3	6	9	3	6	8
Mean (SD/SE)	50.83 (10.44)	57.02 (4.83)	53.60 (7.90)	-3.27 (3.23)	0.08 (1.72)	-1.05 (1.38)
Median	51.90	58.45	57.50	-1.20	0.05	-0.55
IQR: Q1, Q3	39.90, 60.70	55.10, 60.80	48.50, 58.00	-9.60, 1.00	-1.30, 3.20	-4.90, 2.20
Min, Max	39.9, 60.7	48.3, 61.0	38.7, 62.5	-9.6, 1.0	-6.9, 5.4	-5.9, 4.0
Week 52						
m	3	7	9			
n	2	5	8	2	5	7
Mean (SD/SE)	55.95 (7.57)	52.82 (5.58)	53.49 (9.50)	-0.45 (2.05)	-4.12 (1.83)	-2.17 (2.47)
Median	55.95	53.20	57.20	-0.45	-2.80	-1.70
IQR: Q1, Q3	50.60, 61.30	52.60, 55.00	46.40, 60.65	-2.50, 1.60	-2.80, -2.00	-6.60, -0.40
Min, Max	50.6, 61.3	44.0, 59.3	37.9, 61.5	-2.5, 1.6	-11.4, -1.6	-12.8, 8.7

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.7.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=3)	(N=9)	(N=9)	(N=3)	(N=9)	(N=9)
Physical Component Score						
Baseline						
m	3	9	9			
n	3	8	8			
Mean (SD)	42.63 (9.20)	50.41 (6.54)	53.61 (4.52)			
Median	46.10	53.05	53.15			
IQR: Q1, Q3	32.20, 49.60	47.05, 54.60	50.00, 57.00			
Min, Max	32.2, 49.6	37.8, 56.1	47.5, 61.1			
Week 24						
m	3	7	9			
n	3	6	9	3	6	8
Mean (SD/SE)	45.83 (5.78)	51.30 (6.10)	52.29 (8.29)	3.20 (2.00)	0.38 (1.44)	0.20 (2.39)
Median	47.50	52.45	55.60	1.40	1.40	0.05
IQR: Q1, Q3	39.40, 50.60	48.50, 55.50	50.80, 57.10	1.00, 7.20	-3.30, 3.10	-0.80, 2.10
Min, Max	39.4, 50.6	40.9, 58.0	37.3, 61.0	1.0, 7.2	-4.5, 4.2	-12.9, 11.8
Week 52						
m	3	7	9			
n	2	5	8	2	5	7
Mean (SD/SE)	46.00 (2.12)	48.78 (8.39)	53.59 (2.62)	-1.85 (3.25)	-1.48 (1.02)	-0.07 (2.40)
Median	46.00	49.10	53.30	-1.85	-2.30	1.10
IQR: Q1, Q3	44.50, 47.50	49.00, 52.40	51.55, 55.60	-5.10, 1.40	-2.50, -0.60	-6.90, 2.80
Min, Max	44.5, 47.5	35.3, 58.1	50.2, 57.6	-5.1, 1.4	-4.0, 2.0	-8.4, 10.1

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; T2D = Type 2 Diabetes.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.7.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable; T2D = Type 2 Diabetes.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

AMNOG Table SE21.7.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Physical Functioning			
Week 24			
m	5	5	18
n	4	5	16
Baseline Mean (SD)	85.00 (12.91)	79.00 (13.42)	78.44 (25.74)
Analysis Visit Mean (SD)	96.25 (7.50)	82.00 (11.51)	70.94 (28.30)
LS Mean of Change from Baseline (SE)	13.79 (11.28)	2.60 (10.41)	-8.21 (7.30)
95% CI	(-9.54, 37.11)	(-18.94, 24.13)	(-23.31, 6.89)
LS Mean of Change from Baseline Compared to Placebo (SE)	22.00 (12.27)	10.81 (11.42)	
95% CI	(-3.39, 47.38)	(-12.82, 34.43)	
p-value	0.0862	0.3538	
Corrected Hedge's g Statistics	0.747	0.370	
95% CI	(-0.37, 1.87)	(-0.64, 1.38)	
Week 52			
m	5	5	17
n	5	5	16
Baseline Mean (SD)	85.00 (11.18)	79.00 (13.42)	78.44 (25.74)
Analysis Visit Mean (SD)	81.00 (18.84)	72.00 (21.97)	78.23 (25.95)
LS Mean of Change from Baseline (SE)	-2.71 (8.98)	-7.22 (8.88)	-0.58 (6.64)
95% CI	(-21.29, 15.87)	(-25.60, 11.16)	(-14.32, 13.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.13 (9.63)	-6.63 (9.58)	
95% CI	(-22.04, 17.79)	(-26.45, 13.18)	
p-value	0.8272	0.4955	
Corrected Hedge's g Statistics	-0.081	-0.252	
95% CI	(-1.09, 0.92)	(-1.26, 0.76)	
Subgroup*Treatment Interaction p-value	0.3543	0.8061	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE21.7.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Role Physical			
Week 24			
m	5	5	18
n	4	5	16
Baseline Mean (SD)	90.63 (11.97)	90.00 (13.69)	74.62 (29.53)
Analysis Visit Mean (SD)	100.00 (0.00)	81.28 (19.24)	69.93 (34.47)
LS Mean of Change from Baseline (SE)	13.37 (12.50)	-3.96 (11.51)	-3.72 (7.90)
95% CI	(-12.50, 39.24)	(-27.78, 19.86)	(-20.06, 12.61)
LS Mean of Change from Baseline Compared to Placebo (SE)	17.09 (13.79)	-0.24 (12.75)	
95% CI	(-11.43, 45.62)	(-26.62, 26.14)	
p-value	0.2276	0.9854	
Corrected Hedge's g Statistics	0.535	-0.007	
95% CI	(-0.57, 1.64)	(-1.01, 1.00)	
Week 52			
m	5	5	17
n	5	5	16
Baseline Mean (SD)	92.50 (11.18)	90.00 (13.69)	74.62 (29.53)
Analysis Visit Mean (SD)	90.00 (16.30)	70.00 (31.37)	73.45 (28.26)
LS Mean of Change from Baseline (SE)	2.85 (10.41)	-15.37 (10.31)	-0.12 (7.36)
95% CI	(-18.68, 24.39)	(-36.71, 5.96)	(-15.34, 15.11)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.97 (11.39)	-15.25 (11.28)	
95% CI	(-20.59, 26.54)	(-38.59, 8.09)	
p-value	0.7964	0.1896	
Corrected Hedge's g Statistics	0.101	-0.519	
95% CI	(-0.90, 1.11)	(-1.54, 0.50)	
Subgroup*Treatment Interaction p-value	0.1752	0.7505	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 4 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.7.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Bodily Pain			
Week 24			
m	5	5	18
n	4	5	16
Baseline Mean (SD)	79.0 (32.2)	84.8 (20.8)	73.6 (25.5)
Analysis Visit Mean (SD)	87.8 (24.5)	75.6 (22.7)	71.8 (27.4)
LS Mean of Change from Baseline (SE)	10.10 (7.84)	-6.72 (7.27)	-0.70 (4.85)
95% CI	(-6.12, 26.31)	(-21.75, 8.31)	(-10.74, 9.33)
LS Mean of Change from Baseline Compared to Placebo (SE)	10.80 (8.60)	-6.02 (7.96)	
95% CI	(-6.99, 28.59)	(-22.48, 10.44)	
p-value	0.2218	0.4572	
Corrected Hedge's g Statistics	0.549	-0.308	
95% CI	(-0.56, 1.66)	(-1.32, 0.70)	
Week 52			
m	5	5	17
n	5	5	16
Baseline Mean (SD)	83.2 (29.4)	84.8 (20.8)	73.6 (25.5)
Analysis Visit Mean (SD)	70.4 (30.2)	80.0 (20.3)	72.1 (22.1)
LS Mean of Change from Baseline (SE)	-10.19 (6.31)	-1.80 (6.35)	-0.69 (4.44)
95% CI	(-23.25, 2.87)	(-14.94, 11.33)	(-9.88, 8.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	-9.50 (6.82)	-1.11 (6.85)	
95% CI	(-23.61, 4.61)	(-15.27, 13.05)	
p-value	0.1771	0.8723	
Corrected Hedge's g Statistics	-0.534	-0.063	
95% CI	(-1.55, 0.48)	(-1.07, 0.94)	
Subgroup*Treatment Interaction p-value	0.4494	0.7798	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 5 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.7.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
General Health			
Week 24			
m	5	5	18
n	4	5	16
Baseline Mean (SD)	75.75 (13.15)	67.00 (12.75)	68.06 (20.61)
Analysis Visit Mean (SD)	87.00 (10.80)	64.60 (17.36)	64.31 (18.90)
LS Mean of Change from Baseline (SE)	14.18 (6.98)	-2.00 (6.50)	-2.45 (4.87)
95% CI	(-0.26, 28.62)	(-15.45, 11.45)	(-12.54, 7.63)
LS Mean of Change from Baseline Compared to Placebo (SE)	16.63 (7.51)	0.45 (7.01)	
95% CI	(1.09, 32.17)	(-14.06, 14.96)	
p-value	0.0371	0.9490	
Corrected Hedge's g Statistics	0.852	0.023	
95% CI	(-0.27, 1.98)	(-0.98, 1.03)	
Week 52			
m	5	5	17
n	5	5	16
Baseline Mean (SD)	74.00 (12.04)	67.00 (12.75)	68.06 (20.61)
Analysis Visit Mean (SD)	79.60 (16.01)	63.60 (15.82)	62.47 (18.75)
LS Mean of Change from Baseline (SE)	9.06 (7.35)	-3.23 (7.26)	-4.41 (5.20)
95% CI	(-6.15, 24.26)	(-18.25, 11.80)	(-15.16, 6.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	13.46 (7.98)	1.18 (7.93)	
95% CI	(-3.05, 29.97)	(-15.23, 17.59)	
p-value	0.1052	0.8832	
Corrected Hedge's g Statistics	0.648	0.057	
95% CI	(-0.38, 1.67)	(-0.95, 1.06)	
Subgroup*Treatment Interaction p-value	0.0703	0.5190	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 6 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.7.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Vitality			
Week 24			
m	5	5	18
n	4	5	16
Baseline Mean (SD)	67.23 (16.43)	68.78 (17.13)	66.03 (20.15)
Analysis Visit Mean (SD)	62.53 (26.54)	63.76 (11.17)	62.91 (20.46)
LS Mean of Change from Baseline (SE)	-4.49 (8.68)	-3.45 (8.00)	-2.31 (5.61)
95% CI	(-22.45, 13.48)	(-20.00, 13.11)	(-13.91, 9.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.18 (9.51)	-1.13 (8.74)	
95% CI	(-21.85, 17.49)	(-19.21, 16.94)	
p-value	0.8211	0.8978	
Corrected Hedge's g Statistics	-0.096	-0.051	
95% CI	(-1.19, 1.00)	(-1.05, 0.95)	
Week 52			
m	5	5	17
n	5	5	16
Baseline Mean (SD)	65.04 (15.04)	68.78 (17.13)	66.03 (20.15)
Analysis Visit Mean (SD)	55.02 (25.53)	63.78 (20.43)	66.41 (22.58)
LS Mean of Change from Baseline (SE)	-9.52 (7.68)	-4.01 (7.73)	1.34 (5.48)
95% CI	(-25.41, 6.37)	(-20.00, 11.98)	(-10.01, 12.68)
LS Mean of Change from Baseline Compared to Placebo (SE)	-10.85 (8.41)	-5.35 (8.40)	
95% CI	(-28.24, 6.54)	(-22.73, 12.04)	
p-value	0.2096	0.5310	
Corrected Hedge's g Statistics	-0.496	-0.244	
95% CI	(-1.51, 0.52)	(-1.25, 0.76)	
Subgroup*Treatment Interaction p-value	0.6843	0.7065	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 7 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.7.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Social Functioning			
Week 24			
m	5	5	18
n	4	5	16
Baseline Mean (SD)	100.00 (0.00)	80.00 (24.37)	89.06 (20.85)
Analysis Visit Mean (SD)	93.75 (12.50)	85.00 (13.69)	85.16 (26.70)
LS Mean of Change from Baseline (SE)	3.64 (12.35)	-2.19 (11.10)	-3.33 (6.95)
95% CI	(-21.92, 29.19)	(-25.14, 20.77)	(-17.72, 11.05)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.97 (13.56)	1.15 (12.42)	
95% CI	(-21.08, 35.02)	(-24.54, 26.84)	
p-value	0.6120	0.9271	
Corrected Hedge's g Statistics	0.244	0.041	
95% CI	(-0.85, 1.34)	(-0.96, 1.04)	
Week 52			
m	5	5	17
n	5	5	16
Baseline Mean (SD)	100.00 (0.00)	80.00 (24.37)	89.06 (20.85)
Analysis Visit Mean (SD)	92.50 (16.77)	95.00 (11.18)	92.19 (15.05)
LS Mean of Change from Baseline (SE)	0.95 (7.17)	8.67 (7.00)	3.71 (5.12)
95% CI	(-13.89, 15.79)	(-5.81, 23.15)	(-6.88, 14.30)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.76 (7.63)	4.96 (7.63)	
95% CI	(-18.55, 13.03)	(-10.82, 20.73)	
p-value	0.7208	0.5221	
Corrected Hedge's g Statistics	-0.135	0.243	
95% CI	(-1.14, 0.87)	(-0.76, 1.25)	
Subgroup*Treatment Interaction p-value	0.5372	0.3325	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 8 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.7.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Role Emotional			
Week 24			
m	5	5	18
n	4	5	16
Baseline Mean (SD)	95.85 (4.79)	98.34 (3.71)	88.54 (19.68)
Analysis Visit Mean (SD)	93.75 (12.50)	86.66 (21.73)	83.85 (22.66)
LS Mean of Change from Baseline (SE)	-0.28 (8.35)	-7.98 (8.04)	-1.35 (5.90)
95% CI	(-17.54, 16.99)	(-24.61, 8.65)	(-13.56, 10.86)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.07 (9.03)	-6.63 (8.65)	
95% CI	(-17.61, 19.76)	(-24.53, 11.27)	
p-value	0.9063	0.4512	
Corrected Hedge's g Statistics	0.046	-0.283	
95% CI	(-1.05, 1.14)	(-1.29, 0.73)	
Week 52			
m	5	5	17
n	5	5	16
Baseline Mean (SD)	96.68 (4.55)	98.34 (3.71)	88.54 (19.68)
Analysis Visit Mean (SD)	90.00 (14.90)	90.00 (22.36)	86.98 (22.15)
LS Mean of Change from Baseline (SE)	-2.46 (8.83)	-3.58 (8.91)	1.23 (6.28)
95% CI	(-20.73, 15.82)	(-22.01, 14.85)	(-11.76, 14.23)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.69 (9.65)	-4.81 (9.73)	
95% CI	(-23.66, 16.28)	(-24.95, 15.32)	
p-value	0.7058	0.6257	
Corrected Hedge's g Statistics	-0.147	-0.192	
95% CI	(-1.15, 0.86)	(-1.20, 0.81)	
Subgroup*Treatment Interaction p-value	0.3934	0.3843	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE21.7.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Mental Health			
Week 24			
m	5	5	18
n	4	5	16
Baseline Mean (SD)	88.8 (10.3)	86.0 (6.5)	83.4 (15.4)
Analysis Visit Mean (SD)	88.8 (13.1)	82.0 (16.8)	81.3 (18.4)
LS Mean of Change from Baseline (SE)	-0.18 (5.95)	-2.95 (5.52)	-0.69 (4.05)
95% CI	(-12.49, 12.13)	(-14.37, 8.47)	(-9.07, 7.70)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.51 (6.39)	-2.26 (5.93)	
95% CI	(-12.71, 13.73)	(-14.54, 10.01)	
p-value	0.9371	0.7065	
Corrected Hedge's g Statistics	0.031	-0.140	
95% CI	(-1.06, 1.13)	(-1.15, 0.86)	
Week 52			
m	5	5	17
n	5	5	16
Baseline Mean (SD)	87.0 (9.7)	86.0 (6.5)	83.4 (15.4)
Analysis Visit Mean (SD)	86.0 (10.8)	86.0 (6.5)	83.1 (19.7)
LS Mean of Change from Baseline (SE)	0.34 (5.86)	1.21 (5.83)	1.03 (4.19)
95% CI	(-11.77, 12.46)	(-10.85, 13.27)	(-7.63, 9.69)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.69 (6.32)	0.18 (6.31)	
95% CI	(-13.76, 12.39)	(-12.87, 13.23)	
p-value	0.9145	0.9775	
Corrected Hedge's g Statistics	-0.041	0.011	
95% CI	(-1.05, 0.96)	(-0.99, 1.01)	
Subgroup*Treatment Interaction p-value	0.6828	0.8459	

AMNOG Table SE21.7.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Mental Component Score			
Week 24			
m	5	5	18
n	4	5	16
Baseline Mean (SD)	57.65 (3.35)	55.80 (4.01)	55.22 (7.43)
Analysis Visit Mean (SD)	54.25 (9.04)	53.18 (7.42)	54.01 (8.23)
LS Mean of Change from Baseline (SE)	-2.90 (3.26)	-1.92 (2.99)	-0.30 (2.11)
95% CI	(-9.65, 3.85)	(-8.10, 4.25)	(-4.66, 4.06)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.60 (3.54)	-1.62 (3.26)	
95% CI	(-9.93, 4.73)	(-8.37, 5.13)	
p-value	0.4710	0.6242	
Corrected Hedge's g Statistics	-0.306	-0.192	
95% CI	(-1.41, 0.79)	(-1.20, 0.81)	
Week 52			
m	5	5	17
n	5	5	16
Baseline Mean (SD)	56.88 (3.37)	55.80 (4.01)	55.22 (7.43)
Analysis Visit Mean (SD)	54.42 (6.41)	57.06 (2.51)	55.40 (9.05)
LS Mean of Change from Baseline (SE)	-1.61 (2.74)	1.95 (2.72)	1.10 (1.99)
95% CI	(-7.28, 4.06)	(-3.67, 7.58)	(-3.02, 5.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.71 (2.95)	0.85 (2.94)	
95% CI	(-8.82, 3.40)	(-5.23, 6.94)	
p-value	0.3681	0.7745	
Corrected Hedge's g Statistics	-0.342	0.108	
95% CI	(-1.35, 0.67)	(-0.90, 1.11)	
Subgroup*Treatment Interaction p-value	0.7441	0.8764	

Madrigal Pharmaceuticals, Inc. Page 11 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.7.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Physical Component Score			
Week 24			
m	5	5	18
n	4	5	16
Baseline Mean (SD)	51.93 (6.51)	50.76 (7.79)	48.42 (10.15)
Analysis Visit Mean (SD)	57.48 (1.91)	49.98 (5.88)	46.54 (10.77)
LS Mean of Change from Baseline (SE)	6.63 (3.88)	-0.16 (3.54)	-2.09 (2.44)
95% CI	(-1.40, 14.67)	(-7.48, 7.17)	(-7.14, 2.96)
LS Mean of Change from Baseline Compared to Placebo (SE)	8.72 (4.25)	1.93 (3.89)	
95% CI	(-0.08, 17.51)	(-6.12, 9.98)	
p-value	0.0519	0.6249	
Corrected Hedge's g Statistics	0.882	0.197	
95% CI	(-0.25, 2.01)	(-0.81, 1.20)	
Week 52			
m	5	5	17
n	5	5	16
Baseline Mean (SD)	52.60 (5.83)	50.76 (7.79)	48.42 (10.15)
Analysis Visit Mean (SD)	51.18 (8.86)	46.64 (10.46)	47.55 (9.57)
LS Mean of Change from Baseline (SE)	-0.55 (3.28)	-3.68 (3.24)	-0.90 (2.31)
95% CI	(-7.34, 6.24)	(-10.38, 3.02)	(-5.67, 3.87)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.35 (3.56)	-2.78 (3.53)	
95% CI	(-7.02, 7.72)	(-10.08, 4.51)	
p-value	0.9231	0.4385	
Corrected Hedge's g Statistics	0.038	-0.302	
95% CI	(-0.97, 1.04)	(-1.31, 0.71)	
Subgroup*Treatment Interaction p-value	0.1957	0.8507	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 12 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.7.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Physical Functioning			
Week 24			
m	3	7	9
n	3	6	8
Baseline Mean (SD)	60.00 (35.00)	83.33 (21.83)	87.50 (9.64)
Analysis Visit Mean (SD)	66.67 (20.21)	85.00 (20.25)	88.13 (11.00)
LS Mean of Change from Baseline (SE)	-1.31 (6.73)	1.76 (4.19)	2.16 (3.68)
95% CI	(-15.64, 13.03)	(-7.16, 10.68)	(-5.68, 9.99)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.47 (7.92)	-0.40 (5.57)	
95% CI	(-20.34, 13.41)	(-12.26, 11.47)	
p-value	0.6677	0.9438	
Corrected Hedge's g Statistics	-0.296	-0.036	
95% CI	(-1.63, 1.04)	(-1.09, 1.02)	
Week 52			
m	3	7	9
n	2	5	7
Baseline Mean (SD)	80.00 (7.07)	82.00 (24.14)	89.29 (8.86)
Analysis Visit Mean (SD)	75.00 (7.07)	77.00 (22.53)	87.86 (11.13)
LS Mean of Change from Baseline (SE)	-4.41 (7.65)	-6.00 (4.80)	0.19 (4.23)
95% CI	(-20.73, 11.90)	(-16.23, 4.24)	(-8.83, 9.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.61 (8.91)	-6.19 (6.42)	
95% CI	(-23.61, 14.39)	(-19.88, 7.50)	
p-value	0.6129	0.3506	
Corrected Hedge's g Statistics	-0.367	-0.519	
95% CI	(-1.95, 1.21)	(-1.68, 0.65)	
Subgroup*Treatment Interaction p-value	0.3543	0.8061	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 13 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.7.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Role Physical			
Week 24			
m	3	7	9
n	3	6	8
Baseline Mean (SD)	72.93 (3.58)	91.68 (14.62)	86.73 (12.68)
Analysis Visit Mean (SD)	68.77 (10.80)	91.68 (14.62)	91.41 (13.74)
LS Mean of Change from Baseline (SE)	-10.38 (7.97)	2.64 (5.28)	4.98 (4.39)
95% CI	(-27.36, 6.60)	(-8.62, 13.89)	(-4.38, 14.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	-15.37 (9.16)	-2.35 (6.83)	
95% CI	(-34.89, 4.16)	(-16.91, 12.22)	
p-value	0.1141	0.7361	
Corrected Hedge's g Statistics	-1.102	-0.174	
95% CI	(-2.51, 0.30)	(-1.23, 0.89)	
Week 52			
m	3	7	9
n	2	5	7
Baseline Mean (SD)	71.90 (4.38)	91.26 (16.30)	86.61 (13.70)
Analysis Visit Mean (SD)	68.75 (8.84)	82.52 (26.30)	84.83 (19.71)
LS Mean of Change from Baseline (SE)	-16.62 (16.66)	-6.54 (10.33)	-6.58 (8.53)
95% CI	(-52.13, 18.89)	(-28.57, 15.49)	(-24.75, 11.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	-10.04 (18.82)	0.04 (13.34)	
95% CI	(-50.15, 30.06)	(-28.41, 28.48)	
p-value	0.6013	0.9979	
Corrected Hedge's g Statistics	-0.393	0.001	
95% CI	(-1.98, 1.19)	(-1.15, 1.15)	
Subgroup*Treatment Interaction p-value	0.1752	0.7505	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 14 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.7.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Bodily Pain			
Week 24			
m	3	7	9
n	3	6	8
Baseline Mean (SD)	62.7 (11.0)	78.3 (9.3)	83.3 (10.3)
Analysis Visit Mean (SD)	82.0 (19.1)	80.7 (12.6)	80.4 (21.2)
LS Mean of Change from Baseline (SE)	18.89 (11.30)	2.34 (6.53)	-2.72 (6.08)
95% CI	(-5.20, 42.98)	(-11.57, 16.26)	(-15.68, 10.23)
LS Mean of Change from Baseline Compared to Placebo (SE)	21.62 (13.92)	5.07 (8.88)	
95% CI	(-8.06, 51.29)	(-13.87, 24.01)	
p-value	0.1413	0.5769	
Corrected Hedge's g Statistics	1.114	0.284	
95% CI	(-0.29, 2.52)	(-0.78, 1.35)	
Week 52			
m	3	7	9
n	2	5	7
Baseline Mean (SD)	63.0 (15.6)	77.2 (10.0)	83.1 (11.1)
Analysis Visit Mean (SD)	62.0 (0.0)	71.2 (9.3)	79.4 (17.0)
LS Mean of Change from Baseline (SE)	-8.57 (11.05)	-6.60 (6.12)	-3.15 (5.54)
95% CI	(-32.13, 14.98)	(-19.65, 6.45)	(-14.95, 8.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.43 (13.21)	-3.45 (8.31)	
95% CI	(-33.59, 22.73)	(-21.15, 14.25)	
p-value	0.6871	0.6837	
Corrected Hedge's g Statistics	-0.326	-0.223	
95% CI	(-1.90, 1.25)	(-1.37, 0.93)	
Subgroup*Treatment Interaction p-value	0.4494	0.7798	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 15 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.7.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
General Health			
Week 24			
m	3	7	9
n	3	6	8
Baseline Mean (SD)	61.33 (31.56)	68.33 (13.81)	77.38 (9.98)
Analysis Visit Mean (SD)	58.00 (29.55)	66.17 (14.29)	76.13 (17.17)
LS Mean of Change from Baseline (SE)	-5.60 (8.41)	-3.04 (5.74)	-0.32 (5.01)
95% CI	(-23.51, 12.32)	(-15.27, 9.20)	(-11.00, 10.36)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.27 (10.07)	-2.71 (7.76)	
95% CI	(-26.73, 16.18)	(-19.25, 13.82)	
p-value	0.6081	0.7313	
Corrected Hedge's g Statistics	-0.338	-0.180	
95% CI	(-1.67, 1.00)	(-1.24, 0.88)	
Week 52			
m	3	7	9
n	2	5	7
Baseline Mean (SD)	79.50 (3.54)	66.60 (14.69)	78.43 (10.29)
Analysis Visit Mean (SD)	74.50 (3.54)	63.00 (16.36)	79.86 (17.99)
LS Mean of Change from Baseline (SE)	-7.12 (6.86)	-2.62 (4.48)	-0.98 (3.84)
95% CI	(-21.74, 7.50)	(-12.17, 6.94)	(-9.17, 7.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.14 (7.61)	-1.64 (6.22)	
95% CI	(-22.36, 10.08)	(-14.90, 11.63)	
p-value	0.4323	0.7960	
Corrected Hedge's g Statistics	-0.540	-0.150	
95% CI	(-2.13, 1.05)	(-1.30, 1.00)	
Subgroup*Treatment Interaction p-value	0.0703	0.5190	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 16 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.7.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Vitality			
Week 24			
m	3	7	9
n	3	6	8
Baseline Mean (SD)	43.77 (38.03)	65.65 (14.12)	67.21 (17.60)
Analysis Visit Mean (SD)	43.77 (39.04)	68.80 (17.68)	65.65 (22.91)
LS Mean of Change from Baseline (SE)	-0.40 (8.74)	3.17 (5.62)	-1.51 (4.88)
95% CI	(-19.04, 18.24)	(-8.80, 15.14)	(-11.92, 8.90)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.11 (10.19)	4.68 (7.43)	
95% CI	(-20.60, 22.83)	(-11.15, 20.52)	
p-value	0.9144	0.5380	
Corrected Hedge's g Statistics	0.072	0.318	
95% CI	(-1.26, 1.40)	(-0.75, 1.38)	
Week 52			
m	3	7	9
n	2	5	7
Baseline Mean (SD)	65.65 (4.45)	62.52 (13.26)	70.56 (16.03)
Analysis Visit Mean (SD)	62.55 (8.84)	56.28 (9.88)	65.20 (24.18)
LS Mean of Change from Baseline (SE)	-3.35 (8.45)	-8.31 (5.39)	-5.71 (4.74)
95% CI	(-21.36, 14.66)	(-19.81, 3.19)	(-15.81, 4.40)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.36 (9.74)	-2.60 (7.23)	
95% CI	(-18.41, 23.12)	(-18.02, 12.81)	
p-value	0.8121	0.7239	
Corrected Hedge's g Statistics	0.168	-0.195	
95% CI	(-1.41, 1.74)	(-1.34, 0.96)	
Subgroup*Treatment Interaction p-value	0.6843	0.7065	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 17 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.7.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Social Functioning			
Week 24			
m	3	7	9
n	3	6	8
Baseline Mean (SD)	79.17 (19.09)	95.83 (6.45)	98.44 (4.42)
Analysis Visit Mean (SD)	70.83 (26.02)	95.83 (6.45)	92.19 (17.60)
LS Mean of Change from Baseline (SE)	-0.97 (7.95)	-0.31 (4.30)	-7.76 (3.87)
95% CI	(-17.92, 15.98)	(-9.47, 8.86)	(-16.00, 0.48)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.79 (9.43)	7.45 (5.74)	
95% CI	(-13.31, 26.90)	(-4.79, 19.69)	
p-value	0.4825	0.2141	
Corrected Hedge's g Statistics	0.534	0.648	
95% CI	(-0.81, 1.88)	(-0.44, 1.73)	
Week 52			
m	3	7	9
n	2	5	7
Baseline Mean (SD)	87.50 (17.68)	97.50 (5.59)	98.21 (4.72)
Analysis Visit Mean (SD)	81.25 (26.52)	90.00 (10.46)	96.43 (9.45)
LS Mean of Change from Baseline (SE)	-5.60 (7.49)	-6.98 (4.30)	-1.22 (3.78)
95% CI	(-21.57, 10.37)	(-16.13, 2.18)	(-9.28, 6.84)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.38 (8.87)	-5.76 (5.57)	
95% CI	(-23.30, 14.53)	(-17.64, 6.12)	
p-value	0.6285	0.3181	
Corrected Hedge's g Statistics	-0.386	-0.540	
95% CI	(-1.97, 1.20)	(-1.71, 0.63)	
Subgroup*Treatment Interaction p-value	0.5372	0.3325	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 18 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.7.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Role Emotional			
Week 24			
m	3	7	9
n	3	6	8
Baseline Mean (SD)	97.23 (4.79)	97.22 (6.82)	92.71 (12.14)
Analysis Visit Mean (SD)	83.33 (16.65)	95.83 (10.21)	90.63 (13.68)
LS Mean of Change from Baseline (SE)	-13.38 (6.34)	-0.87 (4.52)	-2.47 (3.90)
95% CI	(-26.90, 0.14)	(-10.50, 8.76)	(-10.77, 5.84)
LS Mean of Change from Baseline Compared to Placebo (SE)	-10.91 (7.50)	1.60 (6.04)	
95% CI	(-26.91, 5.08)	(-11.28, 14.48)	
p-value	0.1665	0.7945	
Corrected Hedge's g Statistics	-0.906	0.136	
95% CI	(-2.29, 0.47)	(-0.92, 1.20)	
Week 52			
m	3	7	9
n	2	5	7
Baseline Mean (SD)	95.85 (5.87)	96.66 (7.47)	91.67 (12.72)
Analysis Visit Mean (SD)	91.65 (11.81)	91.66 (11.79)	82.14 (20.10)
LS Mean of Change from Baseline (SE)	-7.49 (9.18)	-4.99 (5.89)	-9.17 (5.06)
95% CI	(-27.05, 12.08)	(-17.54, 7.55)	(-19.95, 1.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.69 (10.53)	4.18 (7.87)	
95% CI	(-20.75, 24.13)	(-12.59, 20.95)	
p-value	0.8747	0.6030	
Corrected Hedge's g Statistics	0.113	0.290	
95% CI	(-1.46, 1.68)	(-0.86, 1.44)	
Subgroup*Treatment Interaction p-value	0.3934	0.3843	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 19 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.7.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Mental Health			
Week 24			
m	3	7	9
n	3	6	8
Baseline Mean (SD)	78.3 (10.4)	86.7 (4.1)	81.9 (16.2)
Analysis Visit Mean (SD)	83.3 (11.5)	87.5 (7.6)	83.1 (16.7)
LS Mean of Change from Baseline (SE)	4.41 (4.69)	1.22 (3.31)	1.07 (2.83)
95% CI	(-5.59, 14.41)	(-5.83, 8.27)	(-4.97, 7.11)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.33 (5.44)	0.15 (4.39)	
95% CI	(-8.26, 14.93)	(-9.21, 9.50)	
p-value	0.5491	0.9739	
Corrected Hedge's g Statistics	0.379	0.017	
95% CI	(-0.96, 1.72)	(-1.04, 1.08)	
Week 52			
m	3	7	9
n	2	5	7
Baseline Mean (SD)	82.5 (10.6)	87.0 (4.5)	82.1 (17.5)
Analysis Visit Mean (SD)	85.0 (7.1)	76.0 (11.4)	82.1 (19.8)
LS Mean of Change from Baseline (SE)	0.98 (7.87)	-10.27 (5.10)	0.12 (4.26)
95% CI	(-15.79, 17.76)	(-21.13, 0.60)	(-8.97, 9.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.86 (8.94)	-10.39 (6.69)	
95% CI	(-18.19, 19.92)	(-24.64, 3.87)	
p-value	0.9243	0.1413	
Corrected Hedge's g Statistics	0.068	-0.846	
95% CI	(-1.50, 1.64)	(-2.04, 0.35)	
Subgroup*Treatment Interaction p-value	0.6828	0.8459	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 20 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.7.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Mental Component Score			
Week 24			
m	3	7	9
n	3	6	8
Baseline Mean (SD)	54.10 (5.17)	56.93 (2.20)	54.93 (7.48)
Analysis Visit Mean (SD)	50.83 (10.44)	57.02 (4.83)	53.88 (8.39)
LS Mean of Change from Baseline (SE)	-3.10 (2.56)	-0.05 (1.82)	-0.97 (1.56)
95% CI	(-8.56, 2.36)	(-3.92, 3.82)	(-4.30, 2.36)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.13 (2.99)	0.92 (2.41)	
95% CI	(-8.49, 4.23)	(-4.22, 6.06)	
p-value	0.4869	0.7091	
Corrected Hedge's g Statistics	-0.440	0.194	
95% CI	(-1.78, 0.90)	(-0.87, 1.25)	
Week 52			
m	3	7	9
n	2	5	7
Baseline Mean (SD)	56.40 (4.67)	56.94 (2.46)	55.00 (8.08)
Analysis Visit Mean (SD)	55.95 (7.57)	52.82 (5.58)	52.83 (10.06)
LS Mean of Change from Baseline (SE)	-1.81 (4.03)	-4.17 (2.59)	-1.83 (2.18)
95% CI	(-10.40, 6.77)	(-9.69, 1.36)	(-6.48, 2.83)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.01 (4.59)	-2.34 (3.41)	
95% CI	(-9.76, 9.79)	(-9.61, 4.92)	
p-value	0.9979	0.5024	
Corrected Hedge's g Statistics	0.002	-0.374	
95% CI	(-1.57, 1.57)	(-1.53, 0.78)	
Subgroup*Treatment Interaction p-value	0.7441	0.8764	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 21 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.7.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Visit Statistic	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Physical Component Score			
Week 24			
m	3	7	9
n	3	6	8
Baseline Mean (SD)	42.63 (9.20)	50.92 (6.62)	53.61 (4.52)
Analysis Visit Mean (SD)	45.83 (5.78)	51.30 (6.10)	53.81 (7.39)
LS Mean of Change from Baseline (SE)	0.77 (3.63)	0.30 (2.16)	0.88 (1.94)
95% CI	(-6.97, 8.50)	(-4.30, 4.89)	(-3.27, 5.02)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.11 (4.37)	-0.58 (2.92)	
95% CI	(-9.42, 9.20)	(-6.80, 5.64)	
p-value	0.9803	0.8450	
Corrected Hedge's g Statistics	-0.018	-0.100	
95% CI	(-1.34, 1.31)	(-1.16, 0.96)	
Week 52			
m	3	7	9
n	2	5	7
Baseline Mean (SD)	47.85 (2.47)	50.26 (7.18)	54.10 (4.65)
Analysis Visit Mean (SD)	46.00 (2.12)	48.78 (8.39)	54.03 (2.49)
LS Mean of Change from Baseline (SE)	-2.84 (3.76)	-2.20 (2.29)	-0.21 (2.07)
95% CI	(-10.86, 5.18)	(-7.08, 2.68)	(-4.63, 4.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.63 (4.50)	-1.99 (3.14)	
95% CI	(-12.22, 6.96)	(-8.68, 4.69)	
p-value	0.5674	0.5348	
Corrected Hedge's g Statistics	-0.428	-0.344	
95% CI	(-2.01, 1.16)	(-1.50, 0.81)	
Subgroup*Treatment Interaction p-value	0.1957	0.8507	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE21.7.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; T2D = Type 2 Diabetes.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis, only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.

AMNOG Table SE21.7.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (16.7)	0	1 (5.3)
No	5 (83.3)	6 (100)	18 (94.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.28	1.05	
95% CI of the inverse odds ratio	(0.01, 5.27)	(0.04, 29.24)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.32	1.05	
95% CI of the inverse risk ratio	(0.02, 4.32)	(0.05, 22.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.40	-0.36	
95% CI of the absolute risk difference	(-20.06, 42.87)	(-22.66, 21.94)	
p-value	0.3694	0.9752	
p-value of Breslow-Day Test for Homogeneity [3]	0.3507	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (16.7)	2 (33.3)	8 (42.1)
No	5 (83.3)	4 (66.7)	11 (57.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.64	1.45	
95% CI of the inverse odds ratio	(0.35, 37.46)	(0.21, 9.98)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.53	1.26	
95% CI of the inverse risk ratio	(0.39, 16.31)	(0.36, 4.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-25.44	-8.77	
95% CI of the absolute risk difference	(-62.61, 11.74)	(-52.54, 35.00)	
p-value	0.2578	0.7022	
p-value of Breslow-Day Test for Homogeneity [3]	0.5361	0.1613	

AMNOG Table SE21.7.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (16.7)	0	3 (15.8)
No	5 (83.3)	6 (100)	16 (84.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	2.76	
95% CI of the inverse odds ratio	(0.08, 11.15)	(0.12, 61.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	2.45	
95% CI of the inverse risk ratio	(0.12, 7.50)	(0.14, 41.74)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.88	-10.36	
95% CI of the absolute risk difference	(-33.15, 34.91)	(-35.68, 14.97)	
p-value	0.9592	0.5068	
p-value of Breslow-Day Test for Homogeneity [3]	0.3969	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (16.7)	0	6 (31.6)
No	5 (83.3)	6 (100)	13 (68.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.31	6.26	
95% CI of the inverse odds ratio	(0.22, 24.32)	(0.30, 128.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.89	4.55	
95% CI of the inverse risk ratio	(0.28, 12.77)	(0.29, 70.79)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-14.91	-25.36	
95% CI of the absolute risk difference	(-51.33, 21.50)	(-53.38, 2.67)	
p-value	0.4782	0.1876	
p-value of Breslow-Day Test for Homogeneity [3]	0.6500	0.4125	

AMNOG Table SE21.7.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	3 (15.8)
No	6 (100)	6 (100)	16 (84.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.76	2.76	
95% CI of the inverse odds ratio	(0.12, 61.16)	(0.12, 61.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.45	2.45	
95% CI of the inverse risk ratio	(0.14, 41.74)	(0.14, 41.74)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.36	-10.36	
95% CI of the absolute risk difference	(-35.68, 14.97)	(-35.68, 14.97)	
p-value	0.5068	0.5068	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (16.7)	4 (21.1)
No	6 (100)	5 (83.3)	15 (78.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.77	1.33	
95% CI of the inverse odds ratio	(0.18, 80.65)	(0.12, 14.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.15	1.26	
95% CI of the inverse risk ratio	(0.19, 51.39)	(0.17, 9.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-15.36	-4.39	
95% CI of the absolute risk difference	(-41.79, 11.08)	(-39.39, 30.62)	
p-value	0.3680	0.8149	
p-value of Breslow-Day Test for Homogeneity [3]	0.1993	0.2590	

AMNOG Table SE21.7.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	3 (15.8)
No	6 (100)	6 (100)	16 (84.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.76	2.76	
95% CI of the inverse odds ratio	(0.12, 61.16)	(0.12, 61.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.45	2.45	
95% CI of the inverse risk ratio	(0.14, 41.74)	(0.14, 41.74)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.36	-10.36	
95% CI of the absolute risk difference	(-35.68, 14.97)	(-35.68, 14.97)	
p-value	0.5068	0.5068	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (66.7)	2 (33.3)	5 (26.3)
No	2 (33.3)	4 (66.7)	14 (73.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.18	0.71	
95% CI of the inverse odds ratio	(0.02, 1.29)	(0.10, 5.18)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.39	0.79	
95% CI of the inverse risk ratio	(0.15, 1.01)	(0.20, 3.07)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	40.35	7.02	
95% CI of the absolute risk difference	(-2.25, 82.95)	(-35.58, 49.62)	
p-value	0.0726	0.7386	
p-value of Breslow-Day Test for Homogeneity [3]	0.0624	0.0784	

AMNOG Table SE21.7.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (10.5)
No	6 (100)	6 (100)	17 (89.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.86	1.86	
95% CI of the inverse odds ratio	(0.08, 44.08)	(0.08, 44.08)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.75	1.75	
95% CI of the inverse risk ratio	(0.10, 32.18)	(0.10, 32.18)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.36	-5.36	
95% CI of the absolute risk difference	(-29.32, 18.60)	(-29.32, 18.60)	
p-value	0.6979	0.6979	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (16.7)	1 (16.7)	7 (36.8)
No	5 (83.3)	5 (83.3)	12 (63.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.92	2.92	
95% CI of the inverse odds ratio	(0.28, 30.30)	(0.28, 30.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.21	2.21	
95% CI of the inverse risk ratio	(0.34, 14.54)	(0.34, 14.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-20.18	-20.18	
95% CI of the absolute risk difference	(-57.05, 16.70)	(-57.05, 16.70)	
p-value	0.3557	0.3557	
p-value of Breslow-Day Test for Homogeneity [3]	0.5965	0.3991	

AMNOG Table SE21.7.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (16.7)	3 (15.8)
No	6 (100)	5 (83.3)	16 (84.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.76	0.94	
95% CI of the inverse odds ratio	(0.12, 61.16)	(0.08, 11.15)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.45	0.95	
95% CI of the inverse risk ratio	(0.14, 41.74)	(0.12, 7.50)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.36	0.88	
95% CI of the absolute risk difference	(-35.68, 14.97)	(-33.15, 34.91)	
p-value	0.5068	0.9592	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	4 (66.7)	4 (21.1)
No	6 (100)	2 (33.3)	15 (78.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.77	0.13	
95% CI of the inverse odds ratio	(0.18, 80.65)	(0.02, 1.01)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.15	0.32	
95% CI of the inverse risk ratio	(0.19, 51.39)	(0.11, 0.89)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-15.36	45.61	
95% CI of the absolute risk difference	(-41.79, 11.08)	(3.68, 87.55)	
p-value	0.3680	0.0368	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.6916	

AMNOG Table SE21.7.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (10.5)
No	6 (100)	6 (100)	17 (89.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.86	1.86	
95% CI of the inverse odds ratio	(0.08, 44.08)	(0.08, 44.08)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.75	1.75	
95% CI of the inverse risk ratio	(0.10, 32.18)	(0.10, 32.18)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.36	-5.36	
95% CI of the absolute risk difference	(-29.32, 18.60)	(-29.32, 18.60)	
p-value	0.6979	0.6979	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (16.7)	1 (16.7)	3 (15.8)
No	5 (83.3)	5 (83.3)	16 (84.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	0.94	
95% CI of the inverse odds ratio	(0.08, 11.15)	(0.08, 11.15)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	0.95	
95% CI of the inverse risk ratio	(0.12, 7.50)	(0.12, 7.50)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.88	0.88	
95% CI of the absolute risk difference	(-33.15, 34.91)	(-33.15, 34.91)	
p-value	0.9592	0.9592	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE21.7.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (16.7)	2 (10.5)
No	6 (100)	5 (83.3)	17 (89.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.86	0.59	
95% CI of the inverse odds ratio	(0.08, 44.08)	(0.04, 7.91)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.75	0.63	
95% CI of the inverse risk ratio	(0.10, 32.18)	(0.07, 5.80)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.36	6.14	
95% CI of the absolute risk difference	(-29.32, 18.60)	(-26.72, 39.00)	
p-value	0.6979	0.6866	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.2731	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (33.3)	2 (33.3)	8 (42.1)
No	4 (66.7)	4 (66.7)	11 (57.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.45	1.45	
95% CI of the inverse odds ratio	(0.21, 9.98)	(0.21, 9.98)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.26	1.26	
95% CI of the inverse risk ratio	(0.36, 4.40)	(0.36, 4.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.77	-8.77	
95% CI of the absolute risk difference	(-52.54, 35.00)	(-52.54, 35.00)	
p-value	0.7022	0.7022	
p-value of Breslow-Day Test for Homogeneity [3]	0.5933	0.2553	

AMNOG Table SE21.7.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	6 (100)	6 (100)	19 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (33.3)	5 (26.3)
No	6 (100)	4 (66.7)	14 (73.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.93	0.71	
95% CI of the inverse odds ratio	(0.24, 103.01)	(0.10, 5.18)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.85	0.79	
95% CI of the inverse risk ratio	(0.24, 61.08)	(0.20, 3.07)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-20.36	7.02	
95% CI of the absolute risk difference	(-47.69, 6.97)	(-35.58, 49.62)	
p-value	0.2648	0.7386	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.2830	

AMNOG Table SE21.7.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Presence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (5.3)
No	6 (100)	6 (100)	18 (94.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	1.05	
95% CI of the inverse odds ratio	(0.04, 29.24)	(0.04, 29.24)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	1.05	
95% CI of the inverse risk ratio	(0.05, 22.91)	(0.05, 22.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.36	-0.36	
95% CI of the absolute risk difference	(-22.66, 21.94)	(-22.66, 21.94)	
p-value	0.9752	0.9752	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (16.7)	0	4 (21.1)
No	5 (83.3)	6 (100)	15 (78.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	3.77	
95% CI of the inverse odds ratio	(0.12, 14.90)	(0.18, 80.65)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.26	3.15	
95% CI of the inverse risk ratio	(0.17, 9.24)	(0.19, 51.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.39	-15.36	
95% CI of the absolute risk difference	(-39.39, 30.62)	(-41.79, 11.08)	
p-value	0.8149	0.3680	
p-value of Breslow-Day Test for Homogeneity [3]	0.6099	NE	

AMNOG Table SE21.7.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (11.1)
No	3 (100)	9 (100)	8 (88.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.24	3.35	
95% CI of the inverse odds ratio	(0.04, 38.30)	(0.12, 93.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	3.00	
95% CI of the inverse risk ratio	(0.06, 23.70)	(0.14, 65.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-10.00	
95% CI of the absolute risk difference	(-41.75, 36.75)	(-35.93, 15.93)	
p-value	0.9039	0.4561	
p-value of Breslow-Day Test for Homogeneity [3]	0.3507	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	3 (33.3)
No	3 (100)	9 (100)	6 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.77	10.23	
95% CI of the inverse odds ratio	(0.15, 95.82)	(0.45, 233.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.80	7.00	
95% CI of the inverse risk ratio	(0.18, 42.80)	(0.41, 118.69)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-22.50	-30.00	
95% CI of the absolute risk difference	(-66.37, 21.37)	(-62.50, 2.50)	
p-value	0.3999	0.0935	
p-value of Breslow-Day Test for Homogeneity [3]	0.5361	0.1613	

AMNOG Table SE21.7.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (22.2)
No	3 (100)	9 (100)	7 (77.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.33	6.33	
95% CI of the inverse odds ratio	(0.09, 62.68)	(0.26, 152.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	5.00	
95% CI of the inverse risk ratio	(0.12, 33.10)	(0.27, 91.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-12.50	-20.00	
95% CI of the absolute risk difference	(-54.58, 29.58)	(-50.05, 10.05)	
p-value	0.6066	0.2104	
p-value of Breslow-Day Test for Homogeneity [3]	0.3969	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (33.3)	1 (11.1)	3 (33.3)
No	2 (66.7)	8 (88.9)	6 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	4.00	
95% CI of the inverse odds ratio	(0.06, 15.99)	(0.33, 48.66)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	3.00	
95% CI of the inverse risk ratio	(0.16, 6.35)	(0.38, 23.68)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	-22.22	
95% CI of the absolute risk difference	(-61.60, 61.60)	(-59.24, 14.79)	
p-value	>0.9999	0.2568	
p-value of Breslow-Day Test for Homogeneity [3]	0.6500	0.4125	

AMNOG Table SE21.7.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (22.2)
No	3 (100)	9 (100)	7 (77.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.33	6.33	
95% CI of the inverse odds ratio	(0.09, 62.68)	(0.26, 152.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	5.00	
95% CI of the inverse risk ratio	(0.12, 33.10)	(0.27, 91.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-12.50	-20.00	
95% CI of the absolute risk difference	(-54.58, 29.58)	(-50.05, 10.05)	
p-value	0.6066	0.2104	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (33.3)	0	2 (22.2)
No	2 (66.7)	9 (100)	7 (77.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	6.33	
95% CI of the inverse odds ratio	(0.03, 10.07)	(0.26, 152.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	5.00	
95% CI of the inverse risk ratio	(0.09, 4.99)	(0.27, 91.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.11	-20.00	
95% CI of the absolute risk difference	(-48.75, 70.97)	(-50.05, 10.05)	
p-value	0.7003	0.2104	
p-value of Breslow-Day Test for Homogeneity [3]	0.1993	0.2590	

AMNOG Table SE21.7.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (11.1)
No	3 (100)	9 (100)	8 (88.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.24	3.35	
95% CI of the inverse odds ratio	(0.04, 38.30)	(0.12, 93.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	3.00	
95% CI of the inverse risk ratio	(0.06, 23.70)	(0.14, 65.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-10.00	
95% CI of the absolute risk difference	(-41.75, 36.75)	(-35.93, 15.93)	
p-value	0.9039	0.4561	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	3 (33.3)
No	3 (100)	9 (100)	6 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.77	10.23	
95% CI of the inverse odds ratio	(0.15, 95.82)	(0.45, 233.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.80	7.00	
95% CI of the inverse risk ratio	(0.18, 42.80)	(0.41, 118.69)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-22.50	-30.00	
95% CI of the absolute risk difference	(-66.37, 21.37)	(-62.50, 2.50)	
p-value	0.3999	0.0935	
p-value of Breslow-Day Test for Homogeneity [3]	0.0624	0.0784	

AMNOG Table SE21.7.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (11.1)
No	3 (100)	9 (100)	8 (88.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.24	3.35	
95% CI of the inverse odds ratio	(0.04, 38.30)	(0.12, 93.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	3.00	
95% CI of the inverse risk ratio	(0.06, 23.70)	(0.14, 65.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-10.00	
95% CI of the absolute risk difference	(-41.75, 36.75)	(-35.93, 15.93)	
p-value	0.9039	0.4561	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	2 (22.2)
No	3 (100)	9 (100)	7 (77.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.33	6.33	
95% CI of the inverse odds ratio	(0.09, 62.68)	(0.26, 152.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	5.00	
95% CI of the inverse risk ratio	(0.12, 33.10)	(0.27, 91.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-12.50	-20.00	
95% CI of the absolute risk difference	(-54.58, 29.58)	(-50.05, 10.05)	
p-value	0.6066	0.2104	
p-value of Breslow-Day Test for Homogeneity [3]	0.5965	0.3991	

Program: t-se18-02-04-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.7.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	3 (100)	9 (100)	9 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (11.1)	0
No	3 (100)	8 (88.9)	9 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.30	
95% CI of the inverse odds ratio	NE	(0.01, 8.35)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.33	
95% CI of the inverse risk ratio	NE	(0.02, 7.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	10.00	
95% CI of the absolute risk difference	NE	(-15.93, 35.93)	
p-value	NE	0.4561	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.6916	

AMNOG Table SE21.7.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	3 (100)	9 (100)	9 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	3 (100)	9 (100)	9 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE21.7.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (11.1)
No	3 (100)	9 (100)	8 (88.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.24	3.35	
95% CI of the inverse odds ratio	(0.04, 38.30)	(0.12, 93.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	3.00	
95% CI of the inverse risk ratio	(0.06, 23.70)	(0.14, 65.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-10.00	
95% CI of the absolute risk difference	(-41.75, 36.75)	(-35.93, 15.93)	
p-value	0.9039	0.4561	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.2731	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (33.3)	0	2 (22.2)
No	2 (66.7)	9 (100)	7 (77.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	6.33	
95% CI of the inverse odds ratio	(0.03, 10.07)	(0.26, 152.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	5.00	
95% CI of the inverse risk ratio	(0.09, 4.99)	(0.27, 91.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.11	-20.00	
95% CI of the absolute risk difference	(-48.75, 70.97)	(-50.05, 10.05)	
p-value	0.7003	0.2104	
p-value of Breslow-Day Test for Homogeneity [3]	0.5933	0.2553	

AMNOG Table SE21.7.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	3 (100)	9 (100)	9 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	1 (11.1)
No	3 (100)	9 (100)	8 (88.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.24	3.35	
95% CI of the inverse odds ratio	(0.04, 38.30)	(0.12, 93.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	3.00	
95% CI of the inverse risk ratio	(0.06, 23.70)	(0.14, 65.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-10.00	
95% CI of the absolute risk difference	(-41.75, 36.75)	(-35.93, 15.93)	
p-value	0.9039	0.4561	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.2830	

AMNOG Table SE21.7.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline T2D Status
(Label Population based on Modified Intent-to-Treat Population)

Baseline T2D Status: Absence

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (11.1)
No	3 (100)	9 (100)	8 (88.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.24	3.35	
95% CI of the inverse odds ratio	(0.04, 38.30)	(0.12, 93.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	3.00	
95% CI of the inverse risk ratio	(0.06, 23.70)	(0.14, 65.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-10.00	
95% CI of the absolute risk difference	(-41.75, 36.75)	(-35.93, 15.93)	
p-value	0.9039	0.4561	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	1 (11.1)
No	3 (100)	9 (100)	8 (88.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.24	3.35	
95% CI of the inverse odds ratio	(0.04, 38.30)	(0.12, 93.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	3.00	
95% CI of the inverse risk ratio	(0.06, 23.70)	(0.14, 65.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-10.00	
95% CI of the absolute risk difference	(-41.75, 36.75)	(-35.93, 15.93)	
p-value	0.9039	0.4561	
p-value of Breslow-Day Test for Homogeneity [3]	0.6099	NE	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.8.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=1)	Visit Result DB MGL-3196 100 mg (N=2)	Visit Result DB Placebo (N=7)	Change from Baseline DB MGL-3196 80 mg (N=1)	Change from Baseline DB MGL-3196 100 mg (N=2)	Change from Baseline DB Placebo (N=7)
Physical Functioning						
Baseline						
m	1	2	7			
n	1	2	7			
Mean (SD)	60.00 (N/A)	82.50 (24.75)	73.57 (26.88)			
Median	60.00	82.50	80.00			
IQR: Q1, Q3	60.00, 60.00	65.00, 100.00	40.00, 100.00			
Min, Max	60.0, 60.0	65.0, 100.0	35.0, 100.0			
Week 24						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	92.50 (10.61)	79.17 (18.28)	N/A	10.00 (10.00)	5.00 (6.95)
Median	N/A	92.50	80.00	N/A	10.00	2.50
IQR: Q1, Q3	N/A	85.00, 100.00	70.00, 95.00	N/A	0.00, 20.00	-5.00, 10.00
Min, Max	N/A	85.0, 100.0	50.0, 100.0	N/A	0.0, 20.0	-15.0, 35.0
Week 52						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	87.50 (17.68)	83.33 (20.90)	N/A	5.00 (5.00)	9.17 (4.90)
Median	N/A	87.50	92.50	N/A	5.00	10.00
IQR: Q1, Q3	N/A	75.00, 100.00	65.00, 100.00	N/A	0.00, 10.00	0.00, 10.00
Min, Max	N/A	75.0, 100.0	50.0, 100.0	N/A	0.0, 10.0	-5.0, 30.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.8.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=2)	(N=7)	(N=1)	(N=2)	(N=7)
Role Physical						
Baseline						
m	1	2	7			
n	1	2	7			
Mean (SD)	50.00 (N/A)	87.50 (17.68)	74.11 (28.97)			
Median	50.00	87.50	87.50			
IQR: Q1, Q3	50.00, 50.00	75.00, 100.00	50.00, 100.00			
Min, Max	50.0, 50.0	75.0, 100.0	25.0, 100.0			
Week 24						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	90.65 (13.22)	73.97 (28.62)	N/A	3.15 (3.15)	3.13 (2.14)
Median	N/A	90.65	78.15	N/A	3.15	0
IQR: Q1, Q3	N/A	81.30, 100.00	62.50, 100.00	N/A	0.00, 6.30	0.00, 6.30
Min, Max	N/A	81.3, 100.0	25.0, 100.0	N/A	0.0, 6.3	0.0, 12.5
Week 52						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	87.50 (17.68)	76.05 (25.11)	N/A	0.00 (0.00)	5.22 (6.93)
Median	N/A	87.50	75.00	N/A	0	9.40
IQR: Q1, Q3	N/A	75.00, 100.00	75.00, 100.00	N/A	0.00, 0.00	0.00, 12.50
Min, Max	N/A	75.0, 100.0	31.3, 100.0	N/A	0.0, 0.0	-25.0, 25.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.8.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=2)	(N=7)	(N=1)	(N=2)	(N=7)
Bodily Pain						
Baseline						
m	1	2	7			
n	1	2	7			
Mean (SD)	62.0 (N/A)	81.0 (26.9)	74.6 (23.5)			
Median	62.0	81.0	84.0			
IQR: Q1, Q3	62.0, 62.0	62.0, 100.0	51.0, 100.0			
Min, Max	62, 62	62, 100	41, 100			
Week 24						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	81.0 (26.9)	69.7 (25.9)	N/A	0.0 (0.0)	-3.3 (4.4)
Median	N/A	81.0	63.0	N/A	0	0
IQR: Q1, Q3	N/A	62.0, 100.0	51.0, 100.0	N/A	0.0, 0.0	-10.0, 1.0
Min, Max	N/A	62, 100	41, 100	N/A	0, 0	-21, 10
Week 52						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	87.0 (18.4)	75.2 (22.7)	N/A	6.0 (6.0)	2.2 (7.0)
Median	N/A	87.0	74.0	N/A	6.0	0
IQR: Q1, Q3	N/A	74.0, 100.0	62.0, 100.0	N/A	0.0, 12.0	-10.0, 21.0
Min, Max	N/A	74, 100	41, 100	N/A	0, 12	-21, 23

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.8.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=2)	(N=7)	(N=1)	(N=2)	(N=7)
General Health						
Baseline						
m	1	2	7			
n	1	2	7			
Mean (SD)	57.00 (N/A)	74.50 (10.61)	75.57 (10.69)			
Median	57.00	74.50	77.00			
IQR: Q1, Q3	57.00, 57.00	67.00, 82.00	62.00, 82.00			
Min, Max	57.0, 57.0	67.0, 82.0	62.0, 92.0			
Week 24						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	82.00 (7.07)	67.83 (13.57)	N/A	7.50 (2.50)	-7.50 (7.27)
Median	N/A	82.00	72.00	N/A	7.50	-7.50
IQR: Q1, Q3	N/A	77.00, 87.00	67.00, 77.00	N/A	5.00, 10.00	-15.00, 5.00
Min, Max	N/A	77.0, 87.0	42.0, 77.0	N/A	5.0, 10.0	-35.0, 15.0
Week 52						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	72.00 (14.14)	69.58 (14.87)	N/A	-2.50 (2.50)	-5.75 (6.79)
Median	N/A	72.00	74.50	N/A	-2.50	-2.50
IQR: Q1, Q3	N/A	62.00, 82.00	57.00, 77.00	N/A	-5.00, 0.00	-20.00, 5.50
Min, Max	N/A	62.0, 82.0	47.0, 87.5	N/A	-5.0, 0.0	-30.0, 15.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.8.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=2)	(N=7)	(N=1)	(N=2)	(N=7)
Vitality						
Baseline						
m	1	2	7			
n	1	2	7			
Mean (SD)	56.30 (N/A)	62.55 (8.84)	66.09 (21.60)			
Median	56.30	62.55	75.00			
IQR: Q1, Q3	56.30, 56.30	56.30, 68.80	43.80, 87.50			
Min, Max	56.3, 56.3	56.3, 68.8	37.5, 87.5			
Week 24						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	65.65 (13.22)	64.60 (19.64)	N/A	3.10 (3.10)	0.00 (2.28)
Median	N/A	65.65	65.65	N/A	3.10	0
IQR: Q1, Q3	N/A	56.30, 75.00	50.00, 81.30	N/A	0.00, 6.20	-6.20, 6.20
Min, Max	N/A	56.3, 75.0	37.5, 87.5	N/A	0.0, 6.2	-6.3, 6.3
Week 52						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	65.65 (13.22)	72.92 (21.53)	N/A	3.10 (3.10)	8.32 (7.51)
Median	N/A	65.65	75.00	N/A	3.10	6.25
IQR: Q1, Q3	N/A	56.30, 75.00	62.50, 87.50	N/A	0.00, 6.20	0.00, 25.00
Min, Max	N/A	56.3, 75.0	37.5, 100.0	N/A	0.0, 6.2	-18.8, 31.2

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.8.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=2)	(N=7)	(N=1)	(N=2)	(N=7)
Social Functioning						
Baseline						
m	1	2	7			
n	1	2	7			
Mean (SD)	75.00 (N/A)	62.50 (35.36)	89.29 (15.19)			
Median	75.00	62.50	100.00			
IQR: Q1, Q3	75.00, 75.00	37.50, 87.50	75.00, 100.00			
Min, Max	75.0, 75.0	37.5, 87.5	62.5, 100.0			
Week 24						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	100.00 (0.00)	89.58 (16.61)	N/A	37.50 (25.00)	0.00 (0.00)
Median	N/A	100.00	100.00	N/A	37.50	0
IQR: Q1, Q3	N/A	100.00, 100.00	75.00, 100.00	N/A	12.50, 62.50	0.00, 0.00
Min, Max	N/A	100.0, 100.0	62.5, 100.0	N/A	12.5, 62.5	0.0, 0.0
Week 52						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	100.00 (0.00)	87.50 (19.36)	N/A	37.50 (25.00)	-2.08 (8.18)
Median	N/A	100.00	100.00	N/A	37.50	0
IQR: Q1, Q3	N/A	100.00, 100.00	62.50, 100.00	N/A	12.50, 62.50	0.00, 0.00
Min, Max	N/A	100.0, 100.0	62.5, 100.0	N/A	12.5, 62.5	-37.5, 25.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.8.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=2)	(N=7)	(N=1)	(N=2)	(N=7)
Role Emotional						
Baseline						
m	1	2	7			
n	1	2	7			
Mean (SD)	50.00 (N/A)	95.85 (5.87)	91.67 (22.04)			
Median	50.00	95.85	100.00			
IQR: Q1, Q3	50.00, 50.00	91.70, 100.00	100.00, 100.00			
Min, Max	50.0, 50.0	91.7, 100.0	41.7, 100.0			
Week 24						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	100.00 (0.00)	87.50 (23.41)	N/A	4.15 (4.15)	-2.78 (2.78)
Median	N/A	100.00	100.00	N/A	4.15	0
IQR: Q1, Q3	N/A	100.00, 100.00	83.30, 100.00	N/A	0.00, 8.30	0.00, 0.00
Min, Max	N/A	100.0, 100.0	41.7, 100.0	N/A	0.0, 8.3	-16.7, 0.0
Week 52						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	100.00 (0.00)	88.88 (18.01)	N/A	4.15 (4.15)	-1.40 (9.72)
Median	N/A	100.00	100.00	N/A	4.15	0
IQR: Q1, Q3	N/A	100.00, 100.00	75.00, 100.00	N/A	0.00, 8.30	0.00, 0.00
Min, Max	N/A	100.0, 100.0	58.3, 100.0	N/A	0.0, 8.3	-41.7, 33.3

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.8.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=1)	Visit Result DB MGL-3196 100 mg (N=2)	Visit Result DB Placebo (N=7)	Change from Baseline DB MGL-3196 80 mg (N=1)	Change from Baseline DB MGL-3196 100 mg (N=2)	Change from Baseline DB Placebo (N=7)
Mental Health						
Baseline						
m	1	2	7			
n	1	2	7			
Mean (SD)	60.0 (N/A)	82.5 (10.6)	85.0 (16.1)			
Median	60.0	82.5	90.0			
IQR: Q1, Q3	60.0, 60.0	75.0, 90.0	85.0, 95.0			
Min, Max	60, 60	75, 90	50, 95			
Week 24						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	92.5 (10.6)	84.2 (20.1)	N/A	10.0 (15.0)	-0.8 (1.5)
Median	N/A	92.5	90.0	N/A	10.0	0
IQR: Q1, Q3	N/A	85.0, 100.0	85.0, 95.0	N/A	-5.0, 25.0	-5.0, 0.0
Min, Max	N/A	85, 100	45, 100	N/A	-5, 25	-5, 5
Week 52						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	85.0 (7.1)	85.0 (18.4)	N/A	2.5 (12.5)	0.0 (3.2)
Median	N/A	85.0	92.5	N/A	2.5	2.5
IQR: Q1, Q3	N/A	80.0, 90.0	70.0, 100.0	N/A	-10.0, 15.0	0.0, 5.0
Min, Max	N/A	80, 90	55, 100	N/A	-10, 15	-15, 5

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.8.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=2)	(N=7)	(N=1)	(N=2)	(N=7)
Mental Component Score						
Baseline						
m	1	2	7			
n	1	2	7			
Mean (SD)	42.90 (N/A)	51.75 (0.92)	56.59 (8.43)			
Median	42.90	51.75	59.00			
IQR: Q1, Q3	42.90, 42.90	51.10, 52.40	56.60, 61.80			
Min, Max	42.9, 42.9	51.1, 52.4	38.1, 62.9			
Week 24						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	58.40 (1.56)	55.23 (9.48)	N/A	6.65 (1.75)	-1.12 (0.82)
Median	N/A	58.40	58.65	N/A	6.65	-1.20
IQR: Q1, Q3	N/A	57.30, 59.50	53.20, 61.00	N/A	4.90, 8.40	-3.20, 1.00
Min, Max	N/A	57.3, 59.5	37.1, 62.8	N/A	4.9, 8.4	-3.4, 1.3
Week 52						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	56.90 (0.14)	55.70 (10.15)	N/A	5.15 (0.75)	-0.65 (3.23)
Median	N/A	56.90	60.45	N/A	5.15	1.10
IQR: Q1, Q3	N/A	56.80, 57.00	45.30, 62.10	N/A	4.40, 5.90	0.30, 2.40
Min, Max	N/A	56.8, 57.0	40.6, 65.3	N/A	4.4, 5.9	-16.0, 7.2

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.8.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=2)	(N=7)	(N=1)	(N=2)	(N=7)
Physical Component Score						
Baseline						
m	1	2	7			
n	1	2	7			
Mean (SD)	45.20 (N/A)	52.00 (11.74)	48.16 (8.77)			
Median	45.20	52.00	50.90			
IQR: Q1, Q3	45.20, 45.20	43.70, 60.30	41.50, 56.90			
Min, Max	45.2, 45.2	43.7, 60.3	34.5, 58.2			
Week 24						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	53.30 (6.65)	47.92 (8.20)	N/A	1.30 (3.60)	0.22 (1.85)
Median	N/A	53.30	46.50	N/A	1.30	-0.10
IQR: Q1, Q3	N/A	48.60, 58.00	41.40, 55.80	N/A	-2.30, 4.90	-3.80, 3.00
Min, Max	N/A	48.6, 58.0	38.2, 59.1	N/A	-2.3, 4.9	-4.6, 6.9
Week 52						
m	0	2	6			
n	0	2	6	0	2	6
Mean (SD/SE)	N/A	52.60 (8.49)	49.67 (8.95)	N/A	0.60 (2.30)	1.97 (2.35)
Median	N/A	52.60	52.15	N/A	0.60	1.20
IQR: Q1, Q3	N/A	46.60, 58.60	42.50, 57.20	N/A	-1.70, 2.90	0.10, 8.00
Min, Max	N/A	46.6, 58.6	35.7, 58.3	N/A	-1.7, 2.9	-7.1, 8.4

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.8.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=8)	Visit Result DB MGL-3196 100 mg (N=13)	Visit Result DB Placebo (N=21)	Change from Baseline DB MGL-3196 80 mg (N=8)	Change from Baseline DB MGL-3196 100 mg (N=13)	Change from Baseline DB Placebo (N=21)
Physical Functioning						
Baseline						
m	8	13	21			
n	8	12	19			
Mean (SD)	75.63 (24.27)	78.75 (19.20)	82.89 (19.17)			
Median	82.50	82.50	90.00			
IQR: Q1, Q3	72.50, 87.50	67.50, 92.50	75.00, 95.00			
Min, Max	20.0, 100.0	40.0, 100.0	25.0, 100.0			
Week 24						
m	8	10	21			
n	7	9	19	7	9	18
Mean (SD/SE)	83.57 (20.35)	81.67 (16.96)	75.53 (26.61)	9.29 (6.31)	0.56 (1.76)	-8.06 (6.00)
Median	85.00	85.00	85.00	10.00	0	0
IQR: Q1, Q3	70.00, 100.00	75.00, 95.00	60.00, 100.00	-5.00, 25.00	-5.00, 5.00	-10.00, 5.00
Min, Max	45.0, 100.0	45.0, 100.0	20.0, 100.0	-15.0, 30.0	-5.0, 10.0	-75.0, 25.0
Week 52						
m	8	10	20			
n	7	8	18	7	8	17
Mean (SD/SE)	79.29 (15.92)	71.25 (21.67)	81.21 (23.36)	-4.29 (5.50)	-8.75 (4.09)	-4.02 (4.48)
Median	80.00	77.50	87.50	-5.00	-7.50	0
IQR: Q1, Q3	70.00, 90.00	50.00, 90.00	70.00, 100.00	-5.00, 0.00	-15.00, 0.00	-10.00, 5.00
Min, Max	50.0, 100.0	40.0, 95.0	20.0, 100.0	-30.0, 20.0	-30.0, 5.0	-60.0, 25.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.8.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=8)	Visit Result DB MGL-3196 100 mg (N=13)	Visit Result DB Placebo (N=21)	Change from Baseline DB MGL-3196 80 mg (N=8)	Change from Baseline DB MGL-3196 100 mg (N=13)	Change from Baseline DB Placebo (N=21)
Role Physical						
Baseline						
m	8	13	21			
n	8	12	19			
Mean (SD)	85.16 (13.33)	89.60 (13.93)	81.59 (23.52)			
Median	81.25	96.90	87.50			
IQR: Q1, Q3	75.00, 100.00	78.15, 100.00	75.00, 100.00			
Min, Max	68.8, 100.0	62.5, 100.0	0.0, 100.0			
Week 24						
m	8	10	21			
n	7	9	19	7	9	18
Mean (SD/SE)	86.61 (17.82)	86.13 (18.15)	76.65 (31.79)	3.57 (5.07)	-5.54 (4.93)	-3.13 (6.65)
Median	100.00	93.80	93.80	0	0	0
IQR: Q1, Q3	75.00, 100.00	68.80, 100.00	62.50, 100.00	0.00, 12.50	-6.20, 0.00	0.00, 18.70
Min, Max	56.3, 100.0	56.3, 100.0	6.3, 100.0	-18.7, 25.0	-43.7, 6.2	-75.0, 31.2
Week 52						
m	8	10	20			
n	7	8	18	7	8	17
Mean (SD/SE)	83.93 (17.25)	73.45 (30.40)	77.79 (26.44)	-2.69 (6.08)	-17.96 (8.22)	-3.68 (5.36)
Median	87.50	87.55	93.75	0	-12.45	0
IQR: Q1, Q3	62.50, 100.00	37.50, 100.00	56.30, 100.00	-12.50, 6.20	-31.25, 0.00	-18.70, 6.20
Min, Max	62.5, 100.0	37.5, 100.0	25.0, 100.0	-25.0, 25.0	-62.5, 6.2	-43.8, 31.3

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.8.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=8)	Visit Result DB MGL-3196 100 mg (N=13)	Visit Result DB Placebo (N=21)	Change from Baseline DB MGL-3196 80 mg (N=8)	Change from Baseline DB MGL-3196 100 mg (N=13)	Change from Baseline DB Placebo (N=21)
Bodily Pain						
Baseline						
m	8	13	21			
n	8	12	19			
Mean (SD)	75.5 (25.4)	77.9 (18.0)	77.7 (20.7)			
Median	79.0	84.0	84.0			
IQR: Q1, Q3	57.0, 100.0	62.0, 92.0	62.0, 84.0			
Min, Max	32, 100	51, 100	12, 100			
Week 24						
m	8	10	21			
n	7	9	19	7	9	18
Mean (SD/SE)	85.3 (20.8)	77.8 (16.5)	75.6 (25.3)	13.3 (3.9)	-3.6 (5.4)	-1.7 (4.3)
Median	100.0	80.0	84.0	16.0	0	0
IQR: Q1, Q3	62.0, 100.0	64.0, 84.0	62.0, 100.0	0.0, 22.0	-10.0, 0.0	0.0, 11.0
Min, Max	51, 100	52, 100	12, 100	0, 26	-36, 18	-53, 16
Week 52						
m	8	10	20			
n	7	8	18	7	8	17
Mean (SD/SE)	68.0 (25.0)	72.8 (14.8)	74.6 (20.0)	-9.4 (4.1)	-8.3 (3.8)	-3.7 (3.5)
Median	62.0	74.0	74.0	-12.0	-5.0	0
IQR: Q1, Q3	62.0, 84.0	62.0, 79.0	52.0, 84.0	-16.0, 0.0	-16.0, 0.0	-10.0, 0.0
Min, Max	22, 100	52, 100	32, 100	-22, 10	-26, 2	-28, 20

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.8.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=8)	Visit Result DB MGL-3196 100 mg (N=13)	Visit Result DB Placebo (N=21)	Change from Baseline DB MGL-3196 80 mg (N=8)	Change from Baseline DB MGL-3196 100 mg (N=13)	Change from Baseline DB Placebo (N=21)
General Health						
Baseline						
m	8	13	21			
n	8	12	19			
Mean (SD)	69.25 (20.26)	66.42 (11.42)	67.68 (21.36)			
Median	77.00	67.00	72.00			
IQR: Q1, Q3	62.00, 82.00	59.50, 74.50	60.00, 82.00			
Min, Max	25.0, 87.0	47.0, 82.0	25.0, 97.0			
Week 24						
m	8	10	21			
n	7	9	19	7	9	18
Mean (SD/SE)	74.57 (24.28)	61.78 (13.75)	67.00 (20.95)	5.00 (3.27)	-4.44 (5.01)	-1.39 (3.35)
Median	82.00	62.00	72.00	10.00	-3.00	0
IQR: Q1, Q3	67.00, 92.00	52.00, 67.00	45.00, 87.00	0.00, 10.00	-15.00, 5.00	-10.00, 10.00
Min, Max	25.0, 97.0	45.0, 87.0	30.0, 92.0	-10.0, 15.0	-27.0, 15.0	-30.0, 20.0
Week 52						
m	8	10	20			
n	7	8	18	7	8	17
Mean (SD/SE)	78.14 (13.38)	61.13 (15.51)	66.28 (21.38)	2.57 (2.71)	-3.75 (3.91)	-2.65 (4.47)
Median	77.00	57.00	66.00	5.00	-2.50	0
IQR: Q1, Q3	72.00, 92.00	48.50, 77.00	52.00, 87.00	-2.00, 10.00	-6.50, 2.50	-10.00, 10.00
Min, Max	55.0, 92.0	42.0, 82.0	15.0, 97.0	-10.0, 10.0	-27.0, 10.0	-57.0, 25.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.8.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter / Visit / Statistic	Visit Result: DB MGL-3196 80 mg (N=8)	Visit Result: DB MGL-3196 100 mg (N=13)	Visit Result: DB Placebo (N=21)	Change from Baseline: DB MGL-3196 80 mg (N=8)	Change from Baseline: DB MGL-3196 100 mg (N=13)	Change from Baseline: DB Placebo (N=21)
Vitality						
Baseline						
m	8	13	21			
n	8	12	19			
Mean (SD)	57.06 (25.77)	68.78 (13.86)	66.14 (17.96)			
Median	65.65	68.80	62.50			
IQR: Q1, Q3	50.05, 71.90	62.50, 78.15	56.30, 75.00			
Min, Max	0.0, 81.3	43.8, 93.8	25.0, 100.0			
Week 24						
m	8	10	21			
n	7	9	19	7	9	18
Mean (SD/SE)	54.49 (31.00)	66.70 (15.63)	62.52 (21.64)	-2.69 (4.06)	-1.38 (6.06)	-3.47 (4.50)
Median	62.50	68.80	62.50	0	0	-3.10
IQR: Q1, Q3	25.00, 81.30	56.30, 75.00	50.00, 75.00	-12.50, 6.20	-12.50, 6.30	-12.50, 12.50
Min, Max	0.0, 81.3	43.8, 93.8	6.3, 93.8	-18.8, 12.5	-31.3, 31.3	-50.0, 31.3
Week 52						
m	8	10	20			
n	7	8	18	7	8	17
Mean (SD/SE)	57.17 (21.47)	58.63 (16.68)	63.91 (22.34)	-8.04 (4.03)	-7.80 (2.57)	-4.78 (3.81)
Median	68.80	59.40	65.65	-6.20	-9.35	-6.20
IQR: Q1, Q3	37.50, 75.00	46.90, 71.90	43.80, 81.30	-18.80, 0.00	-12.50, 0.00	-12.50, 12.50
Min, Max	18.8, 75.0	31.3, 81.3	25.0, 100.0	-25.0, 6.2	-18.7, 0.0	-37.5, 18.7

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.8.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=8)	Visit Result DB MGL-3196 100 mg (N=13)	Visit Result DB Placebo (N=21)	Change from Baseline DB MGL-3196 80 mg (N=8)	Change from Baseline DB MGL-3196 100 mg (N=13)	Change from Baseline DB Placebo (N=21)
Social Functioning						
Baseline						
m	8	13	21			
n	8	12	19			
Mean (SD)	92.19 (14.85)	92.71 (8.36)	92.76 (17.83)			
Median	100.00	93.75	100.00			
IQR: Q1, Q3	87.50, 100.00	87.50, 100.00	87.50, 100.00			
Min, Max	62.5, 100.0	75.0, 100.0	25.0, 100.0			
Week 24						
m	8	10	21			
n	7	9	19	7	9	18
Mean (SD/SE)	83.93 (21.30)	88.89 (11.60)	86.18 (25.65)	-7.14 (3.72)	-5.56 (3.67)	-6.25 (6.65)
Median	100.00	87.50	100.00	0	0	0
IQR: Q1, Q3	62.50, 100.00	75.00, 100.00	75.00, 100.00	-12.50, 0.00	-12.50, 0.00	0.00, 0.00
Min, Max	50.0, 100.0	75.0, 100.0	0.0, 100.0	-25.0, 0.0	-25.0, 12.5	-100.0, 50.0
Week 52						
m	8	10	20			
n	7	8	18	7	8	17
Mean (SD/SE)	89.29 (18.30)	90.63 (11.08)	95.83 (10.50)	-7.14 (5.36)	-4.69 (5.76)	2.94 (2.94)
Median	100.00	93.75	100.00	0	-6.25	0
IQR: Q1, Q3	62.50, 100.00	81.25, 100.00	100.00, 100.00	-12.50, 0.00	-18.75, 12.50	0.00, 0.00
Min, Max	62.5, 100.0	75.0, 100.0	62.5, 100.0	-37.5, 0.0	-25.0, 12.5	-12.5, 37.5

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.8.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter / Visit / Statistic	Visit Result: DB MGL-3196 80 mg (N=8)	Visit Result: DB MGL-3196 100 mg (N=13)	Visit Result: DB Placebo (N=21)	Change from Baseline: DB MGL-3196 80 mg (N=8)	Change from Baseline: DB MGL-3196 100 mg (N=13)	Change from Baseline: DB Placebo (N=21)
Role Emotional						
Baseline						
m	8	13	21			
n	8	12	19			
Mean (SD)	96.89 (4.30)	96.53 (8.31)	89.47 (15.17)			
Median	100.00	100.00	100.00			
IQR: Q1, Q3	91.70, 100.00	100.00, 100.00	83.30, 100.00			
Min, Max	91.7, 100.0	75.0, 100.0	50.0, 100.0			
Week 24						
m	8	10	21			
n	7	9	19	7	9	18
Mean (SD/SE)	89.29 (14.20)	89.81 (17.57)	84.65 (19.49)	-7.16 (5.27)	-8.33 (6.52)	-4.17 (3.18)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	83.30, 100.00	66.70, 100.00	-16.70, 0.00	-16.70, 0.00	0.00, 0.00
Min, Max	66.7, 100.0	50.0, 100.0	41.7, 100.0	-33.3, 8.3	-50.0, 16.7	-50.0, 8.3
Week 52						
m	8	10	20			
n	7	8	18	7	8	17
Mean (SD/SE)	90.47 (13.11)	88.54 (18.33)	85.18 (22.25)	-5.97 (4.35)	-9.38 (6.58)	-4.91 (3.58)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	83.30, 100.00	79.15, 100.00	66.70, 100.00	-16.70, 0.00	-12.50, 0.00	0.00, 0.00
Min, Max	66.7, 100.0	50.0, 100.0	25.0, 100.0	-25.0, 8.3	-50.0, 0.0	-41.7, 16.7

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.8.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter / Visit / Statistic	Visit Result: DB MGL-3196 80 mg (N=8)	Visit Result: DB MGL-3196 100 mg (N=13)	Visit Result: DB Placebo (N=21)	Change from Baseline: DB MGL-3196 80 mg (N=8)	Change from Baseline: DB MGL-3196 100 mg (N=13)	Change from Baseline: DB Placebo (N=21)
Mental Health						
Baseline						
m	8	13	21			
n	8	12	19			
Mean (SD)	83.8 (10.3)	86.3 (7.4)	82.4 (14.6)			
Median	85.0	85.0	85.0			
IQR: Q1, Q3	75.0, 90.0	85.0, 90.0	70.0, 95.0			
Min, Max	70, 100	70, 100	60, 100			
Week 24						
m	8	10	21			
n	7	9	19	7	9	18
Mean (SD/SE)	86.4 (11.8)	83.3 (12.5)	81.6 (16.8)	2.1 (2.9)	-3.9 (4.3)	-1.1 (2.0)
Median	90.0	85.0	90.0	0	0	0
IQR: Q1, Q3	70.0, 95.0	80.0, 90.0	65.0, 95.0	-5.0, 10.0	-5.0, 0.0	-5.0, 5.0
Min, Max	70, 100	55, 95	50, 100	-5, 15	-35, 10	-20, 15
Week 52						
m	8	10	20			
n	7	8	18	7	8	17
Mean (SD/SE)	85.7 (9.3)	80.0 (11.0)	82.5 (19.5)	0.0 (2.2)	-7.5 (3.1)	-0.3 (3.5)
Median	90.0	80.0	87.5	0	-5.0	0
IQR: Q1, Q3	80.0, 95.0	75.0, 87.5	80.0, 95.0	-5.0, 5.0	-10.0, -5.0	-5.0, 5.0
Min, Max	70, 95	60, 95	30, 100	-10, 5	-25, 5	-40, 25

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.8.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter / Visit / Statistic	Visit Result: DB MGL-3196 80 mg (N=8)	Visit Result: DB MGL-3196 100 mg (N=13)	Visit Result: DB Placebo (N=21)	Change from Baseline: DB MGL-3196 80 mg (N=8)	Change from Baseline: DB MGL-3196 100 mg (N=13)	Change from Baseline: DB Placebo (N=21)
Mental Component Score						
Baseline						
m	8	13	21			
n	8	12	19			
Mean (SD)	55.84 (4.03)	57.24 (2.27)	54.66 (6.60)			
Median	55.40	57.30	56.70			
IQR: Q1, Q3	53.20, 59.45	55.40, 58.40	46.80, 60.10			
Min, Max	49.5, 61.1	53.3, 60.9	44.1, 63.2			
Week 24						
m	8	10	21			
n	7	9	19	7	9	18
Mean (SD/SE)	52.79 (8.98)	54.58 (6.62)	53.43 (7.64)	-3.34 (2.01)	-2.88 (2.49)	-1.17 (1.06)
Median	55.50	56.20	57.50	-1.20	-1.30	-0.75
IQR: Q1, Q3	41.10, 60.20	52.10, 59.60	46.50, 58.40	-9.60, 1.00	-5.00, 0.40	-4.20, 0.60
Min, Max	39.9, 60.7	40.8, 61.0	38.7, 62.5	-12.2, 1.0	-20.1, 5.4	-8.1, 10.8
Week 52						
m	8	10	20			
n	7	8	18	7	8	17
Mean (SD/SE)	54.86 (6.13)	54.45 (5.14)	54.45 (8.94)	-1.89 (1.20)	-3.08 (1.61)	-0.49 (1.38)
Median	56.90	54.10	57.70	-1.60	-2.40	-0.10
IQR: Q1, Q3	47.70, 60.60	52.85, 59.05	51.80, 60.90	-5.90, 1.40	-5.30, 0.05	-1.70, 3.20
Min, Max	47.4, 61.3	44.0, 59.6	35.3, 65.5	-6.1, 1.6	-11.4, 2.1	-12.8, 8.7

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.8.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=8)	Visit Result DB MGL-3196 100 mg (N=13)	Visit Result DB Placebo (N=21)	Change from Baseline DB MGL-3196 80 mg (N=8)	Change from Baseline DB MGL-3196 100 mg (N=13)	Change from Baseline DB Placebo (N=21)
Physical Component Score						
Baseline						
m	8	13	21			
n	8	12	19			
Mean (SD)	48.86 (8.38)	49.79 (6.26)	50.56 (8.78)			
Median	49.35	53.05	51.40			
IQR: Q1, Q3	45.10, 55.90	43.60, 54.30	46.60, 56.90			
Min, Max	32.2, 58.0	37.8, 56.1	21.6, 61.1			
Week 24						
m	8	10	21			
n	7	9	19	7	9	18
Mean (SD/SE)	52.49 (7.19)	50.12 (5.79)	48.83 (10.91)	4.54 (1.68)	-0.47 (1.19)	-1.66 (2.22)
Median	54.80	50.90	53.20	1.40	0.50	0.50
IQR: Q1, Q3	47.50, 58.70	48.00, 54.00	40.10, 56.00	1.00, 9.60	-3.30, 1.90	-1.50, 3.00
Min, Max	39.4, 59.0	40.9, 58.0	24.6, 61.0	0.9, 10.7	-6.4, 4.2	-30.0, 11.8
Week 52						
m	8	10	20			
n	7	8	18	7	8	17
Mean (SD/SE)	49.70 (7.71)	46.49 (9.25)	49.53 (8.45)	-1.54 (1.53)	-3.65 (1.97)	-1.54 (1.73)
Median	52.70	49.05	52.65	-1.00	-2.40	-1.10
IQR: Q1, Q3	44.50, 56.80	37.45, 53.70	42.80, 54.90	-5.10, 1.40	-6.20, 0.40	-6.90, 2.80
Min, Max	35.7, 57.0	33.4, 58.1	31.5, 58.9	-8.4, 3.6	-14.8, 2.0	-15.9, 10.1

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; HbA1c = Hemoglobin A1C.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.8.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable; HbA1c = Hemoglobin A1C.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

Madrigal Pharmaceuticals, Inc. Page 2 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.8.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Physical Functioning			
Week 24			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	82.50 (24.75)	74.17 (29.40)
Analysis Visit Mean (SD)	N/A	92.50 (10.61)	79.17 (18.28)
LS Mean of Change from Baseline (SE)	NE	13.04 (7.00)	3.99 (4.02)
95% CI	NE	(-4.09, 30.17)	(-5.85, 13.82)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	9.05 (8.10)	
95% CI	NE	(-10.78, 28.88)	
p-value	NE	0.3067	
Corrected Hedge's g Statistics	NE	0.799	
95% CI	NE	(-0.85, 2.45)	
Week 52			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	82.50 (24.75)	74.17 (29.40)
Analysis Visit Mean (SD)	N/A	87.50 (17.68)	83.33 (20.90)
LS Mean of Change from Baseline (SE)	NE	7.03 (5.03)	8.49 (2.89)
95% CI	NE	(-5.28, 19.34)	(1.42, 15.56)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-1.46 (5.82)	
95% CI	NE	(-15.71, 12.80)	
p-value	NE	0.8108	
Corrected Hedge's g Statistics	NE	-0.179	
95% CI	NE	(-1.78, 1.42)	
Subgroup*Treatment Interaction p-value	NE	0.6352	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE21.8.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Role Physical			
Week 24			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	87.50 (17.68)	70.83 (30.28)
Analysis Visit Mean (SD)	N/A	90.65 (13.22)	73.97 (28.62)
LS Mean of Change from Baseline (SE)	NE	4.15 (3.65)	2.80 (2.07)
95% CI	NE	(-4.79, 13.09)	(-2.26, 7.86)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	1.35 (4.26)	
95% CI	NE	(-9.08, 11.78)	
p-value	NE	0.7622	
Corrected Hedge's g Statistics	NE	0.231	
95% CI	NE	(-1.37, 1.84)	
Week 52			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	87.50 (17.68)	70.83 (30.28)
Analysis Visit Mean (SD)	N/A	87.50 (17.68)	76.05 (25.11)
LS Mean of Change from Baseline (SE)	NE	3.66 (10.41)	4.00 (5.89)
95% CI	NE	(-21.81, 29.13)	(-10.41, 18.40)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-0.33 (12.14)	
95% CI	NE	(-30.04, 29.37)	
p-value	NE	0.9790	
Corrected Hedge's g Statistics	NE	-0.020	
95% CI	NE	(-1.62, 1.58)	
Subgroup*Treatment Interaction p-value	NE	0.4325	

Madrigal Pharmaceuticals, Inc. Page 4 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.8.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Bodily Pain			
Week 24			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	81.0 (26.9)	73.0 (25.3)
Analysis Visit Mean (SD)	N/A	81.0 (26.9)	69.7 (25.9)
LS Mean of Change from Baseline (SE)	NE	0.34 (7.57)	-3.45 (4.34)
95% CI	NE	(-18.19, 18.86)	(-14.08, 7.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	3.78 (8.77)	
95% CI	NE	(-17.67, 25.24)	
p-value	NE	0.6812	
Corrected Hedge's g Statistics	NE	0.309	
95% CI	NE	(-1.30, 1.92)	
Week 52			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	81.0 (26.9)	73.0 (25.3)
Analysis Visit Mean (SD)	N/A	87.0 (18.4)	75.2 (22.7)
LS Mean of Change from Baseline (SE)	NE	7.96 (10.75)	1.51 (6.17)
95% CI	NE	(-18.34, 34.26)	(-13.58, 16.61)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	6.45 (12.45)	
95% CI	NE	(-24.01, 36.91)	
p-value	NE	0.6230	
Corrected Hedge's g Statistics	NE	0.371	
95% CI	NE	(-1.24, 1.98)	
Subgroup*Treatment Interaction p-value	NE	0.4035	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 5 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.8.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
General Health			
Week 24			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	74.50 (10.61)	75.33 (11.69)
Analysis Visit Mean (SD)	N/A	82.00 (7.07)	67.83 (13.57)
LS Mean of Change from Baseline (SE)	NE	6.94 (9.81)	-7.31 (5.66)
95% CI	NE	(-17.07, 30.95)	(-21.17, 6.55)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	14.25 (11.33)	
95% CI	NE	(-13.48, 41.99)	
p-value	NE	0.2552	
Corrected Hedge's g Statistics	NE	0.893	
95% CI	NE	(-0.77, 2.55)	
Week 52			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	74.50 (10.61)	75.33 (11.69)
Analysis Visit Mean (SD)	N/A	72.00 (14.14)	69.58 (14.87)
LS Mean of Change from Baseline (SE)	NE	-2.85 (10.72)	-5.63 (6.19)
95% CI	NE	(-29.08, 23.39)	(-20.78, 9.51)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	2.79 (12.38)	
95% CI	NE	(-27.51, 33.08)	
p-value	NE	0.8294	
Corrected Hedge's g Statistics	NE	0.160	
95% CI	NE	(-1.44, 1.76)	
Subgroup*Treatment Interaction p-value	NE	0.1821	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 6 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.8.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Vitality			
Week 24			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	62.55 (8.84)	64.60 (23.27)
Analysis Visit Mean (SD)	N/A	65.65 (13.22)	64.60 (19.64)
LS Mean of Change from Baseline (SE)	NE	2.86 (3.31)	0.08 (1.91)
95% CI	NE	(-5.23, 10.96)	(-4.59, 4.75)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	2.78 (3.82)	
95% CI	NE	(-6.57, 12.14)	
p-value	NE	0.4938	
Corrected Hedge's g Statistics	NE	0.518	
95% CI	NE	(-1.10, 2.14)	
Week 52			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	62.55 (8.84)	64.60 (23.27)
Analysis Visit Mean (SD)	N/A	65.65 (13.22)	72.92 (21.53)
LS Mean of Change from Baseline (SE)	NE	2.55 (11.63)	8.50 (6.71)
95% CI	NE	(-25.92, 31.02)	(-7.93, 24.93)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-5.95 (13.44)	
95% CI	NE	(-38.84, 26.93)	
p-value	NE	0.6732	
Corrected Hedge's g Statistics	NE	-0.315	
95% CI	NE	(-1.92, 1.29)	
Subgroup*Treatment Interaction p-value	NE	0.9703	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 7 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.8.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Social Functioning			
Week 24			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	62.50 (35.36)	89.58 (16.61)
Analysis Visit Mean (SD)	N/A	100.00 (0.00)	89.58 (16.61)
LS Mean of Change from Baseline (SE)	NE	27.85 (9.28)	3.22 (4.91)
95% CI	NE	(5.13, 50.56)	(-8.81, 15.24)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	24.63 (11.14)	
95% CI	NE	(-2.62, 51.88)	
p-value	NE	0.0690	
Corrected Hedge's g Statistics	NE	1.752	
95% CI	NE	(-0.06, 3.57)	
Week 52			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	62.50 (35.36)	89.58 (16.61)
Analysis Visit Mean (SD)	N/A	100.00 (0.00)	87.50 (19.36)
LS Mean of Change from Baseline (SE)	NE	22.01 (15.06)	3.08 (7.97)
95% CI	NE	(-14.84, 58.87)	(-16.43, 22.59)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	18.94 (18.07)	
95% CI	NE	(-25.28, 63.15)	
p-value	NE	0.3350	
Corrected Hedge's g Statistics	NE	0.830	
95% CI	NE	(-0.82, 2.48)	
Subgroup*Treatment Interaction p-value	NE	0.0190	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE21.8.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Role Emotional			
Week 24			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	95.85 (5.87)	90.28 (23.80)
Analysis Visit Mean (SD)	N/A	100.00 (0.00)	87.50 (23.41)
LS Mean of Change from Baseline (SE)	NE	4.44 (5.06)	-2.88 (2.91)
95% CI	NE	(-7.95, 16.83)	(-10.00, 4.25)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	7.32 (5.86)	
95% CI	NE	(-7.02, 21.65)	
p-value	NE	0.2583	
Corrected Hedge's g Statistics	NE	0.891	
95% CI	NE	(-0.77, 2.55)	
Week 52			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	95.85 (5.87)	90.28 (23.80)
Analysis Visit Mean (SD)	N/A	100.00 (0.00)	88.88 (18.01)
LS Mean of Change from Baseline (SE)	NE	7.15 (11.88)	-2.40 (6.83)
95% CI	NE	(-21.92, 36.21)	(-19.11, 14.31)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	9.55 (13.74)	
95% CI	NE	(-24.08, 43.17)	
p-value	NE	0.5133	
Corrected Hedge's g Statistics	NE	0.496	
95% CI	NE	(-1.12, 2.11)	
Subgroup*Treatment Interaction p-value	NE	0.2934	

Madrigal Pharmaceuticals, Inc. Page 9 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.8.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Mental Health			
Week 24			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	82.5 (10.6)	85.0 (17.6)
Analysis Visit Mean (SD)	N/A	92.5 (10.6)	84.2 (20.1)
LS Mean of Change from Baseline (SE)	NE	9.97 (7.23)	-0.82 (4.17)
95% CI	NE	(-7.72, 27.66)	(-11.02, 9.38)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	10.80 (8.35)	
95% CI	NE	(-9.65, 31.24)	
p-value	NE	0.2438	
Corrected Hedge's g Statistics	NE	0.919	
95% CI	NE	(-0.74, 2.58)	
Week 52			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	82.5 (10.6)	85.0 (17.6)
Analysis Visit Mean (SD)	N/A	85.0 (7.1)	85.0 (18.4)
LS Mean of Change from Baseline (SE)	NE	2.20 (7.57)	0.10 (4.37)
95% CI	NE	(-16.33, 20.73)	(-10.58, 10.78)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	2.11 (8.75)	
95% CI	NE	(-19.31, 23.52)	
p-value	NE	0.8179	
Corrected Hedge's g Statistics	NE	0.171	
95% CI	NE	(-1.43, 1.77)	
Subgroup*Treatment Interaction p-value	NE	0.0935	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 10 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.8.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Mental Component Score			
Week 24			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	51.75 (0.92)	56.35 (9.21)
Analysis Visit Mean (SD)	N/A	58.40 (1.56)	55.23 (9.48)
LS Mean of Change from Baseline (SE)	NE	6.65 (1.66)	-1.12 (0.94)
95% CI	NE	(2.59, 10.71)	(-3.42, 1.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	7.77 (1.93)	
95% CI	NE	(3.04, 12.50)	
p-value	NE	0.0070	
Corrected Hedge's g Statistics	NE	2.921	
95% CI	NE	(0.77, 5.07)	
Week 52			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	51.75 (0.92)	56.35 (9.21)
Analysis Visit Mean (SD)	N/A	56.90 (0.14)	55.70 (10.15)
LS Mean of Change from Baseline (SE)	NE	4.24 (5.49)	-0.35 (3.11)
95% CI	NE	(-9.19, 17.66)	(-7.96, 7.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	4.58 (6.39)	
95% CI	NE	(-11.05, 20.22)	
p-value	NE	0.5002	
Corrected Hedge's g Statistics	NE	0.521	
95% CI	NE	(-1.10, 2.14)	
Subgroup*Treatment Interaction p-value	NE	0.0384	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 11 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.8.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Physical Component Score			
Week 24			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	52.00 (11.74)	47.70 (9.52)
Analysis Visit Mean (SD)	N/A	53.30 (6.65)	47.92 (8.20)
LS Mean of Change from Baseline (SE)	NE	2.22 (2.88)	-0.09 (1.64)
95% CI	NE	(-4.81, 9.26)	(-4.11, 3.92)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	2.32 (3.34)	
95% CI	NE	(-5.85, 10.49)	
p-value	NE	0.5138	
Corrected Hedge's g Statistics	NE	0.500	
95% CI	NE	(-1.12, 2.12)	
Week 52			
m	0	2	6
n	0	2	6
Baseline Mean (SD)	N/A	52.00 (11.74)	47.70 (9.52)
Analysis Visit Mean (SD)	N/A	52.60 (8.49)	49.67 (8.95)
LS Mean of Change from Baseline (SE)	NE	1.41 (3.81)	1.70 (2.17)
95% CI	NE	(-7.91, 10.72)	(-3.62, 7.01)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-0.29 (4.42)	
95% CI	NE	(-11.11, 10.52)	
p-value	NE	0.9495	
Corrected Hedge's g Statistics	NE	-0.048	
95% CI	NE	(-1.65, 1.55)	
Subgroup*Treatment Interaction p-value	NE	0.5087	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 12 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.8.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Physical Functioning			
Week 24			
m	8	10	21
n	7	9	18
Baseline Mean (SD)	74.29 (25.89)	81.11 (17.81)	83.89 (19.22)
Analysis Visit Mean (SD)	83.57 (20.35)	81.67 (16.96)	75.83 (27.35)
LS Mean of Change from Baseline (SE)	9.16 (8.23)	0.87 (7.41)	-4.93 (6.40)
95% CI	(-7.63, 25.94)	(-14.25, 15.98)	(-17.99, 8.13)
LS Mean of Change from Baseline Compared to Placebo (SE)	14.09 (8.79)	5.80 (8.12)	
95% CI	(-3.84, 32.01)	(-10.75, 22.35)	
p-value	0.1191	0.4802	
Corrected Hedge's g Statistics	0.527	0.219	
95% CI	(-0.36, 1.41)	(-0.58, 1.02)	
Week 52			
m	8	10	20
n	7	8	17
Baseline Mean (SD)	83.57 (9.88)	80.00 (18.71)	84.41 (19.68)
Analysis Visit Mean (SD)	79.29 (15.92)	71.25 (21.67)	80.39 (23.81)
LS Mean of Change from Baseline (SE)	-1.04 (7.26)	-8.48 (6.67)	-0.79 (5.98)
95% CI	(-15.85, 13.77)	(-22.09, 5.13)	(-12.98, 11.40)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.25 (7.29)	-7.69 (7.13)	
95% CI	(-15.13, 14.62)	(-22.23, 6.84)	
p-value	0.9725	0.2886	
Corrected Hedge's g Statistics	-0.011	-0.323	
95% CI	(-0.89, 0.87)	(-1.17, 0.52)	
Subgroup*Treatment Interaction p-value	NE	0.6352	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 13 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.8.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Role Physical			
Week 24			
m	8	10	21
n	7	9	18
Baseline Mean (SD)	83.04 (12.86)	91.68 (13.62)	81.26 (24.16)
Analysis Visit Mean (SD)	86.61 (17.82)	86.13 (18.15)	78.13 (32.03)
LS Mean of Change from Baseline (SE)	8.24 (9.34)	-0.25 (8.65)	1.92 (7.31)
95% CI	(-10.81, 27.29)	(-17.90, 17.40)	(-12.98, 16.83)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.31 (9.81)	-2.18 (9.35)	
95% CI	(-13.69, 26.32)	(-21.26, 16.90)	
p-value	0.5244	0.8175	
Corrected Hedge's g Statistics	0.207	-0.072	
95% CI	(-0.67, 1.08)	(-0.87, 0.73)	
Week 52			
m	8	10	20
n	7	8	17
Baseline Mean (SD)	86.61 (13.70)	91.41 (14.54)	80.89 (24.85)
Analysis Visit Mean (SD)	83.93 (17.25)	73.45 (30.40)	77.22 (27.14)
LS Mean of Change from Baseline (SE)	3.21 (9.28)	-12.75 (8.70)	1.33 (7.30)
95% CI	(-15.71, 22.12)	(-30.48, 4.99)	(-13.56, 16.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.88 (9.59)	-14.08 (9.42)	
95% CI	(-17.68, 21.44)	(-33.29, 5.13)	
p-value	0.8462	0.1451	
Corrected Hedge's g Statistics	0.063	-0.477	
95% CI	(-0.82, 0.94)	(-1.33, 0.37)	
Subgroup*Treatment Interaction p-value	NE	0.4325	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE21.8.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Bodily Pain			
Week 24			
m	8	10	21
n	7	9	18
Baseline Mean (SD)	72.0 (25.2)	81.3 (14.0)	78.1 (21.2)
Analysis Visit Mean (SD)	85.3 (20.8)	77.8 (16.5)	76.3 (25.8)
LS Mean of Change from Baseline (SE)	14.65 (6.57)	-0.99 (5.99)	1.61 (4.89)
95% CI	(1.25, 28.05)	(-13.21, 11.23)	(-8.36, 11.58)
LS Mean of Change from Baseline Compared to Placebo (SE)	13.04 (7.27)	-2.60 (6.66)	
95% CI	(-1.78, 27.86)	(-16.18, 10.99)	
p-value	0.0824	0.6991	
Corrected Hedge's g Statistics	0.633	-0.127	
95% CI	(-0.26, 1.52)	(-0.93, 0.67)	
Week 52			
m	8	10	20
n	7	8	17
Baseline Mean (SD)	77.4 (26.8)	81.0 (14.9)	77.7 (21.8)
Analysis Visit Mean (SD)	68.0 (25.0)	72.8 (14.8)	74.0 (20.5)
LS Mean of Change from Baseline (SE)	-5.99 (5.33)	-5.57 (4.96)	-0.40 (4.26)
95% CI	(-16.86, 4.87)	(-15.69, 4.55)	(-9.08, 8.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.60 (5.45)	-5.18 (5.27)	
95% CI	(-16.71, 5.51)	(-15.92, 5.57)	
p-value	0.3120	0.3335	
Corrected Hedge's g Statistics	-0.324	-0.302	
95% CI	(-1.21, 0.56)	(-1.15, 0.54)	
Subgroup*Treatment Interaction p-value	NE	0.4035	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 15 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.8.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
General Health			
Week 24			
m	8	10	21
n	7	9	18
Baseline Mean (SD)	69.57 (21.86)	66.22 (13.15)	69.78 (19.87)
Analysis Visit Mean (SD)	74.57 (24.28)	61.78 (13.75)	68.39 (20.64)
LS Mean of Change from Baseline (SE)	7.36 (5.94)	-3.25 (5.41)	1.27 (4.93)
95% CI	(-4.75, 19.48)	(-14.28, 7.78)	(-8.79, 11.32)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.10 (5.97)	-4.51 (5.72)	
95% CI	(-6.07, 18.27)	(-16.17, 7.14)	
p-value	0.3148	0.4357	
Corrected Hedge's g Statistics	0.299	-0.224	
95% CI	(-0.58, 1.18)	(-1.03, 0.58)	
Week 52			
m	8	10	20
n	7	8	17
Baseline Mean (SD)	75.57 (10.29)	64.88 (13.38)	69.76 (20.48)
Analysis Visit Mean (SD)	78.14 (13.38)	61.13 (15.51)	67.12 (21.73)
LS Mean of Change from Baseline (SE)	5.17 (6.60)	-3.69 (6.00)	-1.03 (5.22)
95% CI	(-8.29, 18.64)	(-15.94, 8.55)	(-11.68, 9.62)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.20 (6.70)	-2.66 (6.54)	
95% CI	(-7.47, 19.87)	(-16.00, 10.68)	
p-value	0.3618	0.6869	
Corrected Hedge's g Statistics	0.292	-0.127	
95% CI	(-0.59, 1.18)	(-0.97, 0.71)	
Subgroup*Treatment Interaction p-value	NE	0.1821	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 16 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.8.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Vitality			
Week 24			
m	8	10	21
n	7	9	18
Baseline Mean (SD)	57.17 (27.83)	68.08 (16.08)	67.03 (18.04)
Analysis Visit Mean (SD)	54.49 (31.00)	66.70 (15.63)	63.56 (21.78)
LS Mean of Change from Baseline (SE)	-4.43 (7.26)	-0.49 (6.53)	-2.08 (5.53)
95% CI	(-19.23, 10.37)	(-13.82, 12.84)	(-13.36, 9.20)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.35 (7.83)	1.59 (7.15)	
95% CI	(-18.32, 13.61)	(-13.00, 16.18)	
p-value	0.7659	0.8253	
Corrected Hedge's g Statistics	-0.101	0.069	
95% CI	(-0.97, 0.77)	(-0.73, 0.87)	
Week 52			
m	8	10	20
n	7	8	17
Baseline Mean (SD)	65.21 (12.42)	66.43 (16.35)	68.40 (17.61)
Analysis Visit Mean (SD)	57.17 (21.47)	58.63 (16.68)	63.62 (23.00)
LS Mean of Change from Baseline (SE)	-7.08 (6.10)	-7.62 (5.65)	-3.80 (5.05)
95% CI	(-19.52, 5.36)	(-19.15, 3.91)	(-14.10, 6.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.27 (6.18)	-3.82 (5.97)	
95% CI	(-15.88, 9.33)	(-15.99, 8.35)	
p-value	0.6002	0.5267	
Corrected Hedge's g Statistics	-0.161	-0.190	
95% CI	(-1.04, 0.72)	(-1.03, 0.65)	
Subgroup*Treatment Interaction p-value	NE	0.9703	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 17 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.8.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Social Functioning			
Week 24			
m	8	10	21
n	7	9	18
Baseline Mean (SD)	91.07 (15.67)	94.44 (6.59)	93.06 (18.30)
Analysis Visit Mean (SD)	83.93 (21.30)	88.89 (11.60)	86.81 (26.25)
LS Mean of Change from Baseline (SE)	-6.80 (8.53)	-3.66 (7.61)	-5.31 (5.96)
95% CI	(-24.19, 10.60)	(-19.18, 11.85)	(-17.48, 6.86)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.49 (9.56)	1.65 (8.83)	
95% CI	(-20.98, 18.01)	(-16.37, 19.66)	
p-value	0.8773	0.8534	
Corrected Hedge's g Statistics	-0.058	0.065	
95% CI	(-0.93, 0.81)	(-0.74, 0.87)	
Week 52			
m	8	10	20
n	7	8	17
Baseline Mean (SD)	96.43 (9.45)	95.31 (6.47)	92.65 (18.78)
Analysis Visit Mean (SD)	89.29 (18.30)	90.63 (11.08)	95.59 (10.77)
LS Mean of Change from Baseline (SE)	-5.36 (5.15)	-2.35 (4.70)	3.63 (4.19)
95% CI	(-15.86, 5.15)	(-11.93, 7.23)	(-4.91, 12.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	-8.99 (5.10)	-5.98 (4.94)	
95% CI	(-19.40, 1.42)	(-16.06, 4.09)	
p-value	0.0881	0.2348	
Corrected Hedge's g Statistics	-0.530	-0.358	
95% CI	(-1.42, 0.36)	(-1.20, 0.49)	
Subgroup*Treatment Interaction p-value	NE	0.0190	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 18 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.8.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Role Emotional			
Week 24			
m	8	10	21
n	7	9	18
Baseline Mean (SD)	96.44 (4.44)	98.14 (5.57)	89.82 (15.54)
Analysis Visit Mean (SD)	89.29 (14.20)	89.81 (17.57)	85.64 (19.55)
LS Mean of Change from Baseline (SE)	-2.66 (6.76)	-3.65 (6.26)	0.07 (5.42)
95% CI	(-16.45, 11.13)	(-16.42, 9.11)	(-10.97, 11.12)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.73 (6.87)	-3.73 (6.58)	
95% CI	(-16.74, 11.27)	(-17.15, 9.70)	
p-value	0.6933	0.5756	
Corrected Hedge's g Statistics	-0.122	-0.166	
95% CI	(-1.00, 0.75)	(-0.97, 0.64)	
Week 52			
m	8	10	20
n	7	8	17
Baseline Mean (SD)	96.44 (4.44)	97.91 (5.90)	89.22 (15.80)
Analysis Visit Mean (SD)	90.47 (13.11)	88.54 (18.33)	84.31 (22.62)
LS Mean of Change from Baseline (SE)	-3.46 (7.07)	-5.22 (6.61)	0.44 (5.60)
95% CI	(-17.88, 10.97)	(-18.70, 8.26)	(-10.98, 11.87)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.90 (7.25)	-5.66 (7.11)	
95% CI	(-18.70, 10.89)	(-20.16, 8.83)	
p-value	0.5943	0.4315	
Corrected Hedge's g Statistics	-0.171	-0.251	
95% CI	(-1.05, 0.71)	(-1.09, 0.59)	
Subgroup*Treatment Interaction p-value	NE	0.2934	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 19 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.8.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Mental Health			
Week 24			
m	8	10	21
n	7	9	18
Baseline Mean (SD)	84.3 (11.0)	87.2 (3.6)	82.2 (15.0)
Analysis Visit Mean (SD)	86.4 (11.8)	83.3 (12.5)	81.1 (17.1)
LS Mean of Change from Baseline (SE)	4.47 (4.08)	-2.28 (3.82)	1.82 (3.33)
95% CI	(-3.85, 12.79)	(-10.07, 5.51)	(-4.98, 8.62)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.66 (4.13)	-4.10 (3.93)	
95% CI	(-5.77, 11.08)	(-12.11, 3.91)	
p-value	0.5250	0.3045	
Corrected Hedge's g Statistics	0.192	-0.298	
95% CI	(-0.68, 1.07)	(-1.10, 0.51)	
Week 52			
m	8	10	20
n	7	8	17
Baseline Mean (SD)	85.7 (9.3)	87.5 (3.8)	82.4 (15.4)
Analysis Visit Mean (SD)	85.7 (9.3)	80.0 (11.0)	82.1 (20.0)
LS Mean of Change from Baseline (SE)	3.26 (5.25)	-5.13 (4.95)	2.80 (3.95)
95% CI	(-7.45, 13.96)	(-15.22, 4.96)	(-5.26, 10.86)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.46 (5.64)	-7.93 (5.48)	
95% CI	(-11.03, 11.96)	(-19.11, 3.26)	
p-value	0.9352	0.1584	
Corrected Hedge's g Statistics	0.028	-0.490	
95% CI	(-0.85, 0.91)	(-1.34, 0.36)	
Subgroup*Treatment Interaction p-value	NE	0.0935	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 20 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.8.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Mental Component Score			
Week 24			
m	8	10	21
n	7	9	18
Baseline Mean (SD)	56.13 (4.26)	57.46 (2.17)	54.71 (6.79)
Analysis Visit Mean (SD)	52.79 (8.98)	54.58 (6.62)	53.54 (7.85)
LS Mean of Change from Baseline (SE)	-2.49 (2.39)	-1.89 (2.21)	0.02 (1.85)
95% CI	(-7.37, 2.39)	(-6.39, 2.61)	(-3.75, 3.79)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.51 (2.54)	-1.91 (2.41)	
95% CI	(-7.69, 2.66)	(-6.82, 3.00)	
p-value	0.3301	0.4343	
Corrected Hedge's g Statistics	-0.325	-0.248	
95% CI	(-1.20, 0.55)	(-1.05, 0.56)	
Week 52			
m	8	10	20
n	7	8	17
Baseline Mean (SD)	56.74 (3.36)	57.53 (2.31)	54.73 (7.00)
Analysis Visit Mean (SD)	54.86 (6.13)	54.45 (5.14)	54.24 (9.17)
LS Mean of Change from Baseline (SE)	-1.11 (2.27)	-2.15 (2.13)	0.87 (1.79)
95% CI	(-5.75, 3.52)	(-6.49, 2.19)	(-2.77, 4.51)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.98 (2.34)	-3.02 (2.29)	
95% CI	(-6.75, 2.79)	(-7.69, 1.66)	
p-value	0.4035	0.1975	
Corrected Hedge's g Statistics	-0.273	-0.418	
95% CI	(-1.16, 0.61)	(-1.27, 0.43)	
Subgroup*Treatment Interaction p-value	NE	0.0384	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 21 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.8.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Physical Component Score			
Week 24			
m	8	10	21
n	7	9	18
Baseline Mean (SD)	47.94 (8.61)	50.59 (6.33)	50.97 (8.85)
Analysis Visit Mean (SD)	52.49 (7.19)	50.12 (5.79)	49.31 (11.01)
LS Mean of Change from Baseline (SE)	4.84 (3.00)	-0.11 (2.70)	-0.38 (2.30)
95% CI	(-1.29, 10.96)	(-5.62, 5.40)	(-5.06, 4.30)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.22 (3.25)	0.27 (2.99)	
95% CI	(-1.41, 11.85)	(-5.82, 6.37)	
p-value	0.1187	0.9279	
Corrected Hedge's g Statistics	0.543	0.029	
95% CI	(-0.34, 1.43)	(-0.77, 0.83)	
Week 52			
m	8	10	20
n	7	8	17
Baseline Mean (SD)	51.24 (5.39)	50.14 (6.61)	51.01 (9.12)
Analysis Visit Mean (SD)	49.70 (7.71)	46.49 (9.25)	49.47 (8.71)
LS Mean of Change from Baseline (SE)	-0.04 (2.67)	-3.37 (2.44)	-0.34 (2.13)
95% CI	(-5.47, 5.40)	(-8.34, 1.60)	(-4.69, 4.01)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.30 (2.71)	-3.03 (2.64)	
95% CI	(-5.23, 5.83)	(-8.41, 2.34)	
p-value	0.9117	0.2590	
Corrected Hedge's g Statistics	0.035	-0.355	
95% CI	(-0.85, 0.92)	(-1.20, 0.49)	
Subgroup*Treatment Interaction p-value	NE	0.5087	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE21.8.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; HbA1c = Hemoglobin A1C.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis, only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.

AMNOG Table SE21.8.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (14.3)
No	1 (100)	2 (100)	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	1.15	
95% CI of the inverse odds ratio	(0.02, 26.90)	(0.03, 38.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	1.13	
95% CI of the inverse risk ratio	(0.05, 12.34)	(0.06, 20.71)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.25	-2.08	
95% CI of the absolute risk difference	(-59.57, 72.07)	(-52.18, 48.02)	
p-value	0.8433	0.9364	
p-value of Breslow-Day Test for Homogeneity [3]	0.5384	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (50.0)	4 (57.1)
No	1 (100)	1 (50.0)	3 (42.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.86	1.33	
95% CI of the inverse odds ratio	(0.12, 126.73)	(0.06, 31.12)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.25	1.14	
95% CI of the inverse risk ratio	(0.19, 26.79)	(0.25, 5.26)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-31.25	-7.14	
95% CI of the absolute risk difference	(-100.00, 37.91)	(-85.54, 71.25)	
p-value	0.4292	0.8577	
p-value of Breslow-Day Test for Homogeneity [3]	0.5626	0.4337	

AMNOG Table SE21.8.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (14.3)
No	1 (100)	2 (100)	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	1.15	
95% CI of the inverse odds ratio	(0.02, 26.90)	(0.03, 38.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	1.13	
95% CI of the inverse risk ratio	(0.05, 12.34)	(0.06, 20.71)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.25	-2.08	
95% CI of the absolute risk difference	(-59.57, 72.07)	(-52.18, 48.02)	
p-value	0.8433	0.9364	
p-value of Breslow-Day Test for Homogeneity [3]	0.7529	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	4 (57.1)
No	1 (100)	2 (100)	3 (42.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.86	6.43	
95% CI of the inverse odds ratio	(0.12, 126.73)	(0.23, 181.82)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.25	3.38	
95% CI of the inverse risk ratio	(0.19, 26.79)	(0.25, 45.58)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-31.25	-39.58	
95% CI of the absolute risk difference	(-100.00, 37.91)	(-93.99, 14.82)	
p-value	0.4292	0.2403	
p-value of Breslow-Day Test for Homogeneity [3]	0.3119	0.4471	

AMNOG Table SE21.8.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (28.6)
No	1 (100)	2 (100)	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	2.27	
95% CI of the inverse odds ratio	(0.04, 46.65)	(0.08, 67.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	1.88	
95% CI of the inverse risk ratio	(0.09, 17.02)	(0.12, 28.78)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.25	-14.58	
95% CI of the absolute risk difference	(-74.32, 61.82)	(-67.59, 38.43)	
p-value	0.8630	0.6286	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (50.0)	2 (28.6)
No	1 (100)	1 (50.0)	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	0.40	
95% CI of the inverse odds ratio	(0.04, 46.65)	(0.02, 10.02)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	0.57	
95% CI of the inverse risk ratio	(0.09, 17.02)	(0.09, 3.51)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.25	21.43	
95% CI of the absolute risk difference	(-74.32, 61.82)	(-55.52, 98.38)	
p-value	0.8630	0.5708	
p-value of Breslow-Day Test for Homogeneity [3]	0.6343	0.0900	

AMNOG Table SE21.8.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (14.3)
No	1 (100)	2 (100)	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	1.15	
95% CI of the inverse odds ratio	(0.02, 26.90)	(0.03, 38.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	1.13	
95% CI of the inverse risk ratio	(0.05, 12.34)	(0.06, 20.71)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.25	-2.08	
95% CI of the absolute risk difference	(-59.57, 72.07)	(-52.18, 48.02)	
p-value	0.8433	0.9364	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	2 (28.6)
No	1 (100)	2 (100)	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	2.27	
95% CI of the inverse odds ratio	(0.04, 46.65)	(0.08, 67.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	1.88	
95% CI of the inverse risk ratio	(0.09, 17.02)	(0.12, 28.78)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.25	-14.58	
95% CI of the absolute risk difference	(-74.32, 61.82)	(-67.59, 38.43)	
p-value	0.8630	0.6286	
p-value of Breslow-Day Test for Homogeneity [3]	0.3749	0.5593	

AMNOG Table SE21.8.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (28.6)
No	1 (100)	2 (100)	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	2.27	
95% CI of the inverse odds ratio	(0.04, 46.65)	(0.08, 67.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	1.88	
95% CI of the inverse risk ratio	(0.09, 17.02)	(0.12, 28.78)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.25	-14.58	
95% CI of the absolute risk difference	(-74.32, 61.82)	(-67.59, 38.43)	
p-value	0.8630	0.6286	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (50.0)	3 (42.9)
No	1 (100)	1 (50.0)	4 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.33	0.75	
95% CI of the inverse odds ratio	(0.07, 76.67)	(0.03, 17.51)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.75	0.86	
95% CI of the inverse risk ratio	(0.14, 21.88)	(0.17, 4.37)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-18.75	7.14	
95% CI of the absolute risk difference	(-87.91, 50.41)	(-71.25, 85.54)	
p-value	0.6283	0.8577	
p-value of Breslow-Day Test for Homogeneity [3]	0.6187	0.0892	

AMNOG Table SE21.8.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (50.0)	1 (14.3)
No	1 (100)	1 (50.0)	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	0.17	
95% CI of the inverse odds ratio	(0.02, 26.90)	(0.01, 5.45)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	0.29	
95% CI of the inverse risk ratio	(0.05, 12.34)	(0.03, 2.80)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.25	35.71	
95% CI of the absolute risk difference	(-59.57, 72.07)	(-38.27, 100.00)	
p-value	0.8433	0.2840	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.1060	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (100)	1 (14.3)
No	1 (100)	0	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	NE	
95% CI of the inverse odds ratio	(0.02, 26.90)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	0.14	
95% CI of the inverse risk ratio	(0.05, 12.34)	(0.02, 0.88)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.25	85.71	
95% CI of the absolute risk difference	(-59.57, 72.07)	(59.79, 100.00)	
p-value	0.8433	0.0233	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.1025	

AMNOG Table SE21.8.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (14.3)
No	1 (100)	2 (100)	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	1.15	
95% CI of the inverse odds ratio	(0.02, 26.90)	(0.03, 38.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	1.13	
95% CI of the inverse risk ratio	(0.05, 12.34)	(0.06, 20.71)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.25	-2.08	
95% CI of the absolute risk difference	(-59.57, 72.07)	(-52.18, 48.02)	
p-value	0.8433	0.9364	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (50.0)	1 (14.3)
No	1 (100)	1 (50.0)	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	0.17	
95% CI of the inverse odds ratio	(0.02, 26.90)	(0.01, 5.45)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	0.29	
95% CI of the inverse risk ratio	(0.05, 12.34)	(0.03, 2.80)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.25	35.71	
95% CI of the absolute risk difference	(-59.57, 72.07)	(-38.27, 100.00)	
p-value	0.8433	0.2840	
p-value of Breslow-Day Test for Homogeneity [3]	0.6492	0.1060	

AMNOG Table SE21.8.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (50.0)	0
No	1 (100)	1 (50.0)	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.07	
95% CI of the inverse odds ratio	NE	(0.00, 2.56)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.13	
95% CI of the inverse risk ratio	NE	(0.01, 2.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	43.75	
95% CI of the absolute risk difference	NE	(-15.26, 100.00)	
p-value	NE	0.0938	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.0088	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (50.0)	3 (42.9)
No	1 (100)	1 (50.0)	4 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.33	0.75	
95% CI of the inverse odds ratio	(0.07, 76.67)	(0.03, 17.51)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.75	0.86	
95% CI of the inverse risk ratio	(0.14, 21.88)	(0.17, 4.37)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-18.75	7.14	
95% CI of the absolute risk difference	(-87.91, 50.41)	(-71.25, 85.54)	
p-value	0.6283	0.8577	
p-value of Breslow-Day Test for Homogeneity [3]	0.3925	0.2703	

AMNOG Table SE21.8.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	1 (100)	2 (100)	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (100)	1 (14.3)
No	1 (100)	0	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	NE	
95% CI of the inverse odds ratio	(0.02, 26.90)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	0.14	
95% CI of the inverse risk ratio	(0.05, 12.34)	(0.02, 0.88)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.25	85.71	
95% CI of the absolute risk difference	(-59.57, 72.07)	(59.79, 100.00)	
p-value	0.8433	0.0233	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.0023	

AMNOG Table SE21.8.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: > 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	1 (100)	2 (100)	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	2 (28.6)
No	1 (100)	2 (100)	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	2.27	
95% CI of the inverse odds ratio	(0.04, 46.65)	(0.08, 67.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	1.88	
95% CI of the inverse risk ratio	(0.09, 17.02)	(0.12, 28.78)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.25	-14.58	
95% CI of the absolute risk difference	(-74.32, 61.82)	(-67.59, 38.43)	
p-value	0.8630	0.6286	
p-value of Breslow-Day Test for Homogeneity [3]	0.5802	NE	

AMNOG Table SE21.8.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (12.5)	0	1 (4.8)
No	7 (87.5)	13 (100)	20 (95.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.35	NE	
95% CI of the inverse odds ratio	(0.02, 6.38)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.38	NE	
95% CI of the inverse risk ratio	(0.03, 5.39)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.74	-4.76	
95% CI of the absolute risk difference	(-16.92, 32.40)	(-13.87, 4.35)	
p-value	0.4623	0.4245	
p-value of Breslow-Day Test for Homogeneity [3]	0.5384	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (12.5)	1 (7.7)	7 (33.3)
No	7 (87.5)	12 (92.3)	14 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.50	6.00	
95% CI of the inverse odds ratio	(0.36, 34.33)	(0.64, 55.95)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.67	4.33	
95% CI of the inverse risk ratio	(0.39, 18.38)	(0.60, 31.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-20.83	-25.64	
95% CI of the absolute risk difference	(-51.36, 9.69)	(-50.47, -0.82)	
p-value	0.2619	0.0867	
p-value of Breslow-Day Test for Homogeneity [3]	0.5626	0.4337	

AMNOG Table SE21.8.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (12.5)	0	4 (19.0)
No	7 (87.5)	13 (100)	17 (81.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.65	6.94	
95% CI of the inverse odds ratio	(0.16, 17.47)	(0.34, 140.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.52	5.73	
95% CI of the inverse risk ratio	(0.20, 11.65)	(0.33, 98.41)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.55	-16.88	
95% CI of the absolute risk difference	(-34.96, 21.86)	(-36.34, 2.57)	
p-value	0.6765	0.1533	
p-value of Breslow-Day Test for Homogeneity [3]	0.7529	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (25.0)	1 (7.7)	5 (23.8)
No	6 (75.0)	12 (92.3)	16 (76.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	3.75	
95% CI of the inverse odds ratio	(0.14, 6.20)	(0.39, 36.43)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	3.10	
95% CI of the inverse risk ratio	(0.23, 3.95)	(0.41, 23.63)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.19	-16.12	
95% CI of the absolute risk difference	(-33.91, 36.29)	(-39.39, 7.16)	
p-value	0.9466	0.2309	
p-value of Breslow-Day Test for Homogeneity [3]	0.3119	0.4471	

AMNOG Table SE21.8.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	3 (14.3)
No	8 (100)	13 (100)	18 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.22	5.11	
95% CI of the inverse odds ratio	(0.15, 69.45)	(0.24, 107.33)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.86	4.45	
95% CI of the inverse risk ratio	(0.16, 50.00)	(0.25, 79.87)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.35	-12.34	
95% CI of the absolute risk difference	(-31.74, 11.04)	(-30.45, 5.78)	
p-value	0.4351	0.2508	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (12.5)	0	4 (19.0)
No	7 (87.5)	13 (100)	17 (81.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.65	6.94	
95% CI of the inverse odds ratio	(0.16, 17.47)	(0.34, 140.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.52	5.73	
95% CI of the inverse risk ratio	(0.20, 11.65)	(0.33, 98.41)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.55	-16.88	
95% CI of the absolute risk difference	(-34.96, 21.86)	(-36.34, 2.57)	
p-value	0.6765	0.1533	
p-value of Breslow-Day Test for Homogeneity [3]	0.6343	0.0900	

AMNOG Table SE21.8.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	3 (14.3)
No	8 (100)	13 (100)	18 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.22	5.11	
95% CI of the inverse odds ratio	(0.15, 69.45)	(0.24, 107.33)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.86	4.45	
95% CI of the inverse risk ratio	(0.16, 50.00)	(0.25, 79.87)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.35	-12.34	
95% CI of the absolute risk difference	(-31.74, 11.04)	(-30.45, 5.78)	
p-value	0.4351	0.2508	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (50.0)	2 (15.4)	6 (28.6)
No	4 (50.0)	11 (84.6)	15 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.40	2.20	
95% CI of the inverse odds ratio	(0.07, 2.14)	(0.37, 13.04)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	1.86	
95% CI of the inverse risk ratio	(0.22, 1.50)	(0.44, 7.86)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	21.43	-13.19	
95% CI of the absolute risk difference	(-18.24, 61.10)	(-40.72, 14.34)	
p-value	0.2779	0.3784	
p-value of Breslow-Day Test for Homogeneity [3]	0.3749	0.5593	

AMNOG Table SE21.8.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (4.8)
No	8 (100)	13 (100)	20 (95.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.76	-4.76	
95% CI of the absolute risk difference	(-13.87, 4.35)	(-13.87, 4.35)	
p-value	0.5299	0.4245	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (12.5)	0	6 (28.6)
No	7 (87.5)	13 (100)	15 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.80	11.32	
95% CI of the inverse odds ratio	(0.28, 27.91)	(0.58, 220.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.29	8.27	
95% CI of the inverse risk ratio	(0.32, 16.13)	(0.50, 135.68)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-16.07	-25.97	
95% CI of the absolute risk difference	(-46.05, 13.90)	(-47.37, -4.57)	
p-value	0.3660	0.0549	
p-value of Breslow-Day Test for Homogeneity [3]	0.6187	0.0892	

AMNOG Table SE21.8.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (9.5)
No	8 (100)	13 (100)	19 (90.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.18	3.46	
95% CI of the inverse odds ratio	(0.09, 50.43)	(0.15, 77.97)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.05	3.18	
95% CI of the inverse risk ratio	(0.11, 38.52)	(0.16, 61.49)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.81	-7.79	
95% CI of the absolute risk difference	(-25.80, 14.19)	(-24.24, 8.65)	
p-value	0.6196	0.4096	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.1060	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	3 (23.1)	3 (14.3)
No	8 (100)	10 (76.9)	18 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.22	0.56	
95% CI of the inverse odds ratio	(0.15, 69.45)	(0.09, 3.29)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.86	0.62	
95% CI of the inverse risk ratio	(0.16, 50.00)	(0.15, 2.62)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.35	8.79	
95% CI of the absolute risk difference	(-31.74, 11.04)	(-18.57, 36.15)	
p-value	0.4351	0.5135	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.1025	

AMNOG Table SE21.8.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (4.8)
No	8 (100)	13 (100)	20 (95.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.76	-4.76	
95% CI of the absolute risk difference	(-13.87, 4.35)	(-13.87, 4.35)	
p-value	0.5299	0.4245	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (12.5)	0	2 (9.5)
No	7 (87.5)	13 (100)	19 (90.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	3.46	
95% CI of the inverse odds ratio	(0.06, 9.46)	(0.15, 77.97)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.76	3.18	
95% CI of the inverse risk ratio	(0.08, 7.29)	(0.16, 61.49)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.98	-7.79	
95% CI of the absolute risk difference	(-23.15, 29.11)	(-24.24, 8.65)	
p-value	0.8140	0.4096	
p-value of Breslow-Day Test for Homogeneity [3]	0.6492	0.1060	

AMNOG Table SE21.8.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	3 (14.3)
No	8 (100)	13 (100)	18 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.22	5.11	
95% CI of the inverse odds ratio	(0.15, 69.45)	(0.24, 107.33)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.86	4.45	
95% CI of the inverse risk ratio	(0.16, 50.00)	(0.25, 79.87)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.35	-12.34	
95% CI of the absolute risk difference	(-31.74, 11.04)	(-30.45, 5.78)	
p-value	0.4351	0.2508	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.0088	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (37.5)	1 (7.7)	7 (33.3)
No	5 (62.5)	12 (92.3)	14 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	6.00	
95% CI of the inverse odds ratio	(0.15, 4.54)	(0.64, 55.95)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	4.33	
95% CI of the inverse risk ratio	(0.30, 2.62)	(0.60, 31.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.17	-25.64	
95% CI of the absolute risk difference	(-34.97, 43.31)	(-50.47, -0.82)	
p-value	0.8329	0.0867	
p-value of Breslow-Day Test for Homogeneity [3]	0.3925	0.2703	

AMNOG Table SE21.8.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	8 (100)	13 (100)	21 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	5 (23.8)
No	8 (100)	13 (100)	16 (76.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.67	9.00	
95% CI of the inverse odds ratio	(0.28, 115.08)	(0.46, 177.74)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.50	7.00	
95% CI of the inverse risk ratio	(0.28, 73.21)	(0.42, 117.02)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-19.44	-21.43	
95% CI of the absolute risk difference	(-42.93, 4.04)	(-41.97, -0.89)	
p-value	0.2136	0.0926	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.0023	

AMNOG Table SE21.8.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline HbA1C
(Label Population based on Modified Intent-to-Treat Population)

Baseline HbA1C: <= 7.5

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (9.5)
No	8 (100)	13 (100)	19 (90.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.18	3.46	
95% CI of the inverse odds ratio	(0.09, 50.43)	(0.15, 77.97)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.05	3.18	
95% CI of the inverse risk ratio	(0.11, 38.52)	(0.16, 61.49)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.81	-7.79	
95% CI of the absolute risk difference	(-25.80, 14.19)	(-24.24, 8.65)	
p-value	0.6196	0.4096	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (12.5)	0	3 (14.3)
No	7 (87.5)	13 (100)	18 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	5.11	
95% CI of the inverse odds ratio	(0.10, 13.20)	(0.24, 107.33)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	4.45	
95% CI of the inverse risk ratio	(0.14, 9.44)	(0.25, 79.87)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.79	-12.34	
95% CI of the absolute risk difference	(-29.16, 25.59)	(-30.45, 5.78)	
p-value	0.9008	0.2508	
p-value of Breslow-Day Test for Homogeneity [3]	0.5802	NE	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.9.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=8)	(N=10)	(N=20)	(N=8)	(N=10)	(N=20)
Physical Functioning						
Baseline						
m	8	10	20			
n	8	9	18			
Mean (SD)	75.63 (24.27)	80.00 (22.78)	82.22 (17.84)			
Median	82.50	90.00	85.00			
IQR: Q1, Q3	72.50, 87.50	65.00, 100.00	75.00, 95.00			
Min, Max	20.0, 100.0	40.0, 100.0	35.0, 100.0			
Week 24						
m	8	7	20			
n	7	6	18	7	6	17
Mean (SD/SE)	83.57 (20.35)	85.83 (20.84)	76.11 (24.59)	9.29 (6.31)	1.67 (2.47)	-6.76 (6.83)
Median	85.00	92.50	77.50	10.00	2.50	0
IQR: Q1, Q3	70.00, 100.00	85.00, 100.00	70.00, 100.00	-5.00, 25.00	-5.00, 5.00	-15.00, 5.00
Min, Max	45.0, 100.0	45.0, 100.0	20.0, 100.0	-15.0, 30.0	-5.0, 10.0	-75.0, 35.0
Week 52						
m	8	7	19			
n	7	5	17	7	5	16
Mean (SD/SE)	79.29 (15.92)	78.00 (23.61)	84.22 (21.65)	-4.29 (5.50)	-5.00 (2.24)	-0.21 (5.03)
Median	80.00	80.00	95.00	-5.00	-5.00	0
IQR: Q1, Q3	70.00, 90.00	75.00, 95.00	70.00, 100.00	-5.00, 0.00	-10.00, 0.00	-5.00, 10.00
Min, Max	50.0, 100.0	40.0, 100.0	20.0, 100.0	-30.0, 20.0	-10.0, 0.0	-60.0, 30.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.9.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=8)	(N=10)	(N=20)	(N=8)	(N=10)	(N=20)
Role Physical						
Baseline						
m	8	10	20			
n	8	9	18			
Mean (SD)	85.16 (13.33)	88.91 (14.58)	86.46 (16.64)			
Median	81.25	93.80	93.75			
IQR: Q1, Q3	75.00, 100.00	81.30, 100.00	75.00, 100.00			
Min, Max	68.8, 100.0	62.5, 100.0	50.0, 100.0			
Week 24						
m	8	7	20			
n	7	6	18	7	6	17
Mean (SD/SE)	86.61 (17.82)	91.68 (14.62)	77.78 (27.56)	3.57 (5.07)	0.00 (1.60)	-6.98 (6.45)
Median	100.00	96.90	90.65	0	0	0
IQR: Q1, Q3	75.00, 100.00	93.80, 100.00	62.50, 100.00	0.00, 12.50	0.00, 0.00	0.00, 6.30
Min, Max	56.3, 100.0	62.5, 100.0	12.5, 100.0	-18.7, 25.0	-6.2, 6.2	-75.0, 25.0
Week 52						
m	8	7	19			
n	7	5	17	7	5	16
Mean (SD/SE)	83.93 (17.25)	86.26 (27.39)	82.72 (22.91)	-2.69 (6.08)	-5.00 (5.37)	-3.91 (4.90)
Median	87.50	100.00	100.00	0	0	0
IQR: Q1, Q3	62.50, 100.00	93.80, 100.00	75.00, 100.00	-12.50, 6.20	-6.20, 0.00	-15.60, 6.25
Min, Max	62.5, 100.0	37.5, 100.0	25.0, 100.0	-25.0, 25.0	-25.0, 6.2	-43.8, 25.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.9.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=8)	(N=10)	(N=20)	(N=8)	(N=10)	(N=20)
Bodily Pain						
Baseline						
m	8	10	20			
n	8	9	18			
Mean (SD)	75.5 (25.4)	76.6 (18.6)	79.3 (18.1)			
Median	79.0	84.0	84.0			
IQR: Q1, Q3	57.0, 100.0	62.0, 84.0	62.0, 100.0			
Min, Max	32, 100	51, 100	41, 100			
Week 24						
m	8	7	20			
n	7	6	18	7	6	17
Mean (SD/SE)	85.3 (20.8)	80.7 (12.6)	76.2 (22.1)	13.3 (3.9)	-0.3 (4.2)	-2.7 (4.6)
Median	100.0	82.0	74.0	16.0	0	0
IQR: Q1, Q3	62.0, 100.0	74.0, 84.0	62.0, 100.0	0.0, 22.0	-10.0, 0.0	0.0, 10.0
Min, Max	51, 100	62, 100	31, 100	0, 26	-10, 18	-53, 16
Week 52						
m	8	7	19			
n	7	5	17	7	5	16
Mean (SD/SE)	68.0 (25.0)	74.4 (15.5)	79.5 (18.3)	-9.4 (4.1)	-6.0 (4.5)	-0.2 (3.7)
Median	62.0	74.0	74.0	-12.0	0	0
IQR: Q1, Q3	62.0, 84.0	62.0, 74.0	72.0, 100.0	-16.0, 0.0	-10.0, 0.0	-10.0, 13.5
Min, Max	22, 100	62, 100	52, 100	-22, 10	-22, 2	-28, 23

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.9.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=8)	(N=10)	(N=20)	(N=8)	(N=10)	(N=20)
General Health						
Baseline						
m	8	10	20			
n	8	9	18			
Mean (SD)	69.25 (20.26)	67.89 (11.22)	72.11 (16.35)			
Median	77.00	67.00	72.00			
IQR: Q1, Q3	62.00, 82.00	62.00, 77.00	62.00, 82.00			
Min, Max	25.0, 87.0	50.0, 82.0	30.0, 97.0			
Week 24						
m	8	7	20			
n	7	6	18	7	6	17
Mean (SD/SE)	74.57 (24.28)	66.17 (14.29)	69.06 (18.57)	5.00 (3.27)	-2.17 (6.27)	-3.94 (3.44)
Median	82.00	64.50	74.50	10.00	1.00	0
IQR: Q1, Q3	67.00, 92.00	57.00, 77.00	62.00, 82.00	0.00, 10.00	-15.00, 10.00	-15.00, 10.00
Min, Max	25.0, 97.0	47.0, 87.0	30.0, 92.0	-10.0, 15.0	-25.0, 15.0	-30.0, 15.0
Week 52						
m	8	7	19			
n	7	5	17	7	5	16
Mean (SD/SE)	78.14 (13.38)	64.00 (17.54)	69.15 (19.17)	2.57 (2.71)	-2.60 (1.66)	-4.66 (4.24)
Median	77.00	57.00	72.00	5.00	0	-2.50
IQR: Q1, Q3	72.00, 92.00	57.00, 82.00	57.00, 82.00	-2.00, 10.00	-5.00, 0.00	-10.00, 7.75
Min, Max	55.0, 92.0	42.0, 82.0	15.0, 92.0	-10.0, 10.0	-8.0, 0.0	-57.0, 15.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.9.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=8)	Visit Result DB MGL-3196 100 mg (N=10)	Visit Result DB Placebo (N=20)	Change from Baseline DB MGL-3196 80 mg (N=8)	Change from Baseline DB MGL-3196 100 mg (N=10)	Change from Baseline DB Placebo (N=20)
Vitality						
Baseline						
m	8	10	20			
n	8	9	18			
Mean (SD)	57.06 (25.77)	68.09 (11.46)	69.82 (17.70)			
Median	65.65	68.80	68.80			
IQR: Q1, Q3	50.05, 71.90	62.50, 75.00	56.30, 87.50			
Min, Max	0.0, 81.3	43.8, 81.3	43.8, 100.0			
Week 24						
m	8	7	20			
n	7	6	18	7	6	17
Mean (SD/SE)	54.49 (31.00)	65.67 (13.54)	64.61 (21.96)	-2.69 (4.06)	-1.03 (4.95)	-5.15 (3.98)
Median	62.50	68.80	68.75	0	3.10	-6.20
IQR: Q1, Q3	25.00, 81.30	56.30, 75.00	50.00, 81.30	-12.50, 6.20	-12.50, 6.30	-6.30, 6.20
Min, Max	0.0, 81.3	43.8, 81.3	6.3, 93.8	-18.8, 12.5	-18.7, 12.5	-50.0, 12.5
Week 52						
m	8	7	19			
n	7	5	17	7	5	16
Mean (SD/SE)	57.17 (21.47)	58.78 (12.95)	70.97 (21.30)	-8.04 (4.03)	-5.00 (3.64)	-1.58 (4.62)
Median	68.80	56.30	75.00	-6.20	-6.20	-3.10
IQR: Q1, Q3	37.50, 75.00	50.00, 68.80	62.50, 87.50	-18.80, 0.00	-12.50, 0.00	-15.60, 12.50
Min, Max	18.8, 75.0	43.8, 75.0	25.0, 100.0	-25.0, 6.2	-12.5, 6.2	-37.5, 31.2

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.9.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=8)	(N=10)	(N=20)	(N=8)	(N=10)	(N=20)
Social Functioning						
Baseline						
m	8	10	20			
n	8	9	18			
Mean (SD)	92.19 (14.85)	91.67 (8.84)	95.14 (8.72)			
Median	100.00	87.50	100.00			
IQR: Q1, Q3	87.50, 100.00	87.50, 100.00	87.50, 100.00			
Min, Max	62.5, 100.0	75.0, 100.0	75.0, 100.0			
Week 24						
m	8	7	20			
n	7	6	18	7	6	17
Mean (SD/SE)	83.93 (21.30)	95.83 (6.45)	86.11 (26.39)	-7.14 (3.72)	2.08 (3.84)	-8.82 (6.14)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	62.50, 100.00	87.50, 100.00	75.00, 100.00	-12.50, 0.00	0.00, 12.50	0.00, 0.00
Min, Max	50.0, 100.0	87.5, 100.0	0.0, 100.0	-25.0, 0.0	-12.5, 12.5	-100.0, 0.0
Week 52						
m	8	7	19			
n	7	5	17	7	5	16
Mean (SD/SE)	89.29 (18.30)	92.50 (11.18)	96.32 (10.61)	-7.14 (5.36)	-2.50 (7.29)	0.78 (3.51)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	62.50, 100.00	87.50, 100.00	100.00, 100.00	-12.50, 0.00	-12.50, 12.50	0.00, 0.00
Min, Max	62.5, 100.0	75.0, 100.0	62.5, 100.0	-37.5, 0.0	-25.0, 12.5	-37.5, 25.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.9.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=8)	(N=10)	(N=20)	(N=8)	(N=10)	(N=20)
Role Emotional						
Baseline						
m	8	10	20			
n	8	9	18			
Mean (SD)	96.89 (4.30)	95.37 (9.43)	93.98 (10.62)			
Median	100.00	100.00	100.00			
IQR: Q1, Q3	91.70, 100.00	100.00, 100.00	83.30, 100.00			
Min, Max	91.7, 100.0	75.0, 100.0	66.7, 100.0			
Week 24						
m	8	7	20			
n	7	6	18	7	6	17
Mean (SD/SE)	89.29 (14.20)	95.83 (10.21)	87.96 (18.57)	-7.16 (5.27)	-1.38 (5.45)	-5.39 (3.35)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	100.00, 100.00	83.30, 100.00	-16.70, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	66.7, 100.0	75.0, 100.0	41.7, 100.0	-33.3, 8.3	-25.0, 16.7	-50.0, 8.3
Week 52						
m	8	7	19			
n	7	5	17	7	5	16
Mean (SD/SE)	90.47 (13.11)	96.66 (7.47)	89.21 (21.61)	-5.97 (4.35)	0.00 (0.00)	-5.73 (4.01)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	83.30, 100.00	100.00, 100.00	91.70, 100.00	-16.70, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	66.7, 100.0	83.3, 100.0	25.0, 100.0	-25.0, 8.3	0.0, 0.0	-41.7, 16.7

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.9.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=8)	Visit Result DB MGL-3196 100 mg (N=10)	Visit Result DB Placebo (N=20)	Change from Baseline DB MGL-3196 80 mg (N=8)	Change from Baseline DB MGL-3196 100 mg (N=10)	Change from Baseline DB Placebo (N=20)
Mental Health						
Baseline						
m	8	10	20			
n	8	9	18			
Mean (SD)	83.8 (10.3)	84.4 (9.2)	85.8 (13.5)			
Median	85.0	85.0	90.0			
IQR: Q1, Q3	75.0, 90.0	80.0, 85.0	80.0, 95.0			
Min, Max	70, 100	70, 100	60, 100			
Week 24						
m	8	7	20			
n	7	6	18	7	6	17
Mean (SD/SE)	86.4 (11.8)	88.3 (8.8)	83.9 (16.7)	2.1 (2.9)	3.3 (4.8)	-2.4 (1.6)
Median	90.0	87.5	90.0	0	0	0
IQR: Q1, Q3	70.0, 95.0	85.0, 95.0	85.0, 95.0	-5.0, 10.0	0.0, 5.0	-5.0, 0.0
Min, Max	70, 100	75, 100	50, 100	-5, 15	-10, 25	-20, 5
Week 52						
m	8	7	19			
n	7	5	17	7	5	16
Mean (SD/SE)	85.7 (9.3)	82.0 (8.4)	85.3 (19.4)	0.0 (2.2)	-3.0 (4.9)	-1.3 (3.4)
Median	90.0	80.0	90.0	0	-5.0	0
IQR: Q1, Q3	80.0, 95.0	80.0, 90.0	80.0, 100.0	-5.0, 5.0	-5.0, -5.0	-5.0, 5.0
Min, Max	70, 95	70, 90	30, 100	-10, 5	-15, 15	-40, 20

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.9.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=8)	(N=10)	(N=20)	(N=8)	(N=10)	(N=20)
Mental Component Score						
Baseline						
m	8	10	20			
n	8	9	18			
Mean (SD)	55.84 (4.03)	56.34 (2.97)	56.78 (5.95)			
Median	55.40	56.90	58.30			
IQR: Q1, Q3	53.20, 59.45	55.20, 57.80	53.70, 61.80			
Min, Max	49.5, 61.1	51.1, 60.9	44.5, 63.2			
Week 24						
m	8	7	20			
n	7	6	18	7	6	17
Mean (SD/SE)	52.79 (8.98)	56.80 (4.65)	54.70 (7.96)	-3.34 (2.01)	0.58 (2.07)	-2.06 (0.75)
Median	55.50	58.40	57.80	-1.20	0.05	-1.80
IQR: Q1, Q3	41.10, 60.20	55.10, 59.60	51.40, 60.40	-9.60, 1.00	-1.30, 3.20	-4.00, 0.00
Min, Max	39.9, 60.7	48.3, 61.0	38.7, 62.8	-12.2, 1.0	-6.9, 8.4	-8.1, 3.6
Week 52						
m	8	7	19			
n	7	5	17	7	5	16
Mean (SD/SE)	54.86 (6.13)	55.42 (2.77)	56.04 (9.34)	-1.89 (1.20)	-0.66 (1.66)	-1.21 (1.46)
Median	56.90	55.00	60.30	-1.60	-2.00	0.25
IQR: Q1, Q3	47.70, 60.60	53.20, 57.00	53.50, 61.20	-5.90, 1.40	-2.80, -1.60	-2.90, 2.80
Min, Max	47.4, 61.3	52.6, 59.3	35.3, 65.5	-6.1, 1.6	-2.8, 5.9	-16.0, 5.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.9.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=8)	(N=10)	(N=20)	(N=8)	(N=10)	(N=20)
Physical Component Score						
Baseline						
m	8	10	20			
n	8	9	18			
Mean (SD)	48.86 (8.38)	50.21 (7.08)	51.07 (7.02)			
Median	49.35	53.00	51.85			
IQR: Q1, Q3	45.10, 55.90	44.40, 54.20	46.60, 56.90			
Min, Max	32.2, 58.0	37.8, 60.3	34.5, 59.8			
Week 24						
m	8	7	20			
n	7	6	18	7	6	17
Mean (SD/SE)	52.49 (7.19)	51.30 (6.10)	48.88 (9.53)	4.54 (1.68)	-0.32 (1.46)	-2.14 (2.36)
Median	54.80	52.45	52.90	1.40	-0.70	0
IQR: Q1, Q3	47.50, 58.70	48.50, 55.50	41.40, 55.80	1.00, 9.60	-3.30, 3.10	-3.80, 2.50
Min, Max	39.4, 59.0	40.9, 58.0	25.9, 59.3	0.9, 10.7	-4.5, 4.2	-30.0, 11.8
Week 52						
m	8	7	19			
n	7	5	17	7	5	16
Mean (SD/SE)	49.70 (7.71)	48.88 (8.53)	51.06 (7.78)	-1.54 (1.53)	-2.22 (0.55)	-0.52 (1.65)
Median	52.70	49.10	53.70	-1.00	-2.30	-0.15
IQR: Q1, Q3	44.50, 56.80	49.00, 52.40	49.90, 57.20	-5.10, 1.40	-2.50, -1.70	-3.25, 2.45
Min, Max	35.7, 57.0	35.3, 58.6	34.3, 58.9	-8.4, 3.6	-4.0, -0.6	-15.9, 10.1

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.9.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=1)	Visit Result DB MGL-3196 100 mg (N=5)	Visit Result DB Placebo (N=8)	Change from Baseline DB MGL-3196 80 mg (N=1)	Change from Baseline DB MGL-3196 100 mg (N=5)	Change from Baseline DB Placebo (N=8)
Physical Functioning						
Baseline						
m	1	5	8			
n	1	5	8			
Mean (SD)	60.00 (N/A)	78.00 (11.51)	76.25 (28.75)			
Median	60.00	80.00	92.50			
IQR: Q1, Q3	60.00, 60.00	70.00, 80.00	55.00, 95.00			
Min, Max	60.0, 60.0	65.0, 95.0	25.0, 100.0			
Week 24						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	81.00 (9.62)	77.14 (26.44)	N/A	3.00 (4.36)	0.00 (2.67)
Median	N/A	80.00	90.00	N/A	0	0
IQR: Q1, Q3	N/A	75.00, 85.00	50.00, 95.00	N/A	0.00, 0.00	-5.00, 5.00
Min, Max	N/A	70.0, 95.0	30.0, 100.0	N/A	-5.0, 20.0	-10.0, 10.0
Week 52						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	71.00 (20.43)	75.71 (24.57)	N/A	-7.00 (7.68)	-1.43 (4.59)
Median	N/A	75.00	80.00	N/A	0	5.00
IQR: Q1, Q3	N/A	50.00, 85.00	50.00, 100.00	N/A	-20.00, 5.00	-15.00, 10.00
Min, Max	N/A	50.0, 95.0	35.0, 100.0	N/A	-30.0, 10.0	-20.0, 10.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.9.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=5)	(N=8)	(N=1)	(N=5)	(N=8)
Role Physical						
Baseline						
m	1	5	8			
n	1	5	8			
Mean (SD)	50.00 (N/A)	90.00 (13.69)	64.09 (33.38)			
Median	50.00	100.00	78.15			
IQR: Q1, Q3	50.00, 50.00	75.00, 100.00	46.90, 84.40			
Min, Max	50.0, 50.0	75.0, 100.0	0.0, 93.8			
Week 24						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	81.28 (19.24)	71.44 (39.16)	N/A	-8.72 (8.97)	11.60 (4.39)
Median	N/A	81.30	87.50	N/A	0	6.30
IQR: Q1, Q3	N/A	68.80, 100.00	25.00, 100.00	N/A	-6.20, 0.00	0.00, 18.70
Min, Max	N/A	56.3, 100.0	6.3, 100.0	N/A	-43.7, 6.3	0.0, 31.2
Week 52						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	66.26 (27.82)	64.31 (28.78)	N/A	-23.74 (11.93)	4.47 (9.12)
Median	N/A	75.00	56.30	N/A	-18.70	6.30
IQR: Q1, Q3	N/A	37.50, 81.30	31.30, 100.00	N/A	-37.50, 0.00	-25.00, 25.00
Min, Max	N/A	37.5, 100.0	31.3, 100.0	N/A	-62.5, 0.0	-31.2, 31.3

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.9.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=5)	(N=8)	(N=1)	(N=5)	(N=8)
Bodily Pain						
Baseline						
m	1	5	8			
n	1	5	8			
Mean (SD)	62.0 (N/A)	81.6 (19.0)	71.5 (27.1)			
Median	62.0	84.0	84.0			
IQR: Q1, Q3	62.0, 62.0	62.0, 100.0	62.0, 84.0			
Min, Max	62, 62	62, 100	12, 100			
Week 24						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	75.6 (22.7)	69.0 (32.8)	N/A	-6.0 (8.6)	-0.7 (4.1)
Median	N/A	64.0	84.0	N/A	0	0
IQR: Q1, Q3	N/A	62.0, 100.0	41.0, 100.0	N/A	-10.0, 0.0	0.0, 0.0
Min, Max	N/A	52, 100	12, 100	N/A	-36, 16	-21, 16
Week 52						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	76.8 (17.5)	63.0 (21.2)	N/A	-4.8 (6.3)	-6.7 (5.8)
Median	N/A	74.0	74.0	N/A	0	-10.0
IQR: Q1, Q3	N/A	74.0, 84.0	41.0, 84.0	N/A	-10.0, 0.0	-21.0, 0.0
Min, Max	N/A	52, 100	32, 84	N/A	-26, 12	-26, 20

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.9.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=5)	(N=8)	(N=1)	(N=5)	(N=8)
General Health						
Baseline						
m	1	5	8			
n	1	5	8			
Mean (SD)	57.00 (N/A)	67.00 (12.75)	64.63 (24.95)			
Median	57.00	67.00	74.50			
IQR: Q1, Q3	57.00, 57.00	67.00, 72.00	48.50, 79.50			
Min, Max	57.0, 57.0	47.0, 82.0	25.0, 87.0			
Week 24						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	64.60 (17.36)	62.43 (21.36)	N/A	-2.40 (6.62)	-0.43 (6.76)
Median	N/A	62.00	67.00	N/A	5.00	0
IQR: Q1, Q3	N/A	52.00, 77.00	42.00, 82.00	N/A	-5.00, 5.00	-5.00, 12.00
Min, Max	N/A	45.0, 87.0	37.0, 92.0	N/A	-27.0, 10.0	-35.0, 20.0
Week 52						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	62.60 (14.47)	62.14 (21.61)	N/A	-4.40 (6.35)	-0.71 (7.67)
Median	N/A	62.00	52.00	N/A	-5.00	0
IQR: Q1, Q3	N/A	52.00, 77.00	47.00, 87.00	N/A	-5.00, 5.00	-20.00, 15.00
Min, Max	N/A	45.0, 77.0	40.0, 97.0	N/A	-27.0, 10.0	-30.0, 25.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.9.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=5)	(N=8)	(N=1)	(N=5)	(N=8)
Vitality						
Baseline						
m	1	5	8			
n	1	5	8			
Mean (SD)	56.30 (N/A)	67.52 (17.35)	57.81 (18.82)			
Median	56.30	62.50	62.50			
IQR: Q1, Q3	56.30, 56.30	56.30, 75.00	43.75, 75.00			
Min, Max	56.3, 56.3	50.0, 93.8	25.0, 75.0			
Week 24						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	67.52 (17.35)	58.94 (18.34)	N/A	0.00 (9.90)	3.59 (6.38)
Median	N/A	62.50	62.50	N/A	0	0
IQR: Q1, Q3	N/A	56.30, 75.00	37.50, 75.00	N/A	0.00, 0.00	-12.50, 12.50
Min, Max	N/A	50.0, 93.8	31.3, 75.0	N/A	-31.3, 31.3	-18.7, 31.3
Week 52						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	61.28 (19.46)	54.47 (20.64)	N/A	-6.24 (3.94)	-0.89 (5.53)
Median	N/A	62.50	62.50	N/A	0	0
IQR: Q1, Q3	N/A	56.30, 75.00	37.50, 75.00	N/A	-12.50, 0.00	-12.50, 12.50
Min, Max	N/A	31.3, 81.3	25.0, 75.0	N/A	-18.7, 0.0	-25.0, 12.5

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.9.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=5)	(N=8)	(N=1)	(N=5)	(N=8)
Social Functioning						
Baseline						
m	1	5	8			
n	1	5	8			
Mean (SD)	75.00 (N/A)	82.50 (25.92)	84.38 (27.35)			
Median	75.00	87.50	100.00			
IQR: Q1, Q3	75.00, 75.00	87.50, 100.00	75.00, 100.00			
Min, Max	75.0, 75.0	37.5, 100.0	25.0, 100.0			
Week 24						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	85.00 (13.69)	89.29 (15.19)	N/A	2.50 (15.51)	5.36 (7.65)
Median	N/A	75.00	100.00	N/A	-12.50	0
IQR: Q1, Q3	N/A	75.00, 100.00	75.00, 100.00	N/A	-12.50, 0.00	0.00, 0.00
Min, Max	N/A	75.0, 100.0	62.5, 100.0	N/A	-25.0, 62.5	-12.5, 50.0
Week 52						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	92.50 (11.18)	87.50 (17.68)	N/A	10.00 (15.00)	3.57 (5.92)
Median	N/A	100.00	100.00	N/A	12.50	0
IQR: Q1, Q3	N/A	87.50, 100.00	62.50, 100.00	N/A	-12.50, 12.50	0.00, 0.00
Min, Max	N/A	75.0, 100.0	62.5, 100.0	N/A	-25.0, 62.5	-12.5, 37.5

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.9.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=5)	(N=8)	(N=1)	(N=5)	(N=8)
Role Emotional						
Baseline						
m	1	5	8			
n	1	5	8			
Mean (SD)	50.00 (N/A)	98.34 (3.71)	81.26 (24.69)			
Median	50.00	100.00	95.85			
IQR: Q1, Q3	50.00, 50.00	100.00, 100.00	58.35, 100.00			
Min, Max	50.0, 50.0	91.7, 100.0	41.7, 100.0			
Week 24						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	86.66 (21.73)	78.57 (23.49)	N/A	-11.68 (10.41)	-0.01 (1.82)
Median	N/A	100.00	83.30	N/A	0	0
IQR: Q1, Q3	N/A	83.30, 100.00	58.30, 100.00	N/A	-16.70, 0.00	0.00, 0.00
Min, Max	N/A	50.0, 100.0	41.7, 100.0	N/A	-50.0, 8.3	-8.4, 8.3
Week 52						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	85.00 (22.36)	78.57 (18.56)	N/A	-13.34 (10.73)	-0.01 (7.50)
Median	N/A	100.00	75.00	N/A	0	0
IQR: Q1, Q3	N/A	75.00, 100.00	58.30, 100.00	N/A	-25.00, 0.00	-8.30, 8.30
Min, Max	N/A	50.0, 100.0	58.3, 100.0	N/A	-50.0, 8.3	-33.4, 33.3

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.9.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=1)	(N=5)	(N=8)	(N=1)	(N=5)	(N=8)
Mental Health						
Baseline						
m	1	5	8			
n	1	5	8			
Mean (SD)	60.0 (N/A)	88.0 (2.7)	76.9 (16.2)			
Median	60.0	90.0	80.0			
IQR: Q1, Q3	60.0, 60.0	85.0, 90.0	65.0, 90.0			
Min, Max	60, 60	85, 90	50, 95			
Week 24						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	81.0 (15.6)	77.9 (19.1)	N/A	-7.0 (7.5)	2.1 (3.4)
Median	N/A	85.0	75.0	N/A	-5.0	5.0
IQR: Q1, Q3	N/A	80.0, 90.0	65.0, 95.0	N/A	-5.0, 0.0	-5.0, 10.0
Min, Max	N/A	55, 95	45, 100	N/A	-35, 10	-10, 15
Week 52						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	80.0 (12.7)	77.9 (17.8)	N/A	-8.0 (4.9)	2.1 (4.6)
Median	N/A	80.0	85.0	N/A	-5.0	0
IQR: Q1, Q3	N/A	80.0, 85.0	60.0, 95.0	N/A	-10.0, -5.0	-5.0, 5.0
Min, Max	N/A	60, 95	55, 100	N/A	-25, 5	-15, 25

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.9.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=1)	Visit Result DB MGL-3196 100 mg (N=5)	Visit Result DB Placebo (N=8)	Change from Baseline DB MGL-3196 80 mg (N=1)	Change from Baseline DB MGL-3196 100 mg (N=5)	Change from Baseline DB Placebo (N=8)
Mental Component Score						
Baseline						
m	1	5	8			
n	1	5	8			
Mean (SD)	42.90 (N/A)	56.66 (3.11)	51.58 (8.27)			
Median	42.90	57.10	54.55			
IQR: Q1, Q3	42.90, 42.90	55.40, 57.50	44.30, 58.60			
Min, Max	42.9, 42.9	52.4, 60.9	38.1, 59.6			
Week 24						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	53.44 (7.72)	51.71 (8.10)	N/A	-3.22 (4.65)	1.06 (1.96)
Median	N/A	56.20	54.90	N/A	-1.30	-0.50
IQR: Q1, Q3	N/A	52.10, 57.30	46.50, 58.40	N/A	-5.00, 4.90	-1.00, 4.00
Min, Max	N/A	40.8, 60.8	37.1, 59.1	N/A	-20.1, 5.4	-5.9, 10.8
Week 52						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	54.46 (6.36)	51.67 (8.06)	N/A	-2.20 (3.11)	1.01 (2.65)
Median	N/A	56.80	53.20	N/A	1.70	2.00
IQR: Q1, Q3	N/A	53.10, 58.80	45.30, 59.10	N/A	-7.80, 2.10	-0.40, 7.20
Min, Max	N/A	44.0, 59.6	39.6, 61.6	N/A	-11.4, 4.4	-12.8, 8.7

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.9.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

	Visit Result			Change from Baseline		
Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Physical Component Score						
Baseline						
m	1	5	8			
n	1	5	8			
Mean (SD)	45.20 (N/A)	49.92 (6.64)	47.30 (11.73)			
Median	45.20	53.60	50.35			
IQR: Q1, Q3	45.20, 45.20	43.70, 54.40	44.30, 53.20			
Min, Max	45.2, 45.2	41.8, 56.1	21.6, 61.1			
Week 24						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	49.98 (5.88)	47.91 (12.46)	N/A	0.06 (1.86)	1.13 (1.14)
Median	N/A	48.60	50.80	N/A	0.50	1.00
IQR: Q1, Q3	N/A	48.00, 53.00	38.20, 56.00	N/A	-0.60, 1.90	-0.10, 3.20
Min, Max	N/A	42.3, 58.0	24.6, 61.0	N/A	-6.4, 4.9	-4.6, 4.6
Week 52						
m	0	5	7			
n	0	5	7	0	5	7
Mean (SD/SE)	N/A	46.54 (10.32)	45.91 (9.27)	N/A	-3.38 (3.51)	-0.87 (3.01)
Median	N/A	46.60	52.20	N/A	1.40	1.10
IQR: Q1, Q3	N/A	39.60, 55.00	35.70, 52.70	N/A	-8.40, 2.00	-8.40, 6.40
Min, Max	N/A	33.4, 58.1	31.5, 53.9	N/A	-14.8, 2.9	-10.8, 9.9

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.9.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

Madrigal Pharmaceuticals, Inc. Page 2 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023
AMNOG Table SE21.9.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Physical Functioning			
Week 24			
m	8	7	20
n	7	6	17
Baseline Mean (SD)	74.29 (25.89)	84.17 (22.45)	83.24 (17.85)
Analysis Visit Mean (SD)	83.57 (20.35)	85.83 (20.84)	76.47 (25.30)
LS Mean of Change from Baseline (SE)	5.12 (10.58)	2.04 (12.65)	-6.71 (10.69)
95% CI	(-16.59, 26.83)	(-23.91, 27.99)	(-28.64, 15.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	11.83 (10.11)	8.75 (10.98)	
95% CI	(-8.92, 32.58)	(-13.78, 31.28)	
p-value	0.2523	0.4326	
Corrected Hedge's g Statistics	0.283	0.204	
95% CI	(-0.60, 1.17)	(-0.73, 1.14)	
Week 52			
m	8	7	19
n	7	5	16
Baseline Mean (SD)	83.57 (9.88)	83.00 (24.90)	83.75 (18.30)
Analysis Visit Mean (SD)	79.29 (15.92)	78.00 (23.61)	83.54 (22.18)
LS Mean of Change from Baseline (SE)	-4.88 (9.38)	-5.65 (11.74)	-0.15 (10.29)
95% CI	(-24.13, 14.36)	(-29.73, 18.43)	(-21.27, 20.97)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.73 (8.15)	-5.50 (9.49)	
95% CI	(-21.45, 11.98)	(-24.97, 13.96)	
p-value	0.5660	0.5668	
Corrected Hedge's g Statistics	-0.123	-0.137	
95% CI	(-1.01, 0.77)	(-1.14, 0.87)	
Subgroup*Treatment Interaction p-value	NE	0.8977	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 3 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023
AMNOG Table SE21.9.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Role Physical			
Week 24			
m	8	7	20
n	7	6	17
Baseline Mean (SD)	83.04 (12.86)	91.68 (14.62)	86.40 (17.15)
Analysis Visit Mean (SD)	86.61 (17.82)	91.68 (14.62)	79.42 (27.49)
LS Mean of Change from Baseline (SE)	3.54 (10.55)	4.03 (12.85)	-4.91 (10.73)
95% CI	(-18.10, 25.18)	(-22.34, 30.39)	(-26.93, 17.10)
LS Mean of Change from Baseline Compared to Placebo (SE)	8.45 (10.16)	8.94 (11.09)	
95% CI	(-12.39, 29.30)	(-13.82, 31.70)	
p-value	0.4127	0.4274	
Corrected Hedge's g Statistics	0.202	0.207	
95% CI	(-0.68, 1.08)	(-0.73, 1.14)	
Week 52			
m	8	7	19
n	7	5	16
Baseline Mean (SD)	86.61 (13.70)	91.26 (16.30)	86.33 (17.71)
Analysis Visit Mean (SD)	83.93 (17.25)	86.26 (27.39)	82.43 (23.63)
LS Mean of Change from Baseline (SE)	-2.13 (9.77)	-1.99 (12.32)	-2.06 (10.48)
95% CI	(-22.17, 17.92)	(-27.27, 23.29)	(-23.56, 19.44)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.07 (8.74)	0.07 (10.22)	
95% CI	(-17.99, 17.86)	(-20.90, 21.04)	
p-value	0.9939	0.9946	
Corrected Hedge's g Statistics	-0.002	0.002	
95% CI	(-0.89, 0.89)	(-1.00, 1.01)	
Subgroup*Treatment Interaction p-value	NE	0.2837	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 4 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023
AMNOG Table SE21.9.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Bodily Pain			
Week 24			
m	8	7	20
n	7	6	17
Baseline Mean (SD)	72.0 (25.2)	81.0 (12.9)	79.7 (18.5)
Analysis Visit Mean (SD)	85.3 (20.8)	80.7 (12.6)	77.0 (22.4)
LS Mean of Change from Baseline (SE)	14.33 (7.13)	4.57 (8.52)	1.82 (6.92)
95% CI	(-0.30, 28.97)	(-12.90, 22.04)	(-12.39, 16.03)
LS Mean of Change from Baseline Compared to Placebo (SE)	12.52 (7.42)	2.75 (7.80)	
95% CI	(-2.71, 27.74)	(-13.24, 18.74)	
p-value	0.1032	0.7270	
Corrected Hedge's g Statistics	0.460	0.098	
95% CI	(-0.43, 1.35)	(-0.83, 1.03)	
Week 52			
m	8	7	19
n	7	5	16
Baseline Mean (SD)	77.4 (26.8)	80.4 (14.3)	79.4 (19.1)
Analysis Visit Mean (SD)	68.0 (25.0)	74.4 (15.5)	79.3 (18.8)
LS Mean of Change from Baseline (SE)	-6.73 (6.34)	-1.35 (7.92)	4.23 (6.62)
95% CI	(-19.73, 6.27)	(-17.60, 14.89)	(-9.36, 17.82)
LS Mean of Change from Baseline Compared to Placebo (SE)	-10.96 (5.96)	-5.58 (6.87)	
95% CI	(-23.18, 1.26)	(-19.67, 8.50)	
p-value	0.0768	0.4232	
Corrected Hedge's g Statistics	-0.438	-0.215	
95% CI	(-1.34, 0.46)	(-1.22, 0.79)	
Subgroup*Treatment Interaction p-value	NE	0.5527	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 5 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023
AMNOG Table SE21.9.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
General Health			
Week 24			
m	8	7	20
n	7	6	17
Baseline Mean (SD)	69.57 (21.86)	68.33 (13.81)	74.59 (12.91)
Analysis Visit Mean (SD)	74.57 (24.28)	66.17 (14.29)	70.65 (17.84)
LS Mean of Change from Baseline (SE)	6.64 (7.11)	0.89 (8.65)	-1.15 (7.79)
95% CI	(-7.94, 21.22)	(-16.87, 18.65)	(-17.13, 14.84)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.79 (6.49)	2.04 (7.07)	
95% CI	(-5.53, 21.10)	(-12.48, 16.55)	
p-value	0.2406	0.7756	
Corrected Hedge's g Statistics	0.258	0.066	
95% CI	(-0.62, 1.14)	(-0.87, 1.00)	
Week 52			
m	8	7	19
n	7	5	16
Baseline Mean (SD)	75.57 (10.29)	66.60 (14.69)	74.88 (13.28)
Analysis Visit Mean (SD)	78.14 (13.38)	64.00 (17.54)	70.22 (19.27)
LS Mean of Change from Baseline (SE)	3.64 (7.53)	-0.47 (9.24)	-2.93 (7.98)
95% CI	(-11.81, 19.09)	(-19.43, 18.50)	(-19.29, 13.44)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.57 (6.84)	2.46 (8.05)	
95% CI	(-7.46, 20.60)	(-14.05, 18.97)	
p-value	0.3451	0.7621	
Corrected Hedge's g Statistics	0.218	0.079	
95% CI	(-0.67, 1.11)	(-0.93, 1.08)	
Subgroup*Treatment Interaction p-value	NE	0.7484	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 6 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.9.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Vitality			
Week 24			
m	8	7	20
n	7	6	17
Baseline Mean (SD)	57.17 (27.83)	66.70 (14.07)	70.98 (17.52)
Analysis Visit Mean (SD)	54.49 (31.00)	65.67 (13.54)	65.83 (22.00)
LS Mean of Change from Baseline (SE)	-2.00 (7.59)	1.42 (9.20)	-1.84 (8.10)
95% CI	(-17.58, 13.59)	(-17.45, 20.29)	(-18.46, 14.79)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.16 (7.45)	3.25 (7.69)	
95% CI	(-15.45, 15.13)	(-12.52, 19.03)	
p-value	0.9831	0.6753	
Corrected Hedge's g Statistics	-0.005	0.101	
95% CI	(-0.89, 0.88)	(-0.83, 1.03)	
Week 52			
m	8	7	19
n	7	5	16
Baseline Mean (SD)	65.21 (12.42)	63.78 (13.55)	72.68 (16.59)
Analysis Visit Mean (SD)	57.17 (21.47)	58.78 (12.95)	71.11 (22.00)
LS Mean of Change from Baseline (SE)	-6.22 (7.97)	-3.41 (9.89)	1.94 (8.45)
95% CI	(-22.57, 10.12)	(-23.71, 16.89)	(-15.39, 19.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	-8.17 (7.82)	-5.35 (8.95)	
95% CI	(-24.20, 7.87)	(-23.72, 13.01)	
p-value	0.3054	0.5546	
Corrected Hedge's g Statistics	-0.256	-0.162	
95% CI	(-1.15, 0.63)	(-1.17, 0.84)	
Subgroup*Treatment Interaction p-value	NE	0.9542	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 7 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023
AMNOG Table SE21.9.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Social Functioning			
Week 24			
m	8	7	20
n	7	6	17
Baseline Mean (SD)	91.07 (15.67)	93.75 (6.85)	95.59 (8.77)
Analysis Visit Mean (SD)	83.93 (21.30)	95.83 (6.45)	86.76 (27.05)
LS Mean of Change from Baseline (SE)	-3.57 (9.43)	8.05 (10.89)	-5.20 (8.64)
95% CI	(-22.93, 15.78)	(-14.30, 30.39)	(-22.94, 12.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.63 (9.84)	13.25 (10.43)	
95% CI	(-18.56, 21.82)	(-8.14, 34.64)	
p-value	0.8697	0.2147	
Corrected Hedge's g Statistics	0.048	0.379	
95% CI	(-0.83, 0.93)	(-0.56, 1.32)	
Week 52			
m	8	7	19
n	7	5	16
Baseline Mean (SD)	96.43 (9.45)	95.00 (6.85)	95.31 (8.98)
Analysis Visit Mean (SD)	89.29 (18.30)	92.50 (11.18)	96.09 (10.92)
LS Mean of Change from Baseline (SE)	-3.64 (7.14)	3.39 (8.89)	4.71 (7.74)
95% CI	(-18.28, 11.00)	(-14.85, 21.62)	(-11.18, 20.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	-8.35 (6.27)	-1.33 (7.32)	
95% CI	(-21.21, 4.51)	(-16.35, 13.69)	
p-value	0.1938	0.8576	
Corrected Hedge's g Statistics	-0.287	-0.044	
95% CI	(-1.18, 0.61)	(-1.05, 0.96)	
Subgroup*Treatment Interaction p-value	NE	0.6397	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 8 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023
AMNOG Table SE21.9.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Role Emotional			
Week 24			
m	8	7	20
n	7	6	17
Baseline Mean (SD)	96.44 (4.44)	97.22 (6.82)	94.61 (10.60)
Analysis Visit Mean (SD)	89.29 (14.20)	95.83 (10.21)	89.21 (18.34)
LS Mean of Change from Baseline (SE)	-4.88 (7.35)	2.86 (8.88)	-1.32 (7.75)
95% CI	(-19.96, 10.19)	(-15.36, 21.08)	(-17.23, 14.59)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.57 (6.65)	4.18 (7.35)	
95% CI	(-17.20, 10.07)	(-10.91, 19.27)	
p-value	0.5958	0.5745	
Corrected Hedge's g Statistics	-0.118	0.135	
95% CI	(-1.00, 0.76)	(-0.80, 1.07)	
Week 52			
m	8	7	19
n	7	5	16
Baseline Mean (SD)	96.44 (4.44)	96.66 (7.47)	94.27 (10.85)
Analysis Visit Mean (SD)	90.47 (13.11)	96.66 (7.47)	88.54 (22.13)
LS Mean of Change from Baseline (SE)	-5.21 (7.27)	3.78 (8.98)	-0.96 (7.76)
95% CI	(-20.14, 9.71)	(-14.63, 22.20)	(-16.88, 14.96)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.25 (6.44)	4.74 (7.47)	
95% CI	(-17.46, 8.95)	(-10.59, 20.07)	
p-value	0.5145	0.5308	
Corrected Hedge's g Statistics	-0.145	0.157	
95% CI	(-1.03, 0.74)	(-0.85, 1.16)	
Subgroup*Treatment Interaction p-value	NE	0.2650	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 9 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.9.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Mental Health			
Week 24			
m	8	7	20
n	7	6	17
Baseline Mean (SD)	84.3 (11.0)	85.0 (6.3)	85.9 (13.9)
Analysis Visit Mean (SD)	86.4 (11.8)	88.3 (8.8)	83.5 (17.1)
LS Mean of Change from Baseline (SE)	-1.75 (4.50)	-0.65 (5.58)	-7.20 (5.14)
95% CI	(-10.99, 7.49)	(-12.09, 10.80)	(-17.75, 3.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.45 (3.89)	6.56 (4.26)	
95% CI	(-2.52, 13.42)	(-2.19, 15.30)	
p-value	0.1719	0.1355	
Corrected Hedge's g Statistics	0.275	0.321	
95% CI	(-0.61, 1.16)	(-0.61, 1.26)	
Week 52			
m	8	7	19
n	7	5	16
Baseline Mean (SD)	85.7 (9.3)	85.0 (7.1)	86.3 (14.3)
Analysis Visit Mean (SD)	85.7 (9.3)	82.0 (8.4)	85.0 (20.0)
LS Mean of Change from Baseline (SE)	-3.67 (5.61)	-6.77 (6.84)	-5.69 (5.60)
95% CI	(-15.18, 7.84)	(-20.81, 7.28)	(-17.17, 5.79)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.02 (5.46)	-1.08 (6.22)	
95% CI	(-9.18, 13.22)	(-13.85, 11.69)	
p-value	0.7144	0.8635	
Corrected Hedge's g Statistics	0.095	-0.049	
95% CI	(-0.79, 0.98)	(-1.05, 0.96)	
Subgroup*Treatment Interaction p-value	NE	0.1186	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 10 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023
AMNOG Table SE21.9.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Mental Component Score			
Week 24			
m	8	7	20
n	7	6	17
Baseline Mean (SD)	56.13 (4.26)	56.22 (3.25)	56.96 (6.08)
Analysis Visit Mean (SD)	52.79 (8.98)	56.80 (4.65)	54.89 (8.16)
LS Mean of Change from Baseline (SE)	-3.32 (2.03)	1.13 (2.47)	-2.34 (2.21)
95% CI	(-7.49, 0.85)	(-3.93, 6.20)	(-6.86, 2.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.98 (1.87)	3.47 (2.03)	
95% CI	(-4.82, 2.86)	(-0.69, 7.63)	
p-value	0.6034	0.0985	
Corrected Hedge's g Statistics	-0.115	0.395	
95% CI	(-1.00, 0.77)	(-0.54, 1.33)	
Week 52			
m	8	7	19
n	7	5	16
Baseline Mean (SD)	56.74 (3.36)	56.08 (3.61)	57.12 (6.25)
Analysis Visit Mean (SD)	54.86 (6.13)	55.42 (2.77)	55.91 (9.63)
LS Mean of Change from Baseline (SE)	-2.26 (2.38)	-0.16 (2.90)	-1.42 (2.36)
95% CI	(-7.13, 2.62)	(-6.12, 5.80)	(-6.27, 3.43)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.84 (2.32)	1.26 (2.68)	
95% CI	(-5.60, 3.93)	(-4.23, 6.75)	
p-value	0.7218	0.6413	
Corrected Hedge's g Statistics	-0.093	0.136	
95% CI	(-0.98, 0.80)	(-0.87, 1.14)	
Subgroup*Treatment Interaction p-value	NE	0.1171	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE21.9.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Visit Statistic	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Physical Component Score			
Week 24			
m	8	7	20
n	7	6	17
Baseline Mean (SD)	47.94 (8.61)	51.62 (7.45)	51.54 (6.95)
Analysis Visit Mean (SD)	52.49 (7.19)	51.30 (6.10)	49.39 (9.56)
LS Mean of Change from Baseline (SE)	4.12 (3.57)	0.99 (4.24)	-0.76 (3.50)
95% CI	(-3.21, 11.45)	(-7.72, 9.69)	(-7.95, 6.43)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.88 (3.58)	1.75 (3.80)	
95% CI	(-2.46, 12.23)	(-6.05, 9.55)	
p-value	0.1839	0.6485	
Corrected Hedge's g Statistics	0.355	0.124	
95% CI	(-0.53, 1.24)	(-0.81, 1.06)	
Week 52			
m	8	7	19
n	7	5	16
Baseline Mean (SD)	51.24 (5.39)	51.10 (8.20)	51.62 (7.17)
Analysis Visit Mean (SD)	49.70 (7.71)	48.88 (8.53)	51.10 (8.03)
LS Mean of Change from Baseline (SE)	-0.80 (3.04)	-1.23 (3.82)	0.57 (3.32)
95% CI	(-7.04, 5.44)	(-9.07, 6.60)	(-6.24, 7.37)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.37 (2.69)	-1.80 (3.13)	
95% CI	(-6.89, 4.16)	(-8.22, 4.63)	
p-value	0.6162	0.5704	
Corrected Hedge's g Statistics	-0.110	-0.139	
95% CI	(-1.00, 0.78)	(-1.14, 0.87)	
Subgroup*Treatment Interaction p-value	NE	0.7529	

Madrigal Pharmaceuticals, Inc. Page 12 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023
AMNOG Table SE21.9.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Physical Functioning			
Week 24			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	78.00 (11.51)	77.14 (30.94)
Analysis Visit Mean (SD)	N/A	81.00 (9.62)	77.14 (26.44)
LS Mean of Change from Baseline (SE)	NE	-0.19 (4.95)	-2.66 (3.98)
95% CI	NE	(-11.60, 11.23)	(-11.83, 6.51)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	2.47 (4.82)	
95% CI	NE	(-8.64, 13.58)	
p-value	NE	0.6218	
Corrected Hedge's g Statistics	NE	0.212	
95% CI	NE	(-0.94, 1.36)	
Week 52			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	78.00 (11.51)	77.14 (30.94)
Analysis Visit Mean (SD)	N/A	71.00 (20.43)	75.71 (24.57)
LS Mean of Change from Baseline (SE)	NE	-10.16 (7.47)	-4.10 (6.18)
95% CI	NE	(-27.39, 7.07)	(-18.36, 10.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-6.06 (8.77)	
95% CI	NE	(-26.28, 14.17)	
p-value	NE	0.5094	
Corrected Hedge's g Statistics	NE	-0.339	
95% CI	NE	(-1.49, 0.82)	
Subgroup*Treatment Interaction p-value	NE	0.8977	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 13 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023
AMNOG Table SE21.9.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Role Physical			
Week 24			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	90.00 (13.69)	59.84 (33.64)
Analysis Visit Mean (SD)	N/A	81.28 (19.24)	71.44 (39.16)
LS Mean of Change from Baseline (SE)	NE	1.30 (13.59)	16.61 (8.41)
95% CI	NE	(-30.03, 32.63)	(-2.78, 35.99)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-15.31 (13.81)	
95% CI	NE	(-47.15, 16.54)	
p-value	NE	0.3000	
Corrected Hedge's g Statistics	NE	-0.547	
95% CI	NE	(-1.72, 0.62)	
Week 52			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	90.00 (13.69)	59.84 (33.64)
Analysis Visit Mean (SD)	N/A	66.26 (27.82)	64.31 (28.78)
LS Mean of Change from Baseline (SE)	NE	-6.10 (16.20)	4.03 (11.11)
95% CI	NE	(-43.45, 31.26)	(-21.60, 29.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-10.13 (18.45)	
95% CI	NE	(-52.67, 32.41)	
p-value	NE	0.5979	
Corrected Hedge's g Statistics	NE	-0.289	
95% CI	NE	(-1.44, 0.86)	
Subgroup*Treatment Interaction p-value	NE	0.2837	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 14 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023
AMNOG Table SE21.9.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Bodily Pain			
Week 24			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	81.6 (19.0)	69.7 (28.8)
Analysis Visit Mean (SD)	N/A	75.6 (22.7)	69.0 (32.8)
LS Mean of Change from Baseline (SE)	NE	5.02 (8.37)	5.03 (6.33)
95% CI	NE	(-14.27, 24.32)	(-9.56, 19.63)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-0.01 (8.09)	
95% CI	NE	(-18.66, 18.64)	
p-value	NE	0.9988	
Corrected Hedge's g Statistics	NE	-0.001	
95% CI	NE	(-1.15, 1.15)	
Week 52			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	81.6 (19.0)	69.7 (28.8)
Analysis Visit Mean (SD)	N/A	76.8 (17.5)	63.0 (21.2)
LS Mean of Change from Baseline (SE)	NE	8.73 (8.65)	-2.76 (6.59)
95% CI	NE	(-11.22, 28.68)	(-17.96, 12.45)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	11.49 (8.60)	
95% CI	NE	(-8.34, 31.32)	
p-value	NE	0.2184	
Corrected Hedge's g Statistics	NE	0.582	
95% CI	NE	(-0.59, 1.75)	
Subgroup*Treatment Interaction p-value	NE	0.5527	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 15 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023
AMNOG Table SE21.9.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
General Health			
Week 24			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	67.00 (12.75)	62.86 (26.40)
Analysis Visit Mean (SD)	N/A	64.60 (17.36)	62.43 (21.36)
LS Mean of Change from Baseline (SE)	NE	12.44 (7.94)	5.67 (6.08)
95% CI	NE	(-5.86, 30.74)	(-8.35, 19.69)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	6.77 (7.78)	
95% CI	NE	(-11.16, 24.70)	
p-value	NE	0.4094	
Corrected Hedge's g Statistics	NE	0.373	
95% CI	NE	(-0.78, 1.53)	
Week 52			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	67.00 (12.75)	62.86 (26.40)
Analysis Visit Mean (SD)	N/A	62.60 (14.47)	62.14 (21.61)
LS Mean of Change from Baseline (SE)	NE	10.64 (8.31)	5.24 (6.43)
95% CI	NE	(-8.53, 29.80)	(-9.58, 20.07)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	5.39 (8.43)	
95% CI	NE	(-14.04, 24.83)	
p-value	NE	0.5400	
Corrected Hedge's g Statistics	NE	0.282	
95% CI	NE	(-0.87, 1.44)	
Subgroup*Treatment Interaction p-value	NE	0.7484	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 16 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023
AMNOG Table SE21.9.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Vitality			
Week 24			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	67.52 (17.35)	55.36 (18.90)
Analysis Visit Mean (SD)	N/A	67.52 (17.35)	58.94 (18.34)
LS Mean of Change from Baseline (SE)	NE	0.07 (11.36)	-1.14 (8.75)
95% CI	NE	(-26.13, 26.27)	(-21.32, 19.04)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	1.21 (12.53)	
95% CI	NE	(-27.69, 30.10)	
p-value	NE	0.9256	
Corrected Hedge's g Statistics	NE	0.046	
95% CI	NE	(-1.10, 1.19)	
Week 52			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	67.52 (17.35)	55.36 (18.90)
Analysis Visit Mean (SD)	N/A	61.28 (19.46)	54.47 (20.64)
LS Mean of Change from Baseline (SE)	NE	-9.27 (9.68)	-3.40 (7.20)
95% CI	NE	(-31.59, 13.06)	(-20.00, 13.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-5.87 (9.67)	
95% CI	NE	(-28.16, 16.42)	
p-value	NE	0.5605	
Corrected Hedge's g Statistics	NE	-0.269	
95% CI	NE	(-1.42, 0.88)	
Subgroup*Treatment Interaction p-value	NE	0.9542	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 17 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023
AMNOG Table SE21.9.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Social Functioning			
Week 24			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	82.50 (25.92)	83.93 (29.50)
Analysis Visit Mean (SD)	N/A	85.00 (13.69)	89.29 (15.19)
LS Mean of Change from Baseline (SE)	NE	6.96 (8.69)	8.75 (7.26)
95% CI	NE	(-13.08, 26.99)	(-8.00, 25.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-1.79 (8.87)	
95% CI	NE	(-22.25, 18.67)	
p-value	NE	0.8449	
Corrected Hedge's g Statistics	NE	-0.086	
95% CI	NE	(-1.23, 1.06)	
Week 52			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	82.50 (25.92)	83.93 (29.50)
Analysis Visit Mean (SD)	N/A	92.50 (11.18)	87.50 (17.68)
LS Mean of Change from Baseline (SE)	NE	14.54 (8.75)	6.90 (7.31)
95% CI	NE	(-5.63, 34.71)	(-9.96, 23.77)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	7.63 (8.97)	
95% CI	NE	(-13.06, 28.32)	
p-value	NE	0.4198	
Corrected Hedge's g Statistics	NE	0.363	
95% CI	NE	(-0.79, 1.52)	
Subgroup*Treatment Interaction p-value	NE	0.6397	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 18 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023
AMNOG Table SE21.9.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Role Emotional			
Week 24			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	98.34 (3.71)	78.59 (25.39)
Analysis Visit Mean (SD)	N/A	86.66 (21.73)	78.57 (23.49)
LS Mean of Change from Baseline (SE)	NE	-4.54 (11.66)	2.89 (8.25)
95% CI	NE	(-31.43, 22.36)	(-16.13, 21.91)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-7.43 (12.20)	
95% CI	NE	(-35.55, 20.69)	
p-value	NE	0.5593	
Corrected Hedge's g Statistics	NE	-0.290	
95% CI	NE	(-1.44, 0.86)	
Week 52			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	98.34 (3.71)	78.59 (25.39)
Analysis Visit Mean (SD)	N/A	85.00 (22.36)	78.57 (18.56)
LS Mean of Change from Baseline (SE)	NE	-1.06 (12.79)	-0.78 (9.32)
95% CI	NE	(-30.55, 28.42)	(-22.26, 20.71)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-0.29 (14.16)	
95% CI	NE	(-32.95, 32.38)	
p-value	NE	0.9844	
Corrected Hedge's g Statistics	NE	-0.010	
95% CI	NE	(-1.16, 1.14)	
Subgroup*Treatment Interaction p-value	NE	0.2650	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 19 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.9.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Mental Health			
Week 24			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	88.0 (2.7)	75.7 (17.2)
Analysis Visit Mean (SD)	N/A	81.0 (15.6)	77.9 (19.1)
LS Mean of Change from Baseline (SE)	NE	-0.56 (7.29)	5.94 (5.77)
95% CI	NE	(-17.38, 16.26)	(-7.37, 19.24)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-6.50 (8.56)	
95% CI	NE	(-26.24, 13.25)	
p-value	NE	0.4699	
Corrected Hedge's g Statistics	NE	-0.382	
95% CI	NE	(-1.54, 0.78)	
Week 52			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	88.0 (2.7)	75.7 (17.2)
Analysis Visit Mean (SD)	N/A	80.0 (12.7)	77.9 (17.8)
LS Mean of Change from Baseline (SE)	NE	-0.82 (6.97)	5.41 (5.49)
95% CI	NE	(-16.89, 15.25)	(-7.25, 18.07)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-6.23 (8.04)	
95% CI	NE	(-24.78, 12.32)	
p-value	NE	0.4607	
Corrected Hedge's g Statistics	NE	-0.385	
95% CI	NE	(-1.54, 0.77)	
Subgroup*Treatment Interaction p-value	NE	0.1186	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 20 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.9.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Mental Component Score			
Week 24			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	56.66 (3.11)	50.66 (8.48)
Analysis Visit Mean (SD)	N/A	53.44 (7.72)	51.71 (8.10)
LS Mean of Change from Baseline (SE)	NE	-0.88 (4.60)	1.02 (3.61)
95% CI	NE	(-11.47, 9.72)	(-7.30, 9.34)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-1.89 (5.40)	
95% CI	NE	(-14.35, 10.57)	
p-value	NE	0.7352	
Corrected Hedge's g Statistics	NE	-0.177	
95% CI	NE	(-1.33, 0.97)	
Week 52			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	56.66 (3.11)	50.66 (8.48)
Analysis Visit Mean (SD)	N/A	54.46 (6.36)	51.67 (8.06)
LS Mean of Change from Baseline (SE)	NE	0.05 (3.84)	1.04 (2.93)
95% CI	NE	(-8.80, 8.89)	(-5.72, 7.80)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-0.99 (4.16)	
95% CI	NE	(-10.59, 8.60)	
p-value	NE	0.8172	
Corrected Hedge's g Statistics	NE	-0.113	
95% CI	NE	(-1.26, 1.04)	
Subgroup*Treatment Interaction p-value	NE	0.1171	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 21 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023
AMNOG Table SE21.9.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Physical Component Score			
Week 24			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	49.92 (6.64)	46.79 (12.57)
Analysis Visit Mean (SD)	N/A	49.98 (5.88)	47.91 (12.46)
LS Mean of Change from Baseline (SE)	NE	1.84 (2.61)	1.75 (1.91)
95% CI	NE	(-4.19, 7.87)	(-2.66, 6.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	0.09 (2.42)	
95% CI	NE	(-5.50, 5.67)	
p-value	NE	0.9717	
Corrected Hedge's g Statistics	NE	0.015	
95% CI	NE	(-1.13, 1.16)	
Week 52			
m	0	5	7
n	0	5	7
Baseline Mean (SD)	N/A	49.92 (6.64)	46.79 (12.57)
Analysis Visit Mean (SD)	N/A	46.54 (10.32)	45.91 (9.27)
LS Mean of Change from Baseline (SE)	NE	-1.08 (3.73)	-0.61 (2.95)
95% CI	NE	(-9.68, 7.51)	(-7.40, 6.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	-0.47 (4.25)	
95% CI	NE	(-10.28, 9.33)	
p-value	NE	0.9144	
Corrected Hedge's g Statistics	NE	-0.054	
95% CI	NE	(-1.20, 1.09)	
Subgroup*Treatment Interaction p-value	NE	0.7529	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE21.9.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis, only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.

AMNOG Table SE21.9.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (12.5)	0	2 (10.0)
No	7 (87.5)	10 (100)	18 (90.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	2.84	
95% CI of the inverse odds ratio	(0.06, 10.00)	(0.12, 64.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	2.62	
95% CI of the inverse risk ratio	(0.08, 7.64)	(0.14, 49.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.50	-7.36	
95% CI of the absolute risk difference	(-23.92, 28.92)	(-25.89, 11.17)	
p-value	0.8468	0.4975	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (12.5)	0	7 (35.0)
No	7 (87.5)	10 (100)	13 (65.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.77	11.67	
95% CI of the inverse odds ratio	(0.38, 37.14)	(0.60, 228.35)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.80	7.86	
95% CI of the inverse risk ratio	(0.41, 19.26)	(0.49, 125.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-22.50	-31.17	
95% CI of the absolute risk difference	(-53.52, 8.52)	(-55.08, -7.26)	
p-value	0.2338	0.0531	
p-value of Breslow-Day Test for Homogeneity [3]	0.6199	0.1341	

AMNOG Table SE21.9.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (12.5)	0	2 (10.0)
No	7 (87.5)	10 (100)	18 (90.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	2.84	
95% CI of the inverse odds ratio	(0.06, 10.00)	(0.12, 64.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	2.62	
95% CI of the inverse risk ratio	(0.08, 7.64)	(0.14, 49.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.50	-7.36	
95% CI of the absolute risk difference	(-23.92, 28.92)	(-25.89, 11.17)	
p-value	0.8468	0.4975	
p-value of Breslow-Day Test for Homogeneity [3]	0.4395	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (25.0)	1 (10.0)	4 (20.0)
No	6 (75.0)	9 (90.0)	16 (80.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	2.25	
95% CI of the inverse odds ratio	(0.11, 5.22)	(0.22, 23.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	2.00	
95% CI of the inverse risk ratio	(0.18, 3.54)	(0.26, 15.62)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.00	-10.00	
95% CI of the absolute risk difference	(-29.75, 39.75)	(-35.55, 15.55)	
p-value	0.7708	0.4884	
p-value of Breslow-Day Test for Homogeneity [3]	0.2326	0.1627	

AMNOG Table SE21.9.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	4 (20.0)
No	8 (100)	10 (100)	16 (80.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.64	5.73	
95% CI of the inverse odds ratio	(0.22, 96.60)	(0.28, 117.65)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.86	4.71	
95% CI of the inverse risk ratio	(0.23, 64.42)	(0.28, 79.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-15.87	-16.88	
95% CI of the absolute risk difference	(-38.94, 7.19)	(-38.32, 4.55)	
p-value	0.2850	0.2116	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (12.5)	0	5 (25.0)
No	7 (87.5)	10 (100)	15 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.33	7.45	
95% CI of the inverse odds ratio	(0.23, 23.91)	(0.37, 149.55)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	5.76	
95% CI of the inverse risk ratio	(0.27, 14.55)	(0.35, 94.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-12.50	-21.65	
95% CI of the absolute risk difference	(-42.25, 17.25)	(-44.12, 0.83)	
p-value	0.4665	0.1362	
p-value of Breslow-Day Test for Homogeneity [3]	0.8046	0.1038	

AMNOG Table SE21.9.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (5.0)
No	8 (100)	10 (100)	19 (95.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.31	1.62	
95% CI of the inverse odds ratio	(0.05, 35.47)	(0.06, 43.25)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	1.57	
95% CI of the inverse risk ratio	(0.06, 28.65)	(0.07, 35.46)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.59	-2.60	
95% CI of the absolute risk difference	(-20.17, 16.99)	(-19.12, 13.92)	
p-value	0.8731	0.7731	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (50.0)	0	5 (25.0)
No	4 (50.0)	10 (100)	15 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	7.45	
95% CI of the inverse odds ratio	(0.06, 1.85)	(0.37, 149.55)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	5.76	
95% CI of the inverse risk ratio	(0.18, 1.40)	(0.35, 94.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	25.00	-21.65	
95% CI of the absolute risk difference	(-14.50, 64.50)	(-44.12, 0.83)	
p-value	0.2007	0.1362	
p-value of Breslow-Day Test for Homogeneity [3]	0.2604	0.1370	

AMNOG Table SE21.9.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	3 (15.0)
No	8 (100)	10 (100)	17 (85.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.40	4.20	
95% CI of the inverse odds ratio	(0.16, 73.57)	(0.20, 89.61)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	3.67	
95% CI of the inverse risk ratio	(0.17, 52.30)	(0.21, 64.80)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.11	-12.12	
95% CI of the absolute risk difference	(-32.97, 10.75)	(-32.26, 8.02)	
p-value	0.4120	0.3248	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (12.5)	1 (10.0)	6 (30.0)
No	7 (87.5)	9 (90.0)	14 (70.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	3.86	
95% CI of the inverse odds ratio	(0.30, 30.02)	(0.40, 37.58)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.40	3.00	
95% CI of the inverse risk ratio	(0.34, 16.90)	(0.42, 21.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-17.50	-20.00	
95% CI of the absolute risk difference	(-47.97, 12.97)	(-47.37, 7.37)	
p-value	0.3340	0.2221	
p-value of Breslow-Day Test for Homogeneity [3]	0.6620	0.4210	

AMNOG Table SE21.9.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (10.0)
No	8 (100)	10 (100)	18 (90.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.30	2.84	
95% CI of the inverse odds ratio	(0.10, 53.24)	(0.12, 64.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.14	2.62	
95% CI of the inverse risk ratio	(0.11, 40.30)	(0.14, 49.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.35	-7.36	
95% CI of the absolute risk difference	(-26.74, 14.04)	(-25.89, 11.17)	
p-value	0.5953	0.4975	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.2734	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (20.0)	3 (15.0)
No	8 (100)	8 (80.0)	17 (85.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.40	0.71	
95% CI of the inverse odds ratio	(0.16, 73.57)	(0.10, 5.10)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	0.75	
95% CI of the inverse risk ratio	(0.17, 52.30)	(0.15, 3.79)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.11	5.00	
95% CI of the absolute risk difference	(-32.97, 10.75)	(-24.32, 34.32)	
p-value	0.4120	0.7290	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.2379	

AMNOG Table SE21.9.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (5.0)
No	8 (100)	10 (100)	19 (95.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.31	1.62	
95% CI of the inverse odds ratio	(0.05, 35.47)	(0.06, 43.25)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	1.57	
95% CI of the inverse risk ratio	(0.06, 28.65)	(0.07, 35.46)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.59	-2.60	
95% CI of the absolute risk difference	(-20.17, 16.99)	(-19.12, 13.92)	
p-value	0.8731	0.7731	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (12.5)	0	1 (5.0)
No	7 (87.5)	10 (100)	19 (95.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.37	1.62	
95% CI of the inverse odds ratio	(0.02, 6.72)	(0.06, 43.25)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.40	1.57	
95% CI of the inverse risk ratio	(0.03, 5.65)	(0.07, 35.46)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.50	-2.60	
95% CI of the absolute risk difference	(-17.33, 32.33)	(-19.12, 13.92)	
p-value	0.4863	0.7731	
p-value of Breslow-Day Test for Homogeneity [3]	0.4233	0.5524	

AMNOG Table SE21.9.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (10.0)	2 (10.0)
No	8 (100)	9 (90.0)	18 (90.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.30	1.00	
95% CI of the inverse odds ratio	(0.10, 53.24)	(0.08, 12.56)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.14	1.00	
95% CI of the inverse risk ratio	(0.11, 40.30)	(0.10, 9.75)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.35	0.00	
95% CI of the absolute risk difference	(-26.74, 14.04)	(-22.77, 22.77)	
p-value	0.5953	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.4494	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (37.5)	1 (10.0)	7 (35.0)
No	5 (62.5)	9 (90.0)	13 (65.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	4.85	
95% CI of the inverse odds ratio	(0.16, 4.92)	(0.51, 46.49)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	3.50	
95% CI of the inverse risk ratio	(0.32, 2.74)	(0.50, 24.67)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.50	-25.00	
95% CI of the absolute risk difference	(-37.03, 42.03)	(-52.98, 2.98)	
p-value	0.9007	0.1444	
p-value of Breslow-Day Test for Homogeneity [3]	0.4488	0.6883	

AMNOG Table SE21.9.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	8 (100)	10 (100)	20 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (10.0)	4 (20.0)
No	8 (100)	9 (90.0)	16 (80.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.64	2.25	
95% CI of the inverse odds ratio	(0.22, 96.60)	(0.22, 23.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.86	2.00	
95% CI of the inverse risk ratio	(0.23, 64.42)	(0.26, 15.62)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-15.87	-10.00	
95% CI of the absolute risk difference	(-38.94, 7.19)	(-35.55, 15.55)	
p-value	0.2850	0.4884	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.7739	

AMNOG Table SE21.9.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (5.0)
No	8 (100)	10 (100)	19 (95.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.31	1.62	
95% CI of the inverse odds ratio	(0.05, 35.47)	(0.06, 43.25)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	1.57	
95% CI of the inverse risk ratio	(0.06, 28.65)	(0.07, 35.46)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.59	-2.60	
95% CI of the absolute risk difference	(-20.17, 16.99)	(-19.12, 13.92)	
p-value	0.8731	0.7731	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (12.5)	0	3 (15.0)
No	7 (87.5)	10 (100)	17 (85.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.24	4.20	
95% CI of the inverse odds ratio	(0.11, 14.01)	(0.20, 89.61)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	3.67	
95% CI of the inverse risk ratio	(0.15, 9.89)	(0.21, 64.80)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-12.12	
95% CI of the absolute risk difference	(-30.25, 25.25)	(-32.26, 8.02)	
p-value	0.8644	0.3248	
p-value of Breslow-Day Test for Homogeneity [3]	0.6182	NE	

AMNOG Table SE21.9.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	1 (100)	5 (100)	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (40.0)	4 (50.0)
No	1 (100)	3 (60.0)	4 (50.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	1.50	
95% CI of the inverse odds ratio	(0.09, 95.17)	(0.16, 14.42)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	1.25	
95% CI of the inverse risk ratio	(0.17, 24.07)	(0.35, 4.49)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-25.00	-10.00	
95% CI of the absolute risk difference	(-93.33, 43.33)	(-65.18, 45.18)	
p-value	0.5207	0.7249	
p-value of Breslow-Day Test for Homogeneity [3]	0.6199	0.1341	

AMNOG Table SE21.9.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	3 (37.5)
No	1 (100)	5 (100)	5 (62.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.91	7.00	
95% CI of the inverse odds ratio	(0.06, 61.34)	(0.29, 170.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.56	4.67	
95% CI of the inverse risk ratio	(0.12, 19.65)	(0.29, 75.02)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-13.89	-30.56	
95% CI of the absolute risk difference	(-81.83, 54.05)	(-69.33, 8.22)	
p-value	0.7119	0.1899	
p-value of Breslow-Day Test for Homogeneity [3]	0.4395	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	5 (62.5)
No	1 (100)	5 (100)	3 (37.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.71	17.29	
95% CI of the inverse odds ratio	(0.15, 151.48)	(0.71, 419.93)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.44	7.33	
95% CI of the inverse risk ratio	(0.21, 28.51)	(0.49, 109.61)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-36.11	-52.78	
95% CI of the absolute risk difference	(-100.00, 31.83)	(-91.55, -14.00)	
p-value	0.3536	0.0409	
p-value of Breslow-Day Test for Homogeneity [3]	0.2326	0.1627	

AMNOG Table SE21.9.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (12.5)
No	1 (100)	5 (100)	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	2.20	
95% CI of the inverse odds ratio	(0.02, 23.07)	(0.07, 64.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	2.00	
95% CI of the inverse risk ratio	(0.04, 11.07)	(0.10, 41.37)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.33	-8.33	
95% CI of the absolute risk difference	(-56.43, 73.10)	(-41.23, 24.56)	
p-value	0.7823	0.6418	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (20.0)	1 (12.5)
No	1 (100)	4 (80.0)	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	0.57	
95% CI of the inverse odds ratio	(0.02, 23.07)	(0.03, 11.85)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	0.63	
95% CI of the inverse risk ratio	(0.04, 11.07)	(0.05, 7.90)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.33	7.50	
95% CI of the absolute risk difference	(-56.43, 73.10)	(-34.39, 49.39)	
p-value	0.7823	0.7154	
p-value of Breslow-Day Test for Homogeneity [3]	0.8046	0.1038	

AMNOG Table SE21.9.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	3 (37.5)
No	1 (100)	5 (100)	5 (62.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.91	7.00	
95% CI of the inverse odds ratio	(0.06, 61.34)	(0.29, 170.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.56	4.67	
95% CI of the inverse risk ratio	(0.12, 19.65)	(0.29, 75.02)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-13.89	-30.56	
95% CI of the absolute risk difference	(-81.83, 54.05)	(-69.33, 8.22)	
p-value	0.7119	0.1899	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (40.0)	3 (37.5)
No	1 (100)	3 (60.0)	5 (62.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.91	0.90	
95% CI of the inverse odds ratio	(0.06, 61.34)	(0.09, 8.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.56	0.94	
95% CI of the inverse risk ratio	(0.12, 19.65)	(0.23, 3.79)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-13.89	2.50	
95% CI of the absolute risk difference	(-81.83, 54.05)	(-51.99, 56.99)	
p-value	0.7119	0.9282	
p-value of Breslow-Day Test for Homogeneity [3]	0.2604	0.1370	

AMNOG Table SE21.9.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	1 (100)	5 (100)	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	3 (37.5)
No	1 (100)	5 (100)	5 (62.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.91	7.00	
95% CI of the inverse odds ratio	(0.06, 61.34)	(0.29, 170.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.56	4.67	
95% CI of the inverse risk ratio	(0.12, 19.65)	(0.29, 75.02)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-13.89	-30.56	
95% CI of the absolute risk difference	(-81.83, 54.05)	(-69.33, 8.22)	
p-value	0.7119	0.1899	
p-value of Breslow-Day Test for Homogeneity [3]	0.6620	0.4210	

AMNOG Table SE21.9.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (20.0)	1 (12.5)
No	1 (100)	4 (80.0)	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	0.57	
95% CI of the inverse odds ratio	(0.02, 23.07)	(0.03, 11.85)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	0.63	
95% CI of the inverse risk ratio	(0.04, 11.07)	(0.05, 7.90)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.33	7.50	
95% CI of the absolute risk difference	(-56.43, 73.10)	(-34.39, 49.39)	
p-value	0.7823	0.7154	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.2734	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	3 (60.0)	1 (12.5)
No	1 (100)	2 (40.0)	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	0.10	
95% CI of the inverse odds ratio	(0.02, 23.07)	(0.01, 1.50)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	0.21	
95% CI of the inverse risk ratio	(0.04, 11.07)	(0.03, 1.49)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.33	47.50	
95% CI of the absolute risk difference	(-56.43, 73.10)	(-1.17, 96.17)	
p-value	0.7823	0.0710	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.2379	

AMNOG Table SE21.9.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (12.5)
No	1 (100)	5 (100)	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	2.20	
95% CI of the inverse odds ratio	(0.02, 23.07)	(0.07, 64.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	2.00	
95% CI of the inverse risk ratio	(0.04, 11.07)	(0.10, 41.37)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.33	-8.33	
95% CI of the absolute risk difference	(-56.43, 73.10)	(-41.23, 24.56)	
p-value	0.7823	0.6418	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (20.0)	2 (25.0)
No	1 (100)	4 (80.0)	6 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	1.33	
95% CI of the inverse odds ratio	(0.03, 38.88)	(0.09, 20.11)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	1.25	
95% CI of the inverse risk ratio	(0.08, 15.28)	(0.15, 10.46)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.78	-5.00	
95% CI of the absolute risk difference	(-69.54, 63.99)	(-51.15, 41.15)	
p-value	0.9364	0.8351	
p-value of Breslow-Day Test for Homogeneity [3]	0.4233	0.5524	

AMNOG Table SE21.9.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (12.5)
No	1 (100)	5 (100)	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	2.20	
95% CI of the inverse odds ratio	(0.02, 23.07)	(0.07, 64.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	2.00	
95% CI of the inverse risk ratio	(0.04, 11.07)	(0.10, 41.37)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.33	-8.33	
95% CI of the absolute risk difference	(-56.43, 73.10)	(-41.23, 24.56)	
p-value	0.7823	0.6418	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.4494	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (20.0)	3 (37.5)
No	1 (100)	4 (80.0)	5 (62.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.91	2.40	
95% CI of the inverse odds ratio	(0.06, 61.34)	(0.18, 32.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.56	1.88	
95% CI of the inverse risk ratio	(0.12, 19.65)	(0.26, 13.42)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-13.89	-17.50	
95% CI of the absolute risk difference	(-81.83, 54.05)	(-66.03, 31.03)	
p-value	0.7119	0.5060	
p-value of Breslow-Day Test for Homogeneity [3]	0.4488	0.6883	

AMNOG Table SE21.9.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	1 (100)	5 (100)	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (20.0)	2 (25.0)
No	1 (100)	4 (80.0)	6 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	1.33	
95% CI of the inverse odds ratio	(0.03, 38.88)	(0.09, 20.11)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	1.25	
95% CI of the inverse risk ratio	(0.08, 15.28)	(0.15, 10.46)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.78	-5.00	
95% CI of the absolute risk difference	(-69.54, 63.99)	(-51.15, 41.15)	
p-value	0.9364	0.8351	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.7739	

AMNOG Table SE21.9.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Modified Intent-to-Treat Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (12.5)
No	1 (100)	5 (100)	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	2.20	
95% CI of the inverse odds ratio	(0.02, 23.07)	(0.07, 64.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	2.00	
95% CI of the inverse risk ratio	(0.04, 11.07)	(0.10, 41.37)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.33	-8.33	
95% CI of the absolute risk difference	(-56.43, 73.10)	(-41.23, 24.56)	
p-value	0.7823	0.6418	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	2 (25.0)
No	1 (100)	5 (100)	6 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	4.23	
95% CI of the inverse odds ratio	(0.03, 38.88)	(0.17, 108.22)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	3.33	
95% CI of the inverse risk ratio	(0.08, 15.28)	(0.19, 57.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.78	-19.44	
95% CI of the absolute risk difference	(-69.54, 63.99)	(-56.12, 17.23)	
p-value	0.9364	0.3564	
p-value of Breslow-Day Test for Homogeneity [3]	0.6182	NE	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.10.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=5)	Visit Result DB MGL-3196 100 mg (N=5)	Visit Result DB Placebo (N=17)	Change from Baseline DB MGL-3196 80 mg (N=5)	Change from Baseline DB MGL-3196 100 mg (N=5)	Change from Baseline DB Placebo (N=17)
Physical Functioning						
Baseline						
m	5	5	17			
n	5	5	15			
Mean (SD)	78.00 (11.51)	73.00 (18.57)	77.00 (23.44)			
Median	80.00	70.00	80.00			
IQR: Q1, Q3	75.00, 85.00	65.00, 80.00	65.00, 95.00			
Min, Max	60.0, 90.0	50.0, 100.0	25.0, 100.0			
Week 24						
m	4	4	16			
n	3	4	14	3	4	13
Mean (SD/SE)	90.00 (8.66)	83.75 (12.50)	78.21 (26.36)	8.33 (7.26)	5.00 (5.00)	0.38 (6.11)
Median	85.00	82.50	87.50	10.00	0	5.00
IQR: Q1, Q3	85.00, 100.00	75.00, 92.50	70.00, 100.00	-5.00, 20.00	0.00, 10.00	0.00, 5.00
Min, Max	85.0, 100.0	70.0, 100.0	20.0, 100.0	-5.0, 20.0	0.0, 20.0	-60.0, 35.0
Week 52						
m	4	4	15			
n	4	4	14	4	4	13
Mean (SD/SE)	71.25 (15.48)	77.50 (21.02)	82.26 (26.43)	-11.25 (6.25)	-1.25 (6.57)	2.82 (6.08)
Median	75.00	80.00	97.50	-5.00	2.50	5.00
IQR: Q1, Q3	60.00, 82.50	62.50, 92.50	66.70, 100.00	-17.50, -5.00	-10.00, 7.50	0.00, 10.00
Min, Max	50.0, 85.0	50.0, 100.0	20.0, 100.0	-30.0, -5.0	-20.0, 10.0	-60.0, 30.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.10.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=5)	(N=5)	(N=17)	(N=5)	(N=5)	(N=17)
Role Physical						
Baseline						
m	5	5	17			
n	5	5	15			
Mean (SD)	81.26 (21.64)	86.26 (12.80)	74.60 (25.71)			
Median	87.50	81.30	81.30			
IQR: Q1, Q3	68.80, 100.00	75.00, 100.00	62.50, 93.80			
Min, Max	50.0, 100.0	75.0, 100.0	0.0, 100.0			
Week 24						
m	4	4	16			
n	3	4	14	3	4	13
Mean (SD/SE)	91.67 (14.43)	87.53 (15.28)	75.90 (32.78)	6.23 (3.61)	0.03 (2.55)	5.76 (5.90)
Median	100.00	90.65	93.75	6.20	0	6.30
IQR: Q1, Q3	75.00, 100.00	75.05, 100.00	62.50, 100.00	0.00, 12.50	-3.10, 3.15	0.00, 18.70
Min, Max	75.0, 100.0	68.8, 100.0	6.3, 100.0	0.0, 12.5	-6.2, 6.3	-56.3, 31.2
Week 52						
m	4	4	15			
n	4	4	14	4	4	13
Mean (SD/SE)	81.25 (16.14)	78.13 (29.54)	76.79 (26.67)	-7.83 (6.92)	-9.38 (9.38)	3.84 (5.90)
Median	81.25	87.50	81.25	-6.25	0	6.20
IQR: Q1, Q3	68.75, 93.75	56.25, 100.00	56.30, 100.00	-18.75, 3.10	-18.75, 0.00	0.00, 18.70
Min, Max	62.5, 100.0	37.5, 100.0	25.0, 100.0	-25.0, 6.2	-37.5, 0.0	-43.8, 31.3

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.10.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=5)	(N=5)	(N=17)	(N=5)	(N=5)	(N=17)
Bodily Pain						
Baseline						
m	5	5	17			
n	5	5	15			
Mean (SD)	69.2 (30.1)	75.0 (23.3)	72.1 (24.5)			
Median	62.0	62.0	84.0			
IQR: Q1, Q3	52.0, 100.0	62.0, 100.0	61.0, 84.0			
Min, Max	32, 100	51, 100	12, 100			
Week 24						
m	4	4	16			
n	3	4	14	3	4	13
Mean (SD/SE)	71.0 (25.7)	78.5 (25.2)	74.2 (24.7)	9.7 (5.5)	-2.5 (2.5)	4.0 (2.1)
Median	62.0	81.0	74.0	10.0	0	0
IQR: Q1, Q3	51.0, 100.0	57.0, 100.0	62.0, 100.0	0.0, 19.0	-5.0, 0.0	0.0, 11.0
Min, Max	51, 100	52, 100	12, 100	0, 19	-10, 0	-10, 16
Week 52						
m	4	4	15			
n	4	4	14	4	4	13
Mean (SD/SE)	67.0 (33.8)	81.5 (23.2)	73.9 (19.8)	-4.0 (5.7)	0.5 (4.5)	1.9 (4.2)
Median	73.0	87.0	74.0	-5.0	0	0
IQR: Q1, Q3	42.0, 92.0	63.0, 100.0	62.0, 84.0	-13.0, 5.0	-5.0, 6.0	-10.0, 16.0
Min, Max	22, 100	52, 100	32, 100	-16, 10	-10, 12	-26, 23

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.10.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=5)	(N=5)	(N=17)	(N=5)	(N=5)	(N=17)
General Health						
Baseline						
m	5	5	17			
n	5	5	15			
Mean (SD)	69.00 (13.04)	66.00 (12.45)	68.27 (23.26)			
Median	67.00	67.00	72.00			
IQR: Q1, Q3	57.00, 77.00	67.00, 67.00	62.00, 82.00			
Min, Max	57.0, 87.0	47.0, 82.0	25.0, 97.0			
Week 24						
m	4	4	16			
n	3	4	14	3	4	13
Mean (SD/SE)	78.67 (16.07)	69.50 (15.55)	66.36 (17.51)	5.00 (7.64)	3.75 (3.15)	-2.31 (3.69)
Median	72.00	69.50	69.50	10.00	5.00	0
IQR: Q1, Q3	67.00, 97.00	57.00, 82.00	45.00, 82.00	-10.00, 15.00	0.00, 7.50	-10.00, 5.00
Min, Max	67.0, 97.0	52.0, 87.0	37.0, 87.0	-10.0, 15.0	-5.0, 10.0	-27.0, 20.0
Week 52						
m	4	4	15			
n	4	4	14	4	4	13
Mean (SD/SE)	74.00 (15.25)	68.25 (13.77)	65.89 (20.89)	2.00 (1.78)	2.50 (3.23)	-3.58 (5.71)
Median	74.50	69.50	72.00	2.50	2.50	0
IQR: Q1, Q3	63.50, 84.50	57.00, 79.50	52.00, 82.00	-1.00, 5.00	-2.50, 7.50	-10.00, 10.00
Min, Max	55.0, 92.0	52.0, 82.0	15.0, 87.5	-2.0, 5.0	-5.0, 10.0	-57.0, 25.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.10.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=5)	(N=5)	(N=17)	(N=5)	(N=5)	(N=17)
Vitality						
Baseline						
m	5	5	17			
n	5	5	15			
Mean (SD)	60.04 (13.69)	65.02 (11.35)	64.59 (17.14)			
Median	56.30	68.80	62.50			
IQR: Q1, Q3	56.30, 62.50	56.30, 75.00	50.00, 75.00			
Min, Max	43.8, 81.3	50.0, 75.0	25.0, 87.5			
Week 24						
m	4	4	16			
n	3	4	14	3	4	13
Mean (SD/SE)	54.20 (28.21)	64.08 (12.87)	67.88 (14.26)	-8.33 (5.53)	1.55 (1.55)	4.82 (3.41)
Median	56.30	65.65	68.75	-6.20	0	6.20
IQR: Q1, Q3	25.00, 81.30	53.15, 75.00	56.30, 81.30	-18.80, 0.00	0.00, 3.10	-6.20, 12.50
Min, Max	25.0, 81.3	50.0, 75.0	43.8, 87.5	-18.8, 0.0	0.0, 6.2	-12.5, 31.3
Week 52						
m	4	4	15			
n	4	4	14	4	4	13
Mean (SD/SE)	46.90 (24.19)	59.40 (20.70)	69.21 (21.58)	-14.08 (4.69)	-3.13 (5.39)	4.32 (5.40)
Median	46.90	65.65	75.00	-12.55	0	12.50
IQR: Q1, Q3	28.15, 65.65	43.80, 75.00	62.50, 87.50	-21.90, -6.25	-9.35, 3.10	-12.50, 12.50
Min, Max	18.8, 75.0	31.3, 75.0	25.0, 100.0	-25.0, -6.2	-18.7, 6.2	-37.5, 31.2

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.10.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=5)	(N=5)	(N=17)	(N=5)	(N=5)	(N=17)
Social Functioning						
Baseline						
m	5	5	17			
n	5	5	15			
Mean (SD)	90.00 (13.69)	77.50 (22.36)	89.17 (19.97)			
Median	100.00	87.50	100.00			
IQR: Q1, Q3	75.00, 100.00	87.50, 87.50	87.50, 100.00			
Min, Max	75.0, 100.0	37.5, 87.5	25.0, 100.0			
Week 24						
m	4	4	16			
n	3	4	14	3	4	13
Mean (SD/SE)	79.17 (19.09)	87.50 (14.43)	90.18 (13.14)	-12.50 (7.22)	12.50 (17.68)	1.92 (4.21)
Median	75.00	87.50	100.00	-12.50	0	0
IQR: Q1, Q3	62.50, 100.00	75.00, 100.00	75.00, 100.00	-25.00, 0.00	-12.50, 37.50	0.00, 0.00
Min, Max	62.5, 100.0	75.0, 100.0	62.5, 100.0	-25.0, 0.0	-12.5, 62.5	-12.5, 50.0
Week 52						
m	4	4	15			
n	4	4	14	4	4	13
Mean (SD/SE)	81.25 (21.65)	100.00 (0.00)	96.43 (10.32)	-12.50 (8.84)	25.00 (12.50)	6.73 (3.91)
Median	81.25	100.00	100.00	-6.25	12.50	0
IQR: Q1, Q3	62.50, 100.00	100.00, 100.00	100.00, 100.00	-25.00, 0.00	12.50, 37.50	0.00, 12.50
Min, Max	62.5, 100.0	100.0, 100.0	62.5, 100.0	-37.5, 0.0	12.5, 62.5	-12.5, 37.5

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.10.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=5)	(N=5)	(N=17)	(N=5)	(N=5)	(N=17)
Role Emotional						
Baseline						
m	5	5	17			
n	5	5	15			
Mean (SD)	86.68 (20.92)	93.34 (10.86)	91.67 (15.75)			
Median	91.70	100.00	100.00			
IQR: Q1, Q3	91.70, 100.00	91.70, 100.00	83.30, 100.00			
Min, Max	50.0, 100.0	75.0, 100.0	50.0, 100.0			
Week 24						
m	4	4	16			
n	3	4	14	3	4	13
Mean (SD/SE)	86.10 (12.73)	95.83 (8.35)	89.29 (19.45)	-8.37 (4.82)	-2.10 (5.25)	-0.65 (2.20)
Median	83.30	100.00	100.00	-8.40	0	0
IQR: Q1, Q3	75.00, 100.00	91.65, 100.00	83.30, 100.00	-16.70, 0.00	-8.35, 4.15	0.00, 0.00
Min, Max	75.0, 100.0	83.3, 100.0	41.7, 100.0	-16.7, 0.0	-16.7, 8.3	-25.0, 8.3
Week 52						
m	4	4	15			
n	4	4	14	4	4	13
Mean (SD/SE)	83.33 (13.59)	100.00 (0.00)	90.48 (21.90)	-12.53 (5.38)	2.08 (2.08)	-1.92 (3.68)
Median	83.30	100.00	100.00	-12.55	0	0
IQR: Q1, Q3	75.00, 91.65	100.00, 100.00	91.70, 100.00	-20.85, -4.20	0.00, 4.15	0.00, 0.00
Min, Max	66.7, 100.0	100.0, 100.0	25.0, 100.0	-25.0, 0.0	0.0, 8.3	-41.7, 16.7

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.10.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=5)	(N=5)	(N=17)	(N=5)	(N=5)	(N=17)
Mental Health						
Baseline						
m	5	5	17			
n	5	5	15			
Mean (SD)	78.0 (14.4)	82.0 (9.1)	88.7 (9.0)			
Median	75.0	85.0	90.0			
IQR: Q1, Q3	75.0, 80.0	75.0, 90.0	85.0, 95.0			
Min, Max	60, 100	70, 90	70, 100			
Week 24						
m	4	4	16			
n	3	4	14	3	4	13
Mean (SD/SE)	85.0 (13.2)	88.8 (8.5)	88.2 (12.7)	1.7 (6.7)	3.8 (7.2)	-1.2 (2.2)
Median	90.0	87.5	90.0	-5.0	-2.5	0
IQR: Q1, Q3	70.0, 95.0	82.5, 95.0	90.0, 95.0	-5.0, 15.0	-5.0, 12.5	-5.0, 5.0
Min, Max	70, 95	80, 100	50, 100	-5, 15	-5, 25	-20, 10
Week 52						
m	4	4	15			
n	4	4	14	4	4	13
Mean (SD/SE)	81.3 (10.3)	86.3 (7.5)	87.1 (18.9)	-1.3 (3.8)	1.3 (5.5)	-2.3 (3.3)
Median	80.0	85.0	92.5	0	0	0
IQR: Q1, Q3	75.0, 87.5	80.0, 92.5	85.0, 100.0	-7.5, 5.0	-7.5, 10.0	-5.0, 5.0
Min, Max	70, 95	80, 95	30, 100	-10, 5	-10, 15	-40, 5

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.10.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=5)	(N=5)	(N=17)	(N=5)	(N=5)	(N=17)
Mental Component Score						
Baseline						
m	5	5	17			
n	5	5	15			
Mean (SD)	52.84 (6.49)	54.28 (2.87)	57.16 (5.35)			
Median	53.30	53.30	59.00			
IQR: Q1, Q3	53.10, 53.80	52.40, 57.10	56.70, 60.10			
Min, Max	42.9, 61.1	51.1, 57.5	44.1, 62.9			
Week 24						
m	4	4	16			
n	3	4	14	3	4	13
Mean (SD/SE)	51.07 (9.58)	56.28 (3.10)	56.84 (4.95)	-4.77 (3.72)	1.75 (3.01)	-0.11 (1.04)
Median	51.90	56.75	57.90	-1.20	1.80	-0.50
IQR: Q1, Q3	41.10, 60.20	54.15, 58.40	56.90, 59.10	-12.20, -0.90	-3.15, 6.65	-1.80, 0.80
Min, Max	41.1, 60.2	52.1, 59.5	42.3, 62.8	-12.2, -0.9	-5.0, 8.4	-4.2, 10.8
Week 52						
m	4	4	15			
n	4	4	14	4	4	13
Mean (SD/SE)	51.30 (5.65)	58.05 (1.37)	57.23 (7.75)	-4.03 (1.16)	3.53 (0.99)	-0.20 (1.07)
Median	49.15	57.90	60.15	-4.20	3.25	0.30
IQR: Q1, Q3	47.55, 55.05	56.90, 59.20	56.30, 61.20	-6.00, -2.05	1.90, 5.15	-0.40, 2.00
Min, Max	47.4, 59.5	56.8, 59.6	35.3, 65.3	-6.1, -1.6	1.7, 5.9	-11.2, 4.3

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.10.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=5)	(N=5)	(N=17)	(N=5)	(N=5)	(N=17)
Physical Component Score						
Baseline						
m	5	5	17			
n	5	5	15			
Mean (SD)	49.44 (5.95)	48.76 (7.90)	47.14 (9.57)			
Median	46.10	44.40	50.20			
IQR: Q1, Q3	45.20, 55.30	43.70, 53.60	43.20, 52.80			
Min, Max	44.1, 56.5	41.8, 60.3	21.6, 59.3			
Week 24						
m	4	4	16			
n	3	4	14	3	4	13
Mean (SD/SE)	53.23 (5.13)	50.48 (6.67)	47.84 (9.84)	4.33 (3.19)	0.63 (1.54)	1.28 (1.69)
Median	54.80	50.80	49.45	1.40	-0.05	2.50
IQR: Q1, Q3	47.50, 57.40	45.45, 55.50	41.40, 55.80	0.90, 10.70	-1.45, 2.70	0.00, 3.20
Min, Max	47.5, 57.4	42.3, 58.0	24.6, 59.3	0.9, 10.7	-2.3, 4.9	-14.2, 11.8
Week 52						
m	4	4	15			
n	4	4	14	4	4	13
Mean (SD/SE)	48.43 (9.32)	48.40 (11.19)	48.54 (8.86)	-2.08 (2.20)	-1.45 (2.51)	1.24 (2.19)
Median	50.60	50.80	51.35	-0.65	-0.15	1.40
IQR: Q1, Q3	41.60, 55.25	40.00, 56.80	42.50, 54.40	-5.00, 0.85	-5.05, 2.15	-0.40, 8.00
Min, Max	35.7, 56.8	33.4, 58.6	31.5, 58.9	-8.4, 1.4	-8.4, 2.9	-15.9, 10.1

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.10.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=10)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=10)	Change from Baseline DB Placebo (N=11)
Physical Functioning						
Baseline						
m	4	10	11			
n	4	9	11			
Mean (SD)	68.75 (34.73)	82.78 (19.38)	85.00 (18.17)			
Median	77.50	90.00	90.00			
IQR: Q1, Q3	45.00, 92.50	80.00, 95.00	75.00, 100.00			
Min, Max	20.0, 100.0	40.0, 100.0	40.0, 100.0			
Week 24						
m	4	8	11			
n	4	7	11	4	7	11
Mean (SD/SE)	78.75 (26.58)	83.57 (18.87)	74.09 (23.11)	10.00 (10.61)	0.71 (2.30)	-10.91 (7.77)
Median	85.00	90.00	80.00	12.50	0	-5.00
IQR: Q1, Q3	57.50, 100.00	75.00, 95.00	60.00, 90.00	-7.50, 27.50	-5.00, 5.00	-15.00, 5.00
Min, Max	45.0, 100.0	45.0, 100.0	20.0, 100.0	-15.0, 30.0	-5.0, 10.0	-75.0, 15.0
Week 52						
m	4	8	11			
n	3	6	10	3	6	10
Mean (SD/SE)	90.00 (10.00)	72.50 (22.97)	81.00 (16.30)	5.00 (7.64)	-9.17 (4.55)	-5.00 (3.07)
Median	90.00	77.50	85.00	0	-7.50	-5.00
IQR: Q1, Q3	80.00, 100.00	50.00, 95.00	70.00, 95.00	-5.00, 20.00	-10.00, 0.00	-10.00, 0.00
Min, Max	80.0, 100.0	40.0, 95.0	50.0, 100.0	-5.0, 20.0	-30.0, 0.0	-20.0, 10.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.10.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=10)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=10)	Change from Baseline DB Placebo (N=11)
Role Physical						
Baseline						
m	4	10	11			
n	4	9	11			
Mean (SD)	81.25 (12.50)	90.99 (14.69)	86.36 (22.68)			
Median	75.00	100.00	100.00			
IQR: Q1, Q3	75.00, 87.50	93.80, 100.00	75.00, 100.00			
Min, Max	75.0, 100.0	62.5, 100.0	25.0, 100.0			
Week 24						
m	4	8	11			
n	4	7	11	4	7	11
Mean (SD/SE)	82.83 (21.25)	86.63 (18.89)	76.15 (28.89)	1.58 (8.97)	-6.24 (6.39)	-10.22 (7.92)
Median	87.50	93.80	87.50	0	0	0
IQR: Q1, Q3	65.65, 100.00	62.50, 100.00	62.50, 100.00	-9.35, 12.50	-6.20, 0.00	-25.00, 0.00
Min, Max	56.3, 100.0	56.3, 100.0	25.0, 100.0	-18.7, 25.0	-43.7, 6.2	-75.0, 18.8
Week 52						
m	4	8	11			
n	3	6	10	3	6	10
Mean (SD/SE)	87.50 (21.65)	75.02 (29.85)	78.14 (25.37)	4.17 (11.02)	-17.70 (10.13)	-8.11 (6.11)
Median	100.00	87.55	87.50	0	-12.45	0
IQR: Q1, Q3	62.50, 100.00	37.50, 100.00	56.30, 100.00	-12.50, 25.00	-25.00, 0.00	-25.00, 0.00
Min, Max	62.5, 100.0	37.5, 100.0	31.3, 100.0	-12.5, 25.0	-62.5, 6.2	-37.5, 25.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.10.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=10)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=10)	Change from Baseline DB Placebo (N=11)
Bodily Pain						
Baseline						
m	4	10	11			
n	4	9	11			
Mean (SD)	80.0 (16.1)	80.2 (16.0)	83.5 (13.5)			
Median	79.0	84.0	84.0			
IQR: Q1, Q3	68.0, 92.0	72.0, 84.0	74.0, 100.0			
Min, Max	62, 100	52, 100	62, 100			
Week 24						
m	4	8	11			
n	4	7	11	4	7	11
Mean (SD/SE)	96.0 (8.0)	78.3 (13.1)	74.1 (26.6)	16.0 (5.7)	-3.1 (6.9)	-9.4 (6.5)
Median	100.0	80.0	84.0	19.0	0	0
IQR: Q1, Q3	92.0, 100.0	64.0, 84.0	41.0, 100.0	8.0, 24.0	-10.0, 16.0	-21.0, 0.0
Min, Max	84, 100	62, 100	31, 100	0, 26	-36, 18	-53, 16
Week 52						
m	4	8	11			
n	3	6	10	3	6	10
Mean (SD/SE)	69.3 (12.7)	71.7 (8.4)	75.9 (21.7)	-16.7 (2.9)	-9.3 (5.0)	-7.5 (4.2)
Median	62.0	74.0	79.0	-16.0	-5.0	-5.0
IQR: Q1, Q3	62.0, 84.0	62.0, 74.0	52.0, 100.0	-22.0, -12.0	-22.0, 0.0	-21.0, 0.0
Min, Max	62, 84	62, 84	41, 100	-22, -12	-26, 2	-28, 16

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.10.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=10)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=10)	Change from Baseline DB Placebo (N=11)
General Health						
Baseline						
m	4	10	11			
n	4	9	11			
Mean (SD)	66.50 (27.77)	68.44 (11.29)	71.91 (12.48)			
Median	79.50	72.00	72.00			
IQR: Q1, Q3	51.00, 82.00	62.00, 77.00	62.00, 82.00			
Min, Max	25.0, 82.0	50.0, 82.0	50.0, 92.0			
Week 24						
m	4	8	11			
n	4	7	11	4	7	11
Mean (SD/SE)	71.50 (31.27)	63.14 (15.30)	68.27 (21.94)	5.00 (2.89)	-5.71 (6.38)	-3.64 (5.27)
Median	84.50	62.00	72.00	5.00	-3.00	0
IQR: Q1, Q3	53.50, 89.50	47.00, 77.00	42.00, 92.00	0.00, 10.00	-25.00, 10.00	-20.00, 10.00
Min, Max	25.0, 92.0	45.0, 87.0	30.0, 92.0	0.0, 10.0	-27.0, 15.0	-35.0, 15.0
Week 52						
m	4	8	11			
n	3	6	10	3	6	10
Mean (SD/SE)	83.67 (10.41)	60.00 (16.37)	68.80 (18.86)	3.33 (6.67)	-7.50 (4.10)	-3.30 (4.43)
Median	87.00	57.00	63.50	10.00	-5.00	-2.50
IQR: Q1, Q3	72.00, 92.00	45.00, 77.00	52.00, 92.00	-10.00, 10.00	-8.00, 0.00	-10.00, 10.00
Min, Max	72.0, 92.0	42.0, 82.0	47.0, 97.0	-10.0, 10.0	-27.0, 0.0	-30.0, 15.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.10.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=10)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=10)	Change from Baseline DB Placebo (N=11)
Vitality						
Baseline						
m	4	10	11			
n	4	9	11			
Mean (SD)	53.15 (35.55)	69.48 (14.48)	68.21 (21.00)			
Median	68.80	68.80	68.80			
IQR: Q1, Q3	34.40, 71.90	62.50, 81.30	50.00, 87.50			
Min, Max	0.0, 75.0	43.8, 93.8	37.5, 100.0			
Week 24						
m	4	8	11			
n	4	7	11	4	7	11
Mean (SD/SE)	54.70 (37.29)	67.90 (16.31)	56.84 (26.43)	1.55 (5.33)	-1.77 (7.93)	-11.37 (5.25)
Median	68.75	68.80	62.50	3.10	0	-6.30
IQR: Q1, Q3	31.25, 78.15	56.30, 81.30	37.50, 75.00	-6.25, 9.35	-18.70, 12.50	-18.70, 0.00
Min, Max	0.0, 81.3	43.8, 93.8	6.3, 93.8	-12.5, 12.5	-31.3, 31.3	-50.0, 6.2
Week 52						
m	4	8	11			
n	3	6	10	3	6	10
Mean (SD/SE)	70.87 (3.58)	60.45 (13.51)	61.89 (23.11)	0.00 (3.58)	-7.28 (2.51)	-8.76 (3.12)
Median	68.80	59.40	62.50	0	-9.35	-6.25
IQR: Q1, Q3	68.80, 75.00	50.00, 68.80	37.50, 81.30	-6.20, 6.20	-12.50, 0.00	-18.80, 0.00
Min, Max	68.8, 75.0	43.8, 81.3	25.0, 100.0	-6.2, 6.2	-12.5, 0.0	-25.0, 6.2

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.10.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=10)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=10)	Change from Baseline DB Placebo (N=11)
Social Functioning						
Baseline						
m	4	10	11			
n	4	9	11			
Mean (SD)	90.63 (18.75)	94.44 (9.08)	95.45 (11.56)			
Median	100.00	100.00	100.00			
IQR: Q1, Q3	81.25, 100.00	87.50, 100.00	100.00, 100.00			
Min, Max	62.5, 100.0	75.0, 100.0	62.5, 100.0			
Week 24						
m	4	8	11			
n	4	7	11	4	7	11
Mean (SD/SE)	87.50 (25.00)	92.86 (9.83)	82.95 (32.73)	-3.13 (3.13)	-3.57 (4.49)	-12.50 (9.38)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	87.50, 100.00	62.50, 100.00	-6.25, 0.00	-12.50, 0.00	0.00, 0.00
Min, Max	50.0, 100.0	75.0, 100.0	0.0, 100.0	-12.5, 0.0	-25.0, 12.5	-100.0, 0.0
Week 52						
m	4	8	11			
n	3	6	10	3	6	10
Mean (SD/SE)	100.00 (0.00)	87.50 (11.18)	90.00 (16.46)	0.00 (0.00)	-10.42 (5.97)	-5.00 (3.82)
Median	100.00	87.50	100.00	0	-12.50	0
IQR: Q1, Q3	100.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 0.00	-25.00, 0.00	0.00, 0.00
Min, Max	100.0, 100.0	75.0, 100.0	62.5, 100.0	0.0, 0.0	-25.0, 12.5	-37.5, 0.0

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.10.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter	Visit Result			Change from Baseline		
Visit	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo	DB MGL-3196 80 mg	DB MGL-3196 100 mg	DB Placebo
Statistic	(N=4)	(N=10)	(N=11)	(N=4)	(N=10)	(N=11)
Role Emotional						
Baseline						
m	4	10	11			
n	4	9	11			
Mean (SD)	97.93 (4.15)	98.14 (5.57)	87.88 (18.76)			
Median	100.00	100.00	100.00			
IQR: Q1, Q3	95.85, 100.00	100.00, 100.00	83.30, 100.00			
Min, Max	91.7, 100.0	83.3, 100.0	41.7, 100.0			
Week 24						
m	4	8	11			
n	4	7	11	4	7	11
Mean (SD/SE)	91.68 (16.65)	89.29 (19.67)	80.30 (20.50)	-6.25 (9.23)	-8.33 (8.34)	-7.58 (4.56)
Median	100.00	100.00	83.30	0	0	0
IQR: Q1, Q3	83.35, 100.00	75.00, 100.00	66.70, 100.00	-16.65, 4.15	-25.00, 0.00	-8.40, 0.00
Min, Max	66.7, 100.0	50.0, 100.0	41.7, 100.0	-33.3, 8.3	-50.0, 16.7	-50.0, 0.0
Week 52						
m	4	8	11			
n	3	6	10	3	6	10
Mean (SD/SE)	100.00 (0.00)	84.72 (20.01)	79.99 (18.93)	2.77 (2.77)	-12.50 (8.54)	-6.68 (6.78)
Median	100.00	91.65	79.15	0	0	0
IQR: Q1, Q3	100.00, 100.00	75.00, 100.00	58.30, 100.00	0.00, 8.30	-25.00, 0.00	-25.00, 0.00
Min, Max	100.0, 100.0	50.0, 100.0	58.3, 100.0	0.0, 8.3	-50.0, 0.0	-41.7, 33.3

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.10.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=10)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=10)	Change from Baseline DB Placebo (N=11)
Mental Health						
Baseline						
m	4	10	11			
n	4	9	11			
Mean (SD)	85.0 (10.0)	87.8 (6.2)	75.5 (17.8)			
Median	90.0	85.0	75.0			
IQR: Q1, Q3	80.0, 90.0	85.0, 90.0	60.0, 95.0			
Min, Max	70, 90	80, 100	50, 100			
Week 24						
m	4	8	11			
n	4	7	11	4	7	11
Mean (SD/SE)	87.5 (12.6)	82.9 (14.1)	74.5 (19.7)	2.5 (2.5)	-4.3 (5.6)	-0.9 (2.1)
Median	90.0	85.0	75.0	0	0	0
IQR: Q1, Q3	80.0, 95.0	75.0, 95.0	55.0, 95.0	0.0, 5.0	-10.0, 5.0	-5.0, 0.0
Min, Max	70, 100	55, 95	45, 100	0, 10	-35, 10	-10, 15
Week 52						
m	4	8	11			
n	3	6	10	3	6	10
Mean (SD/SE)	91.7 (2.9)	77.5 (10.8)	77.5 (18.3)	1.7 (1.7)	-10.0 (3.4)	2.5 (4.5)
Median	90.0	80.0	80.0	0	-5.0	2.5
IQR: Q1, Q3	90.0, 95.0	70.0, 85.0	60.0, 95.0	0.0, 5.0	-15.0, -5.0	-10.0, 15.0
Min, Max	90, 95	60, 90	50, 100	0, 5	-25, -5	-15, 25

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.10.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=10)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=10)	Change from Baseline DB Placebo (N=11)
Mental Component Score						
Baseline						
m	4	10	11			
n	4	9	11			
Mean (SD)	56.35 (4.71)	57.67 (2.23)	52.47 (8.31)			
Median	58.10	57.50	52.40			
IQR: Q1, Q3	53.25, 59.45	55.40, 59.00	44.50, 62.10			
Min, Max	49.5, 59.7	55.2, 60.9	38.1, 63.2			
Week 24						
m	4	8	11			
n	4	7	11	4	7	11
Mean (SD/SE)	54.08 (9.74)	54.70 (7.55)	50.08 (9.57)	-2.28 (2.51)	-2.80 (3.23)	-2.39 (1.21)
Median	57.85	57.30	48.50	-0.25	-0.30	-1.90
IQR: Q1, Q3	47.70, 60.45	48.30, 60.80	40.10, 60.40	-5.55, 1.00	-6.90, 3.20	-5.90, -0.40
Min, Max	39.9, 60.7	40.8, 61.0	37.1, 62.5	-9.6, 1.0	-20.1, 5.4	-8.1, 4.0
Week 52						
m	4	8	11			
n	3	6	10	3	6	10
Mean (SD/SE)	59.60 (2.36)	52.87 (5.00)	51.31 (9.97)	0.97 (0.54)	-4.73 (1.62)	-0.97 (2.68)
Median	60.60	53.15	52.50	1.40	-2.80	0.75
IQR: Q1, Q3	56.90, 61.30	52.60, 55.00	40.60, 60.40	-0.10, 1.60	-7.80, -2.00	-6.60, 5.00
Min, Max	56.9, 61.3	44.0, 59.3	37.9, 65.5	-0.1, 1.6	-11.4, -1.6	-16.0, 8.7

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.10.1
Liver Disease Quality of Life SF-36 (SE21): Summary of Results by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter / Visit / Statistic	Visit Result DB MGL-3196 80 mg (N=4)	Visit Result DB MGL-3196 100 mg (N=10)	Visit Result DB Placebo (N=11)	Change from Baseline DB MGL-3196 80 mg (N=4)	Change from Baseline DB MGL-3196 100 mg (N=10)	Change from Baseline DB Placebo (N=11)
Physical Component Score						
Baseline						
m	4	10	11			
n	4	9	11			
Mean (SD)	47.23 (10.82)	50.86 (6.26)	53.69 (5.71)			
Median	49.35	53.10	55.90			
IQR: Q1, Q3	40.65, 53.80	51.30, 54.40	49.80, 57.10			
Min, Max	32.2, 58.0	37.8, 56.1	42.8, 61.1			
Week 24						
m	4	8	11			
n	4	7	11	4	7	11
Mean (SD/SE)	51.93 (9.21)	50.83 (5.71)	49.59 (10.97)	4.70 (2.19)	-0.59 (1.55)	-4.10 (3.03)
Median	54.65	50.90	53.40	4.10	0.90	-0.10
IQR: Q1, Q3	45.00, 58.85	48.00, 55.50	38.20, 57.10	1.00, 8.40	-4.50, 3.10	-6.60, 1.00
Min, Max	39.4, 59.0	40.9, 58.0	25.9, 61.0	1.0, 9.6	-6.4, 4.2	-30.0, 7.3
Week 52						
m	4	8	11			
n	3	6	10	3	6	10
Mean (SD/SE)	51.40 (6.35)	47.25 (8.39)	50.99 (7.89)	-0.83 (2.51)	-3.70 (2.37)	-3.05 (1.40)
Median	52.70	49.05	53.20	-1.00	-2.40	-2.10
IQR: Q1, Q3	44.50, 57.00	39.60, 52.40	50.20, 56.30	-5.10, 3.60	-4.00, -0.60	-7.10, 0.30
Min, Max	44.5, 57.0	35.3, 58.1	35.7, 58.7	-5.1, 3.6	-14.8, 2.0	-8.7, 2.8

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n under 'Visit Result' is the number of subjects with a result at the given visit; n under 'Change from Baseline' is the number of subjects with results at both baseline and the given visit.
Program: t-se18-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table SE21.10.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not Estimable.
Note: m is the number of subjects in the study at the given visit, derived based on SF-36 analysis visit window in the SAP; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples. The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

AMNOG Table SE21.10.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Physical Functioning			
Week 24			
m	4	4	16
n	3	4	13
Baseline Mean (SD)	81.67 (7.64)	78.75 (15.48)	78.46 (24.95)
Analysis Visit Mean (SD)	90.00 (8.66)	83.75 (12.50)	78.85 (27.32)
LS Mean of Change from Baseline (SE)	13.32 (10.88)	10.70 (11.78)	3.71 (8.79)
95% CI	(-9.64, 36.28)	(-14.16, 35.55)	(-14.84, 22.26)
LS Mean of Change from Baseline Compared to Placebo (SE)	9.61 (11.60)	6.99 (11.03)	
95% CI	(-14.86, 34.08)	(-16.29, 30.26)	
p-value	0.4189	0.5350	
Corrected Hedge's g Statistics	0.301	0.219	
95% CI	(-0.96, 1.56)	(-0.90, 1.34)	
Week 52			
m	4	4	15
n	4	4	13
Baseline Mean (SD)	82.50 (6.45)	78.75 (15.48)	78.46 (24.95)
Analysis Visit Mean (SD)	71.25 (15.48)	77.50 (21.02)	81.28 (27.24)
LS Mean of Change from Baseline (SE)	-7.75 (10.89)	4.47 (12.09)	6.19 (8.92)
95% CI	(-30.71, 15.22)	(-21.04, 29.99)	(-12.63, 25.02)
LS Mean of Change from Baseline Compared to Placebo (SE)	-13.94 (11.48)	-1.72 (11.47)	
95% CI	(-38.16, 10.28)	(-25.92, 22.48)	
p-value	0.2413	0.8825	
Corrected Hedge's g Statistics	-0.436	-0.053	
95% CI	(-1.57, 0.69)	(-1.17, 1.07)	
Subgroup*Treatment Interaction p-value	0.2276	0.6982	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 3 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.10.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline Statin

(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Role Physical			
Week 24			
m	4	4	16
n	3	4	13
Baseline Mean (SD)	85.43 (15.70)	87.50 (14.43)	72.13 (26.84)
Analysis Visit Mean (SD)	91.67 (14.43)	87.53 (15.28)	77.89 (33.22)
LS Mean of Change from Baseline (SE)	10.62 (10.66)	10.18 (11.13)	13.48 (8.06)
95% CI	(-11.87, 33.10)	(-13.29, 33.66)	(-3.51, 30.48)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.87 (11.72)	-3.30 (10.70)	
95% CI	(-27.59, 21.85)	(-25.87, 19.27)	
p-value	0.8096	0.7614	
Corrected Hedge's g Statistics	-0.098	-0.113	
95% CI	(-1.35, 1.16)	(-1.23, 1.01)	
Week 52			
m	4	4	15
n	4	4	13
Baseline Mean (SD)	89.08 (14.75)	87.50 (14.43)	72.13 (26.84)
Analysis Visit Mean (SD)	81.25 (16.14)	78.13 (29.54)	75.97 (27.57)
LS Mean of Change from Baseline (SE)	-0.05 (11.05)	2.43 (11.98)	10.61 (8.45)
95% CI	(-23.37, 23.26)	(-22.85, 27.71)	(-7.21, 28.43)
LS Mean of Change from Baseline Compared to Placebo (SE)	-10.66 (12.04)	-8.18 (11.90)	
95% CI	(-36.06, 14.73)	(-33.29, 16.93)	
p-value	0.3881	0.5012	
Corrected Hedge's g Statistics	-0.349	-0.265	
95% CI	(-1.48, 0.78)	(-1.39, 0.86)	
Subgroup*Treatment Interaction p-value	0.3127	0.7922	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE21.10.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Bodily Pain			
Week 24			
m	4	4	16
n	3	4	13
Baseline Mean (SD)	61.3 (34.9)	81.0 (21.9)	71.2 (26.2)
Analysis Visit Mean (SD)	71.0 (25.7)	78.5 (25.2)	75.2 (25.4)
LS Mean of Change from Baseline (SE)	9.31 (4.42)	0.48 (4.85)	5.25 (3.57)
95% CI	(-0.01, 18.63)	(-9.76, 10.71)	(-2.28, 12.78)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.06 (5.17)	-4.77 (4.33)	
95% CI	(-6.84, 14.95)	(-13.92, 4.37)	
p-value	0.4431	0.2862	
Corrected Hedge's g Statistics	0.313	-0.368	
95% CI	(-0.95, 1.57)	(-1.50, 0.76)	
Week 52			
m	4	4	15
n	4	4	13
Baseline Mean (SD)	71.0 (34.5)	81.0 (21.9)	71.2 (26.2)
Analysis Visit Mean (SD)	67.0 (33.8)	81.5 (23.2)	73.1 (20.4)
LS Mean of Change from Baseline (SE)	-3.31 (6.41)	4.87 (6.91)	2.98 (4.50)
95% CI	(-16.85, 10.22)	(-9.70, 19.44)	(-6.50, 12.47)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.30 (7.10)	1.89 (7.14)	
95% CI	(-21.27, 8.68)	(-13.17, 16.94)	
p-value	0.3873	0.7947	
Corrected Hedge's g Statistics	-0.383	0.114	
95% CI	(-1.51, 0.74)	(-1.01, 1.23)	
Subgroup*Treatment Interaction p-value	0.4100	0.9129	

Madrigal Pharmaceuticals, Inc. Page 5 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.10.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline Statin

(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
General Health			
Week 24			
m	4	4	16
n	3	4	13
Baseline Mean (SD)	73.67 (15.28)	65.75 (14.36)	70.54 (22.30)
Analysis Visit Mean (SD)	78.67 (16.07)	69.50 (15.55)	68.23 (16.70)
LS Mean of Change from Baseline (SE)	8.03 (6.37)	5.15 (6.82)	0.75 (5.23)
95% CI	(-5.40, 21.47)	(-9.24, 19.54)	(-10.28, 11.79)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.28 (6.93)	4.40 (6.33)	
95% CI	(-7.34, 21.90)	(-8.96, 17.75)	
p-value	0.3079	0.4967	
Corrected Hedge's g Statistics	0.384	0.233	
95% CI	(-0.88, 1.65)	(-0.89, 1.36)	
Week 52			
m	4	4	15
n	4	4	13
Baseline Mean (SD)	72.00 (12.91)	65.75 (14.36)	70.54 (22.30)
Analysis Visit Mean (SD)	74.00 (15.25)	68.25 (13.77)	66.96 (21.34)
LS Mean of Change from Baseline (SE)	4.73 (8.32)	3.74 (8.89)	-0.50 (6.11)
95% CI	(-12.82, 22.28)	(-15.02, 22.50)	(-13.38, 12.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.23 (9.06)	4.24 (9.09)	
95% CI	(-13.88, 24.34)	(-14.95, 23.42)	
p-value	0.5715	0.6471	
Corrected Hedge's g Statistics	0.236	0.189	
95% CI	(-0.89, 1.36)	(-0.93, 1.31)	
Subgroup*Treatment Interaction p-value	0.9369	0.1878	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 6 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.10.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline Statin

(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Vitality			
Week 24			
m	4	4	16
n	3	4	13
Baseline Mean (SD)	62.53 (18.75)	62.53 (11.41)	64.92 (17.78)
Analysis Visit Mean (SD)	54.20 (28.21)	64.08 (12.87)	69.73 (12.97)
LS Mean of Change from Baseline (SE)	-7.07 (6.03)	6.18 (6.51)	9.33 (5.13)
95% CI	(-19.80, 5.65)	(-7.56, 19.92)	(-1.49, 20.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	-16.40 (6.78)	-3.15 (6.02)	
95% CI	(-30.70, -2.10)	(-15.84, 9.54)	
p-value	0.0270	0.6075	
Corrected Hedge's g Statistics	-0.883	-0.170	
95% CI	(-2.17, 0.41)	(-1.29, 0.95)	
Week 52			
m	4	4	15
n	4	4	13
Baseline Mean (SD)	60.98 (15.62)	62.53 (11.41)	64.92 (17.78)
Analysis Visit Mean (SD)	46.90 (24.19)	59.40 (20.70)	69.24 (22.46)
LS Mean of Change from Baseline (SE)	-11.58 (8.96)	1.75 (9.48)	8.65 (6.40)
95% CI	(-30.49, 7.33)	(-18.26, 21.76)	(-4.85, 22.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	-20.23 (9.99)	-6.90 (9.92)	
95% CI	(-41.31, 0.85)	(-27.84, 14.04)	
p-value	0.0589	0.4964	
Corrected Hedge's g Statistics	-0.867	-0.293	
95% CI	(-2.03, 0.29)	(-1.42, 0.83)	
Subgroup*Treatment Interaction p-value	0.0141	0.4123	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 7 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.10.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline Statin

(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Social Functioning			
Week 24			
m	4	4	16
n	3	4	13
Baseline Mean (SD)	91.67 (14.43)	75.00 (25.00)	89.42 (21.56)
Analysis Visit Mean (SD)	79.17 (19.09)	87.50 (14.43)	91.35 (12.89)
LS Mean of Change from Baseline (SE)	-8.09 (7.95)	1.06 (7.83)	1.52 (5.37)
95% CI	(-24.87, 8.69)	(-15.47, 17.59)	(-9.80, 12.84)
LS Mean of Change from Baseline Compared to Placebo (SE)	-9.61 (8.68)	-0.46 (8.14)	
95% CI	(-27.92, 8.71)	(-17.63, 16.71)	
p-value	0.2838	0.9556	
Corrected Hedge's g Statistics	-0.487	-0.023	
95% CI	(-1.75, 0.78)	(-1.14, 1.10)	
Week 52			
m	4	4	15
n	4	4	13
Baseline Mean (SD)	93.75 (12.50)	75.00 (25.00)	89.42 (21.56)
Analysis Visit Mean (SD)	81.25 (21.65)	100.00 (0.00)	96.15 (10.69)
LS Mean of Change from Baseline (SE)	-9.66 (6.00)	14.29 (6.62)	6.19 (4.87)
95% CI	(-22.32, 3.00)	(0.32, 28.27)	(-4.08, 16.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	-15.85 (6.28)	8.10 (6.56)	
95% CI	(-29.09, -2.61)	(-5.74, 21.94)	
p-value	0.0217	0.2338	
Corrected Hedge's g Statistics	-0.907	0.458	
95% CI	(-2.07, 0.25)	(-0.67, 1.59)	
Subgroup*Treatment Interaction p-value	0.0117	0.0884	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 8 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.10.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline Statin

(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Role Emotional			
Week 24			
m	4	4	16
n	3	4	13
Baseline Mean (SD)	94.47 (4.79)	97.93 (4.15)	91.67 (16.66)
Analysis Visit Mean (SD)	86.10 (12.73)	95.83 (8.35)	91.02 (19.08)
LS Mean of Change from Baseline (SE)	-7.46 (5.02)	0.70 (5.72)	2.71 (4.15)
95% CI	(-18.04, 3.13)	(-11.37, 12.76)	(-6.04, 11.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	-10.16 (5.41)	-2.01 (5.28)	
95% CI	(-21.58, 1.25)	(-13.14, 9.12)	
p-value	0.0777	0.7077	
Corrected Hedge's g Statistics	-0.675	-0.133	
95% CI	(-1.95, 0.60)	(-1.25, 0.99)	
Week 52			
m	4	4	15
n	4	4	13
Baseline Mean (SD)	95.85 (4.79)	97.93 (4.15)	91.67 (16.66)
Analysis Visit Mean (SD)	83.33 (13.59)	100.00 (0.00)	89.75 (22.61)
LS Mean of Change from Baseline (SE)	-10.59 (6.58)	4.54 (7.17)	1.57 (4.79)
95% CI	(-24.48, 3.31)	(-10.59, 19.66)	(-8.53, 11.67)
LS Mean of Change from Baseline Compared to Placebo (SE)	-12.16 (7.18)	2.96 (7.25)	
95% CI	(-27.30, 2.98)	(-12.34, 18.27)	
p-value	0.1085	0.6878	
Corrected Hedge's g Statistics	-0.698	0.168	
95% CI	(-1.84, 0.45)	(-0.95, 1.29)	
Subgroup*Treatment Interaction p-value	0.2086	0.5638	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE21.10.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Mental Health			
Week 24			
m	4	4	16
n	3	4	13
Baseline Mean (SD)	83.3 (14.4)	85.0 (7.1)	89.2 (9.5)
Analysis Visit Mean (SD)	85.0 (13.2)	88.8 (8.5)	88.1 (13.2)
LS Mean of Change from Baseline (SE)	1.60 (5.67)	8.42 (6.23)	3.40 (5.00)
95% CI	(-10.36, 13.55)	(-4.73, 21.58)	(-7.16, 13.95)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.80 (6.50)	5.03 (6.03)	
95% CI	(-15.51, 11.91)	(-7.70, 17.76)	
p-value	0.7854	0.4160	
Corrected Hedge's g Statistics	-0.099	0.280	
95% CI	(-1.36, 1.16)	(-0.84, 1.40)	
Week 52			
m	4	4	15
n	4	4	13
Baseline Mean (SD)	82.5 (11.9)	85.0 (7.1)	89.2 (9.5)
Analysis Visit Mean (SD)	81.3 (10.3)	86.3 (7.5)	86.9 (19.6)
LS Mean of Change from Baseline (SE)	3.28 (6.18)	7.17 (6.79)	1.21 (5.23)
95% CI	(-9.76, 16.32)	(-7.16, 21.50)	(-9.82, 12.24)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.07 (7.02)	5.96 (6.79)	
95% CI	(-12.74, 16.87)	(-8.37, 20.29)	
p-value	0.7717	0.3924	
Corrected Hedge's g Statistics	0.111	0.316	
95% CI	(-1.01, 1.23)	(-0.81, 1.44)	
Subgroup*Treatment Interaction p-value	0.7028	0.1422	

Madrigal Pharmaceuticals, Inc. Page 10 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.10.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline Statin

(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Mental Component Score			
Week 24			
m	4	4	16
n	3	4	13
Baseline Mean (SD)	55.83 (4.56)	54.53 (3.25)	57.36 (5.68)
Analysis Visit Mean (SD)	51.07 (9.58)	56.28 (3.10)	57.25 (4.89)
LS Mean of Change from Baseline (SE)	-5.31 (2.54)	1.37 (2.61)	0.57 (1.91)
95% CI	(-10.68, 0.06)	(-4.15, 6.88)	(-3.45, 4.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.88 (2.80)	0.79 (2.68)	
95% CI	(-11.79, 0.02)	(-4.87, 6.45)	
p-value	0.0508	0.7709	
Corrected Hedge's g Statistics	-0.845	0.114	
95% CI	(-2.13, 0.44)	(-1.01, 1.24)	
Week 52			
m	4	4	15
n	4	4	13
Baseline Mean (SD)	55.33 (3.86)	54.53 (3.25)	57.36 (5.68)
Analysis Visit Mean (SD)	51.30 (5.65)	58.05 (1.37)	57.16 (8.06)
LS Mean of Change from Baseline (SE)	-3.54 (1.95)	4.27 (2.20)	-0.01 (1.74)
95% CI	(-7.65, 0.57)	(-0.38, 8.92)	(-3.69, 3.67)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.53 (2.12)	4.28 (2.14)	
95% CI	(-7.99, 0.94)	(-0.23, 8.79)	
p-value	0.1138	0.0613	
Corrected Hedge's g Statistics	-0.569	0.682	
95% CI	(-1.71, 0.57)	(-0.46, 1.83)	
Subgroup*Treatment Interaction p-value	0.1305	0.2589	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 11 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.10.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline Statin

(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Visit Statistic	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Physical Component Score			
Week 24			
m	4	4	16
n	3	4	13
Baseline Mean (SD)	48.90 (6.66)	49.85 (8.68)	47.15 (10.21)
Analysis Visit Mean (SD)	53.23 (5.13)	50.48 (6.67)	48.43 (9.98)
LS Mean of Change from Baseline (SE)	5.68 (3.17)	3.33 (3.37)	2.69 (2.48)
95% CI	(-1.01, 12.36)	(-3.78, 10.44)	(-2.56, 7.93)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.99 (3.45)	0.65 (3.12)	
95% CI	(-4.28, 10.27)	(-5.94, 7.24)	
p-value	0.3975	0.8386	
Corrected Hedge's g Statistics	0.331	0.072	
95% CI	(-0.93, 1.59)	(-1.05, 1.19)	
Week 52			
m	4	4	15
n	4	4	13
Baseline Mean (SD)	50.50 (6.31)	49.85 (8.68)	47.15 (10.21)
Analysis Visit Mean (SD)	48.43 (9.32)	48.40 (11.19)	48.39 (9.20)
LS Mean of Change from Baseline (SE)	-0.27 (3.65)	1.31 (3.95)	2.62 (2.74)
95% CI	(-7.97, 7.43)	(-7.02, 9.63)	(-3.16, 8.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.89 (3.93)	-1.31 (3.92)	
95% CI	(-11.17, 5.39)	(-9.57, 6.95)	
p-value	0.4717	0.7419	
Corrected Hedge's g Statistics	-0.291	-0.131	
95% CI	(-1.42, 0.83)	(-1.25, 0.99)	
Subgroup*Treatment Interaction p-value	0.3565	0.7989	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 12 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.10.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Physical Functioning			
Week 24			
m	4	8	11
n	4	7	11
Baseline Mean (SD)	68.75 (34.73)	82.86 (19.97)	85.00 (18.17)
Analysis Visit Mean (SD)	78.75 (26.58)	83.57 (18.87)	74.09 (23.11)
LS Mean of Change from Baseline (SE)	4.04 (9.92)	0.07 (7.39)	-10.06 (5.76)
95% CI	(-16.71, 24.80)	(-15.41, 15.55)	(-22.12, 1.99)
LS Mean of Change from Baseline Compared to Placebo (SE)	14.11 (11.57)	10.13 (9.33)	
95% CI	(-10.12, 38.33)	(-9.40, 29.66)	
p-value	0.2378	0.2911	
Corrected Hedge's g Statistics	0.689	0.501	
95% CI	(-0.48, 1.86)	(-0.46, 1.46)	
Week 52			
m	4	8	11
n	3	6	10
Baseline Mean (SD)	85.00 (15.00)	81.67 (21.60)	86.00 (18.83)
Analysis Visit Mean (SD)	90.00 (10.00)	72.50 (22.97)	81.00 (16.30)
LS Mean of Change from Baseline (SE)	5.65 (6.08)	-10.07 (4.56)	-4.26 (3.33)
95% CI	(-7.08, 18.38)	(-19.61, -0.53)	(-11.23, 2.71)
LS Mean of Change from Baseline Compared to Placebo (SE)	9.91 (6.91)	-5.81 (5.67)	
95% CI	(-4.55, 24.37)	(-17.68, 6.06)	
p-value	0.1678	0.3183	
Corrected Hedge's g Statistics	0.875	-0.511	
95% CI	(-0.46, 2.21)	(-1.54, 0.52)	
Subgroup*Treatment Interaction p-value	0.2276	0.6982	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 13 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.10.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Role Physical			
Week 24			
m	4	8	11
n	4	7	11
Baseline Mean (SD)	81.25 (12.50)	92.87 (13.71)	86.36 (22.68)
Analysis Visit Mean (SD)	82.83 (21.25)	86.63 (18.89)	76.15 (28.89)
LS Mean of Change from Baseline (SE)	-0.67 (10.87)	-8.09 (8.66)	-11.14 (6.50)
95% CI	(-23.43, 22.09)	(-26.21, 10.03)	(-24.74, 2.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	10.47 (12.62)	3.05 (10.78)	
95% CI	(-15.94, 36.88)	(-19.51, 25.61)	
p-value	0.4171	0.7803	
Corrected Hedge's g Statistics	0.456	0.132	
95% CI	(-0.70, 1.61)	(-0.82, 1.08)	
Week 52			
m	4	8	11
n	3	6	10
Baseline Mean (SD)	83.33 (14.43)	92.72 (15.01)	86.25 (23.90)
Analysis Visit Mean (SD)	87.50 (21.65)	75.02 (29.85)	78.14 (25.37)
LS Mean of Change from Baseline (SE)	4.01 (12.54)	-19.93 (9.24)	-8.61 (6.83)
95% CI	(-22.23, 30.25)	(-39.28, -0.58)	(-22.90, 5.68)
LS Mean of Change from Baseline Compared to Placebo (SE)	12.62 (14.25)	-11.32 (11.52)	
95% CI	(-17.21, 42.45)	(-35.44, 12.80)	
p-value	0.3869	0.3382	
Corrected Hedge's g Statistics	0.543	-0.487	
95% CI	(-0.76, 1.85)	(-1.51, 0.54)	
Subgroup*Treatment Interaction p-value	0.3127	0.7922	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 14 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.10.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Bodily Pain			
Week 24			
m	4	8	11
n	4	7	11
Baseline Mean (SD)	80.0 (16.1)	81.4 (11.8)	83.5 (13.5)
Analysis Visit Mean (SD)	96.0 (8.0)	78.3 (13.1)	74.1 (26.6)
LS Mean of Change from Baseline (SE)	15.46 (9.34)	-6.35 (7.30)	-9.56 (5.63)
95% CI	(-4.09, 35.02)	(-21.64, 8.93)	(-21.34, 2.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	25.03 (10.93)	3.21 (9.16)	
95% CI	(2.15, 47.90)	(-15.97, 22.39)	
p-value	0.0337	0.7299	
Corrected Hedge's g Statistics	1.262	0.162	
95% CI	(0.03, 2.49)	(-0.79, 1.11)	
Week 52			
m	4	8	11
n	3	6	10
Baseline Mean (SD)	86.0 (13.1)	81.0 (12.9)	83.4 (14.3)
Analysis Visit Mean (SD)	69.3 (12.7)	71.7 (8.4)	75.9 (21.7)
LS Mean of Change from Baseline (SE)	-15.39 (7.28)	-12.04 (5.42)	-7.82 (3.95)
95% CI	(-30.62, -0.16)	(-23.38, -0.71)	(-16.10, 0.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	-7.57 (8.27)	-4.22 (6.70)	
95% CI	(-24.88, 9.74)	(-18.24, 9.79)	
p-value	0.3715	0.5359	
Corrected Hedge's g Statistics	-0.562	-0.312	
95% CI	(-1.87, 0.75)	(-1.33, 0.71)	
Subgroup*Treatment Interaction p-value	0.4100	0.9129	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 15 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.10.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
General Health			
Week 24			
m	4	8	11
n	4	7	11
Baseline Mean (SD)	66.50 (27.77)	68.86 (12.68)	71.91 (12.48)
Analysis Visit Mean (SD)	71.50 (31.27)	63.14 (15.30)	68.27 (21.94)
LS Mean of Change from Baseline (SE)	4.75 (8.39)	-6.99 (6.68)	-3.73 (5.03)
95% CI	(-12.80, 22.31)	(-20.97, 6.99)	(-14.26, 6.81)
LS Mean of Change from Baseline Compared to Placebo (SE)	8.48 (9.81)	-3.26 (8.30)	
95% CI	(-12.05, 29.01)	(-20.64, 14.12)	
p-value	0.3980	0.6987	
Corrected Hedge's g Statistics	0.478	-0.182	
95% CI	(-0.68, 1.63)	(-1.13, 0.77)	
Week 52			
m	4	8	11
n	3	6	10
Baseline Mean (SD)	80.33 (2.89)	67.50 (13.32)	72.10 (13.14)
Analysis Visit Mean (SD)	83.67 (10.41)	60.00 (16.37)	68.80 (18.86)
LS Mean of Change from Baseline (SE)	2.65 (7.74)	-9.25 (5.80)	-4.48 (4.14)
95% CI	(-13.54, 18.84)	(-21.39, 2.88)	(-13.14, 4.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.13 (8.72)	-4.78 (7.14)	
95% CI	(-11.12, 25.38)	(-19.71, 10.16)	
p-value	0.4238	0.5114	
Corrected Hedge's g Statistics	0.504	-0.334	
95% CI	(-0.80, 1.81)	(-1.35, 0.68)	
Subgroup*Treatment Interaction p-value	0.9369	0.1878	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE21.10.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Vitality			
Week 24			
m	4	8	11
n	4	7	11
Baseline Mean (SD)	53.15 (35.55)	69.67 (16.71)	68.21 (21.00)
Analysis Visit Mean (SD)	54.70 (37.29)	67.90 (16.31)	56.84 (26.43)
LS Mean of Change from Baseline (SE)	-0.97 (9.59)	-0.62 (7.12)	-11.18 (5.55)
95% CI	(-21.05, 19.10)	(-15.52, 14.27)	(-22.80, 0.43)
LS Mean of Change from Baseline Compared to Placebo (SE)	10.21 (11.11)	10.56 (8.99)	
95% CI	(-13.04, 33.46)	(-8.25, 29.38)	
p-value	0.3696	0.2546	
Corrected Hedge's g Statistics	0.517	0.542	
95% CI	(-0.64, 1.68)	(-0.42, 1.51)	
Week 52			
m	4	8	11
n	3	6	10
Baseline Mean (SD)	70.87 (3.58)	67.73 (17.43)	70.65 (20.42)
Analysis Visit Mean (SD)	70.87 (3.58)	60.45 (13.51)	61.89 (23.11)
LS Mean of Change from Baseline (SE)	-0.25 (5.01)	-6.57 (3.75)	-8.55 (2.74)
95% CI	(-10.73, 10.23)	(-14.42, 1.28)	(-14.28, -2.82)
LS Mean of Change from Baseline Compared to Placebo (SE)	8.30 (5.69)	1.98 (4.63)	
95% CI	(-3.61, 20.21)	(-7.71, 11.67)	
p-value	0.1611	0.6739	
Corrected Hedge's g Statistics	0.891	0.211	
95% CI	(-0.44, 2.23)	(-0.80, 1.23)	
Subgroup*Treatment Interaction p-value	0.0141	0.4123	

Madrigal Pharmaceuticals, Inc. Page 17 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.10.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Social Functioning			
Week 24			
m	4	8	11
n	4	7	11
Baseline Mean (SD)	90.63 (18.75)	96.43 (6.10)	95.45 (11.56)
Analysis Visit Mean (SD)	87.50 (25.00)	92.86 (9.83)	82.95 (32.73)
LS Mean of Change from Baseline (SE)	-3.10 (12.15)	-6.61 (9.21)	-12.88 (7.19)
95% CI	(-28.53, 22.33)	(-25.89, 12.68)	(-27.93, 2.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	9.79 (14.10)	6.28 (11.65)	
95% CI	(-19.72, 39.29)	(-18.11, 30.66)	
p-value	0.4959	0.5962	
Corrected Hedge's g Statistics	0.385	0.249	
95% CI	(-0.77, 1.54)	(-0.70, 1.20)	
Week 52			
m	4	8	11
n	3	6	10
Baseline Mean (SD)	100.00 (0.00)	97.92 (5.10)	95.00 (12.08)
Analysis Visit Mean (SD)	100.00 (0.00)	87.50 (11.18)	90.00 (16.46)
LS Mean of Change from Baseline (SE)	2.79 (7.15)	-12.54 (5.24)	-5.24 (3.81)
95% CI	(-12.17, 17.75)	(-23.50, -1.57)	(-13.21, 2.74)
LS Mean of Change from Baseline Compared to Placebo (SE)	8.02 (8.14)	-7.30 (6.49)	
95% CI	(-9.02, 25.07)	(-20.89, 6.29)	
p-value	0.3368	0.2749	
Corrected Hedge's g Statistics	0.617	-0.560	
95% CI	(-0.70, 1.93)	(-1.59, 0.47)	
Subgroup*Treatment Interaction p-value	0.0117	0.0884	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 18 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.10.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Role Emotional			
Week 24			
m	4	8	11
n	4	7	11
Baseline Mean (SD)	97.93 (4.15)	97.61 (6.31)	87.88 (18.76)
Analysis Visit Mean (SD)	91.68 (16.65)	89.29 (19.67)	80.30 (20.50)
LS Mean of Change from Baseline (SE)	-4.07 (8.78)	-9.18 (7.08)	-9.65 (5.37)
95% CI	(-22.44, 14.31)	(-24.00, 5.64)	(-20.89, 1.58)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.59 (10.48)	0.47 (8.98)	
95% CI	(-16.36, 27.53)	(-18.32, 19.26)	
p-value	0.6003	0.9586	
Corrected Hedge's g Statistics	0.296	0.025	
95% CI	(-0.85, 1.45)	(-0.92, 0.97)	
Week 52			
m	4	8	11
n	3	6	10
Baseline Mean (SD)	97.23 (4.79)	97.22 (6.82)	86.67 (19.31)
Analysis Visit Mean (SD)	100.00 (0.00)	84.72 (20.01)	79.99 (18.93)
LS Mean of Change from Baseline (SE)	4.07 (10.63)	-11.45 (7.93)	-10.16 (6.03)
95% CI	(-18.17, 26.31)	(-28.05, 5.14)	(-22.77, 2.45)
LS Mean of Change from Baseline Compared to Placebo (SE)	14.23 (12.44)	-1.29 (10.16)	
95% CI	(-11.80, 40.26)	(-22.57, 19.98)	
p-value	0.2667	0.9002	
Corrected Hedge's g Statistics	0.699	-0.064	
95% CI	(-0.62, 2.02)	(-1.08, 0.95)	
Subgroup*Treatment Interaction p-value	0.2086	0.5638	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 19 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.10.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Mental Health			
Week 24			
m	4	8	11
n	4	7	11
Baseline Mean (SD)	85.0 (10.0)	87.1 (3.9)	75.5 (17.8)
Analysis Visit Mean (SD)	87.5 (12.6)	82.9 (14.1)	74.5 (19.7)
LS Mean of Change from Baseline (SE)	2.49 (5.00)	-5.47 (4.09)	-1.04 (3.14)
95% CI	(-7.97, 12.94)	(-14.03, 3.08)	(-7.61, 5.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.52 (6.00)	-4.43 (5.28)	
95% CI	(-9.04, 16.09)	(-15.48, 6.61)	
p-value	0.5643	0.4111	
Corrected Hedge's g Statistics	0.321	-0.400	
95% CI	(-0.83, 1.47)	(-1.36, 0.56)	
Week 52			
m	4	8	11
n	3	6	10
Baseline Mean (SD)	90.0 (0.0)	87.5 (4.2)	75.0 (18.7)
Analysis Visit Mean (SD)	91.7 (2.9)	77.5 (10.8)	77.5 (18.3)
LS Mean of Change from Baseline (SE)	4.70 (7.20)	-9.08 (5.20)	0.75 (4.00)
95% CI	(-10.36, 19.76)	(-19.96, 1.80)	(-7.62, 9.12)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.95 (8.53)	-9.83 (6.79)	
95% CI	(-13.91, 21.81)	(-24.05, 4.39)	
p-value	0.6487	0.1644	
Corrected Hedge's g Statistics	0.291	-0.733	
95% CI	(-1.00, 1.59)	(-1.78, 0.31)	
Subgroup*Treatment Interaction p-value	0.7028	0.1422	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 20 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.10.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Mental Component Score			
Week 24			
m	4	8	11
n	4	7	11
Baseline Mean (SD)	56.35 (4.71)	57.50 (2.51)	52.47 (8.31)
Analysis Visit Mean (SD)	54.08 (9.74)	54.70 (7.55)	50.08 (9.57)
LS Mean of Change from Baseline (SE)	-2.34 (2.93)	-3.88 (2.41)	-2.40 (1.83)
95% CI	(-8.48, 3.79)	(-8.93, 1.17)	(-6.23, 1.42)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.06 (3.50)	-1.48 (3.09)	
95% CI	(-7.26, 7.37)	(-7.94, 4.99)	
p-value	0.9875	0.6381	
Corrected Hedge's g Statistics	0.009	-0.227	
95% CI	(-1.14, 1.15)	(-1.18, 0.72)	
Week 52			
m	4	8	11
n	3	6	10
Baseline Mean (SD)	58.63 (1.44)	57.60 (2.73)	52.28 (8.74)
Analysis Visit Mean (SD)	59.60 (2.36)	52.87 (5.00)	51.31 (9.97)
LS Mean of Change from Baseline (SE)	1.97 (4.18)	-4.77 (3.05)	-1.61 (2.32)
95% CI	(-6.77, 10.71)	(-11.14, 1.61)	(-6.47, 3.24)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.59 (4.91)	-3.15 (3.95)	
95% CI	(-6.70, 13.87)	(-11.41, 5.11)	
p-value	0.4744	0.4343	
Corrected Hedge's g Statistics	0.456	-0.404	
95% CI	(-0.85, 1.76)	(-1.43, 0.62)	
Subgroup*Treatment Interaction p-value	0.1305	0.2589	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

Madrigal Pharmaceuticals, Inc. Page 21 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table SE21.10.2Liver Disease Quality of Life SF-36 (SE21): Summary of Results - MMRM Model by Domain/Component by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Visit Statistic	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Physical Component Score			
Week 24			
m	4	8	11
n	4	7	11
Baseline Mean (SD)	47.23 (10.82)	51.41 (6.18)	53.69 (5.71)
Analysis Visit Mean (SD)	51.93 (9.21)	50.83 (5.71)	49.59 (10.97)
LS Mean of Change from Baseline (SE)	3.67 (4.12)	-1.71 (3.05)	-3.93 (2.39)
95% CI	(-4.95, 12.29)	(-8.10, 4.68)	(-8.92, 1.07)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.60 (4.86)	2.22 (3.87)	
95% CI	(-2.58, 17.78)	(-5.88, 10.32)	
p-value	0.1348	0.5735	
Corrected Hedge's g Statistics	0.895	0.265	
95% CI	(-0.29, 2.08)	(-0.69, 1.22)	
Week 52			
m	4	8	11
n	3	6	10
Baseline Mean (SD)	52.23 (5.00)	50.95 (6.64)	54.04 (5.89)
Analysis Visit Mean (SD)	51.40 (6.35)	47.25 (8.39)	50.99 (7.89)
LS Mean of Change from Baseline (SE)	-0.42 (2.91)	-4.58 (2.18)	-3.13 (1.62)
95% CI	(-6.50, 5.66)	(-9.15, -0.02)	(-6.53, 0.26)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.72 (3.33)	-1.45 (2.76)	
95% CI	(-4.25, 9.68)	(-7.22, 4.32)	
p-value	0.4246	0.6050	
Corrected Hedge's g Statistics	0.494	-0.263	
95% CI	(-0.81, 1.80)	(-1.28, 0.75)	
Subgroup*Treatment Interaction p-value	0.3565	0.7989	

Program: t-se18-02-02-subgroup.sas Date of creation: 14AUG2025

AMNOG Table SE21.10.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: DB = Double Blinded; SF-36 = 36-Item Short Form Survey; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis, only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.

AMNOG Table SE21.10.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (11.8)
No	5 (100)	5 (100)	15 (88.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.77	1.77	
95% CI of the inverse odds ratio	(0.07, 43.02)	(0.07, 43.02)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	1.67	
95% CI of the inverse risk ratio	(0.09, 30.06)	(0.09, 30.06)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.56	-5.56	
95% CI of the absolute risk difference	(-32.84, 21.73)	(-32.84, 21.73)	
p-value	0.7216	0.7216	
p-value of Breslow-Day Test for Homogeneity [3]	0.0867	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (40.0)	9 (52.9)
No	5 (100)	3 (60.0)	8 (47.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	12.29	1.69	
95% CI of the inverse odds ratio	(0.59, 256.85)	(0.22, 12.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	6.33	1.32	
95% CI of the inverse risk ratio	(0.43, 93.26)	(0.41, 4.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-44.44	-12.94	
95% CI of the absolute risk difference	(-76.40, -12.49)	(-62.00, 36.12)	
p-value	0.0558	0.6109	
p-value of Breslow-Day Test for Homogeneity [3]	0.0669	0.3095	

AMNOG Table SE21.10.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	4 (23.5)
No	5 (100)	5 (100)	13 (76.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.67	3.67	
95% CI of the inverse odds ratio	(0.17, 80.21)	(0.17, 80.21)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	3.00	
95% CI of the inverse risk ratio	(0.19, 47.96)	(0.19, 47.96)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-16.67	-16.67	
95% CI of the absolute risk difference	(-46.49, 13.15)	(-46.49, 13.15)	
p-value	0.3840	0.3840	
p-value of Breslow-Day Test for Homogeneity [3]	0.1285	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (20.0)	0	7 (41.2)
No	4 (80.0)	5 (100)	10 (58.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.80	7.86	
95% CI of the inverse odds ratio	(0.26, 30.70)	(0.37, 164.74)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.06	5.00	
95% CI of the inverse risk ratio	(0.33, 13.00)	(0.33, 75.11)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-21.18	-33.33	
95% CI of the absolute risk difference	(-63.33, 20.97)	(-65.08, -1.59)	
p-value	0.3869	0.1336	
p-value of Breslow-Day Test for Homogeneity [3]	0.4303	0.2562	

AMNOG Table SE21.10.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	4 (23.5)
No	5 (100)	5 (100)	13 (76.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.67	3.67	
95% CI of the inverse odds ratio	(0.17, 80.21)	(0.17, 80.21)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	3.00	
95% CI of the inverse risk ratio	(0.19, 47.96)	(0.19, 47.96)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-16.67	-16.67	
95% CI of the absolute risk difference	(-46.49, 13.15)	(-46.49, 13.15)	
p-value	0.3840	0.3840	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (20.0)	1 (20.0)	5 (29.4)
No	4 (80.0)	4 (80.0)	12 (70.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	1.67	
95% CI of the inverse odds ratio	(0.15, 18.87)	(0.15, 18.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.47	1.47	
95% CI of the inverse risk ratio	(0.22, 9.85)	(0.22, 9.85)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.41	-9.41	
95% CI of the absolute risk difference	(-50.62, 31.80)	(-50.62, 31.80)	
p-value	0.6779	0.6779	
p-value of Breslow-Day Test for Homogeneity [3]	0.6335	0.4775	

AMNOG Table SE21.10.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	3 (17.6)
No	5 (100)	5 (100)	14 (82.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.66	2.66	
95% CI of the inverse odds ratio	(0.12, 60.22)	(0.12, 60.22)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.33	2.33	
95% CI of the inverse risk ratio	(0.14, 38.97)	(0.14, 38.97)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.11	-11.11	
95% CI of the absolute risk difference	(-39.81, 17.58)	(-39.81, 17.58)	
p-value	0.5271	0.5271	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (40.0)	2 (40.0)	5 (29.4)
No	3 (60.0)	3 (60.0)	12 (70.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	0.63	
95% CI of the inverse odds ratio	(0.08, 4.96)	(0.08, 4.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	0.74	
95% CI of the inverse risk ratio	(0.20, 2.70)	(0.20, 2.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	10.59	10.59	
95% CI of the absolute risk difference	(-37.51, 58.68)	(-37.51, 58.68)	
p-value	0.6550	0.6550	
p-value of Breslow-Day Test for Homogeneity [3]	0.7499	0.0839	

AMNOG Table SE21.10.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	3 (17.6)
No	5 (100)	5 (100)	14 (82.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.66	2.66	
95% CI of the inverse odds ratio	(0.12, 60.22)	(0.12, 60.22)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.33	2.33	
95% CI of the inverse risk ratio	(0.14, 38.97)	(0.14, 38.97)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.11	-11.11	
95% CI of the absolute risk difference	(-39.81, 17.58)	(-39.81, 17.58)	
p-value	0.5271	0.5271	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (20.0)	8 (47.1)
No	5 (100)	4 (80.0)	9 (52.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	9.84	3.56	
95% CI of the inverse odds ratio	(0.47, 205.62)	(0.33, 38.78)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.67	2.35	
95% CI of the inverse risk ratio	(0.38, 84.18)	(0.38, 14.58)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-38.89	-27.06	
95% CI of the absolute risk difference	(-70.84, -6.94)	(-69.39, 15.28)	
p-value	0.0884	0.2794	
p-value of Breslow-Day Test for Homogeneity [3]	0.0362	0.6068	

AMNOG Table SE21.10.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (20.0)	3 (17.6)
No	5 (100)	4 (80.0)	14 (82.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.66	0.86	
95% CI of the inverse odds ratio	(0.12, 60.22)	(0.07, 10.67)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.33	0.88	
95% CI of the inverse risk ratio	(0.14, 38.97)	(0.12, 6.73)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.11	2.35	
95% CI of the absolute risk difference	(-39.81, 17.58)	(-37.11, 41.82)	
p-value	0.5271	0.9046	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	4 (80.0)	4 (23.5)
No	5 (100)	1 (20.0)	13 (76.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.67	0.08	
95% CI of the inverse odds ratio	(0.17, 80.21)	(0.01, 0.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	0.29	
95% CI of the inverse risk ratio	(0.19, 47.96)	(0.11, 0.77)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-16.67	56.47	
95% CI of the absolute risk difference	(-46.49, 13.15)	(16.02, 96.92)	
p-value	0.3840	0.0210	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.7490	

AMNOG Table SE21.10.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (5.9)
No	5 (100)	5 (100)	16 (94.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	1.00	
95% CI of the inverse odds ratio	(0.04, 28.30)	(0.04, 28.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	1.00	
95% CI of the inverse risk ratio	(0.05, 21.42)	(0.05, 21.42)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	0.00	
95% CI of the absolute risk difference	(-25.54, 25.54)	(-25.54, 25.54)	
p-value	>0.9999	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (20.0)	2 (11.8)
No	5 (100)	4 (80.0)	15 (88.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.77	0.53	
95% CI of the inverse odds ratio	(0.07, 43.02)	(0.04, 7.49)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	0.59	
95% CI of the inverse risk ratio	(0.09, 30.06)	(0.07, 5.22)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.56	8.24	
95% CI of the absolute risk difference	(-32.84, 21.73)	(-30.02, 46.50)	
p-value	0.7216	0.6371	
p-value of Breslow-Day Test for Homogeneity [3]	0.2579	0.2766	

AMNOG Table SE21.10.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (20.0)	0
No	5 (100)	4 (80.0)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.09	
95% CI of the inverse odds ratio	NE	(0.00, 2.48)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.11	
95% CI of the inverse risk ratio	NE	(0.01, 2.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	22.22	
95% CI of the absolute risk difference	NE	(-13.25, 57.69)	
p-value	NE	0.0881	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.0042	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (40.0)	2 (40.0)	5 (29.4)
No	3 (60.0)	3 (60.0)	12 (70.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	0.63	
95% CI of the inverse odds ratio	(0.08, 4.96)	(0.08, 4.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	0.74	
95% CI of the inverse risk ratio	(0.20, 2.70)	(0.20, 2.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	10.59	10.59	
95% CI of the absolute risk difference	(-37.51, 58.68)	(-37.51, 58.68)	
p-value	0.6550	0.6550	
p-value of Breslow-Day Test for Homogeneity [3]	0.4029	0.0279	

AMNOG Table SE21.10.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	5 (100)	17 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (40.0)	1 (5.9)
No	5 (100)	3 (60.0)	16 (94.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	0.09	
95% CI of the inverse odds ratio	(0.04, 28.30)	(0.01, 1.39)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	0.15	
95% CI of the inverse risk ratio	(0.05, 21.42)	(0.02, 1.31)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	34.12	
95% CI of the absolute risk difference	(-25.54, 25.54)	(-10.26, 78.49)	
p-value	>0.9999	0.0507	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.0011	

AMNOG Table SE21.10.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)
Baseline Statin: Yes (Treated with Statins at baseline)

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (11.8)
No	5 (100)	5 (100)	15 (88.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.77	1.77	
95% CI of the inverse odds ratio	(0.07, 43.02)	(0.07, 43.02)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	1.67	
95% CI of the inverse risk ratio	(0.09, 30.06)	(0.09, 30.06)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.56	-5.56	
95% CI of the absolute risk difference	(-32.84, 21.73)	(-32.84, 21.73)	
p-value	0.7216	0.7216	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	5 (29.4)
No	5 (100)	5 (100)	12 (70.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.84	4.84	
95% CI of the inverse odds ratio	(0.23, 103.62)	(0.23, 103.62)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.67	3.67	
95% CI of the inverse risk ratio	(0.24, 56.99)	(0.24, 56.99)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-22.22	-22.22	
95% CI of the absolute risk difference	(-52.91, 8.47)	(-52.91, 8.47)	
p-value	0.2763	0.2763	
p-value of Breslow-Day Test for Homogeneity [3]	0.0174	NE	

AMNOG Table SE21.10.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (25.0)	0	0
No	3 (75.0)	10 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.10	NE	
95% CI of the inverse odds ratio	(0.00, 3.09)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.14	NE	
95% CI of the inverse risk ratio	(0.01, 2.86)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	25.83	NE	
95% CI of the absolute risk difference	(-15.89, 67.56)	NE	
p-value	0.1320	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.0867	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (25.0)	0	2 (18.2)
No	3 (75.0)	10 (100)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	5.53	
95% CI of the inverse odds ratio	(0.04, 10.25)	(0.23, 130.34)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	4.58	
95% CI of the inverse risk ratio	(0.09, 6.00)	(0.25, 85.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.82	-16.29	
95% CI of the absolute risk difference	(-41.35, 54.99)	(-42.36, 9.78)	
p-value	0.7703	0.2466	
p-value of Breslow-Day Test for Homogeneity [3]	0.0669	0.3095	

AMNOG Table SE21.10.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (25.0)	0	1 (9.1)
No	3 (75.0)	10 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.30	3.00	
95% CI of the inverse odds ratio	(0.01, 6.38)	(0.11, 82.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.36	2.75	
95% CI of the inverse risk ratio	(0.03, 4.54)	(0.12, 60.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	15.91	-7.95	
95% CI of the absolute risk difference	(-29.80, 61.62)	(-30.35, 14.44)	
p-value	0.4228	0.4988	
p-value of Breslow-Day Test for Homogeneity [3]	0.1285	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (25.0)	1 (10.0)	2 (18.2)
No	3 (75.0)	9 (90.0)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	2.00	
95% CI of the inverse odds ratio	(0.04, 10.25)	(0.15, 26.19)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	1.82	
95% CI of the inverse risk ratio	(0.09, 6.00)	(0.19, 17.12)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.82	-8.18	
95% CI of the absolute risk difference	(-41.35, 54.99)	(-37.60, 21.23)	
p-value	0.7703	0.5926	
p-value of Breslow-Day Test for Homogeneity [3]	0.4303	0.2562	

AMNOG Table SE21.10.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (9.1)
No	4 (100)	10 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	3.00	
95% CI of the inverse odds ratio	(0.04, 37.98)	(0.11, 82.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	2.75	
95% CI of the inverse risk ratio	(0.06, 25.76)	(0.12, 60.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-7.95	
95% CI of the absolute risk difference	(-34.77, 29.77)	(-30.35, 14.44)	
p-value	0.8841	0.4988	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	1 (9.1)
No	4 (100)	10 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	3.00	
95% CI of the inverse odds ratio	(0.04, 37.98)	(0.11, 82.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	2.75	
95% CI of the inverse risk ratio	(0.06, 25.76)	(0.12, 60.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-7.95	
95% CI of the absolute risk difference	(-34.77, 29.77)	(-30.35, 14.44)	
p-value	0.8841	0.4988	
p-value of Breslow-Day Test for Homogeneity [3]	0.6335	0.4775	

AMNOG Table SE21.10.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (9.1)
No	4 (100)	10 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	3.00	
95% CI of the inverse odds ratio	(0.04, 37.98)	(0.11, 82.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	2.75	
95% CI of the inverse risk ratio	(0.06, 25.76)	(0.12, 60.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-7.95	
95% CI of the absolute risk difference	(-34.77, 29.77)	(-30.35, 14.44)	
p-value	0.8841	0.4988	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (50.0)	0	3 (27.3)
No	2 (50.0)	10 (100)	8 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.38	8.65	
95% CI of the inverse odds ratio	(0.04, 4.00)	(0.39, 191.58)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.55	6.42	
95% CI of the inverse risk ratio	(0.14, 2.16)	(0.37, 110.71)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	22.73	-24.62	
95% CI of the absolute risk difference	(-32.89, 78.35)	(-53.13, 3.89)	
p-value	0.4090	0.1197	
p-value of Breslow-Day Test for Homogeneity [3]	0.7499	0.0839	

AMNOG Table SE21.10.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	4 (100)	10 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (25.0)	0	1 (9.1)
No	3 (75.0)	10 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.30	3.00	
95% CI of the inverse odds ratio	(0.01, 6.38)	(0.11, 82.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.36	2.75	
95% CI of the inverse risk ratio	(0.03, 4.54)	(0.12, 60.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	15.91	-7.95	
95% CI of the absolute risk difference	(-29.80, 61.62)	(-30.35, 14.44)	
p-value	0.4228	0.4988	
p-value of Breslow-Day Test for Homogeneity [3]	0.0362	0.6068	

AMNOG Table SE21.10.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	4 (100)	10 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (10.0)	0
No	4 (100)	9 (90.0)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.28	
95% CI of the inverse odds ratio	NE	(0.01, 7.57)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.31	
95% CI of the inverse risk ratio	NE	(0.01, 6.74)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	9.47	
95% CI of the absolute risk difference	NE	(-13.75, 32.69)	
p-value	NE	0.4207	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.7490	

AMNOG Table SE21.10.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (9.1)
No	4 (100)	10 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	3.00	
95% CI of the inverse odds ratio	(0.04, 37.98)	(0.11, 82.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	2.75	
95% CI of the inverse risk ratio	(0.06, 25.76)	(0.12, 60.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	-7.95	
95% CI of the absolute risk difference	(-34.77, 29.77)	(-30.35, 14.44)	
p-value	0.8841	0.4988	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (25.0)	0	1 (9.1)
No	3 (75.0)	10 (100)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.30	3.00	
95% CI of the inverse odds ratio	(0.01, 6.38)	(0.11, 82.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.36	2.75	
95% CI of the inverse risk ratio	(0.03, 4.54)	(0.12, 60.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	15.91	-7.95	
95% CI of the absolute risk difference	(-29.80, 61.62)	(-30.35, 14.44)	
p-value	0.4228	0.4988	
p-value of Breslow-Day Test for Homogeneity [3]	0.2579	0.2766	

AMNOG Table SE21.10.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	3 (27.3)
No	4 (100)	10 (100)	8 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.71	8.65	
95% CI of the inverse odds ratio	(0.15, 88.75)	(0.39, 191.58)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.92	6.42	
95% CI of the inverse risk ratio	(0.18, 46.71)	(0.37, 110.71)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-19.17	-24.62	
95% CI of the absolute risk difference	(-55.95, 17.61)	(-53.13, 3.89)	
p-value	0.3959	0.1197	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.0042	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (25.0)	0	5 (45.5)
No	3 (75.0)	10 (100)	6 (54.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.50	17.77	
95% CI of the inverse odds ratio	(0.19, 32.19)	(0.84, 377.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.82	10.08	
95% CI of the inverse risk ratio	(0.30, 11.18)	(0.63, 162.06)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-20.45	-41.29	
95% CI of the absolute risk difference	(-72.09, 31.18)	(-72.05, -10.53)	
p-value	0.4745	0.0243	
p-value of Breslow-Day Test for Homogeneity [3]	0.4029	0.0279	

AMNOG Table SE21.10.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	4 (100)	10 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	5 (45.5)
No	4 (100)	10 (100)	6 (54.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	7.62	17.77	
95% CI of the inverse odds ratio	(0.33, 175.01)	(0.84, 377.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.58	10.08	
95% CI of the inverse risk ratio	(0.31, 68.24)	(0.63, 162.06)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-35.83	-41.29	
95% CI of the absolute risk difference	(-74.38, 2.72)	(-72.05, -10.53)	
p-value	0.1589	0.0243	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.0011	

AMNOG Table SE21.10.3
Liver Disease Quality of Life SF-36 (SE21): Summary of Response at Week 52 by Domain/Component
by Baseline Statin
(Label Population based on Modified Intent-to-Treat Population)

Baseline Statin: No

Parameter Response Statistic/Category	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	4 (100)	10 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (25.0)	0	0
No	3 (75.0)	10 (100)	11 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.10	NE	
95% CI of the inverse odds ratio	(0.00, 3.09)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.14	NE	
95% CI of the inverse risk ratio	(0.01, 2.86)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	25.83	NE	
95% CI of the absolute risk difference	(-15.89, 67.56)	NE	
p-value	0.1320	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.0174	NE	

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Abbreviations: DB = Double Blinded; AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; CV = cardiovascular; DILI = drug-induced liver injury.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as “Grade 3”. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
[3] MACE AE includes cardiovascular mortality, myocardial infarction, and cerebral vascular accident.
[4] Other CV AE includes hospitalization/emergency room treatment for heart failure, hospitalization for unstable angina, urgent or emergent coronary revascularization.

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: < Median

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Events n:			
Total TEAEs	5	30	40
Total Serious TEAEs	0	1	0
Total TEAEs Leading to Discontinuation of Study Drug	0	1	0
Total TEAEs Related to Study Drug	0	8	8
Total TEAEs >= Grade 3 Severity	0	1	0
Patients n (%):			
Any TEAE	2 (100)	9 (81.8)	9 (81.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.00	
95% CI of the odds ratio	NE	(0.11, 8.73)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.22	1.00	
95% CI of the risk ratio	(0.93, 1.61)	(0.67, 1.48)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	18.18	0.00	
95% CI of the absolute risk difference	(-4.61, 40.97)	(-32.23, 32.23)	
p-value	0.5121	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.6007	
Any Serious TEAE	0	1 (9.1)	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.29	
95% CI of the odds ratio	NE	(0.12, 89.81)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.00	
95% CI of the risk ratio	NE	(0.14, 66.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	8.33	
95% CI of the absolute risk difference	NE	(-13.53, 30.20)	
p-value	NE	0.4602	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.6302	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: < Median

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Any TEAEs >= Grade 3 Severity	0	1 (9.1)	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.29	
95% CI of the odds ratio	NE	(0.12, 89.81)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.00	
95% CI of the risk ratio	NE	(0.14, 66.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	8.33	
95% CI of the absolute risk difference	NE	(-13.53, 30.20)	
p-value	NE	0.4602	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.5236	
Any TEAEs <= Grade 2 Severity	2 (100)	9 (81.8)	9 (81.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.00	
95% CI of the odds ratio	NE	(0.11, 8.73)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.22	1.00	
95% CI of the risk ratio	(0.93, 1.61)	(0.67, 1.48)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	18.18	0.00	
95% CI of the absolute risk difference	(-4.61, 40.97)	(-32.23, 32.23)	
p-value	0.5121	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.6007	
Any TEAEs leading to Study-Drug Discontinuation	0	1 (9.1)	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.29	
95% CI of the odds ratio	NE	(0.12, 89.81)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.00	
95% CI of the risk ratio	NE	(0.14, 66.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	8.33	
95% CI of the absolute risk difference	NE	(-13.53, 30.20)	
p-value	NE	0.4602	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.3077	

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: < Median

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAE	0	4 (36.4)	4 (36.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.33	1.00	
95% CI of the odds ratio	(0.01, 8.63)	(0.18, 5.68)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.44	1.00	
95% CI of the risk ratio	(0.03, 6.19)	(0.33, 3.02)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-20.83	0.00	
95% CI of the absolute risk difference	(-71.12, 29.45)	(-40.20, 40.20)	
p-value	0.4936	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	0.4658	0.9592	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: < Median

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: < Median

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Maximum Severity of TEAEs			
Grade 1	0	6 (54.5)	2 (18.2)
Grade 2	2 (100)	2 (18.2)	7 (63.6)
Grade 3	0	1 (9.1)	0
Grade 4	0	0	0
Grade 5	0	0	0

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: < Median

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Maximum Severity of Treatment-related TEAEs			
Grade 1	0	4 (36.4)	4 (36.4)
Grade 2	0	0	0
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0
MACE AE – Adjudicated Event [3]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: < Median

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious MACE AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event [4]	0	0	1 (9.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.40	0.30	
95% CI of the odds ratio	(0.04, 45.68)	(0.01, 8.32)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.33	0.33	
95% CI of the risk ratio	(0.07, 25.22)	(0.02, 7.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	4.17	-8.33	
95% CI of the absolute risk difference	(-41.97, 50.30)	(-30.20, 13.53)	
p-value	0.8494	0.4602	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: < Median

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Other CV AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (9.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.40	0.30	
95% CI of the odds ratio	(0.04, 45.68)	(0.01, 8.32)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.33	0.33	
95% CI of the risk ratio	(0.07, 25.22)	(0.02, 7.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	4.17	-8.33	
95% CI of the absolute risk difference	(-41.97, 50.30)	(-30.20, 13.53)	
p-value	0.8494	0.4602	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious Other CV AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: < Median

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: < Median

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Serious DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

Madrigal Pharmaceuticals, Inc. Page 12 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: >= Median

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Events n:			
Total TEAEs	31	12	65
Total Serious TEAEs	0	1	2
Total TEAEs Leading to Discontinuation of Study Drug	0	0	1
Total TEAEs Related to Study Drug	2	1	4
Total TEAEs >= Grade 3 Severity	0	1	3
Patients n (%):			
Any TEAE	7 (100)	3 (75.0)	15 (88.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.40	
95% CI of the odds ratio	NE	(0.03, 5.96)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.13	0.85	
95% CI of the risk ratio	(0.95, 1.35)	(0.47, 1.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	11.76	-13.24	
95% CI of the absolute risk difference	(-3.55, 27.08)	(-58.35, 31.88)	
p-value	0.3432	0.4961	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.6007	
Any Serious TEAE	0	1 (25.0)	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.73	5.33	
95% CI of the odds ratio	(0.03, 20.18)	(0.26, 110.80)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.75	4.25	
95% CI of the risk ratio	(0.03, 16.49)	(0.33, 54.37)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.08	19.12	
95% CI of the absolute risk difference	(-23.16, 19.00)	(-24.77, 63.00)	
p-value	0.8540	0.2412	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.6302	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: >= Median

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Any TEAEs >= Grade 3 Severity	0	1 (25.0)	2 (11.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.41	2.50	
95% CI of the odds ratio	(0.02, 9.73)	(0.17, 37.26)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.45	2.13	
95% CI of the risk ratio	(0.02, 8.34)	(0.25, 18.05)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-7.64	13.24	
95% CI of the absolute risk difference	(-30.80, 15.53)	(-31.88, 58.35)	
p-value	0.5736	0.4961	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.5236	
Any TEAEs <= Grade 2 Severity	7 (100)	3 (75.0)	15 (88.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.40	
95% CI of the odds ratio	NE	(0.03, 5.96)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.13	0.85	
95% CI of the risk ratio	(0.95, 1.35)	(0.47, 1.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	11.76	-13.24	
95% CI of the absolute risk difference	(-3.55, 27.08)	(-58.35, 31.88)	
p-value	0.3432	0.4961	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.6007	
Any TEAEs leading to Study-Drug Discontinuation	0	0	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.73	1.22	
95% CI of the odds ratio	(0.03, 20.18)	(0.04, 35.40)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.75	1.20	
95% CI of the risk ratio	(0.03, 16.49)	(0.06, 25.17)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.08	1.67	
95% CI of the absolute risk difference	(-23.16, 19.00)	(-27.56, 30.90)	
p-value	0.8540	0.9069	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.3077	

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: >= Median

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Any TEAEs leading to Study Discontinuation	0	0	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.73	1.22	
95% CI of the odds ratio	(0.03, 20.18)	(0.04, 35.40)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.75	1.20	
95% CI of the risk ratio	(0.03, 16.49)	(0.06, 25.17)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.08	1.67	
95% CI of the absolute risk difference	(-23.16, 19.00)	(-27.56, 30.90)	
p-value	0.8540	0.9069	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAE	1 (14.3)	1 (25.0)	4 (23.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.54	1.08	
95% CI of the odds ratio	(0.05, 5.94)	(0.09, 13.54)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.61	1.06	
95% CI of the risk ratio	(0.08, 4.52)	(0.16, 7.11)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-9.24	1.47	
95% CI of the absolute risk difference	(-42.09, 23.60)	(-45.51, 48.45)	
p-value	0.6123	0.9505	
p-value of Breslow-Day Test for Homogeneity [2]	0.4658	0.9592	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: >= Median

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.73	1.22	
95% CI of the odds ratio	(0.03, 20.18)	(0.04, 35.40)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.75	1.20	
95% CI of the risk ratio	(0.03, 16.49)	(0.06, 25.17)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.08	1.67	
95% CI of the absolute risk difference	(-23.16, 19.00)	(-27.56, 30.90)	
p-value	0.8540	0.9069	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: >= Median

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.73	1.22	
95% CI of the odds ratio	(0.03, 20.18)	(0.04, 35.40)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.75	1.20	
95% CI of the risk ratio	(0.03, 16.49)	(0.06, 25.17)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.08	1.67	
95% CI of the absolute risk difference	(-23.16, 19.00)	(-27.56, 30.90)	
p-value	0.8540	0.9069	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Maximum Severity of TEAEs			
Grade 1	4 (57.1)	1 (25.0)	7 (41.2)
Grade 2	3 (42.9)	1 (25.0)	6 (35.3)
Grade 3	0	1 (25.0)	2 (11.8)
Grade 4	0	0	0
Grade 5	0	0	0

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: >= Median

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Maximum Severity of Treatment-related TEAEs			
Grade 1	1 (14.3)	1 (25.0)	4 (23.5)
Grade 2	0	0	0
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0
MACE AE – Adjudicated Event [3]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: >= Median

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious MACE AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event [4]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: >= Median

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Other CV AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious Other CV AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: >= Median

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
DILI AE - Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE - Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE - Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: >= Median

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Serious DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Abbreviations: DB = Double Blinded; AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; CV = cardiovascular; DILI = drug-induced liver injury.
Note: Disease related events include the following preferred terms: Hepatic cirrhosis; Ascites; Varices oesophageal; Oesophageal varices haemorrhage; Hepatic encephalopathy.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
[3] MACE AE includes cardiovascular mortality, myocardial infarction, and cerebral vascular accident.
[4] Other CV AE includes hospitalization/emergency room treatment for heart failure, hospitalization for unstable angina, urgent or emergent coronary revascularization.

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: < Median

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Events n:			
Total TEAEs	5	30	40
Total Serious TEAEs	0	1	0
Total TEAEs Leading to Discontinuation of Study Drug	0	1	0
Total TEAEs Related to Study Drug	0	8	8
Total TEAEs >= Grade 3 Severity	0	1	0
Patients n (%):			
Any TEAE	2 (100)	9 (81.8)	9 (81.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.00	
95% CI of the odds ratio	NE	(0.11, 8.73)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.22	1.00	
95% CI of the risk ratio	(0.93, 1.61)	(0.67, 1.48)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	18.18	0.00	
95% CI of the absolute risk difference	(-4.61, 40.97)	(-32.23, 32.23)	
p-value	0.5121	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.6007	
Any Serious TEAE	0	1 (9.1)	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.29	
95% CI of the odds ratio	NE	(0.12, 89.81)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.00	
95% CI of the risk ratio	NE	(0.14, 66.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	8.33	
95% CI of the absolute risk difference	NE	(-13.53, 30.20)	
p-value	NE	0.4602	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.6302	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: < Median

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Any TEAEs >= Grade 3 Severity	0	1 (9.1)	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.29	
95% CI of the odds ratio	NE	(0.12, 89.81)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.00	
95% CI of the risk ratio	NE	(0.14, 66.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	8.33	
95% CI of the absolute risk difference	NE	(-13.53, 30.20)	
p-value	NE	0.4602	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.5236	
Any TEAEs <= Grade 2 Severity	2 (100)	9 (81.8)	9 (81.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.00	
95% CI of the odds ratio	NE	(0.11, 8.73)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.22	1.00	
95% CI of the risk ratio	(0.93, 1.61)	(0.67, 1.48)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	18.18	0.00	
95% CI of the absolute risk difference	(-4.61, 40.97)	(-32.23, 32.23)	
p-value	0.5121	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.6007	
Any TEAEs leading to Study-Drug Discontinuation	0	1 (9.1)	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.29	
95% CI of the odds ratio	NE	(0.12, 89.81)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.00	
95% CI of the risk ratio	NE	(0.14, 66.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	8.33	
95% CI of the absolute risk difference	NE	(-13.53, 30.20)	
p-value	NE	0.4602	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.3077	

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: < Median

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAE	0	4 (36.4)	4 (36.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.33	1.00	
95% CI of the odds ratio	(0.01, 8.63)	(0.18, 5.68)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.44	1.00	
95% CI of the risk ratio	(0.03, 6.19)	(0.33, 3.02)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-20.83	0.00	
95% CI of the absolute risk difference	(-71.12, 29.45)	(-40.20, 40.20)	
p-value	0.4936	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	0.4658	0.9592	

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: < Median

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: < Median

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Maximum Severity of TEAEs			
Grade 1	0	6 (54.5)	2 (18.2)
Grade 2	2 (100)	2 (18.2)	7 (63.6)
Grade 3	0	1 (9.1)	0
Grade 4	0	0	0
Grade 5	0	0	0

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: < Median

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Maximum Severity of Treatment-related TEAEs			
Grade 1	0	4 (36.4)	4 (36.4)
Grade 2	0	0	0
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0
MACE AE – Adjudicated Event [3]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: < Median

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious MACE AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event [4]	0	0	1 (9.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.40	0.30	
95% CI of the odds ratio	(0.04, 45.68)	(0.01, 8.32)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.33	0.33	
95% CI of the risk ratio	(0.07, 25.22)	(0.02, 7.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	4.17	-8.33	
95% CI of the absolute risk difference	(-41.97, 50.30)	(-30.20, 13.53)	
p-value	0.8494	0.4602	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: < Median

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Other CV AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (9.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.40	0.30	
95% CI of the odds ratio	(0.04, 45.68)	(0.01, 8.32)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.33	0.33	
95% CI of the risk ratio	(0.07, 25.22)	(0.02, 7.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	4.17	-8.33	
95% CI of the absolute risk difference	(-41.97, 50.30)	(-30.20, 13.53)	
p-value	0.8494	0.4602	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious Other CV AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: < Median

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
DILI AE - Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE - Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE - Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: < Median

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=11)	DB Placebo (N=11)
Serious DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: >= Median

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Events n:			
Total TEAEs	31	12	65
Total Serious TEAEs	0	1	2
Total TEAEs Leading to Discontinuation of Study Drug	0	0	1
Total TEAEs Related to Study Drug	2	1	4
Total TEAEs >= Grade 3 Severity	0	1	3
Patients n (%):			
Any TEAE	7 (100)	3 (75.0)	15 (88.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.40	
95% CI of the odds ratio	NE	(0.03, 5.96)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.13	0.85	
95% CI of the risk ratio	(0.95, 1.35)	(0.47, 1.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	11.76	-13.24	
95% CI of the absolute risk difference	(-3.55, 27.08)	(-58.35, 31.88)	
p-value	0.3432	0.4961	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.6007	
Any Serious TEAE	0	1 (25.0)	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.73	5.33	
95% CI of the odds ratio	(0.03, 20.18)	(0.26, 110.80)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.75	4.25	
95% CI of the risk ratio	(0.03, 16.49)	(0.33, 54.37)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.08	19.12	
95% CI of the absolute risk difference	(-23.16, 19.00)	(-24.77, 63.00)	
p-value	0.8540	0.2412	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.6302	

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: >= Median

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Any TEAEs >= Grade 3 Severity	0	1 (25.0)	2 (11.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.41	2.50	
95% CI of the odds ratio	(0.02, 9.73)	(0.17, 37.26)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.45	2.13	
95% CI of the risk ratio	(0.02, 8.34)	(0.25, 18.05)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-7.64	13.24	
95% CI of the absolute risk difference	(-30.80, 15.53)	(-31.88, 58.35)	
p-value	0.5736	0.4961	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.5236	
Any TEAEs <= Grade 2 Severity	7 (100)	3 (75.0)	15 (88.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.40	
95% CI of the odds ratio	NE	(0.03, 5.96)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.13	0.85	
95% CI of the risk ratio	(0.95, 1.35)	(0.47, 1.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	11.76	-13.24	
95% CI of the absolute risk difference	(-3.55, 27.08)	(-58.35, 31.88)	
p-value	0.3432	0.4961	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.6007	
Any TEAEs leading to Study-Drug Discontinuation	0	0	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.73	1.22	
95% CI of the odds ratio	(0.03, 20.18)	(0.04, 35.40)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.75	1.20	
95% CI of the risk ratio	(0.03, 16.49)	(0.06, 25.17)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.08	1.67	
95% CI of the absolute risk difference	(-23.16, 19.00)	(-27.56, 30.90)	
p-value	0.8540	0.9069	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.3077	

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: >= Median

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Any TEAEs leading to Study Discontinuation	0	0	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.73	1.22	
95% CI of the odds ratio	(0.03, 20.18)	(0.04, 35.40)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.75	1.20	
95% CI of the risk ratio	(0.03, 16.49)	(0.06, 25.17)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.08	1.67	
95% CI of the absolute risk difference	(-23.16, 19.00)	(-27.56, 30.90)	
p-value	0.8540	0.9069	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAE	1 (14.3)	1 (25.0)	4 (23.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.54	1.08	
95% CI of the odds ratio	(0.05, 5.94)	(0.09, 13.54)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.61	1.06	
95% CI of the risk ratio	(0.08, 4.52)	(0.16, 7.11)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-9.24	1.47	
95% CI of the absolute risk difference	(-42.09, 23.60)	(-45.51, 48.45)	
p-value	0.6123	0.9505	
p-value of Breslow-Day Test for Homogeneity [2]	0.4658	0.9592	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: >= Median

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.73	1.22	
95% CI of the odds ratio	(0.03, 20.18)	(0.04, 35.40)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.75	1.20	
95% CI of the risk ratio	(0.03, 16.49)	(0.06, 25.17)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.08	1.67	
95% CI of the absolute risk difference	(-23.16, 19.00)	(-27.56, 30.90)	
p-value	0.8540	0.9069	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: >= Median

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.73	1.22	
95% CI of the odds ratio	(0.03, 20.18)	(0.04, 35.40)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.75	1.20	
95% CI of the risk ratio	(0.03, 16.49)	(0.06, 25.17)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.08	1.67	
95% CI of the absolute risk difference	(-23.16, 19.00)	(-27.56, 30.90)	
p-value	0.8540	0.9069	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Maximum Severity of TEAEs			
Grade 1	4 (57.1)	1 (25.0)	7 (41.2)
Grade 2	3 (42.9)	1 (25.0)	6 (35.3)
Grade 3	0	1 (25.0)	2 (11.8)
Grade 4	0	0	0
Grade 5	0	0	0

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: >= Median

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Maximum Severity of Treatment-related TEAEs			
Grade 1	1 (14.3)	1 (25.0)	4 (23.5)
Grade 2	0	0	0
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0
MACE AE – Adjudicated Event [3]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: >= Median

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious MACE AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event [4]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: >= Median

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Other CV AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious Other CV AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: >= Median

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age (Median)
(Label Population based on Safety Population)

Age: >= Median

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=4)	DB Placebo (N=17)
Serious DILI AE - Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.2.2

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Age (Median)
(Label Population based on Safety Population)

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.

AMNOG Table S1.2.2

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Age (Median)
(Label Population based on Safety Population)

Age: < Median

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=2) Patients n (%)	DB MGL-3196 80 mg (N=2) Events n	DB MGL-3196 100 mg (N=11) Patients n (%)	DB MGL-3196 100 mg (N=11) Events n	DB Placebo (N=11) Patients n (%)	DB Placebo (N=11) Events n
Musculoskeletal and connective tissue disorders	2 (100)	2	0	0	5 (45.5)	6
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		0.05			
95% CI of the odds ratio	NE		(0.00, 1.09)			
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.20		0.09			
95% CI of the risk ratio	(1.15, 4.20)		(0.01, 1.47)			
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	54.55		-41.67			
95% CI of the absolute risk difference	(25.12, 83.97)		(-72.04, -11.29)			
p-value	0.1546		0.0184			
p-value of Breslow-Day Test for Homogeneity [2]	0.2535		NE			

Program: t-s01-02-02-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc. Page 3 of 3
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S1.2.2

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Age (Median)
(Label Population based on Safety Population)

Age: >= Median

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=7) Patients n (%)	DB MGL-3196 80 mg (N=7) Events n	DB MGL-3196 100 mg (N=4) Patients n (%)	DB MGL-3196 100 mg (N=4) Events n	DB Placebo (N=17) Patients n (%)	DB Placebo (N=17) Events n
Musculoskeletal and connective tissue disorders	2 (28.6)	2	0	0	4 (23.5)	12
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.30		0.33			
95% CI of the odds ratio	(0.18, 9.47)		(0.01, 7.48)			
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.21		0.40			
95% CI of the risk ratio	(0.28, 5.18)		(0.03, 6.25)			
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	5.04		-15.00			
95% CI of the absolute risk difference	(-34.03, 44.11)		(-48.04, 18.04)			
p-value	0.7954		0.4719			
p-value of Breslow-Day Test for Homogeneity [2]	0.2535		NE			

Program: t-s01-02-02-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age
(Label Population based on Safety Population)

Abbreviations: DB = Double Blinded; AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; CV = cardiovascular; DILI = drug-induced liver injury.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as “Grade 3”. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
[3] MACE AE includes cardiovascular mortality, myocardial infarction, and cerebral vascular accident.
[4] Other CV AE includes hospitalization/emergency room treatment for heart failure, hospitalization for unstable angina, urgent or emergent coronary revascularization.

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: < 65 years

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Events n:			
Total TEAEs	21	42	74
Total Serious TEAEs	0	2	2
Total TEAEs Leading to Discontinuation of Study Drug	0	1	1
Total TEAEs Related to Study Drug	2	9	10
Total TEAEs >= Grade 3 Severity	0	2	2
Patients n (%):			
Any TEAE	6 (100)	12 (80.0)	18 (85.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.67	
95% CI of the odds ratio	NE	(0.11, 3.87)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.17	0.93	
95% CI of the risk ratio	(0.98, 1.39)	(0.69, 1.27)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	14.29	-5.71	
95% CI of the absolute risk difference	(-0.68, 29.25)	(-30.89, 19.46)	
p-value	0.3261	0.6501	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Serious TEAE	0	2 (13.3)	1 (4.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.08	
95% CI of the odds ratio	NE	(0.25, 37.48)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.80	
95% CI of the risk ratio	NE	(0.28, 28.13)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.76	8.57	
95% CI of the absolute risk difference	(-13.87, 4.35)	(-10.89, 28.04)	
p-value	0.5860	0.3590	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: < 65 years

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Any TEAEs >= Grade 3 Severity	0	2 (13.3)	1 (4.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.08	
95% CI of the odds ratio	NE	(0.25, 37.48)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.80	
95% CI of the risk ratio	NE	(0.28, 28.13)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.76	8.57	
95% CI of the absolute risk difference	(-13.87, 4.35)	(-10.89, 28.04)	
p-value	0.5860	0.3590	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any TEAEs <= Grade 2 Severity	6 (100)	12 (80.0)	18 (85.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.67	
95% CI of the odds ratio	NE	(0.11, 3.87)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.17	0.93	
95% CI of the risk ratio	(0.98, 1.39)	(0.69, 1.27)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	14.29	-5.71	
95% CI of the absolute risk difference	(-0.68, 29.25)	(-30.89, 19.46)	
p-value	0.3261	0.6501	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any TEAEs leading to Study-Drug Discontinuation	0	1 (6.7)	1 (4.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.43	
95% CI of the odds ratio	NE	(0.08, 24.81)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.40	
95% CI of the risk ratio	NE	(0.09, 20.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.76	1.90	
95% CI of the absolute risk difference	(-13.87, 4.35)	(-13.66, 17.47)	
p-value	0.5860	0.8057	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc. Page 4 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: < 65 years

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Any TEAEs leading to Study Discontinuation	0	0	1 (4.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.76	-4.76	
95% CI of the absolute risk difference	(-13.87, 4.35)	(-13.87, 4.35)	
p-value	0.5860	0.3914	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAE	1 (16.7)	5 (33.3)	6 (28.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.50	1.25	
95% CI of the odds ratio	(0.05, 5.22)	(0.30, 5.23)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.58	1.17	
95% CI of the risk ratio	(0.09, 3.95)	(0.44, 3.12)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-11.90	4.76	
95% CI of the absolute risk difference	(-47.44, 23.63)	(-25.94, 35.46)	
p-value	0.5573	0.7598	
p-value of Breslow-Day Test for Homogeneity [2]	0.4748	NE	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: < 65 years

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	1 (4.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.76	-4.76	
95% CI of the absolute risk difference	(-13.87, 4.35)	(-13.87, 4.35)	
p-value	0.5860	0.3914	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: < 65 years

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	1 (4.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.76	-4.76	
95% CI of the absolute risk difference	(-13.87, 4.35)	(-13.87, 4.35)	
p-value	0.5860	0.3914	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Maximum Severity of TEAEs			
Grade 1	2 (33.3)	7 (46.7)	7 (33.3)
Grade 2	4 (66.7)	3 (20.0)	10 (47.6)
Grade 3	0	2 (13.3)	1 (4.8)
Grade 4	0	0	0
Grade 5	0	0	0

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: < 65 years

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Maximum Severity of Treatment-related TEAEs			
Grade 1	1 (16.7)	5 (33.3)	6 (28.6)
Grade 2	0	0	0
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0
MACE AE – Adjudicated Event [3]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: < 65 years

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious MACE AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event [4]	0	0	1 (4.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-4.76	-4.76	
95% CI of the absolute risk difference	(-13.87, 4.35)	(-13.87, 4.35)	
p-value	0.5860	0.3914	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: < 65 years

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Other CV AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (4.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-4.76	-4.76	
95% CI of the absolute risk difference	(-13.87, 4.35)	(-13.87, 4.35)	
p-value	0.5860	0.3914	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious Other CV AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: < 65 years

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: < 65 years

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Serious DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: >= 65 years

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Events n:			
Total TEAEs	15	0	31
Total Serious TEAEs	0	0	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	0	0	2
Total TEAEs >= Grade 3 Severity	0	0	1
Patients n (%):			
Any TEAE	3 (100)	0	6 (85.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.17	NE	
95% CI of the risk ratio	(0.86, 1.58)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	14.29	NE	
95% CI of the absolute risk difference	(-11.64, 40.21)	NE	
p-value	0.4902	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: >= 65 years

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Any TEAEs >= Grade 3 Severity	0	0	1 (14.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.62	NE	
95% CI of the odds ratio	(0.02, 19.58)	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.67	NE	
95% CI of the risk ratio	(0.03, 12.96)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.25	NE	
95% CI of the absolute risk difference	(-48.46, 35.96)	NE	
p-value	0.7842	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any TEAEs <= Grade 2 Severity	3 (100)	0	6 (85.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.17	NE	
95% CI of the risk ratio	(0.86, 1.58)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	14.29	NE	
95% CI of the absolute risk difference	(-11.64, 40.21)	NE	
p-value	0.4902	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: >= 65 years

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAE	0	0	2 (28.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.31	NE	
95% CI of the odds ratio	(0.01, 8.68)	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.40	NE	
95% CI of the risk ratio	(0.02, 6.51)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-18.75	NE	
95% CI of the absolute risk difference	(-64.38, 26.88)	NE	
p-value	0.4795	NE	
p-value of Breslow-Day Test for Homogeneity [2]	0.4748	NE	

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: >= 65 years

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: >= 65 years

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Maximum Severity of TEAEs			
Grade 1	2 (66.7)	0	2 (28.6)
Grade 2	1 (33.3)	0	3 (42.9)
Grade 3	0	0	1 (14.3)
Grade 4	0	0	0
Grade 5	0	0	0

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: >= 65 years

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Maximum Severity of Treatment-related TEAEs			
Grade 1	0	0	2 (28.6)
Grade 2	0	0	0
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0
MACE AE – Adjudicated Event [3]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: >= 65 years

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious MACE AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event [4]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: >= 65 years

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Other CV AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious Other CV AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: >= 65 years

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
DILI AE - Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE - Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE - Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: >= 65 years

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Serious DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population based on Safety Population)

Abbreviations: DB = Double Blinded; AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; CV = cardiovascular; DILI = drug-induced liver injury.
Note: Disease related events include the following preferred terms: Hepatic cirrhosis; Ascites; Varices oesophageal; Oesophageal varices haemorrhage; Hepatic encephalopathy.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
[3] MACE AE includes cardiovascular mortality, myocardial infarction, and cerebral vascular accident.
[4] Other CV AE includes hospitalization/emergency room treatment for heart failure, hospitalization for unstable angina, urgent or emergent coronary revascularization.

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: < 65 years

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Events n:			
Total TEAEs	21	42	74
Total Serious TEAEs	0	2	2
Total TEAEs Leading to Discontinuation of Study Drug	0	1	1
Total TEAEs Related to Study Drug	2	9	10
Total TEAEs >= Grade 3 Severity	0	2	2
Patients n (%):			
Any TEAE	6 (100)	12 (80.0)	18 (85.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.67	
95% CI of the odds ratio	NE	(0.11, 3.87)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.17	0.93	
95% CI of the risk ratio	(0.98, 1.39)	(0.69, 1.27)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	14.29	-5.71	
95% CI of the absolute risk difference	(-0.68, 29.25)	(-30.89, 19.46)	
p-value	0.3261	0.6501	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Serious TEAE	0	2 (13.3)	1 (4.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.08	
95% CI of the odds ratio	NE	(0.25, 37.48)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.80	
95% CI of the risk ratio	NE	(0.28, 28.13)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.76	8.57	
95% CI of the absolute risk difference	(-13.87, 4.35)	(-10.89, 28.04)	
p-value	0.5860	0.3590	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: < 65 years

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Any TEAEs >= Grade 3 Severity	0	2 (13.3)	1 (4.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.08	
95% CI of the odds ratio	NE	(0.25, 37.48)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.80	
95% CI of the risk ratio	NE	(0.28, 28.13)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.76	8.57	
95% CI of the absolute risk difference	(-13.87, 4.35)	(-10.89, 28.04)	
p-value	0.5860	0.3590	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any TEAEs <= Grade 2 Severity	6 (100)	12 (80.0)	18 (85.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.67	
95% CI of the odds ratio	NE	(0.11, 3.87)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.17	0.93	
95% CI of the risk ratio	(0.98, 1.39)	(0.69, 1.27)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	14.29	-5.71	
95% CI of the absolute risk difference	(-0.68, 29.25)	(-30.89, 19.46)	
p-value	0.3261	0.6501	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any TEAEs leading to Study-Drug Discontinuation	0	1 (6.7)	1 (4.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.43	
95% CI of the odds ratio	NE	(0.08, 24.81)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.40	
95% CI of the risk ratio	NE	(0.09, 20.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.76	1.90	
95% CI of the absolute risk difference	(-13.87, 4.35)	(-13.66, 17.47)	
p-value	0.5860	0.8057	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: < 65 years

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Any TEAEs leading to Study Discontinuation	0	0	1 (4.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.76	-4.76	
95% CI of the absolute risk difference	(-13.87, 4.35)	(-13.87, 4.35)	
p-value	0.5860	0.3914	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAE	1 (16.7)	5 (33.3)	6 (28.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.50	1.25	
95% CI of the odds ratio	(0.05, 5.22)	(0.30, 5.23)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.58	1.17	
95% CI of the risk ratio	(0.09, 3.95)	(0.44, 3.12)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-11.90	4.76	
95% CI of the absolute risk difference	(-47.44, 23.63)	(-25.94, 35.46)	
p-value	0.5573	0.7598	
p-value of Breslow-Day Test for Homogeneity [2]	0.4748	NE	

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: < 65 years

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	1 (4.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.76	-4.76	
95% CI of the absolute risk difference	(-13.87, 4.35)	(-13.87, 4.35)	
p-value	0.5860	0.3914	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: < 65 years

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	1 (4.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.76	-4.76	
95% CI of the absolute risk difference	(-13.87, 4.35)	(-13.87, 4.35)	
p-value	0.5860	0.3914	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Maximum Severity of TEAEs			
Grade 1	2 (33.3)	7 (46.7)	7 (33.3)
Grade 2	4 (66.7)	3 (20.0)	10 (47.6)
Grade 3	0	2 (13.3)	1 (4.8)
Grade 4	0	0	0
Grade 5	0	0	0

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: < 65 years

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Maximum Severity of Treatment-related TEAEs			
Grade 1	1 (16.7)	5 (33.3)	6 (28.6)
Grade 2	0	0	0
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0
MACE AE – Adjudicated Event [3]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: < 65 years

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious MACE AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event [4]	0	0	1 (4.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-4.76	-4.76	
95% CI of the absolute risk difference	(-13.87, 4.35)	(-13.87, 4.35)	
p-value	0.5860	0.3914	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: < 65 years

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Other CV AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (4.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-4.76	-4.76	
95% CI of the absolute risk difference	(-13.87, 4.35)	(-13.87, 4.35)	
p-value	0.5860	0.3914	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious Other CV AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: < 65 years

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: < 65 years

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=21)
Serious DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: >= 65 years

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Events n:			
Total TEAEs	15	0	31
Total Serious TEAEs	0	0	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	0	0	2
Total TEAEs >= Grade 3 Severity	0	0	1
Patients n (%):			
Any TEAE	3 (100)	0	6 (85.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.17	NE	
95% CI of the risk ratio	(0.86, 1.58)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	14.29	NE	
95% CI of the absolute risk difference	(-11.64, 40.21)	NE	
p-value	0.4902	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: >= 65 years

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Any TEAEs >= Grade 3 Severity	0	0	1 (14.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.62	NE	
95% CI of the odds ratio	(0.02, 19.58)	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.67	NE	
95% CI of the risk ratio	(0.03, 12.96)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.25	NE	
95% CI of the absolute risk difference	(-48.46, 35.96)	NE	
p-value	0.7842	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any TEAEs <= Grade 2 Severity	3 (100)	0	6 (85.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.17	NE	
95% CI of the risk ratio	(0.86, 1.58)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	14.29	NE	
95% CI of the absolute risk difference	(-11.64, 40.21)	NE	
p-value	0.4902	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: >= 65 years

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAE	0	0	2 (28.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.31	NE	
95% CI of the odds ratio	(0.01, 8.68)	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.40	NE	
95% CI of the risk ratio	(0.02, 6.51)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-18.75	NE	
95% CI of the absolute risk difference	(-64.38, 26.88)	NE	
p-value	0.4795	NE	
p-value of Breslow-Day Test for Homogeneity [2]	0.4748	NE	

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: >= 65 years

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: >= 65 years

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Maximum Severity of TEAEs			
Grade 1	2 (66.7)	0	2 (28.6)
Grade 2	1 (33.3)	0	3 (42.9)
Grade 3	0	0	1 (14.3)
Grade 4	0	0	0
Grade 5	0	0	0

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: >= 65 years

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Maximum Severity of Treatment-related TEAEs			
Grade 1	0	0	2 (28.6)
Grade 2	0	0	0
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0
MACE AE – Adjudicated Event [3]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: >= 65 years

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious MACE AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event [4]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: >= 65 years

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Other CV AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious Other CV AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: >= 65 years

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population based on Safety Population)

Age: >= 65 years

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=7)
Serious DILI AE - Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.3.2

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Age
(Label Population based on Safety Population)

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.

AMNOG Table S1.3.2

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Age
(Label Population based on Safety Population)

Age: < 65 years

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=6) Patients n (%)	 Events n	DB MGL-3196 100 mg (N=15) Patients n (%)	 Events n	DB Placebo (N=21) Patients n (%)	 Events n
Musculoskeletal and connective tissue disorders	3 (50.0)	3	0	0	7 (33.3)	14
Odds ratio, Chi-square,						
MGL-3196 treatment group / Placebo [1]	2.00		0.06			
95% CI of the odds ratio	(0.32, 12.59)		(0.00, 1.19)			
Risk ratio, Chi-square,						
MGL-3196 treatment group / Placebo [1]	1.50		0.09			
95% CI of the risk ratio	(0.55, 4.09)		(0.01, 1.49)			
Absolute risk difference, Chi-square,						
MGL-3196 treatment group - Placebo [1]	16.67		-30.97			
95% CI of the absolute risk difference	(-28.13, 61.47)		(-52.53, -9.40)			
p-value	0.4559		0.0208			
p-value of Breslow-Day Test for Homogeneity [2]	0.7886		NE			

Program: t-s01-02-02-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc. Page 3 of 3
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S1.3.2
TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Age
(Label Population based on Safety Population)

Age: >= 65 years

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=3) Patients n (%)	 Events n	DB MGL-3196 100 mg (N=0) Patients n (%)	 Events n	DB Placebo (N=7) Patients n (%)	 Events n
Musculoskeletal and connective tissue disorders	1 (33.3)	1	0	0	2 (28.6)	4
Odds ratio, Chi-square,						
MGL-3196 treatment group / Placebo [1]	1.25		NE			
95% CI of the odds ratio	(0.07, 22.88)		NE			
Risk ratio, Chi-square,						
MGL-3196 treatment group / Placebo [1]	1.17		NE			
95% CI of the risk ratio	(0.16, 8.48)		NE			
Absolute risk difference, Chi-square,						
MGL-3196 treatment group - Placebo [1]	4.76		NE			
95% CI of the absolute risk difference	(-58.21, 67.73)		NE			
p-value	0.8803		NE			
p-value of Breslow-Day Test for Homogeneity [2]	0.7886		NE			

Program: t-s01-02-02-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Abbreviations: DB = Double Blinded; AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; CV = cardiovascular; DILI = drug-induced liver injury.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as “Grade 3”. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
[3] MACE AE includes cardiovascular mortality, myocardial infarction, and cerebral vascular accident.
[4] Other CV AE includes hospitalization/emergency room treatment for heart failure, hospitalization for unstable angina, urgent or emergent coronary revascularization.

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Male

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Events n:			
Total TEAEs	13	28	56
Total Serious TEAEs	0	1	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	0	7	6
Total TEAEs >= Grade 3 Severity	0	1	0
Patients n (%):			
Any TEAE	3 (100)	6 (75.0)	12 (85.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.50	
95% CI of the odds ratio	NE	(0.06, 4.47)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.17	0.88	
95% CI of the risk ratio	(0.94, 1.44)	(0.56, 1.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	14.29	-10.71	
95% CI of the absolute risk difference	(-4.04, 32.62)	(-45.88, 24.45)	
p-value	0.4858	0.5308	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.6880	
Any Serious TEAE	0	1 (12.5)	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	5.80	
95% CI of the odds ratio	NE	(0.21, 160.40)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	5.00	
95% CI of the risk ratio	NE	(0.23, 110.11)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	13.33	
95% CI of the absolute risk difference	NE	(-12.65, 39.32)	
p-value	NE	0.2526	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.4111	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Male

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Any TEAEs >= Grade 3 Severity	0	1 (12.5)	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	5.80	
95% CI of the odds ratio	NE	(0.21, 160.40)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	5.00	
95% CI of the risk ratio	NE	(0.23, 110.11)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	13.33	
95% CI of the absolute risk difference	NE	(-12.65, 39.32)	
p-value	NE	0.2526	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2670	
Any TEAEs <= Grade 2 Severity	3 (100)	6 (75.0)	12 (85.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.50	
95% CI of the odds ratio	NE	(0.06, 4.47)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.17	0.88	
95% CI of the risk ratio	(0.94, 1.44)	(0.56, 1.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	14.29	-10.71	
95% CI of the absolute risk difference	(-4.04, 32.62)	(-45.88, 24.45)	
p-value	0.4858	0.5308	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.6880	
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Male

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAE	0	4 (50.0)	3 (21.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.47	3.67	
95% CI of the odds ratio	(0.02, 11.47)	(0.56, 24.13)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.54	2.33	
95% CI of the risk ratio	(0.03, 8.38)	(0.69, 7.90)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-10.83	28.57	
95% CI of the absolute risk difference	(-49.67, 28.01)	(-12.20, 69.34)	
p-value	0.6368	0.1663	
p-value of Breslow-Day Test for Homogeneity [2]	0.5909	0.0938	

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Male

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Male

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Maximum Severity of TEAEs			
Grade 1	2 (66.7)	3 (37.5)	6 (42.9)
Grade 2	1 (33.3)	2 (25.0)	6 (42.9)
Grade 3	0	1 (12.5)	0
Grade 4	0	0	0
Grade 5	0	0	0

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Male

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Maximum Severity of Treatment-related TEAEs			
Grade 1	0	4 (50.0)	3 (21.4)
Grade 2	0	0	0
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0
MACE AE – Adjudicated Event [3]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Male

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious MACE AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event [4]	0	0	1 (7.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.29	0.53	
95% CI of the odds ratio	(0.04, 38.90)	(0.02, 14.55)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.25	0.56	
95% CI of the risk ratio	(0.06, 25.22)	(0.03, 12.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	2.50	-4.44	
95% CI of the absolute risk difference	(-33.29, 38.29)	(-25.76, 16.87)	
p-value	0.8849	0.7029	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Male

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Other CV AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (7.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.29	0.53	
95% CI of the odds ratio	(0.04, 38.90)	(0.02, 14.55)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.25	0.56	
95% CI of the risk ratio	(0.06, 25.22)	(0.03, 12.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	2.50	-4.44	
95% CI of the absolute risk difference	(-33.29, 38.29)	(-25.76, 16.87)	
p-value	0.8849	0.7029	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious Other CV AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Male

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Male

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Serious DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Female

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Events n:			
Total TEAEs	23	14	49
Total Serious TEAEs	0	1	2
Total TEAEs Leading to Discontinuation of Study Drug	0	1	1
Total TEAEs Related to Study Drug	2	2	6
Total TEAEs >= Grade 3 Severity	0	1	3
Patients n (%):			
Any TEAE	6 (100)	6 (85.7)	12 (85.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.00	
95% CI of the odds ratio	NE	(0.07, 13.37)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.17	1.00	
95% CI of the risk ratio	(0.94, 1.44)	(0.69, 1.45)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	14.29	0.00	
95% CI of the absolute risk difference	(-4.04, 32.62)	(-31.75, 31.75)	
p-value	0.3291	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.6880	
Any Serious TEAE	0	1 (14.3)	1 (7.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.69	2.17	
95% CI of the odds ratio	(0.02, 19.43)	(0.12, 40.81)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.71	2.00	
95% CI of the risk ratio	(0.03, 15.42)	(0.15, 27.45)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.86	7.14	
95% CI of the absolute risk difference	(-27.24, 21.52)	(-22.08, 36.37)	
p-value	0.8281	0.5991	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.4111	

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Female

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Any TEAEs >= Grade 3 Severity	0	1 (14.3)	2 (14.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.38	1.00	
95% CI of the odds ratio	(0.02, 9.26)	(0.07, 13.37)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.43	1.00	
95% CI of the risk ratio	(0.02, 7.80)	(0.11, 9.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-9.52	0.00	
95% CI of the absolute risk difference	(-36.35, 17.30)	(-31.75, 31.75)	
p-value	0.5443	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2670	
Any TEAEs <= Grade 2 Severity	6 (100)	6 (85.7)	12 (85.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.00	
95% CI of the odds ratio	NE	(0.07, 13.37)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.17	1.00	
95% CI of the risk ratio	(0.94, 1.44)	(0.69, 1.45)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	14.29	0.00	
95% CI of the absolute risk difference	(-4.04, 32.62)	(-31.75, 31.75)	
p-value	0.3291	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.6880	
Any TEAEs leading to Study-Drug Discontinuation	0	1 (14.3)	1 (7.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.69	2.17	
95% CI of the odds ratio	(0.02, 19.43)	(0.12, 40.81)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.71	2.00	
95% CI of the risk ratio	(0.03, 15.42)	(0.15, 27.45)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.86	7.14	
95% CI of the absolute risk difference	(-27.24, 21.52)	(-22.08, 36.37)	
p-value	0.8281	0.5991	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Female

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Any TEAEs leading to Study Discontinuation	0	0	1 (7.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.69	0.60	
95% CI of the odds ratio	(0.02, 19.43)	(0.02, 16.64)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.71	0.63	
95% CI of the risk ratio	(0.03, 15.42)	(0.03, 13.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.86	-3.75	
95% CI of the absolute risk difference	(-27.24, 21.52)	(-26.37, 18.87)	
p-value	0.8281	0.7611	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAE	1 (16.7)	1 (14.3)	5 (35.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.36	0.30	
95% CI of the odds ratio	(0.03, 4.01)	(0.03, 3.25)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.47	0.40	
95% CI of the risk ratio	(0.07, 3.19)	(0.06, 2.80)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-19.05	-21.43	
95% CI of the absolute risk difference	(-58.02, 19.93)	(-57.51, 14.65)	
p-value	0.3943	0.3055	
p-value of Breslow-Day Test for Homogeneity [2]	0.5909	0.0938	

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Female

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	1 (7.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.69	0.60	
95% CI of the odds ratio	(0.02, 19.43)	(0.02, 16.64)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.71	0.63	
95% CI of the risk ratio	(0.03, 15.42)	(0.03, 13.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.86	-3.75	
95% CI of the absolute risk difference	(-27.24, 21.52)	(-26.37, 18.87)	
p-value	0.8281	0.7611	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Female

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	1 (7.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.69	0.60	
95% CI of the odds ratio	(0.02, 19.43)	(0.02, 16.64)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.71	0.63	
95% CI of the risk ratio	(0.03, 15.42)	(0.03, 13.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.86	-3.75	
95% CI of the absolute risk difference	(-27.24, 21.52)	(-26.37, 18.87)	
p-value	0.8281	0.7611	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Maximum Severity of TEAEs			
Grade 1	2 (33.3)	4 (57.1)	3 (21.4)
Grade 2	4 (66.7)	1 (14.3)	7 (50.0)
Grade 3	0	1 (14.3)	2 (14.3)
Grade 4	0	0	0
Grade 5	0	0	0

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Female

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Maximum Severity of Treatment-related TEAEs			
Grade 1	1 (16.7)	1 (14.3)	5 (35.7)
Grade 2	0	0	0
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0
MACE AE – Adjudicated Event [3]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Female

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious MACE AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event [4]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Female

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Other CV AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious Other CV AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Female

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Female

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Serious DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Abbreviations: DB = Double Blinded; AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; CV = cardiovascular; DILI = drug-induced liver injury.
Note: Disease related events include the following preferred terms: Hepatic cirrhosis; Ascites; Varices oesophageal; Oesophageal varices haemorrhage; Hepatic encephalopathy.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
[3] MACE AE includes cardiovascular mortality, myocardial infarction, and cerebral vascular accident.
[4] Other CV AE includes hospitalization/emergency room treatment for heart failure, hospitalization for unstable angina, urgent or emergent coronary revascularization.

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Male

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Events n:			
Total TEAEs	13	28	56
Total Serious TEAEs	0	1	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	0	7	6
Total TEAEs >= Grade 3 Severity	0	1	0
Patients n (%):			
Any TEAE	3 (100)	6 (75.0)	12 (85.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.50	
95% CI of the odds ratio	NE	(0.06, 4.47)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.17	0.88	
95% CI of the risk ratio	(0.94, 1.44)	(0.56, 1.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	14.29	-10.71	
95% CI of the absolute risk difference	(-4.04, 32.62)	(-45.88, 24.45)	
p-value	0.4858	0.5308	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.6880	
Any Serious TEAE	0	1 (12.5)	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	5.80	
95% CI of the odds ratio	NE	(0.21, 160.40)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	5.00	
95% CI of the risk ratio	NE	(0.23, 110.11)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	13.33	
95% CI of the absolute risk difference	NE	(-12.65, 39.32)	
p-value	NE	0.2526	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.4111	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Male

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Any TEAEs >= Grade 3 Severity	0	1 (12.5)	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	5.80	
95% CI of the odds ratio	NE	(0.21, 160.40)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	5.00	
95% CI of the risk ratio	NE	(0.23, 110.11)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	13.33	
95% CI of the absolute risk difference	NE	(-12.65, 39.32)	
p-value	NE	0.2526	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2670	
Any TEAEs <= Grade 2 Severity	3 (100)	6 (75.0)	12 (85.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.50	
95% CI of the odds ratio	NE	(0.06, 4.47)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.17	0.88	
95% CI of the risk ratio	(0.94, 1.44)	(0.56, 1.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	14.29	-10.71	
95% CI of the absolute risk difference	(-4.04, 32.62)	(-45.88, 24.45)	
p-value	0.4858	0.5308	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.6880	
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Male

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAE	0	4 (50.0)	3 (21.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.47	3.67	
95% CI of the odds ratio	(0.02, 11.47)	(0.56, 24.13)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.54	2.33	
95% CI of the risk ratio	(0.03, 8.38)	(0.69, 7.90)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-10.83	28.57	
95% CI of the absolute risk difference	(-49.67, 28.01)	(-12.20, 69.34)	
p-value	0.6368	0.1663	
p-value of Breslow-Day Test for Homogeneity [2]	0.5909	0.0938	

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Male

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Male

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Maximum Severity of TEAEs			
Grade 1	2 (66.7)	3 (37.5)	6 (42.9)
Grade 2	1 (33.3)	2 (25.0)	6 (42.9)
Grade 3	0	1 (12.5)	0
Grade 4	0	0	0
Grade 5	0	0	0

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Male

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Maximum Severity of Treatment-related TEAEs			
Grade 1	0	4 (50.0)	3 (21.4)
Grade 2	0	0	0
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0
MACE AE – Adjudicated Event [3]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Male

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious MACE AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event [4]	0	0	1 (7.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.29	0.53	
95% CI of the odds ratio	(0.04, 38.90)	(0.02, 14.55)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.25	0.56	
95% CI of the risk ratio	(0.06, 25.22)	(0.03, 12.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	2.50	-4.44	
95% CI of the absolute risk difference	(-33.29, 38.29)	(-25.76, 16.87)	
p-value	0.8849	0.7029	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Male

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Other CV AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (7.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.29	0.53	
95% CI of the odds ratio	(0.04, 38.90)	(0.02, 14.55)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.25	0.56	
95% CI of the risk ratio	(0.06, 25.22)	(0.03, 12.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	2.50	-4.44	
95% CI of the absolute risk difference	(-33.29, 38.29)	(-25.76, 16.87)	
p-value	0.8849	0.7029	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious Other CV AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Male

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Male

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=8)	DB Placebo (N=14)
Serious DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Female

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Events n:			
Total TEAEs	23	14	49
Total Serious TEAEs	0	1	2
Total TEAEs Leading to Discontinuation of Study Drug	0	1	1
Total TEAEs Related to Study Drug	2	2	6
Total TEAEs >= Grade 3 Severity	0	1	3
Patients n (%):			
Any TEAE	6 (100)	6 (85.7)	12 (85.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.00	
95% CI of the odds ratio	NE	(0.07, 13.37)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.17	1.00	
95% CI of the risk ratio	(0.94, 1.44)	(0.69, 1.45)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	14.29	0.00	
95% CI of the absolute risk difference	(-4.04, 32.62)	(-31.75, 31.75)	
p-value	0.3291	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.6880	
Any Serious TEAE	0	1 (14.3)	1 (7.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.69	2.17	
95% CI of the odds ratio	(0.02, 19.43)	(0.12, 40.81)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.71	2.00	
95% CI of the risk ratio	(0.03, 15.42)	(0.15, 27.45)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.86	7.14	
95% CI of the absolute risk difference	(-27.24, 21.52)	(-22.08, 36.37)	
p-value	0.8281	0.5991	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.4111	

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Female

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Any TEAEs >= Grade 3 Severity	0	1 (14.3)	2 (14.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.38	1.00	
95% CI of the odds ratio	(0.02, 9.26)	(0.07, 13.37)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.43	1.00	
95% CI of the risk ratio	(0.02, 7.80)	(0.11, 9.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-9.52	0.00	
95% CI of the absolute risk difference	(-36.35, 17.30)	(-31.75, 31.75)	
p-value	0.5443	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2670	
Any TEAEs <= Grade 2 Severity	6 (100)	6 (85.7)	12 (85.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.00	
95% CI of the odds ratio	NE	(0.07, 13.37)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.17	1.00	
95% CI of the risk ratio	(0.94, 1.44)	(0.69, 1.45)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	14.29	0.00	
95% CI of the absolute risk difference	(-4.04, 32.62)	(-31.75, 31.75)	
p-value	0.3291	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.6880	
Any TEAEs leading to Study-Drug Discontinuation	0	1 (14.3)	1 (7.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.69	2.17	
95% CI of the odds ratio	(0.02, 19.43)	(0.12, 40.81)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.71	2.00	
95% CI of the risk ratio	(0.03, 15.42)	(0.15, 27.45)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.86	7.14	
95% CI of the absolute risk difference	(-27.24, 21.52)	(-22.08, 36.37)	
p-value	0.8281	0.5991	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Female

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Any TEAEs leading to Study Discontinuation	0	0	1 (7.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.69	0.60	
95% CI of the odds ratio	(0.02, 19.43)	(0.02, 16.64)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.71	0.63	
95% CI of the risk ratio	(0.03, 15.42)	(0.03, 13.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.86	-3.75	
95% CI of the absolute risk difference	(-27.24, 21.52)	(-26.37, 18.87)	
p-value	0.8281	0.7611	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAE	1 (16.7)	1 (14.3)	5 (35.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.36	0.30	
95% CI of the odds ratio	(0.03, 4.01)	(0.03, 3.25)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.47	0.40	
95% CI of the risk ratio	(0.07, 3.19)	(0.06, 2.80)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-19.05	-21.43	
95% CI of the absolute risk difference	(-58.02, 19.93)	(-57.51, 14.65)	
p-value	0.3943	0.3055	
p-value of Breslow-Day Test for Homogeneity [2]	0.5909	0.0938	

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Female

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	1 (7.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.69	0.60	
95% CI of the odds ratio	(0.02, 19.43)	(0.02, 16.64)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.71	0.63	
95% CI of the risk ratio	(0.03, 15.42)	(0.03, 13.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.86	-3.75	
95% CI of the absolute risk difference	(-27.24, 21.52)	(-26.37, 18.87)	
p-value	0.8281	0.7611	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Female

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	1 (7.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.69	0.60	
95% CI of the odds ratio	(0.02, 19.43)	(0.02, 16.64)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.71	0.63	
95% CI of the risk ratio	(0.03, 15.42)	(0.03, 13.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.86	-3.75	
95% CI of the absolute risk difference	(-27.24, 21.52)	(-26.37, 18.87)	
p-value	0.8281	0.7611	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Maximum Severity of TEAEs			
Grade 1	2 (33.3)	4 (57.1)	3 (21.4)
Grade 2	4 (66.7)	1 (14.3)	7 (50.0)
Grade 3	0	1 (14.3)	2 (14.3)
Grade 4	0	0	0
Grade 5	0	0	0

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Female

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Maximum Severity of Treatment-related TEAEs			
Grade 1	1 (16.7)	1 (14.3)	5 (35.7)
Grade 2	0	0	0
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0
MACE AE – Adjudicated Event [3]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Female

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious MACE AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event [4]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Female

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Other CV AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious Other CV AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Female

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population based on Safety Population)

Sex: Female

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=7)	DB Placebo (N=14)
Serious DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.4.2

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Sex
(Label Population based on Safety Population)

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.

AMNOG Table S1.4.2

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Sex
(Label Population based on Safety Population)

Sex: Male

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=3) Patients n (%)	DB MGL-3196 80 mg (N=3) Events n	DB MGL-3196 100 mg (N=8) Patients n (%)	DB MGL-3196 100 mg (N=8) Events n	DB Placebo (N=14) Patients n (%)	DB Placebo (N=14) Events n
Musculoskeletal and connective tissue disorders	1 (33.3)	1	0	0	4 (28.6)	7
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.25		0.14			
95% CI of the odds ratio	(0.09, 17.98)		(0.01, 2.92)			
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.17		0.19			
95% CI of the risk ratio	(0.19, 7.07)		(0.01, 3.05)			
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	4.76		-24.44			
95% CI of the absolute risk difference	(-53.59, 63.12)		(-52.04, 3.16)			
p-value	0.8695		0.1534			
p-value of Breslow-Day Test for Homogeneity [2]	0.8282		NE			

AMNOG Table S1.4.2

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Sex
(Label Population based on Safety Population)

Sex: Female

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=6) Patients n (%)	DB MGL-3196 80 mg (N=6) Events n	DB MGL-3196 100 mg (N=7) Patients n (%)	DB MGL-3196 100 mg (N=7) Events n	DB Placebo (N=14) Patients n (%)	DB Placebo (N=14) Events n
Musculoskeletal and connective tissue disorders	3 (50.0)	3	0	0	5 (35.7)	11
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.80		0.12			
95% CI of the odds ratio	(0.26, 12.50)		(0.01, 2.43)			
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.40		0.17			
95% CI of the risk ratio	(0.48, 4.06)		(0.01, 2.71)			
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	14.29		-30.42			
95% CI of the absolute risk difference	(-32.94, 61.51)		(-60.02, -0.82)			
p-value	0.5501		0.1136			
p-value of Breslow-Day Test for Homogeneity [2]	0.8282		NE			

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Abbreviations: DB = Double Blinded; AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; CV = cardiovascular; DILI = drug-induced liver injury.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as “Grade 3”. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
[3] MACE AE includes cardiovascular mortality, myocardial infarction, and cerebral vascular accident.
[4] Other CV AE includes hospitalization/emergency room treatment for heart failure, hospitalization for unstable angina, urgent or emergent coronary revascularization.

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Hispanic

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Events n:			
Total TEAEs	14	22	38
Total Serious TEAEs	0	0	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	2	8	4
Total TEAEs >= Grade 3 Severity	0	0	0
Patients n (%):			
Any TEAE	4 (100)	5 (83.3)	11 (100)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.83	
95% CI of the risk ratio	NE	(0.58, 1.19)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	-16.67	
95% CI of the absolute risk difference	NE	(-46.49, 13.15)	
p-value	NE	0.1628	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2096	
Any Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Hispanic

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Any TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any TEAEs <= Grade 2 Severity	4 (100)	5 (83.3)	11 (100)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.83	
95% CI of the risk ratio	NE	(0.58, 1.19)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	-16.67	
95% CI of the absolute risk difference	NE	(-46.49, 13.15)	
p-value	NE	0.1628	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2096	
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Hispanic

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAE	1 (25.0)	4 (66.7)	3 (27.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.89	5.33	
95% CI of the odds ratio	(0.06, 12.25)	(0.62, 45.99)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.92	2.44	
95% CI of the risk ratio	(0.13, 6.46)	(0.80, 7.48)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.27	39.39	
95% CI of the absolute risk difference	(-52.21, 47.66)	(-6.60, 85.39)	
p-value	0.9299	0.1148	
p-value of Breslow-Day Test for Homogeneity [2]	0.2543	0.0636	

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Hispanic

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Hispanic

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Maximum Severity of TEAEs			
Grade 1	2 (50.0)	3 (50.0)	7 (63.6)
Grade 2	2 (50.0)	2 (33.3)	4 (36.4)
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Hispanic

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Maximum Severity of Treatment-related TEAEs			
Grade 1	1 (25.0)	4 (66.7)	3 (27.3)
Grade 2	0	0	0
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0
MACE AE – Adjudicated Event [3]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Hispanic

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious MACE AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event [4]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Hispanic

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Other CV AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious Other CV AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Hispanic

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Hispanic

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Serious DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Non-Hispanic

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Events n:			
Total TEAEs	22	20	67
Total Serious TEAEs	0	2	2
Total TEAEs Leading to Discontinuation of Study Drug	0	1	1
Total TEAEs Related to Study Drug	0	1	8
Total TEAEs >= Grade 3 Severity	0	2	3
Patients n (%):			
Any TEAE	5 (100)	7 (77.8)	13 (76.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.08	
95% CI of the odds ratio	NE	(0.16, 7.42)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.31	1.02	
95% CI of the risk ratio	(1.00, 1.70)	(0.66, 1.58)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	23.53	1.31	
95% CI of the absolute risk difference	(3.37, 43.69)	(-32.52, 35.13)	
p-value	0.2305	0.9400	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2096	
Any Serious TEAE	0	2 (22.2)	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	4.57	
95% CI of the odds ratio	(0.04, 28.30)	(0.35, 59.11)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	3.78	
95% CI of the risk ratio	(0.05, 21.42)	(0.39, 36.22)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.00	16.34	
95% CI of the absolute risk difference	(-25.54, 25.54)	(-13.03, 45.71)	
p-value	>0.9999	0.2147	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Non-Hispanic

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Any TEAEs >= Grade 3 Severity	0	2 (22.2)	2 (11.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.56	2.14	
95% CI of the odds ratio	(0.02, 13.67)	(0.25, 18.50)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.60	1.89	
95% CI of the risk ratio	(0.03, 10.82)	(0.32, 11.26)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.56	10.46	
95% CI of the absolute risk difference	(-32.84, 21.73)	(-20.72, 41.64)	
p-value	0.7216	0.4820	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any TEAEs <= Grade 2 Severity	5 (100)	7 (77.8)	13 (76.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.08	
95% CI of the odds ratio	NE	(0.16, 7.42)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.31	1.02	
95% CI of the risk ratio	(1.00, 1.70)	(0.66, 1.58)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	23.53	1.31	
95% CI of the absolute risk difference	(3.37, 43.69)	(-32.52, 35.13)	
p-value	0.2305	0.9400	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2096	
Any TEAEs leading to Study-Drug Discontinuation	0	1 (11.1)	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	2.00	
95% CI of the odds ratio	(0.04, 28.30)	(0.11, 36.31)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	1.89	
95% CI of the risk ratio	(0.05, 21.42)	(0.13, 26.77)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.00	5.23	
95% CI of the absolute risk difference	(-25.54, 25.54)	(-18.15, 28.61)	
p-value	>0.9999	0.6341	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Non-Hispanic

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Any TEAEs leading to Study Discontinuation	0	0	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	0.58	
95% CI of the odds ratio	(0.04, 28.30)	(0.02, 15.68)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	0.60	
95% CI of the risk ratio	(0.05, 21.42)	(0.03, 13.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.00	-3.33	
95% CI of the absolute risk difference	(-25.54, 25.54)	(-21.92, 15.25)	
p-value	>0.9999	0.7428	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAE	0	1 (11.1)	5 (29.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.21	0.30	
95% CI of the odds ratio	(0.01, 4.42)	(0.03, 3.07)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.27	0.38	
95% CI of the risk ratio	(0.02, 4.24)	(0.05, 2.76)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-22.22	-18.30	
95% CI of the absolute risk difference	(-52.91, 8.47)	(-48.15, 11.54)	
p-value	0.2763	0.2920	
p-value of Breslow-Day Test for Homogeneity [2]	0.2543	0.0636	

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Non-Hispanic

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	0.58	
95% CI of the odds ratio	(0.04, 28.30)	(0.02, 15.68)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	0.60	
95% CI of the risk ratio	(0.05, 21.42)	(0.03, 13.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.00	-3.33	
95% CI of the absolute risk difference	(-25.54, 25.54)	(-21.92, 15.25)	
p-value	>0.9999	0.7428	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Non-Hispanic

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	0.58	
95% CI of the odds ratio	(0.04, 28.30)	(0.02, 15.68)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	0.60	
95% CI of the risk ratio	(0.05, 21.42)	(0.03, 13.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.00	-3.33	
95% CI of the absolute risk difference	(-25.54, 25.54)	(-21.92, 15.25)	
p-value	>0.9999	0.7428	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Maximum Severity of TEAEs			
Grade 1	2 (40.0)	4 (44.4)	2 (11.8)
Grade 2	3 (60.0)	1 (11.1)	9 (52.9)
Grade 3	0	2 (22.2)	2 (11.8)
Grade 4	0	0	0
Grade 5	0	0	0

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Non-Hispanic

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Maximum Severity of Treatment-related TEAEs			
Grade 1	0	1 (11.1)	5 (29.4)
Grade 2	0	0	0
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0
MACE AE – Adjudicated Event [3]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Non-Hispanic

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious MACE AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event [4]	0	0	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	0.58	
95% CI of the odds ratio	(0.04, 28.30)	(0.02, 15.68)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	0.60	
95% CI of the risk ratio	(0.05, 21.42)	(0.03, 13.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.00	-3.33	
95% CI of the absolute risk difference	(-25.54, 25.54)	(-21.92, 15.25)	
p-value	>0.9999	0.7428	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Non-Hispanic

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Other CV AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	0.58	
95% CI of the odds ratio	(0.04, 28.30)	(0.02, 15.68)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	0.60	
95% CI of the risk ratio	(0.05, 21.42)	(0.03, 13.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.00	-3.33	
95% CI of the absolute risk difference	(-25.54, 25.54)	(-21.92, 15.25)	
p-value	>0.9999	0.7428	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious Other CV AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Non-Hispanic

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Non-Hispanic

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Serious DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Abbreviations: DB = Double Blinded; AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; CV = cardiovascular; DILI = drug-induced liver injury.
Note: Disease related events include the following preferred terms: Hepatic cirrhosis; Ascites; Varices oesophageal; Oesophageal varices haemorrhage; Hepatic encephalopathy.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
[3] MACE AE includes cardiovascular mortality, myocardial infarction, and cerebral vascular accident.
[4] Other CV AE includes hospitalization/emergency room treatment for heart failure, hospitalization for unstable angina, urgent or emergent coronary revascularization.

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Hispanic

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Events n:			
Total TEAEs	14	22	38
Total Serious TEAEs	0	0	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	2	8	4
Total TEAEs >= Grade 3 Severity	0	0	0
Patients n (%):			
Any TEAE	4 (100)	5 (83.3)	11 (100)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.83	
95% CI of the risk ratio	NE	(0.58, 1.19)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	-16.67	
95% CI of the absolute risk difference	NE	(-46.49, 13.15)	
p-value	NE	0.1628	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2096	
Any Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Hispanic

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Any TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any TEAEs <= Grade 2 Severity	4 (100)	5 (83.3)	11 (100)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.83	
95% CI of the risk ratio	NE	(0.58, 1.19)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	-16.67	
95% CI of the absolute risk difference	NE	(-46.49, 13.15)	
p-value	NE	0.1628	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2096	
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Hispanic

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAE	1 (25.0)	4 (66.7)	3 (27.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.89	5.33	
95% CI of the odds ratio	(0.06, 12.25)	(0.62, 45.99)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.92	2.44	
95% CI of the risk ratio	(0.13, 6.46)	(0.80, 7.48)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.27	39.39	
95% CI of the absolute risk difference	(-52.21, 47.66)	(-6.60, 85.39)	
p-value	0.9299	0.1148	
p-value of Breslow-Day Test for Homogeneity [2]	0.2543	0.0636	

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Hispanic

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Hispanic

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Maximum Severity of TEAEs			
Grade 1	2 (50.0)	3 (50.0)	7 (63.6)
Grade 2	2 (50.0)	2 (33.3)	4 (36.4)
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Hispanic

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Maximum Severity of Treatment-related TEAEs			
Grade 1	1 (25.0)	4 (66.7)	3 (27.3)
Grade 2	0	0	0
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0
MACE AE – Adjudicated Event [3]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Hispanic

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious MACE AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event [4]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Hispanic

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Other CV AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious Other CV AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Hispanic

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Hispanic

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=11)
Serious DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Non-Hispanic

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Events n:			
Total TEAEs	22	20	67
Total Serious TEAEs	0	2	2
Total TEAEs Leading to Discontinuation of Study Drug	0	1	1
Total TEAEs Related to Study Drug	0	1	8
Total TEAEs >= Grade 3 Severity	0	2	3
Patients n (%):			
Any TEAE	5 (100)	7 (77.8)	13 (76.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.08	
95% CI of the odds ratio	NE	(0.16, 7.42)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.31	1.02	
95% CI of the risk ratio	(1.00, 1.70)	(0.66, 1.58)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	23.53	1.31	
95% CI of the absolute risk difference	(3.37, 43.69)	(-32.52, 35.13)	
p-value	0.2305	0.9400	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2096	
Any Serious TEAE	0	2 (22.2)	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	4.57	
95% CI of the odds ratio	(0.04, 28.30)	(0.35, 59.11)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	3.78	
95% CI of the risk ratio	(0.05, 21.42)	(0.39, 36.22)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.00	16.34	
95% CI of the absolute risk difference	(-25.54, 25.54)	(-13.03, 45.71)	
p-value	>0.9999	0.2147	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Non-Hispanic

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Any TEAEs >= Grade 3 Severity	0	2 (22.2)	2 (11.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.56	2.14	
95% CI of the odds ratio	(0.02, 13.67)	(0.25, 18.50)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.60	1.89	
95% CI of the risk ratio	(0.03, 10.82)	(0.32, 11.26)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.56	10.46	
95% CI of the absolute risk difference	(-32.84, 21.73)	(-20.72, 41.64)	
p-value	0.7216	0.4820	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any TEAEs <= Grade 2 Severity	5 (100)	7 (77.8)	13 (76.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.08	
95% CI of the odds ratio	NE	(0.16, 7.42)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.31	1.02	
95% CI of the risk ratio	(1.00, 1.70)	(0.66, 1.58)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	23.53	1.31	
95% CI of the absolute risk difference	(3.37, 43.69)	(-32.52, 35.13)	
p-value	0.2305	0.9400	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2096	
Any TEAEs leading to Study-Drug Discontinuation	0	1 (11.1)	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	2.00	
95% CI of the odds ratio	(0.04, 28.30)	(0.11, 36.31)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	1.89	
95% CI of the risk ratio	(0.05, 21.42)	(0.13, 26.77)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.00	5.23	
95% CI of the absolute risk difference	(-25.54, 25.54)	(-18.15, 28.61)	
p-value	>0.9999	0.6341	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Non-Hispanic

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Any TEAEs leading to Study Discontinuation	0	0	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	0.58	
95% CI of the odds ratio	(0.04, 28.30)	(0.02, 15.68)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	0.60	
95% CI of the risk ratio	(0.05, 21.42)	(0.03, 13.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.00	-3.33	
95% CI of the absolute risk difference	(-25.54, 25.54)	(-21.92, 15.25)	
p-value	>0.9999	0.7428	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAE	0	1 (11.1)	5 (29.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.21	0.30	
95% CI of the odds ratio	(0.01, 4.42)	(0.03, 3.07)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.27	0.38	
95% CI of the risk ratio	(0.02, 4.24)	(0.05, 2.76)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-22.22	-18.30	
95% CI of the absolute risk difference	(-52.91, 8.47)	(-48.15, 11.54)	
p-value	0.2763	0.2920	
p-value of Breslow-Day Test for Homogeneity [2]	0.2543	0.0636	

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Non-Hispanic

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	0.58	
95% CI of the odds ratio	(0.04, 28.30)	(0.02, 15.68)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	0.60	
95% CI of the risk ratio	(0.05, 21.42)	(0.03, 13.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.00	-3.33	
95% CI of the absolute risk difference	(-25.54, 25.54)	(-21.92, 15.25)	
p-value	>0.9999	0.7428	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Non-Hispanic

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	0.58	
95% CI of the odds ratio	(0.04, 28.30)	(0.02, 15.68)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	0.60	
95% CI of the risk ratio	(0.05, 21.42)	(0.03, 13.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.00	-3.33	
95% CI of the absolute risk difference	(-25.54, 25.54)	(-21.92, 15.25)	
p-value	>0.9999	0.7428	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Maximum Severity of TEAEs			
Grade 1	2 (40.0)	4 (44.4)	2 (11.8)
Grade 2	3 (60.0)	1 (11.1)	9 (52.9)
Grade 3	0	2 (22.2)	2 (11.8)
Grade 4	0	0	0
Grade 5	0	0	0

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Non-Hispanic

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Maximum Severity of Treatment-related TEAEs			
Grade 1	0	1 (11.1)	5 (29.4)
Grade 2	0	0	0
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0
MACE AE – Adjudicated Event [3]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Non-Hispanic

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious MACE AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event [4]	0	0	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	0.58	
95% CI of the odds ratio	(0.04, 28.30)	(0.02, 15.68)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	0.60	
95% CI of the risk ratio	(0.05, 21.42)	(0.03, 13.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.00	-3.33	
95% CI of the absolute risk difference	(-25.54, 25.54)	(-21.92, 15.25)	
p-value	>0.9999	0.7428	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Non-Hispanic

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Other CV AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	0.58	
95% CI of the odds ratio	(0.04, 28.30)	(0.02, 15.68)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	0.60	
95% CI of the risk ratio	(0.05, 21.42)	(0.03, 13.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.00	-3.33	
95% CI of the absolute risk difference	(-25.54, 25.54)	(-21.92, 15.25)	
p-value	>0.9999	0.7428	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious Other CV AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Non-Hispanic

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Non-Hispanic

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=17)
Serious DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.5.2

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Ethnicity
(Label Population based on Safety Population)

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.

AMNOG Table S1.5.2

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Hispanic

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=4) Patients n (%)	 Events n	DB MGL-3196 100 mg (N=6) Patients n (%)	 Events n	DB Placebo (N=11) Patients n (%)	 Events n
Musculoskeletal and connective tissue disorders	1 (25.0)	1	0	0	3 (27.3)	8
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.89		0.19			
95% CI of the odds ratio	(0.06, 12.25)		(0.01, 4.29)			
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.92		0.24			
95% CI of the risk ratio	(0.13, 6.46)		(0.01, 4.08)			
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.27		-22.02			
95% CI of the absolute risk difference	(-52.21, 47.66)		(-54.04, 10.00)			
p-value	0.9299		0.2560			
p-value of Breslow-Day Test for Homogeneity [2]	0.5027		NE			

Madrigal Pharmaceuticals, Inc. Page 3 of 3
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S1.5.2
TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Non-Hispanic

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=5) Patients n (%)	 Events n	DB MGL-3196 100 mg (N=9) Patients n (%)	 Events n	DB Placebo (N=17) Patients n (%)	 Events n
Musculoskeletal and connective tissue disorders	3 (60.0)	3	0	0	6 (35.3)	10
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.75		0.09			
95% CI of the odds ratio	(0.36, 21.30)		(0.00, 1.87)			
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.70		0.14			
95% CI of the risk ratio	(0.65, 4.45)		(0.01, 2.21)			
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	24.71		-31.11			
95% CI of the absolute risk difference	(-23.87, 73.29)		(-57.09, -5.13)			
p-value	0.3233		0.0685			
p-value of Breslow-Day Test for Homogeneity [2]	0.5027		NE			

Program: t-s01-02-02-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Abbreviations: DB = Double Blinded; AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; CV = cardiovascular; DILI = drug-induced liver injury.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as “Grade 3”. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
[3] MACE AE includes cardiovascular mortality, myocardial infarction, and cerebral vascular accident.
[4] Other CV AE includes hospitalization/emergency room treatment for heart failure, hospitalization for unstable angina, urgent or emergent coronary revascularization.

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: >200 lbs

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Events n:			
Total TEAEs	9	42	81
Total Serious TEAEs	0	2	2
Total TEAEs Leading to Discontinuation of Study Drug	0	1	1
Total TEAEs Related to Study Drug	0	9	10
Total TEAEs >= Grade 3 Severity	0	2	3
Patients n (%):			
Any TEAE	2 (100)	12 (80.0)	21 (87.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.57	
95% CI of the odds ratio	NE	(0.10, 3.29)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.14	0.91	
95% CI of the risk ratio	(0.98, 1.33)	(0.68, 1.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	12.50	-7.50	
95% CI of the absolute risk difference	(-0.73, 25.73)	(-31.68, 16.68)	
p-value	0.5950	0.5277	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Serious TEAE	0	2 (13.3)	1 (4.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.54	
95% CI of the odds ratio	NE	(0.29, 42.89)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.20	
95% CI of the risk ratio	NE	(0.32, 32.31)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.17	9.17	
95% CI of the absolute risk difference	(-12.16, 3.83)	(-9.80, 28.14)	
p-value	0.7685	0.2959	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: >200 lbs

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Any TEAEs >= Grade 3 Severity	0	2 (13.3)	2 (8.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.80	1.69	
95% CI of the odds ratio	(0.07, 49.08)	(0.21, 13.50)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.67	1.60	
95% CI of the risk ratio	(0.10, 27.14)	(0.25, 10.18)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.67	5.00	
95% CI of the absolute risk difference	(-37.11, 50.45)	(-15.45, 25.45)	
p-value	0.7243	0.6166	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any TEAEs <= Grade 2 Severity	2 (100)	12 (80.0)	21 (87.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.57	
95% CI of the odds ratio	NE	(0.10, 3.29)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.14	0.91	
95% CI of the risk ratio	(0.98, 1.33)	(0.68, 1.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	12.50	-7.50	
95% CI of the absolute risk difference	(-0.73, 25.73)	(-31.68, 16.68)	
p-value	0.5950	0.5277	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any TEAEs leading to Study-Drug Discontinuation	0	1 (6.7)	1 (4.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.64	
95% CI of the odds ratio	NE	(0.09, 28.41)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.60	
95% CI of the risk ratio	NE	(0.11, 23.71)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.17	2.50	
95% CI of the absolute risk difference	(-12.16, 3.83)	(-12.44, 17.44)	
p-value	0.7685	0.7306	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: >200 lbs

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Any TEAEs leading to Study Discontinuation	0	0	1 (4.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.17	-4.17	
95% CI of the absolute risk difference	(-12.16, 3.83)	(-12.16, 3.83)	
p-value	0.7685	0.4232	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAE	0	5 (33.3)	7 (29.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.47	1.21	
95% CI of the odds ratio	(0.02, 10.94)	(0.30, 4.87)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.56	1.14	
95% CI of the risk ratio	(0.04, 7.48)	(0.44, 2.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-13.33	4.17	
95% CI of the absolute risk difference	(-59.17, 32.50)	(-25.83, 34.16)	
p-value	0.6291	0.7839	
p-value of Breslow-Day Test for Homogeneity [2]	0.5276	NE	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: >200 lbs

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	1 (4.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.17	-4.17	
95% CI of the absolute risk difference	(-12.16, 3.83)	(-12.16, 3.83)	
p-value	0.7685	0.4232	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: >200 lbs

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	1 (4.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.17	-4.17	
95% CI of the absolute risk difference	(-12.16, 3.83)	(-12.16, 3.83)	
p-value	0.7685	0.4232	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Maximum Severity of TEAEs			
Grade 1	0	7 (46.7)	8 (33.3)
Grade 2	2 (100)	3 (20.0)	11 (45.8)
Grade 3	0	2 (13.3)	2 (8.3)
Grade 4	0	0	0
Grade 5	0	0	0

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: >200 lbs

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Maximum Severity of Treatment-related TEAEs			
Grade 1	0	5 (33.3)	7 (29.2)
Grade 2	0	0	0
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0
MACE AE – Adjudicated Event [3]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: >200 lbs

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious MACE AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event [4]	0	0	1 (4.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-4.17	-4.17	
95% CI of the absolute risk difference	(-12.16, 3.83)	(-12.16, 3.83)	
p-value	0.7685	0.4232	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: >200 lbs

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Other CV AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (4.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-4.17	-4.17	
95% CI of the absolute risk difference	(-12.16, 3.83)	(-12.16, 3.83)	
p-value	0.7685	0.4232	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious Other CV AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: >200 lbs

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: >200 lbs

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Serious DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: <= 200 lbs

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Events n:			
Total TEAEs	27	0	24
Total Serious TEAEs	0	0	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	2	0	2
Total TEAEs >= Grade 3 Severity	0	0	0
Patients n (%):			
Any TEAE	7 (100)	0	3 (75.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.33	NE	
95% CI of the risk ratio	(0.76, 2.35)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	25.00	NE	
95% CI of the absolute risk difference	(-17.43, 67.43)	NE	
p-value	0.1653	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: <= 200 lbs

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Any TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any TEAEs <= Grade 2 Severity	7 (100)	0	3 (75.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.33	NE	
95% CI of the risk ratio	(0.76, 2.35)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	25.00	NE	
95% CI of the absolute risk difference	(-17.43, 67.43)	NE	
p-value	0.1653	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: <= 200 lbs

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAE	1 (14.3)	0	1 (25.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.50	NE	
95% CI of the odds ratio	(0.02, 11.09)	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.57	NE	
95% CI of the risk ratio	(0.05, 6.86)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-10.71	NE	
95% CI of the absolute risk difference	(-60.44, 39.01)	NE	
p-value	0.6576	NE	
p-value of Breslow-Day Test for Homogeneity [2]	0.5276	NE	

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: <= 200 lbs

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: <= 200 lbs

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Maximum Severity of TEAEs			
Grade 1	4 (57.1)	0	1 (25.0)
Grade 2	3 (42.9)	0	2 (50.0)
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: <= 200 lbs

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Maximum Severity of Treatment-related TEAEs			
Grade 1	1 (14.3)	0	1 (25.0)
Grade 2	0	0	0
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0
MACE AE – Adjudicated Event [3]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: <= 200 lbs

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious MACE AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event [4]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: <= 200 lbs

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Other CV AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious Other CV AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: <= 200 lbs

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

Madrigal Pharmaceuticals, Inc. Page 21 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: <= 200 lbs

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Serious DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Abbreviations: DB = Double Blinded; AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; CV = cardiovascular; DILI = drug-induced liver injury.
Note: Disease related events include the following preferred terms: Hepatic cirrhosis; Ascites; Varices oesophageal; Oesophageal varices haemorrhage; Hepatic encephalopathy.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
[3] MACE AE includes cardiovascular mortality, myocardial infarction, and cerebral vascular accident.
[4] Other CV AE includes hospitalization/emergency room treatment for heart failure, hospitalization for unstable angina, urgent or emergent coronary revascularization.

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: >200 lbs

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Events n:			
Total TEAEs	9	42	81
Total Serious TEAEs	0	2	2
Total TEAEs Leading to Discontinuation of Study Drug	0	1	1
Total TEAEs Related to Study Drug	0	9	10
Total TEAEs >= Grade 3 Severity	0	2	3
Patients n (%):			
Any TEAE	2 (100)	12 (80.0)	21 (87.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.57	
95% CI of the odds ratio	NE	(0.10, 3.29)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.14	0.91	
95% CI of the risk ratio	(0.98, 1.33)	(0.68, 1.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	12.50	-7.50	
95% CI of the absolute risk difference	(-0.73, 25.73)	(-31.68, 16.68)	
p-value	0.5950	0.5277	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Serious TEAE	0	2 (13.3)	1 (4.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.54	
95% CI of the odds ratio	NE	(0.29, 42.89)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.20	
95% CI of the risk ratio	NE	(0.32, 32.31)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.17	9.17	
95% CI of the absolute risk difference	(-12.16, 3.83)	(-9.80, 28.14)	
p-value	0.7685	0.2959	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: >200 lbs

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Any TEAEs >= Grade 3 Severity	0	2 (13.3)	2 (8.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.80	1.69	
95% CI of the odds ratio	(0.07, 49.08)	(0.21, 13.50)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.67	1.60	
95% CI of the risk ratio	(0.10, 27.14)	(0.25, 10.18)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.67	5.00	
95% CI of the absolute risk difference	(-37.11, 50.45)	(-15.45, 25.45)	
p-value	0.7243	0.6166	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any TEAEs <= Grade 2 Severity	2 (100)	12 (80.0)	21 (87.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.57	
95% CI of the odds ratio	NE	(0.10, 3.29)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.14	0.91	
95% CI of the risk ratio	(0.98, 1.33)	(0.68, 1.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	12.50	-7.50	
95% CI of the absolute risk difference	(-0.73, 25.73)	(-31.68, 16.68)	
p-value	0.5950	0.5277	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any TEAEs leading to Study-Drug Discontinuation	0	1 (6.7)	1 (4.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.64	
95% CI of the odds ratio	NE	(0.09, 28.41)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.60	
95% CI of the risk ratio	NE	(0.11, 23.71)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.17	2.50	
95% CI of the absolute risk difference	(-12.16, 3.83)	(-12.44, 17.44)	
p-value	0.7685	0.7306	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: >200 lbs

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Any TEAEs leading to Study Discontinuation	0	0	1 (4.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.17	-4.17	
95% CI of the absolute risk difference	(-12.16, 3.83)	(-12.16, 3.83)	
p-value	0.7685	0.4232	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAE	0	5 (33.3)	7 (29.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.47	1.21	
95% CI of the odds ratio	(0.02, 10.94)	(0.30, 4.87)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.56	1.14	
95% CI of the risk ratio	(0.04, 7.48)	(0.44, 2.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-13.33	4.17	
95% CI of the absolute risk difference	(-59.17, 32.50)	(-25.83, 34.16)	
p-value	0.6291	0.7839	
p-value of Breslow-Day Test for Homogeneity [2]	0.5276	NE	

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: >200 lbs

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	1 (4.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.17	-4.17	
95% CI of the absolute risk difference	(-12.16, 3.83)	(-12.16, 3.83)	
p-value	0.7685	0.4232	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: >200 lbs

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	1 (4.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.17	-4.17	
95% CI of the absolute risk difference	(-12.16, 3.83)	(-12.16, 3.83)	
p-value	0.7685	0.4232	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Maximum Severity of TEAEs			
Grade 1	0	7 (46.7)	8 (33.3)
Grade 2	2 (100)	3 (20.0)	11 (45.8)
Grade 3	0	2 (13.3)	2 (8.3)
Grade 4	0	0	0
Grade 5	0	0	0

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: >200 lbs

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Maximum Severity of Treatment-related TEAEs			
Grade 1	0	5 (33.3)	7 (29.2)
Grade 2	0	0	0
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0
MACE AE – Adjudicated Event [3]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: >200 lbs

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious MACE AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event [4]	0	0	1 (4.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-4.17	-4.17	
95% CI of the absolute risk difference	(-12.16, 3.83)	(-12.16, 3.83)	
p-value	0.7685	0.4232	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: >200 lbs

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Other CV AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (4.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-4.17	-4.17	
95% CI of the absolute risk difference	(-12.16, 3.83)	(-12.16, 3.83)	
p-value	0.7685	0.4232	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious Other CV AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: >200 lbs

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
DILI AE - Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE - Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE - Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: >200 lbs

	DB MGL-3196 80 mg (N=2)	DB MGL-3196 100 mg (N=15)	DB Placebo (N=24)
Serious DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: <= 200 lbs

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Events n:			
Total TEAEs	27	0	24
Total Serious TEAEs	0	0	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	2	0	2
Total TEAEs >= Grade 3 Severity	0	0	0
Patients n (%):			
Any TEAE	7 (100)	0	3 (75.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.33	NE	
95% CI of the risk ratio	(0.76, 2.35)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	25.00	NE	
95% CI of the absolute risk difference	(-17.43, 67.43)	NE	
p-value	0.1653	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: <= 200 lbs

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Any TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any TEAEs <= Grade 2 Severity	7 (100)	0	3 (75.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.33	NE	
95% CI of the risk ratio	(0.76, 2.35)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	25.00	NE	
95% CI of the absolute risk difference	(-17.43, 67.43)	NE	
p-value	0.1653	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: <= 200 lbs

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAE	1 (14.3)	0	1 (25.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.50	NE	
95% CI of the odds ratio	(0.02, 11.09)	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.57	NE	
95% CI of the risk ratio	(0.05, 6.86)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-10.71	NE	
95% CI of the absolute risk difference	(-60.44, 39.01)	NE	
p-value	0.6576	NE	
p-value of Breslow-Day Test for Homogeneity [2]	0.5276	NE	

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: <= 200 lbs

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: <= 200 lbs

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Maximum Severity of TEAEs			
Grade 1	4 (57.1)	0	1 (25.0)
Grade 2	3 (42.9)	0	2 (50.0)
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: <= 200 lbs

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Maximum Severity of Treatment-related TEAEs			
Grade 1	1 (14.3)	0	1 (25.0)
Grade 2	0	0	0
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0
MACE AE – Adjudicated Event [3]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: <= 200 lbs

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious MACE AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event [4]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: <= 200 lbs

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Other CV AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious Other CV AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: <= 200 lbs

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
DILI AE - Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE - Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE - Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population based on Safety Population)

Weight: <= 200 lbs

	DB MGL-3196 80 mg (N=7)	DB MGL-3196 100 mg (N=0)	DB Placebo (N=4)
Serious DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.6.2

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Weight
(Label Population based on Safety Population)

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.

AMNOG Table S1.6.2

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Weight
(Label Population based on Safety Population)

Weight: >200 lbs

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=2) Patients n (%)	 Events n	DB MGL-3196 100 mg (N=15) Patients n (%)	 Events n	DB Placebo (N=24) Patients n (%)	 Events n
Musculoskeletal and connective tissue disorders	1 (50.0)	1	0	0	7 (29.2)	11
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.43		0.08			
95% CI of the odds ratio	(0.13, 44.50)		(0.00, 1.43)			
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.71		0.10			
95% CI of the risk ratio	(0.38, 7.84)		(0.01, 1.70)			
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	20.83		-26.88			
95% CI of the absolute risk difference	(-50.81, 92.47)		(-46.76, -6.99)			
p-value	0.5397		0.0342			
p-value of Breslow-Day Test for Homogeneity [2]	0.5413		NE			

Program: t-s01-02-02-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.6.2

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Weight
(Label Population based on Safety Population)

Weight: <= 200 lbs

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=7) Patients n (%)	 Events n	DB MGL-3196 100 mg (N=0) Patients n (%)	 Events n	DB Placebo (N=4) Patients n (%)	 Events n
Musculoskeletal and connective tissue disorders	3 (42.9)	3	0	0	2 (50.0)	7
Odds ratio, Chi-square,						
MGL-3196 treatment group / Placebo [1]	0.75		NE			
95% CI of the odds ratio	(0.06, 8.83)		NE			
Risk ratio, Chi-square,						
MGL-3196 treatment group / Placebo [1]	0.86		NE			
95% CI of the risk ratio	(0.23, 3.15)		NE			
Absolute risk difference, Chi-square,						
MGL-3196 treatment group - Placebo [1]	-7.14		NE			
95% CI of the absolute risk difference	(-68.34, 54.05)		NE			
p-value	0.8190		NE			
p-value of Breslow-Day Test for Homogeneity [2]	0.5413		NE			

Program: t-s01-02-02-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Abbreviations: DB = Double Blinded; AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; CV = cardiovascular; DILI = drug-induced liver injury; T2D = Type 2 Diabetes.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as “Grade 3”. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
[3] MACE AE includes cardiovascular mortality, myocardial infarction, and cerebral vascular accident.
[4] Other CV AE includes hospitalization/emergency room treatment for heart failure, hospitalization for unstable angina, urgent or emergent coronary revascularization.

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Presence

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Events n:			
Total TEAEs	28	18	73
Total Serious TEAEs	0	1	2
Total TEAEs Leading to Discontinuation of Study Drug	0	1	1
Total TEAEs Related to Study Drug	2	1	5
Total TEAEs >= Grade 3 Severity	0	1	3
Patients n (%):			
Any TEAE	6 (100)	6 (100)	16 (84.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.19	1.19	
95% CI of the risk ratio	(0.98, 1.44)	(0.98, 1.44)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	15.79	15.79	
95% CI of the absolute risk difference	(-0.61, 32.19)	(-0.61, 32.19)	
p-value	0.2995	0.2995	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1375	
Any Serious TEAE	0	1 (16.7)	1 (5.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95	3.60	
95% CI of the odds ratio	(0.03, 26.32)	(0.19, 68.34)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95	3.17	
95% CI of the risk ratio	(0.04, 20.78)	(0.23, 43.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.36	11.40	
95% CI of the absolute risk difference	(-22.66, 21.94)	(-20.06, 42.87)	
p-value	0.9752	0.3694	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.5785	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Presence

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Any TEAEs >= Grade 3 Severity	0	1 (16.7)	2 (10.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.54	1.70	
95% CI of the odds ratio	(0.02, 12.78)	(0.13, 22.87)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.57	1.58	
95% CI of the risk ratio	(0.03, 10.51)	(0.17, 14.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.36	6.14	
95% CI of the absolute risk difference	(-29.32, 18.60)	(-26.72, 39.00)	
p-value	0.6979	0.6866	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.4582	
Any TEAEs <= Grade 2 Severity	6 (100)	6 (100)	16 (84.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.19	1.19	
95% CI of the risk ratio	(0.98, 1.44)	(0.98, 1.44)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	15.79	15.79	
95% CI of the absolute risk difference	(-0.61, 32.19)	(-0.61, 32.19)	
p-value	0.2995	0.2995	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1375	
Any TEAEs leading to Study-Drug Discontinuation	0	1 (16.7)	1 (5.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95	3.60	
95% CI of the odds ratio	(0.03, 26.32)	(0.19, 68.34)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95	3.17	
95% CI of the risk ratio	(0.04, 20.78)	(0.23, 43.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.36	11.40	
95% CI of the absolute risk difference	(-22.66, 21.94)	(-20.06, 42.87)	
p-value	0.9752	0.3694	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Presence

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Any TEAEs leading to Study Discontinuation	0	0	1 (5.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95	0.95	
95% CI of the odds ratio	(0.03, 26.32)	(0.03, 26.32)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95	0.95	
95% CI of the risk ratio	(0.04, 20.78)	(0.04, 20.78)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.36	-0.36	
95% CI of the absolute risk difference	(-22.66, 21.94)	(-22.66, 21.94)	
p-value	0.9752	0.9752	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAE	1 (16.7)	1 (16.7)	4 (21.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.75	0.75	
95% CI of the odds ratio	(0.07, 8.38)	(0.07, 8.38)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.79	0.79	
95% CI of the risk ratio	(0.11, 5.79)	(0.11, 5.79)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.39	-4.39	
95% CI of the absolute risk difference	(-39.39, 30.62)	(-39.39, 30.62)	
p-value	0.8149	0.8149	
p-value of Breslow-Day Test for Homogeneity [2]	0.2713	0.8531	

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Presence

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	1 (5.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95	0.95	
95% CI of the odds ratio	(0.03, 26.32)	(0.03, 26.32)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95	0.95	
95% CI of the risk ratio	(0.04, 20.78)	(0.04, 20.78)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.36	-0.36	
95% CI of the absolute risk difference	(-22.66, 21.94)	(-22.66, 21.94)	
p-value	0.9752	0.9752	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Presence

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	1 (5.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95	0.95	
95% CI of the odds ratio	(0.03, 26.32)	(0.03, 26.32)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95	0.95	
95% CI of the risk ratio	(0.04, 20.78)	(0.04, 20.78)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.36	-0.36	
95% CI of the absolute risk difference	(-22.66, 21.94)	(-22.66, 21.94)	
p-value	0.9752	0.9752	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Maximum Severity of TEAEs			
Grade 1	3 (50.0)	4 (66.7)	6 (31.6)
Grade 2	3 (50.0)	1 (16.7)	8 (42.1)
Grade 3	0	1 (16.7)	2 (10.5)
Grade 4	0	0	0
Grade 5	0	0	0

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Presence

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Maximum Severity of Treatment-related TEAEs			
Grade 1	1 (16.7)	1 (16.7)	4 (21.1)
Grade 2	0	0	0
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0
MACE AE – Adjudicated Event [3]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Presence

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious MACE AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event [4]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Presence

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Other CV AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious Other CV AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Presence

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Presence

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Serious DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Absence

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Events n:			
Total TEAEs	8	24	32
Total Serious TEAEs	0	1	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	0	8	7
Total TEAEs >= Grade 3 Severity	0	1	0
Patients n (%):			
Any TEAE	3 (100)	6 (66.7)	8 (88.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.25	
95% CI of the odds ratio	NE	(0.02, 3.04)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.13	0.75	
95% CI of the risk ratio	(0.89, 1.42)	(0.45, 1.26)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	11.11	-22.22	
95% CI of the absolute risk difference	(-9.42, 31.64)	(-59.24, 14.79)	
p-value	0.5465	0.2568	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1375	
Any Serious TEAE	0	1 (11.1)	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.35	
95% CI of the odds ratio	NE	(0.12, 93.83)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.00	
95% CI of the risk ratio	NE	(0.14, 65.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	10.00	
95% CI of the absolute risk difference	NE	(-15.93, 35.93)	
p-value	NE	0.4561	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.5785	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Absence

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Any TEAEs >= Grade 3 Severity	0	1 (11.1)	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.35	
95% CI of the odds ratio	NE	(0.12, 93.83)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.00	
95% CI of the risk ratio	NE	(0.14, 65.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	10.00	
95% CI of the absolute risk difference	NE	(-15.93, 35.93)	
p-value	NE	0.4561	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.4582	
Any TEAEs <= Grade 2 Severity	3 (100)	6 (66.7)	8 (88.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.25	
95% CI of the odds ratio	NE	(0.02, 3.04)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.13	0.75	
95% CI of the risk ratio	(0.89, 1.42)	(0.45, 1.26)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	11.11	-22.22	
95% CI of the absolute risk difference	(-9.42, 31.64)	(-59.24, 14.79)	
p-value	0.5465	0.2568	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1375	
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Absence

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAE	0	4 (44.4)	4 (44.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.17	1.00	
95% CI of the odds ratio	(0.01, 4.35)	(0.16, 6.42)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.28	1.00	
95% CI of the risk ratio	(0.02, 4.06)	(0.36, 2.81)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-32.50	0.00	
95% CI of the absolute risk difference	(-77.23, 12.23)	(-45.91, 45.91)	
p-value	0.2516	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	0.2713	0.8531	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Absence

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Absence

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Maximum Severity of TEAEs			
Grade 1	1 (33.3)	3 (33.3)	3 (33.3)
Grade 2	2 (66.7)	2 (22.2)	5 (55.6)
Grade 3	0	1 (11.1)	0
Grade 4	0	0	0
Grade 5	0	0	0

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Absence

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Maximum Severity of Treatment-related TEAEs			
Grade 1	0	4 (44.4)	4 (44.4)
Grade 2	0	0	0
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0
MACE AE – Adjudicated Event [3]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Absence

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious MACE AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event [4]	0	0	1 (11.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.81	0.30	
95% CI of the odds ratio	(0.03, 25.10)	(0.01, 8.35)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.83	0.33	
95% CI of the risk ratio	(0.04, 16.46)	(0.02, 7.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-2.50	-10.00	
95% CI of the absolute risk difference	(-41.75, 36.75)	(-35.93, 15.93)	
p-value	0.9039	0.4561	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Absence

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Other CV AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (11.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.81	0.30	
95% CI of the odds ratio	(0.03, 25.10)	(0.01, 8.35)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.83	0.33	
95% CI of the risk ratio	(0.04, 16.46)	(0.02, 7.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-2.50	-10.00	
95% CI of the absolute risk difference	(-41.75, 36.75)	(-35.93, 15.93)	
p-value	0.9039	0.4561	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious Other CV AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Absence

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Absence

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Serious DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Abbreviations: DB = Double Blinded; AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; CV = cardiovascular; DILI = drug-induced liver injury; T2D = Type 2 Diabetes.
Note: Disease related events include the following preferred terms: Hepatic cirrhosis; Ascites; Varices oesophageal; Oesophageal varices haemorrhage; Hepatic encephalopathy.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
[3] MACE AE includes cardiovascular mortality, myocardial infarction, and cerebral vascular accident.
[4] Other CV AE includes hospitalization/emergency room treatment for heart failure, hospitalization for unstable angina, urgent or emergent coronary revascularization.

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Presence

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Events n:			
Total TEAEs	28	18	73
Total Serious TEAEs	0	1	2
Total TEAEs Leading to Discontinuation of Study Drug	0	1	1
Total TEAEs Related to Study Drug	2	1	5
Total TEAEs >= Grade 3 Severity	0	1	3
Patients n (%):			
Any TEAE	6 (100)	6 (100)	16 (84.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.19	1.19	
95% CI of the risk ratio	(0.98, 1.44)	(0.98, 1.44)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	15.79	15.79	
95% CI of the absolute risk difference	(-0.61, 32.19)	(-0.61, 32.19)	
p-value	0.2995	0.2995	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1375	
Any Serious TEAE	0	1 (16.7)	1 (5.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95	3.60	
95% CI of the odds ratio	(0.03, 26.32)	(0.19, 68.34)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95	3.17	
95% CI of the risk ratio	(0.04, 20.78)	(0.23, 43.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.36	11.40	
95% CI of the absolute risk difference	(-22.66, 21.94)	(-20.06, 42.87)	
p-value	0.9752	0.3694	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.5785	

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Presence

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Any TEAEs >= Grade 3 Severity	0	1 (16.7)	2 (10.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.54	1.70	
95% CI of the odds ratio	(0.02, 12.78)	(0.13, 22.87)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.57	1.58	
95% CI of the risk ratio	(0.03, 10.51)	(0.17, 14.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.36	6.14	
95% CI of the absolute risk difference	(-29.32, 18.60)	(-26.72, 39.00)	
p-value	0.6979	0.6866	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.4582	
Any TEAEs <= Grade 2 Severity	6 (100)	6 (100)	16 (84.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.19	1.19	
95% CI of the risk ratio	(0.98, 1.44)	(0.98, 1.44)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	15.79	15.79	
95% CI of the absolute risk difference	(-0.61, 32.19)	(-0.61, 32.19)	
p-value	0.2995	0.2995	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1375	
Any TEAEs leading to Study-Drug Discontinuation	0	1 (16.7)	1 (5.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95	3.60	
95% CI of the odds ratio	(0.03, 26.32)	(0.19, 68.34)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95	3.17	
95% CI of the risk ratio	(0.04, 20.78)	(0.23, 43.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.36	11.40	
95% CI of the absolute risk difference	(-22.66, 21.94)	(-20.06, 42.87)	
p-value	0.9752	0.3694	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Presence

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Any TEAEs leading to Study Discontinuation	0	0	1 (5.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95	0.95	
95% CI of the odds ratio	(0.03, 26.32)	(0.03, 26.32)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95	0.95	
95% CI of the risk ratio	(0.04, 20.78)	(0.04, 20.78)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.36	-0.36	
95% CI of the absolute risk difference	(-22.66, 21.94)	(-22.66, 21.94)	
p-value	0.9752	0.9752	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAE	1 (16.7)	1 (16.7)	4 (21.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.75	0.75	
95% CI of the odds ratio	(0.07, 8.38)	(0.07, 8.38)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.79	0.79	
95% CI of the risk ratio	(0.11, 5.79)	(0.11, 5.79)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.39	-4.39	
95% CI of the absolute risk difference	(-39.39, 30.62)	(-39.39, 30.62)	
p-value	0.8149	0.8149	
p-value of Breslow-Day Test for Homogeneity [2]	0.2713	0.8531	

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Presence

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	1 (5.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95	0.95	
95% CI of the odds ratio	(0.03, 26.32)	(0.03, 26.32)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95	0.95	
95% CI of the risk ratio	(0.04, 20.78)	(0.04, 20.78)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.36	-0.36	
95% CI of the absolute risk difference	(-22.66, 21.94)	(-22.66, 21.94)	
p-value	0.9752	0.9752	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Presence

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	1 (5.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95	0.95	
95% CI of the odds ratio	(0.03, 26.32)	(0.03, 26.32)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95	0.95	
95% CI of the risk ratio	(0.04, 20.78)	(0.04, 20.78)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.36	-0.36	
95% CI of the absolute risk difference	(-22.66, 21.94)	(-22.66, 21.94)	
p-value	0.9752	0.9752	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Maximum Severity of TEAEs			
Grade 1	3 (50.0)	4 (66.7)	6 (31.6)
Grade 2	3 (50.0)	1 (16.7)	8 (42.1)
Grade 3	0	1 (16.7)	2 (10.5)
Grade 4	0	0	0
Grade 5	0	0	0

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Presence

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Maximum Severity of Treatment-related TEAEs			
Grade 1	1 (16.7)	1 (16.7)	4 (21.1)
Grade 2	0	0	0
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0
MACE AE – Adjudicated Event [3]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Presence

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious MACE AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event [4]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Presence

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Other CV AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious Other CV AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Presence

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Presence

	DB MGL-3196 80 mg (N=6)	DB MGL-3196 100 mg (N=6)	DB Placebo (N=19)
Serious DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Absence

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Events n:			
Total TEAEs	8	24	32
Total Serious TEAEs	0	1	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	0	8	7
Total TEAEs >= Grade 3 Severity	0	1	0
Patients n (%):			
Any TEAE	3 (100)	6 (66.7)	8 (88.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.25	
95% CI of the odds ratio	NE	(0.02, 3.04)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.13	0.75	
95% CI of the risk ratio	(0.89, 1.42)	(0.45, 1.26)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	11.11	-22.22	
95% CI of the absolute risk difference	(-9.42, 31.64)	(-59.24, 14.79)	
p-value	0.5465	0.2568	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1375	
Any Serious TEAE	0	1 (11.1)	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.35	
95% CI of the odds ratio	NE	(0.12, 93.83)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.00	
95% CI of the risk ratio	NE	(0.14, 65.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	10.00	
95% CI of the absolute risk difference	NE	(-15.93, 35.93)	
p-value	NE	0.4561	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.5785	

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Absence

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Any TEAEs >= Grade 3 Severity	0	1 (11.1)	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.35	
95% CI of the odds ratio	NE	(0.12, 93.83)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.00	
95% CI of the risk ratio	NE	(0.14, 65.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	10.00	
95% CI of the absolute risk difference	NE	(-15.93, 35.93)	
p-value	NE	0.4561	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.4582	
Any TEAEs <= Grade 2 Severity	3 (100)	6 (66.7)	8 (88.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.25	
95% CI of the odds ratio	NE	(0.02, 3.04)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.13	0.75	
95% CI of the risk ratio	(0.89, 1.42)	(0.45, 1.26)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	11.11	-22.22	
95% CI of the absolute risk difference	(-9.42, 31.64)	(-59.24, 14.79)	
p-value	0.5465	0.2568	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1375	
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Absence

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAE	0	4 (44.4)	4 (44.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.17	1.00	
95% CI of the odds ratio	(0.01, 4.35)	(0.16, 6.42)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.28	1.00	
95% CI of the risk ratio	(0.02, 4.06)	(0.36, 2.81)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-32.50	0.00	
95% CI of the absolute risk difference	(-77.23, 12.23)	(-45.91, 45.91)	
p-value	0.2516	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	0.2713	0.8531	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Absence

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Absence

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Maximum Severity of TEAEs			
Grade 1	1 (33.3)	3 (33.3)	3 (33.3)
Grade 2	2 (66.7)	2 (22.2)	5 (55.6)
Grade 3	0	1 (11.1)	0
Grade 4	0	0	0
Grade 5	0	0	0

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Absence

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Maximum Severity of Treatment-related TEAEs			
Grade 1	0	4 (44.4)	4 (44.4)
Grade 2	0	0	0
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0
MACE AE – Adjudicated Event [3]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Absence

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious MACE AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event [4]	0	0	1 (11.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.81	0.30	
95% CI of the odds ratio	(0.03, 25.10)	(0.01, 8.35)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.83	0.33	
95% CI of the risk ratio	(0.04, 16.46)	(0.02, 7.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-2.50	-10.00	
95% CI of the absolute risk difference	(-41.75, 36.75)	(-35.93, 15.93)	
p-value	0.9039	0.4561	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Absence

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Other CV AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (11.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.81	0.30	
95% CI of the odds ratio	(0.03, 25.10)	(0.01, 8.35)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.83	0.33	
95% CI of the risk ratio	(0.04, 16.46)	(0.02, 7.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-2.50	-10.00	
95% CI of the absolute risk difference	(-41.75, 36.75)	(-35.93, 15.93)	
p-value	0.9039	0.4561	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious Other CV AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Absence

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Absence

	DB MGL-3196 80 mg (N=3)	DB MGL-3196 100 mg (N=9)	DB Placebo (N=9)
Serious DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.7.2

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline T2D Status
(Label Population based on Safety Population)

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event; T2D = Type 2 Diabetes.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.

AMNOG Table S1.7.2

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Presence

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=6) Patients n (%)	 Events n	DB MGL-3196 100 mg (N=6) Patients n (%)	 Events n	DB Placebo (N=19) Patients n (%)	 Events n
Musculoskeletal and connective tissue disorders	2 (33.3)	2	0	0	5 (26.3)	13
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.40		0.20			
95% CI of the odds ratio	(0.19, 10.15)		(0.01, 4.24)			
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.27		0.26			
95% CI of the risk ratio	(0.33, 4.93)		(0.02, 4.12)			
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	7.02		-20.36			
95% CI of the absolute risk difference	(-35.58, 49.62)		(-47.69, 6.97)			
p-value	0.7386		0.2648			
p-value of Breslow-Day Test for Homogeneity [2]	0.7360		NE			

AMNOG Table S1.7.2

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Absence

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=3) Patients n (%)	DB MGL-3196 80 mg (N=3) Events n	DB MGL-3196 100 mg (N=9) Patients n (%)	DB MGL-3196 100 mg (N=9) Events n	DB Placebo (N=9) Patients n (%)	DB Placebo (N=9) Events n
Musculoskeletal and connective tissue disorders	2 (66.7)	2	0	0	4 (44.4)	5
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.50		0.06			
95% CI of the odds ratio	(0.16, 38.60)		(0.00, 1.43)			
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.50		0.11			
95% CI of the risk ratio	(0.51, 4.43)		(0.01, 1.80)			
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	22.22		-40.00			
95% CI of the absolute risk difference	(-40.22, 84.67)		(-73.66, -6.34)			
p-value	0.5050		0.0389			
p-value of Breslow-Day Test for Homogeneity [2]	0.7360		NE			

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Abbreviations: DB = Double Blinded; AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; CV = cardiovascular; DILI = drug-induced liver injury; HbA1c = Hemoglobin A1C.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as “Grade 3”. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
[3] MACE AE includes cardiovascular mortality, myocardial infarction, and cerebral vascular accident.
[4] Other CV AE includes hospitalization/emergency room treatment for heart failure, hospitalization for unstable angina, urgent or emergent coronary revascularization.

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: > 7.5

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Events n:			
Total TEAEs	1	8	13
Total Serious TEAEs	0	1	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	1
Total TEAEs Related to Study Drug	0	0	3
Total TEAEs >= Grade 3 Severity	0	1	0
Patients n (%):			
Any TEAE	1 (100)	2 (100)	5 (71.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.40	1.40	
95% CI of the risk ratio	(0.88, 2.24)	(0.88, 2.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	28.57	28.57	
95% CI of the absolute risk difference	(-4.89, 62.04)	(-4.89, 62.04)	
p-value	0.5371	0.3914	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2283	
Any Serious TEAE	0	1 (50.0)	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	15.00	
95% CI of the odds ratio	NE	(0.39, 576.69)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	8.00	
95% CI of the risk ratio	NE	(0.43, 147.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	43.75	
95% CI of the absolute risk difference	NE	(-15.26, 100.00)	
p-value	NE	0.0938	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1962	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: > 7.5

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Any TEAEs >= Grade 3 Severity	0	1 (50.0)	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	15.00	
95% CI of the odds ratio	NE	(0.39, 576.69)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	8.00	
95% CI of the risk ratio	NE	(0.43, 147.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	43.75	
95% CI of the absolute risk difference	NE	(-15.26, 100.00)	
p-value	NE	0.0938	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.0925	
Any TEAEs <= Grade 2 Severity	1 (100)	2 (100)	5 (71.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.40	1.40	
95% CI of the risk ratio	(0.88, 2.24)	(0.88, 2.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	28.57	28.57	
95% CI of the absolute risk difference	(-4.89, 62.04)	(-4.89, 62.04)	
p-value	0.5371	0.3914	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2283	
Any TEAEs leading to Study-Drug Discontinuation	0	0	1 (14.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.44	0.87	
95% CI of the odds ratio	(0.04, 56.14)	(0.03, 29.20)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.33	0.89	
95% CI of the risk ratio	(0.08, 21.94)	(0.05, 16.36)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.25	-2.08	
95% CI of the absolute risk difference	(-59.57, 72.07)	(-52.18, 48.02)	
p-value	0.8433	0.9364	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2303	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: > 7.5

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Any TEAEs leading to Study Discontinuation	0	0	1 (14.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.44	0.87	
95% CI of the odds ratio	(0.04, 56.14)	(0.03, 29.20)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.33	0.89	
95% CI of the risk ratio	(0.08, 21.94)	(0.05, 16.36)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.25	-2.08	
95% CI of the absolute risk difference	(-59.57, 72.07)	(-52.18, 48.02)	
p-value	0.8433	0.9364	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAE	0	0	2 (28.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.73	0.44	
95% CI of the odds ratio	(0.02, 25.09)	(0.01, 12.98)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.80	0.53	
95% CI of the risk ratio	(0.06, 10.89)	(0.03, 8.19)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.25	-14.58	
95% CI of the absolute risk difference	(-74.32, 61.82)	(-67.59, 38.43)	
p-value	0.8630	0.6286	
p-value of Breslow-Day Test for Homogeneity [2]	0.7090	0.3193	

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: > 7.5

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	1 (14.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.44	0.87	
95% CI of the odds ratio	(0.04, 56.14)	(0.03, 29.20)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.33	0.89	
95% CI of the risk ratio	(0.08, 21.94)	(0.05, 16.36)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.25	-2.08	
95% CI of the absolute risk difference	(-59.57, 72.07)	(-52.18, 48.02)	
p-value	0.8433	0.9364	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: > 7.5

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	1 (14.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.44	0.87	
95% CI of the odds ratio	(0.04, 56.14)	(0.03, 29.20)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.33	0.89	
95% CI of the risk ratio	(0.08, 21.94)	(0.05, 16.36)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.25	-2.08	
95% CI of the absolute risk difference	(-59.57, 72.07)	(-52.18, 48.02)	
p-value	0.8433	0.9364	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Maximum Severity of TEAEs			
Grade 1	1 (100)	1 (50.0)	3 (42.9)
Grade 2	0	0	2 (28.6)
Grade 3	0	1 (50.0)	0
Grade 4	0	0	0
Grade 5	0	0	0

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: > 7.5

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Maximum Severity of Treatment-related TEAEs			
Grade 1	0	0	2 (28.6)
Grade 2	0	0	0
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0
MACE AE – Adjudicated Event [3]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: > 7.5

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious MACE AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event [4]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: > 7.5

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Other CV AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious Other CV AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: > 7.5

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: > 7.5

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Serious DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: <= 7.5

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Events n:			
Total TEAEs	35	34	92
Total Serious TEAEs	0	1	2
Total TEAEs Leading to Discontinuation of Study Drug	0	1	0
Total TEAEs Related to Study Drug	2	9	9
Total TEAEs >= Grade 3 Severity	0	1	3
Patients n (%):			
Any TEAE	8 (100)	10 (76.9)	19 (90.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.35	
95% CI of the odds ratio	NE	(0.05, 2.46)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.11	0.85	
95% CI of the risk ratio	(0.96, 1.27)	(0.61, 1.18)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	9.52	-13.55	
95% CI of the absolute risk difference	(-3.03, 22.08)	(-39.67, 12.57)	
p-value	0.3657	0.2782	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2283	
Any Serious TEAE	0	1 (7.7)	1 (4.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.67	
95% CI of the odds ratio	NE	(0.10, 29.18)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.62	
95% CI of the risk ratio	NE	(0.11, 23.66)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.76	2.93	
95% CI of the absolute risk difference	(-13.87, 4.35)	(-14.18, 20.04)	
p-value	0.5299	0.7242	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1962	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc. Page 13 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: <= 7.5

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Any TEAEs >= Grade 3 Severity	0	1 (7.7)	2 (9.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.46	0.79	
95% CI of the odds ratio	(0.02, 10.62)	(0.06, 9.71)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.49	0.81	
95% CI of the risk ratio	(0.03, 9.21)	(0.08, 8.05)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.81	-1.83	
95% CI of the absolute risk difference	(-25.80, 14.19)	(-21.00, 17.34)	
p-value	0.6196	0.8548	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.0925	
Any TEAEs <= Grade 2 Severity	8 (100)	10 (76.9)	19 (90.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.35	
95% CI of the odds ratio	NE	(0.05, 2.46)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.11	0.85	
95% CI of the risk ratio	(0.96, 1.27)	(0.61, 1.18)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	9.52	-13.55	
95% CI of the absolute risk difference	(-3.03, 22.08)	(-39.67, 12.57)	
p-value	0.3657	0.2782	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2283	
Any TEAEs leading to Study-Drug Discontinuation	0	1 (7.7)	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	5.16	
95% CI of the odds ratio	NE	(0.20, 136.54)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	4.71	
95% CI of the risk ratio	NE	(0.21, 107.80)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	8.44	
95% CI of the absolute risk difference	NE	(-8.92, 25.80)	
p-value	NE	0.2811	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2303	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: <= 7.5

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAE	1 (12.5)	5 (38.5)	6 (28.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.36	1.56	
95% CI of the odds ratio	(0.04, 3.56)	(0.36, 6.76)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.44	1.35	
95% CI of the risk ratio	(0.06, 3.09)	(0.51, 3.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-16.07	9.89	
95% CI of the absolute risk difference	(-46.05, 13.90)	(-22.86, 42.64)	
p-value	0.3660	0.5491	
p-value of Breslow-Day Test for Homogeneity [2]	0.7090	0.3193	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: <= 7.5

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: <= 7.5

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Maximum Severity of TEAEs			
Grade 1	3 (37.5)	6 (46.2)	6 (28.6)
Grade 2	5 (62.5)	3 (23.1)	11 (52.4)
Grade 3	0	1 (7.7)	2 (9.5)
Grade 4	0	0	0
Grade 5	0	0	0

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: <= 7.5

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Maximum Severity of Treatment-related TEAEs			
Grade 1	1 (12.5)	5 (38.5)	6 (28.6)
Grade 2	0	0	0
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0
MACE AE – Adjudicated Event [3]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: <= 7.5

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious MACE AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event [4]	0	0	1 (4.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-4.76	-4.76	
95% CI of the absolute risk difference	(-13.87, 4.35)	(-13.87, 4.35)	
p-value	0.5299	0.4245	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: <= 7.5

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Other CV AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (4.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-4.76	-4.76	
95% CI of the absolute risk difference	(-13.87, 4.35)	(-13.87, 4.35)	
p-value	0.5299	0.4245	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious Other CV AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: <= 7.5

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: <= 7.5

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Serious DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Abbreviations: DB = Double Blinded; AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; CV = cardiovascular; DILI = drug-induced liver injury; HbA1c = Hemoglobin A1C.
Note: Disease related events include the following preferred terms: Hepatic cirrhosis; Ascites; Varices oesophageal; Oesophageal varices haemorrhage; Hepatic encephalopathy.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
[3] MACE AE includes cardiovascular mortality, myocardial infarction, and cerebral vascular accident.
[4] Other CV AE includes hospitalization/emergency room treatment for heart failure, hospitalization for unstable angina, urgent or emergent coronary revascularization.

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: > 7.5

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Events n:			
Total TEAEs	1	8	13
Total Serious TEAEs	0	1	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	1
Total TEAEs Related to Study Drug	0	0	3
Total TEAEs >= Grade 3 Severity	0	1	0
Patients n (%):			
Any TEAE	1 (100)	2 (100)	5 (71.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.40	1.40	
95% CI of the risk ratio	(0.88, 2.24)	(0.88, 2.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	28.57	28.57	
95% CI of the absolute risk difference	(-4.89, 62.04)	(-4.89, 62.04)	
p-value	0.5371	0.3914	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2283	
Any Serious TEAE	0	1 (50.0)	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	15.00	
95% CI of the odds ratio	NE	(0.39, 576.69)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	8.00	
95% CI of the risk ratio	NE	(0.43, 147.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	43.75	
95% CI of the absolute risk difference	NE	(-15.26, 100.00)	
p-value	NE	0.0938	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1962	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: > 7.5

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Any TEAEs >= Grade 3 Severity	0	1 (50.0)	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	15.00	
95% CI of the odds ratio	NE	(0.39, 576.69)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	8.00	
95% CI of the risk ratio	NE	(0.43, 147.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	43.75	
95% CI of the absolute risk difference	NE	(-15.26, 100.00)	
p-value	NE	0.0938	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.0925	
Any TEAEs <= Grade 2 Severity	1 (100)	2 (100)	5 (71.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.40	1.40	
95% CI of the risk ratio	(0.88, 2.24)	(0.88, 2.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	28.57	28.57	
95% CI of the absolute risk difference	(-4.89, 62.04)	(-4.89, 62.04)	
p-value	0.5371	0.3914	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2283	
Any TEAEs leading to Study-Drug Discontinuation	0	0	1 (14.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.44	0.87	
95% CI of the odds ratio	(0.04, 56.14)	(0.03, 29.20)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.33	0.89	
95% CI of the risk ratio	(0.08, 21.94)	(0.05, 16.36)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.25	-2.08	
95% CI of the absolute risk difference	(-59.57, 72.07)	(-52.18, 48.02)	
p-value	0.8433	0.9364	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2303	

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: > 7.5

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Any TEAEs leading to Study Discontinuation	0	0	1 (14.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.44	0.87	
95% CI of the odds ratio	(0.04, 56.14)	(0.03, 29.20)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.33	0.89	
95% CI of the risk ratio	(0.08, 21.94)	(0.05, 16.36)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.25	-2.08	
95% CI of the absolute risk difference	(-59.57, 72.07)	(-52.18, 48.02)	
p-value	0.8433	0.9364	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAE	0	0	2 (28.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.73	0.44	
95% CI of the odds ratio	(0.02, 25.09)	(0.01, 12.98)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.80	0.53	
95% CI of the risk ratio	(0.06, 10.89)	(0.03, 8.19)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.25	-14.58	
95% CI of the absolute risk difference	(-74.32, 61.82)	(-67.59, 38.43)	
p-value	0.8630	0.6286	
p-value of Breslow-Day Test for Homogeneity [2]	0.7090	0.3193	

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: > 7.5

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	1 (14.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.44	0.87	
95% CI of the odds ratio	(0.04, 56.14)	(0.03, 29.20)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.33	0.89	
95% CI of the risk ratio	(0.08, 21.94)	(0.05, 16.36)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.25	-2.08	
95% CI of the absolute risk difference	(-59.57, 72.07)	(-52.18, 48.02)	
p-value	0.8433	0.9364	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: > 7.5

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	1 (14.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.44	0.87	
95% CI of the odds ratio	(0.04, 56.14)	(0.03, 29.20)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.33	0.89	
95% CI of the risk ratio	(0.08, 21.94)	(0.05, 16.36)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.25	-2.08	
95% CI of the absolute risk difference	(-59.57, 72.07)	(-52.18, 48.02)	
p-value	0.8433	0.9364	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Maximum Severity of TEAEs			
Grade 1	1 (100)	1 (50.0)	3 (42.9)
Grade 2	0	0	2 (28.6)
Grade 3	0	1 (50.0)	0
Grade 4	0	0	0
Grade 5	0	0	0

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: > 7.5

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Maximum Severity of Treatment-related TEAEs			
Grade 1	0	0	2 (28.6)
Grade 2	0	0	0
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0
MACE AE – Adjudicated Event [3]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: > 7.5

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious MACE AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event [4]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: > 7.5

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Other CV AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious Other CV AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: > 7.5

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: > 7.5

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=2)	DB Placebo (N=7)
Serious DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: <= 7.5

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Events n:			
Total TEAEs	35	34	92
Total Serious TEAEs	0	1	2
Total TEAEs Leading to Discontinuation of Study Drug	0	1	0
Total TEAEs Related to Study Drug	2	9	9
Total TEAEs >= Grade 3 Severity	0	1	3
Patients n (%):			
Any TEAE	8 (100)	10 (76.9)	19 (90.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.35	
95% CI of the odds ratio	NE	(0.05, 2.46)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.11	0.85	
95% CI of the risk ratio	(0.96, 1.27)	(0.61, 1.18)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	9.52	-13.55	
95% CI of the absolute risk difference	(-3.03, 22.08)	(-39.67, 12.57)	
p-value	0.3657	0.2782	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2283	
Any Serious TEAE	0	1 (7.7)	1 (4.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.67	
95% CI of the odds ratio	NE	(0.10, 29.18)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.62	
95% CI of the risk ratio	NE	(0.11, 23.66)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.76	2.93	
95% CI of the absolute risk difference	(-13.87, 4.35)	(-14.18, 20.04)	
p-value	0.5299	0.7242	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1962	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: <= 7.5

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Any TEAEs >= Grade 3 Severity	0	1 (7.7)	2 (9.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.46	0.79	
95% CI of the odds ratio	(0.02, 10.62)	(0.06, 9.71)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.49	0.81	
95% CI of the risk ratio	(0.03, 9.21)	(0.08, 8.05)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.81	-1.83	
95% CI of the absolute risk difference	(-25.80, 14.19)	(-21.00, 17.34)	
p-value	0.6196	0.8548	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.0925	
Any TEAEs <= Grade 2 Severity	8 (100)	10 (76.9)	19 (90.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.35	
95% CI of the odds ratio	NE	(0.05, 2.46)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.11	0.85	
95% CI of the risk ratio	(0.96, 1.27)	(0.61, 1.18)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	9.52	-13.55	
95% CI of the absolute risk difference	(-3.03, 22.08)	(-39.67, 12.57)	
p-value	0.3657	0.2782	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2283	
Any TEAEs leading to Study-Drug Discontinuation	0	1 (7.7)	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	5.16	
95% CI of the odds ratio	NE	(0.20, 136.54)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	4.71	
95% CI of the risk ratio	NE	(0.21, 107.80)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	8.44	
95% CI of the absolute risk difference	NE	(-8.92, 25.80)	
p-value	NE	0.2811	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2303	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: <= 7.5

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAE	1 (12.5)	5 (38.5)	6 (28.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.36	1.56	
95% CI of the odds ratio	(0.04, 3.56)	(0.36, 6.76)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.44	1.35	
95% CI of the risk ratio	(0.06, 3.09)	(0.51, 3.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-16.07	9.89	
95% CI of the absolute risk difference	(-46.05, 13.90)	(-22.86, 42.64)	
p-value	0.3660	0.5491	
p-value of Breslow-Day Test for Homogeneity [2]	0.7090	0.3193	

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: <= 7.5

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: <= 7.5

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Maximum Severity of TEAEs			
Grade 1	3 (37.5)	6 (46.2)	6 (28.6)
Grade 2	5 (62.5)	3 (23.1)	11 (52.4)
Grade 3	0	1 (7.7)	2 (9.5)
Grade 4	0	0	0
Grade 5	0	0	0

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: <= 7.5

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Maximum Severity of Treatment-related TEAEs			
Grade 1	1 (12.5)	5 (38.5)	6 (28.6)
Grade 2	0	0	0
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0
MACE AE – Adjudicated Event [3]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: <= 7.5

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious MACE AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event [4]	0	0	1 (4.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-4.76	-4.76	
95% CI of the absolute risk difference	(-13.87, 4.35)	(-13.87, 4.35)	
p-value	0.5299	0.4245	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: <= 7.5

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Other CV AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (4.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-4.76	-4.76	
95% CI of the absolute risk difference	(-13.87, 4.35)	(-13.87, 4.35)	
p-value	0.5299	0.4245	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious Other CV AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: <= 7.5

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: <= 7.5

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=13)	DB Placebo (N=21)
Serious DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.8.2

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline HbA1C
(Label Population based on Safety Population)

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event; HbA1c = Hemoglobin A1C.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.

AMNOG Table S1.8.2

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: > 7.5

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=1) Patients n (%)	 Events n	DB MGL-3196 100 mg (N=2) Patients n (%)	 Events n	DB Placebo (N=7) Patients n (%)	 Events n
Musculoskeletal and connective tissue disorders	0	0	0	0	3 (42.9)	4
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.43		0.26			
95% CI of the odds ratio	(0.01, 14.08)		(0.01, 7.27)			
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.57		0.38			
95% CI of the risk ratio	(0.05, 7.14)		(0.03, 5.39)			
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-18.75		-27.08			
95% CI of the absolute risk difference	(-87.91, 50.41)		(-81.49, 27.32)			
p-value	0.6283		0.4056			
p-value of Breslow-Day Test for Homogeneity [2]	0.2538		NE			

AMNOG Table S1.8.2

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: <= 7.5

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=8) Patients n (%)	 Events n	DB MGL-3196 100 mg (N=13) Patients n (%)	 Events n	DB Placebo (N=21) Patients n (%)	 Events n
Musculoskeletal and connective tissue disorders	4 (50.0)	4	0	0	6 (28.6)	14
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.50		0.09			
95% CI of the odds ratio	(0.47, 13.39)		(0.00, 1.72)			
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.75		0.12			
95% CI of the risk ratio	(0.66, 4.61)		(0.01, 1.98)			
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	21.43		-25.97			
95% CI of the absolute risk difference	(-18.24, 61.10)		(-47.37, -4.57)			
p-value	0.2779		0.0549			
p-value of Breslow-Day Test for Homogeneity [2]	0.2538		NE			

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)

Abbreviations: DB = Double Blinded; AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; CV = cardiovascular; DILI = drug-induced liver injury.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as “Grade 3”. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
[3] MACE AE includes cardiovascular mortality, myocardial infarction, and cerebral vascular accident.
[4] Other CV AE includes hospitalization/emergency room treatment for heart failure, hospitalization for unstable angina, urgent or emergent coronary revascularization.

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Events n:			
Total TEAEs	35	28	80
Total Serious TEAEs	0	1	2
Total TEAEs Leading to Discontinuation of Study Drug	0	1	0
Total TEAEs Related to Study Drug	2	6	10
Total TEAEs >= Grade 3 Severity	0	1	3
Patients n (%):			
Any TEAE	8 (100)	7 (70.0)	16 (80.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.58	
95% CI of the odds ratio	NE	(0.10, 3.33)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.25	0.88	
95% CI of the risk ratio	(1.00, 1.56)	(0.55, 1.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	20.00	-10.00	
95% CI of the absolute risk difference	(2.47, 37.53)	(-43.38, 23.38)	
p-value	0.1719	0.5416	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Serious TEAE	0	1 (10.0)	1 (5.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.76	2.11	
95% CI of the odds ratio	(0.03, 20.74)	(0.12, 37.72)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.78	2.00	
95% CI of the risk ratio	(0.03, 17.33)	(0.14, 28.76)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.59	5.00	
95% CI of the absolute risk difference	(-20.17, 16.99)	(-15.90, 25.90)	
p-value	0.8731	0.6048	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.4087	

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Any TEAEs >= Grade 3 Severity	0	1 (10.0)	2 (10.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.44	1.00	
95% CI of the odds ratio	(0.02, 10.09)	(0.08, 12.56)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.47	1.00	
95% CI of the risk ratio	(0.02, 8.78)	(0.10, 9.75)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.35	0.00	
95% CI of the absolute risk difference	(-26.74, 14.04)	(-22.77, 22.77)	
p-value	0.5953	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2697	
Any TEAEs <= Grade 2 Severity	8 (100)	7 (70.0)	16 (80.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.58	
95% CI of the odds ratio	NE	(0.10, 3.33)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.25	0.88	
95% CI of the risk ratio	(1.00, 1.56)	(0.55, 1.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	20.00	-10.00	
95% CI of the absolute risk difference	(2.47, 37.53)	(-43.38, 23.38)	
p-value	0.1719	0.5416	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any TEAEs leading to Study-Drug Discontinuation	0	1 (10.0)	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	6.47	
95% CI of the odds ratio	NE	(0.24, 174.08)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	5.73	
95% CI of the risk ratio	NE	(0.25, 129.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	11.26	
95% CI of the absolute risk difference	NE	(-10.05, 32.56)	
p-value	NE	0.2116	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1252	

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAE	1 (12.5)	3 (30.0)	6 (30.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.33	1.00	
95% CI of the odds ratio	(0.03, 3.34)	(0.19, 5.24)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.42	1.00	
95% CI of the risk ratio	(0.06, 2.93)	(0.31, 3.19)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-17.50	0.00	
95% CI of the absolute risk difference	(-47.97, 12.97)	(-34.79, 34.79)	
p-value	0.3340	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	0.7400	0.6405	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Maximum Severity of TEAEs			
Grade 1	3 (37.5)	4 (40.0)	6 (30.0)
Grade 2	5 (62.5)	2 (20.0)	8 (40.0)
Grade 3	0	1 (10.0)	2 (10.0)
Grade 4	0	0	0
Grade 5	0	0	0

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Maximum Severity of Treatment-related TEAEs			
Grade 1	1 (12.5)	3 (30.0)	6 (30.0)
Grade 2	0	0	0
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0
MACE AE – Adjudicated Event [3]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious MACE AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event [4]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Other CV AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious Other CV AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Serious DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Events n:			
Total TEAEs	1	14	25
Total Serious TEAEs	0	1	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	1
Total TEAEs Related to Study Drug	0	3	2
Total TEAEs >= Grade 3 Severity	0	1	0
Patients n (%):			
Any TEAE	1 (100)	5 (100)	8 (100)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Serious TEAE	0	1 (20.0)	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	5.67	
95% CI of the odds ratio	NE	(0.19, 169.53)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	4.50	
95% CI of the risk ratio	NE	(0.22, 93.07)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	19.44	
95% CI of the absolute risk difference	NE	(-18.30, 57.19)	
p-value	NE	0.2778	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.4087	

Madrigal Pharmaceuticals, Inc. Page 13 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Any TEAEs >= Grade 3 Severity	0	1 (20.0)	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	5.67	
95% CI of the odds ratio	NE	(0.19, 169.53)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	4.50	
95% CI of the risk ratio	NE	(0.22, 93.07)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	19.44	
95% CI of the absolute risk difference	NE	(-18.30, 57.19)	
p-value	NE	0.2778	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2697	
Any TEAEs <= Grade 2 Severity	1 (100)	5 (100)	8 (100)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any TEAEs leading to Study-Drug Discontinuation	0	0	1 (12.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.67	0.45	
95% CI of the odds ratio	(0.04, 64.08)	(0.02, 13.41)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.50	0.50	
95% CI of the risk ratio	(0.09, 24.92)	(0.02, 10.34)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	8.33	-8.33	
95% CI of the absolute risk difference	(-56.43, 73.10)	(-41.23, 24.56)	
p-value	0.7823	0.6418	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1252	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Any TEAEs leading to Study Discontinuation	0	0	1 (12.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.67	0.45	
95% CI of the odds ratio	(0.04, 64.08)	(0.02, 13.41)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.50	0.50	
95% CI of the risk ratio	(0.09, 24.92)	(0.02, 10.34)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	8.33	-8.33	
95% CI of the absolute risk difference	(-56.43, 73.10)	(-41.23, 24.56)	
p-value	0.7823	0.6418	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAE	0	2 (40.0)	2 (25.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.87	2.00	
95% CI of the odds ratio	(0.03, 29.20)	(0.18, 22.06)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.90	1.60	
95% CI of the risk ratio	(0.07, 12.38)	(0.32, 8.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.78	15.00	
95% CI of the absolute risk difference	(-69.54, 63.99)	(-37.39, 67.39)	
p-value	0.9364	0.5686	
p-value of Breslow-Day Test for Homogeneity [2]	0.7400	0.6405	

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	1 (12.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.67	0.45	
95% CI of the odds ratio	(0.04, 64.08)	(0.02, 13.41)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.50	0.50	
95% CI of the risk ratio	(0.09, 24.92)	(0.02, 10.34)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	8.33	-8.33	
95% CI of the absolute risk difference	(-56.43, 73.10)	(-41.23, 24.56)	
p-value	0.7823	0.6418	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	1 (12.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.67	0.45	
95% CI of the odds ratio	(0.04, 64.08)	(0.02, 13.41)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.50	0.50	
95% CI of the risk ratio	(0.09, 24.92)	(0.02, 10.34)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	8.33	-8.33	
95% CI of the absolute risk difference	(-56.43, 73.10)	(-41.23, 24.56)	
p-value	0.7823	0.6418	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Maximum Severity of TEAEs			
Grade 1	1 (100)	3 (60.0)	3 (37.5)
Grade 2	0	1 (20.0)	5 (62.5)
Grade 3	0	1 (20.0)	0
Grade 4	0	0	0
Grade 5	0	0	0

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Maximum Severity of Treatment-related TEAEs			
Grade 1	0	2 (40.0)	2 (25.0)
Grade 2	0	0	0
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0
MACE AE – Adjudicated Event [3]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious MACE AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event [4]	0	0	1 (12.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.67	0.45	
95% CI of the odds ratio	(0.04, 64.08)	(0.02, 13.41)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.50	0.50	
95% CI of the risk ratio	(0.09, 24.92)	(0.02, 10.34)	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	8.33	-8.33	
95% CI of the absolute risk difference	(-56.43, 73.10)	(-41.23, 24.56)	
p-value	0.7823	0.6418	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Other CV AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (12.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.67	0.45	
95% CI of the odds ratio	(0.04, 64.08)	(0.02, 13.41)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.50	0.50	
95% CI of the risk ratio	(0.09, 24.92)	(0.02, 10.34)	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	8.33	-8.33	
95% CI of the absolute risk difference	(-56.43, 73.10)	(-41.23, 24.56)	
p-value	0.7823	0.6418	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious Other CV AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Serious DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.9.1.2

TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)

Abbreviations: DB = Double Blinded; AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; CV = cardiovascular; DILI = drug-induced liver injury.
Note: Disease related events include the following preferred terms: Hepatic cirrhosis; Ascites; Varices oesophageal; Oesophageal varices haemorrhage; Hepatic encephalopathy.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
[3] MACE AE includes cardiovascular mortality, myocardial infarction, and cerebral vascular accident.
[4] Other CV AE includes hospitalization/emergency room treatment for heart failure, hospitalization for unstable angina, urgent or emergent coronary revascularization.

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Events n:			
Total TEAEs	35	28	80
Total Serious TEAEs	0	1	2
Total TEAEs Leading to Discontinuation of Study Drug	0	1	0
Total TEAEs Related to Study Drug	2	6	10
Total TEAEs >= Grade 3 Severity	0	1	3
Patients n (%):			
Any TEAE	8 (100)	7 (70.0)	16 (80.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.58	
95% CI of the odds ratio	NE	(0.10, 3.33)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.25	0.88	
95% CI of the risk ratio	(1.00, 1.56)	(0.55, 1.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	20.00	-10.00	
95% CI of the absolute risk difference	(2.47, 37.53)	(-43.38, 23.38)	
p-value	0.1719	0.5416	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Serious TEAE	0	1 (10.0)	1 (5.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.76	2.11	
95% CI of the odds ratio	(0.03, 20.74)	(0.12, 37.72)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.78	2.00	
95% CI of the risk ratio	(0.03, 17.33)	(0.14, 28.76)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.59	5.00	
95% CI of the absolute risk difference	(-20.17, 16.99)	(-15.90, 25.90)	
p-value	0.8731	0.6048	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.4087	

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Any TEAEs >= Grade 3 Severity	0	1 (10.0)	2 (10.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.44	1.00	
95% CI of the odds ratio	(0.02, 10.09)	(0.08, 12.56)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.47	1.00	
95% CI of the risk ratio	(0.02, 8.78)	(0.10, 9.75)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.35	0.00	
95% CI of the absolute risk difference	(-26.74, 14.04)	(-22.77, 22.77)	
p-value	0.5953	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2697	
Any TEAEs <= Grade 2 Severity	8 (100)	7 (70.0)	16 (80.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.58	
95% CI of the odds ratio	NE	(0.10, 3.33)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.25	0.88	
95% CI of the risk ratio	(1.00, 1.56)	(0.55, 1.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	20.00	-10.00	
95% CI of the absolute risk difference	(2.47, 37.53)	(-43.38, 23.38)	
p-value	0.1719	0.5416	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any TEAEs leading to Study-Drug Discontinuation	0	1 (10.0)	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	6.47	
95% CI of the odds ratio	NE	(0.24, 174.08)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	5.73	
95% CI of the risk ratio	NE	(0.25, 129.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	11.26	
95% CI of the absolute risk difference	NE	(-10.05, 32.56)	
p-value	NE	0.2116	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1252	

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAE	1 (12.5)	3 (30.0)	6 (30.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.33	1.00	
95% CI of the odds ratio	(0.03, 3.34)	(0.19, 5.24)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.42	1.00	
95% CI of the risk ratio	(0.06, 2.93)	(0.31, 3.19)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-17.50	0.00	
95% CI of the absolute risk difference	(-47.97, 12.97)	(-34.79, 34.79)	
p-value	0.3340	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	0.7400	0.6405	

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Maximum Severity of TEAEs			
Grade 1	3 (37.5)	4 (40.0)	6 (30.0)
Grade 2	5 (62.5)	2 (20.0)	8 (40.0)
Grade 3	0	1 (10.0)	2 (10.0)
Grade 4	0	0	0
Grade 5	0	0	0

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Maximum Severity of Treatment-related TEAEs			
Grade 1	1 (12.5)	3 (30.0)	6 (30.0)
Grade 2	0	0	0
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0
MACE AE – Adjudicated Event [3]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious MACE AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event [4]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Other CV AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious Other CV AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
DILI AE - Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE - Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE - Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

	DB MGL-3196 80 mg (N=8)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=20)
Serious DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

Madrigal Pharmaceuticals, Inc. Page 12 of 21
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Events n:			
Total TEAEs	1	14	25
Total Serious TEAEs	0	1	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	1
Total TEAEs Related to Study Drug	0	3	2
Total TEAEs >= Grade 3 Severity	0	1	0
Patients n (%):			
Any TEAE	1 (100)	5 (100)	8 (100)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Serious TEAE	0	1 (20.0)	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	5.67	
95% CI of the odds ratio	NE	(0.19, 169.53)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	4.50	
95% CI of the risk ratio	NE	(0.22, 93.07)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	19.44	
95% CI of the absolute risk difference	NE	(-18.30, 57.19)	
p-value	NE	0.2778	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.4087	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Any TEAEs >= Grade 3 Severity	0	1 (20.0)	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	5.67	
95% CI of the odds ratio	NE	(0.19, 169.53)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	4.50	
95% CI of the risk ratio	NE	(0.22, 93.07)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	19.44	
95% CI of the absolute risk difference	NE	(-18.30, 57.19)	
p-value	NE	0.2778	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2697	
Any TEAEs <= Grade 2 Severity	1 (100)	5 (100)	8 (100)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any TEAEs leading to Study-Drug Discontinuation	0	0	1 (12.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.67	0.45	
95% CI of the odds ratio	(0.04, 64.08)	(0.02, 13.41)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.50	0.50	
95% CI of the risk ratio	(0.09, 24.92)	(0.02, 10.34)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	8.33	-8.33	
95% CI of the absolute risk difference	(-56.43, 73.10)	(-41.23, 24.56)	
p-value	0.7823	0.6418	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1252	

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Any TEAEs leading to Study Discontinuation	0	0	1 (12.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.67	0.45	
95% CI of the odds ratio	(0.04, 64.08)	(0.02, 13.41)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.50	0.50	
95% CI of the risk ratio	(0.09, 24.92)	(0.02, 10.34)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	8.33	-8.33	
95% CI of the absolute risk difference	(-56.43, 73.10)	(-41.23, 24.56)	
p-value	0.7823	0.6418	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAE	0	2 (40.0)	2 (25.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.87	2.00	
95% CI of the odds ratio	(0.03, 29.20)	(0.18, 22.06)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.90	1.60	
95% CI of the risk ratio	(0.07, 12.38)	(0.32, 8.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.78	15.00	
95% CI of the absolute risk difference	(-69.54, 63.99)	(-37.39, 67.39)	
p-value	0.9364	0.5686	
p-value of Breslow-Day Test for Homogeneity [2]	0.7400	0.6405	

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	1 (12.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.67	0.45	
95% CI of the odds ratio	(0.04, 64.08)	(0.02, 13.41)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.50	0.50	
95% CI of the risk ratio	(0.09, 24.92)	(0.02, 10.34)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	8.33	-8.33	
95% CI of the absolute risk difference	(-56.43, 73.10)	(-41.23, 24.56)	
p-value	0.7823	0.6418	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	1 (12.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.67	0.45	
95% CI of the odds ratio	(0.04, 64.08)	(0.02, 13.41)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.50	0.50	
95% CI of the risk ratio	(0.09, 24.92)	(0.02, 10.34)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	8.33	-8.33	
95% CI of the absolute risk difference	(-56.43, 73.10)	(-41.23, 24.56)	
p-value	0.7823	0.6418	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Maximum Severity of TEAEs			
Grade 1	1 (100)	3 (60.0)	3 (37.5)
Grade 2	0	1 (20.0)	5 (62.5)
Grade 3	0	1 (20.0)	0
Grade 4	0	0	0
Grade 5	0	0	0

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Maximum Severity of Treatment-related TEAEs			
Grade 1	0	2 (40.0)	2 (25.0)
Grade 2	0	0	0
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0
MACE AE – Adjudicated Event [3]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious MACE AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event [4]	0	0	1 (12.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.67	0.45	
95% CI of the odds ratio	(0.04, 64.08)	(0.02, 13.41)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.50	0.50	
95% CI of the risk ratio	(0.09, 24.92)	(0.02, 10.34)	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	8.33	-8.33	
95% CI of the absolute risk difference	(-56.43, 73.10)	(-41.23, 24.56)	
p-value	0.7823	0.6418	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Other CV AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (12.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.67	0.45	
95% CI of the odds ratio	(0.04, 64.08)	(0.02, 13.41)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.50	0.50	
95% CI of the risk ratio	(0.09, 24.92)	(0.02, 10.34)	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	8.33	-8.33	
95% CI of the absolute risk difference	(-56.43, 73.10)	(-41.23, 24.56)	
p-value	0.7823	0.6418	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious Other CV AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)
Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
DILI AE - Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE - Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE - Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.9.1.2

TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

	DB MGL-3196 80 mg (N=1)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=8)
Serious DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.9.2

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term

by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)

(Label Population based on Safety Population)

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.

AMNOG Table S1.9.2

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term

by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)

(Label Population based on Safety Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=8) Patients n (%)	DB MGL-3196 80 mg (N=8) Events n	DB MGL-3196 100 mg (N=10) Patients n (%)	DB MGL-3196 100 mg (N=10) Events n	DB Placebo (N=20) Patients n (%)	DB Placebo (N=20) Events n
Musculoskeletal and connective tissue disorders	4 (50.0)	4	0	0	7 (35.0)	15
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.86		0.09			
95% CI of the odds ratio	(0.35, 9.79)		(0.00, 1.68)			
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.43		0.13			
95% CI of the risk ratio	(0.57, 3.57)		(0.01, 2.03)			
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	15.00		-31.17			
95% CI of the absolute risk difference	(-25.47, 55.47)		(-55.08, -7.26)			
p-value	0.4628		0.0531			
p-value of Breslow-Day Test for Homogeneity [2]	0.4658		NE			

Madrigal Pharmaceuticals, Inc. Page 3 of 3
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S1.9.2

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term

by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)

(Label Population based on Safety Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=1) Patients n (%)	DB MGL-3196 80 mg (N=1) Events n	DB MGL-3196 100 mg (N=5) Patients n (%)	DB MGL-3196 100 mg (N=5) Events n	DB Placebo (N=8) Patients n (%)	DB Placebo (N=8) Events n
Musculoskeletal and connective tissue disorders	0	0	0	0	2 (25.0)	3
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.87		0.24			
95% CI of the odds ratio	(0.03, 29.20)		(0.01, 6.05)			
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.90		0.30			
95% CI of the risk ratio	(0.07, 12.38)		(0.02, 5.21)			
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.78		-19.44			
95% CI of the absolute risk difference	(-69.54, 63.99)		(-56.12, 17.23)			
p-value	0.9364		0.3564			
p-value of Breslow-Day Test for Homogeneity [2]	0.4658		NE			

Program: t-s01-02-02-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)

Abbreviations: DB = Double Blinded; AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; CV = cardiovascular; DILI = drug-induced liver injury.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as “Grade 3”. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
[3] MACE AE includes cardiovascular mortality, myocardial infarction, and cerebral vascular accident.
[4] Other CV AE includes hospitalization/emergency room treatment for heart failure, hospitalization for unstable angina, urgent or emergent coronary revascularization.

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)

Baseline Statin: Yes (Treated with Statins at baseline)

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Events n:			
Total TEAEs	22	17	65
Total Serious TEAEs	0	1	0
Total TEAEs Leading to Discontinuation of Study Drug	0	1	1
Total TEAEs Related to Study Drug	2	1	8
Total TEAEs >= Grade 3 Severity	0	1	1
Patients n (%):			
Any TEAE	5 (100)	5 (100)	14 (82.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.21	1.21	
95% CI of the risk ratio	(0.97, 1.51)	(0.97, 1.51)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	17.65	17.65	
95% CI of the absolute risk difference	(-0.47, 35.77)	(-0.47, 35.77)	
p-value	0.3121	0.3121	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1347	
Any Serious TEAE	0	1 (20.0)	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	11.67	
95% CI of the odds ratio	NE	(0.40, 337.25)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	9.00	
95% CI of the risk ratio	NE	(0.42, 192.78)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	22.22	
95% CI of the absolute risk difference	NE	(-13.25, 57.69)	
p-value	NE	0.0881	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1832	

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)

Baseline Statin: Yes (Treated with Statins at baseline)

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Any TEAEs >= Grade 3 Severity	0	1 (20.0)	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	4.00	
95% CI of the odds ratio	(0.04, 28.30)	(0.20, 78.79)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	3.40	
95% CI of the risk ratio	(0.05, 21.42)	(0.26, 45.15)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.00	14.12	
95% CI of the absolute risk difference	(-25.54, 25.54)	(-22.68, 50.92)	
p-value	>0.9999	0.3344	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.5406	
Any TEAEs <= Grade 2 Severity	5 (100)	5 (100)	14 (82.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.21	1.21	
95% CI of the risk ratio	(0.97, 1.51)	(0.97, 1.51)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	17.65	17.65	
95% CI of the absolute risk difference	(-0.47, 35.77)	(-0.47, 35.77)	
p-value	0.3121	0.3121	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1347	
Any TEAEs leading to Study-Drug Discontinuation	0	1 (20.0)	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	4.00	
95% CI of the odds ratio	(0.04, 28.30)	(0.20, 78.79)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	3.40	
95% CI of the risk ratio	(0.05, 21.42)	(0.26, 45.15)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.00	14.12	
95% CI of the absolute risk difference	(-25.54, 25.54)	(-22.68, 50.92)	
p-value	>0.9999	0.3344	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)

Baseline Statin: Yes (Treated with Statins at baseline)

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Any TEAEs leading to Study Discontinuation	0	0	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	1.00	
95% CI of the odds ratio	(0.04, 28.30)	(0.04, 28.30)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	1.00	
95% CI of the risk ratio	(0.05, 21.42)	(0.05, 21.42)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.00	0.00	
95% CI of the absolute risk difference	(-25.54, 25.54)	(-25.54, 25.54)	
p-value	>0.9999	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAE	1 (20.0)	1 (20.0)	6 (35.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.46	0.46	
95% CI of the odds ratio	(0.04, 5.09)	(0.04, 5.09)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.57	0.57	
95% CI of the risk ratio	(0.09, 3.67)	(0.09, 3.67)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-15.29	-15.29	
95% CI of the absolute risk difference	(-57.07, 26.48)	(-57.07, 26.48)	
p-value	0.5186	0.5186	
p-value of Breslow-Day Test for Homogeneity [2]	0.5393	0.2279	

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)

Baseline Statin: Yes (Treated with Statins at baseline)

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	1.00	
95% CI of the odds ratio	(0.04, 28.30)	(0.04, 28.30)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	1.00	
95% CI of the risk ratio	(0.05, 21.42)	(0.05, 21.42)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.00	0.00	
95% CI of the absolute risk difference	(-25.54, 25.54)	(-25.54, 25.54)	
p-value	>0.9999	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)

Baseline Statin: Yes (Treated with Statins at baseline)

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	1.00	
95% CI of the odds ratio	(0.04, 28.30)	(0.04, 28.30)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	1.00	
95% CI of the risk ratio	(0.05, 21.42)	(0.05, 21.42)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.00	0.00	
95% CI of the absolute risk difference	(-25.54, 25.54)	(-25.54, 25.54)	
p-value	>0.9999	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Maximum Severity of TEAEs			
Grade 1	3 (60.0)	3 (60.0)	5 (29.4)
Grade 2	2 (40.0)	1 (20.0)	8 (47.1)
Grade 3	0	1 (20.0)	1 (5.9)
Grade 4	0	0	0
Grade 5	0	0	0

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)

Baseline Statin: Yes (Treated with Statins at baseline)

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Maximum Severity of Treatment-related TEAEs			
Grade 1	1 (20.0)	1 (20.0)	6 (35.3)
Grade 2	0	0	0
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0
MACE AE – Adjudicated Event [3]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)

Baseline Statin: Yes (Treated with Statins at baseline)

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious MACE AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event [4]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)

Baseline Statin: Yes (Treated with Statins at baseline)

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Other CV AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious Other CV AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)
Baseline Statin: Yes (Treated with Statins at baseline)

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)

Baseline Statin: Yes (Treated with Statins at baseline)

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Serious DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)

Baseline Statin: No

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Events n:			
Total TEAEs	14	25	40
Total Serious TEAEs	0	1	2
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	0	8	4
Total TEAEs >= Grade 3 Severity	0	1	2
Patients n (%):			
Any TEAE	4 (100)	7 (70.0)	10 (90.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.23	
95% CI of the odds ratio	NE	(0.02, 2.73)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.10	0.77	
95% CI of the risk ratio	(0.91, 1.33)	(0.49, 1.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	9.09	-20.91	
95% CI of the absolute risk difference	(-7.90, 26.08)	(-54.00, 12.19)	
p-value	0.5325	0.2230	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1347	
Any Serious TEAE	0	1 (10.0)	1 (9.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.78	1.11	
95% CI of the odds ratio	(0.03, 22.98)	(0.06, 20.49)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.80	1.10	
95% CI of the risk ratio	(0.04, 16.49)	(0.08, 15.36)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.50	0.91	
95% CI of the absolute risk difference	(-34.77, 29.77)	(-24.28, 26.10)	
p-value	0.8841	0.9435	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1832	

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)

Baseline Statin: No

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Any TEAEs >= Grade 3 Severity	0	1 (10.0)	1 (9.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.78	1.11	
95% CI of the odds ratio	(0.03, 22.98)	(0.06, 20.49)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.80	1.10	
95% CI of the risk ratio	(0.04, 16.49)	(0.08, 15.36)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.50	0.91	
95% CI of the absolute risk difference	(-34.77, 29.77)	(-24.28, 26.10)	
p-value	0.8841	0.9435	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.5406	
Any TEAEs <= Grade 2 Severity	4 (100)	7 (70.0)	10 (90.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.23	
95% CI of the odds ratio	NE	(0.02, 2.73)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.10	0.77	
95% CI of the risk ratio	(0.91, 1.33)	(0.49, 1.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	9.09	-20.91	
95% CI of the absolute risk difference	(-7.90, 26.08)	(-54.00, 12.19)	
p-value	0.5325	0.2230	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1347	
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)

Baseline Statin: No

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAE	0	4 (40.0)	2 (18.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.42	3.00	
95% CI of the odds ratio	(0.02, 10.75)	(0.41, 21.88)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.48	2.20	
95% CI of the risk ratio	(0.03, 8.31)	(0.51, 9.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-10.83	21.82	
95% CI of the absolute risk difference	(-45.75, 24.09)	(-16.15, 59.78)	
p-value	0.5934	0.2690	
p-value of Breslow-Day Test for Homogeneity [2]	0.5393	0.2279	

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)

Baseline Statin: No

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)

Baseline Statin: No

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Maximum Severity of TEAEs			
Grade 1	1 (25.0)	4 (40.0)	4 (36.4)
Grade 2	3 (75.0)	2 (20.0)	5 (45.5)
Grade 3	0	1 (10.0)	1 (9.1)
Grade 4	0	0	0
Grade 5	0	0	0

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)

Baseline Statin: No

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Maximum Severity of Treatment-related TEAEs			
Grade 1	0	4 (40.0)	2 (18.2)
Grade 2	0	0	0
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0
MACE AE – Adjudicated Event [3]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)

Baseline Statin: No

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious MACE AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event [4]	0	0	1 (9.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.78	0.33	
95% CI of the odds ratio	(0.03, 22.98)	(0.01, 9.16)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.80	0.36	
95% CI of the risk ratio	(0.04, 16.49)	(0.02, 8.03)	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-2.50	-7.95	
95% CI of the absolute risk difference	(-34.77, 29.77)	(-30.35, 14.44)	
p-value	0.8841	0.4988	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)

Baseline Statin: No

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Other CV AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (9.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.78	0.33	
95% CI of the odds ratio	(0.03, 22.98)	(0.01, 9.16)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.80	0.36	
95% CI of the risk ratio	(0.04, 16.49)	(0.02, 8.03)	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-2.50	-7.95	
95% CI of the absolute risk difference	(-34.77, 29.77)	(-30.35, 14.44)	
p-value	0.8841	0.4988	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious Other CV AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)

Baseline Statin: No

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)

Baseline Statin: No

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Serious DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)

Abbreviations: DB = Double Blinded; AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; CV = cardiovascular; DILI = drug-induced liver injury.
Note: Disease related events include the following preferred terms: Hepatic cirrhosis; Ascites; Varices oesophageal; Oesophageal varices haemorrhage; Hepatic encephalopathy.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
[3] MACE AE includes cardiovascular mortality, myocardial infarction, and cerebral vascular accident.
[4] Other CV AE includes hospitalization/emergency room treatment for heart failure, hospitalization for unstable angina, urgent or emergent coronary revascularization.

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)
Baseline Statin: Yes (Treated with Statins at baseline)

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Events n:			
Total TEAEs	22	17	65
Total Serious TEAEs	0	1	0
Total TEAEs Leading to Discontinuation of Study Drug	0	1	1
Total TEAEs Related to Study Drug	2	1	8
Total TEAEs >= Grade 3 Severity	0	1	1
Patients n (%):			
Any TEAE	5 (100)	5 (100)	14 (82.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.21	1.21	
95% CI of the risk ratio	(0.97, 1.51)	(0.97, 1.51)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	17.65	17.65	
95% CI of the absolute risk difference	(-0.47, 35.77)	(-0.47, 35.77)	
p-value	0.3121	0.3121	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1347	
Any Serious TEAE	0	1 (20.0)	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	11.67	
95% CI of the odds ratio	NE	(0.40, 337.25)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	9.00	
95% CI of the risk ratio	NE	(0.42, 192.78)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	22.22	
95% CI of the absolute risk difference	NE	(-13.25, 57.69)	
p-value	NE	0.0881	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1832	

Program: t-s01-02-01-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)
Baseline Statin: Yes (Treated with Statins at baseline)

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Any TEAEs >= Grade 3 Severity	0	1 (20.0)	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	4.00	
95% CI of the odds ratio	(0.04, 28.30)	(0.20, 78.79)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	3.40	
95% CI of the risk ratio	(0.05, 21.42)	(0.26, 45.15)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.00	14.12	
95% CI of the absolute risk difference	(-25.54, 25.54)	(-22.68, 50.92)	
p-value	>0.9999	0.3344	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.5406	
Any TEAEs <= Grade 2 Severity	5 (100)	5 (100)	14 (82.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.21	1.21	
95% CI of the risk ratio	(0.97, 1.51)	(0.97, 1.51)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	17.65	17.65	
95% CI of the absolute risk difference	(-0.47, 35.77)	(-0.47, 35.77)	
p-value	0.3121	0.3121	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1347	
Any TEAEs leading to Study-Drug Discontinuation	0	1 (20.0)	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	4.00	
95% CI of the odds ratio	(0.04, 28.30)	(0.20, 78.79)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	3.40	
95% CI of the risk ratio	(0.05, 21.42)	(0.26, 45.15)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.00	14.12	
95% CI of the absolute risk difference	(-25.54, 25.54)	(-22.68, 50.92)	
p-value	>0.9999	0.3344	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)
Baseline Statin: Yes (Treated with Statins at baseline)

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Any TEAEs leading to Study Discontinuation	0	0	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	1.00	
95% CI of the odds ratio	(0.04, 28.30)	(0.04, 28.30)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	1.00	
95% CI of the risk ratio	(0.05, 21.42)	(0.05, 21.42)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.00	0.00	
95% CI of the absolute risk difference	(-25.54, 25.54)	(-25.54, 25.54)	
p-value	>0.9999	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAE	1 (20.0)	1 (20.0)	6 (35.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.46	0.46	
95% CI of the odds ratio	(0.04, 5.09)	(0.04, 5.09)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.57	0.57	
95% CI of the risk ratio	(0.09, 3.67)	(0.09, 3.67)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-15.29	-15.29	
95% CI of the absolute risk difference	(-57.07, 26.48)	(-57.07, 26.48)	
p-value	0.5186	0.5186	
p-value of Breslow-Day Test for Homogeneity [2]	0.5393	0.2279	

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)
Baseline Statin: Yes (Treated with Statins at baseline)

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	1.00	
95% CI of the odds ratio	(0.04, 28.30)	(0.04, 28.30)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	1.00	
95% CI of the risk ratio	(0.05, 21.42)	(0.05, 21.42)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.00	0.00	
95% CI of the absolute risk difference	(-25.54, 25.54)	(-25.54, 25.54)	
p-value	>0.9999	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)
Baseline Statin: Yes (Treated with Statins at baseline)

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	1.00	
95% CI of the odds ratio	(0.04, 28.30)	(0.04, 28.30)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	1.00	
95% CI of the risk ratio	(0.05, 21.42)	(0.05, 21.42)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.00	0.00	
95% CI of the absolute risk difference	(-25.54, 25.54)	(-25.54, 25.54)	
p-value	>0.9999	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Maximum Severity of TEAEs			
Grade 1	3 (60.0)	3 (60.0)	5 (29.4)
Grade 2	2 (40.0)	1 (20.0)	8 (47.1)
Grade 3	0	1 (20.0)	1 (5.9)
Grade 4	0	0	0
Grade 5	0	0	0

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)
Baseline Statin: Yes (Treated with Statins at baseline)

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Maximum Severity of Treatment-related TEAEs			
Grade 1	1 (20.0)	1 (20.0)	6 (35.3)
Grade 2	0	0	0
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0
MACE AE – Adjudicated Event [3]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)
Baseline Statin: Yes (Treated with Statins at baseline)

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious MACE AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event [4]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)
Baseline Statin: Yes (Treated with Statins at baseline)

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Other CV AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious Other CV AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)
Baseline Statin: Yes (Treated with Statins at baseline)

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)
Baseline Statin: Yes (Treated with Statins at baseline)

	DB MGL-3196 80 mg (N=5)	DB MGL-3196 100 mg (N=5)	DB Placebo (N=17)
Serious DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)

Baseline Statin: No

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Events n:			
Total TEAEs	14	25	40
Total Serious TEAEs	0	1	2
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	0	8	4
Total TEAEs >= Grade 3 Severity	0	1	2
Patients n (%):			
Any TEAE	4 (100)	7 (70.0)	10 (90.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.23	
95% CI of the odds ratio	NE	(0.02, 2.73)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.10	0.77	
95% CI of the risk ratio	(0.91, 1.33)	(0.49, 1.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	9.09	-20.91	
95% CI of the absolute risk difference	(-7.90, 26.08)	(-54.00, 12.19)	
p-value	0.5325	0.2230	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1347	
Any Serious TEAE	0	1 (10.0)	1 (9.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.78	1.11	
95% CI of the odds ratio	(0.03, 22.98)	(0.06, 20.49)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.80	1.10	
95% CI of the risk ratio	(0.04, 16.49)	(0.08, 15.36)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.50	0.91	
95% CI of the absolute risk difference	(-34.77, 29.77)	(-24.28, 26.10)	
p-value	0.8841	0.9435	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1832	

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)

Baseline Statin: No

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Any TEAEs >= Grade 3 Severity	0	1 (10.0)	1 (9.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.78	1.11	
95% CI of the odds ratio	(0.03, 22.98)	(0.06, 20.49)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.80	1.10	
95% CI of the risk ratio	(0.04, 16.49)	(0.08, 15.36)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.50	0.91	
95% CI of the absolute risk difference	(-34.77, 29.77)	(-24.28, 26.10)	
p-value	0.8841	0.9435	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.5406	
Any TEAEs <= Grade 2 Severity	4 (100)	7 (70.0)	10 (90.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.23	
95% CI of the odds ratio	NE	(0.02, 2.73)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.10	0.77	
95% CI of the risk ratio	(0.91, 1.33)	(0.49, 1.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	9.09	-20.91	
95% CI of the absolute risk difference	(-7.90, 26.08)	(-54.00, 12.19)	
p-value	0.5325	0.2230	
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1347	
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)

Baseline Statin: No

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAE	0	4 (40.0)	2 (18.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.42	3.00	
95% CI of the odds ratio	(0.02, 10.75)	(0.41, 21.88)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.48	2.20	
95% CI of the risk ratio	(0.03, 8.31)	(0.51, 9.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-10.83	21.82	
95% CI of the absolute risk difference	(-45.75, 24.09)	(-16.15, 59.78)	
p-value	0.5934	0.2690	
p-value of Breslow-Day Test for Homogeneity [2]	0.5393	0.2279	

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)

Baseline Statin: No

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)

Baseline Statin: No

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Maximum Severity of TEAEs			
Grade 1	1 (25.0)	4 (40.0)	4 (36.4)
Grade 2	3 (75.0)	2 (20.0)	5 (45.5)
Grade 3	0	1 (10.0)	1 (9.1)
Grade 4	0	0	0
Grade 5	0	0	0

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)

Baseline Statin: No

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Maximum Severity of Treatment-related TEAEs			
Grade 1	0	4 (40.0)	2 (18.2)
Grade 2	0	0	0
Grade 3	0	0	0
Grade 4	0	0	0
Grade 5	0	0	0
MACE AE – Adjudicated Event [3]	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)

Baseline Statin: No

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious MACE AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event [4]	0	0	1 (9.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.78	0.33	
95% CI of the odds ratio	(0.03, 22.98)	(0.01, 9.16)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.80	0.36	
95% CI of the risk ratio	(0.04, 16.49)	(0.02, 8.03)	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-2.50	-7.95	
95% CI of the absolute risk difference	(-34.77, 29.77)	(-30.35, 14.44)	
p-value	0.8841	0.4988	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)

Baseline Statin: No

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Other CV AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Other CV AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (9.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.78	0.33	
95% CI of the odds ratio	(0.03, 22.98)	(0.01, 9.16)	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.80	0.36	
95% CI of the risk ratio	(0.04, 16.49)	(0.02, 8.03)	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-2.50	-7.95	
95% CI of the absolute risk difference	(-34.77, 29.77)	(-30.35, 14.44)	
p-value	0.8841	0.4988	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
Serious Other CV AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)

Baseline Statin: No

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline Statin
(Label Population based on Safety Population)

Baseline Statin: No

	DB MGL-3196 80 mg (N=4)	DB MGL-3196 100 mg (N=10)	DB Placebo (N=11)
Serious DILI AE – Adjudicated Event	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the odds ratio	NE	NE	
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE	
95% CI of the risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE	

AMNOG Table S1.10.2

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term

by Baseline Statin

(Label Population based on Safety Population)

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.

AMNOG Table S1.10.2

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline Statin
(Label Population based on Safety Population)

Baseline Statin: Yes (Treated with Statins at baseline)

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=5) Patients n (%)	 Events n	DB MGL-3196 100 mg (N=5) Patients n (%)	 Events n	DB Placebo (N=17) Patients n (%)	 Events n
Musculoskeletal and connective tissue disorders	3 (60.0)	3	0	0	6 (35.3)	12
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.75		0.16			
95% CI of the odds ratio	(0.36, 21.30)		(0.01, 3.40)			
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.70		0.23			
95% CI of the risk ratio	(0.65, 4.45)		(0.02, 3.52)			
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	24.71		-27.78			
95% CI of the absolute risk difference	(-23.87, 73.29)		(-59.11, 3.55)			
p-value	0.3233		0.1948			
p-value of Breslow-Day Test for Homogeneity [2]	0.5027		NE			

AMNOG Table S1.10.2

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term

by Baseline Statin

(Label Population based on Safety Population)

Baseline Statin: No

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=4) Patients n (%)	 Events n	DB MGL-3196 100 mg (N=10) Patients n (%)	 Events n	DB Placebo (N=11) Patients n (%)	 Events n
Musculoskeletal and connective tissue disorders	1 (25.0)	1	0	0	3 (27.3)	6
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.89		0.12			
95% CI of the odds ratio	(0.06, 12.25)		(0.01, 2.56)			
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.92		0.16			
95% CI of the risk ratio	(0.13, 6.46)		(0.01, 2.69)			
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.27		-24.62			
95% CI of the absolute risk difference	(-52.21, 47.66)		(-53.13, 3.89)			
p-value	0.9299		0.1197			
p-value of Breslow-Day Test for Homogeneity [2]	0.5027		NE			

Program: t-s01-02-02-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S2.2.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade
by Age (Median)
(Label Population based on Safety Population)

Age: < Median

	DB MGL-3196 80 mg (N=2)		DB MGL-3196 100 mg (N=11)		DB Placebo (N=11)	
System Organ Class Preferred Term Maximum CTCAE Grade	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Program: t-s02-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc. Page 2 of 2
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S2.2.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade
by Age (Median)
(Label Population based on Safety Population)

Age: >= Median

	DB MGL-3196 80 mg (N=7)		DB MGL-3196 100 mg (N=4)		DB Placebo (N=17)	
System Organ Class Preferred Term Maximum CTCAE Grade	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Program: t-s02-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S2.3.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade
by Age
(Label Population based on Safety Population)

Age: < 65 years

System Organ Class Preferred Term Maximum CTCAE Grade	DB MGL-3196 80 mg (N=6) Patients n (%)	DB MGL-3196 80 mg (N=6) Events n	DB MGL-3196 100 mg (N=15) Patients n (%)	DB MGL-3196 100 mg (N=15) Events n	DB Placebo (N=21) Patients n (%)	DB Placebo (N=21) Events n

Results for the overall population are not statistically significant.

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Program: t-s02-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc. Page 2 of 2
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S2.3.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade
by Age
(Label Population based on Safety Population)

Age: >= 65 years

System Organ Class Preferred Term Maximum CTCAE Grade	DB MGL-3196 80 mg (N=3) Patients n (%)	DB MGL-3196 80 mg (N=3) Events n	DB MGL-3196 100 mg (N=0) Patients n (%)	DB MGL-3196 100 mg (N=0) Events n	DB Placebo (N=7) Patients n (%)	DB Placebo (N=7) Events n

Results for the overall population are not statistically significant.

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Program: t-s02-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S2.4.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade
by Sex
(Label Population based on Safety Population)

Sex: Male

System Organ Class Preferred Term Maximum CTCAE Grade	DB MGL-3196 80 mg (N=3) Patients n (%)	DB MGL-3196 80 mg (N=3) Events n	DB MGL-3196 100 mg (N=8) Patients n (%)	DB MGL-3196 100 mg (N=8) Events n	DB Placebo (N=14) Patients n (%)	DB Placebo (N=14) Events n

Results for the overall population are not statistically significant.

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Program: t-s02-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S2.4.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade
by Sex
(Label Population based on Safety Population)

Sex: Female

System Organ Class Preferred Term Maximum CTCAE Grade	DB MGL-3196 80 mg (N=6) Patients n (%)	DB MGL-3196 80 mg (N=6) Events n	DB MGL-3196 100 mg (N=7) Patients n (%)	DB MGL-3196 100 mg (N=7) Events n	DB Placebo (N=14) Patients n (%)	DB Placebo (N=14) Events n

Results for the overall population are not statistically significant.

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Program: t-s02-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S2.5.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Hispanic

	DB MGL-3196 80 mg (N=4)		DB MGL-3196 100 mg (N=6)		DB Placebo (N=11)	
System Organ Class Preferred Term Maximum CTCAE Grade	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Program: t-s02-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S2.5.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Non-Hispanic

	DB MGL-3196 80 mg (N=5)		DB MGL-3196 100 mg (N=9)		DB Placebo (N=17)	
System Organ Class Preferred Term Maximum CTCAE Grade	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Program: t-s02-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S2.6.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade
by Weight
(Label Population based on Safety Population)

Weight: >200 lbs

	DB MGL-3196 80 mg (N=2)		DB MGL-3196 100 mg (N=15)		DB Placebo (N=24)	
System Organ Class Preferred Term Maximum CTCAE Grade	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Program: t-s02-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S2.6.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade
by Weight
(Label Population based on Safety Population)

Weight: <= 200 lbs

	DB MGL-3196 80 mg (N=7)		DB MGL-3196 100 mg (N=0)		DB Placebo (N=4)	
System Organ Class Preferred Term Maximum CTCAE Grade	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Program: t-s02-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S2.7.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Presence

	DB MGL-3196 80 mg (N=6)		DB MGL-3196 100 mg (N=6)		DB Placebo (N=19)	
System Organ Class Preferred Term Maximum CTCAE Grade	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events; T2D = Type 2 Diabetes.

Note: Adverse events are coded using MedDRA version 25.0.

Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.

Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).

Note: Percentages are based on the number of patients in the label population.

[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.

Program: t-s02-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S2.7.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade
by Baseline T2D Status
(Label Population based on Safety Population)

Baseline T2D Status: Absence

	DB MGL-3196 80 mg (N=3)		DB MGL-3196 100 mg (N=9)		DB Placebo (N=9)	
System Organ Class Preferred Term Maximum CTCAE Grade	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events; T2D = Type 2 Diabetes.

Note: Adverse events are coded using MedDRA version 25.0.

Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.

Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).

Note: Percentages are based on the number of patients in the label population.

[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.

Program: t-s02-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S2.8.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: > 7.5

	DB MGL-3196 80 mg (N=1)		DB MGL-3196 100 mg (N=2)		DB Placebo (N=7)	
System Organ Class Preferred Term Maximum CTCAE Grade	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events; HbA1c = Hemoglobin A1C.

Note: Adverse events are coded using MedDRA version 25.0.

Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.

Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).

Note: Percentages are based on the number of patients in the label population.

[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.

Program: t-s02-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc. Page 2 of 2
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S2.8.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade
by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: <= 7.5

	DB MGL-3196 80 mg (N=8)		DB MGL-3196 100 mg (N=13)		DB Placebo (N=21)	
System Organ Class Preferred Term Maximum CTCAE Grade	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events; HbA1c = Hemoglobin A1C.

Note: Adverse events are coded using MedDRA version 25.0.

Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.

Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).

Note: Percentages are based on the number of patients in the label population.

[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.

Program: t-s02-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S2.9.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

	DB MGL-3196 80 mg (N=8)		DB MGL-3196 100 mg (N=10)		DB Placebo (N=20)	
System Organ Class Preferred Term Maximum CTCAE Grade	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Program: t-s02-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S2.9.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade
by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)
(Label Population based on Safety Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

	DB MGL-3196 80 mg (N=1)		DB MGL-3196 100 mg (N=5)		DB Placebo (N=8)	
System Organ Class Preferred Term Maximum CTCAE Grade	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Program: t-s02-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc. Page 1 of 2
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S2.10.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade
by Baseline Statin
(Label Population based on Safety Population)

Baseline Statin: Yes (Treated with Statins at baseline)

	DB MGL-3196 80 mg (N=5)		DB MGL-3196 100 mg (N=5)		DB Placebo (N=17)	
System Organ Class Preferred Term Maximum CTCAE Grade	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Program: t-s02-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S2.10.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade
by Baseline Statin
(Label Population based on Safety Population)

Baseline Statin: No

	DB MGL-3196 80 mg (N=4)		DB MGL-3196 100 mg (N=10)		DB Placebo (N=11)	
System Organ Class Preferred Term Maximum CTCAE Grade	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Program: t-s02-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S4.2.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Termby Age (Median)

(Label Population based on Safety Population)

Age: < Median

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=2) Patients n (%)	DB MGL-3196 80 mg (N=2) Events n	DB MGL-3196 100 mg (N=11) Patients n (%)	DB MGL-3196 100 mg (N=11) Events n	DB Placebo (N=11) Patients n (%)	DB Placebo (N=11) Events n

Results for the overall population are not statistically significant.

Abbreviation: DB = Double Blinded; SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A SE-TEAE is defined as any serious AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Program: t-s01-02-02-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S4.2.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Termby Age (Median)

(Label Population based on Safety Population)

Age: >= Median

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=7) Patients n (%)	DB MGL-3196 80 mg (N=7) Events n	DB MGL-3196 100 mg (N=4) Patients n (%)	DB MGL-3196 100 mg (N=4) Events n	DB Placebo (N=17) Patients n (%)	DB Placebo (N=17) Events n

Results for the overall population are not statistically significant.

Abbreviation: DB = Double Blinded; SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A SE-TEAE is defined as any serious AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Program: t-s01-02-02-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S4.3.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Termby Age

(Label Population based on Safety Population)

Age: < 65 years

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=6) Patients n (%)	DB MGL-3196 80 mg (N=6) Events n	DB MGL-3196 100 mg (N=15) Patients n (%)	DB MGL-3196 100 mg (N=15) Events n	DB Placebo (N=21) Patients n (%)	DB Placebo (N=21) Events n

Results for the overall population are not statistically significant.

Abbreviation: DB = Double Blinded; SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A SE-TEAE is defined as any serious AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Program: t-s01-02-02-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S4.3.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Termby Age

(Label Population based on Safety Population)

Age: >= 65 years

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=3) Patients n (%)	DB MGL-3196 80 mg (N=3) Events n	DB MGL-3196 100 mg (N=0) Patients n (%)	DB MGL-3196 100 mg (N=0) Events n	DB Placebo (N=7) Patients n (%)	DB Placebo (N=7) Events n

Results for the overall population are not statistically significant.

Abbreviation: DB = Double Blinded; SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A SE-TEAE is defined as any serious AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Program: t-s01-02-02-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S4.4.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Termby Sex
(Label Population based on Safety Population)

Sex: Male

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=3) Patients n (%)	DB MGL-3196 80 mg (N=3) Events n	DB MGL-3196 100 mg (N=8) Patients n (%)	DB MGL-3196 100 mg (N=8) Events n	DB Placebo (N=14) Patients n (%)	DB Placebo (N=14) Events n

Results for the overall population are not statistically significant.

Abbreviation: DB = Double Blinded; SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A SE-TEAE is defined as any serious AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Program: t-s01-02-02-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S4.4.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Termby Sex
(Label Population based on Safety Population)

Sex: Female

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=6) Patients n (%)	DB MGL-3196 80 mg (N=6) Events n	DB MGL-3196 100 mg (N=7) Patients n (%)	DB MGL-3196 100 mg (N=7) Events n	DB Placebo (N=14) Patients n (%)	DB Placebo (N=14) Events n

Results for the overall population are not statistically significant.

Abbreviation: DB = Double Blinded; SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A SE-TEAE is defined as any serious AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Program: t-s01-02-02-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S4.5.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Termby Ethnicity

(Label Population based on Safety Population)

Ethnicity: Hispanic

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=4) Patients n (%)	DB MGL-3196 80 mg (N=4) Events n	DB MGL-3196 100 mg (N=6) Patients n (%)	DB MGL-3196 100 mg (N=6) Events n	DB Placebo (N=11) Patients n (%)	DB Placebo (N=11) Events n

Results for the overall population are not statistically significant.

Abbreviation: DB = Double Blinded; SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A SE-TEAE is defined as any serious AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Program: t-s01-02-02-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S4.5.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Termby Ethnicity

(Label Population based on Safety Population)

Ethnicity: Non-Hispanic

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=5) Patients n (%)	DB MGL-3196 80 mg (N=5) Events n	DB MGL-3196 100 mg (N=9) Patients n (%)	DB MGL-3196 100 mg (N=9) Events n	DB Placebo (N=17) Patients n (%)	DB Placebo (N=17) Events n

Results for the overall population are not statistically significant.

Abbreviation: DB = Double Blinded; SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A SE-TEAE is defined as any serious AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Program: t-s01-02-02-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S4.6.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Termby Weight

(Label Population based on Safety Population)

Weight: >200 lbs

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=2) Patients n (%)	DB MGL-3196 80 mg (N=2) Events n	DB MGL-3196 100 mg (N=15) Patients n (%)	DB MGL-3196 100 mg (N=15) Events n	DB Placebo (N=24) Patients n (%)	DB Placebo (N=24) Events n

Results for the overall population are not statistically significant.

Abbreviation: DB = Double Blinded; SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A SE-TEAE is defined as any serious AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Program: t-s01-02-02-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S4.6.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Termby Weight

(Label Population based on Safety Population)

Weight: <= 200 lbs

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=7) Patients n (%)	DB MGL-3196 80 mg (N=7) Events n	DB MGL-3196 100 mg (N=0) Patients n (%)	DB MGL-3196 100 mg (N=0) Events n	DB Placebo (N=4) Patients n (%)	DB Placebo (N=4) Events n

Results for the overall population are not statistically significant.

Abbreviation: DB = Double Blinded; SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A SE-TEAE is defined as any serious AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Program: t-s01-02-02-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S4.7.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Termby Baseline T2D Status

(Label Population based on Safety Population)

Baseline T2D Status: Presence

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=6) Patients n (%)	DB MGL-3196 80 mg (N=6) Events n	DB MGL-3196 100 mg (N=6) Patients n (%)	DB MGL-3196 100 mg (N=6) Events n	DB Placebo (N=19) Patients n (%)	DB Placebo (N=19) Events n

Results for the overall population are not statistically significant.

Abbreviation: DB = Double Blinded; SE-TEAE = Serious treatment-emergent adverse event; T2D = Type 2 Diabetes.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A SE-TEAE is defined as any serious AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Program: t-s01-02-02-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S4.7.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Termby Baseline T2D Status

(Label Population based on Safety Population)

Baseline T2D Status: Absence

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=3) Patients n (%)	DB MGL-3196 80 mg (N=3) Events n	DB MGL-3196 100 mg (N=9) Patients n (%)	DB MGL-3196 100 mg (N=9) Events n	DB Placebo (N=9) Patients n (%)	DB Placebo (N=9) Events n

Results for the overall population are not statistically significant.

Abbreviation: DB = Double Blinded; SE-TEAE = Serious treatment-emergent adverse event; T2D = Type 2 Diabetes.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A SE-TEAE is defined as any serious AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Program: t-s01-02-02-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S4.8.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Termby Baseline HbA1C

(Label Population based on Safety Population)

Baseline HbA1C: > 7.5

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=1) Patients n (%)	DB MGL-3196 80 mg (N=1) Events n	DB MGL-3196 100 mg (N=2) Patients n (%)	DB MGL-3196 100 mg (N=2) Events n	DB Placebo (N=7) Patients n (%)	DB Placebo (N=7) Events n

Results for the overall population are not statistically significant.

Abbreviation: DB = Double Blinded; SE-TEAE = Serious treatment-emergent adverse event; HbA1c = Hemoglobin A1C.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A SE-TEAE is defined as any serious AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Program: t-s01-02-02-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S4.8.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Termby Baseline HbA1C

(Label Population based on Safety Population)

Baseline HbA1C: <= 7.5

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=8) Patients n (%)	DB MGL-3196 80 mg (N=8) Events n	DB MGL-3196 100 mg (N=13) Patients n (%)	DB MGL-3196 100 mg (N=13) Events n	DB Placebo (N=21) Patients n (%)	DB Placebo (N=21) Events n

Results for the overall population are not statistically significant.

Abbreviation: DB = Double Blinded; SE-TEAE = Serious treatment-emergent adverse event; HbA1c = Hemoglobin A1C.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A SE-TEAE is defined as any serious AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Program: t-s01-02-02-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc. Page 1 of 2
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S4.9.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Termby Sites that participated in Study MAESTRO-NASH (MGL-3196-11)

(Label Population based on Safety Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=8) Patients n (%)	DB MGL-3196 80 mg (N=8) Events n	DB MGL-3196 100 mg (N=10) Patients n (%)	DB MGL-3196 100 mg (N=10) Events n	DB Placebo (N=20) Patients n (%)	DB Placebo (N=20) Events n

Results for the overall population are not statistically significant.

Abbreviation: DB = Double Blinded; SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A SE-TEAE is defined as any serious AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Program: t-s01-02-02-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S4.9.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Termby Sites that participated in Study MAESTRO-NASH (MGL-3196-11)

(Label Population based on Safety Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=1) Patients n (%)	DB MGL-3196 80 mg (N=1) Events n	DB MGL-3196 100 mg (N=5) Patients n (%)	DB MGL-3196 100 mg (N=5) Events n	DB Placebo (N=8) Patients n (%)	DB Placebo (N=8) Events n

Results for the overall population are not statistically significant.

Abbreviation: DB = Double Blinded; SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A SE-TEAE is defined as any serious AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Program: t-s01-02-02-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S4.10.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Termby Baseline Statin

(Label Population based on Safety Population)

Baseline Statin: Yes (Treated with Statins at baseline)

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=5) Patients n (%)	DB MGL-3196 80 mg (N=5) Events n	DB MGL-3196 100 mg (N=5) Patients n (%)	DB MGL-3196 100 mg (N=5) Events n	DB Placebo (N=17) Patients n (%)	DB Placebo (N=17) Events n

Results for the overall population are not statistically significant.

Abbreviation: DB = Double Blinded; SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A SE-TEAE is defined as any serious AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Program: t-s01-02-02-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S4.10.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Termby Baseline Statin

(Label Population based on Safety Population)

Baseline Statin: No

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=4) Patients n (%)	DB MGL-3196 80 mg (N=4) Events n	DB MGL-3196 100 mg (N=10) Patients n (%)	DB MGL-3196 100 mg (N=10) Events n	DB Placebo (N=11) Patients n (%)	DB Placebo (N=11) Events n

Results for the overall population are not statistically significant.

Abbreviation: DB = Double Blinded; SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A SE-TEAE is defined as any serious AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Program: t-s01-02-02-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S6.2.1
TEAE (S6): Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term; by Age (Median)
(Label Population based on Safety Population)

Age: < Median

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=2) Patients n (%)	DB MGL-3196 80 mg (N=2) Events n	DB MGL-3196 100 mg (N=11) Patients n (%)	DB MGL-3196 100 mg (N=11) Events n	DB Placebo (N=11) Patients n (%)	DB Placebo (N=11) Events n
Patients with at least one TEAE leading to study drug discontinuation	0	0	1 (9.1)	1	0	0
Psychiatric disorders	0	0	1 (9.1)	1	0	0
Agitation	0	0	1 (9.1)	1	0	0

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
Program: t-s06-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S6.2.1
TEAE (S6): Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term; by Age (Median)
(Label Population based on Safety Population)

Age: >= Median

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=7) Patients n (%)	DB MGL-3196 80 mg (N=7) Events n	DB MGL-3196 100 mg (N=4) Patients n (%)	DB MGL-3196 100 mg (N=4) Events n	DB Placebo (N=17) Patients n (%)	DB Placebo (N=17) Events n
Patients with at least one TEAE leading to study drug discontinuation	0	0	0	0	1 (5.9)	1
Musculoskeletal and connective tissue disorders	0	0	0	0	1 (5.9)	1
Muscle spasms	0	0	0	0	1 (5.9)	1

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
Program: t-s06-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S6.3.1
TEAE (S6): Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term; by Age
(Label Population based on Safety Population)

Age: < 65 years

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=6) Patients n (%)	DB MGL-3196 80 mg (N=6) Events n	DB MGL-3196 100 mg (N=15) Patients n (%)	DB MGL-3196 100 mg (N=15) Events n	DB Placebo (N=21) Patients n (%)	DB Placebo (N=21) Events n
Patients with at least one TEAE leading to study drug discontinuation	0	0	1 (6.7)	1	1 (4.8)	1
Musculoskeletal and connective tissue disorders	0	0	0	0	1 (4.8)	1
Muscle spasms	0	0	0	0	1 (4.8)	1
Psychiatric disorders	0	0	1 (6.7)	1	0	0
Agitation	0	0	1 (6.7)	1	0	0

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
Program: t-s06-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S6.3.1
TEAE (S6): Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term; by Age
(Label Population based on Safety Population)

Age: >= 65 years

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=3)		DB MGL-3196 100 mg (N=0)		DB Placebo (N=7)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Patients with at least one TEAE leading to study drug discontinuation	0	0	0	0	0	0

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
Program: t-s06-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S6.4.1
TEAE (S6): Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term; by Sex
(Label Population based on Safety Population)

Sex: Male

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=3)		DB MGL-3196 100 mg (N=8)		DB Placebo (N=14)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Patients with at least one TEAE leading to study drug discontinuation	0	0	0	0	0	0

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
Program: t-s06-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S6.4.1

TEAE (S6): Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term; by Sex

(Label Population based on Safety Population)

Sex: Female

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=6) Patients n (%)	DB MGL-3196 80 mg (N=6) Events n	DB MGL-3196 100 mg (N=7) Patients n (%)	DB MGL-3196 100 mg (N=7) Events n	DB Placebo (N=14) Patients n (%)	DB Placebo (N=14) Events n
Patients with at least one TEAE leading to study drug discontinuation	0	0	1 (14.3)	1	1 (7.1)	1
Musculoskeletal and connective tissue disorders	0	0	0	0	1 (7.1)	1
Muscle spasms	0	0	0	0	1 (7.1)	1
Psychiatric disorders	0	0	1 (14.3)	1	0	0
Agitation	0	0	1 (14.3)	1	0	0

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
Program: t-s06-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S6.5.1
TEAE (S6): Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term; by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Hispanic

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=4)		DB MGL-3196 100 mg (N=6)		DB Placebo (N=11)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Patients with at least one TEAE leading to study drug discontinuation	0	0	0	0	0	0

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
Program: t-s06-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S6.5.1
TEAE (S6): Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term; by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Non-Hispanic

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=5) Patients n (%)	DB MGL-3196 80 mg (N=5) Events n	DB MGL-3196 100 mg (N=9) Patients n (%)	DB MGL-3196 100 mg (N=9) Events n	DB Placebo (N=17) Patients n (%)	DB Placebo (N=17) Events n
Patients with at least one TEAE leading to study drug discontinuation	0	0	1 (11.1)	1	1 (5.9)	1
Musculoskeletal and connective tissue disorders	0	0	0	0	1 (5.9)	1
Muscle spasms	0	0	0	0	1 (5.9)	1
Psychiatric disorders	0	0	1 (11.1)	1	0	0
Agitation	0	0	1 (11.1)	1	0	0

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
Program: t-s06-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S6.6.1
TEAE (S6): Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term; by Weight
(Label Population based on Safety Population)

Weight: >200 lbs

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=2) Patients n (%)	DB MGL-3196 80 mg (N=2) Events n	DB MGL-3196 100 mg (N=15) Patients n (%)	DB MGL-3196 100 mg (N=15) Events n	DB Placebo (N=24) Patients n (%)	DB Placebo (N=24) Events n
Patients with at least one TEAE leading to study drug discontinuation	0	0	1 (6.7)	1	1 (4.2)	1
Musculoskeletal and connective tissue disorders	0	0	0	0	1 (4.2)	1
Muscle spasms	0	0	0	0	1 (4.2)	1
Psychiatric disorders	0	0	1 (6.7)	1	0	0
Agitation	0	0	1 (6.7)	1	0	0

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
Program: t-s06-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S6.6.1
TEAE (S6): Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term; by Weight
(Label Population based on Safety Population)

Weight: <= 200 lbs

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=7) Patients n (%)	DB MGL-3196 80 mg (N=7) Events n	DB MGL-3196 100 mg (N=0) Patients n (%)	DB MGL-3196 100 mg (N=0) Events n	DB Placebo (N=4) Patients n (%)	DB Placebo (N=4) Events n
Patients with at least one TEAE leading to study drug discontinuation	0	0	0	0	0	0

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
Program: t-s06-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S6.7.1

TEAE (S6): Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term; by Baseline T2D Status

(Label Population based on Safety Population)

Baseline T2D Status: Presence

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=6) Patients n (%)	DB MGL-3196 80 mg (N=6) Events n	DB MGL-3196 100 mg (N=6) Patients n (%)	DB MGL-3196 100 mg (N=6) Events n	DB Placebo (N=19) Patients n (%)	DB Placebo (N=19) Events n
Patients with at least one TEAE leading to study drug discontinuation	0	0	1 (16.7)	1	1 (5.3)	1
Musculoskeletal and connective tissue disorders	0	0	0	0	1 (5.3)	1
Muscle spasms	0	0	0	0	1 (5.3)	1
Psychiatric disorders	0	0	1 (16.7)	1	0	0
Agitation	0	0	1 (16.7)	1	0	0

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event; T2D = Type 2 Diabetes.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
Program: t-s06-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S6.7.1

TEAE (S6): Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term; by Baseline T2D Status

(Label Population based on Safety Population)

Baseline T2D Status: Absence

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=3) Patients n (%)	DB MGL-3196 80 mg (N=3) Events n	DB MGL-3196 100 mg (N=9) Patients n (%)	DB MGL-3196 100 mg (N=9) Events n	DB Placebo (N=9) Patients n (%)	DB Placebo (N=9) Events n
Patients with at least one TEAE leading to study drug discontinuation	0	0	0	0	0	0

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event; T2D = Type 2 Diabetes.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
Program: t-s06-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S6.8.1
TEAE (S6): Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term; by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: > 7.5

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=1) Patients n (%)	DB MGL-3196 80 mg (N=1) Events n	DB MGL-3196 100 mg (N=2) Patients n (%)	DB MGL-3196 100 mg (N=2) Events n	DB Placebo (N=7) Patients n (%)	DB Placebo (N=7) Events n
Patients with at least one TEAE leading to study drug discontinuation	0	0	0	0	1 (14.3)	1
Musculoskeletal and connective tissue disorders	0	0	0	0	1 (14.3)	1
Muscle spasms	0	0	0	0	1 (14.3)	1

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event; HbA1c = Hemoglobin A1C.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
Program: t-s06-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S6.8.1
TEAE (S6): Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term; by Baseline HbA1C
(Label Population based on Safety Population)

Baseline HbA1C: <= 7.5

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=8) Patients n (%)	DB MGL-3196 80 mg (N=8) Events n	DB MGL-3196 100 mg (N=13) Patients n (%)	DB MGL-3196 100 mg (N=13) Events n	DB Placebo (N=21) Patients n (%)	DB Placebo (N=21) Events n
Patients with at least one TEAE leading to study drug discontinuation	0	0	1 (7.7)	1	0	0
Psychiatric disorders	0	0	1 (7.7)	1	0	0
Agitation	0	0	1 (7.7)	1	0	0

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event; HbA1c = Hemoglobin A1C.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
Program: t-s06-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S6.9.1

TEAE (S6): Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term; by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)

(Label Population based on Safety Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): Yes

	DB MGL-3196 80 mg (N=8)		DB MGL-3196 100 mg (N=10)		DB Placebo (N=20)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Patients with at least one TEAE leading to study drug discontinuation	0	0	1 (10.0)	1	0	0
Psychiatric disorders	0	0	1 (10.0)	1	0	0
Agitation	0	0	1 (10.0)	1	0	0

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
Program: t-s06-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S6.9.1

TEAE (S6): Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term; by Sites that participated in Study MAESTRO-NASH (MGL-3196-11)

(Label Population based on Safety Population)

Sites that participated in Study MAESTRO-NASH (MGL-3196-11): No

	DB MGL-3196 80 mg (N=1)		DB MGL-3196 100 mg (N=5)		DB Placebo (N=8)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Patients with at least one TEAE leading to study drug discontinuation	0	0	0	0	1 (12.5)	1
Musculoskeletal and connective tissue disorders	0	0	0	0	1 (12.5)	1
Muscle spasms	0	0	0	0	1 (12.5)	1

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
Program: t-s06-02-01-subgroup.sas Date of creation: 13AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-14 Data Cut-off Date: 27FEB2023

AMNOG Table S6.10.1

TEAE (S6): Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term; by Baseline Statin

(Label Population based on Safety Population)

Baseline Statin: Yes (Treated with Statins at baseline)

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=5) Patients n (%)	DB MGL-3196 80 mg (N=5) Events n	DB MGL-3196 100 mg (N=5) Patients n (%)	DB MGL-3196 100 mg (N=5) Events n	DB Placebo (N=17) Patients n (%)	DB Placebo (N=17) Events n
Patients with at least one TEAE leading to study drug discontinuation	0	0	1 (20.0)	1	1 (5.9)	1
Musculoskeletal and connective tissue disorders	0	0	0	0	1 (5.9)	1
Muscle spasms	0	0	0	0	1 (5.9)	1
Psychiatric disorders	0	0	1 (20.0)	1	0	0
Agitation	0	0	1 (20.0)	1	0	0

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
Program: t-s06-02-01-subgroup.sas Date of creation: 13AUG2025

AMNOG Table S6.10.1

TEAE (S6): Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term; by Baseline Statin

(Label Population based on Safety Population)

Baseline Statin: No

System Organ Class Preferred Term	DB MGL-3196 80 mg (N=4) Patients n (%)	DB MGL-3196 80 mg (N=4) Events n	DB MGL-3196 100 mg (N=10) Patients n (%)	DB MGL-3196 100 mg (N=10) Events n	DB Placebo (N=11) Patients n (%)	DB Placebo (N=11) Events n
Patients with at least one TEAE leading to study drug discontinuation	0	0	0	0	0	0

Abbreviation: DB = Double Blinded; TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset or post-dose worsening of any pre-existing AE (existing prior to the first dose), either by severity or by study drug relationship, on or after the date of the first dose of study medication up to 30 days after the date of the last dose of study medication.
Note: Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
Program: t-s06-02-01-subgroup.sas Date of creation: 13AUG2025